<SEC-DOCUMENT>0001628280-22-012630.txt : 20220506
<SEC-HEADER>0001628280-22-012630.hdr.sgml : 20220506
<ACCEPTANCE-DATETIME>20220505160634
ACCESSION NUMBER:		0001628280-22-012630
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		76
CONFORMED PERIOD OF REPORT:	20220331
FILED AS OF DATE:		20220505
DATE AS OF CHANGE:		20220505

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARDELYX, INC.
		CENTRAL INDEX KEY:			0001437402
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36485
		FILM NUMBER:		22896187

	BUSINESS ADDRESS:	
		STREET 1:		34175 ARDENWOOD BLVD.
		CITY:			FREMONT
		STATE:			CA
		ZIP:			94555
		BUSINESS PHONE:		510-745-7047

	MAIL ADDRESS:	
		STREET 1:		34175 ARDENWOOD BLVD.
		CITY:			FREMONT
		STATE:			CA
		ZIP:			94555

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NTERYX INC
		DATE OF NAME CHANGE:	20080611
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>ardx-20220331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:9e7cc335-f1e2-4409-ab16-898e4e60d77f,g:bd3d9229-0258-42cf-b897-58fd721121d9,d:711b1a39e0634b15bb7a70766327247a--><html xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ardx="http://www.ardelyx.com/20220331" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>ardx-20220331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80L2ZyYWc6NjFhNDM5YmM5YmUxNDcxZjhlZjhiMGZhZDE0ZDJmZjQvdGFibGU6MDQwYTg2ZDI4ZGQ2NDFhMTk0NDU0OGZmODdjODI4NDUvdGFibGVyYW5nZTowNDBhODZkMjhkZDY0MWExOTQ0NTQ4ZmY4N2M4Mjg0NV8wLTEtMS0xLTIzMDEz_984e6ca6-ce84-468f-8c2e-71617cc7d112">0001437402</ix:nonNumeric><ix:nonNumeric contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80L2ZyYWc6NjFhNDM5YmM5YmUxNDcxZjhlZjhiMGZhZDE0ZDJmZjQvdGFibGU6MDQwYTg2ZDI4ZGQ2NDFhMTk0NDU0OGZmODdjODI4NDUvdGFibGVyYW5nZTowNDBhODZkMjhkZDY0MWExOTQ0NTQ4ZmY4N2M4Mjg0NV8xLTEtMS0xLTIzMDEz_7eab4b1c-60ab-42cd-92b4-f1298fdff1c2">12-31</ix:nonNumeric><ix:nonNumeric contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80L2ZyYWc6NjFhNDM5YmM5YmUxNDcxZjhlZjhiMGZhZDE0ZDJmZjQvdGFibGU6MDQwYTg2ZDI4ZGQ2NDFhMTk0NDU0OGZmODdjODI4NDUvdGFibGVyYW5nZTowNDBhODZkMjhkZDY0MWExOTQ0NTQ4ZmY4N2M4Mjg0NV8yLTEtMS0xLTIzMDEz_309fb75e-051f-4fdc-a607-88e3054961aa">2022</ix:nonNumeric><ix:nonNumeric contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80L2ZyYWc6NjFhNDM5YmM5YmUxNDcxZjhlZjhiMGZhZDE0ZDJmZjQvdGFibGU6MDQwYTg2ZDI4ZGQ2NDFhMTk0NDU0OGZmODdjODI4NDUvdGFibGVyYW5nZTowNDBhODZkMjhkZDY0MWExOTQ0NTQ4ZmY4N2M4Mjg0NV8zLTEtMS0xLTIzMDEz_9aa300f2-fea0-414a-a2c0-44161e5a703c">Q1</ix:nonNumeric><ix:nonNumeric contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80L2ZyYWc6NjFhNDM5YmM5YmUxNDcxZjhlZjhiMGZhZDE0ZDJmZjQvdGFibGU6MDQwYTg2ZDI4ZGQ2NDFhMTk0NDU0OGZmODdjODI4NDUvdGFibGVyYW5nZTowNDBhODZkMjhkZDY0MWExOTQ0NTQ4ZmY4N2M4Mjg0NV80LTEtMS0xLTIzMDEz_0c7bdf14-92fc-4b54-ac4f-33519db37366">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="ardx-20220331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50bec6a618074ef79a40cbc0e7e8aa89_I20220502"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-05-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i6c8486331a7f40578e81f8425fe3e837_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i97ef8572b6ce41c09c8f695ae8a0ca00_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5783cc7426ba453f96f1e7e0af87b0a6_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id194cfe3452f4c7c84f5dfd4fe7d8297_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ardx:ProductSupplyRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f8aa7556d7647dd80cd79f50b30d12a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ardx:ProductSupplyRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c8fadcb7a584b6b81773ef6f2440734_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77926c7e42f94727854dd2729e419202_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i785dbb6e8a754de6a7aa8b0b43cd5de4_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ardx:CollaborativeDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6b9396538454def9c8a29399c6b8d03_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ardx:CollaborativeDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if66cb97858004034a661fde444b21a40_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4cf9b083bea54e30a63681421a4a7088_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i915c4ac55b394c648e3f1e508325bbfe_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77bb1febd93946efb7f1ca68a5cb537e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id37f845e78ea4e4ba399ae4d539dd270_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe48acc39ad24a498bf29293d3b5ff68_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a66e20dad254b89922f8674a7094895_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie996e76b43b94778bbd562ef8363a5f7_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f13863ef82b4ff9891451291774c864_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a994d19646542b883bef3eb77ec041a_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia53bcaf6b509496b9aaca8a740abefe9_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71139a32ab724fed9714f268e212cd3a_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9012898f9a0f44118b5aa8f6b4d02190_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d98dab95e674482969a1c14b83aeabb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35ca663b0a124e6b8c8656e7e070589c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71bfab9599a347c38e447f9dfe33b344_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1302e9e86374f80ab91f5e2e093f6fa_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa47cdf56b6c4c87a3d970dbcf5b0e23_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic32baa0627994f879f796094ade7c7d5_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f6752f99ffb46a6ac848c2977b3c96d_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie42c996fddf8460982e8ef5b6a6dd25a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76348c324fa24beda3b12611828f421a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id70cbf4ca0ff49799aebf60ead1ac83a_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie895873a73154ee881d6a0b9a2729c79_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38a8556738964a7fa1421049694e0b21_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c204a43b4eb4e6d9394547d9b0e2b58_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac98ebf56cf345fb9e32e575ac855e4a_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>ardx:segment</xbrli:measure></xbrli:unit><xbrli:context id="i42e4f62db19a433c9581bbeecf9067e3_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">ardx:AccountsReceivableCollaboratorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9efdb641fb440e39fb4580adc8f5d3f_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">ardx:AccountsReceivableCommercialCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0170fbda0b74504967067c9d57bec75_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">ardx:AccountsReceivableCollaboratorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc13d123a8d14d6babcf8581fd6dcd05_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a085319c0b44680ad033352cd7f1a58_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i390f2ffb21554b849e8f47149934d4fd_D20150601-20150630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:AstrazenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:AstraZenecaTerminationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-06-01</xbrli:startDate><xbrli:endDate>2015-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="id4d3d62533e642adab59317a030f3b30_I20150630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:AstrazenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:AstraZenecaTerminationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8bde55ddcbf0400a8169b35ffe4c6da2_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:AstrazenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7eb8629a82dc4a618ece82cbcdfbe085_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05a2662add9440cc8c7d0f1dc736a702_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i596f9b1e440f4452b6cba1824137da8b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7673f1405fd24051b58473f5a806ecb9_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea208acf5bf04c3b9d76527a7e0ebf16_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37581a46b73b46d5b858164659fbef62_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19273e8da1e4462a88cdc93b1a044f85_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1757ee4e90cc49c3ae9d0a3ce3f93f66_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib27f65921b34451f840e9bfaa2858274_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib232d5bccde74c2c832a58c5854c8659_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f8c132fed8e489a94a6ec129ee5512e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae3a2fe36c17417ca407960547b30624_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="investment"><xbrli:measure>ardx:investment</xbrli:measure></xbrli:unit><xbrli:context id="id7116fb603e844e7b66ea135c246d400_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f95faaaa8ba40ef81fabfd9af749d5a_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifffac340b48d4569a291b906003daa40_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3c8925c35b44d6d9fbe11c422368576_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie320d5dea5f84c1a997114a2a44304ab_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic12ce3ad23f94a40843d57bbafc1b93b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib64b89a6dbb241f9ac74255f0f2faddd_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20743f7a35cf46598f5e61aadaaaf959_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7282cda81b5e403d9d6a82b54ca9e220_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icbe8bcf473664c3cbd7a8d406e6f4b25_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieff5d13f74bb46f19e0bf993fbdb4e1b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c8530d2f63d4dcd99a0d2685f08f090_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22961d74779a41578f711e2cbdab8cc8_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i346bb756dc874f18b4e7ecc3b1fd18fd_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45e9678a2bb9475883b569adf411868a_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i057b3b5e23d74f1b93392611784416da_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec212359212b4b3686fe182249f00160_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c358ffd9da447c0ae8ba16d667ddb3d_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa5d06c90bd0488e864737436b77eb4c_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b1a0008a10b4495b001946a2dbbebcf_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia66c3497d92f4f87983a8808d4c22279_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idccb2dc5b13a4488878f9a05af20f66a_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8a67586059d49f9810370c50eaa57c0_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c1a6f674cd541978439c2f0f7d4fb9a_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0e3ba1f3d18466d8724f70ecdc208fa_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd9cbd3639304bd294cd77b069e2903b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie12d13976cc7450da7913cd451cc1f1d_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7da228130c340edbbb9bf247a589756_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9becbf42740c409189339a2b5a11a4f2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92ef66972cf9427cb63419db9768a298_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i211bb796b7a24967b594b6dbe16c328c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie08734f5a1ee4ae1a8f14c3e0ad81e38_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i702ba55895b343c594a4b5ed37806639_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id48fda4018124a2789eda8fb5e8c7f3b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i864378b20e0f48a2a4a6e9ec27084dd7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i870189fb8682430baf663525b78d14eb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i498f3eb654bb4e63858ae975af11c445_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie76caf10c27b47c9b2d7f93b70732805_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b34d1e5e84949e08757fe31d16851b6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icae86f3621e745dcae0300fcf262e97a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibfe0e960aed543b5988f05f7d3355902_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f334852225945b2a7a93e28e698a7b5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2fbce7b430d746d193e24e71ed55ec24_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77f4939d9c1b4cb9a23a9d1abed49c29_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a918505eebf4610bda0dea154daa7a3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb543391634c44d0a2f40bdc636ebebf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b0ae5504847492aaff354b4bb3eed43_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07deb0701eff4cf3b8159da82875bb77_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2c246545dd44f91b1867420b6787cd5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57236df6e705400089af661d14abc3ab_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9aaa3d02b9854e48a25597ea0974cd4e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec8114b671a2456c81955e87ce50bed9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i157edd1d25424d4e869f567c7ddd2b4a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ardx:ProductIBSRELAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5602110d257243d68fe06a3de7666ba1_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ardx:CardinalHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a2496c68915449aa1b605adb0073d44_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ardx:AmerisourceBergenDrugCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4ede0c6d6294ec1ba539591fc337da1_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ardx:McKessonCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3cd8e102ed0b453abc3afc0ba274b816_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ardx:GrossToNetSalesAccrualAndReserveClassificationAxis">ardx:ContractWithCustomerDiscountsAndChargebacksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e3b20e3d13f464f8136bc69cac78387_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ardx:GrossToNetSalesAccrualAndReserveClassificationAxis">ardx:ContractWithCustomerRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc17b1d2c9354e6ba7867c153f98dd39_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ardx:GrossToNetSalesAccrualAndReserveClassificationAxis">ardx:ContractWithCustomerOtherFeesCopayAndReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia23df3972f1944e3a9fed9c31cbc6587_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ardx:GrossToNetSalesAccrualAndReserveClassificationAxis">ardx:ContractWithCustomerDiscountsAndChargebacksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4eed71377df84e2fad4e2b5044d0f43c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ardx:GrossToNetSalesAccrualAndReserveClassificationAxis">ardx:ContractWithCustomerRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10819c0292d84effb45cc9b78a0c7f30_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ardx:GrossToNetSalesAccrualAndReserveClassificationAxis">ardx:ContractWithCustomerOtherFeesCopayAndReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iede9224697ec4dd1a0adabd2320ebc14_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ardx:GrossToNetSalesAccrualAndReserveClassificationAxis">ardx:ContractWithCustomerDiscountsAndChargebacksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie452822da30341968381616c4727890f_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ardx:GrossToNetSalesAccrualAndReserveClassificationAxis">ardx:ContractWithCustomerRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3971d760f8441f38d00e317c37315fd_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ardx:GrossToNetSalesAccrualAndReserveClassificationAxis">ardx:ContractWithCustomerOtherFeesCopayAndReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23aa3d7663a24dc8865dc922b983040b_D20191101-20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:KyowaKirinCo.LtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:ResearchCollaborationAndOptionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-01</xbrli:startDate><xbrli:endDate>2019-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="item"><xbrli:measure>ardx:item</xbrli:measure></xbrli:unit><xbrli:context id="i9168e70d1cc646808da95d0e5cbe0347_D20191101-20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:KyowaKirinCo.LtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:ResearchCollaborationAndOptionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-01</xbrli:startDate><xbrli:endDate>2019-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i745335ff1da443c2a66acb028f9b9044_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:ResearchCollaborationAndOptionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id32818d38a2f41e79d9416fb0bd0e53a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:ResearchCollaborationAndOptionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ded7d7b952443ff99d1931791c886bb_D20171101-20171130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:KyowaKirinCo.LtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-11-01</xbrli:startDate><xbrli:endDate>2017-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8bba5999a33a4beabc6bda2318d9d5d6_I20171130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:KyowaKirinCo.LtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0212bc236d5d418c889a86710d62cead_D20171101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-11-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic0f6d47945c94e2398355efb64d25b64_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:KyowaKirinCo.LtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="jpy"><xbrli:measure>iso4217:JPY</xbrli:measure></xbrli:unit><xbrli:context id="ic15e7d54e20c401b86da52a356fa5887_I20220411"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:KyowaKirinCo.LtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="payment_tranche"><xbrli:measure>ardx:payment_tranche</xbrli:measure></xbrli:unit><xbrli:context id="ib0326b0e1d934394b35c6b4e5823a0e9_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i777f4b1d2b0a48c995f7a8e8fc2a2d0d_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab42eb33c5f6401eb4cabd7658b0c6bd_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ardx:ProductSupplyRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1760e71a3aab4fd190e7292ba626aa96_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ardx:ProductSupplyRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaafa907a1fc049f59de2c2fcb1b077a8_D20171201-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInChinaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a019b5505f7466ca2f76583b097cdbe_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInChinaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c7ce382bd124359a0a4700a39632df1_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInChinaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9fd94dcca60490e82fbc1d493ab985c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInChinaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i839c245d89c241679804a884e550ef5b_D20180301-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:KnightTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-03-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29560f0f154647109b5c7c80f240890c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:KnightTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73d193d247244f1fb9ce854954086ef6_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:AstrazenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:AstraZenecaTerminationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i025ade055f874ff1a468b7fbd0583eda_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:AstrazenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:AstraZenecaTerminationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3de6eb23c1e24a80807755f0069fc236_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:AstrazenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:AstraZenecaTerminationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34485cae15f04837aa894774e18bbb58_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:ResearchCollaborationAndOptionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia600adb07b6d40c9b3357ac69342a7ad_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:ResearchCollaborationAndOptionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i717222ed03814f8f986a1604095f9214_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:ResearchCollaborationAndOptionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic81523b011734f66b3b288912d844b1d_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:ResearchCollaborationAndOptionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61553ae32dfb40f8b285bdfc4a3d3272_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd27a0a1ac554dc1a75c1884f665b7f6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e8de9754a784d54a397d66dc8d5ebf0_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb1b8b57f3484b4c886d5bcda853744b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2146e1f17bd043f3b77edbd52edab483_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f0cf433f09e4f1e9169aefcedff5d7f_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7f93b8f72cf486bbecc12514b98b015_I20180516"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ardx:TermLoan2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7054c03dafb4f308b95f52c3a43fa1b_I20220223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ardx:TermLoan2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba83d40326b1433ea471109cb11536f8_I20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ardx:ExitFee2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a8be86cba30452780b8d0bca7fe52ef_D20220223-20220223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ardx:TermLoan2022AMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-23</xbrli:startDate><xbrli:endDate>2022-02-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22ce6a39c3434acd91d5ab75ae19b62f_I20220223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ardx:TermLoan2022BMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00d53b360ebd4d39ab0a045093b0d350_D20220223-20220223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ardx:TermLoan2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-23</xbrli:startDate><xbrli:endDate>2022-02-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7137d11d7564018ab80498ef529b584_I20220223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ardx:TermLoan2022AMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icbf434cb3f104e188c9fd0464443c2f4_I20220223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ardx:TermLoan2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d5d94cb725e4caca45734b96460fab2_I20220223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ardx:TermLoan2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5134dd31b2ec46ba9252bb3ccd222425_I20220223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ardx:TermLoan2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia616f3b3f10d4ebda8439302d146953c_I20220223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ardx:TermLoan2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c1d87e6c35c44b9baca5f0c32c93d4e_I20220223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ardx:ExitFee2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie706e05847024bdfbe5174e56d319428_D20220223-20220223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ardx:ExitFee2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-23</xbrli:startDate><xbrli:endDate>2022-02-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59df1925a0574c55bae8311f5941df95_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ardx:ExitFee2018Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89699442d50542d18f061eb0f10ea77b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ardx:ExitFee2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id497bd1485194fabbdb368667104492e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ad56d5e526243f6a24d080e5313c670_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8c70b1e37704cbba96b42d34dac6902_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf0f6a03fb7b4bdc8dace9bdd0e496b2_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e02e812fef941edbaba1967484f0272_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84a8784bf6674ce391d92b932658744b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76c2136d55464302b2f21baaa5e4dd54_I20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia17a982a190740e2954ba6bf67641fdf_I20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ardx:OpenMarketSalesAgreement2020AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide9366ec48e04d7b90b9fb896f92c772_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ardx:OpenMarketSalesAgreement2020AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8a3d4170574424dbc7bd161e8e90f99_I20210831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ardx:OpenMarketSalesAgreement2021AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58ecc0e1f7064678834e4f881aa7d26f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ardx:OpenMarketSalesAgreement2021AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e7f6940c3f94b42ae0826c56712faf3_D20220401-20220427"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ardx:OpenMarketSalesAgreement2021AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-04-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5fb7df19c340473c8180a84b522d3105_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i688a54ef5d904ecc853b9118c446b946_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd425314803a477c8c332384eb697af8_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5dc952c28b244722a46ac91b1208bda9_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a3d5f58f87e49a095847ea09b7bf010_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i097a3193c63e4588b0705a6c382a1938_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5d73f51d15b4a93b70e582a308344c0_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf00f8a3ea3f45eaab148f2ba05a7841_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59d036f63af647faadf250a643250458_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ardx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic35af7bef7ef4aaf9affdc91a3779184_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ardx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14d3b2f9b45b490fbcbe947f54b91b39_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4bedde518aa14e90ae770d42052bfc56_D20220201-20220228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ardx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-01</xbrli:startDate><xbrli:endDate>2022-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i856e705397e44a879c8d4de90f5984b6_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i711b1a39e0634b15bb7a70766327247a_1"></div><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i711b1a39e0634b15bb7a70766327247a_7">Table of Contents</a></span></div></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WASHINGTON, DC 20549</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:23.391%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM&#160;<ix:nonNumeric contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xL2ZyYWc6MGFkODRlZTU5Y2VjNDAyMmIyNTAzYWE1MjgwMDY5ZmUvdGV4dHJlZ2lvbjowYWQ4NGVlNTljZWM0MDIyYjI1MDNhYTUyODAwNjlmZV8yMTE5_93610474-1e6f-4616-a84e-0b033aac47f6">10-Q</ix:nonNumeric></span><span style="font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:23.391%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">(Mark One)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:3.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.062%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xL2ZyYWc6MGFkODRlZTU5Y2VjNDAyMmIyNTAzYWE1MjgwMDY5ZmUvdGFibGU6YWFlOGM4Mzg5YmZmNGRhMTk2NmI5OWZlNWE4MzA4NzEvdGFibGVyYW5nZTphYWU4YzgzODliZmY0ZGExOTY2Yjk5ZmU1YTgzMDg3MV8wLTAtMS0xLTIzMDEz_ba3abc99-357a-42a8-9b87-eae65e3c4c61">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%"></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xL2ZyYWc6MGFkODRlZTU5Y2VjNDAyMmIyNTAzYWE1MjgwMDY5ZmUvdGV4dHJlZ2lvbjowYWQ4NGVlNTljZWM0MDIyYjI1MDNhYTUyODAwNjlmZV8zMjk4NTM0ODg1NTAx_44028974-3aff-4952-8ae2-364b218f7da4">March&#160;31, 2022</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:3.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.062%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xL2ZyYWc6MGFkODRlZTU5Y2VjNDAyMmIyNTAzYWE1MjgwMDY5ZmUvdGFibGU6NGUyOGI0ZGJkNTE4NDE0ZjgyNmEzMmZjYzI5NDM0NWUvdGFibGVyYW5nZTo0ZTI4YjRkYmQ1MTg0MTRmODI2YTMyZmNjMjk0MzQ1ZV8wLTAtMS0xLTIzMDEz_81229009-1908-4fb8-88db-156572b9b1dd">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%"></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission file number:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xL2ZyYWc6MGFkODRlZTU5Y2VjNDAyMmIyNTAzYWE1MjgwMDY5ZmUvdGV4dHJlZ2lvbjowYWQ4NGVlNTljZWM0MDIyYjI1MDNhYTUyODAwNjlmZV8yMTI0_574c9249-c6c6-4d51-a953-ff46494ff5bc">001-36485</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:23.391%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><img src="ardx-20220331_g1.jpg" alt="ardx-20220331_g1.jpg" style="height:60px;margin-bottom:5pt;vertical-align:text-bottom;width:60px"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xL2ZyYWc6MGFkODRlZTU5Y2VjNDAyMmIyNTAzYWE1MjgwMDY5ZmUvdGV4dHJlZ2lvbjowYWQ4NGVlNTljZWM0MDIyYjI1MDNhYTUyODAwNjlmZV8yMTIw_c7a0322e-db9f-4749-8545-ceb2b81516ee">ARDELYX,&#160;INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Exact Name of Registrant as Specified in Its Charter)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:23.391%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xL2ZyYWc6MGFkODRlZTU5Y2VjNDAyMmIyNTAzYWE1MjgwMDY5ZmUvdGFibGU6YmZmY2NlMmU0YWU4NDVkZmFiNWFmZDMzMWMyZWYxOTYvdGFibGVyYW5nZTpiZmZjY2UyZTRhZTg0NWRmYWI1YWZkMzMxYzJlZjE5Nl8wLTAtMS0xLTIzMDEz_f1d65461-20fa-4cdd-8514-35cd4437d868">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xL2ZyYWc6MGFkODRlZTU5Y2VjNDAyMmIyNTAzYWE1MjgwMDY5ZmUvdGFibGU6YmZmY2NlMmU0YWU4NDVkZmFiNWFmZDMzMWMyZWYxOTYvdGFibGVyYW5nZTpiZmZjY2UyZTRhZTg0NWRmYWI1YWZkMzMxYzJlZjE5Nl8wLTEtMS0xLTIzMDEz_80f9d0a0-e00a-4d0f-9edd-fc947d6646fb">26-1303944</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or Other Jurisdiction of Incorporation or Organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification No)</span></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%"></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xL2ZyYWc6MGFkODRlZTU5Y2VjNDAyMmIyNTAzYWE1MjgwMDY5ZmUvdGV4dHJlZ2lvbjowYWQ4NGVlNTljZWM0MDIyYjI1MDNhYTUyODAwNjlmZV8yMTEw_a39d659a-c706-4d12-9484-727422d42482">400 Fifth Avenue</ix:nonNumeric>, <ix:nonNumeric contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xL2ZyYWc6MGFkODRlZTU5Y2VjNDAyMmIyNTAzYWE1MjgwMDY5ZmUvdGV4dHJlZ2lvbjowYWQ4NGVlNTljZWM0MDIyYjI1MDNhYTUyODAwNjlmZV8yMTEz_a7546226-ded2-4323-8c24-477fb4985871">Suite 210</ix:nonNumeric>, <ix:nonNumeric contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xL2ZyYWc6MGFkODRlZTU5Y2VjNDAyMmIyNTAzYWE1MjgwMDY5ZmUvdGV4dHJlZ2lvbjowYWQ4NGVlNTljZWM0MDIyYjI1MDNhYTUyODAwNjlmZV8yMTEx_f20e96b9-915f-4b02-b39f-2d7db11ad575">Waltham</ix:nonNumeric>, <ix:nonNumeric contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xL2ZyYWc6MGFkODRlZTU5Y2VjNDAyMmIyNTAzYWE1MjgwMDY5ZmUvdGV4dHJlZ2lvbjowYWQ4NGVlNTljZWM0MDIyYjI1MDNhYTUyODAwNjlmZV8yMTIy_2762ca9e-c086-4c19-b98a-20c8214fefb0">Massachusetts</ix:nonNumeric> <ix:nonNumeric contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xL2ZyYWc6MGFkODRlZTU5Y2VjNDAyMmIyNTAzYWE1MjgwMDY5ZmUvdGV4dHJlZ2lvbjowYWQ4NGVlNTljZWM0MDIyYjI1MDNhYTUyODAwNjlmZV8yMTE0_9738ddc9-db61-442a-abc0-3a87b6fe1535">02451</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Address of Principal Executive Offices) (Zip Code)</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xL2ZyYWc6MGFkODRlZTU5Y2VjNDAyMmIyNTAzYWE1MjgwMDY5ZmUvdGV4dHJlZ2lvbjowYWQ4NGVlNTljZWM0MDIyYjI1MDNhYTUyODAwNjlmZV8yMTIz_1a43ae9f-b969-483e-b0fa-62a91e4d8059">510</ix:nonNumeric>)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xL2ZyYWc6MGFkODRlZTU5Y2VjNDAyMmIyNTAzYWE1MjgwMDY5ZmUvdGV4dHJlZ2lvbjowYWQ4NGVlNTljZWM0MDIyYjI1MDNhYTUyODAwNjlmZV8yMTI2_13cf20ae-5fa1-4263-89ef-1808b2d6c3ba">745-1700</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Registrant&#8217;s Telephone Number, Including Area Code)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:23.391%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div><span style="font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.987%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.245%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.990%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xL2ZyYWc6MGFkODRlZTU5Y2VjNDAyMmIyNTAzYWE1MjgwMDY5ZmUvdGFibGU6ZTk1OGJlM2M5MTEzNDhmYTk5MTZiZWFlZDhlOGE2MTUvdGFibGVyYW5nZTplOTU4YmUzYzkxMTM0OGZhOTkxNmJlYWVkOGU4YTYxNV8xLTAtMS0xLTIzMDEz_1583c2d2-7883-40d0-b147-8f9b28439fac">Common Stock, par value $0.0001</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xL2ZyYWc6MGFkODRlZTU5Y2VjNDAyMmIyNTAzYWE1MjgwMDY5ZmUvdGFibGU6ZTk1OGJlM2M5MTEzNDhmYTk5MTZiZWFlZDhlOGE2MTUvdGFibGVyYW5nZTplOTU4YmUzYzkxMTM0OGZhOTkxNmJlYWVkOGU4YTYxNV8xLTItMS0xLTIzMDEz_bae6bc63-886e-4c93-9a14-a30574cdca17">ARDX</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xL2ZyYWc6MGFkODRlZTU5Y2VjNDAyMmIyNTAzYWE1MjgwMDY5ZmUvdGFibGU6ZTk1OGJlM2M5MTEzNDhmYTk5MTZiZWFlZDhlOGE2MTUvdGFibGVyYW5nZTplOTU4YmUzYzkxMTM0OGZhOTkxNmJlYWVkOGU4YTYxNV8xLTQtMS0xLTIzMDEz_e0e92e9d-d8eb-4070-96e6-5f3ab2704bea">The Nasdaq Global Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xL2ZyYWc6MGFkODRlZTU5Y2VjNDAyMmIyNTAzYWE1MjgwMDY5ZmUvdGV4dHJlZ2lvbjowYWQ4NGVlNTljZWM0MDIyYjI1MDNhYTUyODAwNjlmZV8yMTEy_6b9e1be1-cb37-4844-a01f-4489506d63e5">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xL2ZyYWc6MGFkODRlZTU5Y2VjNDAyMmIyNTAzYWE1MjgwMDY5ZmUvdGV4dHJlZ2lvbjowYWQ4NGVlNTljZWM0MDIyYjI1MDNhYTUyODAwNjlmZV8yMTI3_a6a2d3cd-cb23-440d-a176-d8d984ded9ad">Yes</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</span><span style="font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%"></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.052%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.052%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.847%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.599%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xL2ZyYWc6MGFkODRlZTU5Y2VjNDAyMmIyNTAzYWE1MjgwMDY5ZmUvdGFibGU6NzEyM2VmZWQzZTQ3NGEyYWFlOWQ1M2FlMWY0ODQ2NTUvdGFibGVyYW5nZTo3MTIzZWZlZDNlNDc0YTJhYWU5ZDUzYWUxZjQ4NDY1NV8wLTEtMS0xLTMxMzYz_2593128b-67bf-4152-8af9-a1c3de96cfb8">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xL2ZyYWc6MGFkODRlZTU5Y2VjNDAyMmIyNTAzYWE1MjgwMDY5ZmUvdGFibGU6NzEyM2VmZWQzZTQ3NGEyYWFlOWQ1M2FlMWY0ODQ2NTUvdGFibGVyYW5nZTo3MTIzZWZlZDNlNDc0YTJhYWU5ZDUzYWUxZjQ4NDY1NV8yLTUtMS0xLTIzMDEz_df0e593c-1cff-4687-9039-d0c84f9b7156">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xL2ZyYWc6MGFkODRlZTU5Y2VjNDAyMmIyNTAzYWE1MjgwMDY5ZmUvdGFibGU6NzEyM2VmZWQzZTQ3NGEyYWFlOWQ1M2FlMWY0ODQ2NTUvdGFibGVyYW5nZTo3MTIzZWZlZDNlNDc0YTJhYWU5ZDUzYWUxZjQ4NDY1NV80LTUtMS0xLTIzMDEz_77a476c7-0951-49bf-bd56-db908eb4267a">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xL2ZyYWc6MGFkODRlZTU5Y2VjNDAyMmIyNTAzYWE1MjgwMDY5ZmUvdGV4dHJlZ2lvbjowYWQ4NGVlNTljZWM0MDIyYjI1MDNhYTUyODAwNjlmZV8yMTI4_14b0979c-66d5-4bb7-aa5c-843503a8295c">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;No</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The number of issued and outstanding shares of the registrant&#8217;s Common Stock, $0.0001 par value per share, as of May&#160;2, 2022, was <ix:nonFraction unitRef="shares" contextRef="i50bec6a618074ef79a40cbc0e7e8aa89_I20220502" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xL2ZyYWc6MGFkODRlZTU5Y2VjNDAyMmIyNTAzYWE1MjgwMDY5ZmUvdGV4dHJlZ2lvbjowYWQ4NGVlNTljZWM0MDIyYjI1MDNhYTUyODAwNjlmZV8xNjQ5MjY3NDQzODAz_2140d969-1ab3-4a24-9aee-094a1b0f802a">144,598,863</ix:nonFraction>.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i711b1a39e0634b15bb7a70766327247a_1185"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i711b1a39e0634b15bb7a70766327247a_7">Table of Contents</a></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless the context requires otherwise, in this Quarterly Report on Form 10-Q the terms &#8220;Ardelyx&#8221;, &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; and &#8220;the Company&#8221; refer to Ardelyx, Inc.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q contains forward-looking statements that involve risks and uncertainties. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as &#8220;aim,&#8221; &#8220;anticipate,&#8221; &#8220;assume,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;due,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;goal,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;objective,&#8221; &#8220;plan,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;positioned,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. These forward-looking statements include, but are not limited to, statements about:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding our participation in a Cardiovascular and Renal Drugs Advisory Committee (&#8220;Advisory Committee&#8221;) meeting in connection with the formal dispute resolution (&#8220;FDR&#8221;) process commenced in response to the Complete Response Letter (&#8220;CRL&#8221;) received from the U.S. Food and Drug Administration (&#8220;FDA&#8221;) relating to our new drug application (&#8220;NDA&#8221;) for XPHOZAH</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (tenapanor) for the control of serum phosphorus in adult patients with chronic kidney disease on dialysis (&#8220;CKD&#8221;) (the &#8220;Hyperphosphatemia Indication&#8221;);  </span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans to address our operating cash flow requirements with our current cash and investments, cash generated from the sales of IBSRELA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, our potential receipt of anticipated milestones from our collaboration partners, our potential receipt of anticipated payments from our Japanese collaboration partner under the second amendment to our License Agreement; our ability to access the capital markets, as well as through the implementation of cash preservation activities to reduce or defer discretionary spending;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans with respect to RDX013 and RDX020; and</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">estimates of our expenses, future revenue, capital requirements, our needs for additional financing and our ability to obtain additional capital.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Factors that could cause actual results or conditions to differ from those anticipated by these and other forward-looking statements include those more fully described in the &#8220;ITEM 1A. RISK FACTORS&#8221; section and elsewhere in this Quarterly Report on Form 10-Q. Except as required by law, we assume no obligation to update any forward-looking statement publicly, or to revise any forward-looking statement to reflect events or developments occurring after the date of this Quarterly Report on Form 10-Q, even if new information becomes available in the future. Thus, you should not assume that our silence over time means that actual events are bearing out as expressed or implied in any such forward-looking statement.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SUMMARY OF PRINCIPAL RISKS ASSOCIATED WITH OUR BUSINESS</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have a limited operating history, have incurred significant losses since our inception and will incur losses in the future, which makes it difficult for us to assess our future viability; although our financial statements have been prepared on a going concern basis, our current level of cash and investments alone is not sufficient to meet our operating plans for the next twelve months, raising substantial doubt regarding our ability to continue as a going concern. </span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will require substantial additional financing to achieve our goals, including our goals of commercializing IBSRELA, and preparing for and participating in a Cardiovascular and Renal Drugs Advisory Committee (&#8220;Advisory Committee&#8221;) meeting in connection with the formal dispute resolution (&#8220;FDR&#8221;) process commenced in response to the Complete Response Letter (&#8220;CRL&#8221;) received from the U.S. Food and Drug Administration (&#8220;FDA&#8221;) relating to our new drug application (&#8220;NDA&#8221;) for XPHOZAH (tenapanor) for the control of serum phosphorus in adult patients with chronic kidney disease (&#8220;CKD&#8221;) on dialysis (&#8220;Hyperphosphatemia Indication&#8221;) and the inability to access necessary capital when needed on acceptable terms, or at all, could force us to limit, reduce or terminate our efforts to commercialize IBSRELA or to seek and obtain approval for XPHOZAH for the Hyperphosphatemia Indication. </span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our failure to meet the continued listing requirements of The Nasdaq Global Market ("Nasdaq") could result in a de-listing of our common stock. </span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have generated limited revenue from product sales and may never be profitable. </span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are substantially dependent on the successful launch and commercialization of IBSRELA for IBS-C, and there is no guarantee that we will achieve sufficient market acceptance for IBSRELA; secure adequate coverage and reimbursement for IBSRELA; or generate sufficient revenue from product sales of IBSRELA.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i711b1a39e0634b15bb7a70766327247a_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are pursuing regulatory approval for XPHOZAH for the Hyperphosphatemia Indication, and there can be no assurances that we will be successful in obtaining such regulatory approval.</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Even if we are successful in obtaining regulatory approval for XPHOZAH for the Hyperphosphatemia Indication, the expense and time required to do so could adversely impact our ability to successfully commercialize XPHOZAH for such indication. </span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">IBSRELA, and/or, if approved and commercialized, XPHOZAH, may cause undesirable side effects or have other properties that could limit the commercial success of the product.</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">As a company, we have no prior experience in the marketing, sale and distribution of pharmaceutical products; and there are significant risks in building and managing a commercial organization.</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Third-party payor coverage and reimbursement status of newly-commercialized products are uncertain. Failure to obtain or maintain adequate coverage and reimbursement for IBSRELA and, if approved, for XPHOZAH could limit our ability to market those products and decrease our ability to generate revenue. </span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely completely on third parties to manufacture IBSRELA and XPHOZAH. If they are unable to comply with applicable regulatory requirements, unable to source sufficient raw materials, experience manufacturing or distribution difficulties or are otherwise unable to manufacture sufficient quantities to meet demand, our commercialization of IBSRELA, and, if approved and commercialized of XPHOZAH, and our future development efforts for tenapanor may be materially harmed.    </span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our operating activities may be restricted as a result of covenants related to the indebtedness under our loan and security agreement and we may be required to repay the outstanding indebtedness in an event of default, which could have a materially adverse effect on our business.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE REGARDING TRADEMARKS</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ARDELYX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, IBSRELA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and XPHOZAH</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are trademarks of Ardelyx. All other trademarks, trade names and service marks appearing in this Quarterly Report on Form 10-Q are the property of their respective owners. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i711b1a39e0634b15bb7a70766327247a_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i711b1a39e0634b15bb7a70766327247a_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARDELYX,&#160;INC.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:90.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.685%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PAGE</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i711b1a39e0634b15bb7a70766327247a_10">PART I. FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i711b1a39e0634b15bb7a70766327247a_13">Item 1. Financial Statements:</a></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i711b1a39e0634b15bb7a70766327247a_16">Condensed Balance Sheets (unaudited)</a></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i711b1a39e0634b15bb7a70766327247a_19">Condensed Statements of Operations and Comprehensive Loss (unaudited)</a></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i711b1a39e0634b15bb7a70766327247a_22">Condensed Statements of Changes in Stockholders' Equity (unaudited)</a></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i711b1a39e0634b15bb7a70766327247a_25">Condensed Statements of Cash Flows (unaudited)</a></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i711b1a39e0634b15bb7a70766327247a_28">Notes to Condensed Financial Statements (unaudited)</a></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i711b1a39e0634b15bb7a70766327247a_73">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i711b1a39e0634b15bb7a70766327247a_109">Item 3. Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i711b1a39e0634b15bb7a70766327247a_112">Item 4. Controls and Procedures</a></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i711b1a39e0634b15bb7a70766327247a_115">PART II. OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i711b1a39e0634b15bb7a70766327247a_118">Item 1. Legal Proceedings</a></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i711b1a39e0634b15bb7a70766327247a_121">Item 1A. Risk Factors</a></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i711b1a39e0634b15bb7a70766327247a_124">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i711b1a39e0634b15bb7a70766327247a_127">Item 3. Defaults Upon Senior Securities</a></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i711b1a39e0634b15bb7a70766327247a_130">Item 4. Mine Safety Disclosures</a></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i711b1a39e0634b15bb7a70766327247a_133">Item 5. Other Information</a></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i711b1a39e0634b15bb7a70766327247a_136">Item 6. Exhibits</a></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i711b1a39e0634b15bb7a70766327247a_139">Signatures</a></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%"></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i711b1a39e0634b15bb7a70766327247a_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i711b1a39e0634b15bb7a70766327247a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;I.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;FINANCIAL INFORMATION</span></div><div><span><br/></span></div><div id="i711b1a39e0634b15bb7a70766327247a_13"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;FINANCIAL STATEMENTS</span></div><div><span><br/></span></div><div id="i711b1a39e0634b15bb7a70766327247a_16"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARDELYX,&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share amounts)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Unaudited)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfNC0xLTEtMS0yMzAxMw_7607cbb1-c3b5-4748-aa57-bc266f4b2f73">47,077</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfNC0zLTEtMS0yMzAxMw_94ad2682-ab98-4ca0-aada-217adc3c0514">72,428</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfNS0xLTEtMS0yMzAxMw_606c045f-4b83-44a9-8aba-aed23c0f934e">42,627</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfNS0zLTEtMS0yMzAxMw_05886ef9-110b-45b2-b080-9602f4f7fb68">44,261</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfNi0xLTEtMS0yOTM3NQ_4428160f-57b8-443c-aae8-3b686c7b5580">4,394</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfNi0zLTEtMS0yOTM3NQ_fe26292f-a612-47e8-acbc-1b347401ee11">502</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfNi0xLTEtMS0yODU1Mg_04ec8afa-0284-444c-a1f6-82c8332891c6">3,487</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfNi0zLTEtMS0yODU1Mg_ba1c72a4-d279-42ec-888b-96079fc3e912">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfNy0xLTEtMS0yMzAxMw_5ebbf0df-0576-4f0d-bf49-5129cc1ecbb3">16,640</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfNy0zLTEtMS0yMzAxMw_1ec19f8c-d407-4fda-84b8-3c1c00eb1153">16,458</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfOC0xLTEtMS0yMzAxMw_3630c222-c007-49d0-a962-5e9cc169df99">114,225</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfOC0zLTEtMS0yMzAxMw_c9577e46-978d-4081-862c-65c9b7aba726">133,649</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMTAtMS0xLTEtMjkzODM_9384a397-8161-4a79-a9a5-7ff99cb0d004">11,910</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMTAtMy0xLTEtMjkzODM_8f20a5a0-5c65-451c-b778-1f09a2cd8fa0">12,752</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfOS0xLTEtMS0yMzAxMw_46514656-2425-4a0e-90e4-169766c5a5a5">2,045</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfOS0zLTEtMS0yMzAxMw_b66219fb-fa04-4d3c-9b87-5f747843dc46">2,362</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMTItMS0xLTEtMjMwMTM_0085053e-801a-4f40-a68c-5f5c0e8cebcc">1,228</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMTItMy0xLTEtMjMwMTM_3f917f74-29d2-4ea2-bb81-4829eb0a9ace">1,150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMTMtMS0xLTEtMjMwMTM_28a707be-127e-48ab-8e84-d77c5c930384">129,408</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMTMtMy0xLTEtMjMwMTM_5db68291-f6f2-41b7-ab8f-e39b99f0be02">149,913</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMTYtMS0xLTEtMjMwMTM_8a4dc68e-c4cc-4ed4-a009-a95e00b7ea05">5,030</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMTYtMy0xLTEtMjMwMTM_efa1f330-51a6-44ff-9829-6928ac151fb0">4,277</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMTctMS0xLTEtMjMwMTM_94b9c537-95dc-4a62-8d6e-c11be1620aac">6,304</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMTctMy0xLTEtMjMwMTM_d665e878-0dd2-4e10-a4ac-70be70ab51da">5,422</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMTktMS0xLTEtMjk0MDA_5c7afd77-ac09-43a3-bcf3-9f053466ec38">26,139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMTktMy0xLTEtMjk0MDA_7df6abc2-77c6-451b-8031-c4b48e5c3e71">32,264</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMTgtMS0xLTEtMjMwMTM_0281b023-7a36-4f59-9b65-bf46be2fb573">3,592</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMTgtMy0xLTEtMjMwMTM_f18ffffd-9eb9-4d1a-b672-02b8028163f5">3,492</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331" decimals="-3" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMjEtMS0xLTEtMjMwMTM_a6cef91d-4e31-4191-bd56-f9242adefb18">6,778</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMjEtMy0xLTEtMjMwMTM_9ab855a4-1028-4c46-a5df-7a9a15c47632">7,366</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMjItMS0xLTEtMjMwMTM_916e0ae1-2858-474d-8dcb-46699c8fc443">47,843</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMjItMy0xLTEtMjMwMTM_44724399-9d2d-4a9e-a319-7eaee02e4384">52,821</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMjMtMS0xLTEtMjMwMTM_18aae981-e795-4ca3-8b90-644e055adf87">8,812</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMjMtMy0xLTEtMjMwMTM_aadc26ac-61c2-4abc-adb2-a76b3775d656">9,748</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue, non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMjUtMS0xLTEtMjMwMTM_da2d4c5a-23ca-45ff-aa9b-f0dd1d6ecaed">8,563</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMjUtMy0xLTEtMjMwMTM_d31fde8b-3d35-46c6-b737-01cd11ca488a">4,727</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMjYtMS0xLTEtMjMwMTM_c675edff-745c-4fb3-a0bc-c05ab2deabb0">65,218</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMjYtMy0xLTEtMjMwMTM_8906667a-958a-4813-a201-22331bac934a">67,296</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 13)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMjctMS0xLTEtMjMwMTM_2c6d2c06-14ac-4cc2-be5b-ffa317690d28"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMjctMy0xLTEtMjMwMTM_fa89fd53-c60d-4316-bdd7-52e0d7c6fdf9"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMjktMC0xLTEtMjMwMTMvdGV4dHJlZ2lvbjpjZDY5ZWJiOTM4NDk0NzA4OTU3ODZlN2RkZmYzMzUyM18xNjQ5MjY3NDQxODMz_d3c82f83-6d6c-47ff-be4b-28b8272aea1a"><ix:nonFraction unitRef="usdPerShare" contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMjktMC0xLTEtMjMwMTMvdGV4dHJlZ2lvbjpjZDY5ZWJiOTM4NDk0NzA4OTU3ODZlN2RkZmYzMzUyM18xNjQ5MjY3NDQxODMz_db165772-d2d1-4211-ad89-2a403a89fa5d">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMjktMC0xLTEtMjMwMTMvdGV4dHJlZ2lvbjpjZDY5ZWJiOTM4NDk0NzA4OTU3ODZlN2RkZmYzMzUyM18xNjQ5MjY3NDQxODQ1_0a868e6a-2304-4ff3-bff4-6ac8c79ed33f"><ix:nonFraction unitRef="shares" contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMjktMC0xLTEtMjMwMTMvdGV4dHJlZ2lvbjpjZDY5ZWJiOTM4NDk0NzA4OTU3ODZlN2RkZmYzMzUyM18xNjQ5MjY3NDQxODQ1_fb4e8233-e9be-4596-8f67-657f4b5c6f63">5,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMjktMC0xLTEtMjMwMTMvdGV4dHJlZ2lvbjpjZDY5ZWJiOTM4NDk0NzA4OTU3ODZlN2RkZmYzMzUyM18xNjQ5MjY3NDQxODUw_1bb4e6bd-04de-44c1-a5ef-88aab3d95be5"><ix:nonFraction unitRef="shares" contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMjktMC0xLTEtMjMwMTMvdGV4dHJlZ2lvbjpjZDY5ZWJiOTM4NDk0NzA4OTU3ODZlN2RkZmYzMzUyM18xNjQ5MjY3NDQxODUw_894199cf-c917-41e7-aa78-bb0438e45fcf"><ix:nonFraction unitRef="shares" contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMjktMC0xLTEtMjMwMTMvdGV4dHJlZ2lvbjpjZDY5ZWJiOTM4NDk0NzA4OTU3ODZlN2RkZmYzMzUyM18xNjQ5MjY3NDQxODUw_cd953609-8559-4dd7-999a-5310550f9e7d"><ix:nonFraction unitRef="shares" contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMjktMC0xLTEtMjMwMTMvdGV4dHJlZ2lvbjpjZDY5ZWJiOTM4NDk0NzA4OTU3ODZlN2RkZmYzMzUyM18xNjQ5MjY3NDQxODUw_ece7b736-487f-4a0a-b9f3-6cb202761679">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding as of March&#160;31, 2022 and December&#160;31, 2021, respectively.</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMjktMS0xLTEtMjMwMTM_e9a0f120-605b-4c59-815c-fdd003bf21f1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMjktMy0xLTEtMjMwMTM_14471c8f-c331-452f-a563-0ac9a5d521b2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMzAtMC0xLTEtMjMwMTMvdGV4dHJlZ2lvbjo4NmY3MWU2Y2I2YmM0YWYwODU3ZThhZmQ4M2Y1MjMzZV8xNjQ5MjY3NDQxODk1_25b70c6e-79c0-4910-b98a-d9adb14e038d"><ix:nonFraction unitRef="usdPerShare" contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMzAtMC0xLTEtMjMwMTMvdGV4dHJlZ2lvbjo4NmY3MWU2Y2I2YmM0YWYwODU3ZThhZmQ4M2Y1MjMzZV8xNjQ5MjY3NDQxODk1_497f6519-68e6-4e8e-b764-e0b191e88aca">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMzAtMC0xLTEtMjMwMTMvdGV4dHJlZ2lvbjo4NmY3MWU2Y2I2YmM0YWYwODU3ZThhZmQ4M2Y1MjMzZV8xNjQ5MjY3NDQxOTA5_3afdb57d-ca8e-417d-a083-a62ea669a308"><ix:nonFraction unitRef="shares" contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMzAtMC0xLTEtMjMwMTMvdGV4dHJlZ2lvbjo4NmY3MWU2Y2I2YmM0YWYwODU3ZThhZmQ4M2Y1MjMzZV8xNjQ5MjY3NDQxOTA5_44abd411-f592-44b9-81ad-57a68a71b88c">300,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMzAtMC0xLTEtMjMwMTMvdGV4dHJlZ2lvbjo4NmY3MWU2Y2I2YmM0YWYwODU3ZThhZmQ4M2Y1MjMzZV8xNjQ5MjY3NDQxOTIy_30b5579c-df45-4365-b24f-5c5e4ebc928b"><ix:nonFraction unitRef="shares" contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMzAtMC0xLTEtMjMwMTMvdGV4dHJlZ2lvbjo4NmY3MWU2Y2I2YmM0YWYwODU3ZThhZmQ4M2Y1MjMzZV8xNjQ5MjY3NDQxOTIy_7ee6674d-84fa-421a-90d7-3d8d7f36dc43">136,330,360</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMzAtMC0xLTEtMjMwMTMvdGV4dHJlZ2lvbjo4NmY3MWU2Y2I2YmM0YWYwODU3ZThhZmQ4M2Y1MjMzZV8xNjQ5MjY3NDQxOTM1_479050f6-74c8-49f4-adf7-7464ca726ae0"><ix:nonFraction unitRef="shares" contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMzAtMC0xLTEtMjMwMTMvdGV4dHJlZ2lvbjo4NmY3MWU2Y2I2YmM0YWYwODU3ZThhZmQ4M2Y1MjMzZV8xNjQ5MjY3NDQxOTM1_479ad88f-d423-4913-904e-bf7d4ec810f9">130,182,535</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of March&#160;31, 2022 and December&#160;31, 2021, respectively.</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMzAtMS0xLTEtMjMwMTM_04de366e-7b1a-48dc-a050-6f798cf0e38b">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMzAtMy0xLTEtMjMwMTM_f8a30f6d-06af-4ad6-b875-7cb2b79dc948">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMzEtMS0xLTEtMjMwMTM_26407be7-a57e-4b9b-8ce7-4419f4bb2f12">805,265</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMzEtMy0xLTEtMjMwMTM_40a51455-3f33-4d57-a540-0212e06195c6">795,540</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMzItMS0xLTEtMjMwMTM_a8884574-791f-4deb-b72a-463be5ca1e67">741,001</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMzItMy0xLTEtMjMwMTM_12139be5-5742-4c7a-8761-1d9fe8e4d22f">712,930</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMzMtMS0xLTEtMjMwMTM_970274b6-59bc-4890-9464-6185519e3bbc">88</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMzMtMy0xLTEtMjMwMTM_ce73280c-e5b5-46df-99bc-c29e1b580aaa">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMzQtMS0xLTEtMjMwMTM_fd7171da-80b7-47bf-a769-5fd56c8791af">64,190</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMzQtMy0xLTEtMjMwMTM_f063b1c5-2e17-4100-84c8-f029f3ad6355">82,617</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMzUtMS0xLTEtMjMwMTM_b007e3bc-2778-40f1-a99a-71c004c43f78">129,408</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMzUtMy0xLTEtMjMwMTM_cf4d5076-78c5-4fb3-bb8c-704c0a732879">149,913</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i711b1a39e0634b15bb7a70766327247a_19"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i711b1a39e0634b15bb7a70766327247a_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARDELYX,&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share amounts)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.578%"><tr><td style="width:1.0%"></td><td style="width:66.821%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.491%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.696%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.492%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97ef8572b6ce41c09c8f695ae8a0ca00_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xOS9mcmFnOjMwZmI4OGM5N2Y4YjQ2NjdhNWY0ZjBmOTQzZjIzZjIwL3RhYmxlOmQ5ZDA5NDIxYTE1ZTRiMTc5MDRkMmNiY2NmMzEwNjU3L3RhYmxlcmFuZ2U6ZDlkMDk0MjFhMTVlNGIxNzkwNGQyY2JjY2YzMTA2NTdfMy0xLTEtMS0yODYwOQ_02408698-bd6c-4d03-bcbc-1c66e5f50028">450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5783cc7426ba453f96f1e7e0af87b0a6_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xOS9mcmFnOjMwZmI4OGM5N2Y4YjQ2NjdhNWY0ZjBmOTQzZjIzZjIwL3RhYmxlOmQ5ZDA5NDIxYTE1ZTRiMTc5MDRkMmNiY2NmMzEwNjU3L3RhYmxlcmFuZ2U6ZDlkMDk0MjFhMTVlNGIxNzkwNGQyY2JjY2YzMTA2NTdfMy0zLTEtMS0yODYzNg_c7da04ff-ae62-44d5-8cdf-e017e7061f36">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product supply revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id194cfe3452f4c7c84f5dfd4fe7d8297_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xOS9mcmFnOjMwZmI4OGM5N2Y4YjQ2NjdhNWY0ZjBmOTQzZjIzZjIwL3RhYmxlOmQ5ZDA5NDIxYTE1ZTRiMTc5MDRkMmNiY2NmMzEwNjU3L3RhYmxlcmFuZ2U6ZDlkMDk0MjFhMTVlNGIxNzkwNGQyY2JjY2YzMTA2NTdfNC0xLTEtMS0zMzI2Nw_1ecf1067-7e87-42e8-b493-cdf0659598ee">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f8aa7556d7647dd80cd79f50b30d12a_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xOS9mcmFnOjMwZmI4OGM5N2Y4YjQ2NjdhNWY0ZjBmOTQzZjIzZjIwL3RhYmxlOmQ5ZDA5NDIxYTE1ZTRiMTc5MDRkMmNiY2NmMzEwNjU3L3RhYmxlcmFuZ2U6ZDlkMDk0MjFhMTVlNGIxNzkwNGQyY2JjY2YzMTA2NTdfNC0zLTEtMS0zMzI2Nw_c2a134c4-0c51-4041-bfa5-12ed5761fb3d">126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c8fadcb7a584b6b81773ef6f2440734_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xOS9mcmFnOjMwZmI4OGM5N2Y4YjQ2NjdhNWY0ZjBmOTQzZjIzZjIwL3RhYmxlOmQ5ZDA5NDIxYTE1ZTRiMTc5MDRkMmNiY2NmMzEwNjU3L3RhYmxlcmFuZ2U6ZDlkMDk0MjFhMTVlNGIxNzkwNGQyY2JjY2YzMTA2NTdfNC0xLTEtMS0zMTMzMw_928c2cba-82ca-4d65-9d82-2e97e78bf14f">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77926c7e42f94727854dd2729e419202_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xOS9mcmFnOjMwZmI4OGM5N2Y4YjQ2NjdhNWY0ZjBmOTQzZjIzZjIwL3RhYmxlOmQ5ZDA5NDIxYTE1ZTRiMTc5MDRkMmNiY2NmMzEwNjU3L3RhYmxlcmFuZ2U6ZDlkMDk0MjFhMTVlNGIxNzkwNGQyY2JjY2YzMTA2NTdfNC0zLTEtMS0zMTMzMw_42ffc98b-7354-47b6-a5c4-1108c9a43d83">5,002</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaborative development revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i785dbb6e8a754de6a7aa8b0b43cd5de4_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xOS9mcmFnOjMwZmI4OGM5N2Y4YjQ2NjdhNWY0ZjBmOTQzZjIzZjIwL3RhYmxlOmQ5ZDA5NDIxYTE1ZTRiMTc5MDRkMmNiY2NmMzEwNjU3L3RhYmxlcmFuZ2U6ZDlkMDk0MjFhMTVlNGIxNzkwNGQyY2JjY2YzMTA2NTdfMy0xLTEtMS0yMzAxMw_6973329d-8fa2-4866-9ad6-187efee62bb9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6b9396538454def9c8a29399c6b8d03_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xOS9mcmFnOjMwZmI4OGM5N2Y4YjQ2NjdhNWY0ZjBmOTQzZjIzZjIwL3RhYmxlOmQ5ZDA5NDIxYTE1ZTRiMTc5MDRkMmNiY2NmMzEwNjU3L3RhYmxlcmFuZ2U6ZDlkMDk0MjFhMTVlNGIxNzkwNGQyY2JjY2YzMTA2NTdfMy0zLTEtMS0yMzAxMw_0eb2a28b-868f-46dc-8ffe-ddf4ae89c884">1,454</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xOS9mcmFnOjMwZmI4OGM5N2Y4YjQ2NjdhNWY0ZjBmOTQzZjIzZjIwL3RhYmxlOmQ5ZDA5NDIxYTE1ZTRiMTc5MDRkMmNiY2NmMzEwNjU3L3RhYmxlcmFuZ2U6ZDlkMDk0MjFhMTVlNGIxNzkwNGQyY2JjY2YzMTA2NTdfNi0xLTEtMS0yMzAxMw_8a6623c4-5302-4cb8-a060-782ba73880e5">468</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xOS9mcmFnOjMwZmI4OGM5N2Y4YjQ2NjdhNWY0ZjBmOTQzZjIzZjIwL3RhYmxlOmQ5ZDA5NDIxYTE1ZTRiMTc5MDRkMmNiY2NmMzEwNjU3L3RhYmxlcmFuZ2U6ZDlkMDk0MjFhMTVlNGIxNzkwNGQyY2JjY2YzMTA2NTdfNi0zLTEtMS0yMzAxMw_995b16a1-0971-47f8-8018-58a59b021f75">6,582</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" decimals="-3" name="us-gaap:CostOfRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xOS9mcmFnOjMwZmI4OGM5N2Y4YjQ2NjdhNWY0ZjBmOTQzZjIzZjIwL3RhYmxlOmQ5ZDA5NDIxYTE1ZTRiMTc5MDRkMmNiY2NmMzEwNjU3L3RhYmxlcmFuZ2U6ZDlkMDk0MjFhMTVlNGIxNzkwNGQyY2JjY2YzMTA2NTdfOC0xLTEtMS0yMzAxMw_c23f0594-888b-4596-a00a-ecc731277a6a">85</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xOS9mcmFnOjMwZmI4OGM5N2Y4YjQ2NjdhNWY0ZjBmOTQzZjIzZjIwL3RhYmxlOmQ5ZDA5NDIxYTE1ZTRiMTc5MDRkMmNiY2NmMzEwNjU3L3RhYmxlcmFuZ2U6ZDlkMDk0MjFhMTVlNGIxNzkwNGQyY2JjY2YzMTA2NTdfOC0zLTEtMS0yMzAxMw_de52b778-802e-4964-b49e-4bcd2829c2d0">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xOS9mcmFnOjMwZmI4OGM5N2Y4YjQ2NjdhNWY0ZjBmOTQzZjIzZjIwL3RhYmxlOmQ5ZDA5NDIxYTE1ZTRiMTc5MDRkMmNiY2NmMzEwNjU3L3RhYmxlcmFuZ2U6ZDlkMDk0MjFhMTVlNGIxNzkwNGQyY2JjY2YzMTA2NTdfOS0xLTEtMS0yMzAxMw_cc0cc213-b981-4865-8165-badf7cee5694">8,851</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xOS9mcmFnOjMwZmI4OGM5N2Y4YjQ2NjdhNWY0ZjBmOTQzZjIzZjIwL3RhYmxlOmQ5ZDA5NDIxYTE1ZTRiMTc5MDRkMmNiY2NmMzEwNjU3L3RhYmxlcmFuZ2U6ZDlkMDk0MjFhMTVlNGIxNzkwNGQyY2JjY2YzMTA2NTdfOS0zLTEtMS0yMzAxMw_f50d62c4-ef35-4233-b5a9-3660128e696c">20,456</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xOS9mcmFnOjMwZmI4OGM5N2Y4YjQ2NjdhNWY0ZjBmOTQzZjIzZjIwL3RhYmxlOmQ5ZDA5NDIxYTE1ZTRiMTc5MDRkMmNiY2NmMzEwNjU3L3RhYmxlcmFuZ2U6ZDlkMDk0MjFhMTVlNGIxNzkwNGQyY2JjY2YzMTA2NTdfMTAtMS0xLTEtMjMwMTM_55f08733-300c-4c22-9269-ea626b68ae3a">19,339</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xOS9mcmFnOjMwZmI4OGM5N2Y4YjQ2NjdhNWY0ZjBmOTQzZjIzZjIwL3RhYmxlOmQ5ZDA5NDIxYTE1ZTRiMTc5MDRkMmNiY2NmMzEwNjU3L3RhYmxlcmFuZ2U6ZDlkMDk0MjFhMTVlNGIxNzkwNGQyY2JjY2YzMTA2NTdfMTAtMy0xLTEtMjMwMTM_fad38914-67c1-4b11-847f-61ab154aac39">17,131</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xOS9mcmFnOjMwZmI4OGM5N2Y4YjQ2NjdhNWY0ZjBmOTQzZjIzZjIwL3RhYmxlOmQ5ZDA5NDIxYTE1ZTRiMTc5MDRkMmNiY2NmMzEwNjU3L3RhYmxlcmFuZ2U6ZDlkMDk0MjFhMTVlNGIxNzkwNGQyY2JjY2YzMTA2NTdfMTEtMS0xLTEtMjMwMTM_6065a14a-eaa6-462a-a1b4-8f52588904ae">28,275</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xOS9mcmFnOjMwZmI4OGM5N2Y4YjQ2NjdhNWY0ZjBmOTQzZjIzZjIwL3RhYmxlOmQ5ZDA5NDIxYTE1ZTRiMTc5MDRkMmNiY2NmMzEwNjU3L3RhYmxlcmFuZ2U6ZDlkMDk0MjFhMTVlNGIxNzkwNGQyY2JjY2YzMTA2NTdfMTEtMy0xLTEtMjMwMTM_9a7ad62c-cacf-462b-a077-ef05b5d8fc77">38,587</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xOS9mcmFnOjMwZmI4OGM5N2Y4YjQ2NjdhNWY0ZjBmOTQzZjIzZjIwL3RhYmxlOmQ5ZDA5NDIxYTE1ZTRiMTc5MDRkMmNiY2NmMzEwNjU3L3RhYmxlcmFuZ2U6ZDlkMDk0MjFhMTVlNGIxNzkwNGQyY2JjY2YzMTA2NTdfMTItMS0xLTEtMjMwMTM_9c677357-894a-4e6b-9067-1bd8aef6c1cb">27,807</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xOS9mcmFnOjMwZmI4OGM5N2Y4YjQ2NjdhNWY0ZjBmOTQzZjIzZjIwL3RhYmxlOmQ5ZDA5NDIxYTE1ZTRiMTc5MDRkMmNiY2NmMzEwNjU3L3RhYmxlcmFuZ2U6ZDlkMDk0MjFhMTVlNGIxNzkwNGQyY2JjY2YzMTA2NTdfMTItMy0xLTEtMjMwMTM_2374706a-7395-4f33-ab05-9f7a6f21fda4">32,005</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xOS9mcmFnOjMwZmI4OGM5N2Y4YjQ2NjdhNWY0ZjBmOTQzZjIzZjIwL3RhYmxlOmQ5ZDA5NDIxYTE1ZTRiMTc5MDRkMmNiY2NmMzEwNjU3L3RhYmxlcmFuZ2U6ZDlkMDk0MjFhMTVlNGIxNzkwNGQyY2JjY2YzMTA2NTdfMTMtMS0xLTEtMjMwMTM_19ea4e44-bdb6-47a8-8b40-40e9295d09c6">746</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xOS9mcmFnOjMwZmI4OGM5N2Y4YjQ2NjdhNWY0ZjBmOTQzZjIzZjIwL3RhYmxlOmQ5ZDA5NDIxYTE1ZTRiMTc5MDRkMmNiY2NmMzEwNjU3L3RhYmxlcmFuZ2U6ZDlkMDk0MjFhMTVlNGIxNzkwNGQyY2JjY2YzMTA2NTdfMTMtMy0xLTEtMjMwMTM_89c1e76d-ea91-4f64-86a1-01a11f0338ce">1,100</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xOS9mcmFnOjMwZmI4OGM5N2Y4YjQ2NjdhNWY0ZjBmOTQzZjIzZjIwL3RhYmxlOmQ5ZDA5NDIxYTE1ZTRiMTc5MDRkMmNiY2NmMzEwNjU3L3RhYmxlcmFuZ2U6ZDlkMDk0MjFhMTVlNGIxNzkwNGQyY2JjY2YzMTA2NTdfMTQtMS0xLTEtMjMwMTM_a37b9ed2-d2be-45bc-b2c4-865515ed3d67">484</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xOS9mcmFnOjMwZmI4OGM5N2Y4YjQ2NjdhNWY0ZjBmOTQzZjIzZjIwL3RhYmxlOmQ5ZDA5NDIxYTE1ZTRiMTc5MDRkMmNiY2NmMzEwNjU3L3RhYmxlcmFuZ2U6ZDlkMDk0MjFhMTVlNGIxNzkwNGQyY2JjY2YzMTA2NTdfMTQtMy0xLTEtMjMwMTM_d47a637e-3f16-46a2-83dd-9909da86af81">49</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xOS9mcmFnOjMwZmI4OGM5N2Y4YjQ2NjdhNWY0ZjBmOTQzZjIzZjIwL3RhYmxlOmQ5ZDA5NDIxYTE1ZTRiMTc5MDRkMmNiY2NmMzEwNjU3L3RhYmxlcmFuZ2U6ZDlkMDk0MjFhMTVlNGIxNzkwNGQyY2JjY2YzMTA2NTdfMTUtMS0xLTEtMjMwMTM_7a56fd36-e02c-47b7-9605-06462c776fb9">28,069</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xOS9mcmFnOjMwZmI4OGM5N2Y4YjQ2NjdhNWY0ZjBmOTQzZjIzZjIwL3RhYmxlOmQ5ZDA5NDIxYTE1ZTRiMTc5MDRkMmNiY2NmMzEwNjU3L3RhYmxlcmFuZ2U6ZDlkMDk0MjFhMTVlNGIxNzkwNGQyY2JjY2YzMTA2NTdfMTUtMy0xLTEtMjMwMTM_3d32bf9c-6da6-42b6-b75f-18041248e814">33,154</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xOS9mcmFnOjMwZmI4OGM5N2Y4YjQ2NjdhNWY0ZjBmOTQzZjIzZjIwL3RhYmxlOmQ5ZDA5NDIxYTE1ZTRiMTc5MDRkMmNiY2NmMzEwNjU3L3RhYmxlcmFuZ2U6ZDlkMDk0MjFhMTVlNGIxNzkwNGQyY2JjY2YzMTA2NTdfMTYtMS0xLTEtMjMwMTM_6195ab97-5461-45c7-9146-f8ff37d5c61d">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xOS9mcmFnOjMwZmI4OGM5N2Y4YjQ2NjdhNWY0ZjBmOTQzZjIzZjIwL3RhYmxlOmQ5ZDA5NDIxYTE1ZTRiMTc5MDRkMmNiY2NmMzEwNjU3L3RhYmxlcmFuZ2U6ZDlkMDk0MjFhMTVlNGIxNzkwNGQyY2JjY2YzMTA2NTdfMTYtMy0xLTEtMjMwMTM_46bc0778-f663-474a-bd75-b1490a30fa7c">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xOS9mcmFnOjMwZmI4OGM5N2Y4YjQ2NjdhNWY0ZjBmOTQzZjIzZjIwL3RhYmxlOmQ5ZDA5NDIxYTE1ZTRiMTc5MDRkMmNiY2NmMzEwNjU3L3RhYmxlcmFuZ2U6ZDlkMDk0MjFhMTVlNGIxNzkwNGQyY2JjY2YzMTA2NTdfMTctMS0xLTEtMjMwMTM_7750d5dc-8bc9-46f1-b4b4-ca4fbacb89b2">28,071</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xOS9mcmFnOjMwZmI4OGM5N2Y4YjQ2NjdhNWY0ZjBmOTQzZjIzZjIwL3RhYmxlOmQ5ZDA5NDIxYTE1ZTRiMTc5MDRkMmNiY2NmMzEwNjU3L3RhYmxlcmFuZ2U6ZDlkMDk0MjFhMTVlNGIxNzkwNGQyY2JjY2YzMTA2NTdfMTctMy0xLTEtMjMwMTM_501e33b4-45cc-4bd3-aef5-4002bcca0f34">33,155</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share, basic and diluted</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xOS9mcmFnOjMwZmI4OGM5N2Y4YjQ2NjdhNWY0ZjBmOTQzZjIzZjIwL3RhYmxlOmQ5ZDA5NDIxYTE1ZTRiMTc5MDRkMmNiY2NmMzEwNjU3L3RhYmxlcmFuZ2U6ZDlkMDk0MjFhMTVlNGIxNzkwNGQyY2JjY2YzMTA2NTdfMTgtMS0xLTEtMjMwMTM_869cd094-5a59-4ec1-a7a5-3344a42b39d7"><ix:nonFraction unitRef="usdPerShare" contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xOS9mcmFnOjMwZmI4OGM5N2Y4YjQ2NjdhNWY0ZjBmOTQzZjIzZjIwL3RhYmxlOmQ5ZDA5NDIxYTE1ZTRiMTc5MDRkMmNiY2NmMzEwNjU3L3RhYmxlcmFuZ2U6ZDlkMDk0MjFhMTVlNGIxNzkwNGQyY2JjY2YzMTA2NTdfMTgtMS0xLTEtMjMwMTM_d0efa5c6-1eb8-43c5-a899-70d957f9cf4f">0.21</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xOS9mcmFnOjMwZmI4OGM5N2Y4YjQ2NjdhNWY0ZjBmOTQzZjIzZjIwL3RhYmxlOmQ5ZDA5NDIxYTE1ZTRiMTc5MDRkMmNiY2NmMzEwNjU3L3RhYmxlcmFuZ2U6ZDlkMDk0MjFhMTVlNGIxNzkwNGQyY2JjY2YzMTA2NTdfMTgtMy0xLTEtMjMwMTM_d0ed3422-d61f-4927-b837-71c68f89504a"><ix:nonFraction unitRef="usdPerShare" contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xOS9mcmFnOjMwZmI4OGM5N2Y4YjQ2NjdhNWY0ZjBmOTQzZjIzZjIwL3RhYmxlOmQ5ZDA5NDIxYTE1ZTRiMTc5MDRkMmNiY2NmMzEwNjU3L3RhYmxlcmFuZ2U6ZDlkMDk0MjFhMTVlNGIxNzkwNGQyY2JjY2YzMTA2NTdfMTgtMy0xLTEtMjMwMTM_d969aa21-0e36-4c2d-948c-cc6b428ebd4d">0.34</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in computing net loss per share - basic and diluted</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xOS9mcmFnOjMwZmI4OGM5N2Y4YjQ2NjdhNWY0ZjBmOTQzZjIzZjIwL3RhYmxlOmQ5ZDA5NDIxYTE1ZTRiMTc5MDRkMmNiY2NmMzEwNjU3L3RhYmxlcmFuZ2U6ZDlkMDk0MjFhMTVlNGIxNzkwNGQyY2JjY2YzMTA2NTdfMTktMS0xLTEtMjMwMTM_6e660f14-88f2-4c59-8759-06ca31e6ecf1"><ix:nonFraction unitRef="shares" contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xOS9mcmFnOjMwZmI4OGM5N2Y4YjQ2NjdhNWY0ZjBmOTQzZjIzZjIwL3RhYmxlOmQ5ZDA5NDIxYTE1ZTRiMTc5MDRkMmNiY2NmMzEwNjU3L3RhYmxlcmFuZ2U6ZDlkMDk0MjFhMTVlNGIxNzkwNGQyY2JjY2YzMTA2NTdfMTktMS0xLTEtMjMwMTM_dd727144-d0b1-4965-a89d-ef8548c01b1f">130,934,795</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xOS9mcmFnOjMwZmI4OGM5N2Y4YjQ2NjdhNWY0ZjBmOTQzZjIzZjIwL3RhYmxlOmQ5ZDA5NDIxYTE1ZTRiMTc5MDRkMmNiY2NmMzEwNjU3L3RhYmxlcmFuZ2U6ZDlkMDk0MjFhMTVlNGIxNzkwNGQyY2JjY2YzMTA2NTdfMTktMy0xLTEtMjMwMTM_e2da8ff1-4237-45da-adbf-11dbd8de8ebf"><ix:nonFraction unitRef="shares" contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xOS9mcmFnOjMwZmI4OGM5N2Y4YjQ2NjdhNWY0ZjBmOTQzZjIzZjIwL3RhYmxlOmQ5ZDA5NDIxYTE1ZTRiMTc5MDRkMmNiY2NmMzEwNjU3L3RhYmxlcmFuZ2U6ZDlkMDk0MjFhMTVlNGIxNzkwNGQyY2JjY2YzMTA2NTdfMTktMy0xLTEtMjMwMTM_ee3a0669-92b4-4b0c-bf2e-11f303d3ca29">97,179,241</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Comprehensive loss:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xOS9mcmFnOjMwZmI4OGM5N2Y4YjQ2NjdhNWY0ZjBmOTQzZjIzZjIwL3RhYmxlOmQ5ZDA5NDIxYTE1ZTRiMTc5MDRkMmNiY2NmMzEwNjU3L3RhYmxlcmFuZ2U6ZDlkMDk0MjFhMTVlNGIxNzkwNGQyY2JjY2YzMTA2NTdfMjEtMS0xLTEtMjMwMTM_cc5ae97a-d2a0-422d-b6c2-022d587efa59">28,071</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xOS9mcmFnOjMwZmI4OGM5N2Y4YjQ2NjdhNWY0ZjBmOTQzZjIzZjIwL3RhYmxlOmQ5ZDA5NDIxYTE1ZTRiMTc5MDRkMmNiY2NmMzEwNjU3L3RhYmxlcmFuZ2U6ZDlkMDk0MjFhMTVlNGIxNzkwNGQyY2JjY2YzMTA2NTdfMjEtMy0xLTEtMjMwMTM_a8c0ed92-97c5-437e-b651-10e85beeffdd">33,155</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized losses on available-for-sale securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xOS9mcmFnOjMwZmI4OGM5N2Y4YjQ2NjdhNWY0ZjBmOTQzZjIzZjIwL3RhYmxlOmQ5ZDA5NDIxYTE1ZTRiMTc5MDRkMmNiY2NmMzEwNjU3L3RhYmxlcmFuZ2U6ZDlkMDk0MjFhMTVlNGIxNzkwNGQyY2JjY2YzMTA2NTdfMjItMS0xLTEtMjMwMTM_523b94e3-b01d-437a-95ad-58877ff0f255">82</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xOS9mcmFnOjMwZmI4OGM5N2Y4YjQ2NjdhNWY0ZjBmOTQzZjIzZjIwL3RhYmxlOmQ5ZDA5NDIxYTE1ZTRiMTc5MDRkMmNiY2NmMzEwNjU3L3RhYmxlcmFuZ2U6ZDlkMDk0MjFhMTVlNGIxNzkwNGQyY2JjY2YzMTA2NTdfMjItMy0xLTEtMjMwMTM_5b010af1-1a79-4ac5-9ad6-71471f70de9d">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xOS9mcmFnOjMwZmI4OGM5N2Y4YjQ2NjdhNWY0ZjBmOTQzZjIzZjIwL3RhYmxlOmQ5ZDA5NDIxYTE1ZTRiMTc5MDRkMmNiY2NmMzEwNjU3L3RhYmxlcmFuZ2U6ZDlkMDk0MjFhMTVlNGIxNzkwNGQyY2JjY2YzMTA2NTdfMjMtMS0xLTEtMjMwMTM_8a4f4ac2-8bdd-4f75-9115-be500e980099">28,153</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xOS9mcmFnOjMwZmI4OGM5N2Y4YjQ2NjdhNWY0ZjBmOTQzZjIzZjIwL3RhYmxlOmQ5ZDA5NDIxYTE1ZTRiMTc5MDRkMmNiY2NmMzEwNjU3L3RhYmxlcmFuZ2U6ZDlkMDk0MjFhMTVlNGIxNzkwNGQyY2JjY2YzMTA2NTdfMjMtMy0xLTEtMjMwMTM_c367540a-fa8c-4ff7-9d5c-b794b152b1c9">33,158</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed financial statements.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i711b1a39e0634b15bb7a70766327247a_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i711b1a39e0634b15bb7a70766327247a_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARDELYX,&#160;INC. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the Three Months ended March&#160;31, 2022 and 2021</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except shares)</span></div><div style="text-align:center"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:27.913%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.651%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.651%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.651%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.651%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.654%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2022</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Income</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders'<br/>Equity</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4cf9b083bea54e30a63681421a4a7088_I20211231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOmQwMTU3YTI0ODRmMTQyNjk5MTYyNjBjZTc3NWFkZmZhL3RhYmxlcmFuZ2U6ZDAxNTdhMjQ4NGYxNDI2OTkxNjI2MGNlNzc1YWRmZmFfMy0xLTEtMS0yMzAxMw_2bb39057-43e4-459d-a793-5cf06fcc0dfb">130,182,535</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cf9b083bea54e30a63681421a4a7088_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOmQwMTU3YTI0ODRmMTQyNjk5MTYyNjBjZTc3NWFkZmZhL3RhYmxlcmFuZ2U6ZDAxNTdhMjQ4NGYxNDI2OTkxNjI2MGNlNzc1YWRmZmFfMy0zLTEtMS0yMzAxMw_25618766-deb0-4da3-8b0e-14a4dd0f2e20">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i915c4ac55b394c648e3f1e508325bbfe_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOmQwMTU3YTI0ODRmMTQyNjk5MTYyNjBjZTc3NWFkZmZhL3RhYmxlcmFuZ2U6ZDAxNTdhMjQ4NGYxNDI2OTkxNjI2MGNlNzc1YWRmZmFfMy01LTEtMS0yMzAxMw_6a4f60ce-4825-4822-b425-c76527438859">795,540</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i77bb1febd93946efb7f1ca68a5cb537e_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOmQwMTU3YTI0ODRmMTQyNjk5MTYyNjBjZTc3NWFkZmZhL3RhYmxlcmFuZ2U6ZDAxNTdhMjQ4NGYxNDI2OTkxNjI2MGNlNzc1YWRmZmFfMy03LTEtMS0yMzAxMw_34bebedf-5077-40b1-b20a-4e90a6e0147d">712,930</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id37f845e78ea4e4ba399ae4d539dd270_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOmQwMTU3YTI0ODRmMTQyNjk5MTYyNjBjZTc3NWFkZmZhL3RhYmxlcmFuZ2U6ZDAxNTdhMjQ4NGYxNDI2OTkxNjI2MGNlNzc1YWRmZmFfMy05LTEtMS0yMzAxMw_e3687eec-16ac-492d-a2d4-0f1465d52b88">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOmQwMTU3YTI0ODRmMTQyNjk5MTYyNjBjZTc3NWFkZmZhL3RhYmxlcmFuZ2U6ZDAxNTdhMjQ4NGYxNDI2OTkxNjI2MGNlNzc1YWRmZmFfMy0xMS0xLTEtMjMwMTM_f822ad49-edc9-4ca2-8cf4-e1484bb5958f">82,617</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock under employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibe48acc39ad24a498bf29293d3b5ff68_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOmQwMTU3YTI0ODRmMTQyNjk5MTYyNjBjZTc3NWFkZmZhL3RhYmxlcmFuZ2U6ZDAxNTdhMjQ4NGYxNDI2OTkxNjI2MGNlNzc1YWRmZmFfNC0xLTEtMS0yMzAxMw_6fe74887-2d81-4469-81a5-24139baa8899">127,100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a66e20dad254b89922f8674a7094895_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOmQwMTU3YTI0ODRmMTQyNjk5MTYyNjBjZTc3NWFkZmZhL3RhYmxlcmFuZ2U6ZDAxNTdhMjQ4NGYxNDI2OTkxNjI2MGNlNzc1YWRmZmFfNC01LTEtMS0yMzAxMw_656c1d5b-cb2f-4b8d-828e-7843b4ab13d7">83</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOmQwMTU3YTI0ODRmMTQyNjk5MTYyNjBjZTc3NWFkZmZhL3RhYmxlcmFuZ2U6ZDAxNTdhMjQ4NGYxNDI2OTkxNjI2MGNlNzc1YWRmZmFfNC0xMS0xLTEtMjMwMTM_50780a95-5e22-4d39-a1f3-946bbfb4aefe">83</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock upon vesting of restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibe48acc39ad24a498bf29293d3b5ff68_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOmQwMTU3YTI0ODRmMTQyNjk5MTYyNjBjZTc3NWFkZmZhL3RhYmxlcmFuZ2U6ZDAxNTdhMjQ4NGYxNDI2OTkxNjI2MGNlNzc1YWRmZmFfNy0xLTEtMS0yMzAxMw_1347ec2f-de8c-4e0a-9f0e-1c04b84fe3e7">113,469</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock in at the market offering</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibe48acc39ad24a498bf29293d3b5ff68_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOmQwMTU3YTI0ODRmMTQyNjk5MTYyNjBjZTc3NWFkZmZhL3RhYmxlcmFuZ2U6ZDAxNTdhMjQ4NGYxNDI2OTkxNjI2MGNlNzc1YWRmZmFfOC0xLTEtMS0yMzAxMw_0371f93a-a26b-419f-bd3f-03eda9d4fc7a">5,907,256</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe48acc39ad24a498bf29293d3b5ff68_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOmQwMTU3YTI0ODRmMTQyNjk5MTYyNjBjZTc3NWFkZmZhL3RhYmxlcmFuZ2U6ZDAxNTdhMjQ4NGYxNDI2OTkxNjI2MGNlNzc1YWRmZmFfOC0zLTEtMS0yMzAxMw_857c9c00-e9aa-4567-a01a-58c7adec4e34">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a66e20dad254b89922f8674a7094895_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOmQwMTU3YTI0ODRmMTQyNjk5MTYyNjBjZTc3NWFkZmZhL3RhYmxlcmFuZ2U6ZDAxNTdhMjQ4NGYxNDI2OTkxNjI2MGNlNzc1YWRmZmFfOC01LTEtMS0yMzAxMw_132ae237-8f09-4a90-b592-5d8b6749991d">5,920</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOmQwMTU3YTI0ODRmMTQyNjk5MTYyNjBjZTc3NWFkZmZhL3RhYmxlcmFuZ2U6ZDAxNTdhMjQ4NGYxNDI2OTkxNjI2MGNlNzc1YWRmZmFfOC0xMS0xLTEtMjMwMTM_27943a4c-8c8a-4b3e-9856-931d17aa577d">5,921</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a66e20dad254b89922f8674a7094895_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOmQwMTU3YTI0ODRmMTQyNjk5MTYyNjBjZTc3NWFkZmZhL3RhYmxlcmFuZ2U6ZDAxNTdhMjQ4NGYxNDI2OTkxNjI2MGNlNzc1YWRmZmFfOS01LTEtMS0yMzAxMw_5146a50b-2ffb-4c8d-86ba-d18469cb15fd">3,722</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOmQwMTU3YTI0ODRmMTQyNjk5MTYyNjBjZTc3NWFkZmZhL3RhYmxlcmFuZ2U6ZDAxNTdhMjQ4NGYxNDI2OTkxNjI2MGNlNzc1YWRmZmFfOS0xMS0xLTEtMjMwMTM_65d26bd5-fcf1-4898-bdd2-5935839b4153">3,722</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized losses on available-for-sale securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie996e76b43b94778bbd562ef8363a5f7_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOmQwMTU3YTI0ODRmMTQyNjk5MTYyNjBjZTc3NWFkZmZhL3RhYmxlcmFuZ2U6ZDAxNTdhMjQ4NGYxNDI2OTkxNjI2MGNlNzc1YWRmZmFfMTAtOS0xLTEtMjMwMTM_cfd85e30-e55a-4548-b13f-ffaae2bbb4a4">82</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOmQwMTU3YTI0ODRmMTQyNjk5MTYyNjBjZTc3NWFkZmZhL3RhYmxlcmFuZ2U6ZDAxNTdhMjQ4NGYxNDI2OTkxNjI2MGNlNzc1YWRmZmFfMTAtMTEtMS0xLTIzMDEz_695dd0f5-d98c-486b-8e28-d14a093dd4c2">82</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f13863ef82b4ff9891451291774c864_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOmQwMTU3YTI0ODRmMTQyNjk5MTYyNjBjZTc3NWFkZmZhL3RhYmxlcmFuZ2U6ZDAxNTdhMjQ4NGYxNDI2OTkxNjI2MGNlNzc1YWRmZmFfMTEtNy0xLTEtMjMwMTM_bc25adda-f78d-40ee-89d9-03b72146c359">28,071</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOmQwMTU3YTI0ODRmMTQyNjk5MTYyNjBjZTc3NWFkZmZhL3RhYmxlcmFuZ2U6ZDAxNTdhMjQ4NGYxNDI2OTkxNjI2MGNlNzc1YWRmZmFfMTEtMTEtMS0xLTIzMDEz_d14df4a1-5a25-4335-96ab-5eb23641cfe0">28,071</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of March 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3a994d19646542b883bef3eb77ec041a_I20220331" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOmQwMTU3YTI0ODRmMTQyNjk5MTYyNjBjZTc3NWFkZmZhL3RhYmxlcmFuZ2U6ZDAxNTdhMjQ4NGYxNDI2OTkxNjI2MGNlNzc1YWRmZmFfMTItMS0xLTEtMjMwMTM_754aa0c2-589c-4f33-a9d6-cb9f9acb07b5">136,330,360</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a994d19646542b883bef3eb77ec041a_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOmQwMTU3YTI0ODRmMTQyNjk5MTYyNjBjZTc3NWFkZmZhL3RhYmxlcmFuZ2U6ZDAxNTdhMjQ4NGYxNDI2OTkxNjI2MGNlNzc1YWRmZmFfMTItMy0xLTEtMjMwMTM_692c3c45-8b3f-415b-860b-164047c10b12">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia53bcaf6b509496b9aaca8a740abefe9_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOmQwMTU3YTI0ODRmMTQyNjk5MTYyNjBjZTc3NWFkZmZhL3RhYmxlcmFuZ2U6ZDAxNTdhMjQ4NGYxNDI2OTkxNjI2MGNlNzc1YWRmZmFfMTItNS0xLTEtMjMwMTM_bb193e20-61fe-4a34-8e9a-57154f2e35f1">805,265</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i71139a32ab724fed9714f268e212cd3a_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOmQwMTU3YTI0ODRmMTQyNjk5MTYyNjBjZTc3NWFkZmZhL3RhYmxlcmFuZ2U6ZDAxNTdhMjQ4NGYxNDI2OTkxNjI2MGNlNzc1YWRmZmFfMTItNy0xLTEtMjMwMTM_96f9c969-0747-4c36-b3c7-dff8ebb43426">741,001</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9012898f9a0f44118b5aa8f6b4d02190_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOmQwMTU3YTI0ODRmMTQyNjk5MTYyNjBjZTc3NWFkZmZhL3RhYmxlcmFuZ2U6ZDAxNTdhMjQ4NGYxNDI2OTkxNjI2MGNlNzc1YWRmZmFfMTItOS0xLTEtMjMwMTM_dc93ae3d-734c-4a16-8a2d-08a12e23e200">88</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOmQwMTU3YTI0ODRmMTQyNjk5MTYyNjBjZTc3NWFkZmZhL3RhYmxlcmFuZ2U6ZDAxNTdhMjQ4NGYxNDI2OTkxNjI2MGNlNzc1YWRmZmFfMTItMTEtMS0xLTIzMDEz_83139117-2e8b-4dbf-b658-ecd99cd67d83">64,190</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"></span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:28.801%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"></span></div><div style="padding-left:18pt;padding-right:18pt;text-align:center;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:27.913%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.651%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.651%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.651%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.651%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.654%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Income</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders'<br/>Equity</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2d98dab95e674482969a1c14b83aeabb_I20201231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOjQ2YzkyNTJhM2RiZTQ5YjFhYmQyN2Y5YTEwMDYzZjNiL3RhYmxlcmFuZ2U6NDZjOTI1MmEzZGJlNDliMWFiZDI3ZjlhMTAwNjNmM2JfMy0xLTEtMS0yMzAxMw_ebe3fea1-5d71-4919-a487-18ccc72e5cb6">93,599,975</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d98dab95e674482969a1c14b83aeabb_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOjQ2YzkyNTJhM2RiZTQ5YjFhYmQyN2Y5YTEwMDYzZjNiL3RhYmxlcmFuZ2U6NDZjOTI1MmEzZGJlNDliMWFiZDI3ZjlhMTAwNjNmM2JfMy0zLTEtMS0yMzAxMw_1bb68ded-6591-4941-b452-2f0e9f5ec73b">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35ca663b0a124e6b8c8656e7e070589c_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOjQ2YzkyNTJhM2RiZTQ5YjFhYmQyN2Y5YTEwMDYzZjNiL3RhYmxlcmFuZ2U6NDZjOTI1MmEzZGJlNDliMWFiZDI3ZjlhMTAwNjNmM2JfMy01LTEtMS0yMzAxMw_b9bcd5bb-f56b-4bd1-952a-4d28e63274ff">680,872</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i71bfab9599a347c38e447f9dfe33b344_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOjQ2YzkyNTJhM2RiZTQ5YjFhYmQyN2Y5YTEwMDYzZjNiL3RhYmxlcmFuZ2U6NDZjOTI1MmEzZGJlNDliMWFiZDI3ZjlhMTAwNjNmM2JfMy03LTEtMS0yMzAxMw_2830d077-e17f-4c51-8784-292cae1234a7">554,765</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie1302e9e86374f80ab91f5e2e093f6fa_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOjQ2YzkyNTJhM2RiZTQ5YjFhYmQyN2Y5YTEwMDYzZjNiL3RhYmxlcmFuZ2U6NDZjOTI1MmEzZGJlNDliMWFiZDI3ZjlhMTAwNjNmM2JfMy05LTEtMS0yMzAxMw_34f76e16-54ad-489d-a5f8-0657fd0842a1">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa47cdf56b6c4c87a3d970dbcf5b0e23_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOjQ2YzkyNTJhM2RiZTQ5YjFhYmQyN2Y5YTEwMDYzZjNiL3RhYmxlcmFuZ2U6NDZjOTI1MmEzZGJlNDliMWFiZDI3ZjlhMTAwNjNmM2JfMy0xMS0xLTEtMjMwMTM_9adc6467-fbf8-451b-9e46-271d4906758d">126,112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock under employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic32baa0627994f879f796094ade7c7d5_D20210101-20210331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOjQ2YzkyNTJhM2RiZTQ5YjFhYmQyN2Y5YTEwMDYzZjNiL3RhYmxlcmFuZ2U6NDZjOTI1MmEzZGJlNDliMWFiZDI3ZjlhMTAwNjNmM2JfNC0xLTEtMS0yMzAxMw_4a5efd73-0efe-456f-97b0-07fdd561bd2c">102,208</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f6752f99ffb46a6ac848c2977b3c96d_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOjQ2YzkyNTJhM2RiZTQ5YjFhYmQyN2Y5YTEwMDYzZjNiL3RhYmxlcmFuZ2U6NDZjOTI1MmEzZGJlNDliMWFiZDI3ZjlhMTAwNjNmM2JfNC01LTEtMS0yMzAxMw_33da9548-120b-435c-a065-204744a00556">478</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOjQ2YzkyNTJhM2RiZTQ5YjFhYmQyN2Y5YTEwMDYzZjNiL3RhYmxlcmFuZ2U6NDZjOTI1MmEzZGJlNDliMWFiZDI3ZjlhMTAwNjNmM2JfNC0xMS0xLTEtMjMwMTM_b6ec7537-ff53-46ce-9819-cbb78a920c3a">478</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic32baa0627994f879f796094ade7c7d5_D20210101-20210331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOjQ2YzkyNTJhM2RiZTQ5YjFhYmQyN2Y5YTEwMDYzZjNiL3RhYmxlcmFuZ2U6NDZjOTI1MmEzZGJlNDliMWFiZDI3ZjlhMTAwNjNmM2JfNi0xLTEtMS0yMzAxMw_5bd8ff0f-ef46-4af1-b8bf-e20c9d866635">10,507</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f6752f99ffb46a6ac848c2977b3c96d_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOjQ2YzkyNTJhM2RiZTQ5YjFhYmQyN2Y5YTEwMDYzZjNiL3RhYmxlcmFuZ2U6NDZjOTI1MmEzZGJlNDliMWFiZDI3ZjlhMTAwNjNmM2JfNi01LTEtMS0yMzAxMw_150bf11b-ba0d-4047-bf92-b8f29fafca94">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOjQ2YzkyNTJhM2RiZTQ5YjFhYmQyN2Y5YTEwMDYzZjNiL3RhYmxlcmFuZ2U6NDZjOTI1MmEzZGJlNDliMWFiZDI3ZjlhMTAwNjNmM2JfNi0xMS0xLTEtMjMwMTM_b2bbbc63-14eb-4f9b-839c-1fe4c6cd6801">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock upon vesting of restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic32baa0627994f879f796094ade7c7d5_D20210101-20210331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOjQ2YzkyNTJhM2RiZTQ5YjFhYmQyN2Y5YTEwMDYzZjNiL3RhYmxlcmFuZ2U6NDZjOTI1MmEzZGJlNDliMWFiZDI3ZjlhMTAwNjNmM2JfNy0xLTEtMS0yMzAxMw_2b88f5e7-de6c-464c-9239-38f4026ebfa8">35,100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock in at the market offering</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic32baa0627994f879f796094ade7c7d5_D20210101-20210331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOjQ2YzkyNTJhM2RiZTQ5YjFhYmQyN2Y5YTEwMDYzZjNiL3RhYmxlcmFuZ2U6NDZjOTI1MmEzZGJlNDliMWFiZDI3ZjlhMTAwNjNmM2JfOC0xLTEtMS0yNDEzNQ_614dcb7d-923d-4240-83e9-b227e80dc5d0">4,940,787</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7.75pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic32baa0627994f879f796094ade7c7d5_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOjQ2YzkyNTJhM2RiZTQ5YjFhYmQyN2Y5YTEwMDYzZjNiL3RhYmxlcmFuZ2U6NDZjOTI1MmEzZGJlNDliMWFiZDI3ZjlhMTAwNjNmM2JfOC0zLTEtMS0yNDEzNQ_b4fc7be8-89e6-4fc2-8d5e-a075595a5108">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7.75pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f6752f99ffb46a6ac848c2977b3c96d_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOjQ2YzkyNTJhM2RiZTQ5YjFhYmQyN2Y5YTEwMDYzZjNiL3RhYmxlcmFuZ2U6NDZjOTI1MmEzZGJlNDliMWFiZDI3ZjlhMTAwNjNmM2JfOC01LTEtMS0yNDEzNQ_7d39fa50-f046-41d1-b4c5-4ef8564bfa1f">34,271</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7.75pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7.75pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7.75pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOjQ2YzkyNTJhM2RiZTQ5YjFhYmQyN2Y5YTEwMDYzZjNiL3RhYmxlcmFuZ2U6NDZjOTI1MmEzZGJlNDliMWFiZDI3ZjlhMTAwNjNmM2JfOC0xMS0xLTEtMjQxMzU_51996180-d827-4f6e-a524-15c1984c3d90">34,272</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7.75pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7.75pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f6752f99ffb46a6ac848c2977b3c96d_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOjQ2YzkyNTJhM2RiZTQ5YjFhYmQyN2Y5YTEwMDYzZjNiL3RhYmxlcmFuZ2U6NDZjOTI1MmEzZGJlNDliMWFiZDI3ZjlhMTAwNjNmM2JfOC01LTEtMS0yMzAxMw_91458b9a-cff2-4243-a813-5f597faf4b21">3,087</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7.75pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7.75pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7.75pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOjQ2YzkyNTJhM2RiZTQ5YjFhYmQyN2Y5YTEwMDYzZjNiL3RhYmxlcmFuZ2U6NDZjOTI1MmEzZGJlNDliMWFiZDI3ZjlhMTAwNjNmM2JfOC0xMS0xLTEtMjMwMTM_61e22e2a-afb3-4b8e-b9df-063cfdc298d5">3,087</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized losses on available-for-sale securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie42c996fddf8460982e8ef5b6a6dd25a_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOjQ2YzkyNTJhM2RiZTQ5YjFhYmQyN2Y5YTEwMDYzZjNiL3RhYmxlcmFuZ2U6NDZjOTI1MmEzZGJlNDliMWFiZDI3ZjlhMTAwNjNmM2JfOS05LTEtMS0yMzAxMw_2d29ea7d-d611-4998-bef8-d12ec8856b56">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOjQ2YzkyNTJhM2RiZTQ5YjFhYmQyN2Y5YTEwMDYzZjNiL3RhYmxlcmFuZ2U6NDZjOTI1MmEzZGJlNDliMWFiZDI3ZjlhMTAwNjNmM2JfOS0xMS0xLTEtMjMwMTM_1312fd8b-b073-4ded-8e94-491432360ba1">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i76348c324fa24beda3b12611828f421a_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOjQ2YzkyNTJhM2RiZTQ5YjFhYmQyN2Y5YTEwMDYzZjNiL3RhYmxlcmFuZ2U6NDZjOTI1MmEzZGJlNDliMWFiZDI3ZjlhMTAwNjNmM2JfMTAtNy0xLTEtMjMwMTM_350f9129-df68-4849-a2ae-eae8065ea0ae">33,155</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOjQ2YzkyNTJhM2RiZTQ5YjFhYmQyN2Y5YTEwMDYzZjNiL3RhYmxlcmFuZ2U6NDZjOTI1MmEzZGJlNDliMWFiZDI3ZjlhMTAwNjNmM2JfMTAtMTEtMS0xLTIzMDEz_b01b7bca-dc55-4f65-ab59-ab86ebfeee69">33,155</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id70cbf4ca0ff49799aebf60ead1ac83a_I20210331" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOjQ2YzkyNTJhM2RiZTQ5YjFhYmQyN2Y5YTEwMDYzZjNiL3RhYmxlcmFuZ2U6NDZjOTI1MmEzZGJlNDliMWFiZDI3ZjlhMTAwNjNmM2JfMTEtMS0xLTEtMjMwMTM_fdf84397-8b45-4c81-81df-31ad9da7a442">98,688,577</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id70cbf4ca0ff49799aebf60ead1ac83a_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOjQ2YzkyNTJhM2RiZTQ5YjFhYmQyN2Y5YTEwMDYzZjNiL3RhYmxlcmFuZ2U6NDZjOTI1MmEzZGJlNDliMWFiZDI3ZjlhMTAwNjNmM2JfMTEtMy0xLTEtMjMwMTM_b392a630-1ebe-4899-bbfe-3c0844ca881b">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie895873a73154ee881d6a0b9a2729c79_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOjQ2YzkyNTJhM2RiZTQ5YjFhYmQyN2Y5YTEwMDYzZjNiL3RhYmxlcmFuZ2U6NDZjOTI1MmEzZGJlNDliMWFiZDI3ZjlhMTAwNjNmM2JfMTEtNS0xLTEtMjMwMTM_68f292f4-a22a-42d4-bc4b-e59416398688">718,728</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38a8556738964a7fa1421049694e0b21_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOjQ2YzkyNTJhM2RiZTQ5YjFhYmQyN2Y5YTEwMDYzZjNiL3RhYmxlcmFuZ2U6NDZjOTI1MmEzZGJlNDliMWFiZDI3ZjlhMTAwNjNmM2JfMTEtNy0xLTEtMjMwMTM_f0cc97ad-aed0-4227-a043-5da0c323e79a">587,920</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7c204a43b4eb4e6d9394547d9b0e2b58_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOjQ2YzkyNTJhM2RiZTQ5YjFhYmQyN2Y5YTEwMDYzZjNiL3RhYmxlcmFuZ2U6NDZjOTI1MmEzZGJlNDliMWFiZDI3ZjlhMTAwNjNmM2JfMTEtOS0xLTEtMjMwMTM_4b32ca5e-1740-405d-b061-fbf336f7f4de">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac98ebf56cf345fb9e32e575ac855e4a_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOjQ2YzkyNTJhM2RiZTQ5YjFhYmQyN2Y5YTEwMDYzZjNiL3RhYmxlcmFuZ2U6NDZjOTI1MmEzZGJlNDliMWFiZDI3ZjlhMTAwNjNmM2JfMTEtMTEtMS0xLTIzMDEz_6b666c47-92cb-4a10-b040-6dd6a16eee2d">130,811</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"></span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:28.801%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed financial statements.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i711b1a39e0634b15bb7a70766327247a_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i711b1a39e0634b15bb7a70766327247a_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARDELYX,&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMy0xLTEtMS0yMzAxMw_16c84604-b87c-4446-ae20-d482d443f90c">28,071</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMy0zLTEtMS0yMzAxMw_b4acfb41-f4d1-4890-b6bf-cef91dab7094">33,155</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" decimals="-3" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfNS0xLTEtMS0yMzAxMw_cc69237d-a19e-4399-8630-3b75016e1ce3">232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331" decimals="-3" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfNS0zLTEtMS0yMzAxMw_020c34f5-3aef-4a80-b6ed-4b873b3f1247">422</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of deferred financing costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfNi0xLTEtMS0yMzAxMw_2d162e63-eeda-4fd9-a263-237e704ec568">169</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfNi0zLTEtMS0yMzAxMw_9fa0195f-daa2-45b2-b0c0-92bc47d9108a">157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of deferred compensation for services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" decimals="-3" name="us-gaap:AmortizationOfDeferredCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfNy0xLTEtMS0yMzAxMw_cb08442f-8646-456f-9767-c10a9b6903c7">47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331" decimals="-3" name="us-gaap:AmortizationOfDeferredCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfNy0zLTEtMS0yMzAxMw_4b86c574-2551-485b-9960-eedf48c0cb04">77</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of (discount) premium on investment securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfOC0xLTEtMS0yMzAxMw_70c99a0b-0ae0-489f-aaa9-c249b3f5a0a5">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfOC0zLTEtMS0yMzAxMw_9f44874d-4a12-41ce-a311-cd1eaa424222">157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash lease expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfOS0xLTEtMS0yMzAxMw_e5bed4b6-6405-42d1-a486-e6670f08bcf6">842</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfOS0zLTEtMS0yMzAxMw_c6ca753f-e404-4750-b886-af54302691c3">607</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMTAtMS0xLTEtMjMwMTM_95bccd18-aa8b-439e-b603-d937c55b49f7">3,722</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMTAtMy0xLTEtMjMwMTM_277e4c4d-09dc-4c4f-845c-5650a2e96dbb">3,087</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in derivative liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInDerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMTEtMS0xLTEtMjMwMTM_79a84821-d7d8-4c07-aa53-2bd383b603ac">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331" decimals="-3" name="us-gaap:IncreaseDecreaseInDerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMTEtMy0xLTEtMjMwMTM_59b5fa99-c330-4ab4-84a9-5fdd96b0b16b">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt refinancing costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:GainsLossesOnRestructuringOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMTItMS0xLTEtMzA5OTA_ec4fde91-fb6e-47c8-85e1-cb81360f6105">102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331" decimals="-3" name="us-gaap:GainsLossesOnRestructuringOfDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMTItMy0xLTEtMzA5OTk_cb0df1cc-d0f4-40fc-b6b4-d1ecdc301acd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" decimals="-3" name="us-gaap:GainLossOnDispositionOfAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMTMtMS0xLTEtMzA5OTA_d5a435bd-4d39-478e-81e9-cb4e306c4e4e">710</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331" decimals="-3" name="us-gaap:GainLossOnDispositionOfAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMTMtMy0xLTEtMzA5OTk_fa0db9b5-e73b-4943-9065-451fc39f7393">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest associated with debt discount accretion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMTItMS0xLTEtMjMwMTM_4fcf6b5f-91c5-4a9a-b864-74c7669ab2e0">109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMTItMy0xLTEtMjMwMTM_baf5bd67-5f9b-4e6a-9889-904fe0a567c0">70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMTQtMS0xLTEtMjMwMTM_3ee0c1df-8d59-4bfe-bf27-09acbebf1a23">3,892</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMTQtMy0xLTEtMjMwMTM_0287092d-b3da-4dab-94cc-ff904704c201">5,783</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMTgtMS0xLTEtMzEwMDc_5cc100ae-befb-4b18-a7ed-d0da942fcc51">3,487</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMTgtMy0xLTEtMzEwMjI_4ca1a4f1-586b-474c-bc63-dfc167e6f6e1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMTUtMS0xLTEtMjMwMTM_62ce0dc0-0fd1-4026-9328-f733e7e5558a">307</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMTUtMy0xLTEtMjMwMTM_ba8e6c8c-f2fb-439b-804b-b9026417518a">13,662</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMTYtMS0xLTEtMjMwMTM_1f2bf343-7e0e-4937-8dfe-24905ce3c4ac">753</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMTYtMy0xLTEtMjMwMTM_950e59c0-5735-4552-8774-d184382d05d8">248</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMTctMS0xLTEtMjMwMTM_a5ed3cc4-36a2-47f3-b910-17496f6ce229">882</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMTctMy0xLTEtMjMwMTM_ea9446e8-6f54-41b9-a5f7-a20279a8ae02">1,324</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMTgtMS0xLTEtMjMwMTM_2d35c635-7bd9-4d54-88b6-69672d038e78">836</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMTgtMy0xLTEtMjMwMTM_4525fdd1-6b68-4fbd-9aa4-c16a4ed1cc1f">721</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMTktMS0xLTEtMjMwMTM_86cad227-3f7b-4449-9dec-5d2576f41800">1,041</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMTktMy0xLTEtMjMwMTM_171ee5f7-80a7-45c9-937d-be2c62d30a74">7,517</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInDeferredRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMjAtMS0xLTEtMjMwMTM_8f22ce12-b130-44e4-859f-bcc61692675c">3,836</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInDeferredRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMjAtMy0xLTEtMjMwMTM_70334999-0ba8-4151-af61-870e535e48e8">1,454</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMjEtMS0xLTEtMjMwMTM_3d1c19a4-09e4-4ce0-88bc-906eb92b5349">27,620</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMjEtMy0xLTEtMjMwMTM_af1f09ec-d46b-4523-b7f9-24503c42920b">44,217</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investing activities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from maturities and redemptions of investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMjQtMS0xLTEtMjM3MjU_bc96d066-5eb6-45e2-9395-23d2d3222552">27,300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMjQtMy0xLTEtMjM3MzY_a944e1bb-cdb7-4e10-8df3-4d7217a2f359">35,370</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquireShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMjQtMS0xLTEtMjMwMTM_e0a97845-d464-4c6a-a683-355af546cd97">25,763</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331" decimals="-3" name="us-gaap:PaymentsToAcquireShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMjQtMy0xLTEtMjMwMTM_a29d7c14-7989-49a3-8e70-2c6d05684657">32,107</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale of equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromSaleOfMachineryAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMjktMS0xLTEtMzEwNDA_f4dff243-e778-41a6-b823-263523de83b2">795</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331" decimals="-3" name="us-gaap:ProceedsFromSaleOfMachineryAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMjktMy0xLTEtMzEwNTA_2aaa11c9-7e38-4734-b545-1c6da49998fe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMjUtMS0xLTEtMjMwMTM_f9bbc0b2-9de0-4b3d-be99-42b441356a16">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMjUtMy0xLTEtMjMwMTM_d653f162-e5ab-48ca-ab67-e44bf7e29004">778</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMjYtMS0xLTEtMjMwMTM_ac17de6a-9c09-4636-9719-d6e80e9ba33b">2,332</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMjYtMy0xLTEtMjMwMTM_b650da66-bb13-4edc-b835-3628516e3cbc">2,485</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financing activities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from 2022 Loan, net of issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSecuredDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMzMtMS0xLTEtMzEwNTg_2fa4402a-5344-4048-993d-208f09a6a1e0">26,971</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSecuredDebt" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMzMtMy0xLTEtMzEwNzE_a6e9d03c-033b-4b23-bdb0-60ca93262e43">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayment of 2018 Loan, net of settlement costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" decimals="-3" name="us-gaap:RepaymentsOfSecuredDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMzQtMS0xLTEtMzEwODE_ae94b8f1-ee43-48ae-a40f-637d2e897854">33,038</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331" decimals="-3" name="us-gaap:RepaymentsOfSecuredDebt" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMzQtMy0xLTEtMzEwODE_bf6331bc-c910-457d-becb-56551e1d4a79">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock in at the market offering, net of issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMzAtMS0xLTEtMjMwMTM_379fa4ef-ec5c-486e-821a-17e14ea179e3">5,921</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMzAtMy0xLTEtMjMwMTM_5b0e8a9a-d577-488f-8050-8565e003db9f">34,272</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock under equity incentive and stock purchase plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMzEtMS0xLTEtMjMwMTM_3c194d4b-27bd-4204-8a7c-2c070c337095">83</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMzEtMy0xLTEtMjMwMTM_f5bfe121-c8cc-4bf2-88c1-962e826ec1f8">498</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMzQtMS0xLTEtMjMwMTM_137a790c-301b-4f5d-a0fe-3d46f2851fcb">63</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMzQtMy0xLTEtMjMwMTM_a0024dbc-a56c-4079-8ef7-2ba3db7f8b36">34,770</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net decrease in cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMzUtMS0xLTEtMjMwMTM_7a9daac5-d1f1-4cfc-809c-72e338e52e6b">25,351</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMzUtMy0xLTEtMjMwMTM_dd62844f-83ec-4fd7-8de5-1fba5aea5500">6,962</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash and cash equivalents at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMzYtMS0xLTEtMjMwMTM_08ff1029-99cc-44e6-975c-3d713cefb3a9">72,428</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa47cdf56b6c4c87a3d970dbcf5b0e23_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMzYtMy0xLTEtMjMwMTM_fbf81dad-8b5f-4c94-988b-e3b5793a2d78">91,032</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash and cash equivalents at end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMzctMS0xLTEtMjMwMTM_bd1e65fe-f4d6-4465-a65c-f32798b3c209">47,077</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac98ebf56cf345fb9e32e575ac855e4a_I20210331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMzctMy0xLTEtMjMwMTM_4c00f401-2e92-4bcd-b953-f6a1c3617aa2">84,070</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplementary disclosure of cash flow information:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for interest</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfNDEtMS0xLTEtMjM3MjU_e8fe76c2-ea2e-4709-a171-0159917c9507">741</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfNDEtMy0xLTEtMjM3MzY_8e2cd04a-ffcd-4fdc-a157-0f4c98e17d8a">963</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for income taxes</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfNDAtMS0xLTEtMjMwMTM_2d9d8b0c-c7d4-4563-a3f4-3cfc8393106d">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfNDAtMy0xLTEtMjMwMTM_a014e974-b7d2-4c94-b8db-3d32699b251d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplementary disclosure of non-cash activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease obligations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfNDQtMS0xLTEtMjM3MjU_4ee6ee37-f6b6-4ee4-96c5-89592f7711f7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfNDQtMy0xLTEtMjM3MzY_21198dbb-ac22-44df-ac8f-80b0820ef28e">450</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of derivative in connection with issuance of loan payable</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" decimals="-3" name="ardx:DerivativeIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfNDQtMS0xLTEtMjMwMTM_800931d3-9987-4080-a609-c5cc9043dbc5">375</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331" decimals="-3" name="ardx:DerivativeIssued" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfNDQtMy0xLTEtMjMwMTM_9e6d97c8-7568-42e0-85f1-7906ce107b17">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i711b1a39e0634b15bb7a70766327247a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i711b1a39e0634b15bb7a70766327247a_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i711b1a39e0634b15bb7a70766327247a_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARDELYX,&#160;INC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(amounts in thousands, except per share amounts and where otherwise noted)</span></div><div id="i711b1a39e0634b15bb7a70766327247a_31"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 1. <ix:nonNumeric contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" name="us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zMS9mcmFnOjIxYzg0YTQwOGU2OTRjMmNiZjg0MDJkZDY0NWVkM2I1L3RleHRyZWdpb246MjFjODRhNDA4ZTY5NGMyY2JmODQwMmRkNjQ1ZWQzYjVfOTA3OQ_cf8fad45-f626-4beb-879c-72a0f0e6d1f7" continuedAt="i3a3f3c6136a9485b9eb741f0ec423d65" escape="true">ORGANIZATION AND BASIS OF PRESENTATION</ix:nonNumeric></span></div><ix:continuation id="i3a3f3c6136a9485b9eb741f0ec423d65" continuedAt="ia21152ba9b484670a968492e0ed7a550"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ardelyx, Inc. (the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221;) is a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in <ix:nonFraction unitRef="segment" contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zMS9mcmFnOjIxYzg0YTQwOGU2OTRjMmNiZjg0MDJkZDY0NWVkM2I1L3RleHRyZWdpb246MjFjODRhNDA4ZTY5NGMyY2JmODQwMmRkNjQ1ZWQzYjVfMTA5OTUxMTYzNzY0OA_daf69010-a8e8-49ad-a199-d1936aa0e6af">one</ix:nonFraction> business segment, which is the development and commercialization of biopharmaceutical products.</span></div><ix:nonNumeric contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zMS9mcmFnOjIxYzg0YTQwOGU2OTRjMmNiZjg0MDJkZDY0NWVkM2I1L3RleHRyZWdpb246MjFjODRhNDA4ZTY5NGMyY2JmODQwMmRkNjQ1ZWQzYjVfOTA3NQ_0d36b3a9-116c-4d63-a7b8-8aad8f00a82f" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and pursuant to the requirements of the Securities and Exchange Commission (&#8220;SEC&#8221;) for interim reporting. As permitted under those rules&#160;and regulations, certain footnotes or other financial information that are normally required by U.S. GAAP have been condensed or omitted. These condensed financial statements have been prepared on the same basis as our most recent annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments necessary to present fairly our financial position, results of operations, changes in stockholders&#8217; equity, and cash flows for the interim periods presented.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed financial statements and related financial information should be read in conjunction with the audited financial statements and the related notes thereto included in our Annual Report on Form 10-K for the&#160;year ended December&#160;31, 2021. The results for the three months ended March&#160;31, 2022 are not necessarily indicative of results to be expected for the entire&#160;year ending December&#160;31, 2022, or for any other interim period or future year.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zMS9mcmFnOjIxYzg0YTQwOGU2OTRjMmNiZjg0MDJkZDY0NWVkM2I1L3RleHRyZWdpb246MjFjODRhNDA4ZTY5NGMyY2JmODQwMmRkNjQ1ZWQzYjVfOTA3Ng_7c186d66-ab51-42ce-a345-22d2bc2cefde" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that affect the amounts reported in the financial statements and accompanying notes thereto. On an ongoing basis, management evaluates its estimates, including those related to recognition of revenue, clinical trial accruals, contract manufacturing accruals, the fair value of assets and liabilities, income taxes and stock-based compensation. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could materially differ from those estimates.</span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, we had cash and investments of approximately $<ix:nonFraction unitRef="usd" contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331" decimals="-5" name="us-gaap:InvestmentsAndCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zMS9mcmFnOjIxYzg0YTQwOGU2OTRjMmNiZjg0MDJkZDY0NWVkM2I1L3RleHRyZWdpb246MjFjODRhNDA4ZTY5NGMyY2JmODQwMmRkNjQ1ZWQzYjVfMTA5OTUxMTY0MTgxNg_cf64a164-f588-4e92-91f2-01ac77b83845">89.7</ix:nonFraction>&#160;million. We have incurred operating losses since inception and our accumulated deficit as of March&#160;31, 2022 is $<ix:nonFraction unitRef="usd" contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zMS9mcmFnOjIxYzg0YTQwOGU2OTRjMmNiZjg0MDJkZDY0NWVkM2I1L3RleHRyZWdpb246MjFjODRhNDA4ZTY5NGMyY2JmODQwMmRkNjQ1ZWQzYjVfMTA5OTUxMTY0MTgyNw_01ca2053-b997-49f9-b981-dfeb3afa989e">741.0</ix:nonFraction>&#160;million. Our current level of cash and investments alone is not sufficient to meet our plans for the next twelve months following the issuance of these financial statements. These factors raise substantial doubt regarding our ability to continue as a going concern for a period of one year from the issuance of these financial statements. We plan to address our operating cash flow requirements with our current cash and investments, cash generated from sales of IBSRELA, our potential receipt of anticipated milestones from our collaboration partners, our ability to access the capital markets, as well as through the implementation of cash preservation activities to reduce or defer discretionary spending.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no assurances that our efforts to meet our operating cash flow requirements will be successful. If our current cash and investments as well as our plans to meet our operating cash flow requirements are not sufficient to fund necessary expenditures and meet our obligations for at least the next twelve months following the issuance of these financial statements, our liquidity, financial condition and business prospects will be materially affected. These financial statements have been prepared on a going concern basis and do not include any adjustments to the amounts and classification of assets and liabilities that may be necessary in the event that we can no longer continue as a going concern. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Significant Accounting Policies</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our significant accounting policies are described in Note 1 to our audited financial statements for the fiscal year ended December&#160;31, 2021, included in our Annual Report on Form 10-K. Our significant accounting policies for the three months ended March&#160;31, 2022 also included the policies discussed below related to accounts receivable, inventory, revenue and cost of </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i711b1a39e0634b15bb7a70766327247a_7">Table of Contents</a></span></div></div><ix:continuation id="ia21152ba9b484670a968492e0ed7a550" continuedAt="id85cc43510594f38add1919c4fabfb89"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">revenue for commercial product sales. With the exception of those noted below, there have been no material changes in our significant accounting policies as previously disclosed in our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zMS9mcmFnOjIxYzg0YTQwOGU2OTRjMmNiZjg0MDJkZDY0NWVkM2I1L3RleHRyZWdpb246MjFjODRhNDA4ZTY5NGMyY2JmODQwMmRkNjQ1ZWQzYjVfMzI5ODUzNDkzODc2OA_b996bf5b-6933-4165-8702-5ae7734a8027" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts Receivable</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable is reported net of allowances for returns, chargebacks and contractual discounts offered to our customers. Our estimate of the allowance for doubtful accounts is based on an evaluation of the aging of our receivables. Trade receivable balances are written off against the allowance when it is probable that the receivable will not be collected. To date, we have determined that an allowance for doubtful accounts is not required. As of March&#160;31, 2022 our accounts receivable balance is comprised of $<ix:nonFraction unitRef="usd" contextRef="i42e4f62db19a433c9581bbeecf9067e3_I20220331" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zMS9mcmFnOjIxYzg0YTQwOGU2OTRjMmNiZjg0MDJkZDY0NWVkM2I1L3RleHRyZWdpb246MjFjODRhNDA4ZTY5NGMyY2JmODQwMmRkNjQ1ZWQzYjVfMTA5OTUxMTY3MzA5OQ_8beb94ce-5b5e-464a-888b-af522c814052">3.8</ix:nonFraction>&#160;million from our collaborators and $<ix:nonFraction unitRef="usd" contextRef="id9efdb641fb440e39fb4580adc8f5d3f_I20220331" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zMS9mcmFnOjIxYzg0YTQwOGU2OTRjMmNiZjg0MDJkZDY0NWVkM2I1L3RleHRyZWdpb246MjFjODRhNDA4ZTY5NGMyY2JmODQwMmRkNjQ1ZWQzYjVfMTA5OTUxMTY3MzEzMA_090b2bbe-b62a-43ab-a8d7-8517a6400180">0.6</ix:nonFraction>&#160;million from commercial customers. As of December&#160;31, 2021 our accounts receivable balance was comprised of $<ix:nonFraction unitRef="usd" contextRef="id0170fbda0b74504967067c9d57bec75_I20211231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zMS9mcmFnOjIxYzg0YTQwOGU2OTRjMmNiZjg0MDJkZDY0NWVkM2I1L3RleHRyZWdpb246MjFjODRhNDA4ZTY5NGMyY2JmODQwMmRkNjQ1ZWQzYjVfMTA5OTUxMTY3MzM0Nw_3f8defdd-5012-43a5-be5d-8809f22db055">0.5</ix:nonFraction>&#160;million from our collaborators.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" name="us-gaap:InventoryPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zMS9mcmFnOjIxYzg0YTQwOGU2OTRjMmNiZjg0MDJkZDY0NWVkM2I1L3RleHRyZWdpb246MjFjODRhNDA4ZTY5NGMyY2JmODQwMmRkNjQ1ZWQzYjVfNDM5ODA0NjU1NDUyOQ_4552fe39-bfab-4056-a650-4e25836d6d00" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the regulatory approval of drug product candidates, we incurred expenses for the manufacture of drug product that could potentially be available to support the commercial launch of our products. We began to capitalize inventory costs associated with IBSRELA during the fourth quarter of 2021, when our intent to commercialize IBSRELA was established and we commenced preparation for the commercial launch of IBSRELA, which was when it was determined that the inventory had a probable future economic benefit.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory is stated at the lower of cost or estimated net realizable value with cost determined under the first-in first-out method. Inventory costs include third-party contract manufacturing, third-party packaging services, freight, labor costs for personnel involved in the manufacturing process, and indirect overhead costs. We primarily use actual costs to determine the cost basis for inventory. The determination of whether inventory costs will be realizable requires management review of the expiration dates of IBSRELA compared to our forecasted sales. If actual market conditions are less favorable than projected by management, write-downs of inventory may be required, which would be recorded as cost of goods sold in the condensed statement of operations and comprehensive loss.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zMS9mcmFnOjIxYzg0YTQwOGU2OTRjMmNiZjg0MDJkZDY0NWVkM2I1L3RleHRyZWdpb246MjFjODRhNDA4ZTY5NGMyY2JmODQwMmRkNjQ1ZWQzYjVfNDM5ODA0NjU1NDUzMA_c410fe2c-d10b-420a-b4a5-eeaf9f794f4c" continuedAt="ifa5b8856dfd74d99b15449037ddc0e05" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Sales, Net</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for our commercial product sales, net in accordance with Topic 606 - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We received approval from the U.S. Food and Drug Administration (&#8220;FDA&#8221;) in September 2019 to market IBSRELA, the first and only sodium hydrogen exchanger 3 (&#8220;NHE3&#8221;) inhibitor for the treatment of irritable bowel syndrome with constipation ("IBS-C") in adults, in the United States ("U.S."). We began selling IBSRELA in the U.S. in March 2022. We distribute our products principally through a limited number of distributors and specialty pharmacy providers (collectively, our "Customers"). Our Customers subsequently sell our products to pharmacies and patients. Separately, we enter into arrangements with third parties that provide for government-mandated and privately-negotiated rebates, chargebacks and discounts. Revenue from product sales is recognized when our performance obligations are satisfied, which is when Customers obtain control of our product and occurs upon delivery.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reserves for Variable Consideration</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration, including rebates, discounts, patient copay assistance programs, and estimated product returns. These estimates are based on the amounts earned or to be claimed for related sales and are classified as reductions of accounts receivable if the amount is payable to our Customers or a current liability if the amount is payable to a party other than a Customer. Where appropriate, these estimates are based on factors such as industry data and forecasted customer buying and payment patterns, our historical experience, current contractual and statutory requirements, specific known market events and trends. Overall, these reductions to gross sales reflect our best estimates of the amount of consideration to which we are entitled based on the terms of the contract. Variable consideration is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from our estimates, we adjust these estimates, which would affect product revenue and earnings in the period such variances become known. As we gain more historical experience, estimates will be more heavily based on the expected utilization from historical data we have accumulated since the IBSRELA product launch.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Rebates: Rebates include mandated discounts under the Medicaid Drug Rebate Program ("Medicaid") and the Medicare Coverage Gap Program ("Medicare"). Rebates are amounts owed after the final dispensing of products to a benefit plan </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i711b1a39e0634b15bb7a70766327247a_7">Table of Contents</a></span></div></div><ix:continuation id="id85cc43510594f38add1919c4fabfb89"><ix:continuation id="ifa5b8856dfd74d99b15449037ddc0e05"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">participant and are based upon contractual agreements or legal requirements with the public-sector benefit providers. These estimates for rebates are recorded in the same period the related gross revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included in accrued expenses on the condensed balance sheets. We estimate our Medicaid and Medicare rebates based upon the estimated payor mix, and statutory discount rates. Our estimates for payor mix are guided by payor information received from specialty pharmacies, expected utilization for specialty distributor sales to pharmacies, and available industry payor information. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Chargebacks: Chargebacks are discounts that occur when contracted purchasers purchase directly from our specialty distributors at a discounted price. The specialty distributor, in turn, charges back the difference between the price initially paid to us by the specialty distributor and the discounted price paid to the specialty distributor by the contracted purchaser. Amounts for estimated chargebacks are established in the same period that the related gross revenue is recognized, resulting in a reduction of product revenue and accounts receivable. The accrual for specialty distributor chargebacks is estimated based on known chargeback rates, known sales to specialty distributors, and estimated utilization by types of contracted purchasers.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discounts and Fees: Our payment terms are generally <ix:nonNumeric contextRef="ibc13d123a8d14d6babcf8581fd6dcd05_D20220101-20220331" name="ardx:RevenueGeneralPaymentTerms" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zMS9mcmFnOjIxYzg0YTQwOGU2OTRjMmNiZjg0MDJkZDY0NWVkM2I1L3RleHRyZWdpb246MjFjODRhNDA4ZTY5NGMyY2JmODQwMmRkNjQ1ZWQzYjVfNDM5ODA0NjU1NDU0MQ_9fb281cc-4d65-4d5d-b2a1-d0c84d80e020">30</ix:nonNumeric> to <ix:nonNumeric contextRef="i3a085319c0b44680ad033352cd7f1a58_D20220101-20220331" name="ardx:RevenueGeneralPaymentTerms" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zMS9mcmFnOjIxYzg0YTQwOGU2OTRjMmNiZjg0MDJkZDY0NWVkM2I1L3RleHRyZWdpb246MjFjODRhNDA4ZTY5NGMyY2JmODQwMmRkNjQ1ZWQzYjVfNDM5ODA0NjU1NDU1NA_efe83b91-5c2e-413e-bb4b-f072a75a3bae">60</ix:nonNumeric> days. Specialty distributors and specialty pharmacies are offered various forms of consideration, including service fees and prompt pay discounts for payment within a specified period. We expect these Customers will earn prompt pay discounts and therefore, we deduct the full amount of these discounts and service fees from product sales when revenue is recognized, resulting in a reduction of product revenue and accounts receivable.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other Reserves: Patients who have commercial insurance may receive co-pay assistance when product is dispensed by pharmacies to patients. We estimate the amount of co-pay assistance provided to eligible patients based on the terms of the program and redemption information provided by third-party claims processing organizations and are recorded in accounts payable, accrued expenses and other current liabilities on the condensed balance sheets.</span></div></ix:continuation><ix:nonNumeric contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" name="us-gaap:CostOfSalesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zMS9mcmFnOjIxYzg0YTQwOGU2OTRjMmNiZjg0MDJkZDY0NWVkM2I1L3RleHRyZWdpb246MjFjODRhNDA4ZTY5NGMyY2JmODQwMmRkNjQ1ZWQzYjVfNDM5ODA0NjU1NDUzNw_d3241a8d-74fb-4f41-88e7-60f45fa0757a" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost of Revenue</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of revenue consists of the cost of commercial goods sold to our Customers, international partners under product supply agreements, and royalty expense based on sales of tenapanor. We capitalize inventory costs associated with the production of our products after regulatory approval or when, based on management&#8217;s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized. Otherwise, such costs are expensed as research and development. A portion of the costs of IBSRELA units recognized as revenue during the three months ended March&#160;31, 2022 were expensed prior to the fourth quarter of 2021, at which time our intent to commercialize IBSRELA was established and we commenced  preparation for the commercial launch of IBSRELA.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of revenue includes payments due to AstraZeneca, which under the terms of a termination agreement entered into in 2015 (the "AZ Termination Agreement") is entitled to (i) future royalties at a rate of <ix:nonFraction unitRef="number" contextRef="i390f2ffb21554b849e8f47149934d4fd_D20150601-20150630" decimals="INF" name="ardx:PercentageOfRoyaltyRevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zMS9mcmFnOjIxYzg0YTQwOGU2OTRjMmNiZjg0MDJkZDY0NWVkM2I1L3RleHRyZWdpb246MjFjODRhNDA4ZTY5NGMyY2JmODQwMmRkNjQ1ZWQzYjVfMjE5OTAyMzI5ODM3MQ_36a14427-40d0-47f8-9d3a-cd7552de954d">10</ix:nonFraction>% of net sales of tenapanor or other NHE3 products by us or our licensees, and (ii) <ix:nonFraction unitRef="number" contextRef="i390f2ffb21554b849e8f47149934d4fd_D20150601-20150630" decimals="INF" name="ardx:PercentageOfNonRoyaltyRevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zMS9mcmFnOjIxYzg0YTQwOGU2OTRjMmNiZjg0MDJkZDY0NWVkM2I1L3RleHRyZWdpb246MjFjODRhNDA4ZTY5NGMyY2JmODQwMmRkNjQ1ZWQzYjVfMjE5OTAyMzI5ODQ1Nw_c3b1a610-cb43-4d3a-bde9-17f354a42902">20</ix:nonFraction>% of non-royalty revenue received from our collaboration partners as a result of the development and commercialization of tenapanor or certain other NHE3 inhibitors.&#160;We have agreed to pay&#160;AstraZeneca up to a maximum of $<ix:nonFraction unitRef="usd" contextRef="id4d3d62533e642adab59317a030f3b30_I20150630" decimals="-5" name="ardx:CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zMS9mcmFnOjIxYzg0YTQwOGU2OTRjMmNiZjg0MDJkZDY0NWVkM2I1L3RleHRyZWdpb246MjFjODRhNDA4ZTY5NGMyY2JmODQwMmRkNjQ1ZWQzYjVfMjE5OTAyMzI5ODY5MQ_6fcfcfa2-65b5-4548-ba76-53802acee91c">75.0</ix:nonFraction> million in the aggregate for (i) and (ii). We recognize these expenses as cost of revenue when we recognize the corresponding revenue that gives rise to payments due to AstraZeneca. To date, we have recognized an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i8bde55ddcbf0400a8169b35ffe4c6da2_I20220331" decimals="-5" name="ardx:CostOfRevenueAggregateAmountRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zMS9mcmFnOjIxYzg0YTQwOGU2OTRjMmNiZjg0MDJkZDY0NWVkM2I1L3RleHRyZWdpb246MjFjODRhNDA4ZTY5NGMyY2JmODQwMmRkNjQ1ZWQzYjVfMTA5OTUxMTY3MTQzMQ_0ae23e44-8c2f-48d9-9a0d-1a6ad72afa56">11.7</ix:nonFraction> million as cost of revenue under the AZ Termination Agreement.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zMS9mcmFnOjIxYzg0YTQwOGU2OTRjMmNiZjg0MDJkZDY0NWVkM2I1L3RleHRyZWdpb246MjFjODRhNDA4ZTY5NGMyY2JmODQwMmRkNjQ1ZWQzYjVfOTA3OA_05c3478b-c417-4e0b-97df-dfe05325b8fd" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New Accounting Pronouncements - Recently Adopted</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted no new accounting pronouncements other than those disclosed in our most recent Annual Report on Form 10-K.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were various accounting standards and interpretations issued recently, none of which are expected to a have a material impact on our financial position, operations or cash flows.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><div id="i711b1a39e0634b15bb7a70766327247a_34"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i711b1a39e0634b15bb7a70766327247a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 2. <ix:nonNumeric contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" name="us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RleHRyZWdpb246MWU2ZGMzNzU5MWE3NDQ5M2I5MmI4ZTJmN2Y1NTI4NDlfMTg2OQ_bb994fa9-2118-4ea1-a982-58620a9018bd" continuedAt="i814b4768989f4291b084291bb476a1d3" escape="true">CASH, CASH EQUIVALENTS AND INVESTMENTS</ix:nonNumeric></span></div><ix:continuation id="i814b4768989f4291b084291bb476a1d3" continuedAt="i7a3f481830444b64a6e7298232baf654"><ix:nonNumeric contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" name="us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RleHRyZWdpb246MWU2ZGMzNzU5MWE3NDQ5M2I5MmI4ZTJmN2Y1NTI4NDlfMTg2OA_337bc1c9-a40c-4b10-a567-8f7299b9c09a" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities classified as cash, cash equivalents and investments as of March&#160;31, 2022 and December&#160;31, 2021 are summarized below (in thousands):</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:43.914%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.659%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7eb8629a82dc4a618ece82cbcdfbe085_I20220331" decimals="-3" name="ardx:CashAndCashEquivalentsAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOmE0ZDEwNjY0NjlhYTQ1MTlhMTczMWQ1NGMyMTY4MTliL3RhYmxlcmFuZ2U6YTRkMTA2NjQ2OWFhNDUxOWExNzMxZDU0YzIxNjgxOWJfNC0xLTEtMS0yMzAxMw_0362df30-8202-4265-b69e-fa471e769107">7,555</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7eb8629a82dc4a618ece82cbcdfbe085_I20220331" decimals="-3" name="ardx:CashAndCashEquivalentsGrossUnrealizedGains" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOmE0ZDEwNjY0NjlhYTQ1MTlhMTczMWQ1NGMyMTY4MTliL3RhYmxlcmFuZ2U6YTRkMTA2NjQ2OWFhNDUxOWExNzMxZDU0YzIxNjgxOWJfNC0zLTEtMS0yMzAxMw_5ea1bf7e-544d-4cf6-82e7-258e2b667631">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7eb8629a82dc4a618ece82cbcdfbe085_I20220331" decimals="-3" name="ardx:CashAndCashEquivalentsGrossUnrealizedLosses" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOmE0ZDEwNjY0NjlhYTQ1MTlhMTczMWQ1NGMyMTY4MTliL3RhYmxlcmFuZ2U6YTRkMTA2NjQ2OWFhNDUxOWExNzMxZDU0YzIxNjgxOWJfNC01LTEtMS0yMzAxMw_d42cd7ae-383e-4659-88d1-38f38443da5a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7eb8629a82dc4a618ece82cbcdfbe085_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOmE0ZDEwNjY0NjlhYTQ1MTlhMTczMWQ1NGMyMTY4MTliL3RhYmxlcmFuZ2U6YTRkMTA2NjQ2OWFhNDUxOWExNzMxZDU0YzIxNjgxOWJfNC03LTEtMS0yMzAxMw_de538290-9024-4a85-a050-d0e5b73cdd0e">7,555</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05a2662add9440cc8c7d0f1dc736a702_I20220331" decimals="-3" name="ardx:CashAndCashEquivalentsAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOmE0ZDEwNjY0NjlhYTQ1MTlhMTczMWQ1NGMyMTY4MTliL3RhYmxlcmFuZ2U6YTRkMTA2NjQ2OWFhNDUxOWExNzMxZDU0YzIxNjgxOWJfNS0xLTEtMS0yMzAxMw_eb451de3-decf-4145-a593-1f5b1170687a">34,524</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05a2662add9440cc8c7d0f1dc736a702_I20220331" decimals="-3" name="ardx:CashAndCashEquivalentsGrossUnrealizedGains" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOmE0ZDEwNjY0NjlhYTQ1MTlhMTczMWQ1NGMyMTY4MTliL3RhYmxlcmFuZ2U6YTRkMTA2NjQ2OWFhNDUxOWExNzMxZDU0YzIxNjgxOWJfNS0zLTEtMS0yMzAxMw_e1384d20-0132-41dd-9941-fc8fc5a8a396">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05a2662add9440cc8c7d0f1dc736a702_I20220331" decimals="-3" name="ardx:CashAndCashEquivalentsGrossUnrealizedLosses" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOmE0ZDEwNjY0NjlhYTQ1MTlhMTczMWQ1NGMyMTY4MTliL3RhYmxlcmFuZ2U6YTRkMTA2NjQ2OWFhNDUxOWExNzMxZDU0YzIxNjgxOWJfNS01LTEtMS0yMzAxMw_bb0058ba-7d8b-4160-bd6b-5bcad53f03d9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05a2662add9440cc8c7d0f1dc736a702_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOmE0ZDEwNjY0NjlhYTQ1MTlhMTczMWQ1NGMyMTY4MTliL3RhYmxlcmFuZ2U6YTRkMTA2NjQ2OWFhNDUxOWExNzMxZDU0YzIxNjgxOWJfNS03LTEtMS0yMzAxMw_2c4034b2-62a5-4965-a5fd-cb98421f2e88">34,524</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596f9b1e440f4452b6cba1824137da8b_I20220331" decimals="-3" name="ardx:CashAndCashEquivalentsAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOmE0ZDEwNjY0NjlhYTQ1MTlhMTczMWQ1NGMyMTY4MTliL3RhYmxlcmFuZ2U6YTRkMTA2NjQ2OWFhNDUxOWExNzMxZDU0YzIxNjgxOWJfNi0xLTEtMS0yMzAxMw_4c80b313-33cd-4e64-889a-a1d601c1de89">4,999</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596f9b1e440f4452b6cba1824137da8b_I20220331" decimals="-3" name="ardx:CashAndCashEquivalentsGrossUnrealizedGains" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOmE0ZDEwNjY0NjlhYTQ1MTlhMTczMWQ1NGMyMTY4MTliL3RhYmxlcmFuZ2U6YTRkMTA2NjQ2OWFhNDUxOWExNzMxZDU0YzIxNjgxOWJfNi0zLTEtMS0yMzAxMw_d68aee39-392a-4047-89ff-d36e51b657e0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i596f9b1e440f4452b6cba1824137da8b_I20220331" decimals="-3" name="ardx:CashAndCashEquivalentsGrossUnrealizedLosses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOmE0ZDEwNjY0NjlhYTQ1MTlhMTczMWQ1NGMyMTY4MTliL3RhYmxlcmFuZ2U6YTRkMTA2NjQ2OWFhNDUxOWExNzMxZDU0YzIxNjgxOWJfNi01LTEtMS0yMzAxMw_9d07ea25-2961-4bc7-b4fb-050c978fea68">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596f9b1e440f4452b6cba1824137da8b_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOmE0ZDEwNjY0NjlhYTQ1MTlhMTczMWQ1NGMyMTY4MTliL3RhYmxlcmFuZ2U6YTRkMTA2NjQ2OWFhNDUxOWExNzMxZDU0YzIxNjgxOWJfNi03LTEtMS0yMzAxMw_1868a825-10f1-48ec-a4e5-26e62e07a8de">4,998</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331" decimals="-3" name="ardx:CashAndCashEquivalentsAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOmE0ZDEwNjY0NjlhYTQ1MTlhMTczMWQ1NGMyMTY4MTliL3RhYmxlcmFuZ2U6YTRkMTA2NjQ2OWFhNDUxOWExNzMxZDU0YzIxNjgxOWJfOC0xLTEtMS0yMzAxMw_d180c066-fd69-497f-84ae-b487169ef982">47,078</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331" decimals="-3" name="ardx:CashAndCashEquivalentsGrossUnrealizedGains" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOmE0ZDEwNjY0NjlhYTQ1MTlhMTczMWQ1NGMyMTY4MTliL3RhYmxlcmFuZ2U6YTRkMTA2NjQ2OWFhNDUxOWExNzMxZDU0YzIxNjgxOWJfOC0zLTEtMS0yMzAxMw_631231a6-a787-444a-bb2f-90b1600d0d5e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331" decimals="-3" name="ardx:CashAndCashEquivalentsGrossUnrealizedLosses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOmE0ZDEwNjY0NjlhYTQ1MTlhMTczMWQ1NGMyMTY4MTliL3RhYmxlcmFuZ2U6YTRkMTA2NjQ2OWFhNDUxOWExNzMxZDU0YzIxNjgxOWJfOC01LTEtMS0yMzAxMw_85331913-7230-42bb-923e-284757cc6310">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOmE0ZDEwNjY0NjlhYTQ1MTlhMTczMWQ1NGMyMTY4MTliL3RhYmxlcmFuZ2U6YTRkMTA2NjQ2OWFhNDUxOWExNzMxZDU0YzIxNjgxOWJfOC03LTEtMS0yMzAxMw_4c2703a4-a3d4-4132-aaeb-0ed65840ed4e">47,077</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7673f1405fd24051b58473f5a806ecb9_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOmE0ZDEwNjY0NjlhYTQ1MTlhMTczMWQ1NGMyMTY4MTliL3RhYmxlcmFuZ2U6YTRkMTA2NjQ2OWFhNDUxOWExNzMxZDU0YzIxNjgxOWJfMTAtMS0xLTEtMjMwMTM_4661f34a-9aa2-4557-a50a-81dec709a74f">28,409</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7673f1405fd24051b58473f5a806ecb9_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOmE0ZDEwNjY0NjlhYTQ1MTlhMTczMWQ1NGMyMTY4MTliL3RhYmxlcmFuZ2U6YTRkMTA2NjQ2OWFhNDUxOWExNzMxZDU0YzIxNjgxOWJfMTAtMy0xLTEtMjMwMTM_011bc0ff-85a9-403d-a1ee-21b143ad76e5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7673f1405fd24051b58473f5a806ecb9_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOmE0ZDEwNjY0NjlhYTQ1MTlhMTczMWQ1NGMyMTY4MTliL3RhYmxlcmFuZ2U6YTRkMTA2NjQ2OWFhNDUxOWExNzMxZDU0YzIxNjgxOWJfMTAtNS0xLTEtMjMwMTM_d3c6cf3b-2c6a-407a-89ea-137721be3e7b">52</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7673f1405fd24051b58473f5a806ecb9_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOmE0ZDEwNjY0NjlhYTQ1MTlhMTczMWQ1NGMyMTY4MTliL3RhYmxlcmFuZ2U6YTRkMTA2NjQ2OWFhNDUxOWExNzMxZDU0YzIxNjgxOWJfMTAtNy0xLTEtMjMwMTM_c4338807-da01-4dda-a076-e51fabff4a03">28,357</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored agency bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea208acf5bf04c3b9d76527a7e0ebf16_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOmE0ZDEwNjY0NjlhYTQ1MTlhMTczMWQ1NGMyMTY4MTliL3RhYmxlcmFuZ2U6YTRkMTA2NjQ2OWFhNDUxOWExNzMxZDU0YzIxNjgxOWJfMTEtMS0xLTEtMjg5NTk_d5e0ebae-f64a-43aa-bba8-86ec8b2c7218">10,777</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea208acf5bf04c3b9d76527a7e0ebf16_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOmE0ZDEwNjY0NjlhYTQ1MTlhMTczMWQ1NGMyMTY4MTliL3RhYmxlcmFuZ2U6YTRkMTA2NjQ2OWFhNDUxOWExNzMxZDU0YzIxNjgxOWJfMTEtMy0xLTEtMjg5NTk_f32b3d30-6002-46f5-b97c-6fc597f2a083">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea208acf5bf04c3b9d76527a7e0ebf16_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOmE0ZDEwNjY0NjlhYTQ1MTlhMTczMWQ1NGMyMTY4MTliL3RhYmxlcmFuZ2U6YTRkMTA2NjQ2OWFhNDUxOWExNzMxZDU0YzIxNjgxOWJfMTEtNS0xLTEtMjg5NTk_7ad554e5-0812-48ed-a2c3-c41f9bd18b42">22</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea208acf5bf04c3b9d76527a7e0ebf16_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOmE0ZDEwNjY0NjlhYTQ1MTlhMTczMWQ1NGMyMTY4MTliL3RhYmxlcmFuZ2U6YTRkMTA2NjQ2OWFhNDUxOWExNzMxZDU0YzIxNjgxOWJfMTEtNy0xLTEtMjg5NTk_5fe6e0db-b03e-4085-af9b-c71d3b5bf838">10,755</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37581a46b73b46d5b858164659fbef62_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOmE0ZDEwNjY0NjlhYTQ1MTlhMTczMWQ1NGMyMTY4MTliL3RhYmxlcmFuZ2U6YTRkMTA2NjQ2OWFhNDUxOWExNzMxZDU0YzIxNjgxOWJfMTEtMS0xLTEtMjMwMTM_5ecb02cf-e143-4122-83f0-cf6e612b9c3e">2,521</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37581a46b73b46d5b858164659fbef62_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOmE0ZDEwNjY0NjlhYTQ1MTlhMTczMWQ1NGMyMTY4MTliL3RhYmxlcmFuZ2U6YTRkMTA2NjQ2OWFhNDUxOWExNzMxZDU0YzIxNjgxOWJfMTEtMy0xLTEtMjMwMTM_a70589d7-8b44-46c2-aa31-6e5ce9ddcac9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i37581a46b73b46d5b858164659fbef62_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOmE0ZDEwNjY0NjlhYTQ1MTlhMTczMWQ1NGMyMTY4MTliL3RhYmxlcmFuZ2U6YTRkMTA2NjQ2OWFhNDUxOWExNzMxZDU0YzIxNjgxOWJfMTEtNS0xLTEtMjMwMTM_303f4df8-9988-41b6-bd18-c7df73dbddda">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37581a46b73b46d5b858164659fbef62_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOmE0ZDEwNjY0NjlhYTQ1MTlhMTczMWQ1NGMyMTY4MTliL3RhYmxlcmFuZ2U6YTRkMTA2NjQ2OWFhNDUxOWExNzMxZDU0YzIxNjgxOWJfMTEtNy0xLTEtMjMwMTM_bce4cfcf-86fe-4214-8a06-a96d2d89ae70">2,511</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19273e8da1e4462a88cdc93b1a044f85_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOmE0ZDEwNjY0NjlhYTQ1MTlhMTczMWQ1NGMyMTY4MTliL3RhYmxlcmFuZ2U6YTRkMTA2NjQ2OWFhNDUxOWExNzMxZDU0YzIxNjgxOWJfMTMtMS0xLTEtMjMwMTM_8f46179c-3e48-4da5-b5d4-a5c82c6080e1">1,007</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19273e8da1e4462a88cdc93b1a044f85_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOmE0ZDEwNjY0NjlhYTQ1MTlhMTczMWQ1NGMyMTY4MTliL3RhYmxlcmFuZ2U6YTRkMTA2NjQ2OWFhNDUxOWExNzMxZDU0YzIxNjgxOWJfMTMtMy0xLTEtMjMwMTM_3d088eed-2287-4f85-b89b-33ded70c6a08">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i19273e8da1e4462a88cdc93b1a044f85_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOmE0ZDEwNjY0NjlhYTQ1MTlhMTczMWQ1NGMyMTY4MTliL3RhYmxlcmFuZ2U6YTRkMTA2NjQ2OWFhNDUxOWExNzMxZDU0YzIxNjgxOWJfMTMtNS0xLTEtMjMwMTM_1741ccbe-b143-4bc7-b560-27b95375fbb8">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19273e8da1e4462a88cdc93b1a044f85_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOmE0ZDEwNjY0NjlhYTQ1MTlhMTczMWQ1NGMyMTY4MTliL3RhYmxlcmFuZ2U6YTRkMTA2NjQ2OWFhNDUxOWExNzMxZDU0YzIxNjgxOWJfMTMtNy0xLTEtMjMwMTM_119ad4a1-e17b-4ca6-b25f-500aca3828c4">1,004</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOmE0ZDEwNjY0NjlhYTQ1MTlhMTczMWQ1NGMyMTY4MTliL3RhYmxlcmFuZ2U6YTRkMTA2NjQ2OWFhNDUxOWExNzMxZDU0YzIxNjgxOWJfMTQtMS0xLTEtMjMwMTM_b389edaa-fc06-465d-a91e-86e0c5b4eb46">42,714</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOmE0ZDEwNjY0NjlhYTQ1MTlhMTczMWQ1NGMyMTY4MTliL3RhYmxlcmFuZ2U6YTRkMTA2NjQ2OWFhNDUxOWExNzMxZDU0YzIxNjgxOWJfMTQtMy0xLTEtMjMwMTM_aac22094-d71c-46ef-abcd-7a17ca898a16">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOmE0ZDEwNjY0NjlhYTQ1MTlhMTczMWQ1NGMyMTY4MTliL3RhYmxlcmFuZ2U6YTRkMTA2NjQ2OWFhNDUxOWExNzMxZDU0YzIxNjgxOWJfMTQtNS0xLTEtMjMwMTM_c50bec36-c344-456f-be5e-9ca8d09eb44d">87</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOmE0ZDEwNjY0NjlhYTQ1MTlhMTczMWQ1NGMyMTY4MTliL3RhYmxlcmFuZ2U6YTRkMTA2NjQ2OWFhNDUxOWExNzMxZDU0YzIxNjgxOWJfMTQtNy0xLTEtMjMwMTM_b23ad5a5-dccb-4f31-8997-e1db4d607208">42,627</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331" decimals="-3" name="ardx:InvestmentsAndCashAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOmE0ZDEwNjY0NjlhYTQ1MTlhMTczMWQ1NGMyMTY4MTliL3RhYmxlcmFuZ2U6YTRkMTA2NjQ2OWFhNDUxOWExNzMxZDU0YzIxNjgxOWJfMTYtMS0xLTEtMjMwMTM_9d15faf1-c650-4c2e-8bab-b02e3112693a">89,792</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331" decimals="-3" name="ardx:CashCashEquivalentsAndInvestmentsGrossUnrealizedGains" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOmE0ZDEwNjY0NjlhYTQ1MTlhMTczMWQ1NGMyMTY4MTliL3RhYmxlcmFuZ2U6YTRkMTA2NjQ2OWFhNDUxOWExNzMxZDU0YzIxNjgxOWJfMTYtMy0xLTEtMjMwMTM_4f47742b-d5c1-493a-910c-d1dce366bf48">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331" decimals="-3" name="ardx:CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOmE0ZDEwNjY0NjlhYTQ1MTlhMTczMWQ1NGMyMTY4MTliL3RhYmxlcmFuZ2U6YTRkMTA2NjQ2OWFhNDUxOWExNzMxZDU0YzIxNjgxOWJfMTYtNS0xLTEtMjMwMTM_1011f5e1-851d-4932-8541-c7893b61c658">88</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331" decimals="-3" name="us-gaap:InvestmentsAndCash" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOmE0ZDEwNjY0NjlhYTQ1MTlhMTczMWQ1NGMyMTY4MTliL3RhYmxlcmFuZ2U6YTRkMTA2NjQ2OWFhNDUxOWExNzMxZDU0YzIxNjgxOWJfMTYtNy0xLTEtMjMwMTM_2046a5dc-5063-44cb-a087-0dd6467a8c86">89,704</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1757ee4e90cc49c3ae9d0a3ce3f93f66_I20211231" decimals="-3" name="ardx:CashAndCashEquivalentsAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOjk3MTg3MDhkMjU2YzQ3YzQ4ZDU3MTk1MWVlN2ExOGI5L3RhYmxlcmFuZ2U6OTcxODcwOGQyNTZjNDdjNDhkNTcxOTUxZWU3YTE4YjlfNC0xLTEtMS0yMzAxMw_c1a80c6f-f4f8-4dd1-8342-9d1a530eb672">1,253</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1757ee4e90cc49c3ae9d0a3ce3f93f66_I20211231" decimals="-3" name="ardx:CashAndCashEquivalentsGrossUnrealizedGains" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOjk3MTg3MDhkMjU2YzQ3YzQ4ZDU3MTk1MWVlN2ExOGI5L3RhYmxlcmFuZ2U6OTcxODcwOGQyNTZjNDdjNDhkNTcxOTUxZWU3YTE4YjlfNC0zLTEtMS0yMzAxMw_2569c6bd-9a5a-4011-8b73-864b91e26793">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1757ee4e90cc49c3ae9d0a3ce3f93f66_I20211231" decimals="-3" name="ardx:CashAndCashEquivalentsGrossUnrealizedLosses" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOjk3MTg3MDhkMjU2YzQ3YzQ4ZDU3MTk1MWVlN2ExOGI5L3RhYmxlcmFuZ2U6OTcxODcwOGQyNTZjNDdjNDhkNTcxOTUxZWU3YTE4YjlfNC01LTEtMS0yMzAxMw_40c07b81-b7d9-47e0-a0b7-5c1082c59b02">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1757ee4e90cc49c3ae9d0a3ce3f93f66_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOjk3MTg3MDhkMjU2YzQ3YzQ4ZDU3MTk1MWVlN2ExOGI5L3RhYmxlcmFuZ2U6OTcxODcwOGQyNTZjNDdjNDhkNTcxOTUxZWU3YTE4YjlfNC03LTEtMS0yMzAxMw_d4e54a2f-cbb0-4ae8-ad83-366affcec7b1">1,253</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib27f65921b34451f840e9bfaa2858274_I20211231" decimals="-3" name="ardx:CashAndCashEquivalentsAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOjk3MTg3MDhkMjU2YzQ3YzQ4ZDU3MTk1MWVlN2ExOGI5L3RhYmxlcmFuZ2U6OTcxODcwOGQyNTZjNDdjNDhkNTcxOTUxZWU3YTE4YjlfNS0xLTEtMS0yMzAxMw_0edeb73a-9ab9-4c58-b620-e781fdc31bb9">71,175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib27f65921b34451f840e9bfaa2858274_I20211231" decimals="-3" name="ardx:CashAndCashEquivalentsGrossUnrealizedGains" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOjk3MTg3MDhkMjU2YzQ3YzQ4ZDU3MTk1MWVlN2ExOGI5L3RhYmxlcmFuZ2U6OTcxODcwOGQyNTZjNDdjNDhkNTcxOTUxZWU3YTE4YjlfNS0zLTEtMS0yMzAxMw_d6e7a08b-9d6a-4d28-a3c7-03bccf78c4c8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib27f65921b34451f840e9bfaa2858274_I20211231" decimals="-3" name="ardx:CashAndCashEquivalentsGrossUnrealizedLosses" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOjk3MTg3MDhkMjU2YzQ3YzQ4ZDU3MTk1MWVlN2ExOGI5L3RhYmxlcmFuZ2U6OTcxODcwOGQyNTZjNDdjNDhkNTcxOTUxZWU3YTE4YjlfNS01LTEtMS0yMzAxMw_043810b3-9904-45b2-b1de-b711cd42b19e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib27f65921b34451f840e9bfaa2858274_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOjk3MTg3MDhkMjU2YzQ3YzQ4ZDU3MTk1MWVlN2ExOGI5L3RhYmxlcmFuZ2U6OTcxODcwOGQyNTZjNDdjNDhkNTcxOTUxZWU3YTE4YjlfNS03LTEtMS0yMzAxMw_a7825278-cfbe-4650-b297-eda423db20b3">71,175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231" decimals="-3" name="ardx:CashAndCashEquivalentsAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOjk3MTg3MDhkMjU2YzQ3YzQ4ZDU3MTk1MWVlN2ExOGI5L3RhYmxlcmFuZ2U6OTcxODcwOGQyNTZjNDdjNDhkNTcxOTUxZWU3YTE4YjlfOC0xLTEtMS0yMzAxMw_b83bd843-fbfb-41bf-88d8-e170672e82cd">72,428</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231" decimals="-3" name="ardx:CashAndCashEquivalentsGrossUnrealizedGains" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOjk3MTg3MDhkMjU2YzQ3YzQ4ZDU3MTk1MWVlN2ExOGI5L3RhYmxlcmFuZ2U6OTcxODcwOGQyNTZjNDdjNDhkNTcxOTUxZWU3YTE4YjlfOC0zLTEtMS0yMzAxMw_3b438e53-29ac-4f3b-94df-3a6fb1542d1b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231" decimals="-3" name="ardx:CashAndCashEquivalentsGrossUnrealizedLosses" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOjk3MTg3MDhkMjU2YzQ3YzQ4ZDU3MTk1MWVlN2ExOGI5L3RhYmxlcmFuZ2U6OTcxODcwOGQyNTZjNDdjNDhkNTcxOTUxZWU3YTE4YjlfOC01LTEtMS0yMzAxMw_903f7207-d6e8-4b71-96e0-5a66a49a6236">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOjk3MTg3MDhkMjU2YzQ3YzQ4ZDU3MTk1MWVlN2ExOGI5L3RhYmxlcmFuZ2U6OTcxODcwOGQyNTZjNDdjNDhkNTcxOTUxZWU3YTE4YjlfOC03LTEtMS0yMzAxMw_08da255d-9a4f-4282-b687-15c49f495da1">72,428</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib232d5bccde74c2c832a58c5854c8659_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOjk3MTg3MDhkMjU2YzQ3YzQ4ZDU3MTk1MWVlN2ExOGI5L3RhYmxlcmFuZ2U6OTcxODcwOGQyNTZjNDdjNDhkNTcxOTUxZWU3YTE4YjlfMTAtMS0xLTEtMjMwMTM_bddaed81-af48-4da3-8118-1bf2b0b23c3f">31,936</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib232d5bccde74c2c832a58c5854c8659_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOjk3MTg3MDhkMjU2YzQ3YzQ4ZDU3MTk1MWVlN2ExOGI5L3RhYmxlcmFuZ2U6OTcxODcwOGQyNTZjNDdjNDhkNTcxOTUxZWU3YTE4YjlfMTAtMy0xLTEtMjMwMTM_39852ccd-5bab-4341-81d1-bd29f3484f7d">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib232d5bccde74c2c832a58c5854c8659_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOjk3MTg3MDhkMjU2YzQ3YzQ4ZDU3MTk1MWVlN2ExOGI5L3RhYmxlcmFuZ2U6OTcxODcwOGQyNTZjNDdjNDhkNTcxOTUxZWU3YTE4YjlfMTAtNS0xLTEtMjMwMTM_d0620fcb-82fb-4b73-ad03-55f8109dcc8d">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib232d5bccde74c2c832a58c5854c8659_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOjk3MTg3MDhkMjU2YzQ3YzQ4ZDU3MTk1MWVlN2ExOGI5L3RhYmxlcmFuZ2U6OTcxODcwOGQyNTZjNDdjNDhkNTcxOTUxZWU3YTE4YjlfMTAtNy0xLTEtMjMwMTM_f8ae0c6d-e8d6-4b1f-b510-39a8e93ca738">31,935</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f8c132fed8e489a94a6ec129ee5512e_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOjk3MTg3MDhkMjU2YzQ3YzQ4ZDU3MTk1MWVlN2ExOGI5L3RhYmxlcmFuZ2U6OTcxODcwOGQyNTZjNDdjNDhkNTcxOTUxZWU3YTE4YjlfMTEtMS0xLTEtMjMwMTM_da1ebeb5-470a-472c-be30-0961c275dc89">7,025</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f8c132fed8e489a94a6ec129ee5512e_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOjk3MTg3MDhkMjU2YzQ3YzQ4ZDU3MTk1MWVlN2ExOGI5L3RhYmxlcmFuZ2U6OTcxODcwOGQyNTZjNDdjNDhkNTcxOTUxZWU3YTE4YjlfMTEtMy0xLTEtMjMwMTM_05f3d6a2-028d-4e29-b840-98703fb1b6b3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5f8c132fed8e489a94a6ec129ee5512e_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOjk3MTg3MDhkMjU2YzQ3YzQ4ZDU3MTk1MWVlN2ExOGI5L3RhYmxlcmFuZ2U6OTcxODcwOGQyNTZjNDdjNDhkNTcxOTUxZWU3YTE4YjlfMTEtNS0xLTEtMjMwMTM_be4e8320-f1db-4a94-a665-babf69171293">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f8c132fed8e489a94a6ec129ee5512e_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOjk3MTg3MDhkMjU2YzQ3YzQ4ZDU3MTk1MWVlN2ExOGI5L3RhYmxlcmFuZ2U6OTcxODcwOGQyNTZjNDdjNDhkNTcxOTUxZWU3YTE4YjlfMTEtNy0xLTEtMjMwMTM_c97c60b5-ac85-496e-ba71-2139f9e0afe8">7,022</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae3a2fe36c17417ca407960547b30624_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOjk3MTg3MDhkMjU2YzQ3YzQ4ZDU3MTk1MWVlN2ExOGI5L3RhYmxlcmFuZ2U6OTcxODcwOGQyNTZjNDdjNDhkNTcxOTUxZWU3YTE4YjlfMTMtMS0xLTEtMjMwMTM_dca63c3e-a144-4e90-b559-bd9fbc8fe772">5,306</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae3a2fe36c17417ca407960547b30624_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOjk3MTg3MDhkMjU2YzQ3YzQ4ZDU3MTk1MWVlN2ExOGI5L3RhYmxlcmFuZ2U6OTcxODcwOGQyNTZjNDdjNDhkNTcxOTUxZWU3YTE4YjlfMTMtMy0xLTEtMjMwMTM_71f32bc9-a3e3-4a3f-b285-73a1032017cc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae3a2fe36c17417ca407960547b30624_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOjk3MTg3MDhkMjU2YzQ3YzQ4ZDU3MTk1MWVlN2ExOGI5L3RhYmxlcmFuZ2U6OTcxODcwOGQyNTZjNDdjNDhkNTcxOTUxZWU3YTE4YjlfMTMtNS0xLTEtMjMwMTM_8a502f15-0b62-4cb0-8d19-b397b0cfa18d">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae3a2fe36c17417ca407960547b30624_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOjk3MTg3MDhkMjU2YzQ3YzQ4ZDU3MTk1MWVlN2ExOGI5L3RhYmxlcmFuZ2U6OTcxODcwOGQyNTZjNDdjNDhkNTcxOTUxZWU3YTE4YjlfMTMtNy0xLTEtMjMwMTM_39c7dba9-a615-403f-a2a6-58115178dca6">5,304</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOjk3MTg3MDhkMjU2YzQ3YzQ4ZDU3MTk1MWVlN2ExOGI5L3RhYmxlcmFuZ2U6OTcxODcwOGQyNTZjNDdjNDhkNTcxOTUxZWU3YTE4YjlfMTQtMS0xLTEtMjMwMTM_e0e7dafb-8b3d-4c0c-8295-c92d63aae2f7">44,267</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOjk3MTg3MDhkMjU2YzQ3YzQ4ZDU3MTk1MWVlN2ExOGI5L3RhYmxlcmFuZ2U6OTcxODcwOGQyNTZjNDdjNDhkNTcxOTUxZWU3YTE4YjlfMTQtMy0xLTEtMjMwMTM_0a883b60-6be3-4b9c-bc31-1dd2a3520478">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOjk3MTg3MDhkMjU2YzQ3YzQ4ZDU3MTk1MWVlN2ExOGI5L3RhYmxlcmFuZ2U6OTcxODcwOGQyNTZjNDdjNDhkNTcxOTUxZWU3YTE4YjlfMTQtNS0xLTEtMjMwMTM_6089904f-1ec4-4945-8030-b3471f3d4a89">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOjk3MTg3MDhkMjU2YzQ3YzQ4ZDU3MTk1MWVlN2ExOGI5L3RhYmxlcmFuZ2U6OTcxODcwOGQyNTZjNDdjNDhkNTcxOTUxZWU3YTE4YjlfMTQtNy0xLTEtMjMwMTM_b64304e8-810f-48a4-b945-59695180a65c">44,261</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231" decimals="-3" name="ardx:InvestmentsAndCashAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOjk3MTg3MDhkMjU2YzQ3YzQ4ZDU3MTk1MWVlN2ExOGI5L3RhYmxlcmFuZ2U6OTcxODcwOGQyNTZjNDdjNDhkNTcxOTUxZWU3YTE4YjlfMTctMS0xLTEtMjMwMTM_abd80f07-d907-4af6-b6a6-773749b7eafb">116,695</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231" decimals="-3" name="ardx:CashCashEquivalentsAndInvestmentsGrossUnrealizedGains" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOjk3MTg3MDhkMjU2YzQ3YzQ4ZDU3MTk1MWVlN2ExOGI5L3RhYmxlcmFuZ2U6OTcxODcwOGQyNTZjNDdjNDhkNTcxOTUxZWU3YTE4YjlfMTctMy0xLTEtMjMwMTM_c31065ba-4da3-4b9e-88ba-e9e47c1c4486">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231" decimals="-3" name="ardx:CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOjk3MTg3MDhkMjU2YzQ3YzQ4ZDU3MTk1MWVlN2ExOGI5L3RhYmxlcmFuZ2U6OTcxODcwOGQyNTZjNDdjNDhkNTcxOTUxZWU3YTE4YjlfMTctNS0xLTEtMjMwMTM_0e58b6ae-6a0b-4154-a283-6cd2d01be964">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231" decimals="-3" name="us-gaap:InvestmentsAndCash" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOjk3MTg3MDhkMjU2YzQ3YzQ4ZDU3MTk1MWVlN2ExOGI5L3RhYmxlcmFuZ2U6OTcxODcwOGQyNTZjNDdjNDhkNTcxOTUxZWU3YTE4YjlfMTctNy0xLTEtMjMwMTM_8c3319ad-57f6-431e-846b-e148f0543579">116,689</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents consist of money market funds and other debt securities with original maturities of three months or less at the time of purchase, and the carrying amount is a reasonable approximation of fair value. We invest our cash in high quality securities of financial and commercial institutions. These securities are carried at fair value, which is based on readily available market information, with unrealized gains and losses included in accumulated other comprehensive income (loss) within stockholders&#8217; equity on our balance sheets. We use the specific identification method to determine the amount of realized gains or losses on sales of marketable securities. Realized gains or losses have been insignificant and are included in other income (expense), net, in the statement of operations and comprehensive loss.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All short-term available-for-sale securities held as of March&#160;31, 2022 had contractual maturities of less than <ix:nonNumeric contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" name="ardx:AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RleHRyZWdpb246MWU2ZGMzNzU5MWE3NDQ5M2I5MmI4ZTJmN2Y1NTI4NDlfMTA5OTUxMTYzNjM5NQ_5fb2996b-591d-4454-bb74-7f9a013eb789">one year</ix:nonNumeric>. Our available-for-sale securities are subject to a periodic impairment review. We consider a debt security to be impaired when its fair value is less than its carrying cost, in which case we would further review the investment to determine whether it is other-than-temporarily impaired. When we evaluate an investment for other-than-temporary impairment, we review factors such as the length of time and extent to which fair value has been below cost basis, the financial condition of the issuer and any changes thereto, intent to sell, and whether it is more likely than not we will be required to sell the investment before the recovery of its cost basis. If an investment is other-than-temporarily impaired, we write it down through the statement of operations and comprehensive loss to its fair value and establishes that value as a new cost basis for the investment. We did <ix:nonFraction unitRef="usd" contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" decimals="INF" name="us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RleHRyZWdpb246MWU2ZGMzNzU5MWE3NDQ5M2I5MmI4ZTJmN2Y1NTI4NDlfMzI5ODUzNDg5MjExMQ_2ca1f2ac-f75b-4602-8910-c4df4e63d18e"><ix:nonFraction unitRef="usd" contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331" decimals="INF" name="us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RleHRyZWdpb246MWU2ZGMzNzU5MWE3NDQ5M2I5MmI4ZTJmN2Y1NTI4NDlfMzI5ODUzNDg5MjExMQ_5f672374-1f5c-4a07-9ca9-93af1637e7a8">no</ix:nonFraction></ix:nonFraction>t identify any of our available-for-sale securities as other-than-temporarily impaired in any of the periods presented. As of March&#160;31, 2022 <ix:nonFraction unitRef="investment" contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RleHRyZWdpb246MWU2ZGMzNzU5MWE3NDQ5M2I5MmI4ZTJmN2Y1NTI4NDlfMTA5OTUxMTYzNjU0MQ_3be823c1-371f-4cdc-acb1-197527899197"><ix:nonFraction unitRef="investment" contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RleHRyZWdpb246MWU2ZGMzNzU5MWE3NDQ5M2I5MmI4ZTJmN2Y1NTI4NDlfMTA5OTUxMTYzNjU0MQ_5a0446b8-11f0-4cc3-b7c1-cce4a69778b3"><ix:nonFraction unitRef="investment" contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RleHRyZWdpb246MWU2ZGMzNzU5MWE3NDQ5M2I5MmI4ZTJmN2Y1NTI4NDlfMTA5OTUxMTYzNjU0MQ_6c4c4b22-a397-4259-8e2e-408253fd3299"><ix:nonFraction unitRef="investment" contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RleHRyZWdpb246MWU2ZGMzNzU5MWE3NDQ5M2I5MmI4ZTJmN2Y1NTI4NDlfMTA5OTUxMTYzNjU0MQ_d317f8aa-5f4b-4f5b-afb0-6c16bdf1a6f6">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i711b1a39e0634b15bb7a70766327247a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i7a3f481830444b64a6e7298232baf654">investment was in a continuous unrealized loss position for more than one year and we believe that it is more likely than not that the investments will be held until maturity or a forecasted recovery of fair value.</ix:continuation></span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i711b1a39e0634b15bb7a70766327247a_37"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 3. <ix:nonNumeric contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RleHRyZWdpb246ZjNkOGM4MTNmMTI2NDQ1NGFhY2Y0NjczMDI0NWRkYTJfMTk5Mw_6ecdfc8d-8207-4843-815c-a7a807d80279" continuedAt="i84eee317eb8649d5aeabfe2f449da20f" escape="true">FAIR VALUE MEASUREMENTS</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i84eee317eb8649d5aeabfe2f449da20f" continuedAt="i00bfcd01fce345e5be5a2bae438dfe1f"><ix:nonNumeric contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RleHRyZWdpb246ZjNkOGM4MTNmMTI2NDQ1NGFhY2Y0NjczMDI0NWRkYTJfMTk5NA_1ebf6ef4-fafe-4547-8a08-bb8311400e4c" escape="true"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The three-level hierarchy for the inputs to valuation techniques is briefly summarized as follows:</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.163%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 1 &#8211;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuations are based on quoted prices in active markets for identical assets or liabilities and readily accessible by us at the reporting date.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2 &#8211;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuations based on inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 3 &#8211;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuations based on unobservable inputs for which there is little or no market data, which require us to develop our own assumptions.</span></td></tr></table></div></ix:nonNumeric><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><ix:nonNumeric contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RleHRyZWdpb246ZjNkOGM4MTNmMTI2NDQ1NGFhY2Y0NjczMDI0NWRkYTJfMTk5NQ_e92af1df-2dd9-4cf8-afbf-3dcb4f4804f4" escape="true"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the fair value of our financial assets and liabilities that are measured or disclosed on a recurring basis by level within the fair value hierarchy (in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total<br/>Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7116fb603e844e7b66ea135c246d400_I20220331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOjE2MjZjZmRjNGNiNDQzOTJhMTAyNjc2NTQzZWExN2JkL3RhYmxlcmFuZ2U6MTYyNmNmZGM0Y2I0NDM5MmExMDI2NzY1NDNlYTE3YmRfMy0xLTEtMS0yMzAxMw_aa5475d2-9068-46e7-8bb3-6c39a8d58716">34,524</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f95faaaa8ba40ef81fabfd9af749d5a_I20220331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOjE2MjZjZmRjNGNiNDQzOTJhMTAyNjc2NTQzZWExN2JkL3RhYmxlcmFuZ2U6MTYyNmNmZGM0Y2I0NDM5MmExMDI2NzY1NDNlYTE3YmRfMy0zLTEtMS0yMzAxMw_e5af89f8-d82e-45d7-b539-6313f094536e">34,524</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifffac340b48d4569a291b906003daa40_I20220331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOjE2MjZjZmRjNGNiNDQzOTJhMTAyNjc2NTQzZWExN2JkL3RhYmxlcmFuZ2U6MTYyNmNmZGM0Y2I0NDM5MmExMDI2NzY1NDNlYTE3YmRfMy01LTEtMS0yMzAxMw_58f9280e-3d4a-4689-b0b2-9f7930420e13">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3c8925c35b44d6d9fbe11c422368576_I20220331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOjE2MjZjZmRjNGNiNDQzOTJhMTAyNjc2NTQzZWExN2JkL3RhYmxlcmFuZ2U6MTYyNmNmZGM0Y2I0NDM5MmExMDI2NzY1NDNlYTE3YmRfMy03LTEtMS0yMzAxMw_89276a86-dd00-4fe1-af7b-617542510a44">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie320d5dea5f84c1a997114a2a44304ab_I20220331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOjE2MjZjZmRjNGNiNDQzOTJhMTAyNjc2NTQzZWExN2JkL3RhYmxlcmFuZ2U6MTYyNmNmZGM0Y2I0NDM5MmExMDI2NzY1NDNlYTE3YmRfNC0xLTEtMS0yMzAxMw_49d8c9c4-0e77-4042-96a9-36186e33f6c4">33,355</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic12ce3ad23f94a40843d57bbafc1b93b_I20220331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOjE2MjZjZmRjNGNiNDQzOTJhMTAyNjc2NTQzZWExN2JkL3RhYmxlcmFuZ2U6MTYyNmNmZGM0Y2I0NDM5MmExMDI2NzY1NDNlYTE3YmRfNC0zLTEtMS0yMzAxMw_23eeac1e-8128-4915-bf49-64c9f8f7f068">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib64b89a6dbb241f9ac74255f0f2faddd_I20220331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOjE2MjZjZmRjNGNiNDQzOTJhMTAyNjc2NTQzZWExN2JkL3RhYmxlcmFuZ2U6MTYyNmNmZGM0Y2I0NDM5MmExMDI2NzY1NDNlYTE3YmRfNC01LTEtMS0yMzAxMw_bf82113e-2555-47bd-a678-486065b86c11">33,355</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20743f7a35cf46598f5e61aadaaaf959_I20220331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOjE2MjZjZmRjNGNiNDQzOTJhMTAyNjc2NTQzZWExN2JkL3RhYmxlcmFuZ2U6MTYyNmNmZGM0Y2I0NDM5MmExMDI2NzY1NDNlYTE3YmRfNC03LTEtMS0yMzAxMw_53d904f2-fc09-478f-9df8-e8bfd60cd753">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored agency bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7282cda81b5e403d9d6a82b54ca9e220_I20220331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOjE2MjZjZmRjNGNiNDQzOTJhMTAyNjc2NTQzZWExN2JkL3RhYmxlcmFuZ2U6MTYyNmNmZGM0Y2I0NDM5MmExMDI2NzY1NDNlYTE3YmRfNS0xLTEtMS0yOTA1MQ_6d3d8679-20b7-4ca4-bf79-9552197d30d2">10,755</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbe8bcf473664c3cbd7a8d406e6f4b25_I20220331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOjE2MjZjZmRjNGNiNDQzOTJhMTAyNjc2NTQzZWExN2JkL3RhYmxlcmFuZ2U6MTYyNmNmZGM0Y2I0NDM5MmExMDI2NzY1NDNlYTE3YmRfNS0zLTEtMS0yOTA1MQ_cc1ca8a8-32a4-4a1c-a44a-3a89edd22a92">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieff5d13f74bb46f19e0bf993fbdb4e1b_I20220331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOjE2MjZjZmRjNGNiNDQzOTJhMTAyNjc2NTQzZWExN2JkL3RhYmxlcmFuZ2U6MTYyNmNmZGM0Y2I0NDM5MmExMDI2NzY1NDNlYTE3YmRfNS01LTEtMS0yOTA1MQ_d049e021-64b6-47f8-9faf-a21961495238">10,755</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c8530d2f63d4dcd99a0d2685f08f090_I20220331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOjE2MjZjZmRjNGNiNDQzOTJhMTAyNjc2NTQzZWExN2JkL3RhYmxlcmFuZ2U6MTYyNmNmZGM0Y2I0NDM5MmExMDI2NzY1NDNlYTE3YmRfNS03LTEtMS0yOTA1MQ_cb5e47f2-63e0-4a81-8bb7-be275cfee3c1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22961d74779a41578f711e2cbdab8cc8_I20220331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOjE2MjZjZmRjNGNiNDQzOTJhMTAyNjc2NTQzZWExN2JkL3RhYmxlcmFuZ2U6MTYyNmNmZGM0Y2I0NDM5MmExMDI2NzY1NDNlYTE3YmRfNS0xLTEtMS0yMzAxMw_6668927b-7e68-409f-b110-90bd3741eec1">2,511</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i346bb756dc874f18b4e7ecc3b1fd18fd_I20220331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOjE2MjZjZmRjNGNiNDQzOTJhMTAyNjc2NTQzZWExN2JkL3RhYmxlcmFuZ2U6MTYyNmNmZGM0Y2I0NDM5MmExMDI2NzY1NDNlYTE3YmRfNS0zLTEtMS0yMzAxMw_a5defca7-d6ae-434e-9682-c683a7a1f2f2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45e9678a2bb9475883b569adf411868a_I20220331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOjE2MjZjZmRjNGNiNDQzOTJhMTAyNjc2NTQzZWExN2JkL3RhYmxlcmFuZ2U6MTYyNmNmZGM0Y2I0NDM5MmExMDI2NzY1NDNlYTE3YmRfNS01LTEtMS0yMzAxMw_d1301130-7bd6-48a8-aa13-6cc492721f09">2,511</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i057b3b5e23d74f1b93392611784416da_I20220331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOjE2MjZjZmRjNGNiNDQzOTJhMTAyNjc2NTQzZWExN2JkL3RhYmxlcmFuZ2U6MTYyNmNmZGM0Y2I0NDM5MmExMDI2NzY1NDNlYTE3YmRfNS03LTEtMS0yMzAxMw_712d028e-1bda-4400-9e5f-4c234ee19211">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec212359212b4b3686fe182249f00160_I20220331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOjE2MjZjZmRjNGNiNDQzOTJhMTAyNjc2NTQzZWExN2JkL3RhYmxlcmFuZ2U6MTYyNmNmZGM0Y2I0NDM5MmExMDI2NzY1NDNlYTE3YmRfNy0xLTEtMS0yMzAxMw_11a1d4c2-0c46-4b21-8dad-96a3cc396450">1,004</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c358ffd9da447c0ae8ba16d667ddb3d_I20220331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOjE2MjZjZmRjNGNiNDQzOTJhMTAyNjc2NTQzZWExN2JkL3RhYmxlcmFuZ2U6MTYyNmNmZGM0Y2I0NDM5MmExMDI2NzY1NDNlYTE3YmRfNy0zLTEtMS0yMzAxMw_3bdc61f3-ffab-423f-9d21-c386c58ee18d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa5d06c90bd0488e864737436b77eb4c_I20220331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOjE2MjZjZmRjNGNiNDQzOTJhMTAyNjc2NTQzZWExN2JkL3RhYmxlcmFuZ2U6MTYyNmNmZGM0Y2I0NDM5MmExMDI2NzY1NDNlYTE3YmRfNy01LTEtMS0yMzAxMw_41a2b159-924e-45eb-a6ac-f36203f1a2ab">1,004</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b1a0008a10b4495b001946a2dbbebcf_I20220331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOjE2MjZjZmRjNGNiNDQzOTJhMTAyNjc2NTQzZWExN2JkL3RhYmxlcmFuZ2U6MTYyNmNmZGM0Y2I0NDM5MmExMDI2NzY1NDNlYTE3YmRfNy03LTEtMS0yMzAxMw_711cde2a-2baf-4a02-9f21-e85cb1a0e5de">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia66c3497d92f4f87983a8808d4c22279_I20220331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOjE2MjZjZmRjNGNiNDQzOTJhMTAyNjc2NTQzZWExN2JkL3RhYmxlcmFuZ2U6MTYyNmNmZGM0Y2I0NDM5MmExMDI2NzY1NDNlYTE3YmRfOS0xLTEtMS0yMzAxMw_5766cb31-24a6-4cf0-b8a1-9757bfdea482">82,149</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idccb2dc5b13a4488878f9a05af20f66a_I20220331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOjE2MjZjZmRjNGNiNDQzOTJhMTAyNjc2NTQzZWExN2JkL3RhYmxlcmFuZ2U6MTYyNmNmZGM0Y2I0NDM5MmExMDI2NzY1NDNlYTE3YmRfOS0zLTEtMS0yMzAxMw_1b3e11bd-018c-40d7-9bb8-55b345171e11">34,524</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8a67586059d49f9810370c50eaa57c0_I20220331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOjE2MjZjZmRjNGNiNDQzOTJhMTAyNjc2NTQzZWExN2JkL3RhYmxlcmFuZ2U6MTYyNmNmZGM0Y2I0NDM5MmExMDI2NzY1NDNlYTE3YmRfOS01LTEtMS0yMzAxMw_88487dcb-fb51-4566-ac3e-7e535df40b3c">47,625</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c1a6f674cd541978439c2f0f7d4fb9a_I20220331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOjE2MjZjZmRjNGNiNDQzOTJhMTAyNjc2NTQzZWExN2JkL3RhYmxlcmFuZ2U6MTYyNmNmZGM0Y2I0NDM5MmExMDI2NzY1NDNlYTE3YmRfOS03LTEtMS0yMzAxMw_c77827a9-5f16-434a-8672-279fa596b667">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 12.25pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liability for exit fees</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0e3ba1f3d18466d8724f70ecdc208fa_I20220331" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOjE2MjZjZmRjNGNiNDQzOTJhMTAyNjc2NTQzZWExN2JkL3RhYmxlcmFuZ2U6MTYyNmNmZGM0Y2I0NDM5MmExMDI2NzY1NDNlYTE3YmRfMTItMS0xLTEtMjMwMTM_502623d3-fec7-4b15-a907-fab90cccfc03">1,088</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd9cbd3639304bd294cd77b069e2903b_I20220331" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOjE2MjZjZmRjNGNiNDQzOTJhMTAyNjc2NTQzZWExN2JkL3RhYmxlcmFuZ2U6MTYyNmNmZGM0Y2I0NDM5MmExMDI2NzY1NDNlYTE3YmRfMTItMy0xLTEtMjMwMTM_6715455d-1744-490a-9bb9-dbdc7542c106">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie12d13976cc7450da7913cd451cc1f1d_I20220331" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOjE2MjZjZmRjNGNiNDQzOTJhMTAyNjc2NTQzZWExN2JkL3RhYmxlcmFuZ2U6MTYyNmNmZGM0Y2I0NDM5MmExMDI2NzY1NDNlYTE3YmRfMTItNS0xLTEtMjMwMTM_401abf1b-0c37-46d5-8645-ec65f8fbf73c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7da228130c340edbbb9bf247a589756_I20220331" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOjE2MjZjZmRjNGNiNDQzOTJhMTAyNjc2NTQzZWExN2JkL3RhYmxlcmFuZ2U6MTYyNmNmZGM0Y2I0NDM5MmExMDI2NzY1NDNlYTE3YmRfMTItNy0xLTEtMjMwMTM_3910a93a-5ab1-4305-9738-ae1bd3b30953">1,088</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia66c3497d92f4f87983a8808d4c22279_I20220331" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOjE2MjZjZmRjNGNiNDQzOTJhMTAyNjc2NTQzZWExN2JkL3RhYmxlcmFuZ2U6MTYyNmNmZGM0Y2I0NDM5MmExMDI2NzY1NDNlYTE3YmRfMTMtMS0xLTEtMjMwMTM_7b2f0fa8-7cf9-4494-8519-a640a34cdb2e">1,088</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idccb2dc5b13a4488878f9a05af20f66a_I20220331" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOjE2MjZjZmRjNGNiNDQzOTJhMTAyNjc2NTQzZWExN2JkL3RhYmxlcmFuZ2U6MTYyNmNmZGM0Y2I0NDM5MmExMDI2NzY1NDNlYTE3YmRfMTMtMy0xLTEtMjMwMTM_c2e3996e-1abd-4885-95c6-f4ee18a32489">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8a67586059d49f9810370c50eaa57c0_I20220331" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOjE2MjZjZmRjNGNiNDQzOTJhMTAyNjc2NTQzZWExN2JkL3RhYmxlcmFuZ2U6MTYyNmNmZGM0Y2I0NDM5MmExMDI2NzY1NDNlYTE3YmRfMTMtNS0xLTEtMjMwMTM_ce900302-d086-4bac-a12a-4c589eaf743f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c1a6f674cd541978439c2f0f7d4fb9a_I20220331" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOjE2MjZjZmRjNGNiNDQzOTJhMTAyNjc2NTQzZWExN2JkL3RhYmxlcmFuZ2U6MTYyNmNmZGM0Y2I0NDM5MmExMDI2NzY1NDNlYTE3YmRfMTMtNy0xLTEtMjMwMTM_3d005be1-d6a6-483f-bd1d-c1a2aea0d590">1,088</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total<br/>Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9becbf42740c409189339a2b5a11a4f2_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOmRiNzQ0NWEzYzEzMzRlZmViNGVhZTY4Y2NmNjRhMDRiL3RhYmxlcmFuZ2U6ZGI3NDQ1YTNjMTMzNGVmZWI0ZWFlNjhjY2Y2NGEwNGJfMy0xLTEtMS0yMzAxMw_d21e1c40-94b6-43ff-821f-ec6d9a86010a">71,175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92ef66972cf9427cb63419db9768a298_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOmRiNzQ0NWEzYzEzMzRlZmViNGVhZTY4Y2NmNjRhMDRiL3RhYmxlcmFuZ2U6ZGI3NDQ1YTNjMTMzNGVmZWI0ZWFlNjhjY2Y2NGEwNGJfMy0zLTEtMS0yMzAxMw_5d73c0d6-75f7-4768-aa55-b79ca9f4d04a">71,175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i211bb796b7a24967b594b6dbe16c328c_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOmRiNzQ0NWEzYzEzMzRlZmViNGVhZTY4Y2NmNjRhMDRiL3RhYmxlcmFuZ2U6ZGI3NDQ1YTNjMTMzNGVmZWI0ZWFlNjhjY2Y2NGEwNGJfMy01LTEtMS0yMzAxMw_1bf0e075-8193-43a6-aa6a-840caa163243">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie08734f5a1ee4ae1a8f14c3e0ad81e38_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOmRiNzQ0NWEzYzEzMzRlZmViNGVhZTY4Y2NmNjRhMDRiL3RhYmxlcmFuZ2U6ZGI3NDQ1YTNjMTMzNGVmZWI0ZWFlNjhjY2Y2NGEwNGJfMy03LTEtMS0yMzAxMw_5bfc6c69-99d0-4a11-b1d6-8fcd266ffd45">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i702ba55895b343c594a4b5ed37806639_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOmRiNzQ0NWEzYzEzMzRlZmViNGVhZTY4Y2NmNjRhMDRiL3RhYmxlcmFuZ2U6ZGI3NDQ1YTNjMTMzNGVmZWI0ZWFlNjhjY2Y2NGEwNGJfNC0xLTEtMS0yMzAxMw_6312c86a-c233-40d0-97ab-d9b53620b223">31,935</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id48fda4018124a2789eda8fb5e8c7f3b_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOmRiNzQ0NWEzYzEzMzRlZmViNGVhZTY4Y2NmNjRhMDRiL3RhYmxlcmFuZ2U6ZGI3NDQ1YTNjMTMzNGVmZWI0ZWFlNjhjY2Y2NGEwNGJfNC0zLTEtMS0yMzAxMw_bec77406-75e7-4b05-b7dd-cc13f683df5d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i864378b20e0f48a2a4a6e9ec27084dd7_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOmRiNzQ0NWEzYzEzMzRlZmViNGVhZTY4Y2NmNjRhMDRiL3RhYmxlcmFuZ2U6ZGI3NDQ1YTNjMTMzNGVmZWI0ZWFlNjhjY2Y2NGEwNGJfNC01LTEtMS0yMzAxMw_6af14edc-a9b9-4f22-995b-b60914a01bb2">31,935</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i870189fb8682430baf663525b78d14eb_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOmRiNzQ0NWEzYzEzMzRlZmViNGVhZTY4Y2NmNjRhMDRiL3RhYmxlcmFuZ2U6ZGI3NDQ1YTNjMTMzNGVmZWI0ZWFlNjhjY2Y2NGEwNGJfNC03LTEtMS0yMzAxMw_433aaf69-9ead-4ba0-bcda-4ab430da2b13">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i498f3eb654bb4e63858ae975af11c445_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOmRiNzQ0NWEzYzEzMzRlZmViNGVhZTY4Y2NmNjRhMDRiL3RhYmxlcmFuZ2U6ZGI3NDQ1YTNjMTMzNGVmZWI0ZWFlNjhjY2Y2NGEwNGJfNS0xLTEtMS0yMzAxMw_5669bcd3-f97f-412b-9d6d-05cbb29fd241">7,022</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie76caf10c27b47c9b2d7f93b70732805_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOmRiNzQ0NWEzYzEzMzRlZmViNGVhZTY4Y2NmNjRhMDRiL3RhYmxlcmFuZ2U6ZGI3NDQ1YTNjMTMzNGVmZWI0ZWFlNjhjY2Y2NGEwNGJfNS0zLTEtMS0yMzAxMw_2e033699-71f3-48b5-9e0d-40c6f94a2e7d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b34d1e5e84949e08757fe31d16851b6_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOmRiNzQ0NWEzYzEzMzRlZmViNGVhZTY4Y2NmNjRhMDRiL3RhYmxlcmFuZ2U6ZGI3NDQ1YTNjMTMzNGVmZWI0ZWFlNjhjY2Y2NGEwNGJfNS01LTEtMS0yMzAxMw_e8528159-9fdc-40bb-ba60-8a371ade6367">7,022</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icae86f3621e745dcae0300fcf262e97a_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOmRiNzQ0NWEzYzEzMzRlZmViNGVhZTY4Y2NmNjRhMDRiL3RhYmxlcmFuZ2U6ZGI3NDQ1YTNjMTMzNGVmZWI0ZWFlNjhjY2Y2NGEwNGJfNS03LTEtMS0yMzAxMw_7087fadb-9648-4038-91b1-19a142ffa661">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfe0e960aed543b5988f05f7d3355902_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOmRiNzQ0NWEzYzEzMzRlZmViNGVhZTY4Y2NmNjRhMDRiL3RhYmxlcmFuZ2U6ZGI3NDQ1YTNjMTMzNGVmZWI0ZWFlNjhjY2Y2NGEwNGJfNy0xLTEtMS0yMzAxMw_bcbe06d2-e533-4c34-9039-41de24ec988a">5,304</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f334852225945b2a7a93e28e698a7b5_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOmRiNzQ0NWEzYzEzMzRlZmViNGVhZTY4Y2NmNjRhMDRiL3RhYmxlcmFuZ2U6ZGI3NDQ1YTNjMTMzNGVmZWI0ZWFlNjhjY2Y2NGEwNGJfNy0zLTEtMS0yMzAxMw_61864cd2-51f6-43f7-be60-39deb1717449">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2fbce7b430d746d193e24e71ed55ec24_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOmRiNzQ0NWEzYzEzMzRlZmViNGVhZTY4Y2NmNjRhMDRiL3RhYmxlcmFuZ2U6ZGI3NDQ1YTNjMTMzNGVmZWI0ZWFlNjhjY2Y2NGEwNGJfNy01LTEtMS0yMzAxMw_a99d7c7b-0c12-4fb5-9861-2af440a3d859">5,304</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77f4939d9c1b4cb9a23a9d1abed49c29_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOmRiNzQ0NWEzYzEzMzRlZmViNGVhZTY4Y2NmNjRhMDRiL3RhYmxlcmFuZ2U6ZGI3NDQ1YTNjMTMzNGVmZWI0ZWFlNjhjY2Y2NGEwNGJfNy03LTEtMS0yMzAxMw_7adbf44f-b1c6-4084-b8d6-e91b386dc943">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a918505eebf4610bda0dea154daa7a3_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOmRiNzQ0NWEzYzEzMzRlZmViNGVhZTY4Y2NmNjRhMDRiL3RhYmxlcmFuZ2U6ZGI3NDQ1YTNjMTMzNGVmZWI0ZWFlNjhjY2Y2NGEwNGJfOS0xLTEtMS0yNDUxMw_1023e160-ea15-404d-b54e-ad7fd8c83dc0">115,436</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb543391634c44d0a2f40bdc636ebebf_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOmRiNzQ0NWEzYzEzMzRlZmViNGVhZTY4Y2NmNjRhMDRiL3RhYmxlcmFuZ2U6ZGI3NDQ1YTNjMTMzNGVmZWI0ZWFlNjhjY2Y2NGEwNGJfOS0zLTEtMS0yNDUxMw_7b47a315-f3fc-4bb9-9076-0a480affeed6">71,175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b0ae5504847492aaff354b4bb3eed43_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOmRiNzQ0NWEzYzEzMzRlZmViNGVhZTY4Y2NmNjRhMDRiL3RhYmxlcmFuZ2U6ZGI3NDQ1YTNjMTMzNGVmZWI0ZWFlNjhjY2Y2NGEwNGJfOS01LTEtMS0yNDUxMw_30217120-e1cc-46ae-b3f8-d0dd6ff5f727">44,261</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07deb0701eff4cf3b8159da82875bb77_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOmRiNzQ0NWEzYzEzMzRlZmViNGVhZTY4Y2NmNjRhMDRiL3RhYmxlcmFuZ2U6ZGI3NDQ1YTNjMTMzNGVmZWI0ZWFlNjhjY2Y2NGEwNGJfOS03LTEtMS0yNDUxMw_0bf3c2ff-9651-4893-a673-1c62c76ab268">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 12.25pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liability for exit fee</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2c246545dd44f91b1867420b6787cd5_I20211231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOmRiNzQ0NWEzYzEzMzRlZmViNGVhZTY4Y2NmNjRhMDRiL3RhYmxlcmFuZ2U6ZGI3NDQ1YTNjMTMzNGVmZWI0ZWFlNjhjY2Y2NGEwNGJfMTItMS0xLTEtMjMwMTM_31d24502-7764-4b42-ba6d-d2f685d549f0">698</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57236df6e705400089af661d14abc3ab_I20211231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOmRiNzQ0NWEzYzEzMzRlZmViNGVhZTY4Y2NmNjRhMDRiL3RhYmxlcmFuZ2U6ZGI3NDQ1YTNjMTMzNGVmZWI0ZWFlNjhjY2Y2NGEwNGJfMTItMy0xLTEtMjMwMTM_e8ff04a4-ac29-428b-a8ec-f5a9e5645bd9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9aaa3d02b9854e48a25597ea0974cd4e_I20211231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOmRiNzQ0NWEzYzEzMzRlZmViNGVhZTY4Y2NmNjRhMDRiL3RhYmxlcmFuZ2U6ZGI3NDQ1YTNjMTMzNGVmZWI0ZWFlNjhjY2Y2NGEwNGJfMTItNS0xLTEtMjMwMTM_b1b9e0eb-4a3e-4c42-869c-552b3ebb429d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec8114b671a2456c81955e87ce50bed9_I20211231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOmRiNzQ0NWEzYzEzMzRlZmViNGVhZTY4Y2NmNjRhMDRiL3RhYmxlcmFuZ2U6ZGI3NDQ1YTNjMTMzNGVmZWI0ZWFlNjhjY2Y2NGEwNGJfMTItNy0xLTEtMjMwMTM_0b7a5727-c8a7-4a4a-98ab-ca3162858b3b">698</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a918505eebf4610bda0dea154daa7a3_I20211231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOmRiNzQ0NWEzYzEzMzRlZmViNGVhZTY4Y2NmNjRhMDRiL3RhYmxlcmFuZ2U6ZGI3NDQ1YTNjMTMzNGVmZWI0ZWFlNjhjY2Y2NGEwNGJfMTMtMS0xLTEtMjQ1MTM_be0cb75d-e9f2-482b-a8e9-0f389ef17919">698</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb543391634c44d0a2f40bdc636ebebf_I20211231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOmRiNzQ0NWEzYzEzMzRlZmViNGVhZTY4Y2NmNjRhMDRiL3RhYmxlcmFuZ2U6ZGI3NDQ1YTNjMTMzNGVmZWI0ZWFlNjhjY2Y2NGEwNGJfMTMtMy0xLTEtMjQ1MTM_2761946d-9af2-427b-ab80-c59bb1775a73">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b0ae5504847492aaff354b4bb3eed43_I20211231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOmRiNzQ0NWEzYzEzMzRlZmViNGVhZTY4Y2NmNjRhMDRiL3RhYmxlcmFuZ2U6ZGI3NDQ1YTNjMTMzNGVmZWI0ZWFlNjhjY2Y2NGEwNGJfMTMtNS0xLTEtMjQ1MTM_c199a885-9a89-481c-b1f2-0068f018281d">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07deb0701eff4cf3b8159da82875bb77_I20211231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOmRiNzQ0NWEzYzEzMzRlZmViNGVhZTY4Y2NmNjRhMDRiL3RhYmxlcmFuZ2U6ZGI3NDQ1YTNjMTMzNGVmZWI0ZWFlNjhjY2Y2NGEwNGJfMTMtNy0xLTEtMjQ1MTM_006a24c2-0698-4caa-9377-b0f0419f0f82">698</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i711b1a39e0634b15bb7a70766327247a_7">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><ix:continuation id="i00bfcd01fce345e5be5a2bae438dfe1f"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Where quoted prices are available in an active market, securities are classified as Level 1. We classify money market funds as Level 1. When quoted market prices are not available for the specific security, we estimate fair value by using benchmark yields, reported trades, broker/dealer quotes and issuer spreads. We classify U.S. government-sponsored agency bonds, U.S. treasury notes, corporate bonds, commercial paper, and asset-backed securities as Level 2. In certain cases, where there is limited activity or less transparency around inputs to valuation, securities or derivative liabilities, such as the Exit Fee, as defined and discussed in Note 8, are classified as Level 3.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts reflected in the balance sheets for cash equivalents, short-term investments, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair values at both March&#160;31, 2022 and December&#160;31, 2021, due to their short-term nature. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Debt</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest rate of our term loan facility approximates the rate at which we could obtain alternative financing. Therefore, the carrying amount of the term loan facility approximated its fair value at March&#160;31, 2022 and December&#160;31, 2021.</span></div></ix:continuation><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i711b1a39e0634b15bb7a70766327247a_1161"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 4. <ix:nonNumeric contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xMTYxL2ZyYWc6YzBhYWJiMTYyZTYyNGUyN2FhODU0YmM2YTYxYzQ5MGMvdGV4dHJlZ2lvbjpjMGFhYmIxNjJlNjI0ZTI3YWE4NTRiYzZhNjFjNDkwY180Mzk4MDQ2NTE2MjU2_2ee294a4-6a63-4e4f-8701-2ac73f0eab36" continuedAt="i2f447e0f12a4451d8071a9d5d92850f5" escape="true">INVENTORY</ix:nonNumeric></span></div><ix:continuation id="i2f447e0f12a4451d8071a9d5d92850f5"><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We began capitalizing inventory during the fourth quarter of 2021, at which time our intent to commercialize IBSRELA was established and we commenced  preparation for the commercial launch of IBSRELA. <ix:nonNumeric contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xMTYxL2ZyYWc6YzBhYWJiMTYyZTYyNGUyN2FhODU0YmM2YTYxYzQ5MGMvdGV4dHJlZ2lvbjpjMGFhYmIxNjJlNjI0ZTI3YWE4NTRiYzZhNjFjNDkwY180Mzk4MDQ2NTE2MjU3_17abd2fc-51bc-47cd-a509-86c329b2adb7" continuedAt="i2691b17ffa2f41ff9d48ce4b387ae8c0" escape="true">Inventory consisted of the following (in thousands):</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><ix:continuation id="i2691b17ffa2f41ff9d48ce4b387ae8c0"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331" decimals="-3" name="us-gaap:InventoryRawMaterials" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xMTYxL2ZyYWc6YzBhYWJiMTYyZTYyNGUyN2FhODU0YmM2YTYxYzQ5MGMvdGFibGU6NGI3ZjI0ZjE4NDllNGQxNDliODZmNWEwOGFiNTY3ZGQvdGFibGVyYW5nZTo0YjdmMjRmMTg0OWU0ZDE0OWI4NmY1YTA4YWI1NjdkZF8xLTctMS0xLTMwNzY0_25f8c50e-baa4-4b87-9332-a3ae26c0a765">460</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331" decimals="-3" name="us-gaap:InventoryWorkInProcess" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xMTYxL2ZyYWc6YzBhYWJiMTYyZTYyNGUyN2FhODU0YmM2YTYxYzQ5MGMvdGFibGU6NGI3ZjI0ZjE4NDllNGQxNDliODZmNWEwOGFiNTY3ZGQvdGFibGVyYW5nZTo0YjdmMjRmMTg0OWU0ZDE0OWI4NmY1YTA4YWI1NjdkZF8yLTItMS0xLTMwODAy_9fdf6061-0215-4de6-ab07-5b39566cc32b">2,507</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331" decimals="-3" name="us-gaap:InventoryFinishedGoods" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xMTYxL2ZyYWc6YzBhYWJiMTYyZTYyNGUyN2FhODU0YmM2YTYxYzQ5MGMvdGFibGU6NGI3ZjI0ZjE4NDllNGQxNDliODZmNWEwOGFiNTY3ZGQvdGFibGVyYW5nZTo0YjdmMjRmMTg0OWU0ZDE0OWI4NmY1YTA4YWI1NjdkZF8yLTctMS0xLTMwNzY0_db3d4d9d-9560-4520-91d4-46e38999ab57">520</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xMTYxL2ZyYWc6YzBhYWJiMTYyZTYyNGUyN2FhODU0YmM2YTYxYzQ5MGMvdGFibGU6NGI3ZjI0ZjE4NDllNGQxNDliODZmNWEwOGFiNTY3ZGQvdGFibGVyYW5nZTo0YjdmMjRmMTg0OWU0ZDE0OWI4NmY1YTA4YWI1NjdkZF8zLTctMS0xLTMwNzY0_6610d7c7-1d74-4b30-b4cf-af5cf1b1b43e">3,487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div><span><br/></span></div><div id="i711b1a39e0634b15bb7a70766327247a_1146"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 5. <ix:nonNumeric contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xMTQ2L2ZyYWc6NjAyZTAzMTg1YTM0NDIwNzg1Y2Y2Mzg0MGY1ZTI4NDQvdGV4dHJlZ2lvbjo2MDJlMDMxODVhMzQ0MjA3ODVjZjYzODQwZjVlMjg0NF80Mzk4MDQ2NTE0NTQ2_7d03a7bd-34d4-44ad-a4ec-bd61ebd01530" continuedAt="ib05aad75f3dc46c3a64a4a55e369a435" escape="true">PRODUCT REVENUE, NET</ix:nonNumeric></span></div><ix:continuation id="ib05aad75f3dc46c3a64a4a55e369a435"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received approval from the FDA in September 2019 to market IBSRELA, the first and only sodium hydrogen exchanger 3 (&#8220;NHE3&#8221;) inhibitor for the treatment of irritable bowel syndrome with constipation ("IBS-C") in adults, in the U.S. We began selling IBSRELA in the U.S. in March 2022. We recorded net revenue for IBSRELA of $<ix:nonFraction unitRef="usd" contextRef="i157edd1d25424d4e869f567c7ddd2b4a_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xMTQ2L2ZyYWc6NjAyZTAzMTg1YTM0NDIwNzg1Y2Y2Mzg0MGY1ZTI4NDQvdGV4dHJlZ2lvbjo2MDJlMDMxODVhMzQ0MjA3ODVjZjYzODQwZjVlMjg0NF8xMDk5NTExNjMxMzUz_09929c4f-8125-486f-8755-c1087c097744">0.5</ix:nonFraction>&#160;million during the three months ended March&#160;31, 2022.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales to Cardinal Health, AmerisourceBergen Drug Corporation, and McKesson Corporation made up <ix:nonFraction unitRef="number" contextRef="i5602110d257243d68fe06a3de7666ba1_D20220101-20220331" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xMTQ2L2ZyYWc6NjAyZTAzMTg1YTM0NDIwNzg1Y2Y2Mzg0MGY1ZTI4NDQvdGV4dHJlZ2lvbjo2MDJlMDMxODVhMzQ0MjA3ODVjZjYzODQwZjVlMjg0NF8xMDk5NTExNjM0MTgx_e4e3ef93-6cc2-4b9c-8acc-92738f798675">17.9</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="i7a2496c68915449aa1b605adb0073d44_D20220101-20220331" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xMTQ2L2ZyYWc6NjAyZTAzMTg1YTM0NDIwNzg1Y2Y2Mzg0MGY1ZTI4NDQvdGV4dHJlZ2lvbjo2MDJlMDMxODVhMzQ0MjA3ODVjZjYzODQwZjVlMjg0NF8xMDk5NTExNjMxNzA3_daad727c-1a14-4f6e-b7e9-ce79e0b5e610">17.1</ix:nonFraction>%, and <ix:nonFraction unitRef="number" contextRef="ib4ede0c6d6294ec1ba539591fc337da1_D20220101-20220331" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xMTQ2L2ZyYWc6NjAyZTAzMTg1YTM0NDIwNzg1Y2Y2Mzg0MGY1ZTI4NDQvdGV4dHJlZ2lvbjo2MDJlMDMxODVhMzQ0MjA3ODVjZjYzODQwZjVlMjg0NF8xMDk5NTExNjMxNjQy_1b1cc701-96a8-46b6-93bc-a13363d58c65">15.4</ix:nonFraction>% of our gross product revenue during the three months ended March&#160;31, 2022.</span></div><ix:nonNumeric contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" name="ardx:ScheduleOfGrossToNetSalesAccrualsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xMTQ2L2ZyYWc6NjAyZTAzMTg1YTM0NDIwNzg1Y2Y2Mzg0MGY1ZTI4NDQvdGV4dHJlZ2lvbjo2MDJlMDMxODVhMzQ0MjA3ODVjZjYzODQwZjVlMjg0NF80Mzk4MDQ2NTE0NTQ3_fafe475d-d250-4aa5-adc5-12b6a1087880" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The activities and ending reserve balances for each significant category of discounts and allowances, which constitute variable consideration, were as follows (in thousands):</span></div><div style="margin-top:12pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Discounts and Chargebacks</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Rebates</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Fees, Copay and Returns</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cd8e102ed0b453abc3afc0ba274b816_I20211231" decimals="-3" name="ardx:ContractWithCustomerGrossToNetSalesAccruals" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xMTQ2L2ZyYWc6NjAyZTAzMTg1YTM0NDIwNzg1Y2Y2Mzg0MGY1ZTI4NDQvdGFibGU6YzRlMzliMGUyNTQxNGI4M2JlMjE5Y2Y3NTJmNTFmYmMvdGFibGVyYW5nZTpjNGUzOWIwZTI1NDE0YjgzYmUyMTljZjc1MmY1MWZiY18xLTEtMS0xLTI5NjAw_6c81a63c-6fa8-42c2-b082-451aeb576a81">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e3b20e3d13f464f8136bc69cac78387_I20211231" decimals="-3" name="ardx:ContractWithCustomerGrossToNetSalesAccruals" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xMTQ2L2ZyYWc6NjAyZTAzMTg1YTM0NDIwNzg1Y2Y2Mzg0MGY1ZTI4NDQvdGFibGU6YzRlMzliMGUyNTQxNGI4M2JlMjE5Y2Y3NTJmNTFmYmMvdGFibGVyYW5nZTpjNGUzOWIwZTI1NDE0YjgzYmUyMTljZjc1MmY1MWZiY18xLTMtMS0xLTMwMDY4_505313bb-0c69-427a-ad25-87d9a4fadeac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc17b1d2c9354e6ba7867c153f98dd39_I20211231" decimals="-3" name="ardx:ContractWithCustomerGrossToNetSalesAccruals" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xMTQ2L2ZyYWc6NjAyZTAzMTg1YTM0NDIwNzg1Y2Y2Mzg0MGY1ZTI4NDQvdGFibGU6YzRlMzliMGUyNTQxNGI4M2JlMjE5Y2Y3NTJmNTFmYmMvdGFibGVyYW5nZTpjNGUzOWIwZTI1NDE0YjgzYmUyMTljZjc1MmY1MWZiY18xLTMtMS0xLTI5NjAw_f8f864ad-9708-406b-94d8-4cdeafb1d5cc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231" decimals="-3" name="ardx:ContractWithCustomerGrossToNetSalesAccruals" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xMTQ2L2ZyYWc6NjAyZTAzMTg1YTM0NDIwNzg1Y2Y2Mzg0MGY1ZTI4NDQvdGFibGU6YzRlMzliMGUyNTQxNGI4M2JlMjE5Y2Y3NTJmNTFmYmMvdGFibGVyYW5nZTpjNGUzOWIwZTI1NDE0YjgzYmUyMTljZjc1MmY1MWZiY18xLTUtMS0xLTI5NjAw_52021ae6-5749-4690-8bec-af510615139d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Activity related to 2022 sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia23df3972f1944e3a9fed9c31cbc6587_D20220101-20220331" decimals="-3" name="ardx:ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xMTQ2L2ZyYWc6NjAyZTAzMTg1YTM0NDIwNzg1Y2Y2Mzg0MGY1ZTI4NDQvdGFibGU6YzRlMzliMGUyNTQxNGI4M2JlMjE5Y2Y3NTJmNTFmYmMvdGFibGVyYW5nZTpjNGUzOWIwZTI1NDE0YjgzYmUyMTljZjc1MmY1MWZiY18zLTEtMS0xLTI5NTg5_016b6b05-563f-4f50-a222-7cd6b9ed1d1b">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4eed71377df84e2fad4e2b5044d0f43c_D20220101-20220331" decimals="-3" name="ardx:ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xMTQ2L2ZyYWc6NjAyZTAzMTg1YTM0NDIwNzg1Y2Y2Mzg0MGY1ZTI4NDQvdGFibGU6YzRlMzliMGUyNTQxNGI4M2JlMjE5Y2Y3NTJmNTFmYmMvdGFibGVyYW5nZTpjNGUzOWIwZTI1NDE0YjgzYmUyMTljZjc1MmY1MWZiY18yLTMtMS0xLTMwMDY4_a58ce767-5920-4103-98db-3581c472e529">40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10819c0292d84effb45cc9b78a0c7f30_D20220101-20220331" decimals="-3" name="ardx:ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xMTQ2L2ZyYWc6NjAyZTAzMTg1YTM0NDIwNzg1Y2Y2Mzg0MGY1ZTI4NDQvdGFibGU6YzRlMzliMGUyNTQxNGI4M2JlMjE5Y2Y3NTJmNTFmYmMvdGFibGVyYW5nZTpjNGUzOWIwZTI1NDE0YjgzYmUyMTljZjc1MmY1MWZiY18zLTMtMS0xLTI5NTg5_23136887-cc2b-4dbc-aafc-099070b7fd10">90</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" decimals="-3" name="ardx:ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xMTQ2L2ZyYWc6NjAyZTAzMTg1YTM0NDIwNzg1Y2Y2Mzg0MGY1ZTI4NDQvdGFibGU6YzRlMzliMGUyNTQxNGI4M2JlMjE5Y2Y3NTJmNTFmYmMvdGFibGVyYW5nZTpjNGUzOWIwZTI1NDE0YjgzYmUyMTljZjc1MmY1MWZiY18zLTUtMS0xLTI5NTg5_c0240e17-41ce-417f-a01b-1aba3abc3f41">154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iede9224697ec4dd1a0adabd2320ebc14_I20220331" decimals="-3" name="ardx:ContractWithCustomerGrossToNetSalesAccruals" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xMTQ2L2ZyYWc6NjAyZTAzMTg1YTM0NDIwNzg1Y2Y2Mzg0MGY1ZTI4NDQvdGFibGU6YzRlMzliMGUyNTQxNGI4M2JlMjE5Y2Y3NTJmNTFmYmMvdGFibGVyYW5nZTpjNGUzOWIwZTI1NDE0YjgzYmUyMTljZjc1MmY1MWZiY181LTEtMS0xLTI5NTg5_12f4e5b0-c9fd-4b43-9584-7c2bc1929433">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie452822da30341968381616c4727890f_I20220331" decimals="-3" name="ardx:ContractWithCustomerGrossToNetSalesAccruals" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xMTQ2L2ZyYWc6NjAyZTAzMTg1YTM0NDIwNzg1Y2Y2Mzg0MGY1ZTI4NDQvdGFibGU6YzRlMzliMGUyNTQxNGI4M2JlMjE5Y2Y3NTJmNTFmYmMvdGFibGVyYW5nZTpjNGUzOWIwZTI1NDE0YjgzYmUyMTljZjc1MmY1MWZiY180LTMtMS0xLTMwMDY4_5796fe2b-c58a-43c8-aae3-47d687fc9be9">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3971d760f8441f38d00e317c37315fd_I20220331" decimals="-3" name="ardx:ContractWithCustomerGrossToNetSalesAccruals" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xMTQ2L2ZyYWc6NjAyZTAzMTg1YTM0NDIwNzg1Y2Y2Mzg0MGY1ZTI4NDQvdGFibGU6YzRlMzliMGUyNTQxNGI4M2JlMjE5Y2Y3NTJmNTFmYmMvdGFibGVyYW5nZTpjNGUzOWIwZTI1NDE0YjgzYmUyMTljZjc1MmY1MWZiY181LTMtMS0xLTI5NTg5_7440605f-b53b-4328-b44e-568c22c319ff">90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331" decimals="-3" name="ardx:ContractWithCustomerGrossToNetSalesAccruals" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xMTQ2L2ZyYWc6NjAyZTAzMTg1YTM0NDIwNzg1Y2Y2Mzg0MGY1ZTI4NDQvdGFibGU6YzRlMzliMGUyNTQxNGI4M2JlMjE5Y2Y3NTJmNTFmYmMvdGFibGVyYW5nZTpjNGUzOWIwZTI1NDE0YjgzYmUyMTljZjc1MmY1MWZiY181LTUtMS0xLTI5NTg5_2e8f2a05-4c82-431e-ba26-5ab6225be500">154</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were <ix:nonFraction unitRef="usd" contextRef="i5783cc7426ba453f96f1e7e0af87b0a6_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xMTQ2L2ZyYWc6NjAyZTAzMTg1YTM0NDIwNzg1Y2Y2Mzg0MGY1ZTI4NDQvdGV4dHJlZ2lvbjo2MDJlMDMxODVhMzQ0MjA3ODVjZjYzODQwZjVlMjg0NF80Mzk4MDQ2NTE0NTQ4_995dd031-33db-4da8-8211-1bbc493dbfce"><ix:nonFraction unitRef="usd" contextRef="iac98ebf56cf345fb9e32e575ac855e4a_I20210331" decimals="-3" name="ardx:ContractWithCustomerGrossToNetSalesAccruals" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xMTQ2L2ZyYWc6NjAyZTAzMTg1YTM0NDIwNzg1Y2Y2Mzg0MGY1ZTI4NDQvdGV4dHJlZ2lvbjo2MDJlMDMxODVhMzQ0MjA3ODVjZjYzODQwZjVlMjg0NF80Mzk4MDQ2NTE0NTQ4_a1901645-7c1d-4744-a15f-6cf52ec5e2a6">no</ix:nonFraction></ix:nonFraction> product sales or gross-to-net accruals during the three months ended March&#160;31, 2021.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><div id="i711b1a39e0634b15bb7a70766327247a_40"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i711b1a39e0634b15bb7a70766327247a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 6&#160;&#160;&#160;&#160;. <ix:nonNumeric contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80MC9mcmFnOmUwYjY2ZWViODRkMDRmN2JhZjFlYjEyNGIyNzE5NmY3L3RleHRyZWdpb246ZTBiNjZlZWI4NGQwNGY3YmFmMWViMTI0YjI3MTk2ZjdfOTYyOQ_ac2099ea-97db-4016-807c-0ed7bc245ae7" continuedAt="ib5a03852fb5c4dce8b4abf16d11382fe" escape="true">COLLABORATION AND LICENSING AGREEMENTS</ix:nonNumeric></span></div><ix:continuation id="ib5a03852fb5c4dce8b4abf16d11382fe" continuedAt="i8ef622e7bee84819a1b23376217392ff"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Kyowa Kirin Co., Ltd. (&#8220;KKC&#8221;)</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2019 KKC Agreement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, we entered into a research collaboration and option agreement with KKC (the &#8220;2019 KKC Agreement&#8221;) for research associated with identifying two preclinical compounds that are ready for designation as development compounds (&#8220;DCs&#8221;), with one compound inhibiting the first undisclosed target (&#8220;Program 1&#8221;), and a second inhibiting the second undisclosed target (&#8220;Program 2&#8221;). Pursuant to the 2019 KKC Agreement, upon completion of the research and designation by the research steering committee of one or more DCs, KKC has the right to execute <ix:nonFraction unitRef="item" contextRef="i23aa3d7663a24dc8865dc922b983040b_D20191101-20191130" decimals="INF" name="ardx:NumberOfSeparateCollaborativeAgreements" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80MC9mcmFnOmUwYjY2ZWViODRkMDRmN2JhZjFlYjEyNGIyNzE5NmY3L3RleHRyZWdpb246ZTBiNjZlZWI4NGQwNGY3YmFmMWViMTI0YjI3MTk2ZjdfNjU4_ccd19f9f-7205-4b9b-999e-67fb6f3bf363">one</ix:nonFraction> or more separate collaborative agreements relating to the development and commercialization of one or both DCs in certain specified territories.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the 2019 KKC Agreement, KKC paid us a non-refundable, non-creditable upfront fee of $<ix:nonFraction unitRef="usd" contextRef="i9168e70d1cc646808da95d0e5cbe0347_D20191101-20191130" decimals="-5" name="ardx:CollaborationAndLicensingAgreementsUpfrontLicenseFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80MC9mcmFnOmUwYjY2ZWViODRkMDRmN2JhZjFlYjEyNGIyNzE5NmY3L3RleHRyZWdpb246ZTBiNjZlZWI4NGQwNGY3YmFmMWViMTI0YjI3MTk2ZjdfMTA5OTUxMTYzNzU1MA_68b4bf05-2968-4778-bff8-36c45b3230af">10.0</ix:nonFraction>&#160;million in two installments as follows: the first installment of $<ix:nonFraction unitRef="usd" contextRef="i9168e70d1cc646808da95d0e5cbe0347_D20191101-20191130" decimals="-5" name="ardx:CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80MC9mcmFnOmUwYjY2ZWViODRkMDRmN2JhZjFlYjEyNGIyNzE5NmY3L3RleHRyZWdpb246ZTBiNjZlZWI4NGQwNGY3YmFmMWViMTI0YjI3MTk2ZjdfMTA5OTUxMTYzNzU1NA_626a70f5-87e1-4f1f-90ab-cd0b26fc2ef9">5.0</ix:nonFraction>&#160;million within <ix:nonNumeric contextRef="i9168e70d1cc646808da95d0e5cbe0347_D20191101-20191130" name="ardx:TermOfPaymentOfLicenseFeeFirstInstallment" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80MC9mcmFnOmUwYjY2ZWViODRkMDRmN2JhZjFlYjEyNGIyNzE5NmY3L3RleHRyZWdpb246ZTBiNjZlZWI4NGQwNGY3YmFmMWViMTI0YjI3MTk2ZjdfOTc5_9e9837b4-f7d6-42e1-8d41-5f14aec945d0">30</ix:nonNumeric> days of November 11, 2019 (the &#8220;Effective Date&#8221;), and the second installment of $<ix:nonFraction unitRef="usd" contextRef="i9168e70d1cc646808da95d0e5cbe0347_D20191101-20191130" decimals="-5" name="ardx:CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80MC9mcmFnOmUwYjY2ZWViODRkMDRmN2JhZjFlYjEyNGIyNzE5NmY3L3RleHRyZWdpb246ZTBiNjZlZWI4NGQwNGY3YmFmMWViMTI0YjI3MTk2ZjdfMTA5OTUxMTYzNzU1OA_bfb4ac7a-9f01-4592-b37d-733db97e89b2">5.0</ix:nonFraction>&#160;million on the first anniversary of the Effective Date. The term of the 2019 KKC Agreement commenced on the Effective Date and ends on the earliest of: (i) <ix:nonNumeric contextRef="i9168e70d1cc646808da95d0e5cbe0347_D20191101-20191130" name="ardx:TermOfAgreement" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80MC9mcmFnOmUwYjY2ZWViODRkMDRmN2JhZjFlYjEyNGIyNzE5NmY3L3RleHRyZWdpb246ZTBiNjZlZWI4NGQwNGY3YmFmMWViMTI0YjI3MTk2ZjdfMTIwOA_38e2020a-d2a9-4efd-b11f-30c335fa5fe3">2</ix:nonNumeric> years following the Effective Date, (ii) the nomination of a program DC for both programs, (iii) the nomination of one program DC and the decision by the parties to cease research for the other program, or (iv) the decision by the parties to cease research for both programs. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no material future obligations under the 2019 KKC Agreement and recorded <ix:nonFraction unitRef="usd" contextRef="i745335ff1da443c2a66acb028f9b9044_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80MC9mcmFnOmUwYjY2ZWViODRkMDRmN2JhZjFlYjEyNGIyNzE5NmY3L3RleHRyZWdpb246ZTBiNjZlZWI4NGQwNGY3YmFmMWViMTI0YjI3MTk2ZjdfMjE5OTAyMzI2Njc2MA_7bb02df7-92c9-48c2-b1da-d88390bf7be8">no</ix:nonFraction> revenue under the 2019 KKC Agreement during the three months ended March&#160;31, 2022. During the three months ended March&#160;31, 2021, we recognized $<ix:nonFraction unitRef="usd" contextRef="id32818d38a2f41e79d9416fb0bd0e53a_D20210101-20210331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80MC9mcmFnOmUwYjY2ZWViODRkMDRmN2JhZjFlYjEyNGIyNzE5NmY3L3RleHRyZWdpb246ZTBiNjZlZWI4NGQwNGY3YmFmMWViMTI0YjI3MTk2ZjdfMTA5OTUxMTYzNzU5OA_1be30f55-0b1a-4fc4-a623-2e71fd9bec17">1.5</ix:nonFraction>&#160;million as collaborative development revenue under the 2019 KKC Agreement in the accompanying condensed statement of operations and comprehensive loss. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2017 KKC Agreement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2017, we entered into an exclusive license agreement with KKC (the &#8220;2017 KKC Agreement&#8221;), for the development, commercialization, and distribution of tenapanor in Japan for cardiorenal indications. We granted KKC an exclusive license to develop and commercialize certain NHE3 inhibitors including tenapanor in Japan for the treatment of cardiorenal diseases and conditions, excluding cancer. We retained the rights to tenapanor outside of Japan, and also retained the rights to tenapanor in Japan for indications other than those stated above. Pursuant to the 2017 KKC Agreement, KKC is responsible for all costs and expenses incurred in the development and commercialization of tenapanor for all licensed indications in Japan. We are responsible for supplying the tenapanor drug substance for KKC&#8217;s use in development and commercialization throughout the term of the 2017 KKC Agreement, provided that KKC may exercise an option to manufacture the tenapanor drug substance under certain conditions.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assessed these arrangements in accordance with Accounting Standards Update (&#8220;ASU&#8221;) No. 2014-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers (Topic 606) and related amendments (&#8220;ASC 606&#8221;) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and concluded that the contract counterparty, KKC, is a customer. Under the terms of the 2017 KKC Agreement, we received</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i6ded7d7b952443ff99d1931791c886bb_D20171101-20171130" decimals="-5" name="ardx:CollaborationAndLicensingAgreementsUpfrontLicenseFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80MC9mcmFnOmUwYjY2ZWViODRkMDRmN2JhZjFlYjEyNGIyNzE5NmY3L3RleHRyZWdpb246ZTBiNjZlZWI4NGQwNGY3YmFmMWViMTI0YjI3MTk2ZjdfMTA5OTUxMTYzODE5Nw_80719ac1-1547-4add-92cd-57c59a90b365">30.0</ix:nonFraction>&#160;million in upfront license fees, which was recognized as revenue when the agreement was executed. Based on our assessment, management determined that the license and the manufacturing supply services were its material performance obligations at the inception of the 2017 KKC Agreement, and as such, each of the performance obligations is distinct. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the up-front license fee received of $<ix:nonFraction unitRef="usd" contextRef="i6ded7d7b952443ff99d1931791c886bb_D20171101-20171130" decimals="-5" name="ardx:CollaborationAndLicensingAgreementsUpfrontLicenseFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80MC9mcmFnOmUwYjY2ZWViODRkMDRmN2JhZjFlYjEyNGIyNzE5NmY3L3RleHRyZWdpb246ZTBiNjZlZWI4NGQwNGY3YmFmMWViMTI0YjI3MTk2ZjdfMTA5OTUxMTYzODIwNA_80719ac1-1547-4add-92cd-57c59a90b365">30.0</ix:nonFraction>&#160;million, we may be entitled to receive up to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i8bba5999a33a4beabc6bda2318d9d5d6_I20171130" decimals="-5" name="ardx:CollaborativeArrangementPotentialDevelopmentMilestones" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80MC9mcmFnOmUwYjY2ZWViODRkMDRmN2JhZjFlYjEyNGIyNzE5NmY3L3RleHRyZWdpb246ZTBiNjZlZWI4NGQwNGY3YmFmMWViMTI0YjI3MTk2ZjdfMTA5OTUxMTYzODIwOA_83ac2fc5-41a8-4fc1-b08a-235d0f10c5b2">55.0</ix:nonFraction>&#160;million in total development milestones, of which $<ix:nonFraction unitRef="usd" contextRef="i0212bc236d5d418c889a86710d62cead_D20171101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80MC9mcmFnOmUwYjY2ZWViODRkMDRmN2JhZjFlYjEyNGIyNzE5NmY3L3RleHRyZWdpb246ZTBiNjZlZWI4NGQwNGY3YmFmMWViMTI0YjI3MTk2ZjdfMTA5OTUxMTYzODIxNQ_00fdb563-e606-48f0-88eb-12e4e32c55a9">10.0</ix:nonFraction>&#160;million has been received and recognized as revenue as of March&#160;31, 2022, and approximately &#165;<ix:nonFraction unitRef="jpy" contextRef="ic0f6d47945c94e2398355efb64d25b64_I20220331" decimals="-8" name="ardx:CollaborativeArrangementPotentialCommercializationMilestones" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80MC9mcmFnOmUwYjY2ZWViODRkMDRmN2JhZjFlYjEyNGIyNzE5NmY3L3RleHRyZWdpb246ZTBiNjZlZWI4NGQwNGY3YmFmMWViMTI0YjI3MTk2ZjdfMTA5OTUxMTYzODIyMg_89adb169-acfa-448f-8f7c-0186c394e609">8.5</ix:nonFraction> billion for commercialization milestones, or approximately $<ix:nonFraction unitRef="usd" contextRef="ic0f6d47945c94e2398355efb64d25b64_I20220331" decimals="-5" name="ardx:CollaborativeArrangementPotentialCommercializationMilestones" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80MC9mcmFnOmUwYjY2ZWViODRkMDRmN2JhZjFlYjEyNGIyNzE5NmY3L3RleHRyZWdpb246ZTBiNjZlZWI4NGQwNGY3YmFmMWViMTI0YjI3MTk2ZjdfMTA5OTUxMTYzODIzMA_8688a18c-8724-4d13-ac56-9d259d571226">69.7</ix:nonFraction>&#160;million at the currency exchange rate on March&#160;31, 2022, as well as reimbursement of costs plus a reasonable overhead for the supply of product and royalties on net sales throughout the term of the agreement. The variable consideration related to the remaining development milestone payments has not been included in the transaction price as these were fully constrained at March&#160;31, 2022.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 14 - Subsequent events</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on April 11, 2022, we entered into a second amendment (the "Amendment") to the 2017 KKC Agreement. Under the terms of the Amendment, the parties have agreed to a reduction in the royalty rate payable to us by KKC upon net sales of tenapanor in Japan. The royalty rate will be reduced from the high teens to low double digits for a two-year period of time following the first commercial sale in Japan, and then to mid-single digits for the remainder of the royalty term. As consideration for the reduction in the royalty rate, KKC has agreed to pay us up to an additional U.S. $<ix:nonFraction unitRef="usd" contextRef="ic15e7d54e20c401b86da52a356fa5887_I20220411" decimals="-3" name="ardx:CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80MC9mcmFnOmUwYjY2ZWViODRkMDRmN2JhZjFlYjEyNGIyNzE5NmY3L3RleHRyZWdpb246ZTBiNjZlZWI4NGQwNGY3YmFmMWViMTI0YjI3MTk2ZjdfMTA5OTUxMTY0MzE2OQ_a32219d3-7124-42c0-bd07-3e4a3fac5e98">40.0</ix:nonFraction> million payable in <ix:nonFraction unitRef="payment_tranche" contextRef="ic15e7d54e20c401b86da52a356fa5887_I20220411" decimals="INF" name="ardx:CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80MC9mcmFnOmUwYjY2ZWViODRkMDRmN2JhZjFlYjEyNGIyNzE5NmY3L3RleHRyZWdpb246ZTBiNjZlZWI4NGQwNGY3YmFmMWViMTI0YjI3MTk2ZjdfODI0NjMzNzIyNTEzOQ_23a71ac9-01ca-4aa8-9ffa-5c5bb2f06626">two</ix:nonFraction> tranches, with the first payment due following KKC's filing with the Japanese Ministry Health, Labour and Welfare (MHLW) of its application for marketing approval for tenapanor and the second payment due following KKC&#8217;s receipt of regulatory approval to market tenapanor for hyperphosphatemia in Japan. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i711b1a39e0634b15bb7a70766327247a_7">Table of Contents</a></span></div></div><ix:continuation id="i8ef622e7bee84819a1b23376217392ff" continuedAt="i54ff91fa72c84ee7bc6e4be988d33fb7"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2022 we recognized <ix:nonFraction unitRef="usd" contextRef="ib0326b0e1d934394b35c6b4e5823a0e9_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80MC9mcmFnOmUwYjY2ZWViODRkMDRmN2JhZjFlYjEyNGIyNzE5NmY3L3RleHRyZWdpb246ZTBiNjZlZWI4NGQwNGY3YmFmMWViMTI0YjI3MTk2ZjdfMTA5OTUxMTYzODIzNw_450491be-83c6-4d48-84bf-fe6cc7bc630a">no</ix:nonFraction> licensing revenue upon the achievement of development milestones. During the three months ended March&#160;31, 2021, we recognized $<ix:nonFraction unitRef="usd" contextRef="i777f4b1d2b0a48c995f7a8e8fc2a2d0d_D20210101-20210331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80MC9mcmFnOmUwYjY2ZWViODRkMDRmN2JhZjFlYjEyNGIyNzE5NmY3L3RleHRyZWdpb246ZTBiNjZlZWI4NGQwNGY3YmFmMWViMTI0YjI3MTk2ZjdfMTA5OTUxMTYzODI2Mw_1b0a1530-daae-4aa3-94bb-6e1a71fca3f4">5.0</ix:nonFraction>&#160;million licensing revenue upon the initiation of phase 3 clinical studies by KKC in Japan to evaluate tenapanor for hyperphosphatemia. During the three months ended March&#160;31, 2022, we recognized $<ix:nonFraction unitRef="usd" contextRef="iab42eb33c5f6401eb4cabd7658b0c6bd_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80MC9mcmFnOmUwYjY2ZWViODRkMDRmN2JhZjFlYjEyNGIyNzE5NmY3L3RleHRyZWdpb246ZTBiNjZlZWI4NGQwNGY3YmFmMWViMTI0YjI3MTk2ZjdfMTA5OTUxMTYzODM3MQ_ce307345-c28a-4c50-b548-396f441cdc19">14</ix:nonFraction> thousand</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product supply revenue related to the manufacturing supply of tenapanor and other materials to KKC pursuant to the 2017 KKC Agreement. During the three months ended March&#160;31, 2021,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we recognized $<ix:nonFraction unitRef="usd" contextRef="i1760e71a3aab4fd190e7292ba626aa96_D20210101-20210331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80MC9mcmFnOmUwYjY2ZWViODRkMDRmN2JhZjFlYjEyNGIyNzE5NmY3L3RleHRyZWdpb246ZTBiNjZlZWI4NGQwNGY3YmFmMWViMTI0YjI3MTk2ZjdfMTA5OTUxMTYzODM4Ng_9d0d44f2-06e2-45c5-aab1-114af7042568">0.1</ix:nonFraction> million as product supply revenue pursuant to the 2017 KKC Agreement.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As detailed below under the heading </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deferred revenue - non-current</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we have received prepayments from KKC for the manufacturing of tenapanor drug substance that will be used to satisfy KKC needs. We also have recorded certain unbilled prepayments from KKC for the manufacturing of tenapanor drug product reflected within prepaid and other current assets. Both amounts are reflected within our deferred revenue, non-current on our condensed balance sheet as of March&#160;31, 2022. The prepayment is reflected within prepaid and other current assets and deferred revenue, non-current on our condensed balance sheet as of March&#160;31, 2022. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. (&#8220;Fosun Pharma&#8221;)</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017, we entered into an exclusive license agreement with Fosun</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharma</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Fosun Agreement&#8221;),</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the development, commercialization and distribution of tenapanor in China for both hyperphosphatemia and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IBS-C.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assessed these arrangements in accordance with ASC 606 and concluded that the contract counterparty, Fosun Pharma, is a customer. Under the terms of the Fosun Agreement, we received</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="iaafa907a1fc049f59de2c2fcb1b077a8_D20171201-20171231" decimals="-5" name="us-gaap:ProceedsFromLicenseFeesReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80MC9mcmFnOmUwYjY2ZWViODRkMDRmN2JhZjFlYjEyNGIyNzE5NmY3L3RleHRyZWdpb246ZTBiNjZlZWI4NGQwNGY3YmFmMWViMTI0YjI3MTk2ZjdfMTA5OTUxMTYzODQwNw_a66740a4-bf4d-4302-a3c1-c6ab3eb2ddf9">12.0</ix:nonFraction> million in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">upfront</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">license fees which was recognized as revenue when the agreement was executed. Based on</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">management&#8217;s</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assessment,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we determined</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that the license and the manufacturing supply services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">represented the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">material performance obligations at the inception of the agreement, and as such,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">each of the performance obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">distinct. &#160;</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be entitled to additional development and commercialization milestones of up to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i0a019b5505f7466ca2f76583b097cdbe_D20220101-20220331" decimals="-5" name="ardx:CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80MC9mcmFnOmUwYjY2ZWViODRkMDRmN2JhZjFlYjEyNGIyNzE5NmY3L3RleHRyZWdpb246ZTBiNjZlZWI4NGQwNGY3YmFmMWViMTI0YjI3MTk2ZjdfMTA5OTUxMTYzODQxMw_f747bab8-55e2-477b-b277-71e532aeaecc">110.0</ix:nonFraction> million, as well as reimbursement of cost plus a reasonable overhead for the supply of product and tiered royalties on net sales ranging from the mid-teens to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i0a019b5505f7466ca2f76583b097cdbe_D20220101-20220331" decimals="INF" name="ardx:ThresholdPercentageOfSalesForTieredRoyalties" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80MC9mcmFnOmUwYjY2ZWViODRkMDRmN2JhZjFlYjEyNGIyNzE5NmY3L3RleHRyZWdpb246ZTBiNjZlZWI4NGQwNGY3YmFmMWViMTI0YjI3MTk2ZjdfMTA5OTUxMTYzODQxNw_9d08252b-56c1-4af4-b5cf-5db2f72a102b">20</ix:nonFraction>%. The variable consideration related to the remaining development milestone payments has not been included in the transaction price as these were fully constrained at March&#160;31, 2022.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have recorded <ix:nonFraction unitRef="usd" contextRef="i9c7ce382bd124359a0a4700a39632df1_D20220101-20220331" decimals="INF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80MC9mcmFnOmUwYjY2ZWViODRkMDRmN2JhZjFlYjEyNGIyNzE5NmY3L3RleHRyZWdpb246ZTBiNjZlZWI4NGQwNGY3YmFmMWViMTI0YjI3MTk2ZjdfMTA5OTUxMTYzODQyNQ_4f90ca6d-7815-4e8b-be10-6876a36d48f2"><ix:nonFraction unitRef="usd" contextRef="ib9fd94dcca60490e82fbc1d493ab985c_D20210101-20210331" decimals="INF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80MC9mcmFnOmUwYjY2ZWViODRkMDRmN2JhZjFlYjEyNGIyNzE5NmY3L3RleHRyZWdpb246ZTBiNjZlZWI4NGQwNGY3YmFmMWViMTI0YjI3MTk2ZjdfMTA5OTUxMTYzODQyNQ_517baf55-06de-437f-9592-5e6025d5acc4">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">revenue during the three months ended March&#160;31, 2022 or 2021 related</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to the Fosun</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Agreement.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Knight Therapeutics, Inc. (&#8220;Knight&#8220;) &#160;</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2018, we entered into an exclusive license agreement with Knight (the &#8220;Knight Agreement&#8221;) for the development, commercialization and distribution of tenapanor in Canada for hyperphosphatemia and IBS-C. We assessed this arrangement in accordance with ASC 606 and concluded that the contract counterparty, Knight, is a customer. Based on management&#8217;s assessment, we determined that the license and the manufacturing supply services represented the material performance obligations at the inception of the agreement, and as such, each of the performance obligations is distinct. Under the terms of the agreement, we received a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i839c245d89c241679804a884e550ef5b_D20180301-20180331" decimals="-5" name="us-gaap:ProceedsFromLicenseFeesReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80MC9mcmFnOmUwYjY2ZWViODRkMDRmN2JhZjFlYjEyNGIyNzE5NmY3L3RleHRyZWdpb246ZTBiNjZlZWI4NGQwNGY3YmFmMWViMTI0YjI3MTk2ZjdfMTA5OTUxMTYzODQzNQ_042002d3-77aa-4f1f-9253-39f3d8253e0d">2.3</ix:nonFraction> million nonrefundable, one-time upfront payment in March 2018 and are eligible to receive additional development and commercialization milestone payments worth up to $<ix:nonFraction unitRef="usd" contextRef="i29560f0f154647109b5c7c80f240890c_D20220101-20220331" decimals="-5" name="ardx:CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80MC9mcmFnOmUwYjY2ZWViODRkMDRmN2JhZjFlYjEyNGIyNzE5NmY3L3RleHRyZWdpb246ZTBiNjZlZWI4NGQwNGY3YmFmMWViMTI0YjI3MTk2ZjdfMTA5OTUxMTYzODQzOQ_afe571c3-7441-4feb-b742-142f8dad93f7">17.8</ix:nonFraction> million. We are also eligible to receive royalties throughout the term of the agreement, and a transfer price for manufacturing services.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The variable consideration related to the remaining development milestone payments has not been included in the transaction price as they were fully constrained at March&#160;31, 2022.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">AstraZeneca AB (&#8220;AstraZeneca&#8221;)</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2015, we entered into a termination agreement with AstraZeneca (the &#8220;AstraZeneca Termination Agreement&#8221;) pursuant to which we have agreed to pay AstraZeneca (i) future royalties at a royalty rate of <ix:nonFraction unitRef="number" contextRef="i390f2ffb21554b849e8f47149934d4fd_D20150601-20150630" decimals="INF" name="ardx:PercentageOfRoyaltyRevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80MC9mcmFnOmUwYjY2ZWViODRkMDRmN2JhZjFlYjEyNGIyNzE5NmY3L3RleHRyZWdpb246ZTBiNjZlZWI4NGQwNGY3YmFmMWViMTI0YjI3MTk2ZjdfMTA5OTUxMTYzODQ1NA_36a14427-40d0-47f8-9d3a-cd7552de954d">10</ix:nonFraction>% of net sales of tenapanor or other NHE3 products by us or our licensees, and (ii) <ix:nonFraction unitRef="number" contextRef="i390f2ffb21554b849e8f47149934d4fd_D20150601-20150630" decimals="INF" name="ardx:PercentageOfNonRoyaltyRevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80MC9mcmFnOmUwYjY2ZWViODRkMDRmN2JhZjFlYjEyNGIyNzE5NmY3L3RleHRyZWdpb246ZTBiNjZlZWI4NGQwNGY3YmFmMWViMTI0YjI3MTk2ZjdfMTA5OTUxMTYzODQ1OA_c3b1a610-cb43-4d3a-bde9-17f354a42902">20</ix:nonFraction>% of non-royalty revenue received from a licensee of tenapanor or another NHE3 inhibitor, up to a maximum of $<ix:nonFraction unitRef="usd" contextRef="id4d3d62533e642adab59317a030f3b30_I20150630" decimals="-5" name="ardx:CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80MC9mcmFnOmUwYjY2ZWViODRkMDRmN2JhZjFlYjEyNGIyNzE5NmY3L3RleHRyZWdpb246ZTBiNjZlZWI4NGQwNGY3YmFmMWViMTI0YjI3MTk2ZjdfMTA5OTUxMTYzODQ2Mg_6fcfcfa2-65b5-4548-ba76-53802acee91c">75.0</ix:nonFraction> million in aggregate for (i) and (ii). As of March&#160;31, 2022, to date in aggregate, we have recognized $<ix:nonFraction unitRef="usd" contextRef="i8bde55ddcbf0400a8169b35ffe4c6da2_I20220331" decimals="-5" name="ardx:CostOfRevenueAggregateAmountRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80MC9mcmFnOmUwYjY2ZWViODRkMDRmN2JhZjFlYjEyNGIyNzE5NmY3L3RleHRyZWdpb246ZTBiNjZlZWI4NGQwNGY3YmFmMWViMTI0YjI3MTk2ZjdfMjE5OTAyMzI2ODUxNQ_9e3233f9-6fa6-473d-99e9-fd643a660047">11.7</ix:nonFraction> million of the $<ix:nonFraction unitRef="usd" contextRef="id4d3d62533e642adab59317a030f3b30_I20150630" decimals="-5" name="ardx:CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80MC9mcmFnOmUwYjY2ZWViODRkMDRmN2JhZjFlYjEyNGIyNzE5NmY3L3RleHRyZWdpb246ZTBiNjZlZWI4NGQwNGY3YmFmMWViMTI0YjI3MTk2ZjdfMjE5OTAyMzI2ODUyMg_6fcfcfa2-65b5-4548-ba76-53802acee91c">75.0</ix:nonFraction> million, which has been recorded as cost of revenue, and have paid AstraZeneca $<ix:nonFraction unitRef="usd" contextRef="i73d193d247244f1fb9ce854954086ef6_I20220331" decimals="-5" name="ardx:PaymentsOfUnchargedLicenseFeesAggregateAmountPaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80MC9mcmFnOmUwYjY2ZWViODRkMDRmN2JhZjFlYjEyNGIyNzE5NmY3L3RleHRyZWdpb246ZTBiNjZlZWI4NGQwNGY3YmFmMWViMTI0YjI3MTk2ZjdfMjE5OTAyMzI2ODUyNg_d65c9835-1c24-4369-abb0-8161f1ce891d">11.6</ix:nonFraction> million. During the three months ended March&#160;31, 2022 we recognized and recorded as cost of revenue $<ix:nonFraction unitRef="usd" contextRef="i025ade055f874ff1a468b7fbd0583eda_D20220101-20220331" decimals="-5" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80MC9mcmFnOmUwYjY2ZWViODRkMDRmN2JhZjFlYjEyNGIyNzE5NmY3L3RleHRyZWdpb246ZTBiNjZlZWI4NGQwNGY3YmFmMWViMTI0YjI3MTk2ZjdfMjE5OTAyMzI2ODUwNw_227f02e1-7f76-4e68-b1db-2b76df819418">0.1</ix:nonFraction> million related to the AstraZeneca Termination Agreement. During the three months ended March&#160;31, 2021 we recognized $<ix:nonFraction unitRef="usd" contextRef="i3de6eb23c1e24a80807755f0069fc236_D20210101-20210331" decimals="-5" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80MC9mcmFnOmUwYjY2ZWViODRkMDRmN2JhZjFlYjEyNGIyNzE5NmY3L3RleHRyZWdpb246ZTBiNjZlZWI4NGQwNGY3YmFmMWViMTI0YjI3MTk2ZjdfMTA5OTUxMTY0NjY4Mg_657cca95-ca09-48b0-8643-b308e5d87e82">1.0</ix:nonFraction> million cost of revenue related to the AstraZeneca Termination Agreement.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i711b1a39e0634b15bb7a70766327247a_7">Table of Contents</a></span></div></div><ix:continuation id="i54ff91fa72c84ee7bc6e4be988d33fb7"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Revenue</span></div><ix:nonNumeric contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80MC9mcmFnOmUwYjY2ZWViODRkMDRmN2JhZjFlYjEyNGIyNzE5NmY3L3RleHRyZWdpb246ZTBiNjZlZWI4NGQwNGY3YmFmMWViMTI0YjI3MTk2ZjdfOTYzMA_9471863a-27d5-4651-967e-6c7211184fcf" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present changes in our current and non-current deferred revenue balances during the reporting period. The March&#160;31, 2021 current deferred revenue balance is attributable entirely to the 2019 KKC Agreement and the non-current deferred revenue balances at March&#160;31, 2022 and 2021 are attributable entirely to the 2017 KKC Agreement (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.300%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred revenue - current</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1,</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34485cae15f04837aa894774e18bbb58_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80MC9mcmFnOmUwYjY2ZWViODRkMDRmN2JhZjFlYjEyNGIyNzE5NmY3L3RhYmxlOmIzZmEzODA5YWM1NTQxOGQ5ZTY1M2IxNjZiOGE1YjlmL3RhYmxlcmFuZ2U6YjNmYTM4MDlhYzU1NDE4ZDllNjUzYjE2NmI4YTViOWZfMS0xLTEtMS0yMzAxMw_ed616e6d-a353-4756-9bc2-c2ce58bd9847">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia600adb07b6d40c9b3357ac69342a7ad_I20201231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80MC9mcmFnOmUwYjY2ZWViODRkMDRmN2JhZjFlYjEyNGIyNzE5NmY3L3RhYmxlOmIzZmEzODA5YWM1NTQxOGQ5ZTY1M2IxNjZiOGE1YjlmL3RhYmxlcmFuZ2U6YjNmYTM4MDlhYzU1NDE4ZDllNjUzYjE2NmI4YTViOWZfMS0zLTEtMS0yNTM0Mg_6f15a7cc-1ff1-4791-8a33-c28ed726a439">4,177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decreases due to revenue recognized in the period for which cash has been received</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i745335ff1da443c2a66acb028f9b9044_D20220101-20220331" decimals="-3" name="ardx:ContractWithCustomerLiabilityRevenueRecognizedCashReceived" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80MC9mcmFnOmUwYjY2ZWViODRkMDRmN2JhZjFlYjEyNGIyNzE5NmY3L3RhYmxlOmIzZmEzODA5YWM1NTQxOGQ5ZTY1M2IxNjZiOGE1YjlmL3RhYmxlcmFuZ2U6YjNmYTM4MDlhYzU1NDE4ZDllNjUzYjE2NmI4YTViOWZfMy0xLTEtMS0yMzAxMw_c732952b-1280-46b5-bd06-fd99c616b9ed">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id32818d38a2f41e79d9416fb0bd0e53a_D20210101-20210331" decimals="-3" name="ardx:ContractWithCustomerLiabilityRevenueRecognizedCashReceived" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80MC9mcmFnOmUwYjY2ZWViODRkMDRmN2JhZjFlYjEyNGIyNzE5NmY3L3RhYmxlOmIzZmEzODA5YWM1NTQxOGQ5ZTY1M2IxNjZiOGE1YjlmL3RhYmxlcmFuZ2U6YjNmYTM4MDlhYzU1NDE4ZDllNjUzYjE2NmI4YTViOWZfMy0zLTEtMS0yNTM0Mg_3631e436-56fd-43f7-a71d-403e71c7c863">1,454</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31,</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i717222ed03814f8f986a1604095f9214_I20220331" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80MC9mcmFnOmUwYjY2ZWViODRkMDRmN2JhZjFlYjEyNGIyNzE5NmY3L3RhYmxlOmIzZmEzODA5YWM1NTQxOGQ5ZTY1M2IxNjZiOGE1YjlmL3RhYmxlcmFuZ2U6YjNmYTM4MDlhYzU1NDE4ZDllNjUzYjE2NmI4YTViOWZfNS0xLTEtMS0yMzAxMw_2d5a1680-40bb-452e-9cb5-f75dee9a0e91">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic81523b011734f66b3b288912d844b1d_I20210331" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80MC9mcmFnOmUwYjY2ZWViODRkMDRmN2JhZjFlYjEyNGIyNzE5NmY3L3RhYmxlOmIzZmEzODA5YWM1NTQxOGQ5ZTY1M2IxNjZiOGE1YjlmL3RhYmxlcmFuZ2U6YjNmYTM4MDlhYzU1NDE4ZDllNjUzYjE2NmI4YTViOWZfNS0zLTEtMS0yNTM0Mg_b3b8df7c-ab70-4227-8e70-b7a8dd234bb7">2,723</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:63.760%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.030%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.325%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred revenue - non-current</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1,</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61553ae32dfb40f8b285bdfc4a3d3272_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80MC9mcmFnOmUwYjY2ZWViODRkMDRmN2JhZjFlYjEyNGIyNzE5NmY3L3RhYmxlOjNlNWFhNTFlZWMxZDRjOTVhNzk5YWI3MGExZGIwODM0L3RhYmxlcmFuZ2U6M2U1YWE1MWVlYzFkNGM5NWE3OTlhYjcwYTFkYjA4MzRfMS0xLTEtMS0yMzAxMw_597482b5-0fe6-4ecb-ab71-e4de9030c586">4,727</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd27a0a1ac554dc1a75c1884f665b7f6_I20201231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80MC9mcmFnOmUwYjY2ZWViODRkMDRmN2JhZjFlYjEyNGIyNzE5NmY3L3RhYmxlOjNlNWFhNTFlZWMxZDRjOTVhNzk5YWI3MGExZGIwODM0L3RhYmxlcmFuZ2U6M2U1YWE1MWVlYzFkNGM5NWE3OTlhYjcwYTFkYjA4MzRfMS0zLTEtMS0yNTM3Nw_ab4b94ee-8b7d-47c2-a4da-dff929f31a5a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases to amounts invoiced, for which cash has not yet been received</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e8de9754a784d54a397d66dc8d5ebf0_D20220101-20220331" decimals="-3" name="ardx:ContractWithCustomerLiabilityIncreaseForAmountsInvoiced" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80MC9mcmFnOmUwYjY2ZWViODRkMDRmN2JhZjFlYjEyNGIyNzE5NmY3L3RhYmxlOjNlNWFhNTFlZWMxZDRjOTVhNzk5YWI3MGExZGIwODM0L3RhYmxlcmFuZ2U6M2U1YWE1MWVlYzFkNGM5NWE3OTlhYjcwYTFkYjA4MzRfMy0xLTEtMS0zMTgwMg_28d7579d-258b-4299-b484-9aaa80f59329">3,829</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb1b8b57f3484b4c886d5bcda853744b_D20210101-20210331" decimals="-3" name="ardx:ContractWithCustomerLiabilityIncreaseForAmountsInvoiced" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80MC9mcmFnOmUwYjY2ZWViODRkMDRmN2JhZjFlYjEyNGIyNzE5NmY3L3RhYmxlOjNlNWFhNTFlZWMxZDRjOTVhNzk5YWI3MGExZGIwODM0L3RhYmxlcmFuZ2U6M2U1YWE1MWVlYzFkNGM5NWE3OTlhYjcwYTFkYjA4MzRfMy0zLTEtMS0zMTgwMg_c6149568-6ba6-442f-a075-6b5c9edbddba">2,947</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase due to unbilled prepayments recorded during the period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e8de9754a784d54a397d66dc8d5ebf0_D20220101-20220331" decimals="-3" name="ardx:ContractWithCustomerLiabilityIncreaseDueToUnbilledPrepaymentsRecorded" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80MC9mcmFnOmUwYjY2ZWViODRkMDRmN2JhZjFlYjEyNGIyNzE5NmY3L3RhYmxlOjNlNWFhNTFlZWMxZDRjOTVhNzk5YWI3MGExZGIwODM0L3RhYmxlcmFuZ2U6M2U1YWE1MWVlYzFkNGM5NWE3OTlhYjcwYTFkYjA4MzRfMy0xLTEtMS0yMzAxMw_c9ec52e4-04e6-4f43-88dd-a2ec0f7704ec">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb1b8b57f3484b4c886d5bcda853744b_D20210101-20210331" decimals="-3" name="ardx:ContractWithCustomerLiabilityIncreaseDueToUnbilledPrepaymentsRecorded" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80MC9mcmFnOmUwYjY2ZWViODRkMDRmN2JhZjFlYjEyNGIyNzE5NmY3L3RhYmxlOjNlNWFhNTFlZWMxZDRjOTVhNzk5YWI3MGExZGIwODM0L3RhYmxlcmFuZ2U6M2U1YWE1MWVlYzFkNGM5NWE3OTlhYjcwYTFkYjA4MzRfMy0zLTEtMS0yNTM3Nw_cdb6b058-5f84-42a4-a808-2d4ca0c92072">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31,</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2146e1f17bd043f3b77edbd52edab483_I20220331" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80MC9mcmFnOmUwYjY2ZWViODRkMDRmN2JhZjFlYjEyNGIyNzE5NmY3L3RhYmxlOjNlNWFhNTFlZWMxZDRjOTVhNzk5YWI3MGExZGIwODM0L3RhYmxlcmFuZ2U6M2U1YWE1MWVlYzFkNGM5NWE3OTlhYjcwYTFkYjA4MzRfNS0xLTEtMS0yMzAxMw_a7df8e8e-0d70-4794-8d36-1b5459a5c55b">8,563</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f0cf433f09e4f1e9169aefcedff5d7f_I20210331" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80MC9mcmFnOmUwYjY2ZWViODRkMDRmN2JhZjFlYjEyNGIyNzE5NmY3L3RhYmxlOjNlNWFhNTFlZWMxZDRjOTVhNzk5YWI3MGExZGIwODM0L3RhYmxlcmFuZ2U6M2U1YWE1MWVlYzFkNGM5NWE3OTlhYjcwYTFkYjA4MzRfNS0zLTEtMS0yNTM3Nw_108dd38e-6d11-4938-b064-dc60b0905c13">2,947</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:5pt;text-align:justify"><span><br/></span></div><div id="i711b1a39e0634b15bb7a70766327247a_43"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 7. <ix:nonNumeric contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80My9mcmFnOmRjNDJmYTBmZjMzMjRhNDVhMTZjODM2MWYzYWMzOGVmL3RleHRyZWdpb246ZGM0MmZhMGZmMzMyNGE0NWExNmM4MzYxZjNhYzM4ZWZfNDUyOQ_997ba1e5-3d6b-4c3c-b06a-4df93451f35f" continuedAt="iac48bc38e81041c496a35aeee85d461c" escape="true">BORROWING </ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="iac48bc38e81041c496a35aeee85d461c" continuedAt="ie0265d7af2c44493bfe7e93dc7b8e761"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Solar Capital and Western Alliance Bank Loan Agreement</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 16, 2018, we entered into a loan and security agreement (as amended on October 9, 2020, March 1, 2021, May 5, 2021, and July 29, 2021) (the "2018 Loan Agreement") with Solar Capital Ltd. and Western Alliance Bank (collectively the &#8220;2018 Lenders&#8221;). The 2018 Loan Agreement provided for a $<ix:nonFraction unitRef="usd" contextRef="ib7f93b8f72cf486bbecc12514b98b015_I20180516" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80My9mcmFnOmRjNDJmYTBmZjMzMjRhNDVhMTZjODM2MWYzYWMzOGVmL3RleHRyZWdpb246ZGM0MmZhMGZmMzMyNGE0NWExNmM4MzYxZjNhYzM4ZWZfMTA5OTUxMTYzMjMyMQ_1c61df0f-a2de-495d-a1b0-b08c28ca7789">50.0</ix:nonFraction> million loan facility with a maturity date of November&#160;1, 2022 (the &#8220;2018 Loan&#8221;). As of the Closing Date for the 2022 Loan, as discussed below, we owed $<ix:nonFraction unitRef="usd" contextRef="ib7054c03dafb4f308b95f52c3a43fa1b_I20220223" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80My9mcmFnOmRjNDJmYTBmZjMzMjRhNDVhMTZjODM2MWYzYWMzOGVmL3RleHRyZWdpb246ZGM0MmZhMGZmMzMyNGE0NWExNmM4MzYxZjNhYzM4ZWZfMTA5OTUxMTY0NDcxMA_4535013a-1f4d-48e2-9b8d-59b29b2c3a12">25.0</ix:nonFraction> million in principal payments from the 2018 Loan, which we repaid in full at that time.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 8. Derivative Liability</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in connection with entering into the 2018 Loan Agreement, we entered into an agreement pursuant to which we agreed to pay $<ix:nonFraction unitRef="usd" contextRef="iba83d40326b1433ea471109cb11536f8_I20180531" decimals="-5" name="us-gaap:DerivativeLiabilityNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80My9mcmFnOmRjNDJmYTBmZjMzMjRhNDVhMTZjODM2MWYzYWMzOGVmL3RleHRyZWdpb246ZGM0MmZhMGZmMzMyNGE0NWExNmM4MzYxZjNhYzM4ZWZfMTA5OTUxMTY0NTc2MQ_59404140-0b18-4e60-ac9e-35a64baab29d">1.5</ix:nonFraction> million in cash upon the occurrence of certain conditions (the "2018 Exit Fee"). Our obligations for the 2018 Exit Fee remain outstanding following the full repayment of the 2018 Loan in February 2022. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">SLR Investments Loan Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 23, 2022 (the &#8220;Closing Date&#8221;), we entered into a loan and security agreement (the &#8220;2022 Loan Agreement&#8221;) with SLR Investment Corp. as collateral agent (the &#8220;Agent&#8221;), and the lenders listed in the 2022 Loan Agreement (collectively the &#8220;2022 Lenders&#8221;). The 2022 Loan Agreement provides for a senior secured loan facility, with $<ix:nonFraction unitRef="usd" contextRef="i3a8be86cba30452780b8d0bca7fe52ef_D20220223-20220223" decimals="-5" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80My9mcmFnOmRjNDJmYTBmZjMzMjRhNDVhMTZjODM2MWYzYWMzOGVmL3RleHRyZWdpb246ZGM0MmZhMGZmMzMyNGE0NWExNmM4MzYxZjNhYzM4ZWZfMTA5OTUxMTY0NTI5Mg_f92197d1-6e8d-4fb3-811b-115ad217f356">27.5</ix:nonFraction> million (the &#8220;Term A Loan&#8221;) funded on the Closing Date and an additional $<ix:nonFraction unitRef="usd" contextRef="i22ce6a39c3434acd91d5ab75ae19b62f_I20220223" decimals="-5" name="ardx:RemainingFundingBasedOnConditionalMilestoneAchievement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80My9mcmFnOmRjNDJmYTBmZjMzMjRhNDVhMTZjODM2MWYzYWMzOGVmL3RleHRyZWdpb246ZGM0MmZhMGZmMzMyNGE0NWExNmM4MzYxZjNhYzM4ZWZfMTA5OTUxMTY0NTMxMg_d5b764dd-0fa4-41f8-917c-8a22fc4abb36">22.5</ix:nonFraction> million that we may borrow on or prior to July 25, 2023; provided that (i) we have received approval by the FDA for our NDA for the control of serum phosphorus in chronic kidney disease patients on dialysis by December 31, 2022, and (ii) we have achieved certain product revenue milestone targets described in the 2022 Loan Agreement (the &#8220;Term B Loan&#8221;, and collectively, the Term A Loan and the Term B Loan, the &#8220;2022 Loan&#8221;). The 2022 Term A Loan funds were used to repay the 2018 Loan with the 2018 Lenders. The 2022 Loan has a maturity date of March 1, 2027.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the 2022 Loan bear interest at a floating per annum rate equal to <ix:nonFraction unitRef="number" contextRef="i00d53b360ebd4d39ab0a045093b0d350_D20220223-20220223" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80My9mcmFnOmRjNDJmYTBmZjMzMjRhNDVhMTZjODM2MWYzYWMzOGVmL3RleHRyZWdpb246ZGM0MmZhMGZmMzMyNGE0NWExNmM4MzYxZjNhYzM4ZWZfMTA5OTUxMTY0NTMyMw_66fb9d55-43ac-4e4b-ae23-2e6f5f076326">7.95</ix:nonFraction>% plus the greater of (i) one tenth percent (<ix:nonFraction unitRef="number" contextRef="i00d53b360ebd4d39ab0a045093b0d350_D20220223-20220223" decimals="INF" name="ardx:DebtInstrumentVariableRateBaseOption" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80My9mcmFnOmRjNDJmYTBmZjMzMjRhNDVhMTZjODM2MWYzYWMzOGVmL3RleHRyZWdpb246ZGM0MmZhMGZmMzMyNGE0NWExNmM4MzYxZjNhYzM4ZWZfMTA5OTUxMTY0NTMzMQ_a805bba7-0c2c-4f44-bd49-805eb54ac932">0.10</ix:nonFraction>%) and (ii) the one-month rate published by the Intercontinental Exchange Benchmark Administration Ltd or its successor. We are permitted to make interest-only payments on the 2022 Loan through March 31, 2024. Accordingly, beginning on April 1, 2024, we will be required to make monthly payments of interest plus repay the 2022 Loan in consecutive equal monthly installments of principal. We were obligated to pay $<ix:nonFraction unitRef="usd" contextRef="id7137d11d7564018ab80498ef529b584_I20220223" decimals="-5" name="ardx:DebtInstrumentClosingFeeAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80My9mcmFnOmRjNDJmYTBmZjMzMjRhNDVhMTZjODM2MWYzYWMzOGVmL3RleHRyZWdpb246ZGM0MmZhMGZmMzMyNGE0NWExNmM4MzYxZjNhYzM4ZWZfMTA5OTUxMTY0NTM0Ng_18f602c7-7c76-4a0c-ae31-a722ea7063be">0.2</ix:nonFraction> million, upon the closing of the Term A Loan, and we are obligated to pay $<ix:nonFraction unitRef="usd" contextRef="i22ce6a39c3434acd91d5ab75ae19b62f_I20220223" decimals="-5" name="ardx:LoanAgreementFutureObligationUponFundingOrOtherEvents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80My9mcmFnOmRjNDJmYTBmZjMzMjRhNDVhMTZjODM2MWYzYWMzOGVmL3RleHRyZWdpb246ZGM0MmZhMGZmMzMyNGE0NWExNmM4MzYxZjNhYzM4ZWZfMTA5OTUxMTY0NTM2Mw_02994257-936e-445f-8e63-7a073c7586b9">0.1</ix:nonFraction> million on the earliest of (i) the funding date of the Term B Loan, (ii) July 25, 2023, and (iii) the prepayment, refinancing, substitution, or replacement of the Term A Loan on or prior to July 25, 2023. We are obligated to pay a final fee equal to <ix:nonFraction unitRef="number" contextRef="icbf434cb3f104e188c9fd0464443c2f4_I20220223" decimals="INF" name="ardx:DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80My9mcmFnOmRjNDJmYTBmZjMzMjRhNDVhMTZjODM2MWYzYWMzOGVmL3RleHRyZWdpb246ZGM0MmZhMGZmMzMyNGE0NWExNmM4MzYxZjNhYzM4ZWZfMTA5OTUxMTY0NTM3NQ_aa2c6d4c-1a21-418b-ae2f-260d5e7050d0">4.95</ix:nonFraction>% of the aggregate original principal amount of the 2022 Loan funded upon the earliest to occur of the maturity date, the acceleration of the 2022 Loan, and the prepayment, refinancing, substitution, or replacement of the 2022 Loan. We may voluntarily prepay the outstanding 2022 Loan balance, subject to a prepayment premium of (i) <ix:nonFraction unitRef="number" contextRef="i5d5d94cb725e4caca45734b96460fab2_I20220223" decimals="INF" name="ardx:DebtInstrumentPrepaymentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80My9mcmFnOmRjNDJmYTBmZjMzMjRhNDVhMTZjODM2MWYzYWMzOGVmL3RleHRyZWdpb246ZGM0MmZhMGZmMzMyNGE0NWExNmM4MzYxZjNhYzM4ZWZfMTA5OTUxMTY0NTM5MA_aca1a0d2-0cf0-4f35-a81b-49a3c4ebde5d">3</ix:nonFraction>% of the </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i711b1a39e0634b15bb7a70766327247a_7">Table of Contents</a></span></div></div><ix:continuation id="ie0265d7af2c44493bfe7e93dc7b8e761"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">outstanding principal amount of the 2022 Loan if prepaid prior to or on the first anniversary of the Closing Date, (ii) <ix:nonFraction unitRef="number" contextRef="i5134dd31b2ec46ba9252bb3ccd222425_I20220223" decimals="INF" name="ardx:DebtInstrumentPrepaymentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80My9mcmFnOmRjNDJmYTBmZjMzMjRhNDVhMTZjODM2MWYzYWMzOGVmL3RleHRyZWdpb246ZGM0MmZhMGZmMzMyNGE0NWExNmM4MzYxZjNhYzM4ZWZfMTA5OTUxMTY0NTM4MA_b290e305-a045-4b1e-b889-a0c9d5f2f65b">2</ix:nonFraction>% of the outstanding principal amount of the 2022 Loan if prepaid after the first anniversary of the Closing Date through and including the second anniversary of the Closing Date, or (iii) <ix:nonFraction unitRef="number" contextRef="ia616f3b3f10d4ebda8439302d146953c_I20220223" decimals="INF" name="ardx:DebtInstrumentPrepaymentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80My9mcmFnOmRjNDJmYTBmZjMzMjRhNDVhMTZjODM2MWYzYWMzOGVmL3RleHRyZWdpb246ZGM0MmZhMGZmMzMyNGE0NWExNmM4MzYxZjNhYzM4ZWZfMTA5OTUxMTY0NTM4NQ_3394f815-8f5d-4a7d-b109-19c5085d8ef7">1</ix:nonFraction>% of the outstanding principal amount of the 2022 Loan if prepaid after the second anniversary of the Closing Date and prior to the maturity date. The 2022 Loan is secured by substantially all of our assets, except for our intellectual property and certain other customary exclusions. Additionally, in connection with the 2022 Loan, we entered into an agreement, whereby we agreed to pay an exit fee in the amount <ix:nonFraction unitRef="number" contextRef="i6c1d87e6c35c44b9baca5f0c32c93d4e_I20220223" decimals="INF" name="ardx:ExitFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80My9mcmFnOmRjNDJmYTBmZjMzMjRhNDVhMTZjODM2MWYzYWMzOGVmL3RleHRyZWdpb246ZGM0MmZhMGZmMzMyNGE0NWExNmM4MzYxZjNhYzM4ZWZfNDM5ODA0NjUyODkwMQ_12bc347d-0ca0-4904-88c7-acfb14acf789">2</ix:nonFraction>% of the 2022 Loan funded (the &#8220;2022 Exit Fee&#8221;) upon (i) any change of control transaction or (ii) our achievement of net revenue from the sale of any products equal to or greater than $<ix:nonFraction unitRef="usd" contextRef="ie706e05847024bdfbe5174e56d319428_D20220223-20220223" decimals="-5" name="ardx:LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80My9mcmFnOmRjNDJmYTBmZjMzMjRhNDVhMTZjODM2MWYzYWMzOGVmL3RleHRyZWdpb246ZGM0MmZhMGZmMzMyNGE0NWExNmM4MzYxZjNhYzM4ZWZfNDM5ODA0NjUyODkyMA_482d1086-1ba4-41a3-b833-4d11c599a950">100.0</ix:nonFraction>&#160;million, measured on a six (6) months basis, tested monthly at the end of each month. Notwithstanding the prepayment or termination of the 2022 Loan, the 2022 Exit Fee will expire <ix:nonNumeric contextRef="ie706e05847024bdfbe5174e56d319428_D20220223-20220223" name="ardx:LoanAgreementExitFeeTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80My9mcmFnOmRjNDJmYTBmZjMzMjRhNDVhMTZjODM2MWYzYWMzOGVmL3RleHRyZWdpb246ZGM0MmZhMGZmMzMyNGE0NWExNmM4MzYxZjNhYzM4ZWZfNDM5ODA0NjUyODkxMw_e6daf060-2854-4d68-8408-8c9f8bc76e3a">10</ix:nonNumeric> years from the Closing Date.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2022 Loan Agreement contains customary representations and warranties and customary affirmative and negative covenants, including, among others, requirements as to financial reporting and insurance and restrictions on our ability to dispose of our business or property, to change our line of business, to liquidate or dissolve, to enter into any change in control transaction, to merge or consolidate with any other entity or to acquire all or substantially all the capital stock or property of another entity, to incur additional indebtedness, to incur liens on our property, to pay any dividends or other distributions on capital stock other than dividends payable solely in capital stock or to redeem capital stock. We have agreed to not allow our cash and cash equivalents to be less than the eighty percent (<ix:nonFraction unitRef="number" contextRef="icbf434cb3f104e188c9fd0464443c2f4_I20220223" decimals="INF" name="ardx:LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80My9mcmFnOmRjNDJmYTBmZjMzMjRhNDVhMTZjODM2MWYzYWMzOGVmL3RleHRyZWdpb246ZGM0MmZhMGZmMzMyNGE0NWExNmM4MzYxZjNhYzM4ZWZfMTA5OTUxMTY0NTM5Ng_038c6b19-f411-4b7a-98db-ef6ed4748607">80</ix:nonFraction>%) of the outstanding 2022 Term Loan balance for any period in which our net revenue from the sale of any products, calculated on a trailing six (6) month basis and tested monthly, is less than sixty percent (<ix:nonFraction unitRef="number" contextRef="icbf434cb3f104e188c9fd0464443c2f4_I20220223" decimals="INF" name="ardx:LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80My9mcmFnOmRjNDJmYTBmZjMzMjRhNDVhMTZjODM2MWYzYWMzOGVmL3RleHRyZWdpb246ZGM0MmZhMGZmMzMyNGE0NWExNmM4MzYxZjNhYzM4ZWZfMTA5OTUxMTY0NTQwMg_259392e3-95b5-4b50-becf-3586b2a0f36b">60</ix:nonFraction>%) of the outstanding 2022 Loan balance.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the 2022 Loan Agreement contains customary events of default that entitle the Agent to cause our indebtedness under the 2022 Loan Agreement to become immediately due and payable, and to exercise remedies against us and the collateral securing the 2022 Term Loan, including our cash. Under the 2022 Loan Agreement, an event of default will occur if, among other things, we fail to make payments under the 2022 Loan Agreement, we breach any of our covenants under the 2022 Loan Agreement, subject to specified cure periods with respect to certain breaches, certain Lenders determine that a material adverse change has occurred, we or our assets become subject to certain legal proceedings, such as bankruptcy proceedings, we are unable to pay our debts as they become due or we default on contracts with third parties which would permit the holder of indebtedness to accelerate the maturity of such indebtedness or that could have a material adverse change on us. Upon the occurrence and for the duration of an event of default, an additional default interest rate equal to <ix:nonFraction unitRef="number" contextRef="icbf434cb3f104e188c9fd0464443c2f4_I20220223" decimals="INF" name="ardx:DebtInstrumentInterestRateOnDefaultPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80My9mcmFnOmRjNDJmYTBmZjMzMjRhNDVhMTZjODM2MWYzYWMzOGVmL3RleHRyZWdpb246ZGM0MmZhMGZmMzMyNGE0NWExNmM4MzYxZjNhYzM4ZWZfMTA5OTUxMTY0NTQxMQ_7326ebdb-9e9b-4cbc-acfb-9420b388e352">4</ix:nonFraction>% per annum will apply to all obligations owed under the 2022 Loan Agreement. We have classified the 2022 Loan balance as a current liability as of March&#160;31, 2022 due to the determination of the existence of substantial doubt about our ability to continue operating as a going concern discussed in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1. Organization and Basis of Presentation: Liquidity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and our assessment that the material adverse change clause under the 2022 Loan Agreement is not within our control. The lenders have not invoked the material adverse change clause as of the date of issuance of these financial statements. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><ix:nonNumeric contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80My9mcmFnOmRjNDJmYTBmZjMzMjRhNDVhMTZjODM2MWYzYWMzOGVmL3RleHRyZWdpb246ZGM0MmZhMGZmMzMyNGE0NWExNmM4MzYxZjNhYzM4ZWZfNDUzMA_4d4bb952-648d-4d9a-bb7c-0678e9c6e379" escape="true"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, our future payment obligations related to the 2022 Loan, excluding interest payments and the 2022 final fee, are as follows (in thousands):</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:86.162%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.638%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total repayment obligations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80My9mcmFnOmRjNDJmYTBmZjMzMjRhNDVhMTZjODM2MWYzYWMzOGVmL3RhYmxlOmZlMjg2ZDJiNmQzNTQ1NTNiMGE2NjczODdlY2FlY2Y0L3RhYmxlcmFuZ2U6ZmUyODZkMmI2ZDM1NDU1M2IwYTY2NzM4N2VjYWVjZjRfMC0xLTEtMS0yMzAxMw_95e1c67c-52d1-4fe3-9cbf-6d96e643b894">28,862</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Unamortized discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80My9mcmFnOmRjNDJmYTBmZjMzMjRhNDVhMTZjODM2MWYzYWMzOGVmL3RhYmxlOmZlMjg2ZDJiNmQzNTQ1NTNiMGE2NjczODdlY2FlY2Y0L3RhYmxlcmFuZ2U6ZmUyODZkMmI2ZDM1NDU1M2IwYTY2NzM4N2VjYWVjZjRfMS0xLTEtMS0yMzAxMw_1a66cce6-bab8-4e93-a780-b5889a528208">1,399</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Unaccreted value of final fee</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331" decimals="-3" name="us-gaap:DebtInstrumentFeeAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80My9mcmFnOmRjNDJmYTBmZjMzMjRhNDVhMTZjODM2MWYzYWMzOGVmL3RhYmxlOmZlMjg2ZDJiNmQzNTQ1NTNiMGE2NjczODdlY2FlY2Y0L3RhYmxlcmFuZ2U6ZmUyODZkMmI2ZDM1NDU1M2IwYTY2NzM4N2VjYWVjZjRfMi0xLTEtMS0yMzAxMw_f518a0a7-a212-490e-81bb-b068bb49bfca">1,324</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80My9mcmFnOmRjNDJmYTBmZjMzMjRhNDVhMTZjODM2MWYzYWMzOGVmL3RhYmxlOmZlMjg2ZDJiNmQzNTQ1NTNiMGE2NjczODdlY2FlY2Y0L3RhYmxlcmFuZ2U6ZmUyODZkMmI2ZDM1NDU1M2IwYTY2NzM4N2VjYWVjZjRfMy0xLTEtMS0yMzAxMw_00ddde78-51f2-4dd1-8edb-24d5ac0fea80">26,139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion of long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80My9mcmFnOmRjNDJmYTBmZjMzMjRhNDVhMTZjODM2MWYzYWMzOGVmL3RhYmxlOmZlMjg2ZDJiNmQzNTQ1NTNiMGE2NjczODdlY2FlY2Y0L3RhYmxlcmFuZ2U6ZmUyODZkMmI2ZDM1NDU1M2IwYTY2NzM4N2VjYWVjZjRfNC0xLTEtMS0yMzAxMw_be12c919-29c9-41ef-86d3-cd4ffc41c12d">26,139</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net of current portion</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80My9mcmFnOmRjNDJmYTBmZjMzMjRhNDVhMTZjODM2MWYzYWMzOGVmL3RhYmxlOmZlMjg2ZDJiNmQzNTQ1NTNiMGE2NjczODdlY2FlY2Y0L3RhYmxlcmFuZ2U6ZmUyODZkMmI2ZDM1NDU1M2IwYTY2NzM4N2VjYWVjZjRfNS0xLTEtMS0yMzAxMw_e7b04133-9375-455f-8319-3bc99e383c78">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i711b1a39e0634b15bb7a70766327247a_46"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 8. &#160;<ix:nonNumeric contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" name="us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80Ni9mcmFnOjk3ZWVkZmEwMmYxYjQyOTFhOWE4NGE4ZDRmNmI2YjQzL3RleHRyZWdpb246OTdlZWRmYTAyZjFiNDI5MWE5YTg0YThkNGY2YjZiNDNfMjY5MQ_a75de47c-99f9-441b-8be1-ff6f0123099b" continuedAt="ib0e410c7605a4a24a3a9c122da57d6ba" escape="true">DERIVATIVE LIABILITY</ix:nonNumeric></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><ix:continuation id="ib0e410c7605a4a24a3a9c122da57d6ba" continuedAt="i620e7229eb8746fbac5520e79be903ea"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2018 Exit Fee</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, in connection with entering into the 2018 Loan Agreement, we entered into an agreement pursuant to which we agreed to pay $<ix:nonFraction unitRef="usd" contextRef="iba83d40326b1433ea471109cb11536f8_I20180531" decimals="-5" name="us-gaap:DerivativeLiabilityNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80Ni9mcmFnOjk3ZWVkZmEwMmYxYjQyOTFhOWE4NGE4ZDRmNmI2YjQzL3RleHRyZWdpb246OTdlZWRmYTAyZjFiNDI5MWE5YTg0YThkNGY2YjZiNDNfMTA5OTUxMTYzMDQ5MQ_59404140-0b18-4e60-ac9e-35a64baab29d">1.5</ix:nonFraction> million in cash (the &#8220;2018 Exit Fee&#8221;) upon any change of control transaction in respect of the Company or if we obtain both (i) FDA approval of tenapanor for the control of serum phosphorus in adult patients with CKD on dialysis and (ii) FDA approval of tenapanor for the treatment of patients with IBS-C, which was obtained on September 12, 2019 when the FDA approved IBSRELA&#174; (tenapanor), a 50 milligram, twice daily oral pill for the treatment of IBS-C in adults (the &#8220;2018 Exit Fee Agreement&#8221;). Notwithstanding the February 2022 prepayment of the 2018 Loan our obligation to pay the 2018 Exit Fee will expire on May 16, 2028. We concluded that the 2018 Exit Fee is a freestanding derivative which should be accounted </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i711b1a39e0634b15bb7a70766327247a_7">Table of Contents</a></span></div></div><ix:continuation id="i620e7229eb8746fbac5520e79be903ea"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for at fair value on a recurring basis. The estimated fair value of the 2018 Exit Fee is recorded as a derivative liability and included in accrued expenses and other current liabilities on the accompanying condensed balance sheets.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the derivative liability was determined using a discounted cash flow analysis and is classified as a Level 3 measurement within the fair value hierarchy since our valuation utilized significant unobservable inputs. Specifically, the key assumptions included in the calculation of the estimated fair value of the 2018 derivative liability include: (i) our estimates of both the probability and timing of a potential $<ix:nonFraction unitRef="usd" contextRef="iba83d40326b1433ea471109cb11536f8_I20180531" decimals="-5" name="us-gaap:DerivativeLiabilityNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80Ni9mcmFnOjk3ZWVkZmEwMmYxYjQyOTFhOWE4NGE4ZDRmNmI2YjQzL3RleHRyZWdpb246OTdlZWRmYTAyZjFiNDI5MWE5YTg0YThkNGY2YjZiNDNfMTA5OTUxMTYzMDQ5OA_59404140-0b18-4e60-ac9e-35a64baab29d">1.5</ix:nonFraction> million payment to the 2018 Lenders as a result of the FDA approvals and (ii) a discount rate which was derived from our estimated cost of debt, adjusted with current LIBOR (or a comparable successor rate if LIBOR no longer exists). Generally, increases or decreases in the probability of occurrence would result in a directionally similar impact in the fair value measurement of the derivative liability and it is estimated that a <ix:nonFraction unitRef="number" contextRef="i59df1925a0574c55bae8311f5941df95_I20220331" decimals="2" name="ardx:FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80Ni9mcmFnOjk3ZWVkZmEwMmYxYjQyOTFhOWE4NGE4ZDRmNmI2YjQzL3RleHRyZWdpb246OTdlZWRmYTAyZjFiNDI5MWE5YTg0YThkNGY2YjZiNDNfMTA5OTUxMTYzMDUwMg_ce913ce9-b982-423a-88e0-fa7f60e22f56">10.0</ix:nonFraction>% increase (decrease), not to exceed 100%, in the probability of occurrence would result in a fair value fluctuation of no more than $<ix:nonFraction unitRef="usd" contextRef="i59df1925a0574c55bae8311f5941df95_I20220331" decimals="-5" name="ardx:FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80Ni9mcmFnOjk3ZWVkZmEwMmYxYjQyOTFhOWE4NGE4ZDRmNmI2YjQzL3RleHRyZWdpb246OTdlZWRmYTAyZjFiNDI5MWE5YTg0YThkNGY2YjZiNDNfMTA5OTUxMTYzMDUwNg_fdcbddbf-db52-477c-961e-8638ed5bae56">0.1</ix:nonFraction> million.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2022 Exit Fee</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 23, 2022, in connection with entering into the 2022 Loan Agreement, we entered into an agreement, whereby we agreed to pay an exit fee in the amount of  <ix:nonFraction unitRef="number" contextRef="i6c1d87e6c35c44b9baca5f0c32c93d4e_I20220223" decimals="INF" name="ardx:ExitFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80Ni9mcmFnOjk3ZWVkZmEwMmYxYjQyOTFhOWE4NGE4ZDRmNmI2YjQzL3RleHRyZWdpb246OTdlZWRmYTAyZjFiNDI5MWE5YTg0YThkNGY2YjZiNDNfMTA5OTUxMTYzMzc1Mw_b53b211e-1e5b-41ac-9886-3424c003aad1">2</ix:nonFraction>% of the 2022 Loan funded (the &#8220;2022 Exit Fee&#8221;) upon (i) any change of control transaction or (ii) our achievement of net revenue from the sale of any products equal to or greater than $<ix:nonFraction unitRef="usd" contextRef="ie706e05847024bdfbe5174e56d319428_D20220223-20220223" decimals="-5" name="ardx:LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80Ni9mcmFnOjk3ZWVkZmEwMmYxYjQyOTFhOWE4NGE4ZDRmNmI2YjQzL3RleHRyZWdpb246OTdlZWRmYTAyZjFiNDI5MWE5YTg0YThkNGY2YjZiNDNfMTA5OTUxMTYzNDUyNA_f5924020-1cd6-44d1-a9ca-b309014a20b8">100.0</ix:nonFraction> million, measured on a six (6) months basis (the "Revenue Milestone"), tested monthly at the end of each month. Notwithstanding the prepayment or termination of the 2022 Loan, the 2022 Exit Fee will expire on February 23, 2032. We concluded that the 2022 Exit Fee is a freestanding derivative which should be accounted for at fair value on a recurring basis. The estimated fair value of the 2022 Exit Fee is recorded as a derivative liability and included in accrued expenses and other current liabilities on the accompanying condensed balance sheets.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the derivative liability was determined using a discounted cash flow analysis and is classified as a Level 3 measurement within the fair value hierarchy since our valuation utilized significant unobservable inputs. Specifically, the key assumptions included in the calculation of the estimated fair value of the 2022 derivative liability include: (i) our estimates of both the probability and timing of achieving the Revenue Milestone and (ii) the probability and timing of funding the Term B Loan, which is dependent upon (a) approval by the FDA for our NDA for the control of serum phosphorus in chronic kidney disease patients on dialysis by December 31, 2022, and (b) achievement of certain product revenue milestone targets. Generally, increases or decreases in the probability of occurrence would result in a directionally similar impact in the fair value measurement of the derivative liability and it is estimated that a <ix:nonFraction unitRef="number" contextRef="i89699442d50542d18f061eb0f10ea77b_I20220331" decimals="2" name="ardx:FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80Ni9mcmFnOjk3ZWVkZmEwMmYxYjQyOTFhOWE4NGE4ZDRmNmI2YjQzL3RleHRyZWdpb246OTdlZWRmYTAyZjFiNDI5MWE5YTg0YThkNGY2YjZiNDNfMTA5OTUxMTYzNDcxNw_ecc8f72c-5767-401f-b853-2606cfc0963b">10.0</ix:nonFraction>% increase (decrease) in the probability of occurrence would not result in a material fair value fluctuation.</span></div><ix:nonNumeric contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80Ni9mcmFnOjk3ZWVkZmEwMmYxYjQyOTFhOWE4NGE4ZDRmNmI2YjQzL3RleHRyZWdpb246OTdlZWRmYTAyZjFiNDI5MWE5YTg0YThkNGY2YjZiNDNfMjY5Mg_50e266e0-03bf-489c-a36d-5cd29404a28d" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the fair value of our exit fee derivative liabilities recurring measurements included in Level 3 of the fair value hierarchy are presented as other income, net in our statements of operations and were as follows for the three months ended March&#160;31, 2022 and 2021 (in thousands):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.028%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id497bd1485194fabbdb368667104492e_I20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80Ni9mcmFnOjk3ZWVkZmEwMmYxYjQyOTFhOWE4NGE4ZDRmNmI2YjQzL3RhYmxlOjA5NWZmMWEyNDAyZjQ0ZTA5YTRkYjY5OTEyYjY1YzA3L3RhYmxlcmFuZ2U6MDk1ZmYxYTI0MDJmNDRlMDlhNGRiNjk5MTJiNjVjMDdfMi0xLTEtMS0yNTY2OA_a33785f7-fe4b-4c5a-9924-53a0d672d886">698</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ad56d5e526243f6a24d080e5313c670_I20201231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80Ni9mcmFnOjk3ZWVkZmEwMmYxYjQyOTFhOWE4NGE4ZDRmNmI2YjQzL3RhYmxlOjA5NWZmMWEyNDAyZjQ0ZTA5YTRkYjY5OTEyYjY1YzA3L3RhYmxlcmFuZ2U6MDk1ZmYxYTI0MDJmNDRlMDlhNGRiNjk5MTJiNjVjMDdfMi0zLTEtMS0yNTY2OA_88c18ca7-4202-4559-9578-8535aaaf384b">1,376</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 Exit Fee addition at fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8c70b1e37704cbba96b42d34dac6902_D20220101-20220331" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80Ni9mcmFnOjk3ZWVkZmEwMmYxYjQyOTFhOWE4NGE4ZDRmNmI2YjQzL3RhYmxlOjA5NWZmMWEyNDAyZjQ0ZTA5YTRkYjY5OTEyYjY1YzA3L3RhYmxlcmFuZ2U6MDk1ZmYxYTI0MDJmNDRlMDlhNGRiNjk5MTJiNjVjMDdfMy0xLTEtMS0yOTEwMA_48980fa0-2e08-45f6-adad-661aaea99f51">375</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf0f6a03fb7b4bdc8dace9bdd0e496b2_D20210101-20210331" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80Ni9mcmFnOjk3ZWVkZmEwMmYxYjQyOTFhOWE4NGE4ZDRmNmI2YjQzL3RhYmxlOjA5NWZmMWEyNDAyZjQ0ZTA5YTRkYjY5OTEyYjY1YzA3L3RhYmxlcmFuZ2U6MDk1ZmYxYTI0MDJmNDRlMDlhNGRiNjk5MTJiNjVjMDdfMy0zLTEtMS0yOTEwMA_cc5dd801-a5cd-474e-9e07-c2627f089ce0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in estimated fair value</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8c70b1e37704cbba96b42d34dac6902_D20220101-20220331" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80Ni9mcmFnOjk3ZWVkZmEwMmYxYjQyOTFhOWE4NGE4ZDRmNmI2YjQzL3RhYmxlOjA5NWZmMWEyNDAyZjQ0ZTA5YTRkYjY5OTEyYjY1YzA3L3RhYmxlcmFuZ2U6MDk1ZmYxYTI0MDJmNDRlMDlhNGRiNjk5MTJiNjVjMDdfMy0xLTEtMS0yNTY2OA_b64f4835-a870-48eb-9415-931cc4900cc8">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf0f6a03fb7b4bdc8dace9bdd0e496b2_D20210101-20210331" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80Ni9mcmFnOjk3ZWVkZmEwMmYxYjQyOTFhOWE4NGE4ZDRmNmI2YjQzL3RhYmxlOjA5NWZmMWEyNDAyZjQ0ZTA5YTRkYjY5OTEyYjY1YzA3L3RhYmxlcmFuZ2U6MDk1ZmYxYTI0MDJmNDRlMDlhNGRiNjk5MTJiNjVjMDdfMy0zLTEtMS0yNTY2OA_335118a2-e60b-4a9f-bb1e-e42393c27832">36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e02e812fef941edbaba1967484f0272_I20220331" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80Ni9mcmFnOjk3ZWVkZmEwMmYxYjQyOTFhOWE4NGE4ZDRmNmI2YjQzL3RhYmxlOjA5NWZmMWEyNDAyZjQ0ZTA5YTRkYjY5OTEyYjY1YzA3L3RhYmxlcmFuZ2U6MDk1ZmYxYTI0MDJmNDRlMDlhNGRiNjk5MTJiNjVjMDdfNC0xLTEtMS0yNTY2OA_24cb0660-8f29-48fd-8322-6d0d5ecc5e7a">1,088</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84a8784bf6674ce391d92b932658744b_I20210331" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80Ni9mcmFnOjk3ZWVkZmEwMmYxYjQyOTFhOWE4NGE4ZDRmNmI2YjQzL3RhYmxlOjA5NWZmMWEyNDAyZjQ0ZTA5YTRkYjY5OTEyYjY1YzA3L3RhYmxlcmFuZ2U6MDk1ZmYxYTI0MDJmNDRlMDlhNGRiNjk5MTJiNjVjMDdfNC0zLTEtMS0yNTY2OA_f2c1dfd4-1f53-4212-9306-dfece44c71a8">1,412</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-indent:18pt"><span><br/></span></div><div id="i711b1a39e0634b15bb7a70766327247a_49"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 9. <ix:nonNumeric contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80OS9mcmFnOmUwMTdhMjQyY2ZlYzQwZGI4YzZjMmFmZjk2NTUxMWI1L3RleHRyZWdpb246ZTAxN2EyNDJjZmVjNDBkYjhjNmMyYWZmOTY1NTExYjVfMTgxMg_a175c92c-f927-4dd6-b568-a7eb904639f2" continuedAt="ia23b4319232a4e2791d8976a1894021d" escape="true">LEASES</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia23b4319232a4e2791d8976a1894021d" continuedAt="id6b085dc51f14d1ea87edb6a65a41aab">All of our leases are operating leases and each contain customary rent escalation clauses. Certain of the leases have both lease and non-lease components. We have elected to account for each separate lease component and the non-lease components associated with that lease component as a single lease component for all classes of underlying assets.</ix:continuation></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i711b1a39e0634b15bb7a70766327247a_7">Table of Contents</a></span></div></div><ix:continuation id="id6b085dc51f14d1ea87edb6a65a41aab"><ix:nonNumeric contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" name="ardx:ScheduleOfAdditionalDetailsOfLeasesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80OS9mcmFnOmUwMTdhMjQyY2ZlYzQwZGI4YzZjMmFmZjk2NTUxMWI1L3RleHRyZWdpb246ZTAxN2EyNDJjZmVjNDBkYjhjNmMyYWZmOTY1NTExYjVfMTgxNg_48d5666a-8dd7-4a1e-9ecf-d7dd327a34ff" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides additional details of our facility leases presented in our condensed balance sheets as of March&#160;31, 2022 and December&#160;31, 2021 (dollars in thousands):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.274%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.714%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Facilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80OS9mcmFnOmUwMTdhMjQyY2ZlYzQwZGI4YzZjMmFmZjk2NTUxMWI1L3RhYmxlOmYxMTU3OGQ4ODhkNjQ1ZDlhNzkzNTc4ODVlYTRlZTE5L3RhYmxlcmFuZ2U6ZjExNTc4ZDg4OGQ2NDVkOWE3OTM1Nzg4NWVhNGVlMTlfMS0xLTEtMS0yMzAxMw_cb14193a-9613-432a-a44d-66925936dbc6">11,910</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80OS9mcmFnOmUwMTdhMjQyY2ZlYzQwZGI4YzZjMmFmZjk2NTUxMWI1L3RhYmxlOmYxMTU3OGQ4ODhkNjQ1ZDlhNzkzNTc4ODVlYTRlZTE5L3RhYmxlcmFuZ2U6ZjExNTc4ZDg4OGQ2NDVkOWE3OTM1Nzg4NWVhNGVlMTlfMS0zLTEtMS0zMzc5Mw_91cf10ca-aebd-4b32-b042-e40c67817d79">12,752</ix:nonFraction></span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80OS9mcmFnOmUwMTdhMjQyY2ZlYzQwZGI4YzZjMmFmZjk2NTUxMWI1L3RhYmxlOmYxMTU3OGQ4ODhkNjQ1ZDlhNzkzNTc4ODVlYTRlZTE5L3RhYmxlcmFuZ2U6ZjExNTc4ZDg4OGQ2NDVkOWE3OTM1Nzg4NWVhNGVlMTlfMy0xLTEtMS0yMzAxMw_f63fd78c-a1b8-4264-81be-a6121d3896e4">3,592</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80OS9mcmFnOmUwMTdhMjQyY2ZlYzQwZGI4YzZjMmFmZjk2NTUxMWI1L3RhYmxlOmYxMTU3OGQ4ODhkNjQ1ZDlhNzkzNTc4ODVlYTRlZTE5L3RhYmxlcmFuZ2U6ZjExNTc4ZDg4OGQ2NDVkOWE3OTM1Nzg4NWVhNGVlMTlfMy0zLTEtMS0zMzc5Mw_30968fd7-ec86-4ae7-ab21-3cc9f12fe77b">3,492</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability, net of current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80OS9mcmFnOmUwMTdhMjQyY2ZlYzQwZGI4YzZjMmFmZjk2NTUxMWI1L3RhYmxlOmYxMTU3OGQ4ODhkNjQ1ZDlhNzkzNTc4ODVlYTRlZTE5L3RhYmxlcmFuZ2U6ZjExNTc4ZDg4OGQ2NDVkOWE3OTM1Nzg4NWVhNGVlMTlfNC0xLTEtMS0yMzAxMw_8e7b92b6-52a0-479d-9953-d4981ee33d6c">8,812</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80OS9mcmFnOmUwMTdhMjQyY2ZlYzQwZGI4YzZjMmFmZjk2NTUxMWI1L3RhYmxlOmYxMTU3OGQ4ODhkNjQ1ZDlhNzkzNTc4ODVlYTRlZTE5L3RhYmxlcmFuZ2U6ZjExNTc4ZDg4OGQ2NDVkOWE3OTM1Nzg4NWVhNGVlMTlfNC0zLTEtMS0zMzc5Mw_a2509323-0df0-4a89-bdbc-9cd8f034a667">9,748</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80OS9mcmFnOmUwMTdhMjQyY2ZlYzQwZGI4YzZjMmFmZjk2NTUxMWI1L3RhYmxlOmYxMTU3OGQ4ODhkNjQ1ZDlhNzkzNTc4ODVlYTRlZTE5L3RhYmxlcmFuZ2U6ZjExNTc4ZDg4OGQ2NDVkOWE3OTM1Nzg4NWVhNGVlMTlfNS0xLTEtMS0yMzAxMw_bb407270-89b8-4866-8be1-994fd2f74308">12,404</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80OS9mcmFnOmUwMTdhMjQyY2ZlYzQwZGI4YzZjMmFmZjk2NTUxMWI1L3RhYmxlOmYxMTU3OGQ4ODhkNjQ1ZDlhNzkzNTc4ODVlYTRlZTE5L3RhYmxlcmFuZ2U6ZjExNTc4ZDg4OGQ2NDVkOWE3OTM1Nzg4NWVhNGVlMTlfNS0zLTEtMS0zMzc5Mw_51ef771b-ac36-40df-acda-80f02be7975d">13,240</ix:nonFraction></span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining life (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80OS9mcmFnOmUwMTdhMjQyY2ZlYzQwZGI4YzZjMmFmZjk2NTUxMWI1L3RhYmxlOmYxMTU3OGQ4ODhkNjQ1ZDlhNzkzNTc4ODVlYTRlZTE5L3RhYmxlcmFuZ2U6ZjExNTc4ZDg4OGQ2NDVkOWE3OTM1Nzg4NWVhNGVlMTlfNy0xLTEtMS0yMzAxMw_2f7b36f1-b202-4085-a626-8ad6d7d45fc3">3.2</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80OS9mcmFnOmUwMTdhMjQyY2ZlYzQwZGI4YzZjMmFmZjk2NTUxMWI1L3RhYmxlOmYxMTU3OGQ4ODhkNjQ1ZDlhNzkzNTc4ODVlYTRlZTE5L3RhYmxlcmFuZ2U6ZjExNTc4ZDg4OGQ2NDVkOWE3OTM1Nzg4NWVhNGVlMTlfNy0zLTEtMS0zMzc5Mw_7c38ee10-ae16-405f-918b-6946ac8bf066">3.4</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80OS9mcmFnOmUwMTdhMjQyY2ZlYzQwZGI4YzZjMmFmZjk2NTUxMWI1L3RhYmxlOmYxMTU3OGQ4ODhkNjQ1ZDlhNzkzNTc4ODVlYTRlZTE5L3RhYmxlcmFuZ2U6ZjExNTc4ZDg4OGQ2NDVkOWE3OTM1Nzg4NWVhNGVlMTlfOC0xLTEtMS0yMzAxMw_824fe17f-beb0-46e0-8937-e029e141dcfa">6.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80OS9mcmFnOmUwMTdhMjQyY2ZlYzQwZGI4YzZjMmFmZjk2NTUxMWI1L3RhYmxlOmYxMTU3OGQ4ODhkNjQ1ZDlhNzkzNTc4ODVlYTRlZTE5L3RhYmxlcmFuZ2U6ZjExNTc4ZDg4OGQ2NDVkOWE3OTM1Nzg4NWVhNGVlMTlfOC0zLTEtMS0zMzc5Mw_5246557c-8ce2-4ece-a939-5dc287039589">6.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80OS9mcmFnOmUwMTdhMjQyY2ZlYzQwZGI4YzZjMmFmZjk2NTUxMWI1L3RleHRyZWdpb246ZTAxN2EyNDJjZmVjNDBkYjhjNmMyYWZmOTY1NTExYjVfMTgxNw_09ab7158-eeeb-49cd-a247-27d6459a76e8" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease costs, which are included in operating expenses in our statements of operations, were as follows (in thousands):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.636%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80OS9mcmFnOmUwMTdhMjQyY2ZlYzQwZGI4YzZjMmFmZjk2NTUxMWI1L3RhYmxlOjAwNTI4YTBjMjEzNzQwYmNiYTdjMzUzZGQwNTAzYmE0L3RhYmxlcmFuZ2U6MDA1MjhhMGMyMTM3NDBiY2JhN2MzNTNkZDA1MDNiYTRfMi0xLTEtMS0yMzAxMw_3a1142af-c2a2-4e6b-8f12-a86a6706c97e">1,064</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80OS9mcmFnOmUwMTdhMjQyY2ZlYzQwZGI4YzZjMmFmZjk2NTUxMWI1L3RhYmxlOjAwNTI4YTBjMjEzNzQwYmNiYTdjMzUzZGQwNTAzYmE0L3RhYmxlcmFuZ2U6MDA1MjhhMGMyMTM3NDBiY2JhN2MzNTNkZDA1MDNiYTRfMi0zLTEtMS0yMzAxMw_e4adc303-587a-4665-9d35-bf99d16528ce">673</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for operating lease</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80OS9mcmFnOmUwMTdhMjQyY2ZlYzQwZGI4YzZjMmFmZjk2NTUxMWI1L3RhYmxlOjAwNTI4YTBjMjEzNzQwYmNiYTdjMzUzZGQwNTAzYmE0L3RhYmxlcmFuZ2U6MDA1MjhhMGMyMTM3NDBiY2JhN2MzNTNkZDA1MDNiYTRfMy0xLTEtMS0yMzAxMw_2bf3e0b4-44a9-4e00-b0f9-15fc1a1f285d">1,058</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80OS9mcmFnOmUwMTdhMjQyY2ZlYzQwZGI4YzZjMmFmZjk2NTUxMWI1L3RhYmxlOjAwNTI4YTBjMjEzNzQwYmNiYTdjMzUzZGQwNTAzYmE0L3RhYmxlcmFuZ2U6MDA1MjhhMGMyMTM3NDBiY2JhN2MzNTNkZDA1MDNiYTRfMy0zLTEtMS0yMzAxMw_bc054238-21b4-4ee2-ba4f-455f4a94c4bf">1,565</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"></span></div></ix:nonNumeric><ix:nonNumeric contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80OS9mcmFnOmUwMTdhMjQyY2ZlYzQwZGI4YzZjMmFmZjk2NTUxMWI1L3RleHRyZWdpb246ZTAxN2EyNDJjZmVjNDBkYjhjNmMyYWZmOTY1NTExYjVfMTgxMQ_b054ed64-b5dd-4b53-bc61-a86f19db6669" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our undiscounted cash payment obligations for our operating lease liabilities as of March&#160;31, 2022 (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.520%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80OS9mcmFnOmUwMTdhMjQyY2ZlYzQwZGI4YzZjMmFmZjk2NTUxMWI1L3RhYmxlOjM4N2I1MGIyMmViNTQyY2FhMjUzMWJiYjljODEzODYzL3RhYmxlcmFuZ2U6Mzg3YjUwYjIyZWI1NDJjYWEyNTMxYmJiOWM4MTM4NjNfMC0yLTEtMS0yNTgzNw_64c4a1e0-1cbf-40cd-be93-b1d725ee4365">3,234</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80OS9mcmFnOmUwMTdhMjQyY2ZlYzQwZGI4YzZjMmFmZjk2NTUxMWI1L3RhYmxlOjM4N2I1MGIyMmViNTQyY2FhMjUzMWJiYjljODEzODYzL3RhYmxlcmFuZ2U6Mzg3YjUwYjIyZWI1NDJjYWEyNTMxYmJiOWM4MTM4NjNfMS0yLTEtMS0yNTgzNw_352778a9-af62-4a09-85ca-467cc4b52744">4,440</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80OS9mcmFnOmUwMTdhMjQyY2ZlYzQwZGI4YzZjMmFmZjk2NTUxMWI1L3RhYmxlOjM4N2I1MGIyMmViNTQyY2FhMjUzMWJiYjljODEzODYzL3RhYmxlcmFuZ2U6Mzg3YjUwYjIyZWI1NDJjYWEyNTMxYmJiOWM4MTM4NjNfMi0yLTEtMS0yNTgzNw_308df95d-7c6d-4f8e-9fda-ee357760600a">4,589</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80OS9mcmFnOmUwMTdhMjQyY2ZlYzQwZGI4YzZjMmFmZjk2NTUxMWI1L3RhYmxlOjM4N2I1MGIyMmViNTQyY2FhMjUzMWJiYjljODEzODYzL3RhYmxlcmFuZ2U6Mzg3YjUwYjIyZWI1NDJjYWEyNTMxYmJiOWM4MTM4NjNfMy0yLTEtMS0yNTgzNw_d0e6767e-61eb-4103-b545-473e896fd08f">1,321</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80OS9mcmFnOmUwMTdhMjQyY2ZlYzQwZGI4YzZjMmFmZjk2NTUxMWI1L3RhYmxlOjM4N2I1MGIyMmViNTQyY2FhMjUzMWJiYjljODEzODYzL3RhYmxlcmFuZ2U6Mzg3YjUwYjIyZWI1NDJjYWEyNTMxYmJiOWM4MTM4NjNfNC0yLTEtMS0yNTgzNw_49153bb4-eed6-415d-b6e0-aa31dfd90493">252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted operating lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80OS9mcmFnOmUwMTdhMjQyY2ZlYzQwZGI4YzZjMmFmZjk2NTUxMWI1L3RhYmxlOjM4N2I1MGIyMmViNTQyY2FhMjUzMWJiYjljODEzODYzL3RhYmxlcmFuZ2U6Mzg3YjUwYjIyZWI1NDJjYWEyNTMxYmJiOWM4MTM4NjNfNi0yLTEtMS0yNTgzNw_6c704e70-1663-4c79-b115-05aac12dc59f">13,836</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Imputed interest expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80OS9mcmFnOmUwMTdhMjQyY2ZlYzQwZGI4YzZjMmFmZjk2NTUxMWI1L3RhYmxlOjM4N2I1MGIyMmViNTQyY2FhMjUzMWJiYjljODEzODYzL3RhYmxlcmFuZ2U6Mzg3YjUwYjIyZWI1NDJjYWEyNTMxYmJiOWM4MTM4NjNfNy0yLTEtMS0yNTgzNw_2cdcd489-8d1f-410a-b1fa-389e7571963e">1,432</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80OS9mcmFnOmUwMTdhMjQyY2ZlYzQwZGI4YzZjMmFmZjk2NTUxMWI1L3RhYmxlOjM4N2I1MGIyMmViNTQyY2FhMjUzMWJiYjljODEzODYzL3RhYmxlcmFuZ2U6Mzg3YjUwYjIyZWI1NDJjYWEyNTMxYmJiOWM4MTM4NjNfOC0yLTEtMS0yNTgzNw_e7b1931b-16c8-4d0a-8782-9d820d969aee">12,404</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion of operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80OS9mcmFnOmUwMTdhMjQyY2ZlYzQwZGI4YzZjMmFmZjk2NTUxMWI1L3RhYmxlOjM4N2I1MGIyMmViNTQyY2FhMjUzMWJiYjljODEzODYzL3RhYmxlcmFuZ2U6Mzg3YjUwYjIyZWI1NDJjYWEyNTMxYmJiOWM4MTM4NjNfOS0yLTEtMS0yNTgzNw_b7365566-c7e9-4165-9fb8-8136c0403ec8">3,592</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability, net of current portion</span></td><td style="background-color:#ffffff;border-bottom:5pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:5pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80OS9mcmFnOmUwMTdhMjQyY2ZlYzQwZGI4YzZjMmFmZjk2NTUxMWI1L3RhYmxlOjM4N2I1MGIyMmViNTQyY2FhMjUzMWJiYjljODEzODYzL3RhYmxlcmFuZ2U6Mzg3YjUwYjIyZWI1NDJjYWEyNTMxYmJiOWM4MTM4NjNfMTAtMi0xLTEtMjU4Mzc_97a203aa-078c-4b12-80a7-69fcd970e0de">8,812</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:5pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i711b1a39e0634b15bb7a70766327247a_52"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 10. <ix:nonNumeric contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81Mi9mcmFnOjBkZmY3ZjU5N2U2MDQ2NTdhMjlkNmM5ZDAxOGFkNGJkL3RleHRyZWdpb246MGRmZjdmNTk3ZTYwNDY1N2EyOWQ2YzlkMDE4YWQ0YmRfMjQyOA_0246ce97-4d23-4d4d-b2ec-ad82cbfb824b" continuedAt="i55e33e611ff14bc1a64c29e23aa9530d" escape="true">STOCKHOLDERS&#8217; EQUITY</ix:nonNumeric></span></div><ix:continuation id="i55e33e611ff14bc1a64c29e23aa9530d" continuedAt="id75c993bdec14a13bc05a5f3be129b49"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">At the Market Offerings Agreement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, we filed a Form S-3 registration statement, which became effective in August 2020 ("Registration Statement"), containing (i) a base prospectus for the offering, issuance and sale by us of up to a maximum aggregate offering price of $<ix:nonFraction unitRef="usd" contextRef="i76c2136d55464302b2f21baaa5e4dd54_I20200731" decimals="INF" name="ardx:MaximumAggregateOfferingPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81Mi9mcmFnOjBkZmY3ZjU5N2U2MDQ2NTdhMjlkNmM5ZDAxOGFkNGJkL3RleHRyZWdpb246MGRmZjdmNTk3ZTYwNDY1N2EyOWQ2YzlkMDE4YWQ0YmRfMTA5OTUxMTYzMDIxNQ_6f2d281a-8177-46cf-85bf-ce21c2f5cc56">250.0</ix:nonFraction> million of our common stock, preferred stock, debt securities, warrants and/or units, from time to time in one or more offerings; and (ii) a prospectus supplement for the offering, issuance and sale by us of up to a maximum aggregate offering price of $<ix:nonFraction unitRef="usd" contextRef="ia17a982a190740e2954ba6bf67641fdf_I20200731" decimals="INF" name="ardx:MaximumAggregateOfferingPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81Mi9mcmFnOjBkZmY3ZjU5N2U2MDQ2NTdhMjlkNmM5ZDAxOGFkNGJkL3RleHRyZWdpb246MGRmZjdmNTk3ZTYwNDY1N2EyOWQ2YzlkMDE4YWQ0YmRfMTA5OTUxMTYzMDIxOQ_1f3a7c1c-28da-4618-8d04-c312f2a161de">100.0</ix:nonFraction> million of our common stock that may be issued and sold, from time to time, under a sales agreement with Jefferies LLC ("Jefferies"), deemed to be &#8220;at the market offerings&#8221; (the "2020 Open Market Sales Agreement"). The 2020 Open Market Sales Agreement was fully utilized as of December 31, 2021. During the three months ended March&#160;31, 2021 we sold <ix:nonFraction unitRef="shares" contextRef="ide9366ec48e04d7b90b9fb896f92c772_D20210101-20210331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81Mi9mcmFnOjBkZmY3ZjU5N2U2MDQ2NTdhMjlkNmM5ZDAxOGFkNGJkL3RleHRyZWdpb246MGRmZjdmNTk3ZTYwNDY1N2EyOWQ2YzlkMDE4YWQ0YmRfMTA5OTUxMTYzMTY3MQ_b3554391-f7b4-4a47-a4e4-0706477ac965">4.9</ix:nonFraction> million shares and received gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="ide9366ec48e04d7b90b9fb896f92c772_D20210101-20210331" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81Mi9mcmFnOjBkZmY3ZjU5N2U2MDQ2NTdhMjlkNmM5ZDAxOGFkNGJkL3RleHRyZWdpb246MGRmZjdmNTk3ZTYwNDY1N2EyOWQ2YzlkMDE4YWQ0YmRfMTA5OTUxMTYzMTY3NQ_bc2d66df-691c-404c-b91f-1a39fd3661b4">35.0</ix:nonFraction> million at a weighted average sales price of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="ide9366ec48e04d7b90b9fb896f92c772_D20210101-20210331" decimals="2" name="ardx:SaleOfStockWeightedAveragePricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81Mi9mcmFnOjBkZmY3ZjU5N2U2MDQ2NTdhMjlkNmM5ZDAxOGFkNGJkL3RleHRyZWdpb246MGRmZjdmNTk3ZTYwNDY1N2EyOWQ2YzlkMDE4YWQ0YmRfMTA5OTUxMTYzMTY3OQ_30c91798-4b62-472d-aa8d-d0bb4ad079bd">7.09</ix:nonFraction> per share under the 2020 Open Market Sales Agreement.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, we filed an additional prospectus supplement under the Registration Statement for the offering, issuance and sale by us of up to a maximum aggregate offering price of $<ix:nonFraction unitRef="usd" contextRef="ic8a3d4170574424dbc7bd161e8e90f99_I20210831" decimals="INF" name="ardx:MaximumAggregateOfferingPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81Mi9mcmFnOjBkZmY3ZjU5N2U2MDQ2NTdhMjlkNmM5ZDAxOGFkNGJkL3RleHRyZWdpb246MGRmZjdmNTk3ZTYwNDY1N2EyOWQ2YzlkMDE4YWQ0YmRfMTA5OTUxMTYzMTA5OA_7cc778a0-05a6-494f-9e07-a80dbf4c03a5">150.0</ix:nonFraction> million of our common stock that may be issued and sold, from time to time, under an additional sales agreement we entered into with Jefferies (the "2021 Open Market Sales Agreement"), pursuant to which we may, from time to time, sell up to $<ix:nonFraction unitRef="usd" contextRef="ic8a3d4170574424dbc7bd161e8e90f99_I20210831" decimals="INF" name="ardx:MaximumAggregateOfferingPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81Mi9mcmFnOjBkZmY3ZjU5N2U2MDQ2NTdhMjlkNmM5ZDAxOGFkNGJkL3RleHRyZWdpb246MGRmZjdmNTk3ZTYwNDY1N2EyOWQ2YzlkMDE4YWQ0YmRfMTA5OTUxMTYzMTEwMg_7cc778a0-05a6-494f-9e07-a80dbf4c03a5">150.0</ix:nonFraction> million in shares of our common stock through Jefferies. We are not required to sell shares under the 2021 Open Market Sales Agreement. Pursuant to the 2021 Open Market </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i711b1a39e0634b15bb7a70766327247a_7">Table of Contents</a></span></div></div><ix:continuation id="id75c993bdec14a13bc05a5f3be129b49"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales Agreement, Jefferies, as our sales agent, receives a commission of up to <ix:nonFraction unitRef="number" contextRef="i58ecc0e1f7064678834e4f881aa7d26f_D20220101-20220331" decimals="INF" name="ardx:StockIssuanceCostCommissionPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81Mi9mcmFnOjBkZmY3ZjU5N2U2MDQ2NTdhMjlkNmM5ZDAxOGFkNGJkL3RleHRyZWdpb246MGRmZjdmNTk3ZTYwNDY1N2EyOWQ2YzlkMDE4YWQ0YmRfMTA5OTUxMTYzMTEwNg_923f7f8a-53fd-4bb1-9982-71ca65e658b5">3</ix:nonFraction>% of the gross sales price for shares of common stock sold under the 2021 Open Market Sales Agreement. During the three months ended March&#160;31, 2022 we sold <ix:nonFraction unitRef="shares" contextRef="i58ecc0e1f7064678834e4f881aa7d26f_D20220101-20220331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81Mi9mcmFnOjBkZmY3ZjU5N2U2MDQ2NTdhMjlkNmM5ZDAxOGFkNGJkL3RleHRyZWdpb246MGRmZjdmNTk3ZTYwNDY1N2EyOWQ2YzlkMDE4YWQ0YmRfMTA5OTUxMTYzMTM2MA_250db3a0-40ef-4698-9a55-00957d9a9711">5.9</ix:nonFraction> million shares and received gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="i58ecc0e1f7064678834e4f881aa7d26f_D20220101-20220331" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81Mi9mcmFnOjBkZmY3ZjU5N2U2MDQ2NTdhMjlkNmM5ZDAxOGFkNGJkL3RleHRyZWdpb246MGRmZjdmNTk3ZTYwNDY1N2EyOWQ2YzlkMDE4YWQ0YmRfMTA5OTUxMTYzMTM2NA_1e377c06-a415-4bc3-94f9-e777fa083caa">6.0</ix:nonFraction> million at a weighted average sales price of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="i58ecc0e1f7064678834e4f881aa7d26f_D20220101-20220331" decimals="2" name="ardx:SaleOfStockWeightedAveragePricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81Mi9mcmFnOjBkZmY3ZjU5N2U2MDQ2NTdhMjlkNmM5ZDAxOGFkNGJkL3RleHRyZWdpb246MGRmZjdmNTk3ZTYwNDY1N2EyOWQ2YzlkMDE4YWQ0YmRfMTA5OTUxMTYzMTM2OA_d009c6f1-fcdb-4c03-b377-ac6dde9ff573">1.02</ix:nonFraction> per share under the 2021 Open Market Sales Agreement.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sold <ix:nonFraction unitRef="shares" contextRef="i1e7f6940c3f94b42ae0826c56712faf3_D20220401-20220427" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81Mi9mcmFnOjBkZmY3ZjU5N2U2MDQ2NTdhMjlkNmM5ZDAxOGFkNGJkL3RleHRyZWdpb246MGRmZjdmNTk3ZTYwNDY1N2EyOWQ2YzlkMDE4YWQ0YmRfMTA5OTUxMTYzMTk1Nw_93da01b3-56a5-4a34-940a-a41bb096e5d5">8.3</ix:nonFraction> million shares of our common stock pursuant to the 2021 Open Market Sales Agreement which were settled</span><span style="color:#bf2115;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">between the dates of April 1, 2022 through April 27, 2022 for gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="i1e7f6940c3f94b42ae0826c56712faf3_D20220401-20220427" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81Mi9mcmFnOjBkZmY3ZjU5N2U2MDQ2NTdhMjlkNmM5ZDAxOGFkNGJkL3RleHRyZWdpb246MGRmZjdmNTk3ZTYwNDY1N2EyOWQ2YzlkMDE4YWQ0YmRfMTA5OTUxMTYzMjExOA_72d546f6-270c-4afe-9182-209f28ad752c">9.0</ix:nonFraction> million at a weighted average sales price of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="i1e7f6940c3f94b42ae0826c56712faf3_D20220401-20220427" decimals="2" name="ardx:SaleOfStockWeightedAveragePricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81Mi9mcmFnOjBkZmY3ZjU5N2U2MDQ2NTdhMjlkNmM5ZDAxOGFkNGJkL3RleHRyZWdpb246MGRmZjdmNTk3ZTYwNDY1N2EyOWQ2YzlkMDE4YWQ0YmRfMTA5OTUxMTYzMjE3Mw_18f96b54-9352-4d7a-a993-c4619ae2f495">1.09</ix:nonFraction> per share. We did not sell any additional shares of our common stock after April 25, 2022 and through the date of filing this Quarterly Report on Form 10-Q.</span></div></ix:continuation><div id="i711b1a39e0634b15bb7a70766327247a_55"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 11. <ix:nonNumeric contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81NS9mcmFnOjFjNTVkN2MzZTAyNzRhODc4NmVkODk4ZWE0MDJlMzI5L3RleHRyZWdpb246MWM1NWQ3YzNlMDI3NGE4Nzg2ZWQ4OThlYTQwMmUzMjlfMTU5NQ_8b749c71-97dd-450e-914f-de28c2cff79a" continuedAt="i532de86f860b4aa6b595034348fe2370" escape="true">EQUITY INCENTIVE PLANS</ix:nonNumeric></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"></span></div><ix:continuation id="i532de86f860b4aa6b595034348fe2370" continuedAt="i7d09547f0b8947c4b5f53a1276a023ae"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><ix:nonNumeric contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81NS9mcmFnOjFjNTVkN2MzZTAyNzRhODc4NmVkODk4ZWE0MDJlMzI5L3RleHRyZWdpb246MWM1NWQ3YzNlMDI3NGE4Nzg2ZWQ4OThlYTQwMmUzMjlfMTU5Ng_b19d1739-5ec8-4686-8cc3-bbe495b9aece" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense recognized for stock options, restricted stock units ("RSUs"), performance-based restricted stock units ("PRSUs") and our employee stock purchase program (the "ESPP") are recorded as operating expenses in our condensed statements of operations and comprehensive loss, as follows (in thousands):</span></div><div style="margin-top:12pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.069%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.867%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fb7df19c340473c8180a84b522d3105_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81NS9mcmFnOjFjNTVkN2MzZTAyNzRhODc4NmVkODk4ZWE0MDJlMzI5L3RhYmxlOjI1YzZmYjljMDNkZDQzNGQ4ODBkZjFjNmI4ZmViNjU1L3RhYmxlcmFuZ2U6MjVjNmZiOWMwM2RkNDM0ZDg4MGRmMWM2YjhmZWI2NTVfMi0xLTEtMS0yMzAxMw_f8eed985-6eca-4e07-a3df-96eb9ca7352f">1,214</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i688a54ef5d904ecc853b9118c446b946_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81NS9mcmFnOjFjNTVkN2MzZTAyNzRhODc4NmVkODk4ZWE0MDJlMzI5L3RhYmxlOjI1YzZmYjljMDNkZDQzNGQ4ODBkZjFjNmI4ZmViNjU1L3RhYmxlcmFuZ2U6MjVjNmZiOWMwM2RkNDM0ZDg4MGRmMWM2YjhmZWI2NTVfMi0zLTEtMS0yMzAxMw_7b52ce1c-fa80-4b33-a411-faee4a29f749">1,092</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd425314803a477c8c332384eb697af8_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81NS9mcmFnOjFjNTVkN2MzZTAyNzRhODc4NmVkODk4ZWE0MDJlMzI5L3RhYmxlOjI1YzZmYjljMDNkZDQzNGQ4ODBkZjFjNmI4ZmViNjU1L3RhYmxlcmFuZ2U6MjVjNmZiOWMwM2RkNDM0ZDg4MGRmMWM2YjhmZWI2NTVfMy0xLTEtMS0yMzAxMw_3cea87dc-5d3a-4742-8bc0-c03a3b4a94ca">2,508</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5dc952c28b244722a46ac91b1208bda9_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81NS9mcmFnOjFjNTVkN2MzZTAyNzRhODc4NmVkODk4ZWE0MDJlMzI5L3RhYmxlOjI1YzZmYjljMDNkZDQzNGQ4ODBkZjFjNmI4ZmViNjU1L3RhYmxlcmFuZ2U6MjVjNmZiOWMwM2RkNDM0ZDg4MGRmMWM2YjhmZWI2NTVfMy0zLTEtMS0yMzAxMw_2db8ff34-eb19-412e-87e5-89da96db34de">1,995</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81NS9mcmFnOjFjNTVkN2MzZTAyNzRhODc4NmVkODk4ZWE0MDJlMzI5L3RhYmxlOjI1YzZmYjljMDNkZDQzNGQ4ODBkZjFjNmI4ZmViNjU1L3RhYmxlcmFuZ2U6MjVjNmZiOWMwM2RkNDM0ZDg4MGRmMWM2YjhmZWI2NTVfNC0xLTEtMS0yMzAxMw_a0e7a9c5-1b43-4612-83f2-0d4dee661ef2">3,722</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81NS9mcmFnOjFjNTVkN2MzZTAyNzRhODc4NmVkODk4ZWE0MDJlMzI5L3RhYmxlOjI1YzZmYjljMDNkZDQzNGQ4ODBkZjFjNmI4ZmViNjU1L3RhYmxlcmFuZ2U6MjVjNmZiOWMwM2RkNDM0ZDg4MGRmMWM2YjhmZWI2NTVfNC0zLTEtMS0yMzAxMw_91ac3d42-4a2a-4c60-8133-574c3a4953f3">3,087</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" name="us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81NS9mcmFnOjFjNTVkN2MzZTAyNzRhODc4NmVkODk4ZWE0MDJlMzI5L3RleHRyZWdpb246MWM1NWQ3YzNlMDI3NGE4Nzg2ZWQ4OThlYTQwMmUzMjlfMTU5Nw_2acbe683-5648-4e0f-8964-7a608afce624" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, our total unrecognized stock-based compensation expense, net of estimated forfeitures, and average remaining vesting period, included the following (dollars in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.958%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.689%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.323%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrecognized Compensation Expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average Remaining Vesting Period (Years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock option grants</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a3d5f58f87e49a095847ea09b7bf010_I20220331" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81NS9mcmFnOjFjNTVkN2MzZTAyNzRhODc4NmVkODk4ZWE0MDJlMzI5L3RhYmxlOjAyYjA1OWFhMDIzYjRiNTVhMmM2N2E3YzkyNWVkNGMwL3RhYmxlcmFuZ2U6MDJiMDU5YWEwMjNiNGI1NWEyYzY3YTdjOTI1ZWQ0YzBfMS0xLTEtMS0yMzAxMw_5056f738-383e-4922-9725-e8d90f212fa0">14,865</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i097a3193c63e4588b0705a6c382a1938_D20220101-20220331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81NS9mcmFnOjFjNTVkN2MzZTAyNzRhODc4NmVkODk4ZWE0MDJlMzI5L3RhYmxlOjAyYjA1OWFhMDIzYjRiNTVhMmM2N2E3YzkyNWVkNGMwL3RhYmxlcmFuZ2U6MDJiMDU5YWEwMjNiNGI1NWEyYzY3YTdjOTI1ZWQ0YzBfMS0zLTEtMS0yMzAxMw_8f6476f2-204c-4d15-8e77-6305c1cfdb52">3.0</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSU grants</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5d73f51d15b4a93b70e582a308344c0_I20220331" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81NS9mcmFnOjFjNTVkN2MzZTAyNzRhODc4NmVkODk4ZWE0MDJlMzI5L3RhYmxlOjAyYjA1OWFhMDIzYjRiNTVhMmM2N2E3YzkyNWVkNGMwL3RhYmxlcmFuZ2U6MDJiMDU5YWEwMjNiNGI1NWEyYzY3YTdjOTI1ZWQ0YzBfMi0xLTEtMS0yMzAxMw_4b986845-8f88-4a42-b622-2d40474f9b9e">4,894</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="idf00f8a3ea3f45eaab148f2ba05a7841_D20220101-20220331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81NS9mcmFnOjFjNTVkN2MzZTAyNzRhODc4NmVkODk4ZWE0MDJlMzI5L3RhYmxlOjAyYjA1OWFhMDIzYjRiNTVhMmM2N2E3YzkyNWVkNGMwL3RhYmxlcmFuZ2U6MDJiMDU5YWEwMjNiNGI1NWEyYzY3YTdjOTI1ZWQ0YzBfMi0zLTEtMS0yMzAxMw_0cf6be51-129b-4e90-85ff-16de84178af9">1.3</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59d036f63af647faadf250a643250458_I20220331" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81NS9mcmFnOjFjNTVkN2MzZTAyNzRhODc4NmVkODk4ZWE0MDJlMzI5L3RhYmxlOjAyYjA1OWFhMDIzYjRiNTVhMmM2N2E3YzkyNWVkNGMwL3RhYmxlcmFuZ2U6MDJiMDU5YWEwMjNiNGI1NWEyYzY3YTdjOTI1ZWQ0YzBfMy0xLTEtMS0yMzAxMw_b72a5a79-7025-4c20-8c26-c4141eeec8c3">53</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic35af7bef7ef4aaf9affdc91a3779184_D20220101-20220331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81NS9mcmFnOjFjNTVkN2MzZTAyNzRhODc4NmVkODk4ZWE0MDJlMzI5L3RhYmxlOjAyYjA1OWFhMDIzYjRiNTVhMmM2N2E3YzkyNWVkNGMwL3RhYmxlcmFuZ2U6MDJiMDU5YWEwMjNiNGI1NWEyYzY3YTdjOTI1ZWQ0YzBfMy0zLTEtMS0yMzAxMw_db5d6298-77fc-40d0-8606-a2d1fb6d96f0">0.8</ix:nonNumeric></span></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><ix:nonNumeric contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81NS9mcmFnOjFjNTVkN2MzZTAyNzRhODc4NmVkODk4ZWE0MDJlMzI5L3RleHRyZWdpb246MWM1NWQ3YzNlMDI3NGE4Nzg2ZWQ4OThlYTQwMmUzMjlfMTU5OA_455ea083-6b83-466c-9341-95152d16fb76" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our stock option activity and related information for the three months ended March&#160;31, 2022 is as follows (in thousands, except dollar amounts):</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.152%"><tr><td style="width:1.0%"></td><td style="width:58.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.446%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.106%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number&#160;of&#160;Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise&#160;Price&#160;per<br/>Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81NS9mcmFnOjFjNTVkN2MzZTAyNzRhODc4NmVkODk4ZWE0MDJlMzI5L3RhYmxlOjViODdkMjFkNTVhMjQ1NDE5YzI4MTdkNjg4YTAzY2IyL3RhYmxlcmFuZ2U6NWI4N2QyMWQ1NWEyNDU0MTljMjgxN2Q2ODhhMDNjYjJfMS0xLTEtMS0yMzAxMw_8218beef-24cb-4649-8cde-a460ee8b9cd4">10,417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81NS9mcmFnOjFjNTVkN2MzZTAyNzRhODc4NmVkODk4ZWE0MDJlMzI5L3RhYmxlOjViODdkMjFkNTVhMjQ1NDE5YzI4MTdkNjg4YTAzY2IyL3RhYmxlcmFuZ2U6NWI4N2QyMWQ1NWEyNDU0MTljMjgxN2Q2ODhhMDNjYjJfMS0zLTEtMS0yMzAxMw_c21918e6-71bf-4480-8b50-fcb1ccef311c">7.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81NS9mcmFnOjFjNTVkN2MzZTAyNzRhODc4NmVkODk4ZWE0MDJlMzI5L3RhYmxlOjViODdkMjFkNTVhMjQ1NDE5YzI4MTdkNjg4YTAzY2IyL3RhYmxlcmFuZ2U6NWI4N2QyMWQ1NWEyNDU0MTljMjgxN2Q2ODhhMDNjYjJfMi0xLTEtMS0yMzAxMw_8f632f31-2424-43d1-9ba5-2bdd1899a00a">3,535</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81NS9mcmFnOjFjNTVkN2MzZTAyNzRhODc4NmVkODk4ZWE0MDJlMzI5L3RhYmxlOjViODdkMjFkNTVhMjQ1NDE5YzI4MTdkNjg4YTAzY2IyL3RhYmxlcmFuZ2U6NWI4N2QyMWQ1NWEyNDU0MTljMjgxN2Q2ODhhMDNjYjJfMi0zLTEtMS0yMzAxMw_a47b8292-546e-40d9-97a8-2f146142c8ca">0.98</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81NS9mcmFnOjFjNTVkN2MzZTAyNzRhODc4NmVkODk4ZWE0MDJlMzI5L3RhYmxlOjViODdkMjFkNTVhMjQ1NDE5YzI4MTdkNjg4YTAzY2IyL3RhYmxlcmFuZ2U6NWI4N2QyMWQ1NWEyNDU0MTljMjgxN2Q2ODhhMDNjYjJfMy0xLTEtMS0yMzAxMw_b777b23b-3dd5-4067-9ff1-e95593b36794">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81NS9mcmFnOjFjNTVkN2MzZTAyNzRhODc4NmVkODk4ZWE0MDJlMzI5L3RhYmxlOjViODdkMjFkNTVhMjQ1NDE5YzI4MTdkNjg4YTAzY2IyL3RhYmxlcmFuZ2U6NWI4N2QyMWQ1NWEyNDU0MTljMjgxN2Q2ODhhMDNjYjJfMy0zLTEtMS0yMzAxMw_4b5fba78-e8a4-4100-b24b-954f854eda8e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options forfeited or canceled</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81NS9mcmFnOjFjNTVkN2MzZTAyNzRhODc4NmVkODk4ZWE0MDJlMzI5L3RhYmxlOjViODdkMjFkNTVhMjQ1NDE5YzI4MTdkNjg4YTAzY2IyL3RhYmxlcmFuZ2U6NWI4N2QyMWQ1NWEyNDU0MTljMjgxN2Q2ODhhMDNjYjJfNC0xLTEtMS0yMzAxMw_1bccf51c-9e0a-4c9c-83c9-cdb077a5fa66">1,006</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81NS9mcmFnOjFjNTVkN2MzZTAyNzRhODc4NmVkODk4ZWE0MDJlMzI5L3RhYmxlOjViODdkMjFkNTVhMjQ1NDE5YzI4MTdkNjg4YTAzY2IyL3RhYmxlcmFuZ2U6NWI4N2QyMWQ1NWEyNDU0MTljMjgxN2Q2ODhhMDNjYjJfNC0zLTEtMS0yMzAxMw_43bc8b2c-ea99-4d97-9f78-139ccc8c67ab">7.18</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81NS9mcmFnOjFjNTVkN2MzZTAyNzRhODc4NmVkODk4ZWE0MDJlMzI5L3RhYmxlOjViODdkMjFkNTVhMjQ1NDE5YzI4MTdkNjg4YTAzY2IyL3RhYmxlcmFuZ2U6NWI4N2QyMWQ1NWEyNDU0MTljMjgxN2Q2ODhhMDNjYjJfNS0xLTEtMS0yMzAxMw_e8cda443-ee27-4141-ba14-f453569cff45">12,946</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81NS9mcmFnOjFjNTVkN2MzZTAyNzRhODc4NmVkODk4ZWE0MDJlMzI5L3RhYmxlOjViODdkMjFkNTVhMjQ1NDE5YzI4MTdkNjg4YTAzY2IyL3RhYmxlcmFuZ2U6NWI4N2QyMWQ1NWEyNDU0MTljMjgxN2Q2ODhhMDNjYjJfNS0zLTEtMS0yMzAxMw_fcefcb16-4733-48d9-a078-9e2307b0b37d">5.34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at March 31, 2022</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81NS9mcmFnOjFjNTVkN2MzZTAyNzRhODc4NmVkODk4ZWE0MDJlMzI5L3RhYmxlOjViODdkMjFkNTVhMjQ1NDE5YzI4MTdkNjg4YTAzY2IyL3RhYmxlcmFuZ2U6NWI4N2QyMWQ1NWEyNDU0MTljMjgxN2Q2ODhhMDNjYjJfNi0xLTEtMS0yMzAxMw_125c7adf-ed00-4bf2-a738-b05da1b4338c">6,476</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81NS9mcmFnOjFjNTVkN2MzZTAyNzRhODc4NmVkODk4ZWE0MDJlMzI5L3RhYmxlOjViODdkMjFkNTVhMjQ1NDE5YzI4MTdkNjg4YTAzY2IyL3RhYmxlcmFuZ2U6NWI4N2QyMWQ1NWEyNDU0MTljMjgxN2Q2ODhhMDNjYjJfNi0zLTEtMS0yMzAxMw_7dfa4719-0eef-4fa8-8d9a-2cab75da9c38">7.16</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i711b1a39e0634b15bb7a70766327247a_7">Table of Contents</a></span></div></div><ix:continuation id="i7d09547f0b8947c4b5f53a1276a023ae" continuedAt="ibe0408c2fac64a29b3755ddb39b3dc99"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><ix:nonNumeric contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81NS9mcmFnOjFjNTVkN2MzZTAyNzRhODc4NmVkODk4ZWE0MDJlMzI5L3RleHRyZWdpb246MWM1NWQ3YzNlMDI3NGE4Nzg2ZWQ4OThlYTQwMmUzMjlfMTU5OQ_a5437a79-ab5f-4ad9-9dea-14dd76c76abf" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our RSUs activity and related information for the three months ended March&#160;31, 2022 is as follows (in thousands, except dollar amounts):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.157%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.929%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.884%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number&#160;of<br/>RSUs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant&#160;Date&#160;Fair<br/>Value Per&#160;Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested restricted stock units at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i14d3b2f9b45b490fbcbe947f54b91b39_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81NS9mcmFnOjFjNTVkN2MzZTAyNzRhODc4NmVkODk4ZWE0MDJlMzI5L3RhYmxlOjQ5ZjFjMTg3NmMyMjQxNTlhM2VlODFhN2FkMjhkZmRlL3RhYmxlcmFuZ2U6NDlmMWMxODc2YzIyNDE1OWEzZWU4MWE3YWQyOGRmZGVfMS0xLTEtMS0yMzAxMw_d890a92f-c62b-4626-b119-39b08e692f5e">3,529</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i14d3b2f9b45b490fbcbe947f54b91b39_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81NS9mcmFnOjFjNTVkN2MzZTAyNzRhODc4NmVkODk4ZWE0MDJlMzI5L3RhYmxlOjQ5ZjFjMTg3NmMyMjQxNTlhM2VlODFhN2FkMjhkZmRlL3RhYmxlcmFuZ2U6NDlmMWMxODc2YzIyNDE1OWEzZWU4MWE3YWQyOGRmZGVfMS0zLTEtMS0yMzAxMw_d2d39333-00cf-4d9e-9023-d50f60e2bfb5">2.04</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idf00f8a3ea3f45eaab148f2ba05a7841_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81NS9mcmFnOjFjNTVkN2MzZTAyNzRhODc4NmVkODk4ZWE0MDJlMzI5L3RhYmxlOjQ5ZjFjMTg3NmMyMjQxNTlhM2VlODFhN2FkMjhkZmRlL3RhYmxlcmFuZ2U6NDlmMWMxODc2YzIyNDE1OWEzZWU4MWE3YWQyOGRmZGVfMi0xLTEtMS0yMzAxMw_d8a3b1b8-5f86-4d8a-8896-ad603bd26379">1,120</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="idf00f8a3ea3f45eaab148f2ba05a7841_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81NS9mcmFnOjFjNTVkN2MzZTAyNzRhODc4NmVkODk4ZWE0MDJlMzI5L3RhYmxlOjQ5ZjFjMTg3NmMyMjQxNTlhM2VlODFhN2FkMjhkZmRlL3RhYmxlcmFuZ2U6NDlmMWMxODc2YzIyNDE1OWEzZWU4MWE3YWQyOGRmZGVfMi0zLTEtMS0yMzAxMw_d4fe70c8-12fe-419b-ad24-2fec4a6343ec">0.98</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="idf00f8a3ea3f45eaab148f2ba05a7841_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81NS9mcmFnOjFjNTVkN2MzZTAyNzRhODc4NmVkODk4ZWE0MDJlMzI5L3RhYmxlOjQ5ZjFjMTg3NmMyMjQxNTlhM2VlODFhN2FkMjhkZmRlL3RhYmxlcmFuZ2U6NDlmMWMxODc2YzIyNDE1OWEzZWU4MWE3YWQyOGRmZGVfMy0xLTEtMS0yMzAxMw_2920d0a0-adcb-4aec-bc72-9ac5efb4c4c1">113</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="idf00f8a3ea3f45eaab148f2ba05a7841_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81NS9mcmFnOjFjNTVkN2MzZTAyNzRhODc4NmVkODk4ZWE0MDJlMzI5L3RhYmxlOjQ5ZjFjMTg3NmMyMjQxNTlhM2VlODFhN2FkMjhkZmRlL3RhYmxlcmFuZ2U6NDlmMWMxODc2YzIyNDE1OWEzZWU4MWE3YWQyOGRmZGVfMy0zLTEtMS0yMzAxMw_7c5c320e-97bb-4a13-9f98-ad5dc517a79e">3.62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="idf00f8a3ea3f45eaab148f2ba05a7841_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81NS9mcmFnOjFjNTVkN2MzZTAyNzRhODc4NmVkODk4ZWE0MDJlMzI5L3RhYmxlOjQ5ZjFjMTg3NmMyMjQxNTlhM2VlODFhN2FkMjhkZmRlL3RhYmxlcmFuZ2U6NDlmMWMxODc2YzIyNDE1OWEzZWU4MWE3YWQyOGRmZGVfNC0xLTEtMS0yMzAxMw_69f37e2e-9537-47a0-a3f8-04070b45be5e">88</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="idf00f8a3ea3f45eaab148f2ba05a7841_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81NS9mcmFnOjFjNTVkN2MzZTAyNzRhODc4NmVkODk4ZWE0MDJlMzI5L3RhYmxlOjQ5ZjFjMTg3NmMyMjQxNTlhM2VlODFhN2FkMjhkZmRlL3RhYmxlcmFuZ2U6NDlmMWMxODc2YzIyNDE1OWEzZWU4MWE3YWQyOGRmZGVfNC0zLTEtMS0yMzAxMw_1fb1d17a-61f1-4d2e-99df-1edfd9bdc088">2.02</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested restricted stock units at March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie5d73f51d15b4a93b70e582a308344c0_I20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81NS9mcmFnOjFjNTVkN2MzZTAyNzRhODc4NmVkODk4ZWE0MDJlMzI5L3RhYmxlOjQ5ZjFjMTg3NmMyMjQxNTlhM2VlODFhN2FkMjhkZmRlL3RhYmxlcmFuZ2U6NDlmMWMxODc2YzIyNDE1OWEzZWU4MWE3YWQyOGRmZGVfNS0xLTEtMS0yMzAxMw_efe9cd85-dcf1-4fa3-9080-9595e067190e">4,448</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie5d73f51d15b4a93b70e582a308344c0_I20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81NS9mcmFnOjFjNTVkN2MzZTAyNzRhODc4NmVkODk4ZWE0MDJlMzI5L3RhYmxlOjQ5ZjFjMTg3NmMyMjQxNTlhM2VlODFhN2FkMjhkZmRlL3RhYmxlcmFuZ2U6NDlmMWMxODc2YzIyNDE1OWEzZWU4MWE3YWQyOGRmZGVfNS0zLTEtMS0yMzAxMw_c7d84ba4-8e03-4639-97b1-8e964d10f735">1.73</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, we sold approximately <ix:nonFraction unitRef="shares" contextRef="i4bedde518aa14e90ae770d42052bfc56_D20220201-20220228" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81NS9mcmFnOjFjNTVkN2MzZTAyNzRhODc4NmVkODk4ZWE0MDJlMzI5L3RleHRyZWdpb246MWM1NWQ3YzNlMDI3NGE4Nzg2ZWQ4OThlYTQwMmUzMjlfMTY0OTI2NzQ0MzM0MA_883d01b8-9115-4fa7-a3a7-7e5587aa1280">0.1</ix:nonFraction> million shares of our common stock under the ESPP. The shares were purchased by employees at a purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i4bedde518aa14e90ae770d42052bfc56_D20220201-20220228" decimals="2" name="ardx:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81NS9mcmFnOjFjNTVkN2MzZTAyNzRhODc4NmVkODk4ZWE0MDJlMzI5L3RleHRyZWdpb246MWM1NWQ3YzNlMDI3NGE4Nzg2ZWQ4OThlYTQwMmUzMjlfMTY0OTI2NzQ0MzM0Nw_f13a96fd-987b-4713-b8e4-aafe42df6dae">0.65</ix:nonFraction> per share resulting in proceeds to us of approximately $<ix:nonFraction unitRef="usd" contextRef="i4bedde518aa14e90ae770d42052bfc56_D20220201-20220228" decimals="-3" name="us-gaap:ProceedsFromStockPlans" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81NS9mcmFnOjFjNTVkN2MzZTAyNzRhODc4NmVkODk4ZWE0MDJlMzI5L3RleHRyZWdpb246MWM1NWQ3YzNlMDI3NGE4Nzg2ZWQ4OThlYTQwMmUzMjlfMTY0OTI2NzQ0MzM1MQ_0bc1abe4-9a6f-468b-8183-ef7467ef6100">0.1</ix:nonFraction> million.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Issuance of Common Stock for Services</span></div></ix:continuation><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ibe0408c2fac64a29b3755ddb39b3dc99">Under Our Amended and Restated Non-Employee Director Compensation Program, members of our board of directors may elect to receive shares of our stock in lieu of their cash fees. During the three months ended March&#160;31, 2022, we issued <ix:nonFraction unitRef="shares" contextRef="i856e705397e44a879c8d4de90f5984b6_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81NS9mcmFnOjFjNTVkN2MzZTAyNzRhODc4NmVkODk4ZWE0MDJlMzI5L3RleHRyZWdpb246MWM1NWQ3YzNlMDI3NGE4Nzg2ZWQ4OThlYTQwMmUzMjlfMTY0OTI2NzQ0MzM1OA_5f127623-2ca4-4665-991a-1bd41aec2cef">no</ix:nonFraction> shares of our common stock to members of the board of directors in accordance with the program.</ix:continuation> </span></div><div id="i711b1a39e0634b15bb7a70766327247a_61"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 12. <ix:nonNumeric contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV82MS9mcmFnOjEwMjViNTNjNGEwYzQ1OTA4MDZiOThhZmRmODQ1ZGZmL3RleHRyZWdpb246MTAyNWI1M2M0YTBjNDU5MDgwNmI5OGFmZGY4NDVkZmZfMTI5Ng_d269e4d5-21d9-43b9-b38b-71c13461ee75" continuedAt="ifd8a4111214047a89b43d793319428e0" escape="true">NET LOSS PER SHARE</ix:nonNumeric></span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><ix:continuation id="ifd8a4111214047a89b43d793319428e0"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period, less shares subject to repurchase, and excludes any dilutive effects of stock-based awards and warrants. Diluted net loss per common share is computed giving effect to all potential dilutive common shares, including common stock issuable upon exercise of stock options, and unvested restricted common stock and stock units. As we had net losses for the three months ended March&#160;31, 2022 and 2021, all potential common shares were determined to be anti-dilutive. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><ix:nonNumeric contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV82MS9mcmFnOjEwMjViNTNjNGEwYzQ1OTA4MDZiOThhZmRmODQ1ZGZmL3RleHRyZWdpb246MTAyNWI1M2M0YTBjNDU5MDgwNmI5OGFmZGY4NDVkZmZfMTI5Nw_1cad9048-16fc-4100-8c8f-83b99e27819f" escape="true"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of net loss per common share (in thousands, except per share amounts): </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"></td><td style="width:69.862%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV82MS9mcmFnOjEwMjViNTNjNGEwYzQ1OTA4MDZiOThhZmRmODQ1ZGZmL3RhYmxlOmY5Y2ZjOWZmYTExZDRiMGU4MjAzMTlhYzUyMjk3ZTFlL3RhYmxlcmFuZ2U6ZjljZmM5ZmZhMTFkNGIwZTgyMDMxOWFjNTIyOTdlMWVfMi0xLTEtMS0yNjIwMg_1d948510-bd17-42af-a031-3e86e2e5825b">28,071</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV82MS9mcmFnOjEwMjViNTNjNGEwYzQ1OTA4MDZiOThhZmRmODQ1ZGZmL3RhYmxlOmY5Y2ZjOWZmYTExZDRiMGU4MjAzMTlhYzUyMjk3ZTFlL3RhYmxlcmFuZ2U6ZjljZmM5ZmZhMTFkNGIwZTgyMDMxOWFjNTIyOTdlMWVfMi0zLTEtMS0yNjIwMg_6164fedc-cb6c-4f2b-804c-e4867487cbac">33,155</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding - basic and diluted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV82MS9mcmFnOjEwMjViNTNjNGEwYzQ1OTA4MDZiOThhZmRmODQ1ZGZmL3RhYmxlOmY5Y2ZjOWZmYTExZDRiMGU4MjAzMTlhYzUyMjk3ZTFlL3RhYmxlcmFuZ2U6ZjljZmM5ZmZhMTFkNGIwZTgyMDMxOWFjNTIyOTdlMWVfNC0xLTEtMS0yNjIwMg_72019096-c8e4-4256-bd65-7296a57ff64e"><ix:nonFraction unitRef="shares" contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV82MS9mcmFnOjEwMjViNTNjNGEwYzQ1OTA4MDZiOThhZmRmODQ1ZGZmL3RhYmxlOmY5Y2ZjOWZmYTExZDRiMGU4MjAzMTlhYzUyMjk3ZTFlL3RhYmxlcmFuZ2U6ZjljZmM5ZmZhMTFkNGIwZTgyMDMxOWFjNTIyOTdlMWVfNC0xLTEtMS0yNjIwMg_857d8233-1d5f-43f5-b201-5773f638c06c">130,935</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV82MS9mcmFnOjEwMjViNTNjNGEwYzQ1OTA4MDZiOThhZmRmODQ1ZGZmL3RhYmxlOmY5Y2ZjOWZmYTExZDRiMGU4MjAzMTlhYzUyMjk3ZTFlL3RhYmxlcmFuZ2U6ZjljZmM5ZmZhMTFkNGIwZTgyMDMxOWFjNTIyOTdlMWVfNC0zLTEtMS0yNjIwMg_316c40b0-2d44-4c36-b890-f65387745f19"><ix:nonFraction unitRef="shares" contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV82MS9mcmFnOjEwMjViNTNjNGEwYzQ1OTA4MDZiOThhZmRmODQ1ZGZmL3RhYmxlOmY5Y2ZjOWZmYTExZDRiMGU4MjAzMTlhYzUyMjk3ZTFlL3RhYmxlcmFuZ2U6ZjljZmM5ZmZhMTFkNGIwZTgyMDMxOWFjNTIyOTdlMWVfNC0zLTEtMS0yNjIwMg_64215c6c-d454-4e8d-8304-043d68854785">97,179</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share - basic and diluted</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV82MS9mcmFnOjEwMjViNTNjNGEwYzQ1OTA4MDZiOThhZmRmODQ1ZGZmL3RhYmxlOmY5Y2ZjOWZmYTExZDRiMGU4MjAzMTlhYzUyMjk3ZTFlL3RhYmxlcmFuZ2U6ZjljZmM5ZmZhMTFkNGIwZTgyMDMxOWFjNTIyOTdlMWVfNS0xLTEtMS0yMzAxMw_e98ea9ca-ec59-4794-ab8c-418c514eaadd"><ix:nonFraction unitRef="usdPerShare" contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV82MS9mcmFnOjEwMjViNTNjNGEwYzQ1OTA4MDZiOThhZmRmODQ1ZGZmL3RhYmxlOmY5Y2ZjOWZmYTExZDRiMGU4MjAzMTlhYzUyMjk3ZTFlL3RhYmxlcmFuZ2U6ZjljZmM5ZmZhMTFkNGIwZTgyMDMxOWFjNTIyOTdlMWVfNS0xLTEtMS0yMzAxMw_efb5df7d-7d9e-4898-8b37-e57142ab2ba5">0.21</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV82MS9mcmFnOjEwMjViNTNjNGEwYzQ1OTA4MDZiOThhZmRmODQ1ZGZmL3RhYmxlOmY5Y2ZjOWZmYTExZDRiMGU4MjAzMTlhYzUyMjk3ZTFlL3RhYmxlcmFuZ2U6ZjljZmM5ZmZhMTFkNGIwZTgyMDMxOWFjNTIyOTdlMWVfNS0zLTEtMS0yMzAxMw_a965a363-dcff-45a2-afe6-369c4ffba198"><ix:nonFraction unitRef="usdPerShare" contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV82MS9mcmFnOjEwMjViNTNjNGEwYzQ1OTA4MDZiOThhZmRmODQ1ZGZmL3RhYmxlOmY5Y2ZjOWZmYTExZDRiMGU4MjAzMTlhYzUyMjk3ZTFlL3RhYmxlcmFuZ2U6ZjljZmM5ZmZhMTFkNGIwZTgyMDMxOWFjNTIyOTdlMWVfNS0zLTEtMS0yMzAxMw_d9364115-0945-4ed5-ae64-ba5bbbaf2d3d">0.34</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2022, the total number of securities that could potentially dilute basic net loss per share in the future that were not included in the computation of diluted net loss per share because the effect would have been antidilutive was <ix:nonFraction unitRef="shares" contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV82MS9mcmFnOjEwMjViNTNjNGEwYzQ1OTA4MDZiOThhZmRmODQ1ZGZmL3RleHRyZWdpb246MTAyNWI1M2M0YTBjNDU5MDgwNmI5OGFmZGY4NDVkZmZfMTA5OTUxMTYyOTE0OQ_a2e6bb00-7cb8-4d65-a174-152123397829">13.3</ix:nonFraction> million.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2021, the total number of securities that could potentially dilute basic net loss per share in the future that were not included in the computation of diluted net loss per share because the effect would have been antidilutive was <ix:nonFraction unitRef="shares" contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV82MS9mcmFnOjEwMjViNTNjNGEwYzQ1OTA4MDZiOThhZmRmODQ1ZGZmL3RleHRyZWdpb246MTAyNWI1M2M0YTBjNDU5MDgwNmI5OGFmZGY4NDVkZmZfMTA5OTUxMTYyOTE1Ng_85b50779-1e02-4725-a3cf-4a2e11579caf">13.0</ix:nonFraction> million.</span></div></ix:continuation><div id="i711b1a39e0634b15bb7a70766327247a_67"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 13. <ix:nonNumeric contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV82Ny9mcmFnOmJkODhkYWUxMTg0MzRkZDA4NzQyNjUzODgxMTBjMTE4L3RleHRyZWdpb246YmQ4OGRhZTExODQzNGRkMDg3NDI2NTM4ODExMGMxMThfMTI0NA_a716246e-7961-4555-90fb-0c5efb6e8c68" continuedAt="i2030dc4d318841c3be99f98a4c3d8cc8" escape="true">CONTINGENCIES</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i2030dc4d318841c3be99f98a4c3d8cc8">From time to time we may be involved in claims arising in connection with our business. Based on information currently available, management believes that the amount, or range, of reasonably possible losses in connection with any pending actions against us will not be material to our financial condition or cash flows, and <ix:nonFraction unitRef="usd" contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331" decimals="INF" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV82Ny9mcmFnOmJkODhkYWUxMTg0MzRkZDA4NzQyNjUzODgxMTBjMTE4L3RleHRyZWdpb246YmQ4OGRhZTExODQzNGRkMDg3NDI2NTM4ODExMGMxMThfMTA5OTUxMTYyOTAzMQ_4a641ac8-ff24-41e0-a03f-d0c67e9bbef3"><ix:nonFraction unitRef="usd" contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231" decimals="INF" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV82Ny9mcmFnOmJkODhkYWUxMTg0MzRkZDA4NzQyNjUzODgxMTBjMTE4L3RleHRyZWdpb246YmQ4OGRhZTExODQzNGRkMDg3NDI2NTM4ODExMGMxMThfMTA5OTUxMTYyOTAzMQ_6e917d93-b89f-4287-93cb-6723713b40f5">no</ix:nonFraction></ix:nonFraction> contingent liabilities were accrued as of March&#160;31, 2022 or 2021.</ix:continuation></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><div id="i711b1a39e0634b15bb7a70766327247a_70"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i711b1a39e0634b15bb7a70766327247a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 14. &#160;<ix:nonNumeric contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV83MC9mcmFnOmQ5NjhhZWM0NGY2NDQ1ODViYTFmZGRkNGIyZDgzODNlL3RleHRyZWdpb246ZDk2OGFlYzQ0ZjY0NDU4NWJhMWZkZGQ0YjJkODM4M2VfMzUzNQ_cbb6e0b0-4ab9-42ea-a0bb-81665cb5835c" continuedAt="if477a0950de848009f0766266f4a54a1" escape="true">SUBSEQUENT EVENTS</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:continuation id="if477a0950de848009f0766266f4a54a1" continuedAt="if764d61a80304659a369b8a456e861b2"> </ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if764d61a80304659a369b8a456e861b2">On April 11, 2022, we entered into a second amendment (the "Amendment") to the 2017 KKC Agreement. Under the terms of the Amendment, the parties have agreed to a reduction in the royalty rate payable to us by KKC upon net sales of tenapanor in Japan. The royalty rate will be reduced from the high teens to low double digits for a two-year period of time following the first commercial sale in Japan, and then to mid-single digits for the remainder of the royalty term. As consideration for the reduction in the royalty rate, KKC has agreed to pay us up to an additional U.S. $<ix:nonFraction unitRef="usd" contextRef="ic15e7d54e20c401b86da52a356fa5887_I20220411" decimals="-3" name="ardx:CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV83MC9mcmFnOmQ5NjhhZWM0NGY2NDQ1ODViYTFmZGRkNGIyZDgzODNlL3RleHRyZWdpb246ZDk2OGFlYzQ0ZjY0NDU4NWJhMWZkZGQ0YjJkODM4M2VfMTA5OTUxMTYzNjE3MQ_a32219d3-7124-42c0-bd07-3e4a3fac5e98">40.0</ix:nonFraction> million payable in <ix:nonFraction unitRef="payment_tranche" contextRef="ic15e7d54e20c401b86da52a356fa5887_I20220411" decimals="INF" name="ardx:CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV83MC9mcmFnOmQ5NjhhZWM0NGY2NDQ1ODViYTFmZGRkNGIyZDgzODNlL3RleHRyZWdpb246ZDk2OGFlYzQ0ZjY0NDU4NWJhMWZkZGQ0YjJkODM4M2VfMzI5ODUzNDg5MjQ4NQ_1000d418-a67e-4c26-b69d-1564843dcaac">two</ix:nonFraction> tranches, with the first payment due following KKC's filing with the Japanese Ministry Health, Labour and Welfare (MHLW) of its application for marketing approval for tenapanor and the second payment due following KKC's receipt of regulatory approval to market tenapanor for hyperphosphatemia in Japan.</ix:continuation> </span></div><div id="i711b1a39e0634b15bb7a70766327247a_73"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should read the following discussion and analysis of our financial condition and results of operations in conjunction with the condensed financial statements and notes thereto included elsewhere in this report and with the audited financial statements and related notes thereto included as part of our Annual Report on Form&#160;10-K for the&#160;year ended December&#160;31, 2021. This discussion and analysis and other parts of this report contain forward-looking statements that involve risk and uncertainties, such as statements of our plans, objectives, expectations and intentions. Our actual results could differ materially from those discussed in these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in the section of this report entitled &#8220;Risk Factors.&#8221; These forward-looking statements speak only as of the date hereof. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason. Unless the context requires otherwise, the terms &#8220;Ardelyx&#8221;, &#8220;Company&#8221;, &#8220;we&#8221;, &#8220;us&#8221;, and &#8220;our&#8221; refer to Ardelyx,&#160;Inc.</span></div><div id="i711b1a39e0634b15bb7a70766327247a_76"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since commencing operations in October 2007, substantially all our efforts have been dedicated to our research and development (&#8220;R&amp;D&#8221;) activities, including developing tenapanor and developing our proprietary drug discovery and design platform. We realized our first product sales of IBSRELA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(tenapanor) in March 2022. As of March&#160;31, 2022, we had an accumulated deficit of $741.0 million.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to incur substantial operating losses for the foreseeable future as we commercialize IBSRELA, seek to gain approval for XPHOZAH</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (tenapanor) for the control of serum phosphorus in adult patients with CKD on dialysis; prepare for the potential commercialization of XPHOZAH, if approved; and incur manufacturing and development cost for, tenapanor. To date, we have funded our operations from the sale and issuance of common stock and convertible preferred stock, funds from our collaboration partnerships, which includes license fees, milestones and product supply revenue, as well as funds from our loan agreements with our lenders.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Product Pipeline</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">IBSRELA for IBS-C</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our unique discovery platform and deep understanding of the primary mechanism of sodium transport in the intestine resulted in our discovery and development of IBSRELA, a first-in-class, U.S. Food and Drug Administration (&#8220;FDA&#8221;) approved, sodium hydrogen exchanger 3 ("NHE3") inhibitor for the treatment of IBS-C in adults. IBSRELA acts locally in the gut and is minimally absorbed. IBS-C is a gastrointestinal disorder characterized by both abdominal pain and altered bowel movements, estimated to affect 11 million people in the U.S. IBS-C is associated with significantly impaired quality of life, reduced productivity, and substantial economic burden.</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In preparation for our commercial launch of IBSRELA, we have built a commercial organization highly experienced in launching novel therapies into specialty areas.  We recognized our first sales of IBSRELA in the U.S. in March 2022. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established commercial agreements with Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. (&#8220;Fosun Pharma&#8221;) in China and Knight Therapeutics, Inc. (&#8220;Knight&#8221;) in Canada for IBSRELA for IBS-C. Knight is currently marketing IBSRELA in Canada.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i711b1a39e0634b15bb7a70766327247a_7">Table of Contents</a></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Development Candidate XPHOZAH for The Control of Serum Phosphorus in Adult Patients with CKD on Dialysis</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XPHOZAH is a first-in-class medicine being developed for the control of serum phosphorus in adult patients with CKD on dialysis. XPHOZAH has a unique mechanism of action and acts locally in the gut to inhibit NHE3. This results in the tightening of the epithelial cell junctions, thereby significantly reducing paracellular uptake of phosphate, the primary pathway of phosphate absorption. If approved, XPHOZAH would be the first therapy for phosphate management that blocks phosphorus absorption at the primary site of uptake. It is not a phosphate binder. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, we submitted a new drug application ("NDA") to the FDA for XPHOZAH for the control of serum phosphorus in adult patients with CKD on dialysis. The NDA was supported by three Phase 3 trials involving over 1,000 adult patients that evaluated the use of tenapanor for the control of serum phosphorus in adult patients with CKD on dialysis, with two trials evaluating tenapanor as monotherapy and one trial evaluating tenapanor as part of a dual mechanism approach with phosphate binders. All three Phase 3 trials met their primary and key secondary endpoints. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 28, 2021, we received a Complete Response Letter ("CRL") from the FDA regarding our NDA for tenapanor for the control of serum phosphorus in adult patients with CKD on dialysis. According to the CRL, while the FDA agrees &#8220;that the submitted data provide substantial evidence that tenapanor is effective in reducing serum phosphorus in adult patients with CKD on dialysis,&#8221; the FDA characterizes the magnitude of the treatment effect as &#8220;small and of unclear clinical significance.&#8221;  In December 2021, we submitted a Formal Dispute Resolution Request (&#8220;FDRR&#8221;). The FDRR was focused on demonstrating that the data submitted in the NDA supported the clinical significance of the treatment effect of tenapanor. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 4, 2022, we received an Appeal Denied Letter (&#8220;ADL&#8221;) from the FDA&#8217;s Office of Cardiology, Hematology, Endocrinology and Nephrology (&#8220;OCHEN&#8221;). On February 18, 2022, we submitted an appeal of the ADL to the FDA&#8217;s Center for Drug Evaluation and Research, Office of New Drugs (&#8220;OND&#8221;). </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 25, 2022, we announced that OND has provided an interim response to our second level of appeal of the CRL. The OND noted that additional input from the Cardiovascular and Renal Drug Advisory Committee (&#8220;Advisory Committee&#8221;) in general, and specifically, from experts, including expert clinicians, would be valuable in further considering the clinical meaningfulness of the phosphate lowering effect observed in our phase 3 clinical program for XPHOZAH. Accordingly, the OND intends to direct the Division of Cardiology and Nephrology to bring the XPHOZAH NDA to the Advisory Committee, and to provide a response to our appeal within thirty (30) days after the conclusion of the Advisory Committee meeting.   There can be no assurances that the Advisory Committee will recommend approval of our NDA for XPHOZAH, or that if approval is recommended, that such approval will ultimately be granted by the FDA. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RDX013 Program: Small Molecule for Treating Hyperkalemia</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our small molecule potassium secretagogue program, RDX013, is focused on the development of a potential treatment for hyperkalemia. Hyperkalemia is a common problem in patients with heart and kidney disease, particularly in patients taking customary blood pressure medications known as renin-angiotensin-aldosterone system (&#8220;RAAS&#8221;) inhibitors. RDX013 is a novel mechanism agent designed to target the underlying biological mechanisms of potassium secretion to lower elevated potassium. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 25, 2022, we reported that we have completed our data analyses of the Phase 2 dose ranging clinical trial for RDX013 evaluating the safety and efficacy of our potassium secretagogue for the treatment of hyperkalemia, or elevated potassium, in chronic kidney disease patients who are not on dialysis. While the results of the study demonstrated an acceptable safety and tolerability profile for RDX013 and supported proof of concept in its ability to lower serum potassium levels, with statistically significant reductions compared to placebo after eight days of treatment, the study did not meet its primary endpoint of significantly reducing serum potassium levels compared to placebo after four weeks of treatment. We currently expect that the next steps for the program will be to evaluate a new formulation that potentially enhances subject compliance and the efficacy of RDX013 in an additional Phase 2 clinical study at such time as we have determined our available resources support conducting such an additional clinical study after prioritization of our launch of IBSRELA and preparations for the Advisory Committee for XPHOZAH.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RDX020 Program: Small molecule for Treating Metabolic Acidosis </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have an ongoing discovery program targeting the inhibition of bicarbonate exchange inhibitor for the treatment of metabolic acidosis, a highly prevalent comorbidity in CKD patients that is strongly correlated with disease progression and adverse outcomes. We have identified lead compounds that are potent, selective and proprietary inhibitors of bicarbonate </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i711b1a39e0634b15bb7a70766327247a_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">secretion. Our research organization was eliminated as part of our October 2021 restructuring, and therefore, we currently expect to continue to advance this discovery program utilizing third-party resources managed by internal non-clinical expertise. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaboration Partners</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have exclusive rights to tenapanor in the U.S. and we have established agreements with Kyowa Kirin Co., Ltd. (&#8220;KKC&#8221;) in Japan, Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. (&#8220;Fosun Pharma&#8221;) in China and Knight Therapeutics, Inc. (&#8220;Knight&#8220;) in Canada for the development and commercialization of tenapanor for certain indications in their respective territories. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Knight has exclusive rights for the development, commercialization and distribution of tenapanor in Canada for hyperphosphatemia and IBS-C. In March 2021, Knight announced the commercial availability of IBSRELA in Canada, following its approval by Health Canada in April 2020. Under the terms of the agreement with Knight, we received a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$2.3 million nonrefundable, one-time upfront payment in March 2018 and are eligible to receive additional development and commercialization milestone payments worth up to $17.8 million. We are also eligible to receive royalties throughout the term of the agreement, and a transfer price for manufacturing services.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KKC has exclusive rights for the development, commercialization and distribution of tenapanor in Japan for cardiorenal indications. In April 2021, we announced that KKC had commenced four phase 3 clinical trials in Japan evaluating tenapanor for hyperphosphatemia. The phase 3 clinical trials consist of a multi-center, randomized, double-blind, placebo-controlled, parallel-group comparative study; a phosphate binder-combination parallel-group comparative study; an open-label, single-arm study evaluating hyperphosphatemia patients on peritoneal dialysis; and a long-term study evaluating serum phosphorus in patients who switch from one or more phosphate binders to tenapanor. Under the terms of the agreement with KKC, we received a $30.0 million upfront payment from KKC, and we may be entitled to receive up to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$55.0 million in total development milestones, of which $10.0 million has been received and recognized as revenue as of March&#160;31, 2022, and approximately &#165;8.5&#160;billion for commercialization milestones, or approximately $69.7 million at the currency exchange rate on March&#160;31, 2022, as well as royalties on net sales throughout the term of the agreement.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 14 - Subsequent events</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on April 11, 2022, we entered into a second amendment (the "Amendment") to the 2017 KKC Agreement. Under the terms of the Amendment, the parties have agreed to a reduction in the royalty rate payable to us by KKC upon net sales of tenapanor in Japan. The royalty rate will be reduced from the high teens to low double digits for a two-year period of time following the first commercial sale in Japan, and then to mid-single digits for the remainder of the royalty term. As consideration for the reduction in the royalty rate, KKC has agreed to pay us up to an additional U.S. $40.0 million payable in two tranches, with the first payment due following KKC's filing with the Japanese Ministry Health, Labour and Welfare (MHLW) of its application for marketing approval for tenapanor and the second payment due following KKC's receipt of regulatory approval to market tenapanor for hyperphosphatemia in Japan.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fosun Pharma has exclusive rights for the development and commercialization for the development, commercialization and distribution of tenapanor in China for both hyperphosphatemia and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IBS-C. Under the terms of the Fosun Agreement, we received</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$12.0 million in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">upfront</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">license, and we may be entitled to additional development and commercialization milestones of up to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$110.0 million, as well as reimbursement of cost plus a reasonable overhead for the supply of product and tiered royalties on net sales ranging from the mid-teens to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20%. </span></div><div id="i711b1a39e0634b15bb7a70766327247a_79"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impact of COVID-19</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The global COVID-19 pandemic has impacted the operational decisions of companies worldwide. It also has created and may continue to create significant uncertainty in the global economy. We have undertaken measures to protect our employees, partners, collaborators, and vendors, some of which impact our normal operations. To date, we have been able to continue our operations with our workforce, most of whom are working remotely, and our pre-existing infrastructure that supports secure access to our internal systems. If, however, the COVID-19 pandemic has a substantial impact on the productivity of our employees, the results of our operations and overall financial performance may be adversely impacted. The extent of the impact from the COVID-19 pandemic on our business will depend largely on future developments that are highly uncertain and cannot be predicted. For a discussion of risks of COVID-19 relating to our business, see &#8220;Part II: Other Information-Item 1A.- Risk Factors- Risks Related to Our Business-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The ongoing effects of the COVID-19 pandemic, or any other outbreak of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">epidemic diseases, or the perception of their effects, could have a material adverse effect on our business, financial condition, results of operations or cash flows</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#8221; As of the date of issuance of this financial report, we are not aware of any specific event or circumstance that would require updates to our estimates and judgments or revisions to the carrying value of our assets or liabilities. These estimates may change as new events occur and additional information is obtained.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><div id="i711b1a39e0634b15bb7a70766327247a_82"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i711b1a39e0634b15bb7a70766327247a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Significant Judgments and Estimates</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our discussion and analysis of financial condition and results of operations is based on our condensed financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Critical accounting policies are those that require significant judgment and/or estimates by management at the time that financial statements are prepared such that materially different results might have been reported if other assumptions had been made. These estimates form the basis for making judgments about the carrying values of assets and liabilities. We base our estimates and judgments on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. Actual results could differ materially from these estimates.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical accounting policies that we believe impact significant judgments and estimates used in the preparation of our condensed financial statements presented in this report are described in Part II, Item 7, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in our Annual Report on Form 10-K filed with the SEC on February 28, 2022. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the&#160;three months ended March&#160;31, 2022, we adopted the following critical accounting policies and significant judgements and estimates:</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Sales, Net</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for our commercial product sales, net in accordance with Topic 606 - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We received approval from the U.S. Food and Drug Administration (&#8220;FDA&#8221;) in September 2019 to market IBSRELA, the first and only sodium hydrogen exchanger 3 (&#8220;NHE3&#8221;) inhibitor for the treatment of irritable bowel syndrome with constipation ("IBS-C") in adults, in the United States (the "U.S."). We began selling IBSRELA in the U.S. in March 2022. We distribute our products principally through a limited number of distributors and specialty pharmacy providers (collectively, our "Customers"). Our Customers subsequently sell our products to pharmacies and patients. Separately, we enter into arrangements with third parties that provide for government-mandated and privately-negotiated rebates, chargebacks and discounts. Revenue from product sales is recognized when our performance obligations are satisfied, which is when Customers obtain control of our product and occurs upon delivery.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reserves for Variable Consideration</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration, including rebates, discounts, patient copay assistance programs, and estimated product returns. These estimates are based on the amounts earned or to be claimed for related sales and are classified as reductions of accounts receivable if the amount is payable to our Customers or a current liability if the amount is payable to a party other than a Customer. Where appropriate, these estimates are based on factors such as industry data and forecasted customer buying and payment patterns, our historical experience, current contractual and statutory requirements, specific known market events and trends. Overall, these reductions to gross sales reflect our best estimates of the amount of consideration to which we are entitled based on the terms of the contract. Variable consideration is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from our estimates, we adjust these estimates, which would affect product revenue and earnings in the period such variances become known. As we gain more historical experience, estimates will be more heavily based on the expected utilization from historical data we have accumulated since the IBSRELA product launch. Rebates are generally invoiced and paid quarterly in arrears.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rebates: Rebates include mandated discounts under the Medicaid Drug Rebate Program ("Medicaid") and the Medicare Coverage Gap Program ("Medicare"). Rebates are amounts owed after the final dispensing of products to a benefit plan participant and are based upon contractual agreements or legal requirements with the public-sector benefit providers. These estimates for rebates are recorded in the same period the related gross revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included in accrued expenses on the condensed balance sheets. We estimate our Medicaid and Medicare rebates based upon the estimated payor mix, and statutory discount rates. Our Our estimates for payor mix are guided by payor information received from specialty pharmacies, expected utilization for specialty distributor sales to pharmacies, and available industry payor information.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i711b1a39e0634b15bb7a70766327247a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chargebacks: Chargebacks are discounts that occur when contracted purchasers purchase directly from our specialty distributors at a discounted price. The specialty distributor, in turn, charges back the difference between the price initially paid to us by the specialty distributor and the discounted price paid to the specialty distributor by the contracted purchaser. Amounts for estimated chargebacks are established in the same period that the related gross revenue is recognized, resulting in a reduction of product revenue and accounts receivable. The accrual for specialty distributor chargebacks is estimated based on known chargeback rates, known sales to specialty distributors, and estimated utilization by types of contracted purchasers.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discounts and Fees: Our payment terms are generally 30 to 60 days. Specialty distributors and specialty pharmacies are offered various forms of consideration, including service fees and prompt pay discounts for payment within a specified period. We expect these Customers will earn prompt pay discounts and therefore, we deduct the full amount of these discounts and service fees from product sales when revenue is recognized, resulting in a reduction of product revenue and accounts receivable.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other Reserves: Patients who have commercial insurance may receive co-pay assistance when product is dispensed by pharmacies to patients. We estimate the amount of co-pay assistance provided to eligible patients based on the terms of the program and redemption information provided by third-party claims processing organizations and are recorded in accounts payable, accrued expenses and other current liabilities on the condensed balance sheets.</span></div><div id="i711b1a39e0634b15bb7a70766327247a_85"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of recent accounting pronouncements that we have adopted or may expect to adopt is included in Note 1 &#8211; Organization and Basis of Presentation to our condensed financial statements (see Part I, Item 1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Notes to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Condensed Financial Statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of this Quarterly Report on Form 10-Q).</span></div><div id="i711b1a39e0634b15bb7a70766327247a_88"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Operations Overview</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue to date has been generated primarily through license, research and development collaborative agreements with various collaboration partners. We realized our first commercial product sales of IBSRELA in March 2022. In the future, we may generate revenue from a combination of our own product sales and payments in connection with our current or future collaborative partnerships, including license fees, other upfront payments, milestone payments, royalties and payments for drug product and/or drug substance. We expect that any revenue we generate will fluctuate in future periods as a result of, among other factors: whether and the extent to which we are successful in our commercialization of IBSRELA, whether we are able to gain approval from the FDA for our NDA for XPHOZAH; the timing and progress of goods and services provided pursuant to our current or future collaborative partnerships; our or our collaborators&#8217; achievement of clinical, regulatory or commercialization milestones, to the extent achieved; the timing and amount of any payments to us relating to the aforementioned milestones; and the extent to which tenapanor is approved and successfully commercialized by a collaboration partner. If our current collaboration partners or any future collaboration partners fail to obtain regulatory approval for tenapanor, our ability to generate future revenue from our collaborative arrangements, and our results of operations and financial position, would be materially and adversely affected. Our past revenue performance is not necessarily indicative of results to be expected in future periods.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Revenue</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of revenue consists of the cost of commercial goods sold to Customers, collaboration partners under product supply agreements, and royalty expense based on sales of tenapanor. We capitalize inventory costs associated with the production of our products after regulatory approval or when, based on management&#8217;s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized. Otherwise, such costs are expensed as research and development. A portion of the costs of IBSRELA units recognized as revenue during the three months ended March&#160;31, 2022 were expensed prior to the fourth quarter of 2021, when our intent to commercialize IBSRELA was established and we commenced preparation for the commercial launch of IBSRELA. We believe our cost of goods sold for the three months ended March&#160;31, 2022 would have been $9&#160;thousand higher, if we had not previously expensed certain material and production costs with respect to the units sold. As of March&#160;31, 2022, we had approximately $32.3&#160;million of inventory on hand that was previously expensed as research and development expense and will not be reported as cost of goods sold in future periods when sales of IBSRELA are recognized as revenue.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of revenue includes payments due to AstraZeneca, which under the terms of a termination agreement entered into in 2015 (the "AZ Termination Agreement") is entitled to (i) future royalties at a rate of 10% of net sales of tenapanor or other </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i711b1a39e0634b15bb7a70766327247a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NHE3 products by us or our licensees, and (ii) 20% of non-royalty revenue received from our collaboration partners in connection with the development and commercialization of tenapanor or certain other NHE3 inhibitors.&#160;We have agreed to pay&#160;AstraZeneca up to a maximum of $75.0 million in the aggregate for (i) and (ii). We recognize these expenses as cost of revenue when we recognize the corresponding revenue that gives rise to payments due to AstraZeneca. To date, we have recognized an aggregate of $11.7 million as cost of revenue under the AZ Termination Agreement.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the October 2021 restructuring plan, we eliminated our internal research organization and expect to continue our discovery efforts with respect to RDX020 through the use of third-parties managed internally by non-clinical expertise. We recognize all research and development expenses as they are incurred to support the discovery, research, development and manufacturing of our product candidates. Research and development expenses include, but are not limited to, the following:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">external research and development expenses incurred under agreements with consultants, third-party contract research organizations (&#8220;CROs&#8221;) and investigative sites where a substantial portion of our clinical studies are conducted, and with contract manufacturing organizations where our clinical supplies are produced;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses associated with supplies and materials consumed in connection with our research operations;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses associated with producing tenapanor for the control of serum phosphorus in adult patients with CKD on dialysis prior to FDA approval;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other costs associated with research, clinical development and regulatory activities;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">employee-related expenses, which include salaries, bonuses, benefits, travel and stock-based compensation; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">facilities and other allocated expenses, which include direct and allocated expenses for rent and maintenance of facilities, depreciation and amortization expense, information technology expense and other supplies.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses consist primarily of salaries and related benefits, including stock-based compensation, for certain of our executives, our board members, and our finance, legal, business development, market development, commercial and support staff. Other selling, general and administrative expenses include facility related costs and professional fees for legal, accounting and audit, investor relations, other consulting services and allocated facility related costs not otherwise included in research and development expenses.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense represents the interest paid on our loan payable.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income, net</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income, net consists of interest income earned on our cash and cash equivalents and available-for-sale investments, the periodic revaluation of the exit fee related to our loan and currency exchange gains and losses. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><div id="i711b1a39e0634b15bb7a70766327247a_91"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i711b1a39e0634b15bb7a70766327247a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESULTS OF OPERATIONS</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of operations are not necessarily indicative of the results to be expected for the year ending December&#160;31, 2022, for any other interim period, or for any other future year.</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">three months ended March&#160;31, 2022 and 2021</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of our total revenue (dollars in thousands):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change <br/>2022 vs. 2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product supply revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(112)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,002&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,998)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaborative development revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,454&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,454)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">468&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,582&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,114)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a) Percent change is not meaningful.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease to total revenues during the three months ended March&#160;31, 2022 is primarily attributable to a $5.0&#160;million milestone that was earned during the prior year upon the initiation of phase 3 clinical studies by KKC in Japan to evaluate tenapanor for hyperphosphatemia that did not recur during the current year, as well as the full recognition of upfront payments associated with the 2019 KKC Agreement through the end of 2021, for which there was no comparable revenue during the three months ended March&#160;31, 2022. Partially offsetting these decreases was recognition of $0.5&#160;million of product sales, net for initial sales of IBSRELA to our Customers in connection with the commercial launch of IBSRELA.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Expenses</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of our operating expenses (dollars in thousands):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change <br/>2022 vs. 2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(915)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,851&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,456&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,605)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,339&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,131&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,208&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,275&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,587&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,312)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost of revenue</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in cost of revenue for the three months ended March&#160;31, 2022 was primarily attributable to $1.0&#160;million payment due to AstraZeneca under the AZ Termination Agreement related to the development milestone we earned upon the initiation by KKC of phase 3 clinical studies in Japan to evaluate tenapanor for hyperphosphatemia during the three months ended March&#160;31, 2021, compared to $0.1&#160;million due to AstraZeneca during the three months ended March&#160;31, 2022. In addition, during the three months ended March&#160;31, 2022, we incurred cost of revenue from initial sales of IBSRELA to our Customers in connection with the commercial launch of IBSRELA.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i711b1a39e0634b15bb7a70766327247a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of our research and development expenses (dollars in thousands): </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change <br/>2022 vs. 2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">External R&amp;D expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,940&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,508&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,568)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee-related expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,177&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,043)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Facilities, equipment and depreciation expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,114&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,284&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(170)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">620&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,851&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,456&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,605)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in our external R&amp;D expenses for the three months ended March&#160;31, 2022 is primarily the result of lower clinical study costs from the OPTIMIZE study, lower tenapanor manufacturing expense as we have begun to capitalize costs associated with the production of IBSRELA to inventory, and lower expenses for research following the elimination of our research function in the fourth quarter of 2021. The decrease in our employee-related expenses for the three months ended March&#160;31, 2022 is due to lower compensation and benefits expenses for our research and development workforce following restructuring actions in 2021. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Selling, General and Administrative </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in general and administrative expenses for the three months ended March&#160;31, 2022 was primarily due to increased costs associated with building and staffing our commercial infrastructure and teams as we prepared for the U.S. launch of IBSRELA. The increase consisted of headcount and related personnel costs and an increase in external spending for disease awareness initiatives, commercial infrastructure and strategy. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income, net</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of our other income, net (dollars in thousands):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change <br/>2022 vs. 2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(746)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,100)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">484&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">533&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,087.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(262)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,149)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">887&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Expense</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in interest expense for the three months ended March&#160;31, 2022 was primarily due to lower principal outstanding on our loan payable.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other&#160;Expense, net</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in other income (expense), net for the three months ended March&#160;31, 2022 primarily resulted from sales of certain lab equipment and supplies for a net gain of $0.7 million. The gain was partially offset by $0.1 million expense incurred upon the settlement of our 2018 Loan, as well as higher unrealized foreign currency exchange losses.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><div id="i711b1a39e0634b15bb7a70766327247a_94"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i711b1a39e0634b15bb7a70766327247a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of our cash, cash equivalents and investments (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.590%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.426%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change $</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change %</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,077&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,428&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,351)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,627&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,261&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,634)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liquid funds</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,704&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,689&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,985)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, we had cash, cash equivalents and investments totaling $89.7 million compared to $116.7 million as of December&#160;31, 2021. We have incurred operating losses since inception and our accumulated deficit as of March&#160;31, 2022 is $741.0 million. Our current level of cash and investments alone is not sufficient to meet our plans for the next twelve months following the filing of these financial statements on May&#160;5, 2022. These factors raise substantial doubt regarding our ability to continue as a going concern for a period of one year from the issuance of these financial statements. We plan to address our operating cash flow requirements with our current cash and investments, cash generated from the product launch of IBSRELA, our potential receipt of anticipated milestone payments from our collaboration partners, our potential receipt of anticipated payments from KKC under the Amendment, our ability to access the capital markets, as well as through the implementation of cash preservation activities to reduce or defer discretionary spending. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no assurances that our efforts to meet our operating cash flow requirements will be successful. If our current cash and investments as well as our plans to meet our operating cash flow requirements are not sufficient to fund necessary expenditures and meet our obligations for at least the next twelve months following the issuance of these financial statements, our liquidity, financial condition and business prospects will be materially affected. These financial statements have been prepared on a going concern basis and do not include any adjustments to the amounts and classification of assets and liabilities that may be necessary in the event that we can no longer continue as a going concern.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, we filed a Form S-3 registration statement, which became effective in August 2020 ("Registration Statement"), containing (i) a base prospectus for the offering, issuance and sale by us of up to a maximum aggregate offering price of $250.0 million of our common stock, preferred stock, debt securities, warrants and/or units, from time to time in one or more offerings; and (ii) a prospectus supplement for the offering, issuance and sale by us of up to a maximum aggregate offering price of $100.0 million of our common stock that may be issued and sold, from time to time, under a sales agreement with Jefferies LLC ("Jefferies"), deemed to be &#8220;at the market offerings&#8221; (the "2020 Open Market Sales Agreement"). The 2020 Open Market Sales Agreement was fully utilized as of December 31, 2021. During the three months ended March&#160;31, 2021 we sold 4.9 million shares and received gross proceeds of $35.0 million at a weighted average sales price of approximately $7.09 per share under the 2021 Open Market Sales Agreement.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, we filed an additional prospectus supplement under the Registration Statement for the offering, issuance and sale by us of up to a maximum aggregate offering price of $150.0 million of our common stock that may be issued and sold, from time to time, under an additional sales agreement we entered into with Jefferies (the "2021 Open Market Sales Agreement"), pursuant to which we may, from time to time, sell up to $150.0 million in shares of our common stock through Jefferies. We are not required to sell shares under the 2021 Open Market Sales Agreement. Pursuant to the 2021 Open Market Sales Agreement, Jefferies, as our sales agent, receives a commission of up to 3% of the gross sales price for shares of common stock sold under the 2021 Open Market Sales Agreement. During the three months ended March&#160;31, 2022 we sold 5.9 million shares and received gross proceeds of $6.0 million at a weighted average sales price of approximately $1.02 per share under the 2021 Open Market Sales Agreement.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, we entered into a loan and security agreement (the &#8220;2022 Loan Agreement&#8221;) with SLR Investment Corp. The 2022 Loan Agreement provides for a senior secured term loan facility, with $27.5 million funded at closing and an additional $22.5 million that we may borrow on or prior to July 25, 2023; provided that (i) we have received approval by the FDA for our NDA for tenapanor for the control of serum phosphorus in chronic kidney disease patients on dialysis by December 31, 2022, and (ii) we have achieved certain product revenue milestone targets described in the 2022 Loan Agreement. The initial funding of $27.5 million is being used to repay the 2018 Loan and to fund our ongoing operations. We had $25.0 million principal from the 2018 Loan outstanding as of the closing date. In connection with entering into the 2022 Loan Agreement, we entered into an agreement, whereby we agreed to pay an exit fee in the amount of  2% of the 2022 Loan funded (the &#8220;2022 Exit Fee&#8221;) upon (i) any change of control transaction or (ii) our achievement of net revenue from the sale of any products equal to or greater than $100.0 million, measured on a six (6) months basis (the "Revenue Milestone"), tested monthly at the end of each month. Notwithstanding the prepayment or termination of the 2022 Loan, the 2022 Exit Fee will </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i711b1a39e0634b15bb7a70766327247a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expire on February 23, 2032. We concluded that the 2022 Exit Fee is a freestanding derivative which should be accounted for at fair value on a recurring basis. The estimated fair value of the 2022 Exit Fee is recorded as a derivative liability and included in accrued expenses and other current liabilities on the accompanying condensed balance sheets.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary sources of cash have been from the sale and issuance of common stock (in both public offerings and private placements) and private placements of convertible preferred stock, funds from our collaboration partnerships and funds from our 2018 Loan Agreement. Our primary uses of cash have been to fund operating expenses, primarily research and development expenditures and pre-commercial expenses. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable and accrued expenses.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future funding requirements are difficult to forecast and will depend on many factors, including:</span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the extent to which we are able to generate product revenue from sales of IBSRELA;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">whether we are successful in our efforts under the FDR process, including the Advisory Committee meeting to be convened as part of the FDR process, to secure approval for our NDA for tenapanor for the Hyperphosphatemia Indication, or to reach resolution with the FDA regarding a path to address the deficiencies in the NDA noted in the CRL and ADL, and the time and cost associated with such path;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the availability of adequate third-party reimbursement for IBSRELA and, if approved, the sales price and the availability of adequate third-party reimbursement for XPHOZAH;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the manufacturing costs of IBSRELA and XPHOZAH; </span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the selling and marketing costs associated with IBSRELA and, if approved, XPHOZAH;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our ability to maintain our existing collaboration partnerships and to establish additional collaboration partnerships, in-license/out-license, joint ventures or other similar arrangements and the financial terms of such agreements;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the timing, receipt and amount of any milestones that may be received from our collaboration partners in connection with tenapanor, if any;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the timing, receipt and amount of revenue, if any, that may be received from KKC in connection with the 2022 KKC Amendment;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the timing, receipt, and amount of sales of, or royalties on, tenapanor, if any;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the cash requirements of any future acquisitions or discovery of product candidates;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">any clinical trials we are required to or decide to pursue for tenapanor or RDX013;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the time and cost necessary to respond to technological and market developments;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the costs of filing, prosecuting, maintaining, defending and enforcing any patent claims and other intellectual property rights, including litigation costs and the outcome of such litigation, including costs of defending any claims of infringement brought by others in connection with the development, manufacture or commercialization of tenapanor or any of our product candidates; and </span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the payment of interest and principal related to our loan and security agreement entered into with SLR Investment Corp. in February 2022. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please see the risk factors set forth in Part II, Item 1A, Risk Factors, in this Quarterly Report on Form 10-Q for additional risks associated with our capital requirements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i711b1a39e0634b15bb7a70766327247a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CASH FLOW ACTIVITIES</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash flows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.198%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.958%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.869%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change $</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change %</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,620)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44,217)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,597&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,332&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,485&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(153)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,770&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34,833)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net decrease in cash and cash equivalents</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,351)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,962)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,389)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div id="i711b1a39e0634b15bb7a70766327247a_97"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Flows from Operating Activities</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities during the three months ended March&#160;31, 2022 decreased by $16.6 million primarily as a result of changes to our operating assets and liabilities as we built and staffed our commercial infrastructure and teams in preparation for the U.S. launch of tenapanor. In addition to the changes in our operating assets and liabilities, our net loss was $5.1 million less than during the three months ended March&#160;31, 2021.</span></div><div id="i711b1a39e0634b15bb7a70766327247a_100"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Flows from Investing Activities</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities decreased by $0.2 million due to the timing of our investment maturities and purchases, as well as $0.8 million proceeds from sale of laboratory equipment and supplies during the three months ended March&#160;31, 2022.</span></div><div id="i711b1a39e0634b15bb7a70766327247a_103"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Flows from Financing Activities</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities decreased by $34.8 million primarily due to net proceeds from issuance of our common stock pursuant to the at the market offerings of $34.3 million during the three months ended March&#160;31, 2021 compared to $5.9 million during the three months ended March&#160;31, 2022. In addition, during the three months ended March&#160;31, 2022, we received net proceeds of $27.0 million pursuant to the 2022 Loan Agreement and repaid $33.0 million, net of settlement costs, to repay the 2018 Loan.</span></div><div id="i711b1a39e0634b15bb7a70766327247a_106"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022 and 2021, respectively, we did not have any off-balance sheet arrangements as defined in Item 303(a)(4) of Regulation S-K as promulgated by the SEC.</span></div><div id="i711b1a39e0634b15bb7a70766327247a_109"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Rate Risk.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We are subject to market risks, including interest rate fluctuation exposure through our investments, in the ordinary course of our business. However, the goals of our investment policy are the preservation of capital, fulfillment of liquidity needs and fiduciary control of cash. To achieve our goal of maximizing income without assuming significant market risk, we maintain our excess cash and cash equivalents in money market funds and short-term debt securities. Because of the short-term maturities of our cash equivalents, we do not believe that a decrease in interest rates would have any material negative impact on the fair value of our cash equivalents.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, we had cash, cash equivalents and investments of $89.7&#160;million, which consist of bank deposits and money market funds, as well as high quality fixed income instruments including corporate bonds, commercial paper, and asset-backed securities collateralized by non-mortgage consumer receivables. The credit rating of our investments must be rated A-1/P-1, or better by Standard and Poor&#8217;s and Moody&#8217;s Investors Service. Asset-backed securities must be rated AAA/Aaa. Money Market funds must be rated AAAm/Aaa. Such interest-earning instruments carry a degree of interest rate risk. However, because our investments are high quality and short-term in duration, we believe that our exposure to interest rate risk is not significant and that a 10% movement in market interest rates would not have a significant impact on the total value of our portfolio, as noted above. We do not enter into investments for trading or speculative purposes.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to interest rate fluctuation exposure through our borrowings under the Loan Agreement and our investment in money market accounts which bear a variable interest rate. Borrowings under the 2022 Loan bear interest at a floating per annum rate equal to 7.95% plus the greater of (i) one tenth percent (0.10%) and (ii) the one-month rate published by the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i711b1a39e0634b15bb7a70766327247a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intercontinental Exchange Benchmark Administration Ltd ("ICE") or its successor. A hypothetical increase in one-month ICE of 100 basis points above the current one-month ICE rates would have increased our interest expense by approximately $0.1&#160;million for the three months ended March&#160;31, 2022. As of March&#160;31, 2022, we had an aggregate principal amount of $27.5&#160;million outstanding pursuant to our 2022 Loan Agreement.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Risk.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The majority of our transactions are denominated in U.S. dollars. However, we do have certain transactions that are denominated in currencies other than the U.S. dollar, primarily Swiss francs and the euro, and we therefore are subject to foreign exchange risk. The fluctuation in the value of the U.S. dollar against other currencies affects the reported amounts of expenses, assets and liabilities associated with a limited number of manufacturing activities.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not use derivative financial instruments for speculative trading purposes, nor do we hedge foreign currency exchange rate exposure in a manner that entirely offsets the earnings effects of changes in foreign currency exchange rates. The counterparties to our forward foreign currency exchange contracts are creditworthy commercial banks, which minimizes the risk of counterparty nonperformance.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, we had no open forward foreign currency exchange contracts.</span></div><div id="i711b1a39e0634b15bb7a70766327247a_112"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;CONTROLS AND PROCEDURES</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As required by Rule&#160;13a-15(b)&#160;under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), our management, under the supervision and with the participation of our principal executive officer and principal financial officer, has evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as such term is defined in Rules&#160;13a-15(e)&#160;and 15d-15(e)&#160;under the Exchange Act) as of March&#160;31, 2022. Any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objective and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on such evaluation, our principal executive officer and principal financial officer have concluded that, as of March&#160;31, 2022, our disclosure controls and procedures were effective at a reasonable assurance level.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended  March&#160;31, 2022, we implemented certain internal controls in connection with our product launch. There were no other changes in our internal control over financial reporting that occurred during our most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inherent Limitations on Effectiveness of Controls</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Internal control over financial reporting has inherent limitations. Internal control over financial reporting is a process that involves human diligence and compliance and is subject to lapses in judgment and breakdowns resulting from human failures. Internal control over financial reporting also can be circumvented by collusion or improper management override. Because of such limitations, there is a risk that material misstatements will not be prevented or detected on a timely basis by internal control over financial reporting. However, these inherent limitations are known features of the financial reporting process. Therefore, it is possible to design into the process safeguards to reduce, though not eliminate, this risk.</span></div><div id="i711b1a39e0634b15bb7a70766327247a_115"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;II.&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OTHER INFORMATION</span></div><div id="i711b1a39e0634b15bb7a70766327247a_118"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;LEGAL PROCEEDINGS</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 30 and August 12, 2021, two putative securities class action lawsuits were commenced in the U.S. District Court for the Northern District of California naming as defendants Ardelyx and two current officers captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Strezsak v. Ardelyx, Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 4:21-cv-05868-HSG, and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Siegel v. Ardelyx, Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 5:21-cv-06228-HSG (together, the &#8220;Securities Class Actions&#8221;). The complaints allege that the defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 thereunder, by making false and misleading statements and omissions of material fact related to tenapanor. The plaintiffs seek to represent all persons who purchased or otherwise acquired Ardelyx securities between August 6, 2020, and July 19, 2021. The plaintiffs seeks damages and interest, and an award of costs, including attorneys&#8217; fees. On September 28, 2021, several shareholders filed motions to consolidate the two putative class actions and to be appointed lead plaintiff and have their selection of counsel be appointed lead counsel. The court has not yet ruled on those motions. Once the court appoints a lead plaintiff and lead counsel, the parties will negotiate and submit a </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i711b1a39e0634b15bb7a70766327247a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">proposed schedule for lead plaintiff to file a consolidated amended complaint and for defendants to file a motion to dismiss. We believe the plaintiff&#8217;s claims are without merit and we have not recorded any accrual for a contingent liability associated with these legal proceedings.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 7, 2021 and March 29, 2022, two verified shareholders derivative lawsuits were filed purportedly on behalf of Ardelyx against certain of Ardelyx&#8217;s executive officers and members of our board of directors, captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Go v. Raab, et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 4:21-cv-09455-HSG, and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Morris v. Raab, et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 4:22-cv-01988-JSC.  The complaints allege violations of Section 14(a) of the Exchange Act, breaches of fiduciary duties, unjust enrichment, abuse of control, gross mismanagement, and waste, and seek contribution under Sections 10(b) and 21D of the Securities Exchange Act of 1934 from two executive officers. On January 19, and April 27, 2022, the court granted the parties&#8217; stipulation to stay the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Go </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Morris</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> actions, respectively, until resolution of the anticipated motion(s) to dismiss in the Securities Class Actions, and the cases remain stayed.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">From time to time, we may be involved in legal proceedings arising in the ordinary course of business. As of March&#160;31, 2022, there is no litigation pending that would reasonably be expected to have a material adverse effect on our results of operations and financial condition, and no contingent liabilities were accrued as of March&#160;31, 2022.</span></div><div id="i711b1a39e0634b15bb7a70766327247a_121"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;1A.&#160;&#160;&#160;&#160;&#160;RISK FACTORS </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our business involves significant risks, some of which are described below. You should carefully consider these risks, as well as other information in this Quarterly Report on Form 10-Q, including our financial statements and the notes thereto and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221; The occurrence of any of the events or developments described below could harm our business, financial condition, results of operations, cash flows, the trading price of our common stock and our growth prospects. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also impair our business operations.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Financial Condition and Capital Requirements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have a limited operating history, have incurred significant losses since our inception and we will incur losses in the future, which makes it difficult to assess our future viability; although our financial statements have been prepared on a going concern basis, our current level of cash and investments alone is not sufficient to meet our operating plans for the next twelve months, raising substantial doubt regarding our ability to continue as a going concern. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biopharmaceutical company with a limited operating history. Biopharmaceutical product development is a highly speculative undertaking and involves a substantial degree of risk. To date, we have focused substantially all of our efforts on our research and development activities, including developing tenapanor and developing our proprietary drug discovery and design platform. We began selling our first product, IBSRELA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(tenapanor) for the treatment of irritable bowel syndrome with constipation (&#8220;IBS-C&#8221;) in March 2022, and have generated limited revenue from product sales to date. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not profitable and have incurred losses in each year since our inception in October 2007, and we do not know whether or when we will become profitable. We continue to incur significant commercialization, development and other expenses related to our ongoing operations. As of March&#160;31, 2022, we had an accumulated deficit of $741.0&#160;million. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to incur substantial operating losses for the foreseeable future as we commercialize IBSRELA, seek to gain approval for XPHOZAH</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(tenapanor) for the control of serum phosphorus in adult patients with chronic kidney disease (&#8220;CKD&#8221;) on dialysis (the &#8220;Hyperphosphatemia Indication&#8221;); prepare for the potential commercialization of XPHOZAH, if approved; and incur manufacturing and development cost for, tenapanor. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ernst &amp; Young LLP, our independent registered public accounting firm for the fiscal year ended December 31, 2021, has included an explanatory paragraph in their opinion that accompanies our audited financial statements as of the year ended December 31, 2021, indicating our current liquidity position raises substantial doubt about our ability to continue as a going concern. We plan to address our operating cash flow requirements with our current cash and investments, cash generated from the product launch of IBSRELA, our potential receipt of anticipated milestone payments from our collaboration partners, our potential receipt of anticipated payments from our collaboration partner, Kyowa Kirin, Co., Ltd. (&#8220;KKC&#8221;) in connection with the transaction entered into with KKC in March 2022 which amended our License Agreement entered into with KKC in 2017 (the &#8220;2022 KKC Amendment&#8221;); our ability to access the capital markets, as well as through the implementation of cash preservation activities to reduce or defer discretionary spending.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i711b1a39e0634b15bb7a70766327247a_7">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no assurances that our efforts to meet our operating cash flow requirements will be successful. If our current cash and investments as well as our plans to meet our operating cash flow requirements are not sufficient to fund necessary expenditures and meet our obligations for at least the next twelve months, our liquidity, financial condition and business prospects will be materially affected. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our prior losses, combined with expected future losses, have had and will continue to have an adverse effect on our stockholders&#8217; equity and working capital. Further, the net losses we incur may fluctuate significantly from quarter-to-quarter and year-to-year, such that a period-to-period comparison of our results of operations may not be a good indication of our future performance. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have substantial net operating loss and tax credit carryforwards for Federal and California income tax purposes. Such net operating losses and tax credits carryforwards may be reduced as a result of certain intercompany restructuring transactions. In addition, the future utilization of such net operating loss and tax credit carryforwards and credits will be subject to limitations, pursuant to Internal Revenue Code Sections 382 and 383, as a result of ownership changes that have occurred previously and additional limitations may be applicable as a result of ownership changes that could occur in the future. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will require substantial additional financing to achieve our goals, including our goals of commercializing IBSRELA and preparing for and participating in a Cardiovascular and Renal Drugs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Advisory Committee (&#8220;Advisory Committee&#8221;) meeting in connection with the formal dispute resolution ("FDR") process commenced in response to the Complete Response Letter (&#8220;CRL&#8221;) received from the U.S. Food and Drug Administration (&#8220;FDA&#8221;) relating to our New Drug Application (&#8220;NDA&#8221;) for tenapanor for the Hyperphosphatemia Indication and the inability to access necessary capital when needed on acceptable terms, or at all, could force us to limit, reduce or terminate our efforts to commercialize IBSRELA or to seek and obtain approval for tenapanor for the Hyperphosphatemia Indication. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, most of our resources have been dedicated to our research and development activities, including developing tenapanor and developing our proprietary drug discovery and design platform. Following the receipt of the CRL, we implemented two restructuring plans in order to reduce operating costs and to better align our workforce with the needs of our business. Notwithstanding the restructurings, we believe that we will continue to expend substantial resources for the foreseeable future, including, costs associated with our efforts to commercialize IBSRELA, which we began selling in the U.S. in March 2022, cost associated with our efforts to pursue approval for our NDA for tenapanor for the Hyperphosphatemia Indication through the FDR process, and Advisory Committee meeting; conducting pediatric clinical trials for IBSRELA and XPHOZAH, if approved, and manufacturing for IBSRELA and, if approved, XPHOZAH. Our future funding requirements will depend on many factors, including, but not limited to:</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which we are able to generate product revenue from sales of IBSRELA;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether we are successful in our efforts under the FDR process, including the Advisory Committee meeting to be convened as part of the FDR process, to secure approval for our NDA for tenapanor for the Hyperphosphatemia Indication, or to reach resolution with the FDA regarding a path to address the deficiencies in the NDA noted in the CRL and ADL, and the time and cost associated with such path;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of adequate third-party reimbursement for IBSRELA and, if approved, the sales price and the availability of adequate third-party reimbursement for XPHOZAH;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the manufacturing costs of IBSRELA and XPHOZAH; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the selling and marketing costs associated with IBSRELA and, if approved, XPHOZAH;</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to maintain our existing collaboration partnerships and to establish additional collaboration partnerships, in-license/out-license, joint ventures or other similar arrangements and the financial terms of such agreements;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing, receipt and amount of any milestones that may be received from our collaboration partners in connection with tenapanor, if any;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing, receipt and amount of revenue, if any, that may be received from KKC in connection with the 2022 KKC Amendment;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing, receipt, and amount of sales of, or royalties on, tenapanor, if any;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cash requirements of any future acquisitions or discovery of product candidates;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any clinical trials we are required to or decide to pursue for tenapanor or RDX013;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the time and cost necessary to respond to technological and market developments;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i711b1a39e0634b15bb7a70766327247a_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of filing, prosecuting, maintaining, defending and enforcing any patent claims and other intellectual property rights, including litigation costs and the outcome of such litigation, including costs of defending any claims of infringement brought by others in connection with the development, manufacture or commercialization of tenapanor or any of our product candidates; and</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the payment of interest and principal related to our loan and security agreement entered into with SLR Investment Corp. in February 2022. </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional funds may not be available when we need them on terms that are acceptable to us, or at all. If adequate funds are not available to us on a timely basis, we may be required to limit, reduce or terminate our commercialization of IBSRELA, delay, limit, reduce or terminate our efforts to secure approval for XPHOZAH for the Hyperphosphatemia Indication, or clinical trials for tenapanor. Additionally, our inability to access capital on a timely basis and on terms that are acceptable to us may force us to restructure certain aspects of our business or identify and complete one or more strategic collaborations or other transactions in order to fund the commercialization of IBSRELA or the development and commercialization of XPHOZAH, if approved, through the use of alternative structures.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our failure to meet the continued listing requirements of The Nasdaq Global Market could result in a de-listing of our common stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we fail to satisfy the continued listing requirements of The Nasdaq Global Market ("Nasdaq") such as the minimum stockholders&#8217; equity requirement or the minimum closing bid price requirement, Nasdaq may take steps to de-list our common stock. For example, on February 28, 2022 we received a letter from Nasdaq indicating that Nasdaq had determined that we had failed to comply with the minimum bid price requirement of Nasdaq Listing Rule 5550(a)(2). Nasdaq Listing Rule 5550(a)(2) requires that companies listed on the Nasdaq Global Market maintain a minimum closing bid price of at least $1.00 per share (the &#8220;Listing Requirement&#8221;). We received a letter from Nasdaq on March 31, 2022, indicating that the Company had regained compliance with the Listing Requirement after the closing bid price for its common stock listed on Nasdaq equaled or exceeded $1.00 per share for ten (10) consecutive business days, and confirming that the Company will remain in compliance with this Listing Requirement as long as the closing bid price of its common stock does not fall below $1.00 for thirty (30) consecutive business days. On April 8, 2022, the closing bid price of our common stock listed on Nasdaq was below $1.00 per share, and there can be no assurances that we will continue to remain in compliance with the Listing Requirement. In the event that we are not able to remain in compliance with the Listing Requirement, there can be no assurances that we will be able  to regain compliance with the Listing Requirement in the time frame that may be afforded us by Nasdaq. We are monitoring the bid price of our common stock and will consider options available to us, including the implementation of a reverse stock split, to maintain or regain, if required, compliance with the Listing Requirement. On April 29, 2022, we filed our definitive Proxy Statement with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;) indicating our intention to seek approval from our stockholders during our Annual Meeting of Stockholders to be held on June 15, 2022, for a proposal to grant our Board of Directors authority to effect a reverse stock split of our authorized common stock and issued and outstanding common stock by amending our Amended and Restated Certificate of Incorporation by September 15, 2022 and within a range of not less than 1-for-2 and not more than 1-for-10, if our Board of Directors deems it within our best interests. There can be no assurances that our stockholders will approve the proposal, or that we will have other options available to maintain compliance with the Listing Requirement. If we fail to maintain compliance with this requirement, or any other of the continued listing requirements of The Nasdaq Global Market, Nasdaq may take steps to de-list our common stock. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If Nasdaq de-lists our securities for trading on the Nasdaq or takes other actions with respect to our Nasdaq listing, we could face significant adverse consequences, including:</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;      a limited availability of market quotations for our common stock;</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;      reduced liquidity with respect to our common stock;</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;      reduced trading volume in and market price of our common stock;</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;      a limited amount of news and analyst coverage for our company; and</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;      a decreased ability to issue additional securities or obtain additional financing in the future.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Such a de-listing would likely have an adverse effect on the price of our common stock and would impair your ability to sell or purchase our common stock when you wish to do so. We may take actions to avoid such a de-listing or in the event of a de-listing, we may take actions to restore our compliance with Nasdaq&#8217;s listing requirements, but we can provide no assurance that any such action taken by us would allow our common stock to remain listed or to become listed again, stabilize the market price or improve the liquidity or trading volume of our common stock, prevent our common capitalization and stockholder&#8217;s </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i711b1a39e0634b15bb7a70766327247a_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">equity from dropping below the Nasdaq minimum requirements, or prevent other future non-compliance with Nasdaq&#8217;s continued listing requirements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have generated limited revenue from product sales and may never be profitable. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We began selling IBSRELA in the U.S. in March 2022, and have generated limited revenue from product sales to date. We have no other products approved for sale and have received a CRL from the FDA for our NDA for the Hyperphosphatemia Indication and an Appeal Denied Letter (&#8220;ADL&#8221;) in response to our first level of appeal of the CRL to the FDA Office of Cardiology, Hematology, Endocrinology and Nephrology (&#8220;OCHEN&#8221;). Additionally, we have received an Interim Response to our second level of appeal to the Office of New Drugs (&#8220;OND&#8221;), Center for Drug Evaluation and Research (CDER), indicating that OND intends to direct the Division of Cardiology and Nephrology of OCHEN (the &#8220;Division&#8221;) to bring the XPHOZAH NDA to the Advisory Committee (the &#8220;Interim Response&#8221;). There can be no assurances that any such Advisory Committee will recommend approval of our NDA for tenapanor for the Hyperphosphatemia Indication, or that if approval is recommended, that such approval will ultimately be granted by the FDA. To date, we have generated limited product revenue from product sales of IBSRELA. There can be no assurances that we will be successful in increasing the amount of product revenue from sales of IBSRELA. Our ability to generate revenue from product sales and achieve profitability depends on our ability to successfully commercialize IBSRELA; obtain approval by the FDA for the Hyperphosphatemia Indication, and subsequently successfully commercialize XPHOZAH for the Hyperphosphatemia Indication; and the ability of our collaboration partners to obtain regulatory approval to market tenapanor in their respective territories. There can be no assurances that we will generate sufficient product revenue from sales of IBSRELA and, if approved, XPHOZAH, to cover our expenses. Our ability to generate product revenue from sales or pursuant to milestone payments depends heavily on many factors, including but not limited to:</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to successfully commercialize IBSRELA;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining market acceptance of IBSRELA as a viable treatment option for IBS-C;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain and sustain an adequate level of coverage and reimbursement for IBSRELA by third-party payors;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether we are successful in our efforts during the Advisory Committee meeting and under the FDR process to secure approval for our NDA for tenapanor for the Hyperphosphatemia Indication, or whether we are otherwise able during the FDR to reach resolution with the FDA regarding a path to addressing the deficiencies in our NDA noted in the CRL, ADL and Interim Response that is achievable in terms of clinical study design, time and cost;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishing and maintaining supply and manufacturing relationships with third parties that can provide an adequate (in amount and quality) supply of product to support the market demand for IBSRELA, and, if approved, XPHOZAH;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">addressing any competing technological and market developments;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintaining, protecting and expanding our portfolio of intellectual property rights, including patents, trade secrets, and know-how, and our ability to develop, manufacture and commercialize our product candidates and products without infringing intellectual property rights of others; and</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">attracting, hiring, and retaining qualified personnel.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to our commercialization of IBSRELA, and if we are successful in obtaining regulatory approval to market XPHOZAH, our revenue will be dependent, in part, upon the size of the markets in the U.S. and the label for which approval is or was granted, acceptance of the price for the product, and the ability to get reimbursement at any price. While there is significant uncertainty related to the insurance coverage and reimbursement of newly approved products in general in the United States, there is additional uncertainty related to insurance coverage and reimbursement for drugs, like XPHOZAH, which, if approved, will be marketed for the control of serum phosphorus in adult patients with CKD on dialysis or for another other related indication. If we are successful in obtaining regulatory approval to market XPHOZAH for such indication, our ability to generate and sustain future revenues from sales of tenapanor for such indication, may be dependent upon whether and when XPHOZAH, along with other oral ESRD related drugs without an injectable or intravenous equivalent, are bundled into the ESRD prospective payment system, and the manner in which such introduction into the ESRD prospective payment system may occur. See &#8220;Third-party payor coverage and reimbursement status of newly-approved products is uncertain. Failure to obtain or maintain adequate coverage and reimbursement for IBSRELA or, if approved, XPHOZAH, could limit our ability to market those products and decrease our ability to generate revenue&#8221; below. Additionally, if the number of adult patients for IBSRELA or, if approved, XPHOZAH is not as significant as we estimate, the indication approved by regulatory authorities for XPHOZAH is narrower than we expect, coverage and reimbursement for either IBSRELA or, if approved, XPHOZAH are not available in the manner and to the extent we expect, or the reasonably accepted population for treatment is narrowed by competition, physician choice or treatment guidelines, we may not generate significant revenue from the sale of IBSRELA or, if approved, XPHOZAH. Even if we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods. Our failure to generate adequate revenue from product sales would likely depress our market value and could impair </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i711b1a39e0634b15bb7a70766327247a_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our ability to raise capital, expand our business, discover or develop other product candidates or continue our operations. A decline in the value of our common stock could cause our stockholders to lose all or part of their investment.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principal Risks Related to Our Business</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are substantially dependent on the successful launch and commercialization of IBSRELA for IBS-C, and there is no guarantee that we will achieve sufficient market acceptance for IBSRELA; secure adequate coverage and reimbursement for IBSRELA; or generate sufficient revenue from product sales of IBSRELA. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We began selling IBSRELA, our approved treatment for IBS-C in adults in the U.S. in March 2022. The overall commercial success of IBSRELA will depend on a number of factors, including the following:</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability of the third-party manufacturers we contract with to provide an adequate (in amount and quality) supply of product to support the launch and market demand for IBSRELA;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain and sustain an adequate level of coverage and reimbursement for IBSRELA by third-party payors;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effectiveness of IBSRELA as a treatment for adult patients with IBS-C;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the size of the treatable patient population; </span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effectiveness of our sales, market access and marketing efforts; </span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether physicians view IBSRELA as a safe and effective treatment for adult patients with IBS-C, which will impact the adoption of IBSRELA by physicians for the treatment of IBS-C;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability, perceived advantages, relative cost, relative safety and relative efficacy of IBSRELA compared to alternative and competing treatments; </span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prevalence and severity of adverse side effects of IBSRELA;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our potential involvement in lawsuits in connection with enforcing intellectual property rights in and to IBSRELA;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our potential involvement in third-party interference, opposition, derivation or similar proceedings with respect to our patent rights directed to IBSRELA, and avoiding other challenges to our patent rights and patent infringement claims; and</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a continued acceptable safety and tolerability profile of IBSRELA following approval.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our potential to achieve revenue from the commercialization of IBSRELA and the amount of such potential revenue is subject to these and other factors, and may be unpredictable from quarter-to-quarter. If the number of patients in the market for IBSRELA or the price that the market can bear is not as significant as we estimate, or if we are not able to secure adequate physician and patient acceptance of IBSRELA or adequate coverage and reimbursement for IBSRELA, we may not generate sufficient revenue from sales of IBSRELA. Any failure of IBSRELA to achieve market acceptance, sufficient third-party coverage or reimbursement, or commercial success for would adversely affect our results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our success is also dependent upon our ability to obtain regulatory approval for tenapanor for the control of serum phosphorus in adult patients with CKD on dialysis, and there can be no assurances that we will be successful in obtaining such regulatory approval.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success is also dependent upon our ability to obtain regulatory approval for tenapanor for the control of serum phosphorus in adult patients with CKD on dialysis. To date, we have invested a significant amount of our efforts and financial resources in the research and development of tenapanor for the control of serum phosphorus in adult patients with CKD on dialysis. On July 28, 2021, we received a CRL from the Division regarding our NDA for tenapanor for the control of serum phosphorus in adult patients with CKD on dialysis. According to the CRL, the FDA has determined that the magnitude of the treatment effect observed in our Phase 3 clinical trials was small and of unclear of clinical significance. Following an End-of-Review Type A meeting (&#8220;End of Review Meeting&#8221;) in October 2021, with the Division, we submitted a Formal Dispute Resolution Request (&#8220;FDRR&#8221;) in December 2021. The FDRR was focused on demonstrating that the data submitted in the NDA supported the clinical significance of the treatment effect of tenapanor. On February 4, 2022, we received an ADL from OCHEN. On February 18, 2022, we submitted an appeal of the ADL to the FDA&#8217;s Center for Drug Evaluation and Research, Office of New Drugs (&#8220;OND&#8221;), and on April 15, 2022, we received an Interim Response from OND. The Interim response indicated that OND intends to direct the Division to bring the XPHOZAH NDA to the Advisory Committee. We are currently awaiting further guidance from OND regarding the timing of the Advisory Committee meeting. OND expects to provide a response to the FDR within thirty (30) days after the conclusion of the Advisory Committee meeting. There can be no </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i711b1a39e0634b15bb7a70766327247a_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assurances that the Advisory Committee will recommend approval of our NDA for tenapanor for the Hyperphosphatemia Indication, or that if approval is recommended, that such approval will ultimately be granted by the FDA. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we are successful in obtaining regulatory approval for tenapanor for control of serum phosphorus in adult patients with CKD on dialysis, the expense and time required to do so could adversely impact our ability to successfully commercialize XPHOZAH for the Hyperphosphatemia Indication. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be successful in obtaining approval for tenapanor for the Hyperphosphatemia Indication, and if we are able to obtain approval, the expense and time to do so could adversely impact our ability to successfully commercialize XPHOZAH for the Hyperphosphatemia Indication, our business and our results of operations. If we are successful in obtaining approval for XPHOZAH for the Hyperphosphatemia Indication, the commercial success of XPHOZAH will depend on a number of factors, including the following:</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability of the third-party manufacturers we contract with to provide an adequate (in amount and quality) supply of product to support the market demand for both IBSRELA and XPHOZAH;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether or not the content and breadth of the label approved by the FDA for XPHOZAH may materially and adversely impact our ability to commercialize the product for the approved indication;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether or when XPHOZAH, along with other oral end-stage renal disease (&#8220;ESRD&#8221;) related drugs without an injectable or intravenous equivalent, are bundled into the ESRD prospective payment system, and the manner in which such introduction into the ESRD prospective payment system may occur; </span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prevalence and severity of adverse side effects of XPHOZAH;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acceptance of XPHOZAH as safe, effective and well-tolerated by patients and the medical community, and, the extent to which the issuance of a CRL by the FDA has impacted the potential acceptance of XPHOZAH as safe, effective and well-tolerated;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to manage the commercialization of IBSRELA and XPHOZAH and the complex pricing and reimbursement negotiations that may arise with marketing the same product at different doses for separate indications;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability, perceived advantages, relative cost, relative safety and relative efficacy of XPHOZAH compared to alternative and competing treatments;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining and sustaining an adequate level of coverage and reimbursement for XPHOZAH by third-party payors;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our potential involvement in lawsuits in connection with enforcing intellectual property rights in and to XPHOZAH;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our potential involvement in third-party interference, opposition, derivation or similar proceedings with respect to our patent rights, and avoiding other challenges to our patent rights and patent infringement claims; and</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a continued acceptable safety and tolerability profile of XPHOZAH following approval. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">IBSRELA, and/or, if approved and commercialized, XPHOZAH, may cause undesirable side effects or have other properties that could limit the commercial success of the product. </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Undesirable side effects caused by IBSRELA, and/or, if approved, XPHOZAH, could cause us or regulatory authorities to interrupt, delay or halt the commercialization of the product. To date, the most common adverse reactions reported in at least 2% of patients in IBSRELA-treated patients and at an incidence greater than placebo in the two Phase 3 trials include: diarrhea, abdominal distension, flatulence and dizziness. Despite our receipt of marketing approval for IBSRELA and the completion of our Phase 3 clinical program for XPHOZAH, the prevalence and/or severity of these or other side effects could result in a number of potentially significant negative consequences could occur, including:</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may withdraw their approval of the product or seize the product;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or a collaboration partner may be required to recall the product;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additional restrictions may be imposed on the marketing of the particular product or the manufacturing processes for the product or any component thereof, including the imposition of a Risk Evaluation and Mitigation Strategy (&#8220;REMS&#8221;) which could require creation of a Medication Guide or patient package insert outlining the risks of such side effects for distribution to patients, a communication plan to educate healthcare providers of the drugs&#8217; risks, as well as other elements to assure safe use of the product, such as a patient registry and training and certification of prescribers;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or a collaboration partner may be subject to fines, injunctions or the imposition of civil or criminal penalties;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i711b1a39e0634b15bb7a70766327247a_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may require the addition of new labeling statements, such as a &#8220;black box&#8221; warning or a contraindication;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we could be sued and held liable for harm caused to patients;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the product may become less competitive; and</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our reputation may suffer. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Any of the foregoing events could prevent us, or a collaboration partner, from achieving or maintaining market acceptance of IBSRELA, and/or, if approved, XPHOZAH, and could result in the loss of significant revenue to us, which would materially and adversely affect our results of operations and business..</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">As a company, we have no prior experience in the marketing, sale and distribution of pharmaceutical products; and there are significant risks in building and managing a commercial organization. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a company, we have no prior experience in building and managing a commercial organization, or in the marketing, sale and distribution of pharmaceutical products. There can be no assurances that we will be successful in our efforts to retain, and incentivize qualified individuals, generate sufficient sales leads, comply with regulatory requirements applicable to the marketing and sale of drug products and effectively manage a geographically dispersed sales and marketing team.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we fail or are delayed in the development of our internal sales, marketing and distribution capabilities, the commercialization of IBSRELA could be adversely impacted.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our operating activities may be restricted as a result of covenants related to the indebtedness under our loan and security agreement and we may be required to repay the outstanding indebtedness in an event of default, which could have a materially adverse effect on our business. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 23, 2022, we entered into a loan and security agreement with SLR Investment Corp. (the &#8220;Lender&#8221;) pursuant to which the Lender agreed to provide us a $50.0 million term loan facility with a maturity date of March 1, 2027. The loan was funded in the amount of $27.5 million on February 23, 2022 and the remaining $22.5 million may be funded upon the satisfaction of both (i) receipt from the FDA of approval of the NDA for tenapanor for the Hyperphosphatemia Indication on or prior to December 31, 2022 and (ii) our achievement of certain product revenue milestone targets described in the 2022 Loan Agreement. Until we have repaid all funded indebtedness, the loan and security agreement subjects us to various customary covenants, including requirements as to financial reporting and insurance and restrictions on our ability to dispose of our business or property, to change our line of business, to liquidate or dissolve, to enter into any change in control transaction, to merge or consolidate with any other entity or to acquire all or substantially all the capital stock or property of another entity, to incur additional indebtedness, to incur liens on our property, to pay any dividends or other distributions on capital stock other than dividends payable solely in capital stock, to redeem capital stock, to enter into licensing agreements, to engage in transactions with affiliates, and to encumber our intellectual property. Our business may be adversely affected by these restrictions on our ability to operate our business. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are permitted to make interest only payments on the loan facility through March 2024, with principal repayments commencing on April 1, 2024, however, we may be required to repay the outstanding indebtedness under the loan facility if an event of default occurs under the loan and security agreement. An event of default will occur if, among other things, we fail to make payments under the loan and security agreement; we breach any of our covenants under the loan and security agreement, subject to specified cure periods with respect to certain breaches; the Lender determines that a material adverse change has occurred; we or our assets become subject to certain legal proceedings, such as bankruptcy proceedings; we are unable to pay our debts as they become due; or we default on contracts with third parties which would permit the Lender to accelerate the maturity of such indebtedness or that could have a material adverse change on us. We may not have enough available cash or be able to raise additional funds through equity or debt financings to repay such indebtedness at the time any such event of default occurs. In this case, we may be required to delay, limit, reduce or terminate our activities necessary to commercialize IBSRELA, and/or if approved, XPHOZAH, or clinical trials for tenapanor. The Lender could also exercise its rights as collateral agent to take possession of and to dispose of the collateral securing the term loans, which collateral includes substantially all of our property (excluding intellectual property, which is subject to a negative pledge). Our business, financial condition and results of operations could be materially adversely affected as a result of any of these events.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third-party payor coverage and reimbursement status of newly commercialized products are uncertain. Failure to obtain or maintain adequate coverage and reimbursement for IBSRELA and, if approved, XPHOZAH, could limit our ability to market those products and decrease our ability to generate revenue.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i711b1a39e0634b15bb7a70766327247a_7">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The pricing, coverage and reimbursement of IBSRELA and, if approved, XPHOZAH, must be adequate to support a commercial infrastructure. The availability and adequacy of coverage and reimbursement by governmental and private payors are essential for most patients to be able to afford treatments. Sales of IBSRELA, and, if approved and commercialized, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">XPHOZAH, will depend substantially, both domestically and abroad, on the extent to which the costs of the product will be paid for by health maintenance, managed care, pharmacy benefit, and similar healthcare management organizations, or reimbursed by government authorities, private health insurers, and other third-party payors. If coverage and reimbursement are not available, or are available only to limited levels, we, or our collaboration partners, may not be able to successfully commercialize IBSRELA, or, if approved, XPHOZAH. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize a return on our investment.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. In the United States, the principal decisions about coverage and reimbursement for new drugs are typically made by the Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;), an agency within the United States Department of Health and Human Services responsible for administering the Medicare program, as CMS decides whether and to what extent a new drug will be covered and reimbursed under Medicare. Private payors tend to follow the coverage reimbursement policies established by CMS to a substantial degree. It is difficult to predict what CMS will decide with respect to reimbursement for products such as ours.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is increased uncertainty related to insurance coverage and reimbursement for drugs, like XPHOZAH for the Hyperphosphatemia Indication, which, if approved, will be marketed for the control of serum phosphorus in adult patients with CKD on dialysis or for another other related indication. In January 2011, CMS implemented a new prospective payment system for dialysis treatment. Under the ESRD prospective payment system, CMS generally makes a single bundled payment to the dialysis facility for each dialysis treatment that covers all items and services routinely required for dialysis treatments furnished to Medicare beneficiaries in Medicare-certified ESRD facilities or at their home, including the cost of certain routine drugs. The inclusion of oral medications without injectable or intravenous equivalents in the bundled payment was initially delayed until January 1, 2014, and through several subsequent legislative actions was delayed until January 1, 2025. As a result, absent further legislation or regulation on this matter, beginning in 2025, oral ESRD-related drugs without injectable or intravenous equivalents may be included in the ESRD bundle and separate Medicare payment for these drugs will no longer be available, as is the case today under Medicare Part D. While it is too early to project the full impact that bundling may have on sales of XPHOZAH, if approved and commercialized, and on our business should XPHOZAH be brought into the bundle in 2025, or at any time, we may be unable to sell XPHOZAH for the Hyperphosphatemia Indication, if approved, to dialysis providers on a profitable basis if third-party payors reduce their current levels of payment, or if our costs of production are higher than levels necessary for an appropriate gross margin after payment of all discounts, rebates and chargebacks. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the United States, international operations are generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost-containment initiatives in Europe, Canada, Japan, China and other countries has and will continue to put pressure on the pricing and usage of IBSRELA and XPHOZAH, even if regulatory approval is received in such countries. In many countries, the prices of medical products are subject to varying price control mechanisms as part of national health systems. Other countries allow companies to fix their own prices for medicinal products, but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our product candidates. Accordingly, in markets outside the United States, the reimbursement for our products may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenue and profits. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, increasing efforts by governmental and third-party payors in the United States and abroad to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, these caps may not cover or provide adequate payment for our product candidates. We expect to experience pricing pressures in connection with the sale of IBSRELA, and if approved and commercialized, XPHOZAH, due to the trend toward managed healthcare, the increasing influence of health maintenance organizations, and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs and surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely completely on third parties to manufacture IBSRELA and XPHOZAH. If they are unable to comply with applicable regulatory requirements, unable to source sufficient raw materials, experience manufacturing or distribution difficulties or are otherwise unable to manufacture sufficient quantities to meet demand, our commercialization of IBSRELA, and, if approved and commercialized, XPHOZAH, and our future development efforts for tenapanor may be materially harmed.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently have, nor do we plan to acquire, the infrastructure or capability internally to manufacture IBSRELA, or any of other our product candidates on a commercial scale, or to manufacture our drug supplies for use in the conduct of our nonclinical and clinical studies. The facilities used by our contract manufacturers to manufacture our drug supply are subject to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i711b1a39e0634b15bb7a70766327247a_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">inspection by the FDA. Our ability to control the manufacturing process of our product candidates is limited to the contractual requirements and obligations we impose on our contract manufacturer. Although they are contractually required to so do, we are completely dependent on our contract manufacturing partners for compliance with the regulatory requirements, known as current Good Manufacturing Practice requirements (&#8220;cGMPs&#8221;), for manufacture of both active drug substances and finished drug products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The manufacture of pharmaceutical products requires significant expertise and capital investment. Manufacturers of pharmaceutical products often encounter difficulties in commercial production. These problems may include difficulties with production costs and yields, quality control, including stability of the product and quality assurance testing, and shortages of qualified personnel, as well as compliance with federal, state and foreign regulations and the challenges associated with complex supply chain management. Even if our contract manufacturers do not experience problems and commercial manufacturing is achieved, their maximum or available manufacturing capacities may be insufficient to meet commercial demand. Finding alternative manufacturers or adding additional manufacturers requires a significant amount of time and involves significant expense. New manufacturers would need to develop and implement the necessary production techniques and processes, which along with their facilities, would need to be inspected and approved by the regulatory authorities in each applicable territory. In addition, the raw materials necessary to make API for our products are acquired from a limited number of sources. Any delay or disruption in the availability of these raw materials could result in production disruptions, delays or higher costs with consequent adverse effects on us.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our contract manufacturers fail to adhere to applicable GMP or other regulatory requirements, experience delays or disruptions in the availability of raw materials or experience manufacturing or distribution problems, we may suffer significant consequences, including the inability to meet our product requirements for our clinical development programs, and if tenapanor is commercialized for any indication, such events could result in product seizures or recalls, loss of product approval, fines and sanctions, reputational damage, shipment delays, inventory shortages, inventory write-offs and other product-related charges and increased manufacturing costs. As a result, or if maximum or available manufacturing capacities are insufficient to meet demand, our development or our commercialization efforts for IBSRELA, and/or, if approved, XPHOZAH, may be materially harmed.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Additional Risks Related to Our Business and Industry</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical drug development involves a lengthy and expensive process with an uncertain outcome. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before obtaining marketing approval from regulatory authorities for the sale of our product candidates, we must conduct extensive clinical studies to demonstrate the safety and efficacy of the product candidates in humans. Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. For example, while the results of our Phase 2 clinical trial evaluating RDX013 for the treatment of hyperkalemia demonstrated an acceptable safety and tolerability profile for RDX013 and supported proof of concept in its ability to lower serum potassium levels, with statistically significant reductions compared to placebo after eight days of treatment, the study did not meet its primary endpoint of significantly reducing serum potassium levels compared to placebo after four weeks of treatment. We currently expect that the next step for the program will be to evaluate a new formulation that potentially enhances subject compliance and the efficacy of RDX013 in an additional Phase 2 clinical study at such time as we have determined that our available resources support conducting such an additional clinical study. There can be no assurances that any additional clinical study that we determine to conduct with RDX013 will be successful. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, if we conduct additional clinical trials with RDX013, we could encounter delays in our future development if any clinical trials are suspended or terminated by us, by the IRBs of the institutions in which the trial is being conducted, or by the FDA or other regulatory authorities. Such authorities may suspend or terminate a clinical trial due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, identifying and qualifying patients to participate in any  clinical trials is critical to the success of the clinical trials. The timing of any future clinical trials, including any additional RDX013 clinical trial that we may determine to conduct, will depend, in part, on the speed at which we can recruit patients to participate in testing our product candidates. Patients may be unwilling to participate in our clinical studies because of concerns about adverse events observed with the current standard of care, competitor products and/or other investigational agents, in each case for the same indications and/or similar patient populations. In addition, patients currently receiving treatment with the current standard of care or a competitor product may be reluctant to participate in a clinical trial with an investigational drug, or our inclusion and exclusion criteria for our clinical trials </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i711b1a39e0634b15bb7a70766327247a_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">may present challenges in identifying acceptable patients. As a result, the timeline for recruiting patients and conducting clinical trials may be delayed. These delays could result in increased costs, delays in advancing our development the program, or termination of the clinical studies altogether. Any of these occurrences may significantly harm our business, financial condition and prospects. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will rely on third parties to conduct all of our nonclinical studies and clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may be unable to obtain regulatory approval for additional products or commercialize our product candidates. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have the ability to independently conduct nonclinical studies or clinical trials. We rely on medical institutions, clinical investigators, contract laboratories, and other third parties, such as CROs, to conduct clinical trials on our product candidates. The third parties with whom we contract for execution of the clinical trials play a significant role in the conduct of these trials and the subsequent collection and analysis of data. However, these third parties are not our employees, and except for contractual duties and obligations, we control only certain aspects of their activities and have limited ability to control the amount or timing of resources that they devote to our programs. Although we rely, and will continue to rely, on these third parties to conduct our nonclinical studies and our clinical trials, we remain responsible for ensuring that each of our studies and clinical trials is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards and our reliance on third parties does not relieve us of our regulatory responsibilities. We, and these third parties are required to comply with current GLPs for nonclinical studies, and good clinical practices (&#8220;GCPs&#8221;) for clinical studies. GLPs and GCPs are regulations and guidelines enforced by the FDA, the Competent Authorities of the Member States of the European Economic Area (&#8220;EEA&#8221;) and comparable foreign regulatory authorities for all of our products in nonclinical and clinical development, respectively. Regulatory authorities enforce GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of our third-party contractors fail to comply with applicable regulatory requirements, including GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA, the European Medicines Agency (&#8220;EMA&#8221;), or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. There can be no assurance that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP regulations. In addition, our clinical trials must be conducted with product produced under cGMP regulations. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face substantial competition, and our competitors may discover, develop or commercialize products faster or more successfully than us.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biotechnology and pharmaceutical industries are highly competitive, and we face significant competition from companies in the biotechnology, pharmaceutical and other related markets that are researching and marketing products designed to address diseases that we are currently developing products to treat. If approved for marketing by the FDA or other regulatory agencies, tenapanor, as well as our other product candidates, would compete against existing treatments. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, numerous treatments exist for constipation and the constipation component of IBS-C, many of which are over-the-counter. These include psyllium husk (such as Metamucil), methylcellulose (such as Citrucel), calcium polycarbophil (such as FiberCon), lactulose (such as Cephulac), polyethylene glycol (such as MiraLax), sennosides (such as Exlax), bisacodyl (such as Ducolax), docusate sodium (such as Colace), magnesium hydroxide (such as Milk of Magnesia), saline enemas (such as Fleet), and sorbitol. These agents are generally inexpensive and work well to temporarily relieve constipation. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are aware of four prescription products marketed for certain patients with IBS-C, including Linzess (linaclotide), Amitiza (lubiprostone), Trulance (plecanatide) and Zelnorm (tegaserod maleate).</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, XPHOZAH, if approved for the Hyperphosphatemia Indication will compete with phosphate binders used for the same or similar indication`. If approved, our label for XPHOZAH may include data comparing the effectiveness of tenapanor to phosphate binders used for the same indication. The various types of phosphate binders commercialized in the United States include the following:</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Calcium carbonate (many over-the-counter brands including Tums and Caltrate);</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Calcium acetate (several prescription brands including PhosLo and Phoslyra);</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Lanthanum carbonate (Fosrenol);</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Sevelamer hydrochloride (Renagel);</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Sevelamer carbonate (Renvela);</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i711b1a39e0634b15bb7a70766327247a_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Sucroferric oxyhydroxide (Velphoro); and</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Ferric citrate (Auryxia). </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the phosphate binders listed above are available as generics in the U.S., with the exception of Velphoro and Auryxia. In addition to the currently available phosphate binders, we are aware of at least two other binders in development, including fermagate (Alpharen), an iron-based binder in Phase 3 being developed by Opko Health, Inc., and PT20, an iron-based binder in Phase 3 being developed by Shield Therapeutics. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that our competitors' drugs may be less expensive and more effective than our product candidates, or that will render our product candidates obsolete. It is also possible that our competitors will commercialize competing drugs or treatments before we or our collaboration partners can launch any products developed from our product candidates. We also anticipate that we will face increased competition in the future as new companies enter into our target markets. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our competitors have materially greater name recognition and financial, manufacturing, marketing, research and drug development resources than we do. Additional mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated in our competitors. Large pharmaceutical companies in particular have extensive expertise in preclinical and clinical testing and in obtaining regulatory approvals for drugs. In addition, academic institutions, government agencies, and other public and private organizations conducting research may seek patent protection with respect to potentially competitive products or technologies. These organizations may also establish exclusive collaboration partnerships or licensing relationships with our competitors. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may experience difficulties in managing our current activities and growth given our level of managerial, operational, financial and other resources. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we have continued to work to optimize our management composition, personnel and systems to support our current activities for future growth, these resources may not be adequate for this purpose. Our need to effectively execute our business strategy requires that we:</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manage any commercialization activities in which we may engage effectively;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manage our clinical trials effectively;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manage our internal development efforts effectively while carrying out our contractual obligations to licensors, contractors, collaborators, government agencies and other third parties;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue to improve our operational, financial and management controls, reporting systems and procedures; and</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">retain and motivate our remaining employees and potentially identify, recruit, and integrate additional employees. </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to maintain or expand our managerial, operational, financial and other resources to the extent required to manage our development and commercialization activities, our business will be materially adversely affected. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of IBSRELA, and/or, if approved, XPHOZAH. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face an inherent risk of product liability as a result of the clinical testing of our product candidates and our commercial launch of IBSRELA. For example, we may be sued if any product we develop allegedly causes injury or is found to be otherwise unsuitable during product testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability, and a breach of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our product candidates. Even successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased demand for the product;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injury to our reputation;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">withdrawal of clinical trial participants;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs to defend the related litigation;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a diversion of management&#8217;s time and our resources;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i711b1a39e0634b15bb7a70766327247a_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">substantial monetary awards to trial participants or patients;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory investigations, product recalls or withdrawals, or labeling, marketing or promotional restrictions;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">loss of revenue; and</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inability to commercialize or co-promote our IBSRELA, and/or, if approved, XPHOZAH. </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our inability to obtain and maintain sufficient product liability insurance at an acceptable cost and scope of coverage to protect against potential product liability claims could prevent or inhibit the commercialization of any products we develop. Although we maintain product liability insurance, any claim that may be brought against us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance coverage. Our insurance policies also have various exclusions and deductibles, and we may be subject to a product liability claim for which we have no coverage. We will have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. Moreover, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to attract, retain and motivate our executives, senior management and key personnel, our business will suffer. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recruiting and retaining qualified scientific, clinical, medical, manufacturing, and sales and marketing personnel is critical to our success. We are highly dependent on our executives, senior management and certain other key employees. The loss of the services of our executives, senior management or other key employee could impede the achievement of our development and commercial objectives and seriously harm our ability to successfully implement our business strategy. Furthermore, replacing executives, senior management and other key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop, gain marketing approval of and commercialize products. We may be unable to hire, train or motivate these key personnel on acceptable terms given the intense competition among numerous biopharmaceutical companies for similar personnel, particularly in our geographic regions. If we are unable to continue to attract and retain high quality personnel, our ability to grow and pursue our business strategy will be limited. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Actual or perceived failures to comply with applicable data protection, privacy and security laws, regulations, standards and other requirements could adversely affect our business, results of operations, and financial condition.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The global data protection landscape is rapidly evolving, and we are or may become subject to numerous state, federal and foreign laws, requirements and regulations governing the collection, use, disclosure, retention, and security of personal data, such as information that we may collect in connection with clinical trials in the U.S. and abroad. Implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future, and we cannot yet determine the impact future laws, regulations, standards, or perception of their requirements may have on our business. This evolution may create uncertainty in our business, affect our ability to operate in certain jurisdictions or to collect, store, transfer use and share personal information, necessitate the acceptance of more onerous obligations in our contracts, result in liability or impose additional costs on us. The cost of compliance with these laws, regulations and standards is high and is likely to increase in the future. Any failure or perceived failure by us to comply with federal, state or foreign laws or regulation, our internal policies and procedures or our contracts governing our processing of personal information could result in negative publicity, government investigations and enforcement actions, claims by third parties and damage to our reputation, any of which could have a material adverse effect on our operations, financial performance and business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As our operations and business grow, we may become subject to or affected by new or additional data protection laws and regulations and face increased scrutiny or attention from regulatory authorities. In the U.S., HIPAA imposes, among other things, certain standards relating to the privacy, security, transmission and breach reporting of individually identifiable health information. We may obtain health information from third parties (including research institutions from which we obtain clinical trial data) that are subject to privacy and security requirements under HIPAA. Depending on the facts and circumstances, we could be subject to significant penalties if we violate HIPAA.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain states have also adopted comparable privacy and security laws and regulations, some of which may be more stringent than HIPAA. Such laws and regulations will be subject to interpretation by various courts and other governmental authorities, thus creating potentially complex compliance issues for us and our future customers and strategic partners. For example, the California Consumer Privacy Act ("CCPA") went into effect on January 1, 2020. The CCPA creates individual privacy rights for California consumers and increases the privacy and security obligations of entities handling certain personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. Further, the California Privacy Rights Act (CPRA) recently passed in California. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i711b1a39e0634b15bb7a70766327247a_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CPRA will impose additional data protection obligations on covered businesses, including additional consumer rights processes, limitations on data uses, new audit requirements for higher risk data, and opt outs for certain uses of sensitive data. It will also create a new California data protection agency authorized to issue substantive regulations and could result in increased privacy and information security enforcement. The majority of the provisions will go into effect on January 1, 2023, and additional compliance investment and potential business process changes may be required. Similar laws have passed in Virginia and Colorado, and have been proposed in other states and at the federal level, reflecting a trend toward more stringent privacy legislation in the United States. The enactment of such laws could have potentially conflicting requirements that would make compliance challenging. In the event that we are subject to or affected by HIPAA, the CCPA, the CPRA or other domestic privacy and data protection laws, any liability from failure to comply with the requirements of these laws could adversely affect our financial condition. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, the Federal Trade Commission (FTC) and many state Attorneys General continue to enforce federal and state consumer protection laws against companies for online collection, use, dissemination and security practices that appear to be unfair or deceptive. For example, according to the FTC, failing to take appropriate steps to keep consumers&#8217; personal information secure can constitute unfair acts or practices in or affecting commerce in violation of Section 5(a) of the Federal Trade Commission Act. The FTC expects a company&#8217;s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also or may become subject to rapidly evolving data protection laws, rules and regulations in foreign jurisdictions. For example, in Europe, the European Union General Data Protection Regulation (GDPR) went into effect in May 2018 and imposes strict requirements for processing the personal data of individuals within the European Economic Area (EEA). Among other requirements, the GDPR regulates transfers of personal data subject to the GDPR to third countries that have not been found to provide adequate protection to such personal data, including the United States; in July 2020, the Court of Justice of the EU (CJEU) limited how organizations could lawfully transfer personal data from the EU/EEA to the United States by invalidating the Privacy Shield for purposes of international transfers and imposing further restrictions on the use of standard contractual clauses. Companies that must comply with the GDPR face increased compliance obligations and risk, including more robust regulatory enforcement of data protection requirements and potential fines for noncompliance of up to &#8364;20 million or 4% of the annual global revenues of the noncompliant company, whichever is greater. Relatedly, following the United Kingdom&#8217;s withdrawal from the European Economic Area and the European Union, and the expiry of the transition period, companies have to comply with both the GDPR and the GDPR as incorporated into United Kingdom national law, the latter regime having the ability to separately fine up to the greater of &#163;17.5 million or 4% of global turnover. The relationship between the United Kingdom and the European Union in relation to certain aspects of data protection law remains unclear, for example around how data can lawfully be transferred between each jurisdiction, which may expose us to further compliance risk.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we work to comply with applicable laws, regulations and standards, our contractual obligations and other legal obligations, these requirements are evolving and may be modified, interpreted and applied in an inconsistent manner from one jurisdiction to another, and may conflict with one another or other legal obligations with which we must comply. Any failure or perceived failure by us or our employees, representatives, contractors, consultants, CROs, collaborators, or other third parties to comply with such requirements or adequately address privacy and security concerns, even if unfounded, could result in additional cost and liability to us, damage our reputation, and adversely affect our business and results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We and our collaborators, CROs and other contractors and consultants depend on information technology systems, and any failure of these systems could harm our business. Security breaches, loss of data, and other disruptions could compromise sensitive information related to our business or prevent us from accessing critical information and expose us to liability, which could adversely affect our business, results of operations and financial condition. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our collaborators, CROs, and other contractors and consultants collect and maintain information in digital form that is necessary to conduct our business, and we are increasingly dependent on information technology systems and infrastructure to operate our business. In the ordinary course of our business, we and our collaborators, CROs and other contractors and consultants collect, store and transmit large amounts of confidential information, including intellectual property, proprietary business information and personal information. It is critical that we and our collaborators, CROs and other contractors and consultants do so in a secure manner to maintain the confidentiality and integrity of such confidential information. We have established physical, electronic and organizational measures designed to safeguard and secure our systems to prevent a data compromise, and rely on commercially available systems, software, tools, and monitoring to provide security for our information technology systems and the processing, transmission and storage of digital information. We have also outsourced elements of our information technology infrastructure, and as a result a number of third-party vendors may or could have access to our confidential information. Our internal information technology systems and infrastructure, and those of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i711b1a39e0634b15bb7a70766327247a_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our current and any future collaborators, CROs, contractors and consultants and other third parties on which we rely, are vulnerable to damage from computer viruses, malware, natural disasters, terrorism, war, telecommunication and electrical failures, cyber-attacks or cyber-intrusions over the Internet, attachments to emails, persons inside our organization, or persons with access to systems inside our organization. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risk of a security breach or disruption or data loss, particularly through cyber-attacks or cyber intrusion, including by computer hackers, foreign governments and cyber terrorists, has generally increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased. In addition, the prevalent use of mobile devices that access confidential information increases the risk of data security breaches, which could lead to the loss of confidential information or other intellectual property. As a result of the COVID-19 pandemic, we may also face increased cybersecurity risks due to our reliance on internet technology and the number of our employees who are working remotely, which may create additional opportunities for cybercriminals to exploit vulnerabilities. Furthermore, because the techniques used to obtain unauthorized access to, or to sabotage, systems change frequently and often are not recognized until launched against a target, we may be unable to anticipate these techniques or implement adequate preventative measures. We may also experience security breaches that may remain undetected for an extended period. The costs to us to mitigate network security problems, bugs, viruses, worms, malicious software programs and security vulnerabilities could be significant, and while we have implemented security measures to protect our data security and information technology systems, our efforts to address these problems may not be successful, and these problems could result in unexpected interruptions, delays, cessation of service and other harm to our business and our competitive position. We and certain of our service providers are from time to time subject to cyberattacks and security incidents. While we do not believe that we have experienced any significant system failure, accident or security breach to date. If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our product development programs, and/or of our efforts to commercialize tenapanor for the control of serum phosphorus in adult patients with CKD on dialysis or for another other related indication, if approved. For example, the loss of clinical trial data from completed or ongoing or planned clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. In addition, such a breach may require notification to governmental agencies, the media or individuals pursuant to various federal and state privacy and security laws, if applicable. Moreover, if a computer security breach affects our systems or those of our collaborators, CROs or other contractors, or results in the unauthorized release of personally identifiable information, our reputation could be materially damaged. We would also be exposed to a risk of loss or litigation and potential liability, which could materially adversely affect our business, results of operations and financial condition. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have previously identified a material weakness in our internal control over financial reporting. If we fail to maintain proper and effective internal controls, our ability to produce accurate and timely financial statements could be impaired, which could harm our operating results, our ability to operate our business and investors&#8217; views of us and could have a material adverse effect on the price of our common stock. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, management and our independent registered public accounting firm identified a control deficiency that constituted a material weakness in our internal control over financial reporting. The material weakness was due to a failure in the design and implementation of controls over the evaluation of the terms of our clinical trial contracts for inclusion into our clinical financial model which estimates clinical trial expenses. Specifically, we had failed to properly interpret an expense in our clinical trial contracts which resulted in the over accrual of our clinical trial expenses during 2018 and the first quarter of 2019. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We developed and implemented a remediation plan for this material weakness which included modifications to the design and implementation of certain internal controls, and the material weakness was remediated as of December 31, 2019. Although we have remediated this material weakness, as attested by our independent registered public accounting firm, we can give no assurance that an additional material weakness or significant deficiency in our internal controls over financial reporting will not be identified in the future. Our failure to implement and maintain effective internal controls over financial reporting could result in errors in our financial statements that could result in a restatement of our financial statements and cause us to fail to meet our reporting obligations. If we cannot in the future favorably assess the effectiveness of our internal controls over financial reporting, investor confidence in the reliability of our financial reports may be adversely affected, which could have a material adverse effect on the trading price of our common stock. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have formed in the past, and may form in the future, collaboration partnerships, joint ventures and/or licensing arrangements, and we may not realize the benefits of such collaborations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have current collaboration partnerships for the commercialization of tenapanor in certain foreign countries, and we may form additional collaboration partnerships, create joint ventures or enter into additional licensing arrangements with third parties in the United States and abroad that we believe will complement or augment our existing business. In particular, we have formed collaboration partnerships with KKC for commercialization of tenapanor for hyperphosphatemia in Japan; with </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i711b1a39e0634b15bb7a70766327247a_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fosun Pharma for commercialization of tenapanor for hyperphosphatemia and IBS-C in China and related territories; and in Canada with Knight for commercialization of tenapanor for IBS-C and hyperphosphatemia. We face significant competition in seeking appropriate collaboration partners, and the process to identify an appropriate partner and negotiate appropriate terms is time-consuming and complex. Any delays in identifying suitable additional collaboration partners and entering into agreements to develop our product candidates could also delay the commercialization of our product candidates, which may reduce their competitiveness even if they reach the market. There is no guarantee that our current collaboration partnerships or any such arrangements we enter into in the future will be successful, or that any collaboration partner will commit sufficient resources to the development, regulatory approval, and commercialization effort for such products, or that such alliances will result in us achieving revenues that justify such transactions. We have received a CRL from the FDA regarding our NDA for the Hyperphosphatemia Indication. While we are pursuing an appeal through the FDR process, and have been notified from OND in an interim response to our second level appeal that OND will direct the Division to bring our NDA to an Advisory Committee, there can be no assurances that the Advisory Committee will recommend approval of our NDA for tenapanor for the Hyperphosphatemia Indication, or that if approval is recommended, that such approval will ultimately be granted by the FDA. Even if we are successful in obtaining approval for the NDA, the delay in obtaining such approval may result in delay in the regulatory process for our partners, which could have a material adverse effect on our business and results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The ongoing effects of the COVID-19 pandemic, or any other outbreak of epidemic diseases, or the perception of their effects, could have a material adverse effect on our business, financial condition, results of operations or cash flows. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outbreaks of epidemic, pandemic, or contagious diseases, such as the current novel coronavirus (&#8220;COVID-19&#8221;) pandemic or, historically, the Ebola virus, Middle East Respiratory Syndrome, Severe Acute Respiratory Syndrome or the H1N1 virus, could disrupt our business. Business disruptions could include disruptions or restrictions on our ability to conduct our clinical trials, as planned, travel, as well as temporary closures of the facilities of our collaboration partners, suppliers or contract manufacturers. Any disruption of our clinical trial operations, collaboration partners, suppliers or contract manufacturers could adversely impact our operating results.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Economic and health conditions related to the COVID-19 pandemic in the United States and across most of the globe remain uncertain and continue to evolve. The continuing effects of the coronavirus outbreak may result in delays in the manufacture of tenapanor, or in the delivery of key intermediates or raw materials required to manufacture tenapanor or delays in clinical development activities by us, or our collaboration partners. Such effects could also materially and negatively impact our ability to successfully commercialize IBSRELA, and/or, if approved, XPHOZAH, or the ability of our collaboration partners to successfully commercialize such products, if approved for marketing and sale by the foreign regulatory authorities, including our ability, and that of our collaboration partners to educate physicians and patients about the benefits, administration and use of the product. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Although we have reopened our offices and invited our personnel to return to the office, we continue to permit our personnel to work remotely, which could negatively impact productivity, or disrupt, delay, or otherwise adversely impact our business. In addition, this could increase our cyber-security risk, create data accessibility concerns, and make us more susceptible to communication disruptions, any of which could adversely impact our business operations or delay necessary interactions with local and federal regulators, ethics committees, manufacturing sites, research or clinical trial sites and important agencies and contractors. </span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The FDA and comparable foreign regulatory agencies may continue to experience operational interruptions or delays, which may impact timelines for regulatory submission, trial initiation and regulatory approval. </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The full effects of the COVID-19 remain unknown. The extent to which the outbreak may continue to impact our business, including, our commercialization and manufacturing will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as access to physician offices for our commercial and medical teams, business closures or business disruptions. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may engage in strategic transactions that could impact our liquidity, increase our expenses and present significant distractions to our management. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may consider strategic transactions, such as acquisitions of companies, asset purchases, and/or in-licensing of products, product candidates or technologies. In addition, if we are unable to access capital on a timely basis and on terms that are acceptable to us, we may be forced to further restructure certain aspects of our business or identify and complete one or more strategic collaborations or other transactions in order to fund the commercialization of IBSRELA, our continued efforts to seek approval for our NDA for tenapanor for the Hyperphosphatemia Indication and/or the development of RDX013 through the use of alternative structures. Additional potential transactions that we may consider include a variety of different business arrangements, including spin-offs, spin outs, collaboration partnerships, joint ventures, restructurings, divestitures, business </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i711b1a39e0634b15bb7a70766327247a_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">combinations and investments. Any such transaction may require us to incur non-recurring or other charges, may increase our near- and long-term expenditures and may pose significant integration challenges or disrupt our management or business, which could adversely affect our operations and financial results. For example, these transactions may entail numerous operational and financial risks, including:</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">up-front, milestone and royalty payments, equity investments and financial support of new research and development candidates including increase of personnel, all of which may be substantial;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">exposure to unknown liabilities;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disruption of our business and diversion of our management&#8217;s time and attention in order to develop acquired products, product candidates or technologies;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">incurrence of substantial debt or dilutive issuances of equity securities;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">higher-than-expected acquisition and integration costs;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">write-downs of assets or goodwill or impairment charges;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased amortization expenses;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulty and cost in combining the operations and personnel of any acquired businesses with our operations and personnel;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impairment of relationships with key suppliers or customers of any acquired businesses due to changes in management and ownership; and</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability to retain key employees of any acquired businesses. </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, although there can be no assurance that we will undertake or successfully complete any transactions of the nature described above, any transactions that we do complete may be subject to the foregoing or other risks and could have a material adverse effect on our business, results of operations, financial condition and prospects. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we seek and obtain approval to commercialize our product candidates outside of the United States, manufacture our product candidates outside of the United States, or otherwise engage in business outside of the United States, a variety of risks associated with international operations could materially adversely affect our business. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We or our collaboration partners may decide to seek marketing approval for certain of our product candidates outside the United States or otherwise engage in business outside the United States, including entering into contractual agreements with third-parties. We currently utilize contract manufacturing organizations located outside of the United States to manufacture our active drug substance for tenapanor. We are subject to additional risks related to entering these international business markets and relationships, including:</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">different regulatory requirements for drug approvals in foreign countries;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">differing United States and foreign drug import and export rules;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reduced protection for intellectual property rights in foreign countries;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unexpected changes in tariffs, trade barriers and regulatory requirements;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">different reimbursement systems, and different competitive drugs;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">economic weakness, including inflation, or political instability in particular foreign economies and markets;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">foreign taxes, including withholding of payroll taxes;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and other obligations incident to doing business in another country;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">workforce uncertainty in countries where labor unrest is more common than in the United States;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential liability resulting from development work conducted by these distributors; and</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">business interruptions resulting from geopolitical actions, including war and terrorism, or natural disasters. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i711b1a39e0634b15bb7a70766327247a_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business involves the use of hazardous materials and we and third-parties with whom we contract must comply with environmental laws and regulations, which can be expensive and restrict how we do business. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our development activities involve the controlled storage, use and disposal of hazardous materials, including the components of our product candidates and other hazardous compounds. We and manufacturers and suppliers with whom we may contract are subject to laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous materials. In some cases, these hazardous materials and various wastes resulting from their use are stored at our and our manufacturers&#8217; facilities pending their use and disposal. We cannot eliminate the risk of contamination, which could cause an interruption of our commercialization efforts, and development efforts and business operations, environmental damage resulting in costly clean-up and liabilities under applicable laws and regulations governing the use, storage, handling and disposal of these materials and specified waste products. We cannot guarantee that the safety procedures utilized by third-party manufacturers and suppliers with whom we may contract will comply with the standards prescribed by laws and regulations or will eliminate the risk of accidental contamination or injury from these materials. In such an event, we may be held liable for any resulting damages and such liability could exceed our resources and state or federal or other applicable authorities may curtail our use of certain materials and/or interrupt our business operations. Furthermore, environmental laws and regulations are complex, change frequently and have tended to become more stringent. We cannot predict the impact of such changes and cannot be certain of our future compliance. We do not currently carry biological or hazardous waste insurance coverage. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be adversely affected by earthquakes or other natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently occupy a leased facility located in the San Francisco Bay Area, which in the past has experienced severe earthquakes. We do not carry earthquake insurance. Earthquakes or other natural disasters could severely disrupt our operations, and have a material adverse effect on our business, results of operations, financial condition and prospects. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a natural disaster, power outage or other event occurred that prevented us from using all or a significant portion of our California facility, that damaged critical infrastructure, such as our enterprise financial systems or manufacturing resource planning and enterprise quality systems, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial period of time. The disaster recovery and business continuity plans we have in place currently are limited and are unlikely to prove adequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which, particularly when taken together with our lack of earthquake insurance, could have a material adverse effect on our business. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Government Regulation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Despite having received regulatory approval for IBSRELA, and even if we receive regulatory approval for XPHOZAH, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense. Additionally, IBSRELA, and, if approved, XPHOZAH, could be subject to other restrictions and market withdrawal, and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our products. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if a drug is approved by the FDA or foreign regulatory authorities, the manufacturing processes, labeling, packaging, distribution, pharmacovigilance, storage, advertising, promotion and recordkeeping for the product will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMPs and GCP regulations for any clinical trials that we conduct post-approval. As such, we and our third-party contract manufacturers will be subject to continual review and periodic inspections to assess compliance with regulatory requirements. Accordingly, we and others with whom we work must continue to expend time, money, and effort in all areas of regulatory compliance, including manufacturing, production, and quality control. Regulatory authorities may also impose significant restrictions on a product&#8217;s indicated uses or marketing or impose ongoing requirements for potentially costly post-marketing studies. Furthermore, any new legislation addressing drug safety issues could result in delays or increased costs to assure compliance. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will also be required to report certain adverse reactions and production problems, if any, to the FDA, and to comply with requirements concerning advertising and promotion for our products. Promotional communications with respect to prescription drugs are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the product&#8217;s approved label. As such, we may not promote our products for indications or uses for which they do not have FDA approval. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i711b1a39e0634b15bb7a70766327247a_7">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things:</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">warning or untitled letters, fines or holds on clinical trials;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on the marketing or manufacturing of the product, withdrawal of the product from the market or voluntary or mandatory product recalls;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injunctions or the imposition of civil or criminal penalties;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspension or revocation of existing regulatory approvals;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspension of any of our ongoing clinical trials;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal to approve pending applications or supplements to approved applications submitted by us;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on our or our contract manufacturers&#8217; operations; or</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product seizure or detention, or refusal to permit the import or export of products. </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to commercialize IBSRELA and, if approved, XPHOZAH. If regulatory sanctions are applied or if regulatory approval is withdrawn, the value of our company and our operating results will be adversely affected. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the FDA&#8217;s policies may change, and additional government regulations may be enacted. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, which would adversely affect our business, prospects and ability to achieve or sustain profitability. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire and retain key leadership and other personnel, or otherwise review and process regulatory submissions in a timely manner, which could negatively impact our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ability of the FDA to review and process regulatory submissions can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Separately, in response to the global COVID-19 pandemic, on March 10, 2020, the FDA announced its intention to postpone most foreign inspections of manufacturing facilities and products through April 2020, and subsequently, on March 18, 2020, the FDA temporarily postponed routine surveillance inspections of domestic manufacturing facilities. Additionally, on April 15, 2021, the FDA issued a guidance document in which the FDA described its plans to conduct voluntary remote interactive evaluations of certain drug manufacturing facilities and clinical research sites, among other facilities. According to the guidance, the FDA may request such remote interactive evaluations where the FDA determines that remote evaluation would be appropriate based on mission needs and travel limitations. In May 2021, the FDA outlined a detailed plan to move toward a more consistent state of inspectional operations, and in July 2021, the FDA resumed standard inspectional operations of domestic facilities. More recently, the FDA has continued to monitor and implement changes to its inspectional activities to ensure the safety of its employees and those of the firms it regulates as it adapts to the evolving COVID-19 pandemic. Regulatory authorities outside the United States may adopt similar restrictions or other policy measures in response to the COVID-19 pandemic. If a prolonged government shutdown occurs, or if global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i711b1a39e0634b15bb7a70766327247a_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We and our contract manufacturers are subject to significant regulation with respect to manufacturing of IBSRELA and XPHOZAH. The manufacturing facilities on which we rely may not continue to meet regulatory requirements or may not be able to meet supply demands. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All entities involved in the preparation of product for commercial sale, or product candidates for clinical trials, including our existing contract manufacturers are subject to extensive regulation. Components of a finished therapeutic product approved for commercial sale or used in late-stage clinical studies must be manufactured in accordance with cGMP regulations. These regulations govern manufacturing processes and procedures (including record keeping) and the implementation and operation of quality systems to control and assure the quality of investigational products and products approved for sale. Poor control of production processes can lead to the introduction of contaminants or to inadvertent changes in the properties or stability of our product candidates that may not be detectable in final product testing. We or our contract manufacturers must supply all necessary documentation in support of an NDA or comparable regulatory filing on a timely basis and must adhere to cGMP regulations enforced by the FDA and other regulatory agencies through their facilities inspection programs. The facilities and quality systems of some or all of our third-party contractors must pass a pre-approval inspection for compliance with the applicable regulations as a condition of regulatory approval of our product candidates. In addition, the regulatory authorities may, at any time, audit or inspect a manufacturing facility involved with the manufacture of our product or the associated quality systems for compliance with the regulations applicable to the activities being conducted. Although we oversee the contract manufacturers, we cannot control the manufacturing process of, and are completely dependent on, our contract manufacturing partners for compliance with the regulatory requirements. If these facilities do not pass a pre-approval plant inspection, regulatory approval of the products may not be granted or may be substantially delayed until any violations are corrected to the satisfaction of the regulatory authority, if ever. In addition, we have no control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The regulatory authorities also may, at any time following approval of a product for sale, audit the manufacturing facilities of our third-party contractors. If any such inspection or audit identifies a failure to comply with applicable regulations or if a violation of our product specifications or applicable regulations occurs independent of such an inspection or audit, we or the relevant regulatory authority may require remedial measures that may be costly and/or time consuming for us or a third party to implement, and that may include the temporary or permanent suspension of a clinical study or commercial sales or the temporary or permanent suspension of production or closure of a facility. Any such remedial measures imposed upon us or third parties with whom we contract could materially harm our business. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or any of our third-party manufacturers fail to maintain regulatory compliance, the FDA or other applicable regulatory authority can impose regulatory sanctions including, among other things, refusal to approve a pending application for a new drug product, withdrawal of an approval, or suspension of production. As a result, our business, financial condition, and results of operations may be materially harmed. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, if supply from one approved manufacturer is interrupted, an alternative manufacturer would need to be qualified through an NDA, a supplemental NDA or equivalent foreign regulatory filing, which could result in further delay. The regulatory agencies may also require additional studies if a new manufacturer is relied upon for commercial production. Switching manufacturers may involve substantial costs and is likely to result in a delay in our desired clinical and commercial timelines. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These factors could cause us to incur higher costs and could cause the delay or termination of clinical studies, regulatory submissions, required approvals, or commercialization of our product candidates. Furthermore, if our suppliers fail to meet contractual requirements and we are unable to secure one or more replacement suppliers capable of production at a substantially equivalent cost, our clinical studies may be delayed, or we could lose potential revenue. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply or are found to have failed to comply with FDA and other regulations related to the promotion of our products for unapproved uses, we could be subject to criminal penalties, substantial fines or other sanctions and damage awards. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The regulations relating to the promotion of products for unapproved uses are complex and subject to substantial interpretation by the FDA and other government agencies. With respect to the commercialization of IBSRELA and/or, if approved, XPHOZAH, we will be restricted from marketing the product outside of its approved labeling, also referred to as off-label promotion. However, physicians may nevertheless prescribe an approved product to their patients in a manner that is inconsistent with the approved label, which is an off-label use. In preparation for the commercial launch of IBSRELA, we have </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i711b1a39e0634b15bb7a70766327247a_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">implemented compliance and training programs designed to ensure that our sales and marketing practices comply with applicable regulations regarding off-label promotion. Notwithstanding these programs, the FDA or other government agencies may allege or find that our practices constitute prohibited promotion of our product candidates for unapproved uses. We also cannot be sure that our employees will comply with company policies and applicable regulations regarding the promotion of products for unapproved uses. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Over the past several years, a significant number of pharmaceutical and biotechnology companies have been the target of inquiries and investigations by various federal and state regulatory, investigative, prosecutorial and administrative entities in connection with the promotion of products for unapproved uses and other sales practices, including the Department of Justice and various U.S. Attorneys&#8217; Offices, the Office of Inspector General of the Department of Health and Human Services, the FDA, the Federal Trade Commission and various state Attorneys General offices. These investigations have alleged violations of various federal and state laws and regulations, including claims asserting antitrust violations, violations of the FFDCA, the False Claims Act, the Prescription Drug Marketing Act, anti-kickback laws, and other alleged violations in connection with the promotion of products for unapproved uses, pricing and Medicare and/or Medicaid reimbursement. Many of these investigations originate as &#8220;qui tam&#8221; actions under the False Claims Act. Under the False Claims Act, any individual can bring a claim on behalf of the government alleging that a person or entity has presented a false claim, or caused a false claim to be submitted, to the government for payment. The person bringing a qui tam suit is entitled to a share of any recovery or settlement. Qui tam suits, also commonly referred to as &#8220;whistleblower suits,&#8221; are often brought by current or former employees. In a qui tam suit, the government must decide whether to intervene and prosecute the case. If it declines, the individual may pursue the case alone. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the FDA or any other governmental agency initiates an enforcement action against us or if we are the subject of a qui tam suit and it is determined that we violated prohibitions relating to the promotion of products for unapproved uses, we could be subject to substantial civil or criminal fines or damage awards and other sanctions such as consent decrees and corporate integrity agreements pursuant to which our activities would be subject to ongoing scrutiny and monitoring to ensure compliance with applicable laws and regulations. Any such fines, awards or other sanctions would have an adverse effect on our revenue, business, financial prospects and reputation. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">IBSRELA and/or, if approved, XPHOZAH, may cause or contribute to adverse medical events that we are required to report to regulatory agencies and if we fail to do so we could be subject to sanctions that would materially harm our business. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some participants in clinical studies of tenapanor have reported adverse effects after being treated with tenapanor, including diarrhea, abdominal distension, flatulence and dizziness. If we are successful in commercializing any products, FDA and foreign regulatory agency regulations require that we report certain information about adverse medical events if those products may have caused or contributed to those adverse events. The timing of our obligation to report would be triggered by the date we become aware of the adverse event as well as the nature of the event. We may fail to report adverse events we become aware of within the prescribed timeframe. We may also fail to appreciate that we have become aware of a reportable adverse event, especially if it is not reported to us as an adverse event or if it is an adverse event that is unexpected or removed in time from the use of our products. If we fail to comply with our reporting obligations, the FDA or a foreign regulatory agency could take action, including criminal prosecution, the imposition of civil monetary penalties, seizure of our products or delay in approval or clearance of future products. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees, independent contractors, principal investigators, CROs, collaboration partners, consultants and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk that our employees, independent contractors, principal investigators, CROs, collaboration partners, consultants and vendors may engage in fraudulent conduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or unauthorized activities that violate any of the following: FDA regulations, including those laws that require the reporting of true, complete and accurate financial and other information to the FDA; manufacturing standards; or federal and state healthcare fraud and abuse laws and regulations. Specifically, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. These activities also include the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with such laws or regulations. Additionally, we are subject to the risk that a person </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i711b1a39e0634b15bb7a70766327247a_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgements, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, individual imprisonment, other sanctions, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure to obtain regulatory approvals in foreign jurisdictions would prevent us from marketing our products internationally. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to market any product in the EEA (which is composed of the 27 Member States of the European Union plus Norway, Iceland and Liechtenstein), and many other foreign jurisdictions, separate regulatory approvals are required. In the EEA, medicinal products can only be commercialized after obtaining a Marketing Authorization (&#8220;MA&#8221;). Before the MA is granted, the EMA or the competent authorities of the Member States of the EEA make an assessment of the risk-benefit balance of the product on the basis of scientific criteria concerning its quality, safety and efficacy. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The approval procedures vary among countries and can involve additional clinical testing, and the time required to obtain approval may differ from that required to obtain FDA approval. Clinical trials conducted in one country may not be accepted by regulatory authorities in other countries. Approval by the FDA does not ensure approval by regulatory authorities in other countries, and approval by one or more foreign regulatory authorities does not ensure approval by regulatory authorities in other foreign countries or by the FDA. However, a failure or delay in obtaining regulatory approval in one country may have a negative effect on the regulatory process in others. The foreign regulatory approval process may include all of the risks associated with obtaining FDA approval. We may not be able to file for regulatory approvals or to do so on a timely basis, and even if we do file, we may not receive necessary approvals to commercialize our products in any market. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We and our collaboration partners may be subject to healthcare laws, regulation and enforcement; our failure or the failure of any such collaboration partners to comply with these laws could have a material adverse effect on our results of operations and financial conditions. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following our commercial introduction of IBSRELA, and the regulatory approval by a foreign government and the commercial introduction of any either IBSRELA or XPHOZAH by our collaboration partner in such jurisdiction, we and our collaboration partners may be subject to additional healthcare statutory and regulatory requirements and enforcement by the federal government and the states and foreign governments in which we conduct our business. The laws that may affect our ability to operate as a commercial organization include:</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual for, or the purchase, order or recommendation of, any good or service for which payment may be made under federal healthcare programs such as the Medicare and Medicaid programs. A person or entity does not need to have actual knowledge of this statute or specific intent to violate it in order to have committed a violation;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal false claims laws which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payors that are false or fraudulent. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the false claims statutes;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Civil Monetary Penalties law, which prohibits, among other things, offering or transferring remuneration to a federal healthcare beneficiary that a person knows or should know is likely to influence the beneficiary&#8217;s decision to order or receive items or services reimbursable by the government from a particular provider or supplier;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal criminal laws that prohibit executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of these statutes or specific intent to violate them in order to have committed a violation;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal physician sunshine requirements under the ACA, which requires manufacturers of drugs, devices, biologics, and medical supplies to report annually to CMS information related to payments and other transfers of value to physicians, (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain non-physician practitioners (physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, anesthesiologist assistants and certified nurse midwives), and teaching hospitals, and ownership and investment interests held by physicians (as defined by the statute) and their immediate family members;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i711b1a39e0634b15bb7a70766327247a_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payor, including commercial insurers;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the applicable compliance guidance promulgated by the federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or pricing information and marketing expenditures; and </span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">European and other foreign law equivalents of each of the laws, including reporting requirements detailing interactions with and payments to healthcare providers. </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities could be subject to challenge under one or more of such laws. The risk of our being found in violation of these laws is increased by the fact that many of them have not been fully interpreted by the regulatory authorities or the courts, and their provisions are open to a variety of interpretations. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business. If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that apply to us, we may be subject to penalties, including civil and criminal penalties, damages, fines, the curtailment or restructuring of our operations, the exclusion from participation in federal and state healthcare programs and imprisonment, any of which could adversely affect our ability to market our products and adversely impact our financial results. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legislative or regulatory healthcare reforms in the United States may make it more difficult and costly for us to obtain regulatory clearance or approval of our product candidates and to produce, market and distribute our products after clearance or approval is obtained. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, legislation is drafted and introduced in Congress that could significantly change the statutory provisions governing the regulatory clearance or approval, manufacture, and marketing of regulated products or the reimbursement thereof. In addition, FDA regulations and guidance are often revised or reinterpreted by the FDA in ways that may significantly affect our business and our products. Any new regulations or revisions or reinterpretations of existing regulations may impose additional costs or lengthen review times of our product candidates. We cannot determine what effect changes in regulations, statutes, legal interpretation or policies, when and if promulgated, enacted or adopted may have on our business in the future. Such changes could, among other things, require:</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additional clinical trials to be conducted prior to obtaining approval;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes to manufacturing methods;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">recall, replacement, or discontinuance of one or more of our products; and</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additional record keeping. </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of these would likely entail substantial time and cost and could materially harm our business and our financial results. In addition, delays in receipt of or failure to receive regulatory clearances or approvals for any future products would harm our business, financial condition and results of operations. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the full impact of recent healthcare reform and other changes in the healthcare industry and in healthcare spending is currently unknown, and may adversely affect our business model. In the United States, the ACA was enacted in 2010 with a goal of reducing the cost of healthcare and substantially changing the way healthcare is financed by both government and private insurers. The ACA, among other things, increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extended the rebate program to individuals enrolled in Medicaid managed care organizations, established annual fees and taxes on manufacturers of certain branded prescription drugs, and created a new Medicare Part D coverage gap discount program, in which manufacturers must now agree to offer 70% point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since its enactment, there have been judicial, executive and Congressional challenges to certain aspects of the ACA. On June 17, 2021, the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. Thus, the ACA will remain in effect in its current form. Further, prior to the U.S. Supreme Court ruling, President Biden issued an executive order that initiated a special enrollment period for purposes of obtaining health insurance coverage through the ACA marketplace from February 15, 2021 through </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i711b1a39e0634b15bb7a70766327247a_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">August 15, 2021. The executive order instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other legislative changes have been proposed and adopted in the United States since the ACA was enacted. These new laws, among other things, included aggregate reductions of Medicare payments of 2% per fiscal year to providers that will remain in effect through 2030, with the exception of a temporary suspension from May 1, 2020 through March 31, 2022 and a 1% reduction from April 1, 2022 through June 30, 2022, unless additional action is taken by Congress, additional specific reductions in Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and an increase in the statute of limitations period for the government to recover overpayments to providers from three to five years. More recently, on March 11, 2021, President Biden signed the American Rescue Plan Act of 2021 into law, which eliminates the statutory Medicaid drug rebate cap, currently set at 100% of a drug&#8217;s average manufacturer price, beginning January 1, 2024. Recently, there has also been heightened governmental scrutiny over the manner in which drug manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed bills designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. By way of example, the Build Back Better Act, if enacted, would introduce substantial drug pricing reforms, including the establishment of a drug price negotiation program within the U.S. Department of Health and Human Services that would require manufacturers to charge a negotiated &#8220;maximum fair price&#8221; for certain selected drugs or pay an excise tax for noncompliance, and the establishment of rebate payment requirements on manufacturers of certain drugs payable under Medicare Parts B and D. If the Build Back Better Act is not enacted, similar or other drug pricing proposals could appear in future legislation. Additionally, individual states have become increasingly active in passing legislation and implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access, and to encourage importation from other countries and bulk purchasing. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot predict the reform initiatives that may be adopted in the future or whether initiatives that have been adopted will be repealed or modified. The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare may adversely affect the demand for any drug products for which we may obtain regulatory approval, our ability to set a price that we believe is fair for our products, our ability to obtain coverage and reimbursement approval for a product, our ability to generate revenues and achieve or maintain profitability, and the level of taxes that we are required to pay.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with our reporting and payment obligations under the Medicaid Drug Rebate Program or other governmental pricing programs in the United States, we could be subject to additional reimbursement requirements, penalties, sanctions and fines, which could have a material adverse effect on our business, results of operations and financial condition.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:28pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With the commercial launch of IBSRELA, we will participate in the Medicaid Drug Rebate Program ("MDRP") and other federal and state government pricing programs in the United States, and we may participate in additional government pricing programs in the future. These programs generally require manufacturers to pay rebates or otherwise provide discounts to government payors in connection with drugs that are dispensed to beneficiaries of these programs. Medicaid drug rebates are based on pricing data that we are obligated to report on a monthly and quarterly basis to the U.S. Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;), the federal agency that administers the MDRP and Medicare programs. For the MDRP, these data include the average manufacturer price (&#8220;AMP&#8221;) and the best price (&#8220;BP&#8221;) for each drug. If we become aware that our MDRP price reporting submission for a prior period was incorrect or has changed as a result of recalculation of the pricing data, we must resubmit the corrected data for up to three years after those data originally were due. In addition, there is increased focus by the Office of Inspector General within the U.S. Department of Health and Human Services on the methodologies used by manufacturers to calculate AMP, and BP to assess manufacturer compliance with MDRP reporting requirements. If we fail to provide information timely or are found to have knowingly submitted false information to the government, we may be subject to civil monetary penalties and other sanctions, including termination from the MDRP, which would result in payment not being available for our covered drugs under Medicaid. Failure to make necessary disclosures and/or to identify overpayments could result in allegations against us under the Federal False Claims Act and other laws and regulations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:28pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal law requires that a manufacturer that participates in the MDRP also participate in the Public Health Service&#8217;s 340B drug pricing program (the &#8220;340B program&#8221;) in order for federal funds to be available for the manufacturer&#8217;s drugs under Medicaid. We participate in the 340B program, which is administered by the Health Resources and Services Administration (&#8220;HRSA&#8221;), and requires us to charge statutorily defined covered entities no more than the 340B &#8220;ceiling price&#8221; for the our covered drugs. These 340B covered entities include a variety of community health clinics and other entities that receive health </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i711b1a39e0634b15bb7a70766327247a_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">services grants from the Public Health Service, as well as hospitals that serve a disproportionate share of low-income patients. The 340B ceiling price is calculated using a statutory formula, which is based on the AMP and rebate amount for the covered drug as calculated under the MDRP. In general, products subject to Medicaid price reporting and rebate liability are also subject to the 340B ceiling price calculation and discount requirement. We will be obligated to report 340B ceiling prices to HRSA on a quarterly basis, and HRSA publishes them to 340B covered entities. HRSA has finalized regulations regarding the calculation of the 340B ceiling price and the imposition of civil monetary penalties on manufacturers that knowingly and intentionally overcharge covered entities for 340B-eligible drugs. HRSA has also finalized an administrative dispute resolution process through which 340B covered entities may pursue claims against participating manufacturers for overcharges, and through which manufacturers may pursue claims against 340B covered entities for engaging in unlawful diversion or duplicate discounting of 340B drugs. In addition, legislation may be introduced that, if passed, would further expand the 340B program, such as adding further covered entities or requiring participating manufacturers to agree to provide 340B discounted pricing on drugs used in an inpatient setting. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:28pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to be eligible to have drug products paid for with federal funds under Medicaid and purchased by certain federal agencies and grantees, we also must participate in the U.S. Department of Veterans Affairs (&#8220;VA&#8221;) Federal Supply Schedule (&#8220;FSS&#8221;) pricing program. Under the VA/FSS program, we are obligated to report the Non-Federal Average Manufacturer Price (&#8220;Non-FAMP&#8221;) for our covered drugs to the VA and charge certain federal agencies no more than the Federal Ceiling Price, which is calculated based on Non-FAMP using a statutory formula. These four agencies are the VA, the U.S. Department of Defense, the U.S. Coast Guard, and the U.S. Public Health Service (including the Indian Health Service). We are also be required to pay rebates on products purchased by military personnel and dependents through the TRICARE retail pharmacy program. If we fail to provide timely information or are found to have knowingly submitted false information, we may be subject to civil monetary penalties. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:28pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Individual states continue to consider and have enacted legislation to limit the growth of healthcare costs, including the cost of prescription drugs and combination products. A number of states have either implemented or are considering implementation of drug price transparency legislation that may prevent or limit our ability to take price increases at certain rates or frequencies. Requirements under such laws include advance notice of planned price increases, reporting price increase amounts and factors considered in taking such increases, wholesale acquisition cost information disclosure to prescribers, purchasers, and state agencies, and new product notice and reporting. Such legislation could limit the price or payment for IBSRELA, and a number of states are authorized to impose civil monetary penalties or pursue other enforcement mechanisms against manufacturers who fail to comply with drug price transparency requirements, including the untimely, inaccurate, or incomplete reporting of drug pricing information. If we are found to have violated state law requirements, we may become subject to penalties or other enforcement mechanisms, which could have a material adverse effect on our business. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:28pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pricing and rebate calculations are complex, vary among products and programs, and are often subject to interpretation by us, governmental or regulatory agencies, and the courts. The terms, scope and complexity of these government pricing programs change frequently, as do interpretations of applicable requirements for pricing and rebate calculations. Responding to current and future changes may increase our costs and the complexity of compliance will be time consuming. Any required refunds to the U.S. government or responding to a government investigation or enforcement action would be expensive and time consuming and could have a material adverse effect on our business, results of operations and financial condition. Price recalculations under the MDRP also may affect the ceiling price at which we are required to offer products under the 340B program. Civil monetary penalties can be applied if we are found to have knowingly submitted any false price or product information to the government, if we fail to submit the required price data on a timely basis, or if we are found to have charged 340B covered entities more than the statutorily mandated ceiling price. In the event that CMS were to terminate our Medicaid rebate agreement, no federal payments would be available under Medicaid or Medicare for IBSRELA. We cannot assure you that our submissions will not be found to be incomplete or incorrect.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Intellectual Property</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our success will depend on our ability to obtain, maintain and protect our intellectual property rights </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success and ability to compete depend in part on our ability to obtain, maintain and enforce issued patents, trademarks and other intellectual property rights and proprietary technology in the United States and elsewhere. If we cannot adequately obtain, maintain and enforce our intellectual property rights and proprietary technology, competitors may be able to use our technologies or the goodwill we have acquired in the marketplace and erode or negate any competitive advantage we may have and our ability to compete, which could harm our business and ability to achieve profitability and/or cause us to incur significant expenses.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i711b1a39e0634b15bb7a70766327247a_7">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on a combination of contractual provisions, confidentiality procedures and patent, trademark, copyright, trade secret and other intellectual property laws to protect the proprietary aspects of our products, product candidates, brands, technologies, trade secrets, know-how and data. These legal measures afford only limited protection, and competitors or others may gain access to or use our intellectual property rights and proprietary information. Our success will depend, in part, on preserving our trade secrets, maintaining the security of our data and know-how and obtaining, maintaining and enforcing other intellectual property rights. We may not be able to obtain, maintain and/or enforce our intellectual property or other proprietary rights necessary to our business or in a form that provides us with a competitive advantage. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to obtain, maintain and/or enforce intellectual property rights necessary to our business and failure to protect, monitor and control the use of our intellectual property rights could negatively impact our ability to compete and cause us to incur significant expenses. The intellectual property laws and other statutory and contractual arrangements in the United States and other jurisdictions we depend upon may not provide sufficient protection in the future to prevent the infringement, use, violation or misappropriation of our patents, trademarks, data, technology and other intellectual property rights and products by others, and may not provide an adequate remedy if our intellectual property rights are infringed, misappropriated or otherwise violated by others.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely in part on our portfolio of issued and pending patent applications in the United States and other countries to protect our intellectual property and competitive position. However, it is also possible that we may fail to identify patentable aspects of inventions made in the course of our development, manufacture and commercialization activities before it is too late to obtain patent protection on them. If we fail to timely file for patent protection in any jurisdiction, we may be precluded from doing so at a later date. Although we enter into non-disclosure and confidentiality agreements with parties who have access to patentable aspects of our research and development output, such as our employees, corporate collaborators, outside scientific collaborators, suppliers, consultants, advisors and other third parties, any of these parties may breach the agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection. Furthermore, publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot be certain that we were the first to make the inventions claimed in any of our patents or pending patent applications, or that we were the first to file for patent protection of such inventions. Moreover, should we become a licensee of a third party&#8217;s patents or patent applications, depending on the terms of any future in-licenses to which we may become a party, we may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain or enforce the patents, covering technology in-licensed from third parties. Therefore, these patents and patent applications may not be prosecuted, maintained and/or enforced in a manner consistent with the best interests of our business. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent positions of companies, including our patent position, may involve complex legal and factual questions that have been the subject of much litigation in recent years, and, therefore, the scope of any patent claims that we have or may obtain cannot be predicted with certainty. Accordingly, we cannot provide any assurances about which of our patent applications will issue, the breadth of any resulting patent, whether any of the issued patents will be found to be infringed, invalid or unenforceable or will be threatened or challenged by third parties, that any of our issued patents have, or that any of our currently pending or future patent applications that mature into issued patents will include, claims with a scope sufficient to protect our products and services. Our pending and future patent applications may not result in the issuance of patents or, if issued, may not issue in a form that will be advantageous to us. The coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. We cannot offer any assurances that the breadth of our granted patents will be sufficient to stop a competitor from developing, manufacturing and commercializing a product or technologies in a non-infringing manner that would be competitive with one or more of our products or technologies, or otherwise provide us with any competitive advantage. Furthermore, any successful challenge to these patents or any other patents owned by or licensed to us after patent issuance could deprive us of rights necessary for our commercial success. Further, there can be no assurance that we will have adequate resources to enforce our patents.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents have a limited lifespan. In the United States, the natural expiration of a utility patent is generally 20 years from the earliest effective non-provisional filing date. Though an issued patent is presumed valid and enforceable, its issuance is not conclusive as to its validity or its enforceability and it may not provide us with adequate proprietary protection or competitive advantages against competitors with similar products or services. Patents, if issued, may be challenged, deemed unenforceable, invalidated, narrowed or circumvented. Proceedings challenging our patents or patent applications could result in either loss of the patent, or denial of the patent application or loss or reduction in the scope of one or more of the claims of the patent or patent application. Any successful challenge to our patents and patent applications could deprive us of exclusive rights necessary for our commercial success. In addition, defending such challenges in such proceedings may be costly. Thus, any patents that we may own may not provide the anticipated level of, or any, protection against competitors. Furthermore, an </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i711b1a39e0634b15bb7a70766327247a_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">adverse decision may result in a third party receiving a patent right sought by us, which in turn could affect our ability to develop, manufacture or commercialize our products or technologies.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of our patents and patent applications may in the future be co-owned with third parties. If we are unable to obtain an exclusive license to any such third-party co-owners&#8217; interest in such patents or patent applications, such co-owners may be able to license their rights to other third parties, including our competitors, and our competitors could market competing products, services and technology. In addition, we may need the cooperation of any such co-owners of our patents in order to enforce such patents against third parties, and such cooperation may not be provided to us.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree of future protection for our proprietary rights is uncertain, and we cannot ensure that:</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Any of our patents, or any of our pending patent applications, if issued, will include claims having a scope sufficient to protect our products or product candidates;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Any of our pending patent applications will issue as patents;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We were the first to make the inventions covered by each of our patents and pending patent applications;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We were the first to file patent applications for these inventions;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Others will not develop, manufacture and/or commercialize similar or alternative products or technologies that do not infringe our patents;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Any of our challenged patents will be found to ultimately be valid and enforceable;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Any patents issued to us will provide a basis for an exclusive market for our commercially viable products or technologies will provide us with any competitive advantages or will not be challenged by third parties;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will develop additional proprietary technologies or products that are separately patentable; or</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our commercial activities or products will not infringe upon the patents of others.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may become subject to third party claims alleging infringement, misappropriation or violation of such third parties&#8217; patents or other intellectual property rights and/or third party claims seeking to invalidate our patents, which would be costly, time consuming and, if successfully asserted against us, delay or prevent the development, manufacture or commercialization of our products or product candidates. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends, in part, on our ability to develop, manufacture or commercialize our products and product candidates without infringing, misappropriating or otherwise violating the intellectual property rights of third parties. There have been many lawsuits and other proceedings asserting infringement or misappropriation of patents and other intellectual property rights in the pharmaceutical and biotechnology industries, and companies in the industry have used intellectual property litigation to gain a competitive advantage. While we take steps to ensure that we do not infringe upon, misappropriate or otherwise violate the intellectual property rights of others, there can be no assurances that we will not be subject to claims alleging that the manufacture, use or sale of IBSRELA or XPHOZAH or of any other product candidates infringes existing or future third-party patents, or that such claims, if any, will not be successful. Because patent applications can take many years to issue and may be confidential for 18 months or more after filing, and because pending patent claims can be revised before issuance, there may be applications now pending which may later result in issued patents that may be infringed by the manufacture, use or sale of IBSRELA or XPHOZAH or other product candidates. Moreover, we may face patent infringement claims from non-practicing entities that have no relevant product revenue and against whom our own patent portfolio may thus have no deterrent effect. We may be unaware of one or more issued patents that would be infringed by the manufacture, sale or use of IBSRELA or XPHOZAH or our other product candidates. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third parties may initiate legal proceedings alleging that we are infringing, misappropriating or otherwise violating their intellectual property rights. These proceedings could cause us to pay substantial damages, including treble damages and attorney&#8217;s fees if we are found to be willfully infringing a third party&#8217;s patents. We may be required to indemnify future collaboration partners against such claims. We are not aware of any threatened or pending claims related to these matters, but in the future litigation may be necessary to defend against such claims. If a patent infringement suit were brought against us, we could be forced to stop or delay development, manufacturing or sales of the product or product candidate that is the subject of the suit. As a result of patent infringement claims, or in order to avoid potential claims, we may choose to seek, or be required to seek, a license from the third party and would most likely be required to pay license fees or royalties or both. These licenses may not be available on acceptable terms, or at all. Even if we were able to obtain a license, we may be unable to maintain such licenses and the rights may be nonexclusive, which would give our competitors access to the same intellectual property. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i711b1a39e0634b15bb7a70766327247a_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ultimately, we could be prevented from commercializing a product, or forced to redesign it if, as a result of actual or threatened patent infringement claims, we are unable to enter into licenses on acceptable terms, or unable to maintain such licenses when granted. Even if we are successful in defending against such claims, such litigation can be expensive and time consuming to litigate and would divert management&#8217;s attention from our core business. Any of these events could harm our business significantly. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also could be ordered to pay substantial damages, including treble damages and attorney&#8217;s fees if we are found to be willfully infringing a third party&#8217;s patents or other intellectual property right. Even if we believe such claims are without merit, a court of competent jurisdiction could hold that these third party patents are valid and enforceable, and infringed by the use of our products and/or technologies, which could have a negative impact on the commercial success of our current and any future products or technologies. If we were to challenge the validity of any such third party U.S. patent in federal court, we would need to overcome a presumption of validity. As this burden is a high one requiring us to present clear and convincing evidence as to the invalidity of any such U.S. patent claim, there is no assurance that a court of competent jurisdiction would invalidate the claims of any such U.S. patent. We will have similar burdens to overcome in foreign courts in order to successfully challenge a third party claim of patent infringement. Even if we are successful in defending against such claims, such litigation can be expensive and time consuming to litigate and would divert management&#8217;s attention from our core business. Any of these events could harm our business significantly. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to infringement claims against us, third parties may also raise similar claims before administrative bodies in the United States or abroad. Such mechanisms include reexamination, post grant review, inter parties review, derivation or opposition proceedings before the United States Patent and Trademark Office (the &#8220;USPTO&#8221;) or other jurisdictional body relating to our intellectual property rights or the intellectual property rights of others. If third parties prepare and file patent applications in the United States that also claim technology similar or identical to ours, we may have to participate in interference or derivation proceedings in the USPTO to determine which party is entitled to a patent on the disputed invention. We may also become involved in similar opposition proceedings in the European Patent Office or similar offices in other jurisdictions regarding our intellectual property rights with respect to our products and technology. Since patent applications are confidential for a period of time after filing, we cannot be certain that we were the first to file any patent application related to our product candidates. Such administrative proceedings could result in revocation of or amendment to our patents in such a way that they no longer cover our products or product candidates. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we, our patent counsel, and the patent examiner were unaware during prosecution. If a third party were to prevail on a legal assertion of invalidity and/or unenforceability, we may lose at least part, and perhaps all, of the patent protection on our products or technologies. Such a loss of patent protection would have a material adverse impact on our business, financial condition, results of operations, and prospects.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our intellectual property related to IBSRELA, XPHOZAH, RDX013 or any future product candidates is not adequate or if we are not able to successfully enforce our intellectual property right, the commercial value of IBSRELA, or our product candidates may be adversely affected and we may not be able to compete effectively in our market.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The strength of patents in the biotechnology and pharmaceutical field involves complex legal and scientific questions and can be uncertain. The patent applications that we own or license may fail to result in issued patents in the United States or in foreign countries. Additionally, our research and development efforts may result in product candidates for which patent protection is limited or not available. Even if patents do successfully issue, third parties may challenge the validity, enforceability or scope thereof, which may result in such patents being narrowed, invalidated or held unenforceable. For example, U.S. patents can be challenged by any person before the new USPTO Patent Trial and Appeals Board at any time before one year after that person is served an infringement complaint based on the patents. Patents granted by the European Patent Office may be similarly opposed by any person within nine months from the publication of the grant. Similar proceedings are available in other jurisdictions, and in the United States, Europe and other jurisdictions third parties can raise questions of validity with a patent office even before a patent has granted. Furthermore, even if they are unchallenged, our patents and patent applications may not adequately protect our intellectual property or prevent others from designing around our claims. For example, a third party may develop a competitive product that provides therapeutic benefits similar to one or more of our product candidates but has a sufficiently different composition to fall outside the scope of our patent protection. If the breadth or strength of protection provided by the patents and patent applications we hold or pursue with respect to IBSRELA, XPHOZAH, RDX013 or any future product candidates is successfully challenged, then our ability to commercialize such product could be negatively affected, and we may face unexpected competition that could have a material adverse impact on our business. Further, we have reported that we have completed the data analysis from our Phase 2 clinical trial evaluating the safety and efficacy of RDX013 for the treatment of hyperkalemia, and that we currently expect that the next steps for the RDX013 program will be to evaluate a new formulation that potentially enhances subject compliance and the efficacy of RDX013 in an additional Phase 2 clinical study. We currently expect to delay further development of RDX013 until such time as we have determined that our available resources support conducting such additional formulation work and an additional </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i711b1a39e0634b15bb7a70766327247a_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">clinical study. As a result of this delay in our development program for RDX013, the period of time during which we or our collaboration partners could market RDX013 under patent protection would be reduced. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even where laws provide protection, costly and time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights, and the outcome of such litigation would be uncertain. If we or one of our collaboration partners were to initiate legal proceedings against a third party to enforce a patent covering a product or product candidate, the defendant could counterclaim that our patent is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to validity, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability against our intellectual property related to a product or a product candidate, we would lose at least part, and perhaps all, of the patent protection on such product or product candidate. Such a loss of patent protection would have a material adverse impact on our business. Moreover, our competitors could counterclaim that we infringe their intellectual property, and some of our competitors have substantially greater intellectual property portfolios than we do. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also rely on trade secret protection and confidentiality agreements to protect proprietary know-how that may not be patentable, processes for which patents may be difficult to obtain and/or enforce and any other elements of our drug discovery and development processes that involve proprietary know-how, information or technology that is not covered by patents. Although we require all of our employees, consultants, advisors and any third parties who have access to our proprietary know-how, information or technology, to assign their inventions to us, and endeavor to execute confidentiality agreements with all such parties, we cannot be certain that we have executed such agreements with all parties who may have helped to develop our intellectual property or who had access to our proprietary information, nor can we be certain that our agreements will not be breached by such consultants, advisors or third parties, or by our former employees. The breach of such agreements by individuals or entities who were actively involved in the discovery and design of our products or potential drug candidates, or in the development of our discovery and design platform, including APECCS, could require us to pursue legal action to protect our trade secrets and confidential information, which would be expensive, and the outcome of which would be unpredictable. If we are not successful in prohibiting the continued breach of such agreements, our business could be negatively impacted. We cannot guarantee that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, the laws of some foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws of the United States. As a result, we may encounter significant problems in protecting and defending our intellectual property both in the United States and abroad. If we are unable to prevent material disclosure of the intellectual property related to our technologies to third parties, we will not be able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business, results of operations and financial condition. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we do not obtain patent term extension in the United States under the Hatch-Waxman Act and in foreign countries under similar legislation, thereby potentially extending the term of marketing exclusivity for IBSRELA or our product candidates, our business may be materially harmed. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the approval by the FDA for our NDA to market tenapanor for IBS-C, we became eligible to seek and sought patent term restoration under the Hatch-Waxman Act for one of the U.S. patents covering our approved product or the use thereof. The Hatch-Waxman Act allows a maximum of one patent to be extended per FDA approved product. Patent term extension also may be available in certain foreign countries upon regulatory approval of our product candidates. Despite seeking patent term extension for tenapanor or other product candidates, we may not be granted patent term extension either in the United States or in any foreign country because of, for example, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the term of extension, as well as the scope of patent protection during any such extension, afforded by the governmental authority could be less than we request. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to obtain patent term extension or restoration, or the term of any such extension is less than we request, the period during which we will have the right to exclusively market our product will be shortened and our competitors may obtain approval of competing products following our patent expiration, and our revenue could be reduced, possibly materially. </span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i711b1a39e0634b15bb7a70766327247a_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The USPTO and various foreign patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions to maintain patent applications and issued patents. Noncompliance with these requirements can result in abandonment or lapse of a patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, competitors might be able to enter the market earlier than would otherwise have been the case. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to enforce our intellectual property rights throughout the world. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The laws of some foreign countries do not protect intellectual property rights to the same extent as the laws of the United States. Many companies have encountered significant problems in protecting and defending intellectual property rights in certain foreign jurisdictions. The legal systems of some countries, particularly developing countries, do not favor the enforcement of patents and other intellectual property protection, especially those relating to life sciences. This could make it difficult for us to stop the infringement of our patents or the misappropriation of our other intellectual property rights. For example, many foreign countries have compulsory licensing laws under which a patent owner must grant licenses to third parties. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceedings to enforce our patent rights in foreign jurisdictions, whether or not successful, could result in substantial costs and divert our efforts and attention from other aspects of our business. Furthermore, while we intend to protect our intellectual property rights in our expected significant markets, we cannot ensure that we will be able to initiate or maintain similar efforts in all jurisdictions in which we may wish to market our products. Accordingly, our efforts to protect our intellectual property rights in such countries may be inadequate. In addition, changes in the law and legal decisions by courts in the United States and foreign countries may affect our ability to obtain and enforce adequate intellectual property protection for our technology. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims that we or our employees have misappropriated the intellectual property, including know-how or trade secrets, of a third party, or claiming ownership of what we regard as our own intellectual property. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our employees, consultants and contractors were previously employed at or engaged by other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Some of these employees, consultants and contractors, executed proprietary rights, non-disclosure and non-competition agreements in connection with such previous employment. Although we try to ensure that our employees, consultants and contractors do not use the intellectual property and other proprietary information or know-how or trade secrets of others in their work for us, and do not perform work for us that is in conflict with their obligations to another employer or any other entity, we may be subject to claims that we or these employees, consultants and contractors have used or disclosed such intellectual property, including know-how, trade secrets or other proprietary information. In addition, an employee, advisor or consultant who performs work for us may have obligations to a third party that are in conflict with their obligations to us, and as a result such third party may claim an ownership interest in the intellectual property arising out of work performed for us. We are not aware of any threatened or pending claims related to these matters, but in the future litigation may be necessary to defend against such claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, or access to consultants and contractors. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, while we typically require our employees, consultants and contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact develops intellectual property that we regard as our own, which may result in claims by or against us related to the ownership of such intellectual property. If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights. Even if we are successful in prosecuting or defending against such claims, litigation could result in substantial costs and be a distraction to our management and scientific personnel. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Common Stock</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our stock price may be volatile and our stockholders may not be able to resell shares of our common stock at or above the price they paid. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i711b1a39e0634b15bb7a70766327247a_7">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading price of our common stock is highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control. These factors include those discussed in this &#8220;Risk Factors&#8221; section and others such as:</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success or lack of success with regards to our commercialization  of IBSRELA;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success or lack of success with regards to the Advisory Committee meeting to consider our NDA seeking marketing approval for tenapanor for the Hyperphosphatemia Indication, and announcements of regulatory decisions regarding our NDA;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements regarding any potential receipt from Nasdaq of notice regarding lack of compliance with the listing requirements of Nasdaq or a de-listing of our common stock; </span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">results of regulatory inspections of our facilities or those of our contract manufacturing organizations, or specific label restrictions or patient populations for XPHOZAH&#8217;s use, if approved, or changes or delays in the regulatory review process;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements regarding whether XPHOZAH, if approved, alone or with other oral only medications, will be included in the bundled prospective payment system for the treatment of ESRD patients, and the time and manner in which such transition is achieved;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements relating to our current or future collaboration partnerships;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements of therapeutic innovations or new products by us or our competitors;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse actions taken by regulatory agencies with respect to our product label, our clinical trials, manufacturing supply chain or sales and marketing activities;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes or developments in laws or regulations applicable to our approved products or our product candidates;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of our testing and clinical trials;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to meet any of our projected timelines or goals with regard to the commercial launch of IBSRELA, or the clinical development and commercialization of any of our product candidates;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of our efforts to acquire or license or discover additional product candidates;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any intellectual property infringement actions in which we may become involved;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of our efforts to obtain adequate intellectual property protection for our product candidates;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements concerning our competitors or the pharmaceutical industry in general;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">achievement of expected product sales and profitability;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manufacture, supply or distribution shortages;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">actual or anticipated fluctuations in our operating results;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">FDA or other U.S. or foreign regulatory actions affecting us or our industry or other healthcare reform measures in the United States;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in financial estimates or recommendations by securities analysts;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">trading volume of our common stock;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales of our common stock by us, our executive officers and directors or our stockholders in the future;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales of debt securities and sales or licensing of assets;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general economic and market conditions and overall fluctuations in the United States equity markets; and</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the loss of any of our key scientific or management personnel. </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the stock markets in general, and the markets for pharmaceutical, biopharmaceutical and biotechnology stocks in particular, have experienced extreme volatility that may have been unrelated to the operating performance of the issuer. These broad market fluctuations may adversely affect the trading price or liquidity of our common stock. In the past, when the market price of a stock has been volatile, holders of that stock have sometimes instituted securities class action litigation against the issuer. If any of our stockholders were to bring such a lawsuit against us, we could incur substantial costs defending the lawsuit and the attention of our management would be diverted from the operation of our business, which could seriously harm our financial position. Any adverse determination in litigation could also subject us to significant liabilities. </span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i711b1a39e0634b15bb7a70766327247a_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our principal stockholders own a significant percentage of our stock and, together with our management, will be able to exert significant control over matters subject to stockholder approval. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the number of shares outstanding as of March 31, 2022, our officers, directors and stockholders who hold at least 5% of our stock together beneficially own approximately 9.3% of our outstanding common stock. If these officers, directors, and principal stockholders or a group of our principal stockholders act together, they will be able to exert a significant degree of influence over our management and affairs and control matters requiring stockholder approval, including the election of directors, amendments to our organizational documents, and approval of any merger, sale of assets or other business combination transactions. The interests of this concentration of ownership may not always coincide with our interests or the interests of other stockholders. For instance, officers, directors and principal stockholders, acting together, could cause us to enter into transactions or agreements that we would not otherwise consider. Similarly, this concentration of ownership may have the effect of delaying or preventing a change in control of our company otherwise favored by our other stockholders. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales of a substantial number of shares of our common stock in the public market could cause our stock price to fall. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our existing stockholders sell, or indicate an intention to sell, substantial amounts of our common stock in the public market, the trading price of our common stock could decline. As of March 31, 2022, we had approximately 136.3 million shares of common stock outstanding. Of those shares, approximately 9.0 million were held by current directors, executive officers and stockholders owning 5% or more of our outstanding common stock. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2022, 4.4 million shares of common stock issuable upon vesting of outstanding restricted stock units and approximately 12.9 million shares of common stock issuable upon exercise of outstanding options were eligible for sale in the public market to the extent permitted by the provisions of the applicable vesting schedules, and Rule 144 and Rule 701 under the Securities Act. If these additional shares of common stock are issued and sold, or if it is perceived that they will be sold, in the public market, the trading price of our common stock could decline. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we sell shares of our common stock in future financings, stockholders may experience immediate dilution and, as a result, our stock price may decline. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may from time to time issue additional shares of common stock at a discount from the current trading price of our common stock. As a result, our stockholders would experience immediate dilution upon the purchase of any shares of our common stock sold at such discount. In addition, as opportunities present themselves, we may enter into financing or similar arrangements in the future, including the issuance of debt securities, preferred stock or common stock. If we issue common stock or securities convertible into common stock, our common stockholders would experience additional dilution and, as a result, our stock price may decline. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risk Factors</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We incur significant costs as a result of operating as a public company, and our management will devote substantial time to new compliance initiatives. We may fail to comply with the rules that apply to public companies, including Section 404 of the Sarbanes-Oxley Act of 2002, which could result in sanctions or other penalties that would harm our business. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incur significant legal, accounting and other expenses as a public company, including costs resulting from public company reporting obligations under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;) and regulations regarding corporate governance practices. The listing requirements of The Nasdaq Global Market require that we satisfy certain corporate governance requirements relating to director independence, distributing annual and interim reports, stockholder meetings, approvals and voting, soliciting proxies, conflicts of interest and a code of conduct. Our management and other personnel will need to devote a substantial amount of time to ensure that we comply with all of these requirements. Moreover, the reporting requirements, rules and regulations will increase our legal and financial compliance costs and will make some activities more time consuming and costly. Any changes we make to comply with these obligations may not be sufficient to allow us to satisfy our obligations as a public company on a timely basis, or at all. These reporting requirements, rules and regulations, coupled with the increase in potential litigation exposure associated with being a public company, could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors or board committees or to serve as executive officers, or to obtain certain types of insurance, including directors&#8217; and officers&#8217; insurance, on acceptable terms. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to Section 404 of The Sarbanes-Oxley Act of 2002 (&#8220;Section 404&#8221;) and the related rules of the Securities and Exchange Commission (&#8220;SEC&#8221;) which require, among other things, our management and independent registered public accounting firm to report on the effectiveness of our internal control over financial reporting. Our compliance with Section 404 requires that we incur substantial expense and expend significant management efforts. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i711b1a39e0634b15bb7a70766327247a_7">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the course of our review and testing of our internal controls, we may identify deficiencies and be unable to remediate them before we must provide the required reports. Furthermore, if we have a material weakness in our internal controls over financial reporting, we may not detect errors on a timely basis and our financial statements may be materially misstated. We or our independent registered public accounting firm may not be able to conclude on an ongoing basis that we have effective internal control over financial reporting, which could harm our operating results, cause investors to lose confidence in our reported financial information and cause the trading price of our stock to fall. In addition, as a public company we are required to file accurate and timely quarterly and annual reports with the SEC under the Exchange Act. Any failure to report our financial results on an accurate and timely basis could result in sanctions, lawsuits, delisting of our shares from The Nasdaq Global Market or other adverse consequences that would materially harm our business. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be adversely affected by the global economic environment. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to attract and retain collaboration partners or customers, invest in and grow our business and meet our financial obligations depends on our operating and financial performance, which, in turn, is subject to numerous factors, including the prevailing economic conditions and financial, business and other factors beyond our control, such as the rate of unemployment, the number of uninsured persons in the United States, presidential elections, other political influences and inflationary pressures. Our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets. The 2008 global financial crisis caused extreme volatility and disruptions in the capital and credit markets. We cannot anticipate all the ways in which the global economic climate and global financial market conditions could adversely impact our business in the future. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to risks associated with reduced profitability and the potential financial instability of our collaboration partners or customers, many of which may be adversely affected by volatile conditions in the financial markets. For example, unemployment and underemployment, and the resultant loss of insurance, may decrease the demand for healthcare services and pharmaceuticals. If fewer patients are seeking medical care because they do not have insurance coverage, our collaboration partners or customers may experience reductions in revenues, profitability and/or cash flow that could lead them to reduce their support of our programs or financing activities. If collaboration partners or customers are not successful in generating sufficient revenue or are precluded from securing financing, they may not be able to pay, or may delay payment of, accounts receivable that are owed to us. In addition, volatility in the financial markets could cause significant fluctuations in the interest rate and currency markets. We currently do not hedge for these risks. The foregoing events, in turn, could adversely affect our financial condition and liquidity. In addition, if economic challenges in the United States result in widespread and prolonged unemployment, either regionally or on a national basis, or if certain provisions of the Patient Protection and ACA, as amended by the Health Care and Education Reconciliation Act, collectively known as the ACA, are repealed, a substantial number of people may become uninsured or underinsured. To the extent economic challenges result in fewer individuals pursuing or being able to afford our product candidates once commercialized, our business, results of operations, financial condition and cash flows could be adversely affected. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provisions in our charter documents and under Delaware law could discourage a takeover that stockholders may consider favorable and may lead to entrenchment of management. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation and amended and restated bylaws contain provisions that could significantly reduce the value of our shares to a potential acquirer or delay or prevent changes in control or changes in our management without the consent of our board of directors. The provisions in our charter documents include the following:</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a classified board of directors with three-year staggered terms, which may delay the ability of stockholders to change the membership of a majority of our board of directors;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">no cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director candidates;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the exclusive right of our board of directors to elect a director to fill a vacancy created by the expansion of the board of directors or the resignation, death or removal of a director, which prevents stockholders from being able to fill vacancies on our board of directors;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the required approval of at least two-thirds of the shares entitled to vote to remove a director for cause, and the prohibition on removal of directors without cause;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability of our board of directors to authorize the issuance of shares of preferred stock and to determine the price and other terms of those shares, including preferences and voting rights, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquirer;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i711b1a39e0634b15bb7a70766327247a_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability of our board of directors to alter our bylaws without obtaining stockholder approval;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the required approval of at least two-thirds of the shares entitled to vote at an election of directors to adopt, amend or repeal our bylaws or repeal the provisions of our amended and restated certificate of incorporation regarding the election and removal of directors;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a prohibition on stockholder action by written consent, which forces stockholder action to be taken at an annual or special meeting of our stockholders;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the requirement that a special meeting of stockholders may be called only by the chairman of the board of directors, the chief executive officer, the president or the board of directors, which may delay the ability of our stockholders to force consideration of a proposal or to take action, including the removal of directors; and</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">advance notice procedures that stockholders must comply with in order to nominate candidates to our board of directors or to propose matters to be acted upon at a stockholders&#8217; meeting, which may discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer&#8217;s own slate of directors or otherwise attempting to obtain control of us. </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, these provisions would apply even if we were to receive an offer that some stockholders may consider beneficial. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to the anti-takeover provisions contained in Section 203 of the Delaware General Corporation Law. Under Section 203, a corporation may not, in general, engage in a business combination with any holder of 15% or more of its capital stock unless the holder has held the stock for three years or, among other exceptions, the board of directors has approved the transaction. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Claims for indemnification by our directors and officers may reduce our available funds to satisfy successful third-party claims against us and may reduce the amount of money available to us. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation and amended and restated bylaws provide that we will indemnify our directors and officers, in each case to the fullest extent permitted by Delaware law. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as permitted by Section 145 of the Delaware General Corporation Law, our amended and restated bylaws and our indemnification agreements that we have entered into with our directors and officers provide that:</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will indemnify our directors and officers for serving us in those capacities or for serving other business enterprises at our request, to the fullest extent permitted by Delaware law. Delaware law provides that a corporation may indemnify such person if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the registrant and, with respect to any criminal proceeding, had no reasonable cause to believe such person&#8217;s conduct was unlawful. </span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may, in our discretion, indemnify employees and agents in those circumstances where indemnification is permitted by applicable law. </span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are required to advance expenses, as incurred, to our directors and officers in connection with defending a proceeding, except that such directors or officers shall undertake to repay such advances if it is ultimately determined that such person is not entitled to indemnification. </span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will not be obligated pursuant to our amended and restated bylaws to indemnify a person with respect to proceedings initiated by that person against us or our other indemnities, except with respect to proceedings authorized by our board of directors or brought to enforce a right to indemnification. </span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The rights conferred in our amended and restated bylaws are not exclusive, and we are authorized to enter into indemnification agreements with our directors, officers, employees and agents and to obtain insurance to indemnify such persons. </span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not retroactively amend our amended and restated bylaw provisions to reduce our indemnification obligations to directors, officers, employees and agents. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We do not currently intend to pay dividends on our common stock, and, consequently, our stockholders&#8217; ability to achieve a return on their investment will depend on appreciation in the price of our common stock. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently intend to pay any cash dividends on our common stock for the foreseeable future. We currently intend to invest our future earnings, if any, to fund our growth. Additionally, the terms of our loan and security agreements could </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i711b1a39e0634b15bb7a70766327247a_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">restrict our ability to pay dividends. Therefore, our stockholders are not likely to receive any dividends on our common stock for the foreseeable future. Since we do not intend to pay dividends, our stockholders&#8217; ability to receive a return on their investment will depend on any future appreciation in the market value of our common stock. There is no guarantee that our common stock will appreciate or even maintain the price at which our holders have purchased it. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The United Kingdom&#8217;s withdrawal from the European Union may have a negative effect on global economic conditions, financial markets and our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following a national referendum and enactment of legislation by the government of the United Kingdom, the United Kingdom formally withdrew from the European Union and ratified a trade and cooperation agreement governing its future relationship with the European Union. The agreement, which is being applied provisionally from January 1, 2021, until it is ratified by the European Parliament and the Council of the European Union, addresses trade, economic arrangements, law enforcement, judicial cooperation and a governance framework including procedures for dispute resolution, among other things. Because the agreement merely sets forth a framework in many respects and will require complex additional bilateral negotiations between the United Kingdom and the European Union as both parties continue to work on the rules for implementation, significant political and economic uncertainty remains about how the precise terms of the relationship between the parties will differ from the terms before withdrawal. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These developments, or the perception that any related developments could occur, have had and may continue to have a material adverse effect on global economic conditions and financial markets, and may significantly reduce global market liquidity, restrict the ability of key market participants to operate in certain financial markets or restrict our access to capital. Any of these factors could have a material adverse effect on our business, financial condition and results of operations and reduce the price of our common stock.</span></div><div id="i711b1a39e0634b15bb7a70766327247a_124"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective February 23, 2022, we entered into a loan and security agreement pursuant to which the Lenders agreed to provide us a loan facility for up to $50.0 million. Covenants in the loan and security agreement limit our ability to pay dividends or make other distributions. For additional information refer to &#8220;NOTE 7. BORROWING&#8221; in the notes to our condensed financial statements in Part I, Item 1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Notes to Condensed Financial Statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unregistered Sales of Equity Securities</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Proceeds</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Purchases of Equity Securities by the Issuer and Affiliated Purchasers</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None. </span></div><div id="i711b1a39e0634b15bb7a70766327247a_127"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;DEFAULTS UPON SENIOR SECURITIES</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i711b1a39e0634b15bb7a70766327247a_130"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;MINE SAFETY DISCLOSURES</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i711b1a39e0634b15bb7a70766327247a_133"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;OTHER INFORMATION</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.&#160;&#160;&#160;&#160;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><div id="i711b1a39e0634b15bb7a70766327247a_136"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary;margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i711b1a39e0634b15bb7a70766327247a_7">Table of Contents</a></span></div></div><div style="-sec-extract:summary;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;6.&#160;&#160;&#160;&#160;&#160;&#160;&#160;Exhibits </span></div><div style="margin-top:17pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:5.811%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.076%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.458%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.458%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.458%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.464%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated by Reference</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filed<br/>Herewith</span></td></tr><tr style="height:9pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="slrloanandsecurityagreemen.htm">Loan and Security Agreement dated February 23, 2022, by and between Ardelyx, Inc. and SLR Investment Corp.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="slrexitfeeagreement-ex102.htm">Exit Fee Agreement dated February 23, 2022, by and between Ardelyx, Inc. and SLR Investment Corp.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3&#8224;&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1437402/000162828022008924/a2ndamendmenttokkc-ardxlic.htm">Amendment Number 2 to License Agreement, dated as of April 11, 2022, by and among Ardelyx, Inc., </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1437402/000162828022008924/a2ndamendmenttokkc-ardxlic.htm">and Kyowa Kirin Co., Ltd.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4/11/2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ardx-20220331xex311.htm">Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ardx-20220331xex312.htm">Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ardx-20220331xex321.htm">Certification of Chief Executive Officer and Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following financial statements, formatted in Inline Extensible Business Reporting Language (XBRL): (i) Condensed Balance Sheets as of March&#160;31, 2022 and December&#160;31, 2021, (ii) Condensed Statements of Operations and Comprehensive Loss for the three months ended March&#160;31, 2022 and 2021, (iii) Condensed Statements of Cash Flows for the three months ended March&#160;31, 2022 and 2021, and (iv) Notes to Unaudited Condensed Financial Statements.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File, formatted in Inline XBRL and contained in Exhibit 101.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8224;&#8224;    Certain portions have been omitted pursuant to a confidential treatment request. Omitted information has been filed separately with the Securities and Exchange Commission.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><div id="i711b1a39e0634b15bb7a70766327247a_139"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i711b1a39e0634b15bb7a70766327247a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:47.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.164%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.813%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ardelyx, Inc.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: May 5, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Robert Felsch</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Robert Felsch</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Senior Vice President and Chief Accounting Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Principal Accounting Officer)</span></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%"></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>slrloanandsecurityagreemen.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i411762c6343a4d74a3d9f0d4e597f682_33"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div></div><div><font><br></font></div><div id="i411762c6343a4d74a3d9f0d4e597f682_38"></div><div style="margin-top:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">LOAN AND SECURITY AGREEMENT</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">THIS LOAN AND SECURITY AGREEMENT </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(as the same may be amended, restated, modified, or supplemented from time to time, this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) dated as of February 23, 2022 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) among SLR Investment Corp., a Maryland corporation with an office located at 500 Park Avenue, 3rd Floor, New York, NY 10022 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SLR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), as collateral agent (in such capacity, together with its successors and assigns in such capacity, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Collateral Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), and the lenders listed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereof or otherwise a party hereto from time to time including SLR (together with any other lenders party hereto, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Lenders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; and each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Lender</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), and ARDELYX, INC., a Delaware corporation with offices located at 400 Fifth Avenue, Suite 210, Waltham, MA 02451 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Borrower</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), provides the terms on which the Lenders shall lend to Borrower and Borrower shall repay the Lenders. The parties agree as follows&#58;</font></div><div style="margin-top:12.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:102%">1.&#160;&#160;&#160;&#160;DEFINITIONS AND OTHER TERMS</font></div><div style="margin-top:11pt;padding-right:3.6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.1&#160;&#160;&#160;&#160;Terms. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Capitalized terms used herein shall have the meanings set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> to the extent defined therein. All other capitalized terms used but not defined herein shall have the meaning given to such terms in the Code. Any accounting term used but not defined herein shall be construed in accordance with GAAP and all calculations shall be made in accordance with GAAP. The term &#8220;financial statements&#8221; shall include the accompanying notes and schedules.</font></div><div style="margin-top:11pt;padding-right:46.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.2&#160;&#160;&#160;&#160;Section References. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Any section, subsection, schedule or exhibit references are to this Agreement unless otherwise specified.</font></div><div style="margin-top:11pt;padding-right:10.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.3&#160;&#160;&#160;&#160;Divisions.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">For all purposes under the Loan Documents, in connection with any division or plan of division under Delaware law (or any comparable event under a different jurisdiction&#8217;s laws)&#58; (a) if any asset, right, obligation or liability of any Person becomes the asset, right, obligation or liability of a different Person, then it shall be deemed to have been transferred from the original Person to the subsequent Person, and (b) if any new Person comes into existence, such new Person shall be deemed to have been organized on the first date of its existence by the holders of its equity interests at such time.</font></div><div style="margin-top:11pt;padding-right:10.8pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.4&#160;&#160;&#160;&#160;Definitions.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> The following terms are defined in the Sections or subsections referenced opposite such terms&#58; </font></div><div style="padding-right:10.8pt;text-indent:36pt"><font><br></font></div><div style="padding-left:72.9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.884%"><tr><td style="width:1.0%"></td><td style="width:53.220%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.580%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Preamble</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Approved Lender</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 12.1</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Borrower</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Preamble</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 12.2</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Collateral Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Preamble</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Collateral Agent Report&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit B, Section 5</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Communications</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 10</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Connection Income Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit C, Section 1</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Default Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 2.3(b)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Preamble</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Event of Default</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 8</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Excluded Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit C, Section 1</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">FATCA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit C, Section 1</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Good Faith Deposit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 2.4(d)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Indemnified Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 12.2</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Indemnified Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit C, Section 1</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Lender</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Lenders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Preamble</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Lender Transfer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 12.1</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:72.9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.884%"><tr><td style="width:1.0%"></td><td style="width:53.220%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.580%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">New Subsidiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 6.10</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Non-Funding Lender</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit B, Section 10(c)(ii)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Other Connection Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit C, Section 1</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Other Lender</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit B, Section 10(c)(ii)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Other Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit C, Section 1</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Participant Register</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 12.1</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Perfection Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Perfection Certificates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 5.1</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Recipient</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit C, Section 1</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Register</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 12.1</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SLR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Preamble</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Term A Loan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section&#160;2.2(a)(i)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Term B Loan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section&#160;2.2(a)(ii)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Term Loan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section&#160;2.2(a)(ii)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Termination Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit B, Section 8</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Transfer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 7.1</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">U.S. Tax Compliance Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit C, Section 7(b)(ii)(C)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Withholding Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit C, Section 1</font></td></tr></table></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In addition to the terms defined elsewhere in this Agreement, the following terms have the following meanings&#58;</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Account</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; is any &#8220;account&#8221; as defined in the Code with such additions to such term as may hereafter be made under the Code, and includes, without limitation, all accounts receivable and other sums owing to Borrower.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Account Debtor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; is any &#8220;account debtor&#8221; as defined in the Code with such additions to such term as may hereafter be made under the Code.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ACH Letter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; is an ACH debit authorization in the form of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit G</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereto.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Acquisition Consideration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall mean the purchase consideration for a Permitted Acquisition and all other payments, directly or indirectly, by Borrower or any of its Subsidiaries in exchange for, or as part of, or in connection with, a Permitted Acquisition, whether paid in cash or by exchange of equity interests or of properties or otherwise and whether payable at or prior to the consummation of a Permitted Acquisition or deferred for payment at any future time, whether or not any such future payment is subject to the occurrence of any contingency, and includes any and all payments representing the purchase price and any assumptions of Indebtedness, &#8220;earnouts&#8221; and other agreements to make any payment the amount of which is, or the terms of payment of which are, in any respect subject to or contingent upon the revenues, income, cash flow or profits (or the like) of any person or business&#59; provided that any such future payment that is subject to a contingency shall be considered Acquisition Consideration only to the extent of the reserve, if any, required under GAAP (as determined at the time of the consummation of such Permitted Acquisition) to be established in respect thereof by the Borrower or any of its Subsidiaries.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; of any Person is a Person that owns or controls directly or indirectly the Person, any Person that controls or is controlled by or is under common control with the Person, and each of that Person&#8217;s senior executive officers, directors, partners and, for any Person that is a limited liability company, that Person&#8217;s managers and members.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amortization Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means April 1, 2024.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Anti-Terrorism Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; are any laws relating to terrorism or money laundering, including without limitation Executive Order No. 13224 (effective September 24, 2001), the USA PATRIOT Act, the laws comprising or implementing the Bank Secrecy Act, and the laws administered by OFAC.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Applicable FDA Threshold</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the greater of (a) One Million Dollars ($1,000,000), and (b) as of any date of determination, ten percent (10%) of the Borrower&#8217;s and its Subsidiaries&#8217; consolidated revenues for the trailing twelve months ending as of the last day of the month immediately prior to such date of determination.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Applicable</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a per annum interest rate equal to the greater of (a) one tenth percent (0.10%) and (b) the rate per annum rate published by the Intercontinental Exchange Benchmark Administration Ltd. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) (or on any successor or substitute page of such Service, or any successor to or substitute for such Service, as determined by Collateral Agent in a manner consistent with other loans in Collateral Agent&#8217;s portfolio) for a term of one month, which determination by Collateral Agent shall be conclusive in the absence of manifest error&#59; provided that if, at any time, Lenders notify Collateral Agent that Lenders have determined that (x) Lenders are unable to determine or ascertain such rate, (y) the applicable regulator has made public statements to the effect that the rate published by the Service is no longer used for determining interest rates for loans or (z) by reason of circumstances affecting the foreign exchange and interbank markets generally, deposits in eurodollars in the applicable amounts or for the relative maturities are not being offered for such period, then the Applicable Rate shall be equal to an alternate benchmark rate and spread agreed between Collateral Agent and Borrowers (which may include SOFR, to the extent publicly available quotes of SOFR exist at the relevant time), giving due consideration to (i) market convention or (ii) selection, endorsement or recommendation by a Relevant Governmental Body.  Such alternative benchmark rate and spread shall be binding unless the Required Lenders object within five (5) days following notification of such amendment.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Approved Fund</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; is any (i) investment company, fund, trust, securitization vehicle or conduit that is (or will be) engaged in making, purchasing, holding or otherwise investing in commercial loans and similar extensions of credit in the ordinary course of its business or (ii) any Person (other than a natural person) which temporarily warehouses loans for any Lender or any entity described in the preceding clause (i) and that, with respect to each of the preceding clauses (i) and (ii), is administered or managed by (a) a Lender, (b) an Affiliate of a Lender or (c) a Person (other than a natural person) or an Affiliate of a Person (other than a natural person) that administers or manages a Lender.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Blocked Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; is any Person&#58; (a) listed in the annex to, or is otherwise subject to the provisions of, Executive Order No. 13224, (b) a Person owned or controlled by, or acting for or on behalf of, any Person that is listed in the annex to, or is otherwise subject to the provisions of, Executive Order No. 13224, (c) a Person with which any Lender is prohibited from dealing or otherwise engaging in any transaction by any Anti-Terrorism Law, (d) a Person that commits, threatens or conspires to commit or supports &#8220;terrorism&#8221; as defined in Executive Order No. 13224, or (e) a Person that is named a &#8220;specially designated national&#8221; or &#8220;blocked person&#8221; on the most current list published by OFAC or other similar list.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Borrower&#8217;s Books</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; are Borrower&#8217;s or any of its Subsidiaries&#8217; books and records including ledgers, federal and state tax returns, records regarding Borrower&#8217;s or its Subsidiaries&#8217; assets or liabilities, the Collateral, business operations or financial condition, and all computer programs or storage or any equipment containing such information.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Business Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; is any day that is not a Saturday, Sunday or a day on which commercial banks in New York, New York are required or authorized to be closed.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Cash Equivalents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; are (a) marketable direct obligations issued or unconditionally guaranteed by the United States or any agency or any State thereof having maturities of not more than one (1) year from the date of acquisition&#59; (b) commercial paper maturing no more than one (1) year after its creation and having the highest rating from either Standard &#38; Poor&#8217;s Ratings Group or Moody&#8217;s Investors Service, Inc., (c) certificates of deposit maturing no more than one (1) year after issue provided that the account in which any such certificate of deposit is maintained is subject to a Control Agreement in favor of Collateral Agent, and (d) any money market or similar funds under Borrower&#8217;s investment policy, as approved by Collateral Agent and the Lenders from time to time.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; is the Uniform Commercial Code, as the same may, from time to time, be enacted and in effect in the State of New York&#59; provided, that, to the extent that the Code is used to define any term herein or in any Loan Document and such term is defined differently in different Articles or Divisions of the Code, the definition of such term contained in Article or Division 9 shall govern&#59; provided further, that in the event that, by reason of mandatory provisions of law, any or all of the attachment, perfection, or priority of, or remedies with respect to, Collateral Agent&#8217;s Lien on any Collateral is governed by the Uniform Commercial Code in effect in a jurisdiction other than the State of New York, the term &#8220;Code&#8221; shall mean the Uniform Commercial Code as enacted and in effect in such other jurisdiction solely for purposes of the provisions thereof relating to such attachment, perfection, priority, or remedies and for purposes of definitions relating to such provisions.</font></div><div style="margin-top:11pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Collateral</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; is any and all properties, rights and assets of Borrower described on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"> </font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Collateral Account</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; is any Deposit Account, Securities Account, or Commodity Account, or any other bank account maintained by Borrower or any Subsidiary at any time.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Collateral Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; is SLR, not in its individual capacity, but solely in its capacity as collateral agent on behalf of and for the ratable benefit of the Secured Parties.</font></div><div style="margin-top:11pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Commitment Percentage</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; is set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, as amended from time to time.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Commodity Account</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; is any &#8220;commodity account&#8221; as defined in the Code with such additions to such term as may hereafter be made under the Code.</font></div><div style="margin-top:11pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Compliance Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; is that certain certificate in substantially the form attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit E</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"> </font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Contingent Obligation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; is, for any Person, any direct or indirect liability, contingent or not, of that Person for (a) any indebtedness, lease, dividend, letter of credit or other obligation of another such as an obligation directly or indirectly guaranteed, endorsed, co-made, discounted or sold with recourse by that Person, or for which that Person is directly or indirectly liable&#59; (b) any obligations for undrawn letters of credit for the account of that Person&#59; and (c) all obligations from any interest rate, currency or commodity swap agreement, interest rate cap or collar agreement, or other agreement or arrangement designated to protect a Person against fluctuation in interest rates, currency exchange rates or commodity prices&#59; but &#8220;Contingent Obligation&#8221; does not include endorsements in the ordinary course of business. The amount of a Contingent Obligation is the stated or determined amount of the primary obligation for which the Contingent Obligation is made or, if not determinable, the maximum reasonably anticipated liability for it determined by the Person in good faith in accordance with GAAP&#59; but the amount may not exceed the maximum of the obligations under any guarantee or other support arrangement.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Control Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; is any control agreement entered into among the depository institution at which Borrower or any of its Subsidiaries maintains a Deposit Account or the securities intermediary or commodity intermediary at which Borrower or any of its Subsidiaries maintains a Securities Account or a Commodity Account, Borrower or such Subsidiary, as applicable, and Collateral Agent pursuant to which Collateral Agent, for the ratable benefit of the Secured Parties, obtains &#8220;control&#8221; (within the meaning of the Code) over such Deposit Account, Securities Account, or Commodity Account.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Convertible Indebtedness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means Indebtedness of the Borrower that is (i) either (A) Subordinated Debt or (B) unsecured Indebtedness that is not-cross defaulted to the Obligations and (ii) convertible into equity securities of the Borrower.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Copyrights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; are any and all copyright rights, copyright applications, copyright registrations and like protections in each work of authorship and derivative work thereof, whether published or unpublished and whether or not the same also constitutes a trade secret.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Default</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; is any event that, with the giving of notice or passage of time or both, would constitute an Event of Default.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">4</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Deposit Account</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; is any &#8220;deposit account&#8221; as defined in the Code with such additions to such term as may hereafter be made under the Code.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Disclosure Schedules</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; the disclosure schedules to this Agreement, as amended or supplemented from time to time by Borrower with the written consent of the Required Lenders (or as supplemented by Borrower pursuant to the terms of the Loan Documents), delivered by Borrower to the Lenders.</font></div><div style="margin-top:11pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Dollars</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">dollars</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; and &#8220;$&#8221; each mean lawful money of the United States. </font></div><div style="margin-top:11pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Domestic Subsidiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; is any Subsidiary that is not a Foreign Subsidiary.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Eligible Assignee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; is (i) a Lender, (ii) an Affiliate of a Lender, (iii) an Approved Fund and (iv) any commercial bank, savings and loan association or savings bank or any other entity which is an &#8220;accredited investor&#8221; (as defined in Regulation D under the Securities Act of 1933, as amended) and which extends credit or buys loans as one of its businesses, including insurance companies, mutual funds, lease financing companies and commercial finance companies, in each case, which either (A) has a rating of BBB or higher from Standard &#38; Poor&#8217;s Rating Group and a rating of Baa2 or higher from Moody&#8217;s Investors Service, Inc. at the date that it becomes a Lender or (B) has total assets in excess of Two Billion Five Hundred Million Dollars ($2,500,000,000.00), and in each case of clauses (i) through (iv), which, through its applicable lending office, is capable of lending to Borrower without the imposition of any withholding or similar taxes&#59; provided that notwithstanding the foregoing, &#8220;Eligible Assignee&#8221; shall not include, unless an Event of Default has occurred and is continuing, (i) Borrower or any of Borrower&#8217;s Affiliates or Subsidiaries or (ii) a direct competitor of Borrower, a vulture hedge fund or a distressed debt fund, each as determined by Collateral Agent in its reasonable discretion. Notwithstanding the foregoing, (x) in connection with any assignment made by a Lender as a result of a forced divestiture at the request of any regulatory agency, the restrictions set forth herein shall not apply and Eligible Assignee shall mean any Person or party and (y) in connection with a Lender&#8217;s own financing or securitization transactions, the restrictions set forth herein shall not apply and Eligible Assignee shall mean any Person or party providing such financing or formed to undertake such securitization transaction and any transferee of such Person or party upon the occurrence of a default, event of default or similar occurrence with respect to such financing or securitization transaction&#59; provided that no such sale, transfer, pledge or assignment under this clause (y) shall release such Lender from any of its obligations hereunder or substitute any such Person or party for such Lender as a party hereto until Collateral Agent shall have received and accepted an effective assignment agreement from such Person or party in form satisfactory to Collateral Agent executed, delivered and fully completed by the applicable parties thereto, and shall have received such other information regarding such Eligible Assignee as Collateral Agent reasonably shall require.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Equipment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; is all &#8220;equipment&#8221; as defined in the Code with such additions to such term as may hereafter be made under the Code, and includes without limitation all machinery, fixtures, goods, vehicles (including motor vehicles and trailers), and any interest in any of the foregoing.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ERISA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; is the Employee Retirement Income Security Act of 1974, as amended, and its regulations.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exigent Circumstance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any event or circumstance that, in the reasonable judgment of Collateral Agent, imminently threatens the ability of Collateral Agent to realize upon all or any material portion of the Collateral, such as, without limitation, fraudulent removal, concealment, or abscondment thereof, destruction or material waste thereof, or failure of Borrower or any of its Subsidiaries after reasonable demand to maintain or reinstate adequate casualty insurance coverage, or which, in the judgment of Collateral Agent, could reasonably be expected to result in a material diminution in value of the Collateral.</font></div><div style="margin-top:11pt;padding-right:3.6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exit Fee Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means that certain Exit Fee Agreement, dated as of the date hereof, by and among Collateral Agent, as agent, Lenders and Borrower, as amended, amended and restated, supplemented or otherwise modified from time to time.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">FDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the U.S. Food and Drug Administration or any successor thereto.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">5</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Fee Letter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means that certain Fee Letter, dated the date hereof, by and among Collateral Agent, as agent, Lenders and Borrower, as amended, amended and restated, supplemented or otherwise modified from time to time.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Foreign Subsidiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; is a Subsidiary that is not an entity organized under the laws of the United States or any state thereof or the District of Columbia.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Funding Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; is any date on which a Term Loan is made to or on account of Borrower which shall be a Business Day.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">GAAP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; is generally accepted accounting principles set forth in the opinions and pronouncements of the Accounting Principles Board of the American Institute of Certified Public Accountants and statements and pronouncements of the Financial Accounting Standards Board or in such other statements by such other Person as may be approved by a significant segment of the accounting profession in the United States, which are applicable to the circumstances as of the date of determination&#59; provided that for purposes of the defined term &#8220;Permitted Indebtedness,&#8221; GAAP shall be GAAP as in effect on the Effective Date.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">General Intangibles</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; are all &#8220;general intangibles&#8221; as defined in the Code in effect on the date hereof with such additions to such term as may hereafter be made under the Code, and includes without limitation, all copyright rights, copyright applications, copyright registrations and like protections in each work of authorship and derivative work, whether published or unpublished, any patents, trademarks, service marks and, to the extent permitted under applicable law, any applications therefor, whether registered or not, any trade secret rights, including any rights to unpatented inventions, payment intangibles, royalties, contract rights, goodwill, franchise agreements, purchase orders, customer lists, route lists, telephone numbers, domain names, claims, income and other tax refunds, security and other deposits, options to purchase or sell real or personal property, rights in all litigation presently or hereafter pending (whether in contract, tort or otherwise), insurance policies (including without limitation key man, property damage, and business interruption insurance), payments of insurance and rights to payment of any kind.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Governmental Approval</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; is any consent, authorization, approval, order, license, franchise, permit, certificate, accreditation, registration, filing or notice, of, issued by, from or to, or other act by or in respect of, any Governmental Authority.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Governmental Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; is any federal, state, municipal, national or other government, governmental department, commission, board, bureau, court, agency or instrumentality or political subdivision thereof (including the FDA) or any entity exercising executive, legislative, judicial, regulatory or administrative functions of or pertaining to any government or any court, in each case whether associated with a state or locality of the United States, the United States, or a foreign government.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Guarantor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; is any Person providing a Guaranty in favor of Collateral Agent for the benefit of the Secured Parties (including without limitation pursuant to Section 6.10).</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Guaranty</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; is any guarantee of all or any part of the Obligations, as the same may from time to time be amended, restated, modified or otherwise supplemented.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Healthcare Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means all laws, rules and regulations relating to the provision or payment of health items and services applicable to the Borrower or its Subsidiaries, including, without limitation, (a) all federal and state fraud and abuse laws, including, without limitation, the federal Anti-Kickback Statute (42 U.S.C. &#167;1320a-7b(b)), the Civil False Claims Act (31 U.S.C. &#167;3729 et seq.), the criminal false statements law (42 U.S.C. &#167; 1320a-7b(a)), all criminal laws relating to health care fraud and abuse, including but not limited to 18 U.S.C. Sections 286, 287, 1347 and 1349, and the health care fraud criminal provisions under the U.S. Health Insurance Portability and Accountability Act of 1996 (42 U.S.C. Section 1320d et seq.), any applicable state fraud and abuse prohibitions, including those that apply to all payors (governmental, commercial insurance and self-payors), the civil monetary penalty laws (42 U.S.C. &#167; 1320a-7a), the exclusion laws (42 U.S.C. &#167; 1320a-7), and any similar state laws or regulations, and (b) any laws relating to any governmental healthcare program, including, without </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">6</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">limitation, the Medicare statute (Title XVIII of the Social Security Act) and the Medicaid statute (Title XIX of the Social Security Act), each of (a) through (b) as may be amended from time to time.</font></div><div style="margin-top:11pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Hyperphosphatemia</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means elevated serum phosphorus.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Immaterial Subsidiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; is any Foreign Subsidiary that holds assets worth less than One Hundred Thousand Dollars ($100,000) in book value.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Indebtedness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; is (a) indebtedness for borrowed money or the deferred price of property or services, such as reimbursement and other obligations for surety bonds and letters of credit, (b) obligations evidenced by notes, bonds, debentures or similar instruments, (c) capital lease obligations, and (d) Contingent Obligations.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Insolvency Proceeding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; is any proceeding by or against any Person under the United States Bankruptcy Code, or any other bankruptcy or insolvency law, including assignments for the benefit of creditors, compositions or proceedings seeking reorganization, arrangement, or other relief.</font></div><div style="margin-top:11pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Insolvent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means not Solvent.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means all of Borrower&#8217;s or any of its Subsidiaries&#8217; right, title and interest in and to the following&#58;</font></div><div style="margin-top:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;its Copyrights, Trademarks and Patents&#59;</font></div><div style="margin-top:11pt;padding-right:10.8pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;any and all trade secrets and trade secret rights, including, without limitation, any rights to unpatented inventions, know-how, operating manuals&#59;</font></div><div style="margin-top:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;any and all source code&#59;</font></div><div style="margin-top:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;any and all design rights which may be available to Borrower&#59;</font></div><div style="margin-top:11pt;padding-right:3.6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)&#160;&#160;&#160;&#160;any and all claims for damages by way of past, present and future infringement of any of the foregoing, with the right, but not the obligation, to sue for and collect such damages for said use or infringement of the Intellectual Property rights identified above&#59; and</font></div><div style="margin-top:11pt;padding-right:32.4pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(f)&#160;&#160;&#160;&#160;all amendments, renewals and extensions of any of the Copyrights, Trademarks or Patents.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Internal Revenue Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the Internal Revenue Code of 1986, as amended, and the Treasury Regulations adopted thereunder.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Inventory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; is all &#8220;inventory&#8221; as defined in the Code in effect on the date hereof with such additions to such term as may hereafter be made under the Code, and includes without limitation all merchandise, raw materials, parts, supplies, packing and shipping materials, work in process and finished products, including without limitation such inventory as is temporarily out of any Person&#8217;s custody or possession or in transit and including any returned goods and any documents of title representing any of the above.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Investment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; is any beneficial ownership interest in any Person (including stock, partnership interest or other securities), and any loan, advance or capital contribution to any Person.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">IRS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the United States Internal Revenue Service.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Key Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; is each of Borrower&#8217;s (i) Chief Executive Officer, who is Mike Raab as of the Effective Date and (ii) Chief Financial Officer, who is Justin Renz as of the Effective Date.</font></div><div style="margin-top:11pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Lender</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; is any one of the Lenders.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">7</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Lenders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; are the Persons identified on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereto and each assignee that becomes a party to this Agreement pursuant to Section 12.1.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Lenders&#8217; Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; are (a) all reasonable audit fees and expenses, costs, and expenses (including reasonable attorneys&#8217; fees and expenses, as well as appraisal fees, fees incurred on account of lien searches, inspection fees, and filing fees) for preparing, amending, negotiating and administering the Loan Documents, and (b) all fees and expenses (including attorneys&#8217; fees and expenses , as well as appraisal fees, fees incurred on account of lien searches, inspection fees, and filing fees) for defending and enforcing the Loan Documents (including, without limitation, those incurred in connection with appeals or Insolvency Proceedings) or otherwise incurred by Collateral Agent and&#47;or the Lenders in connection with the Loan Documents. </font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Lien</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; is a claim, mortgage, deed of trust, levy, charge, pledge, security interest, or other encumbrance of any kind, whether voluntarily incurred or arising by operation of law or otherwise against any property.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Loan Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; are, collectively, this Agreement, the Fee Letter, the Exit Fee Agreement, each Control Agreement, the Perfection Certificates, the Disclosure Schedules, each Compliance Certificate, the ACH Letter, each Loan Payment Request Form, any Guarantees, any subordination agreements, any note, or notes or guaranties executed by Borrower or any other Person, any agreements creating or perfecting rights in the Collateral (including all insurance certificates and endorsements, landlord consents and bailee consents) and any other present or future agreement entered into by Borrower, any Guarantor or any other Person for the benefit of the Lenders and Collateral Agent, as applicable, in connection with this Agreement&#59; all as amended, restated, or otherwise modified.</font></div><div style="margin-top:11pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Loan Payment Request Form</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; is that certain form attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit D</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"> </font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Material Adverse Change</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; is (a) a material adverse change in the business, operations or financial condition of Borrower and its Subsidiaries, when taken as a whole&#59; or (b) a material impairment of (i) the ability of Borrower and Guarantors to repay any portion of the Obligations, (ii) the legality, validity or enforceability of any Loan Document, (iii) the rights and remedies of Collateral Agent or Lenders under any Loan Document except as the result of the action or inaction of the Collateral Agent or Lenders or (iv) the validity, perfection or priority of any Lien in favor of Collateral Agent for the benefit of the Secured Parties on any of the Collateral except as the result of the action or inaction of the Collateral Agent or Lenders.  For the avoidance of doubt, &#8220;Material Adverse Change&#8221; shall not include, in and of themselves, the non-occurrence of any of the events described under the &#8220;Term B Milestone&#8221;.  </font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Material Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; is (i) as long as Borrower is a publicly reporting entity under the Securities Exchange Act of 1934, any license, agreement or other contractual arrangement required to be disclosed (including amendments thereto) under regulations promulgated under the Securities Act of 1933 or Securities Exchange Act of 1934, as each may be amended, or (ii) if Borrower is not such a publicly reporting entity, any license, agreement or other contractual arrangement whereby Borrower or any of its Subsidiaries is reasonably likely to be required to transfer, either in-kind or in cash, prior to the Maturity Date, assets or property valued (book or market) at more than One Million Dollars ($1,000,000) per year.</font></div><div style="margin-top:11pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Maturity Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; is, for each Term Loan, March 1, 2027.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Net Product Revenue</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the revenue, determined in accordance with GAAP, from the sale of any products of Borrower or its Subsidiaries, inclusive of Borrower&#8217;s share of sales generated indirectly through the sales of Borrower&#8217;s products under any licensing or similar arrangement and which amounts are included in the net product revenue of Borrower in accordance with GAAP.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; are all of Borrower&#8217;s obligations to pay when due any debts, principal, interest, Lenders&#8217; Expenses, the Prepayment Premium, all fees under the Fee Letter, and any other amounts Borrower owes the Collateral Agent or the Lenders now or later, in connection with, related to, following, or arising from, out of or under, this Agreement or, the other Loan Documents (other than the Exit Fee Agreement and any fees payable thereunder), and including interest accruing after Insolvency Proceedings begin (whether or not allowed) and debts, liabilities, or obligations of Borrower assigned to the Lenders and&#47;or Collateral Agent in connection with this Agreement and the other Loan Documents </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">8</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(other than the Exit Fee Agreement), and the performance of Borrower&#8217;s duties under the Loan Documents (other than the Exit Fee Agreement and any fees payable thereunder).</font></div><div style="margin-top:11pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">OFAC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; is the U.S. Department of Treasury Office of Foreign Assets Control.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">OFAC Lists</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; are, collectively, the Specially Designated Nationals and Blocked Persons List maintained by OFAC pursuant to Executive Order No. 13224, 66 Fed. Reg. 49079 (Sept. 25, 2001) and&#47;or any other list of terrorists or other restricted Persons maintained pursuant to any of the rules and regulations of OFAC or pursuant to any other applicable Executive Orders.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Operating Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; are, for any Person, such Person&#8217;s formation documents, as certified by the Secretary of State (or equivalent agency) of such Person&#8217;s jurisdiction of organization on a date that is no earlier than thirty (30) days prior to the Effective Date, and, (a) if such Person is a corporation, its bylaws in current form, (b) if such Person is a limited liability company, its limited liability company agreement (or similar agreement), and (c) if such Person is a partnership, its partnership agreement (or similar agreement), each of the foregoing with all current amendments or modifications thereto.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means all patents, patent applications and like protections including without limitation improvements, divisions, continuations, renewals, reissues, extensions and continuations-in-part of the same.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Payment Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; is the first (1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">) calendar day of each calendar month, commencing on April 1, 2022.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Permitted Acquisition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any consensual transaction or series of related transactions for the direct or indirect (a) acquisition of all or substantially all of the property of any Person, or of any business or division of any Person, (b) acquisition of greater than ninety percent (90.0%) of the equity interests of any Person, and otherwise causing such person to become a Subsidiary of such Person, (c) merger or consolidation or any other combination with any Person or (d) the acquisition of any Intellectual Property and related ancillary rights or assets of any person, if each of the following conditions is met&#58;</font></div><div style="margin-top:11pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.63pt">no Default or Event of Default exists immediately prior thereto, and no Default or Event of Default would immediately result therefrom&#59;</font></div><div style="margin-top:11pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.58pt">the Person, business or asset to be acquired (other than non-core assets, if any, with respect to such acquisition) shall be, or shall be engaged in, a business of the type that the Borrower is then permitted to be engaged in and the property acquired in connection with any such transaction shall be made subject to the Lien of the Loan Documents to the extent required in accordance with Section 6.10 and shall be free and clear of any Liens (other than Permitted Liens)&#59;</font></div><div style="margin-top:11pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:19.53pt">the Borrower shall be, after taking into account the payment of the Acquisition Consideration, in compliance with Section 7.13&#59;</font></div><div style="margin-top:11pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.13pt">the Board of Directors or other governing body of the Person to be acquired shall not have indicated its opposition to the consummation of such acquisition (which opposition has not been publicly withdrawn)&#59;</font></div><div style="margin-top:11pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">the Acquisition Consideration in respect of such acquisition is funded with cash or Permitted Investments of the Borrower or the proceeds of a cash equity contribution to any Borrower&#59;</font></div><div style="margin-top:11pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.13pt">the Acquisition Consideration shall not exceed Five Million Dollars ($5,000,000) in the aggregate for all such acquisitions, unless, in each case, funded with the proceeds of an equity contribution or convertible Indebtedness permitted hereunder received by the Borrower&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">9</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:11pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(vii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:17.08pt">on a consolidated basis, the Borrower&#8217;s and its Subsidiaries&#8217; rate of usage of cash and Cash Equivalents shall not increase as a result of such transaction by more than five percent (5%) over the forecasted rate of usage of cash and Cash Equivalents approved by the Lenders as of the Effective Date&#59; provided that the amount of such increase shall be determined net of any proceeds of equity contributions over the succeeding twenty-four (24) months raised in connection with such acquisition&#59; and</font></div><div style="margin-top:11pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(viii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.03pt">on or prior to the proposed date of consummation of such transaction, the Borrower shall have delivered to the Collateral Agent and the Lenders a certificate of a Responsible Officer of the Borrower certifying that such transaction complies with this definition.</font></div><div style="margin-top:11pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Permitted Indebtedness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; is&#58;</font></div><div style="margin-top:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;Borrower&#8217;s Indebtedness to the Lenders and Collateral Agent under this Agreement and the other Loan Documents&#59;</font></div><div style="margin-top:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;Indebtedness existing on the Effective Date and disclosed on the Disclosure Schedules&#59;</font></div><div style="margin-top:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;Subordinated Debt&#59;</font></div><div style="margin-top:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;unsecured Indebtedness to trade creditors incurred in the ordinary course of business&#59;</font></div><div style="margin-top:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)&#160;&#160;&#160;&#160;unsecured Indebtedness in connection with credit cards incurred in the ordinary course of business&#59;</font></div><div style="margin-top:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(f)&#160;&#160;&#160;&#160;Indebtedness consisting of capitalized lease obligations and purchase money Indebtedness, in each case incurred by Borrower or any of its Subsidiaries to finance the acquisition, repair, improvement or construction of fixed or capital assets of such person, provided that (i) the aggregate outstanding principal amount of all such Indebtedness does not exceed Seven Hundred Fifty Thousand Dollars ($750,000) at any time and (ii) the principal amount of such Indebtedness does not exceed the lower of the cost or fair market value of the property so acquired or built or of such repairs or improvements financed with such Indebtedness (each measured at the time of such acquisition, repair, improvement or construction is made)&#59;</font></div><div style="margin-top:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(g)&#160;&#160;&#160;&#160;Indebtedness consisting of the obligation to pay rent when due under real property leases entered into in the ordinary course of Borrower&#8217;s business&#59;</font></div><div style="margin-top:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(h)&#160;&#160;&#160;&#160;other unsecured Indebtedness at any time not to exceed Three Hundred Seventy-Five Thousand Dollars ($375,000) in the aggregate&#59;</font></div><div style="margin-top:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;reimbursement obligations in respect of letters of credit in the aggregate amount not to exceed (1) One Million Five Hundred Thousand Dollars ($1,500,000) at any time for any letters of credit with a maturity date of six (6) months or less, and (2) Five Hundred Thousand Dollars ($500,000) at any time for any letters of credit with a maturity date of six (6) months or more, in each case as incurred in the ordinary course of business&#59;</font></div><div style="margin-top:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(j)&#160;&#160;&#160;&#160;Indebtedness incurred as a result of endorsing negotiable instruments received in the ordinary course of Borrower&#8217;s business&#59;</font></div><div style="margin-top:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(k)&#160;&#160;&#160;&#160;Convertible Indebtedness in the aggregate amount not to exceed Two Hundred Million Dollars ($200,000,000) at any time&#59;</font></div><div style="margin-top:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(l)&#160;&#160;&#160;&#160;Hedges and similar transactions with respect to currency risk entered into in the ordinary course of business and not for speculative purposes&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">10</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(m)&#160;&#160;&#160;&#160;Surety bonds and similar Indebtedness entered into in the ordinary course of business and in an amount not exceeding Two Hundred Fifty Thousand Dollars ($250,000) outstanding at any time&#59; </font></div><div style="margin-top:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(n)&#160;&#160;&#160;&#160;&#8220;earnouts&#8221;, purchase price adjustments, profit sharing arrangements, deferred purchase money amounts and similar payment obligations or continuing obligations of any nature of such Person arising out of purchase and sale contracts (including any indemnification and other similar obligations incurred in an acquisition), in each case subject to the limitations in the definition of &#8220;Permitted Acquisition&#8221;&#59;</font></div><div style="margin-top:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(o)&#160;&#160;&#160;&#160;advances or deposits received in the ordinary course of business from customers or vendors&#59;</font></div><div style="margin-top:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(p)&#160;&#160;&#160;&#160;Indebtedness arising in connection with the financing of insurance premiums in an amount not exceeding Fifty Thousand Dollars ($50,000) outstanding at any time&#59; </font></div><div style="margin-top:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(q)&#160;&#160;&#160;&#160;Indebtedness incurred in the Permitted Royalty Transaction&#59; and </font></div><div style="margin-top:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(r)&#160;&#160;&#160;&#160;extensions, refinancings, modifications, amendments and restatements of any items of Permitted Indebtedness (a) through (q) above, provided that the principal amount thereof is not increased or the terms thereof are not modified to impose materially more burdensome terms upon Borrower, or its Subsidiary, as the case may be.</font></div><div style="margin-top:11pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Permitted Investments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; are&#58;</font></div><div style="margin-top:11pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;Investments disclosed on the Disclosure Schedules and existing on the Effective Date&#59;</font></div><div style="margin-top:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;(i) Investments consisting of cash and Cash Equivalents, and (ii) any Investments permitted by Borrower&#8217;s investment policy, as amended from time to time, provided that such investment policy (and any such amendment thereto) has been approved in writing by Collateral Agent&#59;</font></div><div style="margin-top:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;Investments consisting of the endorsement of negotiable instruments for deposit or collection or similar transactions in the ordinary course of Borrower&#59;</font></div><div style="margin-top:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;Investments consisting of Deposit Accounts in which Collateral Agent has a perfected Lien (subject to the terms of this Agreement) for the ratable benefit of the Secured Parties except as permitted in Section 6.6 hereof&#59;</font></div><div style="margin-top:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)&#160;&#160;&#160;&#160;Investments in connection with Permitted Indebtedness, Permitted Liens and with Transfers permitted by Section 7.1&#59;</font></div><div style="margin-top:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(f)&#160;&#160;&#160;&#160;Investments consisting of (i) travel advances and employee relocation loans and other employee loans and advances in the ordinary course of business, and (ii) loans to employees, officers or directors relating to the purchase of equity securities of Borrower or its Subsidiaries pursuant to employee stock purchase plans or agreements approved by Borrower&#8217;s board of directors&#59; not to exceed Two Hundred Thousand Dollars ($200,000) in the aggregate for (i) and (ii) in any fiscal year&#59;</font></div><div style="margin-top:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(g)&#160;&#160;&#160;&#160;Investments (including debt obligations) received in connection with the bankruptcy or reorganization of customers or suppliers and in settlement of delinquent obligations of, and other disputes with, customers or suppliers arising in the ordinary course of business&#59;</font></div><div style="margin-top:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(h)&#160;&#160;&#160;&#160;Investments consisting of notes receivable of, or prepaid royalties and other credit extensions, to customers and suppliers who are not Affiliates, in the ordinary course of business&#59; provided that this paragraph (h) shall not apply to Investments of Borrower in any Subsidiary&#59;</font></div><div style="margin-top:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;Investments in Subsidiaries that are Guarantors&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">11</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(j)&#160;&#160;&#160;&#160;Investments in Subsidiaries that are not Guarantors, the aggregate of which shall not exceed One Hundred Thousand Dollars ($100,000) per fiscal year&#59;</font></div><div style="margin-top:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(k)&#160;&#160;&#160;&#160;Permitted Acquisitions&#59; </font></div><div style="margin-top:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(l)&#160;&#160;&#160;&#160;Investments in joint ventures, corporate collaborations, or strategic alliances in the ordinary course of Borrower&#8217;s business consisting of the licensing of technology (in compliance with the definition of &#8220;Permitted Licenses&#8221;), the development of technology or the providing of technical support and provided that the aggregate amount for cash consideration for all such Investments cannot exceed Two Hundred Fifty Thousand Dollars ($250,000) per year and Seven Hundred Fifty Thousand Dollars ($750,000) in the aggregate&#59; and </font></div><div style="margin-top:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(m)&#160;&#160;&#160;&#160;other Investments not to exceed One Hundred Thousand Dollars ($100,000) in the aggregate outstanding at any time.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Permitted Licenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; are (A) licenses of over-the-counter software that is commercially available to the public, (B) non-exclusive licenses for the use of the Intellectual Property of Borrower or any of its Subsidiaries entered into in the ordinary course of business, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that, with respect to each such license described in clause (B), the license constitutes an arms-length transaction, the terms of which, on their face, do not provide for a sale or assignment of any Intellectual Property and do not restrict the ability of Borrower or any of its Subsidiaries, as applicable, to pledge, grant a security interest in or lien on, or assign or otherwise Transfer any Intellectual Property, (C) exclusive licenses for the use of the Intellectual Property of Borrower or any of its Subsidiaries entered into in the ordinary course of business, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that, with respect to each such license described in this clause (C), the license (i) constitutes an arms-length transaction, the terms of which, on their face, do not provide for a sale or assignment of any Intellectual Property and do not restrict the ability of Borrower or any of its Subsidiaries, as applicable, to pledge, grant a security interest in or lien on, or assign or otherwise Transfer any Intellectual Property, (ii) is limited in territory with respect to a specific geographic country or region (i.e. Japan, Germany, northern China) outside of the United States, and (iii) Borrower has used commercially reasonable efforts to obtain the consent and acknowledgment of the counterparty to such license for the collateral assignment of such license to the Collateral Agent for the benefit of the Lenders, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">(D) exclusive licenses for the use of the Intellectual Property of Borrower or any of its Subsidiaries (excluding such Intellectual Property related to treatment of Hyperphosphatemia) in the United States entered into in the ordinary course of business, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">, that, with respect to each such license described in this clause (D), the license (i) constitutes an arms-length transaction, the terms of which, on their face, do not provide for a sale or assignment of any Intellectual Property and do not restrict the ability of Borrower or any of its Subsidiaries, as applicable, to pledge, grant a security interest in or lien on, or assign or otherwise Transfer any Intellectual Property, (ii) Borrower has used commercially reasonable efforts to obtain the consent and acknowledgment of the counterparty to such license for the collateral assignment of such license to the Collateral Agent for the benefit of the Lenders, and (iii) Borrower shall have obtained the prior written consent of the Required Lenders to enter into such license, (E) exclusive licenses for the use in the United States of the Intellectual Property of Borrower or any of its Subsidiaries related to treatment of Hyperphosphatemia entered into in the ordinary course of business, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">, that, with respect to each such license described in this clause (E), the Borrower shall have obtained the prior written consent of the Required Lenders to enter into such license, and (F) licenses in connection with the Borrower&#8217;s TGR5 and FXR programs.</font></div><div style="margin-top:11pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Permitted Liens</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; are&#58;</font></div><div style="margin-top:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;Liens existing on the Effective Date and disclosed on the Disclosure Schedules or arising under this Agreement and the other Loan Documents&#59;</font></div><div style="margin-top:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;Liens for taxes, fees, assessments or other government charges or levies, either (i) not due and payable or (ii) being contested in good faith and for which Borrower maintains adequate reserves on its Books in accordance with GAAP, provided that no notice of any such Lien has been filed or recorded in favor of the United States Treasury in accordance with the applicable provisions of the Internal Revenue Code&#59;</font></div><div style="margin-top:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;Liens securing Indebtedness permitted under clause (f) of the definition of &#8220;Permitted Indebtedness,&#8221; provided that (i) such liens exist prior to the acquisition of, or attach </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">12</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">substantially simultaneous with, or within twenty (20) days after the, acquisition, lease, repair, improvement or construction of, such property financed or leased by such Indebtedness and (ii) such liens do not extend to any property of Borrower other than the property (and proceeds thereof) acquired, leased or built, or the improvements or repairs, financed by such Indebtedness&#59;</font></div><div style="margin-top:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;Liens of carriers, warehousemen, suppliers, or other Persons that are possessory in nature arising in the ordinary course of business so long as such Liens attach only to Inventory, securing liabilities in the aggregate amount not to exceed Two Hundred Fifty Thousand Dollars ($250,000), and which are not delinquent or remain payable without penalty or which are being contested in good faith and by appropriate proceedings which proceedings have the effect of preventing the forfeiture or sale of the property subject thereto&#59;</font></div><div style="margin-top:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)&#160;&#160;&#160;&#160;Liens to secure payment of workers&#8217; compensation, employment insurance, old-age pensions, social security and other like obligations incurred in the ordinary course of business (other than Liens imposed by ERISA)&#59;</font></div><div style="margin-top:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(f)&#160;&#160;&#160;&#160;Liens incurred in the extension, renewal or refinancing of the indebtedness secured by Liens described in (a) through (c), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">but</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> any extension, renewal or replacement Lien must be limited to the property encumbered by the existing Lien and the principal amount of the indebtedness may not increase&#59;</font></div><div style="margin-top:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(g)&#160;&#160;&#160;&#160;leases or subleases of real property granted in the ordinary course of Borrower&#8217;s business (or, if referring to another Person, in the ordinary course of such Person&#8217;s business), and leases, subleases, non-exclusive licenses or sublicenses of personal property (other than Intellectual Property) granted in the ordinary course of Borrower&#8217;s business (or, if referring to another Person, in the ordinary course of such Person&#8217;s business), if the leases, subleases, licenses and sublicenses do not prohibit granting Collateral Agent or any Lender a security interest therein&#59;</font></div><div style="margin-top:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(h)&#160;&#160;&#160;&#160;banker&#8217;s liens, rights of setoff and Liens in favor of financial institutions incurred in the ordinary course of business arising in connection with Borrower&#8217;s deposit accounts or securities accounts held at such institutions solely to secure payment of fees and similar costs and expenses and provided such accounts are maintained in compliance with Section 6.6(a) hereof&#59;</font></div><div style="margin-top:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;Liens arising from judgments, decrees or attachments in circumstances not constituting an Event of Default under Section 8.4 or 8.7&#59;</font></div><div style="margin-top:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(j)&#160;&#160;&#160;&#160;Liens on cash that stand as security for letter of credit reimbursement obligations and cash management obligations, together with such amount permitted under clause (k) of &#8220;Permitted Liens&#8221;, in the aggregate amount not to exceed One Million Dollars ($1,000,000)&#59; </font></div><div style="margin-top:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(k)&#160;&#160;&#160;&#160;security deposits under real property leases that are made in the ordinary course of business, together with such amount permitted under clause (j) of &#8220;Permitted Liens&#8221;, in the aggregate amount not to exceed One Million Dollars ($1,000,000)&#59; </font></div><div style="margin-top:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(l)&#160;&#160;&#160;&#160;to the extent constitution a Lien, escrow arrangements securing indemnification obligations associated with any Permitted Acquisition&#59; and </font></div><div style="margin-top:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(m)&#160;&#160;&#160;&#160;Permitted Licenses.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Permitted Royalty Transaction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the purchase of a royalty interest of the Borrower&#8217;s rights to research, develop and commercialize one of Borrower&#8217;s products in Japan, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> that (i) the acquisition constitutes an arms-length transaction, the terms of which, on their face, do not provide for a sale or assignment of any Intellectual Property and do not restrict the ability of Borrower or any of its Subsidiaries, as applicable, to pledge, grant a security interest in or lien on, or assign or otherwise Transfer any Intellectual Property, (ii) the transaction will be structured as a true sale with only precautionary security filings in the purchased royalty in the applicable jurisdiction, (iii) Borrower shall not grant a security interest in or lien on the underlying license agreement or any Intellectual Property and assets underlying the purchased royalty, (iv) Collateral Agent and Lenders will not be required to enter into an intercreditor or similar agreement, and (v) the royalty and sales milestone interest acquisition </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">13</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">agreement and related documents are otherwise in form and substance reasonably satisfactory, including the amount of the upfront cash proceeds received by Borrower,  to Collateral Agent and the Required Lenders.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; is any individual, sole proprietorship, partnership, limited liability company, joint venture, company, trust, unincorporated organization, association, corporation, institution, public benefit corporation, firm, joint stock company, estate, entity or government agency.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Prepayment Premium</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; is, with respect to any Term Loan subject to any prepayment prior to the Maturity Date, whether by mandatory or voluntary prepayment, acceleration or otherwise (including, but not limited to, upon the occurrence of a bankruptcy or insolvency event, an additional fee payable to the Lenders in amount equal to&#58;</font></div><div style="margin-top:11pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;for any prepayment made on or after the Effective Date through and including the first anniversary of the Effective Date, three percent (3.00%) of the principal amount of such Term Loan prepaid&#59;</font></div><div style="margin-top:11pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;for any prepayment made after the date which is after the first anniversary of the Effective Date through and including the second anniversary of the Effective Date, two percent (2.00%) of the principal amount of such Term Loan prepaid&#59; and</font></div><div style="margin-top:11pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;for any prepayment made after the date which is after the second anniversary of the Effective Date and prior to the Maturity Date, one percent (1.00%) of the principal amount of such Term Loan prepaid.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Pro Rata Share</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; is, as of any date of determination, with respect to each Lender, a percentage (expressed as a decimal, rounded to the ninth decimal place) determined by dividing the outstanding principal amount of Term Loans held by such Lender by the aggregate outstanding principal amount of all Term Loans.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any interest in any kind of property or asset, whether real, personal or mixed, and whether tangible or intangible.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Registered Organization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; is any &#8220;registered organization&#8221; as defined in the Code with such additions to such term as may hereafter be made under the Code.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Registration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any registration, authorization, approval, license, permit, clearance, certificate, and exemption issued or allowed by the FDA (including, without limitation, new drug applications, abbreviated new drug applications, biologics license applications, investigational new drug applications, over-the-counter drug monograph, device pre-market approval applications, device pre-market notifications, investigational device exemptions, product recertifications, manufacturing approvals, registrations and authorizations, CE Marks, pricing and reimbursement approvals, labeling approvals or their foreign equivalent, controlled substance registrations, and wholesale distributor permits).</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Regulatory Action</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means an administrative or regulatory enforcement action, proceeding, investigation or inspection, FDA Form 483 notice of inspectional observation, warning letter, untitled letter, other notice of violation letter, recall, seizure, Section 305 notice or other similar written communication, or consent decree, issued by the FDA.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Related Persons</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to any Person, each Affiliate of such Person and each director, officer, employee, agent, trustee, representative, attorney, accountant and each insurance, environmental, legal, financial and other advisor and other consultants and agents of or to such Person or any of its Affiliates.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Relevant Governmental Body</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the Federal Reserve Board, the Federal Reserve Bank of New York, and&#47;or a committee officially endorsed or convened by the Federal Reserve Board and&#47;or the Federal Reserve Bank of New York, or any successor thereto.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">14</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Required Lenders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means (i) for so long as all of the Persons that are Lenders on the Effective Date (each an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Original Lender</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) have not assigned or transferred any of their interests in their Term Loan other than to an Affiliate of such Lender, Lenders holding one hundred percent (100%) of the aggregate outstanding principal balance of the Term Loan, or (ii) at any time from and after any Original Lender has assigned or transferred any interest in its Term Loan, Lenders holding at least sixty six and two thirds percent (66.67%) of the aggregate outstanding principal balance of the Term Loan and, in respect of this clause (ii), (A) each Original Lender that has not assigned or transferred any portion of its Term Loan, (B) each assignee or transferee of an Original Lender&#8217;s interest in the Term Loan, but only to the extent that such assignee or transferee is an Affiliate or Approved Fund of such Original Lender, and (C) any Person providing financing to any Person described in clauses (A) and (B) above&#59; provided, however, that this clause (C) shall only apply upon the occurrence of a default, event of default or similar occurrence with respect to such financing.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Requirement of Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; is as to any Person, the organizational or governing documents of such Person, and any law (statutory or common), treaty, rule or regulation or determination of an arbitrator or a court or other Governmental Authority, in each case applicable to or binding upon such Person or any of its property or to which such Person or any of its property is subject.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Responsible Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; is any of the President, Chief Executive Officer, or Chief Financial Officer of Borrower acting alone.</font></div><div style="margin-top:11pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Secured Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the Collateral Agent and the Lenders.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Securities Account</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; is any &#8220;securities account&#8221; as defined in the Code with such additions to such term as may hereafter be made under the Code.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SOFR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the daily Secured Overnight Financing Rate provided by the Federal Reserve Bank of New York as the administrator of the benchmark (or a successor administrator) on the Federal Reserve Bank of New York&#8217;s Website.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Solvent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to any Person, that (a) the fair salable value of such Person&#8217;s consolidated assets (including goodwill minus disposition costs) exceeds the fair value of such Person&#8217;s liabilities, (b) such Person is not left with unreasonably small capital after giving effect to the transactions contemplated by this Agreement and the other Loan Documents, and (c) such Person is able to pay its debts (including trade debts) as they mature in the ordinary course.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Subordinated Debt</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; is indebtedness incurred by Borrower or any of its Subsidiaries subordinated to all Indebtedness of Borrower and&#47;or its Subsidiaries to the Lenders (pursuant to a subordination, intercreditor, or other similar agreement in form and substance satisfactory to Collateral Agent and the Required Lenders entered into between Collateral Agent, Borrower, and&#47;or any of its Subsidiaries, and the other creditor).</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Subsidiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; is, with respect to any Person, any Person of which more than fifty percent (50%) of the voting stock or other equity interests (in the case of Persons other than corporations) is owned or controlled, directly or indirectly, by such Person or through one or more intermediaries.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means all present or future taxes, levies, imposts, duties, deductions, withholdings (including backup withholding), assessments, fees or other charges imposed by any Governmental Authority, including any interest, additions to tax or penalties applicable thereto.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Tenapanor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; is an inhibitor of NHE3 with the chemical name (S)-N,N'-(10,17-dioxo-3,6,21,24-tetraoxa-9,11,16,18-tetraazahexacosane-1,26-diyl)bis(3-((S)-6,8-dichloro-2-methyl-1,2,3,4 tetrahydroisoquinolin-4-yl)benzenesulfonamide) dihydrochloride.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Term B Draw Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; is the period commencing on the date of the occurrence of the Term B Milestone and ending on July 25, 2023.  </font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Term B Milestone</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; is Collateral Agent&#8217;s receipt of satisfactory evidence that Borrower (i) has received FDA approval of Tenapanor for use in certain patients with Hyperphosphatemia on or prior to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">15</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">December 31, 2022 and (ii) has achieved a minimum of Thirty Million Dollars in Net Product Revenue calculated on a trailing six (6) month basis.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Term Loan Commitment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; is, for any Lender, the obligation of such Lender to make a Term Loan, up to the principal amount shown on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline"> </font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Term Loan Commitments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the aggregate amount of such commitments of all Lenders.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Trademarks</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any trademark and servicemark rights, whether registered or not, applications to register and registrations of the same and like protections, and the entire goodwill of the business of Borrower connected with and symbolized by such trademarks.</font></div><div style="margin-top:12.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:102%">2.&#160;&#160;&#160;&#160;LOANS AND TERMS OF PAYMENT</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.1&#160;&#160;&#160;&#160;Promise to Pay. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Borrower hereby unconditionally promises to pay each Lender, the outstanding principal amount of all Term Loans advanced to Borrower by such Lender and accrued and unpaid interest thereon and any other amounts due hereunder as and when due in accordance with this Agreement.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.2&#160;&#160;&#160;&#160;Term Loans.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Availability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. (i) Subject to the terms and conditions of this Agreement, the Lenders agree, severally and not jointly, to make term loans to Borrower on the Effective Date in an aggregate principal amount of Twenty-Seven Million Five Hundred Thousand Dollars ($27,500,000) according to each Lender&#8217;s Term A Loan Commitment as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereto (such term loans are hereinafter referred to singly as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Term A Loan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; and collectively as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Term A Loans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). After repayment, no Term A Loan may be re-borrowed.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;Subject to the terms and conditions of this Agreement, the Lenders agree, severally and not jointly, during the Term B Draw Period to make term loans to Borrower in an aggregate principal amount of Twenty-Two Million Five Hundred Thousand Dollars ($22,500,000) and disbursed in a single advance according to each Lender&#8217;s Term B Loan Commitment as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereto (such term loans are hereinafter referred to singly as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Term B Loan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; and collectively as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Term B Loans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;&#59; each Term A Loan or Term B Loan is hereinafter referred to singly as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Term Loan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; and the Term A Loans and the Term B Loans are hereinafter referred to collectively as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Term Loans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). After repayment, no Term B Loan may be re-borrowed.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Repayment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Borrower shall make monthly payments of interest only commencing on the first (1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">) Payment Date following the Funding Date of each Term Loan, and continuing on the Payment Date of each successive month thereafter through and including the Payment Date immediately preceding the Amortization Date.  Borrower agrees to pay, on the Funding Date of each Term Loan, any initial partial monthly interest payment otherwise due for the period between the Funding Date of such Term Loan and the first Payment Date after such Funding Date.  Commencing on the Amortization Date, and continuing on the Payment Date of each month thereafter, Borrower shall (i) make monthly payments of interest, to each Lender in accordance with its Pro Rata Share, as calculated by Collateral Agent (which calculations shall be deemed correct absent manifest error) based upon the effective rate of interest applicable to the Term Loan, as determined in Section 2.3(a) plus (ii) make consecutive equal monthly payments of principal to each Lender in accordance with its Pro Rata Share in accordance with their respective Pro Rata Shares, as calculated by Collateral Agent (which calculations shall be deemed correct absent manifest error) based upon&#58; (A) the respective principal amounts of such Lender&#8217;s Term Loans outstanding, and (B) a repayment schedule equal to thirty-six (36) months.  All unpaid principal and accrued and unpaid interest with respect to each such Term Loan is due and payable in full on the Maturity Date.  The Term&#160;Loans may only be prepaid in accordance with Sections 2.2(c)&#160;and 2.2(d).</font></div><div style="margin-top:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Mandatory Prepayments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. If the Term Loans are accelerated (including, but not limited to, upon the occurrence of a bankruptcy or insolvency event (including the acceleration of claims by operation of law)), Borrower shall immediately pay to Lenders, payable to each Lender in accordance </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">16</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">with its respective Pro Rata Share, an amount equal to the sum of&#58; (i) all outstanding principal of the Term Loans plus accrued and unpaid interest thereon through the prepayment date, (ii) any fees payable under the Fee Letter by reason of such prepayment, (iii) the Prepayment Premium plus (iv) all other Obligations that are due and payable, including Lenders&#8217; Expenses and interest at the Default Rate (if any) with respect to any past due amounts. Notwithstanding (but without duplication with) the foregoing, on the Maturity Date, if any fees payable under the Fee Letter by reason of such prepayments had not previously been paid in full in connection with the prepayment of the Term Loans in full, Borrower shall pay to each Lender in accordance with the terms of the Fee Letter.  The Prepayment Premium shall also be payable in the event the Obligations (and&#47;or this Agreement) are satisfied or released by foreclosure (whether by power of judicial proceeding), deed in lieu of foreclosure or by any other means. EACH BORROWER AND GUARANTOR EXPRESSLY WAIVES (TO THE FULLEST EXTENT IT MAY LAWFULLY DO SO) THE PROVISIONS OF ANY PRESENT OR FUTURE STATUTE OR LAW THAT PROHIBITS OR MAY PROHIBIT THE COLLECTION OF THE FOREGOING PREPAYMENT PREMIUM IN CONNECTION WITH ANY SUCH ACCELERATION.  Notwithstanding anything to the contrary contained herein, there shall be no Prepayment Premium due and payable by Borrower to the Lenders hereunder in connection with the voluntary prepayment by Borrower of all, but not less than all, of the outstanding Term Loans in connection with new loans made by either SLR or any Affiliate of SLR.   </font></div><div style="margin-top:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Permitted Prepayment of Term Loans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Borrower shall have the option to prepay all, but not less than all, of the outstanding principal balance of the Term Loans advanced by the Lenders under this Agreement, provided Borrower (i) provides written notice to Collateral Agent of its election to prepay the Term Loans at least five (5) Business Days prior to such prepayment, and (ii) pays to the Lenders on the date of such prepayment, payable to each Lender in accordance with its respective Pro Rata Share in accordance with their respective Pro Rata Shares, an amount equal to the sum of (A)&#160;the outstanding principal of the Term Loans plus accrued and unpaid interest thereon through the prepayment date, (B) any fees payable under the Fee Letter by reason of such prepayment, (C) the Prepayment Premium, plus (D) all other Obligations that are due and payable on such prepayment date, including any Lenders&#8217; Expenses and interest at the Default Rate (if any) with respect to any past due amounts.  </font></div><div style="margin-top:11pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.3&#160;&#160;&#160;&#160;Payment of Interest on the Term Loans.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Interest Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Subject to Section 2.3(b), the principal amount outstanding under the Term Loans shall accrue interest at a floating per annum rate equal to the Applicable Rate in effect from time to time </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">plus </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.95%, which aggregate interest rate shall be determined by Collateral Agent in accordance with the definition of &#8220;Applicable Rate&#8221; on the third Business Day prior to the Funding Date of the applicable Term Loan and on the date occurring on the first Business Day of the month prior to each Payment Date occurring thereafter, which interest shall be payable monthly in arrears in accordance with Sections 2.2(b) and 2.3(e). Except as set forth in Section 2.2(b), such interest shall accrue on each Term Loan commencing on, and including, the Funding Date of such Term Loan, and shall accrue on the principal amount outstanding under such Term Loan through and including the day on which such Term Loan is paid in full (or any payment is made hereunder).</font></div><div style="margin-top:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Default Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Immediately upon the occurrence and during the continuance of an Event of Default, all Obligations shall accrue interest at a fixed per annum rate equal to the rate that is otherwise applicable thereto plus four percentage points (4%) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Default Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). Payment or acceptance of the increased interest rate provided in this Section 2.3(b) is not a permitted alternative to timely payment and shall not constitute a waiver of any Event of Default or otherwise prejudice or limit any rights or remedies of Collateral Agent.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">360-Day Year</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Interest shall be computed on the basis of a three hundred sixty (360) day year for the actual number of days elapsed.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Debit of Accounts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Collateral Agent and each Lender may debit (or ACH) any deposit accounts, maintained by Borrower or any of its Subsidiaries for principal and interest payments or any other amounts Borrower owes the Lenders under the Loan Documents when due. Any such debits (or ACH activity) shall not constitute a set-off.</font></div><div style="margin-top:11pt;padding-left:3.6pt;text-align:justify;text-indent:68.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Except as otherwise expressly provided herein, all payments by Borrower under the Loan Documents shall be made to the respective Lender to which such payments are </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">17</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:11pt;padding-left:3.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">owed, at such Person&#8217;s office in immediately available funds on the date specified herein. Unless otherwise provided, interest is payable monthly on the Payment Date of each month. Payments of principal and&#47;or interest received after 2&#58;00 p.m. Eastern time are considered received at the opening of business on the next Business Day. When a payment is due on a day that is not a Business Day, the payment is due the next Business Day and additional fees or interest, as applicable, shall continue to accrue until paid. All payments to be made by Borrower hereunder or under any other Loan Document, including payments of principal and interest, and all fees, expenses, indemnities and reimbursements, shall be made without set-off, recoupment or counterclaim, in lawful money of the United States and in immediately available funds.  </font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.4&#160;&#160;&#160;&#160;Fees.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Borrower shall pay to Collateral Agent and&#47;or Lenders (as applicable) the following fees, which shall be deemed fully-earned and non-refundable upon payment&#58;</font></div><div style="margin-top:11pt;padding-left:3.6pt;text-align:justify;text-indent:68.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Fee Letter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  When due and payable under the terms of the Fee Letter, to Collateral Agent and each Lender, as applicable, the fees set forth in the Fee Letter. </font></div><div style="margin-top:11pt;padding-left:3.6pt;text-align:justify;text-indent:68.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Prepayment Premium</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The Prepayment Premium, when due hereunder, to be shared between the Lenders in accordance with their respective Pro Rata Shares.  Borrower expressly agrees (to the fullest extent that each may lawfully do so) that&#58; (i) the Prepayment Premium is reasonable and is the product of an arm&#8217;s length transaction between sophisticated business people, ably represented by counsel&#59; (ii) the Prepayment Premium shall be payable notwithstanding the then prevailing market rates at the time payment is made&#59; (iii) there has been a course of conduct between Collateral Agent, Lenders and Borrower giving specific consideration in this transaction for such agreement to pay the Prepayment Premium and (iv) Borrower shall be estopped hereafter from claiming differently than as agreed to in this paragraph. Borrower expressly acknowledges that its agreement to pay the Prepayment Premium to Lenders as herein described is a material inducement to Lenders to provide the Term Loan Commitments and make the Term Loans.</font></div><div style="margin-top:11pt;padding-left:3.6pt;text-align:justify;text-indent:68.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Lenders&#8217; Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  All Lenders&#8217; Expenses (including reasonable attorneys&#8217; fees and expenses for documentation and negotiation of this Agreement) incurred through and after the Effective Date, when due.</font></div><div style="margin-top:11pt;padding-left:3.6pt;text-align:justify;text-indent:68.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Good Faith Deposit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Borrower has paid to SLR a deposit of Fifty Thousand Dollars ($50,000) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Good Faith Deposit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), to initiate Collateral Agent&#8217;s and Lenders&#8217; due diligence review and documentation process.  The Good Faith Deposit shall be utilized to pay Lenders&#8217; Expenses, with the remainder, if any, to pay a portion of the facility fee due in accordance with Section 1 of the Fee Letter.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.5&#160;&#160;&#160;&#160;Taxes&#59; Increased Costs.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Borrower, Collateral Agent and the Lenders each hereby agree to the terms and conditions set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> attached hereto.</font></div><div style="margin-top:12.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:102%">3.&#160;&#160;&#160;&#160;CONDITIONS OF LOANS</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.1&#160;&#160;&#160;&#160;Conditions Precedent to Initial Term Loan.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Each Lender&#8217;s obligation to make a Term A Loan is subject to the condition precedent that Collateral Agent and each Lender shall consent to or shall have received, in form and substance satisfactory to Collateral Agent and each Lender, such documents, and completion of such other matters, as Collateral Agent and each Lender may reasonably deem necessary or appropriate, including, without limitation&#58;</font></div><div style="margin-top:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;original Loan Documents, each duly executed by Borrower and each Subsidiary, as applicable&#59;</font></div><div style="margin-top:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;a completed Perfection Certificate for Borrower and each of its Subsidiaries and Disclosure Schedules for Borrower and each Guarantor&#59;</font></div><div style="margin-top:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;duly executed Control Agreements with respect to Collateral Accounts maintained by Borrower or any of its Subsidiaries to the extent required under Section 6.6&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">18</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;a duly executed Fee Letter&#59;</font></div><div style="margin-top:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)&#160;&#160;&#160;&#160;the Operating Documents and good standing certificates of Borrower and its Subsidiaries certified by the Secretary of State (or equivalent agency) of Borrower&#8217;s and such Subsidiaries&#8217; jurisdiction of organization or formation and each jurisdiction in which Borrower and each Subsidiary is qualified to conduct business, each as of a date no earlier than thirty (30) days prior to the Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#59;</font></div><div style="margin-top:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(f)&#160;&#160;&#160;&#160;a certificate of Borrower in substantially the form of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit F</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereto executed by the Secretary of Borrower with appropriate insertions and attachments, including with respect to (i) the Operating Documents of such Person (which Certificate of Incorporation or Certificate of Formation of such Person shall be certified by the Secretary of State of the State of Delaware) and (ii) the resolutions adopted by such Person&#8217;s board of directors or other governing body for the purpose of approving the transactions contemplated by the Loan Documents&#59;</font></div><div style="margin-top:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(g)&#160;&#160;&#160;&#160;certified copies, dated as of date no earlier than thirty (30) days prior to the Effective Date, of financing statement searches, as Collateral Agent shall request, accompanied by written evidence (including any UCC termination statements) that the Liens indicated in any such financing statements either constitute Permitted Liens or have been or, in connection with the initial Term Loan, will be terminated or released&#59;</font></div><div style="margin-top:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(h)&#160;&#160;&#160;&#160;a duly executed legal opinion of counsel to Borrower dated the Effective Date&#59;</font></div><div style="margin-top:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;evidence satisfactory to Collateral Agent and the Lenders that the insurance policies required by Section 6.5 hereof are in full force and effect, and, subject to Section 6.12, together with appropriate evidence showing loss payable and&#47;or additional insured clauses or endorsements in favor of Collateral Agent, for the ratable benefit of the Secured Parties&#59;</font></div><div style="margin-top:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(j)&#160;&#160;&#160;&#160;the duly executed Exit Fee Agreement&#59;</font></div><div style="margin-top:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(k)&#160;&#160;&#160;&#160;payment of the fees payable under the terms of the Fee Letter and Lenders&#8217; Expenses then due as specified in Section 2.4 hereof&#59; </font></div><div style="margin-top:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(l)&#160;&#160;&#160;&#160;a payoff letter in form and substance satisfactory to Agent and the Lenders evidencing the repayment in full and release of liens with respect to Borrower&#8217;s existing Indebtedness&#59; and </font></div><div style="margin-top:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(m)&#160;&#160;&#160;&#160;a replacement Exit Fee Agreement related to Borrower&#8217;s existing Indebtedness.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.2&#160;&#160;&#160;&#160;Conditions Precedent to all Term Loans.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The obligation of each Lender to extend each Term Loan, including the initial Term Loan, is subject to the following additional conditions precedent&#58;</font></div><div style="margin-top:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;receipt by Collateral Agent of an executed Loan Payment Request Form in the form of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit D</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> attached hereto&#59;</font></div><div style="margin-top:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;the representations and warranties in Section 5 hereof shall be true, accurate and complete in all material respects on the Funding Date of each Term Loan&#59; provided, however, that such materiality qualifier shall not be applicable to any representations and warranties that already are qualified or modified by materiality in the text thereof&#59; and provided, further that those representations and warranties expressly referring to a specific date shall be true, accurate and complete in all material respects as of such date, and no Event of Default shall have occurred and be continuing or result from the funding of such Term Loan&#59;</font></div><div style="margin-top:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;in such Lender&#8217;s reasonable discretion, there has not been any Material Adverse Change&#59;</font></div><div style="margin-top:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;No Event of Default or Default, shall exist&#59; and</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">19</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)&#160;&#160;&#160;&#160;payment of the fees and Lenders&#8217; Expenses then due as specified in Section 2.4 hereof.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.3&#160;&#160;&#160;&#160;Covenant to Deliver.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Borrower agrees to deliver to Collateral Agent and to the extent applicable the Lenders each item required to be delivered to Collateral Agent under this Agreement as a condition precedent to the funding of any Term Loan. Borrower expressly agrees that a Term Loan made prior to the receipt by Collateral Agent or any Lender of any such item shall not constitute a waiver by Collateral Agent or any Lender of Borrower&#8217;s obligation to deliver such item, and any such Term Loan in the absence of a required item shall be made in each Lender&#8217;s sole discretion.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.4&#160;&#160;&#160;&#160;Procedures for Borrowing.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Subject to the prior satisfaction of all other applicable conditions to the making of a Term Loan set forth in this Agreement, to obtain a Term Loan (other than the Term Loan funded on the Effective Date), Borrower shall notify the Lenders (which notice shall be irrevocable) by electronic mail, facsimile, or telephone by 2&#58;00 p.m. New York City time three (3) Business Days prior to the date the Term Loan is to be made. Together with any such electronic, facsimile or telephonic notification, Borrower shall deliver to Collateral Agent by electronic mail or facsimile a completed Loan Payment Request Form executed by a Responsible Officer or his or her designee. The Collateral Agent may rely on any telephone notice given by a person whom Collateral Agent reasonably believes is a Responsible Officer or designee. On the Funding Date related to any Term Loan, each Lender shall credit and&#47;or transfer (as applicable) to accounts designated by Borrower and agreed to by the Lenders, in an amount equal to its Term Loan Commitment in respect of such Term Loan.</font></div><div style="margin-top:12.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:102%">4.&#160;&#160;&#160;&#160;CREATION OF SECURITY INTEREST</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.1&#160;&#160;&#160;&#160;Grant of Security Interest.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Borrower hereby grants Collateral Agent, for the ratable benefit of the Secured Parties, to secure the payment and performance in full of all of the Obligations in full and, until payment in cash of all Obligations (other than (a) inchoate indemnity obligations, and (b) other obligations that, by their terms, survive termination of this Agreement, in each case, for which no claim has been made), a continuing security interest in, and pledges to Collateral Agent, for the ratable benefit of the Secured Parties, the Collateral, wherever located, whether now owned or hereafter acquired or arising, and all proceeds and products and supporting obligations (as defined in the Code) in respect thereof.  If Borrower shall acquire any commercial tort claim (as defined in the Code) in an amount greater than Fifty Thousand Dollars ($50,000), Borrower shall grant to Collateral Agent, for the ratable benefit of the Secured Parties, a security interest therein and in the proceeds and products and supporting obligations (as defined in the Code) thereof, all upon the terms of this Agreement, with such writing to be in form and substance reasonably satisfactory to Collateral Agent.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If this Agreement is terminated, Collateral Agent&#8217;s Lien in the Collateral shall continue until the Obligations (other than (a) inchoate indemnity obligations, and (b) other obligations that, by their terms, survive termination of this Agreement, in each case, for which no claim has been made) are repaid in full in cash. Upon payment in full in cash of the Obligations (other than (a) inchoate indemnity obligations, and (b) other obligations that, by their terms, survive termination of this Agreement, in each case, for which no claim has been made) and at such time as the Lenders&#8217; obligation to extend Term Loans has terminated, Collateral Agent shall, at the sole cost and expense of Borrower, release its Liens in the Collateral (and enter into any documentation reasonably requested by Borrower) and all rights therein shall revert to Borrower.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.2&#160;&#160;&#160;&#160;Authorization to File Financing Statements.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Borrower hereby authorizes Collateral Agent to file financing statements or take any other action required to perfect Collateral Agent&#8217;s security interests in the Collateral (held for the ratable benefit of the Secured Parties), without notice to Borrower, with all appropriate jurisdictions to perfect or protect Collateral Agent&#8217;s interest or rights under the Loan Documents&#59; provided, however, that Borrower shall have no obligation to deliver to Collateral Agent share certificates with respect to its security interests in any Immaterial Subsidiary unless and until the first to occur of (a) an Event of Default or (b) the value of such Immaterial Subsidiary, on a book value, equals or exceeds One Hundred Thousand Dollars ($100,000).</font></div><div style="margin-top:12.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:102%">5.&#160;&#160;&#160;&#160;REPRESENTATIONS AND WARRANTIES</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">20</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:11pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Borrower represents and warrants to Collateral Agent and the Lenders as follows&#58;</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">5.1&#160;&#160;&#160;&#160;Due Organization, Authorization&#58; Power and Authority.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Borrower and each of its Subsidiaries is duly existing and in good standing as a Registered Organization in its jurisdictions of organization or formation and Borrower and each of its Subsidiaries is qualified and licensed to do business and is in good standing in any jurisdiction in which the conduct of its businesses or its ownership of property requires that it be so qualified except where the failure to do so could not reasonably be expected to have a Material Adverse Change. In connection with this Agreement, Borrower and each of its Subsidiaries has delivered to Collateral Agent a completed perfection certificate and any updates or supplements thereto on, before or after the Effective Date (each a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Perfection Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; and collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Perfection Certificates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). Borrower represents and warrants that all the information set forth on the Perfection Certificates pertaining to Borrower and each of its Subsidiaries is accurate and complete (other than clerical mistakes in addresses and other contact information).</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The execution, delivery and performance by Borrower and each of its Subsidiaries of the Loan Documents to which it is, or they are, a party have been duly authorized, and do not (i) conflict with any of Borrower&#8217;s or such Subsidiaries&#8217; organizational documents, including its respective Operating Documents, (ii) contravene, conflict with, constitute a default under or violate any material Requirement of Law applicable thereto, (iii) contravene, conflict or violate any applicable order, writ, judgment, injunction, decree, determination or award of any Governmental Authority by which Borrower or such Subsidiary, or any of their property or assets may be bound or affected, (iv) require any action by, filing, registration, or qualification with, or Governmental Approval from, any Governmental Authority (except such Governmental Approvals which have already been obtained and are in full force and effect) or are being obtained pursuant to Section 6.1(b), or (v) constitute an event of default under any material agreement by which Borrower, any of its Subsidiaries or any of their respective properties, is bound. Neither Borrower nor any of its Subsidiaries is in default under any agreement to which it is a party or by which it or any of its assets is bound in which such default could reasonably be expected to have a Material Adverse Change.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">5.2&#160;&#160;&#160;&#160;Collateral.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Borrower and each of its Subsidiaries have good title to, have rights in, and the power to transfer each item of the Collateral upon which it purports to grant a Lien under the Loan Documents, free and clear of any and all Liens except Permitted Liens, and neither Borrower nor any of its Subsidiaries have any Deposit Accounts, Securities Accounts, Commodity Accounts or other investment accounts other than the Collateral Accounts or the other investment accounts, if any, described in the Perfection Certificates delivered to Collateral Agent in connection herewith in respect of which Borrower or such Subsidiary has given Collateral Agent notice and taken such actions as are necessary to give Collateral Agent a perfected security interest therein as required under this Agreement. The Accounts are bona fide, existing obligations of the Account Debtors.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">The security interest granted herein is and shall at all times continue to be a first priority perfected security interest in the Collateral, subject only to Permitted Liens that, under applicable law, have priority over Collateral Agent&#8217;s Lien.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">On the Effective Date, and except as disclosed on the Disclosure Schedules (i) the Collateral is not in the possession of any third party bailee, and (ii) no such third party bailee possesses components of the Collateral in excess of Five Hundred Thousand Dollars ($500,000) in book value.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">All Inventory and Equipment is in all material respects of good and marketable quality, free from material defects.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Borrower and each of its Subsidiaries is the sole owner of the Intellectual Property each respectively purports to own, free and clear of all Liens other than Permitted Liens. Except as noted on the Disclosure Schedules (which shall be updated within 45 days after the end of each fiscal quarter to reflect the consummation of any transaction not prohibited by this Agreement) or to be included in the next-delivered Compliance Certificate, neither Borrower nor any of its Subsidiaries is a party to, nor is bound by, any material license or other Material Agreement.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">21</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">5.3&#160;&#160;&#160;&#160;Litigation.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Except as disclosed on the Perfection Certificate or with respect to which Borrower has provided notice as required hereunder, there are no actions, suits, investigations, or proceedings pending or, to the knowledge of the Responsible Officers, threatened in writing by or against Borrower or any of its Subsidiaries involving more than Two Hundred Fifty Thousand Dollars ($250,000).</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">5.4&#160;&#160;&#160;&#160;No Material Adverse Change&#59; Financial Statements.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">All consolidated financial statements for Borrower and its consolidated Subsidiaries, delivered to Collateral Agent fairly present, in conformity with GAAP, and in all material respects the consolidated financial condition of Borrower and its consolidated Subsidiaries, and the consolidated results of operations of Borrower and its consolidated Subsidiaries. Since December 31, 2020, there has not been a Material Adverse Change.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">5.5&#160;&#160;&#160;&#160;Solvency.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Borrower is Solvent. Borrower and each of its Subsidiaries, when taken as a whole, is Solvent.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">5.6&#160;&#160;&#160;&#160;Regulatory Compliance.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Neither Borrower nor any of its Subsidiaries is an &#8220;investment company&#8221; or a company &#8220;controlled&#8221; by an &#8220;investment company&#8221; under the Investment Company Act of 1940, as amended. Neither Borrower nor any of its Subsidiaries is engaged as one of its important activities in extending credit for margin stock (under Regulations X, T and U of the Federal Reserve Board of Governors). Borrower and each of its Subsidiaries has complied in all material respects with the Federal Fair Labor Standards Act. Neither Borrower nor any of its Subsidiaries is a &#8220;holding company&#8221; or an &#8220;affiliate&#8221; of a &#8220;holding company&#8221; or a &#8220;subsidiary company&#8221; of a &#8220;holding company&#8221; as each term is defined and used in the Public Utility Holding Company Act of 2005. Neither Borrower nor any of its Subsidiaries has violated any laws, ordinances or rules, the violation of which could reasonably be expected to have a Material Adverse Change. Neither Borrower&#8217;s nor any of its Subsidiaries&#8217; properties or assets has been used by Borrower or such Subsidiary or, to Borrower&#8217;s knowledge, by previous Persons, in disposing, producing, storing, treating, or transporting any hazardous substance other than in material compliance with applicable laws. Borrower and each of its Subsidiaries has obtained all consents, approvals and authorizations of, made all declarations or filings with, and given all notices to, all Governmental Authorities that are necessary to continue their respective businesses as currently conducted.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">None of Borrower, any of its Subsidiaries, or any of Borrower&#8217;s or its Subsidiaries&#8217; Affiliates or any of their respective agents acting or benefiting in any capacity in connection with the transactions contemplated by this Agreement is (i) in violation of any Anti-Terrorism Law, (ii) engaging in or conspiring to engage in any transaction that evades or avoids, or has the purpose of evading or avoiding or attempts to violate, any of the prohibitions set forth in any Anti-Terrorism Law, or (iii) is a Blocked Person. None of Borrower, any of its Subsidiaries, or to the knowledge of Borrower and any of their Affiliates or agents, acting or benefiting in any capacity in connection with the transactions contemplated by this Agreement, (x) conducts any business or engages in making or receiving any contribution of funds, goods or services to or for the benefit of any Blocked Person, or (y) deals in, or otherwise engages in any transaction relating to, any property or interest in property blocked pursuant to Executive Order No. 13224, any similar executive order or other Anti-Terrorism Law.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">5.7&#160;&#160;&#160;&#160;Investments.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Neither Borrower nor any of its Subsidiaries owns any stock, shares, partnership</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">interests or other equity securities except for Permitted Investments.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">5.8&#160;&#160;&#160;&#160;Tax Returns and Payments&#59; Pension Contributions.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Borrower and each of its Subsidiaries has timely filed all required tax returns and reports, each such tax return is true, correct and complete in all material respects, and Borrower and each of its Subsidiaries, has timely paid all foreign, federal, state, and local taxes, assessments, deposits and contributions owed by Borrower and such Subsidiaries in an amount greater than Fifty Thousand Dollars ($50,000), in all jurisdictions in which Borrower or any such Subsidiary is subject to taxes, including the United States, unless such taxes are being contested in accordance with the next sentence. Borrower and each of its Subsidiaries, may defer payment of any contested taxes, provided that Borrower or such Subsidiary, (a) in good faith contests its obligation to pay the taxes by appropriate proceedings promptly and diligently instituted and conducted&#59; (b) notifies Collateral Agent of the commencement of, and any material development in, the proceeding&#59; and (c) maintains adequate reserves or other appropriate provisions on the books of such Borrower or Subsidiary, as applicable, in accordance with GAAP and which do not involve, in the reasonable </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">22</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">judgment of the Collateral Agent, any risk of the sale, forfeiture or loss of any material portion of the Collateral. Neither Borrower nor any of its Subsidiaries is aware of any claims or adjustments proposed for any of Borrower&#8217;s or such Subsidiaries&#8217;, prior tax years which could result in additional taxes becoming due and payable by Borrower or its Subsidiaries. Borrower and each of its Subsidiaries have paid all amounts necessary to fund all present pension, profit sharing and deferred compensation plans in accordance with their terms, and neither Borrower nor any of its Subsidiaries have, withdrawn from participation in, and have not permitted partial or complete termination of, or permitted the occurrence of any other event with respect to, any such plan which could reasonably be expected to result in any liability of Borrower or its Subsidiaries, including any liability to the Pension Benefit Guaranty Corporation or its successors or any other Governmental Authority.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">5.9&#160;&#160;&#160;&#160;Use of Proceeds.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Borrower shall use the proceeds of the Term Loans to repay existing Indebtedness, as working capital (including, without limitation, to fund Permitted Acquisitions) and to fund its general business requirements, and not for personal, family, household or agricultural purposes.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">5.10&#160;&#160;&#160;&#160;Full Disclosure.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">No written representation, warranty or other statement of Borrower or any of its Subsidiaries in any certificate or written statement, when taken as a whole, given to Collateral Agent or any Lender, as of the date such representation, warranty, or other statement was made, taken together with all such written certificates and written statements given to Collateral Agent or any Lender, contains any untrue statement of a material fact or omits to state a material fact necessary to make the statements contained in the certificates or statements not misleading (it being recognized that projections and forecasts provided by Borrower in good faith and based upon reasonable assumptions are not viewed as facts and that actual results during the period or periods covered by such projections and forecasts may differ from the projected or forecasted results).</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">5.11&#160;&#160;&#160;&#160;Healthcare Regulatory Matters.  </font></div><div style="margin-top:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Borrower and each Subsidiary is, and during the past three (3) years has been, in compliance with all applicable Healthcare Laws, except for such noncompliance, whether individually or in the aggregate, as could not reasonably be expected to have a Material Adverse Change. Without limiting the generality of the foregoing, during the past three (3) years, none of Borrower or its Subsidiaries has received written notice by a Governmental Authority of any violation (or of any investigation, audit, or other proceeding involving allegations of any violation) of any Healthcare Laws, which if determined or resolved adversely to the Borrower or any Subsidiary, could reasonably be expected to have a Material Adverse Change, and no such investigation, inspection, audit or other proceeding involving allegations of any such violation is, to Borrower&#8217;s knowledge, threatened in writing or contemplated which could reasonably be expected to have a Material Adverse Change.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Borrower and each Subsidiary, and its respective officers, directors, and employees are not and, during the past three (3) years, has not been, excluded, debarred, suspended or otherwise ineligible to participate in any governmental healthcare program where the same could reasonably be expected to have a Material Adverse Change, and no such action is pending or, to Borrower&#8217;s knowledge, threatened in writing. None of the Borrower or its Subsidiaries&#58; is a party to or has any reporting obligations under a corporate integrity agreement, deferred or non-prosecution agreement, monitoring agreement, consent decree, settlement order, or any similar agreement with any Governmental Authority.</font></div><div style="margin-top:12.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:102%">6.&#160;&#160;&#160;&#160;AFFIRMATIVE COVENANTS</font></div><div style="margin-top:11pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Borrower shall, and shall cause each of its Subsidiaries to, do all of the following&#58;</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">6.1&#160;&#160;&#160;&#160;Government Compliance.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:75.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;Other than specifically permitted hereunder, maintain its and all its Subsidiaries&#8217; legal existence and good standing in their respective jurisdictions of organization and maintain qualification in each jurisdiction in which the failure to so qualify could reasonably be expected to have a Material Adverse Change. Comply with all laws, ordinances and regulations, including all Healthcare </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">23</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Laws, to which Borrower or any of its Subsidiaries is subject, the noncompliance with which could reasonably be expected to have a Material Adverse Change.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:75.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;Obtain and keep in full force and effect, all of the material Governmental Approvals necessary for the performance by Borrower and its Subsidiaries of their respective businesses and obligations under the Loan Documents and the grant of a security interest to Collateral Agent for the ratable benefit of the Secured Parties, in all of the Collateral.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">6.2&#160;&#160;&#160;&#160;Financial Statements, Reports, Certificates&#59; Notices.</font></div><div style="margin-top:11pt;padding-left:75.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;Deliver to Collateral Agent&#58;</font></div><div style="margin-top:11pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.63pt">as soon as available, but no later than thirty (30) days after the last day of each month that is not a quarter-end, a company prepared consolidated and, if prepared by Borrower or if reasonably requested by the Lenders, consolidating balance sheet, income statement and cash flow statement, in each case subject to year-end adjustments and the absence of footnotes, covering the consolidated operations of Borrower and its consolidated Subsidiaries for such month certified by a Responsible Officer and in a form reasonably acceptable to the Collateral Agent&#59;</font></div><div style="margin-top:11pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.58pt">as soon as available, but no later than forty-five (45) days after the last day of each fiscal quarter, a company prepared consolidated and, if prepared by Borrower or if reasonably requested by the Lenders, consolidating balance sheet, income statement and cash flow statement, in each case subject to year-end adjustments and the absence of footnotes, covering the consolidated operations of Borrower and its consolidated Subsidiaries for such fiscal quarter certified by a Responsible Officer and in a form reasonably acceptable to the Collateral Agent&#59;</font></div><div style="margin-top:11pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:19.53pt">as soon as available, but no later than ninety (90) days after the last day of Borrower&#8217;s fiscal year or within five (5) days of filing of the same with the SEC, audited consolidated financial statements covering the consolidated operations of Borrower and its consolidated Subsidiaries for such fiscal year, prepared under GAAP, consistently applied, together with an unqualified opinion (other than with respect to a going concern limitation based solely on the amount of cash and Cash Equivalents held by Borrower) on the financial statements from an independent certified public accounting firm acceptable to Collateral Agent in its reasonable discretion&#59;</font></div><div style="margin-top:11pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.13pt">no later than sixty (60) days after the last day of Borrower&#8217;s fiscal year, but no later than ten (10) days&#8217; after approval thereof by the Borrower&#8217;s board of directors, Borrower&#8217;s annual financial projections for the entire current fiscal year as approved by Borrower&#8217;s board of directors&#59; provided that, any revisions to such projections approved by Borrower&#8217;s board of directors shall be delivered to Collateral Agent and the Lenders no later than seven (7) days after such approval)&#59;</font></div><div style="margin-top:11pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">together with the delivery of the Compliance Certificate, copies of all non-ministerial statements, reports and notices made available to Borrower&#8217;s security holders or holders of Subordinated Debt (except as otherwise required to be delivered hereunder, other than materials provided to members of Borrower&#8217;s board of directors solely in their capacities as board members or management of Borrower) or holders of Subordinated Debt (except as otherwise required to be delivered hereunder, other than materials provided to members of Borrower&#8217;s board of directors solely in their capacities as board members or management of Borrower)&#59;</font></div><div style="margin-top:11pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.13pt">with each Compliance Certificate, copies of the month-end account statements for each Collateral Account maintained by Borrower or its Subsidiaries, which statements may be provided to Collateral Agent and each Lender by Borrower or directly from the applicable institution(s)&#59;</font></div><div style="margin-top:11pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(vii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:17.08pt">prompt delivery of (and in any event within five (5) days after the same are sent or received) copies of all material correspondence, reports, documents and other filings with any Governmental Authority that could reasonably be expected to have a material adverse effect on any of the Governmental Approvals material to Borrower&#8217;s business or that otherwise could reasonably be expected to have a Material Adverse Change&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">24</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:11pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(viii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.03pt">prompt notice of any event that (A) could reasonably be expected to materially and adversely affect the value of the Intellectual Property or (B) could reasonably be expected to result in a Material Adverse Change&#59;</font></div><div style="margin-top:11pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ix)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.13pt">written notice delivered at least five (5) days&#8217; prior to Borrower&#8217;s creation of a New Subsidiary in accordance with the terms of Section 6.10&#59;</font></div><div style="margin-top:11pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(x)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">written notice delivered at least twenty (20) days&#8217; prior to Borrower&#8217;s (A) adding any new offices or business locations, including warehouses (unless such new offices or business locations contain less than Five Hundred Thousand Dollars ($500,000) in assets or property of Borrower or any of its Subsidiaries), (B) changing its respective jurisdiction of organization, (C) changing its organizational structure or type, (D) changing its respective legal name, or (E) changing any organizational number(s) (if any) assigned by its respective jurisdiction of organization&#59;</font></div><div style="margin-top:11pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(xi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.13pt">upon Borrower becoming aware of the existence of any Event of Default or event which, with the giving of notice or passage of time, or both, would constitute an Event of Default, prompt (and in any event within three (3) Business Days) written notice of such occurrence, which such notice shall include a reasonably detailed description of such Event of Default or event which, with the giving of notice or passage of time, or both, would constitute an Event of Default, and Borrower&#8217;s proposal regarding how to cure such Event of Default or event&#59;</font></div><div style="margin-top:11pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(xii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:17.08pt">immediate notice if Borrower or such Subsidiary has knowledge that Borrower, or any Subsidiary or Affiliate of Borrower, is listed on the OFAC Lists or (a) is convicted on, (b) pleads </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">nolo contendere </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">to, (c) is indicted on, or (d) is arraigned and held over on charges involving money laundering or predicate crimes to money laundering&#59;</font></div><div style="margin-top:11pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(xiii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.03pt">together with the delivery of the Compliance Certificate, notice of any commercial tort claim (as defined in the Code) or letter of credit rights (as defined in the Code) held by Borrower or any Guarantor, in each case in an amount greater than One Hundred Thousand Dollars ($100,000) and of the general details thereof&#59;</font></div><div style="margin-top:11pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(xiv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.63pt">if Borrower has any Subsidiaries any of which is not a Registered Organization upon formation thereof but later becomes one, written notice of such occurrence and information regarding such Person&#8217;s organizational identification number within seven (7) Business Days of receiving such organizational identification number&#59;</font></div><div style="margin-top:11pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(xv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:17.68pt">no later than 45 days after the end of each fiscal quarter an updated Perfection Certificate to reflect any amendments, modifications and updates, if any, to certain information in the Perfection Certificate after the Effective Date&#59; and</font></div><div style="margin-top:11pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(xvi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.63pt">other information as reasonably requested by Collateral Agent or any Lender.</font></div><div style="margin-top:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Notwithstanding the terms herein, documents and notices required to be delivered pursuant to the terms hereof (to the extent any such documents and notices are included in materials otherwise filed with the SEC) may be delivered electronically and if so delivered, shall be deemed to have been delivered on the date on which Borrower posts such documents, or provides a link thereto, on Borrower&#8217;s website on the internet at Borrower&#8217;s website address.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;Concurrently with the delivery of the financial statements specified in Section 6.2(a)(i) above but no later than thirty (30) days after the last day of each month, deliver to Collateral Agent&#58;</font></div><div style="margin-top:11pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;a duly completed Compliance Certificate signed by a Responsible Officer&#59;</font></div><div style="margin-top:11pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;copies of any material Governmental Approvals obtained by Borrower or any of its Subsidiaries&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">25</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:11pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;written notice of the commencement of, and any material development in, the proceedings contemplated by Section 5.8 hereof&#59;</font></div><div style="margin-top:11pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iv)&#160;&#160;&#160;&#160;written notice of any litigation or governmental proceedings pending or threatened (in writing) against Borrower or any of its Subsidiaries, which could reasonably be expected to result in damages or costs to Borrower or any of its Subsidiaries of Two Hundred Fifty Thousand Dollars ($250,000)&#59; and</font></div><div style="margin-top:11pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(v)&#160;&#160;&#160;&#160;written notice of all returns, recoveries, disputes and claims regarding Inventory that involve more than Five Hundred Thousand Dollars ($500,000) individually or in the aggregate in any calendar year.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;Keep proper, complete and true books of record and account in accordance with GAAP in all material respects. Borrower shall, and shall cause each of its Subsidiaries to, allow, at the sole cost of Borrower, Collateral Agent or any Lender, during regular business hours upon reasonable prior notice (provided that no notice shall be required when an Event of Default has occurred and is continuing), to visit and inspect any of its properties, to examine and make abstracts or copies from any of its books and records, and to conduct a collateral audit and analysis of its operations and the Collateral. Such audits shall be conducted no more often than twice every year unless (and more frequently if) an Event of Default has occurred and is continuing.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">6.3&#160;&#160;&#160;&#160;Inventory&#59; Returns.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Keep all Inventory in good and marketable condition, free from material defects. Returns and allowances between Borrower, or any of its Subsidiaries, as applicable, and their respective Account Debtors shall follow Borrower&#8217;s, or such Subsidiary&#8217;s, as applicable, customary practices.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">6.4&#160;&#160;&#160;&#160;Taxes&#59; Pensions.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Timely file and require each of its Subsidiaries to timely file, all required tax returns and reports and timely pay, and require each of its Subsidiaries to timely pay, all foreign, federal, state, and local taxes, assessments, deposits and contributions owed by Borrower or its Subsidiaries, as applicable, except as otherwise permitted pursuant to the terms of Section 5.8 hereof, and shall deliver to Collateral Agent, on demand, appropriate certificates attesting to such payments, and pay all amounts necessary to fund all present pension, profit sharing and deferred compensation plans in accordance with the terms of such plans.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">6.5&#160;&#160;&#160;&#160;Insurance.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Keep Borrower&#8217;s and its Subsidiaries&#8217; business and the Collateral insured for risks and in amounts standard for companies in Borrower&#8217;s and its Subsidiaries&#8217; industry and location and as Collateral Agent may reasonably request. Insurance policies shall be in a form, with companies, and in amounts that are standard for companies in Borrower&#8217;s industry and location. All property policies shall have a lender&#8217;s loss payable endorsement showing Collateral Agent as lender loss payee and shall waive subrogation against Collateral Agent, and all liability policies shall show, or have endorsements showing, Collateral Agent (for the ratable benefit of the Secured Parties), as additional insured. The Collateral Agent shall be named as lender loss payee and&#47;or additional insured with respect to any such insurance providing coverage in respect of any Collateral, and each provider of any such insurance shall agree, by endorsement upon the policy or policies issued by it or by independent instruments furnished to the Collateral Agent, that it will give the Collateral Agent thirty (30) days prior written notice before any such policy or policies shall be canceled (except in the case of nonpayment). At Collateral Agent&#8217;s request, Borrower shall deliver to the Collateral Agent certified copies of policies and evidence of all premium payments. Proceeds payable under any policy shall, at Collateral Agent&#8217;s option, be payable to Collateral Agent, for the ratable benefit of the Secured Parties, on account of the then-outstanding Obligations. Notwithstanding the foregoing, (a) so long as no Event of Default has occurred and is continuing, Borrower shall have the option of applying the proceeds of any casualty policy within one hundred eighty (180) days of receipt thereof up to Seven Hundred Fifty Thousand Dollars ($750,000) with respect to any loss, but not exceeding One Million Five Hundred Thousand Dollars ($1,500,000), in the aggregate for all losses under all casualty policies in any one year, toward the replacement or repair of destroyed or damaged property&#59; provided that any such replaced or repaired property (i) shall be of equal or like value as the replaced or repaired Collateral and (ii) shall be deemed Collateral in which Collateral Agent has been granted a first priority security interest, and (b) after the occurrence and during the continuance of an Event of Default, all proceeds payable under such casualty policy shall, at the option of Collateral Agent, be payable to Collateral Agent, for the ratable benefit of the Lenders, on account of the Obligations. If </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">26</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Borrower or any of its Subsidiaries fails to obtain insurance as required under this Section 6.5 or to pay any amount or furnish any required proof of payment to third persons, Collateral Agent may make (but has no obligation to do so), at Borrower&#8217;s expense, all or part of such payment or obtain such insurance policies required in this Section 6.5, and take any action under the policies Collateral Agent deems prudent.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">6.6&#160;&#160;&#160;&#160;Operating Accounts.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;Maintain Borrower&#8217;s and Guarantors Collateral Accounts with depositary institutions that have agreed to execute Control Agreements in favor of Collateral Agent with respect to such Collateral Accounts. The provisions of the previous sentence shall not apply to Deposit Accounts exclusively used for cash collateral for Permitted Liens under clause (j) of the definition thereof, payroll, payroll taxes and other employee wage and benefit payments to or for the benefit of Borrower&#8217;s, or any Guarantor&#8217;s, employees in an aggregate amount not to exceed the amount reasonably expected to be due and payable for the next two (2) succeeding pay periods and identified to Collateral Agent by Borrower as such in the Disclosure Schedules and any deposit accounts at Western Alliance Bank (provided the accounts at Western Alliance Bank do not have an aggregate balance in excess of One Hundred Thousand Dollars ($100,000) from and after the date that is three (3) Business Days after the Effective Date and such accounts are closed as required by Section 6.12(b)).</font></div><div style="margin-top:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;Borrower shall provide Collateral Agent ten (10) days&#8217; prior written notice before Borrower or any Guarantor establishes any Collateral Account. In addition, for each Collateral Account that Borrower or any Guarantor, at any time maintains, Borrower or such Guarantor shall cause the applicable bank or financial institution at or with which such Collateral Account is maintained to execute and deliver a Control Agreement or other appropriate instrument with respect to such Collateral Account to perfect Collateral Agent&#8217;s Lien in such Collateral Account (held for the ratable benefit of the Secured Parties) in accordance with the terms hereunder prior to the establishment of such Collateral Account. The provisions of the previous sentence shall not apply to Deposit Accounts exclusively used for cash collateral for Permitted Liens under clause (j) of the definition thereof, payroll, payroll taxes and other employee wage and benefit payments to or for the benefit of Borrower&#8217;s, or any Guarantor&#8217;s, employees in an aggregate amount not to exceed the amount reasonably expected to be due and payable for the next two (2) succeeding pay periods and identified to Collateral Agent by Borrower as such in the Disclosure Schedules or otherwise in writing to the Collateral Agent and any deposit accounts at Western Alliance Bank (provided the accounts at Western Alliance Bank do not have an aggregate balance in excess of One Hundred Thousand Dollars ($100,000) from and after the date that is three (3) Business Days after the Effective Date and such accounts are closed as required by Section 6.12(b)).</font></div><div style="margin-top:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;Neither Borrower nor any Guarantor shall maintain any Collateral Accounts except Collateral Accounts maintained in accordance with this Section 6.6.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">6.7&#160;&#160;&#160;&#160;Protection of Intellectual Property Rights.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Borrower and each of its Subsidiaries shall&#58; (a) use commercially reasonable efforts to protect, defend and maintain the validity and enforceability of its respective Intellectual Property that is material to its business&#59; (b) promptly advise Collateral Agent in writing of material infringement by a third party of its respective Intellectual Property&#59; and (c) not allow any of its respective Intellectual Property material to its respective business to be abandoned, forfeited or dedicated to the public without Collateral Agent&#8217;s prior written consent.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">6.8&#160;&#160;&#160;&#160;Litigation Cooperation.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Commencing on the Effective Date and continuing through the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">termination of this Agreement, make available to Collateral Agent, without expense to Collateral Agent or the Lenders, Borrower and each of Borrower&#8217;s officers, employees and agents and Borrower&#8217;s Books, to the extent that Collateral Agent may reasonably deem them necessary to prosecute or defend any third-party suit or proceeding instituted by or against Collateral Agent with respect to any Collateral or relating to Borrower.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">6.9&#160;&#160;&#160;&#160;Landlord Waivers&#59; Bailee Waivers.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In the event that Borrower or any of its Subsidiaries, after the Effective Date, intends to add any new offices or business locations, including warehouses, or otherwise store any portion of the Collateral with, or deliver any portion of the Collateral to, a bailee, in each case pursuant to Section 7.2, then, in the event that the Collateral at any new location is valued (based on book value) in excess of Five Hundred Thousand Dollars ($500,000) in the aggregate, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">27</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">at Collateral Agent&#8217;s election, Borrower or such Subsidiary shall use commercially reasonable efforts to cause such bailee or landlord, as applicable, to execute and deliver a bailee waiver or landlord waiver, as applicable, in form and substance reasonably satisfactory to Collateral Agent prior to the addition of any new offices or business locations, or any such storage with or delivery to any such bailee, as the case may be.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">6.10&#160;&#160;&#160;&#160;Creation&#47;Acquisition of Subsidiaries.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In the event any Borrower or any Subsidiary of any</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Borrower creates or acquires any Subsidiary after the Effective Date, Borrower or such Subsidiary shall promptly notify the Collateral Agent of such creation or acquisition, and Borrower or such Subsidiary shall take all actions reasonably requested by the Collateral Agent to achieve any of the following with respect to such &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">New Subsidiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; (defined as a Subsidiary formed after the date hereof during the term of this Agreement)&#58; (i) if such New Subsidiary is a Domestic Subsidiary (except for a Domestic Subsidiary (1) substantially all of the assets of which consist of the equity interests of one or more Foreign Subsidiaries or (2) that is a subsidiary of a Foreign Subsidiary (each, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Excluded Domestic Subsidiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)), to cause such New Subsidiary to become either a co-Borrower hereunder, or a secured guarantor with respect to the Obligations&#59; and (ii) with respect to New Subsidiaries owned directly by Borrower or a Guarantor, to grant and pledge to Collateral Agent a perfected security interest in (A) 100% of the stock, units or other evidence of ownership held by Borrower or its Subsidiaries of any such New Subsidiary that is a Domestic Subsidiary (except if such New Subsidiary is an Excluded Domestic Subsidiary), or (B) 65% of the stock, units or other evidence of ownership held by Borrower or a Guarantor of any such New Subsidiary which is a Foreign Subsidiary or an Excluded Domestic Subsidiary.  </font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">6.11&#160;&#160;&#160;&#160;Further Assurances.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Execute any further instruments and take further action as Collateral Agent or any Lender reasonably requests to perfect or continue Collateral Agent&#8217;s Lien in the Collateral or to effect the purposes of this Agreement.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">6.12&#160;&#160;&#160;&#160;Post-Effective Date Obligations.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Notwithstanding any provision herein or in any other Loan Document to the contrary, to the extent not actually delivered on or prior to the Effective Date, Borrower shall, and shall cause each Subsidiary to&#58;</font></div><div style="margin-top:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;within thirty (30) days after the Effective Date (as such date may be extended by Collateral Agent in its sole discretion), deliver to Collateral Agent the insurance endorsements, in each case satisfying the requirements of Section 6.5&#59; </font></div><div style="margin-top:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;within sixty (60) days after the Effective Date (as such date may be extended by Collateral Agent in its sole discretion), deliver to Collateral Agent evidence in form and substance reasonably acceptable to Collateral Agent, that the Collateral Accounts of Borrower at Western Alliance Bank have been closed&#59; </font></div><div style="margin-top:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;use commercially reasonable efforts to deliver to Collateral Agent a landlord&#8217;s consent executed in favor of Collateral Agent in respect Borrower&#8217;s leased locations at 400 Fifth Avenue, Suites 210 &#38; 300, Waltham, MA 02451 and 34175 Ardenwood Blvd, Fremont, CA 94555 no later than sixty (60) days after the Effective Date (as such date may be extended by Collateral Agent in its sole discretion)&#59;  </font></div><div style="margin-top:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;use commercially reasonable efforts to deliver to Collateral Agent a bailee waiver executed in favor of Collateral Agent in respect of each third party bailee where Borrower or any Subsidiary maintains Collateral having a book value in excess of Five Hundred Thousand Dollars ($500,000) in the aggregate no later than sixty (60) days after the Effective Date (as such date may be extended by Collateral Agent in its sole discretion)&#59; </font></div><div style="margin-top:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)&#160;&#160;&#160;&#160;within two (2) Business Days after the Effective Date (as such date may be extended by Collateral Agent in its sole discretion) deliver to Collateral Agent evidence in form and substance reasonably acceptable to Collateral Agent that Borrower has transferred all of its cash and Cash Equivalents from its Collateral Accounts at Western Alliance Bank to one or more Collateral Accounts at Silicon Valley Bank that are subject to Control Agreements in favor of Collateral Agent&#59; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">28</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(f)&#160;&#160;&#160;&#160;within ten (10) Business Days after the Effective Date (as such date may be extended by Collateral Agent in its sole discretion) deliver to Collateral Agent good standing certificates for each jurisdiction in which Borrower and each Subsidiary is qualified to conduct business&#59; and </font></div><div style="margin-top:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(g) &#160;&#160;&#160;&#160;within ten (10) Business Days after the Effective Date (as such date may be extended by Collateral Agent in its sole discretion) deliver to Collateral Agent an executed Control Agreement in favor of Collateral Agent with respect to the Collateral Account at Capital Advisors Group&#59; provided, however, until such time that the Collateral Account is subject to a Control Agreement, Borrower shall not Transfer any assets into such Collateral Account. </font></div><div style="margin-top:12.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:102%">7.&#160;&#160;&#160;&#160;NEGATIVE COVENANTS</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Borrower shall not, and shall not permit any of its Subsidiaries to, do any of the following without the prior written consent of the Required Lenders&#58;</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">7.1&#160;&#160;&#160;&#160;Dispositions.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Convey, sell, lease, transfer, assign, dispose of, license (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Transfer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), or permit any of its Subsidiaries to Transfer, all or any part of its business or property, except for Transfers (a) of Inventory in the ordinary course of business&#59; (b) of worn-out, surplus, uneconomic or obsolete Equipment&#59; (c) in connection with the Permitted Royalty Transaction, Permitted Liens, Permitted Investments and Permitted Licenses&#59; (d) cash or Cash Equivalents pursuant to transactions not prohibited by this Agreement&#59; (e) sales or discounting of delinquent accounts in the ordinary course of business&#59; or (f) other Transfers not to exceed Two Hundred Fifty Thousand Dollars ($250,000) in any fiscal year.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">7.2&#160;&#160;&#160;&#160;Changes in Business, Management, Ownership, or Business Locations.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a) Engage in or permit any of its Subsidiaries to engage in any business other than the businesses engaged in by Borrower or such Subsidiary, as applicable, as of the Effective Date or reasonably related thereto&#59; (b) liquidate or dissolve&#59; or (c) (i) permit any Key Person to cease being actively engaged in the management of Borrower unless written notice thereof is provided to Collateral Agent within ten (10) Business Days of such cessation, or (ii) enter into any transaction or series of related transactions in which (A) the stockholders of Borrower who were not stockholders immediately prior to the first such transaction own more than 49% of the voting stock of Borrower immediately after giving effect to such transaction or related series of such transactions and (B) except as permitted by Section 7.3, Borrower ceases to own, directly or indirectly, 100% of the ownership interests in each Subsidiary of Borrower. Borrower shall not, and shall not permit any of its Subsidiaries to, without at least twenty (20) days&#8217; prior written notice to Collateral Agent&#58; (A) add any new offices or business locations, including warehouses (unless such new offices or business locations contain less than Five Hundred Thousand Dollars ($500,000) in assets or property of Borrower or any of its Subsidiaries, as applicable)&#59; (B) change its respective jurisdiction of organization, (C) except as permitted by Section 7.3, change its respective organizational structure or type, (D) change its respective legal name, or (E) change any organizational number(s) (if any) assigned by its respective jurisdiction of organization.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">7.3&#160;&#160;&#160;&#160;Mergers or Acquisitions.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Merge or consolidate, or permit any of its Subsidiaries to merge or consolidate, with any other Person, or acquire, or permit any of its Subsidiaries to acquire, all or substantially all of the capital stock, shares or property of another Person, other than Permitted Acquisitions. A Subsidiary may merge or consolidate into another Subsidiary (provided such surviving Subsidiary is a &#8220;co-Borrower&#8221; hereunder or has provided a secured Guaranty of Borrower&#8217;s Obligations hereunder in accordance with Section 6.10) or with (or into) Borrower provided Borrower is the surviving legal entity, and as long as no Event of Default is occurring prior thereto or arises as a result therefrom.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">7.4&#160;&#160;&#160;&#160;Indebtedness.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Create, incur, assume, or be liable for any Indebtedness, or permit any Subsidiary to do so, other than Permitted Indebtedness.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">7.5&#160;&#160;&#160;&#160;Encumbrance.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Create, incur, allow, or suffer any Lien on any of its property, or assign or convey any right to receive income, including the sale of any Accounts, or permit any of its Subsidiaries to do so, except for Permitted Liens, or permit any Collateral not to be subject to the first priority security interest granted herein (except for Permitted Liens), or enter into any agreement, document, instrument or other arrangement (except with or in favor of Collateral Agent, for the ratable </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">29</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">benefit of the Secured Parties) with any Person which directly or indirectly prohibits or has the effect of prohibiting Borrower, or any of its Subsidiaries, from assigning, mortgaging, pledging, granting a security interest in or upon, or encumbering any of Borrower&#8217;s or such Subsidiary&#8217;s Intellectual Property, except as is otherwise permitted in Section 7.1 hereof and the definition of &#8220;Permitted Liens&#8221;.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">7.6&#160;&#160;&#160;&#160;Maintenance of Collateral Accounts.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">With respect to Borrower and any Guarantors, maintain any Collateral Account except pursuant to the terms of Section 6.6 hereof.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">7.7&#160;&#160;&#160;&#160;Restricted Payments.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a) Declare or pay any dividends (other than dividends payable solely in capital stock) or make any other distribution or payment on account of or redeem, retire or purchase any capital stock (other than (i) the declaration or payment of dividends or other distributions to Borrower or any of its Subsidiaries, (ii) so long as no Event of Default or</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Default exists or would result therefrom, the declaration or payment of any dividends solely in the form of equity securities, and (iii) repurchases pursuant to the terms of employee stock purchase plans, employee restricted stock agreements, stockholder rights plans, director or consultant stock option plans, similar plans to any of the foregoing, or payments in connection with tax withholding obligations in connection with the foregoing, provided such repurchases do not exceed Three Hundred Fifty Thousand Dollars ($350,000) in the aggregate per fiscal year and One Million Dollars ($1,000,000) over the term of this Agreement), (b) other than the Obligations in accordance with the terms hereof, purchase, redeem, defease or prepay any principal of, premium, if any, interest or other amount payable in respect of any Indebtedness prior to its scheduled maturity unless being replaced with Indebtedness of at least the same principal amount and such new Indebtedness is Permitted Indebtedness, or (c) be a party to or bound by an agreement that restricts a Subsidiary from paying dividends or otherwise distributing property to Borrower other than this Agreement.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">7.8&#160;&#160;&#160;&#160;Investments.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Directly or indirectly make any Investment other than Permitted Investments, or permit any of its Subsidiaries to do so other than Permitted Investments.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">7.9&#160;&#160;&#160;&#160;Transactions with Affiliates.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Directly or indirectly enter into or permit to exist any material transaction with any Affiliate of Borrower or any of its Subsidiaries, except for (a) transactions that are in the ordinary course of Borrower&#8217;s or such Subsidiary&#8217;s business, upon fair and reasonable terms that are no less favorable to Borrower or such Subsidiary than would be obtained in an arm&#8217;s length transaction with a non-affiliated Person, (b) Subordinated Debt or equity investments by Borrower&#8217;s investors in Borrower or its Subsidiaries, and (c) compensation arrangements for Borrower&#8217;s and its Subsidiaries&#8217; officers, directors and employees that are customary in Borrower&#8217;s industry.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">7.10&#160;&#160;&#160;&#160;Subordinated Debt.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a) Make or permit any payment on any Subordinated Debt, except under the terms of the subordination, intercreditor, or other similar agreement to which such Subordinated Debt is subject, or (b) amend any provision in any document relating to the Subordinated Debt which would increase the amount thereof or adversely affect the subordination thereof to Obligations owed to the Lenders.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">7.11&#160;&#160;&#160;&#160;Compliance.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a) Become an &#8220;investment company&#8221; or a company controlled by an &#8220;investment company&#8221;, under the Investment Company Act of 1940, as amended, or undertake as one of its important activities extending credit to purchase or carry margin stock (as defined in Regulation U of the Board of Governors of the Federal Reserve System), or use the proceeds of any Term Loan for that purpose&#59; (b) fail to meet the minimum funding requirements of ERISA&#59; (c) permit a Reportable Event or Prohibited Transaction, as defined in ERISA, to occur&#59; (d) fail to comply with the Federal Fair Labor Standards Act or violate any other law or regulation, if the violation could reasonably be expected to have a Material Adverse Change, or permit any of its Subsidiaries to do so&#59; or (e) withdraw or permit any Subsidiary to withdraw from participation in, permit partial or complete termination of, or permit the occurrence of any other event with respect to, any present pension, profit sharing and deferred compensation plan which could reasonably be expected to result in any liability of Borrower or any of its Subsidiaries, including any liability to the Pension Benefit Guaranty Corporation or its successors or any other Governmental Authority.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">7.12&#160;&#160;&#160;&#160;Compliance with Anti-Terrorism Laws.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Neither Borrower nor any of its Subsidiaries shall, nor shall Borrower or any of its Subsidiaries permit any Affiliate to, directly or indirectly, knowingly enter into any documents, instruments, agreements or contracts with any Person listed on the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">30</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">OFAC Lists. Neither Borrower nor any of its Subsidiaries shall, nor shall Borrower or any of its Subsidiaries, permit any Affiliate to, directly or indirectly, (a) conduct any business or engage in any transaction or dealing with any Blocked Person, including, without limitation, the making or receiving of any contribution of funds, goods or services to or for the benefit of any Blocked Person, (b) deal in, or otherwise engage in any transaction relating to, any property or interests in property blocked pursuant to Executive Order No. 13224 or any similar executive order or other Anti-Terrorism Law, or (c) engage in or conspire to engage in any transaction that evades or avoids, or has the purpose of evading or avoiding, or attempts to violate, any of the prohibitions set forth in Executive Order No. 13224 or other Anti-Terrorism Law.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">7.13&#160;&#160;&#160;&#160;Minimum Liquidity.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Borrower shall not allow, at any time, the consolidated aggregate balance of its unrestricted cash and Cash Equivalents in Collateral Accounts that are subject to Control Agreements to be less than an amount equal to eighty percent (80%) of the outstanding principal balance of the Term Loans for any measurement period in which the Net Product Revenue of Borrower, calculated on a trailing six (6) month basis as of the last day of each month, is less than an amount equal to sixty percent (60%) of the outstanding principal balance of the Term Loans as of such date.</font></div><div style="margin-top:12.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:102%">8.&#160;&#160;&#160;&#160;EVENTS OF DEFAULT</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Any one of the following shall constitute an event of default (an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Event of Default</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) under this Agreement&#58;</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">8.1&#160;&#160;&#160;&#160;Payment Default.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Borrower fails to (a) make any payment of principal or interest on any Term Loan on its due date, or (b) pay any other Obligation within three (3) Business Days after such Obligations are due and payable (which three (3) Business Day grace period shall not apply to payments due on the Maturity Date or the date or acceleration pursuant to Section 9.1(a) hereof).</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">8.2&#160;&#160;&#160;&#160;Covenant Default.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;Borrower or any of its Subsidiaries fails or neglects to perform any obligation in Sections 6.2 (Financial Statements, Reports, Certificates), 6.4 (Taxes), 6.5 (Insurance), 6.6 (Operating Accounts), 6.7 (Protection of Intellectual Property Rights), 6.9 (Landlord Waivers&#59; Bailee Waivers), 6.10 (Creation&#47;Acquisition of Subsidiaries), 6.12 (Post-Effective Date Obligations) or Borrower violates any provision in Section 7&#59; or</font></div><div style="margin-top:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;Borrower, or any of its Subsidiaries, fails or neglects to perform, keep, or observe any other term, provision, condition, covenant or agreement contained in this Agreement or any other Loan Document to which such person is a party, and as to any default (other than those specified in this Section 8) under such other term, provision, condition, covenant or agreement that can be cured, has failed to cure the default within fifteen (15) days after the occurrence thereof&#59; provided, however, that if the default cannot by its nature be cured within the fifteen (15) day period or cannot after diligent attempts by Borrower or such Subsidiary, as applicable, be cured within such fifteen (15) day period, and such default is likely to be cured within a reasonable time, then Borrower shall have an additional period (which shall not in any case exceed thirty (30) days) to attempt to cure such default, and within such reasonable time period the failure to cure the default shall not be deemed an Event of Default (but no Term Loans shall be made during such cure period).</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">8.3&#160;&#160;&#160;&#160;Material Adverse Change.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Required Lenders determine that a Material Adverse Change has occurred.</font></div><div style="margin-top:11pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">8.4&#160;&#160;&#160;&#160;Attachment&#59; Levy&#59; Restraint on Business.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;(i) The service of process seeking to attach, by trustee or similar process, any funds of Borrower or any of its Subsidiaries or of any entity under control of Borrower or its Subsidiaries on deposit with any institution at which Borrower or any of its Subsidiaries maintains a Collateral Account, or (ii) a notice of lien, levy, or assessment is filed against Borrower or any of its Subsidiaries or their respective assets by any government agency, and the same under subclauses (i) and (ii) of this clause </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">31</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a) are not, within ten (10) days after the occurrence thereof, discharged or stayed (whether through the posting of a bond or otherwise)&#59; and</font></div><div style="margin-top:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;(i) any material portion of Borrower&#8217;s or any of its Subsidiaries&#8217; assets is attached, seized, levied on, or comes into possession of a trustee or receiver, or (ii) any court order enjoins, restrains, or prevents Borrower or any of its Subsidiaries from conducting any part of its business.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">8.5&#160;&#160;&#160;&#160;Insolvency.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a) Borrower or any of its Subsidiaries is or becomes Insolvent&#59; (b) Borrower or any of its Subsidiaries begins an Insolvency Proceeding&#59; or (c) an Insolvency Proceeding is begun against Borrower or any of its Subsidiaries and not dismissed or stayed within forty-five (45) days (but no Term Loans shall be made while Borrower or any Subsidiary is Insolvent and&#47;or until any Insolvency Proceeding is dismissed).</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">8.6&#160;&#160;&#160;&#160;Other Agreements.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">There is a default in any agreement to which Borrower or any of its</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Subsidiaries is a party with a third party or parties resulting in a right by such third party or parties, whether or not exercised, to accelerate the maturity of any Indebtedness in an amount in excess of Three Hundred Fifty Thousand Dollars ($350,000) or that could reasonably be expected to have a Material Adverse Change.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">8.7&#160;&#160;&#160;&#160;Judgments.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">One or more judgments, orders, or decrees for the payment of money in an amount, individually or in the aggregate, of at least Three Hundred Fifty Thousand Dollars ($350,000) (not covered by independent third-party insurance as to which (a) Borrower reasonably believes such insurance carrier will accept liability, (b) Borrower or the applicable Subsidiary has submitted such claim to such insurance carrier and (c) liability has not been rejected by such insurance carrier) shall be rendered against Borrower or any of its Subsidiaries and shall remain unsatisfied, unvacated, or unstayed for a period of ten (10) days after the entry thereof.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">8.8&#160;&#160;&#160;&#160;Misrepresentations.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Borrower or any of its Subsidiaries or any Person acting for Borrower or any of its Subsidiaries makes any representation, warranty, or other statement now or later in this Agreement, any Loan Document or in any writing delivered to Collateral Agent and&#47;or the Lenders or to induce Collateral Agent and&#47;or the Lenders to enter this Agreement or any Loan Document, and such representation, warranty, or other statement, when taken as a whole, is incorrect in any material respect when made.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">8.9&#160;&#160;&#160;&#160;Subordinated Debt.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A default or breach occurs under any subordination agreement, or any</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">creditor that has signed such an agreement with Collateral Agent or the Lenders breaches any terms of such agreement.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">8.10&#160;&#160;&#160;&#160;Guaranty.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a) Any Guaranty terminates or ceases for any reason to be in full force and effect&#59; (b) any Guarantor does not perform any obligation or covenant under any Guaranty&#59; or (c) any circumstance described in Section 8 occurs with respect to any Guarantor.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">8.11&#160;&#160;&#160;&#160;Governmental Approvals&#59; FDA Action.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a) Any Governmental Approval shall have been</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">revoked, rescinded, suspended, modified in an adverse manner, or not renewed in the ordinary course for a full term </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">such revocation, rescission, suspension, modification or non-renewal has resulted in or could reasonably be expected to result in a Material Adverse Change&#59; or (b) (i) the FDA or other Governmental Authority initiates a Regulatory Action or any other enforcement action against Borrower or any of its Subsidiaries or any supplier of Borrower or any of its Subsidiaries that causes Borrower or any of its Subsidiaries to recall, withdraw, remove or discontinue marketing any of its products&#59; (ii) the FDA or any other comparable Governmental Authority issues a warning letter to Borrower or any of its Subsidiaries with respect to any of its activities or products which could reasonably be expected to result in a Material Adverse Change&#59; (iii) Borrower or any of its Subsidiaries conducts a mandatory or voluntary recall which could reasonably be expected to result in liability and expense to Borrower or any of its Subsidiaries of the Applicable FDA Threshold or more&#59; (iv) Borrower or any of its Subsidiaries enters into a settlement agreement with the FDA that results in aggregate liability as to any single or related series of transactions, incidents or conditions, of the Applicable FDA Threshold or more, or that could reasonably be expected to result in a Material Adverse Change&#59; or (v) the FDA or any other comparable Governmental Authority revokes any authorization or permission granted under any </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">32</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Registration, or Borrower or any of its Subsidiaries withdraws any Registration, that could reasonably be expected to result in a Material Adverse Change.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">8.12&#160;&#160;&#160;&#160;Lien Priority.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Except as the result of the action or inaction of the Collateral Agent or the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Lenders, any Lien created hereunder or by any other Loan Document shall at any time fail to constitute a valid and perfected Lien (to the extent required to be perfected) on any material Collateral purported to be secured thereby, subject to no prior or equal Lien, other than Permitted Liens arising as a matter of applicable law.</font></div><div style="margin-top:12.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:102%">9.&#160;&#160;&#160;&#160;RIGHTS AND REMEDIES</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">9.1&#160;&#160;&#160;&#160;Rights and Remedies.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;Upon the occurrence and during the continuance of an Event of Default, Collateral Agent shall at the written direction of Required Lenders, without notice or demand, do any or all of the following&#58; (i) deliver notice of the Event of Default to Borrower, (ii) by notice to Borrower declare all Obligations immediately due and payable (but if an Event of Default described in Section 8.5 occurs all Obligations shall be immediately due and payable without any action by Collateral Agent or the Lenders) or (iii) by notice to Borrower suspend or terminate the obligations, if any, of the Lenders to advance money or extend credit for Borrower&#8217;s benefit under this Agreement or under any other agreement between Borrower and Collateral Agent and&#47;or the Lenders (but if an Event of Default described in Section 8.5 occurs all obligations, if any, of the Lenders to advance money or extend credit for Borrower&#8217;s benefit under this Agreement or under any other agreement between Borrower and Collateral Agent and&#47;or the Lenders shall be immediately terminated without any action by Collateral Agent or the Lenders).</font></div><div style="margin-top:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;Without limiting the rights of Collateral Agent and the Lenders set forth in Section 9.1(a) above, upon the occurrence and during the continuance of an Event of Default, Collateral Agent shall at the written direction of the Required Lenders, without notice or demand, to do any or all of the following&#58;</font></div><div style="margin-top:11pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;foreclose upon and&#47;or sell or otherwise liquidate, the Collateral&#59;</font></div><div style="margin-top:11pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;make a demand for payment upon any Guarantor pursuant to the Guaranty delivered by such Guarantor&#59;</font></div><div style="margin-top:11pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;apply to the Obligations any (A) balances and deposits of Borrower that Collateral Agent or any Lender holds or controls, (B) any amount held or controlled by Collateral Agent or any Lender owing to or for the credit or the account of Borrower, or (C) amounts received from any Guarantors in accordance with the respective Guaranty delivered by such Guarantor&#59; and&#47;or</font></div><div style="margin-top:11pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iv)&#160;&#160;&#160;&#160;commence and prosecute an Insolvency Proceeding or consent to Borrower commencing any Insolvency Proceeding.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;Without limiting the rights of Collateral Agent and the Lenders set forth in Sections 9.1(a) and (b) above, upon the occurrence and during the continuance of an Event of Default, Collateral Agent shall at the written direction of the Required Lenders, without notice or demand, to do any or all of the following&#58;</font></div><div style="margin-top:11pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;settle or adjust disputes and claims directly with Account Debtors for amounts on terms and in any order that Collateral Agent considers advisable, notify any Person owing Borrower money of Collateral Agent&#8217;s security interest in such funds, and verify the amount of such account&#59;</font></div><div style="margin-top:11pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;make any payments and do any acts it considers necessary or reasonable to protect the Collateral and&#47;or its Liens in the Collateral (held for the ratable benefit of the Secured Parties). Borrower shall assemble the Collateral if Collateral Agent requests and make it available at such location as Collateral Agent reasonably designates. Collateral Agent may enter premises where the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">33</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Collateral is located, take and maintain possession of any part of the Collateral, and pay, purchase, contest, or compromise any Lien which appears to be prior or superior to its security interest and pay all expenses incurred. Borrower grants Collateral Agent a license to enter and occupy any of its premises, without charge, to exercise any of Collateral Agent&#8217;s rights or remedies&#59;</font></div><div style="margin-top:11pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;ship, reclaim, recover, store, finish, maintain, repair, prepare for sale, and&#47;or advertise for sale, any of the Collateral. Collateral Agent is hereby granted a non-exclusive, royalty-free license or other right to use, without charge, Borrower&#8217;s and each of its Subsidiaries&#8217; labels, patents, copyrights, mask works, rights of use of any name, trade secrets, trade names, trademarks, service marks, and advertising matter, or any similar property as it pertains to the Collateral, in completing production of, advertising for sale, and selling any Collateral and, in connection with Collateral Agent&#8217;s exercise of its rights under this Section 9.1, Borrower&#8217;s and each of its Subsidiaries&#8217; rights under all licenses and all franchise agreements inure to Collateral Agent, for the benefit of the Lenders&#59;</font></div><div style="margin-top:11pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iv)&#160;&#160;&#160;&#160;place a &#8220;hold&#8221; on any Collateral Account maintained with Collateral Agent or any Lender or otherwise in respect of which a Control Agreement has been delivered in favor of Collateral Agent (for the ratable benefit of the Secured Parties) and&#47;or deliver a notice of exclusive control, any entitlement order, or other directions or instructions pursuant to any Control Agreement or similar agreements providing control of any Collateral&#59;</font></div><div style="margin-top:11pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(v)&#160;&#160;&#160;&#160;demand and receive possession of Borrower&#8217;s Books&#59;</font></div><div style="margin-top:11pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(vi)&#160;&#160;&#160;&#160;appoint a receiver to seize, manage and realize any of the Collateral, and such receiver shall have any right and authority as any competent court will grant or authorize in accordance with any applicable law, including any power or authority to manage the business of Borrower or any of its Subsidiaries&#59; and</font></div><div style="margin-top:11pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(vii)&#160;&#160;&#160;&#160;subject to clauses 9.1(a) and (b), exercise all rights and remedies available to Collateral Agent and each Lender under the Loan Documents or at law or equity, including all remedies provided under the Code (including disposal of the Collateral pursuant to the terms thereof).</font></div><div style="margin-top:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Notwithstanding any provision of this Section 9.1 to the contrary, upon the occurrence of any Event of Default, Collateral Agent shall have the right to exercise any and all remedies referenced in this Section 9.1 without the written consent of Required Lenders following the occurrence and during the continuance of an Exigent Circumstance.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">9.2&#160;&#160;&#160;&#160;Power of Attorney.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Borrower hereby irrevocably appoints Collateral Agent as its lawful attorney-in-fact, exercisable upon the occurrence and during the continuance of an Event of Default, to&#58; (a) endorse Borrower&#8217;s or any of its Subsidiaries&#8217; name on any checks or other forms of payment or security&#59; (b) sign Borrower&#8217;s or any of its Subsidiaries&#8217; name on any invoice or bill of lading for any Account or drafts against Account Debtors&#59; (c) settle and adjust disputes and claims about the Accounts of Borrower directly with the applicable Account Debtors, for amounts and on terms Collateral Agent determines reasonable&#59; (d) make, settle, and adjust all claims under Borrower&#8217;s insurance policies&#59; (e) pay, contest or settle any Lien, charge, encumbrance, security interest, and adverse claim in or to the Collateral, or any judgment based thereon, or otherwise take any action to terminate or discharge the same&#59; and (f) transfer the Collateral into the name of Collateral Agent or a third party as the Code or any applicable law permits. Borrower hereby appoints Collateral Agent as its lawful attorney-in-fact to sign Borrower&#8217;s or any of its Subsidiaries&#8217; name on any documents necessary to perfect or continue the perfection of Collateral Agent&#8217;s security interest in the Collateral regardless of whether an Event of Default has occurred until all Obligations (other than (a) inchoate indemnity obligations, and (b) other obligations that, by their terms, survive termination of this Agreement, in each case, for which no claim has been made) have been satisfied in full and Collateral Agent and the Lenders are under no further obligation to extend Term Loans hereunder. Collateral Agent&#8217;s foregoing appointment as Borrower&#8217;s or any of its Subsidiaries&#8217; attorney in fact, and all of Collateral Agent&#8217;s rights and powers, coupled with an interest, are irrevocable until all Obligations (other than (a) inchoate indemnity obligations, and (b) other obligations that, by their terms, survive termination of this Agreement, in each case, for which no claim has been made) have been fully repaid and performed and Collateral Agent&#8217;s and the Lenders&#8217; obligation to provide Term Loans terminates.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">34</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">9.3&#160;&#160;&#160;&#160;Protective Payments.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If Borrower or any of its Subsidiaries fail to obtain the insurance called for by Section 6.5 or fail to pay any premium thereon or fail to pay any other amount which Borrower or any of its Subsidiaries is obligated to pay under this Agreement or any other Loan Document, Collateral Agent may obtain such insurance or make such payment, and all amounts so paid by Collateral Agent are Lenders&#8217; Expenses and immediately due and payable, bearing interest at the Default Rate, and secured by the Collateral. Collateral Agent will make reasonable efforts to provide Borrower with notice of Collateral Agent obtaining such insurance or making such payment at the time it is obtained or paid or within a reasonable time thereafter. No such payments by Collateral Agent are deemed an agreement to make similar payments in the future or Collateral Agent&#8217;s waiver of any Event of Default.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">9.4&#160;&#160;&#160;&#160;Application of Payments and Proceeds.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Notwithstanding anything to the contrary contained in this Agreement, upon the occurrence and during the continuance of an Event of Default, (a) Borrower irrevocably waives the right to direct the application of any and all payments at any time or times thereafter received by Collateral Agent from or on behalf of Borrower or any of its Subsidiaries of all or any part of the Obligations, and, as between Borrower on the one hand and Collateral Agent and Lenders on the other, Collateral Agent shall have the continuing and exclusive right to apply and to reapply any and all payments received against the Obligations in such manner as Collateral Agent may deem advisable notwithstanding any previous application by Collateral Agent, and (b) the proceeds of any sale of, or other realization upon all or any part of the Collateral shall be applied&#58; first, to the Lenders&#8217; Expenses&#59; second, to accrued and unpaid interest on the Obligations (including any interest which, but for the provisions of the United States Bankruptcy Code, would have accrued on such amounts)&#59; third, to the principal amount of the Obligations outstanding&#59; and fourth, to any other Obligations owing to Collateral Agent or any Lender under the Loan Documents. Any balance remaining shall be delivered to Borrower or to whoever may be lawfully entitled to receive such balance or as a court of competent jurisdiction may direct. In carrying out the foregoing, (x) amounts received shall be applied in the numerical order provided until exhausted prior to the application to the next succeeding category, and (y) each of the Persons entitled to receive a payment in any particular category shall receive an amount equal to its pro rata share of amounts available to be applied pursuant thereto for such category. Any reference in this Agreement to an allocation between or sharing by the Lenders of any right, interest or obligation &#8220;ratably,&#8221; &#8220;proportionally&#8221; or in similar terms shall refer to the Lenders&#8217; Pro Rata Shares unless expressly provided otherwise. Collateral Agent, or if applicable, each Lender, shall promptly remit to the other Lenders such sums as may be necessary to ensure the ratable repayment of each Lender&#8217;s Pro Rata Share of any Term Loan and the ratable distribution of interest, fees and reimbursements paid or made by Borrower. Notwithstanding the foregoing, a Lender receiving a scheduled payment shall not be responsible for determining whether the other Lenders also received their scheduled payment on such date&#59; provided, however, if it is later determined that a Lender received more than its Pro Rata Share of scheduled payments made on any date or dates, then such Lender shall remit to Collateral Agent or other the Lenders such sums as may be necessary to ensure the ratable payment of such scheduled payments, as instructed by Collateral Agent. If any payment or distribution of any kind or character, whether in cash, properties or securities, shall be received by a Lender in excess of its Pro Rata Share, then the portion of such payment or distribution in excess of such Lender&#8217;s Pro Rata Share shall be received and held by such Lender in trust for and shall be promptly paid over to the other Lenders (in accordance with their respective Pro Rata Shares) for application to the payments of amounts due on such other Lenders&#8217; claims. To the extent any payment for the account of Borrower is required to be returned as a voidable transfer or otherwise, the Lenders shall contribute to one another as is necessary to ensure that such return of payment is on a pro rata basis. If any Lender shall obtain possession of any Collateral, it shall hold such Collateral for itself and as agent and bailee for the Secured Parties for purposes of perfecting Collateral Agent&#8217;s security interest therein (held for the ratable benefit of the Secured Parties).</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">9.5&#160;&#160;&#160;&#160;Liability for Collateral.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">So long as Collateral Agent and the Lenders comply with reasonable banking practices regarding the safekeeping of the Collateral in the possession or under the control of Collateral Agent and the Lenders, Collateral Agent and the Lenders shall not be liable or responsible for&#58; (a) the safekeeping of the Collateral&#59; (b) any loss or damage to the Collateral&#59; (c) any diminution in the value of the Collateral&#59; or (d) any act or default of any carrier, warehouseman, bailee, or other Person. Borrower bears all risk of loss, damage or destruction of the Collateral.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">9.6&#160;&#160;&#160;&#160;No Waiver&#59; Remedies Cumulative.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Failure by Collateral Agent or any Lender, at any time or times, to require strict performance by Borrower of any provision of this Agreement or by </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">35</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Borrower or any other Loan Document shall not waive, affect, or diminish any right of Collateral Agent or any Lender thereafter to demand strict performance and compliance herewith or therewith. No waiver hereunder shall be effective unless signed by Collateral Agent and the Required Lenders and then is only effective for the specific instance and purpose for which it is given. The rights and remedies of Collateral Agent and the Lenders under this Agreement and the other Loan Documents are cumulative. Collateral Agent and the Lenders have all rights and remedies provided under the Code, any applicable law, by law, or in equity. The exercise by Collateral Agent or any Lender of one right or remedy is not an election, and Collateral Agent&#8217;s or any Lender&#8217;s waiver of any Event of Default is not a continuing waiver. Collateral Agent&#8217;s or any Lender&#8217;s delay in exercising any remedy is not a waiver, election, or acquiescence.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">9.7&#160;&#160;&#160;&#160;Demand Waiver.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Borrower waives, to the fullest extent permitted by law, demand, notice of default or dishonor, notice of payment and nonpayment, notice of any default, nonpayment at maturity, release, compromise, settlement, extension, or renewal of accounts, documents, instruments, chattel paper, and guarantees held by Collateral Agent or any Lender on which Borrower or any Subsidiary is liable.</font></div><div style="margin-top:12.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:102%">10.&#160;&#160;&#160;&#160;NOTICES </font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other than as specifically provided herein, all notices, consents, requests, approvals, demands, or other communication (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Communications</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) by any party to this Agreement or any other Loan Document must be in writing and shall be deemed to have been validly served, given, or delivered&#58; (a) upon the earlier of actual receipt and three (3) Business Days after deposit in the U.S. mail, first class, registered or certified mail return receipt requested, with proper postage prepaid&#59; (b) upon transmission, when sent by facsimile transmission&#59; (c) one (1) Business Day after deposit with a reputable overnight courier with all charges prepaid&#59; or (d) when delivered, if hand-delivered by messenger, all of which shall be addressed to the party to be notified and sent to the address, facsimile number, or email address indicated below. Any of Collateral Agent, Lender or Borrower may change its mailing address or facsimile number by giving the other party written notice thereof in accordance with the terms of this Section 10.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">36</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.313%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:60.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 78.4pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If to Borrower&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:11pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ARDELYX, INC.<br>400 Fifth Avenue, Suite 210<br>Waltham, MA 02451<br>Attn&#58; Justin Renz <br>Email&#58; </font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 78.4pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">with a copy (which shall not constitute notice) to&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:11pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">LATHAM &#38; WATKINS LLP<br>140 Scott Drive<br>Menlo Park, CA  94025<br>Attn&#58;  Mark Roeder<br>Email&#58;  </font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 78.4pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If to Collateral Agent&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SLR INVESTMENT CORP.<br>500 Park Avenue, 3rd Floor <br>New York, NY  10022 <br>Attn&#58;  Anthony Storino</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Fax&#58; (212) 993-1698<br>Email&#58;  </font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 78.4pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">with a copy (which shall not constitute notice) to&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:11pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">DLA Piper LLP (US) <br>500 8</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Street, NW<br>Washington, DC 20004<br>Attn&#58;  Eric Eisenberg<br>Fax&#58; (202) 799-5211<br>Email&#58;</font></div></td></tr></table></div><div style="margin-top:12.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:102%">11.&#160;&#160;&#160;&#160;CHOICE OF LAW, VENUE AND JURY TRIAL WAIVER</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">11.1&#160;&#160;&#160;&#160;Waiver of Jury Trial.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EACH OF BORROWER, COLLATERAL AGENT AND LENDERS UNCONDITIONALLY WAIVES ANY AND ALL RIGHT TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF THIS AGREEMENT, ANY OF THE OTHER LOAN DOCUMENTS, ANY OF THE INDEBTEDNESS SECURED HEREBY, ANY DEALINGS AMONG BORROWER, COLLATERAL AGENT AND&#47;OR LENDERS RELATING TO THE SUBJECT MATTER OF THIS TRANSACTION OR ANY RELATED TRANSACTIONS, AND&#47;OR THE RELATIONSHIP THAT IS BEING ESTABLISHED AMONG BORROWER, COLLATERAL AGENT AND&#47;OR LENDERS. THE SCOPE OF THIS WAIVER IS INTENDED TO BE ALL ENCOMPASSING OF ANY AND ALL DISPUTES THAT MAY BE FILED IN ANY COURT. THIS WAIVER IS IRREVOCABLE. THIS WAIVER MAY NOT BE MODIFIED</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EITHER ORALLY OR IN WRITING. THE WAIVER ALSO SHALL APPLY TO ANY SUBSEQUENT AMENDMENTS, RENEWALS, SUPPLEMENTS OR MODIFICATIONS TO THIS AGREEMENT, ANY OTHER LOAN DOCUMENTS, OR TO ANY OTHER DOCUMENTS OR AGREEMENTS RELATING TO THIS TRANSACTION OR ANY RELATED TRANSACTION. THIS AGREEMENT MAY BE FILED AS A WRITTEN CONSENT TO A TRIAL BY THE COURT. </font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">11.2&#160;&#160;&#160;&#160;Governing Law and Jurisdiction. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">THIS AGREEMENT, THE OTHER LOAN DOCUMENTS (EXCLUDING THOSE LOAN DOCUMENTS THAT BY THEIR OWN TERMS ARE EXPRESSLY GOVERNED BY THE LAWS OF ANOTHER JURISDICTION) AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES HEREUNDER AND THEREUNDER SHALL IN ALL RESPECTS BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH, THE INTERNAL LAWS OF THE STATE OF NEW YORK (WITHOUT REGARD TO THE CONFLICT OF LAWS PRINCIPLES THAT WOULD RESULT IN THE APPLICATION OF ANY LAW OTHER THAN THE LAW OF SUCH STATE (OTHER THAN SECTION 5-1401 OF THE GENERAL OBLIGATIONS LAW)), INCLUDING ALL MATTERS OF CONSTRUCTION, VALIDITY AND PERFORMANCE, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">37</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">REGARDLESS OF THE LOCATION OF THE COLLATERAL, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">PROVIDED</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">HOWEVER</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, THAT IF THE LAWS OF ANY JURISDICTION OTHER THAN NEW YORK SHALL GOVERN IN REGARD TO THE VALIDITY, PERFECTION OR EFFECT OF PERFECTION OF ANY LIEN OR IN REGARD TO PROCEDURAL MATTERS AFFECTING ENFORCEMENT OF ANY LIENS IN COLLATERAL, SUCH LAWS OF SUCH OTHER JURISDICTIONS SHALL CONTINUE TO APPLY TO THAT EXTENT.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">11.3&#160;&#160;&#160;&#160;Submission to Jurisdiction.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Any legal action or proceeding with respect to the Loan Documents shall be brought exclusively in the courts of the State of New York located in the City of New York, Borough of Manhattan, or of the United States of America for the Southern District of New York and, by execution and delivery of this Agreement, Borrower hereby accepts for itself and in respect of its Property, generally and unconditionally, the jurisdiction of the aforesaid courts. Notwithstanding the foregoing, Collateral Agent and Lenders shall have the right to bring any action or proceeding against Borrower (or any property of Borrower) in the court of any other jurisdiction Collateral Agent or Lenders deem necessary or appropriate in order to realize on the Collateral or other security for the Obligations. The parties hereto hereby irrevocably waive any objection, including any objection to the laying of venue or based on the grounds of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">forum non conveniens</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that any of them may now or hereafter have to the bringing of any such action or proceeding in such jurisdictions.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">11.4&#160;&#160;&#160;&#160;Service of Process.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Borrower irrevocably waives personal service of any and all legal process, summons, notices and other documents and other service of process of any kind and consents to such service in any suit, action or proceeding brought in the United States of America with respect to or otherwise arising out of or in connection with any Loan Document by any means permitted by applicable requirements of law, including by the mailing thereof (by registered or certified mail, postage prepaid) to the address of Borrower specified herein (and shall be effective when such mailing shall be effective, as provided therein). Borrower agrees that a final judgment in any such action or proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by law.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">11.5&#160;&#160;&#160;&#160;Non-exclusive Jurisdiction.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Nothing contained in this Article 11 shall affect the right of Collateral Agent or Lenders to serve process in any other manner permitted by applicable requirements of law or commence legal proceedings or otherwise proceed against Borrower in any other jurisdiction.</font></div><div style="margin-top:12.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:102%">12.&#160;&#160;&#160;&#160;GENERAL PROVISIONS</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">12.1&#160;&#160;&#160;&#160;Successors and Assigns.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Agreement binds and is for the benefit of the successors and permitted assigns of each party. Borrower may not transfer, pledge or assign this Agreement or any rights or obligations under it without Collateral Agent&#8217;s prior written consent (which may be granted or withheld in Collateral Agent&#8217;s discretion, subject to Section 12.5). The Lenders have the right, without the consent of or notice to Borrower, to sell, transfer, assign, pledge, negotiate, or grant participation in (any such sale, transfer, assignment, negotiation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">or grant of a participation, a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8220;Lender Transfer&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">) all or any part of, or any interest in, the Lenders&#8217; obligations, rights, and benefits under this Agreement and the other Loan Documents&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that any such Lender Transfer (other than (i) any Transfer at any time that an Event of Default has occurred and is continuing, or (ii) a transfer, pledge, sale or assignment to an Eligible Assignee) of its obligations, rights, and benefits under this Agreement and the other Loan Documents shall require the prior written consent of the Collateral Agent (such approved assignee, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Approved Lender</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)&#59; and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided, further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that on the date it becomes a party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">to this Agreement, an Approved Lender must be capable, through its applicable lending office, of receiving payments of interest from Borrower without the imposition of any withholding taxes that would be required to be borne by Borrower or requiring the payment of any additional amounts by Borrower pursuant to Section 2.5 hereof. Borrower and Collateral Agent shall be entitled to continue to deal solely and directly with such Lender in connection with the interests so assigned until Collateral Agent shall have received and accepted an effective assignment agreement in form satisfactory to Collateral Agent executed, delivered and fully completed by the applicable parties thereto, and shall have received such other information regarding such Eligible Assignee or Approved Lender as Collateral Agent reasonably shall require. Collateral Agent shall use commercially reasonable efforts to provide notice to Borrower of each Lender Transfer promptly following such Lender Transfer. Notwithstanding anything to the contrary contained herein, so long as no Event of Default has occurred and is continuing, no Lender Transfer </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">38</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(other than a Lender Transfer in connection with (x) assignments by a Lender due to a forced divestiture at the request of any regulatory agency&#59; or (y) upon the occurrence of a default, event of default or similar occurrence with respect to a Lender&#8217;s own financing or securitization transactions) shall be permitted, without Borrower&#8217;s consent, to any Person which is an Affiliate or Subsidiary of Borrower, a direct competitor of Borrower, a vulture hedge fund or a distressed debt fund, each as reasonably determined by Collateral Agent at the time of such assignment.  Collateral Agent, acting solely for this purpose as an agent of Borrower, shall maintain at one of its offices in the United States a register for the recordation of the names and addresses of the Lenders, and the Term Loan Commitments of, and principal amounts (and stated interest) of the Term Loans owing to each Lender pursuant to the terms hereof from time to time (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Register</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  The entries in the Register shall be conclusive absent manifest error, and Borrower, Collateral Agent and Lenders shall treat each Person whose name is recorded in the Register pursuant to the terms hereof as Lender hereunder for all purposes of this Agreement.  The Register shall be available for inspection by Borrower and any Lender at any reasonable time and from time to time upon reasonable prior notice.  Each Lender that sells a participation shall, acting solely for this purpose as a non-fiduciary agent of Borrower, maintain a register on which it enters the name and address of each participant and the principal amounts (and stated interest) of each participant&#8217;s interest in the Term Loans or other obligations under the Loan Documents (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Participant Register</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)&#59; provided that no Lender shall have any obligation to disclose all or any portion of the Participant Register (including the identity of any participant or any information relating to a participant&#8217;s interest in any commitments, loans or its other obligations under any Loan Document) to any Person except to the extent that such disclosure is necessary to establish that such commitment, loan or other obligation is in registered form under Section 5f.103-1(c) of the United States Treasury Regulations.  The entries in the Participant Register shall be conclusive absent manifest error, and such Lender shall treat each Person whose name is recorded in the Participant Register as the owner of such participation for all purposes of this Agreement notwithstanding any notice to the contrary.  For the avoidance of doubt, Collateral Agent (in its capacity as Collateral Agent) shall have no responsibility for maintaining a Participant Register.  Borrower agrees that each participant shall be entitled to the benefits of the provisions in Exhibit C attached hereto (subject to the requirements and limitations therein, including the requirements under Section 7 of Exhibit C attached hereto (it being understood that the documentation required under Section 7 of Exhibit C attached hereto shall be delivered to the participating Lender)) to the same extent as if it were a Lender and had acquired its interest by assignment pursuant to this Section 12.1&#59; provided that such participant shall not be entitled to receive any greater payment under Exhibit C attached hereto, with respect to any participation, than its participating Lender would have been entitled to receive, except to the extent such entitlement to receive a greater payment results from a change in law that occurs after the participant acquired the applicable participation.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">12.2&#160;&#160;&#160;&#160;Indemnification.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Subject to Section 2.5, Borrower agrees to indemnify, defend and hold each Secured Party and their respective directors, officers, employees, consultants, agents, attorneys, or any other Person affiliated with or representing such Secured Party (each, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Indemnified Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) harmless against&#58; (a) all obligations, demands, claims, and liabilities (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) asserted by any other party in connection with&#59; related to&#59; following&#59; or arising from, out of or under, the transactions contemplated by the Loan Documents&#59; and (b) all losses and Lenders&#8217; Expenses incurred, or paid by Indemnified Person in connection with&#59; related to&#59; following&#59; or arising from, out of or under, the transactions contemplated by the Loan Documents (including reasonable attorneys&#8217; fees and expenses), except, in each case, for Claims and&#47;or losses directly caused by such Indemnified Person&#8217;s gross negligence or willful misconduct. Borrower hereby further agrees to indemnify, defend and hold each Indemnified Person harmless from and against any and all liabilities, obligations, losses, damages, penalties, actions, judgments, suits, claims, costs, expenses and disbursements of any kind or nature whatsoever (including the fees and disbursements of counsel for such Indemnified Person) in connection with any investigative, response, remedial, administrative or judicial matter or proceeding, whether or not such Indemnified Person shall be designated a party thereto and including any such proceeding initiated by or on behalf of Borrower, and the reasonable expenses of investigation by engineers, environmental consultants and similar technical personnel and any commission, fee or compensation claimed by any broker (other than any broker retained by Collateral Agent or Lenders) asserting any right to payment for the transactions contemplated hereby which may be imposed on, incurred by or asserted against such Indemnified Person as a result of or in connection with the transactions contemplated hereby and the use or intended use of the proceeds of the loan proceeds except for liabilities, obligations, losses, damages, penalties, actions, judgments, suits, claims, costs, expenses and disbursements directly caused by such Indemnified Person&#8217;s gross negligence or willful misconduct. Notwithstanding the foregoing, if no direct </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">39</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">conflict of interest is apparent in connection with the defense of any Claim, Collateral Agent and the Lenders shall first take commercially reasonable efforts to use the same counsel as Borrower, or, if a conflict does exist, use only one counsel among all Indemnified Persons with respect to the defense of any Claim.  This Section 12.2 shall not apply with respect to any Indemnified Taxes subject to indemnification under Section 2.5 or Excluded Taxes.</font></div><div style="margin-top:11pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">12.3&#160;&#160;&#160;&#160;Severability of Provisions.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Each provision of this Agreement is severable from every other provision in determining the enforceability of any provision.</font></div><div style="margin-top:11pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">12.4&#160;&#160;&#160;&#160;Correction of Loan Documents.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Collateral Agent may correct patent errors and fill in any</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">blanks in this Agreement and the other Loan Documents consistent with the agreement of the parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">.</font></div><div style="margin-top:11pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">12.5&#160;&#160;&#160;&#160;Amendments in Writing&#59; Integration.  </font></div><div style="margin-top:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;No amendment, modification, termination or waiver of any provision of this Agreement or any other Loan Document, no approval or consent thereunder, or any consent to any departure by Borrower or any of its Subsidiaries therefrom, shall in any event be effective unless the same shall be in writing and signed by Borrower, Collateral Agent and the Required Lenders provided that&#58;</font></div><div style="margin-top:11pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;no such amendment, waiver or other modification that would have the effect of increasing or reducing a Lender&#8217;s Term Loan Commitment or Commitment Percentage shall be effective as to such Lender without such Lender&#8217;s written consent&#59;</font></div><div style="margin-top:11pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;no such amendment, waiver or modification that would affect the rights and duties of Collateral Agent shall be effective without Collateral Agent&#8217;s written consent or signature&#59; and</font></div><div style="margin-top:11pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;no such amendment, waiver or other modification shall, unless signed by all the Lenders directly affected thereby, (A) reduce the principal of, rate of interest on or any fees with respect to any Term Loan or forgive any principal, interest (other than default interest) or fees (other than late charges) with respect to any Term Loan (B) postpone the date fixed for, or waive, any payment of principal of any Term Loan or of interest on any Term Loan (other than default interest) or any fees provided for hereunder (other than late charges or for any termination of any commitment)&#59; (C) change the definition of the term &#8220;Required Lenders&#8221; or the percentage of Lenders which shall be required for the Lenders to take any action hereunder&#59; (D) release all or substantially all of any material portion of the Collateral, authorize Borrower to sell or otherwise dispose of all or substantially all or any material portion of the Collateral or release any Guarantor of all or any portion of the Obligations or its Guaranty obligations with respect thereto, except, in each case with respect to this clause (D), as otherwise may be expressly permitted under this Agreement or the other Loan Documents (including in connection with any disposition permitted hereunder)&#59; (E) amend, waive or otherwise modify this Section 12.5 or the definitions of the terms used in this Section 12.5 insofar as the definitions affect the substance of this Section 12.5&#59; (F) consent to the assignment, delegation or other transfer by Borrower of any of its rights and obligations under any Loan Document or release Borrower of its payment obligations under any Loan Document, except, in each case with respect to this clause (F), pursuant to a merger or consolidation permitted pursuant to this Agreement&#59; (G) amend any of the provisions of Section 9.4 or amend any of the definitions of Pro Rata Share, Term Loan Commitment, Commitment Percentage or that provide for the Lenders to receive their Pro Rata Shares of any fees, payments, setoffs or proceeds of Collateral hereunder&#59; (H) subordinate the Liens granted in favor of Collateral Agent securing the Obligations&#59; or (I) amend any of the provisions of Section 12.7 or Section 12.8.  It is hereby understood and agreed that all Lenders shall be deemed directly affected by an amendment, waiver or other modification of the type described in the preceding clauses (C), (D), (E), (F), (G) and (H) of the immediately preceding sentence.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;Other than as expressly provided for in Section 12.5(a)(i)-(iii), Collateral Agent may, if requested by the Required Lenders, from time to time designate covenants in this Agreement less restrictive by notification to a representative of Borrower.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;This Agreement and the Loan Documents represent the entire agreement about this subject matter and supersede prior negotiations or agreements with respect to such subject matter. All prior agreements, understandings, representations, warranties, and negotiations between the parties about </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">40</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">the subject matter of this Agreement and the Loan Documents merge into this Agreement and the Loan Documents.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">12.6&#160;&#160;&#160;&#160;Counterparts.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Agreement may be executed in any number of counterparts and by different parties on separate counterparts, each of which, when executed and delivered, is an original, and all taken together, constitute one Agreement.  Delivery of an executed counterpart of a signature page of this Agreement by facsimile, portable document format (.pdf) or other electronic transmission will be as effective as delivery of a manually executed counterpart hereof.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">12.7&#160;&#160;&#160;&#160;Survival.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">All covenants, representations and warranties made in this Agreement continue in full force and effect until this Agreement has terminated pursuant to its terms and all Obligations (other than (a) inchoate indemnity obligations, and (b) other obligations that, by their terms, survive termination of this Agreement, in each case, for which no claim has been made) have been satisfied. The obligation of Borrower in Section 12.2 to indemnify each Lender and Collateral Agent, as well as the confidentiality provisions in Section 12.8 below, shall survive until the statute of limitations with respect to such claim or cause of action shall have run.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">12.8&#160;&#160;&#160;&#160;Confidentiality.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In handling any confidential information of Borrower, each of the Lenders and Collateral Agent shall exercise the same degree of care that it exercises for their own proprietary information, but disclosure of information may be made&#58; (a) subject to the terms and conditions of this Agreement, to the Lenders&#8217; and Collateral Agent&#8217;s Subsidiaries or Affiliates, or in connection with a Lender&#8217;s own financing or securitization transactions and upon the occurrence of a default, event of default or similar occurrence with respect to such financing or securitization transaction&#59; (b) to prospective transferees (other than those identified in (a) above) or purchasers of any interest in the Term Loans (provided, however, the Lenders and Collateral Agent shall obtain such prospective transferee&#8217;s or purchaser&#8217;s agreement to the terms of this provision or to similar confidentiality terms)&#59; (c) as required by law, regulation, subpoena, or other order&#59; (d) to Lenders&#8217; or Collateral Agent&#8217;s regulators or as otherwise required in connection with an examination or audit&#59; (e) as Collateral Agent reasonably considers appropriate in exercising remedies under the Loan Documents&#59; and (f) to third party service providers of the Lenders and&#47;or Collateral Agent so long as such service providers have executed a confidentiality agreement or have agreed to similar confidentiality terms with the Lenders and&#47;or Collateral Agent, as applicable, with terms no less restrictive than those contained herein. Confidential information does not include information that either&#58; (i) is in the public domain or in the Lenders&#8217; and&#47;or Collateral Agent&#8217;s possession when disclosed to the Lenders and&#47;or Collateral Agent, or becomes part of the public domain after disclosure to the Lenders and&#47;or Collateral Agent through no fault of the Lenders or the Collateral Agent&#59; or (ii) is disclosed to the Lenders and&#47;or Collateral Agent by a third party, if the Lenders and&#47;or Collateral Agent does not know that the third party is prohibited from disclosing the information. Collateral Agent and the Lenders may use confidential information for any purpose, including, without limitation, for the development of client databases, reporting purposes, and market analysis. The provisions of the immediately preceding sentence shall survive the termination of this Agreement. The agreements provided under this Section 12.8 supersede all prior agreements, understanding, representations, warranties, and negotiations between the parties about the subject matter of this Section 12.8.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">12.9&#160;&#160;&#160;&#160;Right of Set Off.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Borrower hereby grants to Collateral Agent and to each Lender, a Lien, security interest and right of set off as security for all Obligations to Secured Parties hereunder, whether now existing or hereafter arising upon and against all deposits, credits, collateral and property, now or hereafter in the possession, custody, safekeeping or control of any Secured Party or any entity under the control of such Secured Party (including a Collateral Agent Affiliate) or in transit to any of them. At any time after the occurrence and during the continuance of an Event of Default, without demand or notice, any Secured Party may set off the same or any part thereof and apply the same to any liability or obligation of Borrower even though unmatured and regardless of the adequacy of any other collateral securing the Obligations.  ANY AND ALL RIGHTS TO REQUIRE COLLATERAL AGENT TO EXERCISE ITS RIGHTS OR REMEDIES WITH RESPECT TO ANY OTHER COLLATERAL WHICH SECURES THE OBLIGATIONS, PRIOR TO EXERCISING ITS RIGHT OF SETOFF WITH RESPECT TO SUCH DEPOSITS, CREDITS OR OTHER PROPERTY OF BORROWER ARE HEREBY KNOWINGLY, VOLUNTARILY AND IRREVOCABLY WAIVED BY BORROWER.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">41</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">12.10&#160;&#160;&#160;&#160;Cooperation of Borrower.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If necessary, Borrower agrees to (i) execute any documents reasonably required to effectuate and acknowledge each assignment of a Term Loan Commitment (or portion thereof) or Term Loan (or portion thereof) to an assignee in accordance with Section 12.1, (ii) make Borrower&#8217;s management personnel available to meet with Collateral Agent and prospective participants and assignees of Term Loan Commitments, the Term Loans or portions thereof (which meetings shall be conducted no more often than twice every twelve months unless an Event of Default has occurred and is continuing), and (iii) assist Collateral Agent and the Lenders in the preparation of information relating to the financial affairs of Borrower for any prospective participant or assignee of a Term Loan Commitment (or portions thereof) or Term Loan (or portions thereof) as Collateral Agent or such Lender may reasonably may request. Subject to the provisions of Section 12.8, Borrower authorizes each Lender to disclose to any prospective participant or assignee of a Term Loan Commitment (or portions thereof), any and all information in such Lender&#8217;s possession concerning Borrower and its financial affairs which has been delivered to such Lender by or on behalf of Borrower pursuant to this Agreement, or which has been delivered to such Lender by or on behalf of Borrower in connection with such Lender&#8217;s credit evaluation of Borrower prior to entering into this Agreement, in each case subject to Section 12.8.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">12.11&#160;&#160;&#160;&#160;Public Announcement.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Collateral Agent and each Lender may, with the prior written consent of Borrower (which consent may not be unreasonably conditioned, withheld or delayed), make a public announcement of the transactions contemplated by this Agreement, and may publicize the same in marketing materials, newspapers and other publications, and otherwise, and in connection therewith may use Borrower&#8217;s name, tradenames and logos. Notwithstanding the foregoing, such prior written consent from Borrower shall not be required for any disclosures by Collateral Agent or the Lenders required by the Securities and Exchange Commission or other governmental agency and any other public disclosure with investors, other governmental agencies or other related persons, in each case, subject to applicable law and regulations.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">12.12&#160;&#160;&#160;&#160;Collateral Agent and Lender Agreement.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Collateral Agent and each Lender hereby agree to the terms and conditions set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> attached hereto. Borrower acknowledges and agrees to the terms and conditions set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> attached hereto.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">12.13&#160;&#160;&#160;&#160;Time of Essence.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Time is of the essence for the performance of Obligations under this Agreement.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">12.14&#160;&#160;&#160;&#160;Termination Prior to Maturity Date&#59; Survival.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  All covenants, representations and warranties made in this Agreement continue in full force until this Agreement has terminated pursuant to its terms and all Obligations have been satisfied (other than (a) inchoate indemnity obligations, and (b) other obligations that, by their terms, survive termination of this Agreement, in each case, for which no claim has been made). So long as Borrower has satisfied the Obligations (other than (a) inchoate indemnity obligations, and (b) other obligations that, by their terms, survive termination of this Agreement, in each case, for which no claim has been made) in accordance with the terms of this Agreement, this Agreement may be terminated prior to the Maturity Date by Borrower, effective three (3) Business Days after written notice of termination is given to the Collateral Agent and the Lenders.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%">12.15&#160;&#160;&#160;&#160;Electronic Execution of Certain Other Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The words &#8220;execution,&#8221; &#8220;execute&#8221;, &#8220;signed,&#8221; &#8220;signature,&#8221; and words of like import in or related to any document to be signed in connection with this Agreement and the transactions contemplated hereby (including without limitation assignments, assumptions, amendments, waivers and consents) shall be deemed to include electronic signatures, the electronic matching of assignment terms and contract formations on electronic platforms approved by the Collateral Agent, or the keeping of records in electronic form, each of which shall be of the same legal effect, validity or enforceability as a manually executed signature or the use of a paper-based recordkeeping system, as the case may be, to the extent and as provided for in any applicable law, including the Federal Electronic Signatures in Global and National Commerce Act, the New York State Electronic Signatures and Records Act, or any other similar state laws based on the Uniform Electronic Transactions Act.</font></div><div style="margin-top:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Balance of Page Intentionally Left Blank</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">42</font></div><div><font><br></font></div></div></div><div id="i411762c6343a4d74a3d9f0d4e597f682_41"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, the parties hereto have caused this Agreement to be executed as of the Effective Date.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.767%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.320%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">BORROWER&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ARDELYX, INC.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By &#47;s&#47; Justin A. Renz</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58; Justin A. Renz</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58; CFO</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">COLLATERAL AGENT AND LENDER&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">SLR INVESTMENT CORP.</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By &#47;s&#47; Anthony Storino</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58; Anthony Storino</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58; Authorized Signatory</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:11pt"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;Signature Page to Loan and Security Agreement&#93;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EAST&#92;188087115.8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">LENDERS&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SLR SENIOR INVESTMENT CORP.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Anthony Storino</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Name&#58; Anthony Storino</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Title&#58; Authorized Signatory</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SCP PRIVATE CREDIT INCOME FUND SPV, LLC</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Anthony Storino</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Name&#58; Anthony Storino</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Title&#58; Authorized Signatory</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SCP PRIVATE CREDIT INCOME BDC SPV LLC</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Anthony Storino</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Name&#58; Anthony Storino</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Title&#58; Authorized Signatory</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SCP PRIVATE CORPORATE LENDING FUND SPV LLC</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Anthony Storino</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Name&#58; Anthony Storino</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Title&#58; Authorized Signatory</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SCP SF DEBT FUND L.P.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Anthony Storino</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Name&#58; Anthony Storino</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Title&#58; Authorized Signatory</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SLR HC FUND SPV, LLC</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Anthony Storino</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Name&#58; Anthony Storino</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Title&#58; Authorized Signatory</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SLR HC BDC LLC</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Anthony Storino</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Name&#58; Anthony Storino</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Title&#58; Authorized Signatory</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;Signature Page to Loan and Security Agreement&#93;</font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div></div></div><div id="i411762c6343a4d74a3d9f0d4e597f682_44"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:11.25pt;margin-top:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SCHEDULE 1.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Lenders and Commitments</font></div><div style="text-align:center"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.126%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.286%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.288%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Term A Loans</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Lender</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Term A Loan Commitment</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Commitment Percentage</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">SLR INVESTMENT CORP.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$7,846,125.90</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">28.53%</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">SLR SENIOR INVESTMENT CORP.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$1,629,125.26</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.92%</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">SCP PRIVATE CREDIT INCOME FUND SPV, LLC</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$4,449,548.38</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16.18%</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">SCP PRIVATE CREDIT INCOME BDC SPV LLC</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$3,319,342.73</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.07%</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">SCP PRIVATE CORPORATE LENDING FUND SPV LLC</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$4,321,998.05</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.72%</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">SCP SF DEBT FUND L.P.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$1,038,567.36</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.78%</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">SLR HC FUND SPV, LLC</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$4,044,074.37</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.71%</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">SLR HC BDC LLC</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$851,217.95</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.10%</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">TOTAL</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">$27,500,000</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">100.00%</font></td></tr></table></div><div style="margin-top:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Term B Loans</font></div><div style="text-align:center"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.340%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.340%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Lender</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Term B Loan Commitment</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Commitment Percentage</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">SLR INVESTMENT CORP.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$6,419,557.56</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">28.53%</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">SLR SENIOR INVESTMENT CORP.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$1,332,920.67</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.92%</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">SCP PRIVATE CREDIT INCOME FUND SPV, LLC</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$3,640,539.58</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16.18%</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">SCP PRIVATE CREDIT INCOME BDC SPV LLC</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$2,715,825.87</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.07%</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">SCP PRIVATE CORPORATE LENDING FUND SPV LLC</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$3,536,180.22</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.72%</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">SCP SF DEBT FUND L.P.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$849,736.93</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.78%</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">SLR HC FUND SPV, LLC</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$3,308,788.12</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.71%</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">SLR HC BDC LLC</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$696,451.05</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.10%</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">TOTAL</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">$22,500,000</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">100.00%</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:11pt;text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Aggregate (all Term Loans)</font></div><div style="text-align:center"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.340%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.340%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Lender</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Term Loan Commitment</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Commitment Percentage</font></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">SLR INVESTMENT CORP.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$14,265,683.46</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">28.53%</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">SLR SENIOR INVESTMENT CORP.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$2,962,045.93</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.92%</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">SCP PRIVATE CREDIT INCOME FUND SPV, LLC</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$8,090,087.96</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16.18%</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">SCP PRIVATE CREDIT INCOME BDC SPV LLC</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$6,035,168.60</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.07%</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">SCP PRIVATE CORPORATE LENDING FUND SPV LLC</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$7,858,178.27</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.72%</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">SCP SF DEBT FUND L.P.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$1,888,304.29</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.78%</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">SLR HC FUND SPV, LLC</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$7,352,862.49</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.71%</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">SLR HC BDC LLC</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$1,547,669.00</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.10%</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">TOTAL</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">$50,000,000</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">100.00%</font></td></tr></table></div><div style="margin-top:11pt;text-align:center"><font><br></font></div><div style="margin-top:11pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div></div></div><div id="i411762c6343a4d74a3d9f0d4e597f682_47"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:11pt;padding-left:1.8pt;padding-right:1.8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT A</font></div><div style="margin-top:11pt;padding-left:1.8pt;padding-right:1.8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Description of Collateral</font></div><div style="margin-top:11pt;padding-left:3.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Collateral consists of all of Borrower&#8217;s and Guarantors&#8217; right, title and interest in and to the following personal property&#58;</font></div><div style="margin-top:11pt;padding-left:3.6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">All goods, Accounts (including health care receivables), Equipment, Inventory, contract rights or rights to payment of money, leases, license agreements, franchise agreements, General Intangibles (except as noted below), commercial tort claims, documents, instruments (including any promissory notes), chattel paper (whether tangible or electronic), cash, deposit accounts and other Collateral Accounts, all certificates of deposit, fixtures, letters of credit rights (whether or not the letter of credit is evidenced by a writing), securities, and all other investment property, supporting obligations, and financial assets, whether now owned or hereafter acquired, wherever located&#59; and</font></div><div style="margin-top:11pt;padding-left:3.6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">All Borrower&#8217;s Books relating to the foregoing, and any and all claims, rights and interests in any of the above and all substitutions for, additions, attachments, accessories, accessions and improvements to and replacements, products, proceeds and insurance proceeds of any or all of the foregoing.</font></div><div style="margin-bottom:203.9pt;margin-top:11pt;padding-left:3.6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Notwithstanding the foregoing, the Collateral does not include (a) (1) more than 65% of the presently existing and hereafter arising issued and outstanding shares of capital stock owned by Borrower or any Guarantor of any Foreign Subsidiary or any Excluded Domestic Subsidiary which shares entitle the holder thereof to vote for directors or any other matter or (2) any of the stock or other equity interests in any Foreign Subsidiary that is not owned by Borrower or a Guarantor, (b) any interest of Borrower as a lessee or sublessee under a real property lease&#59; (c) rights held under a license or other agreement that are not assignable by their terms without the consent of the counterparty thereof (but only to the extent such restriction on assignment is effective under Section 9-406, 9-407, 9408 or 9-409 of the Code (or any successor provision or provisions) of any relevant jurisdiction or any other applicable law (including the Bankruptcy Code) or principles of equity)&#59; (d) any interest of Borrower or any Guarantor as a lessee or borrower under an Equipment lease or Equipment financing if Borrower or such Guarantor, as applicable, is prohibited by the terms of such agreement from granting a security interest in such lease or agreement or under which such an assignment or Lien would cause a default to occur under such lease&#59; provided, however, that upon termination of such prohibition, such interest shall immediately become Collateral without any action by Borrower (or such Guarantor, as applicable), Collateral Agent or any Lender, or (e) any Intellectual Property&#59; provided, however, the Collateral shall include, all Accounts with respect to Intellectual Property and all proceeds of Intellectual Property and any sale of Intellectual Property. If a judicial authority (including a U.S. Bankruptcy Court) would hold that a security interest in the underlying Intellectual Property is necessary to have a security interest in such Accounts and such property that are proceeds of Intellectual Property, then the Collateral shall automatically, and effective as of the Effective Date, include the Intellectual Property to the extent necessary to permit perfection of Collateral Agent&#8217;s security interest in such Accounts and such other property of Borrower that are proceeds of the Intellectual Property.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:1.8pt;padding-right:1.8pt;text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT B</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:1.8pt;padding-right:1.8pt;text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Collateral Agent and Lender Terms</font></div><div style="padding-left:1.8pt;padding-right:1.8pt;text-align:center;text-indent:36pt"><font><br></font></div><div style="margin-bottom:11pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:9.75pt">Appointment of Collateral Agent.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;Each Lender hereby appoints SLR (together with any successor Collateral Agent pursuant to Section&#160;7 of this Exhibit B) as Collateral Agent under the Loan Documents and authorizes Collateral Agent to (i) execute and deliver the Loan Documents and accept delivery thereof on its behalf from Borrower, (ii) take such action on its behalf and to exercise all rights, powers and remedies and perform the duties as are expressly delegated to Collateral Agent under such Loan Documents and (iii)&#160;exercise such powers as are reasonably incidental thereto.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;Without limiting the generality of clause (a) above, Collateral Agent shall have the sole and exclusive right and authority (to the exclusion of the Lenders), and is hereby authorized, to (i)&#160;act as the disbursing and collecting agent for the Lenders with respect to all payments and collections arising in connection with the Loan Documents (including in any other bankruptcy, insolvency or similar proceeding), and each Person making any payment in connection with any Loan Document to any Lender is hereby authorized to make such payment to Collateral Agent, (ii) file and prove claims and file other documents necessary or desirable to allow the claims of Collateral Agent and Lenders with respect to any Obligation in any bankruptcy, insolvency or similar proceeding (but not to vote, consent or otherwise act on behalf of such Lender), (iii) act as collateral agent for the Secured Parties for purposes of the perfection of all Liens created by the Loan Documents and all other purposes stated therein, (iv) manage, supervise and otherwise deal with the Collateral as permitted pursuant to the Loan Agreement, (v) take such other action as is necessary or desirable to maintain the perfection and priority of the Liens created or purported to be created by the Loan Documents, (vi) except as may be otherwise specified in any Loan Document, exercise all remedies given to Collateral Agent and the other Lenders with respect to the Borrower and&#47;or the Collateral, whether under the Loan Documents, applicable Requirements of Law or otherwise and (vii) execute any amendment, consent or waiver under the Loan Documents on behalf of any Lender that has consented in writing to such amendment, consent or waiver&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that Collateral Agent hereby appoints, authorizes and directs each Lender to act as collateral sub-agent for Collateral Agent and the Lenders for purposes of the perfection of all Liens with respect to the Collateral, including any Deposit Account maintained by Borrower or any Guarantor with, and cash and Cash Equivalents held by, such Lender, and may further authorize and direct the Lenders to take further actions as collateral sub-agents for purposes of enforcing such Liens or otherwise to transfer the Collateral subject thereto to Collateral Agent, and each Lender hereby agrees to take such further actions to the extent, and only to the extent, so authorized and directed.  Collateral Agent may, upon any term or condition it specifies, delegate or exercise any of its rights, powers and remedies under, and delegate or perform any of its duties or any other action with respect to, any Loan Document by or through any trustee, co-agent, employee, attorney-in-fact and any other Person (including any Lender).  Any such Person shall benefit from this Exhibit B to the extent provided by Collateral Agent.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;Under the Loan Documents, and except as expressly set forth in this Exhibit B, Collateral Agent (i) is acting solely on behalf of the Lenders, with duties that are entirely administrative in nature, notwithstanding the use of the defined term &#8220;Collateral Agent&#8221;, the terms &#8220;agent&#8221;, &#8220;Collateral Agent&#8221; and &#8220;collateral agent&#8221; and similar terms in any Loan Document to refer to Collateral Agent, which terms are used for title purposes only, (ii) is not assuming any obligation under any Loan Document other than as expressly set forth therein or any role as agent, fiduciary or trustee of or for any Lender or any other Person and (iii) shall have no implied functions, responsibilities, duties, obligations or other liabilities under any Loan Document, and each Lender, by accepting the benefits of the Loan Documents, hereby waives and agrees not to assert any claim against Collateral Agent based on the roles, duties and legal relationships expressly disclaimed in clauses (i) through (iii) above.  Except as expressly set forth in the Loan Documents, Collateral Agent shall not have any duty to disclose, and shall not be liable for failure to disclose, any information relating to Borrower or any of its Subsidiaries that is communicated to or obtained by SLR or any of its Affiliates in any capacity.</font></div><div style="margin-bottom:11pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:9.75pt">Binding Effect&#59; Use of Discretion&#59; E-Systems.  </font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;Each Lender, by accepting the benefits of the Loan Documents, agrees that (i) any action taken by Collateral Agent or the Required Lenders (or, if expressly required in any Loan Document, a </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">greater proportion of the Lenders) in accordance with the provisions of the Loan Documents, (ii) any action taken by Collateral Agent in reliance upon the instructions of the Required Lenders (or, where so required, such greater proportion) and (iii) the exercise by Collateral Agent or the Required Lenders (or, where so required, such greater proportion) of the powers set forth herein or therein, together with such other powers as are reasonably incidental thereto, shall be authorized and binding upon all of Lenders.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;If Collateral Agent shall request instructions from the Required Lenders or all affected Lenders with respect to any act or action (including failure to act) in connection with any Loan Document, then Collateral Agent shall be entitled to refrain from such act or taking such action unless and until Collateral Agent shall have received instructions from the Required Lenders or all affected Lenders, as the case may be, and Collateral Agent shall not incur liability to any Person by reason of so refraining.  Collateral Agent shall be fully justified in failing or refusing to take any action under any Loan Document (i) if such action would, in the opinion of Collateral Agent, be contrary to any Requirement of Law or any Loan Document, (ii) if such action would, in the opinion of Collateral Agent, expose Collateral Agent to any potential liability under any Requirement of Law or (iii) if Collateral Agent shall not first be indemnified to its satisfaction against any and all liability and expense which may be incurred by it by reason of taking or continuing to take any such action.  Without limiting the foregoing, no Lender shall have any right of action whatsoever against Collateral Agent as a result of Collateral Agent acting or refraining from acting under any Loan Document in accordance with the instructions of the Required Lenders or all affected Lenders, as applicable.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;Collateral Agent is hereby authorized by Borrower and each Lender to establish procedures (and to amend such procedures from time to time) to facilitate administration and servicing of the Term Loans and other matters incidental thereto.  Without limiting the generality of the foregoing, Collateral Agent is hereby authorized to establish procedures to make available or deliver, or to accept, notices, documents (including, without limitation, borrowing base certificates) and similar items on, by posting to or submitting and&#47;or completion, on E-Systems.  Borrower and each Lender acknowledges and agrees that the use of transmissions via an E-System or electronic mail is not necessarily secure and that there are risks associated with such use, including risks of interception, disclosure and abuse, and Borrower and each Lender assumes and accepts such risks by hereby authorizing the transmission via E-Systems or electronic mail.  Each &#8220;e-signature&#8221; on any such posting shall be deemed sufficient to satisfy any requirement for a &#8220;signature&#8221;, and each such posting shall be deemed sufficient to satisfy any requirement for a &#8220;writing&#8221;, in each case including pursuant to any Loan Document, any applicable provision of any Code, the federal Uniform Electronic Transactions Act, the Electronic Signatures in Global and National Commerce Act and any substantive or procedural Requirement of Law governing such subject matter. All uses of an E-System shall be governed by and subject to, in addition to this Section, the separate terms, conditions and privacy policy posted or referenced in such E-System (or such terms, conditions and privacy policy as may be updated from time to time, including on such E-System) and related contractual obligations executed by Collateral Agent, Borrower and&#47;or Lenders in connection with the use of such E-System. ALL E-SYSTEMS AND ELECTRONIC TRANSMISSIONS SHALL BE PROVIDED &#8220;AS IS&#8221; AND &#8220;AS AVAILABLE&#8221;.  NO REPRESENTATION OR WARRANTY OF ANY KIND IS MADE BY AGENT, ANY LENDER OR ANY OF THEIR RELATED PERSONS IN CONNECTION WITH ANY E-SYSTEMS.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:9.75pt">Collateral Agent&#8217;s Reliance, Etc</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Collateral Agent may, without incurring any liability hereunder, (a) consult with any of its Related Persons and, whether or not selected by it, any other advisors, accountants and other experts (including advisors to, and accountants and experts engaged by, Borrower) and (b)&#160;rely and act upon any document and information (including those transmitted by electronic transmission) and any telephone message or conversation, in each case believed by it in good faith to be genuine and transmitted, signed or otherwise authenticated by the appropriate parties.  None of Collateral Agent and its Related Persons shall be liable for any action taken or omitted to be taken by any of them under or in connection with any Loan Document, and each Lender and Borrower hereby waives and shall not assert (and Borrower shall cause its Subsidiaries to waive and agree not to assert) any right, claim or cause of action based thereon, except to the extent of liabilities resulting from the gross negligence or willful misconduct of Collateral Agent or, as the case may be, such Related Person (each as determined in a final, non-appealable judgment of a court of competent jurisdiction) in connection with the duties of Collateral Agent expressly set forth herein.  Without limiting the foregoing, Collateral Agent&#58; (i) shall not be responsible or otherwise incur liability for any action or omission taken in reliance upon the instructions of the Required Lenders or for the actions or omissions of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">any of its Related Persons, except to the extent that a court of competent jurisdiction determines in a final non-appealable judgment that Collateral Agent acted with gross negligence or willful misconduct in the selection of such Related Person&#59; (ii) shall not be responsible to any Lender or other Person for the due execution, legality, validity, enforceability, effectiveness, genuineness, sufficiency or value of, or the attachment, perfection or priority of any Lien created or purported to be created under or in connection with, any Loan Document&#59; (iii) makes no warranty or representation, and shall not be responsible, to any Lender or other Person for any statement, document, information, representation or warranty made or furnished by or on behalf of Borrower or any Related Person of Borrower in connection with any Loan Document or any transaction contemplated therein or any other document or information with respect to Borrower, whether or not transmitted or (except for documents expressly required under any Loan Document to be transmitted to the Lenders) omitted to be transmitted by Collateral Agent, including as to completeness, accuracy, scope or adequacy thereof, or for the scope, nature or results of any due diligence performed by Collateral Agent in connection with the Loan Documents&#59; and (iv) shall not have any duty to ascertain or to inquire as to the performance or observance of any provision of any Loan Document, whether any condition set forth in any Loan Document is satisfied or waived, as to the financial condition of Borrower or as to the existence or continuation or possible occurrence or continuation of any Event of Default, and shall not be deemed to have notice or knowledge of such occurrence or continuation unless it has received a notice from Borrower or any Lender describing such Event of Default that is clearly labelled &#8220;notice of default&#8221; (in which case Collateral Agent shall promptly give notice of such receipt to all Lenders, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> that Collateral Agent shall not be liable to any Lender for any failure to do so, except to the extent that such failure is attributable to Collateral Agent&#8217;s gross negligence or willful misconduct as determined by a final non-appealable judgment of a court of competent jurisdiction)&#59; and, for each of the items set forth in clauses (i) through (iv) above, each Lender and Borrower hereby waives and agrees not to assert (and Borrower shall cause its Subsidiaries to waive and agree not to assert) any right, claim or cause of action it might have against Collateral Agent based thereon.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:9.75pt">Collateral Agent Individually.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Collateral Agent and its Affiliates may make loans and other extensions of credit to, acquire stock and stock equivalents of, engage in any kind of business with, Borrower or any Affiliate of Borrower as though it were not acting as Collateral Agent and may receive separate fees and other payments therefor.  To the extent Collateral Agent or any of its Affiliates makes any Term Loans or otherwise becomes a Lender hereunder, it shall have and may exercise the same rights and powers hereunder and shall be subject to the same obligations and liabilities as any other Lender and the terms &#8220;Lender&#8221;, &#8220;Required Lender&#8221; and any similar terms shall, except where otherwise expressly provided in any Loan Document, include, without limitation, Collateral Agent or such Affiliate, as the case may be, in its individual capacity as Lender, or as one of the Required Lenders.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:9.75pt">Lender Credit Decision&#59; Collateral Agent Report.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Each Lender acknowledges that it shall, independently and without reliance upon Collateral Agent, any Lender or any of their Related Persons or upon any document solely or in part because such document was transmitted by Collateral Agent or any of its Related Persons, conduct its own independent investigation of the financial condition and affairs of Borrower and make and continue to make its own credit decisions in connection with entering into, and taking or not taking any action under, any Loan Document or with respect to any transaction contemplated in any Loan Document, in each case based on such documents and information as it shall deem appropriate.  Except for documents expressly required by any Loan Document to be transmitted by Collateral Agent to the Lenders, Collateral Agent shall not have any duty or responsibility to provide any Lender with any credit or other information concerning the business, prospects, operations, Property, financial and other condition or creditworthiness of Borrower or any Affiliate of Borrower that may come in to the possession of Collateral Agent or any of its Related Persons.  Each Lender agrees that is shall not rely on any field examination, audit or other report provided by Collateral Agent or its Related Persons (an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Collateral Agent Report</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  Each Lender further acknowledges that any Collateral Agent Report (a) is provided to the Lenders solely as a courtesy, without consideration, and based upon the understanding that such Lender will not rely on such Collateral Agent Report, (b) was prepared by Collateral Agent or its Related Persons based upon information provided by Borrower solely for Collateral Agent&#8217;s own internal use, and (c) may not be complete and may not reflect all information and findings obtained by Collateral Agent or its Related Persons regarding the operations and condition of Borrower.  Neither Collateral Agent nor any of its Related Persons makes any representations or warranties of any kind with respect to (i) any existing or proposed financing, (ii) the accuracy or completeness of the information contained in any Collateral Agent Report or in any related documentation, (iii) the scope or adequacy of Collateral Agent&#8217;s and its Related Persons&#8217; due diligence, or the presence or absence of any errors or omissions contained in any Collateral Agent Report or in any related documentation, and (iv) any work performed by Collateral Agent or Collateral Agent&#8217;s Related Persons in </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">connection with or using any Collateral Agent Report or any related documentation.  Neither Collateral Agent nor any of its Related Persons shall have any duties or obligations in connection with or as a result of any Lender receiving a copy of any Collateral Agent Report. Without limiting the generality of the forgoing, neither Collateral Agent nor any of its Related Persons shall have any responsibility for the accuracy or completeness of any Collateral Agent Report, or the appropriateness of any Collateral Agent Report for any Lender&#8217;s purposes, and shall have no duty or responsibility to correct or update any Collateral Agent Report or disclose to any Lender any other information not embodied in any Collateral Agent Report, including any supplemental information obtained after the date of any Collateral Agent Report.  Each Lender releases, and agrees that it will not assert, any claim against Collateral Agent or its Related Persons that in any way relates to any Collateral Agent Report or arises out of any Lender having access to any Collateral Agent Report or any discussion of its contents, and agrees to indemnify and hold harmless Collateral Agent and its Related Persons from all claims, liabilities and expenses relating to a breach by any Lender arising out of such Lender&#8217;s access to any Collateral Agent Report or any discussion of its contents.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:9.75pt">Indemnification.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Each Lender agrees to reimburse Collateral Agent and each of its Related Persons (to the extent not reimbursed by Borrower as required under the Loan Documents (including pursuant to Section 12.2 of the Agreement)) promptly upon demand for its Pro Rata Share of any out-of-pocket costs and expenses (including, without limitation, fees, charges and disbursements of financial, legal and other advisors and any Taxes or insurance paid in the name of, or on behalf of, Borrower) incurred by Collateral Agent or any of its Related Persons in connection with the preparation, syndication, execution, delivery, administration, modification, amendment, consent, waiver or enforcement of, or the taking of any other action (whether through negotiations, through any work-out, bankruptcy, restructuring or other legal or other proceeding (including, without limitation, preparation for and&#47;or response to any subpoena or request for document production relating thereto) or otherwise) in respect of, or legal advice with respect to, its rights or responsibilities under, any Loan Document.  Each Lender further agrees to indemnify Collateral Agent and each of its Related Persons (to the extent not reimbursed by Borrower as required under the Loan Documents (including pursuant to Section 12.2 of the Agreement)), ratably according to its Pro Rata Share, from and against any and all liabilities, obligations, losses, damages, penalties, actions, judgments, suits, costs, expenses or disbursements of any kind or nature whatsoever (including, to the extent not indemnified by the applicable Lender, Taxes, interests and penalties imposed for not properly withholding or backup withholding on payments made to or for the account of any Lender) that may be imposed on, incurred by, or asserted against Collateral Agent or any of its Related Persons in any matter relating to or arising out of, in connection with or as a result of any Loan Document or any other act, event or transaction related, contemplated in or attendant to any such document, or, in each case, any action taken or omitted to be taken by Collateral Agent or any of its Related Persons under or with respect to the foregoing&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> that no Lender shall be liable to Collateral Agent or any of its Related Persons under this Section 6 of this Exhibit B to the extent such liability has resulted from the gross negligence or willful misconduct of Collateral Agent or, as the case may be, such Related Person, as determined by a final non-appealable judgment of a court of competent jurisdiction.  To the extent required by any applicable Requirement of Law, Collateral Agent may withhold from any payment to any Lender under a Loan Document an amount equal to any applicable withholding Tax.  If the IRS or any other Governmental Authority asserts a claim that Collateral Agent did not properly withhold Tax from amounts paid to or for the account of any Lender for any reason, or if Collateral Agent reasonably determines that it was required to withhold Taxes from a prior payment to or for the account of any Lender but failed to do so, such Lender shall promptly indemnify Collateral Agent fully for all amounts paid, directly or indirectly, by Collateral Agent as Tax or otherwise, including penalties and interest, and together with all expenses incurred by Collateral Agent.  Collateral Agent may offset against any payment to any Lender under a Loan Document, any applicable withholding Tax that was required to be withheld from any prior payment to such Lender but which was not so withheld, as well as any other amounts for which Collateral Agent is entitled to indemnification from such Lender under the immediately preceding sentence of this Section 6 of this Exhibit B.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">Successor Collateral Agent.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Collateral Agent may resign at any time by delivering notice of such resignation to the Lenders and Borrower, effective on the date set forth in such notice or, if no such date is set forth therein, upon the date such notice shall be effective, in accordance with the terms of this Section 7 of this Exhibit B.  If Collateral Agent delivers any such notice, the Required Lenders shall have the right to appoint a successor Collateral Agent.  If, after thirty (30) days after the date of the retiring Collateral Agent&#8217;s notice of resignation, no successor Collateral Agent has been appointed by the Required Lenders and has accepted such appointment, then the retiring Collateral Agent may, on behalf of the Lenders, appoint a successor Collateral Agent from among the Lenders.  Effective immediately upon its resignation, (a) the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">retiring Collateral Agent shall be discharged from its duties and obligations under the Loan Documents, (b) the Lenders shall assume and perform all of the duties of Collateral Agent until a successor Collateral Agent shall have accepted a valid appointment hereunder, (c) the retiring Collateral Agent and its Related Persons shall no longer have the benefit of any provision of any Loan Document other than with respect to any actions taken or omitted to be taken while such retiring Collateral Agent was, or because such Collateral Agent had been, validly acting as Collateral Agent under the Loan Documents, and (iv) subject to its rights under Section 2(b) of this Exhibit B, the retiring Collateral Agent shall take such action as may be reasonably necessary to assign to the successor Collateral Agent its rights as Collateral Agent under the Loan Documents.  Effective immediately upon its acceptance of a valid appointment as Collateral Agent, a successor Collateral Agent shall succeed to, and become vested with, all the rights, powers, privileges and duties of the retiring Collateral Agent under the Loan Documents.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">Release of Collateral.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Each Lender hereby consents to the release and hereby directs Collateral Agent to release (or in the case of clause (b)(ii) below, release or subordinate) the following&#58;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:70.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;any Guarantor if all of the stock of such Subsidiary owned by Borrower is sold or transferred in a transaction permitted under the Loan Documents (including pursuant to a valid waiver or consent), to the extent that, after giving effect to such transaction, such Subsidiary would not be required to guaranty any Obligations pursuant to any Loan Document&#59; and</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:70.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;any Lien held by Collateral Agent for the benefit of the Secured Parties against (i) any Collateral that is sold or otherwise disposed of by Borrower in a transaction permitted by the Loan Documents (including pursuant to a valid waiver or consent), (ii) any Collateral subject to a Lien that is expressly permitted under clause (c) of the definition of the term &#8220;Permitted Lien&#8221; and (iii) all of the Collateral and Borrower, upon (A) termination of all of the Commitments, (B) the payment in full in cash of all of the Obligations (other than (a) inchoate indemnity obligations, and (ii) other obligations that, by their terms, survive termination of this Agreement, in each case for which no claim has been made), and (C) to the extent requested by Collateral Agent, receipt by Collateral Agent and Lenders of liability releases from Borrower in form and substance acceptable to Collateral Agent (the satisfaction of the conditions in this clause (iii), the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Termination Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">Setoff and Sharing of Payments.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  In addition to any rights now or hereafter granted under any applicable Requirement of Law and not by way of limitation of any such rights, upon the occurrence and during the continuance of any Event of Default and subject to Section 10(d) of this Exhibit B, each Lender is hereby authorized at any time or from time to time upon the direction of Collateral Agent, without notice to Borrower or any other Person, any such notice being hereby expressly waived, to setoff and to appropriate and to apply any and all balances held by it at any of its offices for the account of Borrower (regardless of whether such balances are then due to Borrower) and any other properties or assets at any time held or owing by that Lender or that holder to or for the credit or for the account of Borrower against and on account of any of the Obligations that are not paid when due.  Any Lender exercising a right of setoff or otherwise receiving any payment on account of the Obligations in excess of its Pro Rata Share thereof shall purchase for cash (and the other Lenders or holders shall sell) such participations in each such other Lender&#8217;s or holder&#8217;s Pro Rata Share of the Obligations as would be necessary to cause such Lender to share the amount so offset or otherwise received with each other Lender or holder in accordance with their respective Pro Rata Shares of the Obligations.  Borrower agrees, to the fullest extent permitted by law, that (a) any Lender may exercise its right to offset with respect to amounts in excess of its Pro Rata Share of the Obligations and may purchase participations in accordance with the preceding sentence and (b) any Lender so purchasing a participation in the Term Loans made or other Obligations held by other Lenders or holders may exercise all rights of offset, bankers&#8217; liens, counterclaims or similar rights with respect to such participation as fully as if such Lender or holder were a direct holder of the Term Loans and the other Obligations in the amount of such participation.  Notwithstanding the foregoing, if all or any portion of the offset amount or payment otherwise received is thereafter recovered from the Lender that has exercised the right of offset, the purchase of participations by that Lender shall be rescinded and the purchase price restored without interest.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Advances&#59; Payments&#59; Non-Funding Lenders&#59; Actions in Concert.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:70.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Advances&#59; Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  If Collateral Agent receives any payment with respect to a Term Loan for the account of the Lenders on or prior to 2&#58;00 p.m. (New York time) on any Business Day, Collateral Agent shall pay to each applicable Lender such Lender&#8217;s Pro Rata Share of such payment on such </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Business Day. If Collateral Agent receives any payment with respect to a Term Loan for the account of&#160;Lenders after 2&#58;00 p.m. (New York time) on any Business Day, Collateral Agent shall pay to each applicable Lender such Lender&#8217;s Pro Rata Share of such payment on the next Business Day.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:70.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Return of Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:107.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;If Collateral Agent pays an amount to a Lender under this Agreement in the belief or expectation that a related payment has been or will be received by Collateral Agent or on behalf of from Borrower and such related payment is not received by Collateral Agent, then Collateral Agent will be entitled to recover such amount (including interest accruing on such amount at the rate otherwise applicable to such Obligation) from such Lender on demand without setoff, counterclaim or deduction of any kind.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:107.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;If Collateral Agent determines at any time that any amount received by Collateral Agent under any Loan Document must be returned to Borrower or paid to any other Person pursuant to any insolvency law or otherwise, then, notwithstanding any other term or condition of any Loan Document, Collateral Agent will not be required to distribute any portion thereof to any Lender.  In addition, each Lender will repay to Collateral Agent on demand any portion of such amount that Collateral Agent has distributed to such Lender, together with interest at such rate, if any, as Collateral Agent is required to pay to Borrower or such other Person, without setoff, counterclaim or deduction of any kind and Collateral Agent will be entitled to set off against future distributions to such Lender any such amounts (with interest) that are not repaid on demand.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:70.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Non-Funding Lenders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:107.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;Unless Collateral Agent shall have received notice from a Lender prior to the date of any</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Loan that such Lender will not make available to Collateral Agent such Lender&#8217;s Pro Rata Share of such Term Loan, Collateral Agent may assume that such Lender will make such amount available to it on the date of such Term Loan in accordance with Section 2(b) of this Exhibit B, and Collateral Agent may (but shall not be obligated to), in reliance upon such assumption, make available a corresponding amount for the account of Borrower on such date.  If and to the extent that such Lender shall not have made such amount available to Collateral Agent, such Lender and Borrower severally agree to repay to Collateral Agent forthwith on demand such corresponding amount together with interest thereon, for each day from the day such amount is made available to Borrower until the day such amount is repaid to Collateral Agent, at a rate per annum equal to the interest rate applicable to the Obligation that would have been created when Collateral Agent made available such amount to Borrower had such Lender made a corresponding payment available. If such Lender shall repay such corresponding amount to Collateral Agent, the amount so repaid shall constitute such Lender&#8217;s portion of such Term Loan for purposes of this Agreement.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:107.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;To the extent that any Lender has failed to fund any Term Loan or any other payments required to be made by it under the Loan Documents after any such Term Loan is required to be made or such payment is due (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Non-Funding Lender</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), Collateral Agent shall be entitled to set off the funding short-fall against that Non-Funding Lender&#8217;s Pro&#160;Rata Share of all payments received from or on behalf of Borrower thereunder.  The failure of any Non-Funding Lender to make any Term Loan or any payment required by it hereunder shall not relieve any other Lender (each such other Lender, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Other Lender</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) of its obligations to make such Term Loan, but neither any Other Lender nor Collateral Agent shall be responsible for the failure of any Non-Funding Lender to make such Term Loan or make any other payment required hereunder.  Notwithstanding anything set forth herein to the contrary, a Non-Funding Lender shall not have any voting or consent rights under or with respect to any Loan Document or constitute a &#8220;Lender&#8221; (or be included in the calculation of &#8220;Required Lenders&#8221; hereunder) for any voting or consent rights under or with respect to any Loan Document.  At Borrower&#8217;s request, Collateral Agent or a Person reasonably acceptable to Collateral Agent shall have the right with Collateral Agent&#8217;s consent and in Collateral Agent&#8217;s sole discretion (but Collateral Agent or any such Person shall have no obligation) to purchase from any Non-Funding Lender, and each Lender agrees that if it becomes a Non-Funding Lender it shall, at Collateral Agent&#8217;s request, sell and assign to Collateral Agent or such Person, all of the Term Loan Commitment (if any), and all of the outstanding Term Loan of that Non-Funding Lender for an amount equal to the aggregate outstanding principal balance of the Term Loan held by such Non-Funding Lender and all accrued interest with respect thereto through the date of sale, such purchase and sale to be consummated pursuant to an executed assignment agreement in form and substance reasonably satisfactory to, and acknowledged by, Collateral Agent.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify;text-indent:70.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Actions in Concert</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Anything in this Agreement to the contrary notwithstanding, each Lender hereby agrees with each other Lender that no Lender shall take any action to protect or enforce its rights arising out of any Loan Document (including exercising any rights of setoff) without first obtaining the prior written consent of Collateral Agent or Required Lenders, it being the intent of Lenders that any such action to protect or enforce rights under any Loan Document shall be taken in concert and at the direction or with the consent of Collateral Agent or Required Lenders.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:1.8pt;padding-right:1.8pt;text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT C</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:1.8pt;padding-right:1.8pt;text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Taxes&#59; Increased Costs.</font></div><div style="margin-bottom:11pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:9.75pt">Defined Terms</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">For purposes of this Exhibit C&#58; </font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;(a)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Connection Income Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means Other Connection Taxes that are imposed on or measured by net income (however denominated) or that are franchise Taxes or branch profits Taxes.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Excluded Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any of the following Taxes imposed on or with respect to a Recipient or required to be withheld or deducted from a payment to a Recipient, (i) Taxes imposed on or measured by net income (however denominated), franchise Taxes, and branch profits Taxes, in each case, (A) imposed as a result of such Recipient being organized under the laws of, or having its principal office or, in the case of any Lender, its applicable lending office located in, the jurisdiction imposing such Tax (or any political subdivision thereof) or (B) that are Other Connection Taxes, (ii) in the case of a Lender, U.S. federal withholding Taxes imposed on amounts payable to or for the account of such Lender with respect to an applicable interest in a Term Loan or Term Loan Commitment pursuant to a law in effect on the date on which (A) such Lender acquires such interest in the Term Loan or Term Commitment or (B) such Lender changes its lending office, except in each case to the extent that, pursuant to Section 2 or Section 4 of this Exhibit C, amounts with respect to such Taxes were payable either to such Lender&#8217;s assignor immediately before such Lender became a party hereto or to such Lender immediately before it changed its lending office, (iii) Taxes attributable to such Recipient&#8217;s failure to comply with Section 7 of this Exhibit C and (iv) any withholding Taxes imposed under FATCA.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">FATCA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means Sections 1471 through 1474 of the Internal Revenue Code, as of the date of this Agreement (or any amended or successor version that is substantively comparable and not materially more onerous to comply with), any current or future regulations or official interpretations thereof, any agreements entered into pursuant to Section 1471(b)(1) of the Internal Revenue Code, and any fiscal or regulatory legislation, rules or practices adopted pursuant to any intergovernmental agreement, treaty or convention among Governmental Authorities and implementing such Sections of the Internal Revenue Code.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Foreign Lender</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a Lender that is not a U.S. Person.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;(e)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Indemnified Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means (i) Taxes, other than Excluded Taxes, imposed on or with respect to any payment made by or on account of any obligation of Borrower under any Loan Document and (ii) to the extent not otherwise described in clause (i), Other Taxes.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;(f)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Other Connection Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to any Recipient, Taxes imposed as a result of a present or former connection between such Recipient and the jurisdiction imposing such Tax (other than connections arising from such Recipient having executed, delivered, become a party to, performed its obligations under, received payments under, received or perfected a security interest under, engaged in any other transaction pursuant to or enforced any Loan Document, or sold or assigned an interest in any Term Loan or Loan Document).</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Other Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means all present or future stamp, court or documentary, intangible, recording, filing or similar Taxes that arise from any payment made under, from the execution, delivery, performance, enforcement or registration of, from the receipt or perfection of a security interest under, or otherwise with respect to, any Loan Document, except any such Taxes that are Other Connection Taxes imposed with respect to an assignment.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;(h)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Recipient</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means Collateral Agent or any Lender, as applicable.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;(i)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">U.S. Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any Person that is a &#8220;United States person&#8221; as defined in Section 7701(a)(30) of the Internal Revenue Code.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Withholding Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means Borrower and Collateral Agent.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">Payments Free of Taxes</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Any and all payments by or on account of any obligation of Borrower under any Loan Document shall be made without deduction or withholding for any Taxes, except as required by applicable law.  If any applicable law (as determined in the good faith discretion of an applicable Withholding Agent) requires the deduction or withholding of any Tax from any such payment by a Withholding Agent, then the applicable Withholding Agent shall be entitled to make such deduction or withholding and shall timely pay the full amount deducted or withheld to the relevant Governmental Authority in accordance with applicable law and, if such Tax is an Indemnified Tax, then the sum payable by Borrower shall be increased as necessary so that after such deduction or withholding has been made (including such deductions and withholdings applicable to additional sums payable under this Section 2 or Section 4 of this Exhibit C) the applicable Recipient receives an amount equal to the sum it would have received had no such deduction or withholding been made.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">Payment of Other Taxes by Borrower.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Borrower shall timely pay to the relevant Governmental Authority in accordance with applicable law, or at the option of Collateral Agent timely reimburse it for the payment of, any Other Taxes.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">Indemnification by Borrower. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> Borrower shall indemnify each Recipient, within 10 days after demand therefor, for the full amount of any Indemnified Taxes (including Indemnified Taxes imposed or asserted on or attributable to amounts payable under Section 2 of this Exhibit C or this Section 4) payable or paid by such Recipient or required to be withheld or deducted from a payment to such Recipient and any reasonable expenses arising therefrom or with respect thereto, whether or not such Indemnified Taxes were correctly or legally imposed or asserted by the relevant Governmental Authority.  A certificate as to the amount of such payment or liability delivered to Borrower by a Lender (with a copy to Collateral Agent), or by Collateral Agent on its own behalf or on behalf of a Lender, shall be conclusive absent manifest error.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">Indemnification by the Lenders. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> Each Lender shall severally indemnify Collateral Agent, within 10 days after demand therefor, for (a) any Indemnified Taxes attributable to such Lender (but only to the extent that Borrower has not already indemnified Collateral Agent for such Indemnified Taxes and without limiting the obligation of Borrower to do so), (b) any Taxes attributable to such Lender&#8217;s failure to comply with the provisions of Section 12.1 of the Agreement relating to the maintenance of a Participant Register and (c) any Excluded Taxes attributable to such Lender, in each case, that are payable or paid by Collateral Agent in connection with any Loan Document, and any reasonable expenses arising therefrom or with respect thereto, whether or not such Taxes were correctly or legally imposed or asserted by the relevant Governmental Authority.  A certificate as to the amount of such payment or liability delivered to any Lender by Collateral Agent shall be conclusive absent manifest error.  Each Lender hereby authorizes Collateral Agent to set off and apply any and all amounts at any time owing to such Lender under any Loan Document or otherwise payable by Collateral Agent to the Lender from any other source against any amount due to Collateral Agent under this Section 5.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">Evidence of Payments.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  As soon as practicable after any payment of Taxes by Borrower to a Governmental Authority pursuant to the provisions of this Exhibit C, Borrower shall deliver to Collateral Agent the original or a certified copy of a receipt issued by such Governmental Authority evidencing such payment, a copy of the return reporting such payment or other evidence of such payment reasonably satisfactory to Collateral Agent.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">Status of Lenders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:70.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;Any Lender that is entitled to an exemption from or reduction of withholding Tax with respect to payments made under any Loan Document shall deliver to Borrower and Collateral Agent, at the time or times reasonably requested by Borrower or Collateral Agent, such properly completed and executed documentation reasonably requested by Borrower or Collateral Agent as will permit such payments to be made without withholding or at a reduced rate of withholding.  In addition, any Lender, if reasonably requested by Borrower or Collateral Agent, shall deliver such other documentation prescribed by applicable law or reasonably requested by Borrower or Collateral Agent as will enable Borrower or Collateral Agent to determine whether or not such Lender is subject to backup withholding or information reporting requirements.  Notwithstanding anything to the contrary in the preceding two sentences, the completion, execution and submission of such documentation (other than such documentation set forth in Sections 7(b)(i), 7(b)(ii) and 7(b)(iv) of this Exhibit C) shall not be required if in the Lender&#8217;s reasonable judgment such completion, execution or submission would subject such Lender to any material unreimbursed cost or expense or would materially prejudice the legal or commercial position of such Lender.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify;text-indent:70.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;Without limiting the generality of the foregoing, in the event that Borrower is a U.S. Person,</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:107.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;any Lender that is a U.S. Person shall deliver to Borrower and Collateral Agent on or prior to the date on which such Lender becomes a Lender under this Agreement (and from time to time thereafter upon the reasonable request of Borrower or Collateral Agent), executed copies of IRS Form W-9 certifying that such Lender is exempt from U.S. federal backup withholding tax&#59;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:107.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;any Foreign Lender shall, to the extent it is legally entitled to do so, deliver to Borrower and Collateral Agent (in such number of copies as shall be requested by the recipient) on or prior to the date on which such Foreign Lender becomes a Lender under this Agreement (and from time to time thereafter upon the reasonable request of Borrower or Collateral Agent), whichever of the following is applicable&#58;</font></div><div style="margin-bottom:11pt;padding-left:141.75pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(A)&#160;&#160;&#160;&#160;in the case of a Foreign Lender claiming the benefits of an income tax treaty to which the United States is a party (x) with respect to payments of interest under any Loan Document, executed copies of IRS Form W-8BEN or IRS Form W-8BEN-E establishing an exemption from, or reduction of, U.S. federal withholding Tax pursuant to the &#8220;interest&#8221; article of such tax treaty and (y) with respect to any other applicable payments under any Loan Document, IRS Form W-8BEN or IRS Form W-8BEN-E establishing an exemption from, or reduction of, U.S. federal withholding Tax pursuant to the &#8220;business profits&#8221; or &#8220;other income&#8221; article of such tax treaty&#59;</font></div><div style="margin-bottom:11pt;padding-left:141.75pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(B)&#160;&#160;&#160;&#160;executed copies of IRS Form W-8ECI&#59;</font></div><div style="margin-bottom:11pt;padding-left:141.75pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(C)&#160;&#160;&#160;&#160;in the case of a Foreign Lender claiming the benefits of the exemption for portfolio interest under Section 881(c) of the Internal Revenue Code, (x) a certificate, in form and substance reasonably acceptable to Borrower and Collateral Agent, to the effect that such Foreign Lender (or other applicable Person) is not a &#8220;bank&#8221; within the meaning of Section 881(c)(3)(A) of the Internal Revenue Code, a &#8220;10 percent shareholder&#8221; of Borrower within the meaning of Section 871(h)(3)(B) of the Internal Revenue Code, or a &#8220;controlled foreign corporation&#8221; related to Borrower as described in Section 881(c)(3)(C) of the Internal Revenue Code (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">U.S. Tax Compliance Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and (y) executed copies of IRS Form W-8BEN or IRS Form W-8BEN-E&#59; or</font></div><div style="margin-bottom:11pt;padding-left:141.75pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(D)&#160;&#160;&#160;&#160;to the extent a Foreign Lender is not the beneficial owner, executed copies of IRS Form W-8IMY, accompanied by IRS Form W-8ECI, IRS Form W-8BEN, IRS Form W-8BEN-E, a U.S. Tax Compliance Certificate, IRS Form W-9, and&#47;or other certification documents from each beneficial owner, as applicable&#59; provided that if the Foreign Lender is a partnership and one or more direct or indirect partners of such Foreign Lender are claiming the portfolio interest exemption, such Foreign Lender may provide a U.S. Tax Compliance Certificate on behalf of each such direct and indirect partner&#59;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:107.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;any Foreign Lender shall, to the extent it is legally entitled to do so, deliver to Borrower and Collateral Agent (in such number of copies as shall be requested by the recipient) on or prior to the date on which such Foreign Lender becomes a Lender under this Agreement (and from time to time thereafter upon the reasonable request of Borrower or Collateral Agent), executed copies of any other form prescribed by applicable law as a basis for claiming exemption from or a reduction in U.S. federal withholding Tax, duly completed, together with such supplementary documentation as may be prescribed by applicable law to permit Borrower or Collateral Agent to determine the withholding or deduction required to be made&#59; and</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:107.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iv)&#160;&#160;&#160;&#160;if a payment made to a Lender under any Loan Document would be subject to U.S. federal withholding Tax imposed by FATCA if such Lender were to fail to comply with the applicable reporting requirements of FATCA (including those contained in Section 1471(b) or 1472(b) of the Internal </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Revenue Code, as applicable), such Lender shall deliver to Borrower and Collateral Agent at the time or times prescribed by law and at such time or times reasonably requested by Borrower or Collateral Agent such documentation prescribed by applicable law (including as prescribed by Section 1471(b)(3)(C)(i) of the Internal Revenue Code) and such additional documentation reasonably requested by Borrower or Collateral Agent as may be necessary for Borrower and Collateral Agent to comply with their obligations under FATCA and to determine that such Lender has complied with such Lender&#8217;s obligations under FATCA or to determine the amount, if any, to deduct and withhold from such payment.  Solely for purposes of this clause (iv), &#8220;FATCA&#8221; shall include any amendments made to FATCA after the date of this Agreement.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:107.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(v)&#160;&#160;&#160;&#160;Each Lender agrees that if any form or certification it previously delivered expires or becomes obsolete or inaccurate in any respect, it shall update such form or certification or promptly notify Borrower and Collateral Agent in writing of its legal inability to do so.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">Treatment of Certain Refunds</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  If any party determines, in its sole discretion exercised in good faith, that it has received a refund of any Taxes as to which it has been indemnified pursuant to the provisions of this Exhibit C (including by the payment of additional amounts pursuant to the provisions of this Exhibit C), it shall pay to the indemnifying party an amount equal to such refund (but only to the extent of indemnity payments made under the provisions of this Exhibit C with respect to the Taxes giving rise to such refund), net of all out-of-pocket expenses (including Taxes) of such indemnified party and without interest (other than any interest paid by the relevant Governmental Authority with respect to such refund).  Such indemnifying party, upon the request of such indemnified party, shall repay to such indemnified party the amount paid over pursuant to this Section 8 (plus any penalties, interest or other charges imposed by the relevant Governmental Authority) in the event that such indemnified party is required to repay such refund to such Governmental Authority.  Notwithstanding anything to the contrary in this Section 8, in no event will the indemnified party be required to pay any amount to an indemnifying party pursuant to this Section 8 the payment of which would place the indemnified party in a less favorable net after-Tax position than the indemnified party would have been in if the Tax subject to indemnification and giving rise to such refund had not been deducted, withheld or otherwise imposed and the indemnification payments or additional amounts with respect to such Tax had never been paid.  This Section 8 shall not be construed to require any indemnified party to make available its Tax returns (or any other information relating to its Taxes that it deems confidential) to the indemnifying party or any other Person.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">Increased Costs</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If any change in applicable law shall subject any Recipient to any Taxes (other than (A) Indemnified Taxes, (B) Taxes described in clauses (ii) through (iv) of the definition of Excluded Taxes and (C) Connection Income Taxes) on its loans, loan principal, commitments, or other obligations, or its deposits, reserves, other liabilities or capital attributable thereto, and the result shall be to increase the cost to such Recipient of making, converting to, continuing or maintaining any Term Loan or of maintaining its obligation to make any such Term Loan, or to reduce the amount of any sum received or receivable by such Recipient (whether of principal, interest or any other amount), then, upon the request of such Recipient, Borrower will pay to such Recipient such additional amount or amounts as will compensate such Recipient for such additional costs incurred or reduction suffered.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Survival</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Each party&#8217;s obligations under the provisions of this Exhibit C shall survive the resignation or replacement of Collateral Agent or any assignment of rights by, or the replacement of, a Lender, the termination of the Term Loan Commitments and the repayment, satisfaction or discharge of all obligations under any Loan Document.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT D</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Loan Payment Request Form</font></div><div style="padding-left:12.6pt;padding-right:12.6pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;padding-right:-18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Fax To&#58; (212) 993-1698&#160;&#160;&#160;&#160;Date&#58; _____________________</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-15.25pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:116%">Loan Payment</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:116%">&#58;</font></div><div style="margin-bottom:12pt;padding-right:-7.62pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Ardelyx, Inc.</font></div><div style="padding-right:-7.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:138%">From Account #________________________________&#160;&#160;&#160;&#160;To Account #__________________________________________________</font></div><div style="padding-right:-15.25pt;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:138%">(Deposit Account #)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(Loan Account #)</font></div><div style="margin-bottom:12pt;padding-right:-15.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:138%">Principal $____________________________________&#160;&#160;&#160;&#160;and&#47;or Interest $________________________________________________</font></div><div style="padding-right:-15.25pt"><font><br></font></div><div style="padding-right:-15.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:138%">Authorized Signature&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:138%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:138%">&#160;&#160;&#160;&#160;Phone Number&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:138%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:24pt;padding-right:-15.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:138%">Print Name&#47;Title&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:138%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-right:-15.25pt"><font><br></font></div><div style="margin-bottom:12pt;padding-right:-15.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:116%">Loan Advance</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:116%">&#58;</font></div><div style="padding-right:-15.25pt"><font><br></font></div><div style="margin-bottom:12pt;padding-right:-15.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:138%">Complete </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:138%">Outgoing Wire Request</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:138%"> section below if all or a portion of the funds from this loan advance are for an outgoing wire.</font></div><div style="padding-right:-15.25pt"><font><br></font></div><div style="padding-right:-15.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:138%">From Account #________________________________&#160;&#160;&#160;&#160;To Account #__________________________________________________</font></div><div style="margin-bottom:12pt;padding-right:-15.25pt;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:138%">(Loan Account #)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(Deposit Account #)</font></div><div style="padding-right:-15.25pt"><font><br></font></div><div style="margin-bottom:12pt;padding-right:-15.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:138%">Amount of Advance $___________________________</font></div><div style="padding-right:-15.25pt"><font><br></font></div><div style="margin-bottom:12pt;padding-right:-15.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:138%">All Borrower&#8217;s representations and warranties in the Loan and Security Agreement are true, correct and complete in all material respects on the date of the request for an advance&#59; provided, however, that such materiality qualifier shall not be applicable to any representations and warranties that already are qualified or modified by materiality in the text thereof&#59; and provided, further that those representations and warranties expressly referring to a specific date shall be true, accurate and complete in all material respects as of such date&#58;</font></div><div style="padding-right:-15.25pt"><font><br></font></div><div style="padding-right:-15.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:138%">Authorized Signature&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:138%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:138%">&#160;&#160;&#160;&#160;Phone Number&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:138%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-right:-15.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:138%">Print Name&#47;Title&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:138%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div></td></tr></table></div><div style="padding-right:-18pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-15.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:116%">Outgoing Wire Request</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:116%">&#58;</font></div><div style="margin-bottom:24pt;padding-right:-15.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:138%">Complete only if all or a portion of funds from the loan advance above is to be wired.</font></div><div style="margin-bottom:12pt;padding-right:-15.25pt"><font><br></font></div><div style="padding-right:-15.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:138%">Beneficiary Name&#58; _____________________________</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:138%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:138%">&#160;&#160;&#160;&#160;Amount of Wire&#58; $</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:138%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="padding-right:-15.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:138%">Beneficiary Bank&#58; ______________________________</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:138%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:138%">&#160;&#160;&#160;&#160;Account Number&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:138%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-right:-15.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:138%">City and State&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:138%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="padding-right:-15.25pt"><font><br></font></div><div style="padding-right:-15.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:138%">Beneficiary Bank Transit (ABA) #&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:138%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:138%">&#160;&#160;&#160;&#160;Beneficiary Bank Code (Swift, Sort, Chip, etc.)&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:138%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="padding-right:-15.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:138%">(For International Wire Only)</font></div><div style="padding-right:-15.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:138%">Intermediary Bank&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:138%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:138%">&#160;&#160;&#160;&#160;Transit (ABA) #&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:138%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-right:-15.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:138%">For Further Credit to&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:138%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="padding-right:-15.25pt"><font><br></font></div><div style="padding-right:-15.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:138%">Special Instruction&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:138%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-right:-15.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:138%">By signing below, I (we) acknowledge and agree that my (our) funds transfer request shall be processed in accordance with and subject to the terms and conditions set forth in the agreements(s) covering funds transfer service(s), which agreements(s) were previously received and executed by me (us).</font></div><div style="padding-right:-15.25pt"><font><br></font></div><div style="padding-right:-15.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:138%">Authorized Signature&#58; ___________________________&#160;&#160;&#160;&#160;2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:138%;position:relative;top:-2.8pt;vertical-align:baseline">nd</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:138%"> Signature (if required)&#58; _______________________________________</font></div><div style="padding-right:-15.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:138%">Print Name&#47;Title&#58; ______________________________&#160;&#160;&#160;&#160;Print Name&#47;Title&#58; ______________________________________________</font></div><div style="margin-bottom:24pt;padding-right:-15.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:138%">Telephone #&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:138%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:138%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Telephone #&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:138%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT E</font></div><div style="padding-left:12.6pt;padding-right:12.6pt;text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Compliance Certificate</font></div><div style="margin-top:11pt;padding-left:72pt;text-indent:-73.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">TO&#58;&#160;&#160;&#160;&#160;SLR INVESTMENT CORP., as Collateral Agent and Lender </font></div><div style="margin-top:11pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">FROM&#58;&#160;&#160;&#160;&#160;ARDELYX, INC.</font></div><div style="margin-top:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The undersigned authorized officer (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) of Ardelyx, Inc. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Borrower</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), hereby certifies solely in his&#47;her capacity as an officer of Borrower and not in his&#47;her individual capacity, that in accordance with the terms and conditions of the Loan and Security Agreement dated as of February 23, 2022, by and among Borrower, Collateral Agent, and the Lenders from time to time party thereto (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Loan Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#59;&#8221; capitalized terms used but not otherwise defined herein shall have the meanings given them in the Loan Agreement),</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;Borrower is in complete compliance for the period ending </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">with all required<br>covenants except as noted below&#59;</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;There are no Defaults or Events of Default, except as noted below&#59;</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;Except as noted below, all representations and warranties of Borrower stated in the Loan Documents are true and correct in all material respects on this date and for the period described in (a), above&#59; provided, however, that such materiality qualifier shall not be applicable to any representations and warranties that already are qualified or modified by materiality in the text thereof&#59; and provided, further that those representations and warranties expressly referring to a specific date shall be true, accurate and complete in all material respects as of such date.</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;Borrower, and each of Borrower&#8217;s Subsidiaries, has timely filed all required tax returns and reports, Borrower, and each of Borrower&#8217;s Subsidiaries, has timely paid all foreign, federal, state, and local taxes, assessments, deposits and contributions owed by Borrower, or Subsidiary, except as otherwise permitted pursuant to the terms of Section 5.8 of the Loan Agreement&#59;</font></div><div style="margin-top:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)&#160;&#160;&#160;&#160;No Liens have been levied or claims made against Borrower or any of its Subsidiaries relating to unpaid employee payroll or benefits of which Borrower has not previously provided written notification to Collateral Agent and the Lenders.</font></div><div style="margin-top:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Attached are the required documents, if any, supporting our certification(s). The Officer, on behalf of Borrower, further certifies that the attached financial statements are prepared in accordance with Generally Accepted Accounting Principles (GAAP) and are consistently applied from one period to the next except as explained in an accompanying letter or footnotes and except, in the case of unaudited financial statements, for the absence of footnotes and subject to year-end audit adjustments as to the interim financial statements.</font></div><div style="margin-bottom:10.65pt;margin-top:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Please indicate compliance status since the last Compliance Certificate by circling Yes, No, or N&#47;A under &#8220;Complies&#8221; column.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.241%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.290%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.817%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.779%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.583%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.718%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Reporting Covenant</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Requirement</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Actual</font></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Complies</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Monthly financial statements</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Monthly within 30 days (for each month that is not a quarter end)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Yes</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">No</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">N&#47;A</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Quarterly financial statements</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Quarterly within 45 days</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Yes</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">No</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">N&#47;A</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Annual (CPA Audited) statements</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Within 90 days after FYE or 5 days after filing with SEC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Yes</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">No</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">N&#47;A</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Annual Financial Projections&#47;Budget</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Annually (within 60 days after FYE) or 10 days of approval and when received (7 days of approval)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Yes</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">No</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">N&#47;A</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Account statements for each Collateral Account</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Monthly within 30 days</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Yes</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">No</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">N&#47;A</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Compliance Certificate</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Monthly within 30 days</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Yes</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">No</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">N&#47;A</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">IP notice (events reasonably expected to materially and adversely affect value of IP or result in MAC)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">When required</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Yes</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">No</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">N&#47;A</font></td></tr></table></div><div style="margin-top:11pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Deposit and Securities Accounts <br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">(Please list all accounts&#59; attach separate sheet if additional space needed)</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.210%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.486%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.313%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.834%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Institution Name</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Account Number</font></td><td colspan="6" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">New Account&#63;</font></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Account Control Agreement in Place&#63;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Yes</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">No</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Yes</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">No</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Yes</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">No</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Yes</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">No</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Yes</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">No</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Yes</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">No</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Yes</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">No</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Yes</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">No</font></td></tr></table></div><div style="margin-top:11pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Financial Covenant</font></div><div style="margin-top:11pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">7.13 &#8211; Minimum Liquidity </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(please attach a schedule with the appropriate calculations) Complies&#63; Yes   No</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.444%"><tr><td style="width:1.0%"></td><td style="width:62.625%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.175%"></td><td style="width:0.1%"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:11pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Other Matters</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.053%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:71.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.412%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1)</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Have there been any changes in Key Persons since the last Compliance Certificate&#63;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Yes</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">No</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.053%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:71.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.412%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2)</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Have there been any transfers&#47;sales&#47;disposals&#47;retirement of Collateral or IP prohibited by the Loan Agreement&#63;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Yes</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">No</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Have there been any new or pending claims or causes of action against Borrower that involve more than Two Hundred Fifty Thousand Dollars ($250,000)&#63;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Yes</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">No</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4)</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Has Borrower provided the Collateral Agent with all notices required to be delivered under Sections 6.2(a) and 6.2(b) of the Loan Agreement&#63;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Yes</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">No</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">5)</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">With respect to each Foreign Subsidiary, do any hold assets worth One Hundred Thousand ($100,000) or more in book value&#63;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Yes</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">No</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">6)</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If the answer to question 5 is Yes, has the Company provided certificates representing a pledge of 65% of the stock, units or other evidence of ownership held by Borrower or Guarantor of such Foreign Subsidiary&#63;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Yes</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">No</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">7)</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Have you entered into a Material Agreement since the last Compliance Certificate&#63;  If yes, please provide a copy.</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Yes</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">No</font></td></tr></table></div><div style="padding-left:28.8pt;text-indent:-28.8pt"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:28.8pt;text-indent:-28.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Exceptions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">   </font></div><div style="padding-left:28.8pt;text-indent:-28.8pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Please explain any exceptions with respect to the certification above&#58; (If no exceptions exist, state &#8220;No exceptions.&#8221; Attach separate sheet if additional space needed.)</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ARDELYX, INC.</font></div><div style="padding-left:3.6pt"><font><br></font></div><div style="padding-left:3.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58; &#160;&#160;&#160;&#160; <br>Name&#58; &#160;&#160;&#160;&#160; <br>Title&#58; &#160;&#160;&#160;&#160;</font></div><div style="padding-left:3.6pt"><font><br></font></div><div style="padding-left:3.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date&#58;</font></div><div style="margin-top:11pt;padding-left:205.2pt"><font><br></font></div><div style="margin-top:11pt;padding-left:205.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">COLLATERAL AGENT USE ONLY</font></div><div style="margin-top:11pt;padding-left:205.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Received by&#58;&#160;&#160;&#160;&#160; Date&#58; &#160;&#160;&#160;&#160; </font></div><div style="margin-top:11pt;padding-left:205.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Verified by&#58; &#160;&#160;&#160;&#160; Date&#58; &#160;&#160;&#160;&#160; </font></div><div style="margin-bottom:401.35pt;margin-top:11pt;padding-left:205.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Compliance Status&#58;&#160;&#160;&#160;&#160;Yes&#160;&#160;&#160;&#160;No</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:13.55pt;margin-top:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT F</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CORPORATE BORROWING CERTIFICATE</font></div><div style="margin-top:11pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">BORROWER&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ARDELYX, INC.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">DATE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58; February 23, 2022</font></div><div style="padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">LENDER&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">SLR INVESTMENT CORP., as Collateral Agent and Lender <br></font></div><div style="margin-top:11pt;padding-right:3.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">I hereby certify, solely in my capacity as an officer of Borrower and not in my individual capacity, as follows, as of the date set forth above&#58;</font></div><div style="margin-top:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;I am the Secretary or other officer of Borrower. My title is as set forth below.</font></div><div style="margin-top:11pt;padding-right:3.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;Borrower&#8217;s exact legal name is set forth above. Borrower is a corporation existing under the laws of the State of Delaware.</font></div><div style="margin-top:11pt;padding-right:3.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;Attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, respectively, are true, correct and complete copies of (i) Borrower&#8217;s Certificate of Incorporation (including amendments), as filed with the Secretary of State of the state in which Borrower is incorporated as set forth in paragraph 2 above&#59; and (ii) Borrower&#8217;s Bylaws. Neither such Certificate of Incorporation nor such Bylaws have been amended, annulled, rescinded, revoked or supplemented, and such Certificate of Incorporation and such Bylaws remain in full force and effect as of the date hereof.</font></div><div style="margin-top:11pt;padding-right:3.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.&#160;&#160;&#160;&#160;The following resolutions were duly and validly adopted by Borrower&#8217;s board of directors (or a duly authorized committee thereof) at a duly held meeting of such directors (or pursuant to a unanimous written consent or other authorized corporate action). Such resolutions are in full force and effect as of the date hereof and have not been in any way modified, repealed, rescinded, amended or revoked, and the Lenders may rely on them until each Lender receives written notice of revocation from Borrower.</font></div><div style="margin-bottom:249.65pt;margin-top:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Balance of Page Intentionally Left Blank</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#93;</font></div><div style="margin-top:11pt"><font><br></font></div><div style="margin-bottom:15pt;margin-top:11pt;padding-left:36pt;padding-right:18pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:15pt;margin-top:11pt;padding-left:36pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">RESOLVED, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">that </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">any one </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">of the following officers or employees of Borrower, whose names, titles and signatures are below, may act on behalf of Borrower&#58;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.716%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.069%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.716%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.099%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Name</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Title</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Signature</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Authorized to Add or Remove </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Signatories</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#9633;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#9633;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#9633;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#9633;</font></td></tr></table></div><div style="margin-top:16pt;padding-left:36pt;padding-right:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">RESOLVED FURTHER, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">that </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">any one </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">of the persons designated above with a checked box beside his or her name may, from time to time, add or remove any individuals to and from the above list of persons authorized to act on behalf of Borrower.</font></div><div style="margin-top:11pt;padding-left:36pt;padding-right:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">RESOLVED FURTHER, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">that such individuals may, on behalf of Borrower&#58;</font></div><div style="margin-top:11pt;padding-left:36pt;padding-right:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Borrow Money</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Borrow money from the Lenders.</font></div><div style="margin-top:11pt;padding-left:36pt;padding-right:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Execute Loan Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Execute any loan documents any Lender requires.</font></div><div style="margin-top:11pt;padding-left:36pt;padding-right:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Grant Security</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Grant Collateral Agent a security interest in any of Borrower&#8217;s assets (excluding intellectual property).</font></div><div style="margin-top:11pt;padding-left:36pt;padding-right:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Negotiate Items</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Negotiate or discount all drafts, trade acceptances, promissory notes, or other indebtedness in which Borrower has an interest and receive cash or otherwise use the proceeds.</font></div><div style="margin-top:11pt;padding-left:36pt;padding-right:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Pay Fees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Pay fees under the Loan Agreement or any other Loan Document.</font></div><div style="margin-top:11pt;padding-left:36pt;padding-right:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Further Acts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Designate other individuals to request advances, pay fees and costs and execute other documents or agreements (including documents or agreement that waive Borrower&#8217;s right to a jury trial) they believe to be necessary to effectuate such resolutions.</font></div><div style="margin-top:11pt;padding-left:36pt;padding-right:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">RESOLVED FURTHER, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">that all acts authorized by the above resolutions and any prior acts relating thereto are ratified.</font></div><div style="margin-bottom:182.95pt;margin-top:11pt;padding-left:183.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Balance of Page Intentionally Left Blank</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:11pt;padding-right:3.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.&#160;&#160;&#160;&#160;The persons listed above are Borrower&#8217;s officers or employees with their titles and signatures shown next to their names.</font></div><div style="margin-top:11pt;padding-left:255.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">By&#58;&#160;&#160;&#160;&#160;<br>Name&#58; <br>Title&#58;</font></div><div style="margin-top:11pt;padding-left:3.6pt;padding-right:3.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">*** If the Secretary or other certifying officer executing above is designated by the resolutions set forth in paragraph 4 as one of the authorized signing officers, this Certificate must also be signed by a second authorized officer or director of Borrower.</font></div><div style="margin-top:11pt;padding-right:3.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">I, the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;&#160;&#160;&#160;&#160;&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of Borrower, hereby certify as to paragraphs 1 through 5 above, as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;&#160;&#160;&#160;&#160;&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> on the date set</font></div><div style="margin-top:11pt;padding-left:3.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">forth above.</font></div><div style="margin-top:11pt;padding-left:255.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">By&#58;&#160;&#160;&#160;&#160; </font></div><div style="margin-bottom:423.6pt;margin-top:11pt;padding-left:255.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Name&#58; <br>Title&#58;</font></div><div style="margin-bottom:11pt;margin-top:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT A</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Certificate of Incorporation (including amendments)</font></div><div style="margin-top:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;see attached&#93;</font></div><div style="margin-top:11pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:6pt;margin-top:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT B</font></div><div style="margin-bottom:6pt;margin-top:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Bylaws  </font></div><div style="margin-bottom:6pt;margin-top:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;see attached&#93;</font></div><div style="margin-bottom:6pt;margin-top:11pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div></div></div><div id="i411762c6343a4d74a3d9f0d4e597f682_50"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT G</font></div><div style="margin-top:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ACH LETTER</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:127%">SLR INVESTMENT CORP. </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:127%">500 Park Avenue, 3rd Floor</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:127%">New York, NY 10022</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:127%">Attention&#58; Anthony Storino</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:127%">Fax&#58; (212) 993-1698</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:127%">Email&#58; </font></div><div style="margin-bottom:11pt;padding-left:35.3pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Re&#58;  Loan and Security Agreement dated as of February 23, 2022 (the &#8220;Agreement&#8221;) by and among Ardelyx, Inc. (&#8220;Borrower&#8221;), SLR Investment Corp. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">SLR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), as collateral agent (in such capacity, &#8220;Collateral Agent&#8221;) and the Lenders listed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule&#160;1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> thereof or otherwise a party thereto from time to time, including SLR in its capacity as a Lender (each a &#8220;Lender&#8221; and collectively, the &#8220;Lenders&#8221;).  Capitalized terms used but not otherwise defined herein shall have the meanings given them under the Agreement. </font></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In connection with the above referenced Agreement, the Borrower hereby authorizes the Collateral Agent to, at its discretion and with prior notice of at least one (1) Business Day, initiate debit entries to the Borrower&#8217;s account indicated below (i) on each payment date of all Obligations then due and owing, (ii) at any time any payment due and owing with respect to Lender Expenses, and (iii) upon an Event of Default, any other Obligations outstanding, in each case pursuant to Section 2.3(e) of the Agreement.  The Borrower authorizes the depository institution named below to debit to such account.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:140%;position:relative;top:-3.5pt;vertical-align:baseline">DEPOSITORY NAME</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:140%;position:relative;top:-3.5pt;vertical-align:baseline">BRANCH</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:140%;position:relative;top:-3.5pt;vertical-align:baseline">CITY</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:140%;position:relative;top:-3.5pt;vertical-align:baseline">STATE AND ZIP CODE</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:140%;position:relative;top:-3.5pt;vertical-align:baseline">TRANSIT&#47;ABA NUMBER</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:140%;position:relative;top:-3.5pt;vertical-align:baseline">ACCOUNT NUMBER</font></div></td></tr></table></div><div style="margin-bottom:84pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:127%">This authority will remain in full force and effect so long as any amounts are due under the Agreement. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:140%">ARDELYX, INC.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:140%">By&#58; _________________________________________</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Title&#58; ________________________________________</font></div><div style="margin-bottom:53pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Date&#58; ________________________________________</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>slrexitfeeagreement-ex102.htm
<DESCRIPTION>EX-10.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i7ea323719dbc4b05a11a585f6c663bcd_1"></div><div style="min-height:72pt;width:100%"><div style="padding-right:5pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 10.2</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exit Fee Agreement</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Reference is made to the Loan and Security Agreement, dated as of February 23, 2022 (as may be amended, amended and restated, supplemented or otherwise modified from time to time, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Loan Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) by and among SLR Investment Corp., a Maryland corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SLR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), as collateral agent (in such capacity, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), the lenders party thereto from time to time including SLR in its capacity as a lender (each a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Lender</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; and collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Lenders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), and ARDELYX, INC., a Delaware corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Borrower</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  As a condition precedent to the Lenders&#8217; entry into the Loan Agreement, the Lenders require that Borrower agree to pay to the Lenders a fee upon the occurrence of certain events as described in this Exit Fee Agreement (as amended, amended and restated, supplemented or otherwise modified from time to time, this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exit Fee Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), dated as of the date hereof (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), by and among SLR, as Agent, the Lenders and Borrower.  Capitalized terms used herein and not otherwise defined herein have the meanings assigned to them in the Loan Agreement and, in the event that the Loan Agreement terminates prior to the termination of this Exit Fee Agreement, capitalized terms used herein and not otherwise defined herein have the meanings assigned to them in the Loan Agreement as in effect immediately prior to the termination of the Loan Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Therefore, in consideration of the Lenders entering into the Loan Agreement, Borrower hereby agrees as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt;text-decoration:underline">Trigger Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  For purposes hereof, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Trigger Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall mean the first to occur of an Exit Event or a Revenue Milestone Event, as such terms are defined below</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">.  </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.37pt">For purposes hereof, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exit Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall mean the first to occur of&#58; (a) any liquidation, dissolution or winding up of Borrower, whether voluntary or involuntary, which results in cash or other non-cash consideration to the stockholders of Borrower&#59; (b) a consolidation, merger or reverse merger of Borrower with or into another corporation or entity or other reorganization or similar transaction or series of related transactions involving Borrower which result in stockholders of Borrower immediately prior to such transaction or series of related transactions owning less than fifty percent (50%) of the outstanding capital stock of the surviving entity (treating all securities convertible or exchangeable into or exercisable for shares of common stock as having been fully converted, exchanged and exercised, and deemed to be outstanding for purposes of this clause, without regard to any exercise, conversion or exchange limitations therein)&#59; (c) a sale, lease, transfer, exclusive license, exchange, dividend or other disposition of all or substantially all of the assets of Borrower&#59; (d) the issuance and&#47;or sale by Borrower in one or a series of related transactions of shares of its common stock (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Common Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) (or securities convertible or exchangeable into or exercisable for shares of Common Stock) constituting more than fifty percent (50%) of the shares of Common Stock outstanding immediately following such issuance (treating all securities convertible or exchangeable into or exercisable for shares of Common Stock as having been fully converted, exchanged and exercised, and deemed to be outstanding for purposes of this clause without regard to any exercise, conversion or exchange limitations therein) to parties other than its then existing investors&#59; and (e) any other form of acquisition or business combination where Borrower is the target of such acquisition and where a change of control occurs such that the person that acquires Borrower has the power after such transaction to elect a majority of the board of directors of Borrower as a result of such transaction.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:9.75pt">For purposes hereof, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Revenue Milestone Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall mean the achievement by Borrower of Net Product Revenue equal to or greater than One Hundred Million Dollars ($100,000,000.00), measured on a trailing six (6) month basis, tested monthly at the end of each month.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt;text-decoration:underline">Reporting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Borrower agrees to provide the Lenders, to the extent reasonably practicable with respect to clause (a) of Section 1 and otherwise with (a) five (5) days&#8217; prior written notice of the occurrence of any Exit Event&#59; and (b) written notice of the Trigger Event as soon as practicable following the occurrence of such Trigger Event, but in any event not more than (i) five (5) Business Days after any Exit Event and (ii) thirty (30) days after any Revenue Milestone Event. </font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt;text-decoration:underline">Exit Fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Upon the occurrence of the Trigger Event and in accordance with Section 4 below, Borrower agrees to pay to each Lender in accordance with its Pro Rata Share (provided that if such payment is made after the termination of the Loan Agreement, such payment shall be made in accordance with each such Lender&#8217;s Pro Rata Share as was in effect immediately before the termination of the Loan Agreement), in immediately available funds, a fee (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exit Fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) in the amount equal to two percent (2.00%) of each Term Loan funded.  For the avoidance of doubt, the Exit Fee set forth herein shall be in addition to any fee or amount due and payable pursuant to the Fee Letter or the other Loan Documents.  Borrower expressly agrees (to the fullest extent that it may lawfully do so) that&#58; (i) the Exit Fee is reasonable and is the product of an arm&#8217;s length transaction between sophisticated business people, ably represented by counsel&#59; (ii) the Exit Fee shall be payable notwithstanding the then prevailing market rates at the time payment is made&#59; (iii) there has been a course of conduct between Agent, Lenders and Borrower giving specific consideration in this transaction for such agreement to pay the Exit Fee and (iv) Borrower shall be estopped hereafter from claiming differently than as agreed to in this paragraph. Borrower expressly acknowledges that its agreement to pay the Exit Fee to Lenders as herein described is a material inducement to Lenders to provide the Term Loan Commitments and make the Term Loans.</font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt;text-decoration:underline">Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Exit Fee shall be paid to the Lenders not later than five (5) Business Days after the applicable reporting deadline of the Trigger Event as set forth in Section 2(b) hereof.  Failure to so timely pay the full amount of the Exit Fee to the Lenders shall be an Event of Default under the Loan Agreement, so long as the Loan Agreement is then in effect.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt;text-decoration:underline">Termination&#59; Assignment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  This Exit Fee Agreement shall be binding on Borrower and its respective successors and assigns and shall terminate upon the earlier to occur of (a) payment in full of the Exit Fee pursuant to the terms herein, or (b) February 23, 2032 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Termination Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  For the avoidance of doubt, this Exit Fee Agreement shall survive the termination of the Loan Agreement or any other Loan Document.  If the Trigger Event has not occurred on or before the Termination Date, this Exit Fee Agreement shall automatically terminate and be of no further force and effect and neither Borrower nor any successor of Borrower shall have any obligation to pay the Exit Fee. Borrower may not assign this Exit Fee Agreement.  Each Lender may assign this Exit Fee Agreement solely in connection with, and subject to the terms of, an assignment or transfer made pursuant to the terms of Section 12.1 of the Loan Agreement, which shall govern such an assignment or transfer even if the Loan Agreement has previously been terminated.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt;text-decoration:underline">GOVERNING LAW</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  THIS EXIT FEE AGREEMENT SHALL BE CONSTRUED IN ACCORDANCE WITH AND GOVERNED BY THE LAW OF THE STATE OF NEW YORK, WITHOUT REGARD TO CONFLICTS OF LAW PRINCIPLES THAT WOULD REQUIRE THE APPLICATION OF THE LAWS OF ANOTHER JURISDICTION.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt;text-decoration:underline">Indemnification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Borrower agrees to indemnify, defend and hold Agent and the Lenders and their respective directors, officers, employees, consultants, agents, attorneys, or any other Person affiliated with or representing Agent or the Lenders (each, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Indemnified Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) harmless against&#58;  (a) all obligations, demands, claims, and liabilities (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) asserted by any other party in connection with&#59; related to&#59; following&#59; or arising from, out of or under, the transactions contemplated by this Exit Fee Agreement&#59; and (b) all losses or Lenders&#8217; Expenses incurred, or paid by an Indemnified Person in connection with&#59; related to&#59; following&#59; or arising from, out of or under, the transactions contemplated by this Exit Fee Agreement between Agent, and&#47;or the Lenders and Borrower (including reasonable and documented attorneys&#8217; fees and expenses), except for Claims and&#47;or losses directly caused by such Indemnified Person&#8217;s gross negligence or willful misconduct.  Borrower hereby further indemnifies, defends and holds each Indemnified Person harmless from and against any and all liabilities, obligations, losses, damages, penalties, actions, judgments, suits, claims, costs, expenses and disbursements of any kind or nature whatsoever (including the fees and disbursements of counsel for such Indemnified Person) in connection with any investigative, response, remedial, administrative or judicial matter or proceeding, whether or not such Indemnified Person shall be designated a party thereto and including any such proceeding initiated by or on behalf of Borrower, and any commission, fee or compensation claimed by any broker (other than any broker retained by Agent or Lenders) asserting any right to payment for the transactions contemplated hereby which may be imposed on, incurred by or asserted against such Indemnified Person as a result of or in connection with the transactions contemplated hereby and the use or intended use of the proceeds of the loan proceeds except for liabilities, obligations, losses, damages, penalties, actions, judgments, suits, claims, costs, expenses and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> 2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">disbursements directly caused by such Indemnified Person&#8217;s gross negligence or willful misconduct. The provisions of this Section 7 shall survive repayment of the Indebtedness and satisfaction of all Obligations of Borrower to Agent and the Lenders and termination of this Exit Fee Agreement, subject to any applicable statute of limitations.  </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt;text-decoration:underline">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">No amendment, modification, termination or waiver of any provision of this Exit Fee Agreement shall in any event be effective unless the same shall be in writing and signed by Borrower, Collateral Agent and each Lender (including any permitted assigns of such parties).</font></div><div style="padding-left:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt;text-decoration:underline">Severability of Provisions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Each provision of this Exit Fee Agreement is severable from every other provision in determining the enforceability of any provision.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  This Exit Fee Agreement may be executed in any number of counterparts and by different parties on separate counterparts, each of which, when executed and delivered, is an original, and all taken together, constitute one Exit Fee Agreement.  Delivery of an executed counterpart of a signature page of this Exit Fee Agreement by facsimile, portable document format (.pdf) or other electronic transmission will be as effective as delivery of a manually executed counterpart hereof.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt;text-decoration:underline">Electronic Execution of Certain Other Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The words &#8220;execution,&#8221; &#8220;execute&#8221;, &#8220;signed,&#8221; &#8220;signature,&#8221; and words of like import in or related to any document to be signed in connection with this Exit Fee Agreement and the transactions contemplated hereby (including without limitation assignments, assumptions, amendments, waivers and consents) shall be deemed to include electronic signatures, the electronic matching of assignment terms and contract formations on electronic platforms approved by Agent and the Lenders, or the keeping of records in electronic form, each of which shall be of the same legal effect, validity or enforceability as a manually executed signature or the use of a paper-based recordkeeping system, as the case may be, to the extent and as provided for in any applicable law, including the Federal Electronic Signatures in Global and National Commerce Act, the New York State Electronic Signatures and Records Act, or any other similar state laws based on the Uniform Electronic Transactions Act.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">&#91;Balance of Page Intentionally Left Blank&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> 3</font></div><div><font><br></font></div></div></div><div id="i7ea323719dbc4b05a11a585f6c663bcd_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Agreed&#58;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:96.361%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.339%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SLR INVESTMENT CORP.,</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">as Agent and Lender</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58; _</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Anthony Storino</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">__________</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58; Anthony Storino</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58; Authorized Signatory</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SLR SENIOR INVESTMENT CORP.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SCP PRIVATE CREDIT INCOME FUND SPV, LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SCP PRIVATE CREDIT INCOME BDC SPV LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SCP PRIVATE CORPORATE LENDING FUND SPV LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SCP SF DEBT FUND L.P. </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SLR HC FUND SPV, LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SLR HC BDC LLC,</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">as Lenders </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Anthony Storino</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58; Anthony Storino</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58; Authorized Signatory</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;Signature Page to Exit Fee Agreement&#93; </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div><div><font><br></font></div></div></div><div id="i7ea323719dbc4b05a11a585f6c663bcd_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Agreed&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ARDELYX, INC.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">,</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">as Borrower</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;_</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Justin A. Renz</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">_______________________________</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58; Justin A. Renz</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;   CFO</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;Signature Page to Exit Fee Agreement&#93; </font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>ardx-20220331xex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="icbfcff5c17ff41379902cde7dc8d8a94_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Michael Raab, certify that&#58;</font></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Quarterly Report on Form 10-Q of Ardelyx, Inc.&#59;</font></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.648%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.691%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; May 5, 2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Michael Raab</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Michael Raab<br>President, Chief Executive Officer and Director<br>(Principal Executive Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>ardx-20220331xex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i34dd3bde22f84910b09395c07efef6af_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Justin Renz, certify that&#58;</font></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Quarterly Report on Form 10-Q of Ardelyx, Inc.&#59;</font></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.794%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.691%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; May 5, 2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Justin Renz</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Justin Renz<br>Chief Financial Officer<br>(Principal Financial Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>ardx-20220331xex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ic304bfabb8ca43d28780c4e058ed1301_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:10pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quartlery Report of Ardelyx, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ending March&#160;31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), Michael Raab, President and Chief Executive Officer of the Company, and Justin Renz, Chief Financial Officer of the Company, respectively, do each hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.414%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.502%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.691%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; May 5, 2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Michael Raab</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Michael Raab<br>President, Chief Executive Officer and Director<br>(Principal Executive Officer)</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.779%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.939%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.871%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; May 5, 2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Justin Renz</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Justin Renz<br>Chief Financial Officer<br>(Principal Financial Officer)</font></td></tr></table></div><div style="margin-top:10pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>ardx-20220331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:9e7cc335-f1e2-4409-ab16-898e4e60d77f,g:bd3d9229-0258-42cf-b897-58fd721121d9-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ardx="http://www.ardelyx.com/20220331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.ardelyx.com/20220331">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ardx-20220331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ardx-20220331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ardx-20220331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ardx-20220331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.ardelyx.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDBALANCESHEETS" roleURI="http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS">
        <link:definition>1001002 - Statement - CONDENSED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDBALANCESHEETSParenthetical" roleURI="http://www.ardelyx.com/role/CONDENSEDBALANCESHEETSParenthetical">
        <link:definition>1002003 - Statement - CONDENSED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" roleURI="http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS">
        <link:definition>1003004 - Statement - CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" roleURI="http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY">
        <link:definition>1004005 - Statement - CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS">
        <link:definition>1005006 - Statement - CONDENSED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBasisofPresentation" roleURI="http://www.ardelyx.com/role/OrganizationandBasisofPresentation">
        <link:definition>2101101 - Disclosure - Organization and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBasisofPresentationPolicies" roleURI="http://www.ardelyx.com/role/OrganizationandBasisofPresentationPolicies">
        <link:definition>2202201 - Disclosure - Organization and Basis of Presentation (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBasisofPresentationDetails" roleURI="http://www.ardelyx.com/role/OrganizationandBasisofPresentationDetails">
        <link:definition>2403401 - Disclosure - Organization and Basis of Presentation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsandInvestments" roleURI="http://www.ardelyx.com/role/CashCashEquivalentsandInvestments">
        <link:definition>2104102 - Disclosure - Cash, Cash Equivalents and Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsandInvestmentsTables" roleURI="http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsTables">
        <link:definition>2305301 - Disclosure - Cash, Cash Equivalents and Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails" roleURI="http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails">
        <link:definition>2406402 - Disclosure - Cash, Cash Equivalents and Investments - Securities Classified as Cash, Cash Equivalents and Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsandInvestmentsNarrativeDetails" roleURI="http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsNarrativeDetails">
        <link:definition>2407403 - Disclosure - Cash, Cash Equivalents and Investments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.ardelyx.com/role/FairValueMeasurements">
        <link:definition>2108103 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.ardelyx.com/role/FairValueMeasurementsTables">
        <link:definition>2309302 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails" roleURI="http://www.ardelyx.com/role/FairValueMeasurementsDetails">
        <link:definition>2410404 - Disclosure - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventory" roleURI="http://www.ardelyx.com/role/Inventory">
        <link:definition>2111104 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryTables" roleURI="http://www.ardelyx.com/role/InventoryTables">
        <link:definition>2312303 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryDetails" roleURI="http://www.ardelyx.com/role/InventoryDetails">
        <link:definition>2413405 - Disclosure - Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProductRevenueNet" roleURI="http://www.ardelyx.com/role/ProductRevenueNet">
        <link:definition>2114105 - Disclosure - Product Revenue, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProductRevenueNetTables" roleURI="http://www.ardelyx.com/role/ProductRevenueNetTables">
        <link:definition>2315304 - Disclosure - Product Revenue, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProductRevenueNetNarrativeDetails" roleURI="http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails">
        <link:definition>2416406 - Disclosure - Product Revenue, Net - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProductRevenueNetGrosstoNetSalesAccrualsDetails" roleURI="http://www.ardelyx.com/role/ProductRevenueNetGrosstoNetSalesAccrualsDetails">
        <link:definition>2417407 - Disclosure - Product Revenue, Net - Gross-to-Net Sales Accruals (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicensingAgreements" roleURI="http://www.ardelyx.com/role/CollaborationandLicensingAgreements">
        <link:definition>2118106 - Disclosure - Collaboration and Licensing Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicensingAgreementsTables" roleURI="http://www.ardelyx.com/role/CollaborationandLicensingAgreementsTables">
        <link:definition>2319305 - Disclosure - Collaboration and Licensing Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicensingAgreementsNarrativeDetails" roleURI="http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails">
        <link:definition>2420408 - Disclosure - Collaboration and Licensing Agreements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicensingAgreementsDeferredRevenueDetails" roleURI="http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails">
        <link:definition>2421409 - Disclosure - Collaboration and Licensing Agreements - Deferred Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Borrowing" roleURI="http://www.ardelyx.com/role/Borrowing">
        <link:definition>2122107 - Disclosure - Borrowing</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingTables" roleURI="http://www.ardelyx.com/role/BorrowingTables">
        <link:definition>2323306 - Disclosure - Borrowing (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingNarrativeDetails" roleURI="http://www.ardelyx.com/role/BorrowingNarrativeDetails">
        <link:definition>2424410 - Disclosure - Borrowing - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingFuturePaymentObligationsDetails" roleURI="http://www.ardelyx.com/role/BorrowingFuturePaymentObligationsDetails">
        <link:definition>2425411 - Disclosure - Borrowing - Future Payment Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingFuturePaymentObligationsDetails_1" roleURI="http://www.ardelyx.com/role/BorrowingFuturePaymentObligationsDetails_1">
        <link:definition>2425411 - Disclosure - Borrowing - Future Payment Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeLiability" roleURI="http://www.ardelyx.com/role/DerivativeLiability">
        <link:definition>2126108 - Disclosure - Derivative Liability</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeLiabilityTables" roleURI="http://www.ardelyx.com/role/DerivativeLiabilityTables">
        <link:definition>2327307 - Disclosure - Derivative Liability (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeLiabilityNarrativeDetails" roleURI="http://www.ardelyx.com/role/DerivativeLiabilityNarrativeDetails">
        <link:definition>2428412 - Disclosure - Derivative Liability - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeLiabilityChangesinFairValueDetails" roleURI="http://www.ardelyx.com/role/DerivativeLiabilityChangesinFairValueDetails">
        <link:definition>2429413 - Disclosure - Derivative Liability - Changes in Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.ardelyx.com/role/Leases">
        <link:definition>2130109 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.ardelyx.com/role/LeasesTables">
        <link:definition>2331308 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesAdditionalDetailsofFacilityLeasesDetails" roleURI="http://www.ardelyx.com/role/LeasesAdditionalDetailsofFacilityLeasesDetails">
        <link:definition>2432414 - Disclosure - Leases - Additional Details of Facility Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesLeaseCostsDetails" roleURI="http://www.ardelyx.com/role/LeasesLeaseCostsDetails">
        <link:definition>2433415 - Disclosure - Leases - Lease Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesUndiscountedCashPaymentObligationsDetails" roleURI="http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails">
        <link:definition>2434416 - Disclosure - Leases - Undiscounted Cash Payment Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesUndiscountedCashPaymentObligationsDetails_1" roleURI="http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails_1">
        <link:definition>2434416 - Disclosure - Leases - Undiscounted Cash Payment Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.ardelyx.com/role/StockholdersEquity">
        <link:definition>2135110 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDetails" roleURI="http://www.ardelyx.com/role/StockholdersEquityDetails">
        <link:definition>2436417 - Disclosure - Stockholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentivePlans" roleURI="http://www.ardelyx.com/role/EquityIncentivePlans">
        <link:definition>2137111 - Disclosure - Equity Incentive Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentivePlansTables" roleURI="http://www.ardelyx.com/role/EquityIncentivePlansTables">
        <link:definition>2338309 - Disclosure - Equity Incentive Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentivePlansStockBasedCompensationDetails" roleURI="http://www.ardelyx.com/role/EquityIncentivePlansStockBasedCompensationDetails">
        <link:definition>2439418 - Disclosure - Equity Incentive Plans - Stock-Based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentivePlansUnrecognizedStockBasedCompensationDetails" roleURI="http://www.ardelyx.com/role/EquityIncentivePlansUnrecognizedStockBasedCompensationDetails">
        <link:definition>2440419 - Disclosure - Equity Incentive Plans - Unrecognized Stock-Based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentivePlansStockOptionsDetails" roleURI="http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails">
        <link:definition>2441420 - Disclosure - Equity Incentive Plans - Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentivePlansRestrictedStockUnitsDetails" roleURI="http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails">
        <link:definition>2442421 - Disclosure - Equity Incentive Plans - Restricted Stock Units (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentivePlansNarrativeDetails" roleURI="http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails">
        <link:definition>2443422 - Disclosure - Equity Incentive Plans - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShare" roleURI="http://www.ardelyx.com/role/NetLossPerShare">
        <link:definition>2144112 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareTables" roleURI="http://www.ardelyx.com/role/NetLossPerShareTables">
        <link:definition>2345310 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareComputationofNetLossPerCommonShareDetails" roleURI="http://www.ardelyx.com/role/NetLossPerShareComputationofNetLossPerCommonShareDetails">
        <link:definition>2446423 - Disclosure - Net Loss Per Share - Computation of Net Loss Per Common Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareNarrativeDetails" roleURI="http://www.ardelyx.com/role/NetLossPerShareNarrativeDetails">
        <link:definition>2447424 - Disclosure - Net Loss Per Share - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Contingencies" roleURI="http://www.ardelyx.com/role/Contingencies">
        <link:definition>2148113 - Disclosure - Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesDetails" roleURI="http://www.ardelyx.com/role/ContingenciesDetails">
        <link:definition>2449425 - Disclosure - Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.ardelyx.com/role/SubsequentEvents">
        <link:definition>2150114 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://www.ardelyx.com/role/SubsequentEventsDetails">
        <link:definition>2451426 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="ardx_TermLoan2018Member" abstract="true" name="TermLoan2018Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_ScheduleOfAdditionalDetailsOfLeasesTableTextBlock" abstract="false" name="ScheduleOfAdditionalDetailsOfLeasesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward" abstract="true" name="ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ardx_CashAndCashEquivalentsAmortizedCost" abstract="false" name="CashAndCashEquivalentsAmortizedCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_ContractWithCustomerRebatesMember" abstract="true" name="ContractWithCustomerRebatesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_ExitFee2018Member" abstract="true" name="ExitFee2018Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_LoanAgreementExitFeeTerm" abstract="false" name="LoanAgreementExitFeeTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward" abstract="true" name="ContractWithCustomerGrossToNetSalesAccrualRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ardx_OpenMarketSalesAgreement2020AtTheMarketOfferingMember" abstract="true" name="OpenMarketSalesAgreement2020AtTheMarketOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_TermOfAgreement" abstract="false" name="TermOfAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ardx_AccountsReceivableCommercialCustomerMember" abstract="true" name="AccountsReceivableCommercialCustomerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_ContractWithCustomerLiabilityRevenueRecognizedCashReceived" abstract="false" name="ContractWithCustomerLiabilityRevenueRecognizedCashReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_AmerisourceBergenDrugCorporationMember" abstract="true" name="AmerisourceBergenDrugCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember" abstract="true" name="ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_PercentageOfRoyaltyRevenue" abstract="false" name="PercentageOfRoyaltyRevenue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ardx_CardinalHealthMember" abstract="true" name="CardinalHealthMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_ContractWithCustomerGrossToNetSalesAccruals" abstract="false" name="ContractWithCustomerGrossToNetSalesAccruals" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_AccountsReceivableCollaboratorMember" abstract="true" name="AccountsReceivableCollaboratorMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_AstrazenecaMember" abstract="true" name="AstrazenecaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_McKessonCorporationMember" abstract="true" name="McKessonCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_SaleOfStockWeightedAveragePricePerShare" abstract="false" name="SaleOfStockWeightedAveragePricePerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="ardx_ExitFeePercentage" abstract="false" name="ExitFeePercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ardx_RemainingFundingBasedOnConditionalMilestoneAchievement" abstract="false" name="RemainingFundingBasedOnConditionalMilestoneAchievement" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_ContractWithCustomerOtherFeesCopayAndReturnsMember" abstract="true" name="ContractWithCustomerOtherFeesCopayAndReturnsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_StockIssuanceCostCommissionPercent" abstract="false" name="StockIssuanceCostCommissionPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ardx_ProductSupplyRevenueMember" abstract="true" name="ProductSupplyRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_DerivativeIssued" abstract="false" name="DerivativeIssued" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation" abstract="false" name="FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_ContractWithCustomerDiscountsAndChargebacksMember" abstract="true" name="ContractWithCustomerDiscountsAndChargebacksMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_GrossToNetSalesAccrualAndReserveClassificationDomain" abstract="true" name="GrossToNetSalesAccrualAndReserveClassificationDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_PaymentsOfUnchargedLicenseFeesAggregateAmountPaid" abstract="false" name="PaymentsOfUnchargedLicenseFeesAggregateAmountPaid" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_ProductIBSRELAMember" abstract="true" name="ProductIBSRELAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches" abstract="false" name="CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ardx_OpenMarketSalesAgreement2021AtTheMarketOfferingMember" abstract="true" name="OpenMarketSalesAgreement2021AtTheMarketOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_ContractWithCustomerLiabilityIncreaseForAmountsInvoiced" abstract="false" name="ContractWithCustomerLiabilityIncreaseForAmountsInvoiced" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees" abstract="false" name="CollaborationAndLicensingAgreementsUpfrontLicenseFees" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_DebtInstrumentVariableRateBaseOption" abstract="false" name="DebtInstrumentVariableRateBaseOption" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember" abstract="true" name="LicenseAgreementDevelopmentCommercializationDistributionInJapanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_CollaborativeArrangementPotentialCommercializationMilestones" abstract="false" name="CollaborativeArrangementPotentialCommercializationMilestones" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_CostOfRevenueAggregateAmountRecognized" abstract="false" name="CostOfRevenueAggregateAmountRecognized" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_EmployeeStockPurchasePlanMember" abstract="true" name="EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_AstraZenecaTerminationAgreementMember" abstract="true" name="AstraZenecaTerminationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward" abstract="true" name="ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ardx_CashAndCashEquivalentsGrossUnrealizedLosses" abstract="false" name="CashAndCashEquivalentsGrossUnrealizedLosses" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_ExitFee2022Member" abstract="true" name="ExitFee2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_PercentageOfNonRoyaltyRevenue" abstract="false" name="PercentageOfNonRoyaltyRevenue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ardx_LoanAgreementFutureObligationUponFundingOrOtherEvents" abstract="false" name="LoanAgreementFutureObligationUponFundingOrOtherEvents" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage" abstract="false" name="FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ardx_ResearchCollaborationAndOptionAgreementMember" abstract="true" name="ResearchCollaborationAndOptionAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_TermLoan2022BMember" abstract="true" name="TermLoan2022BMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod" abstract="false" name="ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_TermOfPaymentOfLicenseFeeFirstInstallment" abstract="false" name="TermOfPaymentOfLicenseFeeFirstInstallment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember" abstract="true" name="LicenseAgreementDevelopmentCommercializationDistributionInChinaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_TermLoan2022AMember" abstract="true" name="TermLoan2022AMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum" abstract="false" name="CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_MaximumAggregateOfferingPrice" abstract="false" name="MaximumAggregateOfferingPrice" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_KyowaKirinCo.LtdMember" abstract="true" name="KyowaKirinCo.LtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_CollaborationAndLicensingAgreementsAbstract" abstract="true" name="CollaborationAndLicensingAgreementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ardx_ContractWithCustomerLiabilityIncreaseDueToUnbilledPrepaymentsRecorded" abstract="false" name="ContractWithCustomerLiabilityIncreaseDueToUnbilledPrepaymentsRecorded" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment" abstract="false" name="CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_CashAndCashEquivalentsGrossUnrealizedGains" abstract="false" name="CashAndCashEquivalentsGrossUnrealizedGains" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="ardx_CollaborativeArrangementPotentialDevelopmentMilestones" abstract="false" name="CollaborativeArrangementPotentialDevelopmentMilestones" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_GrossToNetSalesAccrualAndReserveClassificationAxis" abstract="true" name="GrossToNetSalesAccrualAndReserveClassificationAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedGains" abstract="false" name="CashCashEquivalentsAndInvestmentsGrossUnrealizedGains" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_DebtInstrumentInterestRateOnDefaultPercentage" abstract="false" name="DebtInstrumentInterestRateOnDefaultPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ardx_AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum" abstract="false" name="AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ardx_ThresholdPercentageOfSalesForTieredRoyalties" abstract="false" name="ThresholdPercentageOfSalesForTieredRoyalties" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum" abstract="false" name="LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ardx_DebtInstrumentClosingFeeAmount" abstract="false" name="DebtInstrumentClosingFeeAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment" abstract="false" name="CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_DebtInstrumentPrepaymentFeePercentage" abstract="false" name="DebtInstrumentPrepaymentFeePercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage" abstract="false" name="DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ardx_LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum" abstract="false" name="LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ardx_KnightTherapeuticsIncMember" abstract="true" name="KnightTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_RevenueGeneralPaymentTerms" abstract="false" name="RevenueGeneralPaymentTerms" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ardx_ScheduleOfGrossToNetSalesAccrualsTableTextBlock" abstract="false" name="ScheduleOfGrossToNetSalesAccrualsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses" abstract="false" name="CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum" abstract="false" name="LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones" abstract="false" name="CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_CollaborativeDevelopmentMember" abstract="true" name="CollaborativeDevelopmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_InvestmentsAndCashAmortizedCost" abstract="false" name="InvestmentsAndCashAmortizedCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate" abstract="false" name="CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_TermLoan2022Member" abstract="true" name="TermLoan2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_NumberOfSeparateCollaborativeAgreements" abstract="false" name="NumberOfSeparateCollaborativeAgreements" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember" abstract="true" name="LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>ardx-20220331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:9e7cc335-f1e2-4409-ab16-898e4e60d77f,g:bd3d9229-0258-42cf-b897-58fd721121d9-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS" xlink:type="simple" xlink:href="ardx-20220331.xsd#CONDENSEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b8834678-8077-49bd-80cc-e5869e1713d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_9b2eb69c-759d-4a61-a662-e9367ced676b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_b8834678-8077-49bd-80cc-e5869e1713d9" xlink:to="loc_us-gaap_PreferredStockValue_9b2eb69c-759d-4a61-a662-e9367ced676b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_5b99e9d9-002b-4283-a5ee-f44772022b59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_b8834678-8077-49bd-80cc-e5869e1713d9" xlink:to="loc_us-gaap_CommonStockValue_5b99e9d9-002b-4283-a5ee-f44772022b59" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_0ebb4353-8db6-490c-908d-024e3abe8ab8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_b8834678-8077-49bd-80cc-e5869e1713d9" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_0ebb4353-8db6-490c-908d-024e3abe8ab8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d1930197-7c1b-4fe6-86f7-09f5fd8692ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_b8834678-8077-49bd-80cc-e5869e1713d9" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d1930197-7c1b-4fe6-86f7-09f5fd8692ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5e83f5e7-0eaa-4ea1-811b-97cf1c686432" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_b8834678-8077-49bd-80cc-e5869e1713d9" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5e83f5e7-0eaa-4ea1-811b-97cf1c686432" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_2f9b3e3d-5853-428d-83f8-630064349e89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6b46b279-bef5-457f-824b-83458fa4e659" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_2f9b3e3d-5853-428d-83f8-630064349e89" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6b46b279-bef5-457f-824b-83458fa4e659" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_2d562d5e-673e-4364-a920-cd650d8af1ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_2f9b3e3d-5853-428d-83f8-630064349e89" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_2d562d5e-673e-4364-a920-cd650d8af1ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_5fe98197-e5b2-4694-93ea-661b077b8698" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_2f9b3e3d-5853-428d-83f8-630064349e89" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_5fe98197-e5b2-4694-93ea-661b077b8698" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_7da867a7-5ebc-42b8-850b-11b68d086235" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_2f9b3e3d-5853-428d-83f8-630064349e89" xlink:to="loc_us-gaap_InventoryNet_7da867a7-5ebc-42b8-850b-11b68d086235" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_f9398393-2ee9-4264-a550-9bef4a453c1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_2f9b3e3d-5853-428d-83f8-630064349e89" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_f9398393-2ee9-4264-a550-9bef4a453c1e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_8c218275-6dd9-48c3-ae07-d05e59d4373f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_3da8ad33-ec6e-4070-b299-6bf0454ddf4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_8c218275-6dd9-48c3-ae07-d05e59d4373f" xlink:to="loc_us-gaap_Liabilities_3da8ad33-ec6e-4070-b299-6bf0454ddf4e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_84f462d3-d951-4949-9b44-0744401fd591" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_8c218275-6dd9-48c3-ae07-d05e59d4373f" xlink:to="loc_us-gaap_CommitmentsAndContingencies_84f462d3-d951-4949-9b44-0744401fd591" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_8745bd1b-c437-4b43-8e5c-b8b7b9225b14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_8c218275-6dd9-48c3-ae07-d05e59d4373f" xlink:to="loc_us-gaap_StockholdersEquity_8745bd1b-c437-4b43-8e5c-b8b7b9225b14" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_2d6f7cff-3966-41af-9f1d-9db5a3b50c3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_2d7a9790-bfba-49c8-adfb-624bdf669dc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_2d6f7cff-3966-41af-9f1d-9db5a3b50c3c" xlink:to="loc_us-gaap_AssetsCurrent_2d7a9790-bfba-49c8-adfb-624bdf669dc5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_89345fe7-bbc9-46f4-9a26-49b8180f1b62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_2d6f7cff-3966-41af-9f1d-9db5a3b50c3c" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_89345fe7-bbc9-46f4-9a26-49b8180f1b62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_21784129-364b-46fb-a7aa-06a53a80751d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_2d6f7cff-3966-41af-9f1d-9db5a3b50c3c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_21784129-364b-46fb-a7aa-06a53a80751d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_95ce5552-64eb-487b-9fb9-e8ad8da3e85d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_2d6f7cff-3966-41af-9f1d-9db5a3b50c3c" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_95ce5552-64eb-487b-9fb9-e8ad8da3e85d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_22ac1e18-d078-4c84-8f3e-d8ba03f0f8e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_02888a72-5cb8-41d5-934e-c4ffb38b3a06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_22ac1e18-d078-4c84-8f3e-d8ba03f0f8e4" xlink:to="loc_us-gaap_LiabilitiesCurrent_02888a72-5cb8-41d5-934e-c4ffb38b3a06" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_94a43294-e422-4047-97e4-35e5fd5efd7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_22ac1e18-d078-4c84-8f3e-d8ba03f0f8e4" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_94a43294-e422-4047-97e4-35e5fd5efd7e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_411d2911-c98a-4cb3-a959-79e52372cba4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_22ac1e18-d078-4c84-8f3e-d8ba03f0f8e4" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_411d2911-c98a-4cb3-a959-79e52372cba4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_777af324-8f56-48d9-8446-e519a12f96e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_b8e5bf79-2bc7-4d09-9dcf-b80a92e6983d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_777af324-8f56-48d9-8446-e519a12f96e4" xlink:to="loc_us-gaap_AccountsPayableCurrent_b8e5bf79-2bc7-4d09-9dcf-b80a92e6983d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_129fbf20-05a6-407c-ab41-63419c90d239" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_777af324-8f56-48d9-8446-e519a12f96e4" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_129fbf20-05a6-407c-ab41-63419c90d239" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_bb3ed438-f64d-475f-b3d6-372e8a3661a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_777af324-8f56-48d9-8446-e519a12f96e4" xlink:to="loc_us-gaap_LongTermDebtCurrent_bb3ed438-f64d-475f-b3d6-372e8a3661a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_f6e18070-b596-4240-afd4-953f2ca533f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_777af324-8f56-48d9-8446-e519a12f96e4" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_f6e18070-b596-4240-afd4-953f2ca533f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_3b81ab8b-5e31-4a1c-82c3-c124be170540" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_777af324-8f56-48d9-8446-e519a12f96e4" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_3b81ab8b-5e31-4a1c-82c3-c124be170540" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="ardx-20220331.xsd#CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:calculationLink xlink:role="http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_568957e9-363a-4a6b-a364-e64c53cf9315" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_eb45bc99-fe35-48e1-8a52-0d658a7563a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_568957e9-363a-4a6b-a364-e64c53cf9315" xlink:to="loc_us-gaap_NetIncomeLoss_eb45bc99-fe35-48e1-8a52-0d658a7563a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_97bd5a8e-c091-4c2d-bae1-5903cf2a6d83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_568957e9-363a-4a6b-a364-e64c53cf9315" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_97bd5a8e-c091-4c2d-bae1-5903cf2a6d83" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_722676be-d686-424e-ad0e-93e96014089f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_2eeeffc4-50ec-4b39-8ea2-f4652d0147af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_722676be-d686-424e-ad0e-93e96014089f" xlink:to="loc_us-gaap_CostOfRevenue_2eeeffc4-50ec-4b39-8ea2-f4652d0147af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_0ef6e17d-90d5-4b92-95a6-36d98cb12ca3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_722676be-d686-424e-ad0e-93e96014089f" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_0ef6e17d-90d5-4b92-95a6-36d98cb12ca3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_e1f6e7a6-59f6-4078-adf4-a69d9eaae28b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_722676be-d686-424e-ad0e-93e96014089f" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_e1f6e7a6-59f6-4078-adf4-a69d9eaae28b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2a4a7b36-fb32-44d0-9739-a920eca716f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_acc610b0-4347-4766-9d2f-03b335adc8f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2a4a7b36-fb32-44d0-9739-a920eca716f2" xlink:to="loc_us-gaap_OperatingIncomeLoss_acc610b0-4347-4766-9d2f-03b335adc8f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_eaeee16b-bd57-495d-817c-5dd9c5219eff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2a4a7b36-fb32-44d0-9739-a920eca716f2" xlink:to="loc_us-gaap_InterestExpense_eaeee16b-bd57-495d-817c-5dd9c5219eff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_c77b6875-9362-44f5-b0c2-cfad9737f014" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2a4a7b36-fb32-44d0-9739-a920eca716f2" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_c77b6875-9362-44f5-b0c2-cfad9737f014" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_41c2c40d-4e2f-4d8b-912f-360469c83b19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_006a2468-08a7-4026-a929-d3b83dd8f4d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_41c2c40d-4e2f-4d8b-912f-360469c83b19" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_006a2468-08a7-4026-a929-d3b83dd8f4d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_cf0f77a6-a3cd-46ac-ae1f-642a35ed9cec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_41c2c40d-4e2f-4d8b-912f-360469c83b19" xlink:to="loc_us-gaap_CostsAndExpenses_cf0f77a6-a3cd-46ac-ae1f-642a35ed9cec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_87c2f114-ec23-405e-acf2-d8b9c5f3d680" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b66fbf0a-6084-40df-b478-4c0547748ab3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_87c2f114-ec23-405e-acf2-d8b9c5f3d680" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b66fbf0a-6084-40df-b478-4c0547748ab3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_d01cd8bf-b5f6-4122-bd75-9710db0a22a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_87c2f114-ec23-405e-acf2-d8b9c5f3d680" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_d01cd8bf-b5f6-4122-bd75-9710db0a22a8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="ardx-20220331.xsd#CONDENSEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d1051897-71ce-48d0-b8be-a2ec5ca3c41a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1f935ae7-a5cf-4ecf-9ab1-12f8d4c7873e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d1051897-71ce-48d0-b8be-a2ec5ca3c41a" xlink:to="loc_us-gaap_NetIncomeLoss_1f935ae7-a5cf-4ecf-9ab1-12f8d4c7873e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_eaa53740-0eca-426b-9826-5cab5b538b19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d1051897-71ce-48d0-b8be-a2ec5ca3c41a" xlink:to="loc_us-gaap_Depreciation_eaa53740-0eca-426b-9826-5cab5b538b19" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_6a1ae61c-e818-495d-bcf1-50ce6fe6abc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d1051897-71ce-48d0-b8be-a2ec5ca3c41a" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_6a1ae61c-e818-495d-bcf1-50ce6fe6abc2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDeferredCharges_7b72480c-1d75-49bd-ad33-d0db4c9fb7e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDeferredCharges"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d1051897-71ce-48d0-b8be-a2ec5ca3c41a" xlink:to="loc_us-gaap_AmortizationOfDeferredCharges_7b72480c-1d75-49bd-ad33-d0db4c9fb7e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_3c5a62d8-dc3a-482e-80fc-c831fdebe241" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d1051897-71ce-48d0-b8be-a2ec5ca3c41a" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_3c5a62d8-dc3a-482e-80fc-c831fdebe241" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_142780de-e91f-4396-855a-2ba8eeb35a46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d1051897-71ce-48d0-b8be-a2ec5ca3c41a" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_142780de-e91f-4396-855a-2ba8eeb35a46" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_461cb1cc-6c43-4989-b1c3-e7e98aab6e82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d1051897-71ce-48d0-b8be-a2ec5ca3c41a" xlink:to="loc_us-gaap_ShareBasedCompensation_461cb1cc-6c43-4989-b1c3-e7e98aab6e82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_91c9d59d-90b5-4035-b096-8c8c20f40e3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d1051897-71ce-48d0-b8be-a2ec5ca3c41a" xlink:to="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_91c9d59d-90b5-4035-b096-8c8c20f40e3f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnRestructuringOfDebt_283629e3-b495-49af-ba7c-496d3ae069e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnRestructuringOfDebt"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d1051897-71ce-48d0-b8be-a2ec5ca3c41a" xlink:to="loc_us-gaap_GainsLossesOnRestructuringOfDebt_283629e3-b495-49af-ba7c-496d3ae069e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets_69f0488c-1709-408f-99bb-4f976e25866d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d1051897-71ce-48d0-b8be-a2ec5ca3c41a" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets_69f0488c-1709-408f-99bb-4f976e25866d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_d37b8050-562d-49cf-b801-5ae7672d738f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d1051897-71ce-48d0-b8be-a2ec5ca3c41a" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_d37b8050-562d-49cf-b801-5ae7672d738f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_9d9a3646-6d6e-4063-8533-9315b87286e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d1051897-71ce-48d0-b8be-a2ec5ca3c41a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_9d9a3646-6d6e-4063-8533-9315b87286e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_eef8058e-f4f9-488c-8535-4cae18930576" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d1051897-71ce-48d0-b8be-a2ec5ca3c41a" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_eef8058e-f4f9-488c-8535-4cae18930576" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_eee1c50b-9b15-4258-ad19-e6892726407a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d1051897-71ce-48d0-b8be-a2ec5ca3c41a" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_eee1c50b-9b15-4258-ad19-e6892726407a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_12ead395-849c-44b7-b177-aac50384e9fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d1051897-71ce-48d0-b8be-a2ec5ca3c41a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_12ead395-849c-44b7-b177-aac50384e9fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_acbdd1f6-1e5b-462c-a32d-eeec07174abe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d1051897-71ce-48d0-b8be-a2ec5ca3c41a" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_acbdd1f6-1e5b-462c-a32d-eeec07174abe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_abe786c1-ed07-4cfb-bd8a-43d159609be3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="17" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d1051897-71ce-48d0-b8be-a2ec5ca3c41a" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_abe786c1-ed07-4cfb-bd8a-43d159609be3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_d2558dae-0a0c-4a00-a201-567090df30ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="18" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d1051897-71ce-48d0-b8be-a2ec5ca3c41a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_d2558dae-0a0c-4a00-a201-567090df30ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_34a266e3-8f1a-4aa2-8872-a4bbe7c5d698" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:calculationArc order="19" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d1051897-71ce-48d0-b8be-a2ec5ca3c41a" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_34a266e3-8f1a-4aa2-8872-a4bbe7c5d698" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_197f1271-7758-4516-a61b-c0c49ac1ae00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_88c387a6-c787-4c96-babc-648b814216d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_197f1271-7758-4516-a61b-c0c49ac1ae00" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_88c387a6-c787-4c96-babc-648b814216d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_44166854-8e88-46f4-9cc9-184f6983ef9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_197f1271-7758-4516-a61b-c0c49ac1ae00" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_44166854-8e88-46f4-9cc9-184f6983ef9f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfMachineryAndEquipment_a4836b62-66e3-458d-85df-efe4518a48d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfMachineryAndEquipment"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_197f1271-7758-4516-a61b-c0c49ac1ae00" xlink:to="loc_us-gaap_ProceedsFromSaleOfMachineryAndEquipment_a4836b62-66e3-458d-85df-efe4518a48d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6c0ec156-551e-44fc-b3f7-9ed8c3ef31ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_197f1271-7758-4516-a61b-c0c49ac1ae00" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6c0ec156-551e-44fc-b3f7-9ed8c3ef31ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_20d83572-c63e-4965-affd-b00f333b7bea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_542a69a9-42b5-41e1-8ac6-ffbde9fb0fde" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_20d83572-c63e-4965-affd-b00f333b7bea" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_542a69a9-42b5-41e1-8ac6-ffbde9fb0fde" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSecuredDebt_417468f2-9a06-467a-a4f1-d6b441308433" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfSecuredDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_20d83572-c63e-4965-affd-b00f333b7bea" xlink:to="loc_us-gaap_RepaymentsOfSecuredDebt_417468f2-9a06-467a-a4f1-d6b441308433" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_b663b7ce-5af7-493c-b044-a04e2fc79e1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_20d83572-c63e-4965-affd-b00f333b7bea" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_b663b7ce-5af7-493c-b044-a04e2fc79e1c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_c9686cef-a88f-4743-92bd-45b29302a03c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_20d83572-c63e-4965-affd-b00f333b7bea" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_c9686cef-a88f-4743-92bd-45b29302a03c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_19345bc6-eba3-4cb0-8337-dd231c89c49a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_33b80279-932f-4596-b5f6-86e3dbd68608" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_19345bc6-eba3-4cb0-8337-dd231c89c49a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_33b80279-932f-4596-b5f6-86e3dbd68608" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_cde49c87-0a2d-46b1-82d1-1e2ff7364990" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_19345bc6-eba3-4cb0-8337-dd231c89c49a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_cde49c87-0a2d-46b1-82d1-1e2ff7364990" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d77652ea-544b-4646-958e-d7a64ad436eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_19345bc6-eba3-4cb0-8337-dd231c89c49a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d77652ea-544b-4646-958e-d7a64ad436eb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails" xlink:type="simple" xlink:href="ardx-20220331.xsd#CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails"/>
  <link:calculationLink xlink:role="http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CashAndCashEquivalentsAmortizedCost_e6e68521-6c73-449a-8810-94b04e9e3937" xlink:href="ardx-20220331.xsd#ardx_CashAndCashEquivalentsAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CashAndCashEquivalentsGrossUnrealizedGains_b5fab8a0-0760-442d-b724-9c44d96fe9f4" xlink:href="ardx-20220331.xsd#ardx_CashAndCashEquivalentsGrossUnrealizedGains"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ardx_CashAndCashEquivalentsAmortizedCost_e6e68521-6c73-449a-8810-94b04e9e3937" xlink:to="loc_ardx_CashAndCashEquivalentsGrossUnrealizedGains_b5fab8a0-0760-442d-b724-9c44d96fe9f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CashAndCashEquivalentsGrossUnrealizedLosses_365f30ef-33f5-4215-9ecd-3cbcc3e77a54" xlink:href="ardx-20220331.xsd#ardx_CashAndCashEquivalentsGrossUnrealizedLosses"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ardx_CashAndCashEquivalentsAmortizedCost_e6e68521-6c73-449a-8810-94b04e9e3937" xlink:to="loc_ardx_CashAndCashEquivalentsGrossUnrealizedLosses_365f30ef-33f5-4215-9ecd-3cbcc3e77a54" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_21d486e4-e517-4fc1-a66c-31e77cad108d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ardx_CashAndCashEquivalentsAmortizedCost_e6e68521-6c73-449a-8810-94b04e9e3937" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_21d486e4-e517-4fc1-a66c-31e77cad108d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_InvestmentsAndCashAmortizedCost_18917a4e-da70-4151-a59d-9ec9a5b50652" xlink:href="ardx-20220331.xsd#ardx_InvestmentsAndCashAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedGains_e8193abe-f97c-45d5-82c6-69b113d19170" xlink:href="ardx-20220331.xsd#ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedGains"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ardx_InvestmentsAndCashAmortizedCost_18917a4e-da70-4151-a59d-9ec9a5b50652" xlink:to="loc_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedGains_e8193abe-f97c-45d5-82c6-69b113d19170" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses_32f0abe6-afa7-4d92-9e62-dcc1bb3fe5b9" xlink:href="ardx-20220331.xsd#ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ardx_InvestmentsAndCashAmortizedCost_18917a4e-da70-4151-a59d-9ec9a5b50652" xlink:to="loc_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses_32f0abe6-afa7-4d92-9e62-dcc1bb3fe5b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAndCash_c540c9d9-c6ec-4786-9f5b-5fff9693e63b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsAndCash"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ardx_InvestmentsAndCashAmortizedCost_18917a4e-da70-4151-a59d-9ec9a5b50652" xlink:to="loc_us-gaap_InvestmentsAndCash_c540c9d9-c6ec-4786-9f5b-5fff9693e63b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f967bbe6-2f1c-4144-b580-8f2041347d41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_493eac4b-0365-44a9-b038-532df35c9def" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f967bbe6-2f1c-4144-b580-8f2041347d41" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_493eac4b-0365-44a9-b038-532df35c9def" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6429cadf-56d7-4606-8cce-2b752fccf8d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f967bbe6-2f1c-4144-b580-8f2041347d41" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6429cadf-56d7-4606-8cce-2b752fccf8d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_745cac12-8d7d-435d-8499-04a8b0e4c544" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f967bbe6-2f1c-4144-b580-8f2041347d41" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_745cac12-8d7d-435d-8499-04a8b0e4c544" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/InventoryDetails" xlink:type="simple" xlink:href="ardx-20220331.xsd#InventoryDetails"/>
  <link:calculationLink xlink:role="http://www.ardelyx.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_b9c1aac4-76fd-46e4-8e61-88c4a99afa33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_1f86e7bf-7497-45f0-9969-eb92e1e39622" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_b9c1aac4-76fd-46e4-8e61-88c4a99afa33" xlink:to="loc_us-gaap_InventoryRawMaterials_1f86e7bf-7497-45f0-9969-eb92e1e39622" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_9ee06224-1458-428c-9452-624d8836ef97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_b9c1aac4-76fd-46e4-8e61-88c4a99afa33" xlink:to="loc_us-gaap_InventoryWorkInProcess_9ee06224-1458-428c-9452-624d8836ef97" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_3c17dcd2-d8f8-4111-9e14-424d126319ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_b9c1aac4-76fd-46e4-8e61-88c4a99afa33" xlink:to="loc_us-gaap_InventoryFinishedGoods_3c17dcd2-d8f8-4111-9e14-424d126319ec" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/BorrowingFuturePaymentObligationsDetails" xlink:type="simple" xlink:href="ardx-20220331.xsd#BorrowingFuturePaymentObligationsDetails"/>
  <link:calculationLink xlink:role="http://www.ardelyx.com/role/BorrowingFuturePaymentObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_563b36cc-e59a-4b9a-92d9-62a46a2f0449" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_7e51f52d-a7e2-40fc-8130-9d2d73295034" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_563b36cc-e59a-4b9a-92d9-62a46a2f0449" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_7e51f52d-a7e2-40fc-8130-9d2d73295034" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_2f16a584-e3a6-4c12-95f8-faea2b09905c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_563b36cc-e59a-4b9a-92d9-62a46a2f0449" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_2f16a584-e3a6-4c12-95f8-faea2b09905c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount_d4e9ac0f-b44b-46f5-887d-a4256b1387dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_563b36cc-e59a-4b9a-92d9-62a46a2f0449" xlink:to="loc_us-gaap_DebtInstrumentFeeAmount_d4e9ac0f-b44b-46f5-887d-a4256b1387dc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/BorrowingFuturePaymentObligationsDetails_1" xlink:type="simple" xlink:href="ardx-20220331.xsd#BorrowingFuturePaymentObligationsDetails_1"/>
  <link:calculationLink xlink:role="http://www.ardelyx.com/role/BorrowingFuturePaymentObligationsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_d60d0121-e80b-4db1-b416-e33d26380154" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_a6820c7c-0aac-4bd3-aabe-3d511c42b0e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_d60d0121-e80b-4db1-b416-e33d26380154" xlink:to="loc_us-gaap_LongTermDebtCurrent_a6820c7c-0aac-4bd3-aabe-3d511c42b0e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_d47c72db-2a4d-4b32-aecd-03fea6940535" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_d60d0121-e80b-4db1-b416-e33d26380154" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_d47c72db-2a4d-4b32-aecd-03fea6940535" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails" xlink:type="simple" xlink:href="ardx-20220331.xsd#LeasesUndiscountedCashPaymentObligationsDetails"/>
  <link:calculationLink xlink:role="http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4b51ee59-06ee-41a2-9da9-b3530b800e64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_a73738b4-3b51-4d87-bf8a-b90af6a27147" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4b51ee59-06ee-41a2-9da9-b3530b800e64" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_a73738b4-3b51-4d87-bf8a-b90af6a27147" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_d2349b5d-402b-4002-92bd-36d0737a6f23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4b51ee59-06ee-41a2-9da9-b3530b800e64" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_d2349b5d-402b-4002-92bd-36d0737a6f23" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_cc04a6bd-18ae-4037-931d-7bc0ee6cf79d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4b51ee59-06ee-41a2-9da9-b3530b800e64" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_cc04a6bd-18ae-4037-931d-7bc0ee6cf79d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_d9efe493-c3a1-46c4-a667-4577649f09ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4b51ee59-06ee-41a2-9da9-b3530b800e64" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_d9efe493-c3a1-46c4-a667-4577649f09ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_ea3b3c12-341b-4721-8eaa-01c7b7d1ada4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4b51ee59-06ee-41a2-9da9-b3530b800e64" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_ea3b3c12-341b-4721-8eaa-01c7b7d1ada4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_5f8feb7e-1255-4b2f-bb62-3cdd8c0b0768" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_52ef112b-366c-48cd-9147-a557856b4c78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_5f8feb7e-1255-4b2f-bb62-3cdd8c0b0768" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_52ef112b-366c-48cd-9147-a557856b4c78" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_14720be2-f919-4fd6-a1ce-239a190a69e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_5f8feb7e-1255-4b2f-bb62-3cdd8c0b0768" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_14720be2-f919-4fd6-a1ce-239a190a69e5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails_1" xlink:type="simple" xlink:href="ardx-20220331.xsd#LeasesUndiscountedCashPaymentObligationsDetails_1"/>
  <link:calculationLink xlink:role="http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_67fe2716-b202-4af7-9e41-9c14640b085d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_b1d2feb7-1513-453a-996b-b53ec3abeae3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_67fe2716-b202-4af7-9e41-9c14640b085d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_b1d2feb7-1513-453a-996b-b53ec3abeae3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_3546330b-e19d-4dcf-a866-bd1636901aef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_67fe2716-b202-4af7-9e41-9c14640b085d" xlink:to="loc_us-gaap_OperatingLeaseLiability_3546330b-e19d-4dcf-a866-bd1636901aef" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>ardx-20220331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:9e7cc335-f1e2-4409-ab16-898e4e60d77f,g:bd3d9229-0258-42cf-b897-58fd721121d9-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="ardx-20220331.xsd#CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended" id="if2f81fb4e60f445588339f3801fcdc49_CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_59ba96d9-0146-4c65-99cf-85322f4cf2b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_7c3db774-8921-4c4f-bc27-098ac455e20e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_59ba96d9-0146-4c65-99cf-85322f4cf2b3" xlink:to="loc_us-gaap_RevenuesAbstract_7c3db774-8921-4c4f-bc27-098ac455e20e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2fa53fcf-949b-4783-8b67-2e2c56aa0fa5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_7c3db774-8921-4c4f-bc27-098ac455e20e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2fa53fcf-949b-4783-8b67-2e2c56aa0fa5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_8304e41a-cfff-42c6-a049-e3ce884dac8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_59ba96d9-0146-4c65-99cf-85322f4cf2b3" xlink:to="loc_us-gaap_OperatingExpensesAbstract_8304e41a-cfff-42c6-a049-e3ce884dac8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_de7a696e-9112-452a-bb8b-d9229c2e8ecd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_8304e41a-cfff-42c6-a049-e3ce884dac8a" xlink:to="loc_us-gaap_CostOfRevenue_de7a696e-9112-452a-bb8b-d9229c2e8ecd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_71c035a6-ddc5-4955-a5e0-5af438925e7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_8304e41a-cfff-42c6-a049-e3ce884dac8a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_71c035a6-ddc5-4955-a5e0-5af438925e7a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_29469682-111d-480c-963b-9c11831b3417" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_8304e41a-cfff-42c6-a049-e3ce884dac8a" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_29469682-111d-480c-963b-9c11831b3417" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_f82b35e6-4df8-415d-91da-daf6d108022a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_8304e41a-cfff-42c6-a049-e3ce884dac8a" xlink:to="loc_us-gaap_CostsAndExpenses_f82b35e6-4df8-415d-91da-daf6d108022a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_03a267b9-966f-462c-ad05-a0df321a199e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_59ba96d9-0146-4c65-99cf-85322f4cf2b3" xlink:to="loc_us-gaap_OperatingIncomeLoss_03a267b9-966f-462c-ad05-a0df321a199e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_2f3e4861-779e-4552-a396-9d8bfcbec8ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_59ba96d9-0146-4c65-99cf-85322f4cf2b3" xlink:to="loc_us-gaap_InterestExpense_2f3e4861-779e-4552-a396-9d8bfcbec8ba" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_7c20e04f-748e-44ca-b27f-c1356bf0294c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_59ba96d9-0146-4c65-99cf-85322f4cf2b3" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_7c20e04f-748e-44ca-b27f-c1356bf0294c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ace1a649-b079-4cd2-9724-ae479f05a1b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_59ba96d9-0146-4c65-99cf-85322f4cf2b3" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ace1a649-b079-4cd2-9724-ae479f05a1b0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_bf3ec65c-2faa-4a98-9649-3f7078ce85c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_59ba96d9-0146-4c65-99cf-85322f4cf2b3" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_bf3ec65c-2faa-4a98-9649-3f7078ce85c2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2d0db75e-103e-4bd7-8ca5-3bc62405494a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_59ba96d9-0146-4c65-99cf-85322f4cf2b3" xlink:to="loc_us-gaap_NetIncomeLoss_2d0db75e-103e-4bd7-8ca5-3bc62405494a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_d00b51f1-f426-47f3-a9bf-78dc6b703f1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_59ba96d9-0146-4c65-99cf-85322f4cf2b3" xlink:to="loc_us-gaap_EarningsPerShareBasic_d00b51f1-f426-47f3-a9bf-78dc6b703f1e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_53d6144e-4862-474c-8824-e611897059d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_59ba96d9-0146-4c65-99cf-85322f4cf2b3" xlink:to="loc_us-gaap_EarningsPerShareDiluted_53d6144e-4862-474c-8824-e611897059d0" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5c9829db-b322-49fa-af17-a00ec0d58248" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_59ba96d9-0146-4c65-99cf-85322f4cf2b3" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5c9829db-b322-49fa-af17-a00ec0d58248" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_46beb371-0653-4e04-ac2b-1efef6847959" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_59ba96d9-0146-4c65-99cf-85322f4cf2b3" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_46beb371-0653-4e04-ac2b-1efef6847959" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_f78216bd-7510-4e27-aad2-068f993294af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_59ba96d9-0146-4c65-99cf-85322f4cf2b3" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_f78216bd-7510-4e27-aad2-068f993294af" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8a14e578-5287-46db-b682-bdd4058db5c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_cb172748-2c8c-4f8b-9d63-822479eaa97d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_f78216bd-7510-4e27-aad2-068f993294af" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_cb172748-2c8c-4f8b-9d63-822479eaa97d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_59c88361-209c-41a8-8c5c-60c166ba71d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_f78216bd-7510-4e27-aad2-068f993294af" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_59c88361-209c-41a8-8c5c-60c166ba71d4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_48379915-1c00-434c-8eaf-ecbdd5036f25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_59ba96d9-0146-4c65-99cf-85322f4cf2b3" xlink:to="loc_us-gaap_StatementTable_48379915-1c00-434c-8eaf-ecbdd5036f25" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_608ae60b-db75-4b31-bf6d-97f4f62efb13" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_48379915-1c00-434c-8eaf-ecbdd5036f25" xlink:to="loc_srt_ProductOrServiceAxis_608ae60b-db75-4b31-bf6d-97f4f62efb13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_608ae60b-db75-4b31-bf6d-97f4f62efb13_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_608ae60b-db75-4b31-bf6d-97f4f62efb13" xlink:to="loc_srt_ProductsAndServicesDomain_608ae60b-db75-4b31-bf6d-97f4f62efb13_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0cc18914-1ecc-488a-8424-009fc9875feb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_608ae60b-db75-4b31-bf6d-97f4f62efb13" xlink:to="loc_srt_ProductsAndServicesDomain_0cc18914-1ecc-488a-8424-009fc9875feb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_27667d80-92b3-42e1-bc65-344393d8a16f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0cc18914-1ecc-488a-8424-009fc9875feb" xlink:to="loc_us-gaap_ProductMember_27667d80-92b3-42e1-bc65-344393d8a16f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ProductSupplyRevenueMember_6b3a14d0-42d7-4367-96d2-85f9f137358d" xlink:href="ardx-20220331.xsd#ardx_ProductSupplyRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0cc18914-1ecc-488a-8424-009fc9875feb" xlink:to="loc_ardx_ProductSupplyRevenueMember_6b3a14d0-42d7-4367-96d2-85f9f137358d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_39d73a42-55e5-4105-b39a-4f85a37a9386" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0cc18914-1ecc-488a-8424-009fc9875feb" xlink:to="loc_us-gaap_LicenseMember_39d73a42-55e5-4105-b39a-4f85a37a9386" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeDevelopmentMember_be93ba8a-d396-44fe-a6fb-91a4184cbcbf" xlink:href="ardx-20220331.xsd#ardx_CollaborativeDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0cc18914-1ecc-488a-8424-009fc9875feb" xlink:to="loc_ardx_CollaborativeDevelopmentMember_be93ba8a-d396-44fe-a6fb-91a4184cbcbf" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="ardx-20220331.xsd#CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="extended" id="i517075165c8f4b4fb120a4921192e1be_CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_11f1a90e-58a5-4590-bf7a-d4e5d074aba7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_46bd15dd-fd0d-4521-af62-1e3d66c0ebed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_11f1a90e-58a5-4590-bf7a-d4e5d074aba7" xlink:to="loc_us-gaap_StockholdersEquity_46bd15dd-fd0d-4521-af62-1e3d66c0ebed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_622be1b2-bff5-46a8-9d49-91d70e33298c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_11f1a90e-58a5-4590-bf7a-d4e5d074aba7" xlink:to="loc_us-gaap_SharesOutstanding_622be1b2-bff5-46a8-9d49-91d70e33298c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_70b002f1-77e0-4875-9c57-063f9d8ef8ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_11f1a90e-58a5-4590-bf7a-d4e5d074aba7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_70b002f1-77e0-4875-9c57-063f9d8ef8ca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_dc991ade-655c-48e4-9aa8-c15f59dea4eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_11f1a90e-58a5-4590-bf7a-d4e5d074aba7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_dc991ade-655c-48e4-9aa8-c15f59dea4eb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_6d00d96d-a8d3-46c6-bd9a-b565ab98bef0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_11f1a90e-58a5-4590-bf7a-d4e5d074aba7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_6d00d96d-a8d3-46c6-bd9a-b565ab98bef0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_61216108-dbec-4262-8544-17ffa82331e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_11f1a90e-58a5-4590-bf7a-d4e5d074aba7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_61216108-dbec-4262-8544-17ffa82331e1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_8efcaa53-a385-4f23-8976-6b3a69a97714" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_11f1a90e-58a5-4590-bf7a-d4e5d074aba7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_8efcaa53-a385-4f23-8976-6b3a69a97714" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_9bc5fe8f-8bd8-4ab0-a420-b029ba7acc6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_11f1a90e-58a5-4590-bf7a-d4e5d074aba7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_9bc5fe8f-8bd8-4ab0-a420-b029ba7acc6f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_4590298e-a2fd-452d-b7af-50791046ca31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_11f1a90e-58a5-4590-bf7a-d4e5d074aba7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_4590298e-a2fd-452d-b7af-50791046ca31" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_20358046-2dcc-4955-a5a6-1f989d72e361" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_11f1a90e-58a5-4590-bf7a-d4e5d074aba7" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_20358046-2dcc-4955-a5a6-1f989d72e361" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_ed9a0868-a90d-47e0-bb80-9a65d5e18930" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_11f1a90e-58a5-4590-bf7a-d4e5d074aba7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_ed9a0868-a90d-47e0-bb80-9a65d5e18930" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8844952b-50f3-4aba-a3ee-10b20a197000" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_11f1a90e-58a5-4590-bf7a-d4e5d074aba7" xlink:to="loc_us-gaap_NetIncomeLoss_8844952b-50f3-4aba-a3ee-10b20a197000" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d476292c-e762-4841-a8a8-cb6051d32213" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_3010a403-f909-4d3d-8895-9c27a23e7c14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_836b6421-50d8-4cf8-8dc1-8b45229aca7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_11f1a90e-58a5-4590-bf7a-d4e5d074aba7" xlink:to="loc_us-gaap_StatementTable_836b6421-50d8-4cf8-8dc1-8b45229aca7c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_73c98234-8ad8-4dc9-ab53-5c242aef3940" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_836b6421-50d8-4cf8-8dc1-8b45229aca7c" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_73c98234-8ad8-4dc9-ab53-5c242aef3940" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_73c98234-8ad8-4dc9-ab53-5c242aef3940_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_73c98234-8ad8-4dc9-ab53-5c242aef3940" xlink:to="loc_us-gaap_EquityComponentDomain_73c98234-8ad8-4dc9-ab53-5c242aef3940_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a19f4c78-bdb1-4128-94d6-afada28fe9b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_73c98234-8ad8-4dc9-ab53-5c242aef3940" xlink:to="loc_us-gaap_EquityComponentDomain_a19f4c78-bdb1-4128-94d6-afada28fe9b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f771b5b0-0497-45af-ba2e-0764d85842c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a19f4c78-bdb1-4128-94d6-afada28fe9b7" xlink:to="loc_us-gaap_CommonStockMember_f771b5b0-0497-45af-ba2e-0764d85842c5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_7655ff1a-bae3-47ec-8e52-e5be2a613dd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a19f4c78-bdb1-4128-94d6-afada28fe9b7" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_7655ff1a-bae3-47ec-8e52-e5be2a613dd9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_bf2d54e7-d3bf-40bc-b0b0-aa304202e2ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a19f4c78-bdb1-4128-94d6-afada28fe9b7" xlink:to="loc_us-gaap_RetainedEarningsMember_bf2d54e7-d3bf-40bc-b0b0-aa304202e2ba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c73f87b9-afea-4bbe-9edd-78214ec8d00e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a19f4c78-bdb1-4128-94d6-afada28fe9b7" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c73f87b9-afea-4bbe-9edd-78214ec8d00e" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/OrganizationandBasisofPresentationDetails" xlink:type="simple" xlink:href="ardx-20220331.xsd#OrganizationandBasisofPresentationDetails"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/OrganizationandBasisofPresentationDetails" xlink:type="extended" id="ib0331437ac634bd08bec8ca165414bf8_OrganizationandBasisofPresentationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dea229a7-2103-45ff-8d8e-4fdaa9a0c743" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_a9de1e4c-73bf-4d85-89a5-3c227b424a35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dea229a7-2103-45ff-8d8e-4fdaa9a0c743" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_a9de1e4c-73bf-4d85-89a5-3c227b424a35" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_RevenueGeneralPaymentTerms_c5f108e7-4c45-4b5a-ab8c-00219abd0d5a" xlink:href="ardx-20220331.xsd#ardx_RevenueGeneralPaymentTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dea229a7-2103-45ff-8d8e-4fdaa9a0c743" xlink:to="loc_ardx_RevenueGeneralPaymentTerms_c5f108e7-4c45-4b5a-ab8c-00219abd0d5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_PercentageOfRoyaltyRevenue_967a1810-df6e-4b14-9de0-37475603fd99" xlink:href="ardx-20220331.xsd#ardx_PercentageOfRoyaltyRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dea229a7-2103-45ff-8d8e-4fdaa9a0c743" xlink:to="loc_ardx_PercentageOfRoyaltyRevenue_967a1810-df6e-4b14-9de0-37475603fd99" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_PercentageOfNonRoyaltyRevenue_0fb77c61-aadf-4f8d-af33-25454c64238c" xlink:href="ardx-20220331.xsd#ardx_PercentageOfNonRoyaltyRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dea229a7-2103-45ff-8d8e-4fdaa9a0c743" xlink:to="loc_ardx_PercentageOfNonRoyaltyRevenue_0fb77c61-aadf-4f8d-af33-25454c64238c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum_8d7e9369-0f03-4d31-be98-8bc999f132c8" xlink:href="ardx-20220331.xsd#ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dea229a7-2103-45ff-8d8e-4fdaa9a0c743" xlink:to="loc_ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum_8d7e9369-0f03-4d31-be98-8bc999f132c8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CostOfRevenueAggregateAmountRecognized_7d5733f8-bc01-4022-bc74-b8d2f7c88e40" xlink:href="ardx-20220331.xsd#ardx_CostOfRevenueAggregateAmountRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dea229a7-2103-45ff-8d8e-4fdaa9a0c743" xlink:to="loc_ardx_CostOfRevenueAggregateAmountRecognized_7d5733f8-bc01-4022-bc74-b8d2f7c88e40" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9b1476bb-4e51-4f18-9e73-d95a780f9b59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dea229a7-2103-45ff-8d8e-4fdaa9a0c743" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9b1476bb-4e51-4f18-9e73-d95a780f9b59" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_bf020a59-15df-4736-893d-0ed8201cf0c6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9b1476bb-4e51-4f18-9e73-d95a780f9b59" xlink:to="loc_srt_CounterpartyNameAxis_bf020a59-15df-4736-893d-0ed8201cf0c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bf020a59-15df-4736-893d-0ed8201cf0c6_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_bf020a59-15df-4736-893d-0ed8201cf0c6" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bf020a59-15df-4736-893d-0ed8201cf0c6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_02ac0772-baaf-4ebc-8d4f-231d05421e98" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_bf020a59-15df-4736-893d-0ed8201cf0c6" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_02ac0772-baaf-4ebc-8d4f-231d05421e98" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AstrazenecaMember_1270624a-412d-4e38-9c4a-f9df153030bf" xlink:href="ardx-20220331.xsd#ardx_AstrazenecaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_02ac0772-baaf-4ebc-8d4f-231d05421e98" xlink:to="loc_ardx_AstrazenecaMember_1270624a-412d-4e38-9c4a-f9df153030bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_e446eb49-9f04-4f76-8df3-fa72beef812a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9b1476bb-4e51-4f18-9e73-d95a780f9b59" xlink:to="loc_us-gaap_TypeOfArrangementAxis_e446eb49-9f04-4f76-8df3-fa72beef812a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e446eb49-9f04-4f76-8df3-fa72beef812a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_e446eb49-9f04-4f76-8df3-fa72beef812a" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e446eb49-9f04-4f76-8df3-fa72beef812a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d762b465-d7c4-4c7b-b694-ee38ef91ffb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_e446eb49-9f04-4f76-8df3-fa72beef812a" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d762b465-d7c4-4c7b-b694-ee38ef91ffb2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AstraZenecaTerminationAgreementMember_6e2aea10-acda-4dfe-bf3d-36eb15d87928" xlink:href="ardx-20220331.xsd#ardx_AstraZenecaTerminationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d762b465-d7c4-4c7b-b694-ee38ef91ffb2" xlink:to="loc_ardx_AstraZenecaTerminationAgreementMember_6e2aea10-acda-4dfe-bf3d-36eb15d87928" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_591a0042-cd98-47b1-be60-2fdbd4440fb2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9b1476bb-4e51-4f18-9e73-d95a780f9b59" xlink:to="loc_srt_RangeAxis_591a0042-cd98-47b1-be60-2fdbd4440fb2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_591a0042-cd98-47b1-be60-2fdbd4440fb2_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_591a0042-cd98-47b1-be60-2fdbd4440fb2" xlink:to="loc_srt_RangeMember_591a0042-cd98-47b1-be60-2fdbd4440fb2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_56515d0d-acd2-4cab-abbf-3d3f7a2f7e4e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_591a0042-cd98-47b1-be60-2fdbd4440fb2" xlink:to="loc_srt_RangeMember_56515d0d-acd2-4cab-abbf-3d3f7a2f7e4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_848ec922-68e5-4e10-980e-e5d3a5a121ea" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_56515d0d-acd2-4cab-abbf-3d3f7a2f7e4e" xlink:to="loc_srt_MinimumMember_848ec922-68e5-4e10-980e-e5d3a5a121ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2a76257b-3104-4e4b-898c-6c070d20599b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_56515d0d-acd2-4cab-abbf-3d3f7a2f7e4e" xlink:to="loc_srt_MaximumMember_2a76257b-3104-4e4b-898c-6c070d20599b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_82ff2def-6d5c-4425-b4a8-dd4070d6314a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9b1476bb-4e51-4f18-9e73-d95a780f9b59" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_82ff2def-6d5c-4425-b4a8-dd4070d6314a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_82ff2def-6d5c-4425-b4a8-dd4070d6314a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_82ff2def-6d5c-4425-b4a8-dd4070d6314a" xlink:to="loc_us-gaap_ReceivableTypeDomain_82ff2def-6d5c-4425-b4a8-dd4070d6314a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_9d926af1-3f7c-4762-9cfd-593d26cdf331" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_82ff2def-6d5c-4425-b4a8-dd4070d6314a" xlink:to="loc_us-gaap_ReceivableTypeDomain_9d926af1-3f7c-4762-9cfd-593d26cdf331" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AccountsReceivableCollaboratorMember_54dae6cd-600f-42ef-94e2-2248a5f7c561" xlink:href="ardx-20220331.xsd#ardx_AccountsReceivableCollaboratorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReceivableTypeDomain_9d926af1-3f7c-4762-9cfd-593d26cdf331" xlink:to="loc_ardx_AccountsReceivableCollaboratorMember_54dae6cd-600f-42ef-94e2-2248a5f7c561" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AccountsReceivableCommercialCustomerMember_fd8eb6fe-6f0e-481e-8b89-f926ffd12dc2" xlink:href="ardx-20220331.xsd#ardx_AccountsReceivableCommercialCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReceivableTypeDomain_9d926af1-3f7c-4762-9cfd-593d26cdf331" xlink:to="loc_ardx_AccountsReceivableCommercialCustomerMember_fd8eb6fe-6f0e-481e-8b89-f926ffd12dc2" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails" xlink:type="simple" xlink:href="ardx-20220331.xsd#CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails" xlink:type="extended" id="i8aee7a897223475abbc374d7533305d0_CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5416c14c-0353-45a1-960f-5f71411db2fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_511fa983-6d0e-4d7f-b3c0-e74cd07ba670" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5416c14c-0353-45a1-960f-5f71411db2fb" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_511fa983-6d0e-4d7f-b3c0-e74cd07ba670" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CashAndCashEquivalentsAmortizedCost_b74c8bc7-4057-499f-a0a8-fa3f748e3d27" xlink:href="ardx-20220331.xsd#ardx_CashAndCashEquivalentsAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_511fa983-6d0e-4d7f-b3c0-e74cd07ba670" xlink:to="loc_ardx_CashAndCashEquivalentsAmortizedCost_b74c8bc7-4057-499f-a0a8-fa3f748e3d27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CashAndCashEquivalentsGrossUnrealizedGains_2f96fc15-7bb9-42c0-ae2b-16d192e94c3a" xlink:href="ardx-20220331.xsd#ardx_CashAndCashEquivalentsGrossUnrealizedGains"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_511fa983-6d0e-4d7f-b3c0-e74cd07ba670" xlink:to="loc_ardx_CashAndCashEquivalentsGrossUnrealizedGains_2f96fc15-7bb9-42c0-ae2b-16d192e94c3a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CashAndCashEquivalentsGrossUnrealizedLosses_290ac519-f2d9-4305-a22c-b39837e85bfe" xlink:href="ardx-20220331.xsd#ardx_CashAndCashEquivalentsGrossUnrealizedLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_511fa983-6d0e-4d7f-b3c0-e74cd07ba670" xlink:to="loc_ardx_CashAndCashEquivalentsGrossUnrealizedLosses_290ac519-f2d9-4305-a22c-b39837e85bfe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c9d446b7-1b51-4793-aeeb-397b369d17d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_511fa983-6d0e-4d7f-b3c0-e74cd07ba670" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c9d446b7-1b51-4793-aeeb-397b369d17d0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_d1c69962-6022-44b7-b4ef-2cf88f1dcd0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5416c14c-0353-45a1-960f-5f71411db2fb" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_d1c69962-6022-44b7-b4ef-2cf88f1dcd0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ad987ac2-f7ba-42e0-8451-f86cb53cd5e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_d1c69962-6022-44b7-b4ef-2cf88f1dcd0d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ad987ac2-f7ba-42e0-8451-f86cb53cd5e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_987c7493-085e-4b1d-b753-8d4f9d42d9d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_d1c69962-6022-44b7-b4ef-2cf88f1dcd0d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_987c7493-085e-4b1d-b753-8d4f9d42d9d8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_5fb37ac4-dc87-4143-acb3-453fc7d1e47b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_d1c69962-6022-44b7-b4ef-2cf88f1dcd0d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_5fb37ac4-dc87-4143-acb3-453fc7d1e47b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_79ba6c14-9c33-49c7-9d99-2d3cb6ee23e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_d1c69962-6022-44b7-b4ef-2cf88f1dcd0d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_79ba6c14-9c33-49c7-9d99-2d3cb6ee23e7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_InvestmentsAndCashAmortizedCost_fd5cc4a2-563f-46f4-a520-668d8fa405c1" xlink:href="ardx-20220331.xsd#ardx_InvestmentsAndCashAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5416c14c-0353-45a1-960f-5f71411db2fb" xlink:to="loc_ardx_InvestmentsAndCashAmortizedCost_fd5cc4a2-563f-46f4-a520-668d8fa405c1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedGains_f180d09d-32c0-44f3-bb9f-76e25127698e" xlink:href="ardx-20220331.xsd#ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedGains"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5416c14c-0353-45a1-960f-5f71411db2fb" xlink:to="loc_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedGains_f180d09d-32c0-44f3-bb9f-76e25127698e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses_9b6edc65-b5f9-4852-b892-cba82d67eabc" xlink:href="ardx-20220331.xsd#ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5416c14c-0353-45a1-960f-5f71411db2fb" xlink:to="loc_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses_9b6edc65-b5f9-4852-b892-cba82d67eabc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAndCash_d4054c0a-46b8-480e-adc9-e8a5c6219b4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsAndCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5416c14c-0353-45a1-960f-5f71411db2fb" xlink:to="loc_us-gaap_InvestmentsAndCash_d4054c0a-46b8-480e-adc9-e8a5c6219b4a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_9316499e-c14e-444d-914c-5295c2f23c55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5416c14c-0353-45a1-960f-5f71411db2fb" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_9316499e-c14e-444d-914c-5295c2f23c55" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_32eeda5d-7b55-4641-b2d7-a5d5f4886322" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_9316499e-c14e-444d-914c-5295c2f23c55" xlink:to="loc_us-gaap_FinancialInstrumentAxis_32eeda5d-7b55-4641-b2d7-a5d5f4886322" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_32eeda5d-7b55-4641-b2d7-a5d5f4886322_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_32eeda5d-7b55-4641-b2d7-a5d5f4886322" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_32eeda5d-7b55-4641-b2d7-a5d5f4886322_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d75d3ec5-5f8d-41b3-8908-9b95f69d4e21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_32eeda5d-7b55-4641-b2d7-a5d5f4886322" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d75d3ec5-5f8d-41b3-8908-9b95f69d4e21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_5f18f66f-1ba3-4530-9bc8-581d46de21e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d75d3ec5-5f8d-41b3-8908-9b95f69d4e21" xlink:to="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_5f18f66f-1ba3-4530-9bc8-581d46de21e6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_a4abd70f-8714-4424-94eb-bb0dfd91fced" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d75d3ec5-5f8d-41b3-8908-9b95f69d4e21" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_a4abd70f-8714-4424-94eb-bb0dfd91fced" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_6e5c263f-3712-42a4-8684-e88cef1342e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d75d3ec5-5f8d-41b3-8908-9b95f69d4e21" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_6e5c263f-3712-42a4-8684-e88cef1342e0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_6b0a1375-9cda-4768-ab04-402177597e24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d75d3ec5-5f8d-41b3-8908-9b95f69d4e21" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_6b0a1375-9cda-4768-ab04-402177597e24" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_24c6d1d3-406c-41cd-878c-3d3acd8de2ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_9316499e-c14e-444d-914c-5295c2f23c55" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_24c6d1d3-406c-41cd-878c-3d3acd8de2ca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_24c6d1d3-406c-41cd-878c-3d3acd8de2ca_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_24c6d1d3-406c-41cd-878c-3d3acd8de2ca" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_24c6d1d3-406c-41cd-878c-3d3acd8de2ca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_6755f85e-bf6e-4d22-bca1-ef0f00e89f63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_24c6d1d3-406c-41cd-878c-3d3acd8de2ca" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_6755f85e-bf6e-4d22-bca1-ef0f00e89f63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_59602c2d-8e0c-4914-8ab0-a8c7ff1b4057" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_6755f85e-bf6e-4d22-bca1-ef0f00e89f63" xlink:to="loc_us-gaap_CashMember_59602c2d-8e0c-4914-8ab0-a8c7ff1b4057" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_d00fd1a2-8298-4180-9b50-0991e6ea35b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_6755f85e-bf6e-4d22-bca1-ef0f00e89f63" xlink:to="loc_us-gaap_MoneyMarketFundsMember_d00fd1a2-8298-4180-9b50-0991e6ea35b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_6304d02c-b6c3-4388-b965-cae8163de089" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_6755f85e-bf6e-4d22-bca1-ef0f00e89f63" xlink:to="loc_us-gaap_CommercialPaperMember_6304d02c-b6c3-4388-b965-cae8163de089" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="ardx-20220331.xsd#FairValueMeasurementsDetails"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/FairValueMeasurementsDetails" xlink:type="extended" id="iccad8b653dfd4e2788b7045a4a62fea1_FairValueMeasurementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_974878df-94bb-4086-835e-34eb46564047" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_04ccce4f-7638-4362-ad46-94dc16e007ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_974878df-94bb-4086-835e-34eb46564047" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_04ccce4f-7638-4362-ad46-94dc16e007ce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_71920037-e27f-42ae-a71b-bf85c3405758" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_04ccce4f-7638-4362-ad46-94dc16e007ce" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_71920037-e27f-42ae-a71b-bf85c3405758" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_4f768c07-b2ba-43e3-b2df-149f00f59db4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_974878df-94bb-4086-835e-34eb46564047" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_4f768c07-b2ba-43e3-b2df-149f00f59db4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_36b068ee-3241-4487-9877-4a557136ded9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_4f768c07-b2ba-43e3-b2df-149f00f59db4" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_36b068ee-3241-4487-9877-4a557136ded9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e2c38591-cbdc-4fd3-8005-07f0bb2c2819" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_974878df-94bb-4086-835e-34eb46564047" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e2c38591-cbdc-4fd3-8005-07f0bb2c2819" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_54a06e11-895d-435d-aea4-82019963d555" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e2c38591-cbdc-4fd3-8005-07f0bb2c2819" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_54a06e11-895d-435d-aea4-82019963d555" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_54a06e11-895d-435d-aea4-82019963d555_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_54a06e11-895d-435d-aea4-82019963d555" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_54a06e11-895d-435d-aea4-82019963d555_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_20da19d9-d721-4b31-b58f-c0d569f116db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_54a06e11-895d-435d-aea4-82019963d555" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_20da19d9-d721-4b31-b58f-c0d569f116db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_1e63398a-71f7-4a24-9ada-f21e30d70a95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_20da19d9-d721-4b31-b58f-c0d569f116db" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_1e63398a-71f7-4a24-9ada-f21e30d70a95" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_db6fe73a-0ee9-49fa-80c8-5566687d95cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e2c38591-cbdc-4fd3-8005-07f0bb2c2819" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_db6fe73a-0ee9-49fa-80c8-5566687d95cf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_db6fe73a-0ee9-49fa-80c8-5566687d95cf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_db6fe73a-0ee9-49fa-80c8-5566687d95cf" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_db6fe73a-0ee9-49fa-80c8-5566687d95cf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ac84fc8b-5f3a-43ea-b1fa-fb18f58975bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_db6fe73a-0ee9-49fa-80c8-5566687d95cf" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ac84fc8b-5f3a-43ea-b1fa-fb18f58975bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_f7b9a320-c086-4d75-b00e-0a53c7b215a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ac84fc8b-5f3a-43ea-b1fa-fb18f58975bd" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_f7b9a320-c086-4d75-b00e-0a53c7b215a7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_f86d5798-4100-40e3-aace-7877a2a00c74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ac84fc8b-5f3a-43ea-b1fa-fb18f58975bd" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_f86d5798-4100-40e3-aace-7877a2a00c74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_c6a7b6a4-0b19-4628-bb37-0dd7b5b5dfa3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ac84fc8b-5f3a-43ea-b1fa-fb18f58975bd" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_c6a7b6a4-0b19-4628-bb37-0dd7b5b5dfa3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_2df7c15f-e711-4082-9226-82bd3f2cab9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e2c38591-cbdc-4fd3-8005-07f0bb2c2819" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_2df7c15f-e711-4082-9226-82bd3f2cab9c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_2df7c15f-e711-4082-9226-82bd3f2cab9c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_2df7c15f-e711-4082-9226-82bd3f2cab9c" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_2df7c15f-e711-4082-9226-82bd3f2cab9c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_cb668fd3-64ee-4704-8630-9f58fc11b92c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_2df7c15f-e711-4082-9226-82bd3f2cab9c" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_cb668fd3-64ee-4704-8630-9f58fc11b92c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_c08a558d-5fbe-4f75-98ea-c68ee473c0d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_cb668fd3-64ee-4704-8630-9f58fc11b92c" xlink:to="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_c08a558d-5fbe-4f75-98ea-c68ee473c0d3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_a2fea438-fd4d-4f15-b054-a52fec4006ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e2c38591-cbdc-4fd3-8005-07f0bb2c2819" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_a2fea438-fd4d-4f15-b054-a52fec4006ba" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a2fea438-fd4d-4f15-b054-a52fec4006ba_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_a2fea438-fd4d-4f15-b054-a52fec4006ba" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a2fea438-fd4d-4f15-b054-a52fec4006ba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_91a1fac4-664c-433c-940f-8e76e835c730" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_a2fea438-fd4d-4f15-b054-a52fec4006ba" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_91a1fac4-664c-433c-940f-8e76e835c730" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_86f95adb-149d-467d-b481-d2cdb5f24c07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_91a1fac4-664c-433c-940f-8e76e835c730" xlink:to="loc_us-gaap_MoneyMarketFundsMember_86f95adb-149d-467d-b481-d2cdb5f24c07" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_c7d7c41a-c224-4423-99c2-ffc21c4112af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_91a1fac4-664c-433c-940f-8e76e835c730" xlink:to="loc_us-gaap_CommercialPaperMember_c7d7c41a-c224-4423-99c2-ffc21c4112af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_a84370bf-24ed-4210-801e-7cf11f16fdf4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_91a1fac4-664c-433c-940f-8e76e835c730" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_a84370bf-24ed-4210-801e-7cf11f16fdf4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_0ce9a09b-d701-4a24-acb6-af4835ffaaf5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_91a1fac4-664c-433c-940f-8e76e835c730" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_0ce9a09b-d701-4a24-acb6-af4835ffaaf5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_de5725e4-166a-4764-bad6-ddc23e6795cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_91a1fac4-664c-433c-940f-8e76e835c730" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_de5725e4-166a-4764-bad6-ddc23e6795cc" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails" xlink:type="simple" xlink:href="ardx-20220331.xsd#ProductRevenueNetNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails" xlink:type="extended" id="ifd5b1666169d4e01ab7b666c71cb44ed_ProductRevenueNetNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_fdbd0ea2-fc7b-4ebd-b8b5-24aad83070ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2735b908-db36-4144-8bdf-ff7aeb78e8b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_fdbd0ea2-fc7b-4ebd-b8b5-24aad83070ba" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2735b908-db36-4144-8bdf-ff7aeb78e8b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_fd4f531c-a4e3-48bd-9a1a-1dee100f5aa5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_fdbd0ea2-fc7b-4ebd-b8b5-24aad83070ba" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_fd4f531c-a4e3-48bd-9a1a-1dee100f5aa5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerGrossToNetSalesAccruals_3ae8b6be-8171-4fb2-85ec-d485fdef3b59" xlink:href="ardx-20220331.xsd#ardx_ContractWithCustomerGrossToNetSalesAccruals"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_fdbd0ea2-fc7b-4ebd-b8b5-24aad83070ba" xlink:to="loc_ardx_ContractWithCustomerGrossToNetSalesAccruals_3ae8b6be-8171-4fb2-85ec-d485fdef3b59" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_a9327ce1-5677-493d-b262-8b12a79a5a28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_fdbd0ea2-fc7b-4ebd-b8b5-24aad83070ba" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_a9327ce1-5677-493d-b262-8b12a79a5a28" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_890df545-0390-45f3-8028-b3c134178e6e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a9327ce1-5677-493d-b262-8b12a79a5a28" xlink:to="loc_srt_ProductOrServiceAxis_890df545-0390-45f3-8028-b3c134178e6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_890df545-0390-45f3-8028-b3c134178e6e_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_890df545-0390-45f3-8028-b3c134178e6e" xlink:to="loc_srt_ProductsAndServicesDomain_890df545-0390-45f3-8028-b3c134178e6e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_07046f99-4afb-4d02-840b-df699382874a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_890df545-0390-45f3-8028-b3c134178e6e" xlink:to="loc_srt_ProductsAndServicesDomain_07046f99-4afb-4d02-840b-df699382874a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ProductIBSRELAMember_61fb82e9-b716-4ee7-9fdd-a37f795d1ab1" xlink:href="ardx-20220331.xsd#ardx_ProductIBSRELAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_07046f99-4afb-4d02-840b-df699382874a" xlink:to="loc_ardx_ProductIBSRELAMember_61fb82e9-b716-4ee7-9fdd-a37f795d1ab1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_713e801e-ab32-493b-aa13-59c368a5962f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_07046f99-4afb-4d02-840b-df699382874a" xlink:to="loc_us-gaap_ProductMember_713e801e-ab32-493b-aa13-59c368a5962f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a54bff5f-97c6-4c9f-8534-e26507606121" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a9327ce1-5677-493d-b262-8b12a79a5a28" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a54bff5f-97c6-4c9f-8534-e26507606121" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a54bff5f-97c6-4c9f-8534-e26507606121_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a54bff5f-97c6-4c9f-8534-e26507606121" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a54bff5f-97c6-4c9f-8534-e26507606121_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_b32e6f65-96f5-436b-85b3-384815d000e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a54bff5f-97c6-4c9f-8534-e26507606121" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_b32e6f65-96f5-436b-85b3-384815d000e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueProductLineMember_8ef6d3ce-909d-486e-87df-57b4d448f6f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueProductLineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_b32e6f65-96f5-436b-85b3-384815d000e4" xlink:to="loc_us-gaap_SalesRevenueProductLineMember_8ef6d3ce-909d-486e-87df-57b4d448f6f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_8185eedb-acff-4eaf-b03c-3cecf2e20391" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a9327ce1-5677-493d-b262-8b12a79a5a28" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_8185eedb-acff-4eaf-b03c-3cecf2e20391" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_8185eedb-acff-4eaf-b03c-3cecf2e20391_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_8185eedb-acff-4eaf-b03c-3cecf2e20391" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_8185eedb-acff-4eaf-b03c-3cecf2e20391_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_37b673bb-eb4b-41fb-9254-a9aa02fc1f12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_8185eedb-acff-4eaf-b03c-3cecf2e20391" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_37b673bb-eb4b-41fb-9254-a9aa02fc1f12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_5f6ebff2-bb7a-401b-8b60-d57d7550f314" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_37b673bb-eb4b-41fb-9254-a9aa02fc1f12" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_5f6ebff2-bb7a-401b-8b60-d57d7550f314" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_f64c12fa-b2b0-4882-9cdf-03f6410665bf" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a9327ce1-5677-493d-b262-8b12a79a5a28" xlink:to="loc_srt_MajorCustomersAxis_f64c12fa-b2b0-4882-9cdf-03f6410665bf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_f64c12fa-b2b0-4882-9cdf-03f6410665bf_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_f64c12fa-b2b0-4882-9cdf-03f6410665bf" xlink:to="loc_srt_NameOfMajorCustomerDomain_f64c12fa-b2b0-4882-9cdf-03f6410665bf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_2dfde65f-2e7d-4abf-8e14-dbc87a467687" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_f64c12fa-b2b0-4882-9cdf-03f6410665bf" xlink:to="loc_srt_NameOfMajorCustomerDomain_2dfde65f-2e7d-4abf-8e14-dbc87a467687" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AmerisourceBergenDrugCorporationMember_6823e3bc-b912-4bf7-872f-ab226e9dfb2b" xlink:href="ardx-20220331.xsd#ardx_AmerisourceBergenDrugCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_2dfde65f-2e7d-4abf-8e14-dbc87a467687" xlink:to="loc_ardx_AmerisourceBergenDrugCorporationMember_6823e3bc-b912-4bf7-872f-ab226e9dfb2b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CardinalHealthMember_65accbbc-e5ca-4a54-9543-383403c2a1e8" xlink:href="ardx-20220331.xsd#ardx_CardinalHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_2dfde65f-2e7d-4abf-8e14-dbc87a467687" xlink:to="loc_ardx_CardinalHealthMember_65accbbc-e5ca-4a54-9543-383403c2a1e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_McKessonCorporationMember_8d35d9bd-8d42-4b90-a2f3-100ce1964235" xlink:href="ardx-20220331.xsd#ardx_McKessonCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_2dfde65f-2e7d-4abf-8e14-dbc87a467687" xlink:to="loc_ardx_McKessonCorporationMember_8d35d9bd-8d42-4b90-a2f3-100ce1964235" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/ProductRevenueNetGrosstoNetSalesAccrualsDetails" xlink:type="simple" xlink:href="ardx-20220331.xsd#ProductRevenueNetGrosstoNetSalesAccrualsDetails"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/ProductRevenueNetGrosstoNetSalesAccrualsDetails" xlink:type="extended" id="i293dda45075443d988eea18f9c1cd221_ProductRevenueNetGrosstoNetSalesAccrualsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_b896bdc9-9ce9-43c2-9832-af3d68895954" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward_d39ae3fb-c456-49f9-a42a-635dbecf9a1e" xlink:href="ardx-20220331.xsd#ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b896bdc9-9ce9-43c2-9832-af3d68895954" xlink:to="loc_ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward_d39ae3fb-c456-49f9-a42a-635dbecf9a1e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerGrossToNetSalesAccruals_9560ba74-62be-4919-a08c-2f51732a9b50" xlink:href="ardx-20220331.xsd#ardx_ContractWithCustomerGrossToNetSalesAccruals"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward_d39ae3fb-c456-49f9-a42a-635dbecf9a1e" xlink:to="loc_ardx_ContractWithCustomerGrossToNetSalesAccruals_9560ba74-62be-4919-a08c-2f51732a9b50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod_d9ea670d-87ae-4fba-81d0-4f0beb62cd29" xlink:href="ardx-20220331.xsd#ardx_ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward_d39ae3fb-c456-49f9-a42a-635dbecf9a1e" xlink:to="loc_ardx_ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod_d9ea670d-87ae-4fba-81d0-4f0beb62cd29" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerGrossToNetSalesAccruals_dc41463e-7ae4-496d-b3cd-39ac7292bd18" xlink:href="ardx-20220331.xsd#ardx_ContractWithCustomerGrossToNetSalesAccruals"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_9cb7b559-6fb7-4783-89ab-99e7b9abc0c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b896bdc9-9ce9-43c2-9832-af3d68895954" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_9cb7b559-6fb7-4783-89ab-99e7b9abc0c1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_GrossToNetSalesAccrualAndReserveClassificationAxis_90778d95-f324-4a4c-be12-fcc9a11a16e8" xlink:href="ardx-20220331.xsd#ardx_GrossToNetSalesAccrualAndReserveClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_9cb7b559-6fb7-4783-89ab-99e7b9abc0c1" xlink:to="loc_ardx_GrossToNetSalesAccrualAndReserveClassificationAxis_90778d95-f324-4a4c-be12-fcc9a11a16e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_GrossToNetSalesAccrualAndReserveClassificationDomain_90778d95-f324-4a4c-be12-fcc9a11a16e8_default" xlink:href="ardx-20220331.xsd#ardx_GrossToNetSalesAccrualAndReserveClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ardx_GrossToNetSalesAccrualAndReserveClassificationAxis_90778d95-f324-4a4c-be12-fcc9a11a16e8" xlink:to="loc_ardx_GrossToNetSalesAccrualAndReserveClassificationDomain_90778d95-f324-4a4c-be12-fcc9a11a16e8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_GrossToNetSalesAccrualAndReserveClassificationDomain_6a7fe94d-f403-4b32-80a4-a6442227ff29" xlink:href="ardx-20220331.xsd#ardx_GrossToNetSalesAccrualAndReserveClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ardx_GrossToNetSalesAccrualAndReserveClassificationAxis_90778d95-f324-4a4c-be12-fcc9a11a16e8" xlink:to="loc_ardx_GrossToNetSalesAccrualAndReserveClassificationDomain_6a7fe94d-f403-4b32-80a4-a6442227ff29" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerDiscountsAndChargebacksMember_358b9240-2c78-427b-b914-ccc758807a7b" xlink:href="ardx-20220331.xsd#ardx_ContractWithCustomerDiscountsAndChargebacksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ardx_GrossToNetSalesAccrualAndReserveClassificationDomain_6a7fe94d-f403-4b32-80a4-a6442227ff29" xlink:to="loc_ardx_ContractWithCustomerDiscountsAndChargebacksMember_358b9240-2c78-427b-b914-ccc758807a7b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerRebatesMember_66e55a29-1fe9-496a-b978-ff9cf0f9379b" xlink:href="ardx-20220331.xsd#ardx_ContractWithCustomerRebatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ardx_GrossToNetSalesAccrualAndReserveClassificationDomain_6a7fe94d-f403-4b32-80a4-a6442227ff29" xlink:to="loc_ardx_ContractWithCustomerRebatesMember_66e55a29-1fe9-496a-b978-ff9cf0f9379b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerOtherFeesCopayAndReturnsMember_0f3e5ffa-e825-4af8-993e-003a45817647" xlink:href="ardx-20220331.xsd#ardx_ContractWithCustomerOtherFeesCopayAndReturnsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ardx_GrossToNetSalesAccrualAndReserveClassificationDomain_6a7fe94d-f403-4b32-80a4-a6442227ff29" xlink:to="loc_ardx_ContractWithCustomerOtherFeesCopayAndReturnsMember_0f3e5ffa-e825-4af8-993e-003a45817647" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails" xlink:type="simple" xlink:href="ardx-20220331.xsd#CollaborationandLicensingAgreementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails" xlink:type="extended" id="iadebf7c713624ecd9650c59febd3fd91_CollaborationandLicensingAgreementsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_552403e8-ec76-4e01-84bc-4743ad249064" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_NumberOfSeparateCollaborativeAgreements_74603aae-f745-4071-8d71-c4453ce6a276" xlink:href="ardx-20220331.xsd#ardx_NumberOfSeparateCollaborativeAgreements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_552403e8-ec76-4e01-84bc-4743ad249064" xlink:to="loc_ardx_NumberOfSeparateCollaborativeAgreements_74603aae-f745-4071-8d71-c4453ce6a276" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees_53225b2f-70fb-40b4-85d2-e43b9bfed9bb" xlink:href="ardx-20220331.xsd#ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_552403e8-ec76-4e01-84bc-4743ad249064" xlink:to="loc_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees_53225b2f-70fb-40b4-85d2-e43b9bfed9bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment_7c8d2d28-9e7d-437f-8c81-2a89e656c7e5" xlink:href="ardx-20220331.xsd#ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_552403e8-ec76-4e01-84bc-4743ad249064" xlink:to="loc_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment_7c8d2d28-9e7d-437f-8c81-2a89e656c7e5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_TermOfPaymentOfLicenseFeeFirstInstallment_c74e05f1-ad77-4407-89e1-a611a392d0b6" xlink:href="ardx-20220331.xsd#ardx_TermOfPaymentOfLicenseFeeFirstInstallment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_552403e8-ec76-4e01-84bc-4743ad249064" xlink:to="loc_ardx_TermOfPaymentOfLicenseFeeFirstInstallment_c74e05f1-ad77-4407-89e1-a611a392d0b6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment_d29c96b4-15b8-48b6-b325-61ae8f7d56fd" xlink:href="ardx-20220331.xsd#ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_552403e8-ec76-4e01-84bc-4743ad249064" xlink:to="loc_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment_d29c96b4-15b8-48b6-b325-61ae8f7d56fd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_TermOfAgreement_a610afe7-447b-4ab3-9e22-fbc5cd80831e" xlink:href="ardx-20220331.xsd#ardx_TermOfAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_552403e8-ec76-4e01-84bc-4743ad249064" xlink:to="loc_ardx_TermOfAgreement_a610afe7-447b-4ab3-9e22-fbc5cd80831e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_81ed5e1c-cd60-4acc-a670-5c710ecbacfa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_552403e8-ec76-4e01-84bc-4743ad249064" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_81ed5e1c-cd60-4acc-a670-5c710ecbacfa" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeArrangementPotentialDevelopmentMilestones_fe64c483-7c79-472c-a88c-5e80b4b8ceaf" xlink:href="ardx-20220331.xsd#ardx_CollaborativeArrangementPotentialDevelopmentMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_552403e8-ec76-4e01-84bc-4743ad249064" xlink:to="loc_ardx_CollaborativeArrangementPotentialDevelopmentMilestones_fe64c483-7c79-472c-a88c-5e80b4b8ceaf" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeArrangementPotentialCommercializationMilestones_6847a211-4417-42d5-9187-ba962fdc6cbe" xlink:href="ardx-20220331.xsd#ardx_CollaborativeArrangementPotentialCommercializationMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_552403e8-ec76-4e01-84bc-4743ad249064" xlink:to="loc_ardx_CollaborativeArrangementPotentialCommercializationMilestones_6847a211-4417-42d5-9187-ba962fdc6cbe" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate_34f9ef1d-b9f6-413d-a8b8-8160299fa5ed" xlink:href="ardx-20220331.xsd#ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_552403e8-ec76-4e01-84bc-4743ad249064" xlink:to="loc_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate_34f9ef1d-b9f6-413d-a8b8-8160299fa5ed" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches_23989f5c-c18a-48e6-9a71-4f50f87f41fb" xlink:href="ardx-20220331.xsd#ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_552403e8-ec76-4e01-84bc-4743ad249064" xlink:to="loc_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches_23989f5c-c18a-48e6-9a71-4f50f87f41fb" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLicenseFeesReceived_14ffef50-d24e-45fc-8eac-ee97e02953da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_552403e8-ec76-4e01-84bc-4743ad249064" xlink:to="loc_us-gaap_ProceedsFromLicenseFeesReceived_14ffef50-d24e-45fc-8eac-ee97e02953da" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones_85d02120-53a5-4671-b804-4aae28f7afd2" xlink:href="ardx-20220331.xsd#ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_552403e8-ec76-4e01-84bc-4743ad249064" xlink:to="loc_ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones_85d02120-53a5-4671-b804-4aae28f7afd2" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ThresholdPercentageOfSalesForTieredRoyalties_b389d26b-cb3c-473a-8a2c-b247e6e11054" xlink:href="ardx-20220331.xsd#ardx_ThresholdPercentageOfSalesForTieredRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_552403e8-ec76-4e01-84bc-4743ad249064" xlink:to="loc_ardx_ThresholdPercentageOfSalesForTieredRoyalties_b389d26b-cb3c-473a-8a2c-b247e6e11054" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_PercentageOfRoyaltyRevenue_60fc1605-2e13-4fae-9f6c-da1cdfeece6a" xlink:href="ardx-20220331.xsd#ardx_PercentageOfRoyaltyRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_552403e8-ec76-4e01-84bc-4743ad249064" xlink:to="loc_ardx_PercentageOfRoyaltyRevenue_60fc1605-2e13-4fae-9f6c-da1cdfeece6a" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_PercentageOfNonRoyaltyRevenue_ce7608d0-b0ed-448c-b46a-7319b52cf190" xlink:href="ardx-20220331.xsd#ardx_PercentageOfNonRoyaltyRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_552403e8-ec76-4e01-84bc-4743ad249064" xlink:to="loc_ardx_PercentageOfNonRoyaltyRevenue_ce7608d0-b0ed-448c-b46a-7319b52cf190" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum_f5637f30-50a5-4c96-9f5a-8551fc53f936" xlink:href="ardx-20220331.xsd#ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_552403e8-ec76-4e01-84bc-4743ad249064" xlink:to="loc_ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum_f5637f30-50a5-4c96-9f5a-8551fc53f936" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CostOfRevenueAggregateAmountRecognized_6421c75d-ebc8-48ec-bbef-96585e457c1e" xlink:href="ardx-20220331.xsd#ardx_CostOfRevenueAggregateAmountRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_552403e8-ec76-4e01-84bc-4743ad249064" xlink:to="loc_ardx_CostOfRevenueAggregateAmountRecognized_6421c75d-ebc8-48ec-bbef-96585e457c1e" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_1aaefe48-93b3-4503-ab99-2ca0b399cb1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_552403e8-ec76-4e01-84bc-4743ad249064" xlink:to="loc_us-gaap_CostOfRevenue_1aaefe48-93b3-4503-ab99-2ca0b399cb1d" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_PaymentsOfUnchargedLicenseFeesAggregateAmountPaid_6768328a-b570-4cca-9970-3d95b14abea5" xlink:href="ardx-20220331.xsd#ardx_PaymentsOfUnchargedLicenseFeesAggregateAmountPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_552403e8-ec76-4e01-84bc-4743ad249064" xlink:to="loc_ardx_PaymentsOfUnchargedLicenseFeesAggregateAmountPaid_6768328a-b570-4cca-9970-3d95b14abea5" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_88cee372-96e6-4cba-8f32-7e222d32405e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_552403e8-ec76-4e01-84bc-4743ad249064" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_88cee372-96e6-4cba-8f32-7e222d32405e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_0b8e4749-800b-4f98-ae85-61d7125c3ca4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_88cee372-96e6-4cba-8f32-7e222d32405e" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_0b8e4749-800b-4f98-ae85-61d7125c3ca4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_0b8e4749-800b-4f98-ae85-61d7125c3ca4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_0b8e4749-800b-4f98-ae85-61d7125c3ca4" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_0b8e4749-800b-4f98-ae85-61d7125c3ca4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_4649f2a3-a607-4f03-bfdd-9ecb23e5e9fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_0b8e4749-800b-4f98-ae85-61d7125c3ca4" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_4649f2a3-a607-4f03-bfdd-9ecb23e5e9fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_0443fc54-f689-4315-8ba1-5bafbebdf36e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_4649f2a3-a607-4f03-bfdd-9ecb23e5e9fa" xlink:to="loc_us-gaap_SubsequentEventMember_0443fc54-f689-4315-8ba1-5bafbebdf36e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_9ef96de9-d62c-4c85-b0c3-dc9d78be102d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_88cee372-96e6-4cba-8f32-7e222d32405e" xlink:to="loc_us-gaap_TypeOfArrangementAxis_9ef96de9-d62c-4c85-b0c3-dc9d78be102d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9ef96de9-d62c-4c85-b0c3-dc9d78be102d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_9ef96de9-d62c-4c85-b0c3-dc9d78be102d" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9ef96de9-d62c-4c85-b0c3-dc9d78be102d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a0548d12-1478-4cc1-a764-a54fcb611bd6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_9ef96de9-d62c-4c85-b0c3-dc9d78be102d" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a0548d12-1478-4cc1-a764-a54fcb611bd6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ResearchCollaborationAndOptionAgreementMember_2f01b0b0-abe6-4bef-8181-6b83e9db3e50" xlink:href="ardx-20220331.xsd#ardx_ResearchCollaborationAndOptionAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a0548d12-1478-4cc1-a764-a54fcb611bd6" xlink:to="loc_ardx_ResearchCollaborationAndOptionAgreementMember_2f01b0b0-abe6-4bef-8181-6b83e9db3e50" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember_39f67ec3-78b4-4437-bb64-d630fe67f5d3" xlink:href="ardx-20220331.xsd#ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a0548d12-1478-4cc1-a764-a54fcb611bd6" xlink:to="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember_39f67ec3-78b4-4437-bb64-d630fe67f5d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember_926974f1-c86b-4bb0-83aa-1c20fcb5e9bf" xlink:href="ardx-20220331.xsd#ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a0548d12-1478-4cc1-a764-a54fcb611bd6" xlink:to="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember_926974f1-c86b-4bb0-83aa-1c20fcb5e9bf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember_e6c9792a-1cec-48d4-8756-8b5e0f1e19e1" xlink:href="ardx-20220331.xsd#ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a0548d12-1478-4cc1-a764-a54fcb611bd6" xlink:to="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember_e6c9792a-1cec-48d4-8756-8b5e0f1e19e1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AstraZenecaTerminationAgreementMember_2a379f95-1e53-4ba3-8818-4a36bfa8f209" xlink:href="ardx-20220331.xsd#ardx_AstraZenecaTerminationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a0548d12-1478-4cc1-a764-a54fcb611bd6" xlink:to="loc_ardx_AstraZenecaTerminationAgreementMember_2a379f95-1e53-4ba3-8818-4a36bfa8f209" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_c3247b6c-dc9f-4f31-879b-3d09e22b43ed" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_88cee372-96e6-4cba-8f32-7e222d32405e" xlink:to="loc_srt_CounterpartyNameAxis_c3247b6c-dc9f-4f31-879b-3d09e22b43ed" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c3247b6c-dc9f-4f31-879b-3d09e22b43ed_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_c3247b6c-dc9f-4f31-879b-3d09e22b43ed" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c3247b6c-dc9f-4f31-879b-3d09e22b43ed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ea488ca9-1509-4945-9ce3-65b7a3b36e0a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_c3247b6c-dc9f-4f31-879b-3d09e22b43ed" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ea488ca9-1509-4945-9ce3-65b7a3b36e0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_KyowaKirinCo.LtdMember_cf6d49b9-2caa-427c-b433-24b192675c73" xlink:href="ardx-20220331.xsd#ardx_KyowaKirinCo.LtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ea488ca9-1509-4945-9ce3-65b7a3b36e0a" xlink:to="loc_ardx_KyowaKirinCo.LtdMember_cf6d49b9-2caa-427c-b433-24b192675c73" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember_5dfeff0f-a6bb-4372-abfb-5688bea071bf" xlink:href="ardx-20220331.xsd#ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ea488ca9-1509-4945-9ce3-65b7a3b36e0a" xlink:to="loc_ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember_5dfeff0f-a6bb-4372-abfb-5688bea071bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_KnightTherapeuticsIncMember_44b81301-f0b5-4e6f-acff-a75fc1fdc393" xlink:href="ardx-20220331.xsd#ardx_KnightTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ea488ca9-1509-4945-9ce3-65b7a3b36e0a" xlink:to="loc_ardx_KnightTherapeuticsIncMember_44b81301-f0b5-4e6f-acff-a75fc1fdc393" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AstrazenecaMember_d3b439c0-b417-431c-bd0d-de8881300563" xlink:href="ardx-20220331.xsd#ardx_AstrazenecaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ea488ca9-1509-4945-9ce3-65b7a3b36e0a" xlink:to="loc_ardx_AstrazenecaMember_d3b439c0-b417-431c-bd0d-de8881300563" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_9d28259c-2ee7-4d50-8f12-d1b7b74e29b4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_88cee372-96e6-4cba-8f32-7e222d32405e" xlink:to="loc_srt_ProductOrServiceAxis_9d28259c-2ee7-4d50-8f12-d1b7b74e29b4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9d28259c-2ee7-4d50-8f12-d1b7b74e29b4_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_9d28259c-2ee7-4d50-8f12-d1b7b74e29b4" xlink:to="loc_srt_ProductsAndServicesDomain_9d28259c-2ee7-4d50-8f12-d1b7b74e29b4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_08f037e3-d759-4764-bc91-2c8db4ae22f0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_9d28259c-2ee7-4d50-8f12-d1b7b74e29b4" xlink:to="loc_srt_ProductsAndServicesDomain_08f037e3-d759-4764-bc91-2c8db4ae22f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_e4ee0dba-bb10-481c-8830-bc0e11cf6aba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_08f037e3-d759-4764-bc91-2c8db4ae22f0" xlink:to="loc_us-gaap_LicenseMember_e4ee0dba-bb10-481c-8830-bc0e11cf6aba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ProductSupplyRevenueMember_f38ba6f2-2079-4f43-87bf-950ffaaf66b3" xlink:href="ardx-20220331.xsd#ardx_ProductSupplyRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_08f037e3-d759-4764-bc91-2c8db4ae22f0" xlink:to="loc_ardx_ProductSupplyRevenueMember_f38ba6f2-2079-4f43-87bf-950ffaaf66b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f69f0408-58dd-4c78-b8cb-fedbab9c5cba" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_88cee372-96e6-4cba-8f32-7e222d32405e" xlink:to="loc_srt_RangeAxis_f69f0408-58dd-4c78-b8cb-fedbab9c5cba" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f69f0408-58dd-4c78-b8cb-fedbab9c5cba_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_f69f0408-58dd-4c78-b8cb-fedbab9c5cba" xlink:to="loc_srt_RangeMember_f69f0408-58dd-4c78-b8cb-fedbab9c5cba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f762bc2b-96ef-41ab-a8df-fd8cd7edbaef" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_f69f0408-58dd-4c78-b8cb-fedbab9c5cba" xlink:to="loc_srt_RangeMember_f762bc2b-96ef-41ab-a8df-fd8cd7edbaef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d5475be1-dc7d-4486-bb36-f245ec814269" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f762bc2b-96ef-41ab-a8df-fd8cd7edbaef" xlink:to="loc_srt_MinimumMember_d5475be1-dc7d-4486-bb36-f245ec814269" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails" xlink:type="simple" xlink:href="ardx-20220331.xsd#CollaborationandLicensingAgreementsDeferredRevenueDetails"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails" xlink:type="extended" id="ife0715cdfc7943af82b9e2dd00747274_CollaborationandLicensingAgreementsDeferredRevenueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3554260f-c856-4d26-b55d-6e81d94df8ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward_2033729d-23bf-4b66-968c-7fff6db31640" xlink:href="ardx-20220331.xsd#ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3554260f-c856-4d26-b55d-6e81d94df8ca" xlink:to="loc_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward_2033729d-23bf-4b66-968c-7fff6db31640" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_ff78bc63-9a8c-40f6-9f7e-ed292d996de8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward_2033729d-23bf-4b66-968c-7fff6db31640" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_ff78bc63-9a8c-40f6-9f7e-ed292d996de8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerLiabilityRevenueRecognizedCashReceived_f2c62d43-40f8-4925-89f7-d5cc2a123f6a" xlink:href="ardx-20220331.xsd#ardx_ContractWithCustomerLiabilityRevenueRecognizedCashReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward_2033729d-23bf-4b66-968c-7fff6db31640" xlink:to="loc_ardx_ContractWithCustomerLiabilityRevenueRecognizedCashReceived_f2c62d43-40f8-4925-89f7-d5cc2a123f6a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_d8629193-5d2c-46ad-bc2e-4cd58d187b9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward_3f272425-5027-4342-861b-865a7ab198d1" xlink:href="ardx-20220331.xsd#ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3554260f-c856-4d26-b55d-6e81d94df8ca" xlink:to="loc_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward_3f272425-5027-4342-861b-865a7ab198d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_92e926f5-d8a4-42ed-a551-b4eb198dbbf8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward_3f272425-5027-4342-861b-865a7ab198d1" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_92e926f5-d8a4-42ed-a551-b4eb198dbbf8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerLiabilityIncreaseForAmountsInvoiced_f3c2d8e7-5630-4ee4-a9e5-268f0efa8d4b" xlink:href="ardx-20220331.xsd#ardx_ContractWithCustomerLiabilityIncreaseForAmountsInvoiced"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward_3f272425-5027-4342-861b-865a7ab198d1" xlink:to="loc_ardx_ContractWithCustomerLiabilityIncreaseForAmountsInvoiced_f3c2d8e7-5630-4ee4-a9e5-268f0efa8d4b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerLiabilityIncreaseDueToUnbilledPrepaymentsRecorded_4ef41c04-6483-461a-b1e0-fc56bfd27928" xlink:href="ardx-20220331.xsd#ardx_ContractWithCustomerLiabilityIncreaseDueToUnbilledPrepaymentsRecorded"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward_3f272425-5027-4342-861b-865a7ab198d1" xlink:to="loc_ardx_ContractWithCustomerLiabilityIncreaseDueToUnbilledPrepaymentsRecorded_4ef41c04-6483-461a-b1e0-fc56bfd27928" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_69cb716b-c79e-4ede-b04a-fc22689b0d16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1a0ce19e-53e6-4dde-a6ee-90e1d3f5238c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3554260f-c856-4d26-b55d-6e81d94df8ca" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1a0ce19e-53e6-4dde-a6ee-90e1d3f5238c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_b50ddfc9-f434-42a7-a1c9-f3f430e58e3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1a0ce19e-53e6-4dde-a6ee-90e1d3f5238c" xlink:to="loc_us-gaap_TypeOfArrangementAxis_b50ddfc9-f434-42a7-a1c9-f3f430e58e3d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b50ddfc9-f434-42a7-a1c9-f3f430e58e3d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_b50ddfc9-f434-42a7-a1c9-f3f430e58e3d" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b50ddfc9-f434-42a7-a1c9-f3f430e58e3d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3cfd0a01-1d79-496a-a398-96031c990b31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_b50ddfc9-f434-42a7-a1c9-f3f430e58e3d" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3cfd0a01-1d79-496a-a398-96031c990b31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ResearchCollaborationAndOptionAgreementMember_d611502c-0895-4edc-971c-26209c28fd68" xlink:href="ardx-20220331.xsd#ardx_ResearchCollaborationAndOptionAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3cfd0a01-1d79-496a-a398-96031c990b31" xlink:to="loc_ardx_ResearchCollaborationAndOptionAgreementMember_d611502c-0895-4edc-971c-26209c28fd68" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember_5c00fbd4-c69e-4590-99ba-9835c9de5aa7" xlink:href="ardx-20220331.xsd#ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3cfd0a01-1d79-496a-a398-96031c990b31" xlink:to="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember_5c00fbd4-c69e-4590-99ba-9835c9de5aa7" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/BorrowingNarrativeDetails" xlink:type="simple" xlink:href="ardx-20220331.xsd#BorrowingNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/BorrowingNarrativeDetails" xlink:type="extended" id="id288b77d9dd64eca95af940f1d1b48ef_BorrowingNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_150b0062-c15d-46db-bcb6-ac2630707ef2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_18f34ef0-5041-481b-900d-1299c16c4679" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_150b0062-c15d-46db-bcb6-ac2630707ef2" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_18f34ef0-5041-481b-900d-1299c16c4679" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_32c1fa5a-1314-49c6-bad3-3ef11e266da4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_150b0062-c15d-46db-bcb6-ac2630707ef2" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_32c1fa5a-1314-49c6-bad3-3ef11e266da4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotionalAmount_27c3c3ed-3355-4d87-944b-b21d286206e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilityNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_150b0062-c15d-46db-bcb6-ac2630707ef2" xlink:to="loc_us-gaap_DerivativeLiabilityNotionalAmount_27c3c3ed-3355-4d87-944b-b21d286206e1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_8cd70c4d-3dac-4526-b778-c3aa8558a7a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_150b0062-c15d-46db-bcb6-ac2630707ef2" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_8cd70c4d-3dac-4526-b778-c3aa8558a7a7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_RemainingFundingBasedOnConditionalMilestoneAchievement_bbf1c188-1779-42d8-b7db-e2ba66646225" xlink:href="ardx-20220331.xsd#ardx_RemainingFundingBasedOnConditionalMilestoneAchievement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_150b0062-c15d-46db-bcb6-ac2630707ef2" xlink:to="loc_ardx_RemainingFundingBasedOnConditionalMilestoneAchievement_bbf1c188-1779-42d8-b7db-e2ba66646225" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_cab94a1d-ecfa-44a9-9c61-960bf9b59f5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_150b0062-c15d-46db-bcb6-ac2630707ef2" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_cab94a1d-ecfa-44a9-9c61-960bf9b59f5b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DebtInstrumentVariableRateBaseOption_18fbdcd5-72c4-4bfc-ba58-d7358d7bca3b" xlink:href="ardx-20220331.xsd#ardx_DebtInstrumentVariableRateBaseOption"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_150b0062-c15d-46db-bcb6-ac2630707ef2" xlink:to="loc_ardx_DebtInstrumentVariableRateBaseOption_18fbdcd5-72c4-4bfc-ba58-d7358d7bca3b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DebtInstrumentClosingFeeAmount_b4ecd040-a9da-4f18-8816-0dfb762859d0" xlink:href="ardx-20220331.xsd#ardx_DebtInstrumentClosingFeeAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_150b0062-c15d-46db-bcb6-ac2630707ef2" xlink:to="loc_ardx_DebtInstrumentClosingFeeAmount_b4ecd040-a9da-4f18-8816-0dfb762859d0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LoanAgreementFutureObligationUponFundingOrOtherEvents_c3006cee-e7e6-4b3e-8b9b-a11232a88486" xlink:href="ardx-20220331.xsd#ardx_LoanAgreementFutureObligationUponFundingOrOtherEvents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_150b0062-c15d-46db-bcb6-ac2630707ef2" xlink:to="loc_ardx_LoanAgreementFutureObligationUponFundingOrOtherEvents_c3006cee-e7e6-4b3e-8b9b-a11232a88486" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage_fda7a0e3-b7da-4148-9085-c97ae481aff4" xlink:href="ardx-20220331.xsd#ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_150b0062-c15d-46db-bcb6-ac2630707ef2" xlink:to="loc_ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage_fda7a0e3-b7da-4148-9085-c97ae481aff4" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DebtInstrumentPrepaymentFeePercentage_ff9ef49a-acf4-4c7b-af93-9d04161f9cd3" xlink:href="ardx-20220331.xsd#ardx_DebtInstrumentPrepaymentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_150b0062-c15d-46db-bcb6-ac2630707ef2" xlink:to="loc_ardx_DebtInstrumentPrepaymentFeePercentage_ff9ef49a-acf4-4c7b-af93-9d04161f9cd3" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ExitFeePercentage_356b0000-83f0-48ad-808c-85bfe3ab90c5" xlink:href="ardx-20220331.xsd#ardx_ExitFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_150b0062-c15d-46db-bcb6-ac2630707ef2" xlink:to="loc_ardx_ExitFeePercentage_356b0000-83f0-48ad-808c-85bfe3ab90c5" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum_1f93300b-f389-4eec-9e19-a49e34591f3f" xlink:href="ardx-20220331.xsd#ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_150b0062-c15d-46db-bcb6-ac2630707ef2" xlink:to="loc_ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum_1f93300b-f389-4eec-9e19-a49e34591f3f" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LoanAgreementExitFeeTerm_1b55a780-209c-4330-98e9-0bafe66d4268" xlink:href="ardx-20220331.xsd#ardx_LoanAgreementExitFeeTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_150b0062-c15d-46db-bcb6-ac2630707ef2" xlink:to="loc_ardx_LoanAgreementExitFeeTerm_1b55a780-209c-4330-98e9-0bafe66d4268" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum_4a274142-5126-4531-bd66-806792829a9e" xlink:href="ardx-20220331.xsd#ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_150b0062-c15d-46db-bcb6-ac2630707ef2" xlink:to="loc_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum_4a274142-5126-4531-bd66-806792829a9e" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum_8f6b1fd4-2675-4826-8cbe-802dbae751b3" xlink:href="ardx-20220331.xsd#ardx_LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_150b0062-c15d-46db-bcb6-ac2630707ef2" xlink:to="loc_ardx_LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum_8f6b1fd4-2675-4826-8cbe-802dbae751b3" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DebtInstrumentInterestRateOnDefaultPercentage_08770e9f-3c65-411a-9b1b-dfce3d763c33" xlink:href="ardx-20220331.xsd#ardx_DebtInstrumentInterestRateOnDefaultPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_150b0062-c15d-46db-bcb6-ac2630707ef2" xlink:to="loc_ardx_DebtInstrumentInterestRateOnDefaultPercentage_08770e9f-3c65-411a-9b1b-dfce3d763c33" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_eb0b6b9a-d7d0-4c6f-93ac-baab1ae1ab45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_150b0062-c15d-46db-bcb6-ac2630707ef2" xlink:to="loc_us-gaap_DebtInstrumentTable_eb0b6b9a-d7d0-4c6f-93ac-baab1ae1ab45" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_ae457d3a-e696-4f63-9244-35fab7efb034" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_eb0b6b9a-d7d0-4c6f-93ac-baab1ae1ab45" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_ae457d3a-e696-4f63-9244-35fab7efb034" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_ae457d3a-e696-4f63-9244-35fab7efb034_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_ae457d3a-e696-4f63-9244-35fab7efb034" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_ae457d3a-e696-4f63-9244-35fab7efb034_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_7224b168-695e-41e6-b8ff-0f8d7309e1e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_ae457d3a-e696-4f63-9244-35fab7efb034" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_7224b168-695e-41e6-b8ff-0f8d7309e1e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ExitFee2022Member_14b3d38f-f06e-4f4a-ba48-1380b010c9cf" xlink:href="ardx-20220331.xsd#ardx_ExitFee2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_7224b168-695e-41e6-b8ff-0f8d7309e1e9" xlink:to="loc_ardx_ExitFee2022Member_14b3d38f-f06e-4f4a-ba48-1380b010c9cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ExitFee2018Member_c776d6c4-e551-40ad-b483-8a2451e1d886" xlink:href="ardx-20220331.xsd#ardx_ExitFee2018Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_7224b168-695e-41e6-b8ff-0f8d7309e1e9" xlink:to="loc_ardx_ExitFee2018Member_c776d6c4-e551-40ad-b483-8a2451e1d886" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_fe714ddb-e5d9-48c9-bd23-aea6402a5ddd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_eb0b6b9a-d7d0-4c6f-93ac-baab1ae1ab45" xlink:to="loc_us-gaap_DebtInstrumentAxis_fe714ddb-e5d9-48c9-bd23-aea6402a5ddd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_fe714ddb-e5d9-48c9-bd23-aea6402a5ddd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_fe714ddb-e5d9-48c9-bd23-aea6402a5ddd" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_fe714ddb-e5d9-48c9-bd23-aea6402a5ddd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b8830605-f696-40c4-a04c-261f0bc11537" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_fe714ddb-e5d9-48c9-bd23-aea6402a5ddd" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b8830605-f696-40c4-a04c-261f0bc11537" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_TermLoan2018Member_47a740bc-e91c-4b1c-9f6e-5a052f3ce55f" xlink:href="ardx-20220331.xsd#ardx_TermLoan2018Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b8830605-f696-40c4-a04c-261f0bc11537" xlink:to="loc_ardx_TermLoan2018Member_47a740bc-e91c-4b1c-9f6e-5a052f3ce55f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_TermLoan2022Member_c3c36c22-82b4-422d-8977-4d5834afe24a" xlink:href="ardx-20220331.xsd#ardx_TermLoan2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b8830605-f696-40c4-a04c-261f0bc11537" xlink:to="loc_ardx_TermLoan2022Member_c3c36c22-82b4-422d-8977-4d5834afe24a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_TermLoan2022AMember_0c995f69-9dc7-4469-b215-6f74e11ef749" xlink:href="ardx-20220331.xsd#ardx_TermLoan2022AMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ardx_TermLoan2022Member_c3c36c22-82b4-422d-8977-4d5834afe24a" xlink:to="loc_ardx_TermLoan2022AMember_0c995f69-9dc7-4469-b215-6f74e11ef749" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_TermLoan2022BMember_79e56f1a-87d1-4475-aca8-4abaf74c50d4" xlink:href="ardx-20220331.xsd#ardx_TermLoan2022BMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ardx_TermLoan2022Member_c3c36c22-82b4-422d-8977-4d5834afe24a" xlink:to="loc_ardx_TermLoan2022BMember_79e56f1a-87d1-4475-aca8-4abaf74c50d4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_653e8105-425d-44ea-9208-9967704846bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_eb0b6b9a-d7d0-4c6f-93ac-baab1ae1ab45" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_653e8105-425d-44ea-9208-9967704846bd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_653e8105-425d-44ea-9208-9967704846bd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_653e8105-425d-44ea-9208-9967704846bd" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_653e8105-425d-44ea-9208-9967704846bd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ae870d9d-3186-4944-90a1-8373b80618a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_653e8105-425d-44ea-9208-9967704846bd" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ae870d9d-3186-4944-90a1-8373b80618a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_6fe29f0c-8cba-46e3-a22b-47b8e5ebebe4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_ae870d9d-3186-4944-90a1-8373b80618a9" xlink:to="loc_us-gaap_LoansPayableMember_6fe29f0c-8cba-46e3-a22b-47b8e5ebebe4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_e8a30baa-73e8-4968-8de6-dc3816006199" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_eb0b6b9a-d7d0-4c6f-93ac-baab1ae1ab45" xlink:to="loc_us-gaap_VariableRateAxis_e8a30baa-73e8-4968-8de6-dc3816006199" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_e8a30baa-73e8-4968-8de6-dc3816006199_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_e8a30baa-73e8-4968-8de6-dc3816006199" xlink:to="loc_us-gaap_VariableRateDomain_e8a30baa-73e8-4968-8de6-dc3816006199_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_78dc504d-57bf-4741-a887-7a87eaace209" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_e8a30baa-73e8-4968-8de6-dc3816006199" xlink:to="loc_us-gaap_VariableRateDomain_78dc504d-57bf-4741-a887-7a87eaace209" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_e5b7e504-8d00-48b5-8f47-42ab7ea0452b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_78dc504d-57bf-4741-a887-7a87eaace209" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_e5b7e504-8d00-48b5-8f47-42ab7ea0452b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_de773c50-9fa5-48e6-bf06-36066a25c994" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_eb0b6b9a-d7d0-4c6f-93ac-baab1ae1ab45" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_de773c50-9fa5-48e6-bf06-36066a25c994" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_de773c50-9fa5-48e6-bf06-36066a25c994_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_de773c50-9fa5-48e6-bf06-36066a25c994" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_de773c50-9fa5-48e6-bf06-36066a25c994_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_c438cefc-c58d-425c-9fb8-2bb5ff4ac477" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_de773c50-9fa5-48e6-bf06-36066a25c994" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_c438cefc-c58d-425c-9fb8-2bb5ff4ac477" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_cbf97f97-69f2-45de-8c3e-af10d3413256" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_c438cefc-c58d-425c-9fb8-2bb5ff4ac477" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_cbf97f97-69f2-45de-8c3e-af10d3413256" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_82682858-ff27-4e10-a24d-dea5806dcc0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_c438cefc-c58d-425c-9fb8-2bb5ff4ac477" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_82682858-ff27-4e10-a24d-dea5806dcc0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_be50ea7b-9055-4137-adeb-41389481bef3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_c438cefc-c58d-425c-9fb8-2bb5ff4ac477" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_be50ea7b-9055-4137-adeb-41389481bef3" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/DerivativeLiabilityNarrativeDetails" xlink:type="simple" xlink:href="ardx-20220331.xsd#DerivativeLiabilityNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/DerivativeLiabilityNarrativeDetails" xlink:type="extended" id="i08967cd8643c4416a891fa39d6d34572_DerivativeLiabilityNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_f0856ab9-bbde-40a0-8673-359b70c8a674" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotionalAmount_b9ea026d-02d9-40fd-82ff-623da4c432f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilityNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_f0856ab9-bbde-40a0-8673-359b70c8a674" xlink:to="loc_us-gaap_DerivativeLiabilityNotionalAmount_b9ea026d-02d9-40fd-82ff-623da4c432f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage_782adc94-4b5a-4b39-86d6-17dc33f64107" xlink:href="ardx-20220331.xsd#ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_f0856ab9-bbde-40a0-8673-359b70c8a674" xlink:to="loc_ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage_782adc94-4b5a-4b39-86d6-17dc33f64107" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation_d28e49cd-8712-4060-88d6-8e1bdc36d344" xlink:href="ardx-20220331.xsd#ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_f0856ab9-bbde-40a0-8673-359b70c8a674" xlink:to="loc_ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation_d28e49cd-8712-4060-88d6-8e1bdc36d344" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ExitFeePercentage_27208df6-b6c6-439c-9582-f11fc94383fb" xlink:href="ardx-20220331.xsd#ardx_ExitFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_f0856ab9-bbde-40a0-8673-359b70c8a674" xlink:to="loc_ardx_ExitFeePercentage_27208df6-b6c6-439c-9582-f11fc94383fb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum_7c5327e5-7415-4bdc-b30c-8b138d2254c3" xlink:href="ardx-20220331.xsd#ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_f0856ab9-bbde-40a0-8673-359b70c8a674" xlink:to="loc_ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum_7c5327e5-7415-4bdc-b30c-8b138d2254c3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_98b48ee0-39c9-4231-9444-b9bf90dc816f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_f0856ab9-bbde-40a0-8673-359b70c8a674" xlink:to="loc_us-gaap_DerivativeTable_98b48ee0-39c9-4231-9444-b9bf90dc816f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_5edbe0e9-3277-4baa-bf9e-4d5ca8ab5072" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_98b48ee0-39c9-4231-9444-b9bf90dc816f" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_5edbe0e9-3277-4baa-bf9e-4d5ca8ab5072" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_5edbe0e9-3277-4baa-bf9e-4d5ca8ab5072_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_5edbe0e9-3277-4baa-bf9e-4d5ca8ab5072" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_5edbe0e9-3277-4baa-bf9e-4d5ca8ab5072_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_9d9a868b-9984-4031-be1b-be36ab179a70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_5edbe0e9-3277-4baa-bf9e-4d5ca8ab5072" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_9d9a868b-9984-4031-be1b-be36ab179a70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ExitFee2018Member_b9ca2ce6-1aa0-4d93-8738-7821af56d7a2" xlink:href="ardx-20220331.xsd#ardx_ExitFee2018Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_9d9a868b-9984-4031-be1b-be36ab179a70" xlink:to="loc_ardx_ExitFee2018Member_b9ca2ce6-1aa0-4d93-8738-7821af56d7a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ExitFee2022Member_d1692fec-c6d7-4217-9aaf-b692eb9392e7" xlink:href="ardx-20220331.xsd#ardx_ExitFee2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_9d9a868b-9984-4031-be1b-be36ab179a70" xlink:to="loc_ardx_ExitFee2022Member_d1692fec-c6d7-4217-9aaf-b692eb9392e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_23598bb8-6f8e-4723-a4e8-0069e6e9b401" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_98b48ee0-39c9-4231-9444-b9bf90dc816f" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_23598bb8-6f8e-4723-a4e8-0069e6e9b401" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_23598bb8-6f8e-4723-a4e8-0069e6e9b401_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_23598bb8-6f8e-4723-a4e8-0069e6e9b401" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_23598bb8-6f8e-4723-a4e8-0069e6e9b401_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1fda40d7-0c54-4524-8210-831b05db46d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_23598bb8-6f8e-4723-a4e8-0069e6e9b401" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1fda40d7-0c54-4524-8210-831b05db46d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_94d5708f-3ecb-4601-9aec-4be21a1b2600" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1fda40d7-0c54-4524-8210-831b05db46d9" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_94d5708f-3ecb-4601-9aec-4be21a1b2600" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/DerivativeLiabilityChangesinFairValueDetails" xlink:type="simple" xlink:href="ardx-20220331.xsd#DerivativeLiabilityChangesinFairValueDetails"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/DerivativeLiabilityChangesinFairValueDetails" xlink:type="extended" id="i57974d3c27bb40c4935d02a4a7098c64_DerivativeLiabilityChangesinFairValueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_7c14fdf3-3168-4c2f-9800-1b1a73013f54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_c95d9184-dcf5-497d-8cbf-79df9a56bf73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_7c14fdf3-3168-4c2f-9800-1b1a73013f54" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_c95d9184-dcf5-497d-8cbf-79df9a56bf73" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_93f4410e-2f9a-4b9a-8609-04a3af64924d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_c95d9184-dcf5-497d-8cbf-79df9a56bf73" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_93f4410e-2f9a-4b9a-8609-04a3af64924d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_9fb5883e-8476-4a73-b6ca-7a3445a47689" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_c95d9184-dcf5-497d-8cbf-79df9a56bf73" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_9fb5883e-8476-4a73-b6ca-7a3445a47689" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_9b3da089-a6be-45a5-94d1-471bc2025d15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_c95d9184-dcf5-497d-8cbf-79df9a56bf73" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_9b3da089-a6be-45a5-94d1-471bc2025d15" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_fbb81abc-8d37-47e7-bfa7-e31b525d7364" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_6b161408-888c-43b9-bad5-8218d98841f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_7c14fdf3-3168-4c2f-9800-1b1a73013f54" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_6b161408-888c-43b9-bad5-8218d98841f3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_758ab1ca-1aba-40ae-a1df-a15fe7c0dba9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_6b161408-888c-43b9-bad5-8218d98841f3" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_758ab1ca-1aba-40ae-a1df-a15fe7c0dba9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_758ab1ca-1aba-40ae-a1df-a15fe7c0dba9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_758ab1ca-1aba-40ae-a1df-a15fe7c0dba9" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_758ab1ca-1aba-40ae-a1df-a15fe7c0dba9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_f2828ee3-335c-4383-949f-2cd5824c4c09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_758ab1ca-1aba-40ae-a1df-a15fe7c0dba9" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_f2828ee3-335c-4383-949f-2cd5824c4c09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_0a4aff29-a44c-45fc-a793-4ecf593897c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_f2828ee3-335c-4383-949f-2cd5824c4c09" xlink:to="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_0a4aff29-a44c-45fc-a793-4ecf593897c9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="ardx-20220331.xsd#StockholdersEquityDetails"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/StockholdersEquityDetails" xlink:type="extended" id="i94da25d22bf14678b627be90c9ae5ae7_StockholdersEquityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_1a310dae-d934-4408-83c4-7e412dcb4b16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_MaximumAggregateOfferingPrice_3054de6f-8686-46dc-8c8d-1ece77d9e330" xlink:href="ardx-20220331.xsd#ardx_MaximumAggregateOfferingPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_1a310dae-d934-4408-83c4-7e412dcb4b16" xlink:to="loc_ardx_MaximumAggregateOfferingPrice_3054de6f-8686-46dc-8c8d-1ece77d9e330" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_StockIssuanceCostCommissionPercent_3c776050-b792-44dc-bdc1-02dc2ff7696e" xlink:href="ardx-20220331.xsd#ardx_StockIssuanceCostCommissionPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_1a310dae-d934-4408-83c4-7e412dcb4b16" xlink:to="loc_ardx_StockIssuanceCostCommissionPercent_3c776050-b792-44dc-bdc1-02dc2ff7696e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8c2882f2-71be-412e-9c0d-bdf6f1e8c184" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_1a310dae-d934-4408-83c4-7e412dcb4b16" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8c2882f2-71be-412e-9c0d-bdf6f1e8c184" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1fe82a15-cc5b-4e6d-b757-3ef493988a46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_1a310dae-d934-4408-83c4-7e412dcb4b16" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1fe82a15-cc5b-4e6d-b757-3ef493988a46" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_SaleOfStockWeightedAveragePricePerShare_395fb56b-5044-4cc2-8947-14b56f3fc4ad" xlink:href="ardx-20220331.xsd#ardx_SaleOfStockWeightedAveragePricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_1a310dae-d934-4408-83c4-7e412dcb4b16" xlink:to="loc_ardx_SaleOfStockWeightedAveragePricePerShare_395fb56b-5044-4cc2-8947-14b56f3fc4ad" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_b25f95f7-e248-4e6c-ae32-594c62a18d96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_1a310dae-d934-4408-83c4-7e412dcb4b16" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_b25f95f7-e248-4e6c-ae32-594c62a18d96" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_20da06a4-9f01-4f42-ac46-e253a650b945" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_b25f95f7-e248-4e6c-ae32-594c62a18d96" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_20da06a4-9f01-4f42-ac46-e253a650b945" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_20da06a4-9f01-4f42-ac46-e253a650b945_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_20da06a4-9f01-4f42-ac46-e253a650b945" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_20da06a4-9f01-4f42-ac46-e253a650b945_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_89f0f7d3-58c5-4b31-b6da-0d20967f9a63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_20da06a4-9f01-4f42-ac46-e253a650b945" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_89f0f7d3-58c5-4b31-b6da-0d20967f9a63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_OpenMarketSalesAgreement2020AtTheMarketOfferingMember_e5b4737b-cc1f-4d3e-8916-ebecb1e376b3" xlink:href="ardx-20220331.xsd#ardx_OpenMarketSalesAgreement2020AtTheMarketOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_89f0f7d3-58c5-4b31-b6da-0d20967f9a63" xlink:to="loc_ardx_OpenMarketSalesAgreement2020AtTheMarketOfferingMember_e5b4737b-cc1f-4d3e-8916-ebecb1e376b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_OpenMarketSalesAgreement2021AtTheMarketOfferingMember_e20d9987-cf54-4be6-8043-4761f733e816" xlink:href="ardx-20220331.xsd#ardx_OpenMarketSalesAgreement2021AtTheMarketOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_89f0f7d3-58c5-4b31-b6da-0d20967f9a63" xlink:to="loc_ardx_OpenMarketSalesAgreement2021AtTheMarketOfferingMember_e20d9987-cf54-4be6-8043-4761f733e816" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_6d31416b-ff3f-4044-99cd-c1871310fe4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_b25f95f7-e248-4e6c-ae32-594c62a18d96" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_6d31416b-ff3f-4044-99cd-c1871310fe4f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_6d31416b-ff3f-4044-99cd-c1871310fe4f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_6d31416b-ff3f-4044-99cd-c1871310fe4f" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_6d31416b-ff3f-4044-99cd-c1871310fe4f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_78815567-8ca5-4912-97a3-080d3b991838" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_6d31416b-ff3f-4044-99cd-c1871310fe4f" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_78815567-8ca5-4912-97a3-080d3b991838" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_8e62a444-fb39-4cae-bdf9-b58c012307b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_78815567-8ca5-4912-97a3-080d3b991838" xlink:to="loc_us-gaap_SubsequentEventMember_8e62a444-fb39-4cae-bdf9-b58c012307b4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_fb706513-f7cb-4701-8460-94a616db7418" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_b25f95f7-e248-4e6c-ae32-594c62a18d96" xlink:to="loc_us-gaap_StatementClassOfStockAxis_fb706513-f7cb-4701-8460-94a616db7418" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_fb706513-f7cb-4701-8460-94a616db7418_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_fb706513-f7cb-4701-8460-94a616db7418" xlink:to="loc_us-gaap_ClassOfStockDomain_fb706513-f7cb-4701-8460-94a616db7418_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_33c41930-4bf3-4901-b2cb-5f172eecb721" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_fb706513-f7cb-4701-8460-94a616db7418" xlink:to="loc_us-gaap_ClassOfStockDomain_33c41930-4bf3-4901-b2cb-5f172eecb721" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_7f4dfe4e-a88d-4cef-8a78-5948a60e71ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_33c41930-4bf3-4901-b2cb-5f172eecb721" xlink:to="loc_us-gaap_CommonClassAMember_7f4dfe4e-a88d-4cef-8a78-5948a60e71ad" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/EquityIncentivePlansStockBasedCompensationDetails" xlink:type="simple" xlink:href="ardx-20220331.xsd#EquityIncentivePlansStockBasedCompensationDetails"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/EquityIncentivePlansStockBasedCompensationDetails" xlink:type="extended" id="i18c599fa3850467dae5a7cd82c99952d_EquityIncentivePlansStockBasedCompensationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_6ff40f60-13ea-4e3a-99b4-8ce25607a0ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_4ee4ec50-375e-42af-810c-d358587befcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_6ff40f60-13ea-4e3a-99b4-8ce25607a0ce" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_4ee4ec50-375e-42af-810c-d358587befcd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_6a9d74c6-7a2e-49d0-ad8f-0f562f53a001" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_6ff40f60-13ea-4e3a-99b4-8ce25607a0ce" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_6a9d74c6-7a2e-49d0-ad8f-0f562f53a001" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_59a44986-fb27-404c-af2d-bf9bd67ea113" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_6a9d74c6-7a2e-49d0-ad8f-0f562f53a001" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_59a44986-fb27-404c-af2d-bf9bd67ea113" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_59a44986-fb27-404c-af2d-bf9bd67ea113_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_59a44986-fb27-404c-af2d-bf9bd67ea113" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_59a44986-fb27-404c-af2d-bf9bd67ea113_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_b52e18ca-06d3-48c8-b62d-aa975c06c8bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_59a44986-fb27-404c-af2d-bf9bd67ea113" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_b52e18ca-06d3-48c8-b62d-aa975c06c8bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_dc21b2db-7c12-4503-afb8-9c6d40b4d89e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_b52e18ca-06d3-48c8-b62d-aa975c06c8bf" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_dc21b2db-7c12-4503-afb8-9c6d40b4d89e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_543858cf-9ea3-4086-89ab-8bb48f1e83d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_b52e18ca-06d3-48c8-b62d-aa975c06c8bf" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_543858cf-9ea3-4086-89ab-8bb48f1e83d7" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/EquityIncentivePlansUnrecognizedStockBasedCompensationDetails" xlink:type="simple" xlink:href="ardx-20220331.xsd#EquityIncentivePlansUnrecognizedStockBasedCompensationDetails"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/EquityIncentivePlansUnrecognizedStockBasedCompensationDetails" xlink:type="extended" id="if5d0a77df77d4602b9402b709f2f23df_EquityIncentivePlansUnrecognizedStockBasedCompensationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6fba5aaa-9a46-4985-b35b-b675386141d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_d7548361-a0c1-47d7-8b0f-d6dcc79882ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6fba5aaa-9a46-4985-b35b-b675386141d7" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_d7548361-a0c1-47d7-8b0f-d6dcc79882ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_9a890dc4-cdd1-44ed-a2e4-23e00668dac8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6fba5aaa-9a46-4985-b35b-b675386141d7" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_9a890dc4-cdd1-44ed-a2e4-23e00668dac8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f4e0565b-fd10-4c34-89e1-e508af12e62e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6fba5aaa-9a46-4985-b35b-b675386141d7" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f4e0565b-fd10-4c34-89e1-e508af12e62e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_0142d297-96e3-4e0d-9fa0-d5651664cd90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f4e0565b-fd10-4c34-89e1-e508af12e62e" xlink:to="loc_us-gaap_PlanNameAxis_0142d297-96e3-4e0d-9fa0-d5651664cd90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_0142d297-96e3-4e0d-9fa0-d5651664cd90_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_0142d297-96e3-4e0d-9fa0-d5651664cd90" xlink:to="loc_us-gaap_PlanNameDomain_0142d297-96e3-4e0d-9fa0-d5651664cd90_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_7fcc8d74-eed6-49e4-8aa8-52cf78013c84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_0142d297-96e3-4e0d-9fa0-d5651664cd90" xlink:to="loc_us-gaap_PlanNameDomain_7fcc8d74-eed6-49e4-8aa8-52cf78013c84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_EmployeeStockPurchasePlanMember_362dfe3a-b3db-4910-80d9-dfb89a3364fd" xlink:href="ardx-20220331.xsd#ardx_EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_7fcc8d74-eed6-49e4-8aa8-52cf78013c84" xlink:to="loc_ardx_EmployeeStockPurchasePlanMember_362dfe3a-b3db-4910-80d9-dfb89a3364fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2044e5a2-8eae-4f8c-9d8f-77798a1563b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f4e0565b-fd10-4c34-89e1-e508af12e62e" xlink:to="loc_us-gaap_AwardTypeAxis_2044e5a2-8eae-4f8c-9d8f-77798a1563b1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2044e5a2-8eae-4f8c-9d8f-77798a1563b1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2044e5a2-8eae-4f8c-9d8f-77798a1563b1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2044e5a2-8eae-4f8c-9d8f-77798a1563b1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_be5737aa-13f3-492d-a2de-893cb115c7ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2044e5a2-8eae-4f8c-9d8f-77798a1563b1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_be5737aa-13f3-492d-a2de-893cb115c7ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_0cbbd116-ba66-4b4e-8bcc-52d4c806d5fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_be5737aa-13f3-492d-a2de-893cb115c7ab" xlink:to="loc_us-gaap_EmployeeStockOptionMember_0cbbd116-ba66-4b4e-8bcc-52d4c806d5fc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_59ac1ab2-122e-47a8-9555-abd000a1cdbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_be5737aa-13f3-492d-a2de-893cb115c7ab" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_59ac1ab2-122e-47a8-9555-abd000a1cdbb" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="ardx-20220331.xsd#EquityIncentivePlansRestrictedStockUnitsDetails"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails" xlink:type="extended" id="i1d7bff4ece594647bbdbb0673f025d8f_EquityIncentivePlansRestrictedStockUnitsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c8c0adb-823c-44ba-bdbc-dcb66a8bc383" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4cc2f373-3870-413f-87bb-85c744686e55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c8c0adb-823c-44ba-bdbc-dcb66a8bc383" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4cc2f373-3870-413f-87bb-85c744686e55" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_bef9b3b7-49af-4a21-af86-475600383e3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4cc2f373-3870-413f-87bb-85c744686e55" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_bef9b3b7-49af-4a21-af86-475600383e3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_b7c4bc46-534a-48a7-aff3-440579eecc69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4cc2f373-3870-413f-87bb-85c744686e55" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_b7c4bc46-534a-48a7-aff3-440579eecc69" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_b77a4b93-c634-484d-82d3-95ce654164ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4cc2f373-3870-413f-87bb-85c744686e55" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_b77a4b93-c634-484d-82d3-95ce654164ac" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_dab72006-cfc9-4886-afc6-ca55abb81424" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4cc2f373-3870-413f-87bb-85c744686e55" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_dab72006-cfc9-4886-afc6-ca55abb81424" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_426eada4-23d9-4261-a47c-24d8ea431af5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_24e1b2fb-f227-43da-8900-4f45f47b2a0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c8c0adb-823c-44ba-bdbc-dcb66a8bc383" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_24e1b2fb-f227-43da-8900-4f45f47b2a0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5eb15c24-a0b9-4e00-b27b-de8eff92a722" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_24e1b2fb-f227-43da-8900-4f45f47b2a0d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5eb15c24-a0b9-4e00-b27b-de8eff92a722" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7128938e-dbbd-45ae-b830-a53e02f4b115" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_24e1b2fb-f227-43da-8900-4f45f47b2a0d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7128938e-dbbd-45ae-b830-a53e02f4b115" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_9e9ee6d1-4e7a-476c-9f98-22ecb561affc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_24e1b2fb-f227-43da-8900-4f45f47b2a0d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_9e9ee6d1-4e7a-476c-9f98-22ecb561affc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_521f62ff-596f-4af5-baf8-d9e0c979459a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_24e1b2fb-f227-43da-8900-4f45f47b2a0d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_521f62ff-596f-4af5-baf8-d9e0c979459a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_634d2de7-20c7-443a-a0a9-cfbc24fff4bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f42494fb-46d9-40dd-b7da-ac28413223da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c8c0adb-823c-44ba-bdbc-dcb66a8bc383" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f42494fb-46d9-40dd-b7da-ac28413223da" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_c8038126-d80d-4cc2-ab5d-df6dbb181a12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f42494fb-46d9-40dd-b7da-ac28413223da" xlink:to="loc_us-gaap_AwardTypeAxis_c8038126-d80d-4cc2-ab5d-df6dbb181a12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c8038126-d80d-4cc2-ab5d-df6dbb181a12_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_c8038126-d80d-4cc2-ab5d-df6dbb181a12" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c8038126-d80d-4cc2-ab5d-df6dbb181a12_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e9be979f-fe4a-4aa1-9580-43f0d43d05c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_c8038126-d80d-4cc2-ab5d-df6dbb181a12" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e9be979f-fe4a-4aa1-9580-43f0d43d05c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_0aaaa241-f2c9-49e1-87db-68fe5794d575" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e9be979f-fe4a-4aa1-9580-43f0d43d05c3" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_0aaaa241-f2c9-49e1-87db-68fe5794d575" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails" xlink:type="simple" xlink:href="ardx-20220331.xsd#EquityIncentivePlansNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails" xlink:type="extended" id="ib771178aaf304f5dbcf04ce78fc1987a_EquityIncentivePlansNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b92ea75-992a-425f-9a49-a63878f70740" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_9acc6a5c-40a4-48c7-b385-3d63fd1eddff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b92ea75-992a-425f-9a49-a63878f70740" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_9acc6a5c-40a4-48c7-b385-3d63fd1eddff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare_c0e954e7-d6f7-4ffc-b5ec-7d93787b9a05" xlink:href="ardx-20220331.xsd#ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b92ea75-992a-425f-9a49-a63878f70740" xlink:to="loc_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare_c0e954e7-d6f7-4ffc-b5ec-7d93787b9a05" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_8a32f4e9-a49f-47e7-aa43-6276ec716df7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b92ea75-992a-425f-9a49-a63878f70740" xlink:to="loc_us-gaap_ProceedsFromStockPlans_8a32f4e9-a49f-47e7-aa43-6276ec716df7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_315d76dd-80d2-4676-a6f1-a2600ab50cb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b92ea75-992a-425f-9a49-a63878f70740" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_315d76dd-80d2-4676-a6f1-a2600ab50cb3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6e189f04-73c7-4a9b-8673-d482e5f8f8c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b92ea75-992a-425f-9a49-a63878f70740" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6e189f04-73c7-4a9b-8673-d482e5f8f8c5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_1fd6e8be-5b71-4d7e-a260-20db11301241" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6e189f04-73c7-4a9b-8673-d482e5f8f8c5" xlink:to="loc_srt_TitleOfIndividualAxis_1fd6e8be-5b71-4d7e-a260-20db11301241" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1fd6e8be-5b71-4d7e-a260-20db11301241_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_1fd6e8be-5b71-4d7e-a260-20db11301241" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1fd6e8be-5b71-4d7e-a260-20db11301241_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_7280ac43-9ab4-4726-b012-c0203b0d8abe" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_1fd6e8be-5b71-4d7e-a260-20db11301241" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_7280ac43-9ab4-4726-b012-c0203b0d8abe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_b2530e94-13a6-4422-b556-ba0a8739513a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_7280ac43-9ab4-4726-b012-c0203b0d8abe" xlink:to="loc_srt_DirectorMember_b2530e94-13a6-4422-b556-ba0a8739513a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_08f6249f-92d5-402b-8dbf-50059c7b2a92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6e189f04-73c7-4a9b-8673-d482e5f8f8c5" xlink:to="loc_us-gaap_PlanNameAxis_08f6249f-92d5-402b-8dbf-50059c7b2a92" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_08f6249f-92d5-402b-8dbf-50059c7b2a92_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_08f6249f-92d5-402b-8dbf-50059c7b2a92" xlink:to="loc_us-gaap_PlanNameDomain_08f6249f-92d5-402b-8dbf-50059c7b2a92_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_fa7677a8-0939-4170-9d5c-2af53321aa16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_08f6249f-92d5-402b-8dbf-50059c7b2a92" xlink:to="loc_us-gaap_PlanNameDomain_fa7677a8-0939-4170-9d5c-2af53321aa16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_EmployeeStockPurchasePlanMember_839b2916-b78b-4d84-96bf-9606426819ad" xlink:href="ardx-20220331.xsd#ardx_EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_fa7677a8-0939-4170-9d5c-2af53321aa16" xlink:to="loc_ardx_EmployeeStockPurchasePlanMember_839b2916-b78b-4d84-96bf-9606426819ad" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="ardx-20220331.xsd#SubsequentEventsDetails"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/SubsequentEventsDetails" xlink:type="extended" id="ic3ff95279e5d48d884c5319d3136492d_SubsequentEventsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_e19d25f7-dd6b-4184-bc5d-614c075ca51d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate_48bf4a6a-89a6-4e99-949a-180db598ddd3" xlink:href="ardx-20220331.xsd#ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_e19d25f7-dd6b-4184-bc5d-614c075ca51d" xlink:to="loc_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate_48bf4a6a-89a6-4e99-949a-180db598ddd3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches_e06e0ca2-5f39-455f-86a0-04afd29db888" xlink:href="ardx-20220331.xsd#ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_e19d25f7-dd6b-4184-bc5d-614c075ca51d" xlink:to="loc_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches_e06e0ca2-5f39-455f-86a0-04afd29db888" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_5e07948e-f0f0-46ea-9830-ec6fb9d7d9c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_e19d25f7-dd6b-4184-bc5d-614c075ca51d" xlink:to="loc_us-gaap_SubsequentEventTable_5e07948e-f0f0-46ea-9830-ec6fb9d7d9c1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_ddcc4f09-ea2d-4d20-8c8a-255473b02c19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_5e07948e-f0f0-46ea-9830-ec6fb9d7d9c1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_ddcc4f09-ea2d-4d20-8c8a-255473b02c19" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_ddcc4f09-ea2d-4d20-8c8a-255473b02c19_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_ddcc4f09-ea2d-4d20-8c8a-255473b02c19" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_ddcc4f09-ea2d-4d20-8c8a-255473b02c19_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_b22be8f6-7458-4a15-a45b-a2823ff0b5d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_ddcc4f09-ea2d-4d20-8c8a-255473b02c19" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_b22be8f6-7458-4a15-a45b-a2823ff0b5d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_41001a55-3340-4c3d-bb98-8f571da71cc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_b22be8f6-7458-4a15-a45b-a2823ff0b5d3" xlink:to="loc_us-gaap_SubsequentEventMember_41001a55-3340-4c3d-bb98-8f571da71cc3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_0e86676f-0d32-42c7-b239-d0946a6feda8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_5e07948e-f0f0-46ea-9830-ec6fb9d7d9c1" xlink:to="loc_srt_CounterpartyNameAxis_0e86676f-0d32-42c7-b239-d0946a6feda8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0e86676f-0d32-42c7-b239-d0946a6feda8_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_0e86676f-0d32-42c7-b239-d0946a6feda8" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0e86676f-0d32-42c7-b239-d0946a6feda8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9f83d5b8-cd92-4aad-8669-3fcbd777f68e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_0e86676f-0d32-42c7-b239-d0946a6feda8" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9f83d5b8-cd92-4aad-8669-3fcbd777f68e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_KyowaKirinCo.LtdMember_c5b280f6-5477-41d5-bbe3-ec35a286d232" xlink:href="ardx-20220331.xsd#ardx_KyowaKirinCo.LtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9f83d5b8-cd92-4aad-8669-3fcbd777f68e" xlink:to="loc_ardx_KyowaKirinCo.LtdMember_c5b280f6-5477-41d5-bbe3-ec35a286d232" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_ef4eb479-d243-4326-9923-70950157cbea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_5e07948e-f0f0-46ea-9830-ec6fb9d7d9c1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_ef4eb479-d243-4326-9923-70950157cbea" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ef4eb479-d243-4326-9923-70950157cbea_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_ef4eb479-d243-4326-9923-70950157cbea" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ef4eb479-d243-4326-9923-70950157cbea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_299c8673-fe7b-41a6-8bc9-f5e3a7602132" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_ef4eb479-d243-4326-9923-70950157cbea" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_299c8673-fe7b-41a6-8bc9-f5e3a7602132" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember_6a638e92-016f-46e8-beb6-3e0e530c8de7" xlink:href="ardx-20220331.xsd#ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_299c8673-fe7b-41a6-8bc9-f5e3a7602132" xlink:to="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember_6a638e92-016f-46e8-beb6-3e0e530c8de7" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>ardx-20220331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:9e7cc335-f1e2-4409-ab16-898e4e60d77f,g:bd3d9229-0258-42cf-b897-58fd721121d9-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_32b6aa22-5797-472c-81a0-411c414801c8_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplementary disclosure of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_3acd4d2f-6b52-4b58-82ff-1c83865d6bcf_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_787fd549-95a4-4b11-9645-f9f0a4562170_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcess" xlink:to="lab_us-gaap_InventoryWorkInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_3f8d948a-8e19-4cb2-b272-fd4363dc4d12_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e0df0927-1285-4096-ba9c-e762fdb2727c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_281a6461-4e27-45eb-8bc4-2ee5cba6b0ce_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_6bb26f71-eab8-4fdb-98a0-c0edcd101383_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_b30b32eb-6b11-40fa-92aa-ea000fc80ab2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_e13eaf8b-116d-4885-b42e-58c2f1cc6028_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_111677d8-dd8c-4b2a-b2af-dd93853f130a_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_2152ed7b-43ee-4d75-bb0e-96b78da32ab6_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_DebtInstrumentInterestRateOnDefaultPercentage_a7a901ac-6b37-4f42-a145-182e0d82d320_terseLabel_en-US" xlink:label="lab_ardx_DebtInstrumentInterestRateOnDefaultPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional default interest rate</link:label>
    <link:label id="lab_ardx_DebtInstrumentInterestRateOnDefaultPercentage_label_en-US" xlink:label="lab_ardx_DebtInstrumentInterestRateOnDefaultPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate On Default, Percentage</link:label>
    <link:label id="lab_ardx_DebtInstrumentInterestRateOnDefaultPercentage_documentation_en-US" xlink:label="lab_ardx_DebtInstrumentInterestRateOnDefaultPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of additional default interest rate on the event of default.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DebtInstrumentInterestRateOnDefaultPercentage" xlink:href="ardx-20220331.xsd#ardx_DebtInstrumentInterestRateOnDefaultPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_DebtInstrumentInterestRateOnDefaultPercentage" xlink:to="lab_ardx_DebtInstrumentInterestRateOnDefaultPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_3039eafe-db7d-42d9-aa8c-31e881a2edf7_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_69d0fee3-bce3-4233-8163-1f924d6ff632_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_6116ac85-f144-4084-9e7d-4d2a027a7759_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_label_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_2b215160-a3d9-432d-92a8-ff95121961a2_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ScheduleOfAdditionalDetailsOfLeasesTableTextBlock_3ff9387e-ca28-4cf1-a502-887d0766aa64_terseLabel_en-US" xlink:label="lab_ardx_ScheduleOfAdditionalDetailsOfLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Additional Details of Leases</link:label>
    <link:label id="lab_ardx_ScheduleOfAdditionalDetailsOfLeasesTableTextBlock_label_en-US" xlink:label="lab_ardx_ScheduleOfAdditionalDetailsOfLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Additional Details of Leases [Table Text Block]</link:label>
    <link:label id="lab_ardx_ScheduleOfAdditionalDetailsOfLeasesTableTextBlock_documentation_en-US" xlink:label="lab_ardx_ScheduleOfAdditionalDetailsOfLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The tabular disclosure of additional details of the leases.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ScheduleOfAdditionalDetailsOfLeasesTableTextBlock" xlink:href="ardx-20220331.xsd#ardx_ScheduleOfAdditionalDetailsOfLeasesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ScheduleOfAdditionalDetailsOfLeasesTableTextBlock" xlink:to="lab_ardx_ScheduleOfAdditionalDetailsOfLeasesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_dca680e4-6965-4bbc-957c-aef71413e38a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Debt Payment Obligations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_a7c15f5d-dac1-49c4-a4ff-a580368098f7_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_25ad5843-00e6-4be4-91ff-24e773167c23_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_6be49dee-b8d0-4cf4-a042-f727ff8e31f7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_cc3356b7-4180-4cd8-9f79-b8479b96f806_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Changes in Deferred Revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_1489f161-3c70-41be-b726-d0070b8718e1_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_b17283f0-9300-43f2-9900-1ee42e25c97e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options forfeited (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_fbfcf16a-0315-4be4-b448-3e0b74c9a776_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining life (years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_83497728-7061-41c6-8e82-7f949f395e81_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a45366cc-78bc-4c43-864a-cd9b11596f46_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ce9be574-4ba8-4bd4-98c1-7fcc3ceee3b5_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net decrease in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_4d9db613-7ba1-4663-a7ff-32e354cd134a_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_77749bc1-611f-447f-80d7-e6f7c8802fb9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Fair Value of Derivative Liability</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_5a0ad7e3-3798-482b-8ae3-1fae35f2892b_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_10565bdb-a4eb-46d2-b957-433bcec7ac32_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in estimated fair value</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_856f0314-b7e5-41fb-99a6-7640aef6f62b_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9131b923-0dca-4e62-9367-31948f8d41bb_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d8088f00-04de-407a-b5a4-af371b8f975a_verboseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-dilutive securities not included in computation of diluted net loss per share</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_c74c1c07-ee1b-401c-89df-c56002ef5d5e_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_9b333668-41ae-491b-80c5-5cc64863adca_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_2fad3135-610f-4bd7-8979-636001a0ff1b_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_02b70357-f4e1-4d87-91a8-e4ab00c2965b_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_2ff87e83-1989-465e-9257-d5f282459dea_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_04292a1e-6b0a-4c98-8c81-0bf698bc6d4e_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_68a70fb6-b8a2-4ed0-86be-4027505926c6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromLicenseFeesReceived_28c9aff6-7420-4145-a2fc-fd17ac7b0241_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLicenseFeesReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment received</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLicenseFeesReceived_label_en-US" xlink:label="lab_us-gaap_ProceedsFromLicenseFeesReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from License Fees Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLicenseFeesReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLicenseFeesReceived" xlink:to="lab_us-gaap_ProceedsFromLicenseFeesReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_4306690f-2665-489e-a22d-2201ad49b2f1_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_05ecab82-be11-4c3b-ad48-7187ede58aec_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_e3c0739f-dfd4-430c-b413-dc9102c05835_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_6c03bc6f-06e0-4573-9c5d-b7567189cea9_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ContractWithCustomerGrossToNetSalesAccruals_cdb12965-d194-4ad3-a0d8-8b1719ecb15b_terseLabel_en-US" xlink:label="lab_ardx_ContractWithCustomerGrossToNetSalesAccruals" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross-to-net sales accruals</link:label>
    <link:label id="lab_ardx_ContractWithCustomerGrossToNetSalesAccruals_4572c844-1031-4c2a-98cf-a8ad6e729de7_periodStartLabel_en-US" xlink:label="lab_ardx_ContractWithCustomerGrossToNetSalesAccruals" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_ardx_ContractWithCustomerGrossToNetSalesAccruals_c7767561-a97f-4ab0-a10b-d212c2b6a858_periodEndLabel_en-US" xlink:label="lab_ardx_ContractWithCustomerGrossToNetSalesAccruals" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_ardx_ContractWithCustomerGrossToNetSalesAccruals_label_en-US" xlink:label="lab_ardx_ContractWithCustomerGrossToNetSalesAccruals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Gross To Net Sales Accruals</link:label>
    <link:label id="lab_ardx_ContractWithCustomerGrossToNetSalesAccruals_documentation_en-US" xlink:label="lab_ardx_ContractWithCustomerGrossToNetSalesAccruals" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Gross To Net Sales Accruals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerGrossToNetSalesAccruals" xlink:href="ardx-20220331.xsd#ardx_ContractWithCustomerGrossToNetSalesAccruals"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ContractWithCustomerGrossToNetSalesAccruals" xlink:to="lab_ardx_ContractWithCustomerGrossToNetSalesAccruals" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_719f8a87-1272-495e-8406-bf982241d798_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate_97e9191e-37ae-427c-9fee-0734b2a7009d_terseLabel_en-US" xlink:label="lab_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fee receivable for reduction in royalty rate</link:label>
    <link:label id="lab_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate_label_en-US" xlink:label="lab_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Fee Receivable For Reduction In Royalty Rate</link:label>
    <link:label id="lab_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate_documentation_en-US" xlink:label="lab_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Fee Receivable For Reduction In Royalty Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate" xlink:href="ardx-20220331.xsd#ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate" xlink:to="lab_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_31fcaece-8a3a-4f95-8fd4-7ad1a4e6d6d1_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ContractWithCustomerOtherFeesCopayAndReturnsMember_3370cfe1-9ecb-4581-ba58-9be2a675be83_terseLabel_en-US" xlink:label="lab_ardx_ContractWithCustomerOtherFeesCopayAndReturnsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Fees, Copay and Returns</link:label>
    <link:label id="lab_ardx_ContractWithCustomerOtherFeesCopayAndReturnsMember_label_en-US" xlink:label="lab_ardx_ContractWithCustomerOtherFeesCopayAndReturnsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Other Fees, Copay And Returns [Member]</link:label>
    <link:label id="lab_ardx_ContractWithCustomerOtherFeesCopayAndReturnsMember_documentation_en-US" xlink:label="lab_ardx_ContractWithCustomerOtherFeesCopayAndReturnsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Other Fees, Copay And Returns</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerOtherFeesCopayAndReturnsMember" xlink:href="ardx-20220331.xsd#ardx_ContractWithCustomerOtherFeesCopayAndReturnsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ContractWithCustomerOtherFeesCopayAndReturnsMember" xlink:to="lab_ardx_ContractWithCustomerOtherFeesCopayAndReturnsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_KyowaKirinCo.LtdMember_f161f024-e0b4-4830-b4ac-9aab490e6662_terseLabel_en-US" xlink:label="lab_ardx_KyowaKirinCo.LtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">KKC</link:label>
    <link:label id="lab_ardx_KyowaKirinCo.LtdMember_label_en-US" xlink:label="lab_ardx_KyowaKirinCo.LtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kyowa Kirin Co. Ltd [Member]</link:label>
    <link:label id="lab_ardx_KyowaKirinCo.LtdMember_documentation_en-US" xlink:label="lab_ardx_KyowaKirinCo.LtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the information pertaining to Kyowa Kirin Co., Ltd.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_KyowaKirinCo.LtdMember" xlink:href="ardx-20220331.xsd#ardx_KyowaKirinCo.LtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_KyowaKirinCo.LtdMember" xlink:to="lab_ardx_KyowaKirinCo.LtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_441579cc-b498-4b7a-9516-1abf8123f994_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum_02135748-c6cb-4b0d-aebf-be6555a70f90_terseLabel_en-US" xlink:label="lab_ardx_LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan agreement covenant, net product revenue as percentage of outstanding loan balance, minimum</link:label>
    <link:label id="lab_ardx_LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum_label_en-US" xlink:label="lab_ardx_LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Agreement, Covenant, Net Product Revenue As Percentage Of Outstanding Loan Balance, Minimum</link:label>
    <link:label id="lab_ardx_LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum_documentation_en-US" xlink:label="lab_ardx_LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Agreement, Covenant, Net Product Revenue As Percentage Of Outstanding Loan Balance, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum" xlink:href="ardx-20220331.xsd#ardx_LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum" xlink:to="lab_ardx_LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_70f7b948-202b-47e3-99ca-112755e86997_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk (percent)</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_14ccbd1a-d201-4a6c-b1ed-d118f582543d_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.0001 par value; 5,000,000 shares authorized; no shares issued and outstanding as of March&#160;31, 2022 and December&#160;31, 2021, respectively.</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_bf8c5243-551b-44ab-bd0a-1555fe82c5dd_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock under equity incentive and stock purchase plans</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c48817b8-d422-4afd-9ea6-ebc40820b450_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding balance, beginning (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c77dbbe7-112b-43c6-9c67-60d71ea4c7cc_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding balance, ending (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_37cec559-0441-4ed3-a730-c4bbd48e86ce_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_RemainingFundingBasedOnConditionalMilestoneAchievement_e41f9a34-84dd-4f24-aaa7-1d84ae6f1d6a_terseLabel_en-US" xlink:label="lab_ardx_RemainingFundingBasedOnConditionalMilestoneAchievement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining funding based on milestone achievement</link:label>
    <link:label id="lab_ardx_RemainingFundingBasedOnConditionalMilestoneAchievement_label_en-US" xlink:label="lab_ardx_RemainingFundingBasedOnConditionalMilestoneAchievement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining Funding Based On Conditional Milestone Achievement</link:label>
    <link:label id="lab_ardx_RemainingFundingBasedOnConditionalMilestoneAchievement_documentation_en-US" xlink:label="lab_ardx_RemainingFundingBasedOnConditionalMilestoneAchievement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining Funding Based On Conditional Milestone Achievement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_RemainingFundingBasedOnConditionalMilestoneAchievement" xlink:href="ardx-20220331.xsd#ardx_RemainingFundingBasedOnConditionalMilestoneAchievement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_RemainingFundingBasedOnConditionalMilestoneAchievement" xlink:to="lab_ardx_RemainingFundingBasedOnConditionalMilestoneAchievement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_9fc9d964-5855-42de-9d29-079a312cc111_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_CollaborativeArrangementPotentialCommercializationMilestones_2ece36f7-4dd6-4904-974c-70a754f64a84_terseLabel_en-US" xlink:label="lab_ardx_CollaborativeArrangementPotentialCommercializationMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential commercialization milestones</link:label>
    <link:label id="lab_ardx_CollaborativeArrangementPotentialCommercializationMilestones_label_en-US" xlink:label="lab_ardx_CollaborativeArrangementPotentialCommercializationMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Potential Commercialization Milestones</link:label>
    <link:label id="lab_ardx_CollaborativeArrangementPotentialCommercializationMilestones_documentation_en-US" xlink:label="lab_ardx_CollaborativeArrangementPotentialCommercializationMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Potential Commercialization Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeArrangementPotentialCommercializationMilestones" xlink:href="ardx-20220331.xsd#ardx_CollaborativeArrangementPotentialCommercializationMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_CollaborativeArrangementPotentialCommercializationMilestones" xlink:to="lab_ardx_CollaborativeArrangementPotentialCommercializationMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2a31f0fa-4888-447f-b039-6cb582151025_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_4891f870-19ec-49b3-9615-e3b12bee176b_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_01e2aed5-d031-4afc-814b-d4e44ecf8f45_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_4b8dc032-319b-4148-bea7-1cbb1f48726d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_14b3393f-dd5e-4d5d-b386-5b6e7c8f1ff8_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets obtained in exchange for lease obligations</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_d67efe67-8fe2-42ff-920b-91b0d3632fa8_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7eca2a33-385e-42e6-ae10-01764942c155_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_DebtInstrumentClosingFeeAmount_b878b90c-a5a9-4a9e-8d1d-6f58b71e352c_terseLabel_en-US" xlink:label="lab_ardx_DebtInstrumentClosingFeeAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Closing fee</link:label>
    <link:label id="lab_ardx_DebtInstrumentClosingFeeAmount_label_en-US" xlink:label="lab_ardx_DebtInstrumentClosingFeeAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Closing Fee Amount</link:label>
    <link:label id="lab_ardx_DebtInstrumentClosingFeeAmount_documentation_en-US" xlink:label="lab_ardx_DebtInstrumentClosingFeeAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Closing Fee Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DebtInstrumentClosingFeeAmount" xlink:href="ardx-20220331.xsd#ardx_DebtInstrumentClosingFeeAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_DebtInstrumentClosingFeeAmount" xlink:to="lab_ardx_DebtInstrumentClosingFeeAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_a90e3448-ece1-4388-bb64-9ad268d5cbd9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_74421a68-ccd9-48e9-9ff7-2900025f2038_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses_cc123357-8a22-447e-b841-9f9b890aa090_negatedTerseLabel_en-US" xlink:label="lab_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash equivalents and investments, Gross Unrealized Losses</link:label>
    <link:label id="lab_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses_label_en-US" xlink:label="lab_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Cash Equivalents And Investments Gross Unrealized Losses</link:label>
    <link:label id="lab_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses_documentation_en-US" xlink:label="lab_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and investments gross unrealized losses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses" xlink:href="ardx-20220331.xsd#ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses" xlink:to="lab_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_3b5d5ff4-8536-4407-a59b-5ad44cb763e4_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_edbe4ed9-796f-41fe-8627-852d17c510ee_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based Compensation [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_9d326e8e-f3df-45f2-8c85-4a361a8268b0_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per common share - basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_de5fda38-f3b8-4ef7-b02b-e434c885f4c4_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_PercentageOfRoyaltyRevenue_1dbab83e-43de-4761-bc1f-a2e2a0e9086f_terseLabel_en-US" xlink:label="lab_ardx_PercentageOfRoyaltyRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of royalty revenue</link:label>
    <link:label id="lab_ardx_PercentageOfRoyaltyRevenue_label_en-US" xlink:label="lab_ardx_PercentageOfRoyaltyRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Royalty Revenue</link:label>
    <link:label id="lab_ardx_PercentageOfRoyaltyRevenue_documentation_en-US" xlink:label="lab_ardx_PercentageOfRoyaltyRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents percentage of royalty revenue.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_PercentageOfRoyaltyRevenue" xlink:href="ardx-20220331.xsd#ardx_PercentageOfRoyaltyRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_PercentageOfRoyaltyRevenue" xlink:to="lab_ardx_PercentageOfRoyaltyRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_58f3f29b-8d2c-4258-8e67-b374ac171e3e_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Revenue, Net</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ee10a480-eb35-456e-a0a2-0abf50254e04_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding balance, beginning (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7bfb5910-a5b4-47d6-bce1-2c9ca49a028e_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding balance, ending (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_bacd60e6-c95d-4d68-a303-4cc8046b3f64_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of exit fee derivative liability, beginning</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_23bed36c-ace2-4e1d-b6f2-5ab5c3b0d6cd_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of exit fee derivative liability, ending</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterials_d786a70b-27d8-4eea-98f2-e2a8ad0c1e5c_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterials_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterials" xlink:to="lab_us-gaap_InventoryRawMaterials" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ed5797ae-bb20-4cb6-b18d-f8f16a3d591a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number&#160;of RSUs</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_CardinalHealthMember_06f548d2-a5e2-46d3-9898-89f76e3a0d7a_terseLabel_en-US" xlink:label="lab_ardx_CardinalHealthMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardinal Health</link:label>
    <link:label id="lab_ardx_CardinalHealthMember_label_en-US" xlink:label="lab_ardx_CardinalHealthMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardinal Health [Member]</link:label>
    <link:label id="lab_ardx_CardinalHealthMember_documentation_en-US" xlink:label="lab_ardx_CardinalHealthMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardinal Health</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CardinalHealthMember" xlink:href="ardx-20220331.xsd#ardx_CardinalHealthMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_CardinalHealthMember" xlink:to="lab_ardx_CardinalHealthMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_AccountsReceivableCommercialCustomerMember_3621d20d-05b0-40ca-8daf-d46edd9d040b_terseLabel_en-US" xlink:label="lab_ardx_AccountsReceivableCommercialCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial customers</link:label>
    <link:label id="lab_ardx_AccountsReceivableCommercialCustomerMember_label_en-US" xlink:label="lab_ardx_AccountsReceivableCommercialCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Commercial Customer [Member]</link:label>
    <link:label id="lab_ardx_AccountsReceivableCommercialCustomerMember_documentation_en-US" xlink:label="lab_ardx_AccountsReceivableCommercialCustomerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Commercial Customer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AccountsReceivableCommercialCustomerMember" xlink:href="ardx-20220331.xsd#ardx_AccountsReceivableCommercialCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_AccountsReceivableCommercialCustomerMember" xlink:to="lab_ardx_AccountsReceivableCommercialCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_abd13c00-a172-4870-afe7-a8c37eeaa9f7_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_2b33a05f-9a8a-4ed8-85c7-cb44ef3cab1c_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for operating lease</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfMachineryAndEquipment_2e67e750-91cc-47b4-b246-101f20041abf_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfMachineryAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of equipment</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfMachineryAndEquipment_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfMachineryAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Machinery and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfMachineryAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfMachineryAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfMachineryAndEquipment" xlink:to="lab_us-gaap_ProceedsFromSaleOfMachineryAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_2ebc01f7-db4f-4157-8aaf-0ed52ac0b1ef_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal outstanding</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_9443d83c-e71a-45f3-b4f4-938f6a095053_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Gross</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_2649b135-b1b3-48fd-b78c-d566320d97c7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After first anniversary through second anniversary of closing date</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_GrossToNetSalesAccrualAndReserveClassificationAxis_91cf722e-a31d-4f42-94d2-3542f334f7c8_terseLabel_en-US" xlink:label="lab_ardx_GrossToNetSalesAccrualAndReserveClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross To Net Sales Accrual And Reserve Classification [Axis]</link:label>
    <link:label id="lab_ardx_GrossToNetSalesAccrualAndReserveClassificationAxis_label_en-US" xlink:label="lab_ardx_GrossToNetSalesAccrualAndReserveClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross To Net Sales Accrual And Reserve Classification [Axis]</link:label>
    <link:label id="lab_ardx_GrossToNetSalesAccrualAndReserveClassificationAxis_documentation_en-US" xlink:label="lab_ardx_GrossToNetSalesAccrualAndReserveClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross To Net Sales Accrual And Reserve Classification</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_GrossToNetSalesAccrualAndReserveClassificationAxis" xlink:href="ardx-20220331.xsd#ardx_GrossToNetSalesAccrualAndReserveClassificationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_GrossToNetSalesAccrualAndReserveClassificationAxis" xlink:to="lab_ardx_GrossToNetSalesAccrualAndReserveClassificationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ProductIBSRELAMember_25f5482c-6696-474a-a6f4-e22abdd7e863_terseLabel_en-US" xlink:label="lab_ardx_ProductIBSRELAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IBSRELA</link:label>
    <link:label id="lab_ardx_ProductIBSRELAMember_label_en-US" xlink:label="lab_ardx_ProductIBSRELAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product, IBSRELA [Member]</link:label>
    <link:label id="lab_ardx_ProductIBSRELAMember_documentation_en-US" xlink:label="lab_ardx_ProductIBSRELAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product, IBSRELA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ProductIBSRELAMember" xlink:href="ardx-20220331.xsd#ardx_ProductIBSRELAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ProductIBSRELAMember" xlink:to="lab_ardx_ProductIBSRELAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt_18c65ec5-91a6-4bfa-9f2e-919c0e859479_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from 2022 Loan, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Secured Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_fc5c8027-6bb2-4bda-8f1f-0ae85812024b_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_d14d6ab3-4984-4336-afb1-7bfbd123fcd3_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_1a2db403-8db1-43e7-bbfd-33eca9a07a37_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_4b04773c-9467-4a8b-91ab-0cb21070c539_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, fair value</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_0411b9ce-af38-43fe-aebf-9c187548fcac_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7cd52603-96f8-4f41-a92a-f1a9b7b1a5e5_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_bfe25eba-8d65-4d62-a17b-6e9fb2b46b5f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_e1d1a80e-6901-42a9-bc6a-fb24e3da27d6_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare_1a9e4a56-cc4d-4957-90e0-d83012a69374_terseLabel_en-US" xlink:label="lab_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price (in dollars per share)</link:label>
    <link:label id="lab_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare_label_en-US" xlink:label="lab_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement by Share Based Payment Award, Purchased Price of Share</link:label>
    <link:label id="lab_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare_documentation_en-US" xlink:label="lab_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the purchase price per share of shares issued to employees under the plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare" xlink:href="ardx-20220331.xsd#ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare" xlink:to="lab_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_d0f459d5-13ed-46af-ad16-8a0d9b92f24b_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undiscounted cash payment obligations</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_AmerisourceBergenDrugCorporationMember_551f1456-3ac1-42be-bbf2-099a57b6f58b_terseLabel_en-US" xlink:label="lab_ardx_AmerisourceBergenDrugCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AmerisourceBergen Drug Corporation</link:label>
    <link:label id="lab_ardx_AmerisourceBergenDrugCorporationMember_label_en-US" xlink:label="lab_ardx_AmerisourceBergenDrugCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AmerisourceBergen Drug Corporation [Member]</link:label>
    <link:label id="lab_ardx_AmerisourceBergenDrugCorporationMember_documentation_en-US" xlink:label="lab_ardx_AmerisourceBergenDrugCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AmerisourceBergen Drug Corporation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AmerisourceBergenDrugCorporationMember" xlink:href="ardx-20220331.xsd#ardx_AmerisourceBergenDrugCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_AmerisourceBergenDrugCorporationMember" xlink:to="lab_ardx_AmerisourceBergenDrugCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones_fdc204aa-2136-43b6-bf15-1b8b9818cf86_terseLabel_en-US" xlink:label="lab_ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential development and commercialization milestones</link:label>
    <link:label id="lab_ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones_label_en-US" xlink:label="lab_ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Potential Development And Commercialization Milestones</link:label>
    <link:label id="lab_ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones_documentation_en-US" xlink:label="lab_ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the amount of future development and commercialization milestone under collaborative arrangements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones" xlink:href="ardx-20220331.xsd#ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones" xlink:to="lab_ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_1368e936-52b0-4bd6-a9e1-7511471aca2a_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_469814f7-0adf-4003-a24d-5bfe0a891ef7_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_8a7d914b-6406-42fa-b29b-67066ebda74e_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_91468676-a864-49c9-a069-524acff660f2_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from maturities and redemptions of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1a454d31-6d79-4a50-9717-abaafbdd555a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_50289ba3-ac68-4f7d-a8dd-37bd949d3a02_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_1ff69d2d-acfc-4b74-9a57-46f222cc2b2e_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative liability for exit fees</link:label>
    <link:label id="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_84eeb9a9-770b-48c3-97aa-f403db596108_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exit Fee derivative liability</link:label>
    <link:label id="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Financial Instruments, Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:to="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_94db2edf-9261-43fd-8b70-a86fdcceb8a2_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_4d7588fc-e79e-47b0-9789-337145083f0d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Exit Fee addition at fair value</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLineItems_2c4368b2-3424-4960-aa9f-8fec6cf84d48_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLineItems" xlink:to="lab_us-gaap_DerivativeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_GrossToNetSalesAccrualAndReserveClassificationDomain_9180c261-df69-4f6c-a2ba-d9462b057822_terseLabel_en-US" xlink:label="lab_ardx_GrossToNetSalesAccrualAndReserveClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross To Net Sales Accrual And Reserve Classification [Domain]</link:label>
    <link:label id="lab_ardx_GrossToNetSalesAccrualAndReserveClassificationDomain_label_en-US" xlink:label="lab_ardx_GrossToNetSalesAccrualAndReserveClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross To Net Sales Accrual And Reserve Classification [Domain]</link:label>
    <link:label id="lab_ardx_GrossToNetSalesAccrualAndReserveClassificationDomain_documentation_en-US" xlink:label="lab_ardx_GrossToNetSalesAccrualAndReserveClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross To Net Sales Accrual And Reserve Classification [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_GrossToNetSalesAccrualAndReserveClassificationDomain" xlink:href="ardx-20220331.xsd#ardx_GrossToNetSalesAccrualAndReserveClassificationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_GrossToNetSalesAccrualAndReserveClassificationDomain" xlink:to="lab_ardx_GrossToNetSalesAccrualAndReserveClassificationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_bd3e6e5f-2536-4b29-9d8f-614149e5f4ea_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_e5623322-83e3-4c66-8888-00b03a66e733_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_e34849dd-e1b2-4fd2-99c7-9a8b0c1ee94e_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_f1b96da3-24ae-4037-b7dc-bb6b2f4f1f2d_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments:</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value to Amortized Cost, after Allowance for Credit Loss [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_8e2a2926-ed2f-4119-b38a-b2fd69da3f1f_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_7661fed4-9ac8-45de-9a3f-072c4c9cc3ff_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon exercise of options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_69f0847c-c224-4a18-8504-211c4ba3c969_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_TermLoan2022Member_24749f5a-603d-4920-97ac-4e8a5312e22a_terseLabel_en-US" xlink:label="lab_ardx_TermLoan2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Term Loan</link:label>
    <link:label id="lab_ardx_TermLoan2022Member_label_en-US" xlink:label="lab_ardx_TermLoan2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan 2022 [Member]</link:label>
    <link:label id="lab_ardx_TermLoan2022Member_documentation_en-US" xlink:label="lab_ardx_TermLoan2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan 2022</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_TermLoan2022Member" xlink:href="ardx-20220331.xsd#ardx_TermLoan2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_TermLoan2022Member" xlink:to="lab_ardx_TermLoan2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_252b3652-b9a9-4bef-b160-8b8f400018e0_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_c480cfa4-2830-417e-ac22-c1417db28bd5_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, fair value</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial and Nonfinancial Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_a522544b-b242-4c27-9b0a-c090508cf010_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_d4db984d-a4c7-458a-b6ee-5cc2caf922dc_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_08327798-0cd7-4206-afc5-68a66f1a6198_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_28af7ab3-4ebc-4bf1-89ff-77b41effa669_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments, Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_73c772b7-b162-4123-8e94-17026bf7a51d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_7b9bd928-8dab-406d-a5fe-ed8e381d70eb_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_50d006ed-7265-4bf9-9ab7-7d12a22c4145_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government-sponsored agency bonds</link:label>
    <link:label id="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Corporations and Agencies Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivableTypeDomain_84ebd3b1-fc7d-48d3-98f2-58f6312109a0_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Domain]</link:label>
    <link:label id="lab_us-gaap_ReceivableTypeDomain_label_en-US" xlink:label="lab_us-gaap_ReceivableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivableTypeDomain" xlink:to="lab_us-gaap_ReceivableTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_c86e3551-660f-485a-ae0a-46518c9bdef4_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock in at the market offering</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_fbe5f0a9-9f49-4a7c-bac9-634f939766da_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_272634a9-6753-4ff1-b381-84f84afdb460_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowing</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_855f1aa1-abf7-4241-9c74-58292008e3fc_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_6ca9b45e-a044-4df6-9eb9-0e24383b9291_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_b1773be4-1fee-4254-b350-c3a57fa4c073_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_ec2875e4-9cba-4614-8709-cd4089cefb3a_verboseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Plans</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_f752d23d-7be8-48e3-be00-9bfe5545e87f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_7dbee87f-e4ab-483e-a277-8c8371afc92e_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_35c0f4f4-2e34-4dff-9682-f7842e42b00c_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_9eabab5e-1cbd-49ef-b7a2-ff686c4b4ba3_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock in at the market offering (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_TermOfAgreement_d9056512-ac64-49cb-81ad-912b12c71808_terseLabel_en-US" xlink:label="lab_ardx_TermOfAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of agreement</link:label>
    <link:label id="lab_ardx_TermOfAgreement_label_en-US" xlink:label="lab_ardx_TermOfAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Of Agreement</link:label>
    <link:label id="lab_ardx_TermOfAgreement_documentation_en-US" xlink:label="lab_ardx_TermOfAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_TermOfAgreement" xlink:href="ardx-20220331.xsd#ardx_TermOfAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_TermOfAgreement" xlink:to="lab_ardx_TermOfAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_f1be8de4-2d3a-47dc-bf06-54007d1fb64e_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_27b59d5f-930d-4ea4-b0af-e3462639aa45_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_8c7d4920-868d-4b0c-b309-d2528de311e1_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.0001 par value; 300,000,000 shares authorized; 136,330,360 and 130,182,535 shares issued and outstanding as of March&#160;31, 2022 and December&#160;31, 2021, respectively.</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_e7f8b9bd-3948-4f4b-b593-91553b9b9cdc_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_9cb560ed-baef-4864-bbfc-ce4f3665c8df_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNetAbstract_a669e855-9dfd-4183-8155-16ca12896996_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNetAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNetAbstract" xlink:to="lab_us-gaap_InventoryNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_04d16af4-d22f-4429-8db1-fa3915aae218_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average Remaining Vesting Period (Years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_327aa83b-219f-412f-b165-6133c02d2244_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding balance, beginning (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a7b99e8c-d717-4068-9cc1-73cdca0ec06d_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding balance, ending (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_5c2f9ef3-4ab6-43e6-9a4d-284ab265c382_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_f4256d65-e1ab-42a7-9ba6-1f1c5a392821_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_040daa77-08eb-42d2-8e33-b4f06df8767b_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtByMaturityAbstract_7baefd01-ae46-4155-a148-e3cc314de473_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtByMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total repayment obligations</link:label>
    <link:label id="lab_us-gaap_LongTermDebtByMaturityAbstract_label_en-US" xlink:label="lab_us-gaap_LongTermDebtByMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtByMaturityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtByMaturityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract" xlink:to="lab_us-gaap_LongTermDebtByMaturityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_5cc488e3-13ac-407a-8a52-9d3c4e786a2a_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_5a551dd9-409f-4c2f-a356-879faf4676e2_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8ece72b4-32fc-4956-840e-a7b9b7649c29_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_434a2bdc-7108-4e97-969e-7e09e5341731_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_DebtInstrumentPrepaymentFeePercentage_977405f5-877d-49b1-bdb0-ab4fff502d1b_terseLabel_en-US" xlink:label="lab_ardx_DebtInstrumentPrepaymentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment premium (as a percent)</link:label>
    <link:label id="lab_ardx_DebtInstrumentPrepaymentFeePercentage_label_en-US" xlink:label="lab_ardx_DebtInstrumentPrepaymentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Fee, Percentage</link:label>
    <link:label id="lab_ardx_DebtInstrumentPrepaymentFeePercentage_documentation_en-US" xlink:label="lab_ardx_DebtInstrumentPrepaymentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The percentage of fee payable on prepayment of debt.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DebtInstrumentPrepaymentFeePercentage" xlink:href="ardx-20220331.xsd#ardx_DebtInstrumentPrepaymentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_DebtInstrumentPrepaymentFeePercentage" xlink:to="lab_ardx_DebtInstrumentPrepaymentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_8e946d2a-1d83-456e-808a-25ff3818026b_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from loan payable, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Debt, Net of Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:to="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_666f5140-decf-44d2-9896-512f8bb60329_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remainder of 2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum_ee8cdf9e-6935-4240-be72-ce511314a3e8_terseLabel_en-US" xlink:label="lab_ardx_AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term available-for-sale securities contractual maturities, maximum</link:label>
    <link:label id="lab_ardx_AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum_label_en-US" xlink:label="lab_ardx_AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-For-Sale Securities, Debt Securities, Current, Contractual Maturities, Maximum</link:label>
    <link:label id="lab_ardx_AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum_documentation_en-US" xlink:label="lab_ardx_AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-For-Sale Securities, Debt Securities, Current, Contractual Maturities, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum" xlink:href="ardx-20220331.xsd#ardx_AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum" xlink:to="lab_ardx_AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ThresholdPercentageOfSalesForTieredRoyalties_27bf8bea-571b-4fb9-b0da-1d405ed1306e_terseLabel_en-US" xlink:label="lab_ardx_ThresholdPercentageOfSalesForTieredRoyalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold percentage of net sales for tiered royalties</link:label>
    <link:label id="lab_ardx_ThresholdPercentageOfSalesForTieredRoyalties_label_en-US" xlink:label="lab_ardx_ThresholdPercentageOfSalesForTieredRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold Percentage of Sales For Tiered Royalties</link:label>
    <link:label id="lab_ardx_ThresholdPercentageOfSalesForTieredRoyalties_documentation_en-US" xlink:label="lab_ardx_ThresholdPercentageOfSalesForTieredRoyalties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the threshold percentage of net sales for tiered royalties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ThresholdPercentageOfSalesForTieredRoyalties" xlink:href="ardx-20220331.xsd#ardx_ThresholdPercentageOfSalesForTieredRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ThresholdPercentageOfSalesForTieredRoyalties" xlink:to="lab_ardx_ThresholdPercentageOfSalesForTieredRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_67131510-51dc-416a-b32b-7ef28158992d_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents:</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_OpenMarketSalesAgreement2020AtTheMarketOfferingMember_0876e394-5060-46f5-a506-6c13d6b0f4f4_terseLabel_en-US" xlink:label="lab_ardx_OpenMarketSalesAgreement2020AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Open Market Sales Agreement</link:label>
    <link:label id="lab_ardx_OpenMarketSalesAgreement2020AtTheMarketOfferingMember_label_en-US" xlink:label="lab_ardx_OpenMarketSalesAgreement2020AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Open Market Sales Agreement 2020, At The Market Offering [Member]</link:label>
    <link:label id="lab_ardx_OpenMarketSalesAgreement2020AtTheMarketOfferingMember_documentation_en-US" xlink:label="lab_ardx_OpenMarketSalesAgreement2020AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Open Market Sales Agreement 2020, At The Market Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_OpenMarketSalesAgreement2020AtTheMarketOfferingMember" xlink:href="ardx-20220331.xsd#ardx_OpenMarketSalesAgreement2020AtTheMarketOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_OpenMarketSalesAgreement2020AtTheMarketOfferingMember" xlink:to="lab_ardx_OpenMarketSalesAgreement2020AtTheMarketOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_0ce35b8a-63ea-46d3-9913-65441d12490f_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_1f6a62c4-f4b5-4067-b851-dedb082bfed4_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_9c962870-c9ed-4af6-bb70-c7a5870ff018_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_e3432ac8-0585-446e-9d35-4c62fa341d14_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_08f63dae-71a4-4a12-ba39-b31f7fd0932f_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Imputed interest expenses</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_LoanAgreementExitFeeTerm_0c71d7bb-dec6-405a-826b-e9c8322ed3e9_terseLabel_en-US" xlink:label="lab_ardx_LoanAgreementExitFeeTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exit fee, term (in years)</link:label>
    <link:label id="lab_ardx_LoanAgreementExitFeeTerm_label_en-US" xlink:label="lab_ardx_LoanAgreementExitFeeTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Agreement, Exit Fee, Term</link:label>
    <link:label id="lab_ardx_LoanAgreementExitFeeTerm_documentation_en-US" xlink:label="lab_ardx_LoanAgreementExitFeeTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Agreement, Exit Fee, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LoanAgreementExitFeeTerm" xlink:href="ardx-20220331.xsd#ardx_LoanAgreementExitFeeTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_LoanAgreementExitFeeTerm" xlink:to="lab_ardx_LoanAgreementExitFeeTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_183ca295-cb14-4ec4-946c-43bf8a71a443_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_label_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_f5c0c717-d227-4913-97c8-63d4b39c424f_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_40a4926a-4d9f-42de-8def-f55ade8bbcbb_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_CashAndCashEquivalentsAmortizedCost_a143627f-33bb-4855-bd1d-d343e92d2c13_totalLabel_en-US" xlink:label="lab_ardx_CashAndCashEquivalentsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, Amortized Cost</link:label>
    <link:label id="lab_ardx_CashAndCashEquivalentsAmortizedCost_label_en-US" xlink:label="lab_ardx_CashAndCashEquivalentsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Cash Equivalents, Amortized Cost</link:label>
    <link:label id="lab_ardx_CashAndCashEquivalentsAmortizedCost_documentation_en-US" xlink:label="lab_ardx_CashAndCashEquivalentsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Cash Equivalents, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CashAndCashEquivalentsAmortizedCost" xlink:href="ardx-20220331.xsd#ardx_CashAndCashEquivalentsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_CashAndCashEquivalentsAmortizedCost" xlink:to="lab_ardx_CashAndCashEquivalentsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_5adb86b1-ed9b-40a2-9818-89804d07a208_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_457c057e-9abc-4eaa-89b3-cd0a294b6fd8_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2a6ef986-af3f-44c6-a11a-4c7df9821b1c_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6a1ae747-625b-4504-a737-f1c8d288d69d_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember_f2d2f99b-3cef-453a-8e05-a68c8998f538_terseLabel_en-US" xlink:label="lab_ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fosun Pharma</link:label>
    <link:label id="lab_ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember_label_en-US" xlink:label="lab_ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shanghai Fosun Pharmaceutical Industrial Development [Member]</link:label>
    <link:label id="lab_ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember_documentation_en-US" xlink:label="lab_ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents Shanghai Fosun Pharmaceutical Industrial Development.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember" xlink:href="ardx-20220331.xsd#ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember" xlink:to="lab_ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnRestructuringOfDebt_189a9c92-cd83-46fb-ab83-3532a80c1dc1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnRestructuringOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt refinancing costs</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnRestructuringOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnRestructuringOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains (Losses) on Restructuring of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnRestructuringOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnRestructuringOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnRestructuringOfDebt" xlink:to="lab_us-gaap_GainsLossesOnRestructuringOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember_1e59289b-097a-4c92-ac6e-b94d1451e25e_terseLabel_en-US" xlink:label="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Knight Agreement</link:label>
    <link:label id="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember_label_en-US" xlink:label="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement Development Commercialization Distribution In Canada [Member]</link:label>
    <link:label id="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember_documentation_en-US" xlink:label="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement for the development, commercialization and distribution fo tenapanor in Canada. The Knight Agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember" xlink:href="ardx-20220331.xsd#ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember" xlink:to="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_62ff8ea0-fedc-49da-aa88-0399654c323b_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_3fd3d17e-df8a-4672-ab22-d2851089d5ca_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_57687211-2eef-4621-b1a9-6e98257fe2a9_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_033cc68e-9b17-48b4-b7ee-32655b38e571_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_a612924f-282e-4eba-bd65-879254d49d79_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_2a9049c1-4d32-4655-9788-9fed2393c7c1_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2ea9d078-cd1d-4d08-9981-833e5ffeb3d2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_234bbc23-09bb-4dd1-a0e1-03709139dd30_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_2181037a-3e73-4123-a3ad-cdf452d6a1e9_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_e2416551-3c40-4082-9f39-9f4fc98d721c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Current portion of operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_aa75bddb-8a1a-4656-86a9-638ffa398a1b_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments, Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_3e19e005-5a12-43f0-962a-05af58a688bb_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_2a1908b5-a9de-4e1c-aae3-eb8ba2a4ae27_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and Licensing Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_EmployeeStockPurchasePlanMember_85b8c39a-c3c6-489c-90f9-3d30fa15b872_terseLabel_en-US" xlink:label="lab_ardx_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP</link:label>
    <link:label id="lab_ardx_EmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_ardx_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_ardx_EmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_ardx_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_EmployeeStockPurchasePlanMember" xlink:href="ardx-20220331.xsd#ardx_EmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_EmployeeStockPurchasePlanMember" xlink:to="lab_ardx_EmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_b362026a-1401-4145-b8e6-ba07030c27cc_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_4c613759-7c08-4abd-9764-921e66c3a2bc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_2fd96464-b678-4993-8c53-dbdf42417c53_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_474a54d2-2e6e-477d-86e7-0cbde66af7ae_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_c39bb5d5-39ba-439f-9895-1166d7503358_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_9d1031b9-a3de-46d1-afec-3526a1632a19_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, Fair Value</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_fd4d57b5-b948-45d2-8605-8ee97802d650_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_SaleOfStockWeightedAveragePricePerShare_bbcbec77-97ad-4952-9983-c10c25375195_terseLabel_en-US" xlink:label="lab_ardx_SaleOfStockWeightedAveragePricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average sales price per share</link:label>
    <link:label id="lab_ardx_SaleOfStockWeightedAveragePricePerShare_label_en-US" xlink:label="lab_ardx_SaleOfStockWeightedAveragePricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Weighted-Average Price Per Share</link:label>
    <link:label id="lab_ardx_SaleOfStockWeightedAveragePricePerShare_documentation_en-US" xlink:label="lab_ardx_SaleOfStockWeightedAveragePricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Weighted-Average Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_SaleOfStockWeightedAveragePricePerShare" xlink:href="ardx-20220331.xsd#ardx_SaleOfStockWeightedAveragePricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_SaleOfStockWeightedAveragePricePerShare" xlink:to="lab_ardx_SaleOfStockWeightedAveragePricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_afba8223-bb2d-4bcf-80a8-d34f3d9d7eff_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAbstract_9c7883d6-de6c-4e1f-9232-a0dcce317415_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueProductLineMember_e0af6603-6362-4427-815f-e96d99b329df_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueProductLineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross product revenue</link:label>
    <link:label id="lab_us-gaap_SalesRevenueProductLineMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueProductLineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Product and Service Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueProductLineMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueProductLineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueProductLineMember" xlink:to="lab_us-gaap_SalesRevenueProductLineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_CostOfRevenueAggregateAmountRecognized_17b56cc0-aa70-4da2-abcb-0a581f93bb1b_terseLabel_en-US" xlink:label="lab_ardx_CostOfRevenueAggregateAmountRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate cost of revenue recognized</link:label>
    <link:label id="lab_ardx_CostOfRevenueAggregateAmountRecognized_label_en-US" xlink:label="lab_ardx_CostOfRevenueAggregateAmountRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Of Revenue, Aggregate Amount Recognized</link:label>
    <link:label id="lab_ardx_CostOfRevenueAggregateAmountRecognized_documentation_en-US" xlink:label="lab_ardx_CostOfRevenueAggregateAmountRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of revenue, aggregate amount recognized.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CostOfRevenueAggregateAmountRecognized" xlink:href="ardx-20220331.xsd#ardx_CostOfRevenueAggregateAmountRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_CostOfRevenueAggregateAmountRecognized" xlink:to="lab_ardx_CostOfRevenueAggregateAmountRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod_7b1da6da-afdb-48a5-9036-0d2c64819c2a_terseLabel_en-US" xlink:label="lab_ardx_ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Activity related to 2022 sales</link:label>
    <link:label id="lab_ardx_ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod_label_en-US" xlink:label="lab_ardx_ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Gross To Net Sales, Accrual Activity During Current Period</link:label>
    <link:label id="lab_ardx_ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod_documentation_en-US" xlink:label="lab_ardx_ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Gross To Net Sales, Accrual Activity During Current Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod" xlink:href="ardx-20220331.xsd#ardx_ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod" xlink:to="lab_ardx_ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_AstraZenecaTerminationAgreementMember_297bef09-519e-4016-9925-49850e17774d_terseLabel_en-US" xlink:label="lab_ardx_AstraZenecaTerminationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AZ Termination Agreement</link:label>
    <link:label id="lab_ardx_AstraZenecaTerminationAgreementMember_label_en-US" xlink:label="lab_ardx_AstraZenecaTerminationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AstraZeneca Termination Agreement [Member]</link:label>
    <link:label id="lab_ardx_AstraZenecaTerminationAgreementMember_documentation_en-US" xlink:label="lab_ardx_AstraZenecaTerminationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AstraZeneca Termination Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AstraZenecaTerminationAgreementMember" xlink:href="ardx-20220331.xsd#ardx_AstraZenecaTerminationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_AstraZenecaTerminationAgreementMember" xlink:to="lab_ardx_AstraZenecaTerminationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_cb6eaae3-9982-476d-a279-13e7c8521ad6_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8c4bdccd-94dc-48a3-8269-f278e5ea85fb_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b215f086-b8a8-4b6c-800d-a1df4e60bb2e_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_caa31bd9-a89b-448b-b511-8f685f0a3378_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_105bffae-9148-4259-8270-96554bb0d965_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_3e9c5a93-3e43-4f93-b001-3456a99a8ca8_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_9dc70cdb-bb3a-4f44-b6f9-946e03286414_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_e5f06ee1-9223-4f3e-bfad-2fbdfa2bd7d1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a85a6269-06a5-4363-92bc-6c684178df50_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_PercentageOfNonRoyaltyRevenue_94d7e9d1-d96d-490c-aef6-a1addc48ba33_terseLabel_en-US" xlink:label="lab_ardx_PercentageOfNonRoyaltyRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of non-royalty revenue</link:label>
    <link:label id="lab_ardx_PercentageOfNonRoyaltyRevenue_label_en-US" xlink:label="lab_ardx_PercentageOfNonRoyaltyRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Non-Royalty Revenue</link:label>
    <link:label id="lab_ardx_PercentageOfNonRoyaltyRevenue_documentation_en-US" xlink:label="lab_ardx_PercentageOfNonRoyaltyRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents percentage of non-royalty revenue.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_PercentageOfNonRoyaltyRevenue" xlink:href="ardx-20220331.xsd#ardx_PercentageOfNonRoyaltyRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_PercentageOfNonRoyaltyRevenue" xlink:to="lab_ardx_PercentageOfNonRoyaltyRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_d3bd78e9-0f9b-45a6-9cf6-88fb93fae434_verboseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Undiscounted Cash Payment Obligations for Operating Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_05b0988b-f8ce-4fbb-80e2-4d0085a91e72_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_2371cdcd-2a87-4bf1-b42f-7541a1d82b6b_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_478a98d7-f74d-45ee-b0f4-63f4952941b6_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_38c5181b-e9fe-44ef-9192-1a71e7a02e3f_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for services (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_d6be4215-288c-40c8-918a-5ecf06e2f753_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_d67b5ce2-04c0-4a79-83b6-dc99a94fb3e1_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_a2aa5c42-822c-4dc7-9472-32fc315d1a07_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_7927e8b6-d73f-4cad-ba33-82525554e4a6_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ProductSupplyRevenueMember_10130a61-8193-40fd-b768-b5d22ca3959d_terseLabel_en-US" xlink:label="lab_ardx_ProductSupplyRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product supply revenue</link:label>
    <link:label id="lab_ardx_ProductSupplyRevenueMember_label_en-US" xlink:label="lab_ardx_ProductSupplyRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Supply Revenue [Member]</link:label>
    <link:label id="lab_ardx_ProductSupplyRevenueMember_documentation_en-US" xlink:label="lab_ardx_ProductSupplyRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Supply Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ProductSupplyRevenueMember" xlink:href="ardx-20220331.xsd#ardx_ProductSupplyRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ProductSupplyRevenueMember" xlink:to="lab_ardx_ProductSupplyRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ExitFeePercentage_10fa7530-0f36-4f2b-9b31-38083d5c8607_terseLabel_en-US" xlink:label="lab_ardx_ExitFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exit fee (percent)</link:label>
    <link:label id="lab_ardx_ExitFeePercentage_label_en-US" xlink:label="lab_ardx_ExitFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exit Fee, Percentage</link:label>
    <link:label id="lab_ardx_ExitFeePercentage_documentation_en-US" xlink:label="lab_ardx_ExitFeePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exit Fee, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ExitFeePercentage" xlink:href="ardx-20220331.xsd#ardx_ExitFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ExitFeePercentage" xlink:to="lab_ardx_ExitFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_89a6a48f-9589-46d0-b3b0-2ac5305edfee_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_StockIssuanceCostCommissionPercent_21e258f4-0bab-45c4-8299-60a1f2eabe63_terseLabel_en-US" xlink:label="lab_ardx_StockIssuanceCostCommissionPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commission on sale of stock per agreement (percent)</link:label>
    <link:label id="lab_ardx_StockIssuanceCostCommissionPercent_label_en-US" xlink:label="lab_ardx_StockIssuanceCostCommissionPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issuance Cost, Commission, Percent</link:label>
    <link:label id="lab_ardx_StockIssuanceCostCommissionPercent_documentation_en-US" xlink:label="lab_ardx_StockIssuanceCostCommissionPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issuance Cost, Commission, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_StockIssuanceCostCommissionPercent" xlink:href="ardx-20220331.xsd#ardx_StockIssuanceCostCommissionPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_StockIssuanceCostCommissionPercent" xlink:to="lab_ardx_StockIssuanceCostCommissionPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_ee18ce2e-68cf-4aab-8e79-44ac2f78d1cb_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_3f26d257-4e39-455f-8a21-f35fc54ead82_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_09932bbe-f529-4373-b3cc-756082393dd6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_07df8838-03f2-4e86-9aa3-2c1e59f3d193_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_2fc241d0-fe2b-4a2c-91d7-9da763a27d14_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_f96e59a5-df8a-4ba6-9cc5-59c46ce0a8b3_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and benefits</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_CollaborativeDevelopmentMember_172d2ded-de4a-4a64-af16-052cd06f04ea_terseLabel_en-US" xlink:label="lab_ardx_CollaborativeDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative development revenue</link:label>
    <link:label id="lab_ardx_CollaborativeDevelopmentMember_label_en-US" xlink:label="lab_ardx_CollaborativeDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Development [Member]</link:label>
    <link:label id="lab_ardx_CollaborativeDevelopmentMember_documentation_en-US" xlink:label="lab_ardx_CollaborativeDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeDevelopmentMember" xlink:href="ardx-20220331.xsd#ardx_CollaborativeDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_CollaborativeDevelopmentMember" xlink:to="lab_ardx_CollaborativeDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_ebcea214-8305-4024-bc46-c5ebab718714_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_7682be62-7e00-4983-97e1-39c2cf349bb7_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_ffcad330-b46e-4bc2-af33-a73a91774761_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage_0f585491-f139-4c18-8268-dbbac2b09ea8_terseLabel_en-US" xlink:label="lab_ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Final fee due upon maturity, acceleration, prepayment, or termination (percent)</link:label>
    <link:label id="lab_ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage_label_en-US" xlink:label="lab_ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fee Due Upon Maturity, Acceleration, Prepayment, Termination, Percentage</link:label>
    <link:label id="lab_ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage_documentation_en-US" xlink:label="lab_ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fee Due Upon Maturity, Acceleration, Prepayment, Termination, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage" xlink:href="ardx-20220331.xsd#ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage" xlink:to="lab_ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_525233a1-5b1b-4706-853e-e427c20734af_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under employee stock purchase plan (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_c94a30dc-c8ce-40ac-9db7-61227f66acab_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued under ESPP</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_627ad169-6023-41b6-a157-e2077cd94cd6_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_AstrazenecaMember_34320af5-c6f2-46c4-9692-cc025a51a968_terseLabel_en-US" xlink:label="lab_ardx_AstrazenecaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AstraZeneca</link:label>
    <link:label id="lab_ardx_AstrazenecaMember_label_en-US" xlink:label="lab_ardx_AstrazenecaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Astrazeneca [Member]</link:label>
    <link:label id="lab_ardx_AstrazenecaMember_documentation_en-US" xlink:label="lab_ardx_AstrazenecaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to AstraZeneca.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AstrazenecaMember" xlink:href="ardx-20220331.xsd#ardx_AstrazenecaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_AstrazenecaMember" xlink:to="lab_ardx_AstrazenecaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_TermOfPaymentOfLicenseFeeFirstInstallment_77c84754-1047-4592-9b1c-902d35a150ef_terseLabel_en-US" xlink:label="lab_ardx_TermOfPaymentOfLicenseFeeFirstInstallment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of payment of license fee, first installment</link:label>
    <link:label id="lab_ardx_TermOfPaymentOfLicenseFeeFirstInstallment_label_en-US" xlink:label="lab_ardx_TermOfPaymentOfLicenseFeeFirstInstallment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Of Payment Of License Fee, First Installment</link:label>
    <link:label id="lab_ardx_TermOfPaymentOfLicenseFeeFirstInstallment_documentation_en-US" xlink:label="lab_ardx_TermOfPaymentOfLicenseFeeFirstInstallment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of payment of first installment fee.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_TermOfPaymentOfLicenseFeeFirstInstallment" xlink:href="ardx-20220331.xsd#ardx_TermOfPaymentOfLicenseFeeFirstInstallment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_TermOfPaymentOfLicenseFeeFirstInstallment" xlink:to="lab_ardx_TermOfPaymentOfLicenseFeeFirstInstallment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_73005b16-d627-46a1-917e-5e0f72852bb7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other-than-temporary impairment</link:label>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_label_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:to="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage_c78283db-1139-4749-937e-806aa32ac954_terseLabel_en-US" xlink:label="lab_ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value analysis, percentage change in probability of occurrence</link:label>
    <link:label id="lab_ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage_label_en-US" xlink:label="lab_ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Sensitivity Analysis, Change In Probability Of Occurrence, Percentage</link:label>
    <link:label id="lab_ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage_documentation_en-US" xlink:label="lab_ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Sensitivity Analysis, Change In Probability Of Occurrence, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage" xlink:href="ardx-20220331.xsd#ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage" xlink:to="lab_ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_0bb358db-7738-4f28-84a4-ef706c80c70d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches_8ea66a3a-9d51-4f4a-88ca-4edde557c35c_terseLabel_en-US" xlink:label="lab_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of payment tranches for fee receivable for reduction in royalty rate</link:label>
    <link:label id="lab_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches_label_en-US" xlink:label="lab_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Fee Receivable For Reduction In Royalty Rate, Number Of Payment Tranches</link:label>
    <link:label id="lab_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches_documentation_en-US" xlink:label="lab_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Fee Receivable For Reduction In Royalty Rate, Number Of Payment Tranches</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches" xlink:href="ardx-20220331.xsd#ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches" xlink:to="lab_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_f6b32dab-ef04-4f98-b3c1-316daed3fdcb_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_NumberOfSeparateCollaborativeAgreements_9534a04b-8c34-4006-a9c9-40945d13b40f_terseLabel_en-US" xlink:label="lab_ardx_NumberOfSeparateCollaborativeAgreements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of separate collaborative agreements</link:label>
    <link:label id="lab_ardx_NumberOfSeparateCollaborativeAgreements_label_en-US" xlink:label="lab_ardx_NumberOfSeparateCollaborativeAgreements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Separate Collaborative Agreements</link:label>
    <link:label id="lab_ardx_NumberOfSeparateCollaborativeAgreements_documentation_en-US" xlink:label="lab_ardx_NumberOfSeparateCollaborativeAgreements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of separate collaborative agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_NumberOfSeparateCollaborativeAgreements" xlink:href="ardx-20220331.xsd#ardx_NumberOfSeparateCollaborativeAgreements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_NumberOfSeparateCollaborativeAgreements" xlink:to="lab_ardx_NumberOfSeparateCollaborativeAgreements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_5732b18d-12a7-4ece-ba0b-fee6eeb6d516_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_151cd4b2-88c5-4359-a5d5-028e2f4e24a2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Changes in Fair Value of Derivative Liability</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_CashAndCashEquivalentsGrossUnrealizedGains_674557e0-c0f4-46dd-baba-1c0260b2abb9_terseLabel_en-US" xlink:label="lab_ardx_CashAndCashEquivalentsGrossUnrealizedGains" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, Gross Unrealized Gains</link:label>
    <link:label id="lab_ardx_CashAndCashEquivalentsGrossUnrealizedGains_label_en-US" xlink:label="lab_ardx_CashAndCashEquivalentsGrossUnrealizedGains" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Cash Equivalents, Gross Unrealized Gains</link:label>
    <link:label id="lab_ardx_CashAndCashEquivalentsGrossUnrealizedGains_documentation_en-US" xlink:label="lab_ardx_CashAndCashEquivalentsGrossUnrealizedGains" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Cash Equivalents, Gross Unrealized Gains</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CashAndCashEquivalentsGrossUnrealizedGains" xlink:href="ardx-20220331.xsd#ardx_CashAndCashEquivalentsGrossUnrealizedGains"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_CashAndCashEquivalentsGrossUnrealizedGains" xlink:to="lab_ardx_CashAndCashEquivalentsGrossUnrealizedGains" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment_30bf7807-d33f-43a1-b19a-78dc1c307b45_terseLabel_en-US" xlink:label="lab_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second installment of upfront license fees</link:label>
    <link:label id="lab_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment_label_en-US" xlink:label="lab_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And Licensing Agreements, Upfront License Fees, Second Installment</link:label>
    <link:label id="lab_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment_documentation_en-US" xlink:label="lab_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And Licensing Agreements, Upfront License Fees, Second Installment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment" xlink:href="ardx-20220331.xsd#ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment" xlink:to="lab_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_961af645-a2a6-4c06-b2bd-8dfb92971ce5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_52a6d75f-597f-4d98-a7c0-d3997cb449d3_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_TermLoan2018Member_d2b1c46b-b959-42be-9643-eb1c2588b6bd_terseLabel_en-US" xlink:label="lab_ardx_TermLoan2018Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Term Loan</link:label>
    <link:label id="lab_ardx_TermLoan2018Member_label_en-US" xlink:label="lab_ardx_TermLoan2018Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan 2018 [Member]</link:label>
    <link:label id="lab_ardx_TermLoan2018Member_documentation_en-US" xlink:label="lab_ardx_TermLoan2018Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan 2018</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_TermLoan2018Member" xlink:href="ardx-20220331.xsd#ardx_TermLoan2018Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_TermLoan2018Member" xlink:to="lab_ardx_TermLoan2018Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_a9bfd580-4e62-41a6-8cae-0e2d74af0f2c_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_209c2f86-c683-4a41-95f0-f66ad7409d6e_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_2f2a74ba-9ac1-4db9-abd9-d4d7b97ba9a0_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_b347a8bb-f155-4e33-86b2-f0df706d5827_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Securities Classified as Cash, Cash Equivalents and Investments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_965a7115-97de-4a28-b0f3-87ac57810225_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_09a0cb3e-5a82-4db9-852b-c2ec91a8d275_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_e2c117cf-cb3e-41b8-9acd-c28c071a05e8_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_e3c1a423-620b-4f46-826a-b733029ca935_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_94d56d11-d42e-43d3-aefc-3b1abbd03c27_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c20690cf-c255-4343-aa3f-c4d6bc06c9a6_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total undiscounted operating lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_aab3bf42-0e12-41dc-85c2-f81766ca89a3_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_a3265d5a-ee51-4040-9fdd-75d9605c2267_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_f6b14a24-d4af-46ee-96de-0beb0bb1dd22_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_26618e5c-b427-4ddc-a5c6-076a2be407a6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember_1bed217c-20cd-40cf-850d-863e3ad2c873_terseLabel_en-US" xlink:label="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fosun Agreement</link:label>
    <link:label id="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember_label_en-US" xlink:label="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement Development Commercialization Distribution In China [Member]</link:label>
    <link:label id="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember_documentation_en-US" xlink:label="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement for the development, commercialization and distribution of tenapanor in China. The Fosun Agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember" xlink:href="ardx-20220331.xsd#ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember" xlink:to="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_DerivativeIssued_9346afd8-c90c-4295-9e7f-c814411898de_terseLabel_en-US" xlink:label="lab_ardx_DerivativeIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of derivative in connection with issuance of loan payable</link:label>
    <link:label id="lab_ardx_DerivativeIssued_label_en-US" xlink:label="lab_ardx_DerivativeIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Issued</link:label>
    <link:label id="lab_ardx_DerivativeIssued_documentation_en-US" xlink:label="lab_ardx_DerivativeIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DerivativeIssued" xlink:href="ardx-20220331.xsd#ardx_DerivativeIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_DerivativeIssued" xlink:to="lab_ardx_DerivativeIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_fac8e85d-1583-4d33-bf9f-e0d9b028546b_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_87883fe9-7b59-4f48-adb2-f68da1d7a953_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward_d7c85a13-7027-4736-bfbc-07174029ff8e_terseLabel_en-US" xlink:label="lab_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue - non-current</link:label>
    <link:label id="lab_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward_label_en-US" xlink:label="lab_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Contract With Customer Liability, Noncurrent, Rollforward [Roll Forward]</link:label>
    <link:label id="lab_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward_documentation_en-US" xlink:label="lab_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Contract With Customer Liability, Noncurrent, Rollforward</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward" xlink:href="ardx-20220331.xsd#ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward" xlink:to="lab_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ScheduleOfGrossToNetSalesAccrualsTableTextBlock_43b0e228-92a7-4e0e-96b0-e5d70e35d9c1_terseLabel_en-US" xlink:label="lab_ardx_ScheduleOfGrossToNetSalesAccrualsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Chargebacks, Discounts and Reserve Balances</link:label>
    <link:label id="lab_ardx_ScheduleOfGrossToNetSalesAccrualsTableTextBlock_label_en-US" xlink:label="lab_ardx_ScheduleOfGrossToNetSalesAccrualsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Gross To Net Sales Accruals [Table Text Block]</link:label>
    <link:label id="lab_ardx_ScheduleOfGrossToNetSalesAccrualsTableTextBlock_documentation_en-US" xlink:label="lab_ardx_ScheduleOfGrossToNetSalesAccrualsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Gross To Net Sales Accruals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ScheduleOfGrossToNetSalesAccrualsTableTextBlock" xlink:href="ardx-20220331.xsd#ardx_ScheduleOfGrossToNetSalesAccrualsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ScheduleOfGrossToNetSalesAccrualsTableTextBlock" xlink:to="lab_ardx_ScheduleOfGrossToNetSalesAccrualsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_20a02b8c-9355-4249-9c5e-a09c21e21032_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_5fbfe5b1-4a40-4fbb-ad30-bdbae7786d16_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_TermLoan2022AMember_37ee1cc2-ea71-45e3-b1ee-04af0454f0ff_terseLabel_en-US" xlink:label="lab_ardx_TermLoan2022AMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A</link:label>
    <link:label id="lab_ardx_TermLoan2022AMember_label_en-US" xlink:label="lab_ardx_TermLoan2022AMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan 2022 A [Member]</link:label>
    <link:label id="lab_ardx_TermLoan2022AMember_documentation_en-US" xlink:label="lab_ardx_TermLoan2022AMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan 2022 A</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_TermLoan2022AMember" xlink:href="ardx-20220331.xsd#ardx_TermLoan2022AMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_TermLoan2022AMember" xlink:to="lab_ardx_TermLoan2022AMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum_b21ad7bd-c702-4f53-8721-63c9983a61a3_terseLabel_en-US" xlink:label="lab_ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exit fee, net product revenue threshold</link:label>
    <link:label id="lab_ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum_label_en-US" xlink:label="lab_ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Agreement, Exit Fee, Net Product Revenue Threshold Metric, Trailing Six Month Basis, Minimum</link:label>
    <link:label id="lab_ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum_documentation_en-US" xlink:label="lab_ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Agreement, Exit Fee, Net Product Revenue Threshold Metric, Trailing Six Month Basis, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum" xlink:href="ardx-20220331.xsd#ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum" xlink:to="lab_ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ContractWithCustomerLiabilityIncreaseDueToUnbilledPrepaymentsRecorded_7eca3910-9172-487e-9e06-299261ccd01c_terseLabel_en-US" xlink:label="lab_ardx_ContractWithCustomerLiabilityIncreaseDueToUnbilledPrepaymentsRecorded" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase due to unbilled prepayments recorded during the period</link:label>
    <link:label id="lab_ardx_ContractWithCustomerLiabilityIncreaseDueToUnbilledPrepaymentsRecorded_label_en-US" xlink:label="lab_ardx_ContractWithCustomerLiabilityIncreaseDueToUnbilledPrepaymentsRecorded" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Increase Due To Unbilled Prepayments Recorded</link:label>
    <link:label id="lab_ardx_ContractWithCustomerLiabilityIncreaseDueToUnbilledPrepaymentsRecorded_documentation_en-US" xlink:label="lab_ardx_ContractWithCustomerLiabilityIncreaseDueToUnbilledPrepaymentsRecorded" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Increase Due To Unbilled Prepayments Recorded</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerLiabilityIncreaseDueToUnbilledPrepaymentsRecorded" xlink:href="ardx-20220331.xsd#ardx_ContractWithCustomerLiabilityIncreaseDueToUnbilledPrepaymentsRecorded"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ContractWithCustomerLiabilityIncreaseDueToUnbilledPrepaymentsRecorded" xlink:to="lab_ardx_ContractWithCustomerLiabilityIncreaseDueToUnbilledPrepaymentsRecorded" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_292ff34f-3751-4712-ab2a-8510e5fbbc20_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_b994998c-c314-4d55-abb8-a4764262416e_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_f36c6072-4691-4675-a0ca-51888277c494_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember_cee4247c-993e-4fe0-a55d-c6a1d98298d1_terseLabel_en-US" xlink:label="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 KKC Agreement</link:label>
    <link:label id="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember_label_en-US" xlink:label="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement Development Commercialization Distribution In Japan [Member]</link:label>
    <link:label id="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember_documentation_en-US" xlink:label="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement for the development, commercialization and distribution of tenapanor in Japan. The 2017 KKC Agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember" xlink:href="ardx-20220331.xsd#ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember" xlink:to="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_7a14c593-10d6-48db-bb84-2d1c101a0ad8_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_53816403-6e81-405c-8b1a-39793f295bf5_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfDeferredCharges_9430480d-ba3b-4b35-8c5a-a56231acd32b_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfDeferredCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of deferred compensation for services</link:label>
    <link:label id="lab_us-gaap_AmortizationOfDeferredCharges_label_en-US" xlink:label="lab_us-gaap_AmortizationOfDeferredCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Deferred Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDeferredCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDeferredCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfDeferredCharges" xlink:to="lab_us-gaap_AmortizationOfDeferredCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_766618cb-8673-4020-8955-478d425dd73a_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_PaymentsOfUnchargedLicenseFeesAggregateAmountPaid_02678c13-5931-4e24-8b1d-3d1e4c89bfdf_terseLabel_en-US" xlink:label="lab_ardx_PaymentsOfUnchargedLicenseFeesAggregateAmountPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate amount paid</link:label>
    <link:label id="lab_ardx_PaymentsOfUnchargedLicenseFeesAggregateAmountPaid_label_en-US" xlink:label="lab_ardx_PaymentsOfUnchargedLicenseFeesAggregateAmountPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Of Uncharged License Fees, Aggregate Amount Paid</link:label>
    <link:label id="lab_ardx_PaymentsOfUnchargedLicenseFeesAggregateAmountPaid_documentation_en-US" xlink:label="lab_ardx_PaymentsOfUnchargedLicenseFeesAggregateAmountPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of uncharged license fees, aggregate amount paid.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_PaymentsOfUnchargedLicenseFeesAggregateAmountPaid" xlink:href="ardx-20220331.xsd#ardx_PaymentsOfUnchargedLicenseFeesAggregateAmountPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_PaymentsOfUnchargedLicenseFeesAggregateAmountPaid" xlink:to="lab_ardx_PaymentsOfUnchargedLicenseFeesAggregateAmountPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_c2b74c26-0fec-4d23-8a07-655e0730f72e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After second anniversary to maturity date</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_b51a1494-0165-46be-8cb9-a50634216f75_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_OpenMarketSalesAgreement2021AtTheMarketOfferingMember_1ae03c22-129d-4e58-b2e2-a108372b9e96_terseLabel_en-US" xlink:label="lab_ardx_OpenMarketSalesAgreement2021AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Open Market Sales Agreement</link:label>
    <link:label id="lab_ardx_OpenMarketSalesAgreement2021AtTheMarketOfferingMember_label_en-US" xlink:label="lab_ardx_OpenMarketSalesAgreement2021AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Open Market Sales Agreement 2021, At The Market Offering [Member]</link:label>
    <link:label id="lab_ardx_OpenMarketSalesAgreement2021AtTheMarketOfferingMember_documentation_en-US" xlink:label="lab_ardx_OpenMarketSalesAgreement2021AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Open Market Sales Agreement 2021, At The Market Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_OpenMarketSalesAgreement2021AtTheMarketOfferingMember" xlink:href="ardx-20220331.xsd#ardx_OpenMarketSalesAgreement2021AtTheMarketOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_OpenMarketSalesAgreement2021AtTheMarketOfferingMember" xlink:to="lab_ardx_OpenMarketSalesAgreement2021AtTheMarketOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_9d5b3f5f-fbe0-4f6d-8ed2-4797b48e5fe3_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest associated with debt discount accretion</link:label>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_label_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Discount (Premium)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_13be5d1c-2adf-408d-8da6-058745307936_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets_7e34d5a4-7f68-48e7-9672-317f48158887_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sale of equipment</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfAssets" xlink:to="lab_us-gaap_GainLossOnDispositionOfAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAndLiabilitiesLesseeAbstract_7849ddeb-e927-4b24-af0e-c27186fe0f62_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets and lease liabilities</link:label>
    <link:label id="lab_us-gaap_AssetsAndLiabilitiesLesseeAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets and Liabilities, Lessee [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAndLiabilitiesLesseeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:to="lab_us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c9d6890e-b993-4100-a70f-12ad0c581c7d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Exercise&#160;Price&#160;per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ContractWithCustomerLiabilityIncreaseForAmountsInvoiced_c04bdf1b-d973-4eeb-99e9-fe8d11fef8b1_terseLabel_en-US" xlink:label="lab_ardx_ContractWithCustomerLiabilityIncreaseForAmountsInvoiced" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increases to amounts invoiced, for which cash has not yet been received</link:label>
    <link:label id="lab_ardx_ContractWithCustomerLiabilityIncreaseForAmountsInvoiced_label_en-US" xlink:label="lab_ardx_ContractWithCustomerLiabilityIncreaseForAmountsInvoiced" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Increase For Amounts Invoiced</link:label>
    <link:label id="lab_ardx_ContractWithCustomerLiabilityIncreaseForAmountsInvoiced_documentation_en-US" xlink:label="lab_ardx_ContractWithCustomerLiabilityIncreaseForAmountsInvoiced" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Increase For Amounts Invoiced</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerLiabilityIncreaseForAmountsInvoiced" xlink:href="ardx-20220331.xsd#ardx_ContractWithCustomerLiabilityIncreaseForAmountsInvoiced"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ContractWithCustomerLiabilityIncreaseForAmountsInvoiced" xlink:to="lab_ardx_ContractWithCustomerLiabilityIncreaseForAmountsInvoiced" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0c3f4b67-4710-4167-a9d1-67a18c417787_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments, Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ResearchCollaborationAndOptionAgreementMember_faaf65c0-0296-42d7-b913-6f3b6a4d2b78_terseLabel_en-US" xlink:label="lab_ardx_ResearchCollaborationAndOptionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 KKC Agreement</link:label>
    <link:label id="lab_ardx_ResearchCollaborationAndOptionAgreementMember_label_en-US" xlink:label="lab_ardx_ResearchCollaborationAndOptionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Collaboration And Option Agreement [Member]</link:label>
    <link:label id="lab_ardx_ResearchCollaborationAndOptionAgreementMember_documentation_en-US" xlink:label="lab_ardx_ResearchCollaborationAndOptionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pertaining to the research collaboration and option agreement for research associated with identifying two pre-clinical compounds. The 2019 KKC AGreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ResearchCollaborationAndOptionAgreementMember" xlink:href="ardx-20220331.xsd#ardx_ResearchCollaborationAndOptionAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ResearchCollaborationAndOptionAgreementMember" xlink:to="lab_ardx_ResearchCollaborationAndOptionAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_d193513a-0093-4d02-b606-b1b214df5b7f_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_de7e55b0-646a-444b-bbba-eeb631e88cb1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_8fa39dbc-8bf1-4bc0-bd4e-82a4a2418075_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_CollaborativeArrangementPotentialDevelopmentMilestones_d5b857f4-8c21-4e1a-9342-7917377f6c5f_terseLabel_en-US" xlink:label="lab_ardx_CollaborativeArrangementPotentialDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential development milestones</link:label>
    <link:label id="lab_ardx_CollaborativeArrangementPotentialDevelopmentMilestones_label_en-US" xlink:label="lab_ardx_CollaborativeArrangementPotentialDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Potential Development Milestones</link:label>
    <link:label id="lab_ardx_CollaborativeArrangementPotentialDevelopmentMilestones_documentation_en-US" xlink:label="lab_ardx_CollaborativeArrangementPotentialDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Potential Development Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeArrangementPotentialDevelopmentMilestones" xlink:href="ardx-20220331.xsd#ardx_CollaborativeArrangementPotentialDevelopmentMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_CollaborativeArrangementPotentialDevelopmentMilestones" xlink:to="lab_ardx_CollaborativeArrangementPotentialDevelopmentMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_821b86f0-9e76-4425-861d-fd3e6b2a1280_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_1dbed36d-e2d2-40d9-b24c-0a10ebd0f7fd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_5e159e1b-0aca-4ecf-9033-46c39ff3cdb2_verboseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Investments</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_251434a0-6238-46bd-9419-66b9f36932a7_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_4758bf7f-ef92-4722-afc8-4eee718ceb7f_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, non-current</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_cb3d558f-f9c0-4d52-a871-8ff6cffa547b_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_80cf5b09-ac78-404d-b597-65349f9646dc_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ac71ee49-be0d-4625-a14e-1e009de320d1_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments, Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_f0172d8e-7551-40b1-b267-56b3d4ce7b16_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireShortTermInvestments_251b5589-fe3d-477c-90c8-828a29b43794_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_c3993497-3212-4f4f-bcc5-d95f6ab68a05_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_e9864f33-3898-4bf7-b1c5-39cedd774564_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Computation of Net Loss Per Common Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5ac60589-f110-41dd-b0e1-9e02d50ff5f5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_26960ab9-9a35-4bc8-91cb-f0041330b3c8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_d39825db-88d7-4529-bd0e-c662eff4df96_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Stock-Based Compensation Expense Recognized</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_74b6192c-42fd-4575-b66f-d238d8f03e15_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_67481504-61e3-4cbd-8911-0bdfc8a55083_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock in at the market offering, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_21cceb07-345c-4222-9331-b1f98c074033_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_DirectorMember_d63125c7-e8ad-4104-814c-6fab684dbb6b_terseLabel_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Board of directors</link:label>
    <link:label id="lab_srt_DirectorMember_label_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_DirectorMember" xlink:to="lab_srt_DirectorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_f1378dff-db19-44a3-8a88-ac831102b3d4_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_ae7b0caf-ab07-4f09-9237-e4dd2c4a3e77_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_1702c3b4-36c4-4215-99f3-4f77f1a87d16_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_058680bf-622e-47b8-851f-d03d93e77076_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAbstract" xlink:to="lab_us-gaap_NetIncomeLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfSecuredDebt_3774b23a-2003-4ec4-94aa-9179611d4b37_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfSecuredDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of 2018 Loan, net of settlement costs</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfSecuredDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfSecuredDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Secured Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSecuredDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfSecuredDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfSecuredDebt" xlink:to="lab_us-gaap_RepaymentsOfSecuredDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_cab43e36-e4e6-43de-909c-fa0f22064e01_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_8e80c62f-69d2-4adc-9295-44fc4dfb9f7f_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_9e3cade8-d0c7-4dc4-b6ed-866bbef3a61a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restricted Stock Units Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_1c084e05-5261-463c-87a1-640489feb76a_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_2b942e11-6de7-4882-ac53-0a62f177e182_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products and Services [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_5cc35da3-1899-4d4f-a94e-6276298901c2_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9323384b-eeef-47be-a752-acf15895c6fc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_bb33c8ad-15e5-4f83-a185-f25e526d9ffe_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Total Unrecognized Stock-Based Compensation Expense, Net of Estimated Forfeitures</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashMember_ddfc20b7-1082-4a84-a2ef-4b29662f109e_terseLabel_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_CashMember_label_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashMember" xlink:to="lab_us-gaap_CashMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_bf449405-560c-4d8a-8b51-f8d6e6e2cb03_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_b0ed2cba-2258-4920-b1f6-4f7902f8433b_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityNotionalAmount_1c92f5e4-962e-4f5c-ac90-0b3fb52e1a84_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreed amount for exit fee upon occurrence of certain conditions</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityNotionalAmount_8d5f91d2-b2a4-4a58-a3c5-4eecd98c8351_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreed amount for exit fee upon change of control or regulatory approval</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilityNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityNotionalAmount" xlink:to="lab_us-gaap_DerivativeLiabilityNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f2fba73e-8cdd-4cb6-9d73-9b628705f3cb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_d9a7dfee-cafc-4a38-9cea-2629bec3d0b2_verboseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Lease Costs</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_ffda5b4c-4527-4522-a0ca-c2d3c90a3e91_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_9bfc499f-b1bb-4acc-95c5-65a5d90ea03f_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_79ad17fe-49a5-4a3c-b36e-0b93b951e6d2_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper, Not Included with Cash and Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities_a1215eef-f0c6-470b-9c6d-27d7b2bdb402_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities and Other Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFeeAmount_00829a1a-3553-412b-9a1e-1dbb9740e694_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFeeAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Unaccreted value of final fee</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFeeAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFeeAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fee Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFeeAmount" xlink:to="lab_us-gaap_DebtInstrumentFeeAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_04d1fdb8-9fb8-4e09-9676-cbd7d9b2a232_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used in computing net loss per share - basic</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_232bdf99-f0ac-4b65-b475-1bd312f9d0d7_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding - basic</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_42aca389-6b70-4602-9e0a-5d0565192518_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per common share - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_b621597a-741e-4c6f-9fd3-de948d348f6b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash lease expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Amortization Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_KnightTherapeuticsIncMember_37ffeb36-4e57-45c8-93df-ef975c0cf472_terseLabel_en-US" xlink:label="lab_ardx_KnightTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Knight</link:label>
    <link:label id="lab_ardx_KnightTherapeuticsIncMember_label_en-US" xlink:label="lab_ardx_KnightTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Knight Therapeutics Inc [Member]</link:label>
    <link:label id="lab_ardx_KnightTherapeuticsIncMember_documentation_en-US" xlink:label="lab_ardx_KnightTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to Knight Therapeutics Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_KnightTherapeuticsIncMember" xlink:href="ardx-20220331.xsd#ardx_KnightTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_KnightTherapeuticsIncMember" xlink:to="lab_ardx_KnightTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_787a3aaa-d79c-492e-8e67-e36bbb3637cf_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product sales, net</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_75892bc0-63fa-485a-807e-bb03f8c954a2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_837384cc-1aea-4fb0-8530-f241596a1dc2_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostAbstract_ec129073-e10f-4b54-ab0f-7d26ca461018_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease costs</link:label>
    <link:label id="lab_us-gaap_LeaseCostAbstract_label_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostAbstract" xlink:to="lab_us-gaap_LeaseCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_3fb3ab4a-8ae1-4822-b24f-74c3d254cd17_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_CashAndCashEquivalentsGrossUnrealizedLosses_aa0d5187-dd2e-45b2-9339-c12bef1fa4db_negatedTerseLabel_en-US" xlink:label="lab_ardx_CashAndCashEquivalentsGrossUnrealizedLosses" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, Gross Unrealized Losses</link:label>
    <link:label id="lab_ardx_CashAndCashEquivalentsGrossUnrealizedLosses_label_en-US" xlink:label="lab_ardx_CashAndCashEquivalentsGrossUnrealizedLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Cash Equivalents, Gross Unrealized Losses</link:label>
    <link:label id="lab_ardx_CashAndCashEquivalentsGrossUnrealizedLosses_documentation_en-US" xlink:label="lab_ardx_CashAndCashEquivalentsGrossUnrealizedLosses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Cash Equivalents, Gross Unrealized Losses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CashAndCashEquivalentsGrossUnrealizedLosses" xlink:href="ardx-20220331.xsd#ardx_CashAndCashEquivalentsGrossUnrealizedLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_CashAndCashEquivalentsGrossUnrealizedLosses" xlink:to="lab_ardx_CashAndCashEquivalentsGrossUnrealizedLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfRevenue_0ddb1968-fdc9-419b-8de4-e8cda0ff189e_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of revenue</link:label>
    <link:label id="lab_us-gaap_CostOfRevenue_label_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfRevenue" xlink:to="lab_us-gaap_CostOfRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_8b1e1374-1d4f-46be-956f-159897a1a6b3_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LoansPayableMember_3355c386-12f2-4833-a584-558a52445acb_terseLabel_en-US" xlink:label="lab_us-gaap_LoansPayableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan</link:label>
    <link:label id="lab_us-gaap_LoansPayableMember_label_en-US" xlink:label="lab_us-gaap_LoansPayableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans Payable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LoansPayableMember" xlink:to="lab_us-gaap_LoansPayableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_CollaborationAndLicensingAgreementsAbstract_2b9a7e0b-6198-4913-bd04-86533d64a195_terseLabel_en-US" xlink:label="lab_ardx_CollaborationAndLicensingAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and Licensing Agreements</link:label>
    <link:label id="lab_ardx_CollaborationAndLicensingAgreementsAbstract_label_en-US" xlink:label="lab_ardx_CollaborationAndLicensingAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and Licensing Agreements</link:label>
    <link:label id="lab_ardx_CollaborationAndLicensingAgreementsAbstract_documentation_en-US" xlink:label="lab_ardx_CollaborationAndLicensingAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">n/a</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborationAndLicensingAgreementsAbstract" xlink:href="ardx-20220331.xsd#ardx_CollaborationAndLicensingAgreementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_CollaborationAndLicensingAgreementsAbstract" xlink:to="lab_ardx_CollaborationAndLicensingAgreementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_f0804940-ffdb-4e6c-b3e9-fae72db8719a_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate bonds</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_db05e02c-4798-4719-ba85-66221a0c581a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_ad1e0e5f-1aea-470e-9d94-4eb01cc77249_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_5655bf73-cbf9-4ee5-8293-0990de7752aa_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_8614546a-e025-48b4-9a31-094f232302ae_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Fair Value of Financial Assets and Liabilities Measured or Disclosed on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_54cebdee-a19a-45ac-a54c-8ebf7e6f3c7f_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_8324b34f-4a60-411a-9d95-c105e5b590dd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward_63b3046c-d84e-405e-8f76-dae1c8cd88e7_terseLabel_en-US" xlink:label="lab_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue - current</link:label>
    <link:label id="lab_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward_label_en-US" xlink:label="lab_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Contract With Customer Liability, Current, Rollforward [Roll Forward]</link:label>
    <link:label id="lab_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward_documentation_en-US" xlink:label="lab_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Contract With Customer Liability, Current, Rollforward</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward" xlink:href="ardx-20220331.xsd#ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward" xlink:to="lab_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_11a4b144-1a30-44ed-9898-2004ce0116e9_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cab8a2bf-915d-4ec1-9db5-1900d1512850_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTable_9370dc92-8182-456b-9d12-99f7664d3acf_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeTable_label_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTable" xlink:to="lab_us-gaap_DerivativeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_75df9813-2a0e-4f30-a65f-3d0c9613eac0_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_d8529039-5d07-4086-a7b7-71840a7f0ada_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_d5ae203b-7ac9-4034-a5f8-f4aa11acca21_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon vesting of restricted stock units (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_AccountsReceivableCollaboratorMember_d3bade3d-8f2c-438f-a7b0-d280fd1a31e0_terseLabel_en-US" xlink:label="lab_ardx_AccountsReceivableCollaboratorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborators</link:label>
    <link:label id="lab_ardx_AccountsReceivableCollaboratorMember_label_en-US" xlink:label="lab_ardx_AccountsReceivableCollaboratorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Collaborator [Member]</link:label>
    <link:label id="lab_ardx_AccountsReceivableCollaboratorMember_documentation_en-US" xlink:label="lab_ardx_AccountsReceivableCollaboratorMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Collaborator</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AccountsReceivableCollaboratorMember" xlink:href="ardx-20220331.xsd#ardx_AccountsReceivableCollaboratorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_AccountsReceivableCollaboratorMember" xlink:to="lab_ardx_AccountsReceivableCollaboratorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_9cf3a8f1-b688-4a24-b424-01d25c78e0dc_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation_197dfb10-1ec3-4c65-bd9a-94dcc3a34156_terseLabel_en-US" xlink:label="lab_ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value analysis, effect on fair value based on 10% change in probability of occurrence</link:label>
    <link:label id="lab_ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation_label_en-US" xlink:label="lab_ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Sensitivity Analysis, Ten Percent Change In Probability Of Occurrence, Effect On Valuation</link:label>
    <link:label id="lab_ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation_documentation_en-US" xlink:label="lab_ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Sensitivity Analysis, Ten Percent Change In Probability Of Occurrence, Effect On Valuation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation" xlink:href="ardx-20220331.xsd#ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation" xlink:to="lab_ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_02487b13-c238-4da8-82be-5984e9b8dd53_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ContractWithCustomerDiscountsAndChargebacksMember_9e5f88f9-573f-489c-adac-03ebc2b0b412_terseLabel_en-US" xlink:label="lab_ardx_ContractWithCustomerDiscountsAndChargebacksMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discounts and Chargebacks</link:label>
    <link:label id="lab_ardx_ContractWithCustomerDiscountsAndChargebacksMember_label_en-US" xlink:label="lab_ardx_ContractWithCustomerDiscountsAndChargebacksMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Discounts And Chargebacks [Member]</link:label>
    <link:label id="lab_ardx_ContractWithCustomerDiscountsAndChargebacksMember_documentation_en-US" xlink:label="lab_ardx_ContractWithCustomerDiscountsAndChargebacksMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Discounts And Chargebacks</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerDiscountsAndChargebacksMember" xlink:href="ardx-20220331.xsd#ardx_ContractWithCustomerDiscountsAndChargebacksMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ContractWithCustomerDiscountsAndChargebacksMember" xlink:to="lab_ardx_ContractWithCustomerDiscountsAndChargebacksMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_fdf9723a-5241-4304-a56c-1565bb3011c4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number&#160;of&#160;Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_8ab1c14c-7eff-42e0-bf33-f26baf4fc804_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_c202332f-4e59-4b01-9523-d8b67e75d42d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_42ac7a04-215b-4608-ad9c-3ecb3d09c274_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplementary disclosure of non-cash activities:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees_8296002e-1c26-49c0-901d-402fcffab222_terseLabel_en-US" xlink:label="lab_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront license fees</link:label>
    <link:label id="lab_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees_label_en-US" xlink:label="lab_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And Licensing Agreements, Upfront License Fees</link:label>
    <link:label id="lab_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees_documentation_en-US" xlink:label="lab_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And Licensing Agreements, Upfront License Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees" xlink:href="ardx-20220331.xsd#ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees" xlink:to="lab_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum_74e1d55e-c3b3-4c63-aee3-6c67be9cc97a_terseLabel_en-US" xlink:label="lab_ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum potential payment per agreement</link:label>
    <link:label id="lab_ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum_label_en-US" xlink:label="lab_ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Potential Payment Per Termination Agreement, Maximum</link:label>
    <link:label id="lab_ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum_documentation_en-US" xlink:label="lab_ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Potential Payment Per Termination Agreement, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum" xlink:href="ardx-20220331.xsd#ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum" xlink:to="lab_ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_cbb12757-86bf-4dee-9f53-553acb358f1a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ContractWithCustomerRebatesMember_aeb92f9a-f092-495e-b972-9ce79feed407_terseLabel_en-US" xlink:label="lab_ardx_ContractWithCustomerRebatesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rebates</link:label>
    <link:label id="lab_ardx_ContractWithCustomerRebatesMember_label_en-US" xlink:label="lab_ardx_ContractWithCustomerRebatesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Rebates [Member]</link:label>
    <link:label id="lab_ardx_ContractWithCustomerRebatesMember_documentation_en-US" xlink:label="lab_ardx_ContractWithCustomerRebatesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Rebates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerRebatesMember" xlink:href="ardx-20220331.xsd#ardx_ContractWithCustomerRebatesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ContractWithCustomerRebatesMember" xlink:to="lab_ardx_ContractWithCustomerRebatesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsAndCash_41644f8f-2cc1-4413-9991-b0feffb02806_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsAndCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsAndCash_b5cd62ce-ea04-446f-867c-9a7ab31ea699_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsAndCash" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash equivalents and investments, Fair Value</link:label>
    <link:label id="lab_us-gaap_InvestmentsAndCash_label_en-US" xlink:label="lab_us-gaap_InvestmentsAndCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments and Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAndCash" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsAndCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsAndCash" xlink:to="lab_us-gaap_InvestmentsAndCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_38a4371f-9627-4900-8215-45c112984d18_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_0d02c982-0858-435c-afab-239be609d20d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_9799a417-6b49-4e12-bcaf-0b38d352e5d9_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_ace58717-ef3f-41fc-9125-aafb61ad7322_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_LoanAgreementFutureObligationUponFundingOrOtherEvents_fd529634-89f4-4c82-a151-83d7fbd03313_terseLabel_en-US" xlink:label="lab_ardx_LoanAgreementFutureObligationUponFundingOrOtherEvents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future obligation upon loan funding or other events</link:label>
    <link:label id="lab_ardx_LoanAgreementFutureObligationUponFundingOrOtherEvents_label_en-US" xlink:label="lab_ardx_LoanAgreementFutureObligationUponFundingOrOtherEvents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Agreement, Future Obligation Upon Funding Or Other Events</link:label>
    <link:label id="lab_ardx_LoanAgreementFutureObligationUponFundingOrOtherEvents_documentation_en-US" xlink:label="lab_ardx_LoanAgreementFutureObligationUponFundingOrOtherEvents" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Agreement, Future Obligation Upon Funding Or Other Events</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LoanAgreementFutureObligationUponFundingOrOtherEvents" xlink:href="ardx-20220331.xsd#ardx_LoanAgreementFutureObligationUponFundingOrOtherEvents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_LoanAgreementFutureObligationUponFundingOrOtherEvents" xlink:to="lab_ardx_LoanAgreementFutureObligationUponFundingOrOtherEvents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_fa512522-5151-4971-9d0f-44fcc2817343_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods" xlink:to="lab_us-gaap_InventoryFinishedGoods" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_4fa68db8-aa20-4bdd-a06b-a30a4fc32dce_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent liabilities</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_109332d4-73d7-47fe-bf1f-142d3372e235_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding balance, beginning (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2abb3d3c-0090-4446-81d1-743c0578de8f_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding balance, ending (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_827a4bf2-2383-4bb5-8e5f-1e5e6264914d_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, net of current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_8148721d-75ca-489c-ae9e-6916f647bf93_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_372bca0b-5f84-4d74-a4e7-9c0f3b374248_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_8604006d-5f23-4e15-8369-19cf5785ab48_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Revenue</link:label>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Service [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:to="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_caa881e4-4b79-4efd-9d55-44c936b0b830_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d1b47df9-8eb7-40e0-ac12-f6fa80c419b6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Grant&#160;Date&#160;Fair Value Per&#160;Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedGains_9fd1781e-04d1-4cb3-a73d-df517bd827e3_terseLabel_en-US" xlink:label="lab_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedGains" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash equivalents and investments, Gross Unrealized Gains</link:label>
    <link:label id="lab_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedGains_label_en-US" xlink:label="lab_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedGains" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Cash Equivalents And Investments Gross Unrealized Gains</link:label>
    <link:label id="lab_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedGains_documentation_en-US" xlink:label="lab_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedGains" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and investments gross unrealized gains.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedGains" xlink:href="ardx-20220331.xsd#ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedGains"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedGains" xlink:to="lab_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedGains" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum_d66188bb-774e-4b8d-b19f-95c7872d0340_terseLabel_en-US" xlink:label="lab_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan agreement covenant, cash and cash equivalents as percentage of outstanding loan balance, minimum</link:label>
    <link:label id="lab_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum_label_en-US" xlink:label="lab_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Agreement, Covenant, Cash And Cash Equivalents As Percentage Of Outstanding Loan Balance, Minimum</link:label>
    <link:label id="lab_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum_documentation_en-US" xlink:label="lab_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Agreement, Covenant, Cash And Cash Equivalents As Percentage Of Outstanding Loan Balance, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum" xlink:href="ardx-20220331.xsd#ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum" xlink:to="lab_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_8e09c694-c7dc-4b03-aae2-fa942079a35b_negatedLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of (discount) premium on investment securities</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_b37db1d9-9348-4d35-b0b8-25f39a8bc5fb_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of deferred financing costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_59ceaf79-67a2-46af-a6f5-772beb133fa1_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonClassAMember_31088fea-1f8c-492f-b1d5-98c841f8a50c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonClassAMember_label_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Class A [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassAMember" xlink:to="lab_us-gaap_CommonClassAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f29fe59f-d8c3-482c-9c5c-38224cd48e5c_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d4de82ba-4e0c-4733-89a5-9385e92fa57c_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_TermLoan2022BMember_41d0bc98-f84b-4d66-8e02-50084ccd9e41_terseLabel_en-US" xlink:label="lab_ardx_TermLoan2022BMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B</link:label>
    <link:label id="lab_ardx_TermLoan2022BMember_label_en-US" xlink:label="lab_ardx_TermLoan2022BMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan 2022 B [Member]</link:label>
    <link:label id="lab_ardx_TermLoan2022BMember_documentation_en-US" xlink:label="lab_ardx_TermLoan2022BMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan 2022 B</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_TermLoan2022BMember" xlink:href="ardx-20220331.xsd#ardx_TermLoan2022BMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_TermLoan2022BMember" xlink:to="lab_ardx_TermLoan2022BMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_d2b5cbc2-fee2-430d-9819-2a2bea883ccc_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_18bbf8a8-ffdc-4f78-a981-47edb7924dbb_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_RevenueGeneralPaymentTerms_1b01b050-bcfb-40fa-b109-69a39a5ec477_terseLabel_en-US" xlink:label="lab_ardx_RevenueGeneralPaymentTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment terms</link:label>
    <link:label id="lab_ardx_RevenueGeneralPaymentTerms_label_en-US" xlink:label="lab_ardx_RevenueGeneralPaymentTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, General Payment Terms</link:label>
    <link:label id="lab_ardx_RevenueGeneralPaymentTerms_documentation_en-US" xlink:label="lab_ardx_RevenueGeneralPaymentTerms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, General Payment Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_RevenueGeneralPaymentTerms" xlink:href="ardx-20220331.xsd#ardx_RevenueGeneralPaymentTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_RevenueGeneralPaymentTerms" xlink:to="lab_ardx_RevenueGeneralPaymentTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_45c4098e-1bd7-42d3-8ea8-96194aa220d4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior to first anniversary of closing date</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_45fff1bd-634d-435f-b54c-ecbb85382a91_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_6bd384e9-ba6b-4abd-ab83-579991009a8f_terseLabel_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIBOR</link:label>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_label_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">London Interbank Offered Rate (LIBOR) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:to="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_1e535f75-1312-487b-a7ab-7bcc633263ad_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_428162fe-f26b-400e-b314-4977ba74720d_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Sales, Net and Reserves for Variable Consideration</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_cb899fa4-a12e-4c66-a8c9-8fa4cee17017_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon exercise of options (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_ac2bddf8-289d-4747-9b0b-3276894fc20d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ad97f292-5b46-48f9-ad6a-c13a4affba55_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used in computing net loss per share - diluted</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_20773c23-dc5e-4a86-9f97-1e8d3ef0805e_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding - diluted</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_9c131170-587f-42c2-ad66-ad7101c3ad03_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_InvestmentsAndCashAmortizedCost_ab6d36a6-74da-46c0-9054-0c8fa5ee67dd_totalLabel_en-US" xlink:label="lab_ardx_InvestmentsAndCashAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash equivalents and investments, Cost</link:label>
    <link:label id="lab_ardx_InvestmentsAndCashAmortizedCost_label_en-US" xlink:label="lab_ardx_InvestmentsAndCashAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments And Cash, Amortized Cost</link:label>
    <link:label id="lab_ardx_InvestmentsAndCashAmortizedCost_documentation_en-US" xlink:label="lab_ardx_InvestmentsAndCashAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments And Cash, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_InvestmentsAndCashAmortizedCost" xlink:href="ardx-20220331.xsd#ardx_InvestmentsAndCashAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_InvestmentsAndCashAmortizedCost" xlink:to="lab_ardx_InvestmentsAndCashAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities_58824894-9661-4791-a8ed-debac7935932_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in derivative liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Derivative Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_4d1a11b4-4748-4b75-8f15-c6db40432714_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_fc5bc587-d514-4611-9d9b-e9230f869ff6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_509475db-0406-45bf-b5c6-5da25bbe6506_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Floating per annum rate (percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_McKessonCorporationMember_3b55b73a-5131-4d6d-9100-2daf2c196c8e_terseLabel_en-US" xlink:label="lab_ardx_McKessonCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">McKesson Corporation</link:label>
    <link:label id="lab_ardx_McKessonCorporationMember_label_en-US" xlink:label="lab_ardx_McKessonCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">McKesson Corporation [Member]</link:label>
    <link:label id="lab_ardx_McKessonCorporationMember_documentation_en-US" xlink:label="lab_ardx_McKessonCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">McKesson Corporation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_McKessonCorporationMember" xlink:href="ardx-20220331.xsd#ardx_McKessonCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_McKessonCorporationMember" xlink:to="lab_ardx_McKessonCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_f6a2f551-ce1a-4777-92c5-7f8c2e99bb14_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_3c84179c-da9d-499b-b00e-bdb6554c850b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_248650a4-311f-42ee-ac76-a8f69e1a7e9a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_083dd1d3-5e1e-46e4-8ff3-5450d94a2829_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_b266067e-9c08-4c6b-888b-aec543951e24_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_197765b2-d4fe-46ad-9c70-f9cecce3c868_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_046635c0-4868-4262-9542-32edf0e43bd7_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_1d5bfa05-e928-4172-a829-2fe85330b052_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized losses on available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_f11aa91f-9920-47bf-904c-5d45597db285_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized losses on available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_730acc10-eca8-41fd-89ad-6faae6db4390_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_17c200cb-a117-4530-91b2-0893d0d00029_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_1f1b5cd5-9f32-4481-bb2c-9c09d284e6d1_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward_6c9427ba-e03a-4457-9c1c-2147c407e004_terseLabel_en-US" xlink:label="lab_ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross-to-net sales accruals and reserves</link:label>
    <link:label id="lab_ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward_label_en-US" xlink:label="lab_ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Gross To Net Sales Accrual [Roll Forward]</link:label>
    <link:label id="lab_ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward_documentation_en-US" xlink:label="lab_ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Gross To Net Sales Accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward" xlink:href="ardx-20220331.xsd#ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward" xlink:to="lab_ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_ec01ace5-d7d6-42a3-814c-c6ead860dc17_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_4787165d-8524-43ce-9d74-e2107fe40ff8_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseDescriptionAbstract_540a7e96-dbcf-4914-9b6a-35a5a663fcdc_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional details</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseDescriptionAbstract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Description [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseDescriptionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:to="lab_us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_a7e3a4d3-7fcd-4dc4-b229-22d6af4e9a37_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_4238ffe8-d590-48e9-b8e3-3ea48c85f531_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_0c1f8462-897e-449b-a2f0-e9b62a65bfcf_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Unamortized discount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_c62bbd94-c087-4372-972c-85eb65759f42_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_dd1bdfd7-f079-49a6-9601-8ad8d40b2abd_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from ESPP</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockPlans" xlink:to="lab_us-gaap_ProceedsFromStockPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_5514c8ab-e5ad-4153-9b19-afa48c19ad08_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ContractWithCustomerLiabilityRevenueRecognizedCashReceived_c21ee68e-8284-4379-8817-335adac00231_negatedTerseLabel_en-US" xlink:label="lab_ardx_ContractWithCustomerLiabilityRevenueRecognizedCashReceived" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decreases due to revenue recognized in the period for which cash has been received</link:label>
    <link:label id="lab_ardx_ContractWithCustomerLiabilityRevenueRecognizedCashReceived_label_en-US" xlink:label="lab_ardx_ContractWithCustomerLiabilityRevenueRecognizedCashReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer Liability Revenue Recognized Cash Received</link:label>
    <link:label id="lab_ardx_ContractWithCustomerLiabilityRevenueRecognizedCashReceived_documentation_en-US" xlink:label="lab_ardx_ContractWithCustomerLiabilityRevenueRecognizedCashReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerLiabilityRevenueRecognizedCashReceived" xlink:href="ardx-20220331.xsd#ardx_ContractWithCustomerLiabilityRevenueRecognizedCashReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ContractWithCustomerLiabilityRevenueRecognizedCashReceived" xlink:to="lab_ardx_ContractWithCustomerLiabilityRevenueRecognizedCashReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_62c6287a-a1e7-4bd4-b9ca-0329461c9aad_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_c0c66973-3e85-43f7-b34b-fef1e7a0ec69_terseLabel_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-backed securities</link:label>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetBackedSecuritiesMember" xlink:to="lab_us-gaap_AssetBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_5c5d219d-c41e-4e5b-8722-fad306497b5c_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ExitFee2018Member_11f8f582-2d29-43e7-842e-d8a86580f1e7_terseLabel_en-US" xlink:label="lab_ardx_ExitFee2018Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Exit Fee</link:label>
    <link:label id="lab_ardx_ExitFee2018Member_label_en-US" xlink:label="lab_ardx_ExitFee2018Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exit Fee 2018 [Member]</link:label>
    <link:label id="lab_ardx_ExitFee2018Member_documentation_en-US" xlink:label="lab_ardx_ExitFee2018Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exit Fee 2018</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ExitFee2018Member" xlink:href="ardx-20220331.xsd#ardx_ExitFee2018Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ExitFee2018Member" xlink:to="lab_ardx_ExitFee2018Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_9ed223a8-8035-426c-a369-6dcdb4fb378b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in continuous unrealized loss position for more than one year</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_dd039164-79e8-4861-a119-2d404f7a49a0_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Compensation Expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_5643cda7-34ec-4eeb-b328-086b411d666a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_9d7cf7d0-bb1d-4075-aaae-6090b101ba38_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_fc7d22a0-0617-4dd4-8ef8-414ed26e1ecd_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_label_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_078cc8e9-3046-45fd-a4d4-c0a4ee257661_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_7455515c-db57-4f15-a4df-dc48da819212_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ExitFee2022Member_312de139-cf95-44d6-8a51-5393cd14c9c1_terseLabel_en-US" xlink:label="lab_ardx_ExitFee2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Exit Fee</link:label>
    <link:label id="lab_ardx_ExitFee2022Member_label_en-US" xlink:label="lab_ardx_ExitFee2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exit Fee 2022 [Member]</link:label>
    <link:label id="lab_ardx_ExitFee2022Member_documentation_en-US" xlink:label="lab_ardx_ExitFee2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exit Fee 2022</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ExitFee2022Member" xlink:href="ardx-20220331.xsd#ardx_ExitFee2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ExitFee2022Member" xlink:to="lab_ardx_ExitFee2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseMember_b950e893-f0e2-441f-bb65-409396ea3190_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing revenue</link:label>
    <link:label id="lab_us-gaap_LicenseMember_label_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember" xlink:to="lab_us-gaap_LicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_464c860f-d723-42ec-9296-969808b44455_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bb517678-b20a-4102-95b6-59c233d8ebc8_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_DebtInstrumentVariableRateBaseOption_b7ba8d89-65d6-4ce7-81b5-2822706861a7_terseLabel_en-US" xlink:label="lab_ardx_DebtInstrumentVariableRateBaseOption" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Addition to floating per annum rate (percent)</link:label>
    <link:label id="lab_ardx_DebtInstrumentVariableRateBaseOption_label_en-US" xlink:label="lab_ardx_DebtInstrumentVariableRateBaseOption" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Variable Rate, Base Option</link:label>
    <link:label id="lab_ardx_DebtInstrumentVariableRateBaseOption_documentation_en-US" xlink:label="lab_ardx_DebtInstrumentVariableRateBaseOption" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Variable Rate, Base Option</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DebtInstrumentVariableRateBaseOption" xlink:href="ardx-20220331.xsd#ardx_DebtInstrumentVariableRateBaseOption"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_DebtInstrumentVariableRateBaseOption" xlink:to="lab_ardx_DebtInstrumentVariableRateBaseOption" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_44b65705-2976-4c2b-ad33-822771005e72_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_2f13ccfa-c64b-4833-bdcb-00e431000e23_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_dbb392b9-80d7-4b92-bb27-ce97061fb322_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_03c9ee86-6d3c-4498-ae6f-d7c4de8aba97_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_984595f8-3e4c-495d-88f0-6b2cb07b73f2_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_MaximumAggregateOfferingPrice_e4d23963-b322-4c3f-a0aa-b272ed1cacdc_terseLabel_en-US" xlink:label="lab_ardx_MaximumAggregateOfferingPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum aggregate offering price</link:label>
    <link:label id="lab_ardx_MaximumAggregateOfferingPrice_label_en-US" xlink:label="lab_ardx_MaximumAggregateOfferingPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Aggregate Offering Price</link:label>
    <link:label id="lab_ardx_MaximumAggregateOfferingPrice_documentation_en-US" xlink:label="lab_ardx_MaximumAggregateOfferingPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of maximum aggregate offering price.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_MaximumAggregateOfferingPrice" xlink:href="ardx-20220331.xsd#ardx_MaximumAggregateOfferingPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_MaximumAggregateOfferingPrice" xlink:to="lab_ardx_MaximumAggregateOfferingPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment_85e8304d-8fbf-41fe-9a1d-46d177423e26_terseLabel_en-US" xlink:label="lab_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First installment of upfront license fees</link:label>
    <link:label id="lab_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment_label_en-US" xlink:label="lab_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And Licensing Agreements, Upfront License Fees, First Installment</link:label>
    <link:label id="lab_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment_documentation_en-US" xlink:label="lab_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And Licensing Agreements, Upfront License Fees, First Installment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment" xlink:href="ardx-20220331.xsd#ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment" xlink:to="lab_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_235ddb60-3862-44a5-9df6-6f1eb6baf3f8_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>ardx-20220331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:9e7cc335-f1e2-4409-ab16-898e4e60d77f,g:bd3d9229-0258-42cf-b897-58fd721121d9-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.ardelyx.com/role/Cover" xlink:type="simple" xlink:href="ardx-20220331.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_dadb5ec1-fab8-425e-a437-1a951a661a5b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_9a668d2d-c87b-49d0-ad44-8d3735acd111" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dadb5ec1-fab8-425e-a437-1a951a661a5b" xlink:to="loc_dei_DocumentType_9a668d2d-c87b-49d0-ad44-8d3735acd111" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_5891a400-8615-4a0c-a4f2-a0a8275a8546" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dadb5ec1-fab8-425e-a437-1a951a661a5b" xlink:to="loc_dei_DocumentQuarterlyReport_5891a400-8615-4a0c-a4f2-a0a8275a8546" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_e586f9b1-ddc2-4770-9ae9-9f929d236117" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dadb5ec1-fab8-425e-a437-1a951a661a5b" xlink:to="loc_dei_DocumentPeriodEndDate_e586f9b1-ddc2-4770-9ae9-9f929d236117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_788d486b-45af-41c0-a618-5e7db6845d3f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dadb5ec1-fab8-425e-a437-1a951a661a5b" xlink:to="loc_dei_DocumentTransitionReport_788d486b-45af-41c0-a618-5e7db6845d3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_fc71cd06-d090-4d61-bc28-db85e17cdac6" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dadb5ec1-fab8-425e-a437-1a951a661a5b" xlink:to="loc_dei_EntityFileNumber_fc71cd06-d090-4d61-bc28-db85e17cdac6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_1029dc03-320f-4e51-9e4d-90415480515e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dadb5ec1-fab8-425e-a437-1a951a661a5b" xlink:to="loc_dei_EntityRegistrantName_1029dc03-320f-4e51-9e4d-90415480515e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_d5832efc-cf09-49c0-8ad5-28758bf58f0e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dadb5ec1-fab8-425e-a437-1a951a661a5b" xlink:to="loc_dei_EntityIncorporationStateCountryCode_d5832efc-cf09-49c0-8ad5-28758bf58f0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_4b9471c7-bd86-4169-b215-a31d5002ac5f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dadb5ec1-fab8-425e-a437-1a951a661a5b" xlink:to="loc_dei_EntityTaxIdentificationNumber_4b9471c7-bd86-4169-b215-a31d5002ac5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_3049ab96-5600-41b4-8a36-55d6776ba341" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dadb5ec1-fab8-425e-a437-1a951a661a5b" xlink:to="loc_dei_EntityAddressAddressLine1_3049ab96-5600-41b4-8a36-55d6776ba341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_0779f83b-ba72-4df8-bd17-a1d58d1e07a2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dadb5ec1-fab8-425e-a437-1a951a661a5b" xlink:to="loc_dei_EntityAddressAddressLine2_0779f83b-ba72-4df8-bd17-a1d58d1e07a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_c7704d4f-5d3b-4fc0-a768-aac530f40b8c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dadb5ec1-fab8-425e-a437-1a951a661a5b" xlink:to="loc_dei_EntityAddressCityOrTown_c7704d4f-5d3b-4fc0-a768-aac530f40b8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_2a549eb9-160d-45e1-9bcd-bb80dae4ce7c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dadb5ec1-fab8-425e-a437-1a951a661a5b" xlink:to="loc_dei_EntityAddressStateOrProvince_2a549eb9-160d-45e1-9bcd-bb80dae4ce7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_f206409d-6cd0-4e90-8131-0e05b98d4fe8" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dadb5ec1-fab8-425e-a437-1a951a661a5b" xlink:to="loc_dei_EntityAddressPostalZipCode_f206409d-6cd0-4e90-8131-0e05b98d4fe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_3affa02d-170f-4814-b084-919c762ea6d9" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dadb5ec1-fab8-425e-a437-1a951a661a5b" xlink:to="loc_dei_CityAreaCode_3affa02d-170f-4814-b084-919c762ea6d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_5c54bd96-7762-4b85-9471-9f612536270b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dadb5ec1-fab8-425e-a437-1a951a661a5b" xlink:to="loc_dei_LocalPhoneNumber_5c54bd96-7762-4b85-9471-9f612536270b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_381ee440-0f85-49dc-a496-7a096024f4b9" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dadb5ec1-fab8-425e-a437-1a951a661a5b" xlink:to="loc_dei_Security12bTitle_381ee440-0f85-49dc-a496-7a096024f4b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_3a3d17a1-55c6-43c0-952b-5c3020135a5f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dadb5ec1-fab8-425e-a437-1a951a661a5b" xlink:to="loc_dei_TradingSymbol_3a3d17a1-55c6-43c0-952b-5c3020135a5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_0263f29c-441d-405b-9afe-043d1c8db46e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dadb5ec1-fab8-425e-a437-1a951a661a5b" xlink:to="loc_dei_SecurityExchangeName_0263f29c-441d-405b-9afe-043d1c8db46e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_2b909633-ad79-47fd-8705-b58caab5c9e5" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dadb5ec1-fab8-425e-a437-1a951a661a5b" xlink:to="loc_dei_EntityCurrentReportingStatus_2b909633-ad79-47fd-8705-b58caab5c9e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_03d37f09-f4be-496a-966d-56f597c2cc62" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dadb5ec1-fab8-425e-a437-1a951a661a5b" xlink:to="loc_dei_EntityInteractiveDataCurrent_03d37f09-f4be-496a-966d-56f597c2cc62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_d7e4bea3-9fe7-4685-ac76-3fe557a5c164" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dadb5ec1-fab8-425e-a437-1a951a661a5b" xlink:to="loc_dei_EntityFilerCategory_d7e4bea3-9fe7-4685-ac76-3fe557a5c164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_51fa8e50-81dc-4c15-806c-6efdc3908133" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dadb5ec1-fab8-425e-a437-1a951a661a5b" xlink:to="loc_dei_EntitySmallBusiness_51fa8e50-81dc-4c15-806c-6efdc3908133" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_799c7fca-5b95-4281-b57b-3a1c43cde66d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dadb5ec1-fab8-425e-a437-1a951a661a5b" xlink:to="loc_dei_EntityEmergingGrowthCompany_799c7fca-5b95-4281-b57b-3a1c43cde66d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_6d39cb6f-0970-4e6e-8e8b-f2ac0f814b65" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dadb5ec1-fab8-425e-a437-1a951a661a5b" xlink:to="loc_dei_EntityShellCompany_6d39cb6f-0970-4e6e-8e8b-f2ac0f814b65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_85a87d32-ad3f-49ee-8c0c-f74c4ea97cdb" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dadb5ec1-fab8-425e-a437-1a951a661a5b" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_85a87d32-ad3f-49ee-8c0c-f74c4ea97cdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_213d5d72-ad9b-4310-a6d5-6e5c6a196b41" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dadb5ec1-fab8-425e-a437-1a951a661a5b" xlink:to="loc_dei_EntityCentralIndexKey_213d5d72-ad9b-4310-a6d5-6e5c6a196b41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_941fd6fb-3a66-4ff3-8ac9-ba9980bdf6ce" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dadb5ec1-fab8-425e-a437-1a951a661a5b" xlink:to="loc_dei_CurrentFiscalYearEndDate_941fd6fb-3a66-4ff3-8ac9-ba9980bdf6ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_aafe35dd-63a2-4eb0-8300-4f5158f98a78" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dadb5ec1-fab8-425e-a437-1a951a661a5b" xlink:to="loc_dei_DocumentFiscalYearFocus_aafe35dd-63a2-4eb0-8300-4f5158f98a78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_e467d9dc-a08e-4e54-967d-952315030e84" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dadb5ec1-fab8-425e-a437-1a951a661a5b" xlink:to="loc_dei_DocumentFiscalPeriodFocus_e467d9dc-a08e-4e54-967d-952315030e84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_7aa615a1-bda0-441e-a45a-73c3432b060c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dadb5ec1-fab8-425e-a437-1a951a661a5b" xlink:to="loc_dei_AmendmentFlag_7aa615a1-bda0-441e-a45a-73c3432b060c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS" xlink:type="simple" xlink:href="ardx-20220331.xsd#CONDENSEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_bf957044-a3dd-4bbf-a1d2-aa1568b4fa60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_443ee507-a9b3-4299-ba04-20aa5670725a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_bf957044-a3dd-4bbf-a1d2-aa1568b4fa60" xlink:to="loc_us-gaap_AssetsAbstract_443ee507-a9b3-4299-ba04-20aa5670725a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_c4d27266-de9e-490d-b4f2-1632196a871b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_443ee507-a9b3-4299-ba04-20aa5670725a" xlink:to="loc_us-gaap_AssetsCurrentAbstract_c4d27266-de9e-490d-b4f2-1632196a871b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f38724d1-9f19-4224-8ce7-9f37147da87e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c4d27266-de9e-490d-b4f2-1632196a871b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f38724d1-9f19-4224-8ce7-9f37147da87e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_6e71c4f8-76bc-45a6-be41-1d0bbb18bad8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c4d27266-de9e-490d-b4f2-1632196a871b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_6e71c4f8-76bc-45a6-be41-1d0bbb18bad8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_59c3de31-03da-402c-a1b0-1c1a6bd182d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c4d27266-de9e-490d-b4f2-1632196a871b" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_59c3de31-03da-402c-a1b0-1c1a6bd182d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_8ea3f6ca-cdb7-4659-8dc5-ff652b3b0a1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c4d27266-de9e-490d-b4f2-1632196a871b" xlink:to="loc_us-gaap_InventoryNet_8ea3f6ca-cdb7-4659-8dc5-ff652b3b0a1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_63b780ec-b4bb-4d12-bfba-bbb13e918d45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c4d27266-de9e-490d-b4f2-1632196a871b" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_63b780ec-b4bb-4d12-bfba-bbb13e918d45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_4d3ffe52-152b-4277-add3-cea919607adf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c4d27266-de9e-490d-b4f2-1632196a871b" xlink:to="loc_us-gaap_AssetsCurrent_4d3ffe52-152b-4277-add3-cea919607adf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_0b4ccde4-d5b5-438b-aa51-455434128e17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_443ee507-a9b3-4299-ba04-20aa5670725a" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_0b4ccde4-d5b5-438b-aa51-455434128e17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_45b7e98e-1946-4cf4-837c-fa2b35d856fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_443ee507-a9b3-4299-ba04-20aa5670725a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_45b7e98e-1946-4cf4-837c-fa2b35d856fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_1e153a63-3929-4501-879f-e7411c781596" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_443ee507-a9b3-4299-ba04-20aa5670725a" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_1e153a63-3929-4501-879f-e7411c781596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_fd4fe3e1-23c7-4a8d-98d1-cb496baab9df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_443ee507-a9b3-4299-ba04-20aa5670725a" xlink:to="loc_us-gaap_Assets_fd4fe3e1-23c7-4a8d-98d1-cb496baab9df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_622a9265-6ff4-43eb-83f9-5788a8796b77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_bf957044-a3dd-4bbf-a1d2-aa1568b4fa60" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_622a9265-6ff4-43eb-83f9-5788a8796b77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_b4757f79-7775-4c74-a00d-d59900ddb9e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_622a9265-6ff4-43eb-83f9-5788a8796b77" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_b4757f79-7775-4c74-a00d-d59900ddb9e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_745056b0-c821-4493-9a2b-45cbd567436f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_b4757f79-7775-4c74-a00d-d59900ddb9e0" xlink:to="loc_us-gaap_AccountsPayableCurrent_745056b0-c821-4493-9a2b-45cbd567436f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_9b92087c-c9d9-408f-88e8-be43358fa5f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_b4757f79-7775-4c74-a00d-d59900ddb9e0" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_9b92087c-c9d9-408f-88e8-be43358fa5f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_7fdf85fb-11b5-48cd-bc5c-9b47e20e2197" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_b4757f79-7775-4c74-a00d-d59900ddb9e0" xlink:to="loc_us-gaap_LongTermDebtCurrent_7fdf85fb-11b5-48cd-bc5c-9b47e20e2197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_341bd39a-4bdb-4b17-9fd0-47648ca71661" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_b4757f79-7775-4c74-a00d-d59900ddb9e0" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_341bd39a-4bdb-4b17-9fd0-47648ca71661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_76af0c52-37f1-4f08-af78-238050b2c7a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_b4757f79-7775-4c74-a00d-d59900ddb9e0" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_76af0c52-37f1-4f08-af78-238050b2c7a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_7d474ca0-fbd8-4134-8005-7a6bb2199551" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_b4757f79-7775-4c74-a00d-d59900ddb9e0" xlink:to="loc_us-gaap_LiabilitiesCurrent_7d474ca0-fbd8-4134-8005-7a6bb2199551" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b3b2d19a-c3e6-40d7-a08e-d11db71094f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_622a9265-6ff4-43eb-83f9-5788a8796b77" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b3b2d19a-c3e6-40d7-a08e-d11db71094f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_2199e81c-3bb3-40a0-8106-8331c6b94447" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_622a9265-6ff4-43eb-83f9-5788a8796b77" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_2199e81c-3bb3-40a0-8106-8331c6b94447" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_d173cb69-abdf-4931-b22b-8b00ec30b8d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_622a9265-6ff4-43eb-83f9-5788a8796b77" xlink:to="loc_us-gaap_Liabilities_d173cb69-abdf-4931-b22b-8b00ec30b8d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_55cb1bd8-ff87-4f30-8dda-e1059ae658e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_622a9265-6ff4-43eb-83f9-5788a8796b77" xlink:to="loc_us-gaap_CommitmentsAndContingencies_55cb1bd8-ff87-4f30-8dda-e1059ae658e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_aa732807-9133-4a3e-a8fe-2acd81ee324c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_622a9265-6ff4-43eb-83f9-5788a8796b77" xlink:to="loc_us-gaap_StockholdersEquityAbstract_aa732807-9133-4a3e-a8fe-2acd81ee324c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_57feafb7-bcb0-4907-9cb4-8fdf5e5c76c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_aa732807-9133-4a3e-a8fe-2acd81ee324c" xlink:to="loc_us-gaap_PreferredStockValue_57feafb7-bcb0-4907-9cb4-8fdf5e5c76c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_c51a870d-fc1a-45c5-92c3-7de01b1d0e9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_aa732807-9133-4a3e-a8fe-2acd81ee324c" xlink:to="loc_us-gaap_CommonStockValue_c51a870d-fc1a-45c5-92c3-7de01b1d0e9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_d36c8902-6ec5-4bfd-a460-9396db53fa70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_aa732807-9133-4a3e-a8fe-2acd81ee324c" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_d36c8902-6ec5-4bfd-a460-9396db53fa70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ef5b8f17-5cc7-4bb2-85ba-cc35bc3eaf1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_aa732807-9133-4a3e-a8fe-2acd81ee324c" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ef5b8f17-5cc7-4bb2-85ba-cc35bc3eaf1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4e67a1e2-bcca-47cb-9247-6528cb8b1370" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_aa732807-9133-4a3e-a8fe-2acd81ee324c" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4e67a1e2-bcca-47cb-9247-6528cb8b1370" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_30d0c482-7975-4071-81b7-66bfacf3c914" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_aa732807-9133-4a3e-a8fe-2acd81ee324c" xlink:to="loc_us-gaap_StockholdersEquity_30d0c482-7975-4071-81b7-66bfacf3c914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_7083d970-bef0-4e57-adba-6973d6786ed5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_622a9265-6ff4-43eb-83f9-5788a8796b77" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_7083d970-bef0-4e57-adba-6973d6786ed5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/CONDENSEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="ardx-20220331.xsd#CONDENSEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/CONDENSEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_4ef26e9f-7f29-46ca-a5a4-ded1cf1218a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_c1e9d633-0f8b-4da1-adf5-019308706571" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4ef26e9f-7f29-46ca-a5a4-ded1cf1218a7" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_c1e9d633-0f8b-4da1-adf5-019308706571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_2c431f1c-d2d9-46e5-8713-554518c7ac2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4ef26e9f-7f29-46ca-a5a4-ded1cf1218a7" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_2c431f1c-d2d9-46e5-8713-554518c7ac2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_bfb2c6c4-b320-43fb-b42c-c970ba65a5ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4ef26e9f-7f29-46ca-a5a4-ded1cf1218a7" xlink:to="loc_us-gaap_PreferredStockSharesIssued_bfb2c6c4-b320-43fb-b42c-c970ba65a5ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_bd1fc6d5-98c9-4080-a15c-4ba76314f1d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4ef26e9f-7f29-46ca-a5a4-ded1cf1218a7" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_bd1fc6d5-98c9-4080-a15c-4ba76314f1d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_fd51a24b-e2b9-4866-87f0-d40d3a949c38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4ef26e9f-7f29-46ca-a5a4-ded1cf1218a7" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_fd51a24b-e2b9-4866-87f0-d40d3a949c38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_92d71ce4-b1cb-4c56-b2e1-d049331ccad6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4ef26e9f-7f29-46ca-a5a4-ded1cf1218a7" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_92d71ce4-b1cb-4c56-b2e1-d049331ccad6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_7ffb0e95-d7ba-46e7-96a7-ef21b3b277ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4ef26e9f-7f29-46ca-a5a4-ded1cf1218a7" xlink:to="loc_us-gaap_CommonStockSharesIssued_7ffb0e95-d7ba-46e7-96a7-ef21b3b277ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_7731f43d-2739-4ca8-ae3e-95629d9b10e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4ef26e9f-7f29-46ca-a5a4-ded1cf1218a7" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_7731f43d-2739-4ca8-ae3e-95629d9b10e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="ardx-20220331.xsd#CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_92d35ed9-c31e-4b83-b273-ddef9af60fba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_48379915-1c00-434c-8eaf-ecbdd5036f25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_92d35ed9-c31e-4b83-b273-ddef9af60fba" xlink:to="loc_us-gaap_StatementTable_48379915-1c00-434c-8eaf-ecbdd5036f25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_608ae60b-db75-4b31-bf6d-97f4f62efb13" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_48379915-1c00-434c-8eaf-ecbdd5036f25" xlink:to="loc_srt_ProductOrServiceAxis_608ae60b-db75-4b31-bf6d-97f4f62efb13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0cc18914-1ecc-488a-8424-009fc9875feb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_608ae60b-db75-4b31-bf6d-97f4f62efb13" xlink:to="loc_srt_ProductsAndServicesDomain_0cc18914-1ecc-488a-8424-009fc9875feb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_27667d80-92b3-42e1-bc65-344393d8a16f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0cc18914-1ecc-488a-8424-009fc9875feb" xlink:to="loc_us-gaap_ProductMember_27667d80-92b3-42e1-bc65-344393d8a16f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ProductSupplyRevenueMember_6b3a14d0-42d7-4367-96d2-85f9f137358d" xlink:href="ardx-20220331.xsd#ardx_ProductSupplyRevenueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0cc18914-1ecc-488a-8424-009fc9875feb" xlink:to="loc_ardx_ProductSupplyRevenueMember_6b3a14d0-42d7-4367-96d2-85f9f137358d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_39d73a42-55e5-4105-b39a-4f85a37a9386" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0cc18914-1ecc-488a-8424-009fc9875feb" xlink:to="loc_us-gaap_LicenseMember_39d73a42-55e5-4105-b39a-4f85a37a9386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeDevelopmentMember_be93ba8a-d396-44fe-a6fb-91a4184cbcbf" xlink:href="ardx-20220331.xsd#ardx_CollaborativeDevelopmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0cc18914-1ecc-488a-8424-009fc9875feb" xlink:to="loc_ardx_CollaborativeDevelopmentMember_be93ba8a-d396-44fe-a6fb-91a4184cbcbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_59ba96d9-0146-4c65-99cf-85322f4cf2b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_48379915-1c00-434c-8eaf-ecbdd5036f25" xlink:to="loc_us-gaap_StatementLineItems_59ba96d9-0146-4c65-99cf-85322f4cf2b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_7c3db774-8921-4c4f-bc27-098ac455e20e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_59ba96d9-0146-4c65-99cf-85322f4cf2b3" xlink:to="loc_us-gaap_RevenuesAbstract_7c3db774-8921-4c4f-bc27-098ac455e20e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2fa53fcf-949b-4783-8b67-2e2c56aa0fa5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_7c3db774-8921-4c4f-bc27-098ac455e20e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2fa53fcf-949b-4783-8b67-2e2c56aa0fa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_8304e41a-cfff-42c6-a049-e3ce884dac8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_59ba96d9-0146-4c65-99cf-85322f4cf2b3" xlink:to="loc_us-gaap_OperatingExpensesAbstract_8304e41a-cfff-42c6-a049-e3ce884dac8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_de7a696e-9112-452a-bb8b-d9229c2e8ecd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_8304e41a-cfff-42c6-a049-e3ce884dac8a" xlink:to="loc_us-gaap_CostOfRevenue_de7a696e-9112-452a-bb8b-d9229c2e8ecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_71c035a6-ddc5-4955-a5e0-5af438925e7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_8304e41a-cfff-42c6-a049-e3ce884dac8a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_71c035a6-ddc5-4955-a5e0-5af438925e7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_29469682-111d-480c-963b-9c11831b3417" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_8304e41a-cfff-42c6-a049-e3ce884dac8a" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_29469682-111d-480c-963b-9c11831b3417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_f82b35e6-4df8-415d-91da-daf6d108022a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_8304e41a-cfff-42c6-a049-e3ce884dac8a" xlink:to="loc_us-gaap_CostsAndExpenses_f82b35e6-4df8-415d-91da-daf6d108022a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_03a267b9-966f-462c-ad05-a0df321a199e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_59ba96d9-0146-4c65-99cf-85322f4cf2b3" xlink:to="loc_us-gaap_OperatingIncomeLoss_03a267b9-966f-462c-ad05-a0df321a199e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_2f3e4861-779e-4552-a396-9d8bfcbec8ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_59ba96d9-0146-4c65-99cf-85322f4cf2b3" xlink:to="loc_us-gaap_InterestExpense_2f3e4861-779e-4552-a396-9d8bfcbec8ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_7c20e04f-748e-44ca-b27f-c1356bf0294c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_59ba96d9-0146-4c65-99cf-85322f4cf2b3" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_7c20e04f-748e-44ca-b27f-c1356bf0294c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ace1a649-b079-4cd2-9724-ae479f05a1b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_59ba96d9-0146-4c65-99cf-85322f4cf2b3" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ace1a649-b079-4cd2-9724-ae479f05a1b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_bf3ec65c-2faa-4a98-9649-3f7078ce85c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_59ba96d9-0146-4c65-99cf-85322f4cf2b3" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_bf3ec65c-2faa-4a98-9649-3f7078ce85c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2d0db75e-103e-4bd7-8ca5-3bc62405494a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_59ba96d9-0146-4c65-99cf-85322f4cf2b3" xlink:to="loc_us-gaap_NetIncomeLoss_2d0db75e-103e-4bd7-8ca5-3bc62405494a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_d00b51f1-f426-47f3-a9bf-78dc6b703f1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_59ba96d9-0146-4c65-99cf-85322f4cf2b3" xlink:to="loc_us-gaap_EarningsPerShareBasic_d00b51f1-f426-47f3-a9bf-78dc6b703f1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_53d6144e-4862-474c-8824-e611897059d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_59ba96d9-0146-4c65-99cf-85322f4cf2b3" xlink:to="loc_us-gaap_EarningsPerShareDiluted_53d6144e-4862-474c-8824-e611897059d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5c9829db-b322-49fa-af17-a00ec0d58248" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_59ba96d9-0146-4c65-99cf-85322f4cf2b3" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5c9829db-b322-49fa-af17-a00ec0d58248" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_46beb371-0653-4e04-ac2b-1efef6847959" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_59ba96d9-0146-4c65-99cf-85322f4cf2b3" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_46beb371-0653-4e04-ac2b-1efef6847959" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_f78216bd-7510-4e27-aad2-068f993294af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_59ba96d9-0146-4c65-99cf-85322f4cf2b3" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_f78216bd-7510-4e27-aad2-068f993294af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8a14e578-5287-46db-b682-bdd4058db5c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_f78216bd-7510-4e27-aad2-068f993294af" xlink:to="loc_us-gaap_NetIncomeLoss_8a14e578-5287-46db-b682-bdd4058db5c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_cb172748-2c8c-4f8b-9d63-822479eaa97d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_f78216bd-7510-4e27-aad2-068f993294af" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_cb172748-2c8c-4f8b-9d63-822479eaa97d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_59c88361-209c-41a8-8c5c-60c166ba71d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_f78216bd-7510-4e27-aad2-068f993294af" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_59c88361-209c-41a8-8c5c-60c166ba71d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="ardx-20220331.xsd#CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_aa61283a-ee65-4cdb-9f37-36722a9902ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_836b6421-50d8-4cf8-8dc1-8b45229aca7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_aa61283a-ee65-4cdb-9f37-36722a9902ac" xlink:to="loc_us-gaap_StatementTable_836b6421-50d8-4cf8-8dc1-8b45229aca7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_73c98234-8ad8-4dc9-ab53-5c242aef3940" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_836b6421-50d8-4cf8-8dc1-8b45229aca7c" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_73c98234-8ad8-4dc9-ab53-5c242aef3940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a19f4c78-bdb1-4128-94d6-afada28fe9b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_73c98234-8ad8-4dc9-ab53-5c242aef3940" xlink:to="loc_us-gaap_EquityComponentDomain_a19f4c78-bdb1-4128-94d6-afada28fe9b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f771b5b0-0497-45af-ba2e-0764d85842c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a19f4c78-bdb1-4128-94d6-afada28fe9b7" xlink:to="loc_us-gaap_CommonStockMember_f771b5b0-0497-45af-ba2e-0764d85842c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_7655ff1a-bae3-47ec-8e52-e5be2a613dd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a19f4c78-bdb1-4128-94d6-afada28fe9b7" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_7655ff1a-bae3-47ec-8e52-e5be2a613dd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_bf2d54e7-d3bf-40bc-b0b0-aa304202e2ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a19f4c78-bdb1-4128-94d6-afada28fe9b7" xlink:to="loc_us-gaap_RetainedEarningsMember_bf2d54e7-d3bf-40bc-b0b0-aa304202e2ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c73f87b9-afea-4bbe-9edd-78214ec8d00e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a19f4c78-bdb1-4128-94d6-afada28fe9b7" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c73f87b9-afea-4bbe-9edd-78214ec8d00e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_11f1a90e-58a5-4590-bf7a-d4e5d074aba7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_836b6421-50d8-4cf8-8dc1-8b45229aca7c" xlink:to="loc_us-gaap_StatementLineItems_11f1a90e-58a5-4590-bf7a-d4e5d074aba7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_46bd15dd-fd0d-4521-af62-1e3d66c0ebed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_11f1a90e-58a5-4590-bf7a-d4e5d074aba7" xlink:to="loc_us-gaap_StockholdersEquity_46bd15dd-fd0d-4521-af62-1e3d66c0ebed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_622be1b2-bff5-46a8-9d49-91d70e33298c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_11f1a90e-58a5-4590-bf7a-d4e5d074aba7" xlink:to="loc_us-gaap_SharesOutstanding_622be1b2-bff5-46a8-9d49-91d70e33298c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_70b002f1-77e0-4875-9c57-063f9d8ef8ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_11f1a90e-58a5-4590-bf7a-d4e5d074aba7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_70b002f1-77e0-4875-9c57-063f9d8ef8ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_dc991ade-655c-48e4-9aa8-c15f59dea4eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_11f1a90e-58a5-4590-bf7a-d4e5d074aba7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_dc991ade-655c-48e4-9aa8-c15f59dea4eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_6d00d96d-a8d3-46c6-bd9a-b565ab98bef0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_11f1a90e-58a5-4590-bf7a-d4e5d074aba7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_6d00d96d-a8d3-46c6-bd9a-b565ab98bef0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_61216108-dbec-4262-8544-17ffa82331e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_11f1a90e-58a5-4590-bf7a-d4e5d074aba7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_61216108-dbec-4262-8544-17ffa82331e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_8efcaa53-a385-4f23-8976-6b3a69a97714" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_11f1a90e-58a5-4590-bf7a-d4e5d074aba7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_8efcaa53-a385-4f23-8976-6b3a69a97714" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_9bc5fe8f-8bd8-4ab0-a420-b029ba7acc6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_11f1a90e-58a5-4590-bf7a-d4e5d074aba7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_9bc5fe8f-8bd8-4ab0-a420-b029ba7acc6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_4590298e-a2fd-452d-b7af-50791046ca31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_11f1a90e-58a5-4590-bf7a-d4e5d074aba7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_4590298e-a2fd-452d-b7af-50791046ca31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_20358046-2dcc-4955-a5a6-1f989d72e361" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_11f1a90e-58a5-4590-bf7a-d4e5d074aba7" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_20358046-2dcc-4955-a5a6-1f989d72e361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_ed9a0868-a90d-47e0-bb80-9a65d5e18930" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_11f1a90e-58a5-4590-bf7a-d4e5d074aba7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_ed9a0868-a90d-47e0-bb80-9a65d5e18930" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8844952b-50f3-4aba-a3ee-10b20a197000" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_11f1a90e-58a5-4590-bf7a-d4e5d074aba7" xlink:to="loc_us-gaap_NetIncomeLoss_8844952b-50f3-4aba-a3ee-10b20a197000" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d476292c-e762-4841-a8a8-cb6051d32213" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_11f1a90e-58a5-4590-bf7a-d4e5d074aba7" xlink:to="loc_us-gaap_StockholdersEquity_d476292c-e762-4841-a8a8-cb6051d32213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_3010a403-f909-4d3d-8895-9c27a23e7c14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_11f1a90e-58a5-4590-bf7a-d4e5d074aba7" xlink:to="loc_us-gaap_SharesOutstanding_3010a403-f909-4d3d-8895-9c27a23e7c14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="ardx-20220331.xsd#CONDENSEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_aa805348-cecf-4cde-8f26-83f2a76c24eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ffa7f4a3-d173-4bc1-a562-c524afc469d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_aa805348-cecf-4cde-8f26-83f2a76c24eb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ffa7f4a3-d173-4bc1-a562-c524afc469d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_63522fbf-6995-47a0-bbc4-56f74f01dcf9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ffa7f4a3-d173-4bc1-a562-c524afc469d3" xlink:to="loc_us-gaap_NetIncomeLoss_63522fbf-6995-47a0-bbc4-56f74f01dcf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_42476cf9-3f98-4693-8695-1ec6bfd59ec5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ffa7f4a3-d173-4bc1-a562-c524afc469d3" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_42476cf9-3f98-4693-8695-1ec6bfd59ec5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_0f9be479-f22e-4df4-a22e-ef0b9f82e953" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_42476cf9-3f98-4693-8695-1ec6bfd59ec5" xlink:to="loc_us-gaap_Depreciation_0f9be479-f22e-4df4-a22e-ef0b9f82e953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_8ca3b8b1-42b6-4879-ae7c-d1b586b27c3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_42476cf9-3f98-4693-8695-1ec6bfd59ec5" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_8ca3b8b1-42b6-4879-ae7c-d1b586b27c3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDeferredCharges_82ef00ba-cde4-4be0-a70b-28efd0c28f48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDeferredCharges"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_42476cf9-3f98-4693-8695-1ec6bfd59ec5" xlink:to="loc_us-gaap_AmortizationOfDeferredCharges_82ef00ba-cde4-4be0-a70b-28efd0c28f48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_5379f40e-dc7d-4cfa-a62e-bff20313e4d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_42476cf9-3f98-4693-8695-1ec6bfd59ec5" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_5379f40e-dc7d-4cfa-a62e-bff20313e4d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_39c39307-f92a-4238-a15a-5776958506a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_42476cf9-3f98-4693-8695-1ec6bfd59ec5" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_39c39307-f92a-4238-a15a-5776958506a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_3226671e-fd6e-46c4-b377-728d9e689539" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_42476cf9-3f98-4693-8695-1ec6bfd59ec5" xlink:to="loc_us-gaap_ShareBasedCompensation_3226671e-fd6e-46c4-b377-728d9e689539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_4b4c47f3-3b72-4883-97cf-e5f37de60469" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_42476cf9-3f98-4693-8695-1ec6bfd59ec5" xlink:to="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_4b4c47f3-3b72-4883-97cf-e5f37de60469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnRestructuringOfDebt_5cf95fcf-d171-4d14-afb9-807b34789b31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnRestructuringOfDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_42476cf9-3f98-4693-8695-1ec6bfd59ec5" xlink:to="loc_us-gaap_GainsLossesOnRestructuringOfDebt_5cf95fcf-d171-4d14-afb9-807b34789b31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets_06424ee3-aecd-4d51-a0bc-c42a53f886d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_42476cf9-3f98-4693-8695-1ec6bfd59ec5" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets_06424ee3-aecd-4d51-a0bc-c42a53f886d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_ff6c517b-bce5-4781-af65-c70561b3e91d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_42476cf9-3f98-4693-8695-1ec6bfd59ec5" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_ff6c517b-bce5-4781-af65-c70561b3e91d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c1bc5ee3-c628-4959-9ac3-15f6d95fe4e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ffa7f4a3-d173-4bc1-a562-c524afc469d3" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c1bc5ee3-c628-4959-9ac3-15f6d95fe4e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_f454d639-3210-453c-80d4-ee168abba444" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c1bc5ee3-c628-4959-9ac3-15f6d95fe4e7" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_f454d639-3210-453c-80d4-ee168abba444" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_e73e5352-894f-4191-8e09-9373ee3f03c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c1bc5ee3-c628-4959-9ac3-15f6d95fe4e7" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_e73e5352-894f-4191-8e09-9373ee3f03c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_e2fbef9b-6d37-49d5-9fd9-c1af14bf784c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c1bc5ee3-c628-4959-9ac3-15f6d95fe4e7" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_e2fbef9b-6d37-49d5-9fd9-c1af14bf784c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_d7c06242-f7e7-4514-ab6e-3b71812beddf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c1bc5ee3-c628-4959-9ac3-15f6d95fe4e7" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_d7c06242-f7e7-4514-ab6e-3b71812beddf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_dfadfcbb-95d3-46a5-98a3-d4d55226c642" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c1bc5ee3-c628-4959-9ac3-15f6d95fe4e7" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_dfadfcbb-95d3-46a5-98a3-d4d55226c642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_4a2289ad-0af4-4bbf-803f-1ae42abb7dc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c1bc5ee3-c628-4959-9ac3-15f6d95fe4e7" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_4a2289ad-0af4-4bbf-803f-1ae42abb7dc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_9703642d-ffb4-4123-96a6-557a1aa49204" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c1bc5ee3-c628-4959-9ac3-15f6d95fe4e7" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_9703642d-ffb4-4123-96a6-557a1aa49204" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_70e89d6f-b535-4d13-a04e-a59aed58f198" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c1bc5ee3-c628-4959-9ac3-15f6d95fe4e7" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_70e89d6f-b535-4d13-a04e-a59aed58f198" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8ef28e4b-ff70-4c3f-9ab4-1e049faa4993" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ffa7f4a3-d173-4bc1-a562-c524afc469d3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8ef28e4b-ff70-4c3f-9ab4-1e049faa4993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_213cccc7-cc4d-4c52-ba18-baca75d15701" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_aa805348-cecf-4cde-8f26-83f2a76c24eb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_213cccc7-cc4d-4c52-ba18-baca75d15701" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_7545efbe-cb80-4ec8-a36b-8fac87a56bfe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_213cccc7-cc4d-4c52-ba18-baca75d15701" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_7545efbe-cb80-4ec8-a36b-8fac87a56bfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_db573c30-67ab-4fb6-b6af-0bf2040861f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_213cccc7-cc4d-4c52-ba18-baca75d15701" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_db573c30-67ab-4fb6-b6af-0bf2040861f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfMachineryAndEquipment_be74be8d-3c96-4927-b8d2-7ae764d19921" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfMachineryAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_213cccc7-cc4d-4c52-ba18-baca75d15701" xlink:to="loc_us-gaap_ProceedsFromSaleOfMachineryAndEquipment_be74be8d-3c96-4927-b8d2-7ae764d19921" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4032aa41-0e13-4caa-b961-b73a782aaa67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_213cccc7-cc4d-4c52-ba18-baca75d15701" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4032aa41-0e13-4caa-b961-b73a782aaa67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ddd4462d-687f-47f9-9361-334c4ee2e9f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_213cccc7-cc4d-4c52-ba18-baca75d15701" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ddd4462d-687f-47f9-9361-334c4ee2e9f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b701ad79-e913-47aa-8f8b-2efde3c6f3d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_aa805348-cecf-4cde-8f26-83f2a76c24eb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b701ad79-e913-47aa-8f8b-2efde3c6f3d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_c892932d-cbd4-44c2-aec8-3d69b5942a9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b701ad79-e913-47aa-8f8b-2efde3c6f3d8" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_c892932d-cbd4-44c2-aec8-3d69b5942a9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSecuredDebt_c2ab623b-7cb7-4c91-b397-1e36d094e130" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfSecuredDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b701ad79-e913-47aa-8f8b-2efde3c6f3d8" xlink:to="loc_us-gaap_RepaymentsOfSecuredDebt_c2ab623b-7cb7-4c91-b397-1e36d094e130" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_7f89bc4e-2e14-435e-9e09-e9687ee5adcc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b701ad79-e913-47aa-8f8b-2efde3c6f3d8" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_7f89bc4e-2e14-435e-9e09-e9687ee5adcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_dc5f91c8-285c-47d7-95a5-289e663c9b76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b701ad79-e913-47aa-8f8b-2efde3c6f3d8" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_dc5f91c8-285c-47d7-95a5-289e663c9b76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_857e1906-efb3-4255-bd53-72440a6b95ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b701ad79-e913-47aa-8f8b-2efde3c6f3d8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_857e1906-efb3-4255-bd53-72440a6b95ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a675ee1f-fa24-4b05-bbf9-7a260c250962" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_aa805348-cecf-4cde-8f26-83f2a76c24eb" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a675ee1f-fa24-4b05-bbf9-7a260c250962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_156738e9-0e8f-4e32-8c4d-4906355c54c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_aa805348-cecf-4cde-8f26-83f2a76c24eb" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_156738e9-0e8f-4e32-8c4d-4906355c54c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_191901c5-1de1-45b1-aca7-8f3d27c341d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_aa805348-cecf-4cde-8f26-83f2a76c24eb" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_191901c5-1de1-45b1-aca7-8f3d27c341d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_e4ff2922-4cd8-4688-a05b-27de6ff1b44c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_aa805348-cecf-4cde-8f26-83f2a76c24eb" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_e4ff2922-4cd8-4688-a05b-27de6ff1b44c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_4b0c5103-65b7-42c3-8cc6-72f3538dfc1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_e4ff2922-4cd8-4688-a05b-27de6ff1b44c" xlink:to="loc_us-gaap_InterestPaidNet_4b0c5103-65b7-42c3-8cc6-72f3538dfc1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_3d613df8-9c95-4e35-96e5-ace0ac69e348" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_e4ff2922-4cd8-4688-a05b-27de6ff1b44c" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_3d613df8-9c95-4e35-96e5-ace0ac69e348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_4d166a21-f745-47fb-90bb-9d59e05d376f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_aa805348-cecf-4cde-8f26-83f2a76c24eb" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_4d166a21-f745-47fb-90bb-9d59e05d376f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_9e4d80fe-15a2-480e-bf8a-91aa8e9334f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_4d166a21-f745-47fb-90bb-9d59e05d376f" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_9e4d80fe-15a2-480e-bf8a-91aa8e9334f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DerivativeIssued_70346fa8-be44-4b3c-a99e-d5513074c0b3" xlink:href="ardx-20220331.xsd#ardx_DerivativeIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_4d166a21-f745-47fb-90bb-9d59e05d376f" xlink:to="loc_ardx_DerivativeIssued_70346fa8-be44-4b3c-a99e-d5513074c0b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/OrganizationandBasisofPresentation" xlink:type="simple" xlink:href="ardx-20220331.xsd#OrganizationandBasisofPresentation"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/OrganizationandBasisofPresentation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8e4874fd-3a06-46f2-9869-96557a0ac480" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_af0b78d5-3e09-4b6c-96f8-f17500a3d6e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8e4874fd-3a06-46f2-9869-96557a0ac480" xlink:to="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_af0b78d5-3e09-4b6c-96f8-f17500a3d6e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/OrganizationandBasisofPresentationPolicies" xlink:type="simple" xlink:href="ardx-20220331.xsd#OrganizationandBasisofPresentationPolicies"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/OrganizationandBasisofPresentationPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8dba7dcf-a949-4587-b757-e4c3d1c5e9b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_dc186e52-6b92-48ed-a050-f4e6c3611905" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8dba7dcf-a949-4587-b757-e4c3d1c5e9b8" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_dc186e52-6b92-48ed-a050-f4e6c3611905" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_1da5a9e0-17c5-4274-94d0-40976e7c1ba1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8dba7dcf-a949-4587-b757-e4c3d1c5e9b8" xlink:to="loc_us-gaap_UseOfEstimates_1da5a9e0-17c5-4274-94d0-40976e7c1ba1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_c9664c24-8067-44db-8bc4-9a6c7330d02c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8dba7dcf-a949-4587-b757-e4c3d1c5e9b8" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_c9664c24-8067-44db-8bc4-9a6c7330d02c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_b5c86e79-1181-49f9-9ddf-748ad83f77d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8dba7dcf-a949-4587-b757-e4c3d1c5e9b8" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_b5c86e79-1181-49f9-9ddf-748ad83f77d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_3945ed8c-eb76-446b-8961-70ccb61f61bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8dba7dcf-a949-4587-b757-e4c3d1c5e9b8" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_3945ed8c-eb76-446b-8961-70ccb61f61bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock_9ff41c74-334f-41f9-80f4-d528bca58041" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8dba7dcf-a949-4587-b757-e4c3d1c5e9b8" xlink:to="loc_us-gaap_CostOfSalesPolicyTextBlock_9ff41c74-334f-41f9-80f4-d528bca58041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_4a0958f0-63b1-4b29-8ec2-4a23e03dd449" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8dba7dcf-a949-4587-b757-e4c3d1c5e9b8" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_4a0958f0-63b1-4b29-8ec2-4a23e03dd449" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_af67be9f-3ee5-471e-a85c-45fbbfcf5c60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8dba7dcf-a949-4587-b757-e4c3d1c5e9b8" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_af67be9f-3ee5-471e-a85c-45fbbfcf5c60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/OrganizationandBasisofPresentationDetails" xlink:type="simple" xlink:href="ardx-20220331.xsd#OrganizationandBasisofPresentationDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/OrganizationandBasisofPresentationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4928fb49-e2f3-443d-bdab-2d69a2a4fef0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_10f89890-3bdc-405b-bb4e-59c2ccbc0614" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4928fb49-e2f3-443d-bdab-2d69a2a4fef0" xlink:to="loc_us-gaap_NumberOfOperatingSegments_10f89890-3bdc-405b-bb4e-59c2ccbc0614" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAndCash_d8f27839-1a98-4a3f-a6f6-6d13a8d98616" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsAndCash"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4928fb49-e2f3-443d-bdab-2d69a2a4fef0" xlink:to="loc_us-gaap_InvestmentsAndCash_d8f27839-1a98-4a3f-a6f6-6d13a8d98616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_3221ec9f-851e-4d9e-8c1d-442a99ce8f7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4928fb49-e2f3-443d-bdab-2d69a2a4fef0" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_3221ec9f-851e-4d9e-8c1d-442a99ce8f7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9b1476bb-4e51-4f18-9e73-d95a780f9b59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4928fb49-e2f3-443d-bdab-2d69a2a4fef0" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9b1476bb-4e51-4f18-9e73-d95a780f9b59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_bf020a59-15df-4736-893d-0ed8201cf0c6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9b1476bb-4e51-4f18-9e73-d95a780f9b59" xlink:to="loc_srt_CounterpartyNameAxis_bf020a59-15df-4736-893d-0ed8201cf0c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_02ac0772-baaf-4ebc-8d4f-231d05421e98" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_bf020a59-15df-4736-893d-0ed8201cf0c6" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_02ac0772-baaf-4ebc-8d4f-231d05421e98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AstrazenecaMember_1270624a-412d-4e38-9c4a-f9df153030bf" xlink:href="ardx-20220331.xsd#ardx_AstrazenecaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_02ac0772-baaf-4ebc-8d4f-231d05421e98" xlink:to="loc_ardx_AstrazenecaMember_1270624a-412d-4e38-9c4a-f9df153030bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_e446eb49-9f04-4f76-8df3-fa72beef812a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9b1476bb-4e51-4f18-9e73-d95a780f9b59" xlink:to="loc_us-gaap_TypeOfArrangementAxis_e446eb49-9f04-4f76-8df3-fa72beef812a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d762b465-d7c4-4c7b-b694-ee38ef91ffb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_e446eb49-9f04-4f76-8df3-fa72beef812a" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d762b465-d7c4-4c7b-b694-ee38ef91ffb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AstraZenecaTerminationAgreementMember_6e2aea10-acda-4dfe-bf3d-36eb15d87928" xlink:href="ardx-20220331.xsd#ardx_AstraZenecaTerminationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d762b465-d7c4-4c7b-b694-ee38ef91ffb2" xlink:to="loc_ardx_AstraZenecaTerminationAgreementMember_6e2aea10-acda-4dfe-bf3d-36eb15d87928" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_591a0042-cd98-47b1-be60-2fdbd4440fb2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9b1476bb-4e51-4f18-9e73-d95a780f9b59" xlink:to="loc_srt_RangeAxis_591a0042-cd98-47b1-be60-2fdbd4440fb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_56515d0d-acd2-4cab-abbf-3d3f7a2f7e4e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_591a0042-cd98-47b1-be60-2fdbd4440fb2" xlink:to="loc_srt_RangeMember_56515d0d-acd2-4cab-abbf-3d3f7a2f7e4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_848ec922-68e5-4e10-980e-e5d3a5a121ea" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_56515d0d-acd2-4cab-abbf-3d3f7a2f7e4e" xlink:to="loc_srt_MinimumMember_848ec922-68e5-4e10-980e-e5d3a5a121ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2a76257b-3104-4e4b-898c-6c070d20599b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_56515d0d-acd2-4cab-abbf-3d3f7a2f7e4e" xlink:to="loc_srt_MaximumMember_2a76257b-3104-4e4b-898c-6c070d20599b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_82ff2def-6d5c-4425-b4a8-dd4070d6314a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9b1476bb-4e51-4f18-9e73-d95a780f9b59" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_82ff2def-6d5c-4425-b4a8-dd4070d6314a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_9d926af1-3f7c-4762-9cfd-593d26cdf331" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_82ff2def-6d5c-4425-b4a8-dd4070d6314a" xlink:to="loc_us-gaap_ReceivableTypeDomain_9d926af1-3f7c-4762-9cfd-593d26cdf331" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AccountsReceivableCollaboratorMember_54dae6cd-600f-42ef-94e2-2248a5f7c561" xlink:href="ardx-20220331.xsd#ardx_AccountsReceivableCollaboratorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivableTypeDomain_9d926af1-3f7c-4762-9cfd-593d26cdf331" xlink:to="loc_ardx_AccountsReceivableCollaboratorMember_54dae6cd-600f-42ef-94e2-2248a5f7c561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AccountsReceivableCommercialCustomerMember_fd8eb6fe-6f0e-481e-8b89-f926ffd12dc2" xlink:href="ardx-20220331.xsd#ardx_AccountsReceivableCommercialCustomerMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivableTypeDomain_9d926af1-3f7c-4762-9cfd-593d26cdf331" xlink:to="loc_ardx_AccountsReceivableCommercialCustomerMember_fd8eb6fe-6f0e-481e-8b89-f926ffd12dc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dea229a7-2103-45ff-8d8e-4fdaa9a0c743" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9b1476bb-4e51-4f18-9e73-d95a780f9b59" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dea229a7-2103-45ff-8d8e-4fdaa9a0c743" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_a9de1e4c-73bf-4d85-89a5-3c227b424a35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dea229a7-2103-45ff-8d8e-4fdaa9a0c743" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_a9de1e4c-73bf-4d85-89a5-3c227b424a35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_RevenueGeneralPaymentTerms_c5f108e7-4c45-4b5a-ab8c-00219abd0d5a" xlink:href="ardx-20220331.xsd#ardx_RevenueGeneralPaymentTerms"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dea229a7-2103-45ff-8d8e-4fdaa9a0c743" xlink:to="loc_ardx_RevenueGeneralPaymentTerms_c5f108e7-4c45-4b5a-ab8c-00219abd0d5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_PercentageOfRoyaltyRevenue_967a1810-df6e-4b14-9de0-37475603fd99" xlink:href="ardx-20220331.xsd#ardx_PercentageOfRoyaltyRevenue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dea229a7-2103-45ff-8d8e-4fdaa9a0c743" xlink:to="loc_ardx_PercentageOfRoyaltyRevenue_967a1810-df6e-4b14-9de0-37475603fd99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_PercentageOfNonRoyaltyRevenue_0fb77c61-aadf-4f8d-af33-25454c64238c" xlink:href="ardx-20220331.xsd#ardx_PercentageOfNonRoyaltyRevenue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dea229a7-2103-45ff-8d8e-4fdaa9a0c743" xlink:to="loc_ardx_PercentageOfNonRoyaltyRevenue_0fb77c61-aadf-4f8d-af33-25454c64238c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum_8d7e9369-0f03-4d31-be98-8bc999f132c8" xlink:href="ardx-20220331.xsd#ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dea229a7-2103-45ff-8d8e-4fdaa9a0c743" xlink:to="loc_ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum_8d7e9369-0f03-4d31-be98-8bc999f132c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CostOfRevenueAggregateAmountRecognized_7d5733f8-bc01-4022-bc74-b8d2f7c88e40" xlink:href="ardx-20220331.xsd#ardx_CostOfRevenueAggregateAmountRecognized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dea229a7-2103-45ff-8d8e-4fdaa9a0c743" xlink:to="loc_ardx_CostOfRevenueAggregateAmountRecognized_7d5733f8-bc01-4022-bc74-b8d2f7c88e40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/CashCashEquivalentsandInvestments" xlink:type="simple" xlink:href="ardx-20220331.xsd#CashCashEquivalentsandInvestments"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/CashCashEquivalentsandInvestments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_5a1f2093-240d-4873-b78e-c27b69037a98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_81020849-ad59-4256-979b-8f532a44eb07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_5a1f2093-240d-4873-b78e-c27b69037a98" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_81020849-ad59-4256-979b-8f532a44eb07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsTables" xlink:type="simple" xlink:href="ardx-20220331.xsd#CashCashEquivalentsandInvestmentsTables"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_50a834b4-cebd-4462-870d-22b8bedabf2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_a57b23fe-0043-47c5-9094-8eeb14190d0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_50a834b4-cebd-4462-870d-22b8bedabf2b" xlink:to="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_a57b23fe-0043-47c5-9094-8eeb14190d0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails" xlink:type="simple" xlink:href="ardx-20220331.xsd#CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_7292dac9-fa5f-4712-ab9d-3cf56c614361" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_9316499e-c14e-444d-914c-5295c2f23c55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_7292dac9-fa5f-4712-ab9d-3cf56c614361" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_9316499e-c14e-444d-914c-5295c2f23c55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_32eeda5d-7b55-4641-b2d7-a5d5f4886322" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_9316499e-c14e-444d-914c-5295c2f23c55" xlink:to="loc_us-gaap_FinancialInstrumentAxis_32eeda5d-7b55-4641-b2d7-a5d5f4886322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d75d3ec5-5f8d-41b3-8908-9b95f69d4e21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_32eeda5d-7b55-4641-b2d7-a5d5f4886322" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d75d3ec5-5f8d-41b3-8908-9b95f69d4e21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_5f18f66f-1ba3-4530-9bc8-581d46de21e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d75d3ec5-5f8d-41b3-8908-9b95f69d4e21" xlink:to="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_5f18f66f-1ba3-4530-9bc8-581d46de21e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_a4abd70f-8714-4424-94eb-bb0dfd91fced" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d75d3ec5-5f8d-41b3-8908-9b95f69d4e21" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_a4abd70f-8714-4424-94eb-bb0dfd91fced" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_6e5c263f-3712-42a4-8684-e88cef1342e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d75d3ec5-5f8d-41b3-8908-9b95f69d4e21" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_6e5c263f-3712-42a4-8684-e88cef1342e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_6b0a1375-9cda-4768-ab04-402177597e24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d75d3ec5-5f8d-41b3-8908-9b95f69d4e21" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_6b0a1375-9cda-4768-ab04-402177597e24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_24c6d1d3-406c-41cd-878c-3d3acd8de2ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_9316499e-c14e-444d-914c-5295c2f23c55" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_24c6d1d3-406c-41cd-878c-3d3acd8de2ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_6755f85e-bf6e-4d22-bca1-ef0f00e89f63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_24c6d1d3-406c-41cd-878c-3d3acd8de2ca" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_6755f85e-bf6e-4d22-bca1-ef0f00e89f63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_59602c2d-8e0c-4914-8ab0-a8c7ff1b4057" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_6755f85e-bf6e-4d22-bca1-ef0f00e89f63" xlink:to="loc_us-gaap_CashMember_59602c2d-8e0c-4914-8ab0-a8c7ff1b4057" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_d00fd1a2-8298-4180-9b50-0991e6ea35b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_6755f85e-bf6e-4d22-bca1-ef0f00e89f63" xlink:to="loc_us-gaap_MoneyMarketFundsMember_d00fd1a2-8298-4180-9b50-0991e6ea35b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_6304d02c-b6c3-4388-b965-cae8163de089" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_6755f85e-bf6e-4d22-bca1-ef0f00e89f63" xlink:to="loc_us-gaap_CommercialPaperMember_6304d02c-b6c3-4388-b965-cae8163de089" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5416c14c-0353-45a1-960f-5f71411db2fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_9316499e-c14e-444d-914c-5295c2f23c55" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5416c14c-0353-45a1-960f-5f71411db2fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_511fa983-6d0e-4d7f-b3c0-e74cd07ba670" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5416c14c-0353-45a1-960f-5f71411db2fb" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_511fa983-6d0e-4d7f-b3c0-e74cd07ba670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CashAndCashEquivalentsAmortizedCost_b74c8bc7-4057-499f-a0a8-fa3f748e3d27" xlink:href="ardx-20220331.xsd#ardx_CashAndCashEquivalentsAmortizedCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_511fa983-6d0e-4d7f-b3c0-e74cd07ba670" xlink:to="loc_ardx_CashAndCashEquivalentsAmortizedCost_b74c8bc7-4057-499f-a0a8-fa3f748e3d27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CashAndCashEquivalentsGrossUnrealizedGains_2f96fc15-7bb9-42c0-ae2b-16d192e94c3a" xlink:href="ardx-20220331.xsd#ardx_CashAndCashEquivalentsGrossUnrealizedGains"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_511fa983-6d0e-4d7f-b3c0-e74cd07ba670" xlink:to="loc_ardx_CashAndCashEquivalentsGrossUnrealizedGains_2f96fc15-7bb9-42c0-ae2b-16d192e94c3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CashAndCashEquivalentsGrossUnrealizedLosses_290ac519-f2d9-4305-a22c-b39837e85bfe" xlink:href="ardx-20220331.xsd#ardx_CashAndCashEquivalentsGrossUnrealizedLosses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_511fa983-6d0e-4d7f-b3c0-e74cd07ba670" xlink:to="loc_ardx_CashAndCashEquivalentsGrossUnrealizedLosses_290ac519-f2d9-4305-a22c-b39837e85bfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c9d446b7-1b51-4793-aeeb-397b369d17d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_511fa983-6d0e-4d7f-b3c0-e74cd07ba670" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c9d446b7-1b51-4793-aeeb-397b369d17d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_d1c69962-6022-44b7-b4ef-2cf88f1dcd0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5416c14c-0353-45a1-960f-5f71411db2fb" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_d1c69962-6022-44b7-b4ef-2cf88f1dcd0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ad987ac2-f7ba-42e0-8451-f86cb53cd5e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_d1c69962-6022-44b7-b4ef-2cf88f1dcd0d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ad987ac2-f7ba-42e0-8451-f86cb53cd5e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_987c7493-085e-4b1d-b753-8d4f9d42d9d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_d1c69962-6022-44b7-b4ef-2cf88f1dcd0d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_987c7493-085e-4b1d-b753-8d4f9d42d9d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_5fb37ac4-dc87-4143-acb3-453fc7d1e47b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_d1c69962-6022-44b7-b4ef-2cf88f1dcd0d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_5fb37ac4-dc87-4143-acb3-453fc7d1e47b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_79ba6c14-9c33-49c7-9d99-2d3cb6ee23e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_d1c69962-6022-44b7-b4ef-2cf88f1dcd0d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_79ba6c14-9c33-49c7-9d99-2d3cb6ee23e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_InvestmentsAndCashAmortizedCost_fd5cc4a2-563f-46f4-a520-668d8fa405c1" xlink:href="ardx-20220331.xsd#ardx_InvestmentsAndCashAmortizedCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5416c14c-0353-45a1-960f-5f71411db2fb" xlink:to="loc_ardx_InvestmentsAndCashAmortizedCost_fd5cc4a2-563f-46f4-a520-668d8fa405c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedGains_f180d09d-32c0-44f3-bb9f-76e25127698e" xlink:href="ardx-20220331.xsd#ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedGains"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5416c14c-0353-45a1-960f-5f71411db2fb" xlink:to="loc_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedGains_f180d09d-32c0-44f3-bb9f-76e25127698e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses_9b6edc65-b5f9-4852-b892-cba82d67eabc" xlink:href="ardx-20220331.xsd#ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5416c14c-0353-45a1-960f-5f71411db2fb" xlink:to="loc_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses_9b6edc65-b5f9-4852-b892-cba82d67eabc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAndCash_d4054c0a-46b8-480e-adc9-e8a5c6219b4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsAndCash"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5416c14c-0353-45a1-960f-5f71411db2fb" xlink:to="loc_us-gaap_InvestmentsAndCash_d4054c0a-46b8-480e-adc9-e8a5c6219b4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsNarrativeDetails" xlink:type="simple" xlink:href="ardx-20220331.xsd#CashCashEquivalentsandInvestmentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_74315d1e-7586-4cde-9620-0e907d4665de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum_a37d0944-1ada-4b77-9ce4-86b08f873319" xlink:href="ardx-20220331.xsd#ardx_AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_74315d1e-7586-4cde-9620-0e907d4665de" xlink:to="loc_ardx_AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum_a37d0944-1ada-4b77-9ce4-86b08f873319" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_930ea87c-401e-4eb5-8800-66b12ee8bc02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_74315d1e-7586-4cde-9620-0e907d4665de" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_930ea87c-401e-4eb5-8800-66b12ee8bc02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_3a2b7218-08a4-4867-9487-206085226187" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_74315d1e-7586-4cde-9620-0e907d4665de" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_3a2b7218-08a4-4867-9487-206085226187" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="ardx-20220331.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_6c9207a8-d461-41f0-8316-e83e0dc38196" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_966cbf84-3886-43cb-be08-ce57ede3f9e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_6c9207a8-d461-41f0-8316-e83e0dc38196" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_966cbf84-3886-43cb-be08-ce57ede3f9e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="ardx-20220331.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_8d65e6b6-f776-43aa-a623-f325944651d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_ca413b36-39ac-4cc9-87b5-1445f9ce3b61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_8d65e6b6-f776-43aa-a623-f325944651d7" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_ca413b36-39ac-4cc9-87b5-1445f9ce3b61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="ardx-20220331.xsd#FairValueMeasurementsDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_d39451a1-a5e7-4961-a29a-ca15b58d539a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e2c38591-cbdc-4fd3-8005-07f0bb2c2819" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d39451a1-a5e7-4961-a29a-ca15b58d539a" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e2c38591-cbdc-4fd3-8005-07f0bb2c2819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_54a06e11-895d-435d-aea4-82019963d555" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e2c38591-cbdc-4fd3-8005-07f0bb2c2819" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_54a06e11-895d-435d-aea4-82019963d555" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_20da19d9-d721-4b31-b58f-c0d569f116db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_54a06e11-895d-435d-aea4-82019963d555" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_20da19d9-d721-4b31-b58f-c0d569f116db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_1e63398a-71f7-4a24-9ada-f21e30d70a95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_20da19d9-d721-4b31-b58f-c0d569f116db" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_1e63398a-71f7-4a24-9ada-f21e30d70a95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_db6fe73a-0ee9-49fa-80c8-5566687d95cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e2c38591-cbdc-4fd3-8005-07f0bb2c2819" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_db6fe73a-0ee9-49fa-80c8-5566687d95cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ac84fc8b-5f3a-43ea-b1fa-fb18f58975bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_db6fe73a-0ee9-49fa-80c8-5566687d95cf" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ac84fc8b-5f3a-43ea-b1fa-fb18f58975bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_f7b9a320-c086-4d75-b00e-0a53c7b215a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ac84fc8b-5f3a-43ea-b1fa-fb18f58975bd" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_f7b9a320-c086-4d75-b00e-0a53c7b215a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_f86d5798-4100-40e3-aace-7877a2a00c74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ac84fc8b-5f3a-43ea-b1fa-fb18f58975bd" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_f86d5798-4100-40e3-aace-7877a2a00c74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_c6a7b6a4-0b19-4628-bb37-0dd7b5b5dfa3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ac84fc8b-5f3a-43ea-b1fa-fb18f58975bd" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_c6a7b6a4-0b19-4628-bb37-0dd7b5b5dfa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_2df7c15f-e711-4082-9226-82bd3f2cab9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e2c38591-cbdc-4fd3-8005-07f0bb2c2819" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_2df7c15f-e711-4082-9226-82bd3f2cab9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_cb668fd3-64ee-4704-8630-9f58fc11b92c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_2df7c15f-e711-4082-9226-82bd3f2cab9c" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_cb668fd3-64ee-4704-8630-9f58fc11b92c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_c08a558d-5fbe-4f75-98ea-c68ee473c0d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_cb668fd3-64ee-4704-8630-9f58fc11b92c" xlink:to="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_c08a558d-5fbe-4f75-98ea-c68ee473c0d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_a2fea438-fd4d-4f15-b054-a52fec4006ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e2c38591-cbdc-4fd3-8005-07f0bb2c2819" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_a2fea438-fd4d-4f15-b054-a52fec4006ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_91a1fac4-664c-433c-940f-8e76e835c730" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_a2fea438-fd4d-4f15-b054-a52fec4006ba" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_91a1fac4-664c-433c-940f-8e76e835c730" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_86f95adb-149d-467d-b481-d2cdb5f24c07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_91a1fac4-664c-433c-940f-8e76e835c730" xlink:to="loc_us-gaap_MoneyMarketFundsMember_86f95adb-149d-467d-b481-d2cdb5f24c07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_c7d7c41a-c224-4423-99c2-ffc21c4112af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_91a1fac4-664c-433c-940f-8e76e835c730" xlink:to="loc_us-gaap_CommercialPaperMember_c7d7c41a-c224-4423-99c2-ffc21c4112af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_a84370bf-24ed-4210-801e-7cf11f16fdf4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_91a1fac4-664c-433c-940f-8e76e835c730" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_a84370bf-24ed-4210-801e-7cf11f16fdf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_0ce9a09b-d701-4a24-acb6-af4835ffaaf5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_91a1fac4-664c-433c-940f-8e76e835c730" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_0ce9a09b-d701-4a24-acb6-af4835ffaaf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_de5725e4-166a-4764-bad6-ddc23e6795cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_91a1fac4-664c-433c-940f-8e76e835c730" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_de5725e4-166a-4764-bad6-ddc23e6795cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_974878df-94bb-4086-835e-34eb46564047" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e2c38591-cbdc-4fd3-8005-07f0bb2c2819" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_974878df-94bb-4086-835e-34eb46564047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_04ccce4f-7638-4362-ad46-94dc16e007ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_974878df-94bb-4086-835e-34eb46564047" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_04ccce4f-7638-4362-ad46-94dc16e007ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_71920037-e27f-42ae-a71b-bf85c3405758" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_04ccce4f-7638-4362-ad46-94dc16e007ce" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_71920037-e27f-42ae-a71b-bf85c3405758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_4f768c07-b2ba-43e3-b2df-149f00f59db4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_974878df-94bb-4086-835e-34eb46564047" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_4f768c07-b2ba-43e3-b2df-149f00f59db4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_36b068ee-3241-4487-9877-4a557136ded9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_4f768c07-b2ba-43e3-b2df-149f00f59db4" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_36b068ee-3241-4487-9877-4a557136ded9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/Inventory" xlink:type="simple" xlink:href="ardx-20220331.xsd#Inventory"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/Inventory" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_f97e096d-acfc-4448-901b-4b6921d5c863" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_63611b59-00d3-4d0f-ad7e-dd5e834fffc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_f97e096d-acfc-4448-901b-4b6921d5c863" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_63611b59-00d3-4d0f-ad7e-dd5e834fffc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/InventoryTables" xlink:type="simple" xlink:href="ardx-20220331.xsd#InventoryTables"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/InventoryTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_48512034-27c4-4fff-920b-15350e6f3027" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_bae03ef2-b13d-4ab9-b883-ddaa282ebca8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_48512034-27c4-4fff-920b-15350e6f3027" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_bae03ef2-b13d-4ab9-b883-ddaa282ebca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/InventoryDetails" xlink:type="simple" xlink:href="ardx-20220331.xsd#InventoryDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_c4df5341-1042-482c-95c0-ee664904805e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNetAbstract_e7dc5cb3-389d-4f2d-a5cf-7922b36a5c90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_c4df5341-1042-482c-95c0-ee664904805e" xlink:to="loc_us-gaap_InventoryNetAbstract_e7dc5cb3-389d-4f2d-a5cf-7922b36a5c90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_d42f1a6e-a98b-4f87-809d-6a65ca57feed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_e7dc5cb3-389d-4f2d-a5cf-7922b36a5c90" xlink:to="loc_us-gaap_InventoryRawMaterials_d42f1a6e-a98b-4f87-809d-6a65ca57feed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_f7b5c583-d98d-4d94-970b-da3aed02e989" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_e7dc5cb3-389d-4f2d-a5cf-7922b36a5c90" xlink:to="loc_us-gaap_InventoryWorkInProcess_f7b5c583-d98d-4d94-970b-da3aed02e989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_ceec9c20-7261-4672-a94e-acca88b26b28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_e7dc5cb3-389d-4f2d-a5cf-7922b36a5c90" xlink:to="loc_us-gaap_InventoryFinishedGoods_ceec9c20-7261-4672-a94e-acca88b26b28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_a907f30d-4546-473c-9aa9-2e677be93b7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_e7dc5cb3-389d-4f2d-a5cf-7922b36a5c90" xlink:to="loc_us-gaap_InventoryNet_a907f30d-4546-473c-9aa9-2e677be93b7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/ProductRevenueNet" xlink:type="simple" xlink:href="ardx-20220331.xsd#ProductRevenueNet"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/ProductRevenueNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_962c5ed6-aaa3-4aca-86ac-76d2bd28522f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_a860e271-1447-451a-9722-8b919f8b51cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_962c5ed6-aaa3-4aca-86ac-76d2bd28522f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_a860e271-1447-451a-9722-8b919f8b51cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/ProductRevenueNetTables" xlink:type="simple" xlink:href="ardx-20220331.xsd#ProductRevenueNetTables"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/ProductRevenueNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_77f08707-0b3c-4779-9bae-ec647ce217e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ScheduleOfGrossToNetSalesAccrualsTableTextBlock_94c23259-fac6-4aca-8a55-608e2a0872b3" xlink:href="ardx-20220331.xsd#ardx_ScheduleOfGrossToNetSalesAccrualsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_77f08707-0b3c-4779-9bae-ec647ce217e6" xlink:to="loc_ardx_ScheduleOfGrossToNetSalesAccrualsTableTextBlock_94c23259-fac6-4aca-8a55-608e2a0872b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails" xlink:type="simple" xlink:href="ardx-20220331.xsd#ProductRevenueNetNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_29b8750b-3ff0-4591-834c-b1593a6b2b4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_a9327ce1-5677-493d-b262-8b12a79a5a28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_29b8750b-3ff0-4591-834c-b1593a6b2b4d" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_a9327ce1-5677-493d-b262-8b12a79a5a28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_890df545-0390-45f3-8028-b3c134178e6e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a9327ce1-5677-493d-b262-8b12a79a5a28" xlink:to="loc_srt_ProductOrServiceAxis_890df545-0390-45f3-8028-b3c134178e6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_07046f99-4afb-4d02-840b-df699382874a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_890df545-0390-45f3-8028-b3c134178e6e" xlink:to="loc_srt_ProductsAndServicesDomain_07046f99-4afb-4d02-840b-df699382874a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ProductIBSRELAMember_61fb82e9-b716-4ee7-9fdd-a37f795d1ab1" xlink:href="ardx-20220331.xsd#ardx_ProductIBSRELAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_07046f99-4afb-4d02-840b-df699382874a" xlink:to="loc_ardx_ProductIBSRELAMember_61fb82e9-b716-4ee7-9fdd-a37f795d1ab1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_713e801e-ab32-493b-aa13-59c368a5962f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_07046f99-4afb-4d02-840b-df699382874a" xlink:to="loc_us-gaap_ProductMember_713e801e-ab32-493b-aa13-59c368a5962f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a54bff5f-97c6-4c9f-8534-e26507606121" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a9327ce1-5677-493d-b262-8b12a79a5a28" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a54bff5f-97c6-4c9f-8534-e26507606121" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_b32e6f65-96f5-436b-85b3-384815d000e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a54bff5f-97c6-4c9f-8534-e26507606121" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_b32e6f65-96f5-436b-85b3-384815d000e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueProductLineMember_8ef6d3ce-909d-486e-87df-57b4d448f6f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueProductLineMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_b32e6f65-96f5-436b-85b3-384815d000e4" xlink:to="loc_us-gaap_SalesRevenueProductLineMember_8ef6d3ce-909d-486e-87df-57b4d448f6f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_8185eedb-acff-4eaf-b03c-3cecf2e20391" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a9327ce1-5677-493d-b262-8b12a79a5a28" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_8185eedb-acff-4eaf-b03c-3cecf2e20391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_37b673bb-eb4b-41fb-9254-a9aa02fc1f12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_8185eedb-acff-4eaf-b03c-3cecf2e20391" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_37b673bb-eb4b-41fb-9254-a9aa02fc1f12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_5f6ebff2-bb7a-401b-8b60-d57d7550f314" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_37b673bb-eb4b-41fb-9254-a9aa02fc1f12" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_5f6ebff2-bb7a-401b-8b60-d57d7550f314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_f64c12fa-b2b0-4882-9cdf-03f6410665bf" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a9327ce1-5677-493d-b262-8b12a79a5a28" xlink:to="loc_srt_MajorCustomersAxis_f64c12fa-b2b0-4882-9cdf-03f6410665bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_2dfde65f-2e7d-4abf-8e14-dbc87a467687" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_f64c12fa-b2b0-4882-9cdf-03f6410665bf" xlink:to="loc_srt_NameOfMajorCustomerDomain_2dfde65f-2e7d-4abf-8e14-dbc87a467687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AmerisourceBergenDrugCorporationMember_6823e3bc-b912-4bf7-872f-ab226e9dfb2b" xlink:href="ardx-20220331.xsd#ardx_AmerisourceBergenDrugCorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_2dfde65f-2e7d-4abf-8e14-dbc87a467687" xlink:to="loc_ardx_AmerisourceBergenDrugCorporationMember_6823e3bc-b912-4bf7-872f-ab226e9dfb2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CardinalHealthMember_65accbbc-e5ca-4a54-9543-383403c2a1e8" xlink:href="ardx-20220331.xsd#ardx_CardinalHealthMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_2dfde65f-2e7d-4abf-8e14-dbc87a467687" xlink:to="loc_ardx_CardinalHealthMember_65accbbc-e5ca-4a54-9543-383403c2a1e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_McKessonCorporationMember_8d35d9bd-8d42-4b90-a2f3-100ce1964235" xlink:href="ardx-20220331.xsd#ardx_McKessonCorporationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_2dfde65f-2e7d-4abf-8e14-dbc87a467687" xlink:to="loc_ardx_McKessonCorporationMember_8d35d9bd-8d42-4b90-a2f3-100ce1964235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_fdbd0ea2-fc7b-4ebd-b8b5-24aad83070ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a9327ce1-5677-493d-b262-8b12a79a5a28" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_fdbd0ea2-fc7b-4ebd-b8b5-24aad83070ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2735b908-db36-4144-8bdf-ff7aeb78e8b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_fdbd0ea2-fc7b-4ebd-b8b5-24aad83070ba" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2735b908-db36-4144-8bdf-ff7aeb78e8b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_fd4f531c-a4e3-48bd-9a1a-1dee100f5aa5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_fdbd0ea2-fc7b-4ebd-b8b5-24aad83070ba" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_fd4f531c-a4e3-48bd-9a1a-1dee100f5aa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerGrossToNetSalesAccruals_3ae8b6be-8171-4fb2-85ec-d485fdef3b59" xlink:href="ardx-20220331.xsd#ardx_ContractWithCustomerGrossToNetSalesAccruals"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_fdbd0ea2-fc7b-4ebd-b8b5-24aad83070ba" xlink:to="loc_ardx_ContractWithCustomerGrossToNetSalesAccruals_3ae8b6be-8171-4fb2-85ec-d485fdef3b59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/ProductRevenueNetGrosstoNetSalesAccrualsDetails" xlink:type="simple" xlink:href="ardx-20220331.xsd#ProductRevenueNetGrosstoNetSalesAccrualsDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/ProductRevenueNetGrosstoNetSalesAccrualsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a3ceafac-1d36-43b0-b404-8837bd583a67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_9cb7b559-6fb7-4783-89ab-99e7b9abc0c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a3ceafac-1d36-43b0-b404-8837bd583a67" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_9cb7b559-6fb7-4783-89ab-99e7b9abc0c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_GrossToNetSalesAccrualAndReserveClassificationAxis_90778d95-f324-4a4c-be12-fcc9a11a16e8" xlink:href="ardx-20220331.xsd#ardx_GrossToNetSalesAccrualAndReserveClassificationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_9cb7b559-6fb7-4783-89ab-99e7b9abc0c1" xlink:to="loc_ardx_GrossToNetSalesAccrualAndReserveClassificationAxis_90778d95-f324-4a4c-be12-fcc9a11a16e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_GrossToNetSalesAccrualAndReserveClassificationDomain_6a7fe94d-f403-4b32-80a4-a6442227ff29" xlink:href="ardx-20220331.xsd#ardx_GrossToNetSalesAccrualAndReserveClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_GrossToNetSalesAccrualAndReserveClassificationAxis_90778d95-f324-4a4c-be12-fcc9a11a16e8" xlink:to="loc_ardx_GrossToNetSalesAccrualAndReserveClassificationDomain_6a7fe94d-f403-4b32-80a4-a6442227ff29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerDiscountsAndChargebacksMember_358b9240-2c78-427b-b914-ccc758807a7b" xlink:href="ardx-20220331.xsd#ardx_ContractWithCustomerDiscountsAndChargebacksMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_GrossToNetSalesAccrualAndReserveClassificationDomain_6a7fe94d-f403-4b32-80a4-a6442227ff29" xlink:to="loc_ardx_ContractWithCustomerDiscountsAndChargebacksMember_358b9240-2c78-427b-b914-ccc758807a7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerRebatesMember_66e55a29-1fe9-496a-b978-ff9cf0f9379b" xlink:href="ardx-20220331.xsd#ardx_ContractWithCustomerRebatesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_GrossToNetSalesAccrualAndReserveClassificationDomain_6a7fe94d-f403-4b32-80a4-a6442227ff29" xlink:to="loc_ardx_ContractWithCustomerRebatesMember_66e55a29-1fe9-496a-b978-ff9cf0f9379b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerOtherFeesCopayAndReturnsMember_0f3e5ffa-e825-4af8-993e-003a45817647" xlink:href="ardx-20220331.xsd#ardx_ContractWithCustomerOtherFeesCopayAndReturnsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_GrossToNetSalesAccrualAndReserveClassificationDomain_6a7fe94d-f403-4b32-80a4-a6442227ff29" xlink:to="loc_ardx_ContractWithCustomerOtherFeesCopayAndReturnsMember_0f3e5ffa-e825-4af8-993e-003a45817647" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_b896bdc9-9ce9-43c2-9832-af3d68895954" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_9cb7b559-6fb7-4783-89ab-99e7b9abc0c1" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_b896bdc9-9ce9-43c2-9832-af3d68895954" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward_d39ae3fb-c456-49f9-a42a-635dbecf9a1e" xlink:href="ardx-20220331.xsd#ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b896bdc9-9ce9-43c2-9832-af3d68895954" xlink:to="loc_ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward_d39ae3fb-c456-49f9-a42a-635dbecf9a1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerGrossToNetSalesAccruals_9560ba74-62be-4919-a08c-2f51732a9b50" xlink:href="ardx-20220331.xsd#ardx_ContractWithCustomerGrossToNetSalesAccruals"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward_d39ae3fb-c456-49f9-a42a-635dbecf9a1e" xlink:to="loc_ardx_ContractWithCustomerGrossToNetSalesAccruals_9560ba74-62be-4919-a08c-2f51732a9b50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod_d9ea670d-87ae-4fba-81d0-4f0beb62cd29" xlink:href="ardx-20220331.xsd#ardx_ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward_d39ae3fb-c456-49f9-a42a-635dbecf9a1e" xlink:to="loc_ardx_ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod_d9ea670d-87ae-4fba-81d0-4f0beb62cd29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerGrossToNetSalesAccruals_dc41463e-7ae4-496d-b3cd-39ac7292bd18" xlink:href="ardx-20220331.xsd#ardx_ContractWithCustomerGrossToNetSalesAccruals"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward_d39ae3fb-c456-49f9-a42a-635dbecf9a1e" xlink:to="loc_ardx_ContractWithCustomerGrossToNetSalesAccruals_dc41463e-7ae4-496d-b3cd-39ac7292bd18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/CollaborationandLicensingAgreements" xlink:type="simple" xlink:href="ardx-20220331.xsd#CollaborationandLicensingAgreements"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/CollaborationandLicensingAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborationAndLicensingAgreementsAbstract_4e2e4dc3-e788-4346-8255-db96686abb88" xlink:href="ardx-20220331.xsd#ardx_CollaborationAndLicensingAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_1d3ec79d-8dea-41db-9e63-434942804ddc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_CollaborationAndLicensingAgreementsAbstract_4e2e4dc3-e788-4346-8255-db96686abb88" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_1d3ec79d-8dea-41db-9e63-434942804ddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/CollaborationandLicensingAgreementsTables" xlink:type="simple" xlink:href="ardx-20220331.xsd#CollaborationandLicensingAgreementsTables"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/CollaborationandLicensingAgreementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborationAndLicensingAgreementsAbstract_d76ce35d-1720-4c90-8bd9-34834814c3d5" xlink:href="ardx-20220331.xsd#ardx_CollaborationAndLicensingAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_c60e481c-3ee2-4336-9f88-6dd7422d9fda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_CollaborationAndLicensingAgreementsAbstract_d76ce35d-1720-4c90-8bd9-34834814c3d5" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_c60e481c-3ee2-4336-9f88-6dd7422d9fda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails" xlink:type="simple" xlink:href="ardx-20220331.xsd#CollaborationandLicensingAgreementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborationAndLicensingAgreementsAbstract_657981bc-f569-4d5d-a3e5-b7a4aa5117ac" xlink:href="ardx-20220331.xsd#ardx_CollaborationAndLicensingAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_88cee372-96e6-4cba-8f32-7e222d32405e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_CollaborationAndLicensingAgreementsAbstract_657981bc-f569-4d5d-a3e5-b7a4aa5117ac" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_88cee372-96e6-4cba-8f32-7e222d32405e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_0b8e4749-800b-4f98-ae85-61d7125c3ca4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_88cee372-96e6-4cba-8f32-7e222d32405e" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_0b8e4749-800b-4f98-ae85-61d7125c3ca4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_4649f2a3-a607-4f03-bfdd-9ecb23e5e9fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_0b8e4749-800b-4f98-ae85-61d7125c3ca4" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_4649f2a3-a607-4f03-bfdd-9ecb23e5e9fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_0443fc54-f689-4315-8ba1-5bafbebdf36e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_4649f2a3-a607-4f03-bfdd-9ecb23e5e9fa" xlink:to="loc_us-gaap_SubsequentEventMember_0443fc54-f689-4315-8ba1-5bafbebdf36e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_9ef96de9-d62c-4c85-b0c3-dc9d78be102d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_88cee372-96e6-4cba-8f32-7e222d32405e" xlink:to="loc_us-gaap_TypeOfArrangementAxis_9ef96de9-d62c-4c85-b0c3-dc9d78be102d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a0548d12-1478-4cc1-a764-a54fcb611bd6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_9ef96de9-d62c-4c85-b0c3-dc9d78be102d" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a0548d12-1478-4cc1-a764-a54fcb611bd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ResearchCollaborationAndOptionAgreementMember_2f01b0b0-abe6-4bef-8181-6b83e9db3e50" xlink:href="ardx-20220331.xsd#ardx_ResearchCollaborationAndOptionAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a0548d12-1478-4cc1-a764-a54fcb611bd6" xlink:to="loc_ardx_ResearchCollaborationAndOptionAgreementMember_2f01b0b0-abe6-4bef-8181-6b83e9db3e50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember_39f67ec3-78b4-4437-bb64-d630fe67f5d3" xlink:href="ardx-20220331.xsd#ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a0548d12-1478-4cc1-a764-a54fcb611bd6" xlink:to="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember_39f67ec3-78b4-4437-bb64-d630fe67f5d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember_926974f1-c86b-4bb0-83aa-1c20fcb5e9bf" xlink:href="ardx-20220331.xsd#ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a0548d12-1478-4cc1-a764-a54fcb611bd6" xlink:to="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember_926974f1-c86b-4bb0-83aa-1c20fcb5e9bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember_e6c9792a-1cec-48d4-8756-8b5e0f1e19e1" xlink:href="ardx-20220331.xsd#ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a0548d12-1478-4cc1-a764-a54fcb611bd6" xlink:to="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember_e6c9792a-1cec-48d4-8756-8b5e0f1e19e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AstraZenecaTerminationAgreementMember_2a379f95-1e53-4ba3-8818-4a36bfa8f209" xlink:href="ardx-20220331.xsd#ardx_AstraZenecaTerminationAgreementMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a0548d12-1478-4cc1-a764-a54fcb611bd6" xlink:to="loc_ardx_AstraZenecaTerminationAgreementMember_2a379f95-1e53-4ba3-8818-4a36bfa8f209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_c3247b6c-dc9f-4f31-879b-3d09e22b43ed" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_88cee372-96e6-4cba-8f32-7e222d32405e" xlink:to="loc_srt_CounterpartyNameAxis_c3247b6c-dc9f-4f31-879b-3d09e22b43ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ea488ca9-1509-4945-9ce3-65b7a3b36e0a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_c3247b6c-dc9f-4f31-879b-3d09e22b43ed" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ea488ca9-1509-4945-9ce3-65b7a3b36e0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_KyowaKirinCo.LtdMember_cf6d49b9-2caa-427c-b433-24b192675c73" xlink:href="ardx-20220331.xsd#ardx_KyowaKirinCo.LtdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ea488ca9-1509-4945-9ce3-65b7a3b36e0a" xlink:to="loc_ardx_KyowaKirinCo.LtdMember_cf6d49b9-2caa-427c-b433-24b192675c73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember_5dfeff0f-a6bb-4372-abfb-5688bea071bf" xlink:href="ardx-20220331.xsd#ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ea488ca9-1509-4945-9ce3-65b7a3b36e0a" xlink:to="loc_ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember_5dfeff0f-a6bb-4372-abfb-5688bea071bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_KnightTherapeuticsIncMember_44b81301-f0b5-4e6f-acff-a75fc1fdc393" xlink:href="ardx-20220331.xsd#ardx_KnightTherapeuticsIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ea488ca9-1509-4945-9ce3-65b7a3b36e0a" xlink:to="loc_ardx_KnightTherapeuticsIncMember_44b81301-f0b5-4e6f-acff-a75fc1fdc393" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AstrazenecaMember_d3b439c0-b417-431c-bd0d-de8881300563" xlink:href="ardx-20220331.xsd#ardx_AstrazenecaMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ea488ca9-1509-4945-9ce3-65b7a3b36e0a" xlink:to="loc_ardx_AstrazenecaMember_d3b439c0-b417-431c-bd0d-de8881300563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_9d28259c-2ee7-4d50-8f12-d1b7b74e29b4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_88cee372-96e6-4cba-8f32-7e222d32405e" xlink:to="loc_srt_ProductOrServiceAxis_9d28259c-2ee7-4d50-8f12-d1b7b74e29b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_08f037e3-d759-4764-bc91-2c8db4ae22f0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_9d28259c-2ee7-4d50-8f12-d1b7b74e29b4" xlink:to="loc_srt_ProductsAndServicesDomain_08f037e3-d759-4764-bc91-2c8db4ae22f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_e4ee0dba-bb10-481c-8830-bc0e11cf6aba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_08f037e3-d759-4764-bc91-2c8db4ae22f0" xlink:to="loc_us-gaap_LicenseMember_e4ee0dba-bb10-481c-8830-bc0e11cf6aba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ProductSupplyRevenueMember_f38ba6f2-2079-4f43-87bf-950ffaaf66b3" xlink:href="ardx-20220331.xsd#ardx_ProductSupplyRevenueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_08f037e3-d759-4764-bc91-2c8db4ae22f0" xlink:to="loc_ardx_ProductSupplyRevenueMember_f38ba6f2-2079-4f43-87bf-950ffaaf66b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f69f0408-58dd-4c78-b8cb-fedbab9c5cba" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_88cee372-96e6-4cba-8f32-7e222d32405e" xlink:to="loc_srt_RangeAxis_f69f0408-58dd-4c78-b8cb-fedbab9c5cba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f762bc2b-96ef-41ab-a8df-fd8cd7edbaef" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_f69f0408-58dd-4c78-b8cb-fedbab9c5cba" xlink:to="loc_srt_RangeMember_f762bc2b-96ef-41ab-a8df-fd8cd7edbaef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d5475be1-dc7d-4486-bb36-f245ec814269" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f762bc2b-96ef-41ab-a8df-fd8cd7edbaef" xlink:to="loc_srt_MinimumMember_d5475be1-dc7d-4486-bb36-f245ec814269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_552403e8-ec76-4e01-84bc-4743ad249064" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_88cee372-96e6-4cba-8f32-7e222d32405e" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_552403e8-ec76-4e01-84bc-4743ad249064" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_NumberOfSeparateCollaborativeAgreements_74603aae-f745-4071-8d71-c4453ce6a276" xlink:href="ardx-20220331.xsd#ardx_NumberOfSeparateCollaborativeAgreements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_552403e8-ec76-4e01-84bc-4743ad249064" xlink:to="loc_ardx_NumberOfSeparateCollaborativeAgreements_74603aae-f745-4071-8d71-c4453ce6a276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees_53225b2f-70fb-40b4-85d2-e43b9bfed9bb" xlink:href="ardx-20220331.xsd#ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_552403e8-ec76-4e01-84bc-4743ad249064" xlink:to="loc_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees_53225b2f-70fb-40b4-85d2-e43b9bfed9bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment_7c8d2d28-9e7d-437f-8c81-2a89e656c7e5" xlink:href="ardx-20220331.xsd#ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_552403e8-ec76-4e01-84bc-4743ad249064" xlink:to="loc_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment_7c8d2d28-9e7d-437f-8c81-2a89e656c7e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_TermOfPaymentOfLicenseFeeFirstInstallment_c74e05f1-ad77-4407-89e1-a611a392d0b6" xlink:href="ardx-20220331.xsd#ardx_TermOfPaymentOfLicenseFeeFirstInstallment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_552403e8-ec76-4e01-84bc-4743ad249064" xlink:to="loc_ardx_TermOfPaymentOfLicenseFeeFirstInstallment_c74e05f1-ad77-4407-89e1-a611a392d0b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment_d29c96b4-15b8-48b6-b325-61ae8f7d56fd" xlink:href="ardx-20220331.xsd#ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_552403e8-ec76-4e01-84bc-4743ad249064" xlink:to="loc_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment_d29c96b4-15b8-48b6-b325-61ae8f7d56fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_TermOfAgreement_a610afe7-447b-4ab3-9e22-fbc5cd80831e" xlink:href="ardx-20220331.xsd#ardx_TermOfAgreement"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_552403e8-ec76-4e01-84bc-4743ad249064" xlink:to="loc_ardx_TermOfAgreement_a610afe7-447b-4ab3-9e22-fbc5cd80831e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_81ed5e1c-cd60-4acc-a670-5c710ecbacfa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_552403e8-ec76-4e01-84bc-4743ad249064" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_81ed5e1c-cd60-4acc-a670-5c710ecbacfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeArrangementPotentialDevelopmentMilestones_fe64c483-7c79-472c-a88c-5e80b4b8ceaf" xlink:href="ardx-20220331.xsd#ardx_CollaborativeArrangementPotentialDevelopmentMilestones"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_552403e8-ec76-4e01-84bc-4743ad249064" xlink:to="loc_ardx_CollaborativeArrangementPotentialDevelopmentMilestones_fe64c483-7c79-472c-a88c-5e80b4b8ceaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeArrangementPotentialCommercializationMilestones_6847a211-4417-42d5-9187-ba962fdc6cbe" xlink:href="ardx-20220331.xsd#ardx_CollaborativeArrangementPotentialCommercializationMilestones"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_552403e8-ec76-4e01-84bc-4743ad249064" xlink:to="loc_ardx_CollaborativeArrangementPotentialCommercializationMilestones_6847a211-4417-42d5-9187-ba962fdc6cbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate_34f9ef1d-b9f6-413d-a8b8-8160299fa5ed" xlink:href="ardx-20220331.xsd#ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_552403e8-ec76-4e01-84bc-4743ad249064" xlink:to="loc_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate_34f9ef1d-b9f6-413d-a8b8-8160299fa5ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches_23989f5c-c18a-48e6-9a71-4f50f87f41fb" xlink:href="ardx-20220331.xsd#ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_552403e8-ec76-4e01-84bc-4743ad249064" xlink:to="loc_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches_23989f5c-c18a-48e6-9a71-4f50f87f41fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLicenseFeesReceived_14ffef50-d24e-45fc-8eac-ee97e02953da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_552403e8-ec76-4e01-84bc-4743ad249064" xlink:to="loc_us-gaap_ProceedsFromLicenseFeesReceived_14ffef50-d24e-45fc-8eac-ee97e02953da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones_85d02120-53a5-4671-b804-4aae28f7afd2" xlink:href="ardx-20220331.xsd#ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_552403e8-ec76-4e01-84bc-4743ad249064" xlink:to="loc_ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones_85d02120-53a5-4671-b804-4aae28f7afd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ThresholdPercentageOfSalesForTieredRoyalties_b389d26b-cb3c-473a-8a2c-b247e6e11054" xlink:href="ardx-20220331.xsd#ardx_ThresholdPercentageOfSalesForTieredRoyalties"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_552403e8-ec76-4e01-84bc-4743ad249064" xlink:to="loc_ardx_ThresholdPercentageOfSalesForTieredRoyalties_b389d26b-cb3c-473a-8a2c-b247e6e11054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_PercentageOfRoyaltyRevenue_60fc1605-2e13-4fae-9f6c-da1cdfeece6a" xlink:href="ardx-20220331.xsd#ardx_PercentageOfRoyaltyRevenue"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_552403e8-ec76-4e01-84bc-4743ad249064" xlink:to="loc_ardx_PercentageOfRoyaltyRevenue_60fc1605-2e13-4fae-9f6c-da1cdfeece6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_PercentageOfNonRoyaltyRevenue_ce7608d0-b0ed-448c-b46a-7319b52cf190" xlink:href="ardx-20220331.xsd#ardx_PercentageOfNonRoyaltyRevenue"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_552403e8-ec76-4e01-84bc-4743ad249064" xlink:to="loc_ardx_PercentageOfNonRoyaltyRevenue_ce7608d0-b0ed-448c-b46a-7319b52cf190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum_f5637f30-50a5-4c96-9f5a-8551fc53f936" xlink:href="ardx-20220331.xsd#ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_552403e8-ec76-4e01-84bc-4743ad249064" xlink:to="loc_ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum_f5637f30-50a5-4c96-9f5a-8551fc53f936" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CostOfRevenueAggregateAmountRecognized_6421c75d-ebc8-48ec-bbef-96585e457c1e" xlink:href="ardx-20220331.xsd#ardx_CostOfRevenueAggregateAmountRecognized"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_552403e8-ec76-4e01-84bc-4743ad249064" xlink:to="loc_ardx_CostOfRevenueAggregateAmountRecognized_6421c75d-ebc8-48ec-bbef-96585e457c1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_1aaefe48-93b3-4503-ab99-2ca0b399cb1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_552403e8-ec76-4e01-84bc-4743ad249064" xlink:to="loc_us-gaap_CostOfRevenue_1aaefe48-93b3-4503-ab99-2ca0b399cb1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_PaymentsOfUnchargedLicenseFeesAggregateAmountPaid_6768328a-b570-4cca-9970-3d95b14abea5" xlink:href="ardx-20220331.xsd#ardx_PaymentsOfUnchargedLicenseFeesAggregateAmountPaid"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_552403e8-ec76-4e01-84bc-4743ad249064" xlink:to="loc_ardx_PaymentsOfUnchargedLicenseFeesAggregateAmountPaid_6768328a-b570-4cca-9970-3d95b14abea5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails" xlink:type="simple" xlink:href="ardx-20220331.xsd#CollaborationandLicensingAgreementsDeferredRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborationAndLicensingAgreementsAbstract_8b31ee53-c405-4bf5-8b3c-d2fd16386210" xlink:href="ardx-20220331.xsd#ardx_CollaborationAndLicensingAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1a0ce19e-53e6-4dde-a6ee-90e1d3f5238c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_CollaborationAndLicensingAgreementsAbstract_8b31ee53-c405-4bf5-8b3c-d2fd16386210" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1a0ce19e-53e6-4dde-a6ee-90e1d3f5238c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_b50ddfc9-f434-42a7-a1c9-f3f430e58e3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1a0ce19e-53e6-4dde-a6ee-90e1d3f5238c" xlink:to="loc_us-gaap_TypeOfArrangementAxis_b50ddfc9-f434-42a7-a1c9-f3f430e58e3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3cfd0a01-1d79-496a-a398-96031c990b31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_b50ddfc9-f434-42a7-a1c9-f3f430e58e3d" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3cfd0a01-1d79-496a-a398-96031c990b31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ResearchCollaborationAndOptionAgreementMember_d611502c-0895-4edc-971c-26209c28fd68" xlink:href="ardx-20220331.xsd#ardx_ResearchCollaborationAndOptionAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3cfd0a01-1d79-496a-a398-96031c990b31" xlink:to="loc_ardx_ResearchCollaborationAndOptionAgreementMember_d611502c-0895-4edc-971c-26209c28fd68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember_5c00fbd4-c69e-4590-99ba-9835c9de5aa7" xlink:href="ardx-20220331.xsd#ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3cfd0a01-1d79-496a-a398-96031c990b31" xlink:to="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember_5c00fbd4-c69e-4590-99ba-9835c9de5aa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3554260f-c856-4d26-b55d-6e81d94df8ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1a0ce19e-53e6-4dde-a6ee-90e1d3f5238c" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3554260f-c856-4d26-b55d-6e81d94df8ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward_2033729d-23bf-4b66-968c-7fff6db31640" xlink:href="ardx-20220331.xsd#ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3554260f-c856-4d26-b55d-6e81d94df8ca" xlink:to="loc_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward_2033729d-23bf-4b66-968c-7fff6db31640" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_ff78bc63-9a8c-40f6-9f7e-ed292d996de8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward_2033729d-23bf-4b66-968c-7fff6db31640" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_ff78bc63-9a8c-40f6-9f7e-ed292d996de8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerLiabilityRevenueRecognizedCashReceived_f2c62d43-40f8-4925-89f7-d5cc2a123f6a" xlink:href="ardx-20220331.xsd#ardx_ContractWithCustomerLiabilityRevenueRecognizedCashReceived"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward_2033729d-23bf-4b66-968c-7fff6db31640" xlink:to="loc_ardx_ContractWithCustomerLiabilityRevenueRecognizedCashReceived_f2c62d43-40f8-4925-89f7-d5cc2a123f6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_d8629193-5d2c-46ad-bc2e-4cd58d187b9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward_2033729d-23bf-4b66-968c-7fff6db31640" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_d8629193-5d2c-46ad-bc2e-4cd58d187b9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward_3f272425-5027-4342-861b-865a7ab198d1" xlink:href="ardx-20220331.xsd#ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3554260f-c856-4d26-b55d-6e81d94df8ca" xlink:to="loc_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward_3f272425-5027-4342-861b-865a7ab198d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_92e926f5-d8a4-42ed-a551-b4eb198dbbf8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward_3f272425-5027-4342-861b-865a7ab198d1" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_92e926f5-d8a4-42ed-a551-b4eb198dbbf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerLiabilityIncreaseForAmountsInvoiced_f3c2d8e7-5630-4ee4-a9e5-268f0efa8d4b" xlink:href="ardx-20220331.xsd#ardx_ContractWithCustomerLiabilityIncreaseForAmountsInvoiced"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward_3f272425-5027-4342-861b-865a7ab198d1" xlink:to="loc_ardx_ContractWithCustomerLiabilityIncreaseForAmountsInvoiced_f3c2d8e7-5630-4ee4-a9e5-268f0efa8d4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerLiabilityIncreaseDueToUnbilledPrepaymentsRecorded_4ef41c04-6483-461a-b1e0-fc56bfd27928" xlink:href="ardx-20220331.xsd#ardx_ContractWithCustomerLiabilityIncreaseDueToUnbilledPrepaymentsRecorded"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward_3f272425-5027-4342-861b-865a7ab198d1" xlink:to="loc_ardx_ContractWithCustomerLiabilityIncreaseDueToUnbilledPrepaymentsRecorded_4ef41c04-6483-461a-b1e0-fc56bfd27928" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_69cb716b-c79e-4ede-b04a-fc22689b0d16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward_3f272425-5027-4342-861b-865a7ab198d1" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_69cb716b-c79e-4ede-b04a-fc22689b0d16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/Borrowing" xlink:type="simple" xlink:href="ardx-20220331.xsd#Borrowing"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/Borrowing" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_88f69bc5-46ba-4ef4-8a79-19a4449e8290" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_cc77f470-586a-4668-803b-fd95c1e81873" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_88f69bc5-46ba-4ef4-8a79-19a4449e8290" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_cc77f470-586a-4668-803b-fd95c1e81873" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/BorrowingTables" xlink:type="simple" xlink:href="ardx-20220331.xsd#BorrowingTables"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/BorrowingTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_83c16fb5-72f2-426e-b87b-311657f2cfad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_001d3489-e5b4-4697-bacf-0332c8917012" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_83c16fb5-72f2-426e-b87b-311657f2cfad" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_001d3489-e5b4-4697-bacf-0332c8917012" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/BorrowingNarrativeDetails" xlink:type="simple" xlink:href="ardx-20220331.xsd#BorrowingNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/BorrowingNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_d86153ad-097d-4a7b-be63-c7bdd71a868b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_eb0b6b9a-d7d0-4c6f-93ac-baab1ae1ab45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d86153ad-097d-4a7b-be63-c7bdd71a868b" xlink:to="loc_us-gaap_DebtInstrumentTable_eb0b6b9a-d7d0-4c6f-93ac-baab1ae1ab45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_ae457d3a-e696-4f63-9244-35fab7efb034" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_eb0b6b9a-d7d0-4c6f-93ac-baab1ae1ab45" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_ae457d3a-e696-4f63-9244-35fab7efb034" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_7224b168-695e-41e6-b8ff-0f8d7309e1e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_ae457d3a-e696-4f63-9244-35fab7efb034" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_7224b168-695e-41e6-b8ff-0f8d7309e1e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ExitFee2022Member_14b3d38f-f06e-4f4a-ba48-1380b010c9cf" xlink:href="ardx-20220331.xsd#ardx_ExitFee2022Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_7224b168-695e-41e6-b8ff-0f8d7309e1e9" xlink:to="loc_ardx_ExitFee2022Member_14b3d38f-f06e-4f4a-ba48-1380b010c9cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ExitFee2018Member_c776d6c4-e551-40ad-b483-8a2451e1d886" xlink:href="ardx-20220331.xsd#ardx_ExitFee2018Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_7224b168-695e-41e6-b8ff-0f8d7309e1e9" xlink:to="loc_ardx_ExitFee2018Member_c776d6c4-e551-40ad-b483-8a2451e1d886" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_fe714ddb-e5d9-48c9-bd23-aea6402a5ddd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_eb0b6b9a-d7d0-4c6f-93ac-baab1ae1ab45" xlink:to="loc_us-gaap_DebtInstrumentAxis_fe714ddb-e5d9-48c9-bd23-aea6402a5ddd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b8830605-f696-40c4-a04c-261f0bc11537" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_fe714ddb-e5d9-48c9-bd23-aea6402a5ddd" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b8830605-f696-40c4-a04c-261f0bc11537" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_TermLoan2018Member_47a740bc-e91c-4b1c-9f6e-5a052f3ce55f" xlink:href="ardx-20220331.xsd#ardx_TermLoan2018Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b8830605-f696-40c4-a04c-261f0bc11537" xlink:to="loc_ardx_TermLoan2018Member_47a740bc-e91c-4b1c-9f6e-5a052f3ce55f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_TermLoan2022Member_c3c36c22-82b4-422d-8977-4d5834afe24a" xlink:href="ardx-20220331.xsd#ardx_TermLoan2022Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b8830605-f696-40c4-a04c-261f0bc11537" xlink:to="loc_ardx_TermLoan2022Member_c3c36c22-82b4-422d-8977-4d5834afe24a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_TermLoan2022AMember_0c995f69-9dc7-4469-b215-6f74e11ef749" xlink:href="ardx-20220331.xsd#ardx_TermLoan2022AMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_TermLoan2022Member_c3c36c22-82b4-422d-8977-4d5834afe24a" xlink:to="loc_ardx_TermLoan2022AMember_0c995f69-9dc7-4469-b215-6f74e11ef749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_TermLoan2022BMember_79e56f1a-87d1-4475-aca8-4abaf74c50d4" xlink:href="ardx-20220331.xsd#ardx_TermLoan2022BMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_TermLoan2022Member_c3c36c22-82b4-422d-8977-4d5834afe24a" xlink:to="loc_ardx_TermLoan2022BMember_79e56f1a-87d1-4475-aca8-4abaf74c50d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_653e8105-425d-44ea-9208-9967704846bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_eb0b6b9a-d7d0-4c6f-93ac-baab1ae1ab45" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_653e8105-425d-44ea-9208-9967704846bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ae870d9d-3186-4944-90a1-8373b80618a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_653e8105-425d-44ea-9208-9967704846bd" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ae870d9d-3186-4944-90a1-8373b80618a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_6fe29f0c-8cba-46e3-a22b-47b8e5ebebe4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_ae870d9d-3186-4944-90a1-8373b80618a9" xlink:to="loc_us-gaap_LoansPayableMember_6fe29f0c-8cba-46e3-a22b-47b8e5ebebe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_e8a30baa-73e8-4968-8de6-dc3816006199" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_eb0b6b9a-d7d0-4c6f-93ac-baab1ae1ab45" xlink:to="loc_us-gaap_VariableRateAxis_e8a30baa-73e8-4968-8de6-dc3816006199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_78dc504d-57bf-4741-a887-7a87eaace209" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_e8a30baa-73e8-4968-8de6-dc3816006199" xlink:to="loc_us-gaap_VariableRateDomain_78dc504d-57bf-4741-a887-7a87eaace209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_e5b7e504-8d00-48b5-8f47-42ab7ea0452b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_78dc504d-57bf-4741-a887-7a87eaace209" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_e5b7e504-8d00-48b5-8f47-42ab7ea0452b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_de773c50-9fa5-48e6-bf06-36066a25c994" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_eb0b6b9a-d7d0-4c6f-93ac-baab1ae1ab45" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_de773c50-9fa5-48e6-bf06-36066a25c994" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_c438cefc-c58d-425c-9fb8-2bb5ff4ac477" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_de773c50-9fa5-48e6-bf06-36066a25c994" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_c438cefc-c58d-425c-9fb8-2bb5ff4ac477" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_cbf97f97-69f2-45de-8c3e-af10d3413256" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_c438cefc-c58d-425c-9fb8-2bb5ff4ac477" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_cbf97f97-69f2-45de-8c3e-af10d3413256" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_82682858-ff27-4e10-a24d-dea5806dcc0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_c438cefc-c58d-425c-9fb8-2bb5ff4ac477" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_82682858-ff27-4e10-a24d-dea5806dcc0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_be50ea7b-9055-4137-adeb-41389481bef3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_c438cefc-c58d-425c-9fb8-2bb5ff4ac477" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_be50ea7b-9055-4137-adeb-41389481bef3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_150b0062-c15d-46db-bcb6-ac2630707ef2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_eb0b6b9a-d7d0-4c6f-93ac-baab1ae1ab45" xlink:to="loc_us-gaap_DebtInstrumentLineItems_150b0062-c15d-46db-bcb6-ac2630707ef2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_18f34ef0-5041-481b-900d-1299c16c4679" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_150b0062-c15d-46db-bcb6-ac2630707ef2" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_18f34ef0-5041-481b-900d-1299c16c4679" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_32c1fa5a-1314-49c6-bad3-3ef11e266da4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_150b0062-c15d-46db-bcb6-ac2630707ef2" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_32c1fa5a-1314-49c6-bad3-3ef11e266da4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotionalAmount_27c3c3ed-3355-4d87-944b-b21d286206e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilityNotionalAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_150b0062-c15d-46db-bcb6-ac2630707ef2" xlink:to="loc_us-gaap_DerivativeLiabilityNotionalAmount_27c3c3ed-3355-4d87-944b-b21d286206e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_8cd70c4d-3dac-4526-b778-c3aa8558a7a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_150b0062-c15d-46db-bcb6-ac2630707ef2" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_8cd70c4d-3dac-4526-b778-c3aa8558a7a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_RemainingFundingBasedOnConditionalMilestoneAchievement_bbf1c188-1779-42d8-b7db-e2ba66646225" xlink:href="ardx-20220331.xsd#ardx_RemainingFundingBasedOnConditionalMilestoneAchievement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_150b0062-c15d-46db-bcb6-ac2630707ef2" xlink:to="loc_ardx_RemainingFundingBasedOnConditionalMilestoneAchievement_bbf1c188-1779-42d8-b7db-e2ba66646225" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_cab94a1d-ecfa-44a9-9c61-960bf9b59f5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_150b0062-c15d-46db-bcb6-ac2630707ef2" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_cab94a1d-ecfa-44a9-9c61-960bf9b59f5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DebtInstrumentVariableRateBaseOption_18fbdcd5-72c4-4bfc-ba58-d7358d7bca3b" xlink:href="ardx-20220331.xsd#ardx_DebtInstrumentVariableRateBaseOption"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_150b0062-c15d-46db-bcb6-ac2630707ef2" xlink:to="loc_ardx_DebtInstrumentVariableRateBaseOption_18fbdcd5-72c4-4bfc-ba58-d7358d7bca3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DebtInstrumentClosingFeeAmount_b4ecd040-a9da-4f18-8816-0dfb762859d0" xlink:href="ardx-20220331.xsd#ardx_DebtInstrumentClosingFeeAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_150b0062-c15d-46db-bcb6-ac2630707ef2" xlink:to="loc_ardx_DebtInstrumentClosingFeeAmount_b4ecd040-a9da-4f18-8816-0dfb762859d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LoanAgreementFutureObligationUponFundingOrOtherEvents_c3006cee-e7e6-4b3e-8b9b-a11232a88486" xlink:href="ardx-20220331.xsd#ardx_LoanAgreementFutureObligationUponFundingOrOtherEvents"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_150b0062-c15d-46db-bcb6-ac2630707ef2" xlink:to="loc_ardx_LoanAgreementFutureObligationUponFundingOrOtherEvents_c3006cee-e7e6-4b3e-8b9b-a11232a88486" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage_fda7a0e3-b7da-4148-9085-c97ae481aff4" xlink:href="ardx-20220331.xsd#ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_150b0062-c15d-46db-bcb6-ac2630707ef2" xlink:to="loc_ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage_fda7a0e3-b7da-4148-9085-c97ae481aff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DebtInstrumentPrepaymentFeePercentage_ff9ef49a-acf4-4c7b-af93-9d04161f9cd3" xlink:href="ardx-20220331.xsd#ardx_DebtInstrumentPrepaymentFeePercentage"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_150b0062-c15d-46db-bcb6-ac2630707ef2" xlink:to="loc_ardx_DebtInstrumentPrepaymentFeePercentage_ff9ef49a-acf4-4c7b-af93-9d04161f9cd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ExitFeePercentage_356b0000-83f0-48ad-808c-85bfe3ab90c5" xlink:href="ardx-20220331.xsd#ardx_ExitFeePercentage"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_150b0062-c15d-46db-bcb6-ac2630707ef2" xlink:to="loc_ardx_ExitFeePercentage_356b0000-83f0-48ad-808c-85bfe3ab90c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum_1f93300b-f389-4eec-9e19-a49e34591f3f" xlink:href="ardx-20220331.xsd#ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_150b0062-c15d-46db-bcb6-ac2630707ef2" xlink:to="loc_ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum_1f93300b-f389-4eec-9e19-a49e34591f3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LoanAgreementExitFeeTerm_1b55a780-209c-4330-98e9-0bafe66d4268" xlink:href="ardx-20220331.xsd#ardx_LoanAgreementExitFeeTerm"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_150b0062-c15d-46db-bcb6-ac2630707ef2" xlink:to="loc_ardx_LoanAgreementExitFeeTerm_1b55a780-209c-4330-98e9-0bafe66d4268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum_4a274142-5126-4531-bd66-806792829a9e" xlink:href="ardx-20220331.xsd#ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_150b0062-c15d-46db-bcb6-ac2630707ef2" xlink:to="loc_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum_4a274142-5126-4531-bd66-806792829a9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum_8f6b1fd4-2675-4826-8cbe-802dbae751b3" xlink:href="ardx-20220331.xsd#ardx_LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_150b0062-c15d-46db-bcb6-ac2630707ef2" xlink:to="loc_ardx_LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum_8f6b1fd4-2675-4826-8cbe-802dbae751b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DebtInstrumentInterestRateOnDefaultPercentage_08770e9f-3c65-411a-9b1b-dfce3d763c33" xlink:href="ardx-20220331.xsd#ardx_DebtInstrumentInterestRateOnDefaultPercentage"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_150b0062-c15d-46db-bcb6-ac2630707ef2" xlink:to="loc_ardx_DebtInstrumentInterestRateOnDefaultPercentage_08770e9f-3c65-411a-9b1b-dfce3d763c33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/BorrowingFuturePaymentObligationsDetails" xlink:type="simple" xlink:href="ardx-20220331.xsd#BorrowingFuturePaymentObligationsDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/BorrowingFuturePaymentObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_3ff35ea6-0bce-4a37-b95b-f4c1f02444bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtByMaturityAbstract_7ab5fc84-1aef-4efb-960a-dd58fc591881" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtByMaturityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_3ff35ea6-0bce-4a37-b95b-f4c1f02444bd" xlink:to="loc_us-gaap_LongTermDebtByMaturityAbstract_7ab5fc84-1aef-4efb-960a-dd58fc591881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_df077df1-7f10-4cba-b6a4-7beb1a1b3b3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_7ab5fc84-1aef-4efb-960a-dd58fc591881" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_df077df1-7f10-4cba-b6a4-7beb1a1b3b3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_1d643c57-3e25-415d-85b9-d956e6ee8107" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_7ab5fc84-1aef-4efb-960a-dd58fc591881" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_1d643c57-3e25-415d-85b9-d956e6ee8107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount_0b6eefc3-9615-465e-b821-101139d0a1d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_7ab5fc84-1aef-4efb-960a-dd58fc591881" xlink:to="loc_us-gaap_DebtInstrumentFeeAmount_0b6eefc3-9615-465e-b821-101139d0a1d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_0fe1d2a3-7881-4985-a2c4-ebc72b14fce1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_7ab5fc84-1aef-4efb-960a-dd58fc591881" xlink:to="loc_us-gaap_LongTermDebt_0fe1d2a3-7881-4985-a2c4-ebc72b14fce1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_cb824f30-4314-4d5e-8d4d-27318f860790" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_7ab5fc84-1aef-4efb-960a-dd58fc591881" xlink:to="loc_us-gaap_LongTermDebtCurrent_cb824f30-4314-4d5e-8d4d-27318f860790" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_a38ff642-8d8e-4061-80f6-df2b86514ecd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_7ab5fc84-1aef-4efb-960a-dd58fc591881" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_a38ff642-8d8e-4061-80f6-df2b86514ecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/BorrowingFuturePaymentObligationsDetails_1" xlink:type="simple" xlink:href="ardx-20220331.xsd#BorrowingFuturePaymentObligationsDetails_1"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/BorrowingFuturePaymentObligationsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ardelyx.com/role/DerivativeLiability" xlink:type="simple" xlink:href="ardx-20220331.xsd#DerivativeLiability"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/DerivativeLiability" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_5c309266-3c25-4232-9f93-0cad9e5de60f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_0f7526e3-e761-46dd-b69c-b0f175339758" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_5c309266-3c25-4232-9f93-0cad9e5de60f" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_0f7526e3-e761-46dd-b69c-b0f175339758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/DerivativeLiabilityTables" xlink:type="simple" xlink:href="ardx-20220331.xsd#DerivativeLiabilityTables"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/DerivativeLiabilityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_b5cd3428-9bcf-43de-93f9-67ab0ea3122e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_e019f984-7e9b-4f06-aa67-750076c7c159" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_b5cd3428-9bcf-43de-93f9-67ab0ea3122e" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_e019f984-7e9b-4f06-aa67-750076c7c159" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/DerivativeLiabilityNarrativeDetails" xlink:type="simple" xlink:href="ardx-20220331.xsd#DerivativeLiabilityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/DerivativeLiabilityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_e7ae07fc-8e06-4748-8e8a-2251ac20bd2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_98b48ee0-39c9-4231-9444-b9bf90dc816f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_e7ae07fc-8e06-4748-8e8a-2251ac20bd2a" xlink:to="loc_us-gaap_DerivativeTable_98b48ee0-39c9-4231-9444-b9bf90dc816f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_5edbe0e9-3277-4baa-bf9e-4d5ca8ab5072" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_98b48ee0-39c9-4231-9444-b9bf90dc816f" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_5edbe0e9-3277-4baa-bf9e-4d5ca8ab5072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_9d9a868b-9984-4031-be1b-be36ab179a70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_5edbe0e9-3277-4baa-bf9e-4d5ca8ab5072" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_9d9a868b-9984-4031-be1b-be36ab179a70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ExitFee2018Member_b9ca2ce6-1aa0-4d93-8738-7821af56d7a2" xlink:href="ardx-20220331.xsd#ardx_ExitFee2018Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_9d9a868b-9984-4031-be1b-be36ab179a70" xlink:to="loc_ardx_ExitFee2018Member_b9ca2ce6-1aa0-4d93-8738-7821af56d7a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ExitFee2022Member_d1692fec-c6d7-4217-9aaf-b692eb9392e7" xlink:href="ardx-20220331.xsd#ardx_ExitFee2022Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_9d9a868b-9984-4031-be1b-be36ab179a70" xlink:to="loc_ardx_ExitFee2022Member_d1692fec-c6d7-4217-9aaf-b692eb9392e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_23598bb8-6f8e-4723-a4e8-0069e6e9b401" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_98b48ee0-39c9-4231-9444-b9bf90dc816f" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_23598bb8-6f8e-4723-a4e8-0069e6e9b401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1fda40d7-0c54-4524-8210-831b05db46d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_23598bb8-6f8e-4723-a4e8-0069e6e9b401" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1fda40d7-0c54-4524-8210-831b05db46d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_94d5708f-3ecb-4601-9aec-4be21a1b2600" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1fda40d7-0c54-4524-8210-831b05db46d9" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_94d5708f-3ecb-4601-9aec-4be21a1b2600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_f0856ab9-bbde-40a0-8673-359b70c8a674" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_98b48ee0-39c9-4231-9444-b9bf90dc816f" xlink:to="loc_us-gaap_DerivativeLineItems_f0856ab9-bbde-40a0-8673-359b70c8a674" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotionalAmount_b9ea026d-02d9-40fd-82ff-623da4c432f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilityNotionalAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_f0856ab9-bbde-40a0-8673-359b70c8a674" xlink:to="loc_us-gaap_DerivativeLiabilityNotionalAmount_b9ea026d-02d9-40fd-82ff-623da4c432f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage_782adc94-4b5a-4b39-86d6-17dc33f64107" xlink:href="ardx-20220331.xsd#ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_f0856ab9-bbde-40a0-8673-359b70c8a674" xlink:to="loc_ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage_782adc94-4b5a-4b39-86d6-17dc33f64107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation_d28e49cd-8712-4060-88d6-8e1bdc36d344" xlink:href="ardx-20220331.xsd#ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_f0856ab9-bbde-40a0-8673-359b70c8a674" xlink:to="loc_ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation_d28e49cd-8712-4060-88d6-8e1bdc36d344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ExitFeePercentage_27208df6-b6c6-439c-9582-f11fc94383fb" xlink:href="ardx-20220331.xsd#ardx_ExitFeePercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_f0856ab9-bbde-40a0-8673-359b70c8a674" xlink:to="loc_ardx_ExitFeePercentage_27208df6-b6c6-439c-9582-f11fc94383fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum_7c5327e5-7415-4bdc-b30c-8b138d2254c3" xlink:href="ardx-20220331.xsd#ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_f0856ab9-bbde-40a0-8673-359b70c8a674" xlink:to="loc_ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum_7c5327e5-7415-4bdc-b30c-8b138d2254c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/DerivativeLiabilityChangesinFairValueDetails" xlink:type="simple" xlink:href="ardx-20220331.xsd#DerivativeLiabilityChangesinFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/DerivativeLiabilityChangesinFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_e3b25171-0800-4860-8f67-62734aba5ebe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_6b161408-888c-43b9-bad5-8218d98841f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_e3b25171-0800-4860-8f67-62734aba5ebe" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_6b161408-888c-43b9-bad5-8218d98841f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_758ab1ca-1aba-40ae-a1df-a15fe7c0dba9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_6b161408-888c-43b9-bad5-8218d98841f3" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_758ab1ca-1aba-40ae-a1df-a15fe7c0dba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_f2828ee3-335c-4383-949f-2cd5824c4c09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_758ab1ca-1aba-40ae-a1df-a15fe7c0dba9" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_f2828ee3-335c-4383-949f-2cd5824c4c09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_0a4aff29-a44c-45fc-a793-4ecf593897c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_f2828ee3-335c-4383-949f-2cd5824c4c09" xlink:to="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_0a4aff29-a44c-45fc-a793-4ecf593897c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_7c14fdf3-3168-4c2f-9800-1b1a73013f54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_6b161408-888c-43b9-bad5-8218d98841f3" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_7c14fdf3-3168-4c2f-9800-1b1a73013f54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_c95d9184-dcf5-497d-8cbf-79df9a56bf73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_7c14fdf3-3168-4c2f-9800-1b1a73013f54" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_c95d9184-dcf5-497d-8cbf-79df9a56bf73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_93f4410e-2f9a-4b9a-8609-04a3af64924d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_c95d9184-dcf5-497d-8cbf-79df9a56bf73" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_93f4410e-2f9a-4b9a-8609-04a3af64924d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_9fb5883e-8476-4a73-b6ca-7a3445a47689" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_c95d9184-dcf5-497d-8cbf-79df9a56bf73" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_9fb5883e-8476-4a73-b6ca-7a3445a47689" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_9b3da089-a6be-45a5-94d1-471bc2025d15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_c95d9184-dcf5-497d-8cbf-79df9a56bf73" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_9b3da089-a6be-45a5-94d1-471bc2025d15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_fbb81abc-8d37-47e7-bfa7-e31b525d7364" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_c95d9184-dcf5-497d-8cbf-79df9a56bf73" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_fbb81abc-8d37-47e7-bfa7-e31b525d7364" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/Leases" xlink:type="simple" xlink:href="ardx-20220331.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_63aa2cd3-4ffc-480d-a2a1-6d0986aae39f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_93a114e5-4712-4132-a522-5f023f9995b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_63aa2cd3-4ffc-480d-a2a1-6d0986aae39f" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_93a114e5-4712-4132-a522-5f023f9995b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/LeasesTables" xlink:type="simple" xlink:href="ardx-20220331.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_e3664af0-48ea-4e22-9660-497bb61af62a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ScheduleOfAdditionalDetailsOfLeasesTableTextBlock_47400f26-347e-4864-87ff-ec90909ff136" xlink:href="ardx-20220331.xsd#ardx_ScheduleOfAdditionalDetailsOfLeasesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e3664af0-48ea-4e22-9660-497bb61af62a" xlink:to="loc_ardx_ScheduleOfAdditionalDetailsOfLeasesTableTextBlock_47400f26-347e-4864-87ff-ec90909ff136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_2e71ac8b-fc25-4f7b-a951-0a7017187b37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e3664af0-48ea-4e22-9660-497bb61af62a" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_2e71ac8b-fc25-4f7b-a951-0a7017187b37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_d27744ad-3172-4fab-975a-e6449842175e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e3664af0-48ea-4e22-9660-497bb61af62a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_d27744ad-3172-4fab-975a-e6449842175e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/LeasesAdditionalDetailsofFacilityLeasesDetails" xlink:type="simple" xlink:href="ardx-20220331.xsd#LeasesAdditionalDetailsofFacilityLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/LeasesAdditionalDetailsofFacilityLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_26d629bb-a1b8-4e23-9ef1-d2e446e7de47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_078bfeb6-6fe4-464f-a781-c300f222007f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAndLiabilitiesLesseeAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_26d629bb-a1b8-4e23-9ef1-d2e446e7de47" xlink:to="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_078bfeb6-6fe4-464f-a781-c300f222007f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_7f09fe1e-f55b-4418-bd27-9781e2a4072b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_078bfeb6-6fe4-464f-a781-c300f222007f" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_7f09fe1e-f55b-4418-bd27-9781e2a4072b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_d9520fb5-2a94-49ec-be4f-0d276d66f289" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_078bfeb6-6fe4-464f-a781-c300f222007f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_d9520fb5-2a94-49ec-be4f-0d276d66f289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_059b2509-f5a2-4400-b468-01f029b7c9ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_078bfeb6-6fe4-464f-a781-c300f222007f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_059b2509-f5a2-4400-b468-01f029b7c9ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_98d5bea2-309e-4a4b-95a1-19beacca6513" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_078bfeb6-6fe4-464f-a781-c300f222007f" xlink:to="loc_us-gaap_OperatingLeaseLiability_98d5bea2-309e-4a4b-95a1-19beacca6513" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseDescriptionAbstract_22949aed-cea6-407b-9c17-f7752b78bf8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseDescriptionAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_26d629bb-a1b8-4e23-9ef1-d2e446e7de47" xlink:to="loc_us-gaap_LesseeOperatingLeaseDescriptionAbstract_22949aed-cea6-407b-9c17-f7752b78bf8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_c2c2c969-8c5c-4e9c-b8b5-eb4989404aee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeOperatingLeaseDescriptionAbstract_22949aed-cea6-407b-9c17-f7752b78bf8e" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_c2c2c969-8c5c-4e9c-b8b5-eb4989404aee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_8f88afc6-c619-4260-a91d-9b496ac36b67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeOperatingLeaseDescriptionAbstract_22949aed-cea6-407b-9c17-f7752b78bf8e" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_8f88afc6-c619-4260-a91d-9b496ac36b67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/LeasesLeaseCostsDetails" xlink:type="simple" xlink:href="ardx-20220331.xsd#LeasesLeaseCostsDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/LeasesLeaseCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_2446ccba-3cef-4a1a-9ed2-09f169bfdd7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract_d0d4b5ba-0e3e-417a-b664-cee085f82426" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2446ccba-3cef-4a1a-9ed2-09f169bfdd7e" xlink:to="loc_us-gaap_LeaseCostAbstract_d0d4b5ba-0e3e-417a-b664-cee085f82426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_efd8351a-503a-4514-80bb-58dea1bc01d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_d0d4b5ba-0e3e-417a-b664-cee085f82426" xlink:to="loc_us-gaap_OperatingLeaseCost_efd8351a-503a-4514-80bb-58dea1bc01d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_748e58fb-5b8a-4540-ad07-75ed0061d461" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_d0d4b5ba-0e3e-417a-b664-cee085f82426" xlink:to="loc_us-gaap_OperatingLeasePayments_748e58fb-5b8a-4540-ad07-75ed0061d461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails" xlink:type="simple" xlink:href="ardx-20220331.xsd#LeasesUndiscountedCashPaymentObligationsDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_5524f0a0-484c-4059-8c2b-64bf716d83af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_ccb2ca4e-ce30-42d3-9c5a-959e855c9fcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5524f0a0-484c-4059-8c2b-64bf716d83af" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_ccb2ca4e-ce30-42d3-9c5a-959e855c9fcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_5b36ee3c-80e3-4051-b1b6-a292052e799c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_ccb2ca4e-ce30-42d3-9c5a-959e855c9fcd" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_5b36ee3c-80e3-4051-b1b6-a292052e799c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_3ff78742-fcf0-4f2e-8245-82e203adcfc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_ccb2ca4e-ce30-42d3-9c5a-959e855c9fcd" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_3ff78742-fcf0-4f2e-8245-82e203adcfc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_97160874-2885-47b3-9acc-a50f71177797" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_ccb2ca4e-ce30-42d3-9c5a-959e855c9fcd" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_97160874-2885-47b3-9acc-a50f71177797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_18480da4-9f55-4dbe-85e4-0479c23e03ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_ccb2ca4e-ce30-42d3-9c5a-959e855c9fcd" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_18480da4-9f55-4dbe-85e4-0479c23e03ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_aade4664-8195-4ec6-b518-8e637e2b266b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_ccb2ca4e-ce30-42d3-9c5a-959e855c9fcd" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_aade4664-8195-4ec6-b518-8e637e2b266b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d2593811-bfbf-48bd-bfab-6ea50040419f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_ccb2ca4e-ce30-42d3-9c5a-959e855c9fcd" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d2593811-bfbf-48bd-bfab-6ea50040419f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_6d97aa46-9af7-4ed6-a8a3-ced3129ccf23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_ccb2ca4e-ce30-42d3-9c5a-959e855c9fcd" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_6d97aa46-9af7-4ed6-a8a3-ced3129ccf23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_b4f1b0c1-6508-4d30-89b0-f45ee865892d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_ccb2ca4e-ce30-42d3-9c5a-959e855c9fcd" xlink:to="loc_us-gaap_OperatingLeaseLiability_b4f1b0c1-6508-4d30-89b0-f45ee865892d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_f04c4701-4281-4ed1-9b91-13a038f70474" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_ccb2ca4e-ce30-42d3-9c5a-959e855c9fcd" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_f04c4701-4281-4ed1-9b91-13a038f70474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f5ef21f6-218f-4757-805d-3df2cb1c75c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_ccb2ca4e-ce30-42d3-9c5a-959e855c9fcd" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f5ef21f6-218f-4757-805d-3df2cb1c75c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails_1" xlink:type="simple" xlink:href="ardx-20220331.xsd#LeasesUndiscountedCashPaymentObligationsDetails_1"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ardelyx.com/role/StockholdersEquity" xlink:type="simple" xlink:href="ardx-20220331.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_16674ccc-7c53-4ddc-9912-c2d1eb57e88c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_223088ea-e62a-4af2-a8eb-d095376dd38c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_16674ccc-7c53-4ddc-9912-c2d1eb57e88c" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_223088ea-e62a-4af2-a8eb-d095376dd38c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="ardx-20220331.xsd#StockholdersEquityDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/StockholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_72e837e0-1112-4e60-bb11-3ce62c0e2081" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_b25f95f7-e248-4e6c-ae32-594c62a18d96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_72e837e0-1112-4e60-bb11-3ce62c0e2081" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_b25f95f7-e248-4e6c-ae32-594c62a18d96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_20da06a4-9f01-4f42-ac46-e253a650b945" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_b25f95f7-e248-4e6c-ae32-594c62a18d96" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_20da06a4-9f01-4f42-ac46-e253a650b945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_89f0f7d3-58c5-4b31-b6da-0d20967f9a63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_20da06a4-9f01-4f42-ac46-e253a650b945" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_89f0f7d3-58c5-4b31-b6da-0d20967f9a63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_OpenMarketSalesAgreement2020AtTheMarketOfferingMember_e5b4737b-cc1f-4d3e-8916-ebecb1e376b3" xlink:href="ardx-20220331.xsd#ardx_OpenMarketSalesAgreement2020AtTheMarketOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_89f0f7d3-58c5-4b31-b6da-0d20967f9a63" xlink:to="loc_ardx_OpenMarketSalesAgreement2020AtTheMarketOfferingMember_e5b4737b-cc1f-4d3e-8916-ebecb1e376b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_OpenMarketSalesAgreement2021AtTheMarketOfferingMember_e20d9987-cf54-4be6-8043-4761f733e816" xlink:href="ardx-20220331.xsd#ardx_OpenMarketSalesAgreement2021AtTheMarketOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_89f0f7d3-58c5-4b31-b6da-0d20967f9a63" xlink:to="loc_ardx_OpenMarketSalesAgreement2021AtTheMarketOfferingMember_e20d9987-cf54-4be6-8043-4761f733e816" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_6d31416b-ff3f-4044-99cd-c1871310fe4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_b25f95f7-e248-4e6c-ae32-594c62a18d96" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_6d31416b-ff3f-4044-99cd-c1871310fe4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_78815567-8ca5-4912-97a3-080d3b991838" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_6d31416b-ff3f-4044-99cd-c1871310fe4f" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_78815567-8ca5-4912-97a3-080d3b991838" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_8e62a444-fb39-4cae-bdf9-b58c012307b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_78815567-8ca5-4912-97a3-080d3b991838" xlink:to="loc_us-gaap_SubsequentEventMember_8e62a444-fb39-4cae-bdf9-b58c012307b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_fb706513-f7cb-4701-8460-94a616db7418" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_b25f95f7-e248-4e6c-ae32-594c62a18d96" xlink:to="loc_us-gaap_StatementClassOfStockAxis_fb706513-f7cb-4701-8460-94a616db7418" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_33c41930-4bf3-4901-b2cb-5f172eecb721" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_fb706513-f7cb-4701-8460-94a616db7418" xlink:to="loc_us-gaap_ClassOfStockDomain_33c41930-4bf3-4901-b2cb-5f172eecb721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_7f4dfe4e-a88d-4cef-8a78-5948a60e71ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_33c41930-4bf3-4901-b2cb-5f172eecb721" xlink:to="loc_us-gaap_CommonClassAMember_7f4dfe4e-a88d-4cef-8a78-5948a60e71ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_1a310dae-d934-4408-83c4-7e412dcb4b16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_b25f95f7-e248-4e6c-ae32-594c62a18d96" xlink:to="loc_us-gaap_SubsidiarySaleOfStockLineItems_1a310dae-d934-4408-83c4-7e412dcb4b16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_MaximumAggregateOfferingPrice_3054de6f-8686-46dc-8c8d-1ece77d9e330" xlink:href="ardx-20220331.xsd#ardx_MaximumAggregateOfferingPrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_1a310dae-d934-4408-83c4-7e412dcb4b16" xlink:to="loc_ardx_MaximumAggregateOfferingPrice_3054de6f-8686-46dc-8c8d-1ece77d9e330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_StockIssuanceCostCommissionPercent_3c776050-b792-44dc-bdc1-02dc2ff7696e" xlink:href="ardx-20220331.xsd#ardx_StockIssuanceCostCommissionPercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_1a310dae-d934-4408-83c4-7e412dcb4b16" xlink:to="loc_ardx_StockIssuanceCostCommissionPercent_3c776050-b792-44dc-bdc1-02dc2ff7696e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8c2882f2-71be-412e-9c0d-bdf6f1e8c184" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_1a310dae-d934-4408-83c4-7e412dcb4b16" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8c2882f2-71be-412e-9c0d-bdf6f1e8c184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1fe82a15-cc5b-4e6d-b757-3ef493988a46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_1a310dae-d934-4408-83c4-7e412dcb4b16" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1fe82a15-cc5b-4e6d-b757-3ef493988a46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_SaleOfStockWeightedAveragePricePerShare_395fb56b-5044-4cc2-8947-14b56f3fc4ad" xlink:href="ardx-20220331.xsd#ardx_SaleOfStockWeightedAveragePricePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_1a310dae-d934-4408-83c4-7e412dcb4b16" xlink:to="loc_ardx_SaleOfStockWeightedAveragePricePerShare_395fb56b-5044-4cc2-8947-14b56f3fc4ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/EquityIncentivePlans" xlink:type="simple" xlink:href="ardx-20220331.xsd#EquityIncentivePlans"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/EquityIncentivePlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5719ada5-bfb1-4f1f-a064-efc94b19a73e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_ece4dbd0-c510-45bc-a1bc-2265fda35573" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5719ada5-bfb1-4f1f-a064-efc94b19a73e" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_ece4dbd0-c510-45bc-a1bc-2265fda35573" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/EquityIncentivePlansTables" xlink:type="simple" xlink:href="ardx-20220331.xsd#EquityIncentivePlansTables"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/EquityIncentivePlansTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b9b502ac-a066-400c-8aee-3763a4f5f776" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_9d66c253-7c4e-44f6-a362-701eb9c29ee2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b9b502ac-a066-400c-8aee-3763a4f5f776" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_9d66c253-7c4e-44f6-a362-701eb9c29ee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_df500597-88a0-4e8f-b794-c0e9dd7478e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b9b502ac-a066-400c-8aee-3763a4f5f776" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_df500597-88a0-4e8f-b794-c0e9dd7478e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_746d2b22-d11e-4b06-bd5d-2e8a761cd00c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b9b502ac-a066-400c-8aee-3763a4f5f776" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_746d2b22-d11e-4b06-bd5d-2e8a761cd00c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_03a06e38-e916-4c43-97a7-dc4b90deb698" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b9b502ac-a066-400c-8aee-3763a4f5f776" xlink:to="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_03a06e38-e916-4c43-97a7-dc4b90deb698" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/EquityIncentivePlansStockBasedCompensationDetails" xlink:type="simple" xlink:href="ardx-20220331.xsd#EquityIncentivePlansStockBasedCompensationDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/EquityIncentivePlansStockBasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1984e3de-e9a0-4565-8168-63d9bb616e20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_6a9d74c6-7a2e-49d0-ad8f-0f562f53a001" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1984e3de-e9a0-4565-8168-63d9bb616e20" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_6a9d74c6-7a2e-49d0-ad8f-0f562f53a001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_59a44986-fb27-404c-af2d-bf9bd67ea113" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_6a9d74c6-7a2e-49d0-ad8f-0f562f53a001" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_59a44986-fb27-404c-af2d-bf9bd67ea113" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_b52e18ca-06d3-48c8-b62d-aa975c06c8bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_59a44986-fb27-404c-af2d-bf9bd67ea113" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_b52e18ca-06d3-48c8-b62d-aa975c06c8bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_dc21b2db-7c12-4503-afb8-9c6d40b4d89e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_b52e18ca-06d3-48c8-b62d-aa975c06c8bf" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_dc21b2db-7c12-4503-afb8-9c6d40b4d89e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_543858cf-9ea3-4086-89ab-8bb48f1e83d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_b52e18ca-06d3-48c8-b62d-aa975c06c8bf" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_543858cf-9ea3-4086-89ab-8bb48f1e83d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_6ff40f60-13ea-4e3a-99b4-8ce25607a0ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_6a9d74c6-7a2e-49d0-ad8f-0f562f53a001" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_6ff40f60-13ea-4e3a-99b4-8ce25607a0ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_4ee4ec50-375e-42af-810c-d358587befcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_6ff40f60-13ea-4e3a-99b4-8ce25607a0ce" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_4ee4ec50-375e-42af-810c-d358587befcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/EquityIncentivePlansUnrecognizedStockBasedCompensationDetails" xlink:type="simple" xlink:href="ardx-20220331.xsd#EquityIncentivePlansUnrecognizedStockBasedCompensationDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/EquityIncentivePlansUnrecognizedStockBasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1ead80ba-5605-47db-b4fd-aa771692a749" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f4e0565b-fd10-4c34-89e1-e508af12e62e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1ead80ba-5605-47db-b4fd-aa771692a749" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f4e0565b-fd10-4c34-89e1-e508af12e62e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_0142d297-96e3-4e0d-9fa0-d5651664cd90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f4e0565b-fd10-4c34-89e1-e508af12e62e" xlink:to="loc_us-gaap_PlanNameAxis_0142d297-96e3-4e0d-9fa0-d5651664cd90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_7fcc8d74-eed6-49e4-8aa8-52cf78013c84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_0142d297-96e3-4e0d-9fa0-d5651664cd90" xlink:to="loc_us-gaap_PlanNameDomain_7fcc8d74-eed6-49e4-8aa8-52cf78013c84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_EmployeeStockPurchasePlanMember_362dfe3a-b3db-4910-80d9-dfb89a3364fd" xlink:href="ardx-20220331.xsd#ardx_EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_7fcc8d74-eed6-49e4-8aa8-52cf78013c84" xlink:to="loc_ardx_EmployeeStockPurchasePlanMember_362dfe3a-b3db-4910-80d9-dfb89a3364fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2044e5a2-8eae-4f8c-9d8f-77798a1563b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f4e0565b-fd10-4c34-89e1-e508af12e62e" xlink:to="loc_us-gaap_AwardTypeAxis_2044e5a2-8eae-4f8c-9d8f-77798a1563b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_be5737aa-13f3-492d-a2de-893cb115c7ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2044e5a2-8eae-4f8c-9d8f-77798a1563b1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_be5737aa-13f3-492d-a2de-893cb115c7ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_0cbbd116-ba66-4b4e-8bcc-52d4c806d5fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_be5737aa-13f3-492d-a2de-893cb115c7ab" xlink:to="loc_us-gaap_EmployeeStockOptionMember_0cbbd116-ba66-4b4e-8bcc-52d4c806d5fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_59ac1ab2-122e-47a8-9555-abd000a1cdbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_be5737aa-13f3-492d-a2de-893cb115c7ab" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_59ac1ab2-122e-47a8-9555-abd000a1cdbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6fba5aaa-9a46-4985-b35b-b675386141d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f4e0565b-fd10-4c34-89e1-e508af12e62e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6fba5aaa-9a46-4985-b35b-b675386141d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_d7548361-a0c1-47d7-8b0f-d6dcc79882ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6fba5aaa-9a46-4985-b35b-b675386141d7" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_d7548361-a0c1-47d7-8b0f-d6dcc79882ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_9a890dc4-cdd1-44ed-a2e4-23e00668dac8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6fba5aaa-9a46-4985-b35b-b675386141d7" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_9a890dc4-cdd1-44ed-a2e4-23e00668dac8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails" xlink:type="simple" xlink:href="ardx-20220331.xsd#EquityIncentivePlansStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ea456371-9d5d-416c-9fb2-30db92599613" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6526a3e0-f9a9-418a-ae98-eaa07c63c548" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ea456371-9d5d-416c-9fb2-30db92599613" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6526a3e0-f9a9-418a-ae98-eaa07c63c548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3000d383-ad79-4b9e-b8f6-4db180f931bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6526a3e0-f9a9-418a-ae98-eaa07c63c548" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3000d383-ad79-4b9e-b8f6-4db180f931bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_93c1023b-2351-4a84-a373-676d95978db1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6526a3e0-f9a9-418a-ae98-eaa07c63c548" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_93c1023b-2351-4a84-a373-676d95978db1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_37009825-8f0c-4763-88bb-325d3b6ac81c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6526a3e0-f9a9-418a-ae98-eaa07c63c548" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_37009825-8f0c-4763-88bb-325d3b6ac81c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_7ba4b125-411f-4fe3-b3d6-8d607aace2e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6526a3e0-f9a9-418a-ae98-eaa07c63c548" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_7ba4b125-411f-4fe3-b3d6-8d607aace2e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2dfe441d-e8fd-4cb9-96e1-256dd70ae56c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6526a3e0-f9a9-418a-ae98-eaa07c63c548" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2dfe441d-e8fd-4cb9-96e1-256dd70ae56c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_079d6e13-c132-444c-acde-7cd5e917a8eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ea456371-9d5d-416c-9fb2-30db92599613" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_079d6e13-c132-444c-acde-7cd5e917a8eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4db6d542-d61d-4e26-8277-44e6e8fe25d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ea456371-9d5d-416c-9fb2-30db92599613" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4db6d542-d61d-4e26-8277-44e6e8fe25d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ce9a0ad6-579f-4cee-8b87-7ad6f1ddfdaf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4db6d542-d61d-4e26-8277-44e6e8fe25d4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ce9a0ad6-579f-4cee-8b87-7ad6f1ddfdaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c0ad0fd5-9839-4736-ac40-4adf9f3ac59f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4db6d542-d61d-4e26-8277-44e6e8fe25d4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c0ad0fd5-9839-4736-ac40-4adf9f3ac59f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_cfecaaa0-01ca-4e66-bd44-53446de70acf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4db6d542-d61d-4e26-8277-44e6e8fe25d4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_cfecaaa0-01ca-4e66-bd44-53446de70acf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_987af8db-1782-4d29-83b3-eadfb5389309" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4db6d542-d61d-4e26-8277-44e6e8fe25d4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_987af8db-1782-4d29-83b3-eadfb5389309" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8f9c439b-7f2f-4d26-a575-1865fb9bf142" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4db6d542-d61d-4e26-8277-44e6e8fe25d4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8f9c439b-7f2f-4d26-a575-1865fb9bf142" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_4e8cb25b-91f0-4a77-94bc-87228762e7c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ea456371-9d5d-416c-9fb2-30db92599613" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_4e8cb25b-91f0-4a77-94bc-87228762e7c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="ardx-20220331.xsd#EquityIncentivePlansRestrictedStockUnitsDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_93b95538-9e3d-4279-9147-2d917f5b7475" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f42494fb-46d9-40dd-b7da-ac28413223da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_93b95538-9e3d-4279-9147-2d917f5b7475" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f42494fb-46d9-40dd-b7da-ac28413223da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_c8038126-d80d-4cc2-ab5d-df6dbb181a12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f42494fb-46d9-40dd-b7da-ac28413223da" xlink:to="loc_us-gaap_AwardTypeAxis_c8038126-d80d-4cc2-ab5d-df6dbb181a12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e9be979f-fe4a-4aa1-9580-43f0d43d05c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_c8038126-d80d-4cc2-ab5d-df6dbb181a12" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e9be979f-fe4a-4aa1-9580-43f0d43d05c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_0aaaa241-f2c9-49e1-87db-68fe5794d575" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e9be979f-fe4a-4aa1-9580-43f0d43d05c3" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_0aaaa241-f2c9-49e1-87db-68fe5794d575" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c8c0adb-823c-44ba-bdbc-dcb66a8bc383" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f42494fb-46d9-40dd-b7da-ac28413223da" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c8c0adb-823c-44ba-bdbc-dcb66a8bc383" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4cc2f373-3870-413f-87bb-85c744686e55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c8c0adb-823c-44ba-bdbc-dcb66a8bc383" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4cc2f373-3870-413f-87bb-85c744686e55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_bef9b3b7-49af-4a21-af86-475600383e3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4cc2f373-3870-413f-87bb-85c744686e55" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_bef9b3b7-49af-4a21-af86-475600383e3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_b7c4bc46-534a-48a7-aff3-440579eecc69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4cc2f373-3870-413f-87bb-85c744686e55" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_b7c4bc46-534a-48a7-aff3-440579eecc69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_b77a4b93-c634-484d-82d3-95ce654164ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4cc2f373-3870-413f-87bb-85c744686e55" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_b77a4b93-c634-484d-82d3-95ce654164ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_dab72006-cfc9-4886-afc6-ca55abb81424" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4cc2f373-3870-413f-87bb-85c744686e55" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_dab72006-cfc9-4886-afc6-ca55abb81424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_426eada4-23d9-4261-a47c-24d8ea431af5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4cc2f373-3870-413f-87bb-85c744686e55" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_426eada4-23d9-4261-a47c-24d8ea431af5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_24e1b2fb-f227-43da-8900-4f45f47b2a0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c8c0adb-823c-44ba-bdbc-dcb66a8bc383" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_24e1b2fb-f227-43da-8900-4f45f47b2a0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5eb15c24-a0b9-4e00-b27b-de8eff92a722" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_24e1b2fb-f227-43da-8900-4f45f47b2a0d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5eb15c24-a0b9-4e00-b27b-de8eff92a722" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7128938e-dbbd-45ae-b830-a53e02f4b115" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_24e1b2fb-f227-43da-8900-4f45f47b2a0d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7128938e-dbbd-45ae-b830-a53e02f4b115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_9e9ee6d1-4e7a-476c-9f98-22ecb561affc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_24e1b2fb-f227-43da-8900-4f45f47b2a0d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_9e9ee6d1-4e7a-476c-9f98-22ecb561affc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_521f62ff-596f-4af5-baf8-d9e0c979459a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_24e1b2fb-f227-43da-8900-4f45f47b2a0d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_521f62ff-596f-4af5-baf8-d9e0c979459a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_634d2de7-20c7-443a-a0a9-cfbc24fff4bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_24e1b2fb-f227-43da-8900-4f45f47b2a0d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_634d2de7-20c7-443a-a0a9-cfbc24fff4bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails" xlink:type="simple" xlink:href="ardx-20220331.xsd#EquityIncentivePlansNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3333c8b0-5065-420d-bd01-97ad0f9d3b28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6e189f04-73c7-4a9b-8673-d482e5f8f8c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3333c8b0-5065-420d-bd01-97ad0f9d3b28" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6e189f04-73c7-4a9b-8673-d482e5f8f8c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_1fd6e8be-5b71-4d7e-a260-20db11301241" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6e189f04-73c7-4a9b-8673-d482e5f8f8c5" xlink:to="loc_srt_TitleOfIndividualAxis_1fd6e8be-5b71-4d7e-a260-20db11301241" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_7280ac43-9ab4-4726-b012-c0203b0d8abe" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_1fd6e8be-5b71-4d7e-a260-20db11301241" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_7280ac43-9ab4-4726-b012-c0203b0d8abe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_b2530e94-13a6-4422-b556-ba0a8739513a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_7280ac43-9ab4-4726-b012-c0203b0d8abe" xlink:to="loc_srt_DirectorMember_b2530e94-13a6-4422-b556-ba0a8739513a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_08f6249f-92d5-402b-8dbf-50059c7b2a92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6e189f04-73c7-4a9b-8673-d482e5f8f8c5" xlink:to="loc_us-gaap_PlanNameAxis_08f6249f-92d5-402b-8dbf-50059c7b2a92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_fa7677a8-0939-4170-9d5c-2af53321aa16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_08f6249f-92d5-402b-8dbf-50059c7b2a92" xlink:to="loc_us-gaap_PlanNameDomain_fa7677a8-0939-4170-9d5c-2af53321aa16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_EmployeeStockPurchasePlanMember_839b2916-b78b-4d84-96bf-9606426819ad" xlink:href="ardx-20220331.xsd#ardx_EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_fa7677a8-0939-4170-9d5c-2af53321aa16" xlink:to="loc_ardx_EmployeeStockPurchasePlanMember_839b2916-b78b-4d84-96bf-9606426819ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b92ea75-992a-425f-9a49-a63878f70740" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6e189f04-73c7-4a9b-8673-d482e5f8f8c5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b92ea75-992a-425f-9a49-a63878f70740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_9acc6a5c-40a4-48c7-b385-3d63fd1eddff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b92ea75-992a-425f-9a49-a63878f70740" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_9acc6a5c-40a4-48c7-b385-3d63fd1eddff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare_c0e954e7-d6f7-4ffc-b5ec-7d93787b9a05" xlink:href="ardx-20220331.xsd#ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b92ea75-992a-425f-9a49-a63878f70740" xlink:to="loc_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare_c0e954e7-d6f7-4ffc-b5ec-7d93787b9a05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_8a32f4e9-a49f-47e7-aa43-6276ec716df7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b92ea75-992a-425f-9a49-a63878f70740" xlink:to="loc_us-gaap_ProceedsFromStockPlans_8a32f4e9-a49f-47e7-aa43-6276ec716df7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_315d76dd-80d2-4676-a6f1-a2600ab50cb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b92ea75-992a-425f-9a49-a63878f70740" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_315d76dd-80d2-4676-a6f1-a2600ab50cb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/NetLossPerShare" xlink:type="simple" xlink:href="ardx-20220331.xsd#NetLossPerShare"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/NetLossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_01d9634c-712b-4ae6-a3b4-fd473ce5e2d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_69b8e838-30fe-4eb2-bcc2-9dcfe708de82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_01d9634c-712b-4ae6-a3b4-fd473ce5e2d1" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_69b8e838-30fe-4eb2-bcc2-9dcfe708de82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/NetLossPerShareTables" xlink:type="simple" xlink:href="ardx-20220331.xsd#NetLossPerShareTables"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/NetLossPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_27d587b9-98cd-4d0d-8564-ee840f8d64a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_7da2ace9-dde3-4dcd-966c-13c174898a69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_27d587b9-98cd-4d0d-8564-ee840f8d64a8" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_7da2ace9-dde3-4dcd-966c-13c174898a69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/NetLossPerShareComputationofNetLossPerCommonShareDetails" xlink:type="simple" xlink:href="ardx-20220331.xsd#NetLossPerShareComputationofNetLossPerCommonShareDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/NetLossPerShareComputationofNetLossPerCommonShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_762a7d3d-be4c-4edc-af5e-89bd803090b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract_c7daa55f-c9e8-4b26-8fbb-2d2a0d1ee891" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_762a7d3d-be4c-4edc-af5e-89bd803090b7" xlink:to="loc_us-gaap_NetIncomeLossAbstract_c7daa55f-c9e8-4b26-8fbb-2d2a0d1ee891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c7b474b9-cd94-4595-986a-52f96a2bf216" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_c7daa55f-c9e8-4b26-8fbb-2d2a0d1ee891" xlink:to="loc_us-gaap_NetIncomeLoss_c7b474b9-cd94-4595-986a-52f96a2bf216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_b904489a-d914-422c-b72b-6ecbcbd9dea9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_762a7d3d-be4c-4edc-af5e-89bd803090b7" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_b904489a-d914-422c-b72b-6ecbcbd9dea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c5bea7d8-e1a1-4a84-906c-edeec1a892fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_b904489a-d914-422c-b72b-6ecbcbd9dea9" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c5bea7d8-e1a1-4a84-906c-edeec1a892fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0dc3abc8-4877-4e84-819c-bb3d32159046" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_b904489a-d914-422c-b72b-6ecbcbd9dea9" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0dc3abc8-4877-4e84-819c-bb3d32159046" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_f7fd1993-a524-4137-a80d-987aa6176673" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_762a7d3d-be4c-4edc-af5e-89bd803090b7" xlink:to="loc_us-gaap_EarningsPerShareBasic_f7fd1993-a524-4137-a80d-987aa6176673" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_1f16a121-93b3-4901-ac48-3d6cdff7d734" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_762a7d3d-be4c-4edc-af5e-89bd803090b7" xlink:to="loc_us-gaap_EarningsPerShareDiluted_1f16a121-93b3-4901-ac48-3d6cdff7d734" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/NetLossPerShareNarrativeDetails" xlink:type="simple" xlink:href="ardx-20220331.xsd#NetLossPerShareNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/NetLossPerShareNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_4fbbfc7f-d063-4930-b869-4bd44acc28ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d6c0d521-3d68-4391-947a-1eddd20aaeec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_4fbbfc7f-d063-4930-b869-4bd44acc28ef" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d6c0d521-3d68-4391-947a-1eddd20aaeec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/Contingencies" xlink:type="simple" xlink:href="ardx-20220331.xsd#Contingencies"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/Contingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ad547ddf-0c43-42f7-be68-45d607fbc016" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1dfb4358-5f3f-41f9-b4a5-534959f8d473" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ad547ddf-0c43-42f7-be68-45d607fbc016" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1dfb4358-5f3f-41f9-b4a5-534959f8d473" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/ContingenciesDetails" xlink:type="simple" xlink:href="ardx-20220331.xsd#ContingenciesDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/ContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_535a6526-e8df-4420-8371-95695029c5a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_1b7ca6cf-9a88-44a2-b026-46d881e14f6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_535a6526-e8df-4420-8371-95695029c5a7" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_1b7ca6cf-9a88-44a2-b026-46d881e14f6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/SubsequentEvents" xlink:type="simple" xlink:href="ardx-20220331.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_5b01887d-6cdf-459a-83fb-9d81bd3b8d2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_8a76f889-9b65-4f96-b4bb-c24045cc83cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_5b01887d-6cdf-459a-83fb-9d81bd3b8d2f" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_8a76f889-9b65-4f96-b4bb-c24045cc83cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="ardx-20220331.xsd#SubsequentEventsDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_817cc311-8731-439e-a116-7e2521517fbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_5e07948e-f0f0-46ea-9830-ec6fb9d7d9c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_817cc311-8731-439e-a116-7e2521517fbd" xlink:to="loc_us-gaap_SubsequentEventTable_5e07948e-f0f0-46ea-9830-ec6fb9d7d9c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_ddcc4f09-ea2d-4d20-8c8a-255473b02c19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_5e07948e-f0f0-46ea-9830-ec6fb9d7d9c1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_ddcc4f09-ea2d-4d20-8c8a-255473b02c19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_b22be8f6-7458-4a15-a45b-a2823ff0b5d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_ddcc4f09-ea2d-4d20-8c8a-255473b02c19" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_b22be8f6-7458-4a15-a45b-a2823ff0b5d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_41001a55-3340-4c3d-bb98-8f571da71cc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_b22be8f6-7458-4a15-a45b-a2823ff0b5d3" xlink:to="loc_us-gaap_SubsequentEventMember_41001a55-3340-4c3d-bb98-8f571da71cc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_0e86676f-0d32-42c7-b239-d0946a6feda8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_5e07948e-f0f0-46ea-9830-ec6fb9d7d9c1" xlink:to="loc_srt_CounterpartyNameAxis_0e86676f-0d32-42c7-b239-d0946a6feda8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9f83d5b8-cd92-4aad-8669-3fcbd777f68e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_0e86676f-0d32-42c7-b239-d0946a6feda8" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9f83d5b8-cd92-4aad-8669-3fcbd777f68e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_KyowaKirinCo.LtdMember_c5b280f6-5477-41d5-bbe3-ec35a286d232" xlink:href="ardx-20220331.xsd#ardx_KyowaKirinCo.LtdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9f83d5b8-cd92-4aad-8669-3fcbd777f68e" xlink:to="loc_ardx_KyowaKirinCo.LtdMember_c5b280f6-5477-41d5-bbe3-ec35a286d232" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_ef4eb479-d243-4326-9923-70950157cbea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_5e07948e-f0f0-46ea-9830-ec6fb9d7d9c1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_ef4eb479-d243-4326-9923-70950157cbea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_299c8673-fe7b-41a6-8bc9-f5e3a7602132" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_ef4eb479-d243-4326-9923-70950157cbea" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_299c8673-fe7b-41a6-8bc9-f5e3a7602132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember_6a638e92-016f-46e8-beb6-3e0e530c8de7" xlink:href="ardx-20220331.xsd#ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_299c8673-fe7b-41a6-8bc9-f5e3a7602132" xlink:to="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember_6a638e92-016f-46e8-beb6-3e0e530c8de7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_e19d25f7-dd6b-4184-bc5d-614c075ca51d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_5e07948e-f0f0-46ea-9830-ec6fb9d7d9c1" xlink:to="loc_us-gaap_SubsequentEventLineItems_e19d25f7-dd6b-4184-bc5d-614c075ca51d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate_48bf4a6a-89a6-4e99-949a-180db598ddd3" xlink:href="ardx-20220331.xsd#ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_e19d25f7-dd6b-4184-bc5d-614c075ca51d" xlink:to="loc_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate_48bf4a6a-89a6-4e99-949a-180db598ddd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches_e06e0ca2-5f39-455f-86a0-04afd29db888" xlink:href="ardx-20220331.xsd#ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_e19d25f7-dd6b-4184-bc5d-614c075ca51d" xlink:to="loc_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches_e06e0ca2-5f39-455f-86a0-04afd29db888" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>ardx-20220331_g1.jpg
<TEXT>
begin 644 ardx-20220331_g1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 Z17AI9@  34T *@    @  U$0  $
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M3B1N/?\ 2L6\_P""N&DHY^S^"M0E7'!DU!(SG\$;\Z\JIXE\,T_BQ<?DI/\
M*+/5I^&G$U3X<)+YN*_.2/L"BOBNZ_X*[S/%^Y\ QQOGJ^M%QCZ" ?SJG<?\
M%<-6:%A#X)T^.3LSZB[*/PV#^=<<O%CA=;8AO_MRI^L4=D?"?BA[X=+_ +?I
M_I(^X**^%?\ A[7XB_Z%'1?_  )EH_X>U^(O^A1T7_P)EK'_ (BYPS_S^?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %(S!%+,0JJ,DGM7._%'XL^'_@UX5FUCQ%J,.GV<?";CF2=\9"
M1KU9CZ#ZG !-? '[4O[>OB'X[R7&DZ.9_#_A5LH;>-\7%\O3]\X_A/\ SS7Y
M>>2V :^+XNXZR[(*?[]\U5K2"W?F_P"5>;^29]IPCP+F6?U?W"Y:2>LWLO)?
MS/R7S:/H+]I[_@I!HWPY^T:-X*^SZ_K:YCDO2=UC9MTX(_UK#T!VCU/*U\+^
M//B#K7Q.\2SZQKVI76J:A<'YYIFS@=E4=%4=E4 #L*QZ*_E3BGC3,\^J\V+E
M:"V@M(KY=7YO7M9:']5\+<%Y9D-+EPD;S?Q3>LG\^B\E9=[O4****^2/K0HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MC6HU*4W2JIQDG9IJS371H****T,PHHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MI]Q;R6EQ)%+&\<L;%'1UVLC#@@CL1Z4ROYEVT9_35[ZH**** "BBB@ HHHH
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MX/\ >-?:DOL^D7OWEZ:E%%%?N1^&A1110 4444 %%%% !1110 4444 %%%%
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MDTULT]FC^/<1AZE"K*C6BXRBVFGNFMTPHHHK8Q"BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!7;?LZ_"F3XU_&CP_P"'%5VM[ZY#7;*<;+=/GE.>QV*P'N0.]<37VA_P2?\
MA3QXB\:7$7II5BQ'TDF(_P#(0R/]H5]5P3D?]KYU0P4E>+=Y?X8ZO[[6]6?*
M\;9Y_9&2U\;%VDE:/^*6B^Z]_1,^S;:WCL[>.&&-8XHE"(BC"HHX  ]!3Z**
M_N+;1'\.WOJPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "H[JUCOK:2&:-)89E*.CC<KJ1@@CN"*DHH
M>NC!-K5'Y/\ [4/P;D^!'QMUK0 K"Q27[1I[$YWVTGS1\]RO*D^J&O/Z^^?^
M"H_P8_X2KX9V'C"TAW7OAN3R+HJ.7M96 R?79)MQZ"1S7P-7\2\?<._V-G57
M"P5J<O>A_AET^3O'Y']M< \1?VSDM+%3=ZD?=G_BCU^:M+YA1117QI]D%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M;,YY;4?NUE=?XXZ_C&_JTCY.HHHK^6S^I HHHH **** "BBB@ HHHH ****
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MZLK ^%G@&W^%OPXT3P[:;6AT>SCMMX&/-91\SX]6;+'W-;]?W5PKDJRG*:&
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M_+T'Q,4LKO<?EAER1#+[88[2>RNQ[5^E=?V?X=\5+/,IC5J/][3]V?JMI?\
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M["BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MV@N;_MYZ1_5K_"?D_C%GGU+)/JD'[U=\O_;JUE^B?^(]"HHHK^M#^2PHHHH
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MO^V[>/;8>+(?M8P,*MPF$F'X_(Y]Y#7X7XW9#[;!4LUIK6F^67^&6S^4M/\
MMX_=/!'/O8XVKE51Z5%S1_Q1W2]8Z_\ ;I\ZT445_,Y_3 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MZ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** /3OV._BQ_P *<_:%\/ZI))Y5A<S?
M8+XDX7R)OD+-[(Q5_P#@%?JE7XOU^K7[)OQ3/QB_9^\-ZU+()+W[,+6\.<MY
M\1\MR?=MH?Z.*_HCP-SS2OE,W_T\C^$9?^VO[S^=_'+([.AFT%_T[E^,H_\
MMR^X]&HHHK^A#^>PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** /*_P!M/XFGX5?LW>)+Z*0QWEY!_9UJ0<,))ODR#ZJI=O\
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MBBB@ HHHH *^SO\ @DW\3\2^)O!LTGW@NKVBG\(IO_:/'L:^,:](_9'^)/\
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ML"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "OT-_X)A_"K_A#/@7-X@GBV
M7GBJY,JDC#?9XB4C'KRWF-[AA7P-X'\)77C[QEI6AV*[KO5KN*TBXR SL%!/
ML,Y/L*_7OPAX8M?!/A33='L4\NSTJUCM(%]$10H_' K]O\$<C]OF%7,YK2DN
M6/\ BE_E&Z?^)'XAXW9Y[#+Z660>M5\TO\,=OODTU_A9HT445_3I_,04444
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MUZ+XE_X#=^J1^E>%.??V=GU.G-VA6]Q^K^%_^!67HV?GG1117\>G]A!1110
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M9:4[S?\ VZM/_)G$^9:***_C<_L@**** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %=5\#OAM-\7_BWX?\-Q;L:I>)',R]4A'S2M^"!C^%<K7UY_P2
MB^%/]I>*M?\ &5Q'F+38AIMF3T,LF&D(]U0*/I*:^FX/R5YMG%# M>[*5Y?X
M5K+\$UZM'S7&&=+*<GKXY/WHQM'_ !/2/XM/T3/M^RLH=-LH;>WC6&"W18XT
M485% P /8 5+117]RI)*R/X9;;=V%%%%,04444 %%%% !1110 4444 %%%%
M!7Y4_M>?%,?&#]H7Q)JT4GF6,=Q]CLR#E?)A_=J1[,07_P"!U^B'[67Q3/P=
M_9^\2:U%)Y=[]F-K9G/S>?*?+0CW7<7^B&OREK^>O'+.M,/E,'_T\E^,8_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *_5+]CSX4_\ "G?V>?#NES1^7?7$'V^]!7#":;YRK>Z
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M/DFBBBOXG/[8"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M/H__ ()D?%?_ (0?X\R:%<2[+'Q7;&W +847$>7B)^H\Q1[N*_1&OQM\+^([
MKP?XET_5K&0Q7FF7,=U X_A=&#*?S%?KU\/O&=K\1? VD:]9'-KJ]I'=QC/W
M0Z@[3[C.#[BOZ<\$<\]M@*N5U'K2?-'_  RW^Z5W_P!O'\Q^-V1^QQ]+-*:T
MJKEE_BCM]\;+_MTV****_<#\/"BBB@ HHHH **** "BBB@ HHHH **** /SG
M_P""EOPD_P"%?_'TZU;Q[+#Q9#]K!'W1<)A)@/K\CGWDKYWK]*/^"BGPD_X6
M9^SK?7UO$9-0\+N-3BP.3$!B8?3RR7_[9BOS7K^.?%+(O[-SZHX*T*OOKY_$
MO_ KZ=$T?V-X6Y]_:60TU-WG2]Q_+X7_ . VUZM,****_.3]&"BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH ^W?^"1VK^=X=\<6'_/O<VEP/^!K*O_M.OL.OA;_@DIJ?
ME?$+Q=9\?Z1IT,V,?W)".O\ VTK[IK^Q_"FO[3AC#I_9YU_Y/+]&C^./%:A[
M/B?$/^;D?_DD?U3"BBBOT4_.@HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH *^=?\ @I_?_8_V8_+X_P!*U:VBZXZ"1_Q^[7T57R[_ ,%8+S9\"-!M]O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M])GDV6/BJ V+ GY1.OSPGZDAD'_72OT<K^R?"_//[2R"ESN\Z7[N7_;OP_\
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M?>^&,K<3X1^<O_2)'PO1117\8G]GA1110 4444 %%%% !1110 4444 %%%%
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M117 =X4J(TKJJJ69C@ #))I*]@_86^%7_"U_VD="AFC\RPT=SJMWE<KMA(*
M^S2&-3GL3UZ5Z&59?4Q^,I8*C\522BOF[7^6[//S7,*> P=7&UOAIQ<G\E>W
MJ]D?H1^S=\+E^#7P/\.>'BFRXL[17N^G-Q)^\EY[X=F ]@*[BBBO[SP>%IX7
M#PPU%6C!**]$K(_@S&8NIBL1/$UG>4VY/U;NPHHHKI.8**** "BBB@ HHHH
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M6O\ P&BH_P"'2GAW_H;M:_\  :*C_B$?$W_/E?\ @<?\P_XBYPS_ ,_G_P"
M2_R/A6BONR'_ ()+>&EE7S/%FN-'GD+!$I/X\_RJW_PZ;\&?]#)XG_.#_P"-
MU4?"'B5[THK_ +?C_F3+Q>X:6U63_P"W)?Y'P117WO\ \.F_!G_0R>)_S@_^
M-UY5^V'^PMX=_9S^$T?B#2]8UJ^N7OXK0QW1B\O:ZN2?E4'/RCO7'F7A?GV
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M_GZT7_P7K_C1_P /,_BE_P _6B_^"]?\:^?:*/\ 7CB#_H,J?^!,/]1^'_\
MH#I_^ H^@O\ AYG\4O\ GZT7_P %Z_XT?\/,_BE_S]:+_P""]?\ &OGVBC_7
MCB#_ *#*G_@3#_4?A_\ Z Z?_@*/H+_AYG\4O^?K1?\ P7K_ (UX%?7LVI7L
MUQ<2--/<.TDDC'+.Q.23[DFHJ*\O,\^S',5%8ZM*IRWMS-NU][7[V1ZF69#E
MV7.3P-&-/FM?E25[;7MVNPHHHKR3U@HHHH _1[_@GK^SQ9_"CX/6?B"ZMT;Q
M#XH@6ZEF9<M!;-\T42GL"NUV]6.#G:,?059_A&VCLO"FEPQ+MCAM(D1?0!
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MK_Z$:^@J^??^"F?_ ":W=?\ 81M?_0C7RO''_)/XS_KW+\CZK@?_ )*#!_\
M7R'YH_.&BBBOX=/[B"BBB@ HHHH **** "BBB@ HHHH ^R_^"3_Q7\J[\1>"
M[B3B4#5K)2>XVQS ?4>4<?[+'UK[5K\E/V=?BBWP9^-?AWQ%N9;>QNU%T!D[
MK=_DE&.YV,V/<"OUIAF6XB62-EDCD 964Y# ]"#7]7^#>>?7,F>"F_>H.W_;
MLM8_CS+T2/Y1\9<C^IYRL;!>[75_^WHV4OPY7ZMCJ***_73\A"BBB@ HHHH
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M .@M7M<-_P#(VPO_ %\A_P"E(\;B+_D4XK_KW/\ ])9^J5%%%?WD?P8%%%%
M!1110 4444 %%%% !1110 5\*_\ !6O_ )*)X1_[!TO_ *-K[JKX5_X*U_\
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M!@[?\_(_F?G+1117\.G]Q!1110 4444 %%%% !1110 4444 %?IU^P5\5?\
MA:G[-FBM-)YE]H0.D7.>N8@/+/J<Q&,D]SFOS%KZB_X)9_%;_A&/B]J/A>XD
MVVOB:U\R!3_S\0 L/IF,R9]=JU^F^$V>?V?GT*4W[E9<C]7K'_R96^;/S/Q9
MR/\ M#(9U8+WZ+YUZ+27_DK;^2/OZBBBOZ_/X_"BBB@ HHHH **** "BBB@
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M$N;]3^'N.L5[?B#&5/\ IY)?^ OE_0****^K/E HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** /RK_;*\/'PO^U%XVMBNWS-2>[Q_UW FS^/F9KS.
MOHS_ (*@>&?[$_:7%X%PNL:5;W)8#JREX3^.(U_ BOG.OX5XOP?U7.\70Z*I
M.WHVVOP:/[JX0QGUK),)7[TX7]4DG^*84445\Z?1!1110 4444 %%%% !111
M0 4444 %%%% !7HG[)-P]M^TSX&:-MK'6+=2?8L ?T)KSNNX_9DNFL_VC? ;
MIC<WB"Q3GT:=%/Z$UZF1RY<RP\NTX?\ I2/+SR/-EV(CWA/_ -)9^M%%%%?W
MP?P.%%%% !1110 4444 %%%% !1110 5\*_\%:_^2B>$?^P=+_Z-K[JKXA_X
M*Y#_ (J/P/\ ]>UW_P"A15^;>+4;\,5WV</_ $N)^E>$DK<3T%W4_P#TB1\>
MT445_'A_804444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% '['>"[0:?X.TFW5BRPV<,8)[X0"M*JNAP/:Z+9Q2+MDC@16'H0H!
MJU7^@]"/+3C'R1_GO6ES5)/S84445J9A1110 4444 %%%% !1110 5\X?\%2
M/^3:;?\ [#5O_P"BYJ^CZ^8_^"K<NW]GC1EW8+>(H>,]1]FN?_K5\?X@2Y>'
M,8_[C_'0^P\/X\W$6#7]]'Y]T445_$9_;@4444 %%%% !1110 4444 %%%%
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MGM4BF_)[-?)W7R"BBBO'/8"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBKWA?0Y/%'B;3M-BXDU&ZBM4^KN%'\ZJ
M$)3DH1W>A,YJ$7.6RU/U?_9T\._\(I\!/!NG[=KV^C6OF#_;,2L__CQ-=G3+
M:W2SMXX8U"1Q*$11_"!P!3Z_T!P>'6'P\*$=HQ2^Y6/\_<9B'B,1.O+>3;^]
MW"BBBNDYPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /B_\ X*W^
M%CM\%ZVB\?Z38S-_W[>,?^C*^+Z_1W_@IGX1/B3]F"YO%7<V@ZA;WN1U"DF
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MKQ.=82CWJ0OZ<R;_  N?/\68I8;)<77[4YV]>5I?C8_2&BBBO[L/X3"BBB@
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MX@<;UW/$Q]ROF#)[(HK[:K@?VG?A0OQJ^!GB'0%C$EY/;&:R]1<1_/'@]LL
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MYX^DM;?*5U\C^U/#G/?[5R&C6D[S@N27K'2_SC9_,****^&/N HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** -+P;X9G\:^+]
M*T>U_P"/C5KR*SBX_BD<(/U-?L-I6F0Z+I=M9VZ^7;VD2PQ+_=50 !^0K\V?
M^"=G@/\ X3?]J'1YGC\RWT&&74Y>. 579&?PD=#^%?I=7]->!N6>SR_$8^2U
MJ245Z05_SD_N/YE\<LS]IF&'P$7I3BY/UF[?E%/YA1117[D?AH4444 %%%%
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MD,WS-8?#2O2HW2:V<G\37=:)+TNM&%%%%?J1^6A1110 4444 %%%% !1110
M4444 !.!7X[_ !"\1?\ "7^/]<U;.[^U-0N+O///F2,_?GOWK]7?CKXJ_P"$
M'^"_BO5MRJ]AI-S+'DXS((VV#\6P/QK\BJ_G;QVQEYX3"+HIR?SY4OR9_17@
M3@[0Q>+?5PBOES-_F@HHHK^?#^@@HHHH **** "BBB@ HHHH **** "BBB@
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M>_\ A1\RT445_,)_3P4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M #/Z]\(\X^N\/PHR?O46X/TWC^#M\@HHHK\P/T\**** "BBB@ HHHH ****
M"BBB@ HHHH ]6_8C\;_\(%^U#X2NF?9#>7?]GRYZ$3J8AGZ,RG\*_4JOQET[
M4)M)U""ZMW:.XMI%EC<=493D'\"*_7[X8^.+?XE_#O1/$%MM\G6+**Z"J<^6
M64%E^JMD'W%?TAX%YHI8;$Y=)ZQDIKT:Y7]UE]Y_-_CIE;CB,-F,5I).#]4^
M9??=_<;E%%%?OA^!A1110 4444 %%%% !1110 4444 %<W\5OA/H?QI\%W.@
M^(+-;NQN/F!!VR0./NR1M_"PSU]"0<@D'I**QQ&'I5Z<J-:*E&2LTU=-/HT;
M8?$5:%6-:C)QE%W36C375,_,/]I[]B_Q+^SIJ$MWY<FL>&6?]SJ4,?\ J@3P
MLRC[C=L_=/8YX'C=?LY=VD5_:R03Q1S0S*4DCD4,KJ>""#P0?0U\O_M _P#!
M,C0/'4T^I>"[F/PUJ,F6-DZEK"5O]G'S19_V=R^BBOYTXP\&ZU.4L5D7O1W]
MFWJO\+>Z\GKYL_HO@_QDHU(QPN>^[+;VB6C_ ,26S\UIY(^ Z*[;XM?L[^,O
M@A>-'XCT.\LX-VU+M5\RUE]-LJY7GT)!YY KB:_#,5@Z^%JNCB8.$ENI)IKY
M,_<\+C*&*I*OAIJ<7LXM-/YH****YSH"BBB@ HHHH **** "BBB@ HHHH **
MGTW3+G6;^*UL[>>ZNIVV10PQF221O0*.2?85]$_ W_@FIXR^(KPWGB5AX2TI
ML-LF7S+V4=>(L_)Z?.01_=->QD_#^8YK5]CE])S?6RT7JWHOFSQ\XX@R[*J7
MMLPJJ"Z7>K]$M7\DSY_\+>$]3\<:];Z7H]C=:EJ%VVR*WMXR[N?H.PZDG@#D
M\5]Z?L=?L 6OPAEMO$GB];?4/$RXDMK4$26^EMU!ST>4?WONJ>F2 U>R?!3]
MG;PG^S_HQM?#>FI#-*H6XO9CYEU=8_OR8Z=]HPH/0"NXK^DN"/"?#97..-S-
MJI66J7V(OOK\37=V2Z*Z3/YMXW\6,3FD)8++$Z=%Z-_;DNVGPI]E=OJ[-H**
M**_8C\="BBB@ HHHH **** "BBB@ HHHH **** / ?\ @I5XU7PK^S!?68;;
M-X@O;>P3'WL!O.;\-L1!_P![WK\W:^MO^"K_ ,2%U7Q[X=\+0R;ETBU>]N0#
MQYDQ 4'W")GZ25\DU_'_ (M9HL9Q%4A%W5)1A]VK^Z4FOD?V!X2Y6\'P[3G)
M6=5RG]^B^^,4_F%%%%?F9^F!1110 4444 %%%% !1110 4444 %%%% !1110
M 5]+_P#!+_XK?\(=\;;KP[<2;;/Q5;%$!. +B++I^:&0>Y(KYHK2\&>*[OP)
MXNTS6K!MEYI-U'=PGMN1@P!]CC!'<&O<X;SB65YI0Q\?L23?G':2^<6T>'Q)
MD\<URNO@)?;BTO*6\7\I),_8ZBLOP5XMM/'G@_2];L6WV>K6L=W">^UU# 'W
M&<$=B*U*_NVG4C4@JD'=-73[I['\)5*<J<W3FK-.S79H****L@**** "BBB@
M HHHH **** "BBB@ KQ?]OGX2_\ "UOV<-7,,7F:AX?_ .)M:X'S?NP?,4=^
M8B_'<A?:O:*;-$MQ$T<BK)'("K*PR&!Z@BO.S?+:>88*K@:WPU(N/I=;^J>J
M\ST<HS*IE^-I8ZC\5.2EZV>WHUH_(_&&BNX_:0^%;_!?XV^(O#NUEM[.Z+VA
M/\5N_P \1SW^1@#CN#7#U_!N,PM3"XB>&K*TH-Q:\T[,_O+!XNGBL/#$T7>,
MTI)^35T%%%%<QTA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !7:?L[?#<_%SXW^&?#YC\R'4+Y/M*_],$_>2_^0U:N+KZX_P""47PP_M3Q
MKX@\73QYCTJW73[4D?\ +64[G(]U10/I+7TW!N3_ -J9UA\$U>,I)R_PQ]Z7
MX)KU/F>,LX_LO)<1C4[2C%J/^*7NQ_%I^A]T ;1@4445_<Q_#(4444 %%%%
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MW(6BBBOZ,/YS"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>]0E?_MV5D_QY7Z)GV%1117]6'\IA1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M!F98"K@<74P=;XJ<G%^J=O\ A@HHHKN.$**** "BBB@ HHHH **** "BBB@
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M445XY[ 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MI+[D[KS2/R/HJ2ZM9+&ZDAF1HYH6*.C#!5@<$'Z&HZ_AMW6C/[D3NKH****
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MPN)I8BC'$4'S0DDTUU3U3"BBBL#<**** "BBB@ HHHH **** "BBB@ HHHH
M**** "O0O@7^T_XP_9ZU'S- U$FQD??/IUR#):3GW7(*M_M(5;@<XXKSVBNK
M X[$8.LL1A9N$X[-.S_K\SEQV!P^,HO#XJ"G"6Z:NOZ_(_2+X"?\%#O!7Q>2
M&SU:9?"FN287R+V0?9IF_P"F<W"\^C[3DX&>M>^JP=0RD,K#(([U^,%>H_!3
M]L3QY\"?)M]*U9KS2HN!IM^#/; >BC(9/^ ,M?NG#/C94@E1SNGS+^>"2?\
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M@?C5I^FS1L=%T\B]U1\<>2I'[OZNV%]0"3VK]2H($M8$CC18XXU"HBC"J!P
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M_A?G;JS^CO!GB[GIO(L3+6-Y4[]5O*/R^)>5^B1XO1117X"?OP4444 %%%%
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MU+"8>/,OM/WI?)RNU\K!1117R9]8%%%% !1110 4444 %%%% !1110 4444
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M ?CFJO\ PLCP[_T'M%_\#HO_ (JOQYHJ9>/%;I@U_P"!O_Y J/@/1^UC'_X
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M/!G_ $-WAC_P:0?_ !5?D-12_P"([8O_ *!(_P#@3_R'_P 0)PG_ $%R_P#
M5_F?K1XP^(G@+QOX3U/1K[Q9X9>SU:UDM)P-4@SL=2IQ\W7!K\I/$FBMX;\1
M:AIS36]RVGW,EL9H'#Q2E&*[E8<%3C((Z@U2HKX'C;CB7$;I2JT%3E3OJFW=
M.VCNELUIZL^]X)X'CPXJL:5=U(U+.S25FKZJS>]]?1!1117P9]X%%%% !111
M0 4444 %%%% !7T7_P $Z?V<O^%M_%'_ (2/4H-V@^%I%EPP^6ZN^L<?N%^^
MWT4'AJ\(\$>#-0^(GB[3]#TF!KG4=4G6"",=V/<GLH&23V )K]7O@7\(-/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ KZ2_X)]?LF_\ "XO%@\4Z]:[O#&BRCRHI%^74
M;D8(3'>-."W8G"\@MCS']F3]GC4OVC_B3!H]KYEOI\&)M2O ORVL.><=M[<A
M1W//0$C]2/!7@S3?AYX4L-$T>UCL]-TV$0P1)_"H[D]V)R23R223R:_8O"K@
M7^T\0LTQL?W%-Z)_;DOSC'KT;TUU/QWQ5XZ_LS#O*\%+]_46K7V(O\I2Z=4M
M=-#4HHHK^JC^50HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>NWEJ_GGCOPC=Y8_(8^<J7ZP_P#D?_ >D3^AN!/%Q/EP&?2\HU?TG_\ )?\
M@75GP+15[Q+X9U#P;KMSIFJV=QI^H6;^7-;SH4DC/N#^>>A'-4:_GV<)0DX3
M5FM&GNF?T%"I&<5.#NGJFMF@HHHJ2@HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *]*_9R_9;\2_M
M)>(OL^EP_9-*MW O-4F0^1;#T']]\=$!SR,D#FO3_P!DS_@GKJGQ8-KKWB];
MC1O#;8DAMON7>HKU&!UCC/\ >/S$?=&"&'WKX2\(:7X$\/6VDZ/8V^FZ=9KL
MA@@3:J#^I/4D\D\FOV3@7PIQ&9<N-S5.G1W4=I3_ /D8OONUMW/QOCKQ6P^6
M\V"RIJI7V<MXP_\ DI+MLGOLT<O\!?V>/#?[.WA,:;H-K^^FPUW?38:XO''=
MF[ =E& /3))/=445_3V#P=#"48X;#04815DDK)?U^)_,.,QE?%UI8C$S<IR=
MVV[MA11174<H4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@"KK.B6?B+39+/4+.UOK.8;9(+B)98Y!Z%6!!_&OG_XM_\
M!-#P%X^\VXT3[5X3OWR1]E/FVI/O$QX^B,H]J^BJ*\?-^'\NS2G[/,*,:B\U
MJO1K5?)H]C*>(,QRNI[3 5I4WY/1^J>C^:9^;'Q7_P""='Q&^&_F36-C#XHL
M(^1+IC%I@/>%L/GV0-]:\-U+3+G1KZ2UO+>>UNH3MDAFC,<D9]"IY'XU^S-<
M[\0/A%X7^*ME]G\1:#IFKIC:K7$ :2/_ '7^\OU4BOR#._ _"5+U,JK.F_Y9
M^]'Y-6:^?,?K^2>.&+IVAFM%5%_-#W9?-.Z;].4_(&BOO;XF_P#!*GPMKS23
M>%]:U#P_,W(M[A?MEN/89*NOU+-]*^>?B7_P3S^)OP[,DD.D1^(K./)\[2I?
M.8CM^Z.),_12/?I7Y)G'AOQ!EUY5,.YQ7VH>\ON7O)>J1^MY/XD</YC:-.NH
M2?V9^Z_2[]UOT;/#Z*M:OHMYX?U"2TO[2ZL;J$X>&XB:.1#[JP!%5:^'E%Q?
M+)69]Q&2DN:.J"BBBI*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH R: "BO2/AM^
MR+\1?BL(Y-)\+Z@MK)R+J\46L!'J&DQN'^[FOH7X9?\ !)IW$<WC#Q.$_O6F
MD1Y./^NT@_\ :9^M?69/P+GN9V>%P\N5_:E[L?OE:_RN?)YQQUD6676*Q$>9
M?9C[TONC>WSL?&5>E?"K]D/XA?&(QR:3X=O(;&3D7MZ/LMOCU#/@N/\ <#5^
MAWPO_9(^'OPA$4FD>&K%KR+!%Y>+]JN-P_B#/G:?]P*/:O2*_6LD\#=IYMB/
M^W:?_P E)?\ MOS/R7._'+>&4X?_ +>J?_(Q?_MWR/D/X2?\$I=*TLQ7/C37
M)M4F7!:RTT&&WSZ-(PWL/H$-?3'PZ^$/ACX2Z=]E\-Z'I^D1L KM!$/,EQ_?
M<Y9_JQ-=)17[%D?".490O]@H1C+^9ZR_\"=W\D[>1^.YYQ=F^;O_ &^O*4?Y
M5I'_ ,!5E\VK^84445](?-A1110 4444 %%%% !1110 4444 %%%% !1110
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MKK:\O_ I7E^)^<YMQ?G.976-Q,I)]+VC_P" QM'\ HHHKZ0^;"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?]\J/0?E6S117O4J-.G'EIQ279*QX-2M4J2YJC;?=NX4445H9A1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
..444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140314480776040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>May 02, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ARDELYX,&#160;INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-1303944<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">400 Fifth Avenue<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Waltham<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02451<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">745-1700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ARDX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144,598,863<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001437402<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140314480365512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 47,077<span></span>
</td>
<td class="nump">$ 72,428<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">42,627<span></span>
</td>
<td class="nump">44,261<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">4,394<span></span>
</td>
<td class="nump">502<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">3,487<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">16,640<span></span>
</td>
<td class="nump">16,458<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">114,225<span></span>
</td>
<td class="nump">133,649<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">11,910<span></span>
</td>
<td class="nump">12,752<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">2,045<span></span>
</td>
<td class="nump">2,362<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">1,228<span></span>
</td>
<td class="nump">1,150<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">129,408<span></span>
</td>
<td class="nump">149,913<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">5,030<span></span>
</td>
<td class="nump">4,277<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and benefits</a></td>
<td class="nump">6,304<span></span>
</td>
<td class="nump">5,422<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="nump">26,139<span></span>
</td>
<td class="nump">32,264<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liability</a></td>
<td class="nump">3,592<span></span>
</td>
<td class="nump">3,492<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">6,778<span></span>
</td>
<td class="nump">7,366<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">47,843<span></span>
</td>
<td class="nump">52,821<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net of current portion</a></td>
<td class="nump">8,812<span></span>
</td>
<td class="nump">9,748<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, non-current</a></td>
<td class="nump">8,563<span></span>
</td>
<td class="nump">4,727<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">65,218<span></span>
</td>
<td class="nump">67,296<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value; 5,000,000 shares authorized; no shares issued and outstanding as of March&#160;31, 2022 and December&#160;31, 2021, respectively.</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 300,000,000 shares authorized; 136,330,360 and 130,182,535 shares issued and outstanding as of March&#160;31, 2022 and December&#160;31, 2021, respectively.</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">805,265<span></span>
</td>
<td class="nump">795,540<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(741,001)<span></span>
</td>
<td class="num">(712,930)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(88)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">64,190<span></span>
</td>
<td class="nump">82,617<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 129,408<span></span>
</td>
<td class="nump">$ 149,913<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140314480282024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">136,330,360<span></span>
</td>
<td class="nump">130,182,535<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">136,330,360<span></span>
</td>
<td class="nump">130,182,535<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140314485358840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 468<span></span>
</td>
<td class="nump">$ 6,582<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenue</a></td>
<td class="nump">85<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">8,851<span></span>
</td>
<td class="nump">20,456<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">19,339<span></span>
</td>
<td class="nump">17,131<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">28,275<span></span>
</td>
<td class="nump">38,587<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(27,807)<span></span>
</td>
<td class="num">(32,005)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(746)<span></span>
</td>
<td class="num">(1,100)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">484<span></span>
</td>
<td class="num">(49)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before provision for income taxes</a></td>
<td class="num">(28,069)<span></span>
</td>
<td class="num">(33,154)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (28,071)<span></span>
</td>
<td class="num">$ (33,155)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share - basic (in dollars per share)</a></td>
<td class="num">$ (0.21)<span></span>
</td>
<td class="num">$ (0.34)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share - diluted (in dollars per share)</a></td>
<td class="num">$ (0.21)<span></span>
</td>
<td class="num">$ (0.34)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Shares used in computing net loss per share - basic</a></td>
<td class="nump">130,934,795<span></span>
</td>
<td class="nump">97,179,241<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares used in computing net loss per share - diluted</a></td>
<td class="nump">130,934,795<span></span>
</td>
<td class="nump">97,179,241<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (28,071)<span></span>
</td>
<td class="num">$ (33,155)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized losses on available-for-sale securities</a></td>
<td class="num">(82)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">(28,153)<span></span>
</td>
<td class="num">(33,158)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">450<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ardx_ProductSupplyRevenueMember', window );">Product supply revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">126<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">Licensing revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">5,002<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ardx_CollaborativeDevelopmentMember', window );">Collaborative development revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,454<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ardx_ProductSupplyRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ardx_ProductSupplyRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ardx_CollaborativeDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ardx_CollaborativeDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140314481654504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income</div></th>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 126,112<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">$ 680,872<span></span>
</td>
<td class="num">$ (554,765)<span></span>
</td>
<td class="num">$ (4)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,599,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under employee stock purchase plan</a></td>
<td class="nump">478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of options</a></td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of options (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,507<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock upon vesting of restricted stock units (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock in at the market offering</a></td>
<td class="nump">34,272<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">34,271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in at the market offering (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,940,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">3,087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized losses on available-for-sale securities</a></td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(33,155)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(33,155)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2021</a></td>
<td class="nump">130,811<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">718,728<span></span>
</td>
<td class="num">(587,920)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,688,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">82,617<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">795,540<span></span>
</td>
<td class="num">(712,930)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,182,535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under employee stock purchase plan</a></td>
<td class="nump">$ 83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">127,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of options (shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock upon vesting of restricted stock units (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">113,469<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock in at the market offering</a></td>
<td class="nump">$ 5,921<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">5,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in at the market offering (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,907,256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">3,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized losses on available-for-sale securities</a></td>
<td class="num">(82)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(82)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(28,071)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28,071)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="nump">$ 64,190<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">$ 805,265<span></span>
</td>
<td class="num">$ (741,001)<span></span>
</td>
<td class="num">$ (88)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">136,330,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140314480401320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Net Cash Provided by (Used in) Operating Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (28,071)<span></span>
</td>
<td class="num">$ (33,155)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">232<span></span>
</td>
<td class="nump">422<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of deferred financing costs</a></td>
<td class="nump">169<span></span>
</td>
<td class="nump">157<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDeferredCharges', window );">Amortization of deferred compensation for services</a></td>
<td class="nump">47<span></span>
</td>
<td class="nump">77<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of (discount) premium on investment securities</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">157<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Non-cash lease expense</a></td>
<td class="nump">842<span></span>
</td>
<td class="nump">607<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">3,722<span></span>
</td>
<td class="nump">3,087<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities', window );">Change in derivative liabilities</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnRestructuringOfDebt', window );">Debt refinancing costs</a></td>
<td class="nump">102<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets', window );">Gain on sale of equipment</a></td>
<td class="num">(710)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Non-cash interest associated with debt discount accretion</a></td>
<td class="nump">109<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(3,892)<span></span>
</td>
<td class="num">(5,783)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(3,487)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(307)<span></span>
</td>
<td class="num">(13,662)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">753<span></span>
</td>
<td class="num">(248)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation and benefits</a></td>
<td class="nump">882<span></span>
</td>
<td class="num">(1,324)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(836)<span></span>
</td>
<td class="num">(721)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued and other liabilities</a></td>
<td class="num">(1,041)<span></span>
</td>
<td class="nump">7,517<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="nump">3,836<span></span>
</td>
<td class="num">(1,454)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(27,620)<span></span>
</td>
<td class="num">(44,217)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from maturities and redemptions of investments</a></td>
<td class="nump">27,300<span></span>
</td>
<td class="nump">35,370<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireShortTermInvestments', window );">Purchases of investments</a></td>
<td class="num">(25,763)<span></span>
</td>
<td class="num">(32,107)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfMachineryAndEquipment', window );">Proceeds from sale of equipment</a></td>
<td class="nump">795<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(778)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">2,332<span></span>
</td>
<td class="nump">2,485<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt', window );">Proceeds from 2022 Loan, net of issuance costs</a></td>
<td class="nump">26,971<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfSecuredDebt', window );">Repayment of 2018 Loan, net of settlement costs</a></td>
<td class="num">(33,038)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock in at the market offering, net of issuance costs</a></td>
<td class="nump">5,921<span></span>
</td>
<td class="nump">34,272<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from issuance of common stock under equity incentive and stock purchase plans</a></td>
<td class="nump">83<span></span>
</td>
<td class="nump">498<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="num">(63)<span></span>
</td>
<td class="nump">34,770<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash and cash equivalents</a></td>
<td class="num">(25,351)<span></span>
</td>
<td class="num">(6,962)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">72,428<span></span>
</td>
<td class="nump">91,032<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">47,077<span></span>
</td>
<td class="nump">84,070<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplementary disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">741<span></span>
</td>
<td class="nump">963<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for income taxes</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplementary disclosure of non-cash activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for lease obligations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">450<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_DerivativeIssued', window );">Issuance of derivative in connection with issuance of loan payable</a></td>
<td class="nump">$ 375<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_DerivativeIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Derivative Issued</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_DerivativeIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDeferredCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of amortization of deferred charges applied against earnings during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDeferredCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2443-110228<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnRestructuringOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a debtor, the aggregate gain (loss) recognized on the restructuring of payables arises from the difference between the book value of the debt before the restructuring and the fair value of the payments on the debt after restructuring is complete.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 60<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6402221&amp;loc=d3e15743-112638<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnRestructuringOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfMachineryAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sale of machinery and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfMachineryAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfSecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to repay long-term debt that is wholly or partially secured by collateral. Excludes repayments of tax exempt secured debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfSecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140314483241000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock', window );">Organization and Basis of Presentation</a></td>
<td class="text">ORGANIZATION AND BASIS OF PRESENTATION<div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ardelyx, Inc. (the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221;) is a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in one business segment, which is the development and commercialization of biopharmaceutical products.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and pursuant to the requirements of the Securities and Exchange Commission (&#8220;SEC&#8221;) for interim reporting. As permitted under those rules&#160;and regulations, certain footnotes or other financial information that are normally required by U.S. GAAP have been condensed or omitted. These condensed financial statements have been prepared on the same basis as our most recent annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments necessary to present fairly our financial position, results of operations, changes in stockholders&#8217; equity, and cash flows for the interim periods presented.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed financial statements and related financial information should be read in conjunction with the audited financial statements and the related notes thereto included in our Annual Report on Form 10-K for the&#160;year ended December&#160;31, 2021. The results for the three months ended March&#160;31, 2022 are not necessarily indicative of results to be expected for the entire&#160;year ending December&#160;31, 2022, or for any other interim period or future year.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that affect the amounts reported in the financial statements and accompanying notes thereto. On an ongoing basis, management evaluates its estimates, including those related to recognition of revenue, clinical trial accruals, contract manufacturing accruals, the fair value of assets and liabilities, income taxes and stock-based compensation. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could materially differ from those estimates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, we had cash and investments of approximately $89.7&#160;million. We have incurred operating losses since inception and our accumulated deficit as of March&#160;31, 2022 is $741.0&#160;million. Our current level of cash and investments alone is not sufficient to meet our plans for the next twelve months following the issuance of these financial statements. These factors raise substantial doubt regarding our ability to continue as a going concern for a period of one year from the issuance of these financial statements. We plan to address our operating cash flow requirements with our current cash and investments, cash generated from sales of IBSRELA, our potential receipt of anticipated milestones from our collaboration partners, our ability to access the capital markets, as well as through the implementation of cash preservation activities to reduce or defer discretionary spending.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no assurances that our efforts to meet our operating cash flow requirements will be successful. If our current cash and investments as well as our plans to meet our operating cash flow requirements are not sufficient to fund necessary expenditures and meet our obligations for at least the next twelve months following the issuance of these financial statements, our liquidity, financial condition and business prospects will be materially affected. These financial statements have been prepared on a going concern basis and do not include any adjustments to the amounts and classification of assets and liabilities that may be necessary in the event that we can no longer continue as a going concern. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Significant Accounting Policies</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our significant accounting policies are described in Note 1 to our audited financial statements for the fiscal year ended December&#160;31, 2021, included in our Annual Report on Form 10-K. Our significant accounting policies for the three months ended March&#160;31, 2022 also included the policies discussed below related to accounts receivable, inventory, revenue and cost of </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">revenue for commercial product sales. With the exception of those noted below, there have been no material changes in our significant accounting policies as previously disclosed in our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts Receivable</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable is reported net of allowances for returns, chargebacks and contractual discounts offered to our customers. Our estimate of the allowance for doubtful accounts is based on an evaluation of the aging of our receivables. Trade receivable balances are written off against the allowance when it is probable that the receivable will not be collected. To date, we have determined that an allowance for doubtful accounts is not required. As of March&#160;31, 2022 our accounts receivable balance is comprised of $3.8&#160;million from our collaborators and $0.6&#160;million from commercial customers. As of December&#160;31, 2021 our accounts receivable balance was comprised of $0.5&#160;million from our collaborators.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the regulatory approval of drug product candidates, we incurred expenses for the manufacture of drug product that could potentially be available to support the commercial launch of our products. We began to capitalize inventory costs associated with IBSRELA during the fourth quarter of 2021, when our intent to commercialize IBSRELA was established and we commenced preparation for the commercial launch of IBSRELA, which was when it was determined that the inventory had a probable future economic benefit.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory is stated at the lower of cost or estimated net realizable value with cost determined under the first-in first-out method. Inventory costs include third-party contract manufacturing, third-party packaging services, freight, labor costs for personnel involved in the manufacturing process, and indirect overhead costs. We primarily use actual costs to determine the cost basis for inventory. The determination of whether inventory costs will be realizable requires management review of the expiration dates of IBSRELA compared to our forecasted sales. If actual market conditions are less favorable than projected by management, write-downs of inventory may be required, which would be recorded as cost of goods sold in the condensed statement of operations and comprehensive loss.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Sales, Net</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for our commercial product sales, net in accordance with Topic 606 - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We received approval from the U.S. Food and Drug Administration (&#8220;FDA&#8221;) in September 2019 to market IBSRELA, the first and only sodium hydrogen exchanger 3 (&#8220;NHE3&#8221;) inhibitor for the treatment of irritable bowel syndrome with constipation ("IBS-C") in adults, in the United States ("U.S."). We began selling IBSRELA in the U.S. in March 2022. We distribute our products principally through a limited number of distributors and specialty pharmacy providers (collectively, our "Customers"). Our Customers subsequently sell our products to pharmacies and patients. Separately, we enter into arrangements with third parties that provide for government-mandated and privately-negotiated rebates, chargebacks and discounts. Revenue from product sales is recognized when our performance obligations are satisfied, which is when Customers obtain control of our product and occurs upon delivery.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reserves for Variable Consideration</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration, including rebates, discounts, patient copay assistance programs, and estimated product returns. These estimates are based on the amounts earned or to be claimed for related sales and are classified as reductions of accounts receivable if the amount is payable to our Customers or a current liability if the amount is payable to a party other than a Customer. Where appropriate, these estimates are based on factors such as industry data and forecasted customer buying and payment patterns, our historical experience, current contractual and statutory requirements, specific known market events and trends. Overall, these reductions to gross sales reflect our best estimates of the amount of consideration to which we are entitled based on the terms of the contract. Variable consideration is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from our estimates, we adjust these estimates, which would affect product revenue and earnings in the period such variances become known. As we gain more historical experience, estimates will be more heavily based on the expected utilization from historical data we have accumulated since the IBSRELA product launch.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Rebates: Rebates include mandated discounts under the Medicaid Drug Rebate Program ("Medicaid") and the Medicare Coverage Gap Program ("Medicare"). Rebates are amounts owed after the final dispensing of products to a benefit plan </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">participant and are based upon contractual agreements or legal requirements with the public-sector benefit providers. These estimates for rebates are recorded in the same period the related gross revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included in accrued expenses on the condensed balance sheets. We estimate our Medicaid and Medicare rebates based upon the estimated payor mix, and statutory discount rates. Our estimates for payor mix are guided by payor information received from specialty pharmacies, expected utilization for specialty distributor sales to pharmacies, and available industry payor information. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Chargebacks: Chargebacks are discounts that occur when contracted purchasers purchase directly from our specialty distributors at a discounted price. The specialty distributor, in turn, charges back the difference between the price initially paid to us by the specialty distributor and the discounted price paid to the specialty distributor by the contracted purchaser. Amounts for estimated chargebacks are established in the same period that the related gross revenue is recognized, resulting in a reduction of product revenue and accounts receivable. The accrual for specialty distributor chargebacks is estimated based on known chargeback rates, known sales to specialty distributors, and estimated utilization by types of contracted purchasers.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discounts and Fees: Our payment terms are generally 30 to 60 days. Specialty distributors and specialty pharmacies are offered various forms of consideration, including service fees and prompt pay discounts for payment within a specified period. We expect these Customers will earn prompt pay discounts and therefore, we deduct the full amount of these discounts and service fees from product sales when revenue is recognized, resulting in a reduction of product revenue and accounts receivable.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other Reserves: Patients who have commercial insurance may receive co-pay assistance when product is dispensed by pharmacies to patients. We estimate the amount of co-pay assistance provided to eligible patients based on the terms of the program and redemption information provided by third-party claims processing organizations and are recorded in accounts payable, accrued expenses and other current liabilities on the condensed balance sheets.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost of Revenue</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of revenue consists of the cost of commercial goods sold to our Customers, international partners under product supply agreements, and royalty expense based on sales of tenapanor. We capitalize inventory costs associated with the production of our products after regulatory approval or when, based on management&#8217;s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized. Otherwise, such costs are expensed as research and development. A portion of the costs of IBSRELA units recognized as revenue during the three months ended March&#160;31, 2022 were expensed prior to the fourth quarter of 2021, at which time our intent to commercialize IBSRELA was established and we commenced  preparation for the commercial launch of IBSRELA.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of revenue includes payments due to AstraZeneca, which under the terms of a termination agreement entered into in 2015 (the "AZ Termination Agreement") is entitled to (i) future royalties at a rate of 10% of net sales of tenapanor or other NHE3 products by us or our licensees, and (ii) 20% of non-royalty revenue received from our collaboration partners as a result of the development and commercialization of tenapanor or certain other NHE3 inhibitors.&#160;We have agreed to pay&#160;AstraZeneca up to a maximum of $75.0 million in the aggregate for (i) and (ii). We recognize these expenses as cost of revenue when we recognize the corresponding revenue that gives rise to payments due to AstraZeneca. To date, we have recognized an aggregate of $11.7 million as cost of revenue under the AZ Termination Agreement.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New Accounting Pronouncements - Recently Adopted</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted no new accounting pronouncements other than those disclosed in our most recent Annual Report on Form 10-K.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were various accounting standards and interpretations issued recently, none of which are expected to a have a material impact on our financial position, operations or cash flows.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI http://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140314483296504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, Cash Equivalents and Investments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock', window );">Cash, Cash Equivalents and Investments</a></td>
<td class="text">CASH, CASH EQUIVALENTS AND INVESTMENTS<div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities classified as cash, cash equivalents and investments as of March&#160;31, 2022 and December&#160;31, 2021 are summarized below (in thousands):</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:43.914%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.416%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.659%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,555&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,555&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,524&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,524&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,999&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,998&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,078&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,077&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,409&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,357&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored agency bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,777&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,755&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,521&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,511&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,007&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,004&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,714&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,627&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,792&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,704&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.075%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,253&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,253&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,428&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,428&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,936&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,935&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,025&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,022&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,304&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,267&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,261&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,695&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,689&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents consist of money market funds and other debt securities with original maturities of three months or less at the time of purchase, and the carrying amount is a reasonable approximation of fair value. We invest our cash in high quality securities of financial and commercial institutions. These securities are carried at fair value, which is based on readily available market information, with unrealized gains and losses included in accumulated other comprehensive income (loss) within stockholders&#8217; equity on our balance sheets. We use the specific identification method to determine the amount of realized gains or losses on sales of marketable securities. Realized gains or losses have been insignificant and are included in other income (expense), net, in the statement of operations and comprehensive loss.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All short-term available-for-sale securities held as of March&#160;31, 2022 had contractual maturities of less than one year. Our available-for-sale securities are subject to a periodic impairment review. We consider a debt security to be impaired when its fair value is less than its carrying cost, in which case we would further review the investment to determine whether it is other-than-temporarily impaired. When we evaluate an investment for other-than-temporary impairment, we review factors such as the length of time and extent to which fair value has been below cost basis, the financial condition of the issuer and any changes thereto, intent to sell, and whether it is more likely than not we will be required to sell the investment before the recovery of its cost basis. If an investment is other-than-temporarily impaired, we write it down through the statement of operations and comprehensive loss to its fair value and establishes that value as a new cost basis for the investment. We did not identify any of our available-for-sale securities as other-than-temporarily impaired in any of the periods presented. As of March&#160;31, 2022 no </span></div>investment was in a continuous unrealized loss position for more than one year and we believe that it is more likely than not that the investments will be held until maturity or a forecasted recovery of fair value.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of the components of cash, cash equivalents, and short-term investments. Short-term investments may include current marketable securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140314483259064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">FAIR VALUE MEASUREMENTS<div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The three-level hierarchy for the inputs to valuation techniques is briefly summarized as follows:</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:86.163%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 1 &#8211;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuations are based on quoted prices in active markets for identical assets or liabilities and readily accessible by us at the reporting date.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2 &#8211;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuations based on inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 3 &#8211;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuations based on unobservable inputs for which there is little or no market data, which require us to develop our own assumptions.</span></td></tr></table></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the fair value of our financial assets and liabilities that are measured or disclosed on a recurring basis by level within the fair value hierarchy (in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total<br/>Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,524&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,524&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,355&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,355&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored agency bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,755&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,755&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,511&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,511&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,004&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,004&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,149&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,524&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,625&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 12.25pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liability for exit fees</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,088&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,088&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,088&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,088&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total<br/>Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,935&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,935&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,022&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,022&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,304&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,304&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,436&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,175&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,261&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 12.25pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liability for exit fee</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">698&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">698&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Where quoted prices are available in an active market, securities are classified as Level 1. We classify money market funds as Level 1. When quoted market prices are not available for the specific security, we estimate fair value by using benchmark yields, reported trades, broker/dealer quotes and issuer spreads. We classify U.S. government-sponsored agency bonds, U.S. treasury notes, corporate bonds, commercial paper, and asset-backed securities as Level 2. In certain cases, where there is limited activity or less transparency around inputs to valuation, securities or derivative liabilities, such as the Exit Fee, as defined and discussed in Note 8, are classified as Level 3.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts reflected in the balance sheets for cash equivalents, short-term investments, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair values at both March&#160;31, 2022 and December&#160;31, 2021, due to their short-term nature. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Debt</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest rate of our term loan facility approximates the rate at which we could obtain alternative financing. Therefore, the carrying amount of the term loan facility approximated its fair value at March&#160;31, 2022 and December&#160;31, 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140314483304248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
<td class="text">INVENTORY<div style="margin-bottom:3pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We began capitalizing inventory during the fourth quarter of 2021, at which time our intent to commercialize IBSRELA was established and we commenced  preparation for the commercial launch of IBSRELA. Inventory consisted of the following (in thousands):</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">460&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,507&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">520&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,487&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140314485494152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Product Revenue, Net<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Product Revenue, Net</a></td>
<td class="text">PRODUCT REVENUE, NET<div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received approval from the FDA in September 2019 to market IBSRELA, the first and only sodium hydrogen exchanger 3 (&#8220;NHE3&#8221;) inhibitor for the treatment of irritable bowel syndrome with constipation ("IBS-C") in adults, in the U.S. We began selling IBSRELA in the U.S. in March 2022. We recorded net revenue for IBSRELA of $0.5&#160;million during the three months ended March&#160;31, 2022.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales to Cardinal Health, AmerisourceBergen Drug Corporation, and McKesson Corporation made up 17.9%, 17.1%, and 15.4% of our gross product revenue during the three months ended March&#160;31, 2022.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The activities and ending reserve balances for each significant category of discounts and allowances, which constitute variable consideration, were as follows (in thousands):</span></div><div style="margin-top:12pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Discounts and Chargebacks</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Rebates</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Fees, Copay and Returns</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Activity related to 2022 sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no product sales or gross-to-net accruals during the three months ended March&#160;31, 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140314483262088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Licensing Agreements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_CollaborationAndLicensingAgreementsAbstract', window );"><strong>Collaboration and Licensing Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaboration and Licensing Agreements</a></td>
<td class="text">COLLABORATION AND LICENSING AGREEMENTS<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Kyowa Kirin Co., Ltd. (&#8220;KKC&#8221;)</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2019 KKC Agreement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, we entered into a research collaboration and option agreement with KKC (the &#8220;2019 KKC Agreement&#8221;) for research associated with identifying two preclinical compounds that are ready for designation as development compounds (&#8220;DCs&#8221;), with one compound inhibiting the first undisclosed target (&#8220;Program 1&#8221;), and a second inhibiting the second undisclosed target (&#8220;Program 2&#8221;). Pursuant to the 2019 KKC Agreement, upon completion of the research and designation by the research steering committee of one or more DCs, KKC has the right to execute one or more separate collaborative agreements relating to the development and commercialization of one or both DCs in certain specified territories.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the 2019 KKC Agreement, KKC paid us a non-refundable, non-creditable upfront fee of $10.0&#160;million in two installments as follows: the first installment of $5.0&#160;million within 30 days of November 11, 2019 (the &#8220;Effective Date&#8221;), and the second installment of $5.0&#160;million on the first anniversary of the Effective Date. The term of the 2019 KKC Agreement commenced on the Effective Date and ends on the earliest of: (i) 2 years following the Effective Date, (ii) the nomination of a program DC for both programs, (iii) the nomination of one program DC and the decision by the parties to cease research for the other program, or (iv) the decision by the parties to cease research for both programs. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no material future obligations under the 2019 KKC Agreement and recorded no revenue under the 2019 KKC Agreement during the three months ended March&#160;31, 2022. During the three months ended March&#160;31, 2021, we recognized $1.5&#160;million as collaborative development revenue under the 2019 KKC Agreement in the accompanying condensed statement of operations and comprehensive loss. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2017 KKC Agreement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2017, we entered into an exclusive license agreement with KKC (the &#8220;2017 KKC Agreement&#8221;), for the development, commercialization, and distribution of tenapanor in Japan for cardiorenal indications. We granted KKC an exclusive license to develop and commercialize certain NHE3 inhibitors including tenapanor in Japan for the treatment of cardiorenal diseases and conditions, excluding cancer. We retained the rights to tenapanor outside of Japan, and also retained the rights to tenapanor in Japan for indications other than those stated above. Pursuant to the 2017 KKC Agreement, KKC is responsible for all costs and expenses incurred in the development and commercialization of tenapanor for all licensed indications in Japan. We are responsible for supplying the tenapanor drug substance for KKC&#8217;s use in development and commercialization throughout the term of the 2017 KKC Agreement, provided that KKC may exercise an option to manufacture the tenapanor drug substance under certain conditions.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assessed these arrangements in accordance with Accounting Standards Update (&#8220;ASU&#8221;) No. 2014-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers (Topic 606) and related amendments (&#8220;ASC 606&#8221;) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and concluded that the contract counterparty, KKC, is a customer. Under the terms of the 2017 KKC Agreement, we received</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$30.0&#160;million in upfront license fees, which was recognized as revenue when the agreement was executed. Based on our assessment, management determined that the license and the manufacturing supply services were its material performance obligations at the inception of the 2017 KKC Agreement, and as such, each of the performance obligations is distinct. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the up-front license fee received of $30.0&#160;million, we may be entitled to receive up to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$55.0&#160;million in total development milestones, of which $10.0&#160;million has been received and recognized as revenue as of March&#160;31, 2022, and approximately &#165;8.5 billion for commercialization milestones, or approximately $69.7&#160;million at the currency exchange rate on March&#160;31, 2022, as well as reimbursement of costs plus a reasonable overhead for the supply of product and royalties on net sales throughout the term of the agreement. The variable consideration related to the remaining development milestone payments has not been included in the transaction price as these were fully constrained at March&#160;31, 2022.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 14 - Subsequent events</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on April 11, 2022, we entered into a second amendment (the "Amendment") to the 2017 KKC Agreement. Under the terms of the Amendment, the parties have agreed to a reduction in the royalty rate payable to us by KKC upon net sales of tenapanor in Japan. The royalty rate will be reduced from the high teens to low double digits for a two-year period of time following the first commercial sale in Japan, and then to mid-single digits for the remainder of the royalty term. As consideration for the reduction in the royalty rate, KKC has agreed to pay us up to an additional U.S. $40.0 million payable in two tranches, with the first payment due following KKC's filing with the Japanese Ministry Health, Labour and Welfare (MHLW) of its application for marketing approval for tenapanor and the second payment due following KKC&#8217;s receipt of regulatory approval to market tenapanor for hyperphosphatemia in Japan. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2022 we recognized no licensing revenue upon the achievement of development milestones. During the three months ended March&#160;31, 2021, we recognized $5.0&#160;million licensing revenue upon the initiation of phase 3 clinical studies by KKC in Japan to evaluate tenapanor for hyperphosphatemia. During the three months ended March&#160;31, 2022, we recognized $14 thousand</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product supply revenue related to the manufacturing supply of tenapanor and other materials to KKC pursuant to the 2017 KKC Agreement. During the three months ended March&#160;31, 2021,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we recognized $0.1 million as product supply revenue pursuant to the 2017 KKC Agreement.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As detailed below under the heading </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deferred revenue - non-current</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we have received prepayments from KKC for the manufacturing of tenapanor drug substance that will be used to satisfy KKC needs. We also have recorded certain unbilled prepayments from KKC for the manufacturing of tenapanor drug product reflected within prepaid and other current assets. Both amounts are reflected within our deferred revenue, non-current on our condensed balance sheet as of March&#160;31, 2022. The prepayment is reflected within prepaid and other current assets and deferred revenue, non-current on our condensed balance sheet as of March&#160;31, 2022. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. (&#8220;Fosun Pharma&#8221;)</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017, we entered into an exclusive license agreement with Fosun</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharma</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Fosun Agreement&#8221;),</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the development, commercialization and distribution of tenapanor in China for both hyperphosphatemia and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IBS-C.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assessed these arrangements in accordance with ASC 606 and concluded that the contract counterparty, Fosun Pharma, is a customer. Under the terms of the Fosun Agreement, we received</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$12.0 million in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">upfront</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">license fees which was recognized as revenue when the agreement was executed. Based on</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">management&#8217;s</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assessment,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we determined</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that the license and the manufacturing supply services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">represented the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">material performance obligations at the inception of the agreement, and as such,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">each of the performance obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">distinct. &#160;</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be entitled to additional development and commercialization milestones of up to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$110.0 million, as well as reimbursement of cost plus a reasonable overhead for the supply of product and tiered royalties on net sales ranging from the mid-teens to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20%. The variable consideration related to the remaining development milestone payments has not been included in the transaction price as these were fully constrained at March&#160;31, 2022.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have recorded no</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">revenue during the three months ended March&#160;31, 2022 or 2021 related</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to the Fosun</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Agreement.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Knight Therapeutics, Inc. (&#8220;Knight&#8220;) &#160;</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2018, we entered into an exclusive license agreement with Knight (the &#8220;Knight Agreement&#8221;) for the development, commercialization and distribution of tenapanor in Canada for hyperphosphatemia and IBS-C. We assessed this arrangement in accordance with ASC 606 and concluded that the contract counterparty, Knight, is a customer. Based on management&#8217;s assessment, we determined that the license and the manufacturing supply services represented the material performance obligations at the inception of the agreement, and as such, each of the performance obligations is distinct. Under the terms of the agreement, we received a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$2.3 million nonrefundable, one-time upfront payment in March 2018 and are eligible to receive additional development and commercialization milestone payments worth up to $17.8 million. We are also eligible to receive royalties throughout the term of the agreement, and a transfer price for manufacturing services.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The variable consideration related to the remaining development milestone payments has not been included in the transaction price as they were fully constrained at March&#160;31, 2022.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">AstraZeneca AB (&#8220;AstraZeneca&#8221;)</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2015, we entered into a termination agreement with AstraZeneca (the &#8220;AstraZeneca Termination Agreement&#8221;) pursuant to which we have agreed to pay AstraZeneca (i) future royalties at a royalty rate of 10% of net sales of tenapanor or other NHE3 products by us or our licensees, and (ii) 20% of non-royalty revenue received from a licensee of tenapanor or another NHE3 inhibitor, up to a maximum of $75.0 million in aggregate for (i) and (ii). As of March&#160;31, 2022, to date in aggregate, we have recognized $11.7 million of the $75.0 million, which has been recorded as cost of revenue, and have paid AstraZeneca $11.6 million. During the three months ended March&#160;31, 2022 we recognized and recorded as cost of revenue $0.1 million related to the AstraZeneca Termination Agreement. During the three months ended March&#160;31, 2021 we recognized $1.0 million cost of revenue related to the AstraZeneca Termination Agreement.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Revenue</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present changes in our current and non-current deferred revenue balances during the reporting period. The March&#160;31, 2021 current deferred revenue balance is attributable entirely to the 2019 KKC Agreement and the non-current deferred revenue balances at March&#160;31, 2022 and 2021 are attributable entirely to the 2017 KKC Agreement (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.300%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred revenue - current</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1,</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,177&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decreases due to revenue recognized in the period for which cash has been received</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,454)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31,</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,723&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:63.760%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.030%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.325%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred revenue - non-current</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1,</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,727&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases to amounts invoiced, for which cash has not yet been received</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,829&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,947&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase due to unbilled prepayments recorded during the period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31,</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,563&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,947&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_CollaborationAndLicensingAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>n/a</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_CollaborationAndLicensingAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140314483430120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowing<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Borrowing</a></td>
<td class="text">BORROWING <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Solar Capital and Western Alliance Bank Loan Agreement</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 16, 2018, we entered into a loan and security agreement (as amended on October 9, 2020, March 1, 2021, May 5, 2021, and July 29, 2021) (the "2018 Loan Agreement") with Solar Capital Ltd. and Western Alliance Bank (collectively the &#8220;2018 Lenders&#8221;). The 2018 Loan Agreement provided for a $50.0 million loan facility with a maturity date of November&#160;1, 2022 (the &#8220;2018 Loan&#8221;). As of the Closing Date for the 2022 Loan, as discussed below, we owed $25.0 million in principal payments from the 2018 Loan, which we repaid in full at that time.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 8. Derivative Liability</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in connection with entering into the 2018 Loan Agreement, we entered into an agreement pursuant to which we agreed to pay $1.5 million in cash upon the occurrence of certain conditions (the "2018 Exit Fee"). Our obligations for the 2018 Exit Fee remain outstanding following the full repayment of the 2018 Loan in February 2022. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">SLR Investments Loan Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 23, 2022 (the &#8220;Closing Date&#8221;), we entered into a loan and security agreement (the &#8220;2022 Loan Agreement&#8221;) with SLR Investment Corp. as collateral agent (the &#8220;Agent&#8221;), and the lenders listed in the 2022 Loan Agreement (collectively the &#8220;2022 Lenders&#8221;). The 2022 Loan Agreement provides for a senior secured loan facility, with $27.5 million (the &#8220;Term A Loan&#8221;) funded on the Closing Date and an additional $22.5 million that we may borrow on or prior to July 25, 2023; provided that (i) we have received approval by the FDA for our NDA for the control of serum phosphorus in chronic kidney disease patients on dialysis by December 31, 2022, and (ii) we have achieved certain product revenue milestone targets described in the 2022 Loan Agreement (the &#8220;Term B Loan&#8221;, and collectively, the Term A Loan and the Term B Loan, the &#8220;2022 Loan&#8221;). The 2022 Term A Loan funds were used to repay the 2018 Loan with the 2018 Lenders. The 2022 Loan has a maturity date of March 1, 2027.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the 2022 Loan bear interest at a floating per annum rate equal to 7.95% plus the greater of (i) one tenth percent (0.10%) and (ii) the one-month rate published by the Intercontinental Exchange Benchmark Administration Ltd or its successor. We are permitted to make interest-only payments on the 2022 Loan through March 31, 2024. Accordingly, beginning on April 1, 2024, we will be required to make monthly payments of interest plus repay the 2022 Loan in consecutive equal monthly installments of principal. We were obligated to pay $0.2 million, upon the closing of the Term A Loan, and we are obligated to pay $0.1 million on the earliest of (i) the funding date of the Term B Loan, (ii) July 25, 2023, and (iii) the prepayment, refinancing, substitution, or replacement of the Term A Loan on or prior to July 25, 2023. We are obligated to pay a final fee equal to 4.95% of the aggregate original principal amount of the 2022 Loan funded upon the earliest to occur of the maturity date, the acceleration of the 2022 Loan, and the prepayment, refinancing, substitution, or replacement of the 2022 Loan. We may voluntarily prepay the outstanding 2022 Loan balance, subject to a prepayment premium of (i) 3% of the </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">outstanding principal amount of the 2022 Loan if prepaid prior to or on the first anniversary of the Closing Date, (ii) 2% of the outstanding principal amount of the 2022 Loan if prepaid after the first anniversary of the Closing Date through and including the second anniversary of the Closing Date, or (iii) 1% of the outstanding principal amount of the 2022 Loan if prepaid after the second anniversary of the Closing Date and prior to the maturity date. The 2022 Loan is secured by substantially all of our assets, except for our intellectual property and certain other customary exclusions. Additionally, in connection with the 2022 Loan, we entered into an agreement, whereby we agreed to pay an exit fee in the amount 2% of the 2022 Loan funded (the &#8220;2022 Exit Fee&#8221;) upon (i) any change of control transaction or (ii) our achievement of net revenue from the sale of any products equal to or greater than $100.0&#160;million, measured on a six (6) months basis, tested monthly at the end of each month. Notwithstanding the prepayment or termination of the 2022 Loan, the 2022 Exit Fee will expire 10 years from the Closing Date.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2022 Loan Agreement contains customary representations and warranties and customary affirmative and negative covenants, including, among others, requirements as to financial reporting and insurance and restrictions on our ability to dispose of our business or property, to change our line of business, to liquidate or dissolve, to enter into any change in control transaction, to merge or consolidate with any other entity or to acquire all or substantially all the capital stock or property of another entity, to incur additional indebtedness, to incur liens on our property, to pay any dividends or other distributions on capital stock other than dividends payable solely in capital stock or to redeem capital stock. We have agreed to not allow our cash and cash equivalents to be less than the eighty percent (80%) of the outstanding 2022 Term Loan balance for any period in which our net revenue from the sale of any products, calculated on a trailing six (6) month basis and tested monthly, is less than sixty percent (60%) of the outstanding 2022 Loan balance.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the 2022 Loan Agreement contains customary events of default that entitle the Agent to cause our indebtedness under the 2022 Loan Agreement to become immediately due and payable, and to exercise remedies against us and the collateral securing the 2022 Term Loan, including our cash. Under the 2022 Loan Agreement, an event of default will occur if, among other things, we fail to make payments under the 2022 Loan Agreement, we breach any of our covenants under the 2022 Loan Agreement, subject to specified cure periods with respect to certain breaches, certain Lenders determine that a material adverse change has occurred, we or our assets become subject to certain legal proceedings, such as bankruptcy proceedings, we are unable to pay our debts as they become due or we default on contracts with third parties which would permit the holder of indebtedness to accelerate the maturity of such indebtedness or that could have a material adverse change on us. Upon the occurrence and for the duration of an event of default, an additional default interest rate equal to 4% per annum will apply to all obligations owed under the 2022 Loan Agreement. We have classified the 2022 Loan balance as a current liability as of March&#160;31, 2022 due to the determination of the existence of substantial doubt about our ability to continue operating as a going concern discussed in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1. Organization and Basis of Presentation: Liquidity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and our assessment that the material adverse change clause under the 2022 Loan Agreement is not within our control. The lenders have not invoked the material adverse change clause as of the date of issuance of these financial statements. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, our future payment obligations related to the 2022 Loan, excluding interest payments and the 2022 final fee, are as follows (in thousands):</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:86.162%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.638%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total repayment obligations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,862&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Unamortized discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,399)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Unaccreted value of final fee</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,324)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,139&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion of long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,139)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net of current portion</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140314485507704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Liability<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">Derivative Liability</a></td>
<td class="text">DERIVATIVE LIABILITY<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2018 Exit Fee</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, in connection with entering into the 2018 Loan Agreement, we entered into an agreement pursuant to which we agreed to pay $1.5 million in cash (the &#8220;2018 Exit Fee&#8221;) upon any change of control transaction in respect of the Company or if we obtain both (i) FDA approval of tenapanor for the control of serum phosphorus in adult patients with CKD on dialysis and (ii) FDA approval of tenapanor for the treatment of patients with IBS-C, which was obtained on September 12, 2019 when the FDA approved IBSRELA&#174; (tenapanor), a 50 milligram, twice daily oral pill for the treatment of IBS-C in adults (the &#8220;2018 Exit Fee Agreement&#8221;). Notwithstanding the February 2022 prepayment of the 2018 Loan our obligation to pay the 2018 Exit Fee will expire on May 16, 2028. We concluded that the 2018 Exit Fee is a freestanding derivative which should be accounted </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for at fair value on a recurring basis. The estimated fair value of the 2018 Exit Fee is recorded as a derivative liability and included in accrued expenses and other current liabilities on the accompanying condensed balance sheets.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the derivative liability was determined using a discounted cash flow analysis and is classified as a Level 3 measurement within the fair value hierarchy since our valuation utilized significant unobservable inputs. Specifically, the key assumptions included in the calculation of the estimated fair value of the 2018 derivative liability include: (i) our estimates of both the probability and timing of a potential $1.5 million payment to the 2018 Lenders as a result of the FDA approvals and (ii) a discount rate which was derived from our estimated cost of debt, adjusted with current LIBOR (or a comparable successor rate if LIBOR no longer exists). Generally, increases or decreases in the probability of occurrence would result in a directionally similar impact in the fair value measurement of the derivative liability and it is estimated that a 10.0% increase (decrease), not to exceed 100%, in the probability of occurrence would result in a fair value fluctuation of no more than $0.1 million.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2022 Exit Fee</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 23, 2022, in connection with entering into the 2022 Loan Agreement, we entered into an agreement, whereby we agreed to pay an exit fee in the amount of  2% of the 2022 Loan funded (the &#8220;2022 Exit Fee&#8221;) upon (i) any change of control transaction or (ii) our achievement of net revenue from the sale of any products equal to or greater than $100.0 million, measured on a six (6) months basis (the "Revenue Milestone"), tested monthly at the end of each month. Notwithstanding the prepayment or termination of the 2022 Loan, the 2022 Exit Fee will expire on February 23, 2032. We concluded that the 2022 Exit Fee is a freestanding derivative which should be accounted for at fair value on a recurring basis. The estimated fair value of the 2022 Exit Fee is recorded as a derivative liability and included in accrued expenses and other current liabilities on the accompanying condensed balance sheets.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the derivative liability was determined using a discounted cash flow analysis and is classified as a Level 3 measurement within the fair value hierarchy since our valuation utilized significant unobservable inputs. Specifically, the key assumptions included in the calculation of the estimated fair value of the 2022 derivative liability include: (i) our estimates of both the probability and timing of achieving the Revenue Milestone and (ii) the probability and timing of funding the Term B Loan, which is dependent upon (a) approval by the FDA for our NDA for the control of serum phosphorus in chronic kidney disease patients on dialysis by December 31, 2022, and (b) achievement of certain product revenue milestone targets. Generally, increases or decreases in the probability of occurrence would result in a directionally similar impact in the fair value measurement of the derivative liability and it is estimated that a 10.0% increase (decrease) in the probability of occurrence would not result in a material fair value fluctuation.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the fair value of our exit fee derivative liabilities recurring measurements included in Level 3 of the fair value hierarchy are presented as other income, net in our statements of operations and were as follows for the three months ended March&#160;31, 2022 and 2021 (in thousands):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">698&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,376&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 Exit Fee addition at fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in estimated fair value</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,088&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,412&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -URI http://asc.fasb.org/topic&amp;trid=2229140<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123477628&amp;loc=d3e90205-114008<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140314483448360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">LEASESAll of our leases are operating leases and each contain customary rent escalation clauses. Certain of the leases have both lease and non-lease components. We have elected to account for each separate lease component and the non-lease components associated with that lease component as a single lease component for all classes of underlying assets.<div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides additional details of our facility leases presented in our condensed balance sheets as of March&#160;31, 2022 and December&#160;31, 2021 (dollars in thousands):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.274%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.714%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Facilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,910</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,752</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,592</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,492</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability, net of current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,812</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,748</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,404</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,240</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining life (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease costs, which are included in operating expenses in our statements of operations, were as follows (in thousands):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.636%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,064&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">673&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for operating lease</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,058&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,565&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"/></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our undiscounted cash payment obligations for our operating lease liabilities as of March&#160;31, 2022 (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.520%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,234&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,440&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,589&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,321&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted operating lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,836&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Imputed interest expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,432)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,404&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion of operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,592)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability, net of current portion</span></td><td style="background-color:#ffffff;border-bottom:5pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:5pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,812&#160;</span></td><td style="background-color:#ffffff;border-bottom:5pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140314597002168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">STOCKHOLDERS&#8217; EQUITY<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">At the Market Offerings Agreement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, we filed a Form S-3 registration statement, which became effective in August 2020 ("Registration Statement"), containing (i) a base prospectus for the offering, issuance and sale by us of up to a maximum aggregate offering price of $250.0 million of our common stock, preferred stock, debt securities, warrants and/or units, from time to time in one or more offerings; and (ii) a prospectus supplement for the offering, issuance and sale by us of up to a maximum aggregate offering price of $100.0 million of our common stock that may be issued and sold, from time to time, under a sales agreement with Jefferies LLC ("Jefferies"), deemed to be &#8220;at the market offerings&#8221; (the "2020 Open Market Sales Agreement"). The 2020 Open Market Sales Agreement was fully utilized as of December 31, 2021. During the three months ended March&#160;31, 2021 we sold 4.9 million shares and received gross proceeds of $35.0 million at a weighted average sales price of approximately $7.09 per share under the 2020 Open Market Sales Agreement.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, we filed an additional prospectus supplement under the Registration Statement for the offering, issuance and sale by us of up to a maximum aggregate offering price of $150.0 million of our common stock that may be issued and sold, from time to time, under an additional sales agreement we entered into with Jefferies (the "2021 Open Market Sales Agreement"), pursuant to which we may, from time to time, sell up to $150.0 million in shares of our common stock through Jefferies. We are not required to sell shares under the 2021 Open Market Sales Agreement. Pursuant to the 2021 Open Market </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales Agreement, Jefferies, as our sales agent, receives a commission of up to 3% of the gross sales price for shares of common stock sold under the 2021 Open Market Sales Agreement. During the three months ended March&#160;31, 2022 we sold 5.9 million shares and received gross proceeds of $6.0 million at a weighted average sales price of approximately $1.02 per share under the 2021 Open Market Sales Agreement.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sold 8.3 million shares of our common stock pursuant to the 2021 Open Market Sales Agreement which were settled</span><span style="color:#bf2115;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">between the dates of April 1, 2022 through April 27, 2022 for gross proceeds of $9.0 million at a weighted average sales price of approximately $1.09 per share. We did not sell any additional shares of our common stock after April 25, 2022 and through the date of filing this Quarterly Report on Form 10-Q.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140314483467240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Equity Incentive Plans</a></td>
<td class="text">EQUITY INCENTIVE PLANS<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense recognized for stock options, restricted stock units ("RSUs"), performance-based restricted stock units ("PRSUs") and our employee stock purchase program (the "ESPP") are recorded as operating expenses in our condensed statements of operations and comprehensive loss, as follows (in thousands):</span></div><div style="margin-top:12pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.867%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,214&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,092&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,508&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,995&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,722&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,087&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, our total unrecognized stock-based compensation expense, net of estimated forfeitures, and average remaining vesting period, included the following (dollars in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.958%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.323%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrecognized Compensation Expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average Remaining Vesting Period (Years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock option grants</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,865&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSU grants</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,894&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our stock option activity and related information for the three months ended March&#160;31, 2022 is as follows (in thousands, except dollar amounts):</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.152%"><tr><td style="width:1.0%"/><td style="width:58.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.446%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.106%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number&#160;of&#160;Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise&#160;Price&#160;per<br/>Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,417&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,535&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.98&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options forfeited or canceled</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,006)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.18&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,946&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.34&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at March 31, 2022</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,476&#160;</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.16&#160;</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our RSUs activity and related information for the three months ended March&#160;31, 2022 is as follows (in thousands, except dollar amounts):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.157%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.929%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.884%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number&#160;of<br/>RSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant&#160;Date&#160;Fair<br/>Value Per&#160;Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested restricted stock units at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,529&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.04&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,120&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.98&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(113)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.02&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested restricted stock units at March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,448&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.73&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, we sold approximately 0.1 million shares of our common stock under the ESPP. The shares were purchased by employees at a purchase price of $0.65 per share resulting in proceeds to us of approximately $0.1 million.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Issuance of Common Stock for Services</span></div>Under Our Amended and Restated Non-Employee Director Compensation Program, members of our board of directors may elect to receive shares of our stock in lieu of their cash fees. During the three months ended March&#160;31, 2022, we issued no shares of our common stock to members of the board of directors in accordance with the program.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140314483471608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">NET LOSS PER SHARE<div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period, less shares subject to repurchase, and excludes any dilutive effects of stock-based awards and warrants. Diluted net loss per common share is computed giving effect to all potential dilutive common shares, including common stock issuable upon exercise of stock options, and unvested restricted common stock and stock units. As we had net losses for the three months ended March&#160;31, 2022 and 2021, all potential common shares were determined to be anti-dilutive. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of net loss per common share (in thousands, except per share amounts): </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"/><td style="width:69.862%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.122%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,071)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,155)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding - basic and diluted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,935&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,179&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share - basic and diluted</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.21)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.34)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2022, the total number of securities that could potentially dilute basic net loss per share in the future that were not included in the computation of diluted net loss per share because the effect would have been antidilutive was 13.3 million.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2021, the total number of securities that could potentially dilute basic net loss per share in the future that were not included in the computation of diluted net loss per share because the effect would have been antidilutive was 13.0 million.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140314485501320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Contingencies</a></td>
<td class="text">CONTINGENCIESFrom time to time we may be involved in claims arising in connection with our business. Based on information currently available, management believes that the amount, or range, of reasonably possible losses in connection with any pending actions against us will not be material to our financial condition or cash flows, and no contingent liabilities were accrued as of March&#160;31, 2022 or 2021.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140314483469368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">SUBSEQUENT EVENTS On April 11, 2022, we entered into a second amendment (the "Amendment") to the 2017 KKC Agreement. Under the terms of the Amendment, the parties have agreed to a reduction in the royalty rate payable to us by KKC upon net sales of tenapanor in Japan. The royalty rate will be reduced from the high teens to low double digits for a two-year period of time following the first commercial sale in Japan, and then to mid-single digits for the remainder of the royalty term. As consideration for the reduction in the royalty rate, KKC has agreed to pay us up to an additional U.S. $40.0 million payable in two tranches, with the first payment due following KKC's filing with the Japanese Ministry Health, Labour and Welfare (MHLW) of its application for marketing approval for tenapanor and the second payment due following KKC's receipt of regulatory approval to market tenapanor for hyperphosphatemia in Japan.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140314480695336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and pursuant to the requirements of the Securities and Exchange Commission (&#8220;SEC&#8221;) for interim reporting. As permitted under those rules&#160;and regulations, certain footnotes or other financial information that are normally required by U.S. GAAP have been condensed or omitted. These condensed financial statements have been prepared on the same basis as our most recent annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments necessary to present fairly our financial position, results of operations, changes in stockholders&#8217; equity, and cash flows for the interim periods presented.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed financial statements and related financial information should be read in conjunction with the audited financial statements and the related notes thereto included in our Annual Report on Form 10-K for the&#160;year ended December&#160;31, 2021. The results for the three months ended March&#160;31, 2022 are not necessarily indicative of results to be expected for the entire&#160;year ending December&#160;31, 2022, or for any other interim period or future year.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that affect the amounts reported in the financial statements and accompanying notes thereto. On an ongoing basis, management evaluates its estimates, including those related to recognition of revenue, clinical trial accruals, contract manufacturing accruals, the fair value of assets and liabilities, income taxes and stock-based compensation. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could materially differ from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts Receivable</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable is reported net of allowances for returns, chargebacks and contractual discounts offered to our customers. Our estimate of the allowance for doubtful accounts is based on an evaluation of the aging of our receivables. Trade receivable balances are written off against the allowance when it is probable that the receivable will not be collected. To date, we have determined that an allowance for doubtful accounts is not required. As of March&#160;31, 2022 our accounts receivable balance is comprised of $3.8&#160;million from our collaborators and $0.6&#160;million from commercial customers. As of December&#160;31, 2021 our accounts receivable balance was comprised of $0.5&#160;million from our collaborators.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the regulatory approval of drug product candidates, we incurred expenses for the manufacture of drug product that could potentially be available to support the commercial launch of our products. We began to capitalize inventory costs associated with IBSRELA during the fourth quarter of 2021, when our intent to commercialize IBSRELA was established and we commenced preparation for the commercial launch of IBSRELA, which was when it was determined that the inventory had a probable future economic benefit.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory is stated at the lower of cost or estimated net realizable value with cost determined under the first-in first-out method. Inventory costs include third-party contract manufacturing, third-party packaging services, freight, labor costs for personnel involved in the manufacturing process, and indirect overhead costs. We primarily use actual costs to determine the cost basis for inventory. The determination of whether inventory costs will be realizable requires management review of the expiration dates of IBSRELA compared to our forecasted sales. If actual market conditions are less favorable than projected by management, write-downs of inventory may be required, which would be recorded as cost of goods sold in the condensed statement of operations and comprehensive loss.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Product Sales, Net and Reserves for Variable Consideration</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Sales, Net</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for our commercial product sales, net in accordance with Topic 606 - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We received approval from the U.S. Food and Drug Administration (&#8220;FDA&#8221;) in September 2019 to market IBSRELA, the first and only sodium hydrogen exchanger 3 (&#8220;NHE3&#8221;) inhibitor for the treatment of irritable bowel syndrome with constipation ("IBS-C") in adults, in the United States ("U.S."). We began selling IBSRELA in the U.S. in March 2022. We distribute our products principally through a limited number of distributors and specialty pharmacy providers (collectively, our "Customers"). Our Customers subsequently sell our products to pharmacies and patients. Separately, we enter into arrangements with third parties that provide for government-mandated and privately-negotiated rebates, chargebacks and discounts. Revenue from product sales is recognized when our performance obligations are satisfied, which is when Customers obtain control of our product and occurs upon delivery.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reserves for Variable Consideration</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration, including rebates, discounts, patient copay assistance programs, and estimated product returns. These estimates are based on the amounts earned or to be claimed for related sales and are classified as reductions of accounts receivable if the amount is payable to our Customers or a current liability if the amount is payable to a party other than a Customer. Where appropriate, these estimates are based on factors such as industry data and forecasted customer buying and payment patterns, our historical experience, current contractual and statutory requirements, specific known market events and trends. Overall, these reductions to gross sales reflect our best estimates of the amount of consideration to which we are entitled based on the terms of the contract. Variable consideration is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from our estimates, we adjust these estimates, which would affect product revenue and earnings in the period such variances become known. As we gain more historical experience, estimates will be more heavily based on the expected utilization from historical data we have accumulated since the IBSRELA product launch.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Rebates: Rebates include mandated discounts under the Medicaid Drug Rebate Program ("Medicaid") and the Medicare Coverage Gap Program ("Medicare"). Rebates are amounts owed after the final dispensing of products to a benefit plan </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">participant and are based upon contractual agreements or legal requirements with the public-sector benefit providers. These estimates for rebates are recorded in the same period the related gross revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included in accrued expenses on the condensed balance sheets. We estimate our Medicaid and Medicare rebates based upon the estimated payor mix, and statutory discount rates. Our estimates for payor mix are guided by payor information received from specialty pharmacies, expected utilization for specialty distributor sales to pharmacies, and available industry payor information. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Chargebacks: Chargebacks are discounts that occur when contracted purchasers purchase directly from our specialty distributors at a discounted price. The specialty distributor, in turn, charges back the difference between the price initially paid to us by the specialty distributor and the discounted price paid to the specialty distributor by the contracted purchaser. Amounts for estimated chargebacks are established in the same period that the related gross revenue is recognized, resulting in a reduction of product revenue and accounts receivable. The accrual for specialty distributor chargebacks is estimated based on known chargeback rates, known sales to specialty distributors, and estimated utilization by types of contracted purchasers.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discounts and Fees: Our payment terms are generally 30 to 60 days. Specialty distributors and specialty pharmacies are offered various forms of consideration, including service fees and prompt pay discounts for payment within a specified period. We expect these Customers will earn prompt pay discounts and therefore, we deduct the full amount of these discounts and service fees from product sales when revenue is recognized, resulting in a reduction of product revenue and accounts receivable.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other Reserves: Patients who have commercial insurance may receive co-pay assistance when product is dispensed by pharmacies to patients. We estimate the amount of co-pay assistance provided to eligible patients based on the terms of the program and redemption information provided by third-party claims processing organizations and are recorded in accounts payable, accrued expenses and other current liabilities on the condensed balance sheets.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of Revenue</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost of Revenue</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of revenue consists of the cost of commercial goods sold to our Customers, international partners under product supply agreements, and royalty expense based on sales of tenapanor. We capitalize inventory costs associated with the production of our products after regulatory approval or when, based on management&#8217;s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized. Otherwise, such costs are expensed as research and development. A portion of the costs of IBSRELA units recognized as revenue during the three months ended March&#160;31, 2022 were expensed prior to the fourth quarter of 2021, at which time our intent to commercialize IBSRELA was established and we commenced  preparation for the commercial launch of IBSRELA.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of revenue includes payments due to AstraZeneca, which under the terms of a termination agreement entered into in 2015 (the "AZ Termination Agreement") is entitled to (i) future royalties at a rate of 10% of net sales of tenapanor or other NHE3 products by us or our licensees, and (ii) 20% of non-royalty revenue received from our collaboration partners as a result of the development and commercialization of tenapanor or certain other NHE3 inhibitors.&#160;We have agreed to pay&#160;AstraZeneca up to a maximum of $75.0 million in the aggregate for (i) and (ii). We recognize these expenses as cost of revenue when we recognize the corresponding revenue that gives rise to payments due to AstraZeneca. To date, we have recognized an aggregate of $11.7 million as cost of revenue under the AZ Termination Agreement.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New Accounting Pronouncements - Recently Adopted</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted no new accounting pronouncements other than those disclosed in our most recent Annual Report on Form 10-K.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were various accounting standards and interpretations issued recently, none of which are expected to a have a material impact on our financial position, operations or cash flows.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The three-level hierarchy for the inputs to valuation techniques is briefly summarized as follows:</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:86.163%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 1 &#8211;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuations are based on quoted prices in active markets for identical assets or liabilities and readily accessible by us at the reporting date.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2 &#8211;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuations based on inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 3 &#8211;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuations based on unobservable inputs for which there is little or no market data, which require us to develop our own assumptions.</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 705<br> -URI http://asc.fasb.org/topic&amp;trid=2122478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124437754&amp;loc=d3e543-108305<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e4975-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5212-111524<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953423-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5093-111524<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140314483264056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, Cash Equivalents and Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Schedule of Securities Classified as Cash, Cash Equivalents and Investments</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities classified as cash, cash equivalents and investments as of March&#160;31, 2022 and December&#160;31, 2021 are summarized below (in thousands):</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:43.914%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.416%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.659%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,555&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,555&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,524&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,524&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,999&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,998&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,078&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,077&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,409&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,357&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored agency bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,777&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,755&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,521&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,511&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,007&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,004&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,714&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,627&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,792&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,704&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.075%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,253&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,253&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,428&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,428&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,936&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,935&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,025&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,022&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,304&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,267&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,261&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,695&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,689&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash, cash equivalents, and investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140314483353992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Summary of Fair Value of Financial Assets and Liabilities Measured or Disclosed on a Recurring Basis</a></td>
<td class="text"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the fair value of our financial assets and liabilities that are measured or disclosed on a recurring basis by level within the fair value hierarchy (in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total<br/>Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,524&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,524&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,355&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,355&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored agency bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,755&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,755&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,511&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,511&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,004&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,004&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,149&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,524&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,625&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 12.25pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liability for exit fees</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,088&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,088&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,088&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,088&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total<br/>Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,935&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,935&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,022&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,022&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,304&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,304&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,436&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,175&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,261&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 12.25pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liability for exit fee</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">698&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">698&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140314483286600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text">Inventory consisted of the following (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">460&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,507&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">520&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,487&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140314483286600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Product Revenue, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_ScheduleOfGrossToNetSalesAccrualsTableTextBlock', window );">Schedule of Chargebacks, Discounts and Reserve Balances</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The activities and ending reserve balances for each significant category of discounts and allowances, which constitute variable consideration, were as follows (in thousands):</span></div><div style="margin-top:12pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Discounts and Chargebacks</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Rebates</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Fees, Copay and Returns</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Activity related to 2022 sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_ScheduleOfGrossToNetSalesAccrualsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Gross To Net Sales Accruals</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_ScheduleOfGrossToNetSalesAccrualsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140314483257784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Licensing Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_CollaborationAndLicensingAgreementsAbstract', window );"><strong>Collaboration and Licensing Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Schedule of Changes in Deferred Revenue</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present changes in our current and non-current deferred revenue balances during the reporting period. The March&#160;31, 2021 current deferred revenue balance is attributable entirely to the 2019 KKC Agreement and the non-current deferred revenue balances at March&#160;31, 2022 and 2021 are attributable entirely to the 2017 KKC Agreement (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.300%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred revenue - current</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1,</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,177&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decreases due to revenue recognized in the period for which cash has been received</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,454)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31,</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,723&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:63.760%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.030%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.325%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred revenue - non-current</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1,</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,727&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases to amounts invoiced, for which cash has not yet been received</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,829&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,947&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase due to unbilled prepayments recorded during the period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31,</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,563&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,947&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_CollaborationAndLicensingAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>n/a</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_CollaborationAndLicensingAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140314483431240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowing (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Future Debt Payment Obligations</a></td>
<td class="text"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, our future payment obligations related to the 2022 Loan, excluding interest payments and the 2022 final fee, are as follows (in thousands):</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:86.162%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.638%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total repayment obligations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,862&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Unamortized discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,399)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Unaccreted value of final fee</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,324)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,139&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion of long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,139)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net of current portion</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140314481835144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Liability (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of Changes in Fair Value of Derivative Liability</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the fair value of our exit fee derivative liabilities recurring measurements included in Level 3 of the fair value hierarchy are presented as other income, net in our statements of operations and were as follows for the three months ended March&#160;31, 2022 and 2021 (in thousands):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">698&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,376&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 Exit Fee addition at fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in estimated fair value</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,088&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,412&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140314485725240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_ScheduleOfAdditionalDetailsOfLeasesTableTextBlock', window );">Summary of Additional Details of Leases</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides additional details of our facility leases presented in our condensed balance sheets as of March&#160;31, 2022 and December&#160;31, 2021 (dollars in thousands):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.274%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.714%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Facilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,910</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,752</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,592</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,492</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability, net of current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,812</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,748</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,404</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,240</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining life (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Summary of Lease Costs</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease costs, which are included in operating expenses in our statements of operations, were as follows (in thousands):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.636%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,064&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">673&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for operating lease</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,058&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,565&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"/></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Summary of Undiscounted Cash Payment Obligations for Operating Lease Liabilities</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our undiscounted cash payment obligations for our operating lease liabilities as of March&#160;31, 2022 (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.520%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,234&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,440&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,589&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,321&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted operating lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,836&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Imputed interest expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,432)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,404&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion of operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,592)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability, net of current portion</span></td><td style="background-color:#ffffff;border-bottom:5pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:5pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,812&#160;</span></td><td style="background-color:#ffffff;border-bottom:5pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_ScheduleOfAdditionalDetailsOfLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure of additional details of the leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_ScheduleOfAdditionalDetailsOfLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140314480688360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Stock-Based Compensation Expense Recognized</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense recognized for stock options, restricted stock units ("RSUs"), performance-based restricted stock units ("PRSUs") and our employee stock purchase program (the "ESPP") are recorded as operating expenses in our condensed statements of operations and comprehensive loss, as follows (in thousands):</span></div><div style="margin-top:12pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.867%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,214&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,092&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,508&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,995&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,722&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,087&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock', window );">Summary of Total Unrecognized Stock-Based Compensation Expense, Net of Estimated Forfeitures</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, our total unrecognized stock-based compensation expense, net of estimated forfeitures, and average remaining vesting period, included the following (dollars in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.958%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.323%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrecognized Compensation Expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average Remaining Vesting Period (Years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock option grants</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,865&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSU grants</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,894&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our stock option activity and related information for the three months ended March&#160;31, 2022 is as follows (in thousands, except dollar amounts):</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.152%"><tr><td style="width:1.0%"/><td style="width:58.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.446%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.106%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number&#160;of&#160;Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise&#160;Price&#160;per<br/>Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,417&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,535&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.98&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options forfeited or canceled</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,006)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.18&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,946&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.34&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at March 31, 2022</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,476&#160;</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.16&#160;</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of Restricted Stock Units Activity</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our RSUs activity and related information for the three months ended March&#160;31, 2022 is as follows (in thousands, except dollar amounts):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.157%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.929%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.884%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number&#160;of<br/>RSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant&#160;Date&#160;Fair<br/>Value Per&#160;Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested restricted stock units at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,529&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.04&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,120&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.98&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(113)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.02&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested restricted stock units at March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,448&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.73&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost not yet recognized and weighted-average period over which cost is expected to be recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140314483437768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Computation of Net Loss Per Common Share</a></td>
<td class="text"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of net loss per common share (in thousands, except per share amounts): </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"/><td style="width:69.862%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.122%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,071)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,155)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding - basic and diluted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,935&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,179&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share - basic and diluted</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.21)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.34)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140314479985464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAndCash', window );">Cash and investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 89,704<span></span>
</td>
<td class="nump">$ 116,689<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(741,001)<span></span>
</td>
<td class="num">(712,930)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,394<span></span>
</td>
<td class="nump">502<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=ardx_AccountsReceivableCollaboratorMember', window );">Collaborators</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,800<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=ardx_AccountsReceivableCommercialCustomerMember', window );">Commercial customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_RevenueGeneralPaymentTerms', window );">Payment terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_RevenueGeneralPaymentTerms', window );">Payment terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ardx_AstrazenecaMember', window );">AstraZeneca</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_CostOfRevenueAggregateAmountRecognized', window );">Aggregate cost of revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ardx_AstrazenecaMember', window );">AstraZeneca | AZ Termination Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_PercentageOfRoyaltyRevenue', window );">Percentage of royalty revenue</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_PercentageOfNonRoyaltyRevenue', window );">Percentage of non-royalty revenue</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum', window );">Maximum potential payment per agreement</a></td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Potential Payment Per Termination Agreement, Maximum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_CostOfRevenueAggregateAmountRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost of revenue, aggregate amount recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_CostOfRevenueAggregateAmountRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_PercentageOfNonRoyaltyRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents percentage of non-royalty revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_PercentageOfNonRoyaltyRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_PercentageOfRoyaltyRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents percentage of royalty revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_PercentageOfRoyaltyRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_RevenueGeneralPaymentTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue, General Payment Terms</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_RevenueGeneralPaymentTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAndCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of investments and unrestricted cash as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAndCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=ardx_AccountsReceivableCollaboratorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=ardx_AccountsReceivableCollaboratorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=ardx_AccountsReceivableCommercialCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=ardx_AccountsReceivableCommercialCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ardx_AstrazenecaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ardx_AstrazenecaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ardx_AstraZenecaTerminationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ardx_AstraZenecaTerminationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140314477360888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash, Cash Equivalents and Investments - Securities Classified as Cash, Cash Equivalents and Investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract', window );"><strong>Cash and cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_CashAndCashEquivalentsAmortizedCost', window );">Cash and cash equivalents, Amortized Cost</a></td>
<td class="nump">$ 47,078<span></span>
</td>
<td class="nump">$ 72,428<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_CashAndCashEquivalentsGrossUnrealizedGains', window );">Cash and cash equivalents, Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_CashAndCashEquivalentsGrossUnrealizedLosses', window );">Cash and cash equivalents, Gross Unrealized Losses</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, Fair Value</a></td>
<td class="nump">47,077<span></span>
</td>
<td class="nump">72,428<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Short-term investments, Amortized Cost</a></td>
<td class="nump">42,714<span></span>
</td>
<td class="nump">44,267<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Short-term investments, Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Short-term investments, Gross Unrealized Losses</a></td>
<td class="num">(87)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments, Fair Value</a></td>
<td class="nump">42,627<span></span>
</td>
<td class="nump">44,261<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_InvestmentsAndCashAmortizedCost', window );">Total cash equivalents and investments, Cost</a></td>
<td class="nump">89,792<span></span>
</td>
<td class="nump">116,695<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedGains', window );">Total cash equivalents and investments, Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses', window );">Total cash equivalents and investments, Gross Unrealized Losses</a></td>
<td class="num">(88)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAndCash', window );">Total cash equivalents and investments, Fair Value</a></td>
<td class="nump">89,704<span></span>
</td>
<td class="nump">116,689<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract', window );"><strong>Cash and cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_CashAndCashEquivalentsAmortizedCost', window );">Cash and cash equivalents, Amortized Cost</a></td>
<td class="nump">7,555<span></span>
</td>
<td class="nump">1,253<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_CashAndCashEquivalentsGrossUnrealizedGains', window );">Cash and cash equivalents, Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_CashAndCashEquivalentsGrossUnrealizedLosses', window );">Cash and cash equivalents, Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, Fair Value</a></td>
<td class="nump">7,555<span></span>
</td>
<td class="nump">1,253<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract', window );"><strong>Cash and cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_CashAndCashEquivalentsAmortizedCost', window );">Cash and cash equivalents, Amortized Cost</a></td>
<td class="nump">34,524<span></span>
</td>
<td class="nump">71,175<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_CashAndCashEquivalentsGrossUnrealizedGains', window );">Cash and cash equivalents, Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_CashAndCashEquivalentsGrossUnrealizedLosses', window );">Cash and cash equivalents, Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, Fair Value</a></td>
<td class="nump">34,524<span></span>
</td>
<td class="nump">71,175<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract', window );"><strong>Cash and cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_CashAndCashEquivalentsAmortizedCost', window );">Cash and cash equivalents, Amortized Cost</a></td>
<td class="nump">4,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_CashAndCashEquivalentsGrossUnrealizedGains', window );">Cash and cash equivalents, Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_CashAndCashEquivalentsGrossUnrealizedLosses', window );">Cash and cash equivalents, Gross Unrealized Losses</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, Fair Value</a></td>
<td class="nump">4,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Short-term investments, Amortized Cost</a></td>
<td class="nump">28,409<span></span>
</td>
<td class="nump">31,936<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Short-term investments, Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Short-term investments, Gross Unrealized Losses</a></td>
<td class="num">(52)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments, Fair Value</a></td>
<td class="nump">28,357<span></span>
</td>
<td class="nump">31,935<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember', window );">U.S. government-sponsored agency bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Short-term investments, Amortized Cost</a></td>
<td class="nump">10,777<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Short-term investments, Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Short-term investments, Gross Unrealized Losses</a></td>
<td class="num">(22)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments, Fair Value</a></td>
<td class="nump">10,755<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Short-term investments, Amortized Cost</a></td>
<td class="nump">2,521<span></span>
</td>
<td class="nump">7,025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Short-term investments, Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Short-term investments, Gross Unrealized Losses</a></td>
<td class="num">(10)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments, Fair Value</a></td>
<td class="nump">2,511<span></span>
</td>
<td class="nump">7,022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Short-term investments, Amortized Cost</a></td>
<td class="nump">1,007<span></span>
</td>
<td class="nump">5,306<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Short-term investments, Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Short-term investments, Gross Unrealized Losses</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments, Fair Value</a></td>
<td class="nump">$ 1,004<span></span>
</td>
<td class="nump">$ 5,304<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_CashAndCashEquivalentsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash And Cash Equivalents, Amortized Cost</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_CashAndCashEquivalentsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_CashAndCashEquivalentsGrossUnrealizedGains">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash And Cash Equivalents, Gross Unrealized Gains</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_CashAndCashEquivalentsGrossUnrealizedGains</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_CashAndCashEquivalentsGrossUnrealizedLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash And Cash Equivalents, Gross Unrealized Losses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_CashAndCashEquivalentsGrossUnrealizedLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedGains">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, cash equivalents and investments gross unrealized gains.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedGains</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, cash equivalents and investments gross unrealized losses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_InvestmentsAndCashAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investments And Cash, Amortized Cost</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_InvestmentsAndCashAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAndCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of investments and unrestricted cash as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAndCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140314485603032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, Cash Equivalents and Investments - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>investment</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum', window );">Short-term available-for-sale securities contractual maturities, maximum</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale', window );">Other-than-temporary impairment | $</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions', window );">Investment in continuous unrealized loss position for more than one year | investment</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Available-For-Sale Securities, Debt Securities, Current, Contractual Maturities, Maximum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other-than-temporary impairment (OTTI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized in earnings and other comprehensive loss (OCI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8A<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=SL6284422-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140314476680952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets, Fair Value Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">$ 82,149<span></span>
</td>
<td class="nump">$ 115,436<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities, Fair Value Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">1,088<span></span>
</td>
<td class="nump">698<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets, Fair Value Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">34,524<span></span>
</td>
<td class="nump">71,175<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets, Fair Value Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">33,355<span></span>
</td>
<td class="nump">31,935<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. government-sponsored agency bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets, Fair Value Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">10,755<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets, Fair Value Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">2,511<span></span>
</td>
<td class="nump">7,022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets, Fair Value Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">1,004<span></span>
</td>
<td class="nump">5,304<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Derivative liability for exit fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities, Fair Value Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">1,088<span></span>
</td>
<td class="nump">698<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets, Fair Value Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">34,524<span></span>
</td>
<td class="nump">71,175<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities, Fair Value Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets, Fair Value Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">34,524<span></span>
</td>
<td class="nump">71,175<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets, Fair Value Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | U.S. government-sponsored agency bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets, Fair Value Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets, Fair Value Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets, Fair Value Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Derivative liability for exit fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities, Fair Value Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets, Fair Value Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">47,625<span></span>
</td>
<td class="nump">44,261<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities, Fair Value Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets, Fair Value Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets, Fair Value Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">33,355<span></span>
</td>
<td class="nump">31,935<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | U.S. government-sponsored agency bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets, Fair Value Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">10,755<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets, Fair Value Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">2,511<span></span>
</td>
<td class="nump">7,022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets, Fair Value Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">1,004<span></span>
</td>
<td class="nump">5,304<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Derivative liability for exit fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities, Fair Value Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets, Fair Value Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities, Fair Value Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">1,088<span></span>
</td>
<td class="nump">698<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets, Fair Value Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets, Fair Value Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | U.S. government-sponsored agency bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets, Fair Value Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets, Fair Value Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets, Fair Value Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Derivative liability for exit fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities, Fair Value Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">$ 1,088<span></span>
</td>
<td class="nump">$ 698<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140314480741352">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNetAbstract', window );"><strong>Inventory</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in process</a></td>
<td class="nump">2,507<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total</a></td>
<td class="nump">$ 3,487<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140314479951736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Product Revenue, Net - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 468<span></span>
</td>
<td class="nump">$ 6,582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_ContractWithCustomerGrossToNetSalesAccruals', window );">Gross-to-net sales accruals</a></td>
<td class="nump">$ 154<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember', window );">Gross product revenue | Customer | AmerisourceBergen Drug Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (percent)</a></td>
<td class="nump">17.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember', window );">Gross product revenue | Customer | Cardinal Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (percent)</a></td>
<td class="nump">17.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember', window );">Gross product revenue | Customer | McKesson Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (percent)</a></td>
<td class="nump">15.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ardx_ProductIBSRELAMember', window );">IBSRELA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 450<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_ContractWithCustomerGrossToNetSalesAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Gross To Net Sales Accruals</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_ContractWithCustomerGrossToNetSalesAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ardx_AmerisourceBergenDrugCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ardx_AmerisourceBergenDrugCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ardx_CardinalHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ardx_CardinalHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ardx_McKessonCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ardx_McKessonCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ardx_ProductIBSRELAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ardx_ProductIBSRELAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140314481679480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Product Revenue, Net - Gross-to-Net Sales Accruals (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward', window );"><strong>Gross-to-net sales accruals and reserves</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_ContractWithCustomerGrossToNetSalesAccruals', window );">Beginning balance</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod', window );">Activity related to 2022 sales</a></td>
<td class="nump">154<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_ContractWithCustomerGrossToNetSalesAccruals', window );">Ending balance</a></td>
<td class="nump">154<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_GrossToNetSalesAccrualAndReserveClassificationAxis=ardx_ContractWithCustomerDiscountsAndChargebacksMember', window );">Discounts and Chargebacks</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward', window );"><strong>Gross-to-net sales accruals and reserves</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_ContractWithCustomerGrossToNetSalesAccruals', window );">Beginning balance</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod', window );">Activity related to 2022 sales</a></td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_ContractWithCustomerGrossToNetSalesAccruals', window );">Ending balance</a></td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_GrossToNetSalesAccrualAndReserveClassificationAxis=ardx_ContractWithCustomerRebatesMember', window );">Rebates</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward', window );"><strong>Gross-to-net sales accruals and reserves</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_ContractWithCustomerGrossToNetSalesAccruals', window );">Beginning balance</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod', window );">Activity related to 2022 sales</a></td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_ContractWithCustomerGrossToNetSalesAccruals', window );">Ending balance</a></td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_GrossToNetSalesAccrualAndReserveClassificationAxis=ardx_ContractWithCustomerOtherFeesCopayAndReturnsMember', window );">Other Fees, Copay and Returns</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward', window );"><strong>Gross-to-net sales accruals and reserves</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_ContractWithCustomerGrossToNetSalesAccruals', window );">Beginning balance</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod', window );">Activity related to 2022 sales</a></td>
<td class="nump">90<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_ContractWithCustomerGrossToNetSalesAccruals', window );">Ending balance</a></td>
<td class="nump">$ 90<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Gross To Net Sales, Accrual Activity During Current Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Gross To Net Sales Accrual</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_ContractWithCustomerGrossToNetSalesAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Gross To Net Sales Accruals</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_ContractWithCustomerGrossToNetSalesAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_GrossToNetSalesAccrualAndReserveClassificationAxis=ardx_ContractWithCustomerDiscountsAndChargebacksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_GrossToNetSalesAccrualAndReserveClassificationAxis=ardx_ContractWithCustomerDiscountsAndChargebacksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_GrossToNetSalesAccrualAndReserveClassificationAxis=ardx_ContractWithCustomerRebatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_GrossToNetSalesAccrualAndReserveClassificationAxis=ardx_ContractWithCustomerRebatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_GrossToNetSalesAccrualAndReserveClassificationAxis=ardx_ContractWithCustomerOtherFeesCopayAndReturnsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_GrossToNetSalesAccrualAndReserveClassificationAxis=ardx_ContractWithCustomerOtherFeesCopayAndReturnsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140314475259960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Licensing Agreements - Narrative (Details)<br> &#165; in Billions</strong></div></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">53 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 30, 2019 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th">
<div>Mar. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 11, 2022 </div>
<div>USD ($) </div>
<div>payment_tranche</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>JPY (&#165;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 468,000<span></span>
</td>
<td class="nump">$ 6,582,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">Licensing revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="nump">5,002,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ardx_ProductSupplyRevenueMember', window );">Product supply revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,000<span></span>
</td>
<td class="nump">126,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ardx_AstrazenecaMember', window );">AstraZeneca</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_CostOfRevenueAggregateAmountRecognized', window );">Aggregate cost of revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ardx_ResearchCollaborationAndOptionAgreementMember', window );">2019 KKC Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ardx_ResearchCollaborationAndOptionAgreementMember', window );">2019 KKC Agreement | KKC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees', window );">Upfront license fees</a></td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment', window );">First installment of upfront license fees</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_TermOfPaymentOfLicenseFeeFirstInstallment', window );">Term of payment of license fee, first installment</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment', window );">Second installment of upfront license fees</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_TermOfAgreement', window );">Term of agreement</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ardx_ResearchCollaborationAndOptionAgreementMember', window );">2019 KKC Agreement | KKC | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_NumberOfSeparateCollaborativeAgreements', window );">Number of separate collaborative agreements | item</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember', window );">2017 KKC Agreement | Licensing revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember', window );">2017 KKC Agreement | Product supply revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember', window );">2017 KKC Agreement | KKC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees', window );">Upfront license fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_CollaborativeArrangementPotentialDevelopmentMilestones', window );">Potential development milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_CollaborativeArrangementPotentialCommercializationMilestones', window );">Potential commercialization milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 8.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember', window );">Fosun Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember', window );">Fosun Agreement | Fosun Pharma</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLicenseFeesReceived', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones', window );">Potential development and commercialization milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 110,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_ThresholdPercentageOfSalesForTieredRoyalties', window );">Threshold percentage of net sales for tiered royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember', window );">Knight Agreement | Knight</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLicenseFeesReceived', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones', window );">Potential development and commercialization milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ardx_AstraZenecaTerminationAgreementMember', window );">AZ Termination Agreement | AstraZeneca</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_PercentageOfRoyaltyRevenue', window );">Percentage of royalty revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_PercentageOfNonRoyaltyRevenue', window );">Percentage of non-royalty revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum', window );">Maximum potential payment per agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_PaymentsOfUnchargedLicenseFeesAggregateAmountPaid', window );">Aggregate amount paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent event | 2017 KKC Agreement | KKC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate', window );">Fee receivable for reduction in royalty rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches', window );">Number of payment tranches for fee receivable for reduction in royalty rate | payment_tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration And Licensing Agreements, Upfront License Fees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration And Licensing Agreements, Upfront License Fees, First Installment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration And Licensing Agreements, Upfront License Fees, Second Installment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Fee Receivable For Reduction In Royalty Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Fee Receivable For Reduction In Royalty Rate, Number Of Payment Tranches</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_CollaborativeArrangementPotentialCommercializationMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Potential Commercialization Milestones</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_CollaborativeArrangementPotentialCommercializationMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of future development and commercialization milestone under collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_CollaborativeArrangementPotentialDevelopmentMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Potential Development Milestones</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_CollaborativeArrangementPotentialDevelopmentMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Potential Payment Per Termination Agreement, Maximum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_CostOfRevenueAggregateAmountRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost of revenue, aggregate amount recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_CostOfRevenueAggregateAmountRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_NumberOfSeparateCollaborativeAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of separate collaborative agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_NumberOfSeparateCollaborativeAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_PaymentsOfUnchargedLicenseFeesAggregateAmountPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments of uncharged license fees, aggregate amount paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_PaymentsOfUnchargedLicenseFeesAggregateAmountPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_PercentageOfNonRoyaltyRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents percentage of non-royalty revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_PercentageOfNonRoyaltyRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_PercentageOfRoyaltyRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents percentage of royalty revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_PercentageOfRoyaltyRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_TermOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_TermOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_TermOfPaymentOfLicenseFeeFirstInstallment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of payment of first installment fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_TermOfPaymentOfLicenseFeeFirstInstallment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_ThresholdPercentageOfSalesForTieredRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the threshold percentage of net sales for tiered royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_ThresholdPercentageOfSalesForTieredRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLicenseFeesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received from licensees for license fees during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLicenseFeesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ardx_ProductSupplyRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ardx_ProductSupplyRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ardx_AstrazenecaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ardx_AstrazenecaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ardx_ResearchCollaborationAndOptionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ardx_ResearchCollaborationAndOptionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ardx_KyowaKirinCo.LtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ardx_KyowaKirinCo.LtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ardx_KnightTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ardx_KnightTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ardx_AstraZenecaTerminationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ardx_AstraZenecaTerminationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140314481854888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Licensing Agreements - Deferred Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward', window );"><strong>Deferred revenue - non-current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Beginning balance</a></td>
<td class="nump">$ 4,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Ending balance</a></td>
<td class="nump">8,563<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ardx_ResearchCollaborationAndOptionAgreementMember', window );">2019 KKC Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward', window );"><strong>Deferred revenue - current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Beginning balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 4,177<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_ContractWithCustomerLiabilityRevenueRecognizedCashReceived', window );">Decreases due to revenue recognized in the period for which cash has been received</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,454)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Ending balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,723<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember', window );">2017 KKC Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward', window );"><strong>Deferred revenue - non-current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Beginning balance</a></td>
<td class="nump">4,727<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_ContractWithCustomerLiabilityIncreaseForAmountsInvoiced', window );">Increases to amounts invoiced, for which cash has not yet been received</a></td>
<td class="nump">3,829<span></span>
</td>
<td class="nump">2,947<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_ContractWithCustomerLiabilityIncreaseDueToUnbilledPrepaymentsRecorded', window );">Increase due to unbilled prepayments recorded during the period</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Ending balance</a></td>
<td class="nump">$ 8,563<span></span>
</td>
<td class="nump">$ 2,947<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change In Contract With Customer Liability, Current, Rollforward</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change In Contract With Customer Liability, Noncurrent, Rollforward</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_ContractWithCustomerLiabilityIncreaseDueToUnbilledPrepaymentsRecorded">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability, Increase Due To Unbilled Prepayments Recorded</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_ContractWithCustomerLiabilityIncreaseDueToUnbilledPrepaymentsRecorded</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_ContractWithCustomerLiabilityIncreaseForAmountsInvoiced">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability, Increase For Amounts Invoiced</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_ContractWithCustomerLiabilityIncreaseForAmountsInvoiced</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_ContractWithCustomerLiabilityRevenueRecognizedCashReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_ContractWithCustomerLiabilityRevenueRecognizedCashReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ardx_ResearchCollaborationAndOptionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ardx_ResearchCollaborationAndOptionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140314476681992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Borrowing - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Feb. 23, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>May 31, 2018</div></th>
<th class="th"><div>May 16, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,862,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ardx_TermLoan2018Member', window );">2018 Term Loan | Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Term loan face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal outstanding</a></td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ardx_TermLoan2022Member', window );">2022 Term Loan | Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage', window );">Final fee due upon maturity, acceleration, prepayment, or termination (percent)</a></td>
<td class="nump">4.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum', window );">Loan agreement covenant, cash and cash equivalents as percentage of outstanding loan balance, minimum</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum', window );">Loan agreement covenant, net product revenue as percentage of outstanding loan balance, minimum</a></td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_DebtInstrumentInterestRateOnDefaultPercentage', window );">Additional default interest rate</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ardx_TermLoan2022Member', window );">2022 Term Loan | Term Loan | Prior to first anniversary of closing date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_DebtInstrumentPrepaymentFeePercentage', window );">Prepayment premium (as a percent)</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ardx_TermLoan2022Member', window );">2022 Term Loan | Term Loan | After first anniversary through second anniversary of closing date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_DebtInstrumentPrepaymentFeePercentage', window );">Prepayment premium (as a percent)</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ardx_TermLoan2022Member', window );">2022 Term Loan | Term Loan | After second anniversary to maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_DebtInstrumentPrepaymentFeePercentage', window );">Prepayment premium (as a percent)</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ardx_TermLoan2022Member', window );">2022 Term Loan | Term Loan | LIBOR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Floating per annum rate (percent)</a></td>
<td class="nump">7.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_DebtInstrumentVariableRateBaseOption', window );">Addition to floating per annum rate (percent)</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ardx_TermLoan2022AMember', window );">Term Loan A | Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Proceeds from loan payable, net of issuance costs</a></td>
<td class="nump">$ 27,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_DebtInstrumentClosingFeeAmount', window );">Closing fee</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ardx_TermLoan2022BMember', window );">Term Loan B | Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_RemainingFundingBasedOnConditionalMilestoneAchievement', window );">Remaining funding based on milestone achievement</a></td>
<td class="nump">22,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_LoanAgreementFutureObligationUponFundingOrOtherEvents', window );">Future obligation upon loan funding or other events</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=ardx_ExitFee2022Member', window );">2022 Exit Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_ExitFeePercentage', window );">Exit fee (percent)</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum', window );">Exit fee, net product revenue threshold</a></td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_LoanAgreementExitFeeTerm', window );">Exit fee, term (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=ardx_ExitFee2018Member', window );">2018 Exit Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotionalAmount', window );">Agreed amount for exit fee upon occurrence of certain conditions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_DebtInstrumentClosingFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Closing Fee Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_DebtInstrumentClosingFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Fee Due Upon Maturity, Acceleration, Prepayment, Termination, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_DebtInstrumentInterestRateOnDefaultPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of additional default interest rate on the event of default.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_DebtInstrumentInterestRateOnDefaultPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_DebtInstrumentPrepaymentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of fee payable on prepayment of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_DebtInstrumentPrepaymentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_DebtInstrumentVariableRateBaseOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Variable Rate, Base Option</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_DebtInstrumentVariableRateBaseOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_ExitFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exit Fee, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_ExitFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loan Agreement, Covenant, Cash And Cash Equivalents As Percentage Of Outstanding Loan Balance, Minimum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loan Agreement, Covenant, Net Product Revenue As Percentage Of Outstanding Loan Balance, Minimum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loan Agreement, Exit Fee, Net Product Revenue Threshold Metric, Trailing Six Month Basis, Minimum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_LoanAgreementExitFeeTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loan Agreement, Exit Fee, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_LoanAgreementExitFeeTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_LoanAgreementFutureObligationUponFundingOrOtherEvents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loan Agreement, Future Obligation Upon Funding Or Other Events</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_LoanAgreementFutureObligationUponFundingOrOtherEvents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_RemainingFundingBasedOnConditionalMilestoneAchievement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining Funding Based On Conditional Milestone Achievement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_RemainingFundingBasedOnConditionalMilestoneAchievement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payments on the derivative liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDebtNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ardx_TermLoan2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ardx_TermLoan2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ardx_TermLoan2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ardx_TermLoan2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ardx_TermLoan2022AMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ardx_TermLoan2022AMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ardx_TermLoan2022BMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ardx_TermLoan2022BMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=ardx_ExitFee2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=ardx_ExitFee2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=ardx_ExitFee2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=ardx_ExitFee2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140314484230632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Borrowing - Future Payment Obligations (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByMaturityAbstract', window );"><strong>Total repayment obligations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term Debt, Gross</a></td>
<td class="nump">$ 28,862<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Less: Unamortized discount</a></td>
<td class="num">(1,399)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Less: Unaccreted value of final fee</a></td>
<td class="num">(1,324)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">26,139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less: Current portion of long-term debt</a></td>
<td class="num">(26,139)<span></span>
</td>
<td class="num">$ (32,264)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net of current portion</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee that accompanies borrowing money under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtByMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtByMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140314481610968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Derivative Liability - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Feb. 23, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>May 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=ardx_ExitFee2018Member', window );">2018 Exit Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotionalAmount', window );">Agreed amount for exit fee upon change of control or regulatory approval</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=ardx_ExitFee2018Member', window );">2018 Exit Fee | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage', window );">Fair value analysis, percentage change in probability of occurrence</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation', window );">Fair value analysis, effect on fair value based on 10% change in probability of occurrence</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=ardx_ExitFee2022Member', window );">2022 Exit Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_ExitFeePercentage', window );">Exit fee (percent)</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum', window );">Exit fee, net product revenue threshold</a></td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=ardx_ExitFee2022Member', window );">2022 Exit Fee | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage', window );">Fair value analysis, percentage change in probability of occurrence</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_ExitFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exit Fee, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_ExitFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value Sensitivity Analysis, Change In Probability Of Occurrence, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value Sensitivity Analysis, Ten Percent Change In Probability Of Occurrence, Effect On Valuation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loan Agreement, Exit Fee, Net Product Revenue Threshold Metric, Trailing Six Month Basis, Minimum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payments on the derivative liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=ardx_ExitFee2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=ardx_ExitFee2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=ardx_ExitFee2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=ardx_ExitFee2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140314484263800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Liability - Changes in Fair Value (Details) - Exit Fee derivative liability - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Change in Fair Value of Derivative Liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value of exit fee derivative liability, beginning</a></td>
<td class="nump">$ 698<span></span>
</td>
<td class="nump">$ 1,376<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">2022 Exit Fee addition at fair value</a></td>
<td class="nump">375<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Changes in estimated fair value</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value of exit fee derivative liability, ending</a></td>
<td class="nump">$ 1,088<span></span>
</td>
<td class="nump">$ 1,412<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140314479893160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Additional Details of Facility Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAndLiabilitiesLesseeAbstract', window );"><strong>Right-of-use assets and lease liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">$ 11,910<span></span>
</td>
<td class="nump">$ 12,752<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of lease liabilities</a></td>
<td class="nump">3,592<span></span>
</td>
<td class="nump">3,492<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net of current portion</a></td>
<td class="nump">8,812<span></span>
</td>
<td class="nump">9,748<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 12,404<span></span>
</td>
<td class="nump">$ 13,240<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescriptionAbstract', window );"><strong>Additional details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining life (years)</a></td>
<td class="text">3 years 2 months 12 days<span></span>
</td>
<td class="text">3 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">6.90%<span></span>
</td>
<td class="nump">6.90%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAndLiabilitiesLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAndLiabilitiesLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDescriptionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDescriptionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140314486289304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Lease Costs (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease costs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease expense</a></td>
<td class="nump">$ 1,064<span></span>
</td>
<td class="nump">$ 673<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for operating lease</a></td>
<td class="nump">$ 1,058<span></span>
</td>
<td class="nump">$ 1,565<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140314481672616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Undiscounted Cash Payment Obligations (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Undiscounted cash payment obligations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Remainder of 2022</a></td>
<td class="nump">$ 3,234<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">4,440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">4,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">1,321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted operating lease payments</a></td>
<td class="nump">13,836<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Imputed interest expenses</a></td>
<td class="num">(1,432)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">12,404<span></span>
</td>
<td class="nump">$ 13,240<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: Current portion of operating lease liability</a></td>
<td class="num">(3,592)<span></span>
</td>
<td class="num">(3,492)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net of current portion</a></td>
<td class="nump">$ 8,812<span></span>
</td>
<td class="nump">$ 9,748<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140314477325464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details) - USD ($)<br> $ / shares in Units, shares in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 27, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Aug. 31, 2021</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock in at the market offering, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,921,000<span></span>
</td>
<td class="nump">$ 34,272,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_MaximumAggregateOfferingPrice', window );">Maximum aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ardx_OpenMarketSalesAgreement2020AtTheMarketOfferingMember', window );">2020 Open Market Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in at the market offering (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock in at the market offering, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_SaleOfStockWeightedAveragePricePerShare', window );">Weighted-average sales price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ardx_OpenMarketSalesAgreement2020AtTheMarketOfferingMember', window );">2020 Open Market Sales Agreement | Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_MaximumAggregateOfferingPrice', window );">Maximum aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ardx_OpenMarketSalesAgreement2021AtTheMarketOfferingMember', window );">2021 Open Market Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_StockIssuanceCostCommissionPercent', window );">Commission on sale of stock per agreement (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in at the market offering (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock in at the market offering, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_SaleOfStockWeightedAveragePricePerShare', window );">Weighted-average sales price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ardx_OpenMarketSalesAgreement2021AtTheMarketOfferingMember', window );">2021 Open Market Sales Agreement | Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_MaximumAggregateOfferingPrice', window );">Maximum aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ardx_OpenMarketSalesAgreement2021AtTheMarketOfferingMember', window );">2021 Open Market Sales Agreement | Subsequent event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in at the market offering (shares)</a></td>
<td class="nump">8.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock in at the market offering, net of issuance costs</a></td>
<td class="nump">$ 9,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_SaleOfStockWeightedAveragePricePerShare', window );">Weighted-average sales price per share</a></td>
<td class="nump">$ 1.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_MaximumAggregateOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of maximum aggregate offering price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_MaximumAggregateOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_SaleOfStockWeightedAveragePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Weighted-Average Price Per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_SaleOfStockWeightedAveragePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_StockIssuanceCostCommissionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issuance Cost, Commission, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_StockIssuanceCostCommissionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ardx_OpenMarketSalesAgreement2020AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ardx_OpenMarketSalesAgreement2020AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ardx_OpenMarketSalesAgreement2021AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ardx_OpenMarketSalesAgreement2021AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140314477342408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans - Stock-Based Compensation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 3,722<span></span>
</td>
<td class="nump">$ 3,087<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">1,214<span></span>
</td>
<td class="nump">1,092<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 2,508<span></span>
</td>
<td class="nump">$ 1,995<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140314480442936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans - Unrecognized Stock-Based Compensation (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized Compensation Expense</a></td>
<td class="nump">$ 14,865<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Average Remaining Vesting Period (Years)</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized Compensation Expense</a></td>
<td class="nump">$ 4,894<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Average Remaining Vesting Period (Years)</a></td>
<td class="text">1 year 3 months 18 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ardx_EmployeeStockPurchasePlanMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized Compensation Expense</a></td>
<td class="nump">$ 53<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Average Remaining Vesting Period (Years)</a></td>
<td class="text">9 months 18 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ardx_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ardx_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140314480828120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans - Stock Options (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number&#160;of&#160;Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding balance, beginning (shares) | shares</a></td>
<td class="nump">10,417,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (shares) | shares</a></td>
<td class="nump">3,535,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised (shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options forfeited (shares) | shares</a></td>
<td class="num">(1,006,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding balance, ending (shares) | shares</a></td>
<td class="nump">12,946,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable (shares) | shares</a></td>
<td class="nump">6,476,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Exercise&#160;Price&#160;per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding balance, beginning (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 7.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted (in dollars per share) | $ / shares</a></td>
<td class="nump">0.98<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options exercised (in dollars per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Options forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">7.18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding balance, ending (in dollars per share) | $ / shares</a></td>
<td class="nump">5.34<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options exercisable (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 7.16<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140314480446120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans - Restricted Stock Units (Details) - RSUs<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number&#160;of RSUs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding balance, beginning (shares) | shares</a></td>
<td class="nump">3,529,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (shares) | shares</a></td>
<td class="nump">1,120,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (shares) | shares</a></td>
<td class="num">(113,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (shares) | shares</a></td>
<td class="num">(88,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding balance, ending (shares) | shares</a></td>
<td class="nump">4,448,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant&#160;Date&#160;Fair Value Per&#160;Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding balance, beginning (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 2.04<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">0.98<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share) | $ / shares</a></td>
<td class="nump">3.62<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">2.02<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding balance, ending (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.73<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140314477195528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ardx_EmployeeStockPurchasePlanMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Number of shares issued under ESPP</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare', window );">Purchase price (in dollars per share)</a></td>
<td class="nump">$ 0.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from ESPP</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Board of directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock for services (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the purchase price per share of shares issued to employees under the plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ardx_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ardx_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140314481680184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Computation of Net Loss Per Common Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (28,071)<span></span>
</td>
<td class="num">$ (33,155)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding - basic</a></td>
<td class="nump">130,934,795<span></span>
</td>
<td class="nump">97,179,241<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding - diluted</a></td>
<td class="nump">130,934,795<span></span>
</td>
<td class="nump">97,179,241<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share - basic (in dollars per share)</a></td>
<td class="num">$ (0.21)<span></span>
</td>
<td class="num">$ (0.34)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share - diluted (in dollars per share)</a></td>
<td class="num">$ (0.21)<span></span>
</td>
<td class="num">$ (0.34)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140314483481464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Narrative (Details) - shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities not included in computation of diluted net loss per share</a></td>
<td class="nump">13.3<span></span>
</td>
<td class="nump">13.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140314485501320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Contingencies (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Contingent liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140314484284056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events (Details) - Subsequent event - KKC - 2017 KKC Agreement<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Apr. 11, 2022 </div>
<div>USD ($) </div>
<div>payment_tranche</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate', window );">Fee receivable for reduction in royalty rate | $</a></td>
<td class="nump">$ 40,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches', window );">Number of payment tranches for fee receivable for reduction in royalty rate | payment_tranche</a></td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Fee Receivable For Reduction In Royalty Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Fee Receivable For Reduction In Royalty Rate, Number Of Payment Tranches</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ardx_KyowaKirinCo.LtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ardx_KyowaKirinCo.LtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>ardx-20220331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:ardx="http://www.ardelyx.com/20220331"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="ardx-20220331.xsd" xlink:type="simple"/>
    <context id="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i50bec6a618074ef79a40cbc0e7e8aa89_I20220502">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
        </entity>
        <period>
            <instant>2022-05-02</instant>
        </period>
    </context>
    <context id="i6c8486331a7f40578e81f8425fe3e837_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i97ef8572b6ce41c09c8f695ae8a0ca00_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i5783cc7426ba453f96f1e7e0af87b0a6_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id194cfe3452f4c7c84f5dfd4fe7d8297_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ardx:ProductSupplyRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9f8aa7556d7647dd80cd79f50b30d12a_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ardx:ProductSupplyRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i4c8fadcb7a584b6b81773ef6f2440734_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i77926c7e42f94727854dd2729e419202_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i785dbb6e8a754de6a7aa8b0b43cd5de4_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ardx:CollaborativeDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id6b9396538454def9c8a29399c6b8d03_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ardx:CollaborativeDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if66cb97858004034a661fde444b21a40_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i4cf9b083bea54e30a63681421a4a7088_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i915c4ac55b394c648e3f1e508325bbfe_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i77bb1febd93946efb7f1ca68a5cb537e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id37f845e78ea4e4ba399ae4d539dd270_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibe48acc39ad24a498bf29293d3b5ff68_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i0a66e20dad254b89922f8674a7094895_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie996e76b43b94778bbd562ef8363a5f7_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i2f13863ef82b4ff9891451291774c864_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3a994d19646542b883bef3eb77ec041a_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ia53bcaf6b509496b9aaca8a740abefe9_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i71139a32ab724fed9714f268e212cd3a_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i9012898f9a0f44118b5aa8f6b4d02190_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i2d98dab95e674482969a1c14b83aeabb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i35ca663b0a124e6b8c8656e7e070589c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i71bfab9599a347c38e447f9dfe33b344_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie1302e9e86374f80ab91f5e2e093f6fa_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iaa47cdf56b6c4c87a3d970dbcf5b0e23_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic32baa0627994f879f796094ade7c7d5_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i7f6752f99ffb46a6ac848c2977b3c96d_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ie42c996fddf8460982e8ef5b6a6dd25a_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i76348c324fa24beda3b12611828f421a_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id70cbf4ca0ff49799aebf60ead1ac83a_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie895873a73154ee881d6a0b9a2729c79_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i38a8556738964a7fa1421049694e0b21_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i7c204a43b4eb4e6d9394547d9b0e2b58_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="iac98ebf56cf345fb9e32e575ac855e4a_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i42e4f62db19a433c9581bbeecf9067e3_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">ardx:AccountsReceivableCollaboratorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="id9efdb641fb440e39fb4580adc8f5d3f_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">ardx:AccountsReceivableCommercialCustomerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="id0170fbda0b74504967067c9d57bec75_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">ardx:AccountsReceivableCollaboratorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibc13d123a8d14d6babcf8581fd6dcd05_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3a085319c0b44680ad033352cd7f1a58_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i390f2ffb21554b849e8f47149934d4fd_D20150601-20150630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:AstrazenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:AstraZenecaTerminationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-06-01</startDate>
            <endDate>2015-06-30</endDate>
        </period>
    </context>
    <context id="id4d3d62533e642adab59317a030f3b30_I20150630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:AstrazenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:AstraZenecaTerminationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-06-30</instant>
        </period>
    </context>
    <context id="i8bde55ddcbf0400a8169b35ffe4c6da2_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:AstrazenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i7eb8629a82dc4a618ece82cbcdfbe085_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i05a2662add9440cc8c7d0f1dc736a702_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i596f9b1e440f4452b6cba1824137da8b_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i7673f1405fd24051b58473f5a806ecb9_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iea208acf5bf04c3b9d76527a7e0ebf16_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i37581a46b73b46d5b858164659fbef62_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i19273e8da1e4462a88cdc93b1a044f85_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i1757ee4e90cc49c3ae9d0a3ce3f93f66_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib27f65921b34451f840e9bfaa2858274_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib232d5bccde74c2c832a58c5854c8659_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5f8c132fed8e489a94a6ec129ee5512e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iae3a2fe36c17417ca407960547b30624_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id7116fb603e844e7b66ea135c246d400_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i5f95faaaa8ba40ef81fabfd9af749d5a_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ifffac340b48d4569a291b906003daa40_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ib3c8925c35b44d6d9fbe11c422368576_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ie320d5dea5f84c1a997114a2a44304ab_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ic12ce3ad23f94a40843d57bbafc1b93b_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ib64b89a6dbb241f9ac74255f0f2faddd_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i20743f7a35cf46598f5e61aadaaaf959_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i7282cda81b5e403d9d6a82b54ca9e220_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="icbe8bcf473664c3cbd7a8d406e6f4b25_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ieff5d13f74bb46f19e0bf993fbdb4e1b_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i9c8530d2f63d4dcd99a0d2685f08f090_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i22961d74779a41578f711e2cbdab8cc8_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i346bb756dc874f18b4e7ecc3b1fd18fd_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i45e9678a2bb9475883b569adf411868a_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i057b3b5e23d74f1b93392611784416da_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iec212359212b4b3686fe182249f00160_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i5c358ffd9da447c0ae8ba16d667ddb3d_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iaa5d06c90bd0488e864737436b77eb4c_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i8b1a0008a10b4495b001946a2dbbebcf_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ia66c3497d92f4f87983a8808d4c22279_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="idccb2dc5b13a4488878f9a05af20f66a_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ia8a67586059d49f9810370c50eaa57c0_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i7c1a6f674cd541978439c2f0f7d4fb9a_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ie0e3ba1f3d18466d8724f70ecdc208fa_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="icd9cbd3639304bd294cd77b069e2903b_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ie12d13976cc7450da7913cd451cc1f1d_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ie7da228130c340edbbb9bf247a589756_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i9becbf42740c409189339a2b5a11a4f2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i92ef66972cf9427cb63419db9768a298_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i211bb796b7a24967b594b6dbe16c328c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie08734f5a1ee4ae1a8f14c3e0ad81e38_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i702ba55895b343c594a4b5ed37806639_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id48fda4018124a2789eda8fb5e8c7f3b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i864378b20e0f48a2a4a6e9ec27084dd7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i870189fb8682430baf663525b78d14eb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i498f3eb654bb4e63858ae975af11c445_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie76caf10c27b47c9b2d7f93b70732805_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8b34d1e5e84949e08757fe31d16851b6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icae86f3621e745dcae0300fcf262e97a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibfe0e960aed543b5988f05f7d3355902_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0f334852225945b2a7a93e28e698a7b5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2fbce7b430d746d193e24e71ed55ec24_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i77f4939d9c1b4cb9a23a9d1abed49c29_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0a918505eebf4610bda0dea154daa7a3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibb543391634c44d0a2f40bdc636ebebf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6b0ae5504847492aaff354b4bb3eed43_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i07deb0701eff4cf3b8159da82875bb77_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if2c246545dd44f91b1867420b6787cd5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i57236df6e705400089af661d14abc3ab_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9aaa3d02b9854e48a25597ea0974cd4e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iec8114b671a2456c81955e87ce50bed9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i157edd1d25424d4e869f567c7ddd2b4a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ardx:ProductIBSRELAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i5602110d257243d68fe06a3de7666ba1_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ardx:CardinalHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i7a2496c68915449aa1b605adb0073d44_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ardx:AmerisourceBergenDrugCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib4ede0c6d6294ec1ba539591fc337da1_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ardx:McKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3cd8e102ed0b453abc3afc0ba274b816_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ardx:GrossToNetSalesAccrualAndReserveClassificationAxis">ardx:ContractWithCustomerDiscountsAndChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0e3b20e3d13f464f8136bc69cac78387_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ardx:GrossToNetSalesAccrualAndReserveClassificationAxis">ardx:ContractWithCustomerRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibc17b1d2c9354e6ba7867c153f98dd39_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ardx:GrossToNetSalesAccrualAndReserveClassificationAxis">ardx:ContractWithCustomerOtherFeesCopayAndReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia23df3972f1944e3a9fed9c31cbc6587_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ardx:GrossToNetSalesAccrualAndReserveClassificationAxis">ardx:ContractWithCustomerDiscountsAndChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i4eed71377df84e2fad4e2b5044d0f43c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ardx:GrossToNetSalesAccrualAndReserveClassificationAxis">ardx:ContractWithCustomerRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i10819c0292d84effb45cc9b78a0c7f30_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ardx:GrossToNetSalesAccrualAndReserveClassificationAxis">ardx:ContractWithCustomerOtherFeesCopayAndReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iede9224697ec4dd1a0adabd2320ebc14_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ardx:GrossToNetSalesAccrualAndReserveClassificationAxis">ardx:ContractWithCustomerDiscountsAndChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ie452822da30341968381616c4727890f_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ardx:GrossToNetSalesAccrualAndReserveClassificationAxis">ardx:ContractWithCustomerRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ic3971d760f8441f38d00e317c37315fd_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ardx:GrossToNetSalesAccrualAndReserveClassificationAxis">ardx:ContractWithCustomerOtherFeesCopayAndReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i23aa3d7663a24dc8865dc922b983040b_D20191101-20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:KyowaKirinCo.LtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:ResearchCollaborationAndOptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2019-11-30</endDate>
        </period>
    </context>
    <context id="i9168e70d1cc646808da95d0e5cbe0347_D20191101-20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:KyowaKirinCo.LtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:ResearchCollaborationAndOptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2019-11-30</endDate>
        </period>
    </context>
    <context id="i745335ff1da443c2a66acb028f9b9044_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:ResearchCollaborationAndOptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id32818d38a2f41e79d9416fb0bd0e53a_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:ResearchCollaborationAndOptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i6ded7d7b952443ff99d1931791c886bb_D20171101-20171130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:KyowaKirinCo.LtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-11-01</startDate>
            <endDate>2017-11-30</endDate>
        </period>
    </context>
    <context id="i8bba5999a33a4beabc6bda2318d9d5d6_I20171130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:KyowaKirinCo.LtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-11-30</instant>
        </period>
    </context>
    <context id="i0212bc236d5d418c889a86710d62cead_D20171101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-11-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic0f6d47945c94e2398355efb64d25b64_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:KyowaKirinCo.LtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ic15e7d54e20c401b86da52a356fa5887_I20220411">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:KyowaKirinCo.LtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-11</instant>
        </period>
    </context>
    <context id="ib0326b0e1d934394b35c6b4e5823a0e9_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i777f4b1d2b0a48c995f7a8e8fc2a2d0d_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iab42eb33c5f6401eb4cabd7658b0c6bd_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ardx:ProductSupplyRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1760e71a3aab4fd190e7292ba626aa96_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ardx:ProductSupplyRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iaafa907a1fc049f59de2c2fcb1b077a8_D20171201-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInChinaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i0a019b5505f7466ca2f76583b097cdbe_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInChinaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9c7ce382bd124359a0a4700a39632df1_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInChinaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib9fd94dcca60490e82fbc1d493ab985c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInChinaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i839c245d89c241679804a884e550ef5b_D20180301-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:KnightTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="i29560f0f154647109b5c7c80f240890c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:KnightTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i73d193d247244f1fb9ce854954086ef6_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:AstrazenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:AstraZenecaTerminationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i025ade055f874ff1a468b7fbd0583eda_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:AstrazenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:AstraZenecaTerminationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3de6eb23c1e24a80807755f0069fc236_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:AstrazenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:AstraZenecaTerminationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i34485cae15f04837aa894774e18bbb58_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:ResearchCollaborationAndOptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia600adb07b6d40c9b3357ac69342a7ad_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:ResearchCollaborationAndOptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i717222ed03814f8f986a1604095f9214_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:ResearchCollaborationAndOptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ic81523b011734f66b3b288912d844b1d_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:ResearchCollaborationAndOptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i61553ae32dfb40f8b285bdfc4a3d3272_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibd27a0a1ac554dc1a75c1884f665b7f6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5e8de9754a784d54a397d66dc8d5ebf0_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ifb1b8b57f3484b4c886d5bcda853744b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i2146e1f17bd043f3b77edbd52edab483_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i8f0cf433f09e4f1e9169aefcedff5d7f_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ib7f93b8f72cf486bbecc12514b98b015_I20180516">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ardx:TermLoan2018Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-16</instant>
        </period>
    </context>
    <context id="ib7054c03dafb4f308b95f52c3a43fa1b_I20220223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ardx:TermLoan2018Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-23</instant>
        </period>
    </context>
    <context id="iba83d40326b1433ea471109cb11536f8_I20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ardx:ExitFee2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-31</instant>
        </period>
    </context>
    <context id="i3a8be86cba30452780b8d0bca7fe52ef_D20220223-20220223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ardx:TermLoan2022AMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-23</startDate>
            <endDate>2022-02-23</endDate>
        </period>
    </context>
    <context id="i22ce6a39c3434acd91d5ab75ae19b62f_I20220223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ardx:TermLoan2022BMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-23</instant>
        </period>
    </context>
    <context id="i00d53b360ebd4d39ab0a045093b0d350_D20220223-20220223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ardx:TermLoan2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-23</startDate>
            <endDate>2022-02-23</endDate>
        </period>
    </context>
    <context id="id7137d11d7564018ab80498ef529b584_I20220223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ardx:TermLoan2022AMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-23</instant>
        </period>
    </context>
    <context id="icbf434cb3f104e188c9fd0464443c2f4_I20220223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ardx:TermLoan2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-23</instant>
        </period>
    </context>
    <context id="i5d5d94cb725e4caca45734b96460fab2_I20220223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ardx:TermLoan2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-23</instant>
        </period>
    </context>
    <context id="i5134dd31b2ec46ba9252bb3ccd222425_I20220223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ardx:TermLoan2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-23</instant>
        </period>
    </context>
    <context id="ia616f3b3f10d4ebda8439302d146953c_I20220223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ardx:TermLoan2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-23</instant>
        </period>
    </context>
    <context id="i6c1d87e6c35c44b9baca5f0c32c93d4e_I20220223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ardx:ExitFee2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-23</instant>
        </period>
    </context>
    <context id="ie706e05847024bdfbe5174e56d319428_D20220223-20220223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ardx:ExitFee2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-23</startDate>
            <endDate>2022-02-23</endDate>
        </period>
    </context>
    <context id="i59df1925a0574c55bae8311f5941df95_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ardx:ExitFee2018Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i89699442d50542d18f061eb0f10ea77b_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ardx:ExitFee2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="id497bd1485194fabbdb368667104492e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4ad56d5e526243f6a24d080e5313c670_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia8c70b1e37704cbba96b42d34dac6902_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iaf0f6a03fb7b4bdc8dace9bdd0e496b2_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i5e02e812fef941edbaba1967484f0272_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i84a8784bf6674ce391d92b932658744b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i76c2136d55464302b2f21baaa5e4dd54_I20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="ia17a982a190740e2954ba6bf67641fdf_I20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ardx:OpenMarketSalesAgreement2020AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="ide9366ec48e04d7b90b9fb896f92c772_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ardx:OpenMarketSalesAgreement2020AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic8a3d4170574424dbc7bd161e8e90f99_I20210831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ardx:OpenMarketSalesAgreement2021AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-31</instant>
        </period>
    </context>
    <context id="i58ecc0e1f7064678834e4f881aa7d26f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ardx:OpenMarketSalesAgreement2021AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1e7f6940c3f94b42ae0826c56712faf3_D20220401-20220427">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ardx:OpenMarketSalesAgreement2021AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-27</endDate>
        </period>
    </context>
    <context id="i5fb7df19c340473c8180a84b522d3105_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i688a54ef5d904ecc853b9118c446b946_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="idd425314803a477c8c332384eb697af8_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i5dc952c28b244722a46ac91b1208bda9_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i8a3d5f58f87e49a095847ea09b7bf010_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i097a3193c63e4588b0705a6c382a1938_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie5d73f51d15b4a93b70e582a308344c0_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="idf00f8a3ea3f45eaab148f2ba05a7841_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i59d036f63af647faadf250a643250458_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ardx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ic35af7bef7ef4aaf9affdc91a3779184_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ardx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i14d3b2f9b45b490fbcbe947f54b91b39_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4bedde518aa14e90ae770d42052bfc56_D20220201-20220228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ardx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2022-02-28</endDate>
        </period>
    </context>
    <context id="i856e705397e44a879c8d4de90f5984b6_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>ardx:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="investment">
        <measure>ardx:investment</measure>
    </unit>
    <unit id="item">
        <measure>ardx:item</measure>
    </unit>
    <unit id="jpy">
        <measure>iso4217:JPY</measure>
    </unit>
    <unit id="payment_tranche">
        <measure>ardx:payment_tranche</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80L2ZyYWc6NjFhNDM5YmM5YmUxNDcxZjhlZjhiMGZhZDE0ZDJmZjQvdGFibGU6MDQwYTg2ZDI4ZGQ2NDFhMTk0NDU0OGZmODdjODI4NDUvdGFibGVyYW5nZTowNDBhODZkMjhkZDY0MWExOTQ0NTQ4ZmY4N2M4Mjg0NV8wLTEtMS0xLTIzMDEz_984e6ca6-ce84-468f-8c2e-71617cc7d112">0001437402</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80L2ZyYWc6NjFhNDM5YmM5YmUxNDcxZjhlZjhiMGZhZDE0ZDJmZjQvdGFibGU6MDQwYTg2ZDI4ZGQ2NDFhMTk0NDU0OGZmODdjODI4NDUvdGFibGVyYW5nZTowNDBhODZkMjhkZDY0MWExOTQ0NTQ4ZmY4N2M4Mjg0NV8xLTEtMS0xLTIzMDEz_7eab4b1c-60ab-42cd-92b4-f1298fdff1c2">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80L2ZyYWc6NjFhNDM5YmM5YmUxNDcxZjhlZjhiMGZhZDE0ZDJmZjQvdGFibGU6MDQwYTg2ZDI4ZGQ2NDFhMTk0NDU0OGZmODdjODI4NDUvdGFibGVyYW5nZTowNDBhODZkMjhkZDY0MWExOTQ0NTQ4ZmY4N2M4Mjg0NV8yLTEtMS0xLTIzMDEz_309fb75e-051f-4fdc-a607-88e3054961aa">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80L2ZyYWc6NjFhNDM5YmM5YmUxNDcxZjhlZjhiMGZhZDE0ZDJmZjQvdGFibGU6MDQwYTg2ZDI4ZGQ2NDFhMTk0NDU0OGZmODdjODI4NDUvdGFibGVyYW5nZTowNDBhODZkMjhkZDY0MWExOTQ0NTQ4ZmY4N2M4Mjg0NV8zLTEtMS0xLTIzMDEz_9aa300f2-fea0-414a-a2c0-44161e5a703c">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80L2ZyYWc6NjFhNDM5YmM5YmUxNDcxZjhlZjhiMGZhZDE0ZDJmZjQvdGFibGU6MDQwYTg2ZDI4ZGQ2NDFhMTk0NDU0OGZmODdjODI4NDUvdGFibGVyYW5nZTowNDBhODZkMjhkZDY0MWExOTQ0NTQ4ZmY4N2M4Mjg0NV80LTEtMS0xLTIzMDEz_0c7bdf14-92fc-4b54-ac4f-33519db37366">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xL2ZyYWc6MGFkODRlZTU5Y2VjNDAyMmIyNTAzYWE1MjgwMDY5ZmUvdGV4dHJlZ2lvbjowYWQ4NGVlNTljZWM0MDIyYjI1MDNhYTUyODAwNjlmZV8yMTE5_93610474-1e6f-4616-a84e-0b033aac47f6">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xL2ZyYWc6MGFkODRlZTU5Y2VjNDAyMmIyNTAzYWE1MjgwMDY5ZmUvdGFibGU6YWFlOGM4Mzg5YmZmNGRhMTk2NmI5OWZlNWE4MzA4NzEvdGFibGVyYW5nZTphYWU4YzgzODliZmY0ZGExOTY2Yjk5ZmU1YTgzMDg3MV8wLTAtMS0xLTIzMDEz_ba3abc99-357a-42a8-9b87-eae65e3c4c61">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xL2ZyYWc6MGFkODRlZTU5Y2VjNDAyMmIyNTAzYWE1MjgwMDY5ZmUvdGV4dHJlZ2lvbjowYWQ4NGVlNTljZWM0MDIyYjI1MDNhYTUyODAwNjlmZV8zMjk4NTM0ODg1NTAx_44028974-3aff-4952-8ae2-364b218f7da4">2022-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xL2ZyYWc6MGFkODRlZTU5Y2VjNDAyMmIyNTAzYWE1MjgwMDY5ZmUvdGFibGU6NGUyOGI0ZGJkNTE4NDE0ZjgyNmEzMmZjYzI5NDM0NWUvdGFibGVyYW5nZTo0ZTI4YjRkYmQ1MTg0MTRmODI2YTMyZmNjMjk0MzQ1ZV8wLTAtMS0xLTIzMDEz_81229009-1908-4fb8-88db-156572b9b1dd">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xL2ZyYWc6MGFkODRlZTU5Y2VjNDAyMmIyNTAzYWE1MjgwMDY5ZmUvdGV4dHJlZ2lvbjowYWQ4NGVlNTljZWM0MDIyYjI1MDNhYTUyODAwNjlmZV8yMTI0_574c9249-c6c6-4d51-a953-ff46494ff5bc">001-36485</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xL2ZyYWc6MGFkODRlZTU5Y2VjNDAyMmIyNTAzYWE1MjgwMDY5ZmUvdGV4dHJlZ2lvbjowYWQ4NGVlNTljZWM0MDIyYjI1MDNhYTUyODAwNjlmZV8yMTIw_c7a0322e-db9f-4749-8545-ceb2b81516ee">ARDELYX,&#160;INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xL2ZyYWc6MGFkODRlZTU5Y2VjNDAyMmIyNTAzYWE1MjgwMDY5ZmUvdGFibGU6YmZmY2NlMmU0YWU4NDVkZmFiNWFmZDMzMWMyZWYxOTYvdGFibGVyYW5nZTpiZmZjY2UyZTRhZTg0NWRmYWI1YWZkMzMxYzJlZjE5Nl8wLTAtMS0xLTIzMDEz_f1d65461-20fa-4cdd-8514-35cd4437d868">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xL2ZyYWc6MGFkODRlZTU5Y2VjNDAyMmIyNTAzYWE1MjgwMDY5ZmUvdGFibGU6YmZmY2NlMmU0YWU4NDVkZmFiNWFmZDMzMWMyZWYxOTYvdGFibGVyYW5nZTpiZmZjY2UyZTRhZTg0NWRmYWI1YWZkMzMxYzJlZjE5Nl8wLTEtMS0xLTIzMDEz_80f9d0a0-e00a-4d0f-9edd-fc947d6646fb">26-1303944</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xL2ZyYWc6MGFkODRlZTU5Y2VjNDAyMmIyNTAzYWE1MjgwMDY5ZmUvdGV4dHJlZ2lvbjowYWQ4NGVlNTljZWM0MDIyYjI1MDNhYTUyODAwNjlmZV8yMTEw_a39d659a-c706-4d12-9484-727422d42482">400 Fifth Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xL2ZyYWc6MGFkODRlZTU5Y2VjNDAyMmIyNTAzYWE1MjgwMDY5ZmUvdGV4dHJlZ2lvbjowYWQ4NGVlNTljZWM0MDIyYjI1MDNhYTUyODAwNjlmZV8yMTEz_a7546226-ded2-4323-8c24-477fb4985871">Suite 210</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xL2ZyYWc6MGFkODRlZTU5Y2VjNDAyMmIyNTAzYWE1MjgwMDY5ZmUvdGV4dHJlZ2lvbjowYWQ4NGVlNTljZWM0MDIyYjI1MDNhYTUyODAwNjlmZV8yMTEx_f20e96b9-915f-4b02-b39f-2d7db11ad575">Waltham</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xL2ZyYWc6MGFkODRlZTU5Y2VjNDAyMmIyNTAzYWE1MjgwMDY5ZmUvdGV4dHJlZ2lvbjowYWQ4NGVlNTljZWM0MDIyYjI1MDNhYTUyODAwNjlmZV8yMTIy_2762ca9e-c086-4c19-b98a-20c8214fefb0">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xL2ZyYWc6MGFkODRlZTU5Y2VjNDAyMmIyNTAzYWE1MjgwMDY5ZmUvdGV4dHJlZ2lvbjowYWQ4NGVlNTljZWM0MDIyYjI1MDNhYTUyODAwNjlmZV8yMTE0_9738ddc9-db61-442a-abc0-3a87b6fe1535">02451</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xL2ZyYWc6MGFkODRlZTU5Y2VjNDAyMmIyNTAzYWE1MjgwMDY5ZmUvdGV4dHJlZ2lvbjowYWQ4NGVlNTljZWM0MDIyYjI1MDNhYTUyODAwNjlmZV8yMTIz_1a43ae9f-b969-483e-b0fa-62a91e4d8059">510</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xL2ZyYWc6MGFkODRlZTU5Y2VjNDAyMmIyNTAzYWE1MjgwMDY5ZmUvdGV4dHJlZ2lvbjowYWQ4NGVlNTljZWM0MDIyYjI1MDNhYTUyODAwNjlmZV8yMTI2_13cf20ae-5fa1-4263-89ef-1808b2d6c3ba">745-1700</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xL2ZyYWc6MGFkODRlZTU5Y2VjNDAyMmIyNTAzYWE1MjgwMDY5ZmUvdGFibGU6ZTk1OGJlM2M5MTEzNDhmYTk5MTZiZWFlZDhlOGE2MTUvdGFibGVyYW5nZTplOTU4YmUzYzkxMTM0OGZhOTkxNmJlYWVkOGU4YTYxNV8xLTAtMS0xLTIzMDEz_1583c2d2-7883-40d0-b147-8f9b28439fac">Common Stock, par value $0.0001</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xL2ZyYWc6MGFkODRlZTU5Y2VjNDAyMmIyNTAzYWE1MjgwMDY5ZmUvdGFibGU6ZTk1OGJlM2M5MTEzNDhmYTk5MTZiZWFlZDhlOGE2MTUvdGFibGVyYW5nZTplOTU4YmUzYzkxMTM0OGZhOTkxNmJlYWVkOGU4YTYxNV8xLTItMS0xLTIzMDEz_bae6bc63-886e-4c93-9a14-a30574cdca17">ARDX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xL2ZyYWc6MGFkODRlZTU5Y2VjNDAyMmIyNTAzYWE1MjgwMDY5ZmUvdGFibGU6ZTk1OGJlM2M5MTEzNDhmYTk5MTZiZWFlZDhlOGE2MTUvdGFibGVyYW5nZTplOTU4YmUzYzkxMTM0OGZhOTkxNmJlYWVkOGU4YTYxNV8xLTQtMS0xLTIzMDEz_e0e92e9d-d8eb-4070-96e6-5f3ab2704bea">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xL2ZyYWc6MGFkODRlZTU5Y2VjNDAyMmIyNTAzYWE1MjgwMDY5ZmUvdGV4dHJlZ2lvbjowYWQ4NGVlNTljZWM0MDIyYjI1MDNhYTUyODAwNjlmZV8yMTEy_6b9e1be1-cb37-4844-a01f-4489506d63e5">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xL2ZyYWc6MGFkODRlZTU5Y2VjNDAyMmIyNTAzYWE1MjgwMDY5ZmUvdGV4dHJlZ2lvbjowYWQ4NGVlNTljZWM0MDIyYjI1MDNhYTUyODAwNjlmZV8yMTI3_a6a2d3cd-cb23-440d-a176-d8d984ded9ad">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xL2ZyYWc6MGFkODRlZTU5Y2VjNDAyMmIyNTAzYWE1MjgwMDY5ZmUvdGFibGU6NzEyM2VmZWQzZTQ3NGEyYWFlOWQ1M2FlMWY0ODQ2NTUvdGFibGVyYW5nZTo3MTIzZWZlZDNlNDc0YTJhYWU5ZDUzYWUxZjQ4NDY1NV8wLTEtMS0xLTMxMzYz_2593128b-67bf-4152-8af9-a1c3de96cfb8">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xL2ZyYWc6MGFkODRlZTU5Y2VjNDAyMmIyNTAzYWE1MjgwMDY5ZmUvdGFibGU6NzEyM2VmZWQzZTQ3NGEyYWFlOWQ1M2FlMWY0ODQ2NTUvdGFibGVyYW5nZTo3MTIzZWZlZDNlNDc0YTJhYWU5ZDUzYWUxZjQ4NDY1NV8yLTUtMS0xLTIzMDEz_df0e593c-1cff-4687-9039-d0c84f9b7156">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xL2ZyYWc6MGFkODRlZTU5Y2VjNDAyMmIyNTAzYWE1MjgwMDY5ZmUvdGFibGU6NzEyM2VmZWQzZTQ3NGEyYWFlOWQ1M2FlMWY0ODQ2NTUvdGFibGVyYW5nZTo3MTIzZWZlZDNlNDc0YTJhYWU5ZDUzYWUxZjQ4NDY1NV80LTUtMS0xLTIzMDEz_77a476c7-0951-49bf-bd56-db908eb4267a">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xL2ZyYWc6MGFkODRlZTU5Y2VjNDAyMmIyNTAzYWE1MjgwMDY5ZmUvdGV4dHJlZ2lvbjowYWQ4NGVlNTljZWM0MDIyYjI1MDNhYTUyODAwNjlmZV8yMTI4_14b0979c-66d5-4bb7-aa5c-843503a8295c">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i50bec6a618074ef79a40cbc0e7e8aa89_I20220502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xL2ZyYWc6MGFkODRlZTU5Y2VjNDAyMmIyNTAzYWE1MjgwMDY5ZmUvdGV4dHJlZ2lvbjowYWQ4NGVlNTljZWM0MDIyYjI1MDNhYTUyODAwNjlmZV8xNjQ5MjY3NDQzODAz_2140d969-1ab3-4a24-9aee-094a1b0f802a"
      unitRef="shares">144598863</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfNC0xLTEtMS0yMzAxMw_7607cbb1-c3b5-4748-aa57-bc266f4b2f73"
      unitRef="usd">47077000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfNC0zLTEtMS0yMzAxMw_94ad2682-ab98-4ca0-aada-217adc3c0514"
      unitRef="usd">72428000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfNS0xLTEtMS0yMzAxMw_606c045f-4b83-44a9-8aba-aed23c0f934e"
      unitRef="usd">42627000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfNS0zLTEtMS0yMzAxMw_05886ef9-110b-45b2-b080-9602f4f7fb68"
      unitRef="usd">44261000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfNi0xLTEtMS0yOTM3NQ_4428160f-57b8-443c-aae8-3b686c7b5580"
      unitRef="usd">4394000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfNi0zLTEtMS0yOTM3NQ_fe26292f-a612-47e8-acbc-1b347401ee11"
      unitRef="usd">502000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfNi0xLTEtMS0yODU1Mg_04ec8afa-0284-444c-a1f6-82c8332891c6"
      unitRef="usd">3487000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfNi0zLTEtMS0yODU1Mg_ba1c72a4-d279-42ec-888b-96079fc3e912"
      unitRef="usd">0</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfNy0xLTEtMS0yMzAxMw_5ebbf0df-0576-4f0d-bf49-5129cc1ecbb3"
      unitRef="usd">16640000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfNy0zLTEtMS0yMzAxMw_1ec19f8c-d407-4fda-84b8-3c1c00eb1153"
      unitRef="usd">16458000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfOC0xLTEtMS0yMzAxMw_3630c222-c007-49d0-a962-5e9cc169df99"
      unitRef="usd">114225000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfOC0zLTEtMS0yMzAxMw_c9577e46-978d-4081-862c-65c9b7aba726"
      unitRef="usd">133649000</us-gaap:AssetsCurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMTAtMS0xLTEtMjkzODM_9384a397-8161-4a79-a9a5-7ff99cb0d004"
      unitRef="usd">11910000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMTAtMy0xLTEtMjkzODM_8f20a5a0-5c65-451c-b778-1f09a2cd8fa0"
      unitRef="usd">12752000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfOS0xLTEtMS0yMzAxMw_46514656-2425-4a0e-90e4-169766c5a5a5"
      unitRef="usd">2045000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfOS0zLTEtMS0yMzAxMw_b66219fb-fa04-4d3c-9b87-5f747843dc46"
      unitRef="usd">2362000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMTItMS0xLTEtMjMwMTM_0085053e-801a-4f40-a68c-5f5c0e8cebcc"
      unitRef="usd">1228000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMTItMy0xLTEtMjMwMTM_3f917f74-29d2-4ea2-bb81-4829eb0a9ace"
      unitRef="usd">1150000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMTMtMS0xLTEtMjMwMTM_28a707be-127e-48ab-8e84-d77c5c930384"
      unitRef="usd">129408000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMTMtMy0xLTEtMjMwMTM_5db68291-f6f2-41b7-ab8f-e39b99f0be02"
      unitRef="usd">149913000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMTYtMS0xLTEtMjMwMTM_8a4dc68e-c4cc-4ed4-a009-a95e00b7ea05"
      unitRef="usd">5030000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMTYtMy0xLTEtMjMwMTM_efa1f330-51a6-44ff-9829-6928ac151fb0"
      unitRef="usd">4277000</us-gaap:AccountsPayableCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMTctMS0xLTEtMjMwMTM_94b9c537-95dc-4a62-8d6e-c11be1620aac"
      unitRef="usd">6304000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMTctMy0xLTEtMjMwMTM_d665e878-0dd2-4e10-a4ac-70be70ab51da"
      unitRef="usd">5422000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMTktMS0xLTEtMjk0MDA_5c7afd77-ac09-43a3-bcf3-9f053466ec38"
      unitRef="usd">26139000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMTktMy0xLTEtMjk0MDA_7df6abc2-77c6-451b-8031-c4b48e5c3e71"
      unitRef="usd">32264000</us-gaap:LongTermDebtCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMTgtMS0xLTEtMjMwMTM_0281b023-7a36-4f59-9b65-bf46be2fb573"
      unitRef="usd">3592000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMTgtMy0xLTEtMjMwMTM_f18ffffd-9eb9-4d1a-b672-02b8028163f5"
      unitRef="usd">3492000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMjEtMS0xLTEtMjMwMTM_a6cef91d-4e31-4191-bd56-f9242adefb18"
      unitRef="usd">6778000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMjEtMy0xLTEtMjMwMTM_9ab855a4-1028-4c46-a5df-7a9a15c47632"
      unitRef="usd">7366000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:LiabilitiesCurrent
      contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMjItMS0xLTEtMjMwMTM_916e0ae1-2858-474d-8dcb-46699c8fc443"
      unitRef="usd">47843000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMjItMy0xLTEtMjMwMTM_44724399-9d2d-4a9e-a319-7eaee02e4384"
      unitRef="usd">52821000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMjMtMS0xLTEtMjMwMTM_18aae981-e795-4ca3-8b90-644e055adf87"
      unitRef="usd">8812000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMjMtMy0xLTEtMjMwMTM_aadc26ac-61c2-4abc-adb2-a76b3775d656"
      unitRef="usd">9748000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMjUtMS0xLTEtMjMwMTM_da2d4c5a-23ca-45ff-aa9b-f0dd1d6ecaed"
      unitRef="usd">8563000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMjUtMy0xLTEtMjMwMTM_d31fde8b-3d35-46c6-b737-01cd11ca488a"
      unitRef="usd">4727000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMjYtMS0xLTEtMjMwMTM_c675edff-745c-4fb3-a0bc-c05ab2deabb0"
      unitRef="usd">65218000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMjYtMy0xLTEtMjMwMTM_8906667a-958a-4813-a201-22331bac934a"
      unitRef="usd">67296000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMjctMS0xLTEtMjMwMTM_2c6d2c06-14ac-4cc2-be5b-ffa317690d28"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMjctMy0xLTEtMjMwMTM_fa89fd53-c60d-4316-bdd7-52e0d7c6fdf9"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMjktMC0xLTEtMjMwMTMvdGV4dHJlZ2lvbjpjZDY5ZWJiOTM4NDk0NzA4OTU3ODZlN2RkZmYzMzUyM18xNjQ5MjY3NDQxODMz_d3c82f83-6d6c-47ff-be4b-28b8272aea1a"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMjktMC0xLTEtMjMwMTMvdGV4dHJlZ2lvbjpjZDY5ZWJiOTM4NDk0NzA4OTU3ODZlN2RkZmYzMzUyM18xNjQ5MjY3NDQxODMz_db165772-d2d1-4211-ad89-2a403a89fa5d"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMjktMC0xLTEtMjMwMTMvdGV4dHJlZ2lvbjpjZDY5ZWJiOTM4NDk0NzA4OTU3ODZlN2RkZmYzMzUyM18xNjQ5MjY3NDQxODQ1_0a868e6a-2304-4ff3-bff4-6ac8c79ed33f"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMjktMC0xLTEtMjMwMTMvdGV4dHJlZ2lvbjpjZDY5ZWJiOTM4NDk0NzA4OTU3ODZlN2RkZmYzMzUyM18xNjQ5MjY3NDQxODQ1_fb4e8233-e9be-4596-8f67-657f4b5c6f63"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMjktMC0xLTEtMjMwMTMvdGV4dHJlZ2lvbjpjZDY5ZWJiOTM4NDk0NzA4OTU3ODZlN2RkZmYzMzUyM18xNjQ5MjY3NDQxODUw_1bb4e6bd-04de-44c1-a5ef-88aab3d95be5"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMjktMC0xLTEtMjMwMTMvdGV4dHJlZ2lvbjpjZDY5ZWJiOTM4NDk0NzA4OTU3ODZlN2RkZmYzMzUyM18xNjQ5MjY3NDQxODUw_894199cf-c917-41e7-aa78-bb0438e45fcf"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMjktMC0xLTEtMjMwMTMvdGV4dHJlZ2lvbjpjZDY5ZWJiOTM4NDk0NzA4OTU3ODZlN2RkZmYzMzUyM18xNjQ5MjY3NDQxODUw_cd953609-8559-4dd7-999a-5310550f9e7d"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMjktMC0xLTEtMjMwMTMvdGV4dHJlZ2lvbjpjZDY5ZWJiOTM4NDk0NzA4OTU3ODZlN2RkZmYzMzUyM18xNjQ5MjY3NDQxODUw_ece7b736-487f-4a0a-b9f3-6cb202761679"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMjktMS0xLTEtMjMwMTM_e9a0f120-605b-4c59-815c-fdd003bf21f1"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMjktMy0xLTEtMjMwMTM_14471c8f-c331-452f-a563-0ac9a5d521b2"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMzAtMC0xLTEtMjMwMTMvdGV4dHJlZ2lvbjo4NmY3MWU2Y2I2YmM0YWYwODU3ZThhZmQ4M2Y1MjMzZV8xNjQ5MjY3NDQxODk1_25b70c6e-79c0-4910-b98a-d9adb14e038d"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMzAtMC0xLTEtMjMwMTMvdGV4dHJlZ2lvbjo4NmY3MWU2Y2I2YmM0YWYwODU3ZThhZmQ4M2Y1MjMzZV8xNjQ5MjY3NDQxODk1_497f6519-68e6-4e8e-b764-e0b191e88aca"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMzAtMC0xLTEtMjMwMTMvdGV4dHJlZ2lvbjo4NmY3MWU2Y2I2YmM0YWYwODU3ZThhZmQ4M2Y1MjMzZV8xNjQ5MjY3NDQxOTA5_3afdb57d-ca8e-417d-a083-a62ea669a308"
      unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMzAtMC0xLTEtMjMwMTMvdGV4dHJlZ2lvbjo4NmY3MWU2Y2I2YmM0YWYwODU3ZThhZmQ4M2Y1MjMzZV8xNjQ5MjY3NDQxOTA5_44abd411-f592-44b9-81ad-57a68a71b88c"
      unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMzAtMC0xLTEtMjMwMTMvdGV4dHJlZ2lvbjo4NmY3MWU2Y2I2YmM0YWYwODU3ZThhZmQ4M2Y1MjMzZV8xNjQ5MjY3NDQxOTIy_30b5579c-df45-4365-b24f-5c5e4ebc928b"
      unitRef="shares">136330360</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMzAtMC0xLTEtMjMwMTMvdGV4dHJlZ2lvbjo4NmY3MWU2Y2I2YmM0YWYwODU3ZThhZmQ4M2Y1MjMzZV8xNjQ5MjY3NDQxOTIy_7ee6674d-84fa-421a-90d7-3d8d7f36dc43"
      unitRef="shares">136330360</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMzAtMC0xLTEtMjMwMTMvdGV4dHJlZ2lvbjo4NmY3MWU2Y2I2YmM0YWYwODU3ZThhZmQ4M2Y1MjMzZV8xNjQ5MjY3NDQxOTM1_479050f6-74c8-49f4-adf7-7464ca726ae0"
      unitRef="shares">130182535</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMzAtMC0xLTEtMjMwMTMvdGV4dHJlZ2lvbjo4NmY3MWU2Y2I2YmM0YWYwODU3ZThhZmQ4M2Y1MjMzZV8xNjQ5MjY3NDQxOTM1_479ad88f-d423-4913-904e-bf7d4ec810f9"
      unitRef="shares">130182535</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMzAtMS0xLTEtMjMwMTM_04de366e-7b1a-48dc-a050-6f798cf0e38b"
      unitRef="usd">14000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMzAtMy0xLTEtMjMwMTM_f8a30f6d-06af-4ad6-b875-7cb2b79dc948"
      unitRef="usd">13000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMzEtMS0xLTEtMjMwMTM_26407be7-a57e-4b9b-8ce7-4419f4bb2f12"
      unitRef="usd">805265000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMzEtMy0xLTEtMjMwMTM_40a51455-3f33-4d57-a540-0212e06195c6"
      unitRef="usd">795540000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMzItMS0xLTEtMjMwMTM_a8884574-791f-4deb-b72a-463be5ca1e67"
      unitRef="usd">-741001000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMzItMy0xLTEtMjMwMTM_12139be5-5742-4c7a-8761-1d9fe8e4d22f"
      unitRef="usd">-712930000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMzMtMS0xLTEtMjMwMTM_970274b6-59bc-4890-9464-6185519e3bbc"
      unitRef="usd">-88000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMzMtMy0xLTEtMjMwMTM_ce73280c-e5b5-46df-99bc-c29e1b580aaa"
      unitRef="usd">-6000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMzQtMS0xLTEtMjMwMTM_fd7171da-80b7-47bf-a769-5fd56c8791af"
      unitRef="usd">64190000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMzQtMy0xLTEtMjMwMTM_f063b1c5-2e17-4100-84c8-f029f3ad6355"
      unitRef="usd">82617000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMzUtMS0xLTEtMjMwMTM_b007e3bc-2778-40f1-a99a-71c004c43f78"
      unitRef="usd">129408000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xNi9mcmFnOjBkNjlkYjExZGRmMDRhMDdiNzJmZGZjZDQwMjNjYjYwL3RhYmxlOjZjNGYxNTE1NDg2NjRhOWY4ZGMyZTk4NmUxNjhmNzMwL3RhYmxlcmFuZ2U6NmM0ZjE1MTU0ODY2NGE5ZjhkYzJlOTg2ZTE2OGY3MzBfMzUtMy0xLTEtMjMwMTM_cf4d5076-78c5-4fb3-bb8c-704c0a732879"
      unitRef="usd">149913000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i97ef8572b6ce41c09c8f695ae8a0ca00_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xOS9mcmFnOjMwZmI4OGM5N2Y4YjQ2NjdhNWY0ZjBmOTQzZjIzZjIwL3RhYmxlOmQ5ZDA5NDIxYTE1ZTRiMTc5MDRkMmNiY2NmMzEwNjU3L3RhYmxlcmFuZ2U6ZDlkMDk0MjFhMTVlNGIxNzkwNGQyY2JjY2YzMTA2NTdfMy0xLTEtMS0yODYwOQ_02408698-bd6c-4d03-bcbc-1c66e5f50028"
      unitRef="usd">450000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5783cc7426ba453f96f1e7e0af87b0a6_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xOS9mcmFnOjMwZmI4OGM5N2Y4YjQ2NjdhNWY0ZjBmOTQzZjIzZjIwL3RhYmxlOmQ5ZDA5NDIxYTE1ZTRiMTc5MDRkMmNiY2NmMzEwNjU3L3RhYmxlcmFuZ2U6ZDlkMDk0MjFhMTVlNGIxNzkwNGQyY2JjY2YzMTA2NTdfMy0zLTEtMS0yODYzNg_c7da04ff-ae62-44d5-8cdf-e017e7061f36"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id194cfe3452f4c7c84f5dfd4fe7d8297_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xOS9mcmFnOjMwZmI4OGM5N2Y4YjQ2NjdhNWY0ZjBmOTQzZjIzZjIwL3RhYmxlOmQ5ZDA5NDIxYTE1ZTRiMTc5MDRkMmNiY2NmMzEwNjU3L3RhYmxlcmFuZ2U6ZDlkMDk0MjFhMTVlNGIxNzkwNGQyY2JjY2YzMTA2NTdfNC0xLTEtMS0zMzI2Nw_1ecf1067-7e87-42e8-b493-cdf0659598ee"
      unitRef="usd">14000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9f8aa7556d7647dd80cd79f50b30d12a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xOS9mcmFnOjMwZmI4OGM5N2Y4YjQ2NjdhNWY0ZjBmOTQzZjIzZjIwL3RhYmxlOmQ5ZDA5NDIxYTE1ZTRiMTc5MDRkMmNiY2NmMzEwNjU3L3RhYmxlcmFuZ2U6ZDlkMDk0MjFhMTVlNGIxNzkwNGQyY2JjY2YzMTA2NTdfNC0zLTEtMS0zMzI2Nw_c2a134c4-0c51-4041-bfa5-12ed5761fb3d"
      unitRef="usd">126000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4c8fadcb7a584b6b81773ef6f2440734_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xOS9mcmFnOjMwZmI4OGM5N2Y4YjQ2NjdhNWY0ZjBmOTQzZjIzZjIwL3RhYmxlOmQ5ZDA5NDIxYTE1ZTRiMTc5MDRkMmNiY2NmMzEwNjU3L3RhYmxlcmFuZ2U6ZDlkMDk0MjFhMTVlNGIxNzkwNGQyY2JjY2YzMTA2NTdfNC0xLTEtMS0zMTMzMw_928c2cba-82ca-4d65-9d82-2e97e78bf14f"
      unitRef="usd">4000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i77926c7e42f94727854dd2729e419202_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xOS9mcmFnOjMwZmI4OGM5N2Y4YjQ2NjdhNWY0ZjBmOTQzZjIzZjIwL3RhYmxlOmQ5ZDA5NDIxYTE1ZTRiMTc5MDRkMmNiY2NmMzEwNjU3L3RhYmxlcmFuZ2U6ZDlkMDk0MjFhMTVlNGIxNzkwNGQyY2JjY2YzMTA2NTdfNC0zLTEtMS0zMTMzMw_42ffc98b-7354-47b6-a5c4-1108c9a43d83"
      unitRef="usd">5002000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i785dbb6e8a754de6a7aa8b0b43cd5de4_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xOS9mcmFnOjMwZmI4OGM5N2Y4YjQ2NjdhNWY0ZjBmOTQzZjIzZjIwL3RhYmxlOmQ5ZDA5NDIxYTE1ZTRiMTc5MDRkMmNiY2NmMzEwNjU3L3RhYmxlcmFuZ2U6ZDlkMDk0MjFhMTVlNGIxNzkwNGQyY2JjY2YzMTA2NTdfMy0xLTEtMS0yMzAxMw_6973329d-8fa2-4866-9ad6-187efee62bb9"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id6b9396538454def9c8a29399c6b8d03_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xOS9mcmFnOjMwZmI4OGM5N2Y4YjQ2NjdhNWY0ZjBmOTQzZjIzZjIwL3RhYmxlOmQ5ZDA5NDIxYTE1ZTRiMTc5MDRkMmNiY2NmMzEwNjU3L3RhYmxlcmFuZ2U6ZDlkMDk0MjFhMTVlNGIxNzkwNGQyY2JjY2YzMTA2NTdfMy0zLTEtMS0yMzAxMw_0eb2a28b-868f-46dc-8ffe-ddf4ae89c884"
      unitRef="usd">1454000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xOS9mcmFnOjMwZmI4OGM5N2Y4YjQ2NjdhNWY0ZjBmOTQzZjIzZjIwL3RhYmxlOmQ5ZDA5NDIxYTE1ZTRiMTc5MDRkMmNiY2NmMzEwNjU3L3RhYmxlcmFuZ2U6ZDlkMDk0MjFhMTVlNGIxNzkwNGQyY2JjY2YzMTA2NTdfNi0xLTEtMS0yMzAxMw_8a6623c4-5302-4cb8-a060-782ba73880e5"
      unitRef="usd">468000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xOS9mcmFnOjMwZmI4OGM5N2Y4YjQ2NjdhNWY0ZjBmOTQzZjIzZjIwL3RhYmxlOmQ5ZDA5NDIxYTE1ZTRiMTc5MDRkMmNiY2NmMzEwNjU3L3RhYmxlcmFuZ2U6ZDlkMDk0MjFhMTVlNGIxNzkwNGQyY2JjY2YzMTA2NTdfNi0zLTEtMS0yMzAxMw_995b16a1-0971-47f8-8018-58a59b021f75"
      unitRef="usd">6582000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfRevenue
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xOS9mcmFnOjMwZmI4OGM5N2Y4YjQ2NjdhNWY0ZjBmOTQzZjIzZjIwL3RhYmxlOmQ5ZDA5NDIxYTE1ZTRiMTc5MDRkMmNiY2NmMzEwNjU3L3RhYmxlcmFuZ2U6ZDlkMDk0MjFhMTVlNGIxNzkwNGQyY2JjY2YzMTA2NTdfOC0xLTEtMS0yMzAxMw_c23f0594-888b-4596-a00a-ecc731277a6a"
      unitRef="usd">85000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xOS9mcmFnOjMwZmI4OGM5N2Y4YjQ2NjdhNWY0ZjBmOTQzZjIzZjIwL3RhYmxlOmQ5ZDA5NDIxYTE1ZTRiMTc5MDRkMmNiY2NmMzEwNjU3L3RhYmxlcmFuZ2U6ZDlkMDk0MjFhMTVlNGIxNzkwNGQyY2JjY2YzMTA2NTdfOC0zLTEtMS0yMzAxMw_de52b778-802e-4964-b49e-4bcd2829c2d0"
      unitRef="usd">1000000</us-gaap:CostOfRevenue>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xOS9mcmFnOjMwZmI4OGM5N2Y4YjQ2NjdhNWY0ZjBmOTQzZjIzZjIwL3RhYmxlOmQ5ZDA5NDIxYTE1ZTRiMTc5MDRkMmNiY2NmMzEwNjU3L3RhYmxlcmFuZ2U6ZDlkMDk0MjFhMTVlNGIxNzkwNGQyY2JjY2YzMTA2NTdfOS0xLTEtMS0yMzAxMw_cc0cc213-b981-4865-8165-badf7cee5694"
      unitRef="usd">8851000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xOS9mcmFnOjMwZmI4OGM5N2Y4YjQ2NjdhNWY0ZjBmOTQzZjIzZjIwL3RhYmxlOmQ5ZDA5NDIxYTE1ZTRiMTc5MDRkMmNiY2NmMzEwNjU3L3RhYmxlcmFuZ2U6ZDlkMDk0MjFhMTVlNGIxNzkwNGQyY2JjY2YzMTA2NTdfOS0zLTEtMS0yMzAxMw_f50d62c4-ef35-4233-b5a9-3660128e696c"
      unitRef="usd">20456000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xOS9mcmFnOjMwZmI4OGM5N2Y4YjQ2NjdhNWY0ZjBmOTQzZjIzZjIwL3RhYmxlOmQ5ZDA5NDIxYTE1ZTRiMTc5MDRkMmNiY2NmMzEwNjU3L3RhYmxlcmFuZ2U6ZDlkMDk0MjFhMTVlNGIxNzkwNGQyY2JjY2YzMTA2NTdfMTAtMS0xLTEtMjMwMTM_55f08733-300c-4c22-9269-ea626b68ae3a"
      unitRef="usd">19339000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xOS9mcmFnOjMwZmI4OGM5N2Y4YjQ2NjdhNWY0ZjBmOTQzZjIzZjIwL3RhYmxlOmQ5ZDA5NDIxYTE1ZTRiMTc5MDRkMmNiY2NmMzEwNjU3L3RhYmxlcmFuZ2U6ZDlkMDk0MjFhMTVlNGIxNzkwNGQyY2JjY2YzMTA2NTdfMTAtMy0xLTEtMjMwMTM_fad38914-67c1-4b11-847f-61ab154aac39"
      unitRef="usd">17131000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xOS9mcmFnOjMwZmI4OGM5N2Y4YjQ2NjdhNWY0ZjBmOTQzZjIzZjIwL3RhYmxlOmQ5ZDA5NDIxYTE1ZTRiMTc5MDRkMmNiY2NmMzEwNjU3L3RhYmxlcmFuZ2U6ZDlkMDk0MjFhMTVlNGIxNzkwNGQyY2JjY2YzMTA2NTdfMTEtMS0xLTEtMjMwMTM_6065a14a-eaa6-462a-a1b4-8f52588904ae"
      unitRef="usd">28275000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xOS9mcmFnOjMwZmI4OGM5N2Y4YjQ2NjdhNWY0ZjBmOTQzZjIzZjIwL3RhYmxlOmQ5ZDA5NDIxYTE1ZTRiMTc5MDRkMmNiY2NmMzEwNjU3L3RhYmxlcmFuZ2U6ZDlkMDk0MjFhMTVlNGIxNzkwNGQyY2JjY2YzMTA2NTdfMTEtMy0xLTEtMjMwMTM_9a7ad62c-cacf-462b-a077-ef05b5d8fc77"
      unitRef="usd">38587000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xOS9mcmFnOjMwZmI4OGM5N2Y4YjQ2NjdhNWY0ZjBmOTQzZjIzZjIwL3RhYmxlOmQ5ZDA5NDIxYTE1ZTRiMTc5MDRkMmNiY2NmMzEwNjU3L3RhYmxlcmFuZ2U6ZDlkMDk0MjFhMTVlNGIxNzkwNGQyY2JjY2YzMTA2NTdfMTItMS0xLTEtMjMwMTM_9c677357-894a-4e6b-9067-1bd8aef6c1cb"
      unitRef="usd">-27807000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xOS9mcmFnOjMwZmI4OGM5N2Y4YjQ2NjdhNWY0ZjBmOTQzZjIzZjIwL3RhYmxlOmQ5ZDA5NDIxYTE1ZTRiMTc5MDRkMmNiY2NmMzEwNjU3L3RhYmxlcmFuZ2U6ZDlkMDk0MjFhMTVlNGIxNzkwNGQyY2JjY2YzMTA2NTdfMTItMy0xLTEtMjMwMTM_2374706a-7395-4f33-ab05-9f7a6f21fda4"
      unitRef="usd">-32005000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xOS9mcmFnOjMwZmI4OGM5N2Y4YjQ2NjdhNWY0ZjBmOTQzZjIzZjIwL3RhYmxlOmQ5ZDA5NDIxYTE1ZTRiMTc5MDRkMmNiY2NmMzEwNjU3L3RhYmxlcmFuZ2U6ZDlkMDk0MjFhMTVlNGIxNzkwNGQyY2JjY2YzMTA2NTdfMTMtMS0xLTEtMjMwMTM_19ea4e44-bdb6-47a8-8b40-40e9295d09c6"
      unitRef="usd">746000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xOS9mcmFnOjMwZmI4OGM5N2Y4YjQ2NjdhNWY0ZjBmOTQzZjIzZjIwL3RhYmxlOmQ5ZDA5NDIxYTE1ZTRiMTc5MDRkMmNiY2NmMzEwNjU3L3RhYmxlcmFuZ2U6ZDlkMDk0MjFhMTVlNGIxNzkwNGQyY2JjY2YzMTA2NTdfMTMtMy0xLTEtMjMwMTM_89c1e76d-ea91-4f64-86a1-01a11f0338ce"
      unitRef="usd">1100000</us-gaap:InterestExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xOS9mcmFnOjMwZmI4OGM5N2Y4YjQ2NjdhNWY0ZjBmOTQzZjIzZjIwL3RhYmxlOmQ5ZDA5NDIxYTE1ZTRiMTc5MDRkMmNiY2NmMzEwNjU3L3RhYmxlcmFuZ2U6ZDlkMDk0MjFhMTVlNGIxNzkwNGQyY2JjY2YzMTA2NTdfMTQtMS0xLTEtMjMwMTM_a37b9ed2-d2be-45bc-b2c4-865515ed3d67"
      unitRef="usd">484000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xOS9mcmFnOjMwZmI4OGM5N2Y4YjQ2NjdhNWY0ZjBmOTQzZjIzZjIwL3RhYmxlOmQ5ZDA5NDIxYTE1ZTRiMTc5MDRkMmNiY2NmMzEwNjU3L3RhYmxlcmFuZ2U6ZDlkMDk0MjFhMTVlNGIxNzkwNGQyY2JjY2YzMTA2NTdfMTQtMy0xLTEtMjMwMTM_d47a637e-3f16-46a2-83dd-9909da86af81"
      unitRef="usd">-49000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xOS9mcmFnOjMwZmI4OGM5N2Y4YjQ2NjdhNWY0ZjBmOTQzZjIzZjIwL3RhYmxlOmQ5ZDA5NDIxYTE1ZTRiMTc5MDRkMmNiY2NmMzEwNjU3L3RhYmxlcmFuZ2U6ZDlkMDk0MjFhMTVlNGIxNzkwNGQyY2JjY2YzMTA2NTdfMTUtMS0xLTEtMjMwMTM_7a56fd36-e02c-47b7-9605-06462c776fb9"
      unitRef="usd">-28069000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xOS9mcmFnOjMwZmI4OGM5N2Y4YjQ2NjdhNWY0ZjBmOTQzZjIzZjIwL3RhYmxlOmQ5ZDA5NDIxYTE1ZTRiMTc5MDRkMmNiY2NmMzEwNjU3L3RhYmxlcmFuZ2U6ZDlkMDk0MjFhMTVlNGIxNzkwNGQyY2JjY2YzMTA2NTdfMTUtMy0xLTEtMjMwMTM_3d32bf9c-6da6-42b6-b75f-18041248e814"
      unitRef="usd">-33154000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xOS9mcmFnOjMwZmI4OGM5N2Y4YjQ2NjdhNWY0ZjBmOTQzZjIzZjIwL3RhYmxlOmQ5ZDA5NDIxYTE1ZTRiMTc5MDRkMmNiY2NmMzEwNjU3L3RhYmxlcmFuZ2U6ZDlkMDk0MjFhMTVlNGIxNzkwNGQyY2JjY2YzMTA2NTdfMTYtMS0xLTEtMjMwMTM_6195ab97-5461-45c7-9146-f8ff37d5c61d"
      unitRef="usd">2000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xOS9mcmFnOjMwZmI4OGM5N2Y4YjQ2NjdhNWY0ZjBmOTQzZjIzZjIwL3RhYmxlOmQ5ZDA5NDIxYTE1ZTRiMTc5MDRkMmNiY2NmMzEwNjU3L3RhYmxlcmFuZ2U6ZDlkMDk0MjFhMTVlNGIxNzkwNGQyY2JjY2YzMTA2NTdfMTYtMy0xLTEtMjMwMTM_46bc0778-f663-474a-bd75-b1490a30fa7c"
      unitRef="usd">1000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xOS9mcmFnOjMwZmI4OGM5N2Y4YjQ2NjdhNWY0ZjBmOTQzZjIzZjIwL3RhYmxlOmQ5ZDA5NDIxYTE1ZTRiMTc5MDRkMmNiY2NmMzEwNjU3L3RhYmxlcmFuZ2U6ZDlkMDk0MjFhMTVlNGIxNzkwNGQyY2JjY2YzMTA2NTdfMTctMS0xLTEtMjMwMTM_7750d5dc-8bc9-46f1-b4b4-ca4fbacb89b2"
      unitRef="usd">-28071000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xOS9mcmFnOjMwZmI4OGM5N2Y4YjQ2NjdhNWY0ZjBmOTQzZjIzZjIwL3RhYmxlOmQ5ZDA5NDIxYTE1ZTRiMTc5MDRkMmNiY2NmMzEwNjU3L3RhYmxlcmFuZ2U6ZDlkMDk0MjFhMTVlNGIxNzkwNGQyY2JjY2YzMTA2NTdfMTctMy0xLTEtMjMwMTM_501e33b4-45cc-4bd3-aef5-4002bcca0f34"
      unitRef="usd">-33155000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xOS9mcmFnOjMwZmI4OGM5N2Y4YjQ2NjdhNWY0ZjBmOTQzZjIzZjIwL3RhYmxlOmQ5ZDA5NDIxYTE1ZTRiMTc5MDRkMmNiY2NmMzEwNjU3L3RhYmxlcmFuZ2U6ZDlkMDk0MjFhMTVlNGIxNzkwNGQyY2JjY2YzMTA2NTdfMTgtMS0xLTEtMjMwMTM_869cd094-5a59-4ec1-a7a5-3344a42b39d7"
      unitRef="usdPerShare">-0.21</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xOS9mcmFnOjMwZmI4OGM5N2Y4YjQ2NjdhNWY0ZjBmOTQzZjIzZjIwL3RhYmxlOmQ5ZDA5NDIxYTE1ZTRiMTc5MDRkMmNiY2NmMzEwNjU3L3RhYmxlcmFuZ2U6ZDlkMDk0MjFhMTVlNGIxNzkwNGQyY2JjY2YzMTA2NTdfMTgtMS0xLTEtMjMwMTM_d0efa5c6-1eb8-43c5-a899-70d957f9cf4f"
      unitRef="usdPerShare">-0.21</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xOS9mcmFnOjMwZmI4OGM5N2Y4YjQ2NjdhNWY0ZjBmOTQzZjIzZjIwL3RhYmxlOmQ5ZDA5NDIxYTE1ZTRiMTc5MDRkMmNiY2NmMzEwNjU3L3RhYmxlcmFuZ2U6ZDlkMDk0MjFhMTVlNGIxNzkwNGQyY2JjY2YzMTA2NTdfMTgtMy0xLTEtMjMwMTM_d0ed3422-d61f-4927-b837-71c68f89504a"
      unitRef="usdPerShare">-0.34</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xOS9mcmFnOjMwZmI4OGM5N2Y4YjQ2NjdhNWY0ZjBmOTQzZjIzZjIwL3RhYmxlOmQ5ZDA5NDIxYTE1ZTRiMTc5MDRkMmNiY2NmMzEwNjU3L3RhYmxlcmFuZ2U6ZDlkMDk0MjFhMTVlNGIxNzkwNGQyY2JjY2YzMTA2NTdfMTgtMy0xLTEtMjMwMTM_d969aa21-0e36-4c2d-948c-cc6b428ebd4d"
      unitRef="usdPerShare">-0.34</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xOS9mcmFnOjMwZmI4OGM5N2Y4YjQ2NjdhNWY0ZjBmOTQzZjIzZjIwL3RhYmxlOmQ5ZDA5NDIxYTE1ZTRiMTc5MDRkMmNiY2NmMzEwNjU3L3RhYmxlcmFuZ2U6ZDlkMDk0MjFhMTVlNGIxNzkwNGQyY2JjY2YzMTA2NTdfMTktMS0xLTEtMjMwMTM_6e660f14-88f2-4c59-8759-06ca31e6ecf1"
      unitRef="shares">130934795</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xOS9mcmFnOjMwZmI4OGM5N2Y4YjQ2NjdhNWY0ZjBmOTQzZjIzZjIwL3RhYmxlOmQ5ZDA5NDIxYTE1ZTRiMTc5MDRkMmNiY2NmMzEwNjU3L3RhYmxlcmFuZ2U6ZDlkMDk0MjFhMTVlNGIxNzkwNGQyY2JjY2YzMTA2NTdfMTktMS0xLTEtMjMwMTM_dd727144-d0b1-4965-a89d-ef8548c01b1f"
      unitRef="shares">130934795</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xOS9mcmFnOjMwZmI4OGM5N2Y4YjQ2NjdhNWY0ZjBmOTQzZjIzZjIwL3RhYmxlOmQ5ZDA5NDIxYTE1ZTRiMTc5MDRkMmNiY2NmMzEwNjU3L3RhYmxlcmFuZ2U6ZDlkMDk0MjFhMTVlNGIxNzkwNGQyY2JjY2YzMTA2NTdfMTktMy0xLTEtMjMwMTM_e2da8ff1-4237-45da-adbf-11dbd8de8ebf"
      unitRef="shares">97179241</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xOS9mcmFnOjMwZmI4OGM5N2Y4YjQ2NjdhNWY0ZjBmOTQzZjIzZjIwL3RhYmxlOmQ5ZDA5NDIxYTE1ZTRiMTc5MDRkMmNiY2NmMzEwNjU3L3RhYmxlcmFuZ2U6ZDlkMDk0MjFhMTVlNGIxNzkwNGQyY2JjY2YzMTA2NTdfMTktMy0xLTEtMjMwMTM_ee3a0669-92b4-4b0c-bf2e-11f303d3ca29"
      unitRef="shares">97179241</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xOS9mcmFnOjMwZmI4OGM5N2Y4YjQ2NjdhNWY0ZjBmOTQzZjIzZjIwL3RhYmxlOmQ5ZDA5NDIxYTE1ZTRiMTc5MDRkMmNiY2NmMzEwNjU3L3RhYmxlcmFuZ2U6ZDlkMDk0MjFhMTVlNGIxNzkwNGQyY2JjY2YzMTA2NTdfMjEtMS0xLTEtMjMwMTM_cc5ae97a-d2a0-422d-b6c2-022d587efa59"
      unitRef="usd">-28071000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xOS9mcmFnOjMwZmI4OGM5N2Y4YjQ2NjdhNWY0ZjBmOTQzZjIzZjIwL3RhYmxlOmQ5ZDA5NDIxYTE1ZTRiMTc5MDRkMmNiY2NmMzEwNjU3L3RhYmxlcmFuZ2U6ZDlkMDk0MjFhMTVlNGIxNzkwNGQyY2JjY2YzMTA2NTdfMjEtMy0xLTEtMjMwMTM_a8c0ed92-97c5-437e-b651-10e85beeffdd"
      unitRef="usd">-33155000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xOS9mcmFnOjMwZmI4OGM5N2Y4YjQ2NjdhNWY0ZjBmOTQzZjIzZjIwL3RhYmxlOmQ5ZDA5NDIxYTE1ZTRiMTc5MDRkMmNiY2NmMzEwNjU3L3RhYmxlcmFuZ2U6ZDlkMDk0MjFhMTVlNGIxNzkwNGQyY2JjY2YzMTA2NTdfMjItMS0xLTEtMjMwMTM_523b94e3-b01d-437a-95ad-58877ff0f255"
      unitRef="usd">-82000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xOS9mcmFnOjMwZmI4OGM5N2Y4YjQ2NjdhNWY0ZjBmOTQzZjIzZjIwL3RhYmxlOmQ5ZDA5NDIxYTE1ZTRiMTc5MDRkMmNiY2NmMzEwNjU3L3RhYmxlcmFuZ2U6ZDlkMDk0MjFhMTVlNGIxNzkwNGQyY2JjY2YzMTA2NTdfMjItMy0xLTEtMjMwMTM_5b010af1-1a79-4ac5-9ad6-71471f70de9d"
      unitRef="usd">-3000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xOS9mcmFnOjMwZmI4OGM5N2Y4YjQ2NjdhNWY0ZjBmOTQzZjIzZjIwL3RhYmxlOmQ5ZDA5NDIxYTE1ZTRiMTc5MDRkMmNiY2NmMzEwNjU3L3RhYmxlcmFuZ2U6ZDlkMDk0MjFhMTVlNGIxNzkwNGQyY2JjY2YzMTA2NTdfMjMtMS0xLTEtMjMwMTM_8a4f4ac2-8bdd-4f75-9115-be500e980099"
      unitRef="usd">-28153000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xOS9mcmFnOjMwZmI4OGM5N2Y4YjQ2NjdhNWY0ZjBmOTQzZjIzZjIwL3RhYmxlOmQ5ZDA5NDIxYTE1ZTRiMTc5MDRkMmNiY2NmMzEwNjU3L3RhYmxlcmFuZ2U6ZDlkMDk0MjFhMTVlNGIxNzkwNGQyY2JjY2YzMTA2NTdfMjMtMy0xLTEtMjMwMTM_c367540a-fa8c-4ff7-9d5c-b794b152b1c9"
      unitRef="usd">-33158000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="i4cf9b083bea54e30a63681421a4a7088_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOmQwMTU3YTI0ODRmMTQyNjk5MTYyNjBjZTc3NWFkZmZhL3RhYmxlcmFuZ2U6ZDAxNTdhMjQ4NGYxNDI2OTkxNjI2MGNlNzc1YWRmZmFfMy0xLTEtMS0yMzAxMw_2bb39057-43e4-459d-a793-5cf06fcc0dfb"
      unitRef="shares">130182535</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i4cf9b083bea54e30a63681421a4a7088_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOmQwMTU3YTI0ODRmMTQyNjk5MTYyNjBjZTc3NWFkZmZhL3RhYmxlcmFuZ2U6ZDAxNTdhMjQ4NGYxNDI2OTkxNjI2MGNlNzc1YWRmZmFfMy0zLTEtMS0yMzAxMw_25618766-deb0-4da3-8b0e-14a4dd0f2e20"
      unitRef="usd">13000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i915c4ac55b394c648e3f1e508325bbfe_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOmQwMTU3YTI0ODRmMTQyNjk5MTYyNjBjZTc3NWFkZmZhL3RhYmxlcmFuZ2U6ZDAxNTdhMjQ4NGYxNDI2OTkxNjI2MGNlNzc1YWRmZmFfMy01LTEtMS0yMzAxMw_6a4f60ce-4825-4822-b425-c76527438859"
      unitRef="usd">795540000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i77bb1febd93946efb7f1ca68a5cb537e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOmQwMTU3YTI0ODRmMTQyNjk5MTYyNjBjZTc3NWFkZmZhL3RhYmxlcmFuZ2U6ZDAxNTdhMjQ4NGYxNDI2OTkxNjI2MGNlNzc1YWRmZmFfMy03LTEtMS0yMzAxMw_34bebedf-5077-40b1-b20a-4e90a6e0147d"
      unitRef="usd">-712930000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id37f845e78ea4e4ba399ae4d539dd270_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOmQwMTU3YTI0ODRmMTQyNjk5MTYyNjBjZTc3NWFkZmZhL3RhYmxlcmFuZ2U6ZDAxNTdhMjQ4NGYxNDI2OTkxNjI2MGNlNzc1YWRmZmFfMy05LTEtMS0yMzAxMw_e3687eec-16ac-492d-a2d4-0f1465d52b88"
      unitRef="usd">-6000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOmQwMTU3YTI0ODRmMTQyNjk5MTYyNjBjZTc3NWFkZmZhL3RhYmxlcmFuZ2U6ZDAxNTdhMjQ4NGYxNDI2OTkxNjI2MGNlNzc1YWRmZmFfMy0xMS0xLTEtMjMwMTM_f822ad49-edc9-4ca2-8cf4-e1484bb5958f"
      unitRef="usd">82617000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="ibe48acc39ad24a498bf29293d3b5ff68_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOmQwMTU3YTI0ODRmMTQyNjk5MTYyNjBjZTc3NWFkZmZhL3RhYmxlcmFuZ2U6ZDAxNTdhMjQ4NGYxNDI2OTkxNjI2MGNlNzc1YWRmZmFfNC0xLTEtMS0yMzAxMw_6fe74887-2d81-4469-81a5-24139baa8899"
      unitRef="shares">127100</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i0a66e20dad254b89922f8674a7094895_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOmQwMTU3YTI0ODRmMTQyNjk5MTYyNjBjZTc3NWFkZmZhL3RhYmxlcmFuZ2U6ZDAxNTdhMjQ4NGYxNDI2OTkxNjI2MGNlNzc1YWRmZmFfNC01LTEtMS0yMzAxMw_656c1d5b-cb2f-4b8d-828e-7843b4ab13d7"
      unitRef="usd">83000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOmQwMTU3YTI0ODRmMTQyNjk5MTYyNjBjZTc3NWFkZmZhL3RhYmxlcmFuZ2U6ZDAxNTdhMjQ4NGYxNDI2OTkxNjI2MGNlNzc1YWRmZmFfNC0xMS0xLTEtMjMwMTM_50780a95-5e22-4d39-a1f3-946bbfb4aefe"
      unitRef="usd">83000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="ibe48acc39ad24a498bf29293d3b5ff68_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOmQwMTU3YTI0ODRmMTQyNjk5MTYyNjBjZTc3NWFkZmZhL3RhYmxlcmFuZ2U6ZDAxNTdhMjQ4NGYxNDI2OTkxNjI2MGNlNzc1YWRmZmFfNy0xLTEtMS0yMzAxMw_1347ec2f-de8c-4e0a-9f0e-1c04b84fe3e7"
      unitRef="shares">113469</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ibe48acc39ad24a498bf29293d3b5ff68_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOmQwMTU3YTI0ODRmMTQyNjk5MTYyNjBjZTc3NWFkZmZhL3RhYmxlcmFuZ2U6ZDAxNTdhMjQ4NGYxNDI2OTkxNjI2MGNlNzc1YWRmZmFfOC0xLTEtMS0yMzAxMw_0371f93a-a26b-419f-bd3f-03eda9d4fc7a"
      unitRef="shares">5907256</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ibe48acc39ad24a498bf29293d3b5ff68_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOmQwMTU3YTI0ODRmMTQyNjk5MTYyNjBjZTc3NWFkZmZhL3RhYmxlcmFuZ2U6ZDAxNTdhMjQ4NGYxNDI2OTkxNjI2MGNlNzc1YWRmZmFfOC0zLTEtMS0yMzAxMw_857c9c00-e9aa-4567-a01a-58c7adec4e34"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i0a66e20dad254b89922f8674a7094895_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOmQwMTU3YTI0ODRmMTQyNjk5MTYyNjBjZTc3NWFkZmZhL3RhYmxlcmFuZ2U6ZDAxNTdhMjQ4NGYxNDI2OTkxNjI2MGNlNzc1YWRmZmFfOC01LTEtMS0yMzAxMw_132ae237-8f09-4a90-b592-5d8b6749991d"
      unitRef="usd">5920000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOmQwMTU3YTI0ODRmMTQyNjk5MTYyNjBjZTc3NWFkZmZhL3RhYmxlcmFuZ2U6ZDAxNTdhMjQ4NGYxNDI2OTkxNjI2MGNlNzc1YWRmZmFfOC0xMS0xLTEtMjMwMTM_27943a4c-8c8a-4b3e-9856-931d17aa577d"
      unitRef="usd">5921000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i0a66e20dad254b89922f8674a7094895_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOmQwMTU3YTI0ODRmMTQyNjk5MTYyNjBjZTc3NWFkZmZhL3RhYmxlcmFuZ2U6ZDAxNTdhMjQ4NGYxNDI2OTkxNjI2MGNlNzc1YWRmZmFfOS01LTEtMS0yMzAxMw_5146a50b-2ffb-4c8d-86ba-d18469cb15fd"
      unitRef="usd">3722000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOmQwMTU3YTI0ODRmMTQyNjk5MTYyNjBjZTc3NWFkZmZhL3RhYmxlcmFuZ2U6ZDAxNTdhMjQ4NGYxNDI2OTkxNjI2MGNlNzc1YWRmZmFfOS0xMS0xLTEtMjMwMTM_65d26bd5-fcf1-4898-bdd2-5935839b4153"
      unitRef="usd">3722000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ie996e76b43b94778bbd562ef8363a5f7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOmQwMTU3YTI0ODRmMTQyNjk5MTYyNjBjZTc3NWFkZmZhL3RhYmxlcmFuZ2U6ZDAxNTdhMjQ4NGYxNDI2OTkxNjI2MGNlNzc1YWRmZmFfMTAtOS0xLTEtMjMwMTM_cfd85e30-e55a-4548-b13f-ffaae2bbb4a4"
      unitRef="usd">-82000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOmQwMTU3YTI0ODRmMTQyNjk5MTYyNjBjZTc3NWFkZmZhL3RhYmxlcmFuZ2U6ZDAxNTdhMjQ4NGYxNDI2OTkxNjI2MGNlNzc1YWRmZmFfMTAtMTEtMS0xLTIzMDEz_695dd0f5-d98c-486b-8e28-d14a093dd4c2"
      unitRef="usd">-82000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="i2f13863ef82b4ff9891451291774c864_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOmQwMTU3YTI0ODRmMTQyNjk5MTYyNjBjZTc3NWFkZmZhL3RhYmxlcmFuZ2U6ZDAxNTdhMjQ4NGYxNDI2OTkxNjI2MGNlNzc1YWRmZmFfMTEtNy0xLTEtMjMwMTM_bc25adda-f78d-40ee-89d9-03b72146c359"
      unitRef="usd">-28071000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOmQwMTU3YTI0ODRmMTQyNjk5MTYyNjBjZTc3NWFkZmZhL3RhYmxlcmFuZ2U6ZDAxNTdhMjQ4NGYxNDI2OTkxNjI2MGNlNzc1YWRmZmFfMTEtMTEtMS0xLTIzMDEz_d14df4a1-5a25-4335-96ab-5eb23641cfe0"
      unitRef="usd">-28071000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i3a994d19646542b883bef3eb77ec041a_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOmQwMTU3YTI0ODRmMTQyNjk5MTYyNjBjZTc3NWFkZmZhL3RhYmxlcmFuZ2U6ZDAxNTdhMjQ4NGYxNDI2OTkxNjI2MGNlNzc1YWRmZmFfMTItMS0xLTEtMjMwMTM_754aa0c2-589c-4f33-a9d6-cb9f9acb07b5"
      unitRef="shares">136330360</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i3a994d19646542b883bef3eb77ec041a_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOmQwMTU3YTI0ODRmMTQyNjk5MTYyNjBjZTc3NWFkZmZhL3RhYmxlcmFuZ2U6ZDAxNTdhMjQ4NGYxNDI2OTkxNjI2MGNlNzc1YWRmZmFfMTItMy0xLTEtMjMwMTM_692c3c45-8b3f-415b-860b-164047c10b12"
      unitRef="usd">14000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia53bcaf6b509496b9aaca8a740abefe9_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOmQwMTU3YTI0ODRmMTQyNjk5MTYyNjBjZTc3NWFkZmZhL3RhYmxlcmFuZ2U6ZDAxNTdhMjQ4NGYxNDI2OTkxNjI2MGNlNzc1YWRmZmFfMTItNS0xLTEtMjMwMTM_bb193e20-61fe-4a34-8e9a-57154f2e35f1"
      unitRef="usd">805265000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i71139a32ab724fed9714f268e212cd3a_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOmQwMTU3YTI0ODRmMTQyNjk5MTYyNjBjZTc3NWFkZmZhL3RhYmxlcmFuZ2U6ZDAxNTdhMjQ4NGYxNDI2OTkxNjI2MGNlNzc1YWRmZmFfMTItNy0xLTEtMjMwMTM_96f9c969-0747-4c36-b3c7-dff8ebb43426"
      unitRef="usd">-741001000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9012898f9a0f44118b5aa8f6b4d02190_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOmQwMTU3YTI0ODRmMTQyNjk5MTYyNjBjZTc3NWFkZmZhL3RhYmxlcmFuZ2U6ZDAxNTdhMjQ4NGYxNDI2OTkxNjI2MGNlNzc1YWRmZmFfMTItOS0xLTEtMjMwMTM_dc93ae3d-734c-4a16-8a2d-08a12e23e200"
      unitRef="usd">-88000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOmQwMTU3YTI0ODRmMTQyNjk5MTYyNjBjZTc3NWFkZmZhL3RhYmxlcmFuZ2U6ZDAxNTdhMjQ4NGYxNDI2OTkxNjI2MGNlNzc1YWRmZmFfMTItMTEtMS0xLTIzMDEz_83139117-2e8b-4dbf-b658-ecd99cd67d83"
      unitRef="usd">64190000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i2d98dab95e674482969a1c14b83aeabb_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOjQ2YzkyNTJhM2RiZTQ5YjFhYmQyN2Y5YTEwMDYzZjNiL3RhYmxlcmFuZ2U6NDZjOTI1MmEzZGJlNDliMWFiZDI3ZjlhMTAwNjNmM2JfMy0xLTEtMS0yMzAxMw_ebe3fea1-5d71-4919-a487-18ccc72e5cb6"
      unitRef="shares">93599975</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i2d98dab95e674482969a1c14b83aeabb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOjQ2YzkyNTJhM2RiZTQ5YjFhYmQyN2Y5YTEwMDYzZjNiL3RhYmxlcmFuZ2U6NDZjOTI1MmEzZGJlNDliMWFiZDI3ZjlhMTAwNjNmM2JfMy0zLTEtMS0yMzAxMw_1bb68ded-6591-4941-b452-2f0e9f5ec73b"
      unitRef="usd">9000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i35ca663b0a124e6b8c8656e7e070589c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOjQ2YzkyNTJhM2RiZTQ5YjFhYmQyN2Y5YTEwMDYzZjNiL3RhYmxlcmFuZ2U6NDZjOTI1MmEzZGJlNDliMWFiZDI3ZjlhMTAwNjNmM2JfMy01LTEtMS0yMzAxMw_b9bcd5bb-f56b-4bd1-952a-4d28e63274ff"
      unitRef="usd">680872000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i71bfab9599a347c38e447f9dfe33b344_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOjQ2YzkyNTJhM2RiZTQ5YjFhYmQyN2Y5YTEwMDYzZjNiL3RhYmxlcmFuZ2U6NDZjOTI1MmEzZGJlNDliMWFiZDI3ZjlhMTAwNjNmM2JfMy03LTEtMS0yMzAxMw_2830d077-e17f-4c51-8784-292cae1234a7"
      unitRef="usd">-554765000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie1302e9e86374f80ab91f5e2e093f6fa_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOjQ2YzkyNTJhM2RiZTQ5YjFhYmQyN2Y5YTEwMDYzZjNiL3RhYmxlcmFuZ2U6NDZjOTI1MmEzZGJlNDliMWFiZDI3ZjlhMTAwNjNmM2JfMy05LTEtMS0yMzAxMw_34f76e16-54ad-489d-a5f8-0657fd0842a1"
      unitRef="usd">-4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iaa47cdf56b6c4c87a3d970dbcf5b0e23_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOjQ2YzkyNTJhM2RiZTQ5YjFhYmQyN2Y5YTEwMDYzZjNiL3RhYmxlcmFuZ2U6NDZjOTI1MmEzZGJlNDliMWFiZDI3ZjlhMTAwNjNmM2JfMy0xMS0xLTEtMjMwMTM_9adc6467-fbf8-451b-9e46-271d4906758d"
      unitRef="usd">126112000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="ic32baa0627994f879f796094ade7c7d5_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOjQ2YzkyNTJhM2RiZTQ5YjFhYmQyN2Y5YTEwMDYzZjNiL3RhYmxlcmFuZ2U6NDZjOTI1MmEzZGJlNDliMWFiZDI3ZjlhMTAwNjNmM2JfNC0xLTEtMS0yMzAxMw_4a5efd73-0efe-456f-97b0-07fdd561bd2c"
      unitRef="shares">102208</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i7f6752f99ffb46a6ac848c2977b3c96d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOjQ2YzkyNTJhM2RiZTQ5YjFhYmQyN2Y5YTEwMDYzZjNiL3RhYmxlcmFuZ2U6NDZjOTI1MmEzZGJlNDliMWFiZDI3ZjlhMTAwNjNmM2JfNC01LTEtMS0yMzAxMw_33da9548-120b-435c-a065-204744a00556"
      unitRef="usd">478000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOjQ2YzkyNTJhM2RiZTQ5YjFhYmQyN2Y5YTEwMDYzZjNiL3RhYmxlcmFuZ2U6NDZjOTI1MmEzZGJlNDliMWFiZDI3ZjlhMTAwNjNmM2JfNC0xMS0xLTEtMjMwMTM_b6ec7537-ff53-46ce-9819-cbb78a920c3a"
      unitRef="usd">478000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ic32baa0627994f879f796094ade7c7d5_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOjQ2YzkyNTJhM2RiZTQ5YjFhYmQyN2Y5YTEwMDYzZjNiL3RhYmxlcmFuZ2U6NDZjOTI1MmEzZGJlNDliMWFiZDI3ZjlhMTAwNjNmM2JfNi0xLTEtMS0yMzAxMw_5bd8ff0f-ef46-4af1-b8bf-e20c9d866635"
      unitRef="shares">10507</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i7f6752f99ffb46a6ac848c2977b3c96d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOjQ2YzkyNTJhM2RiZTQ5YjFhYmQyN2Y5YTEwMDYzZjNiL3RhYmxlcmFuZ2U6NDZjOTI1MmEzZGJlNDliMWFiZDI3ZjlhMTAwNjNmM2JfNi01LTEtMS0yMzAxMw_150bf11b-ba0d-4047-bf92-b8f29fafca94"
      unitRef="usd">20000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOjQ2YzkyNTJhM2RiZTQ5YjFhYmQyN2Y5YTEwMDYzZjNiL3RhYmxlcmFuZ2U6NDZjOTI1MmEzZGJlNDliMWFiZDI3ZjlhMTAwNjNmM2JfNi0xMS0xLTEtMjMwMTM_b2bbbc63-14eb-4f9b-839c-1fe4c6cd6801"
      unitRef="usd">20000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="ic32baa0627994f879f796094ade7c7d5_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOjQ2YzkyNTJhM2RiZTQ5YjFhYmQyN2Y5YTEwMDYzZjNiL3RhYmxlcmFuZ2U6NDZjOTI1MmEzZGJlNDliMWFiZDI3ZjlhMTAwNjNmM2JfNy0xLTEtMS0yMzAxMw_2b88f5e7-de6c-464c-9239-38f4026ebfa8"
      unitRef="shares">35100</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ic32baa0627994f879f796094ade7c7d5_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOjQ2YzkyNTJhM2RiZTQ5YjFhYmQyN2Y5YTEwMDYzZjNiL3RhYmxlcmFuZ2U6NDZjOTI1MmEzZGJlNDliMWFiZDI3ZjlhMTAwNjNmM2JfOC0xLTEtMS0yNDEzNQ_614dcb7d-923d-4240-83e9-b227e80dc5d0"
      unitRef="shares">4940787</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ic32baa0627994f879f796094ade7c7d5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOjQ2YzkyNTJhM2RiZTQ5YjFhYmQyN2Y5YTEwMDYzZjNiL3RhYmxlcmFuZ2U6NDZjOTI1MmEzZGJlNDliMWFiZDI3ZjlhMTAwNjNmM2JfOC0zLTEtMS0yNDEzNQ_b4fc7be8-89e6-4fc2-8d5e-a075595a5108"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i7f6752f99ffb46a6ac848c2977b3c96d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOjQ2YzkyNTJhM2RiZTQ5YjFhYmQyN2Y5YTEwMDYzZjNiL3RhYmxlcmFuZ2U6NDZjOTI1MmEzZGJlNDliMWFiZDI3ZjlhMTAwNjNmM2JfOC01LTEtMS0yNDEzNQ_7d39fa50-f046-41d1-b4c5-4ef8564bfa1f"
      unitRef="usd">34271000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOjQ2YzkyNTJhM2RiZTQ5YjFhYmQyN2Y5YTEwMDYzZjNiL3RhYmxlcmFuZ2U6NDZjOTI1MmEzZGJlNDliMWFiZDI3ZjlhMTAwNjNmM2JfOC0xMS0xLTEtMjQxMzU_51996180-d827-4f6e-a524-15c1984c3d90"
      unitRef="usd">34272000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i7f6752f99ffb46a6ac848c2977b3c96d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOjQ2YzkyNTJhM2RiZTQ5YjFhYmQyN2Y5YTEwMDYzZjNiL3RhYmxlcmFuZ2U6NDZjOTI1MmEzZGJlNDliMWFiZDI3ZjlhMTAwNjNmM2JfOC01LTEtMS0yMzAxMw_91458b9a-cff2-4243-a813-5f597faf4b21"
      unitRef="usd">3087000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOjQ2YzkyNTJhM2RiZTQ5YjFhYmQyN2Y5YTEwMDYzZjNiL3RhYmxlcmFuZ2U6NDZjOTI1MmEzZGJlNDliMWFiZDI3ZjlhMTAwNjNmM2JfOC0xMS0xLTEtMjMwMTM_61e22e2a-afb3-4b8e-b9df-063cfdc298d5"
      unitRef="usd">3087000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ie42c996fddf8460982e8ef5b6a6dd25a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOjQ2YzkyNTJhM2RiZTQ5YjFhYmQyN2Y5YTEwMDYzZjNiL3RhYmxlcmFuZ2U6NDZjOTI1MmEzZGJlNDliMWFiZDI3ZjlhMTAwNjNmM2JfOS05LTEtMS0yMzAxMw_2d29ea7d-d611-4998-bef8-d12ec8856b56"
      unitRef="usd">-3000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOjQ2YzkyNTJhM2RiZTQ5YjFhYmQyN2Y5YTEwMDYzZjNiL3RhYmxlcmFuZ2U6NDZjOTI1MmEzZGJlNDliMWFiZDI3ZjlhMTAwNjNmM2JfOS0xMS0xLTEtMjMwMTM_1312fd8b-b073-4ded-8e94-491432360ba1"
      unitRef="usd">-3000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="i76348c324fa24beda3b12611828f421a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOjQ2YzkyNTJhM2RiZTQ5YjFhYmQyN2Y5YTEwMDYzZjNiL3RhYmxlcmFuZ2U6NDZjOTI1MmEzZGJlNDliMWFiZDI3ZjlhMTAwNjNmM2JfMTAtNy0xLTEtMjMwMTM_350f9129-df68-4849-a2ae-eae8065ea0ae"
      unitRef="usd">-33155000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOjQ2YzkyNTJhM2RiZTQ5YjFhYmQyN2Y5YTEwMDYzZjNiL3RhYmxlcmFuZ2U6NDZjOTI1MmEzZGJlNDliMWFiZDI3ZjlhMTAwNjNmM2JfMTAtMTEtMS0xLTIzMDEz_b01b7bca-dc55-4f65-ab59-ab86ebfeee69"
      unitRef="usd">-33155000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="id70cbf4ca0ff49799aebf60ead1ac83a_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOjQ2YzkyNTJhM2RiZTQ5YjFhYmQyN2Y5YTEwMDYzZjNiL3RhYmxlcmFuZ2U6NDZjOTI1MmEzZGJlNDliMWFiZDI3ZjlhMTAwNjNmM2JfMTEtMS0xLTEtMjMwMTM_fdf84397-8b45-4c81-81df-31ad9da7a442"
      unitRef="shares">98688577</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="id70cbf4ca0ff49799aebf60ead1ac83a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOjQ2YzkyNTJhM2RiZTQ5YjFhYmQyN2Y5YTEwMDYzZjNiL3RhYmxlcmFuZ2U6NDZjOTI1MmEzZGJlNDliMWFiZDI3ZjlhMTAwNjNmM2JfMTEtMy0xLTEtMjMwMTM_b392a630-1ebe-4899-bbfe-3c0844ca881b"
      unitRef="usd">10000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie895873a73154ee881d6a0b9a2729c79_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOjQ2YzkyNTJhM2RiZTQ5YjFhYmQyN2Y5YTEwMDYzZjNiL3RhYmxlcmFuZ2U6NDZjOTI1MmEzZGJlNDliMWFiZDI3ZjlhMTAwNjNmM2JfMTEtNS0xLTEtMjMwMTM_68f292f4-a22a-42d4-bc4b-e59416398688"
      unitRef="usd">718728000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i38a8556738964a7fa1421049694e0b21_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOjQ2YzkyNTJhM2RiZTQ5YjFhYmQyN2Y5YTEwMDYzZjNiL3RhYmxlcmFuZ2U6NDZjOTI1MmEzZGJlNDliMWFiZDI3ZjlhMTAwNjNmM2JfMTEtNy0xLTEtMjMwMTM_f0cc97ad-aed0-4227-a043-5da0c323e79a"
      unitRef="usd">-587920000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7c204a43b4eb4e6d9394547d9b0e2b58_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOjQ2YzkyNTJhM2RiZTQ5YjFhYmQyN2Y5YTEwMDYzZjNiL3RhYmxlcmFuZ2U6NDZjOTI1MmEzZGJlNDliMWFiZDI3ZjlhMTAwNjNmM2JfMTEtOS0xLTEtMjMwMTM_4b32ca5e-1740-405d-b061-fbf336f7f4de"
      unitRef="usd">-7000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iac98ebf56cf345fb9e32e575ac855e4a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yMi9mcmFnOjM1MThhNDY1ZGU0NjQ5NmZiNjA1NTg0OTg5MzgxOTgwL3RhYmxlOjQ2YzkyNTJhM2RiZTQ5YjFhYmQyN2Y5YTEwMDYzZjNiL3RhYmxlcmFuZ2U6NDZjOTI1MmEzZGJlNDliMWFiZDI3ZjlhMTAwNjNmM2JfMTEtMTEtMS0xLTIzMDEz_6b666c47-92cb-4a10-b040-6dd6a16eee2d"
      unitRef="usd">130811000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMy0xLTEtMS0yMzAxMw_16c84604-b87c-4446-ae20-d482d443f90c"
      unitRef="usd">-28071000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMy0zLTEtMS0yMzAxMw_b4acfb41-f4d1-4890-b6bf-cef91dab7094"
      unitRef="usd">-33155000</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfNS0xLTEtMS0yMzAxMw_cc69237d-a19e-4399-8630-3b75016e1ce3"
      unitRef="usd">232000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfNS0zLTEtMS0yMzAxMw_020c34f5-3aef-4a80-b6ed-4b873b3f1247"
      unitRef="usd">422000</us-gaap:Depreciation>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfNi0xLTEtMS0yMzAxMw_2d162e63-eeda-4fd9-a263-237e704ec568"
      unitRef="usd">169000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfNi0zLTEtMS0yMzAxMw_9fa0195f-daa2-45b2-b0c0-92bc47d9108a"
      unitRef="usd">157000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfDeferredCharges
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfNy0xLTEtMS0yMzAxMw_cb08442f-8646-456f-9767-c10a9b6903c7"
      unitRef="usd">47000</us-gaap:AmortizationOfDeferredCharges>
    <us-gaap:AmortizationOfDeferredCharges
      contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfNy0zLTEtMS0yMzAxMw_4b86c574-2551-485b-9960-eedf48c0cb04"
      unitRef="usd">77000</us-gaap:AmortizationOfDeferredCharges>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfOC0xLTEtMS0yMzAxMw_70c99a0b-0ae0-489f-aaa9-c249b3f5a0a5"
      unitRef="usd">-15000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfOC0zLTEtMS0yMzAxMw_9f44874d-4a12-41ce-a311-cd1eaa424222"
      unitRef="usd">-157000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfOS0xLTEtMS0yMzAxMw_e5bed4b6-6405-42d1-a486-e6670f08bcf6"
      unitRef="usd">842000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfOS0zLTEtMS0yMzAxMw_c6ca753f-e404-4750-b886-af54302691c3"
      unitRef="usd">607000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:ShareBasedCompensation
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMTAtMS0xLTEtMjMwMTM_95bccd18-aa8b-439e-b603-d937c55b49f7"
      unitRef="usd">3722000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMTAtMy0xLTEtMjMwMTM_277e4c4d-09dc-4c4f-845c-5650a2e96dbb"
      unitRef="usd">3087000</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInDerivativeLiabilities
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMTEtMS0xLTEtMjMwMTM_79a84821-d7d8-4c07-aa53-2bd383b603ac"
      unitRef="usd">15000</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
    <us-gaap:IncreaseDecreaseInDerivativeLiabilities
      contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMTEtMy0xLTEtMjMwMTM_59b5fa99-c330-4ab4-84a9-5fdd96b0b16b"
      unitRef="usd">36000</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
    <us-gaap:GainsLossesOnRestructuringOfDebt
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMTItMS0xLTEtMzA5OTA_ec4fde91-fb6e-47c8-85e1-cb81360f6105"
      unitRef="usd">-102000</us-gaap:GainsLossesOnRestructuringOfDebt>
    <us-gaap:GainsLossesOnRestructuringOfDebt
      contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMTItMy0xLTEtMzA5OTk_cb0df1cc-d0f4-40fc-b6b4-d1ecdc301acd"
      unitRef="usd">0</us-gaap:GainsLossesOnRestructuringOfDebt>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMTMtMS0xLTEtMzA5OTA_d5a435bd-4d39-478e-81e9-cb4e306c4e4e"
      unitRef="usd">710000</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMTMtMy0xLTEtMzA5OTk_fa0db9b5-e73b-4943-9065-451fc39f7393"
      unitRef="usd">0</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMTItMS0xLTEtMjMwMTM_4fcf6b5f-91c5-4a9a-b864-74c7669ab2e0"
      unitRef="usd">109000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMTItMy0xLTEtMjMwMTM_baf5bd67-5f9b-4e6a-9889-904fe0a567c0"
      unitRef="usd">70000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMTQtMS0xLTEtMjMwMTM_3ee0c1df-8d59-4bfe-bf27-09acbebf1a23"
      unitRef="usd">3892000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMTQtMy0xLTEtMjMwMTM_0287092d-b3da-4dab-94cc-ff904704c201"
      unitRef="usd">5783000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMTgtMS0xLTEtMzEwMDc_5cc100ae-befb-4b18-a7ed-d0da942fcc51"
      unitRef="usd">3487000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMTgtMy0xLTEtMzEwMjI_4ca1a4f1-586b-474c-bc63-dfc167e6f6e1"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMTUtMS0xLTEtMjMwMTM_62ce0dc0-0fd1-4026-9328-f733e7e5558a"
      unitRef="usd">307000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMTUtMy0xLTEtMjMwMTM_ba8e6c8c-f2fb-439b-804b-b9026417518a"
      unitRef="usd">13662000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMTYtMS0xLTEtMjMwMTM_1f2bf343-7e0e-4937-8dfe-24905ce3c4ac"
      unitRef="usd">753000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMTYtMy0xLTEtMjMwMTM_950e59c0-5735-4552-8774-d184382d05d8"
      unitRef="usd">-248000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMTctMS0xLTEtMjMwMTM_a5ed3cc4-36a2-47f3-b910-17496f6ce229"
      unitRef="usd">882000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMTctMy0xLTEtMjMwMTM_ea9446e8-6f54-41b9-a5f7-a20279a8ae02"
      unitRef="usd">-1324000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMTgtMS0xLTEtMjMwMTM_2d35c635-7bd9-4d54-88b6-69672d038e78"
      unitRef="usd">-836000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMTgtMy0xLTEtMjMwMTM_4525fdd1-6b68-4fbd-9aa4-c16a4ed1cc1f"
      unitRef="usd">-721000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMTktMS0xLTEtMjMwMTM_86cad227-3f7b-4449-9dec-5d2576f41800"
      unitRef="usd">-1041000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMTktMy0xLTEtMjMwMTM_171ee5f7-80a7-45c9-937d-be2c62d30a74"
      unitRef="usd">7517000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMjAtMS0xLTEtMjMwMTM_8f22ce12-b130-44e4-859f-bcc61692675c"
      unitRef="usd">3836000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMjAtMy0xLTEtMjMwMTM_70334999-0ba8-4151-af61-870e535e48e8"
      unitRef="usd">-1454000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMjEtMS0xLTEtMjMwMTM_3d1c19a4-09e4-4ce0-88bc-906eb92b5349"
      unitRef="usd">-27620000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMjEtMy0xLTEtMjMwMTM_af1f09ec-d46b-4523-b7f9-24503c42920b"
      unitRef="usd">-44217000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMjQtMS0xLTEtMjM3MjU_bc96d066-5eb6-45e2-9395-23d2d3222552"
      unitRef="usd">27300000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMjQtMy0xLTEtMjM3MzY_a944e1bb-cdb7-4e10-8df3-4d7217a2f359"
      unitRef="usd">35370000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMjQtMS0xLTEtMjMwMTM_e0a97845-d464-4c6a-a683-355af546cd97"
      unitRef="usd">25763000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMjQtMy0xLTEtMjMwMTM_a29d7c14-7989-49a3-8e70-2c6d05684657"
      unitRef="usd">32107000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:ProceedsFromSaleOfMachineryAndEquipment
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMjktMS0xLTEtMzEwNDA_f4dff243-e778-41a6-b823-263523de83b2"
      unitRef="usd">795000</us-gaap:ProceedsFromSaleOfMachineryAndEquipment>
    <us-gaap:ProceedsFromSaleOfMachineryAndEquipment
      contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMjktMy0xLTEtMzEwNTA_2aaa11c9-7e38-4734-b545-1c6da49998fe"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfMachineryAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMjUtMS0xLTEtMjMwMTM_f9bbc0b2-9de0-4b3d-be99-42b441356a16"
      unitRef="usd">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMjUtMy0xLTEtMjMwMTM_d653f162-e5ab-48ca-ab67-e44bf7e29004"
      unitRef="usd">778000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMjYtMS0xLTEtMjMwMTM_ac17de6a-9c09-4636-9719-d6e80e9ba33b"
      unitRef="usd">2332000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMjYtMy0xLTEtMjMwMTM_b650da66-bb13-4edc-b835-3628516e3cbc"
      unitRef="usd">2485000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfSecuredDebt
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMzMtMS0xLTEtMzEwNTg_2fa4402a-5344-4048-993d-208f09a6a1e0"
      unitRef="usd">26971000</us-gaap:ProceedsFromIssuanceOfSecuredDebt>
    <us-gaap:ProceedsFromIssuanceOfSecuredDebt
      contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMzMtMy0xLTEtMzEwNzE_a6e9d03c-033b-4b23-bdb0-60ca93262e43"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfSecuredDebt>
    <us-gaap:RepaymentsOfSecuredDebt
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMzQtMS0xLTEtMzEwODE_ae94b8f1-ee43-48ae-a40f-637d2e897854"
      unitRef="usd">33038000</us-gaap:RepaymentsOfSecuredDebt>
    <us-gaap:RepaymentsOfSecuredDebt
      contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMzQtMy0xLTEtMzEwODE_bf6331bc-c910-457d-becb-56551e1d4a79"
      unitRef="usd">0</us-gaap:RepaymentsOfSecuredDebt>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMzAtMS0xLTEtMjMwMTM_379fa4ef-ec5c-486e-821a-17e14ea179e3"
      unitRef="usd">5921000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMzAtMy0xLTEtMjMwMTM_5b0e8a9a-d577-488f-8050-8565e003db9f"
      unitRef="usd">34272000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMzEtMS0xLTEtMjMwMTM_3c194d4b-27bd-4204-8a7c-2c070c337095"
      unitRef="usd">83000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMzEtMy0xLTEtMjMwMTM_f5bfe121-c8cc-4bf2-88c1-962e826ec1f8"
      unitRef="usd">498000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMzQtMS0xLTEtMjMwMTM_137a790c-301b-4f5d-a0fe-3d46f2851fcb"
      unitRef="usd">-63000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMzQtMy0xLTEtMjMwMTM_a0024dbc-a56c-4079-8ef7-2ba3db7f8b36"
      unitRef="usd">34770000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMzUtMS0xLTEtMjMwMTM_7a9daac5-d1f1-4cfc-809c-72e338e52e6b"
      unitRef="usd">-25351000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMzUtMy0xLTEtMjMwMTM_dd62844f-83ec-4fd7-8de5-1fba5aea5500"
      unitRef="usd">-6962000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMzYtMS0xLTEtMjMwMTM_08ff1029-99cc-44e6-975c-3d713cefb3a9"
      unitRef="usd">72428000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iaa47cdf56b6c4c87a3d970dbcf5b0e23_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMzYtMy0xLTEtMjMwMTM_fbf81dad-8b5f-4c94-988b-e3b5793a2d78"
      unitRef="usd">91032000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMzctMS0xLTEtMjMwMTM_bd1e65fe-f4d6-4465-a65c-f32798b3c209"
      unitRef="usd">47077000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iac98ebf56cf345fb9e32e575ac855e4a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfMzctMy0xLTEtMjMwMTM_4c00f401-2e92-4bcd-b953-f6a1c3617aa2"
      unitRef="usd">84070000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfNDEtMS0xLTEtMjM3MjU_e8fe76c2-ea2e-4709-a171-0159917c9507"
      unitRef="usd">741000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfNDEtMy0xLTEtMjM3MzY_8e2cd04a-ffcd-4fdc-a157-0f4c98e17d8a"
      unitRef="usd">963000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfNDAtMS0xLTEtMjMwMTM_2d9d8b0c-c7d4-4563-a3f4-3cfc8393106d"
      unitRef="usd">1000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfNDAtMy0xLTEtMjMwMTM_a014e974-b7d2-4c94-b8db-3d32699b251d"
      unitRef="usd">0</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfNDQtMS0xLTEtMjM3MjU_4ee6ee37-f6b6-4ee4-96c5-89592f7711f7"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfNDQtMy0xLTEtMjM3MzY_21198dbb-ac22-44df-ac8f-80b0820ef28e"
      unitRef="usd">450000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <ardx:DerivativeIssued
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfNDQtMS0xLTEtMjMwMTM_800931d3-9987-4080-a609-c5cc9043dbc5"
      unitRef="usd">375000</ardx:DerivativeIssued>
    <ardx:DerivativeIssued
      contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8yNS9mcmFnOmQ2OGIyYWE2MGY2MDQ1NWNiMWFlZjdkYTIxOTdiYmE1L3RhYmxlOjQ1MWRhY2UzNjUwYTRjYzY5NDNhZjNmOGZmMGY1NjMzL3RhYmxlcmFuZ2U6NDUxZGFjZTM2NTBhNGNjNjk0M2FmM2Y4ZmYwZjU2MzNfNDQtMy0xLTEtMjMwMTM_9e6d97c8-7568-42e0-85f1-7906ce107b17"
      unitRef="usd">0</ardx:DerivativeIssued>
    <us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zMS9mcmFnOjIxYzg0YTQwOGU2OTRjMmNiZjg0MDJkZDY0NWVkM2I1L3RleHRyZWdpb246MjFjODRhNDA4ZTY5NGMyY2JmODQwMmRkNjQ1ZWQzYjVfOTA3OQ_cf8fad45-f626-4beb-879c-72a0f0e6d1f7">ORGANIZATION AND BASIS OF PRESENTATION&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Ardelyx, Inc. (the &#x201c;Company,&#x201d; &#x201c;we,&#x201d; &#x201c;us&#x201d; or &#x201c;our&#x201d;) is a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We operate in one business segment, which is the development and commercialization of biopharmaceutical products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) and pursuant to the requirements of the Securities and Exchange Commission (&#x201c;SEC&#x201d;) for interim reporting. As permitted under those rules&#160;and regulations, certain footnotes or other financial information that are normally required by U.S. GAAP have been condensed or omitted. These condensed financial statements have been prepared on the same basis as our most recent annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments necessary to present fairly our financial position, results of operations, changes in stockholders&#x2019; equity, and cash flows for the interim periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying condensed financial statements and related financial information should be read in conjunction with the audited financial statements and the related notes thereto included in our Annual Report on Form 10-K for the&#160;year ended December&#160;31, 2021. The results for the three months ended March&#160;31, 2022 are not necessarily indicative of results to be expected for the entire&#160;year ending December&#160;31, 2022, or for any other interim period or future year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that affect the amounts reported in the financial statements and accompanying notes thereto. On an ongoing basis, management evaluates its estimates, including those related to recognition of revenue, clinical trial accruals, contract manufacturing accruals, the fair value of assets and liabilities, income taxes and stock-based compensation. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could materially differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2022, we had cash and investments of approximately $89.7&#160;million. We have incurred operating losses since inception and our accumulated deficit as of March&#160;31, 2022 is $741.0&#160;million. Our current level of cash and investments alone is not sufficient to meet our plans for the next twelve months following the issuance of these financial statements. These factors raise substantial doubt regarding our ability to continue as a going concern for a period of one year from the issuance of these financial statements. We plan to address our operating cash flow requirements with our current cash and investments, cash generated from sales of IBSRELA, our potential receipt of anticipated milestones from our collaboration partners, our ability to access the capital markets, as well as through the implementation of cash preservation activities to reduce or defer discretionary spending.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There are no assurances that our efforts to meet our operating cash flow requirements will be successful. If our current cash and investments as well as our plans to meet our operating cash flow requirements are not sufficient to fund necessary expenditures and meet our obligations for at least the next twelve months following the issuance of these financial statements, our liquidity, financial condition and business prospects will be materially affected. These financial statements have been prepared on a going concern basis and do not include any adjustments to the amounts and classification of assets and liabilities that may be necessary in the event that we can no longer continue as a going concern. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our significant accounting policies are described in Note 1 to our audited financial statements for the fiscal year ended December&#160;31, 2021, included in our Annual Report on Form 10-K. Our significant accounting policies for the three months ended March&#160;31, 2022 also included the policies discussed below related to accounts receivable, inventory, revenue and cost of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;revenue for commercial product sales. With the exception of those noted below, there have been no material changes in our significant accounting policies as previously disclosed in our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accounts Receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable is reported net of allowances for returns, chargebacks and contractual discounts offered to our customers. Our estimate of the allowance for doubtful accounts is based on an evaluation of the aging of our receivables. Trade receivable balances are written off against the allowance when it is probable that the receivable will not be collected. To date, we have determined that an allowance for doubtful accounts is not required. As of March&#160;31, 2022 our accounts receivable balance is comprised of $3.8&#160;million from our collaborators and $0.6&#160;million from commercial customers. As of December&#160;31, 2021 our accounts receivable balance was comprised of $0.5&#160;million from our collaborators.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the regulatory approval of drug product candidates, we incurred expenses for the manufacture of drug product that could potentially be available to support the commercial launch of our products. We began to capitalize inventory costs associated with IBSRELA during the fourth quarter of 2021, when our intent to commercialize IBSRELA was established and we commenced preparation for the commercial launch of IBSRELA, which was when it was determined that the inventory had a probable future economic benefit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory is stated at the lower of cost or estimated net realizable value with cost determined under the first-in first-out method. Inventory costs include third-party contract manufacturing, third-party packaging services, freight, labor costs for personnel involved in the manufacturing process, and indirect overhead costs. We primarily use actual costs to determine the cost basis for inventory. The determination of whether inventory costs will be realizable requires management review of the expiration dates of IBSRELA compared to our forecasted sales. If actual market conditions are less favorable than projected by management, write-downs of inventory may be required, which would be recorded as cost of goods sold in the condensed statement of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Product Sales, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for our commercial product sales, net in accordance with Topic 606 - &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. We received approval from the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) in September 2019 to market IBSRELA, the first and only sodium hydrogen exchanger 3 (&#x201c;NHE3&#x201d;) inhibitor for the treatment of irritable bowel syndrome with constipation ("IBS-C") in adults, in the United States ("U.S."). We began selling IBSRELA in the U.S. in March 2022. We distribute our products principally through a limited number of distributors and specialty pharmacy providers (collectively, our "Customers"). Our Customers subsequently sell our products to pharmacies and patients. Separately, we enter into arrangements with third parties that provide for government-mandated and privately-negotiated rebates, chargebacks and discounts. Revenue from product sales is recognized when our performance obligations are satisfied, which is when Customers obtain control of our product and occurs upon delivery.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Reserves for Variable Consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration, including rebates, discounts, patient copay assistance programs, and estimated product returns. These estimates are based on the amounts earned or to be claimed for related sales and are classified as reductions of accounts receivable if the amount is payable to our Customers or a current liability if the amount is payable to a party other than a Customer. Where appropriate, these estimates are based on factors such as industry data and forecasted customer buying and payment patterns, our historical experience, current contractual and statutory requirements, specific known market events and trends. Overall, these reductions to gross sales reflect our best estimates of the amount of consideration to which we are entitled based on the terms of the contract. Variable consideration is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from our estimates, we adjust these estimates, which would affect product revenue and earnings in the period such variances become known. As we gain more historical experience, estimates will be more heavily based on the expected utilization from historical data we have accumulated since the IBSRELA product launch.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Rebates: Rebates include mandated discounts under the Medicaid Drug Rebate Program ("Medicaid") and the Medicare Coverage Gap Program ("Medicare"). Rebates are amounts owed after the final dispensing of products to a benefit plan &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;participant and are based upon contractual agreements or legal requirements with the public-sector benefit providers. These estimates for rebates are recorded in the same period the related gross revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included in accrued expenses on the condensed balance sheets. We estimate our Medicaid and Medicare rebates based upon the estimated payor mix, and statutory discount rates. Our estimates for payor mix are guided by payor information received from specialty pharmacies, expected utilization for specialty distributor sales to pharmacies, and available industry payor information. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Chargebacks: Chargebacks are discounts that occur when contracted purchasers purchase directly from our specialty distributors at a discounted price. The specialty distributor, in turn, charges back the difference between the price initially paid to us by the specialty distributor and the discounted price paid to the specialty distributor by the contracted purchaser. Amounts for estimated chargebacks are established in the same period that the related gross revenue is recognized, resulting in a reduction of product revenue and accounts receivable. The accrual for specialty distributor chargebacks is estimated based on known chargeback rates, known sales to specialty distributors, and estimated utilization by types of contracted purchasers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Discounts and Fees: Our payment terms are generally 30 to 60 days. Specialty distributors and specialty pharmacies are offered various forms of consideration, including service fees and prompt pay discounts for payment within a specified period. We expect these Customers will earn prompt pay discounts and therefore, we deduct the full amount of these discounts and service fees from product sales when revenue is recognized, resulting in a reduction of product revenue and accounts receivable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other Reserves: Patients who have commercial insurance may receive co-pay assistance when product is dispensed by pharmacies to patients. We estimate the amount of co-pay assistance provided to eligible patients based on the terms of the program and redemption information provided by third-party claims processing organizations and are recorded in accounts payable, accrued expenses and other current liabilities on the condensed balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cost of Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of revenue consists of the cost of commercial goods sold to our Customers, international partners under product supply agreements, and royalty expense based on sales of tenapanor. We capitalize inventory costs associated with the production of our products after regulatory approval or when, based on management&#x2019;s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized. Otherwise, such costs are expensed as research and development. A portion of the costs of IBSRELA units recognized as revenue during the three months ended March&#160;31, 2022 were expensed prior to the fourth quarter of 2021, at which time our intent to commercialize IBSRELA was established and we commenced  preparation for the commercial launch of IBSRELA.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of revenue includes payments due to AstraZeneca, which under the terms of a termination agreement entered into in 2015 (the "AZ Termination Agreement") is entitled to (i) future royalties at a rate of 10% of net sales of tenapanor or other NHE3 products by us or our licensees, and (ii) 20% of non-royalty revenue received from our collaboration partners as a result of the development and commercialization of tenapanor or certain other NHE3 inhibitors.&#160;We have agreed to pay&#160;AstraZeneca up to a maximum of $75.0 million in the aggregate for (i) and (ii). We recognize these expenses as cost of revenue when we recognize the corresponding revenue that gives rise to payments due to AstraZeneca. To date, we have recognized an aggregate of $11.7 million as cost of revenue under the AZ Termination Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;New Accounting Pronouncements - Recently Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have adopted no new accounting pronouncements other than those disclosed in our most recent Annual Report on Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were various accounting standards and interpretations issued recently, none of which are expected to a have a material impact on our financial position, operations or cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zMS9mcmFnOjIxYzg0YTQwOGU2OTRjMmNiZjg0MDJkZDY0NWVkM2I1L3RleHRyZWdpb246MjFjODRhNDA4ZTY5NGMyY2JmODQwMmRkNjQ1ZWQzYjVfMTA5OTUxMTYzNzY0OA_daf69010-a8e8-49ad-a199-d1936aa0e6af"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zMS9mcmFnOjIxYzg0YTQwOGU2OTRjMmNiZjg0MDJkZDY0NWVkM2I1L3RleHRyZWdpb246MjFjODRhNDA4ZTY5NGMyY2JmODQwMmRkNjQ1ZWQzYjVfOTA3NQ_0d36b3a9-116c-4d63-a7b8-8aad8f00a82f">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) and pursuant to the requirements of the Securities and Exchange Commission (&#x201c;SEC&#x201d;) for interim reporting. As permitted under those rules&#160;and regulations, certain footnotes or other financial information that are normally required by U.S. GAAP have been condensed or omitted. These condensed financial statements have been prepared on the same basis as our most recent annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments necessary to present fairly our financial position, results of operations, changes in stockholders&#x2019; equity, and cash flows for the interim periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying condensed financial statements and related financial information should be read in conjunction with the audited financial statements and the related notes thereto included in our Annual Report on Form 10-K for the&#160;year ended December&#160;31, 2021. The results for the three months ended March&#160;31, 2022 are not necessarily indicative of results to be expected for the entire&#160;year ending December&#160;31, 2022, or for any other interim period or future year.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zMS9mcmFnOjIxYzg0YTQwOGU2OTRjMmNiZjg0MDJkZDY0NWVkM2I1L3RleHRyZWdpb246MjFjODRhNDA4ZTY5NGMyY2JmODQwMmRkNjQ1ZWQzYjVfOTA3Ng_7c186d66-ab51-42ce-a345-22d2bc2cefde">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that affect the amounts reported in the financial statements and accompanying notes thereto. On an ongoing basis, management evaluates its estimates, including those related to recognition of revenue, clinical trial accruals, contract manufacturing accruals, the fair value of assets and liabilities, income taxes and stock-based compensation. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could materially differ from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:InvestmentsAndCash
      contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zMS9mcmFnOjIxYzg0YTQwOGU2OTRjMmNiZjg0MDJkZDY0NWVkM2I1L3RleHRyZWdpb246MjFjODRhNDA4ZTY5NGMyY2JmODQwMmRkNjQ1ZWQzYjVfMTA5OTUxMTY0MTgxNg_cf64a164-f588-4e92-91f2-01ac77b83845"
      unitRef="usd">89700000</us-gaap:InvestmentsAndCash>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zMS9mcmFnOjIxYzg0YTQwOGU2OTRjMmNiZjg0MDJkZDY0NWVkM2I1L3RleHRyZWdpb246MjFjODRhNDA4ZTY5NGMyY2JmODQwMmRkNjQ1ZWQzYjVfMTA5OTUxMTY0MTgyNw_01ca2053-b997-49f9-b981-dfeb3afa989e"
      unitRef="usd">-741000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zMS9mcmFnOjIxYzg0YTQwOGU2OTRjMmNiZjg0MDJkZDY0NWVkM2I1L3RleHRyZWdpb246MjFjODRhNDA4ZTY5NGMyY2JmODQwMmRkNjQ1ZWQzYjVfMzI5ODUzNDkzODc2OA_b996bf5b-6933-4165-8702-5ae7734a8027">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accounts Receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable is reported net of allowances for returns, chargebacks and contractual discounts offered to our customers. Our estimate of the allowance for doubtful accounts is based on an evaluation of the aging of our receivables. Trade receivable balances are written off against the allowance when it is probable that the receivable will not be collected. To date, we have determined that an allowance for doubtful accounts is not required. As of March&#160;31, 2022 our accounts receivable balance is comprised of $3.8&#160;million from our collaborators and $0.6&#160;million from commercial customers. As of December&#160;31, 2021 our accounts receivable balance was comprised of $0.5&#160;million from our collaborators.&lt;/span&gt;&lt;/div&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i42e4f62db19a433c9581bbeecf9067e3_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zMS9mcmFnOjIxYzg0YTQwOGU2OTRjMmNiZjg0MDJkZDY0NWVkM2I1L3RleHRyZWdpb246MjFjODRhNDA4ZTY5NGMyY2JmODQwMmRkNjQ1ZWQzYjVfMTA5OTUxMTY3MzA5OQ_8beb94ce-5b5e-464a-888b-af522c814052"
      unitRef="usd">3800000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="id9efdb641fb440e39fb4580adc8f5d3f_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zMS9mcmFnOjIxYzg0YTQwOGU2OTRjMmNiZjg0MDJkZDY0NWVkM2I1L3RleHRyZWdpb246MjFjODRhNDA4ZTY5NGMyY2JmODQwMmRkNjQ1ZWQzYjVfMTA5OTUxMTY3MzEzMA_090b2bbe-b62a-43ab-a8d7-8517a6400180"
      unitRef="usd">600000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="id0170fbda0b74504967067c9d57bec75_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zMS9mcmFnOjIxYzg0YTQwOGU2OTRjMmNiZjg0MDJkZDY0NWVkM2I1L3RleHRyZWdpb246MjFjODRhNDA4ZTY5NGMyY2JmODQwMmRkNjQ1ZWQzYjVfMTA5OTUxMTY3MzM0Nw_3f8defdd-5012-43a5-be5d-8809f22db055"
      unitRef="usd">500000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zMS9mcmFnOjIxYzg0YTQwOGU2OTRjMmNiZjg0MDJkZDY0NWVkM2I1L3RleHRyZWdpb246MjFjODRhNDA4ZTY5NGMyY2JmODQwMmRkNjQ1ZWQzYjVfNDM5ODA0NjU1NDUyOQ_4552fe39-bfab-4056-a650-4e25836d6d00">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the regulatory approval of drug product candidates, we incurred expenses for the manufacture of drug product that could potentially be available to support the commercial launch of our products. We began to capitalize inventory costs associated with IBSRELA during the fourth quarter of 2021, when our intent to commercialize IBSRELA was established and we commenced preparation for the commercial launch of IBSRELA, which was when it was determined that the inventory had a probable future economic benefit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory is stated at the lower of cost or estimated net realizable value with cost determined under the first-in first-out method. Inventory costs include third-party contract manufacturing, third-party packaging services, freight, labor costs for personnel involved in the manufacturing process, and indirect overhead costs. We primarily use actual costs to determine the cost basis for inventory. The determination of whether inventory costs will be realizable requires management review of the expiration dates of IBSRELA compared to our forecasted sales. If actual market conditions are less favorable than projected by management, write-downs of inventory may be required, which would be recorded as cost of goods sold in the condensed statement of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zMS9mcmFnOjIxYzg0YTQwOGU2OTRjMmNiZjg0MDJkZDY0NWVkM2I1L3RleHRyZWdpb246MjFjODRhNDA4ZTY5NGMyY2JmODQwMmRkNjQ1ZWQzYjVfNDM5ODA0NjU1NDUzMA_c410fe2c-d10b-420a-b4a5-eeaf9f794f4c">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Product Sales, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for our commercial product sales, net in accordance with Topic 606 - &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. We received approval from the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) in September 2019 to market IBSRELA, the first and only sodium hydrogen exchanger 3 (&#x201c;NHE3&#x201d;) inhibitor for the treatment of irritable bowel syndrome with constipation ("IBS-C") in adults, in the United States ("U.S."). We began selling IBSRELA in the U.S. in March 2022. We distribute our products principally through a limited number of distributors and specialty pharmacy providers (collectively, our "Customers"). Our Customers subsequently sell our products to pharmacies and patients. Separately, we enter into arrangements with third parties that provide for government-mandated and privately-negotiated rebates, chargebacks and discounts. Revenue from product sales is recognized when our performance obligations are satisfied, which is when Customers obtain control of our product and occurs upon delivery.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Reserves for Variable Consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration, including rebates, discounts, patient copay assistance programs, and estimated product returns. These estimates are based on the amounts earned or to be claimed for related sales and are classified as reductions of accounts receivable if the amount is payable to our Customers or a current liability if the amount is payable to a party other than a Customer. Where appropriate, these estimates are based on factors such as industry data and forecasted customer buying and payment patterns, our historical experience, current contractual and statutory requirements, specific known market events and trends. Overall, these reductions to gross sales reflect our best estimates of the amount of consideration to which we are entitled based on the terms of the contract. Variable consideration is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from our estimates, we adjust these estimates, which would affect product revenue and earnings in the period such variances become known. As we gain more historical experience, estimates will be more heavily based on the expected utilization from historical data we have accumulated since the IBSRELA product launch.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Rebates: Rebates include mandated discounts under the Medicaid Drug Rebate Program ("Medicaid") and the Medicare Coverage Gap Program ("Medicare"). Rebates are amounts owed after the final dispensing of products to a benefit plan &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;participant and are based upon contractual agreements or legal requirements with the public-sector benefit providers. These estimates for rebates are recorded in the same period the related gross revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included in accrued expenses on the condensed balance sheets. We estimate our Medicaid and Medicare rebates based upon the estimated payor mix, and statutory discount rates. Our estimates for payor mix are guided by payor information received from specialty pharmacies, expected utilization for specialty distributor sales to pharmacies, and available industry payor information. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Chargebacks: Chargebacks are discounts that occur when contracted purchasers purchase directly from our specialty distributors at a discounted price. The specialty distributor, in turn, charges back the difference between the price initially paid to us by the specialty distributor and the discounted price paid to the specialty distributor by the contracted purchaser. Amounts for estimated chargebacks are established in the same period that the related gross revenue is recognized, resulting in a reduction of product revenue and accounts receivable. The accrual for specialty distributor chargebacks is estimated based on known chargeback rates, known sales to specialty distributors, and estimated utilization by types of contracted purchasers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Discounts and Fees: Our payment terms are generally 30 to 60 days. Specialty distributors and specialty pharmacies are offered various forms of consideration, including service fees and prompt pay discounts for payment within a specified period. We expect these Customers will earn prompt pay discounts and therefore, we deduct the full amount of these discounts and service fees from product sales when revenue is recognized, resulting in a reduction of product revenue and accounts receivable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other Reserves: Patients who have commercial insurance may receive co-pay assistance when product is dispensed by pharmacies to patients. We estimate the amount of co-pay assistance provided to eligible patients based on the terms of the program and redemption information provided by third-party claims processing organizations and are recorded in accounts payable, accrued expenses and other current liabilities on the condensed balance sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <ardx:RevenueGeneralPaymentTerms
      contextRef="ibc13d123a8d14d6babcf8581fd6dcd05_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zMS9mcmFnOjIxYzg0YTQwOGU2OTRjMmNiZjg0MDJkZDY0NWVkM2I1L3RleHRyZWdpb246MjFjODRhNDA4ZTY5NGMyY2JmODQwMmRkNjQ1ZWQzYjVfNDM5ODA0NjU1NDU0MQ_9fb281cc-4d65-4d5d-b2a1-d0c84d80e020">P30D</ardx:RevenueGeneralPaymentTerms>
    <ardx:RevenueGeneralPaymentTerms
      contextRef="i3a085319c0b44680ad033352cd7f1a58_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zMS9mcmFnOjIxYzg0YTQwOGU2OTRjMmNiZjg0MDJkZDY0NWVkM2I1L3RleHRyZWdpb246MjFjODRhNDA4ZTY5NGMyY2JmODQwMmRkNjQ1ZWQzYjVfNDM5ODA0NjU1NDU1NA_efe83b91-5c2e-413e-bb4b-f072a75a3bae">P60D</ardx:RevenueGeneralPaymentTerms>
    <us-gaap:CostOfSalesPolicyTextBlock
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zMS9mcmFnOjIxYzg0YTQwOGU2OTRjMmNiZjg0MDJkZDY0NWVkM2I1L3RleHRyZWdpb246MjFjODRhNDA4ZTY5NGMyY2JmODQwMmRkNjQ1ZWQzYjVfNDM5ODA0NjU1NDUzNw_d3241a8d-74fb-4f41-88e7-60f45fa0757a">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cost of Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of revenue consists of the cost of commercial goods sold to our Customers, international partners under product supply agreements, and royalty expense based on sales of tenapanor. We capitalize inventory costs associated with the production of our products after regulatory approval or when, based on management&#x2019;s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized. Otherwise, such costs are expensed as research and development. A portion of the costs of IBSRELA units recognized as revenue during the three months ended March&#160;31, 2022 were expensed prior to the fourth quarter of 2021, at which time our intent to commercialize IBSRELA was established and we commenced  preparation for the commercial launch of IBSRELA.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of revenue includes payments due to AstraZeneca, which under the terms of a termination agreement entered into in 2015 (the "AZ Termination Agreement") is entitled to (i) future royalties at a rate of 10% of net sales of tenapanor or other NHE3 products by us or our licensees, and (ii) 20% of non-royalty revenue received from our collaboration partners as a result of the development and commercialization of tenapanor or certain other NHE3 inhibitors.&#160;We have agreed to pay&#160;AstraZeneca up to a maximum of $75.0 million in the aggregate for (i) and (ii). We recognize these expenses as cost of revenue when we recognize the corresponding revenue that gives rise to payments due to AstraZeneca. To date, we have recognized an aggregate of $11.7 million as cost of revenue under the AZ Termination Agreement.&lt;/span&gt;&lt;/div&gt;</us-gaap:CostOfSalesPolicyTextBlock>
    <ardx:PercentageOfRoyaltyRevenue
      contextRef="i390f2ffb21554b849e8f47149934d4fd_D20150601-20150630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zMS9mcmFnOjIxYzg0YTQwOGU2OTRjMmNiZjg0MDJkZDY0NWVkM2I1L3RleHRyZWdpb246MjFjODRhNDA4ZTY5NGMyY2JmODQwMmRkNjQ1ZWQzYjVfMjE5OTAyMzI5ODM3MQ_36a14427-40d0-47f8-9d3a-cd7552de954d"
      unitRef="number">0.10</ardx:PercentageOfRoyaltyRevenue>
    <ardx:PercentageOfNonRoyaltyRevenue
      contextRef="i390f2ffb21554b849e8f47149934d4fd_D20150601-20150630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zMS9mcmFnOjIxYzg0YTQwOGU2OTRjMmNiZjg0MDJkZDY0NWVkM2I1L3RleHRyZWdpb246MjFjODRhNDA4ZTY5NGMyY2JmODQwMmRkNjQ1ZWQzYjVfMjE5OTAyMzI5ODQ1Nw_c3b1a610-cb43-4d3a-bde9-17f354a42902"
      unitRef="number">0.20</ardx:PercentageOfNonRoyaltyRevenue>
    <ardx:CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum
      contextRef="id4d3d62533e642adab59317a030f3b30_I20150630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zMS9mcmFnOjIxYzg0YTQwOGU2OTRjMmNiZjg0MDJkZDY0NWVkM2I1L3RleHRyZWdpb246MjFjODRhNDA4ZTY5NGMyY2JmODQwMmRkNjQ1ZWQzYjVfMjE5OTAyMzI5ODY5MQ_6fcfcfa2-65b5-4548-ba76-53802acee91c"
      unitRef="usd">75000000</ardx:CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum>
    <ardx:CostOfRevenueAggregateAmountRecognized
      contextRef="i8bde55ddcbf0400a8169b35ffe4c6da2_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zMS9mcmFnOjIxYzg0YTQwOGU2OTRjMmNiZjg0MDJkZDY0NWVkM2I1L3RleHRyZWdpb246MjFjODRhNDA4ZTY5NGMyY2JmODQwMmRkNjQ1ZWQzYjVfMTA5OTUxMTY3MTQzMQ_0ae23e44-8c2f-48d9-9a0d-1a6ad72afa56"
      unitRef="usd">11700000</ardx:CostOfRevenueAggregateAmountRecognized>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zMS9mcmFnOjIxYzg0YTQwOGU2OTRjMmNiZjg0MDJkZDY0NWVkM2I1L3RleHRyZWdpb246MjFjODRhNDA4ZTY5NGMyY2JmODQwMmRkNjQ1ZWQzYjVfOTA3OA_05c3478b-c417-4e0b-97df-dfe05325b8fd">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;New Accounting Pronouncements - Recently Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have adopted no new accounting pronouncements other than those disclosed in our most recent Annual Report on Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were various accounting standards and interpretations issued recently, none of which are expected to a have a material impact on our financial position, operations or cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RleHRyZWdpb246MWU2ZGMzNzU5MWE3NDQ5M2I5MmI4ZTJmN2Y1NTI4NDlfMTg2OQ_bb994fa9-2118-4ea1-a982-58620a9018bd">CASH, CASH EQUIVALENTS AND INVESTMENTS&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Securities classified as cash, cash equivalents and investments as of March&#160;31, 2022 and December&#160;31, 2021 are summarized below (in thousands):&lt;/span&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.914%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.416%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,077&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government-sponsored agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(87)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(88)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.075%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents consist of money market funds and other debt securities with original maturities of three months or less at the time of purchase, and the carrying amount is a reasonable approximation of fair value. We invest our cash in high quality securities of financial and commercial institutions. These securities are carried at fair value, which is based on readily available market information, with unrealized gains and losses included in accumulated other comprehensive income (loss) within stockholders&#x2019; equity on our balance sheets. We use the specific identification method to determine the amount of realized gains or losses on sales of marketable securities. Realized gains or losses have been insignificant and are included in other income (expense), net, in the statement of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All short-term available-for-sale securities held as of March&#160;31, 2022 had contractual maturities of less than one year. Our available-for-sale securities are subject to a periodic impairment review. We consider a debt security to be impaired when its fair value is less than its carrying cost, in which case we would further review the investment to determine whether it is other-than-temporarily impaired. When we evaluate an investment for other-than-temporary impairment, we review factors such as the length of time and extent to which fair value has been below cost basis, the financial condition of the issuer and any changes thereto, intent to sell, and whether it is more likely than not we will be required to sell the investment before the recovery of its cost basis. If an investment is other-than-temporarily impaired, we write it down through the statement of operations and comprehensive loss to its fair value and establishes that value as a new cost basis for the investment. We did not identify any of our available-for-sale securities as other-than-temporarily impaired in any of the periods presented. As of March&#160;31, 2022 no &lt;/span&gt;&lt;/div&gt;investment was in a continuous unrealized loss position for more than one year and we believe that it is more likely than not that the investments will be held until maturity or a forecasted recovery of fair value.</us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock>
    <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RleHRyZWdpb246MWU2ZGMzNzU5MWE3NDQ5M2I5MmI4ZTJmN2Y1NTI4NDlfMTg2OA_337bc1c9-a40c-4b10-a567-8f7299b9c09a">&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Securities classified as cash, cash equivalents and investments as of March&#160;31, 2022 and December&#160;31, 2021 are summarized below (in thousands):&lt;/span&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.914%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.416%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,077&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government-sponsored agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(87)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(88)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.075%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
    <ardx:CashAndCashEquivalentsAmortizedCost
      contextRef="i7eb8629a82dc4a618ece82cbcdfbe085_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOmE0ZDEwNjY0NjlhYTQ1MTlhMTczMWQ1NGMyMTY4MTliL3RhYmxlcmFuZ2U6YTRkMTA2NjQ2OWFhNDUxOWExNzMxZDU0YzIxNjgxOWJfNC0xLTEtMS0yMzAxMw_0362df30-8202-4265-b69e-fa471e769107"
      unitRef="usd">7555000</ardx:CashAndCashEquivalentsAmortizedCost>
    <ardx:CashAndCashEquivalentsGrossUnrealizedGains
      contextRef="i7eb8629a82dc4a618ece82cbcdfbe085_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOmE0ZDEwNjY0NjlhYTQ1MTlhMTczMWQ1NGMyMTY4MTliL3RhYmxlcmFuZ2U6YTRkMTA2NjQ2OWFhNDUxOWExNzMxZDU0YzIxNjgxOWJfNC0zLTEtMS0yMzAxMw_5ea1bf7e-544d-4cf6-82e7-258e2b667631"
      unitRef="usd">0</ardx:CashAndCashEquivalentsGrossUnrealizedGains>
    <ardx:CashAndCashEquivalentsGrossUnrealizedLosses
      contextRef="i7eb8629a82dc4a618ece82cbcdfbe085_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOmE0ZDEwNjY0NjlhYTQ1MTlhMTczMWQ1NGMyMTY4MTliL3RhYmxlcmFuZ2U6YTRkMTA2NjQ2OWFhNDUxOWExNzMxZDU0YzIxNjgxOWJfNC01LTEtMS0yMzAxMw_d42cd7ae-383e-4659-88d1-38f38443da5a"
      unitRef="usd">0</ardx:CashAndCashEquivalentsGrossUnrealizedLosses>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i7eb8629a82dc4a618ece82cbcdfbe085_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOmE0ZDEwNjY0NjlhYTQ1MTlhMTczMWQ1NGMyMTY4MTliL3RhYmxlcmFuZ2U6YTRkMTA2NjQ2OWFhNDUxOWExNzMxZDU0YzIxNjgxOWJfNC03LTEtMS0yMzAxMw_de538290-9024-4a85-a050-d0e5b73cdd0e"
      unitRef="usd">7555000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <ardx:CashAndCashEquivalentsAmortizedCost
      contextRef="i05a2662add9440cc8c7d0f1dc736a702_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOmE0ZDEwNjY0NjlhYTQ1MTlhMTczMWQ1NGMyMTY4MTliL3RhYmxlcmFuZ2U6YTRkMTA2NjQ2OWFhNDUxOWExNzMxZDU0YzIxNjgxOWJfNS0xLTEtMS0yMzAxMw_eb451de3-decf-4145-a593-1f5b1170687a"
      unitRef="usd">34524000</ardx:CashAndCashEquivalentsAmortizedCost>
    <ardx:CashAndCashEquivalentsGrossUnrealizedGains
      contextRef="i05a2662add9440cc8c7d0f1dc736a702_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOmE0ZDEwNjY0NjlhYTQ1MTlhMTczMWQ1NGMyMTY4MTliL3RhYmxlcmFuZ2U6YTRkMTA2NjQ2OWFhNDUxOWExNzMxZDU0YzIxNjgxOWJfNS0zLTEtMS0yMzAxMw_e1384d20-0132-41dd-9941-fc8fc5a8a396"
      unitRef="usd">0</ardx:CashAndCashEquivalentsGrossUnrealizedGains>
    <ardx:CashAndCashEquivalentsGrossUnrealizedLosses
      contextRef="i05a2662add9440cc8c7d0f1dc736a702_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOmE0ZDEwNjY0NjlhYTQ1MTlhMTczMWQ1NGMyMTY4MTliL3RhYmxlcmFuZ2U6YTRkMTA2NjQ2OWFhNDUxOWExNzMxZDU0YzIxNjgxOWJfNS01LTEtMS0yMzAxMw_bb0058ba-7d8b-4160-bd6b-5bcad53f03d9"
      unitRef="usd">0</ardx:CashAndCashEquivalentsGrossUnrealizedLosses>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i05a2662add9440cc8c7d0f1dc736a702_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOmE0ZDEwNjY0NjlhYTQ1MTlhMTczMWQ1NGMyMTY4MTliL3RhYmxlcmFuZ2U6YTRkMTA2NjQ2OWFhNDUxOWExNzMxZDU0YzIxNjgxOWJfNS03LTEtMS0yMzAxMw_2c4034b2-62a5-4965-a5fd-cb98421f2e88"
      unitRef="usd">34524000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <ardx:CashAndCashEquivalentsAmortizedCost
      contextRef="i596f9b1e440f4452b6cba1824137da8b_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOmE0ZDEwNjY0NjlhYTQ1MTlhMTczMWQ1NGMyMTY4MTliL3RhYmxlcmFuZ2U6YTRkMTA2NjQ2OWFhNDUxOWExNzMxZDU0YzIxNjgxOWJfNi0xLTEtMS0yMzAxMw_4c80b313-33cd-4e64-889a-a1d601c1de89"
      unitRef="usd">4999000</ardx:CashAndCashEquivalentsAmortizedCost>
    <ardx:CashAndCashEquivalentsGrossUnrealizedGains
      contextRef="i596f9b1e440f4452b6cba1824137da8b_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOmE0ZDEwNjY0NjlhYTQ1MTlhMTczMWQ1NGMyMTY4MTliL3RhYmxlcmFuZ2U6YTRkMTA2NjQ2OWFhNDUxOWExNzMxZDU0YzIxNjgxOWJfNi0zLTEtMS0yMzAxMw_d68aee39-392a-4047-89ff-d36e51b657e0"
      unitRef="usd">0</ardx:CashAndCashEquivalentsGrossUnrealizedGains>
    <ardx:CashAndCashEquivalentsGrossUnrealizedLosses
      contextRef="i596f9b1e440f4452b6cba1824137da8b_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOmE0ZDEwNjY0NjlhYTQ1MTlhMTczMWQ1NGMyMTY4MTliL3RhYmxlcmFuZ2U6YTRkMTA2NjQ2OWFhNDUxOWExNzMxZDU0YzIxNjgxOWJfNi01LTEtMS0yMzAxMw_9d07ea25-2961-4bc7-b4fb-050c978fea68"
      unitRef="usd">1000</ardx:CashAndCashEquivalentsGrossUnrealizedLosses>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i596f9b1e440f4452b6cba1824137da8b_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOmE0ZDEwNjY0NjlhYTQ1MTlhMTczMWQ1NGMyMTY4MTliL3RhYmxlcmFuZ2U6YTRkMTA2NjQ2OWFhNDUxOWExNzMxZDU0YzIxNjgxOWJfNi03LTEtMS0yMzAxMw_1868a825-10f1-48ec-a4e5-26e62e07a8de"
      unitRef="usd">4998000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <ardx:CashAndCashEquivalentsAmortizedCost
      contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOmE0ZDEwNjY0NjlhYTQ1MTlhMTczMWQ1NGMyMTY4MTliL3RhYmxlcmFuZ2U6YTRkMTA2NjQ2OWFhNDUxOWExNzMxZDU0YzIxNjgxOWJfOC0xLTEtMS0yMzAxMw_d180c066-fd69-497f-84ae-b487169ef982"
      unitRef="usd">47078000</ardx:CashAndCashEquivalentsAmortizedCost>
    <ardx:CashAndCashEquivalentsGrossUnrealizedGains
      contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOmE0ZDEwNjY0NjlhYTQ1MTlhMTczMWQ1NGMyMTY4MTliL3RhYmxlcmFuZ2U6YTRkMTA2NjQ2OWFhNDUxOWExNzMxZDU0YzIxNjgxOWJfOC0zLTEtMS0yMzAxMw_631231a6-a787-444a-bb2f-90b1600d0d5e"
      unitRef="usd">0</ardx:CashAndCashEquivalentsGrossUnrealizedGains>
    <ardx:CashAndCashEquivalentsGrossUnrealizedLosses
      contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOmE0ZDEwNjY0NjlhYTQ1MTlhMTczMWQ1NGMyMTY4MTliL3RhYmxlcmFuZ2U6YTRkMTA2NjQ2OWFhNDUxOWExNzMxZDU0YzIxNjgxOWJfOC01LTEtMS0yMzAxMw_85331913-7230-42bb-923e-284757cc6310"
      unitRef="usd">1000</ardx:CashAndCashEquivalentsGrossUnrealizedLosses>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOmE0ZDEwNjY0NjlhYTQ1MTlhMTczMWQ1NGMyMTY4MTliL3RhYmxlcmFuZ2U6YTRkMTA2NjQ2OWFhNDUxOWExNzMxZDU0YzIxNjgxOWJfOC03LTEtMS0yMzAxMw_4c2703a4-a3d4-4132-aaeb-0ed65840ed4e"
      unitRef="usd">47077000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i7673f1405fd24051b58473f5a806ecb9_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOmE0ZDEwNjY0NjlhYTQ1MTlhMTczMWQ1NGMyMTY4MTliL3RhYmxlcmFuZ2U6YTRkMTA2NjQ2OWFhNDUxOWExNzMxZDU0YzIxNjgxOWJfMTAtMS0xLTEtMjMwMTM_4661f34a-9aa2-4557-a50a-81dec709a74f"
      unitRef="usd">28409000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i7673f1405fd24051b58473f5a806ecb9_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOmE0ZDEwNjY0NjlhYTQ1MTlhMTczMWQ1NGMyMTY4MTliL3RhYmxlcmFuZ2U6YTRkMTA2NjQ2OWFhNDUxOWExNzMxZDU0YzIxNjgxOWJfMTAtMy0xLTEtMjMwMTM_011bc0ff-85a9-403d-a1ee-21b143ad76e5"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i7673f1405fd24051b58473f5a806ecb9_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOmE0ZDEwNjY0NjlhYTQ1MTlhMTczMWQ1NGMyMTY4MTliL3RhYmxlcmFuZ2U6YTRkMTA2NjQ2OWFhNDUxOWExNzMxZDU0YzIxNjgxOWJfMTAtNS0xLTEtMjMwMTM_d3c6cf3b-2c6a-407a-89ea-137721be3e7b"
      unitRef="usd">52000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7673f1405fd24051b58473f5a806ecb9_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOmE0ZDEwNjY0NjlhYTQ1MTlhMTczMWQ1NGMyMTY4MTliL3RhYmxlcmFuZ2U6YTRkMTA2NjQ2OWFhNDUxOWExNzMxZDU0YzIxNjgxOWJfMTAtNy0xLTEtMjMwMTM_c4338807-da01-4dda-a076-e51fabff4a03"
      unitRef="usd">28357000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="iea208acf5bf04c3b9d76527a7e0ebf16_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOmE0ZDEwNjY0NjlhYTQ1MTlhMTczMWQ1NGMyMTY4MTliL3RhYmxlcmFuZ2U6YTRkMTA2NjQ2OWFhNDUxOWExNzMxZDU0YzIxNjgxOWJfMTEtMS0xLTEtMjg5NTk_d5e0ebae-f64a-43aa-bba8-86ec8b2c7218"
      unitRef="usd">10777000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iea208acf5bf04c3b9d76527a7e0ebf16_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOmE0ZDEwNjY0NjlhYTQ1MTlhMTczMWQ1NGMyMTY4MTliL3RhYmxlcmFuZ2U6YTRkMTA2NjQ2OWFhNDUxOWExNzMxZDU0YzIxNjgxOWJfMTEtMy0xLTEtMjg5NTk_f32b3d30-6002-46f5-b97c-6fc597f2a083"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iea208acf5bf04c3b9d76527a7e0ebf16_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOmE0ZDEwNjY0NjlhYTQ1MTlhMTczMWQ1NGMyMTY4MTliL3RhYmxlcmFuZ2U6YTRkMTA2NjQ2OWFhNDUxOWExNzMxZDU0YzIxNjgxOWJfMTEtNS0xLTEtMjg5NTk_7ad554e5-0812-48ed-a2c3-c41f9bd18b42"
      unitRef="usd">22000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iea208acf5bf04c3b9d76527a7e0ebf16_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOmE0ZDEwNjY0NjlhYTQ1MTlhMTczMWQ1NGMyMTY4MTliL3RhYmxlcmFuZ2U6YTRkMTA2NjQ2OWFhNDUxOWExNzMxZDU0YzIxNjgxOWJfMTEtNy0xLTEtMjg5NTk_5fe6e0db-b03e-4085-af9b-c71d3b5bf838"
      unitRef="usd">10755000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i37581a46b73b46d5b858164659fbef62_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOmE0ZDEwNjY0NjlhYTQ1MTlhMTczMWQ1NGMyMTY4MTliL3RhYmxlcmFuZ2U6YTRkMTA2NjQ2OWFhNDUxOWExNzMxZDU0YzIxNjgxOWJfMTEtMS0xLTEtMjMwMTM_5ecb02cf-e143-4122-83f0-cf6e612b9c3e"
      unitRef="usd">2521000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i37581a46b73b46d5b858164659fbef62_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOmE0ZDEwNjY0NjlhYTQ1MTlhMTczMWQ1NGMyMTY4MTliL3RhYmxlcmFuZ2U6YTRkMTA2NjQ2OWFhNDUxOWExNzMxZDU0YzIxNjgxOWJfMTEtMy0xLTEtMjMwMTM_a70589d7-8b44-46c2-aa31-6e5ce9ddcac9"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i37581a46b73b46d5b858164659fbef62_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOmE0ZDEwNjY0NjlhYTQ1MTlhMTczMWQ1NGMyMTY4MTliL3RhYmxlcmFuZ2U6YTRkMTA2NjQ2OWFhNDUxOWExNzMxZDU0YzIxNjgxOWJfMTEtNS0xLTEtMjMwMTM_303f4df8-9988-41b6-bd18-c7df73dbddda"
      unitRef="usd">10000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i37581a46b73b46d5b858164659fbef62_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOmE0ZDEwNjY0NjlhYTQ1MTlhMTczMWQ1NGMyMTY4MTliL3RhYmxlcmFuZ2U6YTRkMTA2NjQ2OWFhNDUxOWExNzMxZDU0YzIxNjgxOWJfMTEtNy0xLTEtMjMwMTM_bce4cfcf-86fe-4214-8a06-a96d2d89ae70"
      unitRef="usd">2511000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i19273e8da1e4462a88cdc93b1a044f85_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOmE0ZDEwNjY0NjlhYTQ1MTlhMTczMWQ1NGMyMTY4MTliL3RhYmxlcmFuZ2U6YTRkMTA2NjQ2OWFhNDUxOWExNzMxZDU0YzIxNjgxOWJfMTMtMS0xLTEtMjMwMTM_8f46179c-3e48-4da5-b5d4-a5c82c6080e1"
      unitRef="usd">1007000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i19273e8da1e4462a88cdc93b1a044f85_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOmE0ZDEwNjY0NjlhYTQ1MTlhMTczMWQ1NGMyMTY4MTliL3RhYmxlcmFuZ2U6YTRkMTA2NjQ2OWFhNDUxOWExNzMxZDU0YzIxNjgxOWJfMTMtMy0xLTEtMjMwMTM_3d088eed-2287-4f85-b89b-33ded70c6a08"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i19273e8da1e4462a88cdc93b1a044f85_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOmE0ZDEwNjY0NjlhYTQ1MTlhMTczMWQ1NGMyMTY4MTliL3RhYmxlcmFuZ2U6YTRkMTA2NjQ2OWFhNDUxOWExNzMxZDU0YzIxNjgxOWJfMTMtNS0xLTEtMjMwMTM_1741ccbe-b143-4bc7-b560-27b95375fbb8"
      unitRef="usd">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i19273e8da1e4462a88cdc93b1a044f85_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOmE0ZDEwNjY0NjlhYTQ1MTlhMTczMWQ1NGMyMTY4MTliL3RhYmxlcmFuZ2U6YTRkMTA2NjQ2OWFhNDUxOWExNzMxZDU0YzIxNjgxOWJfMTMtNy0xLTEtMjMwMTM_119ad4a1-e17b-4ca6-b25f-500aca3828c4"
      unitRef="usd">1004000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOmE0ZDEwNjY0NjlhYTQ1MTlhMTczMWQ1NGMyMTY4MTliL3RhYmxlcmFuZ2U6YTRkMTA2NjQ2OWFhNDUxOWExNzMxZDU0YzIxNjgxOWJfMTQtMS0xLTEtMjMwMTM_b389edaa-fc06-465d-a91e-86e0c5b4eb46"
      unitRef="usd">42714000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOmE0ZDEwNjY0NjlhYTQ1MTlhMTczMWQ1NGMyMTY4MTliL3RhYmxlcmFuZ2U6YTRkMTA2NjQ2OWFhNDUxOWExNzMxZDU0YzIxNjgxOWJfMTQtMy0xLTEtMjMwMTM_aac22094-d71c-46ef-abcd-7a17ca898a16"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOmE0ZDEwNjY0NjlhYTQ1MTlhMTczMWQ1NGMyMTY4MTliL3RhYmxlcmFuZ2U6YTRkMTA2NjQ2OWFhNDUxOWExNzMxZDU0YzIxNjgxOWJfMTQtNS0xLTEtMjMwMTM_c50bec36-c344-456f-be5e-9ca8d09eb44d"
      unitRef="usd">87000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOmE0ZDEwNjY0NjlhYTQ1MTlhMTczMWQ1NGMyMTY4MTliL3RhYmxlcmFuZ2U6YTRkMTA2NjQ2OWFhNDUxOWExNzMxZDU0YzIxNjgxOWJfMTQtNy0xLTEtMjMwMTM_b23ad5a5-dccb-4f31-8997-e1db4d607208"
      unitRef="usd">42627000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <ardx:InvestmentsAndCashAmortizedCost
      contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOmE0ZDEwNjY0NjlhYTQ1MTlhMTczMWQ1NGMyMTY4MTliL3RhYmxlcmFuZ2U6YTRkMTA2NjQ2OWFhNDUxOWExNzMxZDU0YzIxNjgxOWJfMTYtMS0xLTEtMjMwMTM_9d15faf1-c650-4c2e-8bab-b02e3112693a"
      unitRef="usd">89792000</ardx:InvestmentsAndCashAmortizedCost>
    <ardx:CashCashEquivalentsAndInvestmentsGrossUnrealizedGains
      contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOmE0ZDEwNjY0NjlhYTQ1MTlhMTczMWQ1NGMyMTY4MTliL3RhYmxlcmFuZ2U6YTRkMTA2NjQ2OWFhNDUxOWExNzMxZDU0YzIxNjgxOWJfMTYtMy0xLTEtMjMwMTM_4f47742b-d5c1-493a-910c-d1dce366bf48"
      unitRef="usd">0</ardx:CashCashEquivalentsAndInvestmentsGrossUnrealizedGains>
    <ardx:CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses
      contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOmE0ZDEwNjY0NjlhYTQ1MTlhMTczMWQ1NGMyMTY4MTliL3RhYmxlcmFuZ2U6YTRkMTA2NjQ2OWFhNDUxOWExNzMxZDU0YzIxNjgxOWJfMTYtNS0xLTEtMjMwMTM_1011f5e1-851d-4932-8541-c7893b61c658"
      unitRef="usd">88000</ardx:CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses>
    <us-gaap:InvestmentsAndCash
      contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOmE0ZDEwNjY0NjlhYTQ1MTlhMTczMWQ1NGMyMTY4MTliL3RhYmxlcmFuZ2U6YTRkMTA2NjQ2OWFhNDUxOWExNzMxZDU0YzIxNjgxOWJfMTYtNy0xLTEtMjMwMTM_2046a5dc-5063-44cb-a087-0dd6467a8c86"
      unitRef="usd">89704000</us-gaap:InvestmentsAndCash>
    <ardx:CashAndCashEquivalentsAmortizedCost
      contextRef="i1757ee4e90cc49c3ae9d0a3ce3f93f66_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOjk3MTg3MDhkMjU2YzQ3YzQ4ZDU3MTk1MWVlN2ExOGI5L3RhYmxlcmFuZ2U6OTcxODcwOGQyNTZjNDdjNDhkNTcxOTUxZWU3YTE4YjlfNC0xLTEtMS0yMzAxMw_c1a80c6f-f4f8-4dd1-8342-9d1a530eb672"
      unitRef="usd">1253000</ardx:CashAndCashEquivalentsAmortizedCost>
    <ardx:CashAndCashEquivalentsGrossUnrealizedGains
      contextRef="i1757ee4e90cc49c3ae9d0a3ce3f93f66_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOjk3MTg3MDhkMjU2YzQ3YzQ4ZDU3MTk1MWVlN2ExOGI5L3RhYmxlcmFuZ2U6OTcxODcwOGQyNTZjNDdjNDhkNTcxOTUxZWU3YTE4YjlfNC0zLTEtMS0yMzAxMw_2569c6bd-9a5a-4011-8b73-864b91e26793"
      unitRef="usd">0</ardx:CashAndCashEquivalentsGrossUnrealizedGains>
    <ardx:CashAndCashEquivalentsGrossUnrealizedLosses
      contextRef="i1757ee4e90cc49c3ae9d0a3ce3f93f66_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOjk3MTg3MDhkMjU2YzQ3YzQ4ZDU3MTk1MWVlN2ExOGI5L3RhYmxlcmFuZ2U6OTcxODcwOGQyNTZjNDdjNDhkNTcxOTUxZWU3YTE4YjlfNC01LTEtMS0yMzAxMw_40c07b81-b7d9-47e0-a0b7-5c1082c59b02"
      unitRef="usd">0</ardx:CashAndCashEquivalentsGrossUnrealizedLosses>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i1757ee4e90cc49c3ae9d0a3ce3f93f66_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOjk3MTg3MDhkMjU2YzQ3YzQ4ZDU3MTk1MWVlN2ExOGI5L3RhYmxlcmFuZ2U6OTcxODcwOGQyNTZjNDdjNDhkNTcxOTUxZWU3YTE4YjlfNC03LTEtMS0yMzAxMw_d4e54a2f-cbb0-4ae8-ad83-366affcec7b1"
      unitRef="usd">1253000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <ardx:CashAndCashEquivalentsAmortizedCost
      contextRef="ib27f65921b34451f840e9bfaa2858274_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOjk3MTg3MDhkMjU2YzQ3YzQ4ZDU3MTk1MWVlN2ExOGI5L3RhYmxlcmFuZ2U6OTcxODcwOGQyNTZjNDdjNDhkNTcxOTUxZWU3YTE4YjlfNS0xLTEtMS0yMzAxMw_0edeb73a-9ab9-4c58-b620-e781fdc31bb9"
      unitRef="usd">71175000</ardx:CashAndCashEquivalentsAmortizedCost>
    <ardx:CashAndCashEquivalentsGrossUnrealizedGains
      contextRef="ib27f65921b34451f840e9bfaa2858274_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOjk3MTg3MDhkMjU2YzQ3YzQ4ZDU3MTk1MWVlN2ExOGI5L3RhYmxlcmFuZ2U6OTcxODcwOGQyNTZjNDdjNDhkNTcxOTUxZWU3YTE4YjlfNS0zLTEtMS0yMzAxMw_d6e7a08b-9d6a-4d28-a3c7-03bccf78c4c8"
      unitRef="usd">0</ardx:CashAndCashEquivalentsGrossUnrealizedGains>
    <ardx:CashAndCashEquivalentsGrossUnrealizedLosses
      contextRef="ib27f65921b34451f840e9bfaa2858274_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOjk3MTg3MDhkMjU2YzQ3YzQ4ZDU3MTk1MWVlN2ExOGI5L3RhYmxlcmFuZ2U6OTcxODcwOGQyNTZjNDdjNDhkNTcxOTUxZWU3YTE4YjlfNS01LTEtMS0yMzAxMw_043810b3-9904-45b2-b1de-b711cd42b19e"
      unitRef="usd">0</ardx:CashAndCashEquivalentsGrossUnrealizedLosses>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ib27f65921b34451f840e9bfaa2858274_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOjk3MTg3MDhkMjU2YzQ3YzQ4ZDU3MTk1MWVlN2ExOGI5L3RhYmxlcmFuZ2U6OTcxODcwOGQyNTZjNDdjNDhkNTcxOTUxZWU3YTE4YjlfNS03LTEtMS0yMzAxMw_a7825278-cfbe-4650-b297-eda423db20b3"
      unitRef="usd">71175000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <ardx:CashAndCashEquivalentsAmortizedCost
      contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOjk3MTg3MDhkMjU2YzQ3YzQ4ZDU3MTk1MWVlN2ExOGI5L3RhYmxlcmFuZ2U6OTcxODcwOGQyNTZjNDdjNDhkNTcxOTUxZWU3YTE4YjlfOC0xLTEtMS0yMzAxMw_b83bd843-fbfb-41bf-88d8-e170672e82cd"
      unitRef="usd">72428000</ardx:CashAndCashEquivalentsAmortizedCost>
    <ardx:CashAndCashEquivalentsGrossUnrealizedGains
      contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOjk3MTg3MDhkMjU2YzQ3YzQ4ZDU3MTk1MWVlN2ExOGI5L3RhYmxlcmFuZ2U6OTcxODcwOGQyNTZjNDdjNDhkNTcxOTUxZWU3YTE4YjlfOC0zLTEtMS0yMzAxMw_3b438e53-29ac-4f3b-94df-3a6fb1542d1b"
      unitRef="usd">0</ardx:CashAndCashEquivalentsGrossUnrealizedGains>
    <ardx:CashAndCashEquivalentsGrossUnrealizedLosses
      contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOjk3MTg3MDhkMjU2YzQ3YzQ4ZDU3MTk1MWVlN2ExOGI5L3RhYmxlcmFuZ2U6OTcxODcwOGQyNTZjNDdjNDhkNTcxOTUxZWU3YTE4YjlfOC01LTEtMS0yMzAxMw_903f7207-d6e8-4b71-96e0-5a66a49a6236"
      unitRef="usd">0</ardx:CashAndCashEquivalentsGrossUnrealizedLosses>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOjk3MTg3MDhkMjU2YzQ3YzQ4ZDU3MTk1MWVlN2ExOGI5L3RhYmxlcmFuZ2U6OTcxODcwOGQyNTZjNDdjNDhkNTcxOTUxZWU3YTE4YjlfOC03LTEtMS0yMzAxMw_08da255d-9a4f-4282-b687-15c49f495da1"
      unitRef="usd">72428000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ib232d5bccde74c2c832a58c5854c8659_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOjk3MTg3MDhkMjU2YzQ3YzQ4ZDU3MTk1MWVlN2ExOGI5L3RhYmxlcmFuZ2U6OTcxODcwOGQyNTZjNDdjNDhkNTcxOTUxZWU3YTE4YjlfMTAtMS0xLTEtMjMwMTM_bddaed81-af48-4da3-8118-1bf2b0b23c3f"
      unitRef="usd">31936000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ib232d5bccde74c2c832a58c5854c8659_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOjk3MTg3MDhkMjU2YzQ3YzQ4ZDU3MTk1MWVlN2ExOGI5L3RhYmxlcmFuZ2U6OTcxODcwOGQyNTZjNDdjNDhkNTcxOTUxZWU3YTE4YjlfMTAtMy0xLTEtMjMwMTM_39852ccd-5bab-4341-81d1-bd29f3484f7d"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ib232d5bccde74c2c832a58c5854c8659_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOjk3MTg3MDhkMjU2YzQ3YzQ4ZDU3MTk1MWVlN2ExOGI5L3RhYmxlcmFuZ2U6OTcxODcwOGQyNTZjNDdjNDhkNTcxOTUxZWU3YTE4YjlfMTAtNS0xLTEtMjMwMTM_d0620fcb-82fb-4b73-ad03-55f8109dcc8d"
      unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib232d5bccde74c2c832a58c5854c8659_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOjk3MTg3MDhkMjU2YzQ3YzQ4ZDU3MTk1MWVlN2ExOGI5L3RhYmxlcmFuZ2U6OTcxODcwOGQyNTZjNDdjNDhkNTcxOTUxZWU3YTE4YjlfMTAtNy0xLTEtMjMwMTM_f8ae0c6d-e8d6-4b1f-b510-39a8e93ca738"
      unitRef="usd">31935000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i5f8c132fed8e489a94a6ec129ee5512e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOjk3MTg3MDhkMjU2YzQ3YzQ4ZDU3MTk1MWVlN2ExOGI5L3RhYmxlcmFuZ2U6OTcxODcwOGQyNTZjNDdjNDhkNTcxOTUxZWU3YTE4YjlfMTEtMS0xLTEtMjMwMTM_da1ebeb5-470a-472c-be30-0961c275dc89"
      unitRef="usd">7025000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i5f8c132fed8e489a94a6ec129ee5512e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOjk3MTg3MDhkMjU2YzQ3YzQ4ZDU3MTk1MWVlN2ExOGI5L3RhYmxlcmFuZ2U6OTcxODcwOGQyNTZjNDdjNDhkNTcxOTUxZWU3YTE4YjlfMTEtMy0xLTEtMjMwMTM_05f3d6a2-028d-4e29-b840-98703fb1b6b3"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i5f8c132fed8e489a94a6ec129ee5512e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOjk3MTg3MDhkMjU2YzQ3YzQ4ZDU3MTk1MWVlN2ExOGI5L3RhYmxlcmFuZ2U6OTcxODcwOGQyNTZjNDdjNDhkNTcxOTUxZWU3YTE4YjlfMTEtNS0xLTEtMjMwMTM_be4e8320-f1db-4a94-a665-babf69171293"
      unitRef="usd">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5f8c132fed8e489a94a6ec129ee5512e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOjk3MTg3MDhkMjU2YzQ3YzQ4ZDU3MTk1MWVlN2ExOGI5L3RhYmxlcmFuZ2U6OTcxODcwOGQyNTZjNDdjNDhkNTcxOTUxZWU3YTE4YjlfMTEtNy0xLTEtMjMwMTM_c97c60b5-ac85-496e-ba71-2139f9e0afe8"
      unitRef="usd">7022000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="iae3a2fe36c17417ca407960547b30624_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOjk3MTg3MDhkMjU2YzQ3YzQ4ZDU3MTk1MWVlN2ExOGI5L3RhYmxlcmFuZ2U6OTcxODcwOGQyNTZjNDdjNDhkNTcxOTUxZWU3YTE4YjlfMTMtMS0xLTEtMjMwMTM_dca63c3e-a144-4e90-b559-bd9fbc8fe772"
      unitRef="usd">5306000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iae3a2fe36c17417ca407960547b30624_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOjk3MTg3MDhkMjU2YzQ3YzQ4ZDU3MTk1MWVlN2ExOGI5L3RhYmxlcmFuZ2U6OTcxODcwOGQyNTZjNDdjNDhkNTcxOTUxZWU3YTE4YjlfMTMtMy0xLTEtMjMwMTM_71f32bc9-a3e3-4a3f-b285-73a1032017cc"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iae3a2fe36c17417ca407960547b30624_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOjk3MTg3MDhkMjU2YzQ3YzQ4ZDU3MTk1MWVlN2ExOGI5L3RhYmxlcmFuZ2U6OTcxODcwOGQyNTZjNDdjNDhkNTcxOTUxZWU3YTE4YjlfMTMtNS0xLTEtMjMwMTM_8a502f15-0b62-4cb0-8d19-b397b0cfa18d"
      unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iae3a2fe36c17417ca407960547b30624_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOjk3MTg3MDhkMjU2YzQ3YzQ4ZDU3MTk1MWVlN2ExOGI5L3RhYmxlcmFuZ2U6OTcxODcwOGQyNTZjNDdjNDhkNTcxOTUxZWU3YTE4YjlfMTMtNy0xLTEtMjMwMTM_39c7dba9-a615-403f-a2a6-58115178dca6"
      unitRef="usd">5304000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOjk3MTg3MDhkMjU2YzQ3YzQ4ZDU3MTk1MWVlN2ExOGI5L3RhYmxlcmFuZ2U6OTcxODcwOGQyNTZjNDdjNDhkNTcxOTUxZWU3YTE4YjlfMTQtMS0xLTEtMjMwMTM_e0e7dafb-8b3d-4c0c-8295-c92d63aae2f7"
      unitRef="usd">44267000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOjk3MTg3MDhkMjU2YzQ3YzQ4ZDU3MTk1MWVlN2ExOGI5L3RhYmxlcmFuZ2U6OTcxODcwOGQyNTZjNDdjNDhkNTcxOTUxZWU3YTE4YjlfMTQtMy0xLTEtMjMwMTM_0a883b60-6be3-4b9c-bc31-1dd2a3520478"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOjk3MTg3MDhkMjU2YzQ3YzQ4ZDU3MTk1MWVlN2ExOGI5L3RhYmxlcmFuZ2U6OTcxODcwOGQyNTZjNDdjNDhkNTcxOTUxZWU3YTE4YjlfMTQtNS0xLTEtMjMwMTM_6089904f-1ec4-4945-8030-b3471f3d4a89"
      unitRef="usd">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOjk3MTg3MDhkMjU2YzQ3YzQ4ZDU3MTk1MWVlN2ExOGI5L3RhYmxlcmFuZ2U6OTcxODcwOGQyNTZjNDdjNDhkNTcxOTUxZWU3YTE4YjlfMTQtNy0xLTEtMjMwMTM_b64304e8-810f-48a4-b945-59695180a65c"
      unitRef="usd">44261000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <ardx:InvestmentsAndCashAmortizedCost
      contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOjk3MTg3MDhkMjU2YzQ3YzQ4ZDU3MTk1MWVlN2ExOGI5L3RhYmxlcmFuZ2U6OTcxODcwOGQyNTZjNDdjNDhkNTcxOTUxZWU3YTE4YjlfMTctMS0xLTEtMjMwMTM_abd80f07-d907-4af6-b6a6-773749b7eafb"
      unitRef="usd">116695000</ardx:InvestmentsAndCashAmortizedCost>
    <ardx:CashCashEquivalentsAndInvestmentsGrossUnrealizedGains
      contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOjk3MTg3MDhkMjU2YzQ3YzQ4ZDU3MTk1MWVlN2ExOGI5L3RhYmxlcmFuZ2U6OTcxODcwOGQyNTZjNDdjNDhkNTcxOTUxZWU3YTE4YjlfMTctMy0xLTEtMjMwMTM_c31065ba-4da3-4b9e-88ba-e9e47c1c4486"
      unitRef="usd">1000</ardx:CashCashEquivalentsAndInvestmentsGrossUnrealizedGains>
    <ardx:CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses
      contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOjk3MTg3MDhkMjU2YzQ3YzQ4ZDU3MTk1MWVlN2ExOGI5L3RhYmxlcmFuZ2U6OTcxODcwOGQyNTZjNDdjNDhkNTcxOTUxZWU3YTE4YjlfMTctNS0xLTEtMjMwMTM_0e58b6ae-6a0b-4154-a283-6cd2d01be964"
      unitRef="usd">7000</ardx:CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses>
    <us-gaap:InvestmentsAndCash
      contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RhYmxlOjk3MTg3MDhkMjU2YzQ3YzQ4ZDU3MTk1MWVlN2ExOGI5L3RhYmxlcmFuZ2U6OTcxODcwOGQyNTZjNDdjNDhkNTcxOTUxZWU3YTE4YjlfMTctNy0xLTEtMjMwMTM_8c3319ad-57f6-431e-846b-e148f0543579"
      unitRef="usd">116689000</us-gaap:InvestmentsAndCash>
    <ardx:AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RleHRyZWdpb246MWU2ZGMzNzU5MWE3NDQ5M2I5MmI4ZTJmN2Y1NTI4NDlfMTA5OTUxMTYzNjM5NQ_5fb2996b-591d-4454-bb74-7f9a013eb789">P1Y</ardx:AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum>
    <us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RleHRyZWdpb246MWU2ZGMzNzU5MWE3NDQ5M2I5MmI4ZTJmN2Y1NTI4NDlfMzI5ODUzNDg5MjExMQ_2ca1f2ac-f75b-4602-8910-c4df4e63d18e"
      unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale>
    <us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
      contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RleHRyZWdpb246MWU2ZGMzNzU5MWE3NDQ5M2I5MmI4ZTJmN2Y1NTI4NDlfMzI5ODUzNDg5MjExMQ_5f672374-1f5c-4a07-9ca9-93af1637e7a8"
      unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RleHRyZWdpb246MWU2ZGMzNzU5MWE3NDQ5M2I5MmI4ZTJmN2Y1NTI4NDlfMTA5OTUxMTYzNjU0MQ_3be823c1-371f-4cdc-acb1-197527899197"
      unitRef="investment">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RleHRyZWdpb246MWU2ZGMzNzU5MWE3NDQ5M2I5MmI4ZTJmN2Y1NTI4NDlfMTA5OTUxMTYzNjU0MQ_5a0446b8-11f0-4cc3-b7c1-cce4a69778b3"
      unitRef="investment">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RleHRyZWdpb246MWU2ZGMzNzU5MWE3NDQ5M2I5MmI4ZTJmN2Y1NTI4NDlfMTA5OTUxMTYzNjU0MQ_6c4c4b22-a397-4259-8e2e-408253fd3299"
      unitRef="investment">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNC9mcmFnOjFlNmRjMzc1OTFhNzQ0OTNiOTJiOGUyZjdmNTUyODQ5L3RleHRyZWdpb246MWU2ZGMzNzU5MWE3NDQ5M2I5MmI4ZTJmN2Y1NTI4NDlfMTA5OTUxMTYzNjU0MQ_d317f8aa-5f4b-4f5b-afb0-6c16bdf1a6f6"
      unitRef="investment">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RleHRyZWdpb246ZjNkOGM4MTNmMTI2NDQ1NGFhY2Y0NjczMDI0NWRkYTJfMTk5Mw_6ecdfc8d-8207-4843-815c-a7a807d80279">FAIR VALUE MEASUREMENTS&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The three-level hierarchy for the inputs to valuation techniques is briefly summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 1 &#x2013;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuations are based on quoted prices in active markets for identical assets or liabilities and readily accessible by us at the reporting date.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 2 &#x2013;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuations based on inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 3 &#x2013;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuations based on unobservable inputs for which there is little or no market data, which require us to develop our own assumptions.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the fair value of our financial assets and liabilities that are measured or disclosed on a recurring basis by level within the fair value hierarchy (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government-sponsored agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 12.25pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative liability for exit fees&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 12.25pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative liability for exit fee&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Where quoted prices are available in an active market, securities are classified as Level 1. We classify money market funds as Level 1. When quoted market prices are not available for the specific security, we estimate fair value by using benchmark yields, reported trades, broker/dealer quotes and issuer spreads. We classify U.S. government-sponsored agency bonds, U.S. treasury notes, corporate bonds, commercial paper, and asset-backed securities as Level 2. In certain cases, where there is limited activity or less transparency around inputs to valuation, securities or derivative liabilities, such as the Exit Fee, as defined and discussed in Note 8, are classified as Level 3.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts reflected in the balance sheets for cash equivalents, short-term investments, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair values at both March&#160;31, 2022 and December&#160;31, 2021, due to their short-term nature. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Debt&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The interest rate of our term loan facility approximates the rate at which we could obtain alternative financing. Therefore, the carrying amount of the term loan facility approximated its fair value at March&#160;31, 2022 and December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RleHRyZWdpb246ZjNkOGM4MTNmMTI2NDQ1NGFhY2Y0NjczMDI0NWRkYTJfMTk5NA_1ebf6ef4-fafe-4547-8a08-bb8311400e4c">&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The three-level hierarchy for the inputs to valuation techniques is briefly summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 1 &#x2013;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuations are based on quoted prices in active markets for identical assets or liabilities and readily accessible by us at the reporting date.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 2 &#x2013;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuations based on inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 3 &#x2013;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuations based on unobservable inputs for which there is little or no market data, which require us to develop our own assumptions.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RleHRyZWdpb246ZjNkOGM4MTNmMTI2NDQ1NGFhY2Y0NjczMDI0NWRkYTJfMTk5NQ_e92af1df-2dd9-4cf8-afbf-3dcb4f4804f4">&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the fair value of our financial assets and liabilities that are measured or disclosed on a recurring basis by level within the fair value hierarchy (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government-sponsored agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 12.25pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative liability for exit fees&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 12.25pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative liability for exit fee&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="id7116fb603e844e7b66ea135c246d400_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOjE2MjZjZmRjNGNiNDQzOTJhMTAyNjc2NTQzZWExN2JkL3RhYmxlcmFuZ2U6MTYyNmNmZGM0Y2I0NDM5MmExMDI2NzY1NDNlYTE3YmRfMy0xLTEtMS0yMzAxMw_aa5475d2-9068-46e7-8bb3-6c39a8d58716"
      unitRef="usd">34524000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i5f95faaaa8ba40ef81fabfd9af749d5a_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOjE2MjZjZmRjNGNiNDQzOTJhMTAyNjc2NTQzZWExN2JkL3RhYmxlcmFuZ2U6MTYyNmNmZGM0Y2I0NDM5MmExMDI2NzY1NDNlYTE3YmRfMy0zLTEtMS0yMzAxMw_e5af89f8-d82e-45d7-b539-6313f094536e"
      unitRef="usd">34524000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ifffac340b48d4569a291b906003daa40_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOjE2MjZjZmRjNGNiNDQzOTJhMTAyNjc2NTQzZWExN2JkL3RhYmxlcmFuZ2U6MTYyNmNmZGM0Y2I0NDM5MmExMDI2NzY1NDNlYTE3YmRfMy01LTEtMS0yMzAxMw_58f9280e-3d4a-4689-b0b2-9f7930420e13"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib3c8925c35b44d6d9fbe11c422368576_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOjE2MjZjZmRjNGNiNDQzOTJhMTAyNjc2NTQzZWExN2JkL3RhYmxlcmFuZ2U6MTYyNmNmZGM0Y2I0NDM5MmExMDI2NzY1NDNlYTE3YmRfMy03LTEtMS0yMzAxMw_89276a86-dd00-4fe1-af7b-617542510a44"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie320d5dea5f84c1a997114a2a44304ab_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOjE2MjZjZmRjNGNiNDQzOTJhMTAyNjc2NTQzZWExN2JkL3RhYmxlcmFuZ2U6MTYyNmNmZGM0Y2I0NDM5MmExMDI2NzY1NDNlYTE3YmRfNC0xLTEtMS0yMzAxMw_49d8c9c4-0e77-4042-96a9-36186e33f6c4"
      unitRef="usd">33355000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ic12ce3ad23f94a40843d57bbafc1b93b_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOjE2MjZjZmRjNGNiNDQzOTJhMTAyNjc2NTQzZWExN2JkL3RhYmxlcmFuZ2U6MTYyNmNmZGM0Y2I0NDM5MmExMDI2NzY1NDNlYTE3YmRfNC0zLTEtMS0yMzAxMw_23eeac1e-8128-4915-bf49-64c9f8f7f068"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib64b89a6dbb241f9ac74255f0f2faddd_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOjE2MjZjZmRjNGNiNDQzOTJhMTAyNjc2NTQzZWExN2JkL3RhYmxlcmFuZ2U6MTYyNmNmZGM0Y2I0NDM5MmExMDI2NzY1NDNlYTE3YmRfNC01LTEtMS0yMzAxMw_bf82113e-2555-47bd-a678-486065b86c11"
      unitRef="usd">33355000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i20743f7a35cf46598f5e61aadaaaf959_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOjE2MjZjZmRjNGNiNDQzOTJhMTAyNjc2NTQzZWExN2JkL3RhYmxlcmFuZ2U6MTYyNmNmZGM0Y2I0NDM5MmExMDI2NzY1NDNlYTE3YmRfNC03LTEtMS0yMzAxMw_53d904f2-fc09-478f-9df8-e8bfd60cd753"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i7282cda81b5e403d9d6a82b54ca9e220_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOjE2MjZjZmRjNGNiNDQzOTJhMTAyNjc2NTQzZWExN2JkL3RhYmxlcmFuZ2U6MTYyNmNmZGM0Y2I0NDM5MmExMDI2NzY1NDNlYTE3YmRfNS0xLTEtMS0yOTA1MQ_6d3d8679-20b7-4ca4-bf79-9552197d30d2"
      unitRef="usd">10755000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="icbe8bcf473664c3cbd7a8d406e6f4b25_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOjE2MjZjZmRjNGNiNDQzOTJhMTAyNjc2NTQzZWExN2JkL3RhYmxlcmFuZ2U6MTYyNmNmZGM0Y2I0NDM5MmExMDI2NzY1NDNlYTE3YmRfNS0zLTEtMS0yOTA1MQ_cc1ca8a8-32a4-4a1c-a44a-3a89edd22a92"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ieff5d13f74bb46f19e0bf993fbdb4e1b_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOjE2MjZjZmRjNGNiNDQzOTJhMTAyNjc2NTQzZWExN2JkL3RhYmxlcmFuZ2U6MTYyNmNmZGM0Y2I0NDM5MmExMDI2NzY1NDNlYTE3YmRfNS01LTEtMS0yOTA1MQ_d049e021-64b6-47f8-9faf-a21961495238"
      unitRef="usd">10755000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i9c8530d2f63d4dcd99a0d2685f08f090_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOjE2MjZjZmRjNGNiNDQzOTJhMTAyNjc2NTQzZWExN2JkL3RhYmxlcmFuZ2U6MTYyNmNmZGM0Y2I0NDM5MmExMDI2NzY1NDNlYTE3YmRfNS03LTEtMS0yOTA1MQ_cb5e47f2-63e0-4a81-8bb7-be275cfee3c1"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i22961d74779a41578f711e2cbdab8cc8_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOjE2MjZjZmRjNGNiNDQzOTJhMTAyNjc2NTQzZWExN2JkL3RhYmxlcmFuZ2U6MTYyNmNmZGM0Y2I0NDM5MmExMDI2NzY1NDNlYTE3YmRfNS0xLTEtMS0yMzAxMw_6668927b-7e68-409f-b110-90bd3741eec1"
      unitRef="usd">2511000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i346bb756dc874f18b4e7ecc3b1fd18fd_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOjE2MjZjZmRjNGNiNDQzOTJhMTAyNjc2NTQzZWExN2JkL3RhYmxlcmFuZ2U6MTYyNmNmZGM0Y2I0NDM5MmExMDI2NzY1NDNlYTE3YmRfNS0zLTEtMS0yMzAxMw_a5defca7-d6ae-434e-9682-c683a7a1f2f2"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i45e9678a2bb9475883b569adf411868a_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOjE2MjZjZmRjNGNiNDQzOTJhMTAyNjc2NTQzZWExN2JkL3RhYmxlcmFuZ2U6MTYyNmNmZGM0Y2I0NDM5MmExMDI2NzY1NDNlYTE3YmRfNS01LTEtMS0yMzAxMw_d1301130-7bd6-48a8-aa13-6cc492721f09"
      unitRef="usd">2511000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i057b3b5e23d74f1b93392611784416da_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOjE2MjZjZmRjNGNiNDQzOTJhMTAyNjc2NTQzZWExN2JkL3RhYmxlcmFuZ2U6MTYyNmNmZGM0Y2I0NDM5MmExMDI2NzY1NDNlYTE3YmRfNS03LTEtMS0yMzAxMw_712d028e-1bda-4400-9e5f-4c234ee19211"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iec212359212b4b3686fe182249f00160_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOjE2MjZjZmRjNGNiNDQzOTJhMTAyNjc2NTQzZWExN2JkL3RhYmxlcmFuZ2U6MTYyNmNmZGM0Y2I0NDM5MmExMDI2NzY1NDNlYTE3YmRfNy0xLTEtMS0yMzAxMw_11a1d4c2-0c46-4b21-8dad-96a3cc396450"
      unitRef="usd">1004000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i5c358ffd9da447c0ae8ba16d667ddb3d_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOjE2MjZjZmRjNGNiNDQzOTJhMTAyNjc2NTQzZWExN2JkL3RhYmxlcmFuZ2U6MTYyNmNmZGM0Y2I0NDM5MmExMDI2NzY1NDNlYTE3YmRfNy0zLTEtMS0yMzAxMw_3bdc61f3-ffab-423f-9d21-c386c58ee18d"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iaa5d06c90bd0488e864737436b77eb4c_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOjE2MjZjZmRjNGNiNDQzOTJhMTAyNjc2NTQzZWExN2JkL3RhYmxlcmFuZ2U6MTYyNmNmZGM0Y2I0NDM5MmExMDI2NzY1NDNlYTE3YmRfNy01LTEtMS0yMzAxMw_41a2b159-924e-45eb-a6ac-f36203f1a2ab"
      unitRef="usd">1004000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i8b1a0008a10b4495b001946a2dbbebcf_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOjE2MjZjZmRjNGNiNDQzOTJhMTAyNjc2NTQzZWExN2JkL3RhYmxlcmFuZ2U6MTYyNmNmZGM0Y2I0NDM5MmExMDI2NzY1NDNlYTE3YmRfNy03LTEtMS0yMzAxMw_711cde2a-2baf-4a02-9f21-e85cb1a0e5de"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia66c3497d92f4f87983a8808d4c22279_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOjE2MjZjZmRjNGNiNDQzOTJhMTAyNjc2NTQzZWExN2JkL3RhYmxlcmFuZ2U6MTYyNmNmZGM0Y2I0NDM5MmExMDI2NzY1NDNlYTE3YmRfOS0xLTEtMS0yMzAxMw_5766cb31-24a6-4cf0-b8a1-9757bfdea482"
      unitRef="usd">82149000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="idccb2dc5b13a4488878f9a05af20f66a_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOjE2MjZjZmRjNGNiNDQzOTJhMTAyNjc2NTQzZWExN2JkL3RhYmxlcmFuZ2U6MTYyNmNmZGM0Y2I0NDM5MmExMDI2NzY1NDNlYTE3YmRfOS0zLTEtMS0yMzAxMw_1b3e11bd-018c-40d7-9bb8-55b345171e11"
      unitRef="usd">34524000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia8a67586059d49f9810370c50eaa57c0_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOjE2MjZjZmRjNGNiNDQzOTJhMTAyNjc2NTQzZWExN2JkL3RhYmxlcmFuZ2U6MTYyNmNmZGM0Y2I0NDM5MmExMDI2NzY1NDNlYTE3YmRfOS01LTEtMS0yMzAxMw_88487dcb-fb51-4566-ac3e-7e535df40b3c"
      unitRef="usd">47625000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i7c1a6f674cd541978439c2f0f7d4fb9a_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOjE2MjZjZmRjNGNiNDQzOTJhMTAyNjc2NTQzZWExN2JkL3RhYmxlcmFuZ2U6MTYyNmNmZGM0Y2I0NDM5MmExMDI2NzY1NDNlYTE3YmRfOS03LTEtMS0yMzAxMw_c77827a9-5f16-434a-8672-279fa596b667"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ie0e3ba1f3d18466d8724f70ecdc208fa_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOjE2MjZjZmRjNGNiNDQzOTJhMTAyNjc2NTQzZWExN2JkL3RhYmxlcmFuZ2U6MTYyNmNmZGM0Y2I0NDM5MmExMDI2NzY1NDNlYTE3YmRfMTItMS0xLTEtMjMwMTM_502623d3-fec7-4b15-a907-fab90cccfc03"
      unitRef="usd">1088000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="icd9cbd3639304bd294cd77b069e2903b_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOjE2MjZjZmRjNGNiNDQzOTJhMTAyNjc2NTQzZWExN2JkL3RhYmxlcmFuZ2U6MTYyNmNmZGM0Y2I0NDM5MmExMDI2NzY1NDNlYTE3YmRfMTItMy0xLTEtMjMwMTM_6715455d-1744-490a-9bb9-dbdc7542c106"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ie12d13976cc7450da7913cd451cc1f1d_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOjE2MjZjZmRjNGNiNDQzOTJhMTAyNjc2NTQzZWExN2JkL3RhYmxlcmFuZ2U6MTYyNmNmZGM0Y2I0NDM5MmExMDI2NzY1NDNlYTE3YmRfMTItNS0xLTEtMjMwMTM_401abf1b-0c37-46d5-8645-ec65f8fbf73c"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ie7da228130c340edbbb9bf247a589756_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOjE2MjZjZmRjNGNiNDQzOTJhMTAyNjc2NTQzZWExN2JkL3RhYmxlcmFuZ2U6MTYyNmNmZGM0Y2I0NDM5MmExMDI2NzY1NDNlYTE3YmRfMTItNy0xLTEtMjMwMTM_3910a93a-5ab1-4305-9738-ae1bd3b30953"
      unitRef="usd">1088000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ia66c3497d92f4f87983a8808d4c22279_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOjE2MjZjZmRjNGNiNDQzOTJhMTAyNjc2NTQzZWExN2JkL3RhYmxlcmFuZ2U6MTYyNmNmZGM0Y2I0NDM5MmExMDI2NzY1NDNlYTE3YmRfMTMtMS0xLTEtMjMwMTM_7b2f0fa8-7cf9-4494-8519-a640a34cdb2e"
      unitRef="usd">1088000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="idccb2dc5b13a4488878f9a05af20f66a_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOjE2MjZjZmRjNGNiNDQzOTJhMTAyNjc2NTQzZWExN2JkL3RhYmxlcmFuZ2U6MTYyNmNmZGM0Y2I0NDM5MmExMDI2NzY1NDNlYTE3YmRfMTMtMy0xLTEtMjMwMTM_c2e3996e-1abd-4885-95c6-f4ee18a32489"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ia8a67586059d49f9810370c50eaa57c0_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOjE2MjZjZmRjNGNiNDQzOTJhMTAyNjc2NTQzZWExN2JkL3RhYmxlcmFuZ2U6MTYyNmNmZGM0Y2I0NDM5MmExMDI2NzY1NDNlYTE3YmRfMTMtNS0xLTEtMjMwMTM_ce900302-d086-4bac-a12a-4c589eaf743f"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i7c1a6f674cd541978439c2f0f7d4fb9a_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOjE2MjZjZmRjNGNiNDQzOTJhMTAyNjc2NTQzZWExN2JkL3RhYmxlcmFuZ2U6MTYyNmNmZGM0Y2I0NDM5MmExMDI2NzY1NDNlYTE3YmRfMTMtNy0xLTEtMjMwMTM_3d005be1-d6a6-483f-bd1d-c1a2aea0d590"
      unitRef="usd">1088000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i9becbf42740c409189339a2b5a11a4f2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOmRiNzQ0NWEzYzEzMzRlZmViNGVhZTY4Y2NmNjRhMDRiL3RhYmxlcmFuZ2U6ZGI3NDQ1YTNjMTMzNGVmZWI0ZWFlNjhjY2Y2NGEwNGJfMy0xLTEtMS0yMzAxMw_d21e1c40-94b6-43ff-821f-ec6d9a86010a"
      unitRef="usd">71175000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i92ef66972cf9427cb63419db9768a298_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOmRiNzQ0NWEzYzEzMzRlZmViNGVhZTY4Y2NmNjRhMDRiL3RhYmxlcmFuZ2U6ZGI3NDQ1YTNjMTMzNGVmZWI0ZWFlNjhjY2Y2NGEwNGJfMy0zLTEtMS0yMzAxMw_5d73c0d6-75f7-4768-aa55-b79ca9f4d04a"
      unitRef="usd">71175000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i211bb796b7a24967b594b6dbe16c328c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOmRiNzQ0NWEzYzEzMzRlZmViNGVhZTY4Y2NmNjRhMDRiL3RhYmxlcmFuZ2U6ZGI3NDQ1YTNjMTMzNGVmZWI0ZWFlNjhjY2Y2NGEwNGJfMy01LTEtMS0yMzAxMw_1bf0e075-8193-43a6-aa6a-840caa163243"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie08734f5a1ee4ae1a8f14c3e0ad81e38_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOmRiNzQ0NWEzYzEzMzRlZmViNGVhZTY4Y2NmNjRhMDRiL3RhYmxlcmFuZ2U6ZGI3NDQ1YTNjMTMzNGVmZWI0ZWFlNjhjY2Y2NGEwNGJfMy03LTEtMS0yMzAxMw_5bfc6c69-99d0-4a11-b1d6-8fcd266ffd45"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i702ba55895b343c594a4b5ed37806639_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOmRiNzQ0NWEzYzEzMzRlZmViNGVhZTY4Y2NmNjRhMDRiL3RhYmxlcmFuZ2U6ZGI3NDQ1YTNjMTMzNGVmZWI0ZWFlNjhjY2Y2NGEwNGJfNC0xLTEtMS0yMzAxMw_6312c86a-c233-40d0-97ab-d9b53620b223"
      unitRef="usd">31935000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="id48fda4018124a2789eda8fb5e8c7f3b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOmRiNzQ0NWEzYzEzMzRlZmViNGVhZTY4Y2NmNjRhMDRiL3RhYmxlcmFuZ2U6ZGI3NDQ1YTNjMTMzNGVmZWI0ZWFlNjhjY2Y2NGEwNGJfNC0zLTEtMS0yMzAxMw_bec77406-75e7-4b05-b7dd-cc13f683df5d"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i864378b20e0f48a2a4a6e9ec27084dd7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOmRiNzQ0NWEzYzEzMzRlZmViNGVhZTY4Y2NmNjRhMDRiL3RhYmxlcmFuZ2U6ZGI3NDQ1YTNjMTMzNGVmZWI0ZWFlNjhjY2Y2NGEwNGJfNC01LTEtMS0yMzAxMw_6af14edc-a9b9-4f22-995b-b60914a01bb2"
      unitRef="usd">31935000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i870189fb8682430baf663525b78d14eb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOmRiNzQ0NWEzYzEzMzRlZmViNGVhZTY4Y2NmNjRhMDRiL3RhYmxlcmFuZ2U6ZGI3NDQ1YTNjMTMzNGVmZWI0ZWFlNjhjY2Y2NGEwNGJfNC03LTEtMS0yMzAxMw_433aaf69-9ead-4ba0-bcda-4ab430da2b13"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i498f3eb654bb4e63858ae975af11c445_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOmRiNzQ0NWEzYzEzMzRlZmViNGVhZTY4Y2NmNjRhMDRiL3RhYmxlcmFuZ2U6ZGI3NDQ1YTNjMTMzNGVmZWI0ZWFlNjhjY2Y2NGEwNGJfNS0xLTEtMS0yMzAxMw_5669bcd3-f97f-412b-9d6d-05cbb29fd241"
      unitRef="usd">7022000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie76caf10c27b47c9b2d7f93b70732805_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOmRiNzQ0NWEzYzEzMzRlZmViNGVhZTY4Y2NmNjRhMDRiL3RhYmxlcmFuZ2U6ZGI3NDQ1YTNjMTMzNGVmZWI0ZWFlNjhjY2Y2NGEwNGJfNS0zLTEtMS0yMzAxMw_2e033699-71f3-48b5-9e0d-40c6f94a2e7d"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i8b34d1e5e84949e08757fe31d16851b6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOmRiNzQ0NWEzYzEzMzRlZmViNGVhZTY4Y2NmNjRhMDRiL3RhYmxlcmFuZ2U6ZGI3NDQ1YTNjMTMzNGVmZWI0ZWFlNjhjY2Y2NGEwNGJfNS01LTEtMS0yMzAxMw_e8528159-9fdc-40bb-ba60-8a371ade6367"
      unitRef="usd">7022000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="icae86f3621e745dcae0300fcf262e97a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOmRiNzQ0NWEzYzEzMzRlZmViNGVhZTY4Y2NmNjRhMDRiL3RhYmxlcmFuZ2U6ZGI3NDQ1YTNjMTMzNGVmZWI0ZWFlNjhjY2Y2NGEwNGJfNS03LTEtMS0yMzAxMw_7087fadb-9648-4038-91b1-19a142ffa661"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ibfe0e960aed543b5988f05f7d3355902_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOmRiNzQ0NWEzYzEzMzRlZmViNGVhZTY4Y2NmNjRhMDRiL3RhYmxlcmFuZ2U6ZGI3NDQ1YTNjMTMzNGVmZWI0ZWFlNjhjY2Y2NGEwNGJfNy0xLTEtMS0yMzAxMw_bcbe06d2-e533-4c34-9039-41de24ec988a"
      unitRef="usd">5304000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i0f334852225945b2a7a93e28e698a7b5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOmRiNzQ0NWEzYzEzMzRlZmViNGVhZTY4Y2NmNjRhMDRiL3RhYmxlcmFuZ2U6ZGI3NDQ1YTNjMTMzNGVmZWI0ZWFlNjhjY2Y2NGEwNGJfNy0zLTEtMS0yMzAxMw_61864cd2-51f6-43f7-be60-39deb1717449"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2fbce7b430d746d193e24e71ed55ec24_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOmRiNzQ0NWEzYzEzMzRlZmViNGVhZTY4Y2NmNjRhMDRiL3RhYmxlcmFuZ2U6ZGI3NDQ1YTNjMTMzNGVmZWI0ZWFlNjhjY2Y2NGEwNGJfNy01LTEtMS0yMzAxMw_a99d7c7b-0c12-4fb5-9861-2af440a3d859"
      unitRef="usd">5304000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i77f4939d9c1b4cb9a23a9d1abed49c29_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOmRiNzQ0NWEzYzEzMzRlZmViNGVhZTY4Y2NmNjRhMDRiL3RhYmxlcmFuZ2U6ZGI3NDQ1YTNjMTMzNGVmZWI0ZWFlNjhjY2Y2NGEwNGJfNy03LTEtMS0yMzAxMw_7adbf44f-b1c6-4084-b8d6-e91b386dc943"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i0a918505eebf4610bda0dea154daa7a3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOmRiNzQ0NWEzYzEzMzRlZmViNGVhZTY4Y2NmNjRhMDRiL3RhYmxlcmFuZ2U6ZGI3NDQ1YTNjMTMzNGVmZWI0ZWFlNjhjY2Y2NGEwNGJfOS0xLTEtMS0yNDUxMw_1023e160-ea15-404d-b54e-ad7fd8c83dc0"
      unitRef="usd">115436000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ibb543391634c44d0a2f40bdc636ebebf_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOmRiNzQ0NWEzYzEzMzRlZmViNGVhZTY4Y2NmNjRhMDRiL3RhYmxlcmFuZ2U6ZGI3NDQ1YTNjMTMzNGVmZWI0ZWFlNjhjY2Y2NGEwNGJfOS0zLTEtMS0yNDUxMw_7b47a315-f3fc-4bb9-9076-0a480affeed6"
      unitRef="usd">71175000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6b0ae5504847492aaff354b4bb3eed43_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOmRiNzQ0NWEzYzEzMzRlZmViNGVhZTY4Y2NmNjRhMDRiL3RhYmxlcmFuZ2U6ZGI3NDQ1YTNjMTMzNGVmZWI0ZWFlNjhjY2Y2NGEwNGJfOS01LTEtMS0yNDUxMw_30217120-e1cc-46ae-b3f8-d0dd6ff5f727"
      unitRef="usd">44261000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i07deb0701eff4cf3b8159da82875bb77_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOmRiNzQ0NWEzYzEzMzRlZmViNGVhZTY4Y2NmNjRhMDRiL3RhYmxlcmFuZ2U6ZGI3NDQ1YTNjMTMzNGVmZWI0ZWFlNjhjY2Y2NGEwNGJfOS03LTEtMS0yNDUxMw_0bf3c2ff-9651-4893-a673-1c62c76ab268"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="if2c246545dd44f91b1867420b6787cd5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOmRiNzQ0NWEzYzEzMzRlZmViNGVhZTY4Y2NmNjRhMDRiL3RhYmxlcmFuZ2U6ZGI3NDQ1YTNjMTMzNGVmZWI0ZWFlNjhjY2Y2NGEwNGJfMTItMS0xLTEtMjMwMTM_31d24502-7764-4b42-ba6d-d2f685d549f0"
      unitRef="usd">698000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i57236df6e705400089af661d14abc3ab_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOmRiNzQ0NWEzYzEzMzRlZmViNGVhZTY4Y2NmNjRhMDRiL3RhYmxlcmFuZ2U6ZGI3NDQ1YTNjMTMzNGVmZWI0ZWFlNjhjY2Y2NGEwNGJfMTItMy0xLTEtMjMwMTM_e8ff04a4-ac29-428b-a8ec-f5a9e5645bd9"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i9aaa3d02b9854e48a25597ea0974cd4e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOmRiNzQ0NWEzYzEzMzRlZmViNGVhZTY4Y2NmNjRhMDRiL3RhYmxlcmFuZ2U6ZGI3NDQ1YTNjMTMzNGVmZWI0ZWFlNjhjY2Y2NGEwNGJfMTItNS0xLTEtMjMwMTM_b1b9e0eb-4a3e-4c42-869c-552b3ebb429d"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="iec8114b671a2456c81955e87ce50bed9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOmRiNzQ0NWEzYzEzMzRlZmViNGVhZTY4Y2NmNjRhMDRiL3RhYmxlcmFuZ2U6ZGI3NDQ1YTNjMTMzNGVmZWI0ZWFlNjhjY2Y2NGEwNGJfMTItNy0xLTEtMjMwMTM_0b7a5727-c8a7-4a4a-98ab-ca3162858b3b"
      unitRef="usd">698000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i0a918505eebf4610bda0dea154daa7a3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOmRiNzQ0NWEzYzEzMzRlZmViNGVhZTY4Y2NmNjRhMDRiL3RhYmxlcmFuZ2U6ZGI3NDQ1YTNjMTMzNGVmZWI0ZWFlNjhjY2Y2NGEwNGJfMTMtMS0xLTEtMjQ1MTM_be0cb75d-e9f2-482b-a8e9-0f389ef17919"
      unitRef="usd">698000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ibb543391634c44d0a2f40bdc636ebebf_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOmRiNzQ0NWEzYzEzMzRlZmViNGVhZTY4Y2NmNjRhMDRiL3RhYmxlcmFuZ2U6ZGI3NDQ1YTNjMTMzNGVmZWI0ZWFlNjhjY2Y2NGEwNGJfMTMtMy0xLTEtMjQ1MTM_2761946d-9af2-427b-ab80-c59bb1775a73"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i6b0ae5504847492aaff354b4bb3eed43_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOmRiNzQ0NWEzYzEzMzRlZmViNGVhZTY4Y2NmNjRhMDRiL3RhYmxlcmFuZ2U6ZGI3NDQ1YTNjMTMzNGVmZWI0ZWFlNjhjY2Y2NGEwNGJfMTMtNS0xLTEtMjQ1MTM_c199a885-9a89-481c-b1f2-0068f018281d"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i07deb0701eff4cf3b8159da82875bb77_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8zNy9mcmFnOmYzZDhjODEzZjEyNjQ0NTRhYWNmNDY3MzAyNDVkZGEyL3RhYmxlOmRiNzQ0NWEzYzEzMzRlZmViNGVhZTY4Y2NmNjRhMDRiL3RhYmxlcmFuZ2U6ZGI3NDQ1YTNjMTMzNGVmZWI0ZWFlNjhjY2Y2NGEwNGJfMTMtNy0xLTEtMjQ1MTM_006a24c2-0698-4caa-9377-b0f0419f0f82"
      unitRef="usd">698000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xMTYxL2ZyYWc6YzBhYWJiMTYyZTYyNGUyN2FhODU0YmM2YTYxYzQ5MGMvdGV4dHJlZ2lvbjpjMGFhYmIxNjJlNjI0ZTI3YWE4NTRiYzZhNjFjNDkwY180Mzk4MDQ2NTE2MjU2_2ee294a4-6a63-4e4f-8701-2ac73f0eab36">INVENTORY&lt;div style="margin-bottom:3pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We began capitalizing inventory during the fourth quarter of 2021, at which time our intent to commercialize IBSRELA was established and we commenced  preparation for the commercial launch of IBSRELA. Inventory consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xMTYxL2ZyYWc6YzBhYWJiMTYyZTYyNGUyN2FhODU0YmM2YTYxYzQ5MGMvdGV4dHJlZ2lvbjpjMGFhYmIxNjJlNjI0ZTI3YWE4NTRiYzZhNjFjNDkwY180Mzk4MDQ2NTE2MjU3_17abd2fc-51bc-47cd-a509-86c329b2adb7">Inventory consisted of the following (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials
      contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xMTYxL2ZyYWc6YzBhYWJiMTYyZTYyNGUyN2FhODU0YmM2YTYxYzQ5MGMvdGFibGU6NGI3ZjI0ZjE4NDllNGQxNDliODZmNWEwOGFiNTY3ZGQvdGFibGVyYW5nZTo0YjdmMjRmMTg0OWU0ZDE0OWI4NmY1YTA4YWI1NjdkZF8xLTctMS0xLTMwNzY0_25f8c50e-baa4-4b87-9332-a3ae26c0a765"
      unitRef="usd">460000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryWorkInProcess
      contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xMTYxL2ZyYWc6YzBhYWJiMTYyZTYyNGUyN2FhODU0YmM2YTYxYzQ5MGMvdGFibGU6NGI3ZjI0ZjE4NDllNGQxNDliODZmNWEwOGFiNTY3ZGQvdGFibGVyYW5nZTo0YjdmMjRmMTg0OWU0ZDE0OWI4NmY1YTA4YWI1NjdkZF8yLTItMS0xLTMwODAy_9fdf6061-0215-4de6-ab07-5b39566cc32b"
      unitRef="usd">2507000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods
      contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xMTYxL2ZyYWc6YzBhYWJiMTYyZTYyNGUyN2FhODU0YmM2YTYxYzQ5MGMvdGFibGU6NGI3ZjI0ZjE4NDllNGQxNDliODZmNWEwOGFiNTY3ZGQvdGFibGVyYW5nZTo0YjdmMjRmMTg0OWU0ZDE0OWI4NmY1YTA4YWI1NjdkZF8yLTctMS0xLTMwNzY0_db3d4d9d-9560-4520-91d4-46e38999ab57"
      unitRef="usd">520000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryNet
      contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xMTYxL2ZyYWc6YzBhYWJiMTYyZTYyNGUyN2FhODU0YmM2YTYxYzQ5MGMvdGFibGU6NGI3ZjI0ZjE4NDllNGQxNDliODZmNWEwOGFiNTY3ZGQvdGFibGVyYW5nZTo0YjdmMjRmMTg0OWU0ZDE0OWI4NmY1YTA4YWI1NjdkZF8zLTctMS0xLTMwNzY0_6610d7c7-1d74-4b30-b4cf-af5cf1b1b43e"
      unitRef="usd">3487000</us-gaap:InventoryNet>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xMTQ2L2ZyYWc6NjAyZTAzMTg1YTM0NDIwNzg1Y2Y2Mzg0MGY1ZTI4NDQvdGV4dHJlZ2lvbjo2MDJlMDMxODVhMzQ0MjA3ODVjZjYzODQwZjVlMjg0NF80Mzk4MDQ2NTE0NTQ2_7d03a7bd-34d4-44ad-a4ec-bd61ebd01530">PRODUCT REVENUE, NET&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We received approval from the FDA in September 2019 to market IBSRELA, the first and only sodium hydrogen exchanger 3 (&#x201c;NHE3&#x201d;) inhibitor for the treatment of irritable bowel syndrome with constipation ("IBS-C") in adults, in the U.S. We began selling IBSRELA in the U.S. in March 2022. We recorded net revenue for IBSRELA of $0.5&#160;million during the three months ended March&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sales to Cardinal Health, AmerisourceBergen Drug Corporation, and McKesson Corporation made up 17.9%, 17.1%, and 15.4% of our gross product revenue during the three months ended March&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The activities and ending reserve balances for each significant category of discounts and allowances, which constitute variable consideration, were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Discounts and Chargebacks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Rebates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other Fees, Copay and Returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Activity related to 2022 sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no product sales or gross-to-net accruals during the three months ended March&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i157edd1d25424d4e869f567c7ddd2b4a_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xMTQ2L2ZyYWc6NjAyZTAzMTg1YTM0NDIwNzg1Y2Y2Mzg0MGY1ZTI4NDQvdGV4dHJlZ2lvbjo2MDJlMDMxODVhMzQ0MjA3ODVjZjYzODQwZjVlMjg0NF8xMDk5NTExNjMxMzUz_09929c4f-8125-486f-8755-c1087c097744"
      unitRef="usd">500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i5602110d257243d68fe06a3de7666ba1_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xMTQ2L2ZyYWc6NjAyZTAzMTg1YTM0NDIwNzg1Y2Y2Mzg0MGY1ZTI4NDQvdGV4dHJlZ2lvbjo2MDJlMDMxODVhMzQ0MjA3ODVjZjYzODQwZjVlMjg0NF8xMDk5NTExNjM0MTgx_e4e3ef93-6cc2-4b9c-8acc-92738f798675"
      unitRef="number">0.179</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i7a2496c68915449aa1b605adb0073d44_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xMTQ2L2ZyYWc6NjAyZTAzMTg1YTM0NDIwNzg1Y2Y2Mzg0MGY1ZTI4NDQvdGV4dHJlZ2lvbjo2MDJlMDMxODVhMzQ0MjA3ODVjZjYzODQwZjVlMjg0NF8xMDk5NTExNjMxNzA3_daad727c-1a14-4f6e-b7e9-ce79e0b5e610"
      unitRef="number">0.171</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ib4ede0c6d6294ec1ba539591fc337da1_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xMTQ2L2ZyYWc6NjAyZTAzMTg1YTM0NDIwNzg1Y2Y2Mzg0MGY1ZTI4NDQvdGV4dHJlZ2lvbjo2MDJlMDMxODVhMzQ0MjA3ODVjZjYzODQwZjVlMjg0NF8xMDk5NTExNjMxNjQy_1b1cc701-96a8-46b6-93bc-a13363d58c65"
      unitRef="number">0.154</us-gaap:ConcentrationRiskPercentage1>
    <ardx:ScheduleOfGrossToNetSalesAccrualsTableTextBlock
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xMTQ2L2ZyYWc6NjAyZTAzMTg1YTM0NDIwNzg1Y2Y2Mzg0MGY1ZTI4NDQvdGV4dHJlZ2lvbjo2MDJlMDMxODVhMzQ0MjA3ODVjZjYzODQwZjVlMjg0NF80Mzk4MDQ2NTE0NTQ3_fafe475d-d250-4aa5-adc5-12b6a1087880">&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The activities and ending reserve balances for each significant category of discounts and allowances, which constitute variable consideration, were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Discounts and Chargebacks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Rebates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other Fees, Copay and Returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Activity related to 2022 sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ardx:ScheduleOfGrossToNetSalesAccrualsTableTextBlock>
    <ardx:ContractWithCustomerGrossToNetSalesAccruals
      contextRef="i3cd8e102ed0b453abc3afc0ba274b816_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xMTQ2L2ZyYWc6NjAyZTAzMTg1YTM0NDIwNzg1Y2Y2Mzg0MGY1ZTI4NDQvdGFibGU6YzRlMzliMGUyNTQxNGI4M2JlMjE5Y2Y3NTJmNTFmYmMvdGFibGVyYW5nZTpjNGUzOWIwZTI1NDE0YjgzYmUyMTljZjc1MmY1MWZiY18xLTEtMS0xLTI5NjAw_6c81a63c-6fa8-42c2-b082-451aeb576a81"
      unitRef="usd">0</ardx:ContractWithCustomerGrossToNetSalesAccruals>
    <ardx:ContractWithCustomerGrossToNetSalesAccruals
      contextRef="i0e3b20e3d13f464f8136bc69cac78387_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xMTQ2L2ZyYWc6NjAyZTAzMTg1YTM0NDIwNzg1Y2Y2Mzg0MGY1ZTI4NDQvdGFibGU6YzRlMzliMGUyNTQxNGI4M2JlMjE5Y2Y3NTJmNTFmYmMvdGFibGVyYW5nZTpjNGUzOWIwZTI1NDE0YjgzYmUyMTljZjc1MmY1MWZiY18xLTMtMS0xLTMwMDY4_505313bb-0c69-427a-ad25-87d9a4fadeac"
      unitRef="usd">0</ardx:ContractWithCustomerGrossToNetSalesAccruals>
    <ardx:ContractWithCustomerGrossToNetSalesAccruals
      contextRef="ibc17b1d2c9354e6ba7867c153f98dd39_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xMTQ2L2ZyYWc6NjAyZTAzMTg1YTM0NDIwNzg1Y2Y2Mzg0MGY1ZTI4NDQvdGFibGU6YzRlMzliMGUyNTQxNGI4M2JlMjE5Y2Y3NTJmNTFmYmMvdGFibGVyYW5nZTpjNGUzOWIwZTI1NDE0YjgzYmUyMTljZjc1MmY1MWZiY18xLTMtMS0xLTI5NjAw_f8f864ad-9708-406b-94d8-4cdeafb1d5cc"
      unitRef="usd">0</ardx:ContractWithCustomerGrossToNetSalesAccruals>
    <ardx:ContractWithCustomerGrossToNetSalesAccruals
      contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xMTQ2L2ZyYWc6NjAyZTAzMTg1YTM0NDIwNzg1Y2Y2Mzg0MGY1ZTI4NDQvdGFibGU6YzRlMzliMGUyNTQxNGI4M2JlMjE5Y2Y3NTJmNTFmYmMvdGFibGVyYW5nZTpjNGUzOWIwZTI1NDE0YjgzYmUyMTljZjc1MmY1MWZiY18xLTUtMS0xLTI5NjAw_52021ae6-5749-4690-8bec-af510615139d"
      unitRef="usd">0</ardx:ContractWithCustomerGrossToNetSalesAccruals>
    <ardx:ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod
      contextRef="ia23df3972f1944e3a9fed9c31cbc6587_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xMTQ2L2ZyYWc6NjAyZTAzMTg1YTM0NDIwNzg1Y2Y2Mzg0MGY1ZTI4NDQvdGFibGU6YzRlMzliMGUyNTQxNGI4M2JlMjE5Y2Y3NTJmNTFmYmMvdGFibGVyYW5nZTpjNGUzOWIwZTI1NDE0YjgzYmUyMTljZjc1MmY1MWZiY18zLTEtMS0xLTI5NTg5_016b6b05-563f-4f50-a222-7cd6b9ed1d1b"
      unitRef="usd">24000</ardx:ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod>
    <ardx:ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod
      contextRef="i4eed71377df84e2fad4e2b5044d0f43c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xMTQ2L2ZyYWc6NjAyZTAzMTg1YTM0NDIwNzg1Y2Y2Mzg0MGY1ZTI4NDQvdGFibGU6YzRlMzliMGUyNTQxNGI4M2JlMjE5Y2Y3NTJmNTFmYmMvdGFibGVyYW5nZTpjNGUzOWIwZTI1NDE0YjgzYmUyMTljZjc1MmY1MWZiY18yLTMtMS0xLTMwMDY4_a58ce767-5920-4103-98db-3581c472e529"
      unitRef="usd">40000</ardx:ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod>
    <ardx:ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod
      contextRef="i10819c0292d84effb45cc9b78a0c7f30_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xMTQ2L2ZyYWc6NjAyZTAzMTg1YTM0NDIwNzg1Y2Y2Mzg0MGY1ZTI4NDQvdGFibGU6YzRlMzliMGUyNTQxNGI4M2JlMjE5Y2Y3NTJmNTFmYmMvdGFibGVyYW5nZTpjNGUzOWIwZTI1NDE0YjgzYmUyMTljZjc1MmY1MWZiY18zLTMtMS0xLTI5NTg5_23136887-cc2b-4dbc-aafc-099070b7fd10"
      unitRef="usd">90000</ardx:ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod>
    <ardx:ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xMTQ2L2ZyYWc6NjAyZTAzMTg1YTM0NDIwNzg1Y2Y2Mzg0MGY1ZTI4NDQvdGFibGU6YzRlMzliMGUyNTQxNGI4M2JlMjE5Y2Y3NTJmNTFmYmMvdGFibGVyYW5nZTpjNGUzOWIwZTI1NDE0YjgzYmUyMTljZjc1MmY1MWZiY18zLTUtMS0xLTI5NTg5_c0240e17-41ce-417f-a01b-1aba3abc3f41"
      unitRef="usd">154000</ardx:ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod>
    <ardx:ContractWithCustomerGrossToNetSalesAccruals
      contextRef="iede9224697ec4dd1a0adabd2320ebc14_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xMTQ2L2ZyYWc6NjAyZTAzMTg1YTM0NDIwNzg1Y2Y2Mzg0MGY1ZTI4NDQvdGFibGU6YzRlMzliMGUyNTQxNGI4M2JlMjE5Y2Y3NTJmNTFmYmMvdGFibGVyYW5nZTpjNGUzOWIwZTI1NDE0YjgzYmUyMTljZjc1MmY1MWZiY181LTEtMS0xLTI5NTg5_12f4e5b0-c9fd-4b43-9584-7c2bc1929433"
      unitRef="usd">24000</ardx:ContractWithCustomerGrossToNetSalesAccruals>
    <ardx:ContractWithCustomerGrossToNetSalesAccruals
      contextRef="ie452822da30341968381616c4727890f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xMTQ2L2ZyYWc6NjAyZTAzMTg1YTM0NDIwNzg1Y2Y2Mzg0MGY1ZTI4NDQvdGFibGU6YzRlMzliMGUyNTQxNGI4M2JlMjE5Y2Y3NTJmNTFmYmMvdGFibGVyYW5nZTpjNGUzOWIwZTI1NDE0YjgzYmUyMTljZjc1MmY1MWZiY180LTMtMS0xLTMwMDY4_5796fe2b-c58a-43c8-aae3-47d687fc9be9"
      unitRef="usd">40000</ardx:ContractWithCustomerGrossToNetSalesAccruals>
    <ardx:ContractWithCustomerGrossToNetSalesAccruals
      contextRef="ic3971d760f8441f38d00e317c37315fd_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xMTQ2L2ZyYWc6NjAyZTAzMTg1YTM0NDIwNzg1Y2Y2Mzg0MGY1ZTI4NDQvdGFibGU6YzRlMzliMGUyNTQxNGI4M2JlMjE5Y2Y3NTJmNTFmYmMvdGFibGVyYW5nZTpjNGUzOWIwZTI1NDE0YjgzYmUyMTljZjc1MmY1MWZiY181LTMtMS0xLTI5NTg5_7440605f-b53b-4328-b44e-568c22c319ff"
      unitRef="usd">90000</ardx:ContractWithCustomerGrossToNetSalesAccruals>
    <ardx:ContractWithCustomerGrossToNetSalesAccruals
      contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xMTQ2L2ZyYWc6NjAyZTAzMTg1YTM0NDIwNzg1Y2Y2Mzg0MGY1ZTI4NDQvdGFibGU6YzRlMzliMGUyNTQxNGI4M2JlMjE5Y2Y3NTJmNTFmYmMvdGFibGVyYW5nZTpjNGUzOWIwZTI1NDE0YjgzYmUyMTljZjc1MmY1MWZiY181LTUtMS0xLTI5NTg5_2e8f2a05-4c82-431e-ba26-5ab6225be500"
      unitRef="usd">154000</ardx:ContractWithCustomerGrossToNetSalesAccruals>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5783cc7426ba453f96f1e7e0af87b0a6_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xMTQ2L2ZyYWc6NjAyZTAzMTg1YTM0NDIwNzg1Y2Y2Mzg0MGY1ZTI4NDQvdGV4dHJlZ2lvbjo2MDJlMDMxODVhMzQ0MjA3ODVjZjYzODQwZjVlMjg0NF80Mzk4MDQ2NTE0NTQ4_995dd031-33db-4da8-8211-1bbc493dbfce"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <ardx:ContractWithCustomerGrossToNetSalesAccruals
      contextRef="iac98ebf56cf345fb9e32e575ac855e4a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV8xMTQ2L2ZyYWc6NjAyZTAzMTg1YTM0NDIwNzg1Y2Y2Mzg0MGY1ZTI4NDQvdGV4dHJlZ2lvbjo2MDJlMDMxODVhMzQ0MjA3ODVjZjYzODQwZjVlMjg0NF80Mzk4MDQ2NTE0NTQ4_a1901645-7c1d-4744-a15f-6cf52ec5e2a6"
      unitRef="usd">0</ardx:ContractWithCustomerGrossToNetSalesAccruals>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80MC9mcmFnOmUwYjY2ZWViODRkMDRmN2JhZjFlYjEyNGIyNzE5NmY3L3RleHRyZWdpb246ZTBiNjZlZWI4NGQwNGY3YmFmMWViMTI0YjI3MTk2ZjdfOTYyOQ_ac2099ea-97db-4016-807c-0ed7bc245ae7">COLLABORATION AND LICENSING AGREEMENTS&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Kyowa Kirin Co., Ltd. (&#x201c;KKC&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2019 KKC Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2019, we entered into a research collaboration and option agreement with KKC (the &#x201c;2019 KKC Agreement&#x201d;) for research associated with identifying two preclinical compounds that are ready for designation as development compounds (&#x201c;DCs&#x201d;), with one compound inhibiting the first undisclosed target (&#x201c;Program 1&#x201d;), and a second inhibiting the second undisclosed target (&#x201c;Program 2&#x201d;). Pursuant to the 2019 KKC Agreement, upon completion of the research and designation by the research steering committee of one or more DCs, KKC has the right to execute one or more separate collaborative agreements relating to the development and commercialization of one or both DCs in certain specified territories.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the 2019 KKC Agreement, KKC paid us a non-refundable, non-creditable upfront fee of $10.0&#160;million in two installments as follows: the first installment of $5.0&#160;million within 30 days of November 11, 2019 (the &#x201c;Effective Date&#x201d;), and the second installment of $5.0&#160;million on the first anniversary of the Effective Date. The term of the 2019 KKC Agreement commenced on the Effective Date and ends on the earliest of: (i) 2 years following the Effective Date, (ii) the nomination of a program DC for both programs, (iii) the nomination of one program DC and the decision by the parties to cease research for the other program, or (iv) the decision by the parties to cease research for both programs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have no material future obligations under the 2019 KKC Agreement and recorded no revenue under the 2019 KKC Agreement during the three months ended March&#160;31, 2022. During the three months ended March&#160;31, 2021, we recognized $1.5&#160;million as collaborative development revenue under the 2019 KKC Agreement in the accompanying condensed statement of operations and comprehensive loss. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2017 KKC Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2017, we entered into an exclusive license agreement with KKC (the &#x201c;2017 KKC Agreement&#x201d;), for the development, commercialization, and distribution of tenapanor in Japan for cardiorenal indications. We granted KKC an exclusive license to develop and commercialize certain NHE3 inhibitors including tenapanor in Japan for the treatment of cardiorenal diseases and conditions, excluding cancer. We retained the rights to tenapanor outside of Japan, and also retained the rights to tenapanor in Japan for indications other than those stated above. Pursuant to the 2017 KKC Agreement, KKC is responsible for all costs and expenses incurred in the development and commercialization of tenapanor for all licensed indications in Japan. We are responsible for supplying the tenapanor drug substance for KKC&#x2019;s use in development and commercialization throughout the term of the 2017 KKC Agreement, provided that KKC may exercise an option to manufacture the tenapanor drug substance under certain conditions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We assessed these arrangements in accordance with Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2014-09, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers (Topic 606) and related amendments (&#x201c;ASC 606&#x201d;) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and concluded that the contract counterparty, KKC, is a customer. Under the terms of the 2017 KKC Agreement, we received&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$30.0&#160;million in upfront license fees, which was recognized as revenue when the agreement was executed. Based on our assessment, management determined that the license and the manufacturing supply services were its material performance obligations at the inception of the 2017 KKC Agreement, and as such, each of the performance obligations is distinct. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the up-front license fee received of $30.0&#160;million, we may be entitled to receive up to&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$55.0&#160;million in total development milestones, of which $10.0&#160;million has been received and recognized as revenue as of March&#160;31, 2022, and approximately &#xa5;8.5 billion for commercialization milestones, or approximately $69.7&#160;million at the currency exchange rate on March&#160;31, 2022, as well as reimbursement of costs plus a reasonable overhead for the supply of product and royalties on net sales throughout the term of the agreement. The variable consideration related to the remaining development milestone payments has not been included in the transaction price as these were fully constrained at March&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As discussed in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 14 - Subsequent events&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, on April 11, 2022, we entered into a second amendment (the "Amendment") to the 2017 KKC Agreement. Under the terms of the Amendment, the parties have agreed to a reduction in the royalty rate payable to us by KKC upon net sales of tenapanor in Japan. The royalty rate will be reduced from the high teens to low double digits for a two-year period of time following the first commercial sale in Japan, and then to mid-single digits for the remainder of the royalty term. As consideration for the reduction in the royalty rate, KKC has agreed to pay us up to an additional U.S. $40.0 million payable in two tranches, with the first payment due following KKC's filing with the Japanese Ministry Health, Labour and Welfare (MHLW) of its application for marketing approval for tenapanor and the second payment due following KKC&#x2019;s receipt of regulatory approval to market tenapanor for hyperphosphatemia in Japan. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2022 we recognized no licensing revenue upon the achievement of development milestones. During the three months ended March&#160;31, 2021, we recognized $5.0&#160;million licensing revenue upon the initiation of phase 3 clinical studies by KKC in Japan to evaluate tenapanor for hyperphosphatemia. During the three months ended March&#160;31, 2022, we recognized $14 thousand&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;as&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;product supply revenue related to the manufacturing supply of tenapanor and other materials to KKC pursuant to the 2017 KKC Agreement. During the three months ended March&#160;31, 2021,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;we recognized $0.1 million as product supply revenue pursuant to the 2017 KKC Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As detailed below under the heading &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Deferred revenue - non-current&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, we have received prepayments from KKC for the manufacturing of tenapanor drug substance that will be used to satisfy KKC needs. We also have recorded certain unbilled prepayments from KKC for the manufacturing of tenapanor drug product reflected within prepaid and other current assets. Both amounts are reflected within our deferred revenue, non-current on our condensed balance sheet as of March&#160;31, 2022. The prepayment is reflected within prepaid and other current assets and deferred revenue, non-current on our condensed balance sheet as of March&#160;31, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. (&#x201c;Fosun Pharma&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2017, we entered into an exclusive license agreement with Fosun&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pharma&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(the&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201c;Fosun Agreement&#x201d;),&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for the development, commercialization and distribution of tenapanor in China for both hyperphosphatemia and&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;IBS-C.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We assessed these arrangements in accordance with ASC 606 and concluded that the contract counterparty, Fosun Pharma, is a customer. Under the terms of the Fosun Agreement, we received&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$12.0 million in&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;upfront&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;license fees which was recognized as revenue when the agreement was executed. Based on&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;management&#x2019;s&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;assessment,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;we determined&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;that the license and the manufacturing supply services&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;represented the&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;material performance obligations at the inception of the agreement, and as such,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;each of the performance obligations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;is&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;distinct. &#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We may be entitled to additional development and commercialization milestones of up to&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$110.0 million, as well as reimbursement of cost plus a reasonable overhead for the supply of product and tiered royalties on net sales ranging from the mid-teens to&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20%. The variable consideration related to the remaining development milestone payments has not been included in the transaction price as these were fully constrained at March&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have recorded no&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;revenue during the three months ended March&#160;31, 2022 or 2021 related&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;to the Fosun&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Knight Therapeutics, Inc. (&#x201c;Knight&#x201c;) &#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2018, we entered into an exclusive license agreement with Knight (the &#x201c;Knight Agreement&#x201d;) for the development, commercialization and distribution of tenapanor in Canada for hyperphosphatemia and IBS-C. We assessed this arrangement in accordance with ASC 606 and concluded that the contract counterparty, Knight, is a customer. Based on management&#x2019;s assessment, we determined that the license and the manufacturing supply services represented the material performance obligations at the inception of the agreement, and as such, each of the performance obligations is distinct. Under the terms of the agreement, we received a&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$2.3 million nonrefundable, one-time upfront payment in March 2018 and are eligible to receive additional development and commercialization milestone payments worth up to $17.8 million. We are also eligible to receive royalties throughout the term of the agreement, and a transfer price for manufacturing services.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The variable consideration related to the remaining development milestone payments has not been included in the transaction price as they were fully constrained at March&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;AstraZeneca AB (&#x201c;AstraZeneca&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2015, we entered into a termination agreement with AstraZeneca (the &#x201c;AstraZeneca Termination Agreement&#x201d;) pursuant to which we have agreed to pay AstraZeneca (i) future royalties at a royalty rate of 10% of net sales of tenapanor or other NHE3 products by us or our licensees, and (ii) 20% of non-royalty revenue received from a licensee of tenapanor or another NHE3 inhibitor, up to a maximum of $75.0 million in aggregate for (i) and (ii). As of March&#160;31, 2022, to date in aggregate, we have recognized $11.7 million of the $75.0 million, which has been recorded as cost of revenue, and have paid AstraZeneca $11.6 million. During the three months ended March&#160;31, 2022 we recognized and recorded as cost of revenue $0.1 million related to the AstraZeneca Termination Agreement. During the three months ended March&#160;31, 2021 we recognized $1.0 million cost of revenue related to the AstraZeneca Termination Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Deferred Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present changes in our current and non-current deferred revenue balances during the reporting period. The March&#160;31, 2021 current deferred revenue balance is attributable entirely to the 2019 KKC Agreement and the non-current deferred revenue balances at March&#160;31, 2022 and 2021 are attributable entirely to the 2017 KKC Agreement (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.300%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred revenue - current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at January 1,&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Decreases due to revenue recognized in the period for which cash has been received&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,454)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at March 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.760%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.030%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.325%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred revenue - non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at January 1,&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases to amounts invoiced, for which cash has not yet been received&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increase due to unbilled prepayments recorded during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at March 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <ardx:NumberOfSeparateCollaborativeAgreements
      contextRef="i23aa3d7663a24dc8865dc922b983040b_D20191101-20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80MC9mcmFnOmUwYjY2ZWViODRkMDRmN2JhZjFlYjEyNGIyNzE5NmY3L3RleHRyZWdpb246ZTBiNjZlZWI4NGQwNGY3YmFmMWViMTI0YjI3MTk2ZjdfNjU4_ccd19f9f-7205-4b9b-999e-67fb6f3bf363"
      unitRef="item">1</ardx:NumberOfSeparateCollaborativeAgreements>
    <ardx:CollaborationAndLicensingAgreementsUpfrontLicenseFees
      contextRef="i9168e70d1cc646808da95d0e5cbe0347_D20191101-20191130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80MC9mcmFnOmUwYjY2ZWViODRkMDRmN2JhZjFlYjEyNGIyNzE5NmY3L3RleHRyZWdpb246ZTBiNjZlZWI4NGQwNGY3YmFmMWViMTI0YjI3MTk2ZjdfMTA5OTUxMTYzNzU1MA_68b4bf05-2968-4778-bff8-36c45b3230af"
      unitRef="usd">10000000</ardx:CollaborationAndLicensingAgreementsUpfrontLicenseFees>
    <ardx:CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment
      contextRef="i9168e70d1cc646808da95d0e5cbe0347_D20191101-20191130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80MC9mcmFnOmUwYjY2ZWViODRkMDRmN2JhZjFlYjEyNGIyNzE5NmY3L3RleHRyZWdpb246ZTBiNjZlZWI4NGQwNGY3YmFmMWViMTI0YjI3MTk2ZjdfMTA5OTUxMTYzNzU1NA_626a70f5-87e1-4f1f-90ab-cd0b26fc2ef9"
      unitRef="usd">5000000</ardx:CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment>
    <ardx:TermOfPaymentOfLicenseFeeFirstInstallment
      contextRef="i9168e70d1cc646808da95d0e5cbe0347_D20191101-20191130"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80MC9mcmFnOmUwYjY2ZWViODRkMDRmN2JhZjFlYjEyNGIyNzE5NmY3L3RleHRyZWdpb246ZTBiNjZlZWI4NGQwNGY3YmFmMWViMTI0YjI3MTk2ZjdfOTc5_9e9837b4-f7d6-42e1-8d41-5f14aec945d0">P30D</ardx:TermOfPaymentOfLicenseFeeFirstInstallment>
    <ardx:CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment
      contextRef="i9168e70d1cc646808da95d0e5cbe0347_D20191101-20191130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80MC9mcmFnOmUwYjY2ZWViODRkMDRmN2JhZjFlYjEyNGIyNzE5NmY3L3RleHRyZWdpb246ZTBiNjZlZWI4NGQwNGY3YmFmMWViMTI0YjI3MTk2ZjdfMTA5OTUxMTYzNzU1OA_bfb4ac7a-9f01-4592-b37d-733db97e89b2"
      unitRef="usd">5000000</ardx:CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment>
    <ardx:TermOfAgreement
      contextRef="i9168e70d1cc646808da95d0e5cbe0347_D20191101-20191130"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80MC9mcmFnOmUwYjY2ZWViODRkMDRmN2JhZjFlYjEyNGIyNzE5NmY3L3RleHRyZWdpb246ZTBiNjZlZWI4NGQwNGY3YmFmMWViMTI0YjI3MTk2ZjdfMTIwOA_38e2020a-d2a9-4efd-b11f-30c335fa5fe3">P2Y</ardx:TermOfAgreement>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i745335ff1da443c2a66acb028f9b9044_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80MC9mcmFnOmUwYjY2ZWViODRkMDRmN2JhZjFlYjEyNGIyNzE5NmY3L3RleHRyZWdpb246ZTBiNjZlZWI4NGQwNGY3YmFmMWViMTI0YjI3MTk2ZjdfMjE5OTAyMzI2Njc2MA_7bb02df7-92c9-48c2-b1da-d88390bf7be8"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id32818d38a2f41e79d9416fb0bd0e53a_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80MC9mcmFnOmUwYjY2ZWViODRkMDRmN2JhZjFlYjEyNGIyNzE5NmY3L3RleHRyZWdpb246ZTBiNjZlZWI4NGQwNGY3YmFmMWViMTI0YjI3MTk2ZjdfMTA5OTUxMTYzNzU5OA_1be30f55-0b1a-4fc4-a623-2e71fd9bec17"
      unitRef="usd">1500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <ardx:CollaborationAndLicensingAgreementsUpfrontLicenseFees
      contextRef="i6ded7d7b952443ff99d1931791c886bb_D20171101-20171130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80MC9mcmFnOmUwYjY2ZWViODRkMDRmN2JhZjFlYjEyNGIyNzE5NmY3L3RleHRyZWdpb246ZTBiNjZlZWI4NGQwNGY3YmFmMWViMTI0YjI3MTk2ZjdfMTA5OTUxMTYzODE5Nw_80719ac1-1547-4add-92cd-57c59a90b365"
      unitRef="usd">30000000</ardx:CollaborationAndLicensingAgreementsUpfrontLicenseFees>
    <ardx:CollaborationAndLicensingAgreementsUpfrontLicenseFees
      contextRef="i6ded7d7b952443ff99d1931791c886bb_D20171101-20171130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80MC9mcmFnOmUwYjY2ZWViODRkMDRmN2JhZjFlYjEyNGIyNzE5NmY3L3RleHRyZWdpb246ZTBiNjZlZWI4NGQwNGY3YmFmMWViMTI0YjI3MTk2ZjdfMTA5OTUxMTYzODIwNA_80719ac1-1547-4add-92cd-57c59a90b365"
      unitRef="usd">30000000</ardx:CollaborationAndLicensingAgreementsUpfrontLicenseFees>
    <ardx:CollaborativeArrangementPotentialDevelopmentMilestones
      contextRef="i8bba5999a33a4beabc6bda2318d9d5d6_I20171130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80MC9mcmFnOmUwYjY2ZWViODRkMDRmN2JhZjFlYjEyNGIyNzE5NmY3L3RleHRyZWdpb246ZTBiNjZlZWI4NGQwNGY3YmFmMWViMTI0YjI3MTk2ZjdfMTA5OTUxMTYzODIwOA_83ac2fc5-41a8-4fc1-b08a-235d0f10c5b2"
      unitRef="usd">55000000</ardx:CollaborativeArrangementPotentialDevelopmentMilestones>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0212bc236d5d418c889a86710d62cead_D20171101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80MC9mcmFnOmUwYjY2ZWViODRkMDRmN2JhZjFlYjEyNGIyNzE5NmY3L3RleHRyZWdpb246ZTBiNjZlZWI4NGQwNGY3YmFmMWViMTI0YjI3MTk2ZjdfMTA5OTUxMTYzODIxNQ_00fdb563-e606-48f0-88eb-12e4e32c55a9"
      unitRef="usd">10000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <ardx:CollaborativeArrangementPotentialCommercializationMilestones
      contextRef="ic0f6d47945c94e2398355efb64d25b64_I20220331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80MC9mcmFnOmUwYjY2ZWViODRkMDRmN2JhZjFlYjEyNGIyNzE5NmY3L3RleHRyZWdpb246ZTBiNjZlZWI4NGQwNGY3YmFmMWViMTI0YjI3MTk2ZjdfMTA5OTUxMTYzODIyMg_89adb169-acfa-448f-8f7c-0186c394e609"
      unitRef="jpy">8500000000</ardx:CollaborativeArrangementPotentialCommercializationMilestones>
    <ardx:CollaborativeArrangementPotentialCommercializationMilestones
      contextRef="ic0f6d47945c94e2398355efb64d25b64_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80MC9mcmFnOmUwYjY2ZWViODRkMDRmN2JhZjFlYjEyNGIyNzE5NmY3L3RleHRyZWdpb246ZTBiNjZlZWI4NGQwNGY3YmFmMWViMTI0YjI3MTk2ZjdfMTA5OTUxMTYzODIzMA_8688a18c-8724-4d13-ac56-9d259d571226"
      unitRef="usd">69700000</ardx:CollaborativeArrangementPotentialCommercializationMilestones>
    <ardx:CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate
      contextRef="ic15e7d54e20c401b86da52a356fa5887_I20220411"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80MC9mcmFnOmUwYjY2ZWViODRkMDRmN2JhZjFlYjEyNGIyNzE5NmY3L3RleHRyZWdpb246ZTBiNjZlZWI4NGQwNGY3YmFmMWViMTI0YjI3MTk2ZjdfMTA5OTUxMTY0MzE2OQ_a32219d3-7124-42c0-bd07-3e4a3fac5e98"
      unitRef="usd">40000000</ardx:CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate>
    <ardx:CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches
      contextRef="ic15e7d54e20c401b86da52a356fa5887_I20220411"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80MC9mcmFnOmUwYjY2ZWViODRkMDRmN2JhZjFlYjEyNGIyNzE5NmY3L3RleHRyZWdpb246ZTBiNjZlZWI4NGQwNGY3YmFmMWViMTI0YjI3MTk2ZjdfODI0NjMzNzIyNTEzOQ_23a71ac9-01ca-4aa8-9ffa-5c5bb2f06626"
      unitRef="payment_tranche">2</ardx:CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib0326b0e1d934394b35c6b4e5823a0e9_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80MC9mcmFnOmUwYjY2ZWViODRkMDRmN2JhZjFlYjEyNGIyNzE5NmY3L3RleHRyZWdpb246ZTBiNjZlZWI4NGQwNGY3YmFmMWViMTI0YjI3MTk2ZjdfMTA5OTUxMTYzODIzNw_450491be-83c6-4d48-84bf-fe6cc7bc630a"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i777f4b1d2b0a48c995f7a8e8fc2a2d0d_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80MC9mcmFnOmUwYjY2ZWViODRkMDRmN2JhZjFlYjEyNGIyNzE5NmY3L3RleHRyZWdpb246ZTBiNjZlZWI4NGQwNGY3YmFmMWViMTI0YjI3MTk2ZjdfMTA5OTUxMTYzODI2Mw_1b0a1530-daae-4aa3-94bb-6e1a71fca3f4"
      unitRef="usd">5000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iab42eb33c5f6401eb4cabd7658b0c6bd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80MC9mcmFnOmUwYjY2ZWViODRkMDRmN2JhZjFlYjEyNGIyNzE5NmY3L3RleHRyZWdpb246ZTBiNjZlZWI4NGQwNGY3YmFmMWViMTI0YjI3MTk2ZjdfMTA5OTUxMTYzODM3MQ_ce307345-c28a-4c50-b548-396f441cdc19"
      unitRef="usd">14000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1760e71a3aab4fd190e7292ba626aa96_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80MC9mcmFnOmUwYjY2ZWViODRkMDRmN2JhZjFlYjEyNGIyNzE5NmY3L3RleHRyZWdpb246ZTBiNjZlZWI4NGQwNGY3YmFmMWViMTI0YjI3MTk2ZjdfMTA5OTUxMTYzODM4Ng_9d0d44f2-06e2-45c5-aab1-114af7042568"
      unitRef="usd">100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ProceedsFromLicenseFeesReceived
      contextRef="iaafa907a1fc049f59de2c2fcb1b077a8_D20171201-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80MC9mcmFnOmUwYjY2ZWViODRkMDRmN2JhZjFlYjEyNGIyNzE5NmY3L3RleHRyZWdpb246ZTBiNjZlZWI4NGQwNGY3YmFmMWViMTI0YjI3MTk2ZjdfMTA5OTUxMTYzODQwNw_a66740a4-bf4d-4302-a3c1-c6ab3eb2ddf9"
      unitRef="usd">12000000</us-gaap:ProceedsFromLicenseFeesReceived>
    <ardx:CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones
      contextRef="i0a019b5505f7466ca2f76583b097cdbe_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80MC9mcmFnOmUwYjY2ZWViODRkMDRmN2JhZjFlYjEyNGIyNzE5NmY3L3RleHRyZWdpb246ZTBiNjZlZWI4NGQwNGY3YmFmMWViMTI0YjI3MTk2ZjdfMTA5OTUxMTYzODQxMw_f747bab8-55e2-477b-b277-71e532aeaecc"
      unitRef="usd">110000000</ardx:CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones>
    <ardx:ThresholdPercentageOfSalesForTieredRoyalties
      contextRef="i0a019b5505f7466ca2f76583b097cdbe_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80MC9mcmFnOmUwYjY2ZWViODRkMDRmN2JhZjFlYjEyNGIyNzE5NmY3L3RleHRyZWdpb246ZTBiNjZlZWI4NGQwNGY3YmFmMWViMTI0YjI3MTk2ZjdfMTA5OTUxMTYzODQxNw_9d08252b-56c1-4af4-b5cf-5db2f72a102b"
      unitRef="number">0.20</ardx:ThresholdPercentageOfSalesForTieredRoyalties>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9c7ce382bd124359a0a4700a39632df1_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80MC9mcmFnOmUwYjY2ZWViODRkMDRmN2JhZjFlYjEyNGIyNzE5NmY3L3RleHRyZWdpb246ZTBiNjZlZWI4NGQwNGY3YmFmMWViMTI0YjI3MTk2ZjdfMTA5OTUxMTYzODQyNQ_4f90ca6d-7815-4e8b-be10-6876a36d48f2"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib9fd94dcca60490e82fbc1d493ab985c_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80MC9mcmFnOmUwYjY2ZWViODRkMDRmN2JhZjFlYjEyNGIyNzE5NmY3L3RleHRyZWdpb246ZTBiNjZlZWI4NGQwNGY3YmFmMWViMTI0YjI3MTk2ZjdfMTA5OTUxMTYzODQyNQ_517baf55-06de-437f-9592-5e6025d5acc4"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ProceedsFromLicenseFeesReceived
      contextRef="i839c245d89c241679804a884e550ef5b_D20180301-20180331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80MC9mcmFnOmUwYjY2ZWViODRkMDRmN2JhZjFlYjEyNGIyNzE5NmY3L3RleHRyZWdpb246ZTBiNjZlZWI4NGQwNGY3YmFmMWViMTI0YjI3MTk2ZjdfMTA5OTUxMTYzODQzNQ_042002d3-77aa-4f1f-9253-39f3d8253e0d"
      unitRef="usd">2300000</us-gaap:ProceedsFromLicenseFeesReceived>
    <ardx:CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones
      contextRef="i29560f0f154647109b5c7c80f240890c_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80MC9mcmFnOmUwYjY2ZWViODRkMDRmN2JhZjFlYjEyNGIyNzE5NmY3L3RleHRyZWdpb246ZTBiNjZlZWI4NGQwNGY3YmFmMWViMTI0YjI3MTk2ZjdfMTA5OTUxMTYzODQzOQ_afe571c3-7441-4feb-b742-142f8dad93f7"
      unitRef="usd">17800000</ardx:CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones>
    <ardx:PercentageOfRoyaltyRevenue
      contextRef="i390f2ffb21554b849e8f47149934d4fd_D20150601-20150630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80MC9mcmFnOmUwYjY2ZWViODRkMDRmN2JhZjFlYjEyNGIyNzE5NmY3L3RleHRyZWdpb246ZTBiNjZlZWI4NGQwNGY3YmFmMWViMTI0YjI3MTk2ZjdfMTA5OTUxMTYzODQ1NA_36a14427-40d0-47f8-9d3a-cd7552de954d"
      unitRef="number">0.10</ardx:PercentageOfRoyaltyRevenue>
    <ardx:PercentageOfNonRoyaltyRevenue
      contextRef="i390f2ffb21554b849e8f47149934d4fd_D20150601-20150630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80MC9mcmFnOmUwYjY2ZWViODRkMDRmN2JhZjFlYjEyNGIyNzE5NmY3L3RleHRyZWdpb246ZTBiNjZlZWI4NGQwNGY3YmFmMWViMTI0YjI3MTk2ZjdfMTA5OTUxMTYzODQ1OA_c3b1a610-cb43-4d3a-bde9-17f354a42902"
      unitRef="number">0.20</ardx:PercentageOfNonRoyaltyRevenue>
    <ardx:CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum
      contextRef="id4d3d62533e642adab59317a030f3b30_I20150630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80MC9mcmFnOmUwYjY2ZWViODRkMDRmN2JhZjFlYjEyNGIyNzE5NmY3L3RleHRyZWdpb246ZTBiNjZlZWI4NGQwNGY3YmFmMWViMTI0YjI3MTk2ZjdfMTA5OTUxMTYzODQ2Mg_6fcfcfa2-65b5-4548-ba76-53802acee91c"
      unitRef="usd">75000000</ardx:CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum>
    <ardx:CostOfRevenueAggregateAmountRecognized
      contextRef="i8bde55ddcbf0400a8169b35ffe4c6da2_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80MC9mcmFnOmUwYjY2ZWViODRkMDRmN2JhZjFlYjEyNGIyNzE5NmY3L3RleHRyZWdpb246ZTBiNjZlZWI4NGQwNGY3YmFmMWViMTI0YjI3MTk2ZjdfMjE5OTAyMzI2ODUxNQ_9e3233f9-6fa6-473d-99e9-fd643a660047"
      unitRef="usd">11700000</ardx:CostOfRevenueAggregateAmountRecognized>
    <ardx:CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum
      contextRef="id4d3d62533e642adab59317a030f3b30_I20150630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80MC9mcmFnOmUwYjY2ZWViODRkMDRmN2JhZjFlYjEyNGIyNzE5NmY3L3RleHRyZWdpb246ZTBiNjZlZWI4NGQwNGY3YmFmMWViMTI0YjI3MTk2ZjdfMjE5OTAyMzI2ODUyMg_6fcfcfa2-65b5-4548-ba76-53802acee91c"
      unitRef="usd">75000000</ardx:CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum>
    <ardx:PaymentsOfUnchargedLicenseFeesAggregateAmountPaid
      contextRef="i73d193d247244f1fb9ce854954086ef6_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80MC9mcmFnOmUwYjY2ZWViODRkMDRmN2JhZjFlYjEyNGIyNzE5NmY3L3RleHRyZWdpb246ZTBiNjZlZWI4NGQwNGY3YmFmMWViMTI0YjI3MTk2ZjdfMjE5OTAyMzI2ODUyNg_d65c9835-1c24-4369-abb0-8161f1ce891d"
      unitRef="usd">11600000</ardx:PaymentsOfUnchargedLicenseFeesAggregateAmountPaid>
    <us-gaap:CostOfRevenue
      contextRef="i025ade055f874ff1a468b7fbd0583eda_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80MC9mcmFnOmUwYjY2ZWViODRkMDRmN2JhZjFlYjEyNGIyNzE5NmY3L3RleHRyZWdpb246ZTBiNjZlZWI4NGQwNGY3YmFmMWViMTI0YjI3MTk2ZjdfMjE5OTAyMzI2ODUwNw_227f02e1-7f76-4e68-b1db-2b76df819418"
      unitRef="usd">100000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="i3de6eb23c1e24a80807755f0069fc236_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80MC9mcmFnOmUwYjY2ZWViODRkMDRmN2JhZjFlYjEyNGIyNzE5NmY3L3RleHRyZWdpb246ZTBiNjZlZWI4NGQwNGY3YmFmMWViMTI0YjI3MTk2ZjdfMTA5OTUxMTY0NjY4Mg_657cca95-ca09-48b0-8643-b308e5d87e82"
      unitRef="usd">1000000</us-gaap:CostOfRevenue>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80MC9mcmFnOmUwYjY2ZWViODRkMDRmN2JhZjFlYjEyNGIyNzE5NmY3L3RleHRyZWdpb246ZTBiNjZlZWI4NGQwNGY3YmFmMWViMTI0YjI3MTk2ZjdfOTYzMA_9471863a-27d5-4651-967e-6c7211184fcf">&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present changes in our current and non-current deferred revenue balances during the reporting period. The March&#160;31, 2021 current deferred revenue balance is attributable entirely to the 2019 KKC Agreement and the non-current deferred revenue balances at March&#160;31, 2022 and 2021 are attributable entirely to the 2017 KKC Agreement (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.300%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred revenue - current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at January 1,&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Decreases due to revenue recognized in the period for which cash has been received&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,454)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at March 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.760%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.030%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.325%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred revenue - non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at January 1,&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases to amounts invoiced, for which cash has not yet been received&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increase due to unbilled prepayments recorded during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at March 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i34485cae15f04837aa894774e18bbb58_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80MC9mcmFnOmUwYjY2ZWViODRkMDRmN2JhZjFlYjEyNGIyNzE5NmY3L3RhYmxlOmIzZmEzODA5YWM1NTQxOGQ5ZTY1M2IxNjZiOGE1YjlmL3RhYmxlcmFuZ2U6YjNmYTM4MDlhYzU1NDE4ZDllNjUzYjE2NmI4YTViOWZfMS0xLTEtMS0yMzAxMw_ed616e6d-a353-4756-9bc2-c2ce58bd9847"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ia600adb07b6d40c9b3357ac69342a7ad_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80MC9mcmFnOmUwYjY2ZWViODRkMDRmN2JhZjFlYjEyNGIyNzE5NmY3L3RhYmxlOmIzZmEzODA5YWM1NTQxOGQ5ZTY1M2IxNjZiOGE1YjlmL3RhYmxlcmFuZ2U6YjNmYTM4MDlhYzU1NDE4ZDllNjUzYjE2NmI4YTViOWZfMS0zLTEtMS0yNTM0Mg_6f15a7cc-1ff1-4791-8a33-c28ed726a439"
      unitRef="usd">4177000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <ardx:ContractWithCustomerLiabilityRevenueRecognizedCashReceived
      contextRef="i745335ff1da443c2a66acb028f9b9044_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80MC9mcmFnOmUwYjY2ZWViODRkMDRmN2JhZjFlYjEyNGIyNzE5NmY3L3RhYmxlOmIzZmEzODA5YWM1NTQxOGQ5ZTY1M2IxNjZiOGE1YjlmL3RhYmxlcmFuZ2U6YjNmYTM4MDlhYzU1NDE4ZDllNjUzYjE2NmI4YTViOWZfMy0xLTEtMS0yMzAxMw_c732952b-1280-46b5-bd06-fd99c616b9ed"
      unitRef="usd">0</ardx:ContractWithCustomerLiabilityRevenueRecognizedCashReceived>
    <ardx:ContractWithCustomerLiabilityRevenueRecognizedCashReceived
      contextRef="id32818d38a2f41e79d9416fb0bd0e53a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80MC9mcmFnOmUwYjY2ZWViODRkMDRmN2JhZjFlYjEyNGIyNzE5NmY3L3RhYmxlOmIzZmEzODA5YWM1NTQxOGQ5ZTY1M2IxNjZiOGE1YjlmL3RhYmxlcmFuZ2U6YjNmYTM4MDlhYzU1NDE4ZDllNjUzYjE2NmI4YTViOWZfMy0zLTEtMS0yNTM0Mg_3631e436-56fd-43f7-a71d-403e71c7c863"
      unitRef="usd">1454000</ardx:ContractWithCustomerLiabilityRevenueRecognizedCashReceived>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i717222ed03814f8f986a1604095f9214_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80MC9mcmFnOmUwYjY2ZWViODRkMDRmN2JhZjFlYjEyNGIyNzE5NmY3L3RhYmxlOmIzZmEzODA5YWM1NTQxOGQ5ZTY1M2IxNjZiOGE1YjlmL3RhYmxlcmFuZ2U6YjNmYTM4MDlhYzU1NDE4ZDllNjUzYjE2NmI4YTViOWZfNS0xLTEtMS0yMzAxMw_2d5a1680-40bb-452e-9cb5-f75dee9a0e91"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ic81523b011734f66b3b288912d844b1d_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80MC9mcmFnOmUwYjY2ZWViODRkMDRmN2JhZjFlYjEyNGIyNzE5NmY3L3RhYmxlOmIzZmEzODA5YWM1NTQxOGQ5ZTY1M2IxNjZiOGE1YjlmL3RhYmxlcmFuZ2U6YjNmYTM4MDlhYzU1NDE4ZDllNjUzYjE2NmI4YTViOWZfNS0zLTEtMS0yNTM0Mg_b3b8df7c-ab70-4227-8e70-b7a8dd234bb7"
      unitRef="usd">2723000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i61553ae32dfb40f8b285bdfc4a3d3272_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80MC9mcmFnOmUwYjY2ZWViODRkMDRmN2JhZjFlYjEyNGIyNzE5NmY3L3RhYmxlOjNlNWFhNTFlZWMxZDRjOTVhNzk5YWI3MGExZGIwODM0L3RhYmxlcmFuZ2U6M2U1YWE1MWVlYzFkNGM5NWE3OTlhYjcwYTFkYjA4MzRfMS0xLTEtMS0yMzAxMw_597482b5-0fe6-4ecb-ab71-e4de9030c586"
      unitRef="usd">4727000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="ibd27a0a1ac554dc1a75c1884f665b7f6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80MC9mcmFnOmUwYjY2ZWViODRkMDRmN2JhZjFlYjEyNGIyNzE5NmY3L3RhYmxlOjNlNWFhNTFlZWMxZDRjOTVhNzk5YWI3MGExZGIwODM0L3RhYmxlcmFuZ2U6M2U1YWE1MWVlYzFkNGM5NWE3OTlhYjcwYTFkYjA4MzRfMS0zLTEtMS0yNTM3Nw_ab4b94ee-8b7d-47c2-a4da-dff929f31a5a"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <ardx:ContractWithCustomerLiabilityIncreaseForAmountsInvoiced
      contextRef="i5e8de9754a784d54a397d66dc8d5ebf0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80MC9mcmFnOmUwYjY2ZWViODRkMDRmN2JhZjFlYjEyNGIyNzE5NmY3L3RhYmxlOjNlNWFhNTFlZWMxZDRjOTVhNzk5YWI3MGExZGIwODM0L3RhYmxlcmFuZ2U6M2U1YWE1MWVlYzFkNGM5NWE3OTlhYjcwYTFkYjA4MzRfMy0xLTEtMS0zMTgwMg_28d7579d-258b-4299-b484-9aaa80f59329"
      unitRef="usd">3829000</ardx:ContractWithCustomerLiabilityIncreaseForAmountsInvoiced>
    <ardx:ContractWithCustomerLiabilityIncreaseForAmountsInvoiced
      contextRef="ifb1b8b57f3484b4c886d5bcda853744b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80MC9mcmFnOmUwYjY2ZWViODRkMDRmN2JhZjFlYjEyNGIyNzE5NmY3L3RhYmxlOjNlNWFhNTFlZWMxZDRjOTVhNzk5YWI3MGExZGIwODM0L3RhYmxlcmFuZ2U6M2U1YWE1MWVlYzFkNGM5NWE3OTlhYjcwYTFkYjA4MzRfMy0zLTEtMS0zMTgwMg_c6149568-6ba6-442f-a075-6b5c9edbddba"
      unitRef="usd">2947000</ardx:ContractWithCustomerLiabilityIncreaseForAmountsInvoiced>
    <ardx:ContractWithCustomerLiabilityIncreaseDueToUnbilledPrepaymentsRecorded
      contextRef="i5e8de9754a784d54a397d66dc8d5ebf0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80MC9mcmFnOmUwYjY2ZWViODRkMDRmN2JhZjFlYjEyNGIyNzE5NmY3L3RhYmxlOjNlNWFhNTFlZWMxZDRjOTVhNzk5YWI3MGExZGIwODM0L3RhYmxlcmFuZ2U6M2U1YWE1MWVlYzFkNGM5NWE3OTlhYjcwYTFkYjA4MzRfMy0xLTEtMS0yMzAxMw_c9ec52e4-04e6-4f43-88dd-a2ec0f7704ec"
      unitRef="usd">7000</ardx:ContractWithCustomerLiabilityIncreaseDueToUnbilledPrepaymentsRecorded>
    <ardx:ContractWithCustomerLiabilityIncreaseDueToUnbilledPrepaymentsRecorded
      contextRef="ifb1b8b57f3484b4c886d5bcda853744b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80MC9mcmFnOmUwYjY2ZWViODRkMDRmN2JhZjFlYjEyNGIyNzE5NmY3L3RhYmxlOjNlNWFhNTFlZWMxZDRjOTVhNzk5YWI3MGExZGIwODM0L3RhYmxlcmFuZ2U6M2U1YWE1MWVlYzFkNGM5NWE3OTlhYjcwYTFkYjA4MzRfMy0zLTEtMS0yNTM3Nw_cdb6b058-5f84-42a4-a808-2d4ca0c92072"
      unitRef="usd">0</ardx:ContractWithCustomerLiabilityIncreaseDueToUnbilledPrepaymentsRecorded>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i2146e1f17bd043f3b77edbd52edab483_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80MC9mcmFnOmUwYjY2ZWViODRkMDRmN2JhZjFlYjEyNGIyNzE5NmY3L3RhYmxlOjNlNWFhNTFlZWMxZDRjOTVhNzk5YWI3MGExZGIwODM0L3RhYmxlcmFuZ2U6M2U1YWE1MWVlYzFkNGM5NWE3OTlhYjcwYTFkYjA4MzRfNS0xLTEtMS0yMzAxMw_a7df8e8e-0d70-4794-8d36-1b5459a5c55b"
      unitRef="usd">8563000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i8f0cf433f09e4f1e9169aefcedff5d7f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80MC9mcmFnOmUwYjY2ZWViODRkMDRmN2JhZjFlYjEyNGIyNzE5NmY3L3RhYmxlOjNlNWFhNTFlZWMxZDRjOTVhNzk5YWI3MGExZGIwODM0L3RhYmxlcmFuZ2U6M2U1YWE1MWVlYzFkNGM5NWE3OTlhYjcwYTFkYjA4MzRfNS0zLTEtMS0yNTM3Nw_108dd38e-6d11-4938-b064-dc60b0905c13"
      unitRef="usd">2947000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80My9mcmFnOmRjNDJmYTBmZjMzMjRhNDVhMTZjODM2MWYzYWMzOGVmL3RleHRyZWdpb246ZGM0MmZhMGZmMzMyNGE0NWExNmM4MzYxZjNhYzM4ZWZfNDUyOQ_997ba1e5-3d6b-4c3c-b06a-4df93451f35f">BORROWING &lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Solar Capital and Western Alliance Bank Loan Agreement&lt;/span&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 16, 2018, we entered into a loan and security agreement (as amended on October 9, 2020, March 1, 2021, May 5, 2021, and July 29, 2021) (the "2018 Loan Agreement") with Solar Capital Ltd. and Western Alliance Bank (collectively the &#x201c;2018 Lenders&#x201d;). The 2018 Loan Agreement provided for a $50.0 million loan facility with a maturity date of November&#160;1, 2022 (the &#x201c;2018 Loan&#x201d;). As of the Closing Date for the 2022 Loan, as discussed below, we owed $25.0 million in principal payments from the 2018 Loan, which we repaid in full at that time.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As discussed in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 8. Derivative Liability&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, in connection with entering into the 2018 Loan Agreement, we entered into an agreement pursuant to which we agreed to pay $1.5 million in cash upon the occurrence of certain conditions (the "2018 Exit Fee"). Our obligations for the 2018 Exit Fee remain outstanding following the full repayment of the 2018 Loan in February 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;SLR Investments Loan Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 23, 2022 (the &#x201c;Closing Date&#x201d;), we entered into a loan and security agreement (the &#x201c;2022 Loan Agreement&#x201d;) with SLR Investment Corp. as collateral agent (the &#x201c;Agent&#x201d;), and the lenders listed in the 2022 Loan Agreement (collectively the &#x201c;2022 Lenders&#x201d;). The 2022 Loan Agreement provides for a senior secured loan facility, with $27.5 million (the &#x201c;Term A Loan&#x201d;) funded on the Closing Date and an additional $22.5 million that we may borrow on or prior to July 25, 2023; provided that (i) we have received approval by the FDA for our NDA for the control of serum phosphorus in chronic kidney disease patients on dialysis by December 31, 2022, and (ii) we have achieved certain product revenue milestone targets described in the 2022 Loan Agreement (the &#x201c;Term B Loan&#x201d;, and collectively, the Term A Loan and the Term B Loan, the &#x201c;2022 Loan&#x201d;). The 2022 Term A Loan funds were used to repay the 2018 Loan with the 2018 Lenders. The 2022 Loan has a maturity date of March 1, 2027.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Borrowings under the 2022 Loan bear interest at a floating per annum rate equal to 7.95% plus the greater of (i) one tenth percent (0.10%) and (ii) the one-month rate published by the Intercontinental Exchange Benchmark Administration Ltd or its successor. We are permitted to make interest-only payments on the 2022 Loan through March 31, 2024. Accordingly, beginning on April 1, 2024, we will be required to make monthly payments of interest plus repay the 2022 Loan in consecutive equal monthly installments of principal. We were obligated to pay $0.2 million, upon the closing of the Term A Loan, and we are obligated to pay $0.1 million on the earliest of (i) the funding date of the Term B Loan, (ii) July 25, 2023, and (iii) the prepayment, refinancing, substitution, or replacement of the Term A Loan on or prior to July 25, 2023. We are obligated to pay a final fee equal to 4.95% of the aggregate original principal amount of the 2022 Loan funded upon the earliest to occur of the maturity date, the acceleration of the 2022 Loan, and the prepayment, refinancing, substitution, or replacement of the 2022 Loan. We may voluntarily prepay the outstanding 2022 Loan balance, subject to a prepayment premium of (i) 3% of the &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;outstanding principal amount of the 2022 Loan if prepaid prior to or on the first anniversary of the Closing Date, (ii) 2% of the outstanding principal amount of the 2022 Loan if prepaid after the first anniversary of the Closing Date through and including the second anniversary of the Closing Date, or (iii) 1% of the outstanding principal amount of the 2022 Loan if prepaid after the second anniversary of the Closing Date and prior to the maturity date. The 2022 Loan is secured by substantially all of our assets, except for our intellectual property and certain other customary exclusions. Additionally, in connection with the 2022 Loan, we entered into an agreement, whereby we agreed to pay an exit fee in the amount 2% of the 2022 Loan funded (the &#x201c;2022 Exit Fee&#x201d;) upon (i) any change of control transaction or (ii) our achievement of net revenue from the sale of any products equal to or greater than $100.0&#160;million, measured on a six (6) months basis, tested monthly at the end of each month. Notwithstanding the prepayment or termination of the 2022 Loan, the 2022 Exit Fee will expire 10 years from the Closing Date.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2022 Loan Agreement contains customary representations and warranties and customary affirmative and negative covenants, including, among others, requirements as to financial reporting and insurance and restrictions on our ability to dispose of our business or property, to change our line of business, to liquidate or dissolve, to enter into any change in control transaction, to merge or consolidate with any other entity or to acquire all or substantially all the capital stock or property of another entity, to incur additional indebtedness, to incur liens on our property, to pay any dividends or other distributions on capital stock other than dividends payable solely in capital stock or to redeem capital stock. We have agreed to not allow our cash and cash equivalents to be less than the eighty percent (80%) of the outstanding 2022 Term Loan balance for any period in which our net revenue from the sale of any products, calculated on a trailing six (6) month basis and tested monthly, is less than sixty percent (60%) of the outstanding 2022 Loan balance.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, the 2022 Loan Agreement contains customary events of default that entitle the Agent to cause our indebtedness under the 2022 Loan Agreement to become immediately due and payable, and to exercise remedies against us and the collateral securing the 2022 Term Loan, including our cash. Under the 2022 Loan Agreement, an event of default will occur if, among other things, we fail to make payments under the 2022 Loan Agreement, we breach any of our covenants under the 2022 Loan Agreement, subject to specified cure periods with respect to certain breaches, certain Lenders determine that a material adverse change has occurred, we or our assets become subject to certain legal proceedings, such as bankruptcy proceedings, we are unable to pay our debts as they become due or we default on contracts with third parties which would permit the holder of indebtedness to accelerate the maturity of such indebtedness or that could have a material adverse change on us. Upon the occurrence and for the duration of an event of default, an additional default interest rate equal to 4% per annum will apply to all obligations owed under the 2022 Loan Agreement. We have classified the 2022 Loan balance as a current liability as of March&#160;31, 2022 due to the determination of the existence of substantial doubt about our ability to continue operating as a going concern discussed in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 1. Organization and Basis of Presentation: Liquidity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and our assessment that the material adverse change clause under the 2022 Loan Agreement is not within our control. The lenders have not invoked the material adverse change clause as of the date of issuance of these financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2022, our future payment obligations related to the 2022 Loan, excluding interest payments and the 2022 final fee, are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.162%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total repayment obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Unamortized discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,399)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Unaccreted value of final fee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,324)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26,139)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ib7f93b8f72cf486bbecc12514b98b015_I20180516"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80My9mcmFnOmRjNDJmYTBmZjMzMjRhNDVhMTZjODM2MWYzYWMzOGVmL3RleHRyZWdpb246ZGM0MmZhMGZmMzMyNGE0NWExNmM4MzYxZjNhYzM4ZWZfMTA5OTUxMTYzMjMyMQ_1c61df0f-a2de-495d-a1b0-b08c28ca7789"
      unitRef="usd">50000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ib7054c03dafb4f308b95f52c3a43fa1b_I20220223"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80My9mcmFnOmRjNDJmYTBmZjMzMjRhNDVhMTZjODM2MWYzYWMzOGVmL3RleHRyZWdpb246ZGM0MmZhMGZmMzMyNGE0NWExNmM4MzYxZjNhYzM4ZWZfMTA5OTUxMTY0NDcxMA_4535013a-1f4d-48e2-9b8d-59b29b2c3a12"
      unitRef="usd">25000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="iba83d40326b1433ea471109cb11536f8_I20180531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80My9mcmFnOmRjNDJmYTBmZjMzMjRhNDVhMTZjODM2MWYzYWMzOGVmL3RleHRyZWdpb246ZGM0MmZhMGZmMzMyNGE0NWExNmM4MzYxZjNhYzM4ZWZfMTA5OTUxMTY0NTc2MQ_59404140-0b18-4e60-ac9e-35a64baab29d"
      unitRef="usd">1500000</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts
      contextRef="i3a8be86cba30452780b8d0bca7fe52ef_D20220223-20220223"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80My9mcmFnOmRjNDJmYTBmZjMzMjRhNDVhMTZjODM2MWYzYWMzOGVmL3RleHRyZWdpb246ZGM0MmZhMGZmMzMyNGE0NWExNmM4MzYxZjNhYzM4ZWZfMTA5OTUxMTY0NTI5Mg_f92197d1-6e8d-4fb3-811b-115ad217f356"
      unitRef="usd">27500000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <ardx:RemainingFundingBasedOnConditionalMilestoneAchievement
      contextRef="i22ce6a39c3434acd91d5ab75ae19b62f_I20220223"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80My9mcmFnOmRjNDJmYTBmZjMzMjRhNDVhMTZjODM2MWYzYWMzOGVmL3RleHRyZWdpb246ZGM0MmZhMGZmMzMyNGE0NWExNmM4MzYxZjNhYzM4ZWZfMTA5OTUxMTY0NTMxMg_d5b764dd-0fa4-41f8-917c-8a22fc4abb36"
      unitRef="usd">22500000</ardx:RemainingFundingBasedOnConditionalMilestoneAchievement>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i00d53b360ebd4d39ab0a045093b0d350_D20220223-20220223"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80My9mcmFnOmRjNDJmYTBmZjMzMjRhNDVhMTZjODM2MWYzYWMzOGVmL3RleHRyZWdpb246ZGM0MmZhMGZmMzMyNGE0NWExNmM4MzYxZjNhYzM4ZWZfMTA5OTUxMTY0NTMyMw_66fb9d55-43ac-4e4b-ae23-2e6f5f076326"
      unitRef="number">0.0795</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <ardx:DebtInstrumentVariableRateBaseOption
      contextRef="i00d53b360ebd4d39ab0a045093b0d350_D20220223-20220223"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80My9mcmFnOmRjNDJmYTBmZjMzMjRhNDVhMTZjODM2MWYzYWMzOGVmL3RleHRyZWdpb246ZGM0MmZhMGZmMzMyNGE0NWExNmM4MzYxZjNhYzM4ZWZfMTA5OTUxMTY0NTMzMQ_a805bba7-0c2c-4f44-bd49-805eb54ac932"
      unitRef="number">0.0010</ardx:DebtInstrumentVariableRateBaseOption>
    <ardx:DebtInstrumentClosingFeeAmount
      contextRef="id7137d11d7564018ab80498ef529b584_I20220223"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80My9mcmFnOmRjNDJmYTBmZjMzMjRhNDVhMTZjODM2MWYzYWMzOGVmL3RleHRyZWdpb246ZGM0MmZhMGZmMzMyNGE0NWExNmM4MzYxZjNhYzM4ZWZfMTA5OTUxMTY0NTM0Ng_18f602c7-7c76-4a0c-ae31-a722ea7063be"
      unitRef="usd">200000</ardx:DebtInstrumentClosingFeeAmount>
    <ardx:LoanAgreementFutureObligationUponFundingOrOtherEvents
      contextRef="i22ce6a39c3434acd91d5ab75ae19b62f_I20220223"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80My9mcmFnOmRjNDJmYTBmZjMzMjRhNDVhMTZjODM2MWYzYWMzOGVmL3RleHRyZWdpb246ZGM0MmZhMGZmMzMyNGE0NWExNmM4MzYxZjNhYzM4ZWZfMTA5OTUxMTY0NTM2Mw_02994257-936e-445f-8e63-7a073c7586b9"
      unitRef="usd">100000</ardx:LoanAgreementFutureObligationUponFundingOrOtherEvents>
    <ardx:DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage
      contextRef="icbf434cb3f104e188c9fd0464443c2f4_I20220223"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80My9mcmFnOmRjNDJmYTBmZjMzMjRhNDVhMTZjODM2MWYzYWMzOGVmL3RleHRyZWdpb246ZGM0MmZhMGZmMzMyNGE0NWExNmM4MzYxZjNhYzM4ZWZfMTA5OTUxMTY0NTM3NQ_aa2c6d4c-1a21-418b-ae2f-260d5e7050d0"
      unitRef="number">0.0495</ardx:DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage>
    <ardx:DebtInstrumentPrepaymentFeePercentage
      contextRef="i5d5d94cb725e4caca45734b96460fab2_I20220223"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80My9mcmFnOmRjNDJmYTBmZjMzMjRhNDVhMTZjODM2MWYzYWMzOGVmL3RleHRyZWdpb246ZGM0MmZhMGZmMzMyNGE0NWExNmM4MzYxZjNhYzM4ZWZfMTA5OTUxMTY0NTM5MA_aca1a0d2-0cf0-4f35-a81b-49a3c4ebde5d"
      unitRef="number">0.03</ardx:DebtInstrumentPrepaymentFeePercentage>
    <ardx:DebtInstrumentPrepaymentFeePercentage
      contextRef="i5134dd31b2ec46ba9252bb3ccd222425_I20220223"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80My9mcmFnOmRjNDJmYTBmZjMzMjRhNDVhMTZjODM2MWYzYWMzOGVmL3RleHRyZWdpb246ZGM0MmZhMGZmMzMyNGE0NWExNmM4MzYxZjNhYzM4ZWZfMTA5OTUxMTY0NTM4MA_b290e305-a045-4b1e-b889-a0c9d5f2f65b"
      unitRef="number">0.02</ardx:DebtInstrumentPrepaymentFeePercentage>
    <ardx:DebtInstrumentPrepaymentFeePercentage
      contextRef="ia616f3b3f10d4ebda8439302d146953c_I20220223"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80My9mcmFnOmRjNDJmYTBmZjMzMjRhNDVhMTZjODM2MWYzYWMzOGVmL3RleHRyZWdpb246ZGM0MmZhMGZmMzMyNGE0NWExNmM4MzYxZjNhYzM4ZWZfMTA5OTUxMTY0NTM4NQ_3394f815-8f5d-4a7d-b109-19c5085d8ef7"
      unitRef="number">0.01</ardx:DebtInstrumentPrepaymentFeePercentage>
    <ardx:ExitFeePercentage
      contextRef="i6c1d87e6c35c44b9baca5f0c32c93d4e_I20220223"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80My9mcmFnOmRjNDJmYTBmZjMzMjRhNDVhMTZjODM2MWYzYWMzOGVmL3RleHRyZWdpb246ZGM0MmZhMGZmMzMyNGE0NWExNmM4MzYxZjNhYzM4ZWZfNDM5ODA0NjUyODkwMQ_12bc347d-0ca0-4904-88c7-acfb14acf789"
      unitRef="number">0.02</ardx:ExitFeePercentage>
    <ardx:LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum
      contextRef="ie706e05847024bdfbe5174e56d319428_D20220223-20220223"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80My9mcmFnOmRjNDJmYTBmZjMzMjRhNDVhMTZjODM2MWYzYWMzOGVmL3RleHRyZWdpb246ZGM0MmZhMGZmMzMyNGE0NWExNmM4MzYxZjNhYzM4ZWZfNDM5ODA0NjUyODkyMA_482d1086-1ba4-41a3-b833-4d11c599a950"
      unitRef="usd">100000000</ardx:LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum>
    <ardx:LoanAgreementExitFeeTerm
      contextRef="ie706e05847024bdfbe5174e56d319428_D20220223-20220223"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80My9mcmFnOmRjNDJmYTBmZjMzMjRhNDVhMTZjODM2MWYzYWMzOGVmL3RleHRyZWdpb246ZGM0MmZhMGZmMzMyNGE0NWExNmM4MzYxZjNhYzM4ZWZfNDM5ODA0NjUyODkxMw_e6daf060-2854-4d68-8408-8c9f8bc76e3a">P10Y</ardx:LoanAgreementExitFeeTerm>
    <ardx:LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum
      contextRef="icbf434cb3f104e188c9fd0464443c2f4_I20220223"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80My9mcmFnOmRjNDJmYTBmZjMzMjRhNDVhMTZjODM2MWYzYWMzOGVmL3RleHRyZWdpb246ZGM0MmZhMGZmMzMyNGE0NWExNmM4MzYxZjNhYzM4ZWZfMTA5OTUxMTY0NTM5Ng_038c6b19-f411-4b7a-98db-ef6ed4748607"
      unitRef="number">0.80</ardx:LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum>
    <ardx:LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum
      contextRef="icbf434cb3f104e188c9fd0464443c2f4_I20220223"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80My9mcmFnOmRjNDJmYTBmZjMzMjRhNDVhMTZjODM2MWYzYWMzOGVmL3RleHRyZWdpb246ZGM0MmZhMGZmMzMyNGE0NWExNmM4MzYxZjNhYzM4ZWZfMTA5OTUxMTY0NTQwMg_259392e3-95b5-4b50-becf-3586b2a0f36b"
      unitRef="number">0.60</ardx:LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum>
    <ardx:DebtInstrumentInterestRateOnDefaultPercentage
      contextRef="icbf434cb3f104e188c9fd0464443c2f4_I20220223"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80My9mcmFnOmRjNDJmYTBmZjMzMjRhNDVhMTZjODM2MWYzYWMzOGVmL3RleHRyZWdpb246ZGM0MmZhMGZmMzMyNGE0NWExNmM4MzYxZjNhYzM4ZWZfMTA5OTUxMTY0NTQxMQ_7326ebdb-9e9b-4cbc-acfb-9420b388e352"
      unitRef="number">0.04</ardx:DebtInstrumentInterestRateOnDefaultPercentage>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80My9mcmFnOmRjNDJmYTBmZjMzMjRhNDVhMTZjODM2MWYzYWMzOGVmL3RleHRyZWdpb246ZGM0MmZhMGZmMzMyNGE0NWExNmM4MzYxZjNhYzM4ZWZfNDUzMA_4d4bb952-648d-4d9a-bb7c-0678e9c6e379">&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2022, our future payment obligations related to the 2022 Loan, excluding interest payments and the 2022 final fee, are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.162%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total repayment obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Unamortized discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,399)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Unaccreted value of final fee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,324)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26,139)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80My9mcmFnOmRjNDJmYTBmZjMzMjRhNDVhMTZjODM2MWYzYWMzOGVmL3RhYmxlOmZlMjg2ZDJiNmQzNTQ1NTNiMGE2NjczODdlY2FlY2Y0L3RhYmxlcmFuZ2U6ZmUyODZkMmI2ZDM1NDU1M2IwYTY2NzM4N2VjYWVjZjRfMC0xLTEtMS0yMzAxMw_95e1c67c-52d1-4fe3-9cbf-6d96e643b894"
      unitRef="usd">28862000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80My9mcmFnOmRjNDJmYTBmZjMzMjRhNDVhMTZjODM2MWYzYWMzOGVmL3RhYmxlOmZlMjg2ZDJiNmQzNTQ1NTNiMGE2NjczODdlY2FlY2Y0L3RhYmxlcmFuZ2U6ZmUyODZkMmI2ZDM1NDU1M2IwYTY2NzM4N2VjYWVjZjRfMS0xLTEtMS0yMzAxMw_1a66cce6-bab8-4e93-a780-b5889a528208"
      unitRef="usd">1399000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentFeeAmount
      contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80My9mcmFnOmRjNDJmYTBmZjMzMjRhNDVhMTZjODM2MWYzYWMzOGVmL3RhYmxlOmZlMjg2ZDJiNmQzNTQ1NTNiMGE2NjczODdlY2FlY2Y0L3RhYmxlcmFuZ2U6ZmUyODZkMmI2ZDM1NDU1M2IwYTY2NzM4N2VjYWVjZjRfMi0xLTEtMS0yMzAxMw_f518a0a7-a212-490e-81bb-b068bb49bfca"
      unitRef="usd">1324000</us-gaap:DebtInstrumentFeeAmount>
    <us-gaap:LongTermDebt
      contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80My9mcmFnOmRjNDJmYTBmZjMzMjRhNDVhMTZjODM2MWYzYWMzOGVmL3RhYmxlOmZlMjg2ZDJiNmQzNTQ1NTNiMGE2NjczODdlY2FlY2Y0L3RhYmxlcmFuZ2U6ZmUyODZkMmI2ZDM1NDU1M2IwYTY2NzM4N2VjYWVjZjRfMy0xLTEtMS0yMzAxMw_00ddde78-51f2-4dd1-8edb-24d5ac0fea80"
      unitRef="usd">26139000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtCurrent
      contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80My9mcmFnOmRjNDJmYTBmZjMzMjRhNDVhMTZjODM2MWYzYWMzOGVmL3RhYmxlOmZlMjg2ZDJiNmQzNTQ1NTNiMGE2NjczODdlY2FlY2Y0L3RhYmxlcmFuZ2U6ZmUyODZkMmI2ZDM1NDU1M2IwYTY2NzM4N2VjYWVjZjRfNC0xLTEtMS0yMzAxMw_be12c919-29c9-41ef-86d3-cd4ffc41c12d"
      unitRef="usd">26139000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80My9mcmFnOmRjNDJmYTBmZjMzMjRhNDVhMTZjODM2MWYzYWMzOGVmL3RhYmxlOmZlMjg2ZDJiNmQzNTQ1NTNiMGE2NjczODdlY2FlY2Y0L3RhYmxlcmFuZ2U6ZmUyODZkMmI2ZDM1NDU1M2IwYTY2NzM4N2VjYWVjZjRfNS0xLTEtMS0yMzAxMw_e7b04133-9375-455f-8319-3bc99e383c78"
      unitRef="usd">0</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80Ni9mcmFnOjk3ZWVkZmEwMmYxYjQyOTFhOWE4NGE4ZDRmNmI2YjQzL3RleHRyZWdpb246OTdlZWRmYTAyZjFiNDI5MWE5YTg0YThkNGY2YjZiNDNfMjY5MQ_a75de47c-99f9-441b-8be1-ff6f0123099b">DERIVATIVE LIABILITY&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2018 Exit Fee&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2018, in connection with entering into the 2018 Loan Agreement, we entered into an agreement pursuant to which we agreed to pay $1.5 million in cash (the &#x201c;2018 Exit Fee&#x201d;) upon any change of control transaction in respect of the Company or if we obtain both (i) FDA approval of tenapanor for the control of serum phosphorus in adult patients with CKD on dialysis and (ii) FDA approval of tenapanor for the treatment of patients with IBS-C, which was obtained on September 12, 2019 when the FDA approved IBSRELA&#xae; (tenapanor), a 50 milligram, twice daily oral pill for the treatment of IBS-C in adults (the &#x201c;2018 Exit Fee Agreement&#x201d;). Notwithstanding the February 2022 prepayment of the 2018 Loan our obligation to pay the 2018 Exit Fee will expire on May 16, 2028. We concluded that the 2018 Exit Fee is a freestanding derivative which should be accounted &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for at fair value on a recurring basis. The estimated fair value of the 2018 Exit Fee is recorded as a derivative liability and included in accrued expenses and other current liabilities on the accompanying condensed balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the derivative liability was determined using a discounted cash flow analysis and is classified as a Level 3 measurement within the fair value hierarchy since our valuation utilized significant unobservable inputs. Specifically, the key assumptions included in the calculation of the estimated fair value of the 2018 derivative liability include: (i) our estimates of both the probability and timing of a potential $1.5 million payment to the 2018 Lenders as a result of the FDA approvals and (ii) a discount rate which was derived from our estimated cost of debt, adjusted with current LIBOR (or a comparable successor rate if LIBOR no longer exists). Generally, increases or decreases in the probability of occurrence would result in a directionally similar impact in the fair value measurement of the derivative liability and it is estimated that a 10.0% increase (decrease), not to exceed 100%, in the probability of occurrence would result in a fair value fluctuation of no more than $0.1 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2022 Exit Fee&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 23, 2022, in connection with entering into the 2022 Loan Agreement, we entered into an agreement, whereby we agreed to pay an exit fee in the amount of  2% of the 2022 Loan funded (the &#x201c;2022 Exit Fee&#x201d;) upon (i) any change of control transaction or (ii) our achievement of net revenue from the sale of any products equal to or greater than $100.0 million, measured on a six (6) months basis (the "Revenue Milestone"), tested monthly at the end of each month. Notwithstanding the prepayment or termination of the 2022 Loan, the 2022 Exit Fee will expire on February 23, 2032. We concluded that the 2022 Exit Fee is a freestanding derivative which should be accounted for at fair value on a recurring basis. The estimated fair value of the 2022 Exit Fee is recorded as a derivative liability and included in accrued expenses and other current liabilities on the accompanying condensed balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the derivative liability was determined using a discounted cash flow analysis and is classified as a Level 3 measurement within the fair value hierarchy since our valuation utilized significant unobservable inputs. Specifically, the key assumptions included in the calculation of the estimated fair value of the 2022 derivative liability include: (i) our estimates of both the probability and timing of achieving the Revenue Milestone and (ii) the probability and timing of funding the Term B Loan, which is dependent upon (a) approval by the FDA for our NDA for the control of serum phosphorus in chronic kidney disease patients on dialysis by December 31, 2022, and (b) achievement of certain product revenue milestone targets. Generally, increases or decreases in the probability of occurrence would result in a directionally similar impact in the fair value measurement of the derivative liability and it is estimated that a 10.0% increase (decrease) in the probability of occurrence would not result in a material fair value fluctuation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the fair value of our exit fee derivative liabilities recurring measurements included in Level 3 of the fair value hierarchy are presented as other income, net in our statements of operations and were as follows for the three months ended March&#160;31, 2022 and 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.028%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022 Exit Fee addition at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes in estimated fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="iba83d40326b1433ea471109cb11536f8_I20180531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80Ni9mcmFnOjk3ZWVkZmEwMmYxYjQyOTFhOWE4NGE4ZDRmNmI2YjQzL3RleHRyZWdpb246OTdlZWRmYTAyZjFiNDI5MWE5YTg0YThkNGY2YjZiNDNfMTA5OTUxMTYzMDQ5MQ_59404140-0b18-4e60-ac9e-35a64baab29d"
      unitRef="usd">1500000</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="iba83d40326b1433ea471109cb11536f8_I20180531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80Ni9mcmFnOjk3ZWVkZmEwMmYxYjQyOTFhOWE4NGE4ZDRmNmI2YjQzL3RleHRyZWdpb246OTdlZWRmYTAyZjFiNDI5MWE5YTg0YThkNGY2YjZiNDNfMTA5OTUxMTYzMDQ5OA_59404140-0b18-4e60-ac9e-35a64baab29d"
      unitRef="usd">1500000</us-gaap:DerivativeLiabilityNotionalAmount>
    <ardx:FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage
      contextRef="i59df1925a0574c55bae8311f5941df95_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80Ni9mcmFnOjk3ZWVkZmEwMmYxYjQyOTFhOWE4NGE4ZDRmNmI2YjQzL3RleHRyZWdpb246OTdlZWRmYTAyZjFiNDI5MWE5YTg0YThkNGY2YjZiNDNfMTA5OTUxMTYzMDUwMg_ce913ce9-b982-423a-88e0-fa7f60e22f56"
      unitRef="number">0.100</ardx:FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage>
    <ardx:FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation
      contextRef="i59df1925a0574c55bae8311f5941df95_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80Ni9mcmFnOjk3ZWVkZmEwMmYxYjQyOTFhOWE4NGE4ZDRmNmI2YjQzL3RleHRyZWdpb246OTdlZWRmYTAyZjFiNDI5MWE5YTg0YThkNGY2YjZiNDNfMTA5OTUxMTYzMDUwNg_fdcbddbf-db52-477c-961e-8638ed5bae56"
      unitRef="usd">100000</ardx:FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation>
    <ardx:ExitFeePercentage
      contextRef="i6c1d87e6c35c44b9baca5f0c32c93d4e_I20220223"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80Ni9mcmFnOjk3ZWVkZmEwMmYxYjQyOTFhOWE4NGE4ZDRmNmI2YjQzL3RleHRyZWdpb246OTdlZWRmYTAyZjFiNDI5MWE5YTg0YThkNGY2YjZiNDNfMTA5OTUxMTYzMzc1Mw_b53b211e-1e5b-41ac-9886-3424c003aad1"
      unitRef="number">0.02</ardx:ExitFeePercentage>
    <ardx:LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum
      contextRef="ie706e05847024bdfbe5174e56d319428_D20220223-20220223"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80Ni9mcmFnOjk3ZWVkZmEwMmYxYjQyOTFhOWE4NGE4ZDRmNmI2YjQzL3RleHRyZWdpb246OTdlZWRmYTAyZjFiNDI5MWE5YTg0YThkNGY2YjZiNDNfMTA5OTUxMTYzNDUyNA_f5924020-1cd6-44d1-a9ca-b309014a20b8"
      unitRef="usd">100000000</ardx:LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum>
    <ardx:FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage
      contextRef="i89699442d50542d18f061eb0f10ea77b_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80Ni9mcmFnOjk3ZWVkZmEwMmYxYjQyOTFhOWE4NGE4ZDRmNmI2YjQzL3RleHRyZWdpb246OTdlZWRmYTAyZjFiNDI5MWE5YTg0YThkNGY2YjZiNDNfMTA5OTUxMTYzNDcxNw_ecc8f72c-5767-401f-b853-2606cfc0963b"
      unitRef="number">0.100</ardx:FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80Ni9mcmFnOjk3ZWVkZmEwMmYxYjQyOTFhOWE4NGE4ZDRmNmI2YjQzL3RleHRyZWdpb246OTdlZWRmYTAyZjFiNDI5MWE5YTg0YThkNGY2YjZiNDNfMjY5Mg_50e266e0-03bf-489c-a36d-5cd29404a28d">&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the fair value of our exit fee derivative liabilities recurring measurements included in Level 3 of the fair value hierarchy are presented as other income, net in our statements of operations and were as follows for the three months ended March&#160;31, 2022 and 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.028%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022 Exit Fee addition at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes in estimated fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="id497bd1485194fabbdb368667104492e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80Ni9mcmFnOjk3ZWVkZmEwMmYxYjQyOTFhOWE4NGE4ZDRmNmI2YjQzL3RhYmxlOjA5NWZmMWEyNDAyZjQ0ZTA5YTRkYjY5OTEyYjY1YzA3L3RhYmxlcmFuZ2U6MDk1ZmYxYTI0MDJmNDRlMDlhNGRiNjk5MTJiNjVjMDdfMi0xLTEtMS0yNTY2OA_a33785f7-fe4b-4c5a-9924-53a0d672d886"
      unitRef="usd">698000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i4ad56d5e526243f6a24d080e5313c670_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80Ni9mcmFnOjk3ZWVkZmEwMmYxYjQyOTFhOWE4NGE4ZDRmNmI2YjQzL3RhYmxlOjA5NWZmMWEyNDAyZjQ0ZTA5YTRkYjY5OTEyYjY1YzA3L3RhYmxlcmFuZ2U6MDk1ZmYxYTI0MDJmNDRlMDlhNGRiNjk5MTJiNjVjMDdfMi0zLTEtMS0yNTY2OA_88c18ca7-4202-4559-9578-8535aaaf384b"
      unitRef="usd">1376000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
      contextRef="ia8c70b1e37704cbba96b42d34dac6902_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80Ni9mcmFnOjk3ZWVkZmEwMmYxYjQyOTFhOWE4NGE4ZDRmNmI2YjQzL3RhYmxlOjA5NWZmMWEyNDAyZjQ0ZTA5YTRkYjY5OTEyYjY1YzA3L3RhYmxlcmFuZ2U6MDk1ZmYxYTI0MDJmNDRlMDlhNGRiNjk5MTJiNjVjMDdfMy0xLTEtMS0yOTEwMA_48980fa0-2e08-45f6-adad-661aaea99f51"
      unitRef="usd">375000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
      contextRef="iaf0f6a03fb7b4bdc8dace9bdd0e496b2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80Ni9mcmFnOjk3ZWVkZmEwMmYxYjQyOTFhOWE4NGE4ZDRmNmI2YjQzL3RhYmxlOjA5NWZmMWEyNDAyZjQ0ZTA5YTRkYjY5OTEyYjY1YzA3L3RhYmxlcmFuZ2U6MDk1ZmYxYTI0MDJmNDRlMDlhNGRiNjk5MTJiNjVjMDdfMy0zLTEtMS0yOTEwMA_cc5dd801-a5cd-474e-9e07-c2627f089ce0"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="ia8c70b1e37704cbba96b42d34dac6902_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80Ni9mcmFnOjk3ZWVkZmEwMmYxYjQyOTFhOWE4NGE4ZDRmNmI2YjQzL3RhYmxlOjA5NWZmMWEyNDAyZjQ0ZTA5YTRkYjY5OTEyYjY1YzA3L3RhYmxlcmFuZ2U6MDk1ZmYxYTI0MDJmNDRlMDlhNGRiNjk5MTJiNjVjMDdfMy0xLTEtMS0yNTY2OA_b64f4835-a870-48eb-9415-931cc4900cc8"
      unitRef="usd">15000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="iaf0f6a03fb7b4bdc8dace9bdd0e496b2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80Ni9mcmFnOjk3ZWVkZmEwMmYxYjQyOTFhOWE4NGE4ZDRmNmI2YjQzL3RhYmxlOjA5NWZmMWEyNDAyZjQ0ZTA5YTRkYjY5OTEyYjY1YzA3L3RhYmxlcmFuZ2U6MDk1ZmYxYTI0MDJmNDRlMDlhNGRiNjk5MTJiNjVjMDdfMy0zLTEtMS0yNTY2OA_335118a2-e60b-4a9f-bb1e-e42393c27832"
      unitRef="usd">36000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i5e02e812fef941edbaba1967484f0272_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80Ni9mcmFnOjk3ZWVkZmEwMmYxYjQyOTFhOWE4NGE4ZDRmNmI2YjQzL3RhYmxlOjA5NWZmMWEyNDAyZjQ0ZTA5YTRkYjY5OTEyYjY1YzA3L3RhYmxlcmFuZ2U6MDk1ZmYxYTI0MDJmNDRlMDlhNGRiNjk5MTJiNjVjMDdfNC0xLTEtMS0yNTY2OA_24cb0660-8f29-48fd-8322-6d0d5ecc5e7a"
      unitRef="usd">1088000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i84a8784bf6674ce391d92b932658744b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80Ni9mcmFnOjk3ZWVkZmEwMmYxYjQyOTFhOWE4NGE4ZDRmNmI2YjQzL3RhYmxlOjA5NWZmMWEyNDAyZjQ0ZTA5YTRkYjY5OTEyYjY1YzA3L3RhYmxlcmFuZ2U6MDk1ZmYxYTI0MDJmNDRlMDlhNGRiNjk5MTJiNjVjMDdfNC0zLTEtMS0yNTY2OA_f2c1dfd4-1f53-4212-9306-dfece44c71a8"
      unitRef="usd">1412000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80OS9mcmFnOmUwMTdhMjQyY2ZlYzQwZGI4YzZjMmFmZjk2NTUxMWI1L3RleHRyZWdpb246ZTAxN2EyNDJjZmVjNDBkYjhjNmMyYWZmOTY1NTExYjVfMTgxMg_a175c92c-f927-4dd6-b568-a7eb904639f2">LEASESAll of our leases are operating leases and each contain customary rent escalation clauses. Certain of the leases have both lease and non-lease components. We have elected to account for each separate lease component and the non-lease components associated with that lease component as a single lease component for all classes of underlying assets.&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides additional details of our facility leases presented in our condensed balance sheets as of March&#160;31, 2022 and December&#160;31, 2021 (dollars in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.274%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.128%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Facilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,910&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,752&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,592&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,492&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liability, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,812&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,748&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,404&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,240&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining life (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease costs, which are included in operating expenses in our statements of operations, were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.636%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for operating lease&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our undiscounted cash payment obligations for our operating lease liabilities as of March&#160;31, 2022 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remainder of 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total undiscounted operating lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Imputed interest expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,432)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Current portion of operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,592)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liability, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:5pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:5pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:5pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <ardx:ScheduleOfAdditionalDetailsOfLeasesTableTextBlock
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80OS9mcmFnOmUwMTdhMjQyY2ZlYzQwZGI4YzZjMmFmZjk2NTUxMWI1L3RleHRyZWdpb246ZTAxN2EyNDJjZmVjNDBkYjhjNmMyYWZmOTY1NTExYjVfMTgxNg_48d5666a-8dd7-4a1e-9ecf-d7dd327a34ff">&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides additional details of our facility leases presented in our condensed balance sheets as of March&#160;31, 2022 and December&#160;31, 2021 (dollars in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.274%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.128%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Facilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,910&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,752&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,592&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,492&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liability, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,812&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,748&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,404&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,240&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining life (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ardx:ScheduleOfAdditionalDetailsOfLeasesTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80OS9mcmFnOmUwMTdhMjQyY2ZlYzQwZGI4YzZjMmFmZjk2NTUxMWI1L3RhYmxlOmYxMTU3OGQ4ODhkNjQ1ZDlhNzkzNTc4ODVlYTRlZTE5L3RhYmxlcmFuZ2U6ZjExNTc4ZDg4OGQ2NDVkOWE3OTM1Nzg4NWVhNGVlMTlfMS0xLTEtMS0yMzAxMw_cb14193a-9613-432a-a44d-66925936dbc6"
      unitRef="usd">11910000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80OS9mcmFnOmUwMTdhMjQyY2ZlYzQwZGI4YzZjMmFmZjk2NTUxMWI1L3RhYmxlOmYxMTU3OGQ4ODhkNjQ1ZDlhNzkzNTc4ODVlYTRlZTE5L3RhYmxlcmFuZ2U6ZjExNTc4ZDg4OGQ2NDVkOWE3OTM1Nzg4NWVhNGVlMTlfMS0zLTEtMS0zMzc5Mw_91cf10ca-aebd-4b32-b042-e40c67817d79"
      unitRef="usd">12752000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80OS9mcmFnOmUwMTdhMjQyY2ZlYzQwZGI4YzZjMmFmZjk2NTUxMWI1L3RhYmxlOmYxMTU3OGQ4ODhkNjQ1ZDlhNzkzNTc4ODVlYTRlZTE5L3RhYmxlcmFuZ2U6ZjExNTc4ZDg4OGQ2NDVkOWE3OTM1Nzg4NWVhNGVlMTlfMy0xLTEtMS0yMzAxMw_f63fd78c-a1b8-4264-81be-a6121d3896e4"
      unitRef="usd">3592000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80OS9mcmFnOmUwMTdhMjQyY2ZlYzQwZGI4YzZjMmFmZjk2NTUxMWI1L3RhYmxlOmYxMTU3OGQ4ODhkNjQ1ZDlhNzkzNTc4ODVlYTRlZTE5L3RhYmxlcmFuZ2U6ZjExNTc4ZDg4OGQ2NDVkOWE3OTM1Nzg4NWVhNGVlMTlfMy0zLTEtMS0zMzc5Mw_30968fd7-ec86-4ae7-ab21-3cc9f12fe77b"
      unitRef="usd">3492000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80OS9mcmFnOmUwMTdhMjQyY2ZlYzQwZGI4YzZjMmFmZjk2NTUxMWI1L3RhYmxlOmYxMTU3OGQ4ODhkNjQ1ZDlhNzkzNTc4ODVlYTRlZTE5L3RhYmxlcmFuZ2U6ZjExNTc4ZDg4OGQ2NDVkOWE3OTM1Nzg4NWVhNGVlMTlfNC0xLTEtMS0yMzAxMw_8e7b92b6-52a0-479d-9953-d4981ee33d6c"
      unitRef="usd">8812000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80OS9mcmFnOmUwMTdhMjQyY2ZlYzQwZGI4YzZjMmFmZjk2NTUxMWI1L3RhYmxlOmYxMTU3OGQ4ODhkNjQ1ZDlhNzkzNTc4ODVlYTRlZTE5L3RhYmxlcmFuZ2U6ZjExNTc4ZDg4OGQ2NDVkOWE3OTM1Nzg4NWVhNGVlMTlfNC0zLTEtMS0zMzc5Mw_a2509323-0df0-4a89-bdbc-9cd8f034a667"
      unitRef="usd">9748000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80OS9mcmFnOmUwMTdhMjQyY2ZlYzQwZGI4YzZjMmFmZjk2NTUxMWI1L3RhYmxlOmYxMTU3OGQ4ODhkNjQ1ZDlhNzkzNTc4ODVlYTRlZTE5L3RhYmxlcmFuZ2U6ZjExNTc4ZDg4OGQ2NDVkOWE3OTM1Nzg4NWVhNGVlMTlfNS0xLTEtMS0yMzAxMw_bb407270-89b8-4866-8be1-994fd2f74308"
      unitRef="usd">12404000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80OS9mcmFnOmUwMTdhMjQyY2ZlYzQwZGI4YzZjMmFmZjk2NTUxMWI1L3RhYmxlOmYxMTU3OGQ4ODhkNjQ1ZDlhNzkzNTc4ODVlYTRlZTE5L3RhYmxlcmFuZ2U6ZjExNTc4ZDg4OGQ2NDVkOWE3OTM1Nzg4NWVhNGVlMTlfNS0zLTEtMS0zMzc5Mw_51ef771b-ac36-40df-acda-80f02be7975d"
      unitRef="usd">13240000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80OS9mcmFnOmUwMTdhMjQyY2ZlYzQwZGI4YzZjMmFmZjk2NTUxMWI1L3RhYmxlOmYxMTU3OGQ4ODhkNjQ1ZDlhNzkzNTc4ODVlYTRlZTE5L3RhYmxlcmFuZ2U6ZjExNTc4ZDg4OGQ2NDVkOWE3OTM1Nzg4NWVhNGVlMTlfNy0xLTEtMS0yMzAxMw_2f7b36f1-b202-4085-a626-8ad6d7d45fc3">P3Y2M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80OS9mcmFnOmUwMTdhMjQyY2ZlYzQwZGI4YzZjMmFmZjk2NTUxMWI1L3RhYmxlOmYxMTU3OGQ4ODhkNjQ1ZDlhNzkzNTc4ODVlYTRlZTE5L3RhYmxlcmFuZ2U6ZjExNTc4ZDg4OGQ2NDVkOWE3OTM1Nzg4NWVhNGVlMTlfNy0zLTEtMS0zMzc5Mw_7c38ee10-ae16-405f-918b-6946ac8bf066">P3Y4M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80OS9mcmFnOmUwMTdhMjQyY2ZlYzQwZGI4YzZjMmFmZjk2NTUxMWI1L3RhYmxlOmYxMTU3OGQ4ODhkNjQ1ZDlhNzkzNTc4ODVlYTRlZTE5L3RhYmxlcmFuZ2U6ZjExNTc4ZDg4OGQ2NDVkOWE3OTM1Nzg4NWVhNGVlMTlfOC0xLTEtMS0yMzAxMw_824fe17f-beb0-46e0-8937-e029e141dcfa"
      unitRef="number">0.069</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80OS9mcmFnOmUwMTdhMjQyY2ZlYzQwZGI4YzZjMmFmZjk2NTUxMWI1L3RhYmxlOmYxMTU3OGQ4ODhkNjQ1ZDlhNzkzNTc4ODVlYTRlZTE5L3RhYmxlcmFuZ2U6ZjExNTc4ZDg4OGQ2NDVkOWE3OTM1Nzg4NWVhNGVlMTlfOC0zLTEtMS0zMzc5Mw_5246557c-8ce2-4ece-a939-5dc287039589"
      unitRef="number">0.069</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80OS9mcmFnOmUwMTdhMjQyY2ZlYzQwZGI4YzZjMmFmZjk2NTUxMWI1L3RleHRyZWdpb246ZTAxN2EyNDJjZmVjNDBkYjhjNmMyYWZmOTY1NTExYjVfMTgxNw_09ab7158-eeeb-49cd-a247-27d6459a76e8">&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease costs, which are included in operating expenses in our statements of operations, were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.636%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for operating lease&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80OS9mcmFnOmUwMTdhMjQyY2ZlYzQwZGI4YzZjMmFmZjk2NTUxMWI1L3RhYmxlOjAwNTI4YTBjMjEzNzQwYmNiYTdjMzUzZGQwNTAzYmE0L3RhYmxlcmFuZ2U6MDA1MjhhMGMyMTM3NDBiY2JhN2MzNTNkZDA1MDNiYTRfMi0xLTEtMS0yMzAxMw_3a1142af-c2a2-4e6b-8f12-a86a6706c97e"
      unitRef="usd">1064000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80OS9mcmFnOmUwMTdhMjQyY2ZlYzQwZGI4YzZjMmFmZjk2NTUxMWI1L3RhYmxlOjAwNTI4YTBjMjEzNzQwYmNiYTdjMzUzZGQwNTAzYmE0L3RhYmxlcmFuZ2U6MDA1MjhhMGMyMTM3NDBiY2JhN2MzNTNkZDA1MDNiYTRfMi0zLTEtMS0yMzAxMw_e4adc303-587a-4665-9d35-bf99d16528ce"
      unitRef="usd">673000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80OS9mcmFnOmUwMTdhMjQyY2ZlYzQwZGI4YzZjMmFmZjk2NTUxMWI1L3RhYmxlOjAwNTI4YTBjMjEzNzQwYmNiYTdjMzUzZGQwNTAzYmE0L3RhYmxlcmFuZ2U6MDA1MjhhMGMyMTM3NDBiY2JhN2MzNTNkZDA1MDNiYTRfMy0xLTEtMS0yMzAxMw_2bf3e0b4-44a9-4e00-b0f9-15fc1a1f285d"
      unitRef="usd">1058000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80OS9mcmFnOmUwMTdhMjQyY2ZlYzQwZGI4YzZjMmFmZjk2NTUxMWI1L3RhYmxlOjAwNTI4YTBjMjEzNzQwYmNiYTdjMzUzZGQwNTAzYmE0L3RhYmxlcmFuZ2U6MDA1MjhhMGMyMTM3NDBiY2JhN2MzNTNkZDA1MDNiYTRfMy0zLTEtMS0yMzAxMw_bc054238-21b4-4ee2-ba4f-455f4a94c4bf"
      unitRef="usd">1565000</us-gaap:OperatingLeasePayments>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80OS9mcmFnOmUwMTdhMjQyY2ZlYzQwZGI4YzZjMmFmZjk2NTUxMWI1L3RleHRyZWdpb246ZTAxN2EyNDJjZmVjNDBkYjhjNmMyYWZmOTY1NTExYjVfMTgxMQ_b054ed64-b5dd-4b53-bc61-a86f19db6669">&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our undiscounted cash payment obligations for our operating lease liabilities as of March&#160;31, 2022 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remainder of 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total undiscounted operating lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Imputed interest expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,432)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Current portion of operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,592)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liability, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:5pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:5pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:5pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80OS9mcmFnOmUwMTdhMjQyY2ZlYzQwZGI4YzZjMmFmZjk2NTUxMWI1L3RhYmxlOjM4N2I1MGIyMmViNTQyY2FhMjUzMWJiYjljODEzODYzL3RhYmxlcmFuZ2U6Mzg3YjUwYjIyZWI1NDJjYWEyNTMxYmJiOWM4MTM4NjNfMC0yLTEtMS0yNTgzNw_64c4a1e0-1cbf-40cd-be93-b1d725ee4365"
      unitRef="usd">3234000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80OS9mcmFnOmUwMTdhMjQyY2ZlYzQwZGI4YzZjMmFmZjk2NTUxMWI1L3RhYmxlOjM4N2I1MGIyMmViNTQyY2FhMjUzMWJiYjljODEzODYzL3RhYmxlcmFuZ2U6Mzg3YjUwYjIyZWI1NDJjYWEyNTMxYmJiOWM4MTM4NjNfMS0yLTEtMS0yNTgzNw_352778a9-af62-4a09-85ca-467cc4b52744"
      unitRef="usd">4440000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80OS9mcmFnOmUwMTdhMjQyY2ZlYzQwZGI4YzZjMmFmZjk2NTUxMWI1L3RhYmxlOjM4N2I1MGIyMmViNTQyY2FhMjUzMWJiYjljODEzODYzL3RhYmxlcmFuZ2U6Mzg3YjUwYjIyZWI1NDJjYWEyNTMxYmJiOWM4MTM4NjNfMi0yLTEtMS0yNTgzNw_308df95d-7c6d-4f8e-9fda-ee357760600a"
      unitRef="usd">4589000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80OS9mcmFnOmUwMTdhMjQyY2ZlYzQwZGI4YzZjMmFmZjk2NTUxMWI1L3RhYmxlOjM4N2I1MGIyMmViNTQyY2FhMjUzMWJiYjljODEzODYzL3RhYmxlcmFuZ2U6Mzg3YjUwYjIyZWI1NDJjYWEyNTMxYmJiOWM4MTM4NjNfMy0yLTEtMS0yNTgzNw_d0e6767e-61eb-4103-b545-473e896fd08f"
      unitRef="usd">1321000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80OS9mcmFnOmUwMTdhMjQyY2ZlYzQwZGI4YzZjMmFmZjk2NTUxMWI1L3RhYmxlOjM4N2I1MGIyMmViNTQyY2FhMjUzMWJiYjljODEzODYzL3RhYmxlcmFuZ2U6Mzg3YjUwYjIyZWI1NDJjYWEyNTMxYmJiOWM4MTM4NjNfNC0yLTEtMS0yNTgzNw_49153bb4-eed6-415d-b6e0-aa31dfd90493"
      unitRef="usd">252000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80OS9mcmFnOmUwMTdhMjQyY2ZlYzQwZGI4YzZjMmFmZjk2NTUxMWI1L3RhYmxlOjM4N2I1MGIyMmViNTQyY2FhMjUzMWJiYjljODEzODYzL3RhYmxlcmFuZ2U6Mzg3YjUwYjIyZWI1NDJjYWEyNTMxYmJiOWM4MTM4NjNfNi0yLTEtMS0yNTgzNw_6c704e70-1663-4c79-b115-05aac12dc59f"
      unitRef="usd">13836000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80OS9mcmFnOmUwMTdhMjQyY2ZlYzQwZGI4YzZjMmFmZjk2NTUxMWI1L3RhYmxlOjM4N2I1MGIyMmViNTQyY2FhMjUzMWJiYjljODEzODYzL3RhYmxlcmFuZ2U6Mzg3YjUwYjIyZWI1NDJjYWEyNTMxYmJiOWM4MTM4NjNfNy0yLTEtMS0yNTgzNw_2cdcd489-8d1f-410a-b1fa-389e7571963e"
      unitRef="usd">1432000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80OS9mcmFnOmUwMTdhMjQyY2ZlYzQwZGI4YzZjMmFmZjk2NTUxMWI1L3RhYmxlOjM4N2I1MGIyMmViNTQyY2FhMjUzMWJiYjljODEzODYzL3RhYmxlcmFuZ2U6Mzg3YjUwYjIyZWI1NDJjYWEyNTMxYmJiOWM4MTM4NjNfOC0yLTEtMS0yNTgzNw_e7b1931b-16c8-4d0a-8782-9d820d969aee"
      unitRef="usd">12404000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80OS9mcmFnOmUwMTdhMjQyY2ZlYzQwZGI4YzZjMmFmZjk2NTUxMWI1L3RhYmxlOjM4N2I1MGIyMmViNTQyY2FhMjUzMWJiYjljODEzODYzL3RhYmxlcmFuZ2U6Mzg3YjUwYjIyZWI1NDJjYWEyNTMxYmJiOWM4MTM4NjNfOS0yLTEtMS0yNTgzNw_b7365566-c7e9-4165-9fb8-8136c0403ec8"
      unitRef="usd">3592000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV80OS9mcmFnOmUwMTdhMjQyY2ZlYzQwZGI4YzZjMmFmZjk2NTUxMWI1L3RhYmxlOjM4N2I1MGIyMmViNTQyY2FhMjUzMWJiYjljODEzODYzL3RhYmxlcmFuZ2U6Mzg3YjUwYjIyZWI1NDJjYWEyNTMxYmJiOWM4MTM4NjNfMTAtMi0xLTEtMjU4Mzc_97a203aa-078c-4b12-80a7-69fcd970e0de"
      unitRef="usd">8812000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81Mi9mcmFnOjBkZmY3ZjU5N2U2MDQ2NTdhMjlkNmM5ZDAxOGFkNGJkL3RleHRyZWdpb246MGRmZjdmNTk3ZTYwNDY1N2EyOWQ2YzlkMDE4YWQ0YmRfMjQyOA_0246ce97-4d23-4d4d-b2ec-ad82cbfb824b">STOCKHOLDERS&#x2019; EQUITY&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;At the Market Offerings Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2020, we filed a Form S-3 registration statement, which became effective in August 2020 ("Registration Statement"), containing (i) a base prospectus for the offering, issuance and sale by us of up to a maximum aggregate offering price of $250.0 million of our common stock, preferred stock, debt securities, warrants and/or units, from time to time in one or more offerings; and (ii) a prospectus supplement for the offering, issuance and sale by us of up to a maximum aggregate offering price of $100.0 million of our common stock that may be issued and sold, from time to time, under a sales agreement with Jefferies LLC ("Jefferies"), deemed to be &#x201c;at the market offerings&#x201d; (the "2020 Open Market Sales Agreement"). The 2020 Open Market Sales Agreement was fully utilized as of December 31, 2021. During the three months ended March&#160;31, 2021 we sold 4.9 million shares and received gross proceeds of $35.0 million at a weighted average sales price of approximately $7.09 per share under the 2020 Open Market Sales Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2021, we filed an additional prospectus supplement under the Registration Statement for the offering, issuance and sale by us of up to a maximum aggregate offering price of $150.0 million of our common stock that may be issued and sold, from time to time, under an additional sales agreement we entered into with Jefferies (the "2021 Open Market Sales Agreement"), pursuant to which we may, from time to time, sell up to $150.0 million in shares of our common stock through Jefferies. We are not required to sell shares under the 2021 Open Market Sales Agreement. Pursuant to the 2021 Open Market &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sales Agreement, Jefferies, as our sales agent, receives a commission of up to 3% of the gross sales price for shares of common stock sold under the 2021 Open Market Sales Agreement. During the three months ended March&#160;31, 2022 we sold 5.9 million shares and received gross proceeds of $6.0 million at a weighted average sales price of approximately $1.02 per share under the 2021 Open Market Sales Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We sold 8.3 million shares of our common stock pursuant to the 2021 Open Market Sales Agreement which were settled&lt;/span&gt;&lt;span style="color:#bf2115;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;between the dates of April 1, 2022 through April 27, 2022 for gross proceeds of $9.0 million at a weighted average sales price of approximately $1.09 per share. We did not sell any additional shares of our common stock after April 25, 2022 and through the date of filing this Quarterly Report on Form 10-Q.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <ardx:MaximumAggregateOfferingPrice
      contextRef="i76c2136d55464302b2f21baaa5e4dd54_I20200731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81Mi9mcmFnOjBkZmY3ZjU5N2U2MDQ2NTdhMjlkNmM5ZDAxOGFkNGJkL3RleHRyZWdpb246MGRmZjdmNTk3ZTYwNDY1N2EyOWQ2YzlkMDE4YWQ0YmRfMTA5OTUxMTYzMDIxNQ_6f2d281a-8177-46cf-85bf-ce21c2f5cc56"
      unitRef="usd">250000000</ardx:MaximumAggregateOfferingPrice>
    <ardx:MaximumAggregateOfferingPrice
      contextRef="ia17a982a190740e2954ba6bf67641fdf_I20200731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81Mi9mcmFnOjBkZmY3ZjU5N2U2MDQ2NTdhMjlkNmM5ZDAxOGFkNGJkL3RleHRyZWdpb246MGRmZjdmNTk3ZTYwNDY1N2EyOWQ2YzlkMDE4YWQ0YmRfMTA5OTUxMTYzMDIxOQ_1f3a7c1c-28da-4618-8d04-c312f2a161de"
      unitRef="usd">100000000</ardx:MaximumAggregateOfferingPrice>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ide9366ec48e04d7b90b9fb896f92c772_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81Mi9mcmFnOjBkZmY3ZjU5N2U2MDQ2NTdhMjlkNmM5ZDAxOGFkNGJkL3RleHRyZWdpb246MGRmZjdmNTk3ZTYwNDY1N2EyOWQ2YzlkMDE4YWQ0YmRfMTA5OTUxMTYzMTY3MQ_b3554391-f7b4-4a47-a4e4-0706477ac965"
      unitRef="shares">4900000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ide9366ec48e04d7b90b9fb896f92c772_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81Mi9mcmFnOjBkZmY3ZjU5N2U2MDQ2NTdhMjlkNmM5ZDAxOGFkNGJkL3RleHRyZWdpb246MGRmZjdmNTk3ZTYwNDY1N2EyOWQ2YzlkMDE4YWQ0YmRfMTA5OTUxMTYzMTY3NQ_bc2d66df-691c-404c-b91f-1a39fd3661b4"
      unitRef="usd">35000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <ardx:SaleOfStockWeightedAveragePricePerShare
      contextRef="ide9366ec48e04d7b90b9fb896f92c772_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81Mi9mcmFnOjBkZmY3ZjU5N2U2MDQ2NTdhMjlkNmM5ZDAxOGFkNGJkL3RleHRyZWdpb246MGRmZjdmNTk3ZTYwNDY1N2EyOWQ2YzlkMDE4YWQ0YmRfMTA5OTUxMTYzMTY3OQ_30c91798-4b62-472d-aa8d-d0bb4ad079bd"
      unitRef="usdPerShare">7.09</ardx:SaleOfStockWeightedAveragePricePerShare>
    <ardx:MaximumAggregateOfferingPrice
      contextRef="ic8a3d4170574424dbc7bd161e8e90f99_I20210831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81Mi9mcmFnOjBkZmY3ZjU5N2U2MDQ2NTdhMjlkNmM5ZDAxOGFkNGJkL3RleHRyZWdpb246MGRmZjdmNTk3ZTYwNDY1N2EyOWQ2YzlkMDE4YWQ0YmRfMTA5OTUxMTYzMTA5OA_7cc778a0-05a6-494f-9e07-a80dbf4c03a5"
      unitRef="usd">150000000</ardx:MaximumAggregateOfferingPrice>
    <ardx:MaximumAggregateOfferingPrice
      contextRef="ic8a3d4170574424dbc7bd161e8e90f99_I20210831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81Mi9mcmFnOjBkZmY3ZjU5N2U2MDQ2NTdhMjlkNmM5ZDAxOGFkNGJkL3RleHRyZWdpb246MGRmZjdmNTk3ZTYwNDY1N2EyOWQ2YzlkMDE4YWQ0YmRfMTA5OTUxMTYzMTEwMg_7cc778a0-05a6-494f-9e07-a80dbf4c03a5"
      unitRef="usd">150000000</ardx:MaximumAggregateOfferingPrice>
    <ardx:StockIssuanceCostCommissionPercent
      contextRef="i58ecc0e1f7064678834e4f881aa7d26f_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81Mi9mcmFnOjBkZmY3ZjU5N2U2MDQ2NTdhMjlkNmM5ZDAxOGFkNGJkL3RleHRyZWdpb246MGRmZjdmNTk3ZTYwNDY1N2EyOWQ2YzlkMDE4YWQ0YmRfMTA5OTUxMTYzMTEwNg_923f7f8a-53fd-4bb1-9982-71ca65e658b5"
      unitRef="number">0.03</ardx:StockIssuanceCostCommissionPercent>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i58ecc0e1f7064678834e4f881aa7d26f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81Mi9mcmFnOjBkZmY3ZjU5N2U2MDQ2NTdhMjlkNmM5ZDAxOGFkNGJkL3RleHRyZWdpb246MGRmZjdmNTk3ZTYwNDY1N2EyOWQ2YzlkMDE4YWQ0YmRfMTA5OTUxMTYzMTM2MA_250db3a0-40ef-4698-9a55-00957d9a9711"
      unitRef="shares">5900000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i58ecc0e1f7064678834e4f881aa7d26f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81Mi9mcmFnOjBkZmY3ZjU5N2U2MDQ2NTdhMjlkNmM5ZDAxOGFkNGJkL3RleHRyZWdpb246MGRmZjdmNTk3ZTYwNDY1N2EyOWQ2YzlkMDE4YWQ0YmRfMTA5OTUxMTYzMTM2NA_1e377c06-a415-4bc3-94f9-e777fa083caa"
      unitRef="usd">6000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <ardx:SaleOfStockWeightedAveragePricePerShare
      contextRef="i58ecc0e1f7064678834e4f881aa7d26f_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81Mi9mcmFnOjBkZmY3ZjU5N2U2MDQ2NTdhMjlkNmM5ZDAxOGFkNGJkL3RleHRyZWdpb246MGRmZjdmNTk3ZTYwNDY1N2EyOWQ2YzlkMDE4YWQ0YmRfMTA5OTUxMTYzMTM2OA_d009c6f1-fcdb-4c03-b377-ac6dde9ff573"
      unitRef="usdPerShare">1.02</ardx:SaleOfStockWeightedAveragePricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i1e7f6940c3f94b42ae0826c56712faf3_D20220401-20220427"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81Mi9mcmFnOjBkZmY3ZjU5N2U2MDQ2NTdhMjlkNmM5ZDAxOGFkNGJkL3RleHRyZWdpb246MGRmZjdmNTk3ZTYwNDY1N2EyOWQ2YzlkMDE4YWQ0YmRfMTA5OTUxMTYzMTk1Nw_93da01b3-56a5-4a34-940a-a41bb096e5d5"
      unitRef="shares">8300000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i1e7f6940c3f94b42ae0826c56712faf3_D20220401-20220427"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81Mi9mcmFnOjBkZmY3ZjU5N2U2MDQ2NTdhMjlkNmM5ZDAxOGFkNGJkL3RleHRyZWdpb246MGRmZjdmNTk3ZTYwNDY1N2EyOWQ2YzlkMDE4YWQ0YmRfMTA5OTUxMTYzMjExOA_72d546f6-270c-4afe-9182-209f28ad752c"
      unitRef="usd">9000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <ardx:SaleOfStockWeightedAveragePricePerShare
      contextRef="i1e7f6940c3f94b42ae0826c56712faf3_D20220401-20220427"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81Mi9mcmFnOjBkZmY3ZjU5N2U2MDQ2NTdhMjlkNmM5ZDAxOGFkNGJkL3RleHRyZWdpb246MGRmZjdmNTk3ZTYwNDY1N2EyOWQ2YzlkMDE4YWQ0YmRfMTA5OTUxMTYzMjE3Mw_18f96b54-9352-4d7a-a993-c4619ae2f495"
      unitRef="usdPerShare">1.09</ardx:SaleOfStockWeightedAveragePricePerShare>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81NS9mcmFnOjFjNTVkN2MzZTAyNzRhODc4NmVkODk4ZWE0MDJlMzI5L3RleHRyZWdpb246MWM1NWQ3YzNlMDI3NGE4Nzg2ZWQ4OThlYTQwMmUzMjlfMTU5NQ_8b749c71-97dd-450e-914f-de28c2cff79a">EQUITY INCENTIVE PLANS&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense recognized for stock options, restricted stock units ("RSUs"), performance-based restricted stock units ("PRSUs") and our employee stock purchase program (the "ESPP") are recorded as operating expenses in our condensed statements of operations and comprehensive loss, as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:75.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.867%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2022, our total unrecognized stock-based compensation expense, net of estimated forfeitures, and average remaining vesting period, included the following (dollars in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.323%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrecognized Compensation Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Average Remaining Vesting Period (Years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock option grants&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSU grants&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of our stock option activity and related information for the three months ended March&#160;31, 2022 is as follows (in thousands, except dollar amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.152%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.106%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number&#160;of&#160;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Exercise&#160;Price&#160;per&lt;br/&gt;Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options forfeited or canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,006)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of our RSUs activity and related information for the three months ended March&#160;31, 2022 is as follows (in thousands, except dollar amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.884%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Grant&#160;Date&#160;Fair&lt;br/&gt;Value Per&#160;Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested restricted stock units at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(113)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(88)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested restricted stock units at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2022, we sold approximately 0.1 million shares of our common stock under the ESPP. The shares were purchased by employees at a purchase price of $0.65 per share resulting in proceeds to us of approximately $0.1 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Issuance of Common Stock for Services&lt;/span&gt;&lt;/div&gt;Under Our Amended and Restated Non-Employee Director Compensation Program, members of our board of directors may elect to receive shares of our stock in lieu of their cash fees. During the three months ended March&#160;31, 2022, we issued no shares of our common stock to members of the board of directors in accordance with the program.</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81NS9mcmFnOjFjNTVkN2MzZTAyNzRhODc4NmVkODk4ZWE0MDJlMzI5L3RleHRyZWdpb246MWM1NWQ3YzNlMDI3NGE4Nzg2ZWQ4OThlYTQwMmUzMjlfMTU5Ng_b19d1739-5ec8-4686-8cc3-bbe495b9aece">&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense recognized for stock options, restricted stock units ("RSUs"), performance-based restricted stock units ("PRSUs") and our employee stock purchase program (the "ESPP") are recorded as operating expenses in our condensed statements of operations and comprehensive loss, as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:75.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.867%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5fb7df19c340473c8180a84b522d3105_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81NS9mcmFnOjFjNTVkN2MzZTAyNzRhODc4NmVkODk4ZWE0MDJlMzI5L3RhYmxlOjI1YzZmYjljMDNkZDQzNGQ4ODBkZjFjNmI4ZmViNjU1L3RhYmxlcmFuZ2U6MjVjNmZiOWMwM2RkNDM0ZDg4MGRmMWM2YjhmZWI2NTVfMi0xLTEtMS0yMzAxMw_f8eed985-6eca-4e07-a3df-96eb9ca7352f"
      unitRef="usd">1214000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i688a54ef5d904ecc853b9118c446b946_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81NS9mcmFnOjFjNTVkN2MzZTAyNzRhODc4NmVkODk4ZWE0MDJlMzI5L3RhYmxlOjI1YzZmYjljMDNkZDQzNGQ4ODBkZjFjNmI4ZmViNjU1L3RhYmxlcmFuZ2U6MjVjNmZiOWMwM2RkNDM0ZDg4MGRmMWM2YjhmZWI2NTVfMi0zLTEtMS0yMzAxMw_7b52ce1c-fa80-4b33-a411-faee4a29f749"
      unitRef="usd">1092000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="idd425314803a477c8c332384eb697af8_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81NS9mcmFnOjFjNTVkN2MzZTAyNzRhODc4NmVkODk4ZWE0MDJlMzI5L3RhYmxlOjI1YzZmYjljMDNkZDQzNGQ4ODBkZjFjNmI4ZmViNjU1L3RhYmxlcmFuZ2U6MjVjNmZiOWMwM2RkNDM0ZDg4MGRmMWM2YjhmZWI2NTVfMy0xLTEtMS0yMzAxMw_3cea87dc-5d3a-4742-8bc0-c03a3b4a94ca"
      unitRef="usd">2508000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5dc952c28b244722a46ac91b1208bda9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81NS9mcmFnOjFjNTVkN2MzZTAyNzRhODc4NmVkODk4ZWE0MDJlMzI5L3RhYmxlOjI1YzZmYjljMDNkZDQzNGQ4ODBkZjFjNmI4ZmViNjU1L3RhYmxlcmFuZ2U6MjVjNmZiOWMwM2RkNDM0ZDg4MGRmMWM2YjhmZWI2NTVfMy0zLTEtMS0yMzAxMw_2db8ff34-eb19-412e-87e5-89da96db34de"
      unitRef="usd">1995000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81NS9mcmFnOjFjNTVkN2MzZTAyNzRhODc4NmVkODk4ZWE0MDJlMzI5L3RhYmxlOjI1YzZmYjljMDNkZDQzNGQ4ODBkZjFjNmI4ZmViNjU1L3RhYmxlcmFuZ2U6MjVjNmZiOWMwM2RkNDM0ZDg4MGRmMWM2YjhmZWI2NTVfNC0xLTEtMS0yMzAxMw_a0e7a9c5-1b43-4612-83f2-0d4dee661ef2"
      unitRef="usd">3722000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81NS9mcmFnOjFjNTVkN2MzZTAyNzRhODc4NmVkODk4ZWE0MDJlMzI5L3RhYmxlOjI1YzZmYjljMDNkZDQzNGQ4ODBkZjFjNmI4ZmViNjU1L3RhYmxlcmFuZ2U6MjVjNmZiOWMwM2RkNDM0ZDg4MGRmMWM2YjhmZWI2NTVfNC0zLTEtMS0yMzAxMw_91ac3d42-4a2a-4c60-8133-574c3a4953f3"
      unitRef="usd">3087000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81NS9mcmFnOjFjNTVkN2MzZTAyNzRhODc4NmVkODk4ZWE0MDJlMzI5L3RleHRyZWdpb246MWM1NWQ3YzNlMDI3NGE4Nzg2ZWQ4OThlYTQwMmUzMjlfMTU5Nw_2acbe683-5648-4e0f-8964-7a608afce624">&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2022, our total unrecognized stock-based compensation expense, net of estimated forfeitures, and average remaining vesting period, included the following (dollars in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.323%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrecognized Compensation Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Average Remaining Vesting Period (Years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock option grants&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSU grants&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i8a3d5f58f87e49a095847ea09b7bf010_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81NS9mcmFnOjFjNTVkN2MzZTAyNzRhODc4NmVkODk4ZWE0MDJlMzI5L3RhYmxlOjAyYjA1OWFhMDIzYjRiNTVhMmM2N2E3YzkyNWVkNGMwL3RhYmxlcmFuZ2U6MDJiMDU5YWEwMjNiNGI1NWEyYzY3YTdjOTI1ZWQ0YzBfMS0xLTEtMS0yMzAxMw_5056f738-383e-4922-9725-e8d90f212fa0"
      unitRef="usd">14865000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i097a3193c63e4588b0705a6c382a1938_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81NS9mcmFnOjFjNTVkN2MzZTAyNzRhODc4NmVkODk4ZWE0MDJlMzI5L3RhYmxlOjAyYjA1OWFhMDIzYjRiNTVhMmM2N2E3YzkyNWVkNGMwL3RhYmxlcmFuZ2U6MDJiMDU5YWEwMjNiNGI1NWEyYzY3YTdjOTI1ZWQ0YzBfMS0zLTEtMS0yMzAxMw_8f6476f2-204c-4d15-8e77-6305c1cfdb52">P3Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="ie5d73f51d15b4a93b70e582a308344c0_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81NS9mcmFnOjFjNTVkN2MzZTAyNzRhODc4NmVkODk4ZWE0MDJlMzI5L3RhYmxlOjAyYjA1OWFhMDIzYjRiNTVhMmM2N2E3YzkyNWVkNGMwL3RhYmxlcmFuZ2U6MDJiMDU5YWEwMjNiNGI1NWEyYzY3YTdjOTI1ZWQ0YzBfMi0xLTEtMS0yMzAxMw_4b986845-8f88-4a42-b622-2d40474f9b9e"
      unitRef="usd">4894000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="idf00f8a3ea3f45eaab148f2ba05a7841_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81NS9mcmFnOjFjNTVkN2MzZTAyNzRhODc4NmVkODk4ZWE0MDJlMzI5L3RhYmxlOjAyYjA1OWFhMDIzYjRiNTVhMmM2N2E3YzkyNWVkNGMwL3RhYmxlcmFuZ2U6MDJiMDU5YWEwMjNiNGI1NWEyYzY3YTdjOTI1ZWQ0YzBfMi0zLTEtMS0yMzAxMw_0cf6be51-129b-4e90-85ff-16de84178af9">P1Y3M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i59d036f63af647faadf250a643250458_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81NS9mcmFnOjFjNTVkN2MzZTAyNzRhODc4NmVkODk4ZWE0MDJlMzI5L3RhYmxlOjAyYjA1OWFhMDIzYjRiNTVhMmM2N2E3YzkyNWVkNGMwL3RhYmxlcmFuZ2U6MDJiMDU5YWEwMjNiNGI1NWEyYzY3YTdjOTI1ZWQ0YzBfMy0xLTEtMS0yMzAxMw_b72a5a79-7025-4c20-8c26-c4141eeec8c3"
      unitRef="usd">53000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ic35af7bef7ef4aaf9affdc91a3779184_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81NS9mcmFnOjFjNTVkN2MzZTAyNzRhODc4NmVkODk4ZWE0MDJlMzI5L3RhYmxlOjAyYjA1OWFhMDIzYjRiNTVhMmM2N2E3YzkyNWVkNGMwL3RhYmxlcmFuZ2U6MDJiMDU5YWEwMjNiNGI1NWEyYzY3YTdjOTI1ZWQ0YzBfMy0zLTEtMS0yMzAxMw_db5d6298-77fc-40d0-8606-a2d1fb6d96f0">P0Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81NS9mcmFnOjFjNTVkN2MzZTAyNzRhODc4NmVkODk4ZWE0MDJlMzI5L3RleHRyZWdpb246MWM1NWQ3YzNlMDI3NGE4Nzg2ZWQ4OThlYTQwMmUzMjlfMTU5OA_455ea083-6b83-466c-9341-95152d16fb76">&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of our stock option activity and related information for the three months ended March&#160;31, 2022 is as follows (in thousands, except dollar amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.152%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.106%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number&#160;of&#160;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Exercise&#160;Price&#160;per&lt;br/&gt;Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options forfeited or canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,006)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81NS9mcmFnOjFjNTVkN2MzZTAyNzRhODc4NmVkODk4ZWE0MDJlMzI5L3RhYmxlOjViODdkMjFkNTVhMjQ1NDE5YzI4MTdkNjg4YTAzY2IyL3RhYmxlcmFuZ2U6NWI4N2QyMWQ1NWEyNDU0MTljMjgxN2Q2ODhhMDNjYjJfMS0xLTEtMS0yMzAxMw_8218beef-24cb-4649-8cde-a460ee8b9cd4"
      unitRef="shares">10417000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81NS9mcmFnOjFjNTVkN2MzZTAyNzRhODc4NmVkODk4ZWE0MDJlMzI5L3RhYmxlOjViODdkMjFkNTVhMjQ1NDE5YzI4MTdkNjg4YTAzY2IyL3RhYmxlcmFuZ2U6NWI4N2QyMWQ1NWEyNDU0MTljMjgxN2Q2ODhhMDNjYjJfMS0zLTEtMS0yMzAxMw_c21918e6-71bf-4480-8b50-fcb1ccef311c"
      unitRef="usdPerShare">7.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81NS9mcmFnOjFjNTVkN2MzZTAyNzRhODc4NmVkODk4ZWE0MDJlMzI5L3RhYmxlOjViODdkMjFkNTVhMjQ1NDE5YzI4MTdkNjg4YTAzY2IyL3RhYmxlcmFuZ2U6NWI4N2QyMWQ1NWEyNDU0MTljMjgxN2Q2ODhhMDNjYjJfMi0xLTEtMS0yMzAxMw_8f632f31-2424-43d1-9ba5-2bdd1899a00a"
      unitRef="shares">3535000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81NS9mcmFnOjFjNTVkN2MzZTAyNzRhODc4NmVkODk4ZWE0MDJlMzI5L3RhYmxlOjViODdkMjFkNTVhMjQ1NDE5YzI4MTdkNjg4YTAzY2IyL3RhYmxlcmFuZ2U6NWI4N2QyMWQ1NWEyNDU0MTljMjgxN2Q2ODhhMDNjYjJfMi0zLTEtMS0yMzAxMw_a47b8292-546e-40d9-97a8-2f146142c8ca"
      unitRef="usdPerShare">0.98</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81NS9mcmFnOjFjNTVkN2MzZTAyNzRhODc4NmVkODk4ZWE0MDJlMzI5L3RhYmxlOjViODdkMjFkNTVhMjQ1NDE5YzI4MTdkNjg4YTAzY2IyL3RhYmxlcmFuZ2U6NWI4N2QyMWQ1NWEyNDU0MTljMjgxN2Q2ODhhMDNjYjJfMy0xLTEtMS0yMzAxMw_b777b23b-3dd5-4067-9ff1-e95593b36794"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81NS9mcmFnOjFjNTVkN2MzZTAyNzRhODc4NmVkODk4ZWE0MDJlMzI5L3RhYmxlOjViODdkMjFkNTVhMjQ1NDE5YzI4MTdkNjg4YTAzY2IyL3RhYmxlcmFuZ2U6NWI4N2QyMWQ1NWEyNDU0MTljMjgxN2Q2ODhhMDNjYjJfMy0zLTEtMS0yMzAxMw_4b5fba78-e8a4-4100-b24b-954f854eda8e"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81NS9mcmFnOjFjNTVkN2MzZTAyNzRhODc4NmVkODk4ZWE0MDJlMzI5L3RhYmxlOjViODdkMjFkNTVhMjQ1NDE5YzI4MTdkNjg4YTAzY2IyL3RhYmxlcmFuZ2U6NWI4N2QyMWQ1NWEyNDU0MTljMjgxN2Q2ODhhMDNjYjJfNC0xLTEtMS0yMzAxMw_1bccf51c-9e0a-4c9c-83c9-cdb077a5fa66"
      unitRef="shares">1006000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81NS9mcmFnOjFjNTVkN2MzZTAyNzRhODc4NmVkODk4ZWE0MDJlMzI5L3RhYmxlOjViODdkMjFkNTVhMjQ1NDE5YzI4MTdkNjg4YTAzY2IyL3RhYmxlcmFuZ2U6NWI4N2QyMWQ1NWEyNDU0MTljMjgxN2Q2ODhhMDNjYjJfNC0zLTEtMS0yMzAxMw_43bc8b2c-ea99-4d97-9f78-139ccc8c67ab"
      unitRef="usdPerShare">7.18</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81NS9mcmFnOjFjNTVkN2MzZTAyNzRhODc4NmVkODk4ZWE0MDJlMzI5L3RhYmxlOjViODdkMjFkNTVhMjQ1NDE5YzI4MTdkNjg4YTAzY2IyL3RhYmxlcmFuZ2U6NWI4N2QyMWQ1NWEyNDU0MTljMjgxN2Q2ODhhMDNjYjJfNS0xLTEtMS0yMzAxMw_e8cda443-ee27-4141-ba14-f453569cff45"
      unitRef="shares">12946000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81NS9mcmFnOjFjNTVkN2MzZTAyNzRhODc4NmVkODk4ZWE0MDJlMzI5L3RhYmxlOjViODdkMjFkNTVhMjQ1NDE5YzI4MTdkNjg4YTAzY2IyL3RhYmxlcmFuZ2U6NWI4N2QyMWQ1NWEyNDU0MTljMjgxN2Q2ODhhMDNjYjJfNS0zLTEtMS0yMzAxMw_fcefcb16-4733-48d9-a078-9e2307b0b37d"
      unitRef="usdPerShare">5.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81NS9mcmFnOjFjNTVkN2MzZTAyNzRhODc4NmVkODk4ZWE0MDJlMzI5L3RhYmxlOjViODdkMjFkNTVhMjQ1NDE5YzI4MTdkNjg4YTAzY2IyL3RhYmxlcmFuZ2U6NWI4N2QyMWQ1NWEyNDU0MTljMjgxN2Q2ODhhMDNjYjJfNi0xLTEtMS0yMzAxMw_125c7adf-ed00-4bf2-a738-b05da1b4338c"
      unitRef="shares">6476000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81NS9mcmFnOjFjNTVkN2MzZTAyNzRhODc4NmVkODk4ZWE0MDJlMzI5L3RhYmxlOjViODdkMjFkNTVhMjQ1NDE5YzI4MTdkNjg4YTAzY2IyL3RhYmxlcmFuZ2U6NWI4N2QyMWQ1NWEyNDU0MTljMjgxN2Q2ODhhMDNjYjJfNi0zLTEtMS0yMzAxMw_7dfa4719-0eef-4fa8-8d9a-2cab75da9c38"
      unitRef="usdPerShare">7.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81NS9mcmFnOjFjNTVkN2MzZTAyNzRhODc4NmVkODk4ZWE0MDJlMzI5L3RleHRyZWdpb246MWM1NWQ3YzNlMDI3NGE4Nzg2ZWQ4OThlYTQwMmUzMjlfMTU5OQ_a5437a79-ab5f-4ad9-9dea-14dd76c76abf">&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of our RSUs activity and related information for the three months ended March&#160;31, 2022 is as follows (in thousands, except dollar amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.884%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Grant&#160;Date&#160;Fair&lt;br/&gt;Value Per&#160;Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested restricted stock units at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(113)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(88)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested restricted stock units at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i14d3b2f9b45b490fbcbe947f54b91b39_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81NS9mcmFnOjFjNTVkN2MzZTAyNzRhODc4NmVkODk4ZWE0MDJlMzI5L3RhYmxlOjQ5ZjFjMTg3NmMyMjQxNTlhM2VlODFhN2FkMjhkZmRlL3RhYmxlcmFuZ2U6NDlmMWMxODc2YzIyNDE1OWEzZWU4MWE3YWQyOGRmZGVfMS0xLTEtMS0yMzAxMw_d890a92f-c62b-4626-b119-39b08e692f5e"
      unitRef="shares">3529000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i14d3b2f9b45b490fbcbe947f54b91b39_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81NS9mcmFnOjFjNTVkN2MzZTAyNzRhODc4NmVkODk4ZWE0MDJlMzI5L3RhYmxlOjQ5ZjFjMTg3NmMyMjQxNTlhM2VlODFhN2FkMjhkZmRlL3RhYmxlcmFuZ2U6NDlmMWMxODc2YzIyNDE1OWEzZWU4MWE3YWQyOGRmZGVfMS0zLTEtMS0yMzAxMw_d2d39333-00cf-4d9e-9023-d50f60e2bfb5"
      unitRef="usdPerShare">2.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="idf00f8a3ea3f45eaab148f2ba05a7841_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81NS9mcmFnOjFjNTVkN2MzZTAyNzRhODc4NmVkODk4ZWE0MDJlMzI5L3RhYmxlOjQ5ZjFjMTg3NmMyMjQxNTlhM2VlODFhN2FkMjhkZmRlL3RhYmxlcmFuZ2U6NDlmMWMxODc2YzIyNDE1OWEzZWU4MWE3YWQyOGRmZGVfMi0xLTEtMS0yMzAxMw_d8a3b1b8-5f86-4d8a-8896-ad603bd26379"
      unitRef="shares">1120000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="idf00f8a3ea3f45eaab148f2ba05a7841_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81NS9mcmFnOjFjNTVkN2MzZTAyNzRhODc4NmVkODk4ZWE0MDJlMzI5L3RhYmxlOjQ5ZjFjMTg3NmMyMjQxNTlhM2VlODFhN2FkMjhkZmRlL3RhYmxlcmFuZ2U6NDlmMWMxODc2YzIyNDE1OWEzZWU4MWE3YWQyOGRmZGVfMi0zLTEtMS0yMzAxMw_d4fe70c8-12fe-419b-ad24-2fec4a6343ec"
      unitRef="usdPerShare">0.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="idf00f8a3ea3f45eaab148f2ba05a7841_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81NS9mcmFnOjFjNTVkN2MzZTAyNzRhODc4NmVkODk4ZWE0MDJlMzI5L3RhYmxlOjQ5ZjFjMTg3NmMyMjQxNTlhM2VlODFhN2FkMjhkZmRlL3RhYmxlcmFuZ2U6NDlmMWMxODc2YzIyNDE1OWEzZWU4MWE3YWQyOGRmZGVfMy0xLTEtMS0yMzAxMw_2920d0a0-adcb-4aec-bc72-9ac5efb4c4c1"
      unitRef="shares">113000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="idf00f8a3ea3f45eaab148f2ba05a7841_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81NS9mcmFnOjFjNTVkN2MzZTAyNzRhODc4NmVkODk4ZWE0MDJlMzI5L3RhYmxlOjQ5ZjFjMTg3NmMyMjQxNTlhM2VlODFhN2FkMjhkZmRlL3RhYmxlcmFuZ2U6NDlmMWMxODc2YzIyNDE1OWEzZWU4MWE3YWQyOGRmZGVfMy0zLTEtMS0yMzAxMw_7c5c320e-97bb-4a13-9f98-ad5dc517a79e"
      unitRef="usdPerShare">3.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="idf00f8a3ea3f45eaab148f2ba05a7841_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81NS9mcmFnOjFjNTVkN2MzZTAyNzRhODc4NmVkODk4ZWE0MDJlMzI5L3RhYmxlOjQ5ZjFjMTg3NmMyMjQxNTlhM2VlODFhN2FkMjhkZmRlL3RhYmxlcmFuZ2U6NDlmMWMxODc2YzIyNDE1OWEzZWU4MWE3YWQyOGRmZGVfNC0xLTEtMS0yMzAxMw_69f37e2e-9537-47a0-a3f8-04070b45be5e"
      unitRef="shares">88000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="idf00f8a3ea3f45eaab148f2ba05a7841_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81NS9mcmFnOjFjNTVkN2MzZTAyNzRhODc4NmVkODk4ZWE0MDJlMzI5L3RhYmxlOjQ5ZjFjMTg3NmMyMjQxNTlhM2VlODFhN2FkMjhkZmRlL3RhYmxlcmFuZ2U6NDlmMWMxODc2YzIyNDE1OWEzZWU4MWE3YWQyOGRmZGVfNC0zLTEtMS0yMzAxMw_1fb1d17a-61f1-4d2e-99df-1edfd9bdc088"
      unitRef="usdPerShare">2.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ie5d73f51d15b4a93b70e582a308344c0_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81NS9mcmFnOjFjNTVkN2MzZTAyNzRhODc4NmVkODk4ZWE0MDJlMzI5L3RhYmxlOjQ5ZjFjMTg3NmMyMjQxNTlhM2VlODFhN2FkMjhkZmRlL3RhYmxlcmFuZ2U6NDlmMWMxODc2YzIyNDE1OWEzZWU4MWE3YWQyOGRmZGVfNS0xLTEtMS0yMzAxMw_efe9cd85-dcf1-4fa3-9080-9595e067190e"
      unitRef="shares">4448000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ie5d73f51d15b4a93b70e582a308344c0_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81NS9mcmFnOjFjNTVkN2MzZTAyNzRhODc4NmVkODk4ZWE0MDJlMzI5L3RhYmxlOjQ5ZjFjMTg3NmMyMjQxNTlhM2VlODFhN2FkMjhkZmRlL3RhYmxlcmFuZ2U6NDlmMWMxODc2YzIyNDE1OWEzZWU4MWE3YWQyOGRmZGVfNS0zLTEtMS0yMzAxMw_c7d84ba4-8e03-4639-97b1-8e964d10f735"
      unitRef="usdPerShare">1.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i4bedde518aa14e90ae770d42052bfc56_D20220201-20220228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81NS9mcmFnOjFjNTVkN2MzZTAyNzRhODc4NmVkODk4ZWE0MDJlMzI5L3RleHRyZWdpb246MWM1NWQ3YzNlMDI3NGE4Nzg2ZWQ4OThlYTQwMmUzMjlfMTY0OTI2NzQ0MzM0MA_883d01b8-9115-4fa7-a3a7-7e5587aa1280"
      unitRef="shares">100000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <ardx:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare
      contextRef="i4bedde518aa14e90ae770d42052bfc56_D20220201-20220228"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81NS9mcmFnOjFjNTVkN2MzZTAyNzRhODc4NmVkODk4ZWE0MDJlMzI5L3RleHRyZWdpb246MWM1NWQ3YzNlMDI3NGE4Nzg2ZWQ4OThlYTQwMmUzMjlfMTY0OTI2NzQ0MzM0Nw_f13a96fd-987b-4713-b8e4-aafe42df6dae"
      unitRef="usdPerShare">0.65</ardx:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare>
    <us-gaap:ProceedsFromStockPlans
      contextRef="i4bedde518aa14e90ae770d42052bfc56_D20220201-20220228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81NS9mcmFnOjFjNTVkN2MzZTAyNzRhODc4NmVkODk4ZWE0MDJlMzI5L3RleHRyZWdpb246MWM1NWQ3YzNlMDI3NGE4Nzg2ZWQ4OThlYTQwMmUzMjlfMTY0OTI2NzQ0MzM1MQ_0bc1abe4-9a6f-468b-8183-ef7467ef6100"
      unitRef="usd">100000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="i856e705397e44a879c8d4de90f5984b6_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV81NS9mcmFnOjFjNTVkN2MzZTAyNzRhODc4NmVkODk4ZWE0MDJlMzI5L3RleHRyZWdpb246MWM1NWQ3YzNlMDI3NGE4Nzg2ZWQ4OThlYTQwMmUzMjlfMTY0OTI2NzQ0MzM1OA_5f127623-2ca4-4665-991a-1bd41aec2cef"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV82MS9mcmFnOjEwMjViNTNjNGEwYzQ1OTA4MDZiOThhZmRmODQ1ZGZmL3RleHRyZWdpb246MTAyNWI1M2M0YTBjNDU5MDgwNmI5OGFmZGY4NDVkZmZfMTI5Ng_d269e4d5-21d9-43b9-b38b-71c13461ee75">NET LOSS PER SHARE&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period, less shares subject to repurchase, and excludes any dilutive effects of stock-based awards and warrants. Diluted net loss per common share is computed giving effect to all potential dilutive common shares, including common stock issuable upon exercise of stock options, and unvested restricted common stock and stock units. As we had net losses for the three months ended March&#160;31, 2022 and 2021, all potential common shares were determined to be anti-dilutive. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the computation of net loss per common share (in thousands, except per share amounts): &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.862%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28,071)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33,155)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended March&#160;31, 2022, the total number of securities that could potentially dilute basic net loss per share in the future that were not included in the computation of diluted net loss per share because the effect would have been antidilutive was 13.3 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended March&#160;31, 2021, the total number of securities that could potentially dilute basic net loss per share in the future that were not included in the computation of diluted net loss per share because the effect would have been antidilutive was 13.0 million.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV82MS9mcmFnOjEwMjViNTNjNGEwYzQ1OTA4MDZiOThhZmRmODQ1ZGZmL3RleHRyZWdpb246MTAyNWI1M2M0YTBjNDU5MDgwNmI5OGFmZGY4NDVkZmZfMTI5Nw_1cad9048-16fc-4100-8c8f-83b99e27819f">&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the computation of net loss per common share (in thousands, except per share amounts): &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.862%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28,071)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33,155)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV82MS9mcmFnOjEwMjViNTNjNGEwYzQ1OTA4MDZiOThhZmRmODQ1ZGZmL3RhYmxlOmY5Y2ZjOWZmYTExZDRiMGU4MjAzMTlhYzUyMjk3ZTFlL3RhYmxlcmFuZ2U6ZjljZmM5ZmZhMTFkNGIwZTgyMDMxOWFjNTIyOTdlMWVfMi0xLTEtMS0yNjIwMg_1d948510-bd17-42af-a031-3e86e2e5825b"
      unitRef="usd">-28071000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV82MS9mcmFnOjEwMjViNTNjNGEwYzQ1OTA4MDZiOThhZmRmODQ1ZGZmL3RhYmxlOmY5Y2ZjOWZmYTExZDRiMGU4MjAzMTlhYzUyMjk3ZTFlL3RhYmxlcmFuZ2U6ZjljZmM5ZmZhMTFkNGIwZTgyMDMxOWFjNTIyOTdlMWVfMi0zLTEtMS0yNjIwMg_6164fedc-cb6c-4f2b-804c-e4867487cbac"
      unitRef="usd">-33155000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV82MS9mcmFnOjEwMjViNTNjNGEwYzQ1OTA4MDZiOThhZmRmODQ1ZGZmL3RhYmxlOmY5Y2ZjOWZmYTExZDRiMGU4MjAzMTlhYzUyMjk3ZTFlL3RhYmxlcmFuZ2U6ZjljZmM5ZmZhMTFkNGIwZTgyMDMxOWFjNTIyOTdlMWVfNC0xLTEtMS0yNjIwMg_72019096-c8e4-4256-bd65-7296a57ff64e"
      unitRef="shares">130935000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV82MS9mcmFnOjEwMjViNTNjNGEwYzQ1OTA4MDZiOThhZmRmODQ1ZGZmL3RhYmxlOmY5Y2ZjOWZmYTExZDRiMGU4MjAzMTlhYzUyMjk3ZTFlL3RhYmxlcmFuZ2U6ZjljZmM5ZmZhMTFkNGIwZTgyMDMxOWFjNTIyOTdlMWVfNC0xLTEtMS0yNjIwMg_857d8233-1d5f-43f5-b201-5773f638c06c"
      unitRef="shares">130935000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV82MS9mcmFnOjEwMjViNTNjNGEwYzQ1OTA4MDZiOThhZmRmODQ1ZGZmL3RhYmxlOmY5Y2ZjOWZmYTExZDRiMGU4MjAzMTlhYzUyMjk3ZTFlL3RhYmxlcmFuZ2U6ZjljZmM5ZmZhMTFkNGIwZTgyMDMxOWFjNTIyOTdlMWVfNC0zLTEtMS0yNjIwMg_316c40b0-2d44-4c36-b890-f65387745f19"
      unitRef="shares">97179000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV82MS9mcmFnOjEwMjViNTNjNGEwYzQ1OTA4MDZiOThhZmRmODQ1ZGZmL3RhYmxlOmY5Y2ZjOWZmYTExZDRiMGU4MjAzMTlhYzUyMjk3ZTFlL3RhYmxlcmFuZ2U6ZjljZmM5ZmZhMTFkNGIwZTgyMDMxOWFjNTIyOTdlMWVfNC0zLTEtMS0yNjIwMg_64215c6c-d454-4e8d-8304-043d68854785"
      unitRef="shares">97179000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV82MS9mcmFnOjEwMjViNTNjNGEwYzQ1OTA4MDZiOThhZmRmODQ1ZGZmL3RhYmxlOmY5Y2ZjOWZmYTExZDRiMGU4MjAzMTlhYzUyMjk3ZTFlL3RhYmxlcmFuZ2U6ZjljZmM5ZmZhMTFkNGIwZTgyMDMxOWFjNTIyOTdlMWVfNS0xLTEtMS0yMzAxMw_e98ea9ca-ec59-4794-ab8c-418c514eaadd"
      unitRef="usdPerShare">-0.21</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV82MS9mcmFnOjEwMjViNTNjNGEwYzQ1OTA4MDZiOThhZmRmODQ1ZGZmL3RhYmxlOmY5Y2ZjOWZmYTExZDRiMGU4MjAzMTlhYzUyMjk3ZTFlL3RhYmxlcmFuZ2U6ZjljZmM5ZmZhMTFkNGIwZTgyMDMxOWFjNTIyOTdlMWVfNS0xLTEtMS0yMzAxMw_efb5df7d-7d9e-4898-8b37-e57142ab2ba5"
      unitRef="usdPerShare">-0.21</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV82MS9mcmFnOjEwMjViNTNjNGEwYzQ1OTA4MDZiOThhZmRmODQ1ZGZmL3RhYmxlOmY5Y2ZjOWZmYTExZDRiMGU4MjAzMTlhYzUyMjk3ZTFlL3RhYmxlcmFuZ2U6ZjljZmM5ZmZhMTFkNGIwZTgyMDMxOWFjNTIyOTdlMWVfNS0zLTEtMS0yMzAxMw_a965a363-dcff-45a2-afe6-369c4ffba198"
      unitRef="usdPerShare">-0.34</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV82MS9mcmFnOjEwMjViNTNjNGEwYzQ1OTA4MDZiOThhZmRmODQ1ZGZmL3RhYmxlOmY5Y2ZjOWZmYTExZDRiMGU4MjAzMTlhYzUyMjk3ZTFlL3RhYmxlcmFuZ2U6ZjljZmM5ZmZhMTFkNGIwZTgyMDMxOWFjNTIyOTdlMWVfNS0zLTEtMS0yMzAxMw_d9364115-0945-4ed5-ae64-ba5bbbaf2d3d"
      unitRef="usdPerShare">-0.34</us-gaap:EarningsPerShareBasic>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV82MS9mcmFnOjEwMjViNTNjNGEwYzQ1OTA4MDZiOThhZmRmODQ1ZGZmL3RleHRyZWdpb246MTAyNWI1M2M0YTBjNDU5MDgwNmI5OGFmZGY4NDVkZmZfMTA5OTUxMTYyOTE0OQ_a2e6bb00-7cb8-4d65-a174-152123397829"
      unitRef="shares">13300000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="if66cb97858004034a661fde444b21a40_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV82MS9mcmFnOjEwMjViNTNjNGEwYzQ1OTA4MDZiOThhZmRmODQ1ZGZmL3RleHRyZWdpb246MTAyNWI1M2M0YTBjNDU5MDgwNmI5OGFmZGY4NDVkZmZfMTA5OTUxMTYyOTE1Ng_85b50779-1e02-4725-a3cf-4a2e11579caf"
      unitRef="shares">13000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV82Ny9mcmFnOmJkODhkYWUxMTg0MzRkZDA4NzQyNjUzODgxMTBjMTE4L3RleHRyZWdpb246YmQ4OGRhZTExODQzNGRkMDg3NDI2NTM4ODExMGMxMThfMTI0NA_a716246e-7961-4555-90fb-0c5efb6e8c68">CONTINGENCIESFrom time to time we may be involved in claims arising in connection with our business. Based on information currently available, management believes that the amount, or range, of reasonably possible losses in connection with any pending actions against us will not be material to our financial condition or cash flows, and no contingent liabilities were accrued as of March&#160;31, 2022 or 2021.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="i6c8486331a7f40578e81f8425fe3e837_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV82Ny9mcmFnOmJkODhkYWUxMTg0MzRkZDA4NzQyNjUzODgxMTBjMTE4L3RleHRyZWdpb246YmQ4OGRhZTExODQzNGRkMDg3NDI2NTM4ODExMGMxMThfMTA5OTUxMTYyOTAzMQ_4a641ac8-ff24-41e0-a03f-d0c67e9bbef3"
      unitRef="usd">0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="i8c5aec2dbac44fa0944e95aedc29fe22_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV82Ny9mcmFnOmJkODhkYWUxMTg0MzRkZDA4NzQyNjUzODgxMTBjMTE4L3RleHRyZWdpb246YmQ4OGRhZTExODQzNGRkMDg3NDI2NTM4ODExMGMxMThfMTA5OTUxMTYyOTAzMQ_6e917d93-b89f-4287-93cb-6723713b40f5"
      unitRef="usd">0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="iff15b538dbf24507841b01b99c6a5325_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV83MC9mcmFnOmQ5NjhhZWM0NGY2NDQ1ODViYTFmZGRkNGIyZDgzODNlL3RleHRyZWdpb246ZDk2OGFlYzQ0ZjY0NDU4NWJhMWZkZGQ0YjJkODM4M2VfMzUzNQ_cbb6e0b0-4ab9-42ea-a0bb-81665cb5835c">SUBSEQUENT EVENTS On April 11, 2022, we entered into a second amendment (the "Amendment") to the 2017 KKC Agreement. Under the terms of the Amendment, the parties have agreed to a reduction in the royalty rate payable to us by KKC upon net sales of tenapanor in Japan. The royalty rate will be reduced from the high teens to low double digits for a two-year period of time following the first commercial sale in Japan, and then to mid-single digits for the remainder of the royalty term. As consideration for the reduction in the royalty rate, KKC has agreed to pay us up to an additional U.S. $40.0 million payable in two tranches, with the first payment due following KKC's filing with the Japanese Ministry Health, Labour and Welfare (MHLW) of its application for marketing approval for tenapanor and the second payment due following KKC's receipt of regulatory approval to market tenapanor for hyperphosphatemia in Japan.</us-gaap:SubsequentEventsTextBlock>
    <ardx:CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate
      contextRef="ic15e7d54e20c401b86da52a356fa5887_I20220411"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV83MC9mcmFnOmQ5NjhhZWM0NGY2NDQ1ODViYTFmZGRkNGIyZDgzODNlL3RleHRyZWdpb246ZDk2OGFlYzQ0ZjY0NDU4NWJhMWZkZGQ0YjJkODM4M2VfMTA5OTUxMTYzNjE3MQ_a32219d3-7124-42c0-bd07-3e4a3fac5e98"
      unitRef="usd">40000000</ardx:CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate>
    <ardx:CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches
      contextRef="ic15e7d54e20c401b86da52a356fa5887_I20220411"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxMWIxYTM5ZTA2MzRiMTViYjdhNzA3NjYzMjcyNDdhL3NlYzo3MTFiMWEzOWUwNjM0YjE1YmI3YTcwNzY2MzI3MjQ3YV83MC9mcmFnOmQ5NjhhZWM0NGY2NDQ1ODViYTFmZGRkNGIyZDgzODNlL3RleHRyZWdpb246ZDk2OGFlYzQ0ZjY0NDU4NWJhMWZkZGQ0YjJkODM4M2VfMzI5ODUzNDg5MjQ4NQ_1000d418-a67e-4c26-b69d-1564843dcaac"
      unitRef="payment_tranche">2</ardx:CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>71
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( ,V I50'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " #-@*54QA9N^.X    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M2L0P$(9?17)O)TUQ#Z&;B^))07!!\1:2V=U@DX9DI-VW-ZV[740?0,@E,W^^
M^0;2F2C-D/ Y#1$3.<PWD^]#EB9NV9$H2H!LCNAUKDLBE.9^2%Y3N:8#1&T^
M] %!<+X!CZ2M)@TSL(HKD:G.&FD2:AK2&6_-BH^?J5]@U@#VZ#%0AJ9N@*EY
M8CQ-?0=7P PC3#Y_%]"NQ*7Z)W;I #LGI^S6U#B.]=@NN;)# V]/CR_+NI4+
MF70P6%YE)^D4<<LNDU_;N_O= U.""U'QVW)V@DN^D4W[/KO^\+L*^\&ZO?O'
MQA=!U<&O?Z&^ %!+ P04    " #-@*54F5R<(Q &  "<)P  $P   'AL+W1H
M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.
M'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X
M8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#W(*+"$MX%,O6
M7.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S^!7+5(UEHP$3
M5T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4PL3 :F<_5FO'
MT=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:X./Q>#BVR]*+
M<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;:)P*C5M/TVMW
MW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ$A6UY4#3( !8
M<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&<IV0!0X -\31
M3%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD,WJ=?3K.:Y1_
M::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z'&="?,_V]I&E
M)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S(M>41B1%G\@M
MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7
MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V<
M/!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/:;,CIW0FS>@S
M&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:K<(1*T(^8ADV
M&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1DEXW0CYBSHN0
M$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0'
MHYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y
M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RS<C'5*^3*=@Y
MG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;)0G+5--E-XH2
MGD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R2^JVE+ZU)CA*
M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*
MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#
MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B
M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P
MOFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_13.V$I<8O./F
MQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W
MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2
MD 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2)1(4BK ,!2$7
M<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%V^)4S;L:OB9@
M2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F
M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+
M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5
M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0    (
M ,V I53/TYC"004  /$5   8    >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
MI9A=;Z-&%(:OM[]BY%95*\4!!OR1K6/)<9S6:I)UXK2[VZH78Q@;%&"\PV#'
M_[YGP ;'P@?4WL1\G3</9P[OF9G!5LC7Q.=<D;<HC)/KEJ_4^J-A)*[/(Y9<
MBC6/X<Y2R(@I.)4K(UE+SKPL* H-:II=(V)!W!H.LFLS.1R(5(5!S&>2)&D4
M,;F[X:'87K>LUN'"<[#RE;Y@# =KMN)SKOY8SR2<&86*%T0\3@(1$\F7UZV1
M]7%LVSH@>^+/@&^3HV.B7V4AQ*L^F7K7+5,3\9"[2DLP^-GP,0]#K00<W_:B
MK>)_ZL#CXX/Z7?;R\#(+EO"Q"#\'GO*O6_T6\?B2I:%Z%MO?^/Z%.EK/%6&2
M_27;_%G':1$W392(]L% $ 5Q_LO>]HDX"K#IF0"Z#Z G 99])L#>!V29,W*R
M[+5NF6+#@11;(O73H*8/LMQDT? V0:R'<:XDW T@3@W'8L,E:9/$9Y(G T.!
MIKYCN/OXFSR>GHFWR8.(E9^02>QQ[WV\ 2P%$#T W5!4\(')2V);%X2:E%;P
MC.O"=\2D5='O:.PB/78F9Z/I^7NT2)2$BOL'D70*22>3=,Y(W@HWA>] D9?=
MFE<E' ^WS/830M$I*#K-*)Y2)A67X8X\\[60JHH(EU(RY0A1MR#J-B.:<1D(
M3Q<4@9*N3!&N="BA[SY\J"F#7L'6:SAFDH&#909T/EVXUI*%"9:O?L'41W4F
ML0K4CMP%(2>/:;3@LHH%US!-JVUWG7X'X;DJ>*Z:\#SS5: _%DC6(XLJ1P_7
M&3W?3NZ_?KGX\7NK:_XR?1Q?(G"66?J<V01O&KM"PL Q/8879*Z@PHB09"S2
M6,D=_'J5S#7JMQ,,\LB,K2:0+^R-3#VHMV 9N!DI,L(UDK3;MFS3OG(<C)"6
MA+0)X<CSH%TD%X<#<@_/D4]Q=>YP2<<TH8J7RB>C#8]1+[%*W[;L_\[YLA65
MG+CD/ V@5JAE8H!E%[!P'S\%'.LS*,07L8TKX7"YSRQ4/HLPM+(U6+BAGZ(5
M'\E,BDT0N]6#C&L^C#"TLD=8N+6?HLU$HEA(_@K6Y[]<7-&D3L?"V,H>8>'&
MGHW@".;2YU%P@0Y>6F5CL'!7OQ<NY&3FBQCK##4B/:?3MGHF2E2V!@OW])=
M09<22V+1GQ8_DSEW4PG9JL3"E<8BBL .YTJXKQ=DS239L##EY ?STH1NADU
MRU9!<3.')N\%\8K,=]%"A%60-0+0PKY@)&4_H+AY'Q)%)F^NS^(5/]M3:X0>
M1_/;$39OI&4'H(TZP#B54L^(\FE0EBZPB;1R"5&C^/5TX?&>K/1\VLCSIS',
M9_/EH9Y L@-J)1FN6$-6FCUM9/9ZK@93#7#3E9"5U5^C<\\DU,#(=6$9#%,8
M[N62&&/I^K21Z\\C%H;D)DW@=E(]FKA.W?R6EF9/&YG]).)RI0OL5U" 60)8
MP)K%U>G#!6O12J^GN%4?DN5S2!8&]/_6 K3T?-IH-?#>'N?9HIY\2A5TR5A[
M6N6".E?N9,IZVV<SM!RG<]7O=^V!L:G"*HV?-EH4C.'SD]"3IK''W\COO#I7
MN)2V=\?N.2:ZKB]-WL8]^N!?=T&BN^57#JT$6W+6R+7;%FW;6/^Q2]>W<;,N
M5IO';'=PL?)SK!&KVP@I?=_&7?J4:K],/\^%RSVAN3K:G\$=>@1(7HX5LJKR
MOJD1./L)&D>;:MJ!LKW&A+AZH9COKQ57B_W,4;:+9Y2/YYNA#TP;6$)"OH10
M\[('WYK,]Q?S$R76V1;=0B@EHNS0Y\SC4C\ ]Y="J,.)_@?%+N_P7U!+ P04
M    " #-@*54_X^W*0H&   &&   &    'AL+W=O<FMS:&5E=',O<VAE970R
M+GAM;,68:V_;-A2&_PKA%L4&Q+%(ZIJ+@33)T );&]3M]EF6Z5BH)+HDE33[
M]3N4'<D6+\F  ?L01Y=#\N71X7D.>?'(Q7>Y84RAGW75R,O)1JGMV6PFBPVK
M<WG*MZR!-VLNZES!K;B?R:U@^:IK5%<S$@3QK,[+9C*_Z)[=B?D%;U55-NQ.
M(-G6=2Z>WK.*/UY.\.3YP9?R?J/T@]G\8IO?LP53W[9W NYF?2^KLF:-+'F#
M!%M?3J[PV37M&G06?Y;L41Y<(SV5)>??]<W'U>4DT(I8Q0JEN\CAWP.[9E6E
M>P(=/_:=3OHQ=</#Z^?>?^LF#Y-9YI)=\^JO<J4VEY-T@E9LG;>5^L(?/[#]
MA"+=7\$KV?VBQ[UM,$%%*Q6O]XU!05TVN__YS[TC#AK@T-& [!N0US:@^P:T
MF^A.63>MFUSE\PO!'Y'0UM";ONA\T[6&V92-_HP+)>!M">W4_/KSIYO;3XO;
M&_3^ZO>K3]>W:/'A]O;K DW1M\4-^N7MK^@M*AOT=<-;F3<K>3%3,*QN/"OV
M0[S?#4$<0_R1BU-$\0DB 2&6YM?^YC>LZ)OCX^8SF&P_8]+/F'3]4=>,6R%8
MHU N)5/RS-,C[7ND78^AJ\=<;A#X!A7Z@OUHRX>\@B&LOMIU%7==Z37V, ^3
M($DN9@^'+C&M$A*2M+<ZTAGV.D.OSL6&"S553-3P11^85+5+Y*Z?Z% DB<E8
MI,4*S+!=9-2+C+PBKXJ"MR +<D3!P)'+BMD41N;8- M' DVC*"!V>7$O+_;*
M^PB.:Q073S91L3$>#=.QUTRCP"XIZ24E7DEW@FWS<H783\CMDLDN%+G:, $)
MY##6;9(30PV.XS 8:;99A9$C'-->=^K5_96KO'J%Q-0<'(>$1".-%C-*XS"S
MB\QZD9E79,>U*5]/6\D\&C.+Q@R/W6BQ(DGDB$@<#"D\>"$ @.I"/74?7J>?
MK5[8)ZAARIJM T,&"<*Q.VU6-'9I/< -]FK]W,6EVY'[YL<^.DA\>W$6*QPY
MUA$>R(#)*R+2(XY8Q&5A8,BSV(59AJE#X  :3%_%KJK,EV55JI)Y 88',F _
M&OJLN\V?7"D7F_D^"N@XQBU6(3G@V[' @0KX12R(E@%B>:VS7+ZK 2'>EZQA
MZ]+QO4P Q#084\)B%87$%>D#*+"?%,_?:@O0U6+Y&E6\N=_Q=\66]K5IT@&(
M2K.Q9 MI"(E#A^:!)-B/$HMFG5K V\T]JAB4RWWH60&(35#0*"-C]1:K,',Y
M?, )]O/D.40\'#Q8-U;Y)D/B)#%6MVF5T#AVR!] @_VD.<;A2TI-E(1)&M*Q
M5-,L(BEQE&AD( [Q$^>S*R@ZZ.BP*8XCR38'8A(F3?$X6"Q661(Z2@\R<(CX
M.73#U@P4KJ#,A(*N92"<-].]:JM:$SEI%(\=;K$*$^+(?N1@R_(:,+T0$\2D
M3AP1/ Y?FUE",D?\DH%-Y(5=$*_K<K>EV&V&>*,CA#6%2Z^W/WU^<2:W><$N
M)UO!)!,/;#)'MOWC?]#1\9P';)+0R^.%XL7W#:]63,AW;V!A)>== ::>?%@F
M _6(GWI0VN_#5.J13M#;X#0( @R8%@@VF2T[1]$)/-%_2&YRH=->JV"C5_[-
M5N<0U,]/2REU<NQR8JND@@N]?G.I5RMLT8O-NS<X#LZ?-^J=)>R]6;UDXN@5
M_$*'6]8=P%1/I]9O:S)U7"AX38[]-3"7O,!<B$' EMM9=.<JE[LPC4\H#4YH
M''3SQW"-4W(2T>A_\J,)>CRN7VPVCDJ3#)4 \5<"5ZM5J1,WI!V]N9R6#2KR
M;0EIR"K3)'H:1"0>;RHL=DD61:'KPP_L)R^ROZW;*E?P:590#Q:E/8F;Z)XF
M(88@&0NU&4*M3UU*!\P3/^8/E>Z+$RAI!=OHH]$'0"F7]FQIHGR:&KG=8N1(
M['2 /?7#?@<?Z4QUUE,ND]IQB+-Q#K"8I5#O.GA)![I3/]T-7G:K\%]. 1MG
M<-;-GLW.MMF;'1S2ZA-RR!7W92.A@EI#P^ T 2^(W:'S[D;Q;7=NN^1*\;J[
MW+ <Q&L#>+_F7#W?Z*/@_NA__@]02P,$%     @ S8"E5$:Q,[79 @  > D
M !@   !X;"]W;W)K<VAE971S+W-H965T,RYX;6REEFUOVC 0Q[^*%>U%*W7$
M20C0"I H4'72QE#9PXMI+TQR$*M.G-D&NGWZV4Z:01N>.EZ [=S_[G>7"Y?N
MAHM'F0 H])2R3/:<1*G\QG5EE$!*9(/GD.DK"RY2HO16+%V9"R"Q%:7,]3%N
MN2FAF=/OVK.IZ'?Y2C&:P50@N4I3(G[? N.;GN,YSP</=)DH<^#VNSE9P@S4
MUWPJ],ZMO,0TA4Q2GB$!BYXS\&Z&'C8":_&-PD9NK9%)9<[YH]E\B'L.-D3
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MM+4348SY8J-X;B?EG"L]=^TRT:]&((R!OK[@7#UOS/"M7K;Z?P%02P,$%
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MGHD2DN+3BF[MC8%;<>V6E:B\L'\JO3$,NFQF"[/:EG(GYUY8,-$$SU"'N=[
MK4CDN 5$1>1DWDC[^\R=3RAL: '5!8G,L37Y][[K(Z&I^C7PWJ]#9QO.5R2=
M!%#.O@>5+I8B0\*7Q%!#0,<P#T6DD%B-_@(Y\E9DM]_[:B4$)5DLEQ1,;/*&
MLFZ("6M(K[>ZP,@Q1SXP5>\)&L#8*T<_<BZ8E,R9*UWWS)0%M<SB)'H/+8JI
M,?H8I$$8.U3#I"6/0M;V!M$'),$UJO/$)=CR<#@*2[@'H1[:N%_BCUZ20'Z
MQ4/$*^*&[8(Z;*)XM=5S6W/R9[8<DEJGKZ,>.<Z/"6AS"47S$=A^4_AAEI)^
MWI.0 F!ML=HSR^1UWAJJ?405/U[!55T?HC>A _EBNN, WR08D (<ZJ-,&M"C
M;#@'1<A0;&UJ"P4E[T:P!]?J>6URX4&"MW[1-[ JMD=AGT%!G"TE+!:<*(AI
M4BNBI[)P%KBS=TTT3I9JJOYNX8$5N>:,T^,X&I&=#0I&3'\DA&W!7)>+K=X
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MVOKJF&#Y[I:&?S)Z9H/D*AF-0+9=D*<N/9^*311'0=R ] Y<BK:Y-31#NW)
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M2V&4R&B""'H'[37V>K)78Y)[*B\IHQQGQH8\+66EKWI;2<,HWY<777):DO/
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M].6QK'6$I'DY1K=)*'JG\!YHHD?7;N>58F$#ZQV%.!B$S214/3IG #(ID^&
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MP/-Q4;AX00RJ_R7@S7\ 4$L#!!0    ( ,V I53O('W>I@P  !(B   9
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MU!U\N5(2L*0!>+\P"*MX0PMT/P.Y^C=02P,$%     @ S8"E5+ND;X_$!P
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M=]U+IF+;MZQQ[R-BJ5! ]*D4.DY*'[\G=D^[K[%G\2/D>GK\E(M P&LO"K7
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MM8VH$DFB2LF*0M)L2=BIY]34Y#2<@.VJ;$H2&9+,$*XWAVN5\"T]BG>B,()
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M3]O3%*(@ 688;0P3"(-)9^5WUP PZ^\FRZ#V>7^X"X3;FDNCL+(U*QMW,;(
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M6R,,2WK<H?8&M+]5%.-NX@_HGXNSOP%02P,$%     @ S8"E5'1(NW+0 @
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M<.U<:0]D-[&75Y9X,L1MQ:,873#@]]):.AR"@VZXS_X 4$L#!!0    ( ,V
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MPY*>7[1L0/M[8_QIP@3#@[[X&U!+ P04    " #-@*54$U1E)MP3   ..@
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M>K[@*G7!?.'M]UWVR',LM0)>KN%C^8A*%W;>^\)7.:K^=* IJ#$=)$V NSH
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MVFFA?U90& .MSSE7O6  AM^?S7]02P,$%     @ S8"E5,MFCL!3 @  ZP0
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MM6]+.W&F#OU\9QR_#F%8\G.,Y -X?V^,ZR>>8'C@-_\"4$L#!!0    ( ,V
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M6DT#;4A8J""N-KPI-R07-L3H5G"]5>A'GD#2$K_PQT>>^, D7RM 'A2X(5[
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MA$8T0KR9-)XGP6BX/9]"FHD=#A1#T@J'PXJ@<>P.Q[0!/>T%^G3&3#L98UM
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MH<L3XOE\2Q,EQ4_TM(^5V8K+79*:33DX.]Z$\?YW\*-,1&T 9D<&D'( Z3N
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M\2>WQHWLWH NT*)Q;;01VC2E&U;FV01I$\QZ*80^!+8SAX<X^PU02P,$%
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M<[R]0-D W$^E-*\3VR"[^S#Z#5!+ P04    " #-@*54MP,QL30#  "R"@
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M-+@E8K-ID#83IZNF99AK1PU(,RRHJ43C#]!^KK7;3GP7TK6IT[\ 4$L#!!0
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M2A#&0._GG*O]Q 1HG][T#U!+ P04    " #-@*541KJ*2.\"  #-"   &0
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M;4HN<*9 KZN*J?<)EG([]@;>WO'"\\)8AY_$-<MQCN:UGBFR_(XEXQ4*S:4
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MA30TH^Y8T!9%90/H?B6EV1LV0;>7DS]02P,$%     @ S8"E5(_<?. ) P
M8 D  !D   !X;"]W;W)K<VAE971S+W-H965T-#<N>&ULC5;M;Z(P&/]7&K(/
M6[(-**"XJ,E-<[DEN\SLY>YSA2K-"N7:,K?__IXBHH[B]D4H]/?\7FS[,-X(
M^:HR2C5ZSWFA)DZF=7GCNBK):$[4M2AI 6]60N9$PU"N755*2M(:E',7>][
MS0DKG.FX?K:0T[&H-&<%74BDJCPG\N.6<K&9.+ZS>_#(UIDV#]SIN"1K^D3U
M2[F0,'+;*BG+::&8*)"DJXGSP[^9^=@ ZAE_&-VH@WMDK"R%>#6#NW3B>$81
MY331I@2!RQN=4<Y-)=#QKRGJM)P&>'B_J_ZS-@]FED31F>!_6:JSB1,[**4K
M4G']*#:_:&,H,O42P57]BS;-7,]!2:6TR!LP*,A9L;V2]R:( X ?]@!P \#?
M!00-(*B-;I75MN9$D^E8B@V29C94,S=U-C4:W+#"_(U/6L);!C@]O:>0@4)7
MZ*5(F4I$56B:HAE1&5J0#_B_-'I8<K8F)G2%SN=4$\;5A4$\S='YV04Z0ZQ
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M2O',7JZ )B#,!/W_@G/U-# .ZO/$R=]02P,$%     @ S8"E5*<(I*&] @
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MPU"8!?K[G'.U&Y@-JLJN_QM02P,$%     @ S8"E5#-K&-P[ P  NPL  !D
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M2Y/#+S,:[JC=!7J^5LJ^;9R!^N_"Y#=02P,$%     @ S8"E5,E-LPOJ @
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ML"7*:/*! C)="W<;U(WO@HU&ZBF_K&CJ@7$.=+[5&H\;=\$P1_._4$L#!!0
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M8T)DQYS O%6V*%T8Z6)"E@G19RM0+]'*;L@Z(;)U8$PWNR/(.A&R=8XMSW%
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M5T\O5F51C.R^F9A(FA]^8W3X?=2W?P%02P,$%     @ S8"E5/,@BWGI 0
M$B(  !H   !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<\W:.T[#0!2%X:U$
M7@"3^YCP4$)%0XO8@!4F#Y'$EF<0R>Z)0A&.14&#YE36V/+U7WVRQIZ_I%U;
MMMTA;[9]GASWNT->-)M2^H<0\G*3]FV^Z?IT.%]9=<.^+>?EL Y]NWQOURGH
M=#H+P\\9S>/\Y\S)ZZE/?YG8K5;;97KJEA_[="B_# Z?W?">-RF59O+:#NM4
M%DTX[JZG<[@<Y.8\N9D\ORV:X?E-FE [2"%(ZP<9!%G]((<@KQ\4(2C6#YI!
MT*Q^T"T$W=8/NH.@N_I!]Q!T7S](IBCCE"!IA#6!UH)<"X'7@F +@=B"9 N!
MV8)H"X':@FP+@=N"< N!W()T"X'=@G@+@=Z*>BN!WHIZ*X'>.GK9)M!;46\E
MT%M1;R706U%O)=!;46\ET%M1;R706U%O)=!;46\ET-M0;R/0VU!O(]#;4&\C
MT-M&FR4$>AOJ;01Z&^IM!'H;ZFT$>AOJ;01Z&^IM!'H;ZFT$>COJ[01Z.^KM
M!'H[ZNT$>COJ[01Z^VBSFT!O1[V=0&]'O9U ;T>]G4!O1[V=0&]'O9U [XAZ
M1P*](^H="?2.J'<DT#NBWI% [XAZ1P*]X^AC)8'>$?6.!'I'U#O^I]ZYG'8I
M7WN^U_C\_Z2ZG.]-U\=?EM\G1^Q<< [P"\CC%U!+ P04    " #-@*54LFA)
MV-4!  "_(0  $P   %M#;VYT96YT7U1Y<&5S72YX;6S-VEU/@S 4!N"_LG!K
M1M>O^1'GC7JK7O@'*IP-,J!-V\WY[RU,331*7&;B>P.!MN<]M,ESQ>7CBZ,P
MV;5-%Q99%:.[8"P4%;4FY-91ET:6UK<FID>_8LX4:[,B)F:S.2ML%ZF+T]C7
MR*XN;VAI-DV<W.[2ZU#;;I%Y:D(VN=Y/[+,6F7&NJ0L3TSC;=N67E.E;0IY6
M#G-"5;MPDB9D[-N$?N3G@+=U]UOROBYI\F!\O#-MFL5V#0OQI:&0CY?XID>[
M7-8%E;;8M&E)'IPG4X:**+9-OB]Z,IX<TP[3_LJ/SA_*C 6FF0_>NI!.S-/A
M<>]'TJ^>NE2(?*S'/_$C,94^^ONH/^V2RE]FI^U]MGX]G$=@P^WX/?Y\QA_U
M#^Q#@/0A0?I0('UHD#[F('V<@O1Q!M+'.4@??(;2"(JH'(54CF(J1T&5HZC*
M45CE**YR%%@YBJP"15:!(JM D56@R"I09!4HL@H4606*K )%5H$BJT215:+(
M*E%DE2BR2A19)8JL$D56B2*K1)%5HLBJ4&15*+(J%%D5BJP*15:%(JM"D56A
MR*I09%4HLFH4636*K!I%5HTBJT:15:/(JE%DU?\IZY.UZ[_^I:"_YZVIN_=\
M-ORW<?4*4$L! A0#%     @ S8"E5 =!36*!    L0   !
M ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " #-@*54QA9N^.X
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M=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ S8"E5$:Q,[79 @
M> D  !@              ("!Q!,  'AL+W=O<FMS:&5E=',O<VAE970S+GAM
M;%!+ 0(4 Q0    ( ,V I51]4HTY> 4  ) 6   8              " @=,6
M  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " #-@*54GZ!^
M9Z4%  !<&0  &               @(&!'   >&PO=V]R:W-H965T<R]S:&5E
M=#4N>&UL4$L! A0#%     @ S8"E5!O>2*[]!P  62$  !@
M ("!7"(  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( ,V
MI510OC$1Y10  "P\   8              " @8\J  !X;"]W;W)K<VAE971S
M+W-H965T-RYX;6Q02P$"% ,4    " #-@*54:JQ"U0D'  "0$0  &
M        @(&J/P  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%
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M+GAM;%!+ 0(4 Q0    ( ,V I53O('W>I@P  !(B   9              "
M@11D  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ S8"E
M5+ND;X_$!P  KQ8  !D              ("!\7   'AL+W=O<FMS:&5E=',O
M<VAE970Q-"YX;6Q02P$"% ,4    " #-@*549N8I2%\$   X"@  &0
M        @('L>   >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0
M   ( ,V I51:>MB\$@4  $ .   9              " @8)]  !X;"]W;W)K
M<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ S8"E5%^,,34_!0  * P
M !D              ("!RX(  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q0
M2P$"% ,4    " #-@*54E7-=VA($   Z"@  &0              @(%!B
M>&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( ,V I51T2+MR
MT (  .@%   9              " @8J,  !X;"]W;W)K<VAE971S+W-H965T
M,3DN>&UL4$L! A0#%     @ S8"E5&A(-C>9 P  W <  !D
M ("!D8\  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    " #-
M@*54$U1E)MP3   ..@  &0              @(%ADP  >&PO=V]R:W-H965T
M<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( ,V I51;'<W.X ,  -L)   9
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M970R-BYX;6Q02P$"% ,4    " #-@*54P[TM"<\"  #[!0  &0
M    @(&&N   >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    (
M ,V I53,",5X" ,  (X&   9              " @8R[  !X;"]W;W)K<VAE
M971S+W-H965T,C@N>&UL4$L! A0#%     @ S8"E5+=:+@0;!   9 H  !D
M             ("!R[X  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"
M% ,4    " #-@*54T_ =Q <%   7#0  &0              @($=PP  >&PO
M=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( ,V I53UD3HNK (
M ,<%   9              " @5O(  !X;"]W;W)K<VAE971S+W-H965T,S$N
M>&UL4$L! A0#%     @ S8"E5,"AJF)P!   7!(  !D              ("!
M/LL  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    " #-@*54
MN*QL.2H&  !8)0  &0              @('ESP  >&PO=V]R:W-H965T<R]S
M:&5E=#,S+GAM;%!+ 0(4 Q0    ( ,V I53F7%!LN (  +,&   9
M      " @4;6  !X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%
M  @ S8"E5.W1@#"1!@  'R\  !D              ("!-=D  'AL+W=O<FMS
M:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    " #-@*54]-T!CBT"  "4!0
M&0              @(']WP  >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+
M 0(4 Q0    ( ,V I50:<[%1A@,  $@-   9              " @6'B  !X
M;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ S8"E5. *M&@>
M P  * P  !D              ("!'N8  'AL+W=O<FMS:&5E=',O<VAE970S
M."YX;6Q02P$"% ,4    " #-@*54=\?IJU4'  !$*0  &0
M@(%SZ0  >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( ,V
MI51H808?AP,  -X+   9              " @?_P  !X;"]W;W)K<VAE971S
M+W-H965T-# N>&UL4$L! A0#%     @ S8"E5!B-$6Z2!0  )!D  !D
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M=#0U+GAM;%!+ 0(4 Q0    ( ,V I512@,^O2@(  *,%   9
M  " @=<& 0!X;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @
MS8"E5(_<?. ) P  8 D  !D              ("!6 D! 'AL+W=O<FMS:&5E
M=',O<VAE970T-RYX;6Q02P$"% ,4    " #-@*54PGM&0W($  !;%   &0
M            @(&8# $ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4
M Q0    ( ,V I52G"*2AO0(  "H(   9              " @4$1 0!X;"]W
M;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @ S8"E5(]Y_U7V @
MY0D  !D              ("!-10! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX
M;6Q02P$"% ,4    " #-@*54,VL8W#L#  "["P  &0              @(%B
M%P$ >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    ( ,V I50*
MD;-3)P,  $X*   9              " @=0: 0!X;"]W;W)K<VAE971S+W-H
M965T-3(N>&UL4$L! A0#%     @ S8"E5&@)X"T$ P  .@@  !D
M     ("!,AX! 'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ,V I52170/U/0,   X4   -              "
M < K 0!X;"]S='EL97,N>&UL4$L! A0#%     @ S8"E5)>*NQS     $P(
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9>&UL4$L%!@    !! $$ OA$  !<Y 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>196</ContextCount>
  <ElementCount>275</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>68</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="ardx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ardx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - CONDENSED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS</Role>
      <ShortName>CONDENSED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ardx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - CONDENSED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/CONDENSEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONDENSED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ardx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS</Role>
      <ShortName>CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ardx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ardx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - CONDENSED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONDENSED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ardx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Organization and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/OrganizationandBasisofPresentation</Role>
      <ShortName>Organization and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ardx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2104102 - Disclosure - Cash, Cash Equivalents and Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/CashCashEquivalentsandInvestments</Role>
      <ShortName>Cash, Cash Equivalents and Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ardx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2108103 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ardx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2111104 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ardx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2114105 - Disclosure - Product Revenue, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/ProductRevenueNet</Role>
      <ShortName>Product Revenue, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ardx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2118106 - Disclosure - Collaboration and Licensing Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/CollaborationandLicensingAgreements</Role>
      <ShortName>Collaboration and Licensing Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ardx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2122107 - Disclosure - Borrowing</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/Borrowing</Role>
      <ShortName>Borrowing</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ardx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2126108 - Disclosure - Derivative Liability</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/DerivativeLiability</Role>
      <ShortName>Derivative Liability</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ardx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2130109 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ardx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2135110 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ardx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2137111 - Disclosure - Equity Incentive Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/EquityIncentivePlans</Role>
      <ShortName>Equity Incentive Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ardx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2144112 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ardx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2148113 - Disclosure - Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/Contingencies</Role>
      <ShortName>Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ardx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2150114 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ardx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Organization and Basis of Presentation (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/OrganizationandBasisofPresentationPolicies</Role>
      <ShortName>Organization and Basis of Presentation (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ardx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Cash, Cash Equivalents and Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsTables</Role>
      <ShortName>Cash, Cash Equivalents and Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ardelyx.com/role/CashCashEquivalentsandInvestments</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="ardx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2309302 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ardelyx.com/role/FairValueMeasurements</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="ardx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2312303 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ardelyx.com/role/Inventory</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="ardx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2315304 - Disclosure - Product Revenue, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/ProductRevenueNetTables</Role>
      <ShortName>Product Revenue, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ardelyx.com/role/ProductRevenueNet</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="ardx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2319305 - Disclosure - Collaboration and Licensing Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/CollaborationandLicensingAgreementsTables</Role>
      <ShortName>Collaboration and Licensing Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ardelyx.com/role/CollaborationandLicensingAgreements</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="ardx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2323306 - Disclosure - Borrowing (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/BorrowingTables</Role>
      <ShortName>Borrowing (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ardelyx.com/role/Borrowing</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="ardx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2327307 - Disclosure - Derivative Liability (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/DerivativeLiabilityTables</Role>
      <ShortName>Derivative Liability (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ardelyx.com/role/DerivativeLiability</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="ardx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2331308 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ardelyx.com/role/Leases</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ardx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2338309 - Disclosure - Equity Incentive Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/EquityIncentivePlansTables</Role>
      <ShortName>Equity Incentive Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ardelyx.com/role/EquityIncentivePlans</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ardx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2345310 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ardelyx.com/role/NetLossPerShare</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ardx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2403401 - Disclosure - Organization and Basis of Presentation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/OrganizationandBasisofPresentationDetails</Role>
      <ShortName>Organization and Basis of Presentation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ardelyx.com/role/OrganizationandBasisofPresentationPolicies</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ardx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Cash, Cash Equivalents and Investments - Securities Classified as Cash, Cash Equivalents and Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails</Role>
      <ShortName>Cash, Cash Equivalents and Investments - Securities Classified as Cash, Cash Equivalents and Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="ardx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Cash, Cash Equivalents and Investments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsNarrativeDetails</Role>
      <ShortName>Cash, Cash Equivalents and Investments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="ardx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2410404 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ardelyx.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="ardx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2413405 - Disclosure - Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/InventoryDetails</Role>
      <ShortName>Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ardelyx.com/role/InventoryTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="ardx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2416406 - Disclosure - Product Revenue, Net - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails</Role>
      <ShortName>Product Revenue, Net - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="ardx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2417407 - Disclosure - Product Revenue, Net - Gross-to-Net Sales Accruals (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/ProductRevenueNetGrosstoNetSalesAccrualsDetails</Role>
      <ShortName>Product Revenue, Net - Gross-to-Net Sales Accruals (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="ardx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2420408 - Disclosure - Collaboration and Licensing Agreements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails</Role>
      <ShortName>Collaboration and Licensing Agreements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="ardx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2421409 - Disclosure - Collaboration and Licensing Agreements - Deferred Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails</Role>
      <ShortName>Collaboration and Licensing Agreements - Deferred Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="ardx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2424410 - Disclosure - Borrowing - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/BorrowingNarrativeDetails</Role>
      <ShortName>Borrowing - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="ardx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2425411 - Disclosure - Borrowing - Future Payment Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/BorrowingFuturePaymentObligationsDetails</Role>
      <ShortName>Borrowing - Future Payment Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="ardx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2428412 - Disclosure - Derivative Liability - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/DerivativeLiabilityNarrativeDetails</Role>
      <ShortName>Derivative Liability - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="ardx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2429413 - Disclosure - Derivative Liability - Changes in Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/DerivativeLiabilityChangesinFairValueDetails</Role>
      <ShortName>Derivative Liability - Changes in Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="ardx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2432414 - Disclosure - Leases - Additional Details of Facility Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/LeasesAdditionalDetailsofFacilityLeasesDetails</Role>
      <ShortName>Leases - Additional Details of Facility Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="ardx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2433415 - Disclosure - Leases - Lease Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/LeasesLeaseCostsDetails</Role>
      <ShortName>Leases - Lease Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="ardx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2434416 - Disclosure - Leases - Undiscounted Cash Payment Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails</Role>
      <ShortName>Leases - Undiscounted Cash Payment Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="ardx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2436417 - Disclosure - Stockholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/StockholdersEquityDetails</Role>
      <ShortName>Stockholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ardelyx.com/role/StockholdersEquity</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="ardx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2439418 - Disclosure - Equity Incentive Plans - Stock-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/EquityIncentivePlansStockBasedCompensationDetails</Role>
      <ShortName>Equity Incentive Plans - Stock-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="ardx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2440419 - Disclosure - Equity Incentive Plans - Unrecognized Stock-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/EquityIncentivePlansUnrecognizedStockBasedCompensationDetails</Role>
      <ShortName>Equity Incentive Plans - Unrecognized Stock-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="ardx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2441420 - Disclosure - Equity Incentive Plans - Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails</Role>
      <ShortName>Equity Incentive Plans - Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="ardx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2442421 - Disclosure - Equity Incentive Plans - Restricted Stock Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails</Role>
      <ShortName>Equity Incentive Plans - Restricted Stock Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="ardx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2443422 - Disclosure - Equity Incentive Plans - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails</Role>
      <ShortName>Equity Incentive Plans - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="ardx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2446423 - Disclosure - Net Loss Per Share - Computation of Net Loss Per Common Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/NetLossPerShareComputationofNetLossPerCommonShareDetails</Role>
      <ShortName>Net Loss Per Share - Computation of Net Loss Per Common Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="ardx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2447424 - Disclosure - Net Loss Per Share - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/NetLossPerShareNarrativeDetails</Role>
      <ShortName>Net Loss Per Share - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="ardx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2449425 - Disclosure - Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/ContingenciesDetails</Role>
      <ShortName>Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ardelyx.com/role/Contingencies</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="ardx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2451426 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ardelyx.com/role/SubsequentEvents</ParentRole>
      <Position>57</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="ardx-20220331.htm">ardx-20220331.htm</File>
    <File>ardx-20220331.xsd</File>
    <File>ardx-20220331_cal.xml</File>
    <File>ardx-20220331_def.xml</File>
    <File>ardx-20220331_lab.xml</File>
    <File>ardx-20220331_pre.xml</File>
    <File>ardx-20220331xex311.htm</File>
    <File>ardx-20220331xex312.htm</File>
    <File>ardx-20220331xex321.htm</File>
    <File>slrexitfeeagreement-ex102.htm</File>
    <File>slrloanandsecurityagreemen.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>ardx-20220331_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="527">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>76
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "ardx-20220331.htm": {
   "axisCustom": 1,
   "axisStandard": 27,
   "contextCount": 196,
   "dts": {
    "calculationLink": {
     "local": [
      "ardx-20220331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "ardx-20220331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "ardx-20220331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ardx-20220331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ardx-20220331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "ardx-20220331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 472,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021q4": 5,
    "total": 5
   },
   "keyCustom": 51,
   "keyStandard": 224,
   "memberCustom": 29,
   "memberStandard": 34,
   "nsprefix": "ardx",
   "nsuri": "http://www.ardelyx.com/20220331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "iff15b538dbf24507841b01b99c6a5325_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.ardelyx.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "iff15b538dbf24507841b01b99c6a5325_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "iff15b538dbf24507841b01b99c6a5325_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2111104 - Disclosure - Inventory",
     "role": "http://www.ardelyx.com/role/Inventory",
     "shortName": "Inventory",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "iff15b538dbf24507841b01b99c6a5325_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "iff15b538dbf24507841b01b99c6a5325_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2114105 - Disclosure - Product Revenue, Net",
     "role": "http://www.ardelyx.com/role/ProductRevenueNet",
     "shortName": "Product Revenue, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "iff15b538dbf24507841b01b99c6a5325_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "iff15b538dbf24507841b01b99c6a5325_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2118106 - Disclosure - Collaboration and Licensing Agreements",
     "role": "http://www.ardelyx.com/role/CollaborationandLicensingAgreements",
     "shortName": "Collaboration and Licensing Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "iff15b538dbf24507841b01b99c6a5325_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "iff15b538dbf24507841b01b99c6a5325_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2122107 - Disclosure - Borrowing",
     "role": "http://www.ardelyx.com/role/Borrowing",
     "shortName": "Borrowing",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "iff15b538dbf24507841b01b99c6a5325_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "iff15b538dbf24507841b01b99c6a5325_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2126108 - Disclosure - Derivative Liability",
     "role": "http://www.ardelyx.com/role/DerivativeLiability",
     "shortName": "Derivative Liability",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "iff15b538dbf24507841b01b99c6a5325_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "iff15b538dbf24507841b01b99c6a5325_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2130109 - Disclosure - Leases",
     "role": "http://www.ardelyx.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "iff15b538dbf24507841b01b99c6a5325_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "iff15b538dbf24507841b01b99c6a5325_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2135110 - Disclosure - Stockholders' Equity",
     "role": "http://www.ardelyx.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "iff15b538dbf24507841b01b99c6a5325_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "iff15b538dbf24507841b01b99c6a5325_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2137111 - Disclosure - Equity Incentive Plans",
     "role": "http://www.ardelyx.com/role/EquityIncentivePlans",
     "shortName": "Equity Incentive Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "iff15b538dbf24507841b01b99c6a5325_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "iff15b538dbf24507841b01b99c6a5325_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2144112 - Disclosure - Net Loss Per Share",
     "role": "http://www.ardelyx.com/role/NetLossPerShare",
     "shortName": "Net Loss Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "iff15b538dbf24507841b01b99c6a5325_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "iff15b538dbf24507841b01b99c6a5325_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2148113 - Disclosure - Contingencies",
     "role": "http://www.ardelyx.com/role/Contingencies",
     "shortName": "Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "iff15b538dbf24507841b01b99c6a5325_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "i6c8486331a7f40578e81f8425fe3e837_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - CONDENSED BALANCE SHEETS",
     "role": "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS",
     "shortName": "CONDENSED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "i6c8486331a7f40578e81f8425fe3e837_I20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "iff15b538dbf24507841b01b99c6a5325_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2150114 - Disclosure - Subsequent Events",
     "role": "http://www.ardelyx.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "iff15b538dbf24507841b01b99c6a5325_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "iff15b538dbf24507841b01b99c6a5325_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - Organization and Basis of Presentation (Policies)",
     "role": "http://www.ardelyx.com/role/OrganizationandBasisofPresentationPolicies",
     "shortName": "Organization and Basis of Presentation (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "iff15b538dbf24507841b01b99c6a5325_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "iff15b538dbf24507841b01b99c6a5325_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Cash, Cash Equivalents and Investments (Tables)",
     "role": "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsTables",
     "shortName": "Cash, Cash Equivalents and Investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "iff15b538dbf24507841b01b99c6a5325_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "iff15b538dbf24507841b01b99c6a5325_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2309302 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.ardelyx.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "iff15b538dbf24507841b01b99c6a5325_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "iff15b538dbf24507841b01b99c6a5325_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2312303 - Disclosure - Inventory (Tables)",
     "role": "http://www.ardelyx.com/role/InventoryTables",
     "shortName": "Inventory (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "iff15b538dbf24507841b01b99c6a5325_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "iff15b538dbf24507841b01b99c6a5325_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ardx:ScheduleOfGrossToNetSalesAccrualsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2315304 - Disclosure - Product Revenue, Net (Tables)",
     "role": "http://www.ardelyx.com/role/ProductRevenueNetTables",
     "shortName": "Product Revenue, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "iff15b538dbf24507841b01b99c6a5325_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ardx:ScheduleOfGrossToNetSalesAccrualsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "iff15b538dbf24507841b01b99c6a5325_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2319305 - Disclosure - Collaboration and Licensing Agreements (Tables)",
     "role": "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsTables",
     "shortName": "Collaboration and Licensing Agreements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "iff15b538dbf24507841b01b99c6a5325_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "iff15b538dbf24507841b01b99c6a5325_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2323306 - Disclosure - Borrowing (Tables)",
     "role": "http://www.ardelyx.com/role/BorrowingTables",
     "shortName": "Borrowing (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "iff15b538dbf24507841b01b99c6a5325_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "iff15b538dbf24507841b01b99c6a5325_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2327307 - Disclosure - Derivative Liability (Tables)",
     "role": "http://www.ardelyx.com/role/DerivativeLiabilityTables",
     "shortName": "Derivative Liability (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "iff15b538dbf24507841b01b99c6a5325_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "iff15b538dbf24507841b01b99c6a5325_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ardx:ScheduleOfAdditionalDetailsOfLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2331308 - Disclosure - Leases (Tables)",
     "role": "http://www.ardelyx.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "iff15b538dbf24507841b01b99c6a5325_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ardx:ScheduleOfAdditionalDetailsOfLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "i6c8486331a7f40578e81f8425fe3e837_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - CONDENSED BALANCE SHEETS (Parenthetical)",
     "role": "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETSParenthetical",
     "shortName": "CONDENSED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "i6c8486331a7f40578e81f8425fe3e837_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "iff15b538dbf24507841b01b99c6a5325_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2338309 - Disclosure - Equity Incentive Plans (Tables)",
     "role": "http://www.ardelyx.com/role/EquityIncentivePlansTables",
     "shortName": "Equity Incentive Plans (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "iff15b538dbf24507841b01b99c6a5325_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "iff15b538dbf24507841b01b99c6a5325_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2345310 - Disclosure - Net Loss Per Share (Tables)",
     "role": "http://www.ardelyx.com/role/NetLossPerShareTables",
     "shortName": "Net Loss Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "iff15b538dbf24507841b01b99c6a5325_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "iff15b538dbf24507841b01b99c6a5325_D20220101-20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403401 - Disclosure - Organization and Basis of Presentation (Details)",
     "role": "http://www.ardelyx.com/role/OrganizationandBasisofPresentationDetails",
     "shortName": "Organization and Basis of Presentation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "iff15b538dbf24507841b01b99c6a5325_D20220101-20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "i6c8486331a7f40578e81f8425fe3e837_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ardx:CashAndCashEquivalentsAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Cash, Cash Equivalents and Investments - Securities Classified as Cash, Cash Equivalents and Investments (Details)",
     "role": "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails",
     "shortName": "Cash, Cash Equivalents and Investments - Securities Classified as Cash, Cash Equivalents and Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "i6c8486331a7f40578e81f8425fe3e837_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ardx:CashAndCashEquivalentsAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "iff15b538dbf24507841b01b99c6a5325_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ardx:AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Cash, Cash Equivalents and Investments - Narrative (Details)",
     "role": "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsNarrativeDetails",
     "shortName": "Cash, Cash Equivalents and Investments - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "iff15b538dbf24507841b01b99c6a5325_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ardx:AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "ia66c3497d92f4f87983a8808d4c22279_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410404 - Disclosure - Fair Value Measurements (Details)",
     "role": "http://www.ardelyx.com/role/FairValueMeasurementsDetails",
     "shortName": "Fair Value Measurements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "ia66c3497d92f4f87983a8808d4c22279_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "i6c8486331a7f40578e81f8425fe3e837_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413405 - Disclosure - Inventory (Details)",
     "role": "http://www.ardelyx.com/role/InventoryDetails",
     "shortName": "Inventory (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "i6c8486331a7f40578e81f8425fe3e837_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "iff15b538dbf24507841b01b99c6a5325_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416406 - Disclosure - Product Revenue, Net - Narrative (Details)",
     "role": "http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails",
     "shortName": "Product Revenue, Net - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "iac98ebf56cf345fb9e32e575ac855e4a_I20210331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "ardx:ContractWithCustomerGrossToNetSalesAccruals",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ardx:ScheduleOfGrossToNetSalesAccrualsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "i8c5aec2dbac44fa0944e95aedc29fe22_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ardx:ContractWithCustomerGrossToNetSalesAccruals",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417407 - Disclosure - Product Revenue, Net - Gross-to-Net Sales Accruals (Details)",
     "role": "http://www.ardelyx.com/role/ProductRevenueNetGrosstoNetSalesAccrualsDetails",
     "shortName": "Product Revenue, Net - Gross-to-Net Sales Accruals (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ardx:ScheduleOfGrossToNetSalesAccrualsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "iff15b538dbf24507841b01b99c6a5325_D20220101-20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "ardx:ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "iff15b538dbf24507841b01b99c6a5325_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420408 - Disclosure - Collaboration and Licensing Agreements - Narrative (Details)",
     "role": "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails",
     "shortName": "Collaboration and Licensing Agreements - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "i745335ff1da443c2a66acb028f9b9044_D20220101-20220331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "iff15b538dbf24507841b01b99c6a5325_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "role": "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
     "shortName": "CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "iff15b538dbf24507841b01b99c6a5325_D20220101-20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "i8c5aec2dbac44fa0944e95aedc29fe22_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiabilityNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421409 - Disclosure - Collaboration and Licensing Agreements - Deferred Revenue (Details)",
     "role": "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails",
     "shortName": "Collaboration and Licensing Agreements - Deferred Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "i34485cae15f04837aa894774e18bbb58_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiabilityCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "i6c8486331a7f40578e81f8425fe3e837_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424410 - Disclosure - Borrowing - Narrative (Details)",
     "role": "http://www.ardelyx.com/role/BorrowingNarrativeDetails",
     "shortName": "Borrowing - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "ib7f93b8f72cf486bbecc12514b98b015_I20180516",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "i6c8486331a7f40578e81f8425fe3e837_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425411 - Disclosure - Borrowing - Future Payment Obligations (Details)",
     "role": "http://www.ardelyx.com/role/BorrowingFuturePaymentObligationsDetails",
     "shortName": "Borrowing - Future Payment Obligations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "i6c8486331a7f40578e81f8425fe3e837_I20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "iba83d40326b1433ea471109cb11536f8_I20180531",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeLiabilityNotionalAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428412 - Disclosure - Derivative Liability - Narrative (Details)",
     "role": "http://www.ardelyx.com/role/DerivativeLiabilityNarrativeDetails",
     "shortName": "Derivative Liability - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "i59df1925a0574c55bae8311f5941df95_I20220331",
      "decimals": "2",
      "lang": "en-US",
      "name": "ardx:FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "id497bd1485194fabbdb368667104492e_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429413 - Disclosure - Derivative Liability - Changes in Fair Value (Details)",
     "role": "http://www.ardelyx.com/role/DerivativeLiabilityChangesinFairValueDetails",
     "shortName": "Derivative Liability - Changes in Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "id497bd1485194fabbdb368667104492e_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ardx:ScheduleOfAdditionalDetailsOfLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "i6c8486331a7f40578e81f8425fe3e837_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432414 - Disclosure - Leases - Additional Details of Facility Leases (Details)",
     "role": "http://www.ardelyx.com/role/LeasesAdditionalDetailsofFacilityLeasesDetails",
     "shortName": "Leases - Additional Details of Facility Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ardx:ScheduleOfAdditionalDetailsOfLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "i6c8486331a7f40578e81f8425fe3e837_I20220331",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "iff15b538dbf24507841b01b99c6a5325_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433415 - Disclosure - Leases - Lease Costs (Details)",
     "role": "http://www.ardelyx.com/role/LeasesLeaseCostsDetails",
     "shortName": "Leases - Lease Costs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "iff15b538dbf24507841b01b99c6a5325_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "i6c8486331a7f40578e81f8425fe3e837_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434416 - Disclosure - Leases - Undiscounted Cash Payment Obligations (Details)",
     "role": "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails",
     "shortName": "Leases - Undiscounted Cash Payment Obligations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "i6c8486331a7f40578e81f8425fe3e837_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "iff15b538dbf24507841b01b99c6a5325_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436417 - Disclosure - Stockholders' Equity (Details)",
     "role": "http://www.ardelyx.com/role/StockholdersEquityDetails",
     "shortName": "Stockholders' Equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "i76c2136d55464302b2f21baaa5e4dd54_I20200731",
      "decimals": "INF",
      "lang": "en-US",
      "name": "ardx:MaximumAggregateOfferingPrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "iff15b538dbf24507841b01b99c6a5325_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439418 - Disclosure - Equity Incentive Plans - Stock-Based Compensation (Details)",
     "role": "http://www.ardelyx.com/role/EquityIncentivePlansStockBasedCompensationDetails",
     "shortName": "Equity Incentive Plans - Stock-Based Compensation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "iff15b538dbf24507841b01b99c6a5325_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "iaa47cdf56b6c4c87a3d970dbcf5b0e23_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY",
     "role": "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
     "shortName": "CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "iaa47cdf56b6c4c87a3d970dbcf5b0e23_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "i8a3d5f58f87e49a095847ea09b7bf010_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2440419 - Disclosure - Equity Incentive Plans - Unrecognized Stock-Based Compensation (Details)",
     "role": "http://www.ardelyx.com/role/EquityIncentivePlansUnrecognizedStockBasedCompensationDetails",
     "shortName": "Equity Incentive Plans - Unrecognized Stock-Based Compensation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "i8a3d5f58f87e49a095847ea09b7bf010_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "i8c5aec2dbac44fa0944e95aedc29fe22_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441420 - Disclosure - Equity Incentive Plans - Stock Options (Details)",
     "role": "http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails",
     "shortName": "Equity Incentive Plans - Stock Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "i8c5aec2dbac44fa0944e95aedc29fe22_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "i14d3b2f9b45b490fbcbe947f54b91b39_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442421 - Disclosure - Equity Incentive Plans - Restricted Stock Units (Details)",
     "role": "http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails",
     "shortName": "Equity Incentive Plans - Restricted Stock Units (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "i14d3b2f9b45b490fbcbe947f54b91b39_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "i4bedde518aa14e90ae770d42052bfc56_D20220201-20220228",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2443422 - Disclosure - Equity Incentive Plans - Narrative (Details)",
     "role": "http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails",
     "shortName": "Equity Incentive Plans - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "i4bedde518aa14e90ae770d42052bfc56_D20220201-20220228",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "iff15b538dbf24507841b01b99c6a5325_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446423 - Disclosure - Net Loss Per Share - Computation of Net Loss Per Common Share (Details)",
     "role": "http://www.ardelyx.com/role/NetLossPerShareComputationofNetLossPerCommonShareDetails",
     "shortName": "Net Loss Per Share - Computation of Net Loss Per Common Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "iff15b538dbf24507841b01b99c6a5325_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2447424 - Disclosure - Net Loss Per Share - Narrative (Details)",
     "role": "http://www.ardelyx.com/role/NetLossPerShareNarrativeDetails",
     "shortName": "Net Loss Per Share - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "iff15b538dbf24507841b01b99c6a5325_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "i6c8486331a7f40578e81f8425fe3e837_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyAccrualAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2449425 - Disclosure - Contingencies (Details)",
     "role": "http://www.ardelyx.com/role/ContingenciesDetails",
     "shortName": "Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "i6c8486331a7f40578e81f8425fe3e837_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyAccrualAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "ic15e7d54e20c401b86da52a356fa5887_I20220411",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ardx:CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2451426 - Disclosure - Subsequent Events (Details)",
     "role": "http://www.ardelyx.com/role/SubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "iff15b538dbf24507841b01b99c6a5325_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - CONDENSED STATEMENTS OF CASH FLOWS",
     "role": "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONDENSED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "iff15b538dbf24507841b01b99c6a5325_D20220101-20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "iff15b538dbf24507841b01b99c6a5325_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Organization and Basis of Presentation",
     "role": "http://www.ardelyx.com/role/OrganizationandBasisofPresentation",
     "shortName": "Organization and Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "iff15b538dbf24507841b01b99c6a5325_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "iff15b538dbf24507841b01b99c6a5325_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2104102 - Disclosure - Cash, Cash Equivalents and Investments",
     "role": "http://www.ardelyx.com/role/CashCashEquivalentsandInvestments",
     "shortName": "Cash, Cash Equivalents and Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "iff15b538dbf24507841b01b99c6a5325_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "iff15b538dbf24507841b01b99c6a5325_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2108103 - Disclosure - Fair Value Measurements",
     "role": "http://www.ardelyx.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220331.htm",
      "contextRef": "iff15b538dbf24507841b01b99c6a5325_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 68,
   "tag": {
    "ardx_AccountsReceivableCollaboratorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Receivable, Collaborator",
        "label": "Accounts Receivable, Collaborator [Member]",
        "terseLabel": "Collaborators"
       }
      }
     },
     "localname": "AccountsReceivableCollaboratorMember",
     "nsuri": "http://www.ardelyx.com/20220331",
     "presentation": [
      "http://www.ardelyx.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_AccountsReceivableCommercialCustomerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Receivable, Commercial Customer",
        "label": "Accounts Receivable, Commercial Customer [Member]",
        "terseLabel": "Commercial customers"
       }
      }
     },
     "localname": "AccountsReceivableCommercialCustomerMember",
     "nsuri": "http://www.ardelyx.com/20220331",
     "presentation": [
      "http://www.ardelyx.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_AmerisourceBergenDrugCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AmerisourceBergen Drug Corporation",
        "label": "AmerisourceBergen Drug Corporation [Member]",
        "terseLabel": "AmerisourceBergen Drug Corporation"
       }
      }
     },
     "localname": "AmerisourceBergenDrugCorporationMember",
     "nsuri": "http://www.ardelyx.com/20220331",
     "presentation": [
      "http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_AstraZenecaTerminationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AstraZeneca Termination Agreement",
        "label": "AstraZeneca Termination Agreement [Member]",
        "terseLabel": "AZ Termination Agreement"
       }
      }
     },
     "localname": "AstraZenecaTerminationAgreementMember",
     "nsuri": "http://www.ardelyx.com/20220331",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails",
      "http://www.ardelyx.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_AstrazenecaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to AstraZeneca.",
        "label": "Astrazeneca [Member]",
        "terseLabel": "AstraZeneca"
       }
      }
     },
     "localname": "AstrazenecaMember",
     "nsuri": "http://www.ardelyx.com/20220331",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails",
      "http://www.ardelyx.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Available-For-Sale Securities, Debt Securities, Current, Contractual Maturities, Maximum",
        "label": "Available-For-Sale Securities, Debt Securities, Current, Contractual Maturities, Maximum",
        "terseLabel": "Short-term available-for-sale securities contractual maturities, maximum"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum",
     "nsuri": "http://www.ardelyx.com/20220331",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ardx_CardinalHealthMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cardinal Health",
        "label": "Cardinal Health [Member]",
        "terseLabel": "Cardinal Health"
       }
      }
     },
     "localname": "CardinalHealthMember",
     "nsuri": "http://www.ardelyx.com/20220331",
     "presentation": [
      "http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_CashAndCashEquivalentsAmortizedCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash And Cash Equivalents, Amortized Cost",
        "label": "Cash And Cash Equivalents, Amortized Cost",
        "totalLabel": "Cash and cash equivalents, Amortized Cost"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAmortizedCost",
     "nsuri": "http://www.ardelyx.com/20220331",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_CashAndCashEquivalentsGrossUnrealizedGains": {
     "auth_ref": [],
     "calculation": {
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "ardx_CashAndCashEquivalentsAmortizedCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash And Cash Equivalents, Gross Unrealized Gains",
        "label": "Cash And Cash Equivalents, Gross Unrealized Gains",
        "terseLabel": "Cash and cash equivalents, Gross Unrealized Gains"
       }
      }
     },
     "localname": "CashAndCashEquivalentsGrossUnrealizedGains",
     "nsuri": "http://www.ardelyx.com/20220331",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_CashAndCashEquivalentsGrossUnrealizedLosses": {
     "auth_ref": [],
     "calculation": {
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "ardx_CashAndCashEquivalentsAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash And Cash Equivalents, Gross Unrealized Losses",
        "label": "Cash And Cash Equivalents, Gross Unrealized Losses",
        "negatedTerseLabel": "Cash and cash equivalents, Gross Unrealized Losses"
       }
      }
     },
     "localname": "CashAndCashEquivalentsGrossUnrealizedLosses",
     "nsuri": "http://www.ardelyx.com/20220331",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedGains": {
     "auth_ref": [],
     "calculation": {
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "ardx_InvestmentsAndCashAmortizedCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, cash equivalents and investments gross unrealized gains.",
        "label": "Cash Cash Equivalents And Investments Gross Unrealized Gains",
        "terseLabel": "Total cash equivalents and investments, Gross Unrealized Gains"
       }
      }
     },
     "localname": "CashCashEquivalentsAndInvestmentsGrossUnrealizedGains",
     "nsuri": "http://www.ardelyx.com/20220331",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses": {
     "auth_ref": [],
     "calculation": {
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "ardx_InvestmentsAndCashAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, cash equivalents and investments gross unrealized losses.",
        "label": "Cash Cash Equivalents And Investments Gross Unrealized Losses",
        "negatedTerseLabel": "Total cash equivalents and investments, Gross Unrealized Losses"
       }
      }
     },
     "localname": "CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses",
     "nsuri": "http://www.ardelyx.com/20220331",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change In Contract With Customer Liability, Current, Rollforward",
        "label": "Change In Contract With Customer Liability, Current, Rollforward [Roll Forward]",
        "terseLabel": "Deferred revenue - current"
       }
      }
     },
     "localname": "ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward",
     "nsuri": "http://www.ardelyx.com/20220331",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change In Contract With Customer Liability, Noncurrent, Rollforward",
        "label": "Change In Contract With Customer Liability, Noncurrent, Rollforward [Roll Forward]",
        "terseLabel": "Deferred revenue - non-current"
       }
      }
     },
     "localname": "ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward",
     "nsuri": "http://www.ardelyx.com/20220331",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ardx_CollaborationAndLicensingAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "n/a",
        "label": "Collaboration and Licensing Agreements",
        "terseLabel": "Collaboration and Licensing Agreements"
       }
      }
     },
     "localname": "CollaborationAndLicensingAgreementsAbstract",
     "nsuri": "http://www.ardelyx.com/20220331",
     "xbrltype": "stringItemType"
    },
    "ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration And Licensing Agreements, Upfront License Fees",
        "label": "Collaboration And Licensing Agreements, Upfront License Fees",
        "terseLabel": "Upfront license fees"
       }
      }
     },
     "localname": "CollaborationAndLicensingAgreementsUpfrontLicenseFees",
     "nsuri": "http://www.ardelyx.com/20220331",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration And Licensing Agreements, Upfront License Fees, First Installment",
        "label": "Collaboration And Licensing Agreements, Upfront License Fees, First Installment",
        "terseLabel": "First installment of upfront license fees"
       }
      }
     },
     "localname": "CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment",
     "nsuri": "http://www.ardelyx.com/20220331",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration And Licensing Agreements, Upfront License Fees, Second Installment",
        "label": "Collaboration And Licensing Agreements, Upfront License Fees, Second Installment",
        "terseLabel": "Second installment of upfront license fees"
       }
      }
     },
     "localname": "CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment",
     "nsuri": "http://www.ardelyx.com/20220331",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Fee Receivable For Reduction In Royalty Rate",
        "label": "Collaborative Arrangement, Fee Receivable For Reduction In Royalty Rate",
        "terseLabel": "Fee receivable for reduction in royalty rate"
       }
      }
     },
     "localname": "CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate",
     "nsuri": "http://www.ardelyx.com/20220331",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails",
      "http://www.ardelyx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Fee Receivable For Reduction In Royalty Rate, Number Of Payment Tranches",
        "label": "Collaborative Arrangement, Fee Receivable For Reduction In Royalty Rate, Number Of Payment Tranches",
        "terseLabel": "Number of payment tranches for fee receivable for reduction in royalty rate"
       }
      }
     },
     "localname": "CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches",
     "nsuri": "http://www.ardelyx.com/20220331",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails",
      "http://www.ardelyx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ardx_CollaborativeArrangementPotentialCommercializationMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Potential Commercialization Milestones",
        "label": "Collaborative Arrangement, Potential Commercialization Milestones",
        "terseLabel": "Potential commercialization milestones"
       }
      }
     },
     "localname": "CollaborativeArrangementPotentialCommercializationMilestones",
     "nsuri": "http://www.ardelyx.com/20220331",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of future development and commercialization milestone under collaborative arrangements.",
        "label": "Collaborative Arrangement, Potential Development And Commercialization Milestones",
        "terseLabel": "Potential development and commercialization milestones"
       }
      }
     },
     "localname": "CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones",
     "nsuri": "http://www.ardelyx.com/20220331",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_CollaborativeArrangementPotentialDevelopmentMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Potential Development Milestones",
        "label": "Collaborative Arrangement, Potential Development Milestones",
        "terseLabel": "Potential development milestones"
       }
      }
     },
     "localname": "CollaborativeArrangementPotentialDevelopmentMilestones",
     "nsuri": "http://www.ardelyx.com/20220331",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Potential Payment Per Termination Agreement, Maximum",
        "label": "Collaborative Arrangement, Potential Payment Per Termination Agreement, Maximum",
        "terseLabel": "Maximum potential payment per agreement"
       }
      }
     },
     "localname": "CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum",
     "nsuri": "http://www.ardelyx.com/20220331",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails",
      "http://www.ardelyx.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_CollaborativeDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Development [Member]",
        "label": "Collaborative Development [Member]",
        "terseLabel": "Collaborative development revenue"
       }
      }
     },
     "localname": "CollaborativeDevelopmentMember",
     "nsuri": "http://www.ardelyx.com/20220331",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_ContractWithCustomerDiscountsAndChargebacksMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Discounts And Chargebacks",
        "label": "Contract With Customer, Discounts And Chargebacks [Member]",
        "terseLabel": "Discounts and Chargebacks"
       }
      }
     },
     "localname": "ContractWithCustomerDiscountsAndChargebacksMember",
     "nsuri": "http://www.ardelyx.com/20220331",
     "presentation": [
      "http://www.ardelyx.com/role/ProductRevenueNetGrosstoNetSalesAccrualsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Gross To Net Sales, Accrual Activity During Current Period",
        "label": "Contract With Customer, Gross To Net Sales, Accrual Activity During Current Period",
        "terseLabel": "Activity related to 2022 sales"
       }
      }
     },
     "localname": "ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod",
     "nsuri": "http://www.ardelyx.com/20220331",
     "presentation": [
      "http://www.ardelyx.com/role/ProductRevenueNetGrosstoNetSalesAccrualsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Gross To Net Sales Accrual",
        "label": "Contract With Customer, Gross To Net Sales Accrual [Roll Forward]",
        "terseLabel": "Gross-to-net sales accruals and reserves"
       }
      }
     },
     "localname": "ContractWithCustomerGrossToNetSalesAccrualRollForward",
     "nsuri": "http://www.ardelyx.com/20220331",
     "presentation": [
      "http://www.ardelyx.com/role/ProductRevenueNetGrosstoNetSalesAccrualsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ardx_ContractWithCustomerGrossToNetSalesAccruals": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Gross To Net Sales Accruals",
        "label": "Contract With Customer, Gross To Net Sales Accruals",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Gross-to-net sales accruals"
       }
      }
     },
     "localname": "ContractWithCustomerGrossToNetSalesAccruals",
     "nsuri": "http://www.ardelyx.com/20220331",
     "presentation": [
      "http://www.ardelyx.com/role/ProductRevenueNetGrosstoNetSalesAccrualsDetails",
      "http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_ContractWithCustomerLiabilityIncreaseDueToUnbilledPrepaymentsRecorded": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Liability, Increase Due To Unbilled Prepayments Recorded",
        "label": "Contract With Customer, Liability, Increase Due To Unbilled Prepayments Recorded",
        "terseLabel": "Increase due to unbilled prepayments recorded during the period"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityIncreaseDueToUnbilledPrepaymentsRecorded",
     "nsuri": "http://www.ardelyx.com/20220331",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_ContractWithCustomerLiabilityIncreaseForAmountsInvoiced": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Liability, Increase For Amounts Invoiced",
        "label": "Contract With Customer, Liability, Increase For Amounts Invoiced",
        "terseLabel": "Increases to amounts invoiced, for which cash has not yet been received"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityIncreaseForAmountsInvoiced",
     "nsuri": "http://www.ardelyx.com/20220331",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_ContractWithCustomerLiabilityRevenueRecognizedCashReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received.",
        "label": "Contract with Customer Liability Revenue Recognized Cash Received",
        "negatedTerseLabel": "Decreases due to revenue recognized in the period for which cash has been received"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognizedCashReceived",
     "nsuri": "http://www.ardelyx.com/20220331",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_ContractWithCustomerOtherFeesCopayAndReturnsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Other Fees, Copay And Returns",
        "label": "Contract With Customer, Other Fees, Copay And Returns [Member]",
        "terseLabel": "Other Fees, Copay and Returns"
       }
      }
     },
     "localname": "ContractWithCustomerOtherFeesCopayAndReturnsMember",
     "nsuri": "http://www.ardelyx.com/20220331",
     "presentation": [
      "http://www.ardelyx.com/role/ProductRevenueNetGrosstoNetSalesAccrualsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_ContractWithCustomerRebatesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Rebates",
        "label": "Contract With Customer, Rebates [Member]",
        "terseLabel": "Rebates"
       }
      }
     },
     "localname": "ContractWithCustomerRebatesMember",
     "nsuri": "http://www.ardelyx.com/20220331",
     "presentation": [
      "http://www.ardelyx.com/role/ProductRevenueNetGrosstoNetSalesAccrualsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_CostOfRevenueAggregateAmountRecognized": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of revenue, aggregate amount recognized.",
        "label": "Cost Of Revenue, Aggregate Amount Recognized",
        "terseLabel": "Aggregate cost of revenue recognized"
       }
      }
     },
     "localname": "CostOfRevenueAggregateAmountRecognized",
     "nsuri": "http://www.ardelyx.com/20220331",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails",
      "http://www.ardelyx.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_DebtInstrumentClosingFeeAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Closing Fee Amount",
        "label": "Debt Instrument, Closing Fee Amount",
        "terseLabel": "Closing fee"
       }
      }
     },
     "localname": "DebtInstrumentClosingFeeAmount",
     "nsuri": "http://www.ardelyx.com/20220331",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Fee Due Upon Maturity, Acceleration, Prepayment, Termination, Percentage",
        "label": "Debt Instrument, Fee Due Upon Maturity, Acceleration, Prepayment, Termination, Percentage",
        "terseLabel": "Final fee due upon maturity, acceleration, prepayment, or termination (percent)"
       }
      }
     },
     "localname": "DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage",
     "nsuri": "http://www.ardelyx.com/20220331",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ardx_DebtInstrumentInterestRateOnDefaultPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of additional default interest rate on the event of default.",
        "label": "Debt Instrument, Interest Rate On Default, Percentage",
        "terseLabel": "Additional default interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateOnDefaultPercentage",
     "nsuri": "http://www.ardelyx.com/20220331",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ardx_DebtInstrumentPrepaymentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of fee payable on prepayment of debt.",
        "label": "Debt Instrument, Prepayment Fee, Percentage",
        "terseLabel": "Prepayment premium (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentFeePercentage",
     "nsuri": "http://www.ardelyx.com/20220331",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ardx_DebtInstrumentVariableRateBaseOption": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Variable Rate, Base Option",
        "label": "Debt Instrument, Variable Rate, Base Option",
        "terseLabel": "Addition to floating per annum rate (percent)"
       }
      }
     },
     "localname": "DebtInstrumentVariableRateBaseOption",
     "nsuri": "http://www.ardelyx.com/20220331",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ardx_DerivativeIssued": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative Issued",
        "label": "Derivative Issued",
        "terseLabel": "Issuance of derivative in connection with issuance of loan payable"
       }
      }
     },
     "localname": "DerivativeIssued",
     "nsuri": "http://www.ardelyx.com/20220331",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Stock Purchase Plan [Member]",
        "label": "Employee Stock Purchase Plan [Member]",
        "terseLabel": "ESPP"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMember",
     "nsuri": "http://www.ardelyx.com/20220331",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails",
      "http://www.ardelyx.com/role/EquityIncentivePlansUnrecognizedStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_ExitFee2018Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exit Fee 2018",
        "label": "Exit Fee 2018 [Member]",
        "terseLabel": "2018 Exit Fee"
       }
      }
     },
     "localname": "ExitFee2018Member",
     "nsuri": "http://www.ardelyx.com/20220331",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails",
      "http://www.ardelyx.com/role/DerivativeLiabilityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_ExitFee2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exit Fee 2022",
        "label": "Exit Fee 2022 [Member]",
        "terseLabel": "2022 Exit Fee"
       }
      }
     },
     "localname": "ExitFee2022Member",
     "nsuri": "http://www.ardelyx.com/20220331",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails",
      "http://www.ardelyx.com/role/DerivativeLiabilityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_ExitFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exit Fee, Percentage",
        "label": "Exit Fee, Percentage",
        "terseLabel": "Exit fee (percent)"
       }
      }
     },
     "localname": "ExitFeePercentage",
     "nsuri": "http://www.ardelyx.com/20220331",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails",
      "http://www.ardelyx.com/role/DerivativeLiabilityNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value Sensitivity Analysis, Change In Probability Of Occurrence, Percentage",
        "label": "Fair Value Sensitivity Analysis, Change In Probability Of Occurrence, Percentage",
        "terseLabel": "Fair value analysis, percentage change in probability of occurrence"
       }
      }
     },
     "localname": "FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage",
     "nsuri": "http://www.ardelyx.com/20220331",
     "presentation": [
      "http://www.ardelyx.com/role/DerivativeLiabilityNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value Sensitivity Analysis, Ten Percent Change In Probability Of Occurrence, Effect On Valuation",
        "label": "Fair Value Sensitivity Analysis, Ten Percent Change In Probability Of Occurrence, Effect On Valuation",
        "terseLabel": "Fair value analysis, effect on fair value based on 10% change in probability of occurrence"
       }
      }
     },
     "localname": "FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation",
     "nsuri": "http://www.ardelyx.com/20220331",
     "presentation": [
      "http://www.ardelyx.com/role/DerivativeLiabilityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_GrossToNetSalesAccrualAndReserveClassificationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross To Net Sales Accrual And Reserve Classification",
        "label": "Gross To Net Sales Accrual And Reserve Classification [Axis]",
        "terseLabel": "Gross To Net Sales Accrual And Reserve Classification [Axis]"
       }
      }
     },
     "localname": "GrossToNetSalesAccrualAndReserveClassificationAxis",
     "nsuri": "http://www.ardelyx.com/20220331",
     "presentation": [
      "http://www.ardelyx.com/role/ProductRevenueNetGrosstoNetSalesAccrualsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ardx_GrossToNetSalesAccrualAndReserveClassificationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross To Net Sales Accrual And Reserve Classification [Domain]",
        "label": "Gross To Net Sales Accrual And Reserve Classification [Domain]",
        "terseLabel": "Gross To Net Sales Accrual And Reserve Classification [Domain]"
       }
      }
     },
     "localname": "GrossToNetSalesAccrualAndReserveClassificationDomain",
     "nsuri": "http://www.ardelyx.com/20220331",
     "presentation": [
      "http://www.ardelyx.com/role/ProductRevenueNetGrosstoNetSalesAccrualsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_InvestmentsAndCashAmortizedCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments And Cash, Amortized Cost",
        "label": "Investments And Cash, Amortized Cost",
        "totalLabel": "Total cash equivalents and investments, Cost"
       }
      }
     },
     "localname": "InvestmentsAndCashAmortizedCost",
     "nsuri": "http://www.ardelyx.com/20220331",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_KnightTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Knight Therapeutics Inc.",
        "label": "Knight Therapeutics Inc [Member]",
        "terseLabel": "Knight"
       }
      }
     },
     "localname": "KnightTherapeuticsIncMember",
     "nsuri": "http://www.ardelyx.com/20220331",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_KyowaKirinCo.LtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Kyowa Kirin Co., Ltd.",
        "label": "Kyowa Kirin Co. Ltd [Member]",
        "terseLabel": "KKC"
       }
      }
     },
     "localname": "KyowaKirinCo.LtdMember",
     "nsuri": "http://www.ardelyx.com/20220331",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails",
      "http://www.ardelyx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement for the development, commercialization and distribution fo tenapanor in Canada. The Knight Agreement.",
        "label": "License Agreement Development Commercialization Distribution In Canada [Member]",
        "terseLabel": "Knight Agreement"
       }
      }
     },
     "localname": "LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember",
     "nsuri": "http://www.ardelyx.com/20220331",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement for the development, commercialization and distribution of tenapanor in China. The Fosun Agreement.",
        "label": "License Agreement Development Commercialization Distribution In China [Member]",
        "terseLabel": "Fosun Agreement"
       }
      }
     },
     "localname": "LicenseAgreementDevelopmentCommercializationDistributionInChinaMember",
     "nsuri": "http://www.ardelyx.com/20220331",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement for the development, commercialization and distribution of tenapanor in Japan. The 2017 KKC Agreement.",
        "label": "License Agreement Development Commercialization Distribution In Japan [Member]",
        "terseLabel": "2017 KKC Agreement"
       }
      }
     },
     "localname": "LicenseAgreementDevelopmentCommercializationDistributionInJapanMember",
     "nsuri": "http://www.ardelyx.com/20220331",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails",
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails",
      "http://www.ardelyx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loan Agreement, Covenant, Cash And Cash Equivalents As Percentage Of Outstanding Loan Balance, Minimum",
        "label": "Loan Agreement, Covenant, Cash And Cash Equivalents As Percentage Of Outstanding Loan Balance, Minimum",
        "terseLabel": "Loan agreement covenant, cash and cash equivalents as percentage of outstanding loan balance, minimum"
       }
      }
     },
     "localname": "LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum",
     "nsuri": "http://www.ardelyx.com/20220331",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ardx_LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loan Agreement, Covenant, Net Product Revenue As Percentage Of Outstanding Loan Balance, Minimum",
        "label": "Loan Agreement, Covenant, Net Product Revenue As Percentage Of Outstanding Loan Balance, Minimum",
        "terseLabel": "Loan agreement covenant, net product revenue as percentage of outstanding loan balance, minimum"
       }
      }
     },
     "localname": "LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum",
     "nsuri": "http://www.ardelyx.com/20220331",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loan Agreement, Exit Fee, Net Product Revenue Threshold Metric, Trailing Six Month Basis, Minimum",
        "label": "Loan Agreement, Exit Fee, Net Product Revenue Threshold Metric, Trailing Six Month Basis, Minimum",
        "terseLabel": "Exit fee, net product revenue threshold"
       }
      }
     },
     "localname": "LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum",
     "nsuri": "http://www.ardelyx.com/20220331",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails",
      "http://www.ardelyx.com/role/DerivativeLiabilityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_LoanAgreementExitFeeTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loan Agreement, Exit Fee, Term",
        "label": "Loan Agreement, Exit Fee, Term",
        "terseLabel": "Exit fee, term (in years)"
       }
      }
     },
     "localname": "LoanAgreementExitFeeTerm",
     "nsuri": "http://www.ardelyx.com/20220331",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ardx_LoanAgreementFutureObligationUponFundingOrOtherEvents": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loan Agreement, Future Obligation Upon Funding Or Other Events",
        "label": "Loan Agreement, Future Obligation Upon Funding Or Other Events",
        "terseLabel": "Future obligation upon loan funding or other events"
       }
      }
     },
     "localname": "LoanAgreementFutureObligationUponFundingOrOtherEvents",
     "nsuri": "http://www.ardelyx.com/20220331",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_MaximumAggregateOfferingPrice": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of maximum aggregate offering price.",
        "label": "Maximum Aggregate Offering Price",
        "terseLabel": "Maximum aggregate offering price"
       }
      }
     },
     "localname": "MaximumAggregateOfferingPrice",
     "nsuri": "http://www.ardelyx.com/20220331",
     "presentation": [
      "http://www.ardelyx.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_McKessonCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "McKesson Corporation",
        "label": "McKesson Corporation [Member]",
        "terseLabel": "McKesson Corporation"
       }
      }
     },
     "localname": "McKessonCorporationMember",
     "nsuri": "http://www.ardelyx.com/20220331",
     "presentation": [
      "http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_NumberOfSeparateCollaborativeAgreements": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of separate collaborative agreements.",
        "label": "Number Of Separate Collaborative Agreements",
        "terseLabel": "Number of separate collaborative agreements"
       }
      }
     },
     "localname": "NumberOfSeparateCollaborativeAgreements",
     "nsuri": "http://www.ardelyx.com/20220331",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ardx_OpenMarketSalesAgreement2020AtTheMarketOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Open Market Sales Agreement 2020, At The Market Offering",
        "label": "Open Market Sales Agreement 2020, At The Market Offering [Member]",
        "terseLabel": "2020 Open Market Sales Agreement"
       }
      }
     },
     "localname": "OpenMarketSalesAgreement2020AtTheMarketOfferingMember",
     "nsuri": "http://www.ardelyx.com/20220331",
     "presentation": [
      "http://www.ardelyx.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_OpenMarketSalesAgreement2021AtTheMarketOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Open Market Sales Agreement 2021, At The Market Offering",
        "label": "Open Market Sales Agreement 2021, At The Market Offering [Member]",
        "terseLabel": "2021 Open Market Sales Agreement"
       }
      }
     },
     "localname": "OpenMarketSalesAgreement2021AtTheMarketOfferingMember",
     "nsuri": "http://www.ardelyx.com/20220331",
     "presentation": [
      "http://www.ardelyx.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_PaymentsOfUnchargedLicenseFeesAggregateAmountPaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments of uncharged license fees, aggregate amount paid.",
        "label": "Payments Of Uncharged License Fees, Aggregate Amount Paid",
        "terseLabel": "Aggregate amount paid"
       }
      }
     },
     "localname": "PaymentsOfUnchargedLicenseFeesAggregateAmountPaid",
     "nsuri": "http://www.ardelyx.com/20220331",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_PercentageOfNonRoyaltyRevenue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents percentage of non-royalty revenue.",
        "label": "Percentage Of Non-Royalty Revenue",
        "terseLabel": "Percentage of non-royalty revenue"
       }
      }
     },
     "localname": "PercentageOfNonRoyaltyRevenue",
     "nsuri": "http://www.ardelyx.com/20220331",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails",
      "http://www.ardelyx.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ardx_PercentageOfRoyaltyRevenue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents percentage of royalty revenue.",
        "label": "Percentage of Royalty Revenue",
        "terseLabel": "Percentage of royalty revenue"
       }
      }
     },
     "localname": "PercentageOfRoyaltyRevenue",
     "nsuri": "http://www.ardelyx.com/20220331",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails",
      "http://www.ardelyx.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ardx_ProductIBSRELAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product, IBSRELA",
        "label": "Product, IBSRELA [Member]",
        "terseLabel": "IBSRELA"
       }
      }
     },
     "localname": "ProductIBSRELAMember",
     "nsuri": "http://www.ardelyx.com/20220331",
     "presentation": [
      "http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_ProductSupplyRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product Supply Revenue",
        "label": "Product Supply Revenue [Member]",
        "terseLabel": "Product supply revenue"
       }
      }
     },
     "localname": "ProductSupplyRevenueMember",
     "nsuri": "http://www.ardelyx.com/20220331",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_RemainingFundingBasedOnConditionalMilestoneAchievement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining Funding Based On Conditional Milestone Achievement",
        "label": "Remaining Funding Based On Conditional Milestone Achievement",
        "terseLabel": "Remaining funding based on milestone achievement"
       }
      }
     },
     "localname": "RemainingFundingBasedOnConditionalMilestoneAchievement",
     "nsuri": "http://www.ardelyx.com/20220331",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_ResearchCollaborationAndOptionAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pertaining to the research collaboration and option agreement for research associated with identifying two pre-clinical compounds. The 2019 KKC AGreement.",
        "label": "Research Collaboration And Option Agreement [Member]",
        "terseLabel": "2019 KKC Agreement"
       }
      }
     },
     "localname": "ResearchCollaborationAndOptionAgreementMember",
     "nsuri": "http://www.ardelyx.com/20220331",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails",
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_RevenueGeneralPaymentTerms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, General Payment Terms",
        "label": "Revenue, General Payment Terms",
        "terseLabel": "Payment terms"
       }
      }
     },
     "localname": "RevenueGeneralPaymentTerms",
     "nsuri": "http://www.ardelyx.com/20220331",
     "presentation": [
      "http://www.ardelyx.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ardx_SaleOfStockWeightedAveragePricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Weighted-Average Price Per Share",
        "label": "Sale Of Stock, Weighted-Average Price Per Share",
        "terseLabel": "Weighted-average sales price per share"
       }
      }
     },
     "localname": "SaleOfStockWeightedAveragePricePerShare",
     "nsuri": "http://www.ardelyx.com/20220331",
     "presentation": [
      "http://www.ardelyx.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ardx_ScheduleOfAdditionalDetailsOfLeasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The tabular disclosure of additional details of the leases.",
        "label": "Schedule of Additional Details of Leases [Table Text Block]",
        "terseLabel": "Summary of Additional Details of Leases"
       }
      }
     },
     "localname": "ScheduleOfAdditionalDetailsOfLeasesTableTextBlock",
     "nsuri": "http://www.ardelyx.com/20220331",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ardx_ScheduleOfGrossToNetSalesAccrualsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Gross To Net Sales Accruals",
        "label": "Schedule Of Gross To Net Sales Accruals [Table Text Block]",
        "terseLabel": "Schedule of Chargebacks, Discounts and Reserve Balances"
       }
      }
     },
     "localname": "ScheduleOfGrossToNetSalesAccrualsTableTextBlock",
     "nsuri": "http://www.ardelyx.com/20220331",
     "presentation": [
      "http://www.ardelyx.com/role/ProductRevenueNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Shanghai Fosun Pharmaceutical Industrial Development.",
        "label": "Shanghai Fosun Pharmaceutical Industrial Development [Member]",
        "terseLabel": "Fosun Pharma"
       }
      }
     },
     "localname": "ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember",
     "nsuri": "http://www.ardelyx.com/20220331",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the purchase price per share of shares issued to employees under the plan.",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award, Purchased Price of Share",
        "terseLabel": "Purchase price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare",
     "nsuri": "http://www.ardelyx.com/20220331",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ardx_StockIssuanceCostCommissionPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issuance Cost, Commission, Percent",
        "label": "Stock Issuance Cost, Commission, Percent",
        "terseLabel": "Commission on sale of stock per agreement (percent)"
       }
      }
     },
     "localname": "StockIssuanceCostCommissionPercent",
     "nsuri": "http://www.ardelyx.com/20220331",
     "presentation": [
      "http://www.ardelyx.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ardx_TermLoan2018Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan 2018",
        "label": "Term Loan 2018 [Member]",
        "terseLabel": "2018 Term Loan"
       }
      }
     },
     "localname": "TermLoan2018Member",
     "nsuri": "http://www.ardelyx.com/20220331",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_TermLoan2022AMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan 2022 A",
        "label": "Term Loan 2022 A [Member]",
        "terseLabel": "Term Loan A"
       }
      }
     },
     "localname": "TermLoan2022AMember",
     "nsuri": "http://www.ardelyx.com/20220331",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_TermLoan2022BMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan 2022 B",
        "label": "Term Loan 2022 B [Member]",
        "terseLabel": "Term Loan B"
       }
      }
     },
     "localname": "TermLoan2022BMember",
     "nsuri": "http://www.ardelyx.com/20220331",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_TermLoan2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan 2022",
        "label": "Term Loan 2022 [Member]",
        "terseLabel": "2022 Term Loan"
       }
      }
     },
     "localname": "TermLoan2022Member",
     "nsuri": "http://www.ardelyx.com/20220331",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_TermOfAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of agreement.",
        "label": "Term Of Agreement",
        "terseLabel": "Term of agreement"
       }
      }
     },
     "localname": "TermOfAgreement",
     "nsuri": "http://www.ardelyx.com/20220331",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ardx_TermOfPaymentOfLicenseFeeFirstInstallment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of payment of first installment fee.",
        "label": "Term Of Payment Of License Fee, First Installment",
        "terseLabel": "Term of payment of license fee, first installment"
       }
      }
     },
     "localname": "TermOfPaymentOfLicenseFeeFirstInstallment",
     "nsuri": "http://www.ardelyx.com/20220331",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ardx_ThresholdPercentageOfSalesForTieredRoyalties": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the threshold percentage of net sales for tiered royalties.",
        "label": "Threshold Percentage of Sales For Tiered Royalties",
        "terseLabel": "Threshold percentage of net sales for tiered royalties"
       }
      }
     },
     "localname": "ThresholdPercentageOfSalesForTieredRoyalties",
     "nsuri": "http://www.ardelyx.com/20220331",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r47",
      "r49",
      "r101",
      "r102",
      "r239",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails",
      "http://www.ardelyx.com/role/OrganizationandBasisofPresentationDetails",
      "http://www.ardelyx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r170"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]",
        "terseLabel": "Board of directors"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r169",
      "r314",
      "r319",
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r238",
      "r274",
      "r335",
      "r336",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r485",
      "r521",
      "r524",
      "r535",
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r238",
      "r274",
      "r335",
      "r336",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r485",
      "r521",
      "r524",
      "r535",
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails",
      "http://www.ardelyx.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r169",
      "r314",
      "r319",
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r167",
      "r314",
      "r317",
      "r488",
      "r520",
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails",
      "http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r167",
      "r314",
      "r317",
      "r488",
      "r520",
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Products and Services [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails",
      "http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r238",
      "r274",
      "r326",
      "r335",
      "r336",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r485",
      "r521",
      "r524",
      "r535",
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails",
      "http://www.ardelyx.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r238",
      "r274",
      "r326",
      "r335",
      "r336",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r485",
      "r521",
      "r524",
      "r535",
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails",
      "http://www.ardelyx.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r48",
      "r49",
      "r101",
      "r102",
      "r239",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails",
      "http://www.ardelyx.com/role/OrganizationandBasisofPresentationDetails",
      "http://www.ardelyx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r170",
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of receivable.",
        "label": "Receivable Type [Axis]",
        "terseLabel": "Receivable Type [Axis]"
       }
      }
     },
     "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r31",
      "r451"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r4",
      "r17",
      "r171",
      "r172"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS",
      "http://www.ardelyx.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedLabel": "Amortization of (discount) premium on investment securities"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.",
        "label": "Accrued Liabilities and Other Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndOtherLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r20",
      "r51",
      "r52",
      "r53",
      "r509",
      "r529",
      "r530"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r50",
      "r53",
      "r59",
      "r60",
      "r61",
      "r105",
      "r106",
      "r107",
      "r384",
      "r525",
      "r526",
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r105",
      "r106",
      "r107",
      "r361",
      "r362",
      "r363",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r337",
      "r339",
      "r366",
      "r367"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r339",
      "r357",
      "r365"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r73",
      "r88",
      "r258",
      "r431"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Amortization of Debt Discount (Premium)",
        "terseLabel": "Non-cash interest associated with debt discount accretion"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfDeferredCharges": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of amortization of deferred charges applied against earnings during the period.",
        "label": "Amortization of Deferred Charges",
        "terseLabel": "Amortization of deferred compensation for services"
       }
      }
     },
     "localname": "AmortizationOfDeferredCharges",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r67",
      "r88",
      "r258",
      "r433"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "terseLabel": "Amortization of deferred financing costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "verboseLabel": "Anti-dilutive securities not included in computation of diluted net loss per share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/NetLossPerShareNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Arrangements and Non-arrangement Transactions [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails",
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails",
      "http://www.ardelyx.com/role/OrganizationandBasisofPresentationDetails",
      "http://www.ardelyx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetBackedSecuritiesMember": {
     "auth_ref": [
      "r188",
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.",
        "label": "Asset-backed Securities [Member]",
        "terseLabel": "Asset-backed securities"
       }
      }
     },
     "localname": "AssetBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails",
      "http://www.ardelyx.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r99",
      "r156",
      "r159",
      "r165",
      "r194",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r381",
      "r385",
      "r421",
      "r449",
      "r451",
      "r490",
      "r507"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsAndLiabilitiesLesseeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets and Liabilities, Lessee [Abstract]",
        "verboseLabel": "Right-of-use assets and lease liabilities"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesLesseeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesAdditionalDetailsofFacilityLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r5",
      "r6",
      "r46",
      "r99",
      "r194",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r381",
      "r385",
      "r421",
      "r449",
      "r451"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r408"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Assets, fair value"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets, Fair Value Disclosure [Abstract]"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r186"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Short-term investments, Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r187"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Short-term investments, Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r184",
      "r201"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Short-term investments, Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r180",
      "r185",
      "r201",
      "r494"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Short-term investments, Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r182",
      "r201"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Current",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Fair Value to Amortized Cost, after Allowance for Credit Loss [Abstract]",
        "terseLabel": "Short-term investments:"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r340",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails",
      "http://www.ardelyx.com/role/EquityIncentivePlansUnrecognizedStockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/OrganizationandBasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Abstract]",
        "terseLabel": "Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r29",
      "r90"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails": {
       "order": 3.0,
       "parentTag": "ardx_CashAndCashEquivalentsAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash and cash equivalents, Fair Value"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS",
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, at Carrying Value [Abstract]",
        "terseLabel": "Cash and cash equivalents:"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock": {
     "auth_ref": [
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of the components of cash, cash equivalents, and short-term investments. Short-term investments may include current marketable securities.",
        "label": "Cash, Cash Equivalents, and Short-term Investments [Text Block]",
        "verboseLabel": "Cash, Cash Equivalents and Investments"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestmentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r83",
      "r90",
      "r92"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r83",
      "r422"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net decrease in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplementary disclosure of non-cash activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashMember": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.",
        "label": "Cash [Member]",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "CashMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r96",
      "r99",
      "r121",
      "r122",
      "r123",
      "r125",
      "r127",
      "r136",
      "r137",
      "r138",
      "r194",
      "r224",
      "r228",
      "r229",
      "r230",
      "r233",
      "r234",
      "r272",
      "r273",
      "r277",
      "r281",
      "r421",
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r375",
      "r376",
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaboration and Licensing Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails",
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails",
      "http://www.ardelyx.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails",
      "http://www.ardelyx.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r327",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds that is excluded from cash and cash equivalents.",
        "label": "Commercial Paper, Not Included with Cash and Cash Equivalents [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperNotIncludedWithCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r38",
      "r219",
      "r495",
      "r513"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r216",
      "r217",
      "r218",
      "r220",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "verboseLabel": "Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/Contingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonClassAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification of common stock representing ownership interest in a corporation.",
        "label": "Common Class A [Member]",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonClassAMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r105",
      "r106",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r16",
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r16",
      "r451"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.0001 par value; 300,000,000 shares authorized; 136,330,360 and 130,182,535 shares issued and outstanding as of March\u00a031, 2022 and December\u00a031, 2021, respectively."
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r55",
      "r57",
      "r58",
      "r65",
      "r498",
      "r516"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]",
        "terseLabel": "Comprehensive loss:"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r145",
      "r146",
      "r169",
      "r419",
      "r420",
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r145",
      "r146",
      "r169",
      "r419",
      "r420",
      "r532",
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r145",
      "r146",
      "r169",
      "r419",
      "r420",
      "r532",
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r145",
      "r146",
      "r169",
      "r419",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk (percent)"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r145",
      "r146",
      "r169",
      "r419",
      "r420",
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "terseLabel": "Schedule of Changes in Deferred Revenue"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r295",
      "r296",
      "r315"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r295",
      "r296",
      "r315"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Deferred revenue, non-current"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS",
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r327",
      "r334",
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate bonds"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails",
      "http://www.ardelyx.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfRevenue": {
     "auth_ref": [
      "r69",
      "r99",
      "r194",
      "r224",
      "r225",
      "r226",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r421"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.",
        "label": "Cost of Revenue",
        "terseLabel": "Cost of revenue"
       }
      }
     },
     "localname": "CostOfRevenue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered.",
        "label": "Cost of Goods and Service [Policy Text Block]",
        "terseLabel": "Cost of Revenue"
       }
      }
     },
     "localname": "CostOfSalesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/OrganizationandBasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r143",
      "r169"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r95",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r252",
      "r259",
      "r260",
      "r262",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Borrowing"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/Borrowing"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r11",
      "r12",
      "r13",
      "r98",
      "r103",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r242",
      "r248",
      "r249",
      "r250",
      "r251",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r266",
      "r267",
      "r268",
      "r269",
      "r434",
      "r491",
      "r492",
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Floating per annum rate (percent)"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r13",
      "r263",
      "r492",
      "r506"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/BorrowingFuturePaymentObligationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross",
        "terseLabel": "Principal outstanding",
        "verboseLabel": "Long-term Debt, Gross"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingFuturePaymentObligationsDetails",
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r235",
      "r266",
      "r267",
      "r432",
      "r434",
      "r435"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Term loan face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFeeAmount": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/BorrowingFuturePaymentObligationsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument.",
        "label": "Debt Instrument, Fee Amount",
        "negatedTerseLabel": "Less: Unaccreted value of final fee"
       }
      }
     },
     "localname": "DebtInstrumentFeeAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingFuturePaymentObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r37",
      "r98",
      "r103",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r242",
      "r248",
      "r249",
      "r250",
      "r251",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r266",
      "r267",
      "r268",
      "r269",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodAxis": {
     "auth_ref": [
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about timing of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period [Axis]",
        "terseLabel": "Debt Instrument, Redemption, Period [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodDomain": {
     "auth_ref": [
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period as defined under terms of the debt agreement for debt redemption features.",
        "label": "Debt Instrument, Redemption, Period [Domain]",
        "terseLabel": "Debt Instrument, Redemption, Period [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodOneMember": {
     "auth_ref": [
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period one representing most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period One [Member]",
        "terseLabel": "Prior to first anniversary of closing date"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodOneMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodThreeMember": {
     "auth_ref": [
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period three representing third most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period Three [Member]",
        "terseLabel": "After second anniversary to maturity date"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodThreeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodTwoMember": {
     "auth_ref": [
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period two representing second most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period Two [Member]",
        "terseLabel": "After first anniversary through second anniversary of closing date"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r37",
      "r98",
      "r103",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r242",
      "r248",
      "r249",
      "r250",
      "r251",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r261",
      "r266",
      "r267",
      "r268",
      "r269",
      "r289",
      "r290",
      "r291",
      "r292",
      "r431",
      "r432",
      "r434",
      "r435",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r248",
      "r264",
      "r266",
      "r267",
      "r433"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/BorrowingFuturePaymentObligationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "negatedLabel": "Less: Unamortized discount"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingFuturePaymentObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions": {
     "auth_ref": [
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions",
        "terseLabel": "Investment in continuous unrealized loss position for more than one year"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r88",
      "r211"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails",
      "http://www.ardelyx.com/role/DerivativeLiabilityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents derivative instrument obligations meeting the definition of a liability which are reported as of the balance sheet date. Derivative instrument obligations are generally measured at fair value, and adjustments to the carrying amount of hedged items reflect changes in their fair value (that is, losses) that are attributable to the risk being hedged and that arise while the hedge is in effect.",
        "label": "Derivative Financial Instruments, Liabilities [Member]",
        "terseLabel": "Exit Fee derivative liability",
        "verboseLabel": "Derivative liability for exit fees"
       }
      }
     },
     "localname": "DerivativeFinancialInstrumentsLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/DerivativeLiabilityChangesinFairValueDetails",
      "http://www.ardelyx.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r49",
      "r395",
      "r396",
      "r398",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails",
      "http://www.ardelyx.com/role/DerivativeLiabilityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r403",
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]",
        "verboseLabel": "Derivative Liability"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/DerivativeLiability"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DerivativeLiabilityNotionalAmount": {
     "auth_ref": [
      "r389",
      "r390",
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payments on the derivative liability.",
        "label": "Derivative Liability, Notional Amount",
        "terseLabel": "Agreed amount for exit fee upon change of control or regulatory approval",
        "verboseLabel": "Agreed amount for exit fee upon occurrence of certain conditions"
       }
      }
     },
     "localname": "DerivativeLiabilityNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails",
      "http://www.ardelyx.com/role/DerivativeLiabilityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative [Line Items]",
        "terseLabel": "Derivative [Line Items]"
       }
      }
     },
     "localname": "DerivativeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/DerivativeLiabilityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeTable": {
     "auth_ref": [
      "r388",
      "r391",
      "r392",
      "r393",
      "r394",
      "r397",
      "r398",
      "r400",
      "r401",
      "r402",
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
        "label": "Derivative [Table]",
        "terseLabel": "Derivative [Table]"
       }
      }
     },
     "localname": "DerivativeTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/DerivativeLiabilityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/ProductRevenueNetGrosstoNetSalesAccrualsDetails",
      "http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r314",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/ProductRevenueNetGrosstoNetSalesAccrualsDetails",
      "http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "verboseLabel": "Equity Incentive Plans"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r66",
      "r110",
      "r111",
      "r112",
      "r113",
      "r114",
      "r119",
      "r121",
      "r125",
      "r126",
      "r127",
      "r131",
      "r132",
      "r405",
      "r406",
      "r499",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per common share - basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.ardelyx.com/role/NetLossPerShareComputationofNetLossPerCommonShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r66",
      "r110",
      "r111",
      "r112",
      "r113",
      "r114",
      "r121",
      "r125",
      "r126",
      "r127",
      "r131",
      "r132",
      "r405",
      "r406",
      "r499",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per common share - diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.ardelyx.com/role/NetLossPerShareComputationofNetLossPerCommonShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r128",
      "r129",
      "r130",
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/NetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation and benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Stock-based Compensation [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r358"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized Compensation Expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansUnrecognizedStockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Average Remaining Vesting Period (Years)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansUnrecognizedStockBasedCompensationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansUnrecognizedStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r59",
      "r60",
      "r61",
      "r105",
      "r106",
      "r107",
      "r109",
      "r115",
      "r117",
      "r135",
      "r195",
      "r288",
      "r293",
      "r361",
      "r362",
      "r363",
      "r371",
      "r372",
      "r404",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r525",
      "r526",
      "r527",
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r408",
      "r409",
      "r410",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class [Domain]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r408",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r250",
      "r266",
      "r267",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r409",
      "r458",
      "r459",
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/DerivativeLiabilityNarrativeDetails",
      "http://www.ardelyx.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "auth_ref": [
      "r416",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of liability.",
        "label": "Liability Class [Axis]",
        "terseLabel": "Liability Class [Axis]"
       }
      }
     },
     "localname": "FairValueByLiabilityClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/DerivativeLiabilityChangesinFairValueDetails",
      "http://www.ardelyx.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r408",
      "r409",
      "r411",
      "r412",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r250",
      "r327",
      "r328",
      "r333",
      "r334",
      "r409",
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r250",
      "r266",
      "r267",
      "r327",
      "r328",
      "r333",
      "r334",
      "r409",
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r250",
      "r266",
      "r267",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r409",
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/DerivativeLiabilityNarrativeDetails",
      "http://www.ardelyx.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "auth_ref": [
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents classes of liabilities measured and disclosed at fair value.",
        "label": "Fair Value by Liability Class [Domain]",
        "terseLabel": "Fair Value by Liability Class [Domain]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/DerivativeLiabilityChangesinFairValueDetails",
      "http://www.ardelyx.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Change in Fair Value of Derivative Liability"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/DerivativeLiabilityChangesinFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/DerivativeLiabilityChangesinFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r413",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/DerivativeLiabilityChangesinFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r413",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Changes in Fair Value of Derivative Liability"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/DerivativeLiabilityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/OrganizationandBasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r414"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "terseLabel": "Changes in estimated fair value"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/DerivativeLiabilityChangesinFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases": {
     "auth_ref": [
      "r415"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases",
        "terseLabel": "2022 Exit Fee addition at fair value"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/DerivativeLiabilityChangesinFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r413"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Fair value of exit fee derivative liability, ending",
        "periodStartLabel": "Fair value of exit fee derivative liability, beginning"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/DerivativeLiabilityChangesinFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r250",
      "r266",
      "r267",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r458",
      "r459",
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/DerivativeLiabilityNarrativeDetails",
      "http://www.ardelyx.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r416",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r188",
      "r189",
      "r191",
      "r192",
      "r193",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r203",
      "r204",
      "r205",
      "r206",
      "r261",
      "r286",
      "r403",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GainLossOnDispositionOfAssets": {
     "auth_ref": [
      "r88",
      "r210",
      "r213"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property",
        "negatedTerseLabel": "Gain on sale of equipment"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnRestructuringOfDebt": {
     "auth_ref": [
      "r270"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For a debtor, the aggregate gain (loss) recognized on the restructuring of payables arises from the difference between the book value of the debt before the restructuring and the fair value of the payments on the debt after restructuring is complete.",
        "label": "Gains (Losses) on Restructuring of Debt",
        "negatedTerseLabel": "Debt refinancing costs"
       }
      }
     },
     "localname": "GainsLossesOnRestructuringOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r63",
      "r156",
      "r158",
      "r161",
      "r164",
      "r166",
      "r489",
      "r496",
      "r501",
      "r518"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before provision for income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r214",
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r100",
      "r116",
      "r117",
      "r155",
      "r370",
      "r373",
      "r374",
      "r519"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "verboseLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r91"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Cash paid for income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedTerseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Deferred Revenue",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDerivativeLiabilities": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).",
        "label": "Increase (Decrease) in Derivative Liabilities",
        "terseLabel": "Change in derivative liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInDerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Increase (Decrease) in Employee Related Liabilities",
        "terseLabel": "Accrued compensation and benefits"
       }
      }
     },
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedTerseLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r87",
      "r440"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r62",
      "r154",
      "r430",
      "r433",
      "r500"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r82",
      "r85",
      "r91"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/Inventory"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/InventoryDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Inventory, Finished Goods, Gross",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r3",
      "r44",
      "r451"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.ardelyx.com/role/InventoryDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS",
      "http://www.ardelyx.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Net [Abstract]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/InventoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r7",
      "r45",
      "r93",
      "r134",
      "r207",
      "r208",
      "r209",
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/OrganizationandBasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterials": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/InventoryDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Raw Materials, Gross",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterials",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcess": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/InventoryDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.",
        "label": "Inventory, Work in Process, Gross",
        "terseLabel": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcess",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsAndCash": {
     "auth_ref": [
      "r514"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails": {
       "order": 3.0,
       "parentTag": "ardx_InvestmentsAndCashAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of investments and unrestricted cash as of the balance sheet date.",
        "label": "Investments and Cash",
        "terseLabel": "Cash and investments",
        "verboseLabel": "Total cash equivalents and investments, Fair Value"
       }
      }
     },
     "localname": "InvestmentsAndCash",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails",
      "http://www.ardelyx.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Abstract]",
        "terseLabel": "Lease costs"
       }
      }
     },
     "localname": "LeaseCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesLeaseCostsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "verboseLabel": "Summary of Lease Costs"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseDescriptionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Description [Abstract]",
        "terseLabel": "Additional details"
       }
      }
     },
     "localname": "LesseeOperatingLeaseDescriptionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesAdditionalDetailsofFacilityLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "verboseLabel": "Summary of Undiscounted Cash Payment Obligations for Operating Lease Liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r445"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total undiscounted operating lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r445"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r445"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r445"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r445"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r445"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "Remainder of 2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r445"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Imputed interest expenses"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r33",
      "r99",
      "r160",
      "r194",
      "r224",
      "r225",
      "r226",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r382",
      "r385",
      "r386",
      "r421",
      "r449",
      "r450"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r23",
      "r99",
      "r194",
      "r421",
      "r451",
      "r493",
      "r511"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r35",
      "r99",
      "r194",
      "r224",
      "r225",
      "r226",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r382",
      "r385",
      "r386",
      "r421",
      "r449",
      "r450",
      "r451"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r408"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure",
        "terseLabel": "Liabilities, fair value"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities, Fair Value Disclosure [Abstract]"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseMember": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License [Member]",
        "terseLabel": "Licensing revenue"
       }
      }
     },
     "localname": "LicenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LoansPayableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing supported by a written promise to pay an obligation.",
        "label": "Loans Payable [Member]",
        "terseLabel": "Term Loan"
       }
      }
     },
     "localname": "LoansPayableMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LondonInterbankOfferedRateLIBORMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.",
        "label": "London Interbank Offered Rate (LIBOR) [Member]",
        "terseLabel": "LIBOR"
       }
      }
     },
     "localname": "LondonInterbankOfferedRateLIBORMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r13",
      "r249",
      "r265",
      "r266",
      "r267",
      "r492",
      "r508"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/BorrowingFuturePaymentObligationsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.ardelyx.com/role/BorrowingFuturePaymentObligationsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "totalLabel": "Long-term debt"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingFuturePaymentObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtByMaturityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term Debt, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Total repayment obligations"
       }
      }
     },
     "localname": "LongTermDebtByMaturityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingFuturePaymentObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/BorrowingFuturePaymentObligationsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      },
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Current Maturities",
        "negatedTerseLabel": "Less: Current portion of long-term debt",
        "terseLabel": "Current portion of long-term debt"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingFuturePaymentObligationsDetails",
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/BorrowingFuturePaymentObligationsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt, net of current portion"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingFuturePaymentObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r37",
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "auth_ref": [
      "r219"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss contingency liability.",
        "label": "Loss Contingency Accrual",
        "terseLabel": "Contingent liabilities"
       }
      }
     },
     "localname": "LossContingencyAccrualAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/ContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails",
      "http://www.ardelyx.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by (used in) financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r83",
      "r86",
      "r89"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r54",
      "r56",
      "r61",
      "r64",
      "r89",
      "r99",
      "r108",
      "r110",
      "r111",
      "r112",
      "r113",
      "r116",
      "r117",
      "r124",
      "r156",
      "r158",
      "r161",
      "r164",
      "r166",
      "r194",
      "r224",
      "r225",
      "r226",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r406",
      "r421",
      "r497",
      "r515"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS",
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.ardelyx.com/role/NetLossPerShareComputationofNetLossPerCommonShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/NetLossPerShareComputationofNetLossPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/OrganizationandBasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r156",
      "r158",
      "r161",
      "r164",
      "r166"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r439",
      "r446"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "verboseLabel": "Operating lease expense"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]",
        "verboseLabel": "Undiscounted cash payment obligations"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r437"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "totalLabel": "Total operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesAdditionalDetailsofFacilityLeasesDetails",
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r437"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "negatedTerseLabel": "Less: Current portion of operating lease liability",
        "terseLabel": "Current portion of lease liabilities",
        "verboseLabel": "Current portion of operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS",
      "http://www.ardelyx.com/role/LeasesAdditionalDetailsofFacilityLeasesDetails",
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r437"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liability, net of current portion",
        "verboseLabel": "Operating lease liability, net of current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS",
      "http://www.ardelyx.com/role/LeasesAdditionalDetailsofFacilityLeasesDetails",
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r438",
      "r440"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "verboseLabel": "Cash paid for operating lease"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r436"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use assets",
        "verboseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS",
      "http://www.ardelyx.com/role/LeasesAdditionalDetailsofFacilityLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Operating Lease, Right-of-Use Asset, Amortization Expense",
        "terseLabel": "Non-cash lease expense"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r443",
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "verboseLabel": "Weighted-average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesAdditionalDetailsofFacilityLeasesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r442",
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "verboseLabel": "Weighted-average remaining life (years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesAdditionalDetailsofFacilityLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r104",
      "r118",
      "r150",
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.",
        "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]",
        "terseLabel": "Organization and Basis of Presentation"
       }
      }
     },
     "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/OrganizationandBasisofPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r379",
      "r380",
      "r383"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.",
        "label": "Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Unrealized losses on available-for-sale securities",
        "verboseLabel": "Unrealized losses on available-for-sale securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale": {
     "auth_ref": [
      "r183"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other-than-temporary impairment (OTTI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized in earnings and other comprehensive loss (OCI).",
        "label": "Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale",
        "terseLabel": "Other-than-temporary impairment"
       }
      }
     },
     "localname": "OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireShortTermInvestments": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Payments to Acquire Short-term Investments",
        "negatedLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r340",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails",
      "http://www.ardelyx.com/role/EquityIncentivePlansUnrecognizedStockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails",
      "http://www.ardelyx.com/role/EquityIncentivePlansUnrecognizedStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r15",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r15",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r15",
      "r451"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.0001 par value; 5,000,000 shares authorized; no shares issued and outstanding as of March\u00a031, 2022 and December\u00a031, 2021, respectively."
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r5",
      "r27",
      "r28"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": {
     "auth_ref": [
      "r80"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.",
        "label": "Proceeds from Debt, Net of Issuance Costs",
        "terseLabel": "Proceeds from loan payable, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromDebtNetOfIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock in at the market offering, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS",
      "http://www.ardelyx.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSecuredDebt": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt.",
        "label": "Proceeds from Issuance of Secured Debt",
        "terseLabel": "Proceeds from 2022 Loan, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSecuredDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "auth_ref": [
      "r79",
      "r360"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.",
        "label": "Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised",
        "verboseLabel": "Proceeds from issuance of common stock under equity incentive and stock purchase plans"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLicenseFeesReceived": {
     "auth_ref": [
      "r84"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received from licensees for license fees during the current period.",
        "label": "Proceeds from License Fees Received",
        "terseLabel": "Upfront payment received"
       }
      }
     },
     "localname": "ProceedsFromLicenseFeesReceived",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r74",
      "r75",
      "r181"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-sale",
        "verboseLabel": "Proceeds from maturities and redemptions of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfMachineryAndEquipment": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from sale of machinery and equipment.",
        "label": "Proceeds from Sale of Machinery and Equipment",
        "terseLabel": "Proceeds from sale of equipment"
       }
      }
     },
     "localname": "ProceedsFromSaleOfMachineryAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockPlans": {
     "auth_ref": [
      "r79"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period.",
        "label": "Proceeds from Stock Plans",
        "terseLabel": "Proceeds from ESPP"
       }
      }
     },
     "localname": "ProceedsFromStockPlans",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product sales, net"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r9",
      "r10",
      "r212",
      "r451",
      "r503",
      "r512"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivableTypeDomain": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates.",
        "label": "Receivable [Domain]",
        "terseLabel": "Receivable [Domain]"
       }
      }
     },
     "localname": "ReceivableTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RepaymentsOfSecuredDebt": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to repay long-term debt that is wholly or partially secured by collateral. Excludes repayments of tax exempt secured debt.",
        "label": "Repayments of Secured Debt",
        "negatedTerseLabel": "Repayment of 2018 Loan, net of settlement costs"
       }
      }
     },
     "localname": "RepaymentsOfSecuredDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r369",
      "r487",
      "r537"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "RSUs"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails",
      "http://www.ardelyx.com/role/EquityIncentivePlansUnrecognizedStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r19",
      "r293",
      "r364",
      "r451",
      "r510",
      "r528",
      "r530"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS",
      "http://www.ardelyx.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r105",
      "r106",
      "r107",
      "r109",
      "r115",
      "r117",
      "r195",
      "r361",
      "r362",
      "r363",
      "r371",
      "r372",
      "r404",
      "r525",
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r152",
      "r153",
      "r157",
      "r162",
      "r163",
      "r167",
      "r168",
      "r169",
      "r313",
      "r314",
      "r488"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Total revenues",
        "verboseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails",
      "http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r94",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Product Sales, Net and Reserves for Variable Consideration"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/OrganizationandBasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r316",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Product Revenue, Net"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/ProductRevenueNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r441",
      "r446"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use assets obtained in exchange for lease obligations"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SalesRevenueProductLineMember": {
     "auth_ref": [
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from specified product or service, when it serves as benchmark in concentration of risk calculation. Includes, but is not limited to, revenue from contract with customer and other sources.",
        "label": "Revenue, Product and Service Benchmark [Member]",
        "terseLabel": "Gross product revenue"
       }
      }
     },
     "localname": "SalesRevenueProductLineMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments.",
        "label": "Cash, Cash Equivalents and Investments [Table Text Block]",
        "terseLabel": "Schedule of Securities Classified as Cash, Cash Equivalents and Investments"
       }
      }
     },
     "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails",
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails",
      "http://www.ardelyx.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "verboseLabel": "Schedule of Computation of Net Loss Per Common Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/NetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r339",
      "r356",
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r339",
      "r356",
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Summary of Stock-Based Compensation Expense Recognized"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r408",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Summary of Fair Value of Financial Assets and Liabilities Measured or Disclosed on a Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r7",
      "r24",
      "r25",
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/InventoryTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-term Debt [Table Text Block]",
        "terseLabel": "Schedule of Future Debt Payment Obligations"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.",
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "terseLabel": "Schedule of Restricted Stock Units Activity"
       }
      }
     },
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r340",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails",
      "http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails",
      "http://www.ardelyx.com/role/EquityIncentivePlansUnrecognizedStockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r342",
      "r353",
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock": {
     "auth_ref": [
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost not yet recognized and weighted-average period over which cost is expected to be recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost [Table Text Block]",
        "terseLabel": "Summary of Total Unrecognized Stock-Based Compensation Expense, Net of Estimated Forfeitures"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedTerseLabel": "Forfeited (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Outstanding balance, ending (shares)",
        "periodStartLabel": "Outstanding balance, beginning (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number\u00a0of RSUs"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Outstanding balance, ending (in dollars per share)",
        "periodStartLabel": "Outstanding balance, beginning (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted-Average Grant\u00a0Date\u00a0Fair Value Per\u00a0Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedTerseLabel": "Vested (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails",
      "http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails",
      "http://www.ardelyx.com/role/EquityIncentivePlansUnrecognizedStockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Options exercisable (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Options exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedTerseLabel": "Options forfeited (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Options granted (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r344",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Options outstanding balance, ending (shares)",
        "periodStartLabel": "Options outstanding balance, beginning (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number\u00a0of\u00a0Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Options outstanding balance, ending (in dollars per share)",
        "periodStartLabel": "Options outstanding balance, beginning (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted-Average Exercise\u00a0Price\u00a0per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r338",
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails",
      "http://www.ardelyx.com/role/EquityIncentivePlansUnrecognizedStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Options exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Options forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Options granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (shares)",
        "periodStartLabel": "Beginning balance (shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r14",
      "r15",
      "r16",
      "r96",
      "r99",
      "r121",
      "r122",
      "r123",
      "r125",
      "r127",
      "r136",
      "r137",
      "r138",
      "r194",
      "r224",
      "r228",
      "r229",
      "r230",
      "r233",
      "r234",
      "r272",
      "r273",
      "r277",
      "r281",
      "r288",
      "r421",
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r39",
      "r59",
      "r60",
      "r61",
      "r105",
      "r106",
      "r107",
      "r109",
      "r115",
      "r117",
      "r135",
      "r195",
      "r288",
      "r293",
      "r361",
      "r362",
      "r363",
      "r371",
      "r372",
      "r404",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r525",
      "r526",
      "r527",
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r105",
      "r106",
      "r107",
      "r135",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r15",
      "r16",
      "r288",
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Issuance of common stock under employee stock purchase plan (shares)",
        "verboseLabel": "Number of shares issued under ESPP"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "terseLabel": "Issuance of common stock for services (shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r15",
      "r16",
      "r288",
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock in at the market offering (shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.ardelyx.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r15",
      "r16",
      "r288",
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "verboseLabel": "Issuance of common stock upon vesting of restricted stock units (shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r15",
      "r16",
      "r288",
      "r293",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Options exercised (shares)",
        "terseLabel": "Issuance of common stock upon exercise of options (shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r15",
      "r16",
      "r288",
      "r293"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuance of common stock under employee stock purchase plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r15",
      "r16",
      "r288",
      "r293"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock in at the market offering"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r39",
      "r288",
      "r293"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Issuance of common stock upon exercise of options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r16",
      "r21",
      "r22",
      "r99",
      "r178",
      "r194",
      "r421",
      "r451"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS",
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]",
        "terseLabel": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r97",
      "r273",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r287",
      "r293",
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r429",
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails",
      "http://www.ardelyx.com/role/StockholdersEquityDetails",
      "http://www.ardelyx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r429",
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r429",
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails",
      "http://www.ardelyx.com/role/StockholdersEquityDetails",
      "http://www.ardelyx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r429",
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails",
      "http://www.ardelyx.com/role/StockholdersEquityDetails",
      "http://www.ardelyx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r452",
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]",
        "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "terseLabel": "Subsidiary, Sale of Stock [Line Items]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplementary disclosure of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "auth_ref": [
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for accounts receivable.",
        "label": "Accounts Receivable [Policy Text Block]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/OrganizationandBasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r188",
      "r189",
      "r191",
      "r192",
      "r193",
      "r261",
      "r286",
      "r403",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails",
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails",
      "http://www.ardelyx.com/role/OrganizationandBasisofPresentationDetails",
      "http://www.ardelyx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember": {
     "auth_ref": [
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt issued by US Government Corporations and Agencies. Investments in such US Government Corporations may include debt securities issued by the Government National Mortgage Association (Ginnie Mae) and by the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac).",
        "label": "US Government Corporations and Agencies Securities [Member]",
        "terseLabel": "U.S. government-sponsored agency bonds"
       }
      }
     },
     "localname": "USGovernmentCorporationsAndAgenciesSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails",
      "http://www.ardelyx.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r139",
      "r140",
      "r141",
      "r142",
      "r147",
      "r148",
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/OrganizationandBasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r120",
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average common shares outstanding - diluted",
        "verboseLabel": "Shares used in computing net loss per share - diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.ardelyx.com/role/NetLossPerShareComputationofNetLossPerCommonShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r119",
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average common shares outstanding - basic",
        "verboseLabel": "Shares used in computing net loss per share - basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.ardelyx.com/role/NetLossPerShareComputationofNetLossPerCommonShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/NetLossPerShareComputationofNetLossPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 9
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "http://asc.fasb.org/topic&trid=2122394"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e543-108305"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=SL6284422-111562"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2443-110228"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6402221&loc=d3e15743-112638"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "705",
   "URI": "http://asc.fasb.org/topic&trid=2122478"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41641-113959"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "815",
   "URI": "http://asc.fasb.org/topic&trid=2229140"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "e",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1,2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r538": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r539": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r540": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r541": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r542": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r543": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r544": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r545": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r546": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r547": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r548": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r549": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r550": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3151-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>77
<FILENAME>0001628280-22-012630-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-22-012630-xbrl.zip
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M"=@8YWR0S!&G*#%<.:YX6O/,]?P3IWX0;WK4XU$Y3$D,7@6FM-', ##'1(?
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M3*7T4;% HO'PUW*42F@BH^Y%TO_1M/'LZ8V1PMHAHHD'>L<(&,HY;:4R*'4
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M59A%%;42!@O$D.91DWE>55P76DUQ]:G"G%"+,):412$LM40IC5-'@%324.G
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M3<+\U[U>H=;[W-B\ X,K-\:Y":\FK/0V[YE>*MBXY*G!Y,J\-EN#,N/!<O/
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M;%J<?,;4 4XR(>/1@+(F K"L#C'#"BE+O'#4FJ4WDO$, WUJIZ\OTU+_\P]
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M+0M6,#&:.39YIPP]C&E0R4L*/HS&T;0J[E+&%L8S5+)3DH4!V/5>LE;':6C
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M2UY@)*,RVD<,+--8TJ1FCJ5094.#C$4Y[ZN<L^="M66): 6$I<V).D$BIY5
MRCOJE G><)VWP@8I9ZU-.U:@?5@:=9YQ>]0ZL=V NKV6MR?=D3TJY1R7WBKL
M8NY?I:G?[;V83/PE%"KU5NI#I_D^851RK%Q.>Q8*$'?&(>W3/SDGR29TCD9"
M-S8U%FTJYTEZ25):&X6NK5-84>B'5>C9#AS8"L*%0"RR9'D'D56;8Y2$1P%+
M8H27&YO*B'9ZMT$*76LAQQ7@'-Z/C\='.7,CJ5/L^N[=:D>OKFWSCP=A&\/T
MG.G5+$J]@9%-(PH[=M!+\S:\)([MB30*2M6'4O,=PJS6F@O%D3(D&44!''**
M6L0E<R"\)2!50BE.VM?EQ,Q5$BL>BU74ZKM3CJ+5S=#JV:1I2IA)^HN29E/$
MO;)(*TD0"4F>&GB@-":M)K1MV#SW>!2M?FJNCDNT8]H@O7]\,H!#Z V[7Z%U
MU!_>JUGIFB-6[3SDDCRJ;LHO+DMCMY>$ W\ED71@M!\/[/>"4 LAU'Q7+Z,P
M5=Q))(SSB&N#D>&2(TFT$,0 <\YO;.KY.M*W!Z?BY&BP M=..8H"+UF!9RB&
M!\6HQAZ!<+E+18C(9%5.\@/BA,;6YOK0S=#?.GT:JN',8M*;8GACC<^EM*I8
M_P+V=<59+A=?W:D$4DRA^G#J]1S1B$$114(R@+!3B"L7<Z]!@T0,(LE4&6*3
M*21YFYA[>V$7U9(5\H \8<VO*R!3-'_)FC^;[X$E<\0+1*$J*84QTCG'-N(D
M-V:#9$(D$X.V);EW(ZV'TOPZO22K060N-=FJ$DAO3VQNV2!@\HS/69J5T!^[
M([@0V/TPKW'S^9^/.$%KLQDLH6G95B^4K6&96\-\VU2'L0*6K%6JE$8<1X)L
M+@BGB,>8>\ZBRJF U+0YOG<KL]JUZ9&]6 57"ZXVEF077'U07)UU"D8>!%82
MJ23/28=(Y[1'*H$JMMEAF&LA$F[:YOYYUHW!U8J4_S:RZ4?/SRQ=JL9T; >?
MNKW)S].K4.8A:<!@\DZW%]*_GA/]&,6::,6W#Z%E?0Y#VMYI/LG5ZX\RZ1ZD
MMWNM;AKJIT&5F3T8Y1->HT,80E;B-.XAA%;L]FS/=RO?HQU!U=MJYB37I5F9
M_C*GDU#M27]8)2L^'\"1S:? ?O_6#:/#<QRY],6IG/&/KUB71#H>W?R5N1E_
MI FF,^?:+OW-HZT01Q'BB&4&DO'*'1'.*:N21DE&%>7*?B15[ZKJ2X>#'Q6_
M/@%R [!?D(WI 9_;HV_V=+CQV]65F);AS+S?-&4_6;2?Q\-1-Y[>/(<Q+FT.
M)^-(:-T?V$KV"0Y@D*]*P[&-&4OK<) WM?_XM3154KN,&UFA<A>XK#3_^LUN
M7K=2'G5%JVM7]-:;[9V_WO]/>X+<NYT7-RM\4X;\8K^SO=-YN[/=>GNP=;"S
MM],Y>-O:?]G:?[7S9NM@=[_SMK75V6Z]V-][]6;GO]*5N_^]T_IK_^W;QC_9
M/][U[#AT1Q#^V?RQ=GMI ^F/TSW"L-V"[Q[RUGPXV6Q"ZP0&Y_\Z3GO^:+C8
M(U5[\8\=H]K_TZ,=V9,A/#]_\7OH#D^.[.GS;J\:8/6EWZ?(-]UF,D;.[/W5
M[TT^GL*G)L^$TAE!IYZYZ0]/P?59!:XS=&;RF93/-"4W?HR?W?S9SVY+^#-N
M[G;;GW\FC5S.8.EM;WN- 7LNQD0EH1E7_L)+^\MXC)F[]!H[>$H>'\3>T[]2
MZHG#-FU[T-I+UQT.6SMI-PR3,@ M1MJW:"SYN'-^R2&R@+W0;(%D5^1M.GK>
MYH&?VL21I:_81]""M6AR_@:^0F\,P[LUJ_U5=^A?K-7F.=DFW/MZWTFM28ME
M5A]?OY>(!"N<\O9JT ]CG]:;/8)D3?1@[@C?O0_X-.Z9;Q]UN.X1FZU\"\0-
MC(*HA:).>N#$8^-UE#EPH"WV%N./VU4\EF"";A>8G>XN+P?]X^R0R4/XNSLZ
M?#$>IOF P<YW?S3.\[@U'$+Z7VA2+O'^V_.PP=ZW#\>[?/_//=&A[_G[SZ]I
M)__&W^_QA\]_'.\?O#[[\'DW__]'V.#XM?BPO24ZVWE\.^3#01Z;%WO;;[[L
M'7>Z[VGG>.]L)XWA'9L-&WS8/OJRM_T%[WU^>9B>YZCSY^[WSMF7;YT_7Y^^
MI__^_)ZFYTK/VSD(\2)D\!:?[F^__[;_^B.F'&MI-')54^F &7+>>42\E""B
MP)CJC4TNZLK/:U *7L&E-<4EH33S7G$JG>6"12,C 0781JT<MK+")7*.2V1)
MN-3PGC0K@E=GE_#JK//IHU?!8AXCLB!S,>T@D/8A(L!$@<*21"9K:TFS=,Q:
M ^JZPDF.%]1U?')R=-H:3+3\B9W\7 !7 S'<1V"Y$13WRFL>18B!1U!!4Z,*
MWVL8?G9>7/"]LS1VVOGVD8"/!$N%%&B%.(7$_+AA*&$HEL((HP'JJ))9#H V
M5X]-U-8J(610DJL0-/9!F<3U'<.!4/LP_*CH\2)Z?#:CQYY:PKCG"'M!$,><
M(!>M0(1"$"K1(,="SJ*=/P3:-$5> PZTPNZ[O[H^']/N?;H7_5G=4CT+P";W
M.MK@G;)"<R>=)DHQB#)2SK%BO-"?YL'F#_ISL'>V]^VCH=I3[RS2U%O$@Q3(
M).Z**)AD/FH7"8\;FZ5&^!JKL5*&2J^ TVBXHDH+'@)5U  G)BGNPWN'FIH)
MOR(Z?C:CXTFPT1OMD&*"YU/G$EF1F!(A6'MC.0N:;6R*-L:T\7J^!N1HA1U$
M+W*VHJMRC+]"PH"O<-0_R<GUQ5?T2Y35(C@G02=#DP>05EFK'7:<^2 "/!!9
M*C[X6F.&>V=;WQ/ 2J,8HR:@Q(<IXEI*9')'!Z(51 !)G3--; M?'$EU.X2E
M,\Q(P33/2AZ-UY:F=XQ/UE' K%"I%=/TLQE-Q^"HI8E*::EC+C3FD\Y'0"%$
M;D$G>6N^L4G:2?R-U_,UH%(_J_;.&LZE)A5%IKSI;N55?U7H9<W1-D8B7,+:
MX"+E BO-B</$9;2U@E%1_$\- ]1.=XXZ:2LE9<D8%0SGXM!.(XLE1DI39Q73
M&H/8V.3RWH4O%M*5%?)-/5GEE]([DZPJC3''C*=U1&*RHSAWE%B."]5:,628
MI5K&"$>D)0@;11!742.-B49"6V%<$FE4"1ED6^BZO%:/@0UK0,)6\-3._@ED
M'U;O4PN^G^2*$4LZOU/+.9:EGH59Y.YKL%97.##]HC^L2IV4L/1#FP5YYO?C
ME!^4;7V!;7W_Q1SA]Y1%+ Q'6FN'N# R$7YL$7BO&*%*66DW-O6]NTJ6B'.#
M-;1N[CZCH865UZ:^LZP\@* NUZG4F +B1O*<+IM[Q/I -36>!IP=H&FM-5Z#
MUX#/K' L^0T,H2K(D4OL7 HEEQ#R _H[)R+8ZH7M'P+8F9A$!49K@]&W\RS(
M8^\I8<@937+$6"!-TA]G0U1I+0MI>&)!;2WF^UPV+8Y4XL7-(4)%HQ]*HV>)
M410X2.HY@L@$XI0EW1;6("8E)E2#--+G6CYM+LH1A.+I^1F O(6C].:G=NL3
M]"!7N<T,R8;C;J\['$UR[XKWY\%(TE0:?TYDD8!UZXHD"K;6G75SL#77(D&(
MB+5*D,HP]HA[2I&ATB"PDDHGM05FD]5IVHR9QIN=Q7'4'+Y4E/L1E'NV-98-
M3!O"D50^V4*.$*2YBD@2ZXC@UGJ6Z_2K-F'W-H:*3^E>/J452:KKSX5W[^-4
M>K(9-LN(H^5&*%-4'198K0]6=^8XD\126,)M(DE6(BZI198XCG045&AM,+<)
M(ZAN4W7O8-M"FK)"WJ<GJ_K+"- 5U5^:ZL\P*F.5S<XHY*W/IQ2H0Q8KA2#B
MA.A!1Z_4QB;3;:'OW6ST$55_#;C6"GNI_NH/AZTXZ!^?TZU^KYQB.)^<?SPL
MSQJF!TZO9E'W(LUQM^?[QY E5H"W/N#=G>-<261*,:&0-HEX<9 .F5Q;C+B@
M+43IB7>)<ZFVQO/ ^\]5R%<N9QF6 @'WYUL% AX) F:X%V6**RPM4LSDKI.,
M(>NP0"8J*R--8K4\<2_:QGC>[%H)"%@#VK7":5.[N3T-#$?GKJTGEB[UP,3J
M*IB>S_U%6*!@Y0)8N3='EX@!R],NAUQP$G%E-=*.8\0Q&&I$P$E2&YN*SR=,
MW!XH2_I3DS6T;C_3G(86JE.C^LY0'6T\ 24# FM(HCJ2(UT=V"26D)B$I7TN
MG=PFU^2"-TB!UX#/K+ ;:7]T"(-6M[).6O^8DII_7MLWJ>1!+(W9=/J]_E5+
ML7"<NX#DZSF.8YER!@)%@3I 7#B/7$X3U5(((B"P(-7&)M>EQ.JJZ6LS'#Q%
M<VO3W!EZ$Y)!(ID"Q"+) 71+D68A(&.P"38QG:A)TMSYA,.%O3B%VZQ7>8DJ
M-.8@V1[0.AGTOW:'&1[2/\]YSLA^+SE)#0N6_7"0GY< ZO;&:2;W+Z*;?U02
MG5QWD"6X\WTTL$D2W9X=G.Z.X'B8T#@/=]"OTDK/K=%BAM:'T^_F&):R0L;
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M!Z^OCCT>V.^O^H/\ %NCT:#KQE4;]X/^J\3L>Z/"PQ>IMGFP-=J?X>$^!BV
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M%91KTH,O5B[+Q4S4C+&,*\\T<*ZB"1$8<XSSFV&NE,MZ#+QC,WA'-<,!*X6
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MRA"HL+<@YS<TW*@:QE_I%3]I$[]USB(2B<@<XNT%A?C!ZZLC40?V^ZO^(#_
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M)E=R\^I+S[DQ2>^:/+UF3Q[%E-Y8\F7!!WYJ$T<665UK43AH_P0R\4I&3,Z
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M4F]L$FEJ*LS2H,I416.7QAB*QM:GL;,,PD2+B1$1!6LIXL)1Y+#'R%#G<YU
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MH4EB^S0=+&2QY5%M@BX7OZ56_/I-M79ES8H@#(T,E6=G2=BN)?9-4><LY']
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M^-FMS"^>)OAE6G.!V06E>V#XJ]R:(EG-+L'<O7ZSK:'7-&M6VJ1\6\P]<OF
M[1(3:D_8W@((G_4R?[W4PVQ%#GMP]Z@T.6/UJ!<S#\Y/A2^_ , /I^,&>4&.
M/T<0*$#T' %JK20,7R94X_'TJ#Z^NXD6+;PZ]GLP0*U-R"<*#0=E$:TEH<#S
M>B,_/8)9A=>/@:K" !725!L37ZQM;G0>UG[>:PO" M _&AXUDS/KU14VX'Z"
MS;][H%3 )4X> ,IL%^IZ#KL ^AR!T8?Y.8:] 8C-9.82V>/CT?!;F6:0@?_[
M\\N3B[,U$68-VAZ4LKO7J[4K'QD=6 C#X9W]@V] #7R2W!+)41):(YYKYQJ2
M*,+$>J6<9IJ+C6?:;%U4/!Q$L5]0[>]8^WT A.!299>O#8U6_>$XP]RXEU$L
M_RB05.,9D&B V^G1M$;Q$ '$>I/B'9XKCCG*]VMD[(*#W-[$>K_;2SO*QT:-
MM^>M?U$WOA.^:PC?R>[7CYAX2[%@"!B]0MPD []I@D**CMEDC3:Q5(S<NF@_
MVTSZ]D".BMR!9>OG /"LA/ R8MG^<!"S%&6/:3Q-><I:-I374K)$'O<!26?>
MT0"$J9I\C?TO,U\L#?O@J-<D))[:&E7G<YV;Q=4$3S+/&(Z 1MF\*#Z>NFQ?
M)_G:G'F;@R$'=E0(3E&.>N=D;EZ[<I>5PU8U<8+/?!P-:G=LYGZE*O>Q>'*-
M,;Y^(T&/<_?S"VT(HQQGS^V8:_.\,/.IX%@AG,.%:3AO]#?K3^NP7?% <_/&
MME_'Z%[]S]LW+_^]O5E/PC#G\?3J*$WL'9=TN3Q2OG=<[H7)A^<.\U)8>4QY
M.4R,=4TN44FR@S>--Y>',D<+Q_5R 3@]V> W1 HNA=&%N>[G?\'_'DX/ZJA!
M[ZBM*M+RR]*5$I(9?:D_G%<5J>EHF.;Q'F54 UZ4U_V _,*%.;0$C*TXV=?*
MM[F"+#S[IQO]?G$2\?JRCOV2(E+'+PI;'16J69/5/&<Q@637@8N9=EY#%&'Z
M7-:M,LUIVM^J7J4KA7-QYN<H<*,WMY&8T[B2@%$O!!4SI8>IS_&1VE68/W]>
M7*36Z$FI.C)9)0S5NM!OJ>OFPD4Y ->;F>;9,AO0N^Q>+ SL N>O_<-Y:/@&
M >%E#&OBPO#J,"RCV$9L<YQI,3[;Q.87<XW*VGA9 F^U\WQ'K76#3G(WYE/2
M>++989S4EWS-R##(8@GVXB".+D/?K>H6#L#:>#-OIT='>2Q@[-XNY!/,UR:K
M-D'H ;@[F2\L9DTL+B\UO2S*'$JNE*N#';M@D2J2Q:^8D\O"R"UW2+U,]ZHK
MX[^;-P@MUVSGJM;?-(;<'R^$M_.-LR=ENS4=YSB&BS7BS2(NS8O'M8G^DL,'
MFP52!T!Q3C;;$$RS#C\N)OQL)& QC>G1I[>K;O=+EZE^<8+?E0E[2PE^00OO
M.1,$"\,3T\#IB2'&\V1=<MJL3Z3_4JUH@22CVCRAITW:J3T(\%W:);XZ+[EA
M G4HLF0?UPBV68>A%VC)8#CC-(M+ML/K6(FR+/LEAV3[LW*#-UDAO+:-..LI
M7,S^?^ZBVO[(AK@]"'MY'!N",'XS,P%U^M)CBV]\?R7V7KS[OOOB\_>]%Y[N
M;7^$,94N"8>D80QQ(@72"E,D;%2*<:LQ5>>MN]W1+I36EL\G\@$0O>VS#"4'
M?V9K6(-8QQ6R(U7[GEDMP4V?CIK\C=%!S!NK&S^C63'*.EWR>*=U%!S\^YH1
MU4[F&-A''(UKIM8N@K3Y0[-WE5>5H ^XJ',N!<VKEXV*(]:NA,W #!YPT)Q7
MGU\V[U>.,&7%7.RJL_VZ5YG,?AWE+)[\&.CP@>T-&L]RWJ"OA_!U;Y*; -#J
MRB.*.U2G1,P>6QS![**Y6$(NK0LXK )TM%DR^)+I\R3G-@T*I<RKB8/K]#X_
MN$U/*@E2%X2"F^#QF?EM.IT?E5?>1KTRF.E&<6-.(T^2!D>,Y8QY(S1Q8"M\
M,EBJR*Z[-G$6'7?CY'D=A>@"Q5<$BMG.=_C]]4?MHC/<1P2&*R(NN44ZGU1M
MDZ#4:\*QH!O/V-9%)](W8>+SPH0Y$IL5^R:R$4Q,P4E.DN,<1V;@7Z&Q#5XG
M$5CJ9./7R,;+[SO;'['!CH)F(B>I19Q9$ L=%-*"*"O!*!"--Y[A+7D=V5B@
ME@L@7B/0^:3L2A#Z:F^!0@$3A9,+%CL%7(T;8/Q2>1.$<M$K41]<2F@G:3]7
MTG;P[M>/+.D BA^0P(1F21/(11$ BK!)%$P%%B)+VD7UKBY'H3O-DGO5AFP>
M]\Z#W1<[P.&W\>ZG=V3WQ;L3,#U<")H XI$#AQF!H9'Y?&V,>*1",QEDP'A=
M<^<NI?NS*7\ )/\_HU[VI=N4_9(H#SVK4U. /I?JEJ/IP2Q> -Y\R!ME<^;6
MUX6<A;(T,UZ(GLX3P^*9AQ1&6R=!S=8J^V5AP7ZQO7Y-GH?5>'I<?/^RV#BW
M+WT['?C#EL7/=A_E]5<7#^H%V&9MLMX0V$Q7B:/FL,-X",^9M#L,FZ73*M0I
M;"6N  ^&;_X[M>#IC/*;ZDAS(?GYI;T2?ZJ7EA<W'[;/RJ8+G!?H2&]\""\J
MF[J;3H!I"Z?2$ML1.[>+LX7=.A4_/[AU-?+ORVY"G?O>=C@G']FY/])D%D?
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M?RGU+=K.+LP1#-G!:)BKX)0Y;8L?Y$8Z&)/3PKLPZB6$L"#!^4&-/U=G8N=
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M=HC4.Q,$X%YCQPA#C/F >)0<:6TLLB1(3#P),9^_Q#>-,6L4EUS1NDFGR[]
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MD#0R1FLPXDZB'"D -R,DQ8(+(=CL9CRH=(H'KLUKH,Q=S.#7Q@QJ978^<I^
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MI]"=0E^IT%T4X*Y4>CD*8)6F@BJ-?'(Q5R#%R-%<4BA83EEP%-1]#2GW%6&
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M*&$FF8AMBKHFY+<^M+S;7;K^5SZF[*;M\3A.JMRE"%([PYO;;()\V,AO([.
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MH M5W 8+ED,5$NM<G3PA$CU'W'"!-&88.<9S=#)P6U) ;Y\]TL' ^L/ &J!
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MF+((E@GE&0.CQ@-R@D=D@TI!>\V"SS6%B=CD3*YH'>!Z&K+F.XL[C'M$&.=
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M?1"0\U2GV37]7A\4T$C@8[-NXN2;"*C#\'PEW$>T#U]^[TTWE6A&*;M6>PK
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MK=O6/"N?H@WP6IG3 G:1G)NTAEG;"793!-ILUD/@FHYM.XX:NMP'"PQK:N/
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MK:-; =@*P&D@+\]CML5C&WMJ\##T;#/P==T++<L)?,NYJ5JT%8#/+P!_30E
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MC U5BT '<<?1>6Q@FP;7>&"O_@$X:SWBGJV,;67L$C+6<<+ =SW;T[!)BL6
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M(R/V[+%L "R4%Y;NBJ#Q& <E5^Q='?SX)SD\/?P!5'WU]=<G_>ATVSK8_98
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M-[M2&OQ.!_"7B5!F5=<4>2<%:1KF?.T+4G)9.LP2/L+>N5$V/BMI:B*O1HI
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MD*'%R:Z4L>@(3$3<H&[$8/0>9A$JP1BF.L?VNSVK/3]?[0^D=J[.,8HNP/(
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M=7%=0]85B?@M4.HR0*DO5WK7XU.W=C 6>),/%@:AV!@^C2 $YH9"7JQY)T-
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M_3\WFET8#TW;1?);SOHETXFD*T'20OX7G-JPFHLT"9%-UJC1JB7)UIF<.*Q
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M$.]*!.Y?#-_"0/X[9AFL/EZ.=?1=9>X&+4H5O\,&2>P^N1]I'Q\D1HQS#?B
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MPO:7!K6#)?:9'(*T2"RP^"_J&VO6[(NF]>/IGO-G/"CYXX/OYB))J5G\\Z:
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M3M+3I2B<2U;XS,ZB/"$(C>LZIF7.$3H&R!6#" O]W\F+_WET\'BW;C>H)8.
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M+N32#Z"TLPVU5V1M+<K%K\"4[)8U[T!8R!%K&:\&M$N@.R>V_P>S!(49+?E
MD93L.2BO'D)?X?X7?65ZOAD9 5I.06V$ZD\8_%A]'#SZ-Y)'[:8)Q29S,ZI)
MO!D7/2W6(JL&#%^1&@%CV(Q.AX;%7-J;9!-Z*;>T4[7&I>;"UA;.#L?GVDQZ
MM;8)C,M>Z+_@LM"'?QU]K#;/^VN>Z](DF'U8WUEGQ'\;'-K#H\PU#A,U-BG
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M9326QDS7(I#L<)0M5&PSF_'2L=2)G]>A324O?(!0*.M+7F9^,??4;M$0J/3
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M,D9@VF@H5GO'GK4HQ(U;?7Y0VS1J(BLHL_>:U3;;!<G0" =+JM,U#]=-!"2
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MK",82" 8&RFF-'Q\J)O=B)G-.!AP&C<I<ND+1HD*-9?86T#G*"T:XU,[SH_
M\_;IWON4?,1NM<D"9K3JFB'T<#S".P:A'*]#^_W0S^M1EV^0,WC<)ZN0D9'?
MIQ877\2*CY!["#R""7<BK>G.A[#@DI-"KN<Z2A;[=EHXS=T:%8R@*7V_G UX
M[A_U.>] (EZY7AH'Z:"91L0AY.AF?$WEQ:6>?\0(CZ;31MZE2$<NQ+3JSGG6
M;;3PD*.-EF+5YW&,6?J%J9Z=T)#.I+X37_&>&20?;[:%Q7&X0!J:3^\9T+@5
M3LNHK-.M/!#XK[S!5(.R:*^9[9T4')'[N%X6R9$KK36^H)?R:+U(R=]#6J5W
M9"[@N-<UL@)76Q%>-C(WN'(7Z_:J:1>@;"J[94_'XHDOC@4+.)C+[=6O7IR<
MA&]Z08N_L%=)'AZ7\#S,FFG?25N'O%C0F83645&W"]H;63 0E6M(B"9,"VT8
M-39SV]=J%C;>>A?T@'D2</Z'E$XHU&6Y9>:C^)Z#[X.;@DFK!^Q4>(9GIW*,
M<E>D<TJO3A"EG<"DC8&G\S^_A*5*ON_G%[)(]F='P*7(9ML55V"1NCX%E.LP
M099?*ZPZV7E6LDS,^I9-72"#!:"CXPW4QVING=#=I&^M0]_G>P7=W$4Y_(AT
MS K#E:D_['6"MB9AUY@&J!#CS[KLY4..G1U&-\3H?K?#Z.XPNG< W3DNGD.3
M?,M>_R+9YNZ35QA6?URSC&YSX?X(_T\J;YCR3'Q!$'J$;4^9;US!U][5UQSJ
MU8FNKL-'=]]@J$%]SS:!N,0OO)PWT,N<!;L&=(1;1.%V)""-N\!: <)X5.D*
M9:F_HXUN'$\-X;OVG!U\]_[E).X6?'<3LTO+/8\B_CM&G5O%-=&20,-;2*G0
M)88KD:.^?!80,(15O"%!K.D;'!>PJ%HI:.$<YR5J.=;$ 3^#4X+NI;Z<>"<K
MMR8K5R$BH..&K$_D;-H"5!1YV7'INHO(?3AQ$9JOC[!@A[KZ,E!7NW/G=C 3
M48[:L3%TC)I( P MTYX45;4G& KUS9W3Z+8PTOJ9%++U-:,OF;4O(&Z@'2S;
MFTDI.I!@:[-NSL$$AQE2'G).:2S=8P]^Q[AW(G:K]4GT#IQ%5X*?N'55Z>(.
M.,5G1G<8@UT,FZB+TX8$1/N26=OHK$6I.A^,'L(O=!P+;^+0Q7DY8^ 9_:OI
ME 6E*\A6A]GM+9Y= =17ANDV0;LVIGLG!S>K2WRDQM<W:OKYVB6.MNB[$L>[
ML+(W!O_>69IW;X%O#/Y]RU!OSMWNI.DVL=X^JK^!];Y.J. .YP[#JH:_# CF
M-OF50RY$V,I"G(3<>5>V,JF1J]X*&-"Q.$'+>C;X@$QQ>T(DB"M>*X5W5U)Q
M_]@V.3QW[!A?M 8;Y),ZY9V JD?I&)DK%IVP^N4*BK#*UK(4U7"B U<JFF<'
MYV0WO>'NY<R:91$9-)<0OZDM%+^&0Q,M#3.Z^O#?A@A\_<8]-H>+/ X&9!HU
MG-+\P$L_Y8N4/W)99=-BTAAH;G7>.%"B8A$E#U;\!S+0;3LO,IK)2=XL2HU@
MDC(6-.",)JOWH::\_->_.!>XG[R@8Z!<%9H0)&=AR? Z[P!&R;YAU8.XFC:3
MH[!)NONTS1:A+9DFF^&OO[ /Z2-@4B#1&']N+$ L#Y*^Y-D/BQ_L\$1#MP!_
M2RZO^3RU4#H"_2%/XA!HD%7<Y1&_T/-NBUJ PH;-D[?9N9+8A5B>,('#4CC(
MZNQLX!O.W/"^S\;[)5IQ5 BJ(;T%//9NR6ZSU8EQN)-:IM-)STA=K')![HG@
MQ'V"/0#Y<J^<::]^BFU$378%S7:TSU3AB22"RZW'2E-+.1;Y1LULB!7AD91V
M8&7,[CA$;+^EOY_*CQ\ :"^"7L(G+]]^<&E "=#;:<3RF(#QVC_^;>'8I/\&
M0F1ATU1.FVSZ"6&7DLXC\&OVJTJB-%SYP:R35DT8G7Y,=%]BDB>"X ?^08V*
ME+<-)Q7TM61$\!4%31/"/F0D5*OY%"E(!4VTSMKD=*;BVF4$J53[H=BATY.X
MJ*15.@?_@*,4?R)A(M%(F:8*8.RDTY86X9UBZ.I\M$&8"I3F?%C;[($<>4H?
M6>S"3'=2 P?5K#/A^2[K7_M:=[[NSWB_3<NSDAEE:5W%2%TBV8Y#>OL2WTO\
M_/<[_/P./[]3=K?L--BA+N16N=-C-8V&T65<K(N&-@LY??V!I_;"A'SX3\FD
M^6P]+LZSEH\\U:\UGX$[C-BMG7-BO?%QIG&_><'!.2%=X.A1N["856!J[=;J
M-A!38NV+!4*&+M*87>?[DI UL*.4N96D55LL^Y78B5@=$&. G.3B2-JM!JD/
M#FE&P?JA7@OM]>*T8=K*,W9P1#4LF3=D1?Y->H%1G$HUJU"%J'X/^\=>U!C]
MLO"W;P?C0YZ,;VXD43#62H<4%0:L/(U\\U:0\V5$(X*MUNJ1_7M%.W+4B4--
M@UE[BH<:!0<E^C9]1E<@#F&7@]!&*DV,)-H>..MP;'&B9-."?J$!<FZ9]3Q@
M#^'JFW!9.1Q [YCT996;R\P@,?XA3"$U[6E6:W[C7M5^76NQKCF10G/TN]=X
MLVS\ZNPP 6T(QSRA6K0:K8:S2K[UOXJ@*2C,RK,RIY])$8P1(@D'4E5D>9=*
M)F=MT !G$:L%+!$?TDVT;:SB+8[D,=)(VW8ACA1W@G-(TVIMT,:,QH3,T'*.
M&4(KD;)#'],BUX'%5,*K(EO<)_H;J<(#(16?.FTAZ4S/H3&@@X%X<.X3496(
MFME6)Q+1:;:4K'^IO3@OAIDZ*WE8&E/D]^H\>.<;+F%6(=+>6^2LA 2_X4IT
M0D2! UM1=G6&7;31:#4O)O0SEV9R,('7LFJ4)XU9U) 4S4[;0ON[,EI[/!.R
MS 09WO0KM.G)!?(5O$(Z'8A-@[U:S#(:8AH%LUEQ9I'%H.EO(V"IHY+2>W7,
MA-0QAX\#<A8.&%I)3W;A"K*:_?#F)'GMFFDEQTV[W$\>8/$T>/ &9 "M2S<L
M^Q9E (/: +E(GIV'M9 ]!/#;IX_V'R4T"Q5G"@IR97E<LVPJF!\>"2^UC!'H
M!\B%]-XYX,_[3AAE^$:F_8&8.D7DF:V^I2N?NI<U(_/D@ -TI*AE_.WA87"3
MRK2^P?=<I@W7S01Y@3=Q0>:#\J&#+#A.*E1$-+.-_.YOXVI(!$,G]@--K>-"
M>GP0?,^#D@;"^'TA"C25K$U:G==JMCE]*ZUY4],I2NXHVD?GFNEP<\K/?H/Y
M/C*9V4_^06=\Y>P:;/4RYQ9M;CW\-D_50]@N@AJ^[R G]&EG&7TD_7-*FXWV
M2+OV&BO,H<7V0*?!?\=?!D2,G3>^:[, BX.TX"9W&P[_IG.MZERM>N/04V32
MH?1RGM6G@E;A/G>0!=='#VWKRG_VI<@P9\DZX"?Y+\+2)'L3F4)YD$!EF?=A
M18/M1,3X!CH-A<$1B)&FDJ?*=H'3*,DP6I(58XR8)U*BA=HU+VZ49@EJ[028
M2!>^X/-8:NOPL:G@F::8*9]?':RR75&12><F-IHRG @8,5N#3/?D4#6A2< W
M#T;'%S$6R=],CQ-(5U.Q&3"X*95C*"<I&_E#L ATX *=!&$QF>STFE-)BX8K
MHJ!5<E5)9*2!N *5R:!7\(]:0!O@9FG9ZD1*5<S0_W45PEUQF;"*!5#<WR-0
M2;Z6H-E;J2VSR#X58H&"3:ZIJ[55FW:6]X]/GM6\;?K3N>_R]D2)[):N]R*;
M,PL-QH ;AQ'LGAHMU=OFS3F@8^EOMXK$\-H<)"(RF]:2(,8V[AK7M*"6W7P"
M.WG\&'I'BD/4 :W!4W8J;9/9_K?)=7-QI=<^Q_U(#DY585D34+-#K_24-$SS
M C NOB43^VI'Y TXN9U[\O*B>Q[:*8Z<4?U=;V4Z&U-5,^H:>8)H%?EC&MGC
MY#'CS-3X;S \>V]5G,KN-\"[S\M,LOH3P*'3=?CWYT9XTM?FW$)@\#*(B!QT
M\\+%G/.^X,Z0YX47B-J14G1&QUBVN2!;T/@Y",3)M@DGA0^/:2&EE^I8JSUF
M$)!(6HU!:M1:'\XC#:WOF)C/F''X!I2ET^[SK<2G63?'DX.^V-*\-CA\8&ET
M;N=BB\GIA[&9(8 * [?I-L>N=%M,AP.YY"NV;+!]LL4PD< ,=\6V[<V.<2IX
M:E2SD;$ES<A9T$Q1!\Y:72"N AMG@\QA$)+=$I&%43"@!8V,2[&7=7&5Z@?\
MM<5GO E<C/ #M6RBDXCR"KTM:>-I\>^*=WP#L),Q$NJ!%YA*XK>[FV7[&HVB
MV?J=]^W<E0H<[D:,%-43SBQY4'PVXV_T=+6GQ_SFF0?<+JLB/RT>QJ=P&IB-
MM'$TM:J&XD@(V@4@-GW2\ 0?.-U9'6")):I_K\(5'X<%>Q<5^R&/W7>:WA[R
M3>5!/(\5I2K;_>25<J9[#JP@]7%=$G<I@[^H"D"J)C:JI3F[LIIC7T2!Q[P
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MT^)&E^65K,BTE)*1!T=]N_Y<9@__D,C6C<<S)$7/J,D-_[Q"PQV@9)JS8M!
M*^LD(%A./?7O_H?]U -"!,^CF"036'8#=,*BE*AC^G+9 _^NC8$Y,BX71\M
MJ9]UJV1UWFCPWSZ"1A?A"H*RJ:)=9*>RAA62)D4M38S*MJ%=P\A3>0H>(A6/
MC[4:3!\I&(QWRT^-]C)*Z:.F^Q),??_Q\-%O>MZ'.=B6.,^=+3F-<\^S$=('
M"8V/&<GD2DB#%.K_I83 "H*H$,:*P]2<*75Q+DF3;BLUMU[:"E;E-=M&RPG3
MK5BY;DW<T_G"H;K@7Y#9U3]#$O@SFI"XV. 1OMWY>',ZQD1465]K=_<@>6?2
MQ0G$"_BJ>?3(6FMIB67V>,B<F@Q1V3XQJ3I ZZ&RCBN1?:*235;IY,'@&?"0
MK"P/>;]E^VT(* F$A(&* 8/)*<2!)K%&L+4E,^^T]OARASM/8T:6U*=54Y?E
MY3LV2"\B@&/-!=%-U'6 I/6T4'@4LTZ)[S*>A;XD!R[P$P/Z<U,(WIY^$*[H
M%NY.#'ORD[2?O.'N!(,710ERSR"N+>X=:X3GY6-&GV(<E&8U<D*:$[!<C$!@
M.M\/; #XR:997BP$DQ8 CL/&F"ZM'1#X]).*[LF"]JTQ+7Y0:N%6EPL5BN(3
MDD5*A+0*B>6#_G A,T" 18@0ZFY-C0FX&PX"+Y1.]J['I):2G15;--6\7$I%
M;#G%8O#P%9K$?^*!;BSV?6*G^45*#$+^K@'7(_,2&E;.P*H#M/-IVYS33 KZ
MC1-#UBA!6 U;5AFN9%LYJK2$)02..!*Y>P3LD1Y91F%AR&UI)HF4-PZS)1#B
M6KD1-,1EQ$-G]:'&8BDI=NDD$_:!WK* T"5ZH,HZI@[(9UHR;$;KBLK9>(&]
MU+>@PA5DH/$9.@.(V490-E ,&G&QMCUU\$"'[MDEW;Y0AU7D4C@S-MC5 GES
M[!=:WE34I[@OD)A=8/I65FX,+;Q;E;NP*M;=8;3%1JAJA<N+RP[ER#:OT%<Z
MA3SFW.X(IE%4?J8_5*X*;=R"W%:7MI.3FY63L-:K7# \1\"IV\VMR(20MFY,
M$$KRQ%Q8:CLX4F-N=K0+ M_\VK:%5!MR7&FEKAE7HBW4/73EC;):@:=E9?>I
M5= K02#IDE-A(?).MWO*%QE=EL*IN),3MQ%CJDPF%;9JB-_FC[CV6]+7/2SE
M"[1TJ)R'?9.&5E :6\.^&[<+Q"AS#?[%"AX\!O?),WWMF8U17R85M%5VWO6E
M0H6M<Z^AZWM?,E_64Q2;!K4Q]@P[N!S9C5]*Z?QW:8.LK83 ]SO : 5)3 8D
MI*-)6W:?0HIJOY!!1\3-8G*CB]K:NB6H;;)^ QJ/]FLU9#EU7 H=G&LE][-G
MGSOJ/U23%J=%7FF72/@KO_8MD]FCWWO3UT;8'S9E@U2RZLE=^QDAR+/V$]OB
MI0RVS:I"*$$8++\Y6],J*P<--7B8Q@8WH]$+M;T$;,(W!7^1XAH2XK" [SQK
M:RFKKT\ED:6+5UK3W4:XP>KBE.0.,2*TP."FKFZ$VILQ 1A#5H$>VV+K%4QM
MR\,7XA4.X2&0T)&@K5RAH335 (0?52!A-#%C/A/1\20#&R0;^$"1!]*63*>L
M^F#;/%Y12S3M-13$MEP'=_+PPY7!DL2<*PF-E$:&=5A;+;4@.G9"2]_F54 B
M1R,J)9#*3&=LZ L+<#HN1RXLOHNW?*&V85Y8ADRX[D/N7LCAS@^[V?70<T)S
MC[[=PFX=;G8=D-3)V^P\XP3$@*_0\1G6JUV@XL8#%=U*.?/YQ)8"?ZD5QIE[
MNMLNM[ J64)33(:?&C+>X,!X#[Y[WOGF6J+7U K9 98CP/+C'6!Y!UC>::R;
MT%BAP[9HZF*%9AK :.9*_# \Z.$664GS[GBYZ0BV@R]%'-%,C&7-UKBC&5;)
MVVZ"CN0"X\V "=V)<#B'KNE XF $GKE;W)M=7&M!UR+HT!>[#-'-+\%&+\,!
MU2N"I'NR7R1+<7.A[)M>H7><*0^F0KER)8ZFZ:"@5>!F?!"=!(7BC1G80K9J
M."]**]DLM=, ZI)/.8BJX4H?>K0\W/9@KD1#E[QUF 2TK.?EI-2>*F,QQ@AK
M[2/6,1&H^] +OB[5QC8T#D%=:61\,Z&R098-0H>^726_]OFI]5/LBM5*6^5J
M R<A-N5'ET*FR9-52%.)\SDX8?F+M<'$9*TP!YM^ \:7TN'V<]@O@Z.PCI/3
MWV/K(4 T__ME4Y6"5T#DF4%V1AKA6A%(2B&7CE^TW)WCR7)) ^ECQ5URMJPI
M!^ <M(E?5#?!L(R56AB'T5MA+7T[>+HZ,6&D-,.F&72@Q2D==89,SL+9%G95
MFIS"TB$JD3Q%07<<(^ *5F)CSJ,O-F+D5*/@,?MT&NXB:S2N'R1T/_)%^\G;
MIBV$;"Y"[J?A>X+'.^'=7%7>D0D"GDWM-Z0(43 :F\M@3_8^(X#SJNCN-6^@
MY%%<R]\5(WX $1@'&BCE\QG331=UV43X4US^J5B'#=0WT]K2F/=>07I/?,L"
M3)%,+G[R/><].['G T^-+WPC72B]?"N7NW:\>0[S.^@SQ%S+DG:2@AO/!NBH
MS8T6_/(U=FU'&1:!%0\ (V#A,4.0:7J*]HQYB55#7_QX1[T7/E6/G7*Q+)23
M1WO66W/)B^$6I*9^%4B<=D$N6-V'O10"*R%*)OJN[Z-HY?WD%:EE&B[*2!@R
M567<'^+R.1R9.T>E:Y![ATS@-I]9+8 3G E"-NQ:W0<-C]R1&'5C!TW269GW
MS*M=JZ:7YKN^=A*1J'S%Z=KN4UDI$WM0"Q F/P<Y5Y[[-(%B'6O$RN9*GHSS
MBK)$;G0VF)>84IIH >TX-21@]$C-)$UDFX$XM]/J [&'5YQD#2O'Z&"@\3F*
MP4G9;*WFF85MF;QF\Q4^3$['<WI:@(Q]26<^ZG24@7<$C11B]%3G!IJ!=Z;H
MAM6&,@TD%?!\@7GU;==O ]0;EDB%XI[SY!XIZI67$MVR4)THZ ??/7>30)NY
MRSP((97"J*DRR]->;PV.Y'CG):@QH)I7'%G0]%!1$ -TUZ#!2]B)US4Z3.,:
M/-_[Y3I4>5_ZT8K3YK1J)D97'@!%*E!"D3G*C8]I5Y8 \13HL>W.4-V8K)VA
M?KA-<F#;._W <)0TF='YTRH4PPC);=&#-96M[&FO!2UMI'>^ET4*0KN4*9CI
MQ.SE"&%/T1B;G6@!-<6*0#_4=_LH04:_"!KOJBVMKX%JFD)_!+5X&YT6?"F]
M '?(\\M(4[RVTT^>'LNRDN OQ'6VY@.8SJK\!$EF=F_N!^$;E1LF01MG"K.[
M^@"Z((KI61>KB .=NW%RYQ&I3;IHKZ5N?SLJ .G*$:T2)HE]+[5[;+O!A$&S
M[3.DFG [SR;7P?HO63F=[W=IL'7#J -O6*[VM%GXE=:TRTO?HI,5#R\7OJ+1
M@Z_NR%"&B(@H@"K "T&P[,!BX2PN5]9U7 ]#=IUG4N/:U"+)(=[?E;8*T-\I
M&OS!.[-PJE!7%B&$)7G;,.4WFWSB?\W"SLX!"?S&:LDG.8&B^>9#CQ')72!!
M5O<=.XR"CC/4VI@RE]Z[0XVN^S=5>!DJW8)=G#1M,,0T+K7P88,(!>]+XW4.
M@\VN(#!>&L$OCJW>1DRE9B ?ZF&Y#I?A=$&]11PVW]B*VO@UM;@2TUI'S4<0
MV<@6&JF*L2EI$O$CR\AXCV0.B^Q[:*JXUW%Y0=2/3)LPN$;?;H_=HR/JJ!M,
M4#03;,4%>-3A$83^'PKXQEJ"X"#NZ[5Y[)UOGD!\8,4\"AWYI&2$\OXF&U1.
M'6%JV-92^G5(N?+CZ_='1ZH9H/S8H';U/_4I1%#UG=_GDO.73JZ"36,S*G4'
MG2J^1=FY!J$*(O7U*)$_XRL;I.O(G E1P@WFW N-_VY>(5\=;Y,'GK'%U;A'
M7;OY'A?>TV</&VG3VCST\;9@64?MQ^AX$APLS_)^\H*==/YXU8/9U/H>ENVT
M7W2L[;N@M7D<I0PAI?2H3.NYV3<Y*QN@;O1=]VAG'GOY!(Q<%!U3D>3-<E5$
MC8>V&OS#O4:RC"WLE*@ZMM(Q8X7XC<9J:UM<[M0^NFW-=PL6D@^D)1Q%:S-C
MT6L.$8=^1M0N/-C(*.C&]3!I.&HTX&.HBL_A,:Y-S6&Z]1YK;SVH:47I<UL[
MT-GI)/?7*!<&L'MN%X685T-'9 ;LA."[W^OLDGN6//CF^/C]T3</233YN'/E
MXY#]OV=UC_S^09H</CI\)+8'KE<+K0M4@UNS%FLN7Q"\W,#EG=9!B6+L0KTT
ML,$#TXF6%W/&NXB6,N?VU(XO?>28#T;*W89RG=(I#;8*MB1^)QM2?3S?8B)S
M=!S\01Q4$9W/_!\X!T176O5\V?D^DJ$M%5P:(.U<,&MCF6QU3F0>>9&.WY\<
M/>2.T\R;M01^GU,2_KX+0@WW$A/V9(<)VV'";C-6=FDD!9M:#IU-CV]H9T;:
ML/9Y1+5KBZB[7.0YJLY7K:P>$JZ/\I2UO+'GO\#LS>A1J]A&@MZ#W\A/ZSYI
M9(2/J"4<<;W$]#+7;R&Z#?8?=K&D>>AKI5SCLU\]_8S?&2C!X?=GTKI.S]5_
MJ8K%6>E+B,XV&RIN;S<=GCFA<>K.G\#-D]-DD?W:6'1(*SW.RLY;#J?-Q<?G
M8ZW3"A?''_OL9[I\A8<P.,]%5P[MO;FW]Z"&D@P;C9JS;</6E3\F_KN$6J)Y
M979]R#@973(>OG)2% Q:@!@*!1;;-&JJ\; %&V$Q.>880HQAQM$U"!W([+@\
M#YGTH05FTUV1O=+)"HWV@I"IIO-YNK)T4^<,ML!#CJVH>E:5QI 5"*P$Z/BF
M!7(ZP7Q;DW2ZQWE: @8)^UQM]PS9F-2CFZP,_1<VM,NIY62ID8J91J(VYC]*
M',"'@-C7V=[E+_Y&U\XWF*'1^/98Z/H^I86CW"'W'E-1_DA[@=NJFAO\X-7'
MXX=6 +C6Z-4164)M7:R[Y&_2)"E**UF/TC!DO;VH4KP/A47$J:^FYOY-8U'K
MKG!-[B-#V8>#Q?5=+LE_UBK9OB8YXAZ"=-XB/GM6#'P$Z?,;! GHXU.6/OL=
M9T.16B0YYEY5JV+)L;Y/1;'T=KU6+(Q'W7BPTL]3&D6M^I4;7:8L=/Y#) DI
MPBL4@9S)Y+BD,]<A^A]T1I\^(,]?]?+6=25+6M0+?:*:ZEVB37+JM:NXX"WJ
M9G=!QX6EJUC=.@P,:\5@7CB,JYZ"I.+EW..*:[H6$>Z%@M=4)L(IHM-VWE2Y
MMH6%9+MNO.0BZKD#[%40 G>-V"0:[.ET5TU3=2$GB?L><7K1930YZRM(LNNB
M?(^4@?7H@@FR-1\US&)M4=YM;]"0T/J0] M'NZ,$Q&#[T672J'?0M)<.17J!
MJ9H7>/%[_^(3]Z+DP=]>O#\9\=[IP6_IJPX?'7PO-HZ$#JUX?,.P"T+G;-R$
MZ:\AI@$GD1[>VWI+OWQY]' _.0K"E'$K9-R+D=N<88-I#J;;2+^%B^)NY'\C
MALCMA)AQE/6?0O]68M,XR@ - W@*O6 =!6 Q'^;\O$&]8:8\Q_S^O:_6'!>Q
MQMP,&IS1[W'L.WS(RW^0__[WE_]XZ) B\^9\@^,3YS;)D[9WM714/ T:.,4C
M_T(3;-,1-].:,-:?=EVNL5^ZPD(*2CK-ZRW$@9VL+:==U"KUZ^#DAIFTY?R,
M(/\6'U4TC$6>(\JK:<5,#OO<N%P..H&]]GKXA:8-K^P(!;'UBP^\(-YPY(:$
MZR3\LLT$CP["ZF'&ALD6XFV\D4WVUO>,^V9;8_A@(+.D7V+^Z=1X_.S)\\-'
M"6FIBD^E-GGR;[;V65UC#C1GKDA]!]8*GFEVP%J;,:/M$B)*R@@,U@&NU41'
M.M<B+5S]G^AGLCC=*184XGJQ&=^L=HS$RL<?+W14EJUS>U@\!-8CN*@T,&$,
M71NNZZ0)%]<>*C]P$ZFF13=)P=C2O?$')4XN:7?(1JN00.'D(=!8]$J;BA!7
M5B"4O((-C#74U<)%QK%,G_/O_^?@V>/G!]_M/]U</5VR5=_6\+7%< @);$F_
MK,Z+HAY9A"TS"IUA3^!)4D<YZ\04&1%-^F9-ZR-%,:W(LDM9'/4 H5.,%1PT
MBG3\8W9P52.3PFUF#A;H@#D2&1Y*:1 \I\5&*$*RN;;G \G'EKM/ED(([S=&
MV"VPI4O2[NF%;( ^D0!JF>AOGA(VU%,@NC?#).!46C0Y8UQ3G[M >P>Q5:M2
M@>P<":%'H_E#C1*$F@P-)8ZGW1(*!Z/FZD9"U?8B<[F5Q+DN[!+O_FY\AESK
MV4>]_K\RP$#3_P[#R2!0) P9-,/XSP&/8HW(3\8FQ_')NTUJ13?<.!\Y6&2V
M#F*WNW66!-.%2;/LT40&\YNW6$;F0"]G\'NP:PM6G8,2CQCTP4_RD0$:%GBV
M%%"PB2:X!-JF1NH(NNTF=O2=027^X@OJ!]( $0EV8B!+ZHLY<5(@=\):/8"$
M>7)\Y7'490GEVR(VQO1H82U%1WMDU <3(4LTI0[K'<1>)=A4=FV_#(U)R"_M
M9S!D^0AL.%9C?U!<BA,2=@8D%M9KXCV;FF_@8.[ADQ2X[,^-@)HJQ+;\%MSE
M5MCE?8I=72RQZ15%UC"*44E>%(*H28Y.N: (O_0U9 QXRUHM<>1V!$,TGL=W
MJN5.TC*L=[AXIU@HOLTZ-')?:?33$'WQUM"0+8>N,+ I,Y!9=8(?U_D?L==C
MM*!8=X*;6=&AC^845ODDP9V98&2&N$'OI^!HYD=*WAR?B+TBL20IJ7?;<;C1
MQM/=TI?&%Z%8$/OWZSFRI1LK?N,@GAH+8<68!*'\=UN@2>A.-7;%A^BVV6'8
MD/3NL 832-+,UYV4Y!28K;:IM5-&Z#USVQ(-T@G)GM9,9#,RQ>".NN-8I"A@
MYS=%E_E^V:(S4STK280YW6:5%%'3*J?BNV:V0INJ5 )O:B?1:&E*-8QJ\0=G
M%LS4F+G"IM!LD^K@$= 6Y)(M@IG;P*-S*_&N?B4L,CEFU641+AA+O"GU1 LX
M)+.@]H7MJ#W84>N$IC:'3#$<K(T CGR@V-&S72C>A:#0:ZL/<V$;T0P[?$2(
MCWBZPT?L\!%W%A\1M4LQ UI!<&,6T$5'F#_H8B>O"7IA0-.G;+Y85D1JQ]35
M8BL8IT./T-%9V0I08H'M #U39S0TA&G+CM0/MR^D_VU)^W>+%'2L^+E"AF'1
M [+JS68^U_C,ML(H^I@U*=.];+7*II_8'I=?D")LM6 >(2D^%EZS<BQ +X[+
MYYKX;A($C7 2B;D ,Z+#\</8Z.#PM.*-SCGH7C6;8MURZ_UF7.9PH#(L!^E"
MX^ -/;+$\()PW@:EC*LYTSYL6?+$+7EH/4[67A3G=#V+FR6;/ Q5-P(_QX01
M<9"Y]?44.+>+LV<"QI2C/-4Z3K/DNF8Y+Y'6\(08*Q(.QNW:J-7B,QD5SU'B
MDWCP>=/:\>]>.NB@)H9.<995XGUJ0<T$?37RXBQ(<HN0;C,<!OA26Z<XL^N=
MZM!'K8HLMU"Q.=M;7^.B1Z,&_7YRM$FT??SNOU^_V#OX(0$K/KK%N6H$-LZ&
MN0^LGD>LTW>0C=L'M226CZC53"I6R:!!GU]35Q/N2J#/YPWK/ 0V!3T#IIIJ
M'0:$#:'E U,-=[3J:]_!BH=)S@< "I)W+C[3.\@]&N:8XQ)NJZ3FO *&7?X3
MZ9&^T["$P/S[.H!].?64:BE71V?!BG1TZN,IC) B^2OH:=)G%B< V2^U(^+0
MYHK_8@KL56D4YGB!XC(R[6 9LI?[FN*H?2:".<'PI81+*]F#?".[&E)L9 Z+
MJY:0WGJ^^'M#2CU7C"OS0\$>XY&P!)OUZKY2K)/ (;ML D"F22A6',X.8"0-
M?1N\F4F/<A)WR-%E"SGKZ(NY/%.]'=QRVF:+SCM8>-!@R8,""5\5H0&#J/F:
MF[,B'X=?&*<(\P]$6WD(XAL+P['D:]<>+*"&;&7U[.-#7A1?<^]28>&5P\AM
M7SOT-V]%"\>!!+XBFQD%.EWGU*<2-03&"0< A\$X[\ 'G1O5V1!NB9 A0O:W
M/5I=SE:2!9(%1,8,VJV,H0Z\@4,][J:6=!&K/HBJ+5?>Z!Q5H(5PP09MO6DR
M+$9;6 HC:V&&#F./RMSQ&,4G*-M>W'%7(P=9K0"]\T(#0U,0R//WLQ*)9MVJ
M+<-".::/'S(JN4*[\+R.*>5#K@L3>6/P<CK52U9,NT!;,B-5+\6/%BA!TQ\5
M@GZAO:\;VFZ2 <#8C#%1;++CGUXP1)>>N>[*3DLI?<Y%$_.5)E%S/:8C>K&1
MVA!WOFW647F+M^($$D/33ANC *P0 \HW2IN'TRN2;VLQTDS5S1O+G!>5P#!1
M\5<M!KU])FDFI'X:!C+A6Q1;'%H3(C8F4*(ZA?*?YHU?9/FMN';'-6E=,;<_
MS;I0'7D #%- 0*+I7BL(VH3^7<!:(.NBB<.(J6FFB#2V[H:;0L+F713%8JEJ
M?.QS+-3G[)0H.\9S*"%WC>%%)RW)D\R_1^,,R_^B\&:<CO)J/VBK(]Y4+FQ<
M44,*21_D0O%E]IK(9QM4S0S@&5OR#!<T\KFQE,/71^9A0408,LKH8\( 7>\U
MZ7F1?=+0=5S5[30?=K"?8%=K:O0M1I 5TNG1ZHC#[)J[#Q_;;5"VF'[(<%*P
M$8MCG&9)4"'Z>MZL(3W(1-@/2J;,BVNS-46GLB+5JA"@C5>/92W43 '0O_%X
MV;.R.&<![,.2A<O+P+5P;AIL_,6">2.:Z:=[E1TCI7_XZ."'=(/T27B77 8*
M@"$$9V A:]/M*8,'&=Y6TMI&\FS2FA?";S==BZ7C <Q_E-1+=<GP.>>9\_5\
MSR!5U)+G,(!>2!LB[BKO!Q\E@D?=N[^+MP76)I.<^/SW[ HS/O>4IE'06='U
M_FL6#9WUNEE0];!@+.+@P; -:\8"?B!+F4_@BIU-:!;!>A0&UJ3]PT: 8EC$
MO^';'9'&ME'+*&1G"MZ%4X68#%KPMA>&K)%'V/BLCY0#SW+E2]F25TB^7*OH
M,<C<_8Z!_>)H4!5B%+IP"'RP\2100;(8?=?J$6'G-=/^6KFBF*:^4^KE0J\^
MT,BI8"LXOL5LE!(!HR>]**8%ATL><]T6%CD$@;%F#FX:_R N)4:(K%N%=)_7
M4$:ITO,PM1JX3+/.:#DE!!:!A3:_C7G4O.\5:+$M"JK;JJ&DODW=XD!'#EAB
MD*P+RI:"&$@(.+C@ -\^@*%CP>%,IVI'SW+5U4-_#_!EO<:TP.CMWJ]4**39
M)$7Q_[/W;DUN'%?6Z%]!S(GYPHXHTJ0DC\>C. \M2K+H&5H\)&U-G+<"D.@N
M$ZB"JPK=A'_]EWOM2^ZL"[I;MIJD&R^VV #JDI>=^[+V6KVZNLJ0D3!N ZFT
M;(#B):X;*BP<(;_&N8<T'+6P[-YO:@IS*"Q+N;)3 NE!Y14:OBM?POH(QXJ7
M0]_G+@Y)M,!K5N#[9S@F_[H^-(5-:0/MRZY/V$I ;P:,O2FH@S$5NH>K:A\-
MS5]C5-XO(#S7<B/*;Q SD;0TP*&D!7BIC1<"U-$\5XPK.4U!C)1Q#6Z$W5G
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M8+2YLL-\WDY8NTO/QF^Y90B#D*BX>FHGO/.<9I7.2?Q03!!? &#84INK?[(
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M15/FQ"LE$JS#6/N$)A DLO=AFKH#9=ID!X.4@!LNU3U(9?>3*:XS#0A7^\B
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MTN.6$#/</J/CT&/490-AG\CIHT0\W)Q ",9XYV,HVPSA^[A/C5MMD!D>@_3
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M\+G;W;>$SV1!KFI?2A9Q5#HA!R5$$U;61 =< I--4Q36@UT69X>25H(A[-L
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M_2V<OF5(R2542]=H7N6(2RJJZ '8Q.=).37?ON+#!^FY*4ZDIWV;"O.EY 4
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M-7-XL)^N*+Z^"4QNV/5A+^@HRVJC'Z\96_MA?]ED>]F=9E [X69!70FQX-U
MS_4YL*B&$'2KM^#&2I*VX=JL$ G1G_[W]0\__O\7/^ 5-A[I-E[..@9=](6K
M3A>O]AVZHI=/+3-%/:HP>%(810 I\A=2*_ET\4W@7LU)E$E9\W1A;3.N2N&L
MUDX(HYRZE."HIZ81Q<CDS2-8E'KC/"\F(VSPS>NJ2\!/!5?I%&IYSC]TW=S8
M-1.$GMNO4G%Y ,GUNJ(&0%:AE)\QMS.3ZCM(K(ENE<"LWBC(0 #'QH U\I'0
M&QXR61+LTIJ(DK>!MIO=5Z0PF?I$CL";JX:)40B.8Z!X;4:D!^JO#IU=<TU<
MT""O8_2<]9PO4:J]$<D#CX::&ED[OD^/+0]JJXW),V-[.#6^C^C0?>?/(RFZ
M0_!6N1>RDR>S6%)L_YDG974;+\$[50E,B#XL -\53AS1F<IXN2LO\[)YWP;H
M$O GO(QC#-;6(;54;0*9RC$]W9)-.#N"#B%]LC'+KVY/^T=SO:NIPU7I&ZV[
M$:S"\5JHI.LF<P;8>++1'J?[A<QIWKB@%DMV?9N(TSCUO"M)RYM(.0Z&V5<Q
M[G0*R[-G% $,Z9M^MI>;A*;)C \Y,9PC7[:,K_$^M!=<E38JQ;L#8$D>]HQ+
M+2N+=GJ"2B:$^VA+\WJMNF'##?^SB@;I(I<BG#>EVK-HZ(;RNB%%DZ:7DTN_
M)I9Y==4TC#6A, 6_'JP+_KMU_B7,L0]U4,5G; <1'6^K]Y*<'#*FVU6"Z#4T
MQ\1[NXQ[T9A5M/W/DW\8JV'#1"E[;OT5SE1*JDEOYG?Q4) =@PD>XFWT\KZS
M.:%RK,V/J:7U292P5'PM78?Q7- \7A[)79)W.$3 I-YES&ZYF_'H3ECY1XGR
M_,\SRO.,\OQDX5!_MHI,?G!(_D4[?V<;GV"\TBD3#6:@YC 0/FR*H1*M]&TB
M%++S]=29,,(=.D(&,V]S-O56NWAS%8VMM(MEIA>IZ-0 $'^8H/<31W6AU[6C
M7@*DD\S+> 7\(KAC"#I&8),O>2S,#2(?HT[]R&R?R0>8[G;&_*EO-V9<S%KX
M'I5G_I/(HMA:A\N13OI/S>^]4QXW6[[+L 5]IENB> [-P<6M7/4%LD&'MM?.
M[(!MZ!DH=/$TV[7E4KK<?[(L6#M3SY7.SV%DZ=BM?.;P-Z,.QPG1 .6Z<IWV
M?2Y6KRG.O$68YRIQ-<PBQP7QK,S6KO_G*KCN,(?7]4,")G<S:L9UC;&&1;L1
MQBYA+2>Y-.&%0 ?;7C.,>B=XT?$.7=R]<:F"$:5<7,5I1VB?E,,D=B,&&=C0
M4!JMV'5<P$A.4+&5&N!*<^4DMS]\)?\:6$-.N'O<:GG[6N*W=H6$O"MKZKY)
M6A SKV 1'H4N&[P*R-U 1P^+$F2Q1%9X2-.9]S#@66:"E//I\%A.!P?7Y^3"
M..GG@^U^E.;!V=*6E)?1!2N_4Y*C7*=QV:Q==C\G!J+ ,(;XY5I4<9SLC,*-
MVQ ^E"K'7A"%1L\N#;*SX:;@+@M[1/TK:25=6V6QV9O(I4\,N8[^_,%>2SXZ
M+LQW2HJW^)$@SB%3WO[SV]?O?C2%-SO(O&&(IC$.P9&3*K+R;Z6X$U[KNY44
M8,_SB6)&G2!J%3/0PLDI86L'_P'VPI5N')B-\^U4X>&W27D+9OH929UCDC:A
MA6U&FL:FQT^(/A(-*Z>/6'8AR#G)EJSJ. F]Y1/&DDAR4(HRZ#HA)BVU)GIQ
M8E+!OP(R"'NUZ74BC_7=@:8@[EE9'K(@**.DO\=?V#A/$%XEG=9;5P# 0J20
M(K6?40W2]^"\K>K5]!R+=EA>("E)]:YJUC"79);S^L@]2;.POAR)C.]F=IE$
M]P)9SAP;?V SQLG;5#N)&[Q9I5)X?)MHN]8[Z3P8]!(QE]SB!I4%=O H:;78
M-M'FB13CG<KI/PVF(_.4E*>G8/G6:*_VVY/D8][1,(]!E$CHC5"LWAB[5N%9
M<8AIL0O;)%(D?V<S&5\',Z3ED34G/1V3EN1=O6>@CB %Q41'"'9IH2/BFC$/
MMO.DQ)=UW?:HJ9L9  ->?-/HHXGTIW#&A?:JW*,B4 R:U7..Q).MC[)HK,E^
M?(6;DY(_TQ16Q92PSXP.4&$$92 W?%3HGY<G.5J=Z(I*UDG]K%B\^?9_GSW_
M4KN0\C EJSX+H9]2360B0/A$$A^9XWM'!8IB&$W%17WP);]""WT33Z8U7UY(
M6U5R$@+5FTE*;*4F-@H09F2E.S"\]#ZK9\Z/_&P=TG=09XJ.P253'#GK#?*C
M##V"39=#3#95X+B+#O-N@DW-,5TF0C6FB:ZYO""VF;FB9CFUXN12V3JQ &4T
MM+/%_3G'-X_HF#PW!C&&+*6,Y4F^U$"<]E+N2'>?6+/0>!;W:40JVQDI#JFA
MT-;26DZ*"?55UH,-9W1LPQAA.J-0#)EFR'%"]R#.0R+>2)")]$99^^\RT'&F
M1"X9OPM=[HK60D8!\W3QO3^37?1M,(\<: U/!J+ /CP@64_V2L7W>\<'2IR3
MBWWT";?=XILF^G8+(6^#6R6_IR3&$;D*N%E,4L]WJ#HT5K/ ?1Z+T3JFM&[2
M;7:X4V/%,38PR3O-N*BJ&\QN*@E(D*,[>F%R.N.(U^1P"X3&JHJ.4U8/;MR;
MO$^C[TD5_]97!:?=84V=33$P\7O,,L?F2X[FD2/2M,%=?DG9[31*X"&A#,&(
ME_>J[%+"/&-W";(7X$%RSMZS#]V5F6"@I'0[4[;#BHHBA?"X(85!&9D6V5<D
M1*2PGJWXW-7;I>+X "VGAB/74*!;EGO8VCA8==B XTXFG/SM638W;X$(-G"%
M6DGJ$XYOOZXV" EYM6O@12%%'%CC=<Z9CQR;IF,_?KG)F?+:_$A)]LYX &2_
MW#9GQ())Z>'&Q'*'@=D_Y.5,)^Z8K',$5AVTE@D?$E]5<_U.)T$]D\*[)@!\
M10/Y8<]>BZ>!Q<R?ULJ<X7Y-C'7*&LIZO6&]R+A$58>0 Q?1)RFW1[3>:%KO
M-4DL+[Z(JSF&A$@QX!$"N6D)+]N5FR#XAD!+BN38XU3+V$O7)!4S2A.GOSK&
M+?6^W(9=56KXQ ^7.#9Y8!*R,HY4+WA1O:;<8L]ZFXD*M-%'Y!S^#?@I#UY]
MV\ ><%:O&/.IL!*GKZJ1W<2+,2>)ZS\9C5;7']9')I<<O54C\)@-3U=.OV[W
M8.IMSOLC.]#9!%H^1L8.*]3,?&(>),;U./\(HXC#3"F]W(/[T;EIVO=2O?!?
M.0,M/-#B]V>@Q1EH\<D"+8;V9P",0WF/C8^$OM[VJ"TE$\M&B(/T09I2DEE&
M.F]-F9-XR(S2R$S;.DPX$ DB+%R_]RH)_<N%Y(C[H '*0DC:P^H5T[@5RBI[
M3U)ESQ<"DUOB,*&:I^& 5A/\8S=OQ%"4<IY"=6]]8NZ>-I4NKN=Z-RV7VBX_
MLVHT%WH*S2SUL=RS]B^6<K6B.I 1*8]<P4+:P*C(6M;J@R$K$/T]+L/H:>N8
MIVL#) Q2L5L6LY:OYL3P$[%6=F.[9=:Y=UO>5^H,NQ@T0F3UZ>(/"$NDHSJ%
M8BDS8&N#SGRZ4\CTPW8A& UZ1XI ,"TJPR7HU1VWGB3P2KSW>_I%'0=^2QF'
M9GE=-8=.I>*HE2$ -L55[^PIZXG7LO3WZ'&=7T<Z)+2RXAZH0Z+$'\A7N%0W
M?8Q4A75->!5U"[F1<"B8@1]-ZKNJV\8(!^X431[CFZ=R_._<)MG$E0Y)]V%.
MOQLG]<=# %8P(?OGI36LA:3\SB]3_O@'*QUI>?_SZAQF ^Z4",]V?SFU_PTU
M\P_73;*P<,K8_$+%$]]<-$TN.+9G-ZDEYU1GA[#[.0Y(?W&&SB1,6SR4+H&]
MG)L8:SA"7K?FQK_'?> K9%"U93/55T^"?%H4S#&_^</;Y$>MSTU)&8T"H> #
MMNLFTM56=*%T4;4BA](3=&;:E8J XYQAV,J#J<Q;>[@T&:OC**&>'H';/D2?
M9>I5BLQ@^_+DT7I&F'_=F+DL<^OUU^0<6R#?M1E+GLV)E7$+C\^!3FBP#9VH
M.SQ\ 7/5 >*L.])HQL";4@@ <AW*ZX9I.C] Z.A6M3AZ1\GEJ\;0*: !7D:N
M+=R>4U?T[V_XDWBV[MGT:J[S9(*5QVY]8NC<@!5Q8ENDG&_"Z+F1#_%/F=I>
M63&.UX(PE4[-;C-B<J7^FR.N3,\0W KA8UZDZ-05=K=?HMVZBK[[@0H4V"?2
MNTFOS TXJ2*9X#""HLGV"=;$%/F =3!A>WD)9ZYR#2@.;#-.73\ZCSV]I??I
M+EY_]^+%V\* (+QC! O*.5DYPU>:/_9I]4PT>63!\ID=T#T8@'$R\!A\>> D
MO<SJU3F<,C[>5;6L+)=)6FA5347#V;DL<OSB5+Z7SV6*79.PS.6A1#4CI.4Y
M'@]5\'2C,K/VLP6M0H=K:_W.A1WDFZF-<RBC/7H8K!>F;9 "@>S>_'BG%1 =
MM#!PFPT455$5Z'$?Z%Y!AF-X6E(<# QJSLIZ,'5R)XYIZXF+[Q>8-$)%*>BO
M(OU3=MD-1[%FEA8RK%"HQ37,9)KC<U"8ULF&@0LB,D4)CCQOUJEE<;KVCO-3
M4*=3U-]:;C/'UZFBJI#8;1X_UG9&[-<,S?J YL$:@#HR(%5WQ6&?2G1/$UOD
M,)*\F4 ?GY(T [3* /4T"7 2Z.@(#_4@8.E/">J4>$%R25_*6_%NZ.92*Y)N
MI+__4/:KJR<_E1_B0RXN5KV6OL?;D7^C)5;*P'1;.9YZT8?-ZDCT!&L]2?!0
MI B(!8&&"&F!)8^,/&M':S!=K!V<-.)[N]5$\)O'GB']WE(J-.J@+K@FH#<7
ME;__]L(8 _\4_QL=>DA#Q[DJX^-R3R'-Q9,7A<BXPKC&=ZT4VD9"OQSXH@7>
M+SL2%=#,Y8DUMDD93ZS-#/NBJ4FXK'B!L/:) ^UB$FP.^YKC94SCT"%-\*':
M'7;*QZ%/V[ ?16LT((N!P1G>3^$LPTV%H%0A=QY-HD[WQ/;9 W9\2:5%RA3:
MW,RB$YXNO@W=/FY;(P2;WN&H_]K\G>!9*08XP%RP;WA9T8LZ 1,#BB![T:/Q
MUQ!H*LNZ40I5N@P(R'!43(^@&M#:%\HU+>ENXMN<@4-4YV7/$KO+H&</CIV[
M2A=_TFV._G8^5^NS1-Y>V7 47&W>;M67L)+ .$VU5N%"":C\10@;YV >EW3+
MFAZ!XH1##,!;9*/5C=[")Y5L$#UPW&"/V\*=$$697L=-Z\U2H29$9W@\2\ >
M3HQ[5OH;EOQ2MYP1/O!J%:*'[5%-K=_L)I%Y1: 4$6(>91*=S*VW&F,U%)=1
M=R69M&.2Q(J2(*T&]44T,G71U!_=R?H+N%:/$2CQ'\_.0(DS4.(S"C)^A,W1
MX%9COH%U\><>$ULN4)4TT!@RHM=E2^5.3F6O2;^TB-'+ZB"T2LM=U?$!N0GD
MHQUWVN7(OHP_JBF?I!#A[/A4F.1EC-N-QG'Z28=F#RE(PIO7")0W4I$=O@6W
M\.9^PV,^B]]92R0-M<ZQNH2#^; ,Z7!4RT5]V"U#*XC8T?HHV^/<NMBK7&V7
ML8U,-AQ27)MU0#Q=_*FI;Y]B1G$G_;UEO%)3*T/IMMPSHT*"<4]IJ&DR@U$+
MG&QA0A:%G@[+GCE]J?FY'FX., 7G8VMN+"]ROP%>B,_AU+V$9.*+L IP*YX.
M-D7RGA.)*W+!91<>5X[EI\FFJ3LV<Y'W"(XXXOV@\;MIVNTC3TZ\NW?.]_0
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M/$*;:'-ZB\?CI:(?+JT"':N<"XZ2W[\U^6#^*V')CIZH^:1)NL]J<-H?3>N
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MK5>R9<UAJ<"PZCU-WC2[NJ>8T#B4XG>H* 9DYA("'7-4'Z3VC@1?M9,!SAU
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M#@_1V<0JY"6NSDH.V;33!RR*T*U-U_[NA5V3_1C9.E1Z:N@@A*'LK]A 3Y3
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M]DD+[BETZ33A+@&YH^^'_T@6;:.\9@PBN6:7V7P.)UD;C;.ULLE4T8J&R)*
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M\L*P2_S?+[^%=#">XOSDXNU5HZ"<--$(6+DBI>OER#H7(&=%8^'HQ_=DRFX
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M:X=Q@B6;@%&(3Y,A2PBUB$%FS7E2HJ[ =1?L#,Q@@YB[:/^JQ=AVT)LYCHM
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MKQSD-6'969<,!Z'KT*SVS!X\04]*]162L&I'_0(Z,]1J2U !N'++E4P()2S
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MM@&;2XYKGU&7V2"V4M_$Q9R(<B)Q'5,6E4K1=4>6>VZ+3HLKN^BC]9NCM92
MZXUZ.%H>^C)Y0"!$4YI+"ZY,G 1..)?6*P2M5HO*;;LX:C!:]_=&ARME6%.B
M;2=;; +X^7.I^NLOGT_'DR%^O4S33A:"SD!T1@-;6@;$!NM(1MGDG!A/D>^M
M^,UC/D;UMR#=K>N^U>9)?GQ1_EMR.;_ZRV*=^4%Z/?@*B\*%UR7<GE_Z\;B?
M^Y#\^-Y_=D"R8VU(+;1FZE)H*XF5U@,8;YWA7$BCT!.+PLADE!""HIO6JPVN
MK0C8JUJ!KX:C#[=J!;ZY[B0MF8Y,1D*%*L&5GA&G<??$[9))QE+@N5)?BUU@
M'ER+!,6.QLB*],\FS_UH]!V-DUFMSZLNZHJQ[)T5:(N4+2293(*(E("1,5$3
MO#9U"EKM!/,(U0JK,6NMMDDU?;5][F]!^KF4WOQ7J3@[GO0"XK A&B*IPC^<
MR\13M&VSQW-06L##SS0Z\!L,=H3LA'JZ&E84=-LV_V9\?QT-Q^/?!B/PEP7E
M7U&@XQ[/3N?(%#$A.+13<?H>>"!,I](LT,DHFF7?-A_SB='B8+&WWCBU"<Q2
MM140IZ,^*H8F*T^($VT.XCF/I<NK%0:L"OE>"V_709\V/_80?(7648TDTHLN
M2:F#(2R4FUKC!+(8 A'.!*%=8B8=T3AYC#RJIY\*%]K;+;-7OC^:0?PXO'5J
MSNK"7 DHL:B=0\=<E\P]*7$B04(F/&9K,TLHI3I=5 \$_IBMX2YU6N-A< 7^
M"PB3&V7KUW#W?'+6^,A)Q@59[O$HL1(74[8Z!B5B4E I)G-'I$>(QNN2"O?0
ML%4]=L^[ZT)H&ZS%9Z6_ GSTWWHXA6@D[N+4JEF=CM+;!I=P2=_ K1XMA=0H
M;ZEM,C:#_X.A=35>(T%BSTD4(_9Z$BJ'4AI.DA0MNL),HAD20SEY1(XF,9"F
MSKU>*_!_T+:NQBMX+]L%>'LZ/>/0RHZEW%$4B,Y%0UQRCO D8M  I5-&QQ;F
M;81/FWRMZ*WM2C W'DD6'MCMB[^<5(S2<Z*TR$3J+(E7G!*M;;+92ZIBL[?T
M>P9ZC%Y&ZP*N<7>VZG3?>C?;>-N7F:6)ND1$N>B3,@L2@LO$:."*<:.=;7Z+
MMO/PCY8H]971>EFS'1$O+@,=[FDI:D6"RHY(JS@)UG$2@[<\:0,^-*N"M]_X
M/PBTOSHJ7*NM[X^]A)N>C!0=6QTL(J) ?.G: =:KJ#ESH5+(\CJ6QTB6EB1?
MH<38BGF^,O]%/+5@6CH'!*>-/J24B;@B ,6=BCQS$56=(LT-P'761ZTSCK2M
MD6.7[5K.:Q$\ZR]?#]#2GUYE8 L.D+Q*Q 2E<!5(1@)/!DVRI+*T5@M>YX)T
M"Z!C)4*TKO=A^_*O<+$Y2]_(,"H;XKQ[<7_PZ3QO0#LNP9?CS3]:Q&0VF4O5
M9(<V9W.<)(E6:+):N^78.CYUWB:CDH"H\("PB4@6!+&.6N*"4UF[)('7R;<X
M?;[>DZ=Q\G3=1;65&M?-0\O?>3R,W@Y+4^7+:8+TC_[D8G,4P#(# 1W=K'4F
M+/C9S2M%T-$295F2.B%N:%16<_?@C+TQ=^\['(\K&SKH=:#H"D78?OOPU^%7
M& WF%>=&7V8IGL-9PM79)T!1P8T8] 5D+WU(!BUJBP9UR;"2)3LFD!!HRLFQ
M'*%.9,<>8)\P*6NKMLJ&.8>Y\G!U5;$'[>QR:RP,XT1R+XG55J*W;B-D)DI<
M0*4]\0Y83YAA[:FKQNOW> R39S[^#FD=6J">":.(F]5^,MH2'TJI ]2_,<H9
MX++.R^%V4$^81VVIJKM0VF+E<AEU8@D/;:HCSC@FW#5M++4V?$P6C^Y8Y]IV
M.Z;'>GW2DA8J[#+O 1="/TX@;<9XI^W7!'OE\A#[HS_.#4E;3%A+_.]8C56*
M21PP!VT4;MRJU$ L3<32K-F*9P0RS92"=5G7Z99Y>A2\Y]+C%!FXB_9JF.T(
MZJH,GZ8\<IPX4!0![O#$^M(DVD:3,PLEGZ[:H7B\$@5=Z6[#N;B'X"O<(_PZ
M',#W7_WH=YB\F@[250U72G-BGA/+2TU 9LOMAJ*$.L= @Q<JU#&T-^-Y0M1H
M02'U;T27\Q14)EKRXW3$S5-82X+3BD0/EFF1@-HZ?;$VPGE")#E<'5M-ZC8+
MGUS%KOX*?CP=P:%52^[\O,-+CC2'NU(O)$:?;-!*I%S\96-M,%0J+[WF&3SK
MW?G)!T8(+#]ZYHR7*X$W?1_ZEPM??#9<.A^\+U[>J#_X-*\+.%K^=19&_.8J
M!L,9B99/*F632BE :C6Q CDJ))22WEI26<<,:'4:K5Q!74=>O^B/2\P'(KB*
MMZ8RQ@BRQ"\*W(Z%YL0GJ5%L*3(-E)K8J$SP?A=1=T'K?A<\'@,WWD>UIK<*
MUM96@#W#'*=4&(+;1ZE<YH%XPP(>#E9%48Q 52G);!ND(R1!M*N^IN382?85
M;*L;J^6NN9<V&S920P(ON90"1'F<SX1)A_9"5BY5,LF;X7O*^TX%#7;.LY[0
M@6H+.&,N&9$H#>*L,41ZI0P3&LV=.L;\W;BZYU4-;>Y$F)U448$H;2RL^=L!
M\"BL<HS$D&)IURN(I501:C(-@4=N61U.M3:%KD*E3V<S.X[V3R;@>CG[9]]O
M^&JO1O#/*0SB]WG##.FI!L:(=2KARL<_/)17<DZ9<^AHJTJA_0W '>LE\4BL
MV<;=EK17<W/=!'#Q)M\$8M7WQ08@CQ1HW;:"MQ&H9>T<B4B<)L]<<B09U+,,
M@I&@;":1)J5=9DRG.C4@CD:@^R*?3X _NRBE(]Z,K_;E98MAT$(XZXEAN=B=
M)9[0)T\R9R!H,M2[RD?<'>B.Z&JVI=8&M#E()Q7NKFXLG:LO_]:'$0YR\?T-
M?(7+V>I)I?2Z$9Y0 $?0%_)X?)>X:*6UMB8Y%7-MX^@.?#_LHY9U6"$V:^-J
M6,>[#&!L +9S8VDKW*.;3:WIO<D6UJK2NCH+MX+VT<H<;2 JB]F-CR>!(?(<
MF,W*.J-"G?R)$V!8<[OJ- BVBZYJ$NOUX,MT,IY)@"W[DYC@O. 4+0.K2P5:
M10*E0*A7(IK F?*5WUC709V&2=62.K<1YT!=U+2I;D#C2VA6)V5FP3Z4$DE!
M$.\C$&.-\=Q3&DV=]YX[0#TUFNRCBXYV$[& %K4W0:-[2@/#+55S2T(0AM"4
M3%!!I>SK! #? >JIT60?7=2TFY]]7SH7WV?MA^9!SBF;R%0F8!@K;P*<.,XU
ML3PDD7GTP<7:CMDZK!_^6#L:JY!"=07N;LG,1/';8!C&,)HU9ILM#/SQ<!#Q
M7\UR5U>GM[PR:3#!;ERW6E,\NKMW**VV$?:D.%'SR*TVT1C0Y2F[A98 1!I:
MTFQ+%0$\@7)D+#A>>3]^6*1O[H$^.,[O0H4*7'\!H_[768?P37G"MV8]-W.H
M]4K9A.83'K8RER1?BS94+#$KTHA(4QV3<T>@1S1#3X,J:T7RZNFY[H/#S$B[
M7LV^1-5+84E.,I5>]<5K5[."Q!FBI%2'.AG<6R'],&,/UU2%HJTKXME[*5[/
M:NE!-IA7-Y9KRS,[NL%Z"('NCF0[KO;KQVFV-S_'/,NED836$O<"(2)QLA07
M J/!"A6-J%.PYV&QNKE%^A!(O8O2*Y!Y2]ZKU=DIGT()JT91:9-(D):1Q&,*
M*G,9:9W'DE-)1#X-?3=+4MY%614,QLU9L=$D$R5#LY7S66DT09PK+<ERY Q_
MP+BO$Y!R(DG*)TF@PU5580O:J_">E<+0D F7@)3GC*+9S("8F!G+3.>4Z[S2
M/8B:BB?)O=IJKO"R<W?!/AK!>>H"209Y,@L,]#%HXK-$4>3L?:X3K'EB]15/
MDFWMJ:Y&R[8["O@E4(8KD(1I/2O@)TGP29.4(A>@C5.QSOWT2=5:/$E.M:6V
MK3<N;18!>3<:IFE$@7R%P13>PN2M'XUFMY '5 *Y_T,/+P>R(_"5FB YJ8 J
MT&Q60Y,R'TS OT;#8I!XB/3N__@#;_7[8__ITP@^S1AXGA<#O;E*$LPI) H>
MS:MH I$0T%JW0>$1YWVR@N)Y5^<6]3YDAQ?4FWW>*US,SX>#6;;NK)SW=#P9
MHM7Y\ELI\5TN0TM?J3&DTCN3&Z%"J7N:@M"E=Z8D-J2,IJ?Q$(P%&^HT$]@#
M;/>[8*M<6J^@5U==53S-080"M8CC?7_\^SMT9O ;_A,PE(7,2K!(O 1!).(B
MSJ-3PQ( *YGAWM<RQ[:C>F2<:4T!+;J1\^9V&Q@\ZV?W<8A;?*FJ6]KYCJ;^
M<MP3'FFJ Q#+#!I_.7!B%422I%49522"<O<=A+L.^DAX4%76%1RX+4*8/[UY
M)[B)P(C2I<B#$R@ KA%@8-P;YY7G=6K_W(6JJ\('5;>)UL1^[/($X]%D:3">
MC^8UWV'VE& =35E)1:APE$B5R[-MB3L5D0G)\"34C0J1X0 W>(-_6^7,-@1'
M*UW>FFJ'+8JXQ>/D!I[K0O^P=!^;@-KE 7H7_:_#Z?;5N!U-K:N])3%WQ@'<
M^J3.SA'I,^Z,B2+!)0TD9>V<L-R:9OUG3U'W6]Y6.U3]+M)MVXI<H'K][,/[
MEV_.EN5=60Z6@R/!,/1Y  QQ.27BA<G&J<3\JHNZQ5S<].G=V84M2GW8IL@J
MN(D+3 LPA@F8/1KX('@YE +QG@FB7!3:>N4TK_,0>0O&0U;TX7*M4AI[Q15]
M]OT9#.+%9S_Z?1[MH63(667B3$021I?1]1"2 ->*&DTUJ]2G\CYDC\9TJZ**
M*L]XJ_B6Z):!90WP50TKO _AD9K'M*K7>TG3@E(ZV6=6<.+N!SIK19S.JA3'
M#8@S""*LM$PE2BG4"44X#FGN:_=R5,[LHHL*7)G=?2VVU<5A62Y4EF%:D'42
M$8BC)4S+:B#6I$R4"3)):;.N%"]P)ZSN;R;;U>*PE@JZ>+]X]KUT"IQ[4LPJ
M@(1&5,P9;6:?2: B$D0;,P?T)5QGYLH2U%.P5/920(W.B:O0"K#E=4@#:-W:
M)]?@3L8TV4^1]Q'D0"UT89#<@"A,T$:$0"!(].[0#2>.EPAWYSWE.;+,^.,@
MR.YF2'5^["+\&KQ8/,6M0;SJG*X!+2].0C">2,KP5 V:DJ1,,DK1+%@E._5N
M8"=@@.RKQ%5RM*B!%JV/<B'TJ_]_P]$2WSP;)FL9&<^^%-*G: N5W.R(MA 5
M^!-&M5:AT;U8HVOL]?$?C6W1@GA;3,$L:-[ZSW">;V%:L+L)J-:?K[;"Z?[Y
MZE ]#6L)N>7'J^W@>,H)-+K?' QZ0#Z4T%<F20K1&B^UT;918M<I:OZ.QZM.
M%+^+;-M^NCI#&/WQ<#J*\ Q&GV#P8C3]="/-8ODR8[D $2()CG$B0S;H /-,
M?.!<@TL9A='H,:O9>-V^>K2DF6%=L;9XLL_#L?#/_L!?_@W\Y639WE8K'V-
M0*"B+PUL)'%*EBL4(='6Y9Z!;:3G39_^X+5ZL,C:7KV_QO^"\7@X6&>634(E
M%Q*Q219F.4H\SX(P2M%.<5IRH1HI<NL0#UZ;[0BOD\ZL:\D'L[C)R5K<9)LI
M&O<,42%A8Y=)K:1O<#2YDY>*&B6E2,Y: ,]L=I'%Q#E;3]^X9[#*R1S!.AU2
M=&@ZE,K*N$T09P4G/HNDK74*MY 'E<RQ8X3O^^'EY:OAZ _\9[TDG >!#G.4
M2I<JTXYXR3W1N @#Q.QP!VTYKOK&\"<88;T+.?:,L-Y7_JT;(3O$A#NE:?!&
M$LU+?2O'$">UD?"LF!'<EP;K#S?^OBL%[AN1OXOTCY>E<18G_:_]R?<7TY+K
M^7PZ&L%@\@YM\2&*R8'7AN*I;GRICQ8\L2RA"Y=I@* Y'A1MYV_< ><'L]K5
M6(OQ/SNOC10EDUH 09@2Q:13"61-!*47#7<\)-;0:]IW9VHYQ<7%8()2CN@<
M#)'&"F*=#\0Y*!7X0Z2QSJ/R@TAQV>=\;EWLQTYQF?%URY(>I/=0TNMAED'?
MS_TXF^WL^LQ18VQRBF11BL9X&4D 5M*%(NXFS#/=\(9A][%/\NE@)YT/NY-]
MVV?X;G"751<: -[\[M *:8[QW-");O?GT0&*.0E&:6\R.)E(EE24MG^<6.HE
M\5I*SKG)N:$1>#I,VO)\\3"(M(L^NG K2EOWX70P2X%X?N%'GR#X^/NR6HM0
M-C@N*>'16"*Y">7F7I(8HU'64N--LV>0G8?NV%VHK\O[O(7V%-'%G<5[1#>Y
M*NJC-2CEN2,LS_JF:8_H$&?.+F::G3!N?YK<&NK)T6)_07>Q>YQ/+F#T"F#\
M?/C%?Y_)93(=#:[*AV4!I4H8 <M5R:2R:.:AVTBI\%)99K0T>_/B[K&?'%%:
M5$4G3SS/AY?(L,4[E"^%X6,YX >?SM!SF#?(:J,2US[#'/[4<_#D5IY[?(*0
M331,:"XA)J<5C<IE*.U!DF.]?08\-+SV:L2O<(8?/?@T'V=>PS]N^?%'_&J,
MU$68X^L;!J7P;!-@"413$F$I(U:&B.ZA%#YQZ:BNE1O4WBP.VEW?3LLR/<\?
MX(LOY1AO [M28L](C2O6 \E&XCJF!B65\(\HI1(1M.=&-]I2&PYXC*C3(Q'K
MUA9;0Q_M&V8W%OW9QD7_VQ<4\& R_PF4XZ&G!.<J\$P,+9G--$AB5>($I @N
M9$@N-#76]AC^J?*IOJ[:M_?V0/RJ/QI/2M<>?WE9?J5GHDT\<;0V9M$JPF1B
MHV6$>^M *QT--(O+:07.#_9UI<NVGZ<^PNCS>7[GOQ<DY_D:YAK*:% P*C/B
M4XE-QRV9(#S\JV;,"\<3#<U.R,9#/E56U=%)BSF#^W/_0ZF/G&Y.(7$7G<8-
MF*E@2]5&3=!A4T0S#S:;I'1.]3:R-3Q/E7-'T&:+62<WELT5WAXN NHSE'51
M*@CZ('"#Y9SD$%5,EEK1,!YLY8.?*D4.D>^ZKM4QRCU;!DD!BR0F31%RC*0$
MAA 5#:,0@X^Y3NWK!U'N^>@TZTJUZVS4;1V%MR3S;CC!/_O^\D5I%S_\4K[W
M:_\2<!H#]$(R:!FE%<1$XU P'"%;&XD"BQY)L!%66Q3=?_3M,/X3)%A7VEHG
MF*E+L.O&2OU_S3,0KH%K*XWGI?^Q9+A9\Z2(8]:0X$N)M!1U#$WCHO='\8-L
ME36W3CE;A7)H][V'"/U9SY-7P]%[*/D0B/OUX/WPN[^<?'_O)] 3,CO(+)'@
M<JG4+Q*N%C0)+=.4.Y>]@IW-^CUP_*!==>VM$\\=D7C+^^6%]US$&B]P*7'A
MK,L*S0-F/3HFH(GSLY+PBF9K<JFTT $?M\#[0=-CZ7K#[6X;]5\C0!H7^_6&
MMSR?$:0>DSD#8B$H&BA%BR.QX",!< 9P?2F1ZG@A]P![@BRLH;(-E&KMQ>!>
M@[5$.=UA45B5D!H<W2+A56G5RDBPM(3G>> V&Y\3;]WEN!O3$V3=,;6Z@9T'
MOB @3\87P\MTW8OG/,^B=7#C_MB'$:3YGMU'I$%8E[@.) 919"0\L1X]J<"E
M 0V,T=5\U6UW<CN,^E095DTS&SATV%O"38#+ WY^!]33-$>T.A7AP 0>X1X(
MVJ21),]BR@ E%J 18[:/\53YT9+4-[#AL(O\F[A0&BO0(AA-;:(DT-*35UKD
MJ-2>&,%<4#QFYIJE[]XYS ].'"K[#;38^\Z_V8&Y\ -P"N6IHC^8OV4MWRM^
M]=_ZGZ>?>UEI8;+ PY*6PS(Z] ZRPMU.*9:C$MF)9N_8[>!YJD0[@C8W,/+0
M>__QY"H-[VR1F@=GGTN^0>D$_&G0_Q<Z#UIR%HU*!$(LCZ* JR9 )DXKJT J
M$QL7IF@RWM-E5.O:V,"8O2_RKX5U V:/H8F>05KB1,"#5E%!?'".\.AI$,[%
MP%;N25N+T+T!XPE2YG!U;"#'85?NBQUO?)Y_&\19JE*Z<1>QPNAWOH]<-MH*
M;CT)RE#<_:(GSN%7(CD5F,3/7^TYN\T6VG7H)\B8#G2T@5)[7Z9?=22(%Y"F
MEVC/M2#!>:ZYM1% &(Y[)I0>&J6>1A:<&."<)X&B58VZ3^[>2:+UN715#.+H
M[#T1.AR[W,25&*9A#/^<XB>]_%HFM2S.3H,%%*,CEM* CJ^SQ(,M 6S),*ZB
MB+Y.QLP60,>J-7%LFJRRM@5UU6BXLPYKV>>N ;"J+3.V0CM.PXQ6%'@_*0Z0
M?J?TD%JZS#U:EYJ:4H=*D% Z5#J(@0M0X"H%(G9,BWO:9'3+BEV$7I\-RP1B
M*46.2I*L;2D"Q12QP3.B@L\!0LJB62?O0YEPK&88+:GK;A+L(>L*[;?*W,[S
MC3-R7B<%LM,)'$F:HPD7D>:!1D%2=,G8 (SR.C< &^'\L#=:4E6+B5I+4.O"
M\)OGOZ![$[A5;9 = 1_',FE!U</N]53A?-H5MJ=*VL0X8;+4SHF1$6^T)%[)
M'(-F+"3]>&EUCV5S?%;MHIZV<YQ+=1;\M(O5K++S+[<?<>9(>:8LT$ )?@IN
MU.4RWC++B Y6@$L!S_IF+[H[#=N]J5-5@\-.Q-]VJ87%W>D5I!LQ3VL!3R_Z
MX\FH'Z;S.-#_Z;_X99\%X;(V@.L(UY D:.09$@(**FE!,VB351*-"-0*G$=,
MK.[5U?;.M/\,GE_T!WYY8G/MC,R,1*O1/PVX>*SPGK#(*4H079/5WG6M$^X&
MG!^$:U%=;1=8.& &?N#3<@J@HS..%\R EH--DEBC-/JO"FAFP!RPVHR[@><'
MY=I46-NE&<X0E?^_,(#H-\;.+,Y]+XS+3A$&JI3)\X)8//B)]$*'[&WFM%D)
MVT;#/6+&M"_NEAMR/B^/T3#ZXD>3[Z4!ULP7B8)+$TI,9W29R"P8$M0%(A(M
M:?Q!BM4,O0,Z,6Y"\,2OFEI13(L[1\'S'KY,T6_P-[:_58B+R]DF(%OOY-H8
M7O>=70_7Y+ K-;3<Z[4Y6/ 2%XIWA"E:JNQ*53I?"*)5,%X$H8$V>O1Z"%RY
MHQ?LD:BRB_3;]KK^Z_OP#_]?_5%_\'SXIS>3M#@28]9)NC +K_.E^G8))Q>"
M<!D8VNQ&1=/,;]_\^=UVEJRDB6&[8FS[ N?#!9Z*%[[_:CB>#MY=^-%G'P'M
MX>@O7P_2M)C'MPMJ+%K1IPPYTTR\#J&4O./$AQR(TM8&\-2PA@[T?N,_.F9T
MH(;6]X1!_]/%Y.,%C/R7&=3QZT%<X)(R6"9P0\\T*")!(\*8\0^C<F0Y1>$:
M;@S;!WET'&A+H&W?@,S<HW_-W*,%FB1P?W*1XC95ZIH(AAM6H@DM+&L+3*IT
M,_6N??2C4^IAPFO9/5@TOST??8#1UWZ<6RXN<<N5BX1#J067%$7?![WHQ(()
M1@)WH5'$9".K;A."'W[DX8II^<)A@:?,?X%HO&SXU !4ZW[C5CC=^XF':VI=
M[2V)N66_<#LX:C,5!G>_9%2II*8E"=$Q-%]M"M(CUS-]J+J_P^_K2/6[2+="
M%,GB^GQY"RX!:,)M+ 1&B;1X6%DK\.R*%!A#Q\6'.G&NMV!T:Q6TI)IA6W)M
MV^5;S._#],N7RV5F^ )6%C9XG3EJI=1(S%(0:T(F3M&<O<]:AV:&W?8Q'K(N
MVQ1?V[=XQ2B9[4A9NTPEM439E- &,98$&P/)@'P++JK8;,DVNZ5;#OO#B-M3
M!2U65KX"L:1C QCMW_%? ^C>.MM3!:M*/$!^-9;U$H[1/$0>"B\SD<P'XFW*
M)"<;DRF8(#\<-=YA:+6LQ1W$UK+V?D5)?9Y^7CK^2AH5@)$4S:SXBL;37VB2
MN500+9-<N];T=VOHCF]5]A7^L W);;66.F[2]P(RC$J%KKF%4+=5WY;!.FG8
MUV2B*VW[,E##5$PY&B>%SY8'!SPE2HTTW,@F;?NV#'M"S?N$4DA,FDFT"NV(
MQ)&U2B6BP;+D9,HVUO&=3J9YW_/RJ@&O!YN: +SI^]"_[$^^/Y^B&@>3]X@J
M#T=_X#\L7[Z:?]DKR\!PEP@7:$C+H#5N)382DW/6*0BF9;/8\L.Q//"2&;O0
M\79=GFZU6"%QKPGR7L[&AJ@%<1Z129I+)2H#!!)W/+F2]V$K+=?[T77<MK=K
ME:_5]&E97UWT?+X"N#B1KDM6/??CBZM*Q)E'S9,4!;$ETG%%+.(F2<7(/>,B
M-ZR'N3^&IT&F+A55(5FTT1I(5G/'G" JE7PT[1-!:QO04TKH,3%K@JM5?6S7
M/:N&Z5#.P#MY(S(W7*+F%.7EK55R8C4+^(?RQ@?F4$CM60_WP?EA0'2ERPKO
M(@W!]QP'QW56)%DOB>20B%>*D2!AAC&$? 0SXAK@*6[^[>I^%V-B3\5U:D^\
M'L01^''IHS$O2S=^/?@Z1(\8SR@1>;)@B-*"$@D@B7>@"-<V4\C>)MFT*\I>
M )X,F3K34MO!6XTPOYC"Q^%O _SF):1W(_BR*))8+",$D7H2LF212J)+ S6I
MF2>! 24Y*AURXL9QVQ[/[H/S@W5U-=ABU-FNF[!V,1A6NA@8AV8L)""!2H\P
M.:X6%VAB=6I2['5Z[BZ'"L^5S--8LA&)$N6Y,J'(O 8@C@)+(BLN;*PBLA_%
M//<VBT^$#J=2S'-SL96@:$HY.I)QMT2#S!OB6?FKP&]04!;$C\):U2G2J+#6
M+JHZ@<I'3>#^**S5@JH/+(&TCYY.@%XBYD0]:IVE$@;FM"=>.$N<I@+A.QH$
M>[RTVJNP5I>LVD4]QRVLE31CZ"Y$0JTK63\I$F=81,>14Q>YS4DW<[L>66&M
MG32X?V&M7<1_FH6U5*0TAR1)U,6=4HX2YX(GS@H570+EO6E$H"=26&MO8G6O
MKJT[4YMQ3L^&H]'PC_[@T]LBMV)8'A#'M/W##H]3:@AT)0XI<6N#,<FEI"5$
M[Y3/3M+,$@O20NYM_]C#+(H7$":O!TB#:6'(M2^)VTV@5',2&7J04J= 0@R:
M^,BUH(8:R+R*Y; %T*&6T^V/?>7CHK%*C]DL).32]DNRDO\0T/N@B3#N7&0Z
M2FT:Q4(>.-%K1-WO36UP8-44:D7>%0)P;N-ZCHOI>PGFFV,3/++LE2=,,+3]
M7-0D^"2(@,P8<*U3I98==Z%ZC'PX0.X5O*H7,.I_G>VI-^Y99_&>EPN W$01
M!20BA$+[*UE#G)0X?<YPYT8C3*_6S&N-&/= >RSL:%,#%6)@;G9U+P)X"Y/S
M_'H\GOI!A-+X;=PK8>0T2D28?$23J=R^&F-)%-Y;I:PWJQ9N2QRY']OC($G+
M.FB[5.)[*)+!3>W5=)#P?Y[Y,:3S\E:7^G,J7_59/XL7?33+BVAZ(606F;6$
MF6+H\V01,HH%>/!::ZDY;]9X;[_Q'S8UNA)\BT4--HL!,??''[Z,P"/RO_M1
MOUR/O_<38+WH@Y.>)0(Q>R*E=P0/2%8\P9!=4"ZKT(%1LAWAPZ9057VTF%(Y
MH_IMD#=Q%=+/[XZ*A1U23(H8'M&:"CFB-:4L248HFTR(7C0+Q6DRVL-6?AVA
MKFO]L.;0*[;SY;#D'[V"I4<5),1$)27>)21D9K:4@]6$IAR,YE:YU"PQY>YQ
M'IVF#Q+DNH[W;N<\O[8;^NM;WU?3R70$Y^&R_VEV3_?;E^%@<;B=C\XG%S":
M]:(JM1Y1#F@4$3"SA@L"B TN$,\8%]Q;*VVS#O1[#?\(&%%?[.M$.:RU\\K%
M"I2 JP+T5X_@T6\ZBQ$N8?Z><!U^=:.:]#L81?R._P2]G- @IB"*X8.$9Z5;
M-;6*1&<\2,M\SG*/G>,@4(^ 5,=2T3K5]F[YO&$>UTAQ1C<19@=9.E_* ,J2
M&8_K(#M!<+.43+/L8L.6*8V&>W3T:$.L&^[$#GOS>_FMOP)'*(VSI:7=12YE
M@GPBEMI(K H9!)K$-#9S4]<^^A%H]#!Q;=#>@9UI;AYJ"VQO8;(H%[3(-?N(
M6AI?#"_3KS 9]>/'D>_CAWWZT/_VZW PN9@Y0(O:!SUDFQ"E?VH6I=LE0"0.
MF"->.A!2.99%PR8U+2-[!-PYJK(V4._ 'C4;9E,.MAX+2GEC*2D!"T0B0N(L
M.$*#SZ!UDKQA ,FV$1XI%786W@:5'G:O>0O5\R'RT9<'G/'%V6"6IOKRG]/^
M5W\Y"VP87V^!Y_E\.AE/_,Q\+I_QS%^6B]HE3:7G!LT93A3C:$,KP4A(6N,V
MJ4L& '?>W?N.7Q'?8Z/3<12W@8Q[7YQNG]/:=KG+=&S6@>4D22EOCR<USLG&
M@ X=Y:4FD%&L8:'!UJ$]5@IVIJX-[&OS^O5U*<\-XTFY*3P?O)@'_]ZP :DU
MAH++1$2-4!GSQ 462,H11#):1+&/8W3/L(^ -?7$O($1>U_-;I[^/*\! @TZ
MH/.63$+S/^I,G/#ERM@'YH'Y(%>\I2IO-IVF,M5_E-E=MJ>25G0=WW ]F_?]
M\>^SB',/4IDD/ 'M\$#-I9 ,EY((E7U Z00J:D4=;4=UK"2C@S6^-;+D0,E7
MC3M:YGR6E(1%5> FV*IF!MV%[CAI0.WI<BM)6E)$UV0QO'1HTI9HIP#/0- D
MV)P)S3890='_AUI!K%V3Y)ZDGN-P9!?YMYW(L[@H*&;C(GB?R2"2L)EDJJ$4
M__:X54I+F+!X%#,:76QV7;?VT<<P+ML2^X8+VSUEUG:&S14:9I=]V(S124=)
MH-1]D;14TRK5$JSG4C%@R39\UUW[Z$>GP;UD5F5_OFFXS&M&@V$RE9 RE1SZ
MJM&1D+@@'KR6E'N54IVT\74LC\><.TC*%2*#;R.ZT:BK":[*!MQF9,<RW@[3
MW)U$.%#LU;>#&_A"Z:ZBJ2)Y9H-0W+ \E265DV4:(F-*U D3[Y8.]YIIW;!A
M%VFW;9B5IYMR@WGCC)+&&XGC$G L$CSY(G$9[0WEJ>)91#RZFEEFZY]]['N_
M?84^;$]B;=MEUW"NS,22A*(CY\3R4*H#\$2L,[-V6U9(GX'+9C5SUS_[<2EP
M+XG56X&<GRWPH"7O%,Z+N!01A<2O F>*Z&PD, ;X/VYG#9YUK<)6I+U-<_N(
MJJ;JGBWP& =*9^:)-0DM?&D4\=%;(GWPB"4JFIJ%*V[X\$>BNGU$5<$H?C,<
M?)H@K++#%&]O=L!K)< RW%4D+P\!$CQQG%KBG#:&2BMUJ.,.;4+S6!RB@R5=
MH<3B*J;%J=($556':#.NX[A#A^OM'B(<(/0*[M 6=!ZLH<DEU)35I9FU)(YZ
M1JPP(EBJF?5U[JV[I,(]KE!73-A%UE48X ?C=_Y[V?$6AY3&,\UE&DL$AR=2
M SI[G <B3;"@(.#_UWGX7,?2O?'=AI;6%'^0B"M4V[B93#?C-5@O*)YKQ""_
M2UDC2VP"35(4EFF*\W-U%OPJDL=R_A\DX0IIS3?Q+"C=!%'5<W\=TW'._,-T
M=8?B#Q!TA9U^ S)C$[H<,A%5FA!+(QGQUAIBO#7@?01.ZR_[(Y[QM36_BWSK
M6'>I5)##\RSXP>_G.4/IAXCXWKQ^=OY^V6E<!0.($F=*2TY,4,1F:4J-3?R!
MIU+Q.H4,&L'KW@(X5(_K9E_+2JA>?NL])/C\99'QV!^FV=)(8(Q *1"7?8GP
M+4_"F6HB--7:<Q6=ZZ((UR9LC\5H:%D++5:Y:(9PL5J:8.SPA74SRE-X;3U<
MPSL1Z #U5'^)W8(U2F$CY$BBLJDXW>69*5C"0U Y2Q^EZ>)5MDL*[?1">QP&
M[:*5SIES/E@ZV3%D9_ _1+O,B50)T-T60'QF- G)!%=U6L4T!'CLE\4VM+L3
M??933>?FSL<_A@N8EFO+K;(DY]*2"1@EGJ,9F, K2W6*D781*;85X)-CT'ZJ
MZ7P/*GGA2ZH'-.O!FU).MU3(9,(0GR"4KZPK=78ABV-PZ!KBTV/1GNK9^B+;
M9D7U33576ZBMWN1C#Z^ROC/XE7KKU#IM8K):BB@ET]XZEKUP2>.IH S?6)&V
M[<KKUR,L<^4RM4K[X$@(>%))ZBFQV@@BE N&1NNUJ9T*]J:]BNOWU?0-#CSE
M.A'*2\0?S8E8GC/17"0O<5GR7,MN.L&JRH>Q8?>*RKM(O^W(NE>^/_J[OYS"
MA^*-(,I2%0NA?1_WQ\LFE^]&P[! ?I[/X[SM8;Q99,=8[E-TI1RC\J4,FT/Y
M)$V825&(K"6CS7J*M +GX7+F2"II.V3LKAE\A&51M7OF\C)GB)-2\_5R.JO%
MUDO<@G015X=AZ$)0C1*U."4++."DRH'1+.JL#KY'3+N.E-9B_-N6:F#<<&I3
MUB3HJ(D4#BU,93G)C&5<+,**W*PB[TD43VM1^X>)JNT*[JV7XC)1"6Y $2,9
MVOS(/!)$"<8(:/0GSI6,>]26>:!UTUJDS5$55:46_%(X\[<=9TO3)Z $Z5]*
MTPM6FEU($ES(CJ9HF<Z5#>..2X?4,GYWE^>#*!FB( 6@X BRUB!?O2<X$RBQ
MXM%;'Q0UM;ISG6+)D .TO4NYD%VDWG4%B";8?I0+V5.7NY2"V$<179/%)>>M
MMH$X9]%5HZ6$'QK&^(? +9<9YPU])"0YI%Q(-8[L(O]JY4*N4BR#BYY'0"?=
MXR$KDQ/H-0E+T)=G/BN=C.>[>"<G6VQB)['?76QB%YE5*Q=RE3J6F'8<76 2
M<6 \\9@ASON,/I3C$)S /YM=A)UZP9?#-;B7S"KLSU?W'L^^7WWYMSZ,<)"+
M[V]*S][9%L31W+4A6**SQ8W'E'QX"990JAUH<$'2.HT'F^%[#"9?!4U4R*B\
M@O8K^/%T-&\DO8YWL4Z:@*UJ#>X$]SCF80V];Z-6-:75W)D:@68Y>4EQ!Z51
MR=)Q41(\ DO? Q:H2D'J5">R_P08=H]M>7($VT57-8GU>O!E.AG/)" 6I[%#
MF]I0FXF &(C4J&_GH13\ #2H6.":UO%([@#5O>U349W;B'.@+K;:MI4C5>8/
M0N/^X&HB[8:L;/_\*K$K#:>S$L2BC#,RB<A-"*5(BQ,J4>XE&L'.1BTW!0%L
M'ZFEQ;T<J0_C!8O3^> ]E*>Z>6_6_OBWP3",8?2UF&XS_N&/AX.(_\HOA+FX
M S:1R9RRP$6K+9&19^(LI80%YHV@3&15)QRFQFQ:VSX/Q_3<7\;IY>S+]\/+
MRU?#T1_(TEYT*CF&CE6*61'I3"IIPYD8E[+S2H=LZD005I_:$;?R8ZV'K3O^
M2="G0JSUIL/S'_W)Q=IDQK=G,[X]]ZN=<O99/2>RE(P"X3@'/ +Q#ZNI(U1Z
MX;.6CLLZD=E5IO.@UT$;M&M@/W?+F8X<N":3VC*G=U.T.?T8QCV7@[*V-#N5
M1A,T,T2)TO#$>"&E\OA-VYVOU\:,?BR'$V1.1Y=G!\SKKZCI-\/Q^/4@7D[1
M''\]>.E' _PUG&@0R5/KB-<!G7GE%4%WBJ%;ST)$=JO$ZC1^Z6R*/];,0^!6
MA:IN=<[*'()E/D1BDS X%3 D9&\("!843LD(7=G%JV=?'=7'FS^,Z, TD[0T
MLK>E<V2)I_))E8LBFYRUDE5*"FM[)EV%HCUFOVUW2IQ*,-R-J_3KFZQ+/Q[/
M;M"-LCXP-"=P(_$E5!"(9RGC'RJ#B32%2E4$[X1UK+?1XQ)F^^/J@8JKZ2@=
M+JG5Z2WK^3288#?OL+6F>/2WVT-I56^[;9$3#Y+\F5MN ?#4$ZKL&U:@O>HR
MX3$IRV64L5+1MP=*^N;/R0^.\[M0H6HP[*O^P"-:?WD=[CF^->MYX7LO?<X<
M/2TI$:[*D7CC!)& _J$3UIE8NYU>(Z /VA=O@RI;@V[;UW,G+]T?)L/X>\E9
M@M&XM&>??#_@67O[AQW^AMT0Z,J#M9/)HT_/><A,:F.#YB: H]%Y4!Y,;_O'
M'K8!?)B&<3_U_>C[!W\)YWDVSK5_QKQ@-.&6F9R01,YL71$E,2 93S&4%G55
MUOO=N Z*$O[5?RNI;6>?/HW@4VF=7>I!XM)\-^I'Z FJ9 *=B=6ES+1.I4*T
M381!!&.2 R'H??RZ?YCN]Z<6%7TK?K@]:;8=#3Z;X>OQ>(K['3P?CB?/AY\_
M]\?C>1&:DE;;$Z4U(E64!.,XSKID-Z;(2N&'R',VVNE[-Y.&8ST>C;<LUPI6
MS15"2"^F,S+.B@Y]N/ C&+^%/V8_&O=LY-;RS(EAY=J8<2 .[4&$FG5F8".S
M=6Y8F^%[%(RIJ)(*SV'O1L,(D,:O4#1+AI_GPN_A8#:#'LM@.;H.)$85T!S2
MB,TH0P1DZ82SULLZ!^*]T!X57=I51-OE$&Y,]Q_0_W0Q@73V%4;^$\Q./:3V
MC-<]X50.2@>BJ$0)Q,B)==(0)O&[6>0H?6IVO#0;\%%0H)J$*Y0GN)[^^6AN
ME?\*DXMA>CWX"N,)P(UI//N^_LO+7YO?)@>N,D['$.#2%D:CSP6"$^5DU$AU
MFUQM6_OP673U&E7SJ#J64D_E36FC;.<9&2A3JKTD+B.-9):<^"@U3DX)KQ4-
M3M8)XM@*Z5AO2<<CR5:V'J*L&D;X-9S20/4\?QSYP=C'HIUE7E<#A%4?@>['
M>)Q7G):4NDJ5.AHY#G<L(LPF":)L+(6)2L*S3I[0Q*G3)CNOZ\1O'(LS]SR"
M'(TRNRBB[9(-YU]@\*L?_0Z3 G1\5?D*54?/)A\O8/[#Y9W4=:<7:80)Z#JP
M3&0JT9>.H4 "Q,! &!V:%1_;:_@C&.DM*W'8J0;:OA:\ S&[ S&N(N>L(3&7
ME,( FE@J!9%&LVQ$Z4FI#^7,]N&?#&=:TD"-(PGW5_CGM)35^UI:#5WU(TV"
M288>:$9WD\CBAKI27C,R:Q@Z(1EDG8IT6P#],(A;4%2%J\4-L):-B!L JVL%
M;X-V/./W8 7>3XH#I-_-]G+5^<XRI;0A-I9>0HYQXHP7A%J:1'".66$? RT:
MV+?=L6(7H==GP[+A"N#>5XKWY%(]7$8/Y5W$D8 ',&5<4!,JO5=M@G.<R^86
MU'4W"?:0=864W0\3/YG91+, H)O>7 Z&:L4$R:;4H#"H+2LU)4YZS70*1K)*
MV\$V2#\LCE:452$QZ2:>91!9 T15C8UU3$>R,MI1VK"*Q"L<*1N0"1$E<X*B
M,Y71CW*(+'#$J#(S'- 3-[Q.";VN.'"?2=$5!781= W5SY[-YQ'1B^/-9)G0
M,H+21#GA\0:96&]LV>ZLUQ0,6WV9;DOU:UBZMR,.U="JP@\3;R?AL\LCKT1G
M];_"NTL_&,]/1C^&A#/X@FMF%GQ\0%CM[H,<'FY[X,16PG"9C<JY[(555&J3
M2O!M:8;&HW-.\=3;?;C#ENY+E/OP.]HR,/K:CS +>E@;ZNQR]D'XU7DND>2?
M!OU_09H'6)7XO/&;JW=QG;.D&7<R)L"CF2,\>DM!HMT,7&EJ/(U09=VW/)%#
MM\3%2) V WGYK7P)/0FXB$L?7V$4E$[PN(X9C20)994U 7*LLTTVP]?]UGE,
M/J[NNQ5T6,.3BQ>0IL43:4=VB\Q3[Y)!SX08SW%2+E'BD\V$9J5Y5L+32M6/
MJTRGJZ"A4V+O\7EQ*N%&>)H./\.5,?YF,<]YHP'GI716DQQ*CV$JT2W//)5N
M R%I YZQ.J_\=X ZVGW'\1DSK*.Y"C[/%FC+5B0-P%6]!;D3WG$N1%I39C.2
M'*")SND2% =T#3RA.J%W:*,E02-([YU1D>IH0YTWWB/0Y)X[D^.P9!<%5&#'
M>Q@#?N#%V2"]*/6@AU_F[?5F!N:R:T;D+/ 4B(FEKZ:B B<?+'%1)TF#3-;5
M\:P:@.O>3VA1G<.ZNJAA\L,E_NC37V$ (W^)0,_29Y3X>#)ODK[ NDRU5E*@
M'Q(S<>!1&!37CW4^$!N"M"7G2213QY3?!>9CHE ]_6S=>VK?Y?TV&%V9>)W<
MZS4?L,X=WYX37KGORRI1;TS*^%^I*0].XA^&NLPS%REOO.]K/O2!V\AFLWXT
M*G7JRY)X]OWZ5][Y[^5;9Z5JXTT'-7CE/;JE7FHT[JTB0:B 2\4H8363K-;>
M<C#V0S?A1C[2V^'\$3C-QAY_'$[\Y<V?%S_I[7#R?V!R[4'UDE'2"LT(NO>E
MQF0RN!?03)).,1IG+8<ZEX+5IG2$4(YNN;UZ IP&.2J8'M4F-K\W>#4<+;Y5
M?H_UG+>EB9@D,95RJQ+P .8@"1= J=8V^5@G&*7;>?Y8'Z=#HQK1=E<7:_>*
M?;Q-[O/+M"R!*HU"SHE1(J.0:"L"(Z"H]9EQT+R.$]C:%#K+WSTNP8^C\E.Y
M<2]F;,GJF-W:4"9YXLX0IZ$4^**)N.PI23@KIK6,R=5I,'83Q?'OU#OEP6JU
MBWWU46$S7&)9^-E-T%2]*;^-YSA7X_OK9XNB#Q!N?96;'*--1A* 5/95/(BM
M]Y8H'K.QE(E8J2Q2%ZJ^YWJ[EJ9WD6GK?<V7QERYJUAV'BGX%A=<0O.4R]MU
M$"F4X'E*+$V.I!RL\T)HF9M5J;EGH.ZMZ$.4,*PDP0I.W_P46B;$<(H&M/*<
M6/! 9+:1N/*@:PRZGYXI+4*=T)!;,)[V@;Z_1FID'NXMB.MI#-+*6FHRI[I)
MBQ5F=1SKX@"RK'HUIZ+I&DYZC;D%4$88="&9F(5]EP<DGDHQ A$#8RH:'YXX
M>^\QF$Z<O+LHN )I;QD.YU_*A)8%MF,(B3%-@M=HBP2)F$*,:(LD&2W52>58
M]^9T%=()7G)6U_BV:\^#U%7!PGL/X\FH'R>+!\??4#/C]Q]^6[Y0.Q^9#YPP
M7D+X#)JT3BE%?$B44L]B"G5VL3MA_>!3BVH[6F#!IBFT'$IPUQ!U@@<:3VHU
M/2B9D-$OB*"<U-+@GA "U4;DTF/0;@X7N&NPHP<(J&@C]>BT6BXBD3*@#YM"
M)"D&K3UN<<)6JJ)V] "!O1$LE7S5/N-\<@&CCQ=^,#\RQE</8S<[:9;:M%D8
M080UZ$[B;D(L$HA8W$&DU%:#JE0ZL]-YGN"NW^XJV-EL/1Z-:H0VUI_MV^GL
M= R071#!X)'K,Y$>N>USZ2%AE*84%0*B4EVMKJ;X@)9*!USM?EGM0;1CW&OL
M/=&_XD=,QJ\'\YB+7C!1AE+W4PGIB;3>X#R+22NI,@X@1EVG=5=7,_RQGHZR
MG@Z@V3$NN_>>Y]]G^K@Q3^-E<()$72K,6YG0>D@"7;@(6DFFI:]S@=/5#'\L
MIZ,LIP-H5J&"5+UYHA8R]&].-?E@.*6:Q!P=3A7/8)\C_M4KY4.P3/)*Y>VZ
MF^2/17641748V6HTCNG,O)5<@T^^!-,FG"@OH>G21,)ELN"E8#X_V'N'37[4
M2>IBI8?1S&1ZX2=PU33VYA+B$EC@.9#,2QJM2)Y81VFIW*^R-(%[6B>_Y,0$
M\8#VR@=SE52-B _*,VXNCIZ"P%3DDG@:7(D!I"1P$T@""SD[[@WGCW8Q/J 5
M> I+X 27\T[\?5!K^/:UP_V",(Q;)RR0%$(B4I6"SE90XI4 RK,L;[D/;"'O
M*((?J_DT5W--)C_@&[;[!>'  >B2,0C&ESXPD;CL+.$<8E :/9M*,50G(X(?
M2_HTEW1-)C_$6[[I",8-;!7.LN8Y$^5T>8G+B@2?+4D.:'3&2>7\ UO/N\S_
MQV(^S<5<C<,/\U[Q?AEH(1-/8'"Y152C%!Z]#^](S $]D9S11#E25'WG/O-Q
MBQ%PZ22N)JG+S2]-B02#2\I';B43G./Z^E&,X!3N_8ZB\E,I1G [@R1:*BSC
MFB1+2^>$R(D/*I&4-;H[S#+/ZMRW/;KLQ1V8<&?VXBX:>2AY7TWF]"-[<8_L
MQ9W(TD4"V#Z:?B@L!A< 3<I,,I10*^\9<<JBN2PR36@]4Q6/%+Q_,NS=*7OQ
MY,B[BX+KE#V^(WV)>OP_+ADZ:R6"HJ3&6X,&D+89%#HZ29DZ%^I/(>ML)\WO
ME'6VB]J.UIKJK1_-:_&VG&JV]KEU\LONAK^25!:,8<Q8[[.@,BMT&C*5$8S-
MD3EK_,:DLK41CIY))H+CX(TBSG%D+%>YU&5SQ&MA<2Z&&EFGC-@)9)*59?9Z
M/)Y">C$M'>OGU[ZS4<=;:\>,>\['J+U"=Y'Z$ML9#0G"*B*2%CDQ2"E72G'9
M#_ )[JWM\G*]L6M]Q;:8I#6K5;2WR)932._P\%AZH+U(P2D)AB2=#9$Y1Q(4
M1&*2$\::X#Q5]^W$%7 ]&2H>6Z<URLV-AA$@C5^AC.>+9[9HK!<\2T!Q2+1[
MI$%\WDM!-#<:HF$ZY3JURC?C>3(,:U$M-:(-[MJ"Y]]_-1PMZA2C )A*1J=4
MZJ]Q(K71./?,B.>:4G3F: R57.*=<#XY<E548XWW\-:N834PZ]">)T:4IS#O
M K':")*DY:"RS396BCI[@F\P!Q'T*"H_]AO,>#3I?>Q/RK1?#U+_:S]-_>7L
M+HSEI,$&("H81F0R,%M\2+<4&!.4<=FHBB2.<(.T^+=5PFZ%\/#?8'9BPK!-
MC;1HM6T$](_^Y.(]7,[D,;[H?_DX?#F8]"??%[=73:#N\KRR'XGN!MGM:TE+
M:KV+)!5T<F0:&6ZICVAK.A_0C39<DX X2:3H6P::+'[\XZ+/EN>*X[-G%U6T
MS)H7_1%$_/'B_CIP)=!_E80)KXF4G*/SJDIA/NJM$4[A]ULCQ>VQN[/:JZMH
MV(I\*Q08NEV W6;-B]OI>%*DM&8C-H5,%*7*Q1(/Z.H$@SRNUA3[V"$'ZZ/"
M7<!J]X0&:)Y8:XI=]'-/:XH]A%N_-47V1IM2*),ZX8ADAA*75"3<9R4$9]XS
M_6!5O5-KBO8TO8M,NVY-884+W)6RN\8&-&^L)$[C-)VF6G)MF?./HS7%3DK8
MI37%+A+LY+G_PS2,X9]3/*%>?BU'UP$O_-L^ZO!'_48@5][QH\C9*6X<*#Q8
MD[4R*L%<$DSH4C:XM^U##[RKO/VIU[=A@&-SE0U)2:/F&6H^1)6(9C)2HZ)7
MK%(9B2V(#MHIG@\O\5O#>=###=/G%2#U(O2_%DMGUE<P36/1]^O!^^%W?SGY
M_O_;NYK6-F(@>N]_F:+5MRZ%D)R:T$#HO>AC% R)USA.2_KK*]F;.C%VO+:E
M75QZ\6'!YGGFH7EZ,]+>V07^X-I%;F4^3Y)5+1H#AAL+C4X;)6%T"('U6DA.
MPS&"[U^"'N]6G $S4;HW?AKTU6TSM[$3V-_3UY-$3Y$D$HFW%$3,:[<0,<EK
M2X!P&P,UP6FM!^#6#GC_*5<B;S5&@M^':;55$TB4X1HADDB 2[1@\MEN]#(Z
M$U0POL[+F[:A&:SU4Y(PQ<([=F]FUQ]YG58.P7L>B0&T-"1E1PEHKRU0(;AB
MCE#?5+K/=3N@T7R2DQ.]ASG'!'R ]2)]K=L\] %6]S3++FCC>")%$KB?%"=$
M?U!Z.$H=ZBA!<:&!VT: Y<*!I9JF/0MQ8E/[GB<M]O@GP[+BD*#79T-G!O"&
MD,8* 8SQY2L- SAG-.@H5!.L:GRM T/;X(RN3(]-U\<D."+6!?<YN:-SV3XG
M)3*?V?GB9>T8HI92R0@D, J<YIEDFG1O((9+*R,&J_ODOE??;!N"L]<'14);
ML"V2\=SAK//\+N[GN!2>FQ!?#?T>((O/9/2&-_PTQNF9;(=*0^&&>G^P)FH6
MA-/@@Z'Y%%I(.V1I@$7O@E(J2EUN &-DKGPP>C$250Z)?NG&S/5+^\M>3^:3
MZ67[^681NJ+FA:.:I#*9I)%*&_(@4E%#EI9-)E*IE(&RC8;\#JMK^^\/.V!1
M*1-MV3!6F+'(NN<VOO'1EH3&R-%QE1A,.0/.J,QSM P4,8(T0GF'=:Z+V0KG
M[-5"N6!7&'!_.SMR,0W?VJE=/\D&Z9-=^JA/'6'[P*WJ,!P(>!S?H4"J-V]B
M&2!/%7:?A\*FQOCE1%)$E7U>*_/;=0U$@<PJF2BQ65;^)5KM\2W&9]4AZ2DM
M1&XF/L5I7:&O\"<^M+-5L7Y\3 O[Q#Y,?B\GXJXF^>(#][SJ 'VUL[]3$#(?
M <%4NTF3;^63J,&AD\"0H&#$ZX"JEVXI F=XXZ-JQMM1TW7HT$KW.'^X)/V^
M?/H#4$L#!!0    ( ,V I53X._K8*-H  (LG 0 4    87)D>"TR,#(R,#,S
M,5]G,2YJ<&?LO =8D]W6-O@@*HH%09 F1 6D"2A% 8&(O("(@( 0>E1$>E4Z
M) H"4B-%4$"B(-*)=&F)= $1J9'0";TFE!!(F_C--_//-7/.S/>=]SW_N?YK
MSB8K/->5PEY[K76O>ZV]'QB_&%/ J=LZ>CH "PL+<)_Y S"F 57M .?' &!@
M $@! ' $8#4^!; PKUA^/QES @=_7P. K(@QU_^X9OX&&*. %G" A>7WXS\'
MZR'6W^/PP8.LA]@.L[']EB-'CQT]<H3]"!L;^PEV]F/'F8/MZ$F.$\=/_K[^
M_26_/_[[4\S'\2-L1X[_MP?C*\!YY.#G@Y]962X !SA96#E9&*T B#G70RS_
M,8#_'"P'6 \>.LR<$OLQYANJ3C&GS\IZ@#G90P>9JK&$,E\'#G(>XCI_1?/P
M:>,';!>\N>6?)WXX(G*SK(G'I(\@JO#0)^PH^QE>/GX!L8OB$I)2BDI7KRFK
MJ&K]H:VC>TOOMND],W.(A:65_2.'QXY.SBY/GOKZ^0<$!H6_B(B,>AD=DY2<
M\CHU[<W;].R<C[F?\O(+"LLK*JNJ:[[4UC6WM+:U=WSK[.H?&!P:QOX:P4W/
MX&?GYA<6EY:)FUO;.Z1=\M[^;[U8 %:6_V/\3;TXF7H=8-K@(-MOO5@.^/]^
M ^?!0^>O'.;2-&9[X'WZ@OSS(]PW$S^4-1T543 A\#STZ6,_(ZHX+4;\K=I_
M:/9?4RSL']+L_U3L?^B% XZSLC"-Q\H)@ $:-3M& OBW_%O^+?^6?\M_43Y@
M!DNVBYXH#;5>_8F"O&Z6P*L;";%0BY*Q8"<40';[C";F1:R-!UQY9WA:'#Y]
MW,@>5UO&-Z9^*&@K+M0*^G8@JFE&NOYNGF30108@4I[= +>@-<*X%B-2C?BL
MOW]])-.8VSKZY8=\6>)>^KPOE"S9VTQ31EYT#Z((37T>15+6TI;LA&#RWYP8
MP&E^_3GEFMV+O3Y1AQ>&,%'A15LODB@XW9^#D&Y5!)4GMND**PE\DEP(3T.H
MG(M%&HIZJ#. VVT-#"#LB[/$PBJ=?5#,QNO1()<"LDEP"R65%QVB8#33UC'[
MD0%(5 SE3>>=OD?V2MK[@OIQBW(@AERZ0F??4&BC(($.P86B%>UVC3 6ZO*[
M#BI/B[F3A=;4.PV5ZPK+LEW@$^%[V+,-%M.^U><Q%)^\%6X_W6:81/!T/P.H
M6:(G:4QEHWD80%05.98>(<3+  XXY-"%L3-R^]Q/H=2CJ64,X&5M"WAKCP%,
M<3%7R9/\(L2  6A Z&R@+8WE;+1@)5.%&M=;/23$X24?667.B6]OJ(-#W5"R
M=.Z,/F6#9?3;F\7T6BUDP0L&(-6O(>-5/WD*2ZL%]U_Z8<=%O#EZ$DG#< S?
MHCR,(4_TTMF7G);HB5/77XZJBPRUAH-,V>EF5?8,X-!C0N8+6EXS_4)4(D)R
M.CF!9NE:CHP>NV(ZW8;*?(Q1SDG(BU0S,III!J>\9P"2"LO+TO,T!3K[:\(P
M%7%UM.V,I>AC5XD?X(UHZR7;BXG,;SQ)UB]\;4Y43/48/X,WK+4;61:1WL<6
M:,638:BFN+RM=&B&;IIUV)-]J/#)O*X3=+VL$>U 4C0%0E4BLAA[XA$GBJY\
M/3V16RN>T,^S4]JA180ES_B.?UI.A[W_\L.]U,0#/"6*K8G\_OD-8C>H#$E^
MA)SM/7TZ=8;  #:X<SF(VJ@> 6YC;;],36WNNRS_OY*#:_Q*"_!3<%>.*/CQ
MX[%% 16WK5^278.=3PQ^W>=^>85M)6:VW9[PZU:PC=FM9O79?FAP&3;\ZT/O
M)R0+*Y_,>NVK]-FWBRF03I@&T_W* H(-QD&15*5"EZ3CSY6VBYQ!@X<FOJLG
M#-A)XU%D2?_6WC-GK(^]DVOY7 -8X-A"@BOK]W;Y4+U;1F>^/&'S94\H6CM2
M0T9;T'J0[QU@7$1A^1]/A\0F?/0)-OV4?K"N[;#HX\?LA?)ZR@#D&%X.%SR]
M\8SU!*1=X+B\[NZ'A"7'M["RCEIF0%,;B'EMO=Q4;1_?#4Y7J_*%\[(HT22E
M?<GKD$6@U _->H6(RZG[^L!D*Q/% )+:Y&@2%&K]UW277E",9Q=G#=V "47;
MR=M:;0R <,\H2O7HHX$'V*H.D._[RE.MDZ;2TAR46>S; !2=?32_I_8I^/"(
M-0/PTU\9S@#?T[X#G]1!JV6C181F)KD>:K 7IJ_QH7[8]!(U1EFG02>F=]Z)
M&^^F(.>$S<C">S,(LJ1NF]&I]3/[J6DYTHYSY9^UG@6SRFYJU/8V!NY&@YTW
M7F9=DB%M" 0D:8>L)UQ?.A_' +Z>BJ!)O\A&Z_.W\;=+T_ \)G:&/C7CP3 V
M['TR5+R9 =1/.W?TW+Q&68.WEN6[I%DU=KSS]_;VE5S>_&:+F'%IY(9$2%Y=
M[_6[HF=YB-OXUH._YR.W$_I4R\O,35]I-AU.B@&6U:X3Z]OM.-D5,3QDA)$9
M_8@2?R*8YT3X3U^A(@QADLK-,=,1Q8ZBBL[OGV< ES8N3:>!"3+/&0!QF1@C
MC6TB'G:,8"Y5JZ%P<A+UM%J<(\?<&]1NIKK*?K/<ENY0UIG?CD2N_IH_K';M
MO<NMO&2W35P]1X'\<3K/4A83^L)0 6"37W4=43LT*1UE&9:$9<7]S!S8;=>I
M(.D5+PTI;UE!H^(GI?UQ4+R#7.O>)?^($*5H[#(5T> @1K;M((!-&@0IGB$R
M1/10#1'VSE'$U^"&4NK 4MW=0O@!UP'%>(_>UC.NW@\"74,])OVL \W_ -_\
M&$-U+L)Q1/O*';,K&4[+ASK72/=;6^)X002Q<UB< UWU(=XAH47'SLL#'#Y/
M[2,&1CT/T'-]WMJE87H;&C-'?4L1TX8]"  QBXZ\*4\9WM;^Y6KB3JQIM&P-
MS3;J+0- 8"O(;'3V(55N1)LP5Z31QI@SY-"5[9@["W0Z9-(AZXH7_6)?Z9P>
M PBZ!@T)1),2"2K(\ ;-R(9\B6'H^&ODN"RTJ6+-1;J-#J)/,H!C#3!.\/0Y
M>ML7^)Y]8:M[->W1O!P5U@C7&W;;H1Q9+_8H0;D_XM=[__I1/#WN8S@TVV&O
MG14D',+C- @=3_+;T3?; E__+A\".V#S!B?_B0$TGD$M3B!F+;-CI/O5?O[+
M2<=?+EN>L? JS#.-8T=%AM4T72]^$-;]=8D!]'M4+)H%:-'WC&T"5EN.A7]<
M>;BLPVG[J!\:/?*\FVC159C E9DGWB]90Q9.-AZWU;7WV#(0]6KA&UM?Y;D7
ME!3 0]AM\R1+S9<4[*723_QTW_YB>*-AT+HW,Z%5YXLVV&0&[4%.)&+:)GD]
M&B:Y L)-A@+'+J3:?CZ_8Y%V!!,60\U3(^:(-T_P'>EJJ*=>H> PXX*!R*)'
ML&,+?$5&((F?",\8J(\?90XNLGU]QG-MC] [G://01K!REV8&EVZ0LL1I]<]
MTF:ZV#PZD/R:F7!MB&>*'T4UUQU&YK1DRK2M9!1\VV&_FHVT_P+IK(3,ONV(
MS=2,;W#J,48XR< )XOYP?5#)+)V30&?O+V&SLIW?9L*/V>M&#S\D)]P)<3;$
MPIGMI9I!$;3EHK_UWH09AK9_1WS)QI8;LL!7[!!B8.3Z,B,3:7EU<F('K-L\
MM?B@@'))D?M"G;8H>NZ]L3;/CZ=,_+GQI\25K-6!6VBA::U9"9<5+.[RS^M?
M3WM14X;3T2V;&M;FR96JR!-3=?]4[3R">OO.ZFX!+WNTXJZ!+3AQ&]+B299$
MM1H=?C,SQ  J0HQ=&D!5-\\CA?MUGY/+JT*/$5KH[(%3(/Y KY57R\(\=1Y'
MWVH,N",U1>W]9[[E3&#4)%#H3NK=F;/H/M)$OW2N43"Q'[IWA:#2$4%5?V-G
MUS&BMY.W3A?H8 !B8'LU,?P[W@[<_<:?.^Y@\RIEVEIN\_<<]6@3KU"$4@$T
M'GV6J),[13.YOB9^MW% [H**WMICIT?0',G#C91I")6[MX-^^$I+B4Q:S*HI
M$)N[*7M#Z$7^%7)=&6JXW$CP,T_)\1_)3*J:KK$=:M6O/_L1IO^.+(+("9Q[
M;69&+=]U6,PJ@U\[O6T20X"^F"08PZ.@7'?\=K') ="[R:Q=@VENHI0[M7>"
MT9.YP27Q5('<3/\S ]K>GO)1"1:9JJI9+SB;A&<P-EU;WP\[&.&FI'6R-_U=
MASS0SJ#$^;<7P3(%JV7;#@9[1>*+)/C%3J?LF!V.2Q+9,<#_LE+L>9;ZQT\Z
M_V)\04"X>5F_6PJ^IS;EXM9B3A'H_E%4"OT:O.G>FENZ*XC%&>SF_5H@ZV/N
MA?V/YR(UVKHH!:B,WB_U4IT?>A#%V?O:KN)+/*B>D4"DWBM"JFMF;QJ+=J=O
M<K_TL)%14OVF1AU6B0(Z[OP$Z@))K0M]_67\TJY\L7&[NOX5 /(#RH^9RK,[
M0;B6X3J=$8S@66:_O9=OT)@NC R-G&< SPK8*$-,/MNZ$:\A1>XN#$6UUHV3
M"BYD?O2Y^NL! _!1:I:;.N2S0S8Z11Z)1P59:BO=!O=(WX:*$5#(:P64&HX
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M(8MYU-/79IJ("U]U^CQ$M^0:Q+W< RGM$W<:_J!QO G'78&^\]U $@R-8A@
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MAZD\V,O# R77\Y#QR(]NPK%F\(7ZSPBA605VT]:7Z<$IVW1$O5ID<4]ZB"/
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M[CN%_>Q07I&C.Z)4=1;<P9&"]$+@J-ENI^\AN3%3RVHM"AC%9N<<_,*#[0W
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M/M"(8^P17H4'\6!3.W#@>NP[ GD"V$N8G-7AP2I\("B$4Y<1(:CEU0_0FLJ
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M6-,D/"#'[P3!]TO8=!T*;>A:& ?;O\)LT?&/*Y!]5C[ #X55[7)C*")E<HZ
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MXD! 7J+[[:;M2:?\?<FP[&-9[W_0BT\DF2KV23\3"7HOM"[+# QHQYXX6]<
M!7$GM^O1_#EBYFG_U'2*.@M4F"+&^EUXL#E55Q[LPP0^978"P3@V6 (XAHMY
MWBH(?C^JI=N7 [!Z:.!!@[B@4U@VEM;.%A8>;:FV4.6N8/SX5W$)>/#+%=]'
M:]%2B54XR;NLU3B.W]VU1T.U*E6O;WG@;F\2_OK91T%?U5'_7JJ:DTX:SB'_
M2FO^4;. 5!,;94/5(2TQ]A$RL*N?455EB<FVDTMTS!C0=1? 4G2O-@+2R*Q)
M.$,668-E&&$$M%\\4F0O"MV40.^)96O&>V%'T#52]0I3,^ B>7!8+,U*%R[,
M]-Y+BNXW&.M"23,N!G^+'_>.N;^!!QL?3+!Q]B(D.''X94UW:+^L:OJ".<K8
M1*3$564[5Q6\V<>J^1A;0\/)OT'G"&9^W^_[C!^W/E7FGS/-Q(O))BPDAXMW
M9*NK2ILGYGWH,LZU3,.H,@(N%E-KR_S22)=L2[L69+XGJW!V2XO8,G;J7,.G
M($;2$%L(9 $&7;7)BV[!^#9H?6?;T<(K,BDTY@%VO?.D.K@3$@O>-O:06/!Y
M[.2=W<7,0L1S257,/)4KWR.TDWL.)R[YJBYYHO@*KD[KZ;]>"U%&]MMAO-<K
MT:CK-L7PTHS"=5;)"WAKYL[78^\EAY^WWMOE%MMT;16@/Z$N<@[CUFE*I,_W
MTUFJ^#>(@5,*"%#3T.-)D_.3W(*(_=TRCX[^;L(Y^'"C-J']@)2D+97Z7C)E
M;_FX'8=;>UM*>I?ZTK AH6P0 HOI<_^GBD)A2'Z/9(/[--"BV1]H8+2="D J
M" .F&AGE!%U@) VS2UN&^T;15<3S3, GJ^$Q=R&]IR"\7)#:=H]#P8\A1*D(
M)$4_1OUZF#WC,:'V.%A*#9!<C9!(-\X^IP_1/XX,=,?Q36W=?[B(8JP_$M?'
M@XEQI!]->-M<RG>4Y8PZR%W$51;Y=%+M%^F>8:<3PS:QM<:4;ZV<?>B<M?%:
M'T6^+2^:'=\2GCY_<O70\ F_*6X$=&.XZQ%MOYXM&T88R:&'M7MM&CG:G_WI
M4@M);JY:N"-KKI^I! IUI7D3MJ/E?/.!CM5S!]O.25!.K$#J"DA%"X?LY:9O
MN_VA1(?;%<H5+J>6XW,IZ.,X;Z7RW:@,*G\20:T<_>%?I1'7^]W3Z8'O-Q:Z
ME*-#I>:>--1<M!:MU#H]BQ+AG')X%UO2DVT+4YQ;B!<TXOJ8_[QGTYOGQ(.I
M&"PZG$TH;WR="1QS7="=785^=>H4B/YE\@^= E$+A^+K# -RL#=)-N>FCZWM
M0V#E$ J)K"-0D1(\F%*5S>;\082?FZ?BX&./XQ<1$#GM+=]3W9B4I!**,4&A
M*81K"QR5]+;JGSJ3<FL7C%>T^4-P&(5@QQ]F3F?!+1TT%"A"F!>SL]-,/*YI
M(M8ELX'SP?3BA4>SI1OX8\XA+:L\71S&TDYQ]726ONCF?+AE;^A:BOO!#*F1
MI\ZK72.D:@OM$YSC[6@]UWPD,E=O:.^8CNRIP\"/F\J@"%=^!.,]?S+_6R;6
M0AO2Q(&6JE-O<=Q20)5!CF1KFAWH3>ATCD)1(C)8^9 V>O!6%=JD4GC 'R5(
MI:#XLW$7OPYMJQK]":&T(!3SGNP)=C]_]K^.XE)8-B<X+-Y_W_TYK: PW,&?
M+'YN5R!_&)=?L"I3FD8DAY$V@8JSH$2<QY#B?-2F!]\ND$X;,FH;,6F$1/3#
M^K)DV0@70R?5!B6SSZ@6:V @?27N&7,QK\J\\9[6+>8H*/HQK@$R_8&Z(U @
M'$E?_)?'4-JDL$48%@P"/95JG3/4Y(I1PA:\RCX#G*WQ=O?3@M1&%A5+KZNS
M1IH_.;$O//6L.3CWK3B3!QOUUV<]V/J#ZZ95>75J1H=PN=R1(8MN$[<K3X^\
M39.\+A/W.>X8QQ+Q&S_S-8$(_&4]SW]Y[4#0_:D 1XX'$^#<2,F,ERGOS-FW
M4Y"3O]D2P4&?P.@2YS=B?N<\HJ(X"O@PC%Q[CV9AWI"1E^U^R-G.M\4">X\!
MXJ 7;4")N#4"-1S .0+G%H)!5+F372+/@*$$CIT2-V^<7]CE@WC_9PL2[O.3
MN"K^/=+Y28G'T(6H\'2%Y:.:<*-[+8^A#5%%S!/\P9VE8]S<W[\ERMAIO+O8
M1<OY0&B_<L35^8(($"^WEH6;'#Z&_8971S7VL]]"^)43D/1/F<A)*(A+A?3C
MYYJCGU[N<@]UCIX3:A %N_$I"HT$%])VN BF<5BYP&RP_<;6BCKI^DA9N:6+
M#(=RU["'^%V1MZ>RA\X-],@2*=B/(W.F59.%^FWVIJ(K+G(,E:5.OG)W8[_[
MRPU*G8@[VR78OO2W5,W]0^,S7V^NM+%2)B#*$3.QNLB#40WAVR4]Z>E?BP<*
M[_:*(H,&Y/G/9[/M+0]X3L7O>6M[="UC*\M-%G(&'*+F36I@PR-W]K6W9=Z6
MJ'!LISA$Z4N$R2=_B:O!4/3(L<0F4N "?0L\F(FK]YG!)\/M89,DQVG4 ^0/
M@&K&M9J''\B3.#GP(B<P:J>$QHW)Q#"/L[]AGB,G,(J]8^2$#M )$K<-8-!T
M\BZ32<H]9="B!1)6V9CTIB<F.@ <]_./:QZ?\& 5\AA(#3I[*5A3W:OC$_7>
MW-MWSUA6S.N5L/TK@=78\GUX$VXX1@$70,K3#5J5EUF:<Y4%V\HFQY<<*J/\
M8KX3..O+FZHXRVP%K??!T7D2XW$,^U122EZY;BWC&:0@[HV946G(A)L=/-A>
M]V^K2&PSUYC_;(J[X)$_% R,.%"HA!HW5_S]V:CS76J<_I.L_\'<>T<UO7;K
MHK&B"&(!D1J5)B"$*DB+J("(@" 0BA 5:2(@(CTD(@)*BQ1!$(A21&J0+B61
M+DVD=P*A]X0:4F]8W[[CG'/W<NVOW;/W&,X_9 SXM?D^\WG>=Q8\"]^ 1T/S
M*/J]G/^%,,KC"N"P]^0UZF,2#UY@G^TI&\,G]D5;W">IQ(GM-D &618=,Y4<
M3H$*HU^%5:]T (DZICLK\YWY$T]V*$*JG\)C2T!M($*;SH[;(K)E6-SBEJS9
M(0N#(^K9DJ07=-P_K' H]?2C5R;6EM>"Z:(#%I?+LK]DIIU2R9!=_;$])L^1
M,U"[17Y'.>DC1C]A..1==[F]RKZZA-[U=L=6E0<"UK(#!L._36"@*QMSKYUO
MW8G=K=*"L].:I^$*]H+UY\V?;^4JHV.J4?B$<;]2)B[WLZS[_#WA$C)G2.5<
M8G)]0@2\6\SXYG8]7DJ#+ZW^4[3\,8X"H6N(<737XUT=.FO-!'#%+410@,CI
M5*E_9G?%[MPSH12/V&5>$2 ![,&4"%_C SQ")5JDG)0[8"DHIE0%ZQ)0\F34
MR>YP/U/CH-U<-#51&,;'!&'B)"WD+TN"OL ;A[';N.7BB43LMZQP!&5S!4AO
ML?ED<X@)+CT#B%(&P,[E,NX*O0U364JV-U1B>M  9F '>O2A.D;W5>YXL@;=
M!(5'L+J[ @<=?"JM<PQ79UW@3'>&_$*I_2<1A,+C.+3P:ZR+?K<9@$5%/5T7
M80; Z\9%Q'5+3I/>+)[&.LNL=(D4W6NWGG;E&Y$Z<YR*'8=3&E/JSJY*B3C:
M7:=>RG@)WB]1X\^Q,DF8Q/#1>S 7(FV'G/-N*CI[T&8^7&( XM(T21 DA"#M
MDM!Y("K_9>KFS$7:SX'=542 '<\KV4%>Y4$78]F$<;1;?"WS+E/]_KY&R';,
MI2E,/6NYTR1X(1IN<E-AWDK@F:4NRV09Z"=& =T#)8GAZKU(GA19Q\^.[=Z6
M&QIH&:&2BI-T]TL.1'1O-;!U7/*UK07:*\).;'% @FJ'B-YUB^!)JR-L?LE:
M,XM[6'-Z%O'*94.]8*\!<OHNYY]"XX8;G162QP XT?LLXU2+:2FVSFX1F^T/
MH;1L\L"""!P"'^;=H0HC2D&1!4JNZUNGG9/G:+?RS*F7'V)YB54G6V*,,\K?
M:>U<;-OZ2@&]5(;#5O,A)4[8FE9P9N?>V<7N?7K67VX<F($?H?]H>(YP8 ".
M+\GISD*EL$,@CYUJ$D9;C+;,0E9&WT2',H$T#LQ%K\6#]MHB7_VZ>#+2N$.W
M>>WNT8N"F6\_D6\XK[+21R?4-BA60I_"8JN[F3B5GNXVH OKQ&NH_6  BCQ:
M2>:YFAC'/7:44:.(W!LO3#DP]3L%P-$.'"F>5*)*N V#+</.4FO EFXKSK?9
MV(MB[G%<+7H#$'P!B1K ,>_<!/4*1XBCGN^AFKH)+J'91I^DO)@>N7TMF8S7
M%%0_(+N%?B%)*FYX$DZ1U,C7EOCU80Z945K>"H$*4>[6)^]0(.?3+0TV7DXG
MY#W'_KS\1];C)++B'\$GA6J^R42J,YXFJ<-<7\A(RW5)Y0JZ./\YFCZ\WLGR
MD8IT@HN#*\:Z)D./38_6=P< ?(ON0)'$'%XP )-*M"_/?5/!<CC-$&L#&^5#
MD$<.A.A?="ZR-;3'YO!,:B>HP7:Z-%N$:^$0XJ?A*C@1]JR=]OE!Z'>M!0-I
MPWY77-S=O:U.Z#=@R-^51.S+C*V&! 9@K\OK#KY#P'9#6K30=V6 1TK!/%Y&
M(^\%7'&>$R*MRL)FQOOY#+I>N0*KS?10^=P#$:G<IPVY]/"OXA)RO*'1)*R6
M%ZX$45],2)_*"E,X"4Q@?T<IK21?90"JF;+M?.7 :>CWP7:IVY<O^#S&<O*%
M;QET$L&80I\<GV0U604,3Z;(?-_ !!-'/ 1^>_@TAB+HNIT,1X>,7^KV]K#-
M;O1%&JI(H2C7-]'YDA,(D@A+&+88(T,*U;$?KOP<)V:$K":T5@!WV@L0K!0\
MMDA-O"G -N2+=.%L^*[N",&1KDRT.DR@ZEEOHBXE_)1@ ,+VRASG0^?^C-NR
MM.*8WO5R#8\-5?&.N/0)Y#E9+F/CLMA?=)*I2E[H(NNTQ3)A)Z%%P[-OG/#6
MO&N&V/*HQ2;RF9<^]V!%Z?MY#'M/0Q/ I0[+0U_H';A3HH71]J@;-?8)>M62
MZQUGX%."J0\?'09>CY!!SZ)X*@PR+QEWRA"KQ>Q4G\=T*<V(V"V6]J63K6I3
M+V5!6-?5;M20K.MH#[><?!O'R.J7'1+V"D-T*87_=;#ZW_/I ,MP $RXDC1%
M]- BC%6X"VQ.C-W$KM>-P9V@A#ONJ1F!XUA+!<J1Y[E'7%RFS%U6TLW3(K6Y
MN+0!@M_9()U8@N':D)EA((8M%CH@145S.G>]Z"H?+RS[8?>:+'^"IT8F/2>9
M=A(Z8,-)2%Z/^(J7E2VU['=1[X74H1QRW?H[31 72/F-;SLV%$/K;VU^&1,M
M>X8X;=W_!J27?W8O:SIZ]T\K74X'0J,8@!/5>Y.C$,BM#BM5;*GBL?#JC<Y$
M(3#<?P?=AXO"2.SU'9C AFVYM*(?9(RV"1K(GXLLXV@L!/-2P]!S;@)?$U)/
M'ZD4;Z'N&E,3:5P3!L=_->)QD"/H!'E$TM[I!8IC_MQ?)3?GD;B(<M @''<U
M&'^S;:5[[>2<":7[&MS"!%'#)T-UWJK[N2ZE_5/RM;#NQY2#T3]")1:U-5E^
MA5%MT3U_]%5T(UG@BKT2V+I]$^A\MIF&L1M<5]ET!%.M+LQ]NPZM\0&F^JMI
MP3ZG=SNG:N3J@LR82V^EAP#EEP,[A7[Z<->R=EVO:XE[/F6 5NV_M^R[=39^
M5QFT[]T4ZH@E["K!/O<33GI)W;)?3]=G6C+['M(]&>D.?3LN2RC%!59;9#N6
MM\R,.T&,+6^#1[0EW%>:!?LH E 4F& "9D)K*-6QF"A5;?6$>M<E\>;>M!N=
M;1[#2^38B@&\QN5'-CCIK*2[-EMB3H@0Z(RD%?4VK:I6;6?07E&N%3F6@V9R
M0^J4/P,0#)3[D]$<_^6&YU-$K2A<D!9;1[](O)V]83.J\WGDJ\ 9Q0WAYJ]R
MYSIS>"G[JP>V-4E,6<U:M>U.*$@0AEOW#(6W12/?Z\G*%6HL58.HAVLDL!45
M0''ZSQ^%@V;YTB8X4N8:^%L5##FYJMR!+?$8-1!7;4[,I)^EY*[=8@#V8L B
M,N[OQ?^]XL^7!=3+]!92\"0#P'6=9[TT7+NHXK[RJ;IG&2@SG>9NE5TYK#X#
MX+86XH"'++?E[QKM)B0=M;8\KN)KL0%>/ZU+PF/E)'>/-;:C%N]IJG39K#SZ
M7..5\'.1B;SDG3JUJ:5J,*L<?.O,!$T).;&RON>K,F##WVYY6&T+$;'4<]!2
MCE<%B=O7?;UI*&F_DRKO0^ 1K0A6VBUTD[7JG0^ZO><JR[VB\,-:\4H"1G'3
MP.]A-#C)=BH<\09Q?-/PA)7+NF?XQ8*7V9WQ%IIVY-Q'0'=HM^"AV3#S)P;6
M8GG,6^2=07@FC".42 OO*O R0Q%F,08<?1IV.V.TIAFF=V* @7\:E#P07)C3
M\PA>&+?'1]++#M=E5XW[FB/"QS66H\L)A9W0:YH_A 5CPII/AF;:)'_I#XM[
ME-<#T=>(Y'M Y'(TC7PLYQYGW6.I,&#2V0X>]M\&$4'+"U_TO&=:\GSL4#LJ
M<;(,0,Y!0O%%2N0(^/GVE0F?,?A/ZV$MA+/PZ4;^7^V9PE%:; 59+X^HG0A@
MAV$I>T,$Y10X!/0U,B>JWE,5O[3$7S;(S!-QVW;?T$)M>X.8JO[Y%,?AI;MQ
M7RVX:P1H'_S0A/+*=;_=8C(HB/HHW5BV;@ZS7+;]ADEO&N([.YRFD2_F"T;P
M \MK4Z"7W)' UYNJ;<I*+GJE4+E^J'Y1 01U37/NK>0;=+VLN0K)LB!*]/@I
MJVS1I%WY'35IN1")&'1(4K+-3RF%/V8USZG\^68"2K]'VO,#*?_)REQE94J9
M%IMLHG!TS?XHW6VN3</O.))H5@3F0K52JLB#22GQPA%1J-RVT<#KXG4_V/1)
M6H]-DV'];I0S9'!F,QEG)<6=ZP?ZH :;>BVWG)-0UB[Q13K!#WNC%"'<B:)*
M3:H;-O-N81+2!\<>6P:// D;'Y=;G9M7/9Z1"I@F0OW@S=#"0^@Z'I=J7?Q6
M>:_:[8J8X=Z3(ICX,<U.G3B$_VKV0LP!2!&,DY92+48!SS<-U/L]OJZ0<P:_
M;3MK;6U+6;?-"DAGY;@J68%>D#Y"0+&_^ZD\VI'S+CX[X#6&3-7W]M)+J[Q-
M=YE"G)&]DB'RLNUTEM8\;B1F):L.9>=%KKJ\MY$[B&S^W<X+QS[F&GWGTP>3
MI,A +4)&E%Z#7)9/ _WW5<]2+S=H,@#^XU@EYR4W$C.&- 3WP?PG<<>NB\YT
M2]EL3Q]H3I3=I[ES))&L"Q4>(#( X19I3>Y<-[7&C(U"QW(IF:(8G6V65]^L
M:@DK5UHL^IZA<&F4*4[Z'K68=5@(_$LAHL?T/1!=$E$G0"Q;JB\_Y5),-/UZ
MX^#$L==%"[N?WOK'2,Z&=1,<PE:I1_$K\I:%+@E)^KW>3U-'HH,  5$R.D^=
M1R>K\18V3M>!P*_"N&2OF-W&$A^8;FRS8NO2A,@VOGL]GH@0%^X<7)0$U=I(
ME1#G@C9K7!O+AQ;[OX[5^:]XLNW;X:D5>)U_B[ZR=WB>HSFF^)R2]94J8IR<
MW=&35&S0X;7GA$5_ZH/5T.W=/S8JK;:?]K7+^B:%,K4"WL4Y< .^#)35@3\$
M-3_C'JY)^Z"@YWY:YT)>] _6HL(?]_U>2O[L6!_V#6$M.%Q>;RRMD6!%SLK9
M4.=/E\M.F'*R_4(UF<Y<<BA/MP0+$4/"5L%.',%N!.B4V^MJU=+X\9_S-9_
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M1\D-K)5"!4^MRF6^M5MU=^I/Z>5&68 OTJ7;LG?N':@M]:#67M/-D2G^L+[
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M3E78H^O#P[:,D7.</EQ41?QCZ)E3AEU-T+C$31K71A^*RCDW&= J[ENZ],Q
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M==-2@R!+%.[6P <YPZQI'6?XF*Y-UTW$6HS?RDSN[EP45<@['GP>F9P-+V0
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M7,PF3-U1L69P7O-&YBQ8-:S*MWQ$+H=68E'I/IB,>8>.SM2[4%"@=.U7P!'
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M/JSUVSL6-1ANVBTWTR\QF;ZWT./.XQ79( -A[BE-Y%KI7BA_9"!0SR>6##5
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M<=9_">2A\\G/#]2W6;F)*)3B+2W-*K1)\DBYY'&<P0#CT#34BB!-HP!RS)C
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ME+%5.97.4:;F#M:R@8>U<*X9F:=0M*/>J['Q3)T;^30):H0V(K9Y8$-F7'8
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MTYHZ0KK4%S,&6&REKE_C:D?N?_TC06'ZE[K&]^K9,:'J$OQV+J(A0?7M%CI
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M=?>K'1?0M3W#SF%O1U!>$/5,4F=ZB!WDEVS32WPV$[N EN>F8N=&?^'F8A=
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MY!/BRZH?'Q-;W#-H1&YSN+*- \TD993%$H:<F?KOIEQR2C6-J(0D'#/3A6&
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M0""660JS)),PE4$FXPB':61UG'1AG*DQ62,J6,L*&F%!*ZU]C90N:+NY:D#
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M%GQ6'^%N'4*F%]:IV];7]R]8.MA7P-(9]T(3ZWFU>)$Y[55D=6CP!R_..IB
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MTH-&? <'7\\)L'">^H?5MZW=*@!VH5VK +8Z@!TE^A0XZ3D%#FY7_U,Q?GW
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MSX/BJB?GO_];@>+\?]69N=MGQ]#P,:0HR6,NN("(%CG$3,608:1@GN*8QJ)
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MT?_P3I;+G\UV8]>4;N1*X7.^'5>)5YK%P"O$?J9N^ET-0*>BZ3J]4Q+46MZ
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MC*0$8L0D)!E.H-2_1FE1L(Q957.?>?[<G%0C6=V2 Q@Y'2GO7D!G$?ZY#I#
MG_D.!E"C,H)N]=3[Y$;X-QZ<*9G]=B!YI.\[K?E%GKX7MTU+R'=:YB/FO3.7
MC?-C;CG?/&GG:E_']EENW]9D%]L%)4R)M(@@-JU6<:PW\@6G$D82B1Q3%2ED
M53UN,]C<3%DG:Z_:V\V-&436SI?QA5=@2[>#:B_G#:!*SQ*X7:TV?]8M7HQ/
M^+:48MG1V[5Z^/-X;-#RZO8,#CBI[V.C^DL'R.H>]]K46[UJB+HX=D6_+U!$
M.%)%!GE6)!!3'$.2J@B:ECG:A$1$9-*V*/7@R;,S%YUPP$AG7X5Z"->P6;@*
MA- VP$Y_IWK3D[J.+C0]?-ID%:8GE>B7EIZ^X,KNQTV[4A-)V:Q-[.3VU[):
M((5HCAF%A/(88L$(I$P0*+#(&<D9)30:U?7XU&AS^T#;YKM[(<$?1LRQG8U/
M FP9W/8%6^!/VAFQ\5V+AY (TZWXY(BOTZ5X2/FSW8D';QII/-J,\CMETGM>
MI/C<KL77'YNR[JIH2LVJ;1V3K9.-]XG=+,$Y+1B#*DY3O6M($EAD#$$5"4-?
MI_<2R(EQ^WJ1YF:&^FG[>^K>IE!HJ992 %K5>6\W1]EO=8)G3U%'RW7][%J:
MMTGG++ -M)N)H$GW_O#T:TFO%VM:<^L-QB.;[._)8ZF OM%?'X5^KK8@O([8
M-07O"Y*E-(_C%))<2+W]0@5DD=)&.:<\S8LX0L@J">/B2',SLXVP]1G+H;@M
MH9<K3= Y@"]OV+S!%MK;&XO8" JA"VA<R25T[ND3DPI=4/*87>C2#5<6;.YY
M :H]V;#>\7&62)C2 C4[0M,6!7(D.8EI(5#NE*0U--C<3$2O4K(G[6C>X4&<
M[3PG7^@%MA3C@1M?<#B 2)C"P5,#ODX!X(#J9POYANYQ]S'>M6>!'_13Z:I)
MK?F@?U<M).)QG',%:R."8U:8V)+0]J/@41[3*)56340'1YF;X>@$!8VD;58=
MJ&6U]RO.@WK9I_ "56 K,0HE)U_B(@JC_8CS3Y[,A[BH7-]_N'SQR,/AFGJB
M.[.4"8\I1@G,4,0,EW@&"Y11R/(DB1#AE"3:6=ALZ<KR-+C_=*>/?#=&P,0$
M,P9HNCYL :U%=3S_/0#/\L!W+"2A3W=JN4*<V9Y2V.\A[<$(TY[*GE+NZ!CV
MY$4C([C41"&^;C?\GX:@]$X9KN&*UI3$+4$3P2+-1!Q#@9%>L1.10"H5APF+
M*6,B2KACA/;BD'-;OHW$=?35R#R2/\L":,M@J5?X EL!1^3<(YW68/B-9%X>
M=MI(I34,1Y%(^SO'&9A/4ELK>?<H33';^OLG2:L=:<ASFY-?O7N2"XZBC$1F
M8X#,05""M9FAB?XK%AGC4<8)S5Q\!=N!Y^E&/*V%]LQ,MHVA]>F4 "NC1==F
MQ-&[L)X).SL4 M_ UJ@1V10[=7C64N_)E)YOP'8#F 3W="G\62E7J+S:*NO!
M)[58KI"\M%O.]X^S7F^--NMM4XC[95G]\YM^3KM<4\H2IC""D8Q-JJO@L$@Y
M@JJ(\RSCM" T<?&+!L::FT-T("HPL@(C[$C7: AD.UOD";K0)\-C47,V.!9X
M>+4Q0^--:E8L%']I26QN&6<\WBTK^OU[*;_7C[Y37^1/N7Z2]4'N@B8H2T5*
MH92FS5J$(TB4$#!/!<DB;4=0YK2K&AIL;N;C4%:S/VBE;;,B'.W'(,YV!L07
M>J$CI*.!<S8A-HAXM2&# TYJ1&Q4?VE%K.X99T9>E"3O&A.8RN;J[FE;;:G>
M+*R_OUNNGO1E^X.<CUOYL#]05!F+,448"DP5Q)DT=85"PHA)%C$6"X&<&'/]
MB#4[TR37FX?EVGP<?W6S0IZFR<Y>30]^8,MVQ"^Q;X;2* 5Z6AT1V 8X1_:+
ML%=+Z4FT26VJ7SA?6E_/3P_$EW2.C:))S#;$365])E?=;7_(\ML/NC[DJ9"B
M8ZE8H"R+"YERR##*(19Z[TE3GL$HSRAB$D<YS19KLQI)\<TC8Y(_%:QL#VEL
MSY$B 3-5]EQ)-3E2Y9L=R>-+8'E>,+,YG0\GT@5*I+:8I0< J!$ 6PW!$6&2
M%'NZI G9D/Q/WK1$2![EGQ<'DO^)<:8_"B#""(J3EJ%PQUSX3N^,5IM'\Z.6
M^\'P*QD.X%KX=Z97YI(]-0UQW_[0CGC+8A$S*5"<<_VB<0&Q.2<JTDC (DMD
M0@7B16X5;/4GTMQV+A^T0[/><X4ZD(;XF:'AU>AU< ]]GM22L.X4 CV-P)%*
MH*^3Z1M>:S6&YL7/C#DPPTP^<Q.1R>QGSI!-:#,(Q%ZS&\"/IM"4<8G^-.H-
MZE:NZ2-=UPQFS9S^!_CVP_2)/_@B??7L]#H7@_0V?D::CA''*S(')#I^GSQB
M%=VW9?I854]2+$B",ZI$ 3F).,2(I)#(7$%>Q!C'<4$*8463<?+I<UO;C%0U
M)8S^VL2^097^W/1KL99UM@KX<[G] 9:]*U>&).J1/ML3\9R&VF)ENP; T&<&
M>[P:V:Z!PF')N :2B:R_/31N%OJ<ZH/&]NBFZ>SF.7D/3.#9BZ[L?/Q9;A>*
M\D(6J8!Q:CA_1)) IHB",A*$1:A(<<9<SB;Z#Y^=+>MD<Z4X[>%5Y$61*$E@
MS@Q'I,(%I,*0)F2%H+'(*4D3EURYT7A-E0]W!59V4;*Q" 0VWCNQ;H 6+$";
M[)ZZ8?IBFP%>IQ%V3[6SG:_[UXSI.E1WT=1.WF9=GR#\0[L@;Y^J[49[A+ML
MM,]:[B97_\MFM=+[#!.#,3]^:'Y<B)P7*8T3F$<FF)\GF;9^C,,HCW,<(:)4
M8>_*>1%I;C;SG52R- TNRS;= 8+U9@WYA=J24!-FX1!./@V!#5&C3QVT:#4"
M1B70Z=1/H=VK=0-ZBH$_S%] JYM+N,/39^;09FCJV9NJR]#UL^BKL9!/A(?[
M"GD9:<*V0CZ1.>PJY/7)(Y;+/>U-W?[OVT8OOZ8 I;KEO'RBJY?L43AAD42H
M@ 11O3#*R*0LL0C*5.213%)!>&R],#H./K<E\$7S[O*[9)3_L[JI"14:+ET3
MF_PB3:M="=[0E0F#N/3@<YT=BU4P(.:ASX\[N.]4VT'TV\:XX* 6'W3RN]!X
M78^XPPH6$/F)UBK+&?"T'HW$:W#E<7WF=&O,2&T/5I.QS[B2DZ@I?JY[X@UU
M'M<7Z)6L/&A$_FFY;A*^%BBB$6(%AR0QM88($TAX*B$UW-.Q1'&4..7">I5N
M;BO/GKSG!C3ZU2M-3T/0J0A,74NG57U57TU0ZPG^,)J"6M6QA$E>7@*[P-"K
M36W@!>Y59G4\FY-/],/0/WF1\'7XHGR">Y9@RNL@5W*=WZD/R[7VCY=T=;^I
MEG7>5)> GRJF9,IBTWH@@E@Q!JE((L@$HS+/BTS$V2C*\X%!YV;R=S*;W<9.
M:M")/9KQSFH"[.RR;UA#[R>N1W0\5[H%1&$HTX<&?AWF= LHSA*HV]Q[50\X
MA&[;U*PDES+F'$%)<VV)4IE %DL)(]-"":=814J-: *W&V!N!F??U.MV5+>S
M/7(648DK\0AL*?K]S1 "M]>U@=L#,ZH/W"B 7J$1G '*>RNX(^4M>\'M[WN-
M9G!'4I_I!G=\W9CD;OVH75+<^U_+[0=I>D+=EQOQQ+==$:S&K?JQ68F_RVVY
MY-]*JMV_]?>ORU]_WZRW/VH7[^_+]?+AZ6'!4$Q%S@3D>82T]Y4:YG&]R&0)
MU^]#0K/8CE0CB'1SLYI&): ,H\U:;L%CH];NC'3;*>:26.Q[/BW,\6O.4F!;
MWJQHG6XWH)ZP#V;"3""SU7!7P[_3$31*WH!.3:#U!+6BS6[[!K2ZON;4NJ2/
MO^(43[0:O=Y4.V:/!YJ*X41RWX-.F%,>"*_#]/)0@XS):1HZ'?ZXYJ6AVGJG
MQ=G\OM:_7$EQ7\J.D<X4YNN!Q"*7G"8DCB")<[V.%[F$1$891(2@3.]L1!1;
M]8'U)]+<%N].;B#,6KT!3ZWH>AW?R6XZR=;"ZXOJ6*NI4'D<KC$--:,V24]3
MSU/HI*>323('=(&[67QGK/H&=(J!GF:@4VWR.7-)>9IZ[J9*>9IJ#AWSGWS"
M/9S_Y&6D"?.??")SF/_D]<E7GF.W1Q_FV?>;U9(_-__?)WL@@I1*L());@CB
M\AA!RA"%11I',E6,<>34>M5ZY+DME+WF,3W1'<EO[7%W/!;VB>9D1[Y](&]
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M4P ;V+PU*MR G1*@UN*@#D4O(DS6_O -^-^2EN!N[?'HX%H0_2;YC15FVDS
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M6V%OZ@+!/W\L^0]0'Z;\T)OL]68+GJ4VAE*N#8>R7/[TS[Y[8O8LSN@GF)/
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MM/VQ*4VH;4%ESB).%:3&D\4J(I"@1"^T6 C$]4<M<R=2F(&QYO9)O^WMF6]
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M39 IF:2YPH4)X3],#*EAS%QOM5CZJP"E_/ZT,B;M&=#'1_UMT97OB7$]A_8
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M4$BPX#RA"8[3S-H1"R/CW Q*7>?XLRYCI:UR-T#64INZ1K7_9T;;BM4X^K\
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MHC0G4A%=?R6?YO)O_HUL)'BC+T15__X[?1YN6_(()[SG3;VGXJ@W8",_J $
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M++.%V-C.3H>J42JMEDLE@=YV21>6;T\]V :WH[8+!&+?.NT OZHR;5&LK3D
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MC"F;'9S0R&=C\F=A;'O-!2?3[FYF)TKG^*$.$W:5>R_0-+RMFZ_K#(3R^#F
M.(3GKXV-,7@ '6!R] 2ZC-3Q NUD.F CD_3#Z^Z1.M&T+'-<16_NLG"*<F/X
M\<CF=1KA?ZIB97FOCJ\'Q0A_-N.O?F(KM:T6-HES8; 7'+(XSB%.DPC2F",8
M$9K(2$919",H/"[EQB+9V-1[Q3YX9VO3+&8SMFP4P?4M(3X6C%VO!\?"[XCV
MF@ %S^O _ 8\H#K?K Q NW+H]8>WK85^ XY*T99( 0L5V)5]#'BK.;;Y#WM3
M.AKIAKU]'8W8YVYT1\=@U^BA7Q_5;&:%8//72:QCG@J90JH3!#$F,>0<"1M%
M1"4BV!R>G!K7GAY^;+MF'053L@AJ'GUCA/;@<PT.Z@K*,%%!;GATB 0Z)?:5
M(4![0PX<^W-*G..@GY-/=4A>/]6$Z>?EHBA^+,P)H^R =BO$<LUFWXT%^'FQ
MM-IFD@F*4<X95%'"S().<[.68P%1C'.!HUQ%D5,<8'<6QK;H2X;A:@%MNPA[
MJU4 5C%=1?\LZ^9Q'OG=W::F75D, WC/"F7;'.Z?S>9P-Z"4 ?Q8E+?<I1B@
ME@/\;B4!M2@^2?;=)L$C ;_WR1@H.=]_4@*E[E\%8&M:?[>1ATOYOTKRO7(
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M*L(XHUZ=O"^3')L2<4HP[*!.',!W4RMA(1WZDL<?S<#)FKTI' >R(TK4;%-
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MFFO+8C Z:'QL),BP\#JG:>R4V C0VD$9G<+J^CR#F'E)M5V]=VE=P,\@<)U
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M"#;RF5CR%V6=IYGKC#OEM8:@D8$.14FRVYJ8;72\/4+6N.:F#8B&TT,'H/J
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M%VMYU)$!4Y[B;AT*Q" 0F#4J.^V42&W>(-XA95S@#*#>A_L-[B#K#L#RP*#
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M66"13B9EK0<? P(FHVQ"P2VV&5W2V&2MI[5=92O7LTX_SDGF=;Q/'6Z_.*6
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M^#K(*&]XV!!ON<3U2^80I:A6,T((7(+V21IRY+UIE 6[0<8XMU;#@V1_&7<
M$'+-$E;OK,K__73Y]U_.?L%9^GP2%G\_;[FC52Q%%_"VAGS)%W!:*D!A-+.&
M&2[:3.C['F7C7GX.[ITT44B7 +O@9K/U:)N@*4:#-T779TJ1^%E?[RC'=6:,
M89NG-]^C;%SW=U@<?!=D>RBE Y"M<U:;+;@QQV^F,[SHD(3%9)D0?*TX4<X@
M.)L+:$NAI5*NF$8M,!XEJS=X[8. V[6H@ZFC VS=LQ$_TC\]CR^XTX@YUK<!
MA;S!4" RF8"X2T4@><S^8(?C!5'C5G8<\ES<20T](JHRLMEVTD9C98R 4<4Z
MC#R"%[7#H0^!B9)XX>(PB+HBJC=+M:/BOP>H';70 Z V.=4[+&TLKBX&R5<0
M$*,-H.KK)1<-@ZQMMEJS(GDC%^MQPCH#UJX N VL ;4Q<KKQU_!_YXL+?LY;
ML!:C$A<EU!>UC$[OVM\]T>G-)/V$,V-TW"J'L%6>\>[ZXQ:D-<E)[RGDD2'R
M-IS@4;G!P\5$QUPR&@I0!-KU0Z/:=XHKR#$Y&Y2QQFWU"FXKI#Q(QG@IR7WU
M.A]:R&/GHY\1V=/E_'21\!=<?,+9B\7IIVM-&2]2K$Y(E#%!]%P !;F6X@-1
M($0A#/I<2'A;9:BW6V\\@ RDU7E;$8^-FN?TYW06CO^,X7CU^8(!'5**Q #J
M%&K+!05>JQJ=2D4.H @<W588N>_3QTM0-T#$WN(;6_^_IK_@<CF?W46QRU)G
M'S.X7!^W1<\@B"*!,T;'L#=*2+T5"!Y<8IQ8NA$2AA%D!^'. U[8F\L60R7'
MS# (*,F2]X[$6711@U A9">998WFB'R/LG&;+C;+S0RJD X ]IW2I9??TO%I
MKHVNEDO:49@_AF\38:6FC>-H'TI#$:-2)#IR[4JQ :-UZ&[?JQ^F_.T^8KLL
M[-D1+4\KKM];=5U,4+J367B'B_J-\ DY24\5+7F"H%!2C$'2\X$'X!F1UYY7
M(;1J^/TP55U>U@Z#N,&4,;:C==]^>: L?"(#;0H3$1RW'!3%"^ T)LC*:7)/
MBHS:;^=_;[]HEQ<;^V&HJ=Q_E +\-:^K.[P.68[_G26:%.<_A:T#E^H'F3"4
MD,@,U0-/1@91U1F%3MJ8M9/!M.E/U4.IOD_11JT]F!+)T;5.@O,A@O=8A]''
MQ%(;1^W'+]5_"FZ>5*K_%)V,?4S>;YJ?S?)[K,,9<#U_85JFZ5Q]->WKF;4N
M>PU%UC%)H;YN0%Y/BD3>  _<;)FM>OK:7;KZ.RA]?C@-_%@ VV2%3+ %O<I0
M%"-'L]:>.A84!*.4$,*6(K9SR'99?1R0'00+N^-N!\6,C;S[C']M*C8_G:V+
MII]_#HM/&$/Z^\4@&*E=]$(Q$,DZ4((\W^BY@I22U<XQ&VXW*7E"'/#HTC\,
MYG;!P??"@^&4TB/DWA,WJ\M90\:@UD%XX"0_4-X$XH;X*L6GPHJ7UN\.L1M+
MC9.DZ 12NPN]1P@=K3[CXA7B\OG\2SA;RW%UNIA=3E,K$NO0-$ G='WSX<CK
MD A$6E":8FMS>X33$S#U^-KC9#$Z =F :NG@FN"[*:'HO(DY>?"I[B*9!'A'
M @Q%9N.<UUZWJ;L;Y!YJG+<SNT0%3132HUF[?P>_GQ\?OYHO?J-_-LG2!Y0E
M0E*:0G1?/ 0E ABI<\14R,/];OIL]^6[C#9W5/]N*=I==?'CH(T"*&U8#%:!
M$1&)+TY\,9= %,VM%,%'S0;&V$AYC$,I?]?K@*=H8F>$?<'%=)X_K,)B=4B<
M/4NKZ=?IZNS%:1TBM>EE_VY-RR1[#,:R#,X&K-<@ 1S/C+YB$:,1*6^9[1B$
MG!'CAFZQ.93V?B2[F)/BRI"_2FRI&C3EVF@B TD[6>%%S'S+HL3>+T7[QM[3
M-+&G77PYR\VN2I^3W$+<U.J%.G8OX6Q9JU?(R\$ZTGZGZ]%M/G:(*]$GD[_G
M->@&)M<6?7;OHE?S5E"@RDD"6E<G9"H#%'AJR-$;XTR(T6V[8;=>=/_:G\NE
MON*SQ2+,/JT7N&_"%,\2D_6UKA,#*)XIC$(C*Z=>"<=4SFTFK3^!R%$=NS90
MN5LAU$9EG19X;+'M=^\"N_V''\B"->@4^V1P9FL2TOD)W I66T&P6L#H02I'
M_^,JR;Q=(?Q![=@]A09UONRU\;)GM]J/)L.0^$D@$05M"6G %]J.)F>KA,B^
MY#9UW3L0^X/8M:= YY[*QZ8J_''MVQ ]97=9YD VKVG?V2=#V&CK'8\)BC8>
M5-:U&QMJB#:H$#3G-J3>K-]5X^6'G(/E^13M],"//])72R*$*#T_@B;.)41I
M!7B#M1]0C:J+%&!1T+Z20K4:_38\+S^([7P*\!X>US@* #JX/?MP&I?XCU-B
MY64=RG+9TX-%A\HJ#XZQ.BG,.PCH-!B>+1<ZR13:7)H]0-"X=QICX^0V; =0
M6I_8VUQW*Z-\$4%",,S6C*2$6/M[>DQ1T.9&7]JXF ^2-#+^AE#X]T&T@_3[
M@]%%%8-2LB2MH!A7;QFY)I<Z<- QE(@Q%[E=W^Y](=1#CYV!5/TX@':0>P?@
MJ;(X*M<L]7EQ*A9O,GK(1B0RSK2E(DL2<O+9NHB<B393%.XE9]PZD<[.OOT5
MU@'J[@HOW"^OS:8*3"N7N0"N:BUI2AR"-0J"5B5%PWG,;:80/9'0<<W< -"8
M'TY/8]^IUG)#6OWS[5CKZ,OZBXM :\.9*(Q'%AG0I]"6C5C <<?!1"?1YTAG
MQ7;5)D]:=EP\-=7^_""J&!MDYX$[7K+P K_B\?Q+_?+Y_.0$%VD:CJ?_/"]U
MG5)$/XVG]>O7L_\O? D7G5&D+\8B[5G:KPK(P; 0(PDV&\D*&EMTWF[NV"#D
MC'L<'PR4AU?=CPO6YY^GL[#AV OCK2H<DC,4DT7:J$Z& #P)1A(GE_IV:\;!
MP7J-G'&?Z_\ 8-U5=3\P6,,LY N6T21OO:@\(GE'+BMP5AN*V32RPI%[W&X0
MS3#TC-M8]$> ZZ[*&QNOSVJZ_K]PABE\Q,4);;I[?9L@K2]> T==W[D$"8Z<
M&U!!FEB"*X)M5U*ZU7+C-@([&-J&%_W(W6Z?UU>7N" QK\YJB[YUG)>D4#::
M5 .[ JI(3IO!1Y"9>10B*HE;Y6RV:G1['P7C'K6=I&D&4<_(\'J/7TXI&@O7
M#/1MEC;I4PR*A!0\<,WJ TVEZZ,6"49'&V24!MEPX_ZV)FN\7KK[:W[>6@UC
MGX-_.9O_%OXR74QGS^=_?+/*&^N;BLG*1P\BD<.IA$U @I$@5.3DEEJ=['8A
M[OV?/QXD&FEQ/JQ(QT;%A\]DAC^'Z:OY\G3V[G-8G(2$Y/*E</QZED^K!QB.
MKWF)%T,,<L%26(%@(@4LU5:'6")HXUS$P"S?,M;<;?WQ6C0? %4'4,G8J/O+
M;/KI\^KC9UR$+VO6EJ]G:<.'4M%Q22=085&#0E/.Q[L$J^O@C9RDW](@/;S(
M>(V=#V&5!A+NV"!91P__7$</&^JS)#OJ4VT[QFV]XB7#FEF&C,Y5MI@VVT'C
MSD>/$_X?"!#[";*/D=<W!SO[+)S0/H&H$WA5UHP"! I0,X\V6H7"QZV*Q-K.
M1F^6+NHHY-I;/7W Z[Z9P*XP:6E_9:MIN]6$1TR>DU/G<E2!Y%+8T!CK?J+Z
MDS2[W43U)XBY@P**30+U(@^J$%FFO1(CKP-]R(XZ)\FL)H:<4QP0&DT:N$'&
MZ!C95ZWSH60\MLNRD<>'TR]?CL\V_4<V;!3I8C!%D$8M":0H"<[& EZS4D(H
MQL3M?)>'U^ARLOH..!A2E&-G].J)NYG]Y0M3S(%V.=,!:QU$ER(4)&Q'GW3:
MSE1LE[&[6';<BX:._)3=%-$#>BY ;XV(2<3*> '%0X3@ZI2*[%*VE78<;O#B
MM85'3.#MIK+;2M]!?F./W9S.IB>G)Q>QFE961^204QWXI)RADU :*$)I3(XK
M8?Q@BK^Q],BJWT5Q\R&DV(&;.8"]?'/9]TQK,HL2'6"R9#.15.Y43'0:*QFR
M4)Z91O-_!^1B*S":W_E)-CH\QG:PWY[6W7Q4/B#I+:SPIB NWVA.K#),AH!0
MK-*@F"6>,OV1E-(RH0G"FJV\[2T7''N4]5APF#?6S=AXV^(]\%^_D$)FJTW0
M6KO;3K040D=1P+(2B<.HP.DL )6,/I+7XN.V/:MW6'[<,N$^L-A>;S\D,E]-
M%\O5Z]ER%8Z/ZZ],+(7A(@L'?CU-5-H"CKPA$,%Y--HDBX.UCOD^.>,6,OW
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M ^G+/4(:2[7CHWEY<3,U_-5ZDCB^^E)OXU-4-O\TF_X/Q65&"9ZLSH QU;H
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M#KA@/7 ?E%(>G=B\]C?06GR8GD--T(]/_4BR^XE^_(])2M8655O9.4-L&N/
M,1FA9*\3IRC.;0ZY;L+F#4'CGM<,@(5-LS&$X#NM5+]9EZO3UKWJSS<?,:BY
M>(BLQD9#)FY*U&!%$13S&;+]SD;"/C?:%I%*:),9;6,T;H_D?PD7EXMI[1%P
M5M[/2;2X^%+?N1+Q+:@9XUDJYP%UI)C7^-K4+14@?8OD/+?LMGU-HY+P[2CM
MT\SL@)['R[L;J*IW^_-KK8NJ^<H#;L(\_K!!;=+3I+:U3IE\72U#!N;KZ(-
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M-L>=+;@9]]BA3X]G++"\K 7S.IRGR_/5MQ_FY^?OYHL_PR)/DM?9<Z<@D\4
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M$JU5YT,$%Z-RM3!,YC8C5W8B<]SD;#OXM=-5!T <QCMY?U-[9$I1K!@&7&(
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M)O<6SX\E;9-HDXI)F5H&0ZZV"Y:D4SMY*D;^,&)*9J2JCX$X/-&"R9>T(@^
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MN*=R[8;1,E0A;[67*GR$>)5^7>4SEY*JSWA%*ES6.OTO4$L#!!0    ( ,V
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M=&TB^=T07AN) E%S:D,*KGK]=%KL=5C5>-WU$D)__<VN#8%0>K1JFUS5*++
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M8ZOK48BUNJ<D9*AISK]0B94:(I3Y'K5VN$6C(;<HHF6]5J]53TZ1#[LJM;D
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MWT,E\3M-!5T$(K2A:P,<R0BL XW$B\80>=F^P8! V(!]])4"^M, 6&+;1^3
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MGBY@S1"36!5C10Y)Z(/44F:2,$Q8S6;@MFOR=KVK7.)*\"QHK#O"K@U/:"F
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MGR+;<3=@Q'4!"0GDK"+*D/\[Y5,<5I#TFVP6L8D?@ZB/OT\ '70D_T0.;<K
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ML>&O0&9G"Q57B0KVG)7S&#,8@!PJ4+AP:F4HD[>Z@/,M6$5YN:;OX-#:.,%
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M>XCI6,G",_^FC9'=IH79LWF6%!W'#DD07Q?Z]Z-[V&OQDL+\F8 T3M?R&>\
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M=UR5.T6I$)]Z'5B['__:]HKQ!F)@(G8<>8/PU[OU=.U_8<@1./ _535B_"C
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M48X5T)3EH$@G_2M55UFIH])$?TQ]L<I-_7*]D:M7 )$DFV_D3\7][Q]\V0E
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M0 _S[V:+K,TG4;OH&QZH><?06D7"QY)K8KFS;XKQA&TP5&6U/I'>7;;^GI,
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M;3A5L,5=7<H<]9<-HSW#&-J-0+XPTP@/QA?YB $AGU+F:1*+L^Q@^>3B5.I
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MOX>&3+^7Z3\8,OV?69E'-7":P0['!I5&7HM35YKJWI<F!,@A @<4!^4"TEB
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MN^'>BYU89Q^RG8/P>;B_%^X?[I0*[/'L0[3S0[BW%^X]#_=>\F?17]%"?8C
MD8E@*/#;YW#M.AE/=3$ZV!GA?9^'+^&SV0(F(-O9WUFJ<K%.\*?A07@8T%T6
MZSC/=)'!*9"")Y7N'.[@/53ZEP+KK$K@O6&R8BP,U/1;NIL>8DI;$UVP/5\%
M)WETBP>BSAZ52<Z382I-I@$Q99_T3TA=O;28%?64M$WBOT+&4N'5(HQK*@"0
MX+\JL GVGX7!_N[^P238&I7F($C^I/=$C)J>C^.)1&*I%5>[^\Z6PD@E"A.%
MA*QGB%@Q!*I8/BJL2+"50E1\+&< 0<JDH2]6^7!;'CB ,8M-2GBS\2Z;H;:
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M2VY.6AO,B:QW79B*>$/[6W3<XN<JRJ,4-MR3F>?NB$A=#$&I8]]WYWP7&X6
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M3UIN,D8^3T!3S0$SJ3!(8Q1A ^5N!1<F>F0"\%QVD^B%^S./%,'+)^4P2_&
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M!X6:17J"E3 .;@=P)IZ.I5/Q[67*JA>$(=;@$P*3\Q0C.0RP>QNEG[W$:+S
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M*88=R)-JRL*@9=[=_OLRIY'/7+_,.46=L?/W8$N9(]'DN\.$!C^N1; %XNH
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M#SNDIR&_']"!'*Y,)71LJGQMI>Q--B-.*&IO)$C%2B&M^P&^1E':!)M[*4U
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MP.)$S\L^C+4J,[6J\(1T"0-Y%U%H=I:I/:)1%5P+]OAS2M5P_I'0=94*%Y.
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M*1D)GQG ]_P<8T.C\:Q(5*3.2\V\G*6HN-&Z/;2>*_@I3I#6Q/N=/+'GKMN
M;_1RJ/;;16KGA,Z\!-5ZN/8G;:[]C8H+W<)4N1Z-ENS;5^MS*4E9-++VT@+T
M6/R0C!%SFZ$5:S0>%UYMA)2*&/]##&^>K&/UI,X4$(8F0<4=!<NJM:=H8J@(
M1YQ,*R6HE=CDX7IUP?"@84Q!?:S:@P?P'_8=F>-0=3]K(H6Z)YF-!'X,DRX;
MSI!O?Q1_CN.)-(=(AC(#C?%Y'\0FQ<R/9=T3YT=-;!%.G6Q]8,R9H:.[)#JB
MB0%?L=UY[ :GCO* I4=Q''H&$9K\LP1J%%O1H%-@+2DS,%A)FK#AY=%DZU0P
MQSRUTKBCELH$B$-'54[F,GD7K>2<^1(_7B $3R_HJN!6.DT?*:#)856F?QX+
MW1VA0(;@JD8#4QG#?K$S+]H2\K!N477Y].H\0/'DFXM??KV[1<7DF][__7AQ
MXTJ4!Z>_H$XS?-?[9^_F[.*V%US M?*3ZQOXR?O>^47O-OAT<?<K_.OV TI%
MHPPS/($%FYV[??KUXNS7X+9W]A&N),WIZ[>7%[^0/OIM&'RXN8!;VH>A7+1Y
M',E ]^ZNW[VK/8O4H<]['ZYOX>HP.+N!)G'SN 4?;JX_]&[N?L=;O+V^N;G^
M!!^>PHO"E[VWOP?_<W7]"9YU^7L8_'9]^?'J[O3FXI([Z.+FIO?;]=GI6_CW
MI].+WWKG ?Q ;])N\7_&'-[.SY/#6Z'M>F>[/12'>T+-R"P[)#>R'(2-3$EX
ME)(S)B/\'+" .4J[ @D<>9]&I;""#M"39\TU85 V'&84*VJL#$"%:452BBVG
M/<E%XC9<P>HT*O!"Z;8!41F;()/+DA;R.><1T:LU&FKH69C_3+5FN1H,$RP\
MZ3&.I3:LT<-Q SH.<9AD%J2)M'TT\B6'U3B3?=_";&\J)P<M(7%'EX012_MA
M1. (^)A1M+*DS0P/W\\81^#*3W"RQT^(N4S+AT*QYJ_7$>I(LB,A*:$"*^=>
M/GA9E!;E-F5AM!%Z$BD!AP0C4MF,DMR7D37GM.:>MTI&<;S8U"M>GGO.)4WA
M)B5;4;F3:.8N&_XG0:*ZP:T?*FY%XAV[RU21T(67EW$)6)6"[]OW2>B1Y+C#
MIC'-2GS9"9X@26B<4W&QQZ",^;?Z(/,L-UDMCWC1[=XYY"YS4*A<*? -'M$0
MHVSJ!CXTP/J+QM.ZS\G':+2CZ#XPU+JAR1YDMUD+<EU.P#NMZJ8?.&!VFJ;9
M%.:3@!16JCR;<M&19P%"&UYMU3$STT$LO'ZE<J9]S(OZL6Q.)ZFT FF)PKUA
M(D>S>-@)>9N+-,@8.7UF0+3SN<6J8DZL><WWPV(,<\)*4HE@X>S5R@K48X^?
MBTDTT:2(D [0[]V,N8G^A\+LY*XJ,C[4?QJVJ^W<2!A,&J,P=XUJP3B[SXH7
MF6XD$],T*+Z>E,>=ZI7&2!6$!&V+-@(F=Q]TDRWX^:WDNJ3IO2]2Z'-F&*)L
MXN4^ S.EM%,L"6(8I=P.=@/)U'U,9L7TE2UWDDPB?ZWL=>P,%544@F."7-FN
MZ%F/RX92>DV,4BLGZAS5 P]+M=)F2JFS*'$^+WF-41ADPGG /7%YK\0S8X@4
MX33-_D8!,;SJ+_^M9,5OERHA7R%*=D7=[ FIL+43Q:;;_XQN7Q/KT\I-="=:
M0SUPM=U2E:5T?D"M24R,-.9&F009["5T:)"P\'6#:(>7H5J3P6OE';IS\G,?
M]!SP'L/.&*<^!XO-&5J#X5SNZ/Z9&,YO"]QL0$#^H&#.;G!K<2$VYX;Y,/-F
MU;KC'_--FZ)W=8R3"YIKQ-Z[\T67%-[&6U8^>8Q%D)</Z/]L[76"M],"5D!1
MP.4SE030(X)(@V"3G!Z QB [0JH/?"D<MMK6K9YV:+=OK?1./8O>[U%(66;*
M69P3$(XK#PVV:IG6391OGF'Z%4JC$&N;0R50\+Z(Y5-#"L^4'=6+36F$^8(,
M)3V(D,V?F4 W)[!A9D]>2KFD)1(L1BR\((TTF(VU02_RY3HYXCJZQ=6R1.17
M,7V<J-DPY%U:LVO<5MP57!U(*?XE8#G#N9S"#M-!$@-WOGJ,RL$#ZT![HO2N
MBPSO-]#Z$0Z?INXM\%WQR\(*PLNQNQ&GA5^8E/Q(1(@H=.W<$^]7J<6Q[YHY
M*6HD!QB+?0D#V,&3H62@*_2*Q'Y<+U>Q9372-,6V!Q17>8.XHJ$T4EM=S H8
MXM# \2-#"F%PQJI*0XF)6ITO17F],WU5KN==/*1N<];WK1E$O,4OXZPOT(@K
M&I5H3-$,++L/3@<E#S0NW=^S_#,K4K7<#>]Q(Z- O_1XS1362()RV%3842*F
MHJ9'?$P3TL9R[GWGK@>XXU?9X3\IV;N83_D?_W:R\V<K4- =_P9& *;! DUZ
M&XW5J_^ !6#(WI?RP(]1(W$$YT*D95PF<R)TVUX[*=C/"!G8_3K( +Y,,ORO
MOR3[.SM'A[N#P[W]O6A_>+0?[0U/1MO#_?C@Y&AT>+S[_^WO_&7E<08RA"M^
MCKRX0MS-5>_V-OB$N)GK=\OTED(/IBFR#'3H$K+ZBB_"KHN%KIL(0<^XWNB6
MUTWQ?_\?KA,URPWK#MX0RFI2Q'_3/_Z./$3C:/:W)*7&TH_^[@\PKHDGU#X8
M1&,98QI;_MI.L.XV3[(2)E YU"?+UUWZZC_+8?V[@YWNT>%1Z]?;W9W6[^;>
MMGNXL_?-[[IWTMW;;?_:O>U_4D=P9T!_%Y,H_:^_[/W%KN8A^@5_VYU\"2I+
M: QFO];EV61)*TA18S[GI[S]G!?;QM?ZR^LOE7ZK["\[S!;RYSSR]:W[@4:U
MI:[XYKQW^?L_P^#BZJR[&=4?H74__)Q[.PNHGJ6@_Q_\ SV%-#CMPCDE_=_O
M-P=_^'Z\@B,RUV]MNO!K^4=0^Y3[\.S=]<;^_0BM^X$F78L 9;5  :'ZE[VK
M\XUS-6>@3U9YH%L$=B]OP*_ZK7=[]QZ'^>SZYH/O8_T0P[#:K?N!K,%"WM!I
M6CYD6,!59GF29IN]_"O<H4T??@-_Z%2Q\D-))V3Y['OUY']2 .KEE$)[M+(Y
MQ.ES&,[_V3H%M!=4I3[9^;O)''$> HE)LHA+>F^U@-CAHV[*",SKW&_\9B>+
MR;R=WMY!4W?_OG-\O'U\M+-ST#W^$0KZOF-'ONRY4K23G=3;9MF?93:W-O"[
MZG_=]JZP++?5#5O=UH-CL*0<Q>Y\I.HB[LIRN^YE5V"Y[5MTFUW=R7E[]@$+
MWG^#<ZQ4K&,$^?I]+WCW$4ZSMQ]^"X/+R[,?X$TVRVRSS!:>G*LT<=N7X-OS
M,UR!FP6X68";!?B=%B XE=<W^!?ZR$C]HOO@9A5N5N%F%?ZYJ_#V77#>>WO'
M:^ZRNSG>;1;<>BVX941.?CW;G.4V:VI5VK?FFQBO-SRX;5;:9J6MS4K;)-/^
M8#+MI?=ZI8'[RC*4_1^H#*6[BY4*JUI[=GOV:^_\XV4OV.G6"4>_WR1>I+'S
MK*POUF%(&+_9]/UAJE;VD-KH\-O7E^QV=X__I-L>?\NRE5? /!K +SP75@>9
M262.ITP@^K58EQ<Z3B8SPG[^1H6& 8F !_IR\CT:KJ:O?Z#.9!NQ0#?^/%WB
MS"_';'Z[+J*]<\W[L%&&O@E5^WVF6X#_W>L>':TRK.]%(/+/LS";.^BO1^'Q
M_F&XLWO0/=G>K,?7=-WN<?=@[]\W"_#%!?@2$FVS#F$=[H2'NR>T#G</-^OP
M-5T'EFMWLPQ?6(:O1*UMEB0LR?UP?_\D/-@_[NX=;Y;D:[INY["[<[Q9DU^[
M)IM@;)L5"2MR+]S;.0GW]G>[1WN;%?FJ%;G;W3[:K,A7K,C%<&V;94D;Y=[N
M3GAR<MS=/M@LRU<MRX/NT<9Y76!9M@/=-BN03H_;>\?AP>%1=V]S>GQ5U\'D
MWWBJ"P1Q6D%QF_5'.^#V/OSO:+^[=[19?Z_: ?>[1SN;!;C0 JRBY#9+#Y;>
M\<%.N+MSU#W9N)ZOW/AVMK]FW2DVK;USUFK6M>2SK^].+Q>?;YL^PY6Z>Q0>
M;&^'\)3OV7/KM99;Q#0(Q]6PFA?EDUD9F" !1=Y6@$@_$ZAN>T%VY5?>=F]_
MJ;?=8,,VV+ %EOP&&[;!AFVP8:O207\]#/=W3L*#@Z/NP2:JN,&&;;!A2XON
M[^WMAB>[V]W#371Q@PW;8,.6WF=_W0L/][?#@[V3[L$&&[;!AFVP8<ONL;_N
MAD<[!^'Q[D'W>+-);K!A&VS82G0;;)0'>X?ASO%V=W=WLRPWV+ --NR[)\CW
M3\*CO</NR08RO4&&;9!AW[]D8?LX/#H^[NYL]K\-,FR##/N.Z8N3PW#_8&=3
ME+!!AFV08:O<9W_=W=T@PU8%&;9TQL(_P.RWLB1]+^+L%E9R6]JOON/,)0C<
MZ?U]'M]'91QL1>-Q0"@A@@5V-KC #2YPW>ST!A?8C O<H *_!RJPLO?/53K^
M1A-P ?[,E7O2'YXSR^/+_&&"&1LDV%PDV'ZX>W@0'A[O=?<WD,P-)',#R5P:
MVN3D<#?<WC_8I-4VD,P-)',%^NROQ^'VR7:X?7S4/=ELC1M(Y@:2N>P>^^MA
MN+UW$.X<'G</-]S2&TCF!I*Y$MV&E.\'Q^'.T7%W=X.4WD R-Y#,)13T'1\?
MAWO;^]W=D\T*W( R-Z#,[[T#[AWLAL>'N]W]S?K;@#(WH,SON?4=[!^%AX<G
MW=> O39+;P/+W, ROS<L\X @F1M8YBK ,K\-D+!REX5^\R,#0E\A]7STEQ\'
M12HSG9?23O?8^8A7#W^V E!.ZH7>/W^]>'MQ%YPN.B]_K!><IQ=]'A>#/)G@
MQT$V"LX05 KMC,9?UQ5[W4/_M?\U+<ID-%N22W+W$#NO!+M"6B1%6>";(F87
M_O,VR_/L.<[_X]^.=W>._L["V;],HSQ*RRPOY.. !C4,RJ0<QW1)@J,9%R7\
M0?\NLZ"$AXW@8=DS=$<PB?,B2^&ADSR#O\O9?_S;P7&[C/Q7]2I_E,!HIG#1
MH;&7W[N;3Z$O[[-L6(3!Z6"035/HXJTD'8RG^ [!0QR-RX=@$.5QD,>#.'G"
M/:3HA$'O_TV3">+_PN B?8JQRV<A#E.91X.2>QU&*]>_H)<GT8P @S!VCUD:
MP^7C."IB>/0X@356P/#<YW%,JN=A,()Q'#PDE4]_B5.:#Q=I&:7W"38FV(J_
M#&+8LJ,B2+,R'@;]&$:R@ZUY?(SS00+70_/*8#".DD>XR3 ;3.5^25J4.?_#
M?>\HG>'H/R9% >]%M\67'CQ$91G#Q(A@7@1;SP\QS)P\T*;@Z\;C>%#F69H,
M\/JH>(#'Q;11!9%V,,ZZC'[IS'#M_I#F]P#=B1$X%/!@[#"Y!W1+\J6<YM1I
M,;0EIV\'>3Q,3*>;=D%SH.4TN_EBY]JD".*G!*;? #ML%D3!<PZ;:7H/S2[B
MP13_@4_!MM*"HSLF,-0%PSYU<<#ET\D$NA?[+>O#)"=+)3\=)2D,(XY 5!0Q
MOITV+LV>@^PYA:=#,^&#F+9!Z"286-!$NC"/P:T*QAEVPQ!6X<G?\:;KNQ)K
M)NUMEGTN O:(H'N-J<KC^PP^D.&!R:K#I%-<IH)K[PHV>#.<!'B7J)\]Q>:'
MQ;0/W5%.:>SP"7!OZ#T=RK*,!@^R9F >Q[@N>'[0/^A']+!'F!=/O%JQN?A9
M'D_&T4!7,'P_G [DKT$<#[65Q117?&P_1E./S<W5XGOOWGUI&HB;N+N]USV!
M$?BA)\=55CXGY4,!EH;L4V46E/YF.<QB,H4!&S0L<^D$6SL=,+M@Q\N'* T.
M#_Y=>W0"DP->;SP+XB^PQ;+Y&[I+,D\*_!2,X30>LO6:EJ8MQ0/L#FR&HDE2
MPO.+,AM\EL4-ID5G-8TD#*C9HW6$WT&SH-.#6YB#R3")\IE>VOM"+S ,SC/H
M33A@N=<\/R2#!WT\O 'M\/A&#]EXB&897P%?,@N>P(!CAP5#L"T#= _T"6S7
M'B,VCV#4=SON(I%7R>6Z&(Q3.:LOJ88W@&XF*XOCT-P5MB/"8*O/CS7.B>/@
MX,86@04' TI;#"Q5^0=Y@_ =C)3U5GA796NY->BH*7B(QT/S ]UPS8N9/9;;
MC?L]-AR,-KP6U3+U\97B!+HUSA^+ *<CS +J)'3.9&/G?T[Q+281-D8'8:L/
M%V<IS#(Q8K"P\#?%%,80WSA/!NS*IO)4:@UN4Z,1#!D<"*7UM_'_W]Z7/[>-
M9&G^*XCJW@YR F;KEMR.G0A9DJL4XY*]DJJKO;],@ 0HH0T"'!R2N7_]YCOR
M A(D)<LB2+-CIBQ18"+/E^_XWO?HP;=O#G:.?/SG6/QSL',"PX%?W\J>G&6P
M^7FEQ9M(;L%,/<0%OLSXI>C+_2CD;?0@%L;[M[@&BU!VS-PPP70JYA G)@D>
M3=4!WOL^2+_FU;0<S; +?7J/>":>)G14:"/U>97".8O?.#2UW3"4#_+:IEHU
MHYT #^F/^$*&XVR_!!?"V)'P&C5('Q9"S-1]/(Q+VLHP3MH*HK?X9;V'QD)U
M\NZ@)90F4J&86;HW?D?U4'\YDT/A\XU-6YM"//$QCE+O,:O$GAX%%2B)0D4:
M!U52PO[*1N)]W(I^#4TVKG<("L:]&+K0+WS:\M54K#$,2$R0M*GPNW+8XC.?
M/E&C$+)'W$RQT#+%F1>*X4RHGD+IM(2Q/"AX2]-.,@5!;]'4"WW,U!+O> *@
M.<KL\E%L1;2%A%X<):""5N+AS]I^:1NXU54>#ET:I(<JHP"& >=T*MJ&*7:^
M2&D3YAT^YTDXE0'HS2U/#;Q+<2+%,11G$'7(2LPE;B135_?^&-P,[#-7Y66?
MMP=<!BS4W/L0)H',ZADTY^XN"/((Q >*]LR[#T!WFK.Q3TUE7^XC:DM)V(6S
MA"N4NI=)S(70*]#GF,Q($=22,BBD"+Q0GYV+K_M*)8"_N8=JRV=KU%,X'B7\
M,V8A;#D>:'<JY?4IDT-254V1*0"=T]7:_7:U<)V=C9WU&QI9RH:"??@=?K;7
M5[GG>Q;?+VEG;. 4-.X=.*YTZ6#2?'L9G9<>^5*A!UZ(IG6'9V"!<?=F]V1E
MUMVN$EHK\#!;,_5V<'P(TW ZG0K+LI3NNOI&6-;VKH>37!-_O+>R>1=F\=_^
MLGNT\Z[YWXM 7$J\U<&" 0\9S4GA 0:C5V9WY,="Q<BV+QKG9EKE104&A;A#
MV7RAUQS372:TBXMOJ&1Z[_MP>3=:(%T6;CU,6S^7'DS2HT@M^G^1XXOBC;VX
M+VYS<1F7Y.X)HR1^F-/:"+VI_)2VX,1M'XM'AI%0/\:DXLL[6MBOL7A)&7R-
M6%]7MISQ%7:VBZ[D(_3K"BV&C%/?FT(S!;N+0)V.Z!=0-;)\@GT-JQ(_+E ;
MB+Z!XZ(0.K?H*;)Y8.LM,X>]<@Q6]#OF3:#Z1=H:=XA>)NY;" D,$U!F1N V
M!3\'SDR9;<II&+:>AC_9ADGB25Q*(_>.7/$QJ6NC!,TP\#2A8]%AM9#>BIHS
MNE8R#LA$X.0I0$7%W6!N:=#TE3Z*3Y'.B5L73R>XY=%_6*AS*D^#L'1H]],@
M("PAEA-W4EP,Q9&4KB[@8X%3";]B3\%39+RB8?R@B4/1C,)J =V@TEV6@F,D
M9449FW"<.,.0D>Y9%"M#9<Y@D")+'J)TA'ZQ0BQ"$N12'2:7/<XCR*S/&+SR
M)L%7%<?@L(NC/VA$FOTAEZVT+)V3"H],U$&7C3M.'@N%<<S+C(YA=E!S; !,
M/QRMBL@8]@9XZZ(BSM')0I.>/9*#B=IP7$R&AN)8-3&P3RI (:?[*1--7BR,
MJ9!/T=>^+_:D/:)D&X&O2\H]Z4B@?O5]$CH>[\>1'H*]^6[ ?!+S_3G(4>[!
MY^(B$79(I$P@VQ*#;0F.D0*"/('AIW%)>17346T6)0E16/(XA6X^],52IZ);
M&.2)\@<<G(Q>X5##B'T<=2M5#(W,16C3O !5ATZERT>\ZL&\/=C%1N,2[<3S
MML4D$)=RP':\,1^TY6(2(E)D6),CYS/GJV,8S9\WZ"9>I3+:. G X6-,!FRU
M>!Q'H=Q<5@-^[>J3]]R=$'VI\^["&_->'I*V?8T>1^4K3L.__>7@^!UO(MVD
MCKRUZ1*^Z=6\CC .1QM&3-_'X+&VQ^'V?(@MW4+("?&%D 9KG(S' !6.5B7&
M.BN&_$'3_QX/";9%$\N!2A@Z*1MSWDFNK]=1KUW7ZCP AW3(K:YWO_RGW]&Y
M81?E:J<&MU_C4-;, =]4OU&]QA!30=>QW,B90]P7U?"-%OFMAU\>^Z?(?Y>(
M,$6!C70X9X "N^642%T4OH.WD.H!0 ?\X0Q^@&C#0Y#@T<:PTW#FFU<@?0>D
MY[C*2=;+*31FT!H\C 'N!_4%J6RY9[0Y6U$J/L&X!W4$I\D2:/ *,;!B'-5%
M)[3[;^X1*/QN;4>I8#6S$6XY/0!\>WT4ELN56FJ&RL049J8>IF<J"@=><_^(
M^?4IJ@&K!I$-&*^0D!35%Y:9NJ\ $\-&%&)8U#5%@5"PX>89:I5>5+,9:;L9
MK; )9X?2#(54;UG?H9P.\?8O[_.LNB/EM<R%#16A&D8++^[8R33)9O!9(*RN
M/(UFPK82$F)4JI@#O9<UY1KJAY4T,:&G9-,KE9K,EZ&P>L8QA[ALR[WF.9?B
M';J]J0Z44:O)^$>[DD$F'^M0VHPO(A2$Y3T%9<R9=1B3X-00CP1DMH$M*9JP
M] A#?/BTNWCWJ8 "8 9R^%X03N(T+LH<8P'P_C0 E)4/NGX#> %V+K<?BKT
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MN ?BXIYBZ2$D,'H]Q@-A^$Y!I.5?2=**0>(N%?_VX0=Q0N 0@(/9]-FQ.Z>
M"#7Z^'E5=64?';7F7)_"!>1IV?@VTJ5V%):;H+9)D&"*X$'(XH!S2!EZA<!^
MO#G!W$)?9#R*S/Q5XZKU5:(!=CV@= 5*#H%Q@(_'RBKM6^["&&Q9#[\" K"0
M7@]*-X(H/H-E9'!YE$VF241O$=-OVL.M.R$8?4VS1W%SW]D.*S0-3<\JA&$@
M]Q9/Z$,<8%8+O\%.LH5852(=D!(D$*-+"= 3'$0+.'1#6F5<? 45L\A&,3IH
MM!):%9$9&Z,GP44#1AO:O#!<]A?)YH-A)9U-[2,'UVADXNL*SGS"5X@YKVT9
MN?7,J<"94!/MF ?PKL%+V4T<O<'D+7!D2P\Q!X,8X4:KK#2$$- 8<!+'8HO$
M?"'2Q33CO"A]]:&'5;ZI_A[#O?G2K^+@OWJ1D/'X'M2O]-*9@!.G]W5F@AV,
MA##"'T#6%CGLQU&(9_L/<5]#,.M"3_DMK(T,X9V.2'$U'[B1TX)>O5^3; @>
M>S$S5W@\@P3+#\'.@J_KE!A(Q87<J8>($]106HC'';K'728D1:I471FI)"$W
M\""KN.(0J'F(U$K0]SD''.4PASHSG%N9 TRQ+7'.&+Y*8RVB:9"#,,9P@:^#
MBX6$WSP$(Y G8J))K!#L!L,/E'HN4T)4SU1"U%)M:A1.-0WQ-#<N#O-$9[6W
M]3F0F>!7)7L!Y).8GGT&N#@C>;X3>B.UB!8,(,LYJRMBK3Y^A-^^W-Q>_'[C
MG5Z=>Q<?+\YNKS]=79YYM]>G5S>_7][<7'ZZNO%N?H.'WU]XGZ\__?/R_.)<
M'H_3&^_R1IYV:$)_?OK/T\N/I^\_7O"?A;2X^N1=7WR^OKBYN+H]O14M>Y^N
MO3]/K\6[;K]XGSZ(%KYX_W4IFKF\\7X_/;_PWG_Q3G\53_OX)R!$OKB&+\%O
MXOG;WRXNKT6;'T]O19\^7US?0&\OK[RS3U=78BSPBC\O;W_#Y]587U*+.CQ8
MF1:UWSF'=FMJUC7[H7SOHARMV^R[DU5>:?+=2]\&OY Z&9EF,C:J;3FX]1D]
M <AI@*^!%:0<(QP>NF8!11X %(0:SL<L'P4J ]+Z\TV 12@NMRPGL@8 ^ 0V
M"0D8DWF-_X2_PD",L/%-^9THO0ON(D+X2$'([D?IHZ((.[91:CR*U&$)O&W$
MW*Q4:C#3604J>6R&SF,J1WUU?9;BB>E]ED;>!+3!NXBM7G'/%:P66TK#4)R%
MZ$&9S>)O0(@#SA&0U@@+%0LJ#&;6)G5W? \4'[K2#&!D!?ZKDJ-_C"05RD:>
MB;L++LLI 7I!_D(OVV#,KH57U[81R6SXGJ$W/%_4?>62UL0&$S::LWQ)GUQ#
MHS75W68H6GL]. S=L[Y ?Z;,[684-:.6M(E@A[3[VM/@<V@;5CC@6U4F66-0
MFY)74E\B3FR(CGC:#-:3#T)Y%]#TR[,"T,=W0N2!PH+(TCA)QE7BB9T'RDDU
M<KLM.).[X?S#6]]>6*^'4RN>#B-*0>=X%J;K)V#ZI6_$%HH"LA'_785W4@D,
M@&\AQQ_!)HMP8"9Q@=/K:N33N/KN"LV3\WX)YU#SUCD\>8?>0BL8KU 5260?
MH+K[L[;):7N3140[^_F!%8:*X F5C^KF\7O;\.%/'SYLOXE;Y K3#2PXF/JP
M%\9A;SWK;C1R,%(NC"5E%7O(25\PB2[LL3$U23SOV-K90@H Q4)-GJRPBMB$
MPLL7X40QD!L\B']#_(G0N1&?>%\S&8BY$9/,]R_]HIP&E*4C&JE [OLRDJFY
MJGP+'YU;Z2#8;R 162(;9,Y5Z8"IJHF+^^C; ]^4N-!R $W/R/IERB761AHP
M)6.*_27F&'T&X!.E,8?JSC;4*K_V5LJ0X#Y-@A WR[C*T[BX)ZT%WF3"*>OX
MI]H-9CZQ5*89-U-J)PK:WP#?-=.0;.Q>:'S;5!KK04F=F%KGPC.42:1-H>.+
MU%#*J^H E[2%&%C!,EJ5&4X26%!3Q6QEMNE-,'1PU(38S\I[/P!BFP!2U<1Q
MGA)Q3BCZ"!X1SM/US4L-G_(9S4I[#U0<Q:T&1S.,I;Q@P+:[:\OE,RJ2/LH>
MFP/3"PKP1@>,#,A$\SC5/&R9W  KS*(L&X)_GWZCWC?<=C6=5:X]XND4[MT"
M&SJ"1C(8%],6054T](U^:4Y#W6C]@!B8_K@HI33FV)LZ@4('8/UGA*$[YV,T
MM(L'UO?.B>;((3;8J2K9:2A< .TIK[L2]7/>QU'RF!*O5!@\D.U9B=\V$Q$D
MYHWR>*B\D?5.:X!D$@6Y.%_BB@,*%X5LEGT>2S8GZ<KJ0=X7!CM1EVZ)L@)E
MYQ28[""ESM.-,<F8&,I4Y>^J@%XW$Z"ZD!S6HG*X(+7V+25O)1-DFWE%-D]=
MHL08_@(@^\M2;*6JE,VW^K*65'MLXPH93^?K6TO95DK>^3AH-./8V*"0FB5M
MW.CH!Y4R_P0#VXGU?G4C6TB)"4;\2;S/!YBS+;XAWMZ#SGM[O4MQ.PDA4@%#
M6-?<H]+#92#?P4&"P?"D%K%',:$,<B8P1L\DD04S2R=>B/A39"0@@D9$7DIY
MWW^-H>6Q-P3$$]QUI,C7[S35LSH7)W@_Q,$5?7B,)$\FLT<X"%ADJB/?I#IF
M-HXB<Y"*3P*/B1 9 \^[M<1D&PU@,X> S [XFX& L'PLQ%,(P!LC6Y$]T7%I
MHWJH_PI$BGIE,(E,CF'&;:I&#.5D&!DQ1?UE,[Z&22:&'RXH#)7?$(>-!"KZ
M6SV#JN;E,;.CT%2R,J2PD^I>(KRKGB9M":AL/C?,7)$FNE 8KH4C'CRY9&Y/
M84ST.;$ZQBHK!!XWV!^![B^-VKQ<&R)P#SLG<'EKGI% .H]&:(R02M!8\^L(
M? LK%L,7;6@<4LQ+>1Q@M:<1+CD';^2^MAVMKBSH1M8=[LHX;P0S@.BU$0Z2
MF9SH18!("8@JU#KPQ*CG'N' S#>F:_*QX;I3#C&X)1Y3<]!,="\S&"7JRV'X
MH509"[V5F/@M!! AN])0&EB1@GO)5_)=%O+6<0(&T.5+_$ R&J?1G*BS::X?
M$['KRJ#FI/TZ?KO5"=,F[,SPF4P>M-9'DKIK%TU0Z(L%+%4S)*;3 A<Z8CB*
MM<@+X]H.MF?F"4F%Y#?1*:#$A4H7@KGAE:>+EU4YZ\QY$/,[8L0.9D^Q$H)T
M^+@HD%8ZC7)914%SP1JU%)368'@@<G[M(U@;I-@XW'9NK0://UP[R%X<I\H%
M(TPKHO=O"7'-.6"#FK@QL'YQ8<QUSIG;:##&0!<1?0LD"S.P:UA3F:,8G9M<
MC\+#$3P5UI%4$59WDSC4=+H95GDQL(K4KRV9IJFHWQ2$D7.. X$,Q!9.*V0?
M.RG@$?2-UG54&$ )K/,3\NXG84<"1L7U4+89^?C2=:#.8&U;X1];^DJ\^W"5
M"#DC+ING[2>C8^8!-[>FML5IU"ZB%^7(H#M(_ 6\$@I3"A3^<#+9WR+]P4HO
MI[&.(9CC$7VW(7.I @O,5&%E("\[Q#RZ"W)%?*#%DKS5FMY/0#5$<5DO;H,O
M2>?*"\-JL6,5A1&LB"/ENT8SKGZ;R0135<HBXR0U9#&0W/>2KQ+#ON11]S2F
M.9*RD\+(ENCF*>1[L>T(D/;"I01PC/).XWVM<_.:?OQYE-HMN!!9Z\IRYZN
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MS([[\CCZK/Z:!@6=<EJ_.)>DN$65/X ^51L)JHQ&66TK44M[+H663BY]Y0"
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M%'(DC]EL@8E>@=*  I#"2>!/3&9XY(.<D(M,J03AJCQ&". $1$Z61J*K14U
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M,K8L$7(FU#V.(P?!Z5@R^CAZ8C#[8^%4R:_08LT"3;OH+S"BROIZ"X>T*,.
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M8*&IGDUO!'X*#801BO0"2*[%9#_H(ADRHS@F\W043&.LQ&0E=,L,:2EFN6J
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M\K4TUQCX>:9%2$89MC6(^+@@=6"4>@KR/$@QXB[9^U!8BC_=R$+..OD09"<
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MQR__$@;1U=G"2+(:<&<2T&_OF6L2S#LP:[2BGXW%]H:Z4!VH1_2)^M*)ND.
M[C53>#LQ01)>VX49\CV GPJ;F%F8(^*231"C>A\7J*DC^V4P#488'"LP 8(W
MG%D6!*0)X&AKWX0*- ]Q"%RKLA')0]MT(;3Z#!C\.P]C'&*)+T*G?HB&>06>
MZ[U]W]O;V=OSD48>O!Z3++U3G?8=-=@DKPQ)QL)1,T7QC *AF-<S:B2N<E]1
MLH&<CM7NKL.W[R1G.Y.QH9RBI:V0/K4J<;=H&DPDF1-_@6F-95EFI.8T2L8A
M6VZ$;J.)!3Q7 ^\OK&H]1[1WA=*K%[0FBYC5O(&[3^*L1EKA&3/1TE2\/ N]
MB-A@5[<C7B&*\Z*S3]Y,I!HFGPYHO."63 ,@GHJ^045'D#1B \-6!C?K4H6U
MUF'GM=>BOX63B5D.:>:=1^.@2HB4]N)!EKKA3_T-GZ-1>\4%U[A]WDQS<S?,
MJ[0H\2XSY=NY*H8G<VGXBJ1TFOD9-$)4A#+!HR8<+")0(79\ EYN\VE6E4_S
M/99)9PY(N/#Z(CT+:Q8:.U^EG-U4PR(&\ &RL4/Q ="\H'!,#,7Y3.&,):4E
MZ30T2I6X"M_[WG<A?3R\BDO+^K*.F$\GE-I-LA'4$2"&W: HQ(9A-EM)6"N5
M66*C)7WVT:X>A.2(JB,S4X!J#8EJS)6.P@ND6!GE= \')Y;.K-2CC9'!4>L6
MN\J\CW$D)EGSNB?1 \L0+"S(E1N"NR!."[MH'Q+>4B$9<U]8G.55BCLC$B<[
MFT5(7P\UB*DRCJY"34%*U?@]70IFB%(5*H42-F644LD;R?LNWN1TV1C&R1JZ
M,4[+4AQ$.,-YI!(Z\1RK>J^ZL!349N2J>EE5JQ74*_H##YPB[''P[7*H^F1)
MN:]M7+X!(F"(ILX(TT.HSB"7\63KFW8*]**Y.^#]JUCL'*N&GF*1;_$4HW2A
MP\Q;E "Q]J^GIY^IR!C6B!42("Z@KDC"M<TB+I8%(0J^F/EDIW"I:6$@;J1$
M%0T,4E6W%QGQQ3U3TBX>9UD)"DC!P6_XNB_O25E/O4J#2MC7+:/WE:80#,4-
M.<*OV.T:P?Y9%.1O(A@?-.D%(6PRGL5"T_?#W3=QOF[IU(Z=P5&-$'15^]MM
MAG].D$$<W!Y8H]>PRV"T5>$5<<K<W4D@I$]+;5]PRL3Y*(&%_0)7RU6&E\05
M>E9.F;Z6_0[41E0HHSM+JLF<0@C;X,]+!']>.[-0='JP0QU_:FKA_F#O8+?U
MKV9FX5-:W7L[V'N[7,+BDYH5VLON\8LWN[L[.#Y^^^+-'@].CO=^0*N')_LO
MWNK1X'CWY"423&5JYPXD=AKMS7G4D05*(L&=![H*V7VM:OB>L;='G?P-&9^J
M3+Q9 SL=E951;* ^IK?K."9YIUNC6O)8.H8G[;<5C*^E;$5_7?>@>SR_BR?N
MT4/1U&XW<Z1@! F;8G_'"X7:Y?7 8$ ORP0>X" ?&;T!>/)RL$Z$D?"4A5_7
M"\8]<U^B#=L*5]F&C8>LJTV5N7L;)G/_#PF5GT+JZK&RW#TX1+F[%::;,J"M
M,%TK8;J_8<+T-$T!I=4[^WSJG9)GN+^QTO1/DJ%O67=%_Z'WX<L%N%@/S<_&
M<4),OT*CO;DXVTK;31G05MJNE;0]V$QI^T'IK9_S[-\4O2?P[/LJO(O6UD\W
M;]!"A>VQ#GM4E[]]$,"[_"E4;9Q"D!P*PP(TYSY*=5YO[[CQU-:SL#%;92N>
MUTH\'VZ:>&:Z-0,.HMR;)BJ''MNLL;O]NUO1NBD#VHK6M1*M1QLF6A>DYF[$
M&+<B="M"UVH\FRU"CS=,A%Y^1JBXD*"]B)*O\B@HLC08"ID3?8/$D@@AQ#+=
M).'LUU ,H8#<AF \!NBNL)DK1/:*%C,@_"JJ!+.)?C\]V[ Y^Y.<!YS1MY7$
M&S*@GT82MS+YU*#P*X&KS4OQE57FC+Q]2,)@T[GP3(3U#^HYMNCB4'1#[WH,
MXD_BHL0$L(#[RFF%F#7B%9 90OE_451BSDI(? 6 0I@&(\C>B,(H;/+\KA=R
M?/<'0+R/!@<G1R_?[.Y@?_?E8=/'@\.]EY^#']/J[L'@X,> YT_V#U8+'??@
MW_W!\;$MP=MK";V^' 3B;*'[EICFB62'3[^=UF*8=CF*UD$>K?4@H1D>Z-_^
M<K3_[NG#[(:F,7\)S\23>9885#I"__^<!%!5LS[HI]F$'5OD%\"A/T%H;>V&
M3@]HT^R&35^@#90\3T)C;R7/I@QH*WDZ/J#-ESQ/@BYO)<^F#&@K>3H^H,V7
M/$^"\6XESZ8,:"MY.CX@E^19VXB3!M4W>#RZ.)1?_O-XL+N/7$Z[N^^\W^,T
MGE03[V/\/U4< L'E*LEP>U.*A7'0*_ *($RK$H.Q&]'WTSQ&NJL@&54)T6GV
M/<U+=;3_#FBL/,\S=MJJPF%O#P8'!P?/B88=[0V.]@Y?/+JR?SC8/5ZN6=8)
MY .\5E#MZ)<?=9VNMS#XA.1_OP? C5<XMAY]X*8C6YLH[=%@Y_ 'Q#UW!T<[
M+Q^B/!D<[K_\&7H[.-A=CH?K^< V]ZT]B<,PB59T=3R'1N<)EL(KC<U]]_S&
M[/\YT[@".>OH/DCO(N2^_Z]HYGT6AQJ+2BY#JC@_B-?]'?"JNNA*Q^0VA&N7
MWN[>#[ST5G&5;FDY?S):SNVU_;->V\]A8EKG:UN6<:;<]B)((OH)#F$F?J7?
M\JAD?DK I!MYEED."'5A9M['PYCK.+O([;?W^WJ,::/O]TV14=]+<#17,+65
M)-T;',.M:Y<DI0\[),Y2T;2025.NK<55):"^1% 55,TGH$H<C2(37/ON(4M$
MLY,,JR ((7;[F'F_56D(M08^Q.-RYMW>9U4!H/ESD(-YX?7^NG>XXXO!]FU!
MITO^KM>N^]G%W;J-S2TEGD/,LSZ:3*$/KJK6 HK'6;TRBRH:1XEYA5&?*(/:
M4&&4"",.?J?*#5RII_".!GN]@(J#P(_#?EOAGJUNLQYCVN3#_AR:EW4Y[$ )
M*,NRP:%%KI</5/K+JLT54BV[^RP)L>!767B/62Z^_"F-U!VN;N_>7T7S>&M3
M#;L<:\$-L^PK9=]N#_:ZC&F3#_9S2$;6Y6!?TGTJ6D#]._/^IXH**I,'_/1?
M5-D_O->QG):^['7-,;S3N5XD*/V!-TVB\ [3YX\._Y>\MHLR&WWUQ2T?4W54
MK-_G1= :5]'*'M,H+^[CJ7<?)5890'C^URJ ^I-9KLI"-F705F:LRY@V668\
MAU5C760&&OVSK/)PVK'>'E9^_5W6;]79<LN''CU/B*(9B!L&U;"4$>V.LNEL
ML'&[_V<YT:T1/=NU=3(XD</C"JIOZ+/GA=^VD<,7CAP^;]6Z W6BZN/@57@=
MQ*#[6O \KW6?OMQY>.UCSY0@7( 5#<!(33=Y?PS;$>NLFM5J55GUDW=>3]P"
M:69^/?H6%R57E98U/:_,)P:RLN?I$[E'!B[RD:[-[>GU^<7'+__RO<NKL_:B
MI=;>V1\<+=@F"[_VVJ-\/Z/E;ZM;C40X0!FQQ&.W<9DL>&YCY_$<U2DQ]*6+
M7]M29^=PL+?DF)_0T&M+V;-/'S^>WEY<GW[T3G^]N+KU_KBY\#Y=??S2[<&X
ME_1:<KH/Z8RT[GVU]G..QQJ._Y_PM5B/OWUT+S !K/4=[.P.]EVEM#LT+X8M
M=8/%L^?NCB^ *7'_R9%TL%6=?X3J7*O6OC\X7%"MW9J*UQ:B%__Z[?+]Y:WW
MH75W=*6G9Y^N/W^Z%@+?>__I^OK3GY=7OWIG%]>WEQ\NS\2G'<]OHCY?7)/D
M6F4ZDZ5J+E*=5C%5Y\9JKF*":(D^1,.\"O*9M[?O>WL[>WO+J84H52Q[[GAU
M&M+'BZMSWG*K76CW1-]\O!:;\)\7-[>_@_H&!WS@>T'1A!9 %/%CA*B!9VFK
MA*%"E=W!TKRJH(P'B*KAC,WDF;!^LP28B85Q/1&?!L*(A=Q',2%!ZF5C84A'
M&!)1L1*8%J@M3%\0&RY^B$.HJ22_B[,Y%K.9/1;X,T=H0C2<A=D\QJBMMLR7
MGMG.S.)NJPR[](()CO8F&N51"6=9!:,<LSGP?I]Y)5B5$!(3<Z7G9QB)"6PW
MR]=JU^VUSI><",S"/7X'/IE@5'I)="=V5"JL<IB7VJ89Z,T(D^:-LGS*;CER
MZ4"8D. ^%!YX5'OP!ET]XI=SH6D^!GFT(1.\WSK!Y+D2-@Z<>XBE%"M4!.9[
M41%D[IVN\G9 Z=;M^7F_ROGQI;=5&&D)2'K T>95Y,,AS,$+"Q,X OLQ@K3T
M;!H3++<7][W&63<"=4B&GYHGN1>GHZ1"G*\0 VF(U:#Z=+G$B=C0*A'>$+5C
M?<()% "_B)OJ\3X>W5MB(U8OBT);\(K'P<M[EP?3>V]/W5/ 0 VXHM@UDO<S
MD#(#,<TQBGH$$,P=7IKQ4_15[QXBGP1TAM%&H1AIFE9) C^)21_%]&$>/61?
M19?QZU,QS3 O]'2XQ&O54_S:/)J 7UW\WUB\"V9@%.%#$54JJ%W?($2R\88(
MS8-6H7DKQDL:#&P_,?O@8J"( ^#1PXH+.SR(883P<YA-.3VFL36&69"',(EA
M# <D T2Y6+R 6ZG*^RP7G<93,XG+,F+4>S;N>T$IGT/(RB2*\&Z3"!6[Q6F5
M%U608B D$/=?D,:3K!)=SJ'55+2?%ICB(_41Z]U\%A@_WQ]X-_ &<^@!0>B>
ML$_P =S8H##BYN88SF,P\R99B-XWV-/3**AO=#X&5!\#]SSM<<3HHEI>>!/1
M3 [:J]C9XO.)&'49)P0A9-6=ZU;J:> *'J)WT"R'B<9Y-M%*V9*NO+V#MX.C
M+OM9_O:7M[L_VMC"%I?G^'\?) 'CL3X'=Y&03B7@NB" )I;QH[!FO??BB:^K
M] 6(::NG>2QT[2P5T)#NN87NW_VCANS<712?W3I67\&Q^ITK]]H[^?KBYM/'
M?UZ<^RMU_F'JU2H/--PX61JM=!+X=M1:!7L#$*P:"7TYFT6D*LMKR!=::U9$
M: 47/GD)"E+@Q$X.RBJ/Z%)&3X&/ER'8SN(Z&T;W03(V&W,[6M8H9W]O=W"\
M^_*E2_:/!SM';U^\V1_4V]W#P<[;Y7K[TI!76L>5:.KSK.+GU?I8V^$B .4G
M&N^-E'0OGQ*M1OR,E.@5:/@M<35MP@FK[S1$<^DZFF0/J[SM%J^HZ'-48X7[
M046,?EHR6V'%'.T_KX[,=GJWT[N=WI]R>I?B&SU:TNI=A:MWOB'L??CC^O:W
MB^NM0=P5@WC*3))A1%8M1&,@XL+,#M[H/AI!O&.8?1-F;0%I6_<Q&LW@PL8(
ML3!\??+@EJ*#F <@_O4!FT_>8U2'8,P:K5"@EUS8TO0]R%/%MV+M4=$UV:W
M4K!:S>NG1T2VY^:9YP8C'^9"XO(_P>FQ&2M#8_1^%\=XMLHUD6 ,;P(]T<>)
M0S2;>C NOD6CJF2VF/-L5&%X>K4+(?L$DBZ!?H6R7_B1"H@A0<[&KLROD,8O
M*UZO^&A07YK(0J_@[D%^<R06HY2!44MZ<029R4YZT3<)B(!O)4DT*@%W!U4
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MX2\* +L!5Q:";RH$5M?@.INZOSIHD8#P%Y:A92PR43(9E1:*2NPH8CJ*87?
MUPB<(39.*3&ZN?A.4"(Z:EDPTN[)WN#M0GC"[LG*,'A;B-*K092V$* ?  %:
M#TSKX5Q,J_1J@9=+.=I VC0N)#<Z14*NX[P%CE+<9X^IN*.^23J.F'QTS[V.
M]@X/7X7RH$42S$^+MXDC;'Z(9]Z^@^;U^X,Y'UJ%HWM__<=__(?'Q'Z.#"=.
M*C/@3:P](8H?=UMLN7KYFC0OR!8@_@%"C%,%[3?N6FC-1%0)$PQ<Q"8.?E*!
MII<4J$+!\_1N-,0SN)%U:RI+*U?XZN_S]'923ESZ.(O=Q B@4M!VZJRK;Q53
M9V/T['1*V*1"\*EM6WB[8I[SK+J[]P[I!/C=3<'J^KRG5A[I=XC8%1TZ,X=Q
M ^_#I2E0]D@8=GBDS[W6I3&VV^&L$,F^<;JU'U9B/W1C'\R[!YZ1E_F<'/Z5
M(B?QKBLB66$Y"I^4]=,ZC&UNSNL=K.>M@2VI7?=0-PZH%M3OUWXL\X0-)R(O
MJSQT8Y O*5.>,;#-E3+0>AS^[U_B@]W=XZ.]T='^P7YP$!X?!/OAV_%.>! =
MOCT>'YWL_??ASB_=%4VKWZ'S1<JO';ZOW3T_/?O-^WAQ>WMQO0QIG.U<F7]<
MNN"3V3MNH:9J%XN=Z?;ASH[W.<B_>J</40I4(/MYZ'U(LBSO?M^AF2]9_M7W
MKKYX8J/-85SK3)]/2XY'D8%ZFI;W63KS;B"I)FTGW.Q,_S\$WYB0>V]WK^^]
M?;O_9O?H[<FRIO5*:%&QXQ>3($YL+L5E_ "V^^EPL-\E/_ UNSD(G +1'(F<
M,U LH23)$<9@@Z+0ZX%3CMG3C;IY2)S>1R\[.-@GF3 83_,P2F;??# I!UZ/
MOV0&G^ [OH>2,'V(BA+??R;,3_UX-WVGHLNKY8^4<R>6::0!AP$"#H7-3@ 1
MS=''DUG')JIUJU.M<,@P2SOJN[X!?;L"-QVX(G<'NRMU53.#CXW."R N4,X4
MS,.1LJ!]*W $@)BI+&Q21@GC[2')32#7D3Z5Y0H(P(0(42;J,LXHKZA<Z8'G
MG053# !BED.43PH $H;>L"J1N$>/((S&<<I<<K"E[@'Z<L^%>KU)%$ <KO#N
MQ$L5(8]$QBG1,$>G<4C/SDC*2V102JE^J"8?DPB?L9B2="3F1HV3)ETC.2E0
MI"*-LO!9#1M<9C[0/L&Z [H42K,S;1>^DF!#FL,H *Y$J'\$H='>;M][7Q4Q
M8DG/(2TB3F,"JX81<,>)%T#BK2R5T40:CPC."E"Y$05H@5L"V=N 7!&VW#28
MJ4L!>R"VP*>A6*" XK>BX=0+*V*'0JH+GTC3 "D%)>EAPR,"2C9D/MLHZ<';
M_>+;-$H+0.DQ"9MHL)KBS'@7#URY_CP:!U52^@;FTNQ95I5%&6#I:)@9&LX(
M"T(9U%E<(=;;&^SW(E45UMB]WJVYK+7U#",TGP'I"_6GX[(BMK=@HB93O(-6
M0_R 0IEGO1D26B-ZCH.3P=N=]C\_E_#B"<TNR [ER4,E;&<@I@.(;^/0DX*#
M_PYVK^O/3R07H,S.N4IL+=RU'-G #Q*!1S#B^3+P0%R_36<23->;_8%C=PW%
MN:*;^?SB\Z>;R]M/UU^\J]/?:YSI<])IEUPQFJKMDK[FDKZ_/KTZ^^WI_ W;
M0[BJ%3N[O/VR/7GKOXXWMU",XO3JW/N_EY^]LT_G+GFZW"F4#O_V]=N>TU=?
MWULA6<5E^;>_'!R_.WU_ZEW]\?O[NLM[\<G]_J7=GNW77_O3L[-/?US=MJ_Y
M4@P=/',G!QTQGM%U>@N 7#:5RIDP\H31N(AZNLB\!)R& :4O!Q,PDHCQ$$S&
M[_(L[+W.Y.PL"FT=+%^'L1LC<&UW76/QOY?]WUJ.TJC^^,+C/'REF,!RX]3%
M[KY[F.L,1?C[, MGXI_[<I+\Y_\'4$L! A0#%     @ S8"E5)["_$]YH (
M9?D7 !$              ( !     &%R9'@M,C R,C S,S$N:'1M4$L! A0#
M%     @ S8"E5$+MDY'%$0  >\,  !$              ( !J* " &%R9'@M
M,C R,C S,S$N>'-D4$L! A0#%     @ S8"E5+L:R;#8&0  *O<  !4
M         ( !G+(" &%R9'@M,C R,C S,S%?8V%L+GAM;%!+ 0(4 Q0    (
M ,V I535(,2G%E(  *F, P 5              "  :?, @!A<F1X+3(P,C(P
M,S,Q7V1E9BYX;6Q02P$"% ,4    " #-@*54^#OZV"C:  "+)P$ %
M        @ 'P'@, 87)D>"TR,#(R,#,S,5]G,2YJ<&=02P$"% ,4    " #-
M@*54\[V#\B'C  #L80D %0              @ %*^0, 87)D>"TR,#(R,#,S
M,5]L86(N>&UL4$L! A0#%     @ S8"E5&4Z>N(+A0  NQ0& !4
M     ( !GMP$ &%R9'@M,C R,C S,S%?<')E+GAM;%!+ 0(4 Q0    ( ,V
MI51TS=;J[ <   <F   7              "  =QA!0!A<F1X+3(P,C(P,S,Q
M>&5X,S$Q+FAT;5!+ 0(4 Q0    ( ,V I52P*>18V0<   PF   7
M      "  ?UI!0!A<F1X+3(P,C(P,S,Q>&5X,S$R+FAT;5!+ 0(4 Q0    (
M ,V I51AT>-;004    9   7              "  0MR!0!A<F1X+3(P,C(P
M,S,Q>&5X,S(Q+FAT;5!+ 0(4 Q0    ( ,V I52.IW97L18  !R(   =
M          "  8%W!0!S;')E>&ET9F5E86=R965M96YT+65X,3 R+FAT;5!+
M 0(4 Q0    ( ,V I51^T=Y[\3\! !,1"0 >              "  6V.!0!S
M;')L;V%N86YD<V5C=7)I='EA9W)E96UE;BYH=&U02P4&      P #  R P
&FLX&

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
